FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Pique-Gili, M
   Pinyol, R
   Torrecilla, S
   Wang, H
   Montironi, C
   Ramadori, P
   Willoughby, CE
   Andreu-Oller, C
   Torres-Martin, M
   Leow, WQ
   Moeini, A
   Taik, P
   Gallofre, JP
   Oliveira, CPMS
   Alves, VAF
   Lachenmayer, A
   Roessler, S
   Minguez, B
   Schirmacher, P
   Boffetta, P
   Dufour, JF
   Thung, SN
   Reeves, H
   Uzilov, A
   Carrilho, FJ
   Chang, CY
   Heikenwalder, M
   Sanyal, AJ
   Friedman, SL
   Sia, D
   Llovet, JM
AF Pique-Gili, Marta
   Pinyol, Roser
   Torrecilla, Sara
   Wang, Huan
   Montironi, Carla
   Ramadori, Pierluigi
   Willoughby, Catherine E.
   Andreu-Oller, Carmen
   Torres-Martin, Miguel
   Leow, Wei-Qiang
   Moeini, Agrin
   Taik, Patricia
   Peix Gallofre, Judit
   Oliveira, Claudia P. M. S.
   Alves, Venancio A. F.
   Lachenmayer, Anja
   Roessler, Stephanie
   Minguez, Beatriz
   Schirmacher, Peter
   Boffetta, Paolo
   Dufour, Jean-Francois
   Thung, Swan N.
   Reeves, Helen
   Uzilov, Andrew
   Carrilho, Flair J.
   Chang, Charissa Y.
   Heikenwaelder, Mathias
   Sanyal, Arun J.
   Friedman, Scott L.
   Sia, Daniela
   Llovet, Josep M.
TI MOLECULAR AND MUTATIONAL LANDSCAPE OF HEPATOCELLULAR CARCINOMA (HCC)
   RELATED TO NONALCOHOLIC STEATOHEPATITIS (NASH)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Liver Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 13-16, 2020
CL ELECTR NETWORK
SP Amer Assoc Study Liver Dis
C1 [Pique-Gili, Marta; Pinyol, Roser; Torrecilla, Sara; Montironi, Carla; Willoughby, Catherine E.; Andreu-Oller, Carmen; Moeini, Agrin; Peix Gallofre, Judit; Llovet, Josep M.] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Catalonia, Spain.
   [Wang, Huan; Taik, Patricia; Uzilov, Andrew] Sema4, Stamford, CT USA.
   [Ramadori, Pierluigi] German Canc Res Ctr Heidelberg DKFZ, Div Chron Inflammat & Canc, Heidelberg, Germany.
   [Torres-Martin, Miguel] Icahn Sch Med Mt Sinai, Dept Med, Tisch Canc Inst, Liver Canc Program, New York, NY 10029 USA.
   [Leow, Wei-Qiang] Icahn Sch Med Mt Sinai, Dept Med, Tisch Canc Inst, Liver Canc Program,Div Liver Dis,Transplant Inst, New York, NY 10029 USA.
   [Leow, Wei-Qiang] Icahn Sch Med Mt Sinai, Dept Med, Tisch Canc Inst, Liver Canc Program,Div RM,Transplant Inst, New York, NY 10029 USA.
   [Oliveira, Claudia P. M. S.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Oliveira, Claudia P. M. S.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol LIM 14, Sao Paulo, Brazil.
   [Lachenmayer, Anja] Univ Bern, Univ Hosp Bern, Dept Visceral Surg & Med, Bern, Switzerland.
   [Roessler, Stephanie] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.
   [Minguez, Beatriz] Hosp Valle De Hebron, Liver Unit, Barcelona, Spain.
   [Schirmacher, Peter] Inst Pathol, Stony Brook, NY USA.
   [Boffetta, Paolo] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.
   [Dufour, Jean-Francois] Univ Bern, Univ Clin Visceral Surg & Med, Inselspital, Bern, Switzerland.
   [Thung, Swan N.] Icahn Sch Med Mt Sinai, Dept Pathol, Liver Canc Program, New York, NY 10029 USA.
   [Reeves, Helen] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England.
   [Chang, Charissa Y.; Friedman, Scott L.; Sia, Daniela] Icahn Sch Med Mt Sinai, Mt Sinai Liver Canc Program, Dept Hematol Oncol, Div Liver Dis,Dept Med,Dept Pathol,Tisch Canc Ins, New York, NY 10029 USA.
   [Heikenwaelder, Mathias] German Canc Res Ctr Heidelberg DKFZ, Div Chron Inflammat & Canc, Heidelberg, Germany.
   [Sanyal, Arun J.] VCU Sch Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA.
   [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Catalonia, Spain.
   [Llovet, Josep M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD NOV
PY 2020
VL 72
SU 1
MA 112
BP 83A
EP 84A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NV0MH
UT WOS:000574027000113
DA 2020-12-08
ER

PT J
AU Fernandes, GD
   Campos, D
   Ballalai, A
   Palhares, R
   Alvares-da-Silva, MR
   Palhares, DMF
   Neto, BF
   Barros, FMD
   Gil, RD
   Chagas, A
   Carrilho, FJ
AF Fernandes, Gustavo dos Santos
   Campos, Daniel
   Ballalai, Andre
   Palhares, Rodrigo
   Alvares-da-Silva, Mario R.
   Palhares, Daniel M. F.
   Neto, Ben-Hur F.
   Barros, Fabio M. do R.
   Gil, Roberto de A.
   Chagas, Aline
   Carrilho, Flair Jose
TI Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular
   Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based
   on Real-World Data (vol, pg, )
SO JOURNAL OF GASTROINTESTINAL CANCER
LA English
DT Correction; Early Access
C1 [Fernandes, Gustavo dos Santos; Palhares, Daniel M. F.] Hosp Sirio Libanes, Ctr Oncol, SGAS 613-614,Conjunto E,Lote 95, CEP 7020073 Brasilia, DF, Brazil.
   [Fernandes, Gustavo dos Santos] Sociedade Brasileira Oncol Clin, Sao Paulo, SP, Brazil.
   [Campos, Daniel; Ballalai, Andre] IQVIA Brasil, Sao Paulo, SP, Brazil.
   [Palhares, Rodrigo] Bayer Brasil, Sao Paulo, SP, Brazil.
   [Alvares-da-Silva, Mario R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
   [Neto, Ben-Hur F.] Amer SA DASA, Diagnost, Sao Paulo, SP, Brazil.
   [Neto, Ben-Hur F.] Associacao Brasileira Linfoma & Leucemia ABRALE, Sao Paulo, SP, Brazil.
   [Barros, Fabio M. do R.] Real Hosp Portugues Beneficencia, Recife, Pe, Brazil.
   [Gil, Roberto de A.] Serv Oncol Clin INCA, Rio De Janeiro, RJ, Brazil.
   [Gil, Roberto de A.] Oncoclin Ctr Tratamento Oncol, Rio De Janeiro, RJ, Brazil.
   [Chagas, Aline; Carrilho, Flair Jose] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, SP, Brazil.
   [Chagas, Aline; Carrilho, Flair Jose] Inst Canc Estado Sao Paulo ICESP, Sao Paulo, SP, Brazil.
RP Fernandes, GD (corresponding author), Hosp Sirio Libanes, Ctr Oncol, SGAS 613-614,Conjunto E,Lote 95, CEP 7020073 Brasilia, DF, Brazil.; Fernandes, GD (corresponding author), Sociedade Brasileira Oncol Clin, Sao Paulo, SP, Brazil.
EM gustavo.fernandes@hsl.org.br
CR Fernandes GD, 2020, J GASTROINTEST CANC, DOI 10.1007/s12029-020-00508-7
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1941-6628
EI 1941-6636
J9 J GASTROINTEST CANC
JI J. Gastrointest. Cancer
DI 10.1007/s12029-020-00539-0
EA OCT 2020
PG 1
WC Oncology; Gastroenterology & Hepatology
SC Oncology; Gastroenterology & Hepatology
GA OH2SZ
UT WOS:000582420700001
PM 33103212
OA Bronze
DA 2020-12-08
ER

PT J
AU Fernandes, GD
   Campos, D
   Ballalai, A
   Palhares, R
   da Silva, MRA
   Palhares, DMF
   Neto, BF
   Barros, FMD
   Gil, RD
   Chagas, A
   Carrilho, FJ
AF Fernandes, Gustavo dos Santos
   Campos, Daniel
   Ballalai, Andre
   Palhares, Rodrigo
   da Silva, Mario R. A.
   Palhares, Daniel M. F.
   Neto, Ben-Hur F.
   Barros, Fabio M. do R.
   Gil, Roberto de A.
   Chagas, Aline
   Carrilho, Flair Jose
TI Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular
   Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based
   on Real-World Data
SO JOURNAL OF GASTROINTESTINAL CANCER
LA English
DT Article; Early Access
DE Hepatocellular carcinoma; Epidemiology; Public health system; Brazil
ID RISK-FACTORS; SURVIVAL; TRENDS
AB Purpose Describe sociodemographic and clinical characteristics of patients with hepatocellular carcinoma (HCC) and establish their history in the Brazilian public health system.
   Methods Retrospective observational study was conducted using the database from the Department of Informatics of the Unified Health System (DataSUS). Patients with at least one claim of HCC between July/2011 and June/2016 were included. A record linkage methodology was performed to obtain longitudinal data across different databases. Demographic and clinical data were evaluated, including the time elapsed between diagnosis of HCC risk-factors and the cancer development. Data was analyzed using descriptive statistics.
   Results A total of 28,822 HCC cases were identified between July/2011 and June/2016. Mean age was 59.7 years (SD = 14.7), and most patients were men (55.9%). The highest relative number of HCC cases was detected in the south of Brazil (> 20 cases/100,000 inhabitants). About 86.5% of the patients had diagnosis of HCC without previous liver diseases. Only 8% had diagnosis of chronic viral hepatitis and 3.5% cirrhosis. About 76% were diagnosed at an advanced stage, and only 11% of the patients had early stage HCC. Approximately 58% of patients with previous underlying liver diseases were diagnosed at early stages, compared with only 24% of patients without prior record of underlying diseases.
   Conclusion The diagnosis of HCC in the Brazilian public health is usually made in patients with no previous diagnosis of liver disease and in advanced stages, when no curative treatment is available and survival rates are low. Public health policies are key for the screening and monitoring liver disease and, consequently, HCC.
C1 [Fernandes, Gustavo dos Santos; Palhares, Daniel M. F.] Hosp Sirio Libanes, Ctr Oncol, SGAS 613-614,Conjunto E,Lote 95, BR-70200730 Brasilia, DF, Brazil.
   [Fernandes, Gustavo dos Santos] Soc Brasileira Oncol Clin, Sao Paulo, SP, Brazil.
   [Campos, Daniel; Ballalai, Andre] IQVIA Brasil, Sao Paulo, SP, Brazil.
   [Palhares, Rodrigo] Bayer Brasil, Sao Paulo, SP, Brazil.
   [da Silva, Mario R. A.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
   [Neto, Ben-Hur F.] Diagnost Amer SA DASA, Sao Paulo, SP, Brazil.
   [Neto, Ben-Hur F.] Associacao Brasileira Linfoma & Leucemia ABRALE, Sao Paulo, SP, Brazil.
   [Barros, Fabio M. do R.] Real Hosp Portugues Beneficencia, Recife, Pe, Brazil.
   [Gil, Roberto de A.] Serv Oncol Clin INCA, Rio De Janeiro, RJ, Brazil.
   [Gil, Roberto de A.] Oncoclin Ctr Tratamento Oncol, Rio De Janeiro, RJ, Brazil.
   [Chagas, Aline; Carrilho, Flair Jose] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, SP, Brazil.
   [Chagas, Aline; Carrilho, Flair Jose] Inst Canc Estado Sao Paulo ICESP, Sao Paulo, SP, Brazil.
RP Fernandes, GD (corresponding author), Hosp Sirio Libanes, Ctr Oncol, SGAS 613-614,Conjunto E,Lote 95, BR-70200730 Brasilia, DF, Brazil.; Fernandes, GD (corresponding author), Soc Brasileira Oncol Clin, Sao Paulo, SP, Brazil.
EM gustavo.fernandes@hsl.org.br
RI Alvares-da-Silva, Mario Reis/L-3910-2014
OI Alvares-da-Silva, Mario Reis/0000-0002-5001-246X; Reis,
   AlessanRSS/0000-0001-8486-7469
CR Almeida-Carvalho Sandra R, 2017, Ann Hepatol, V16, P255, DOI 10.5604/16652681.1231586
   Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753
   Brechot C, 2004, GASTROENTEROLOGY, V127, pS56, DOI 10.1053/j.gastro.2004.09.016
   Carrilho FJ, 2019, SEMIN LIV DIS
   Castelo A, 2007, REV ASSOC MED BRAS, V53, P486, DOI 10.1590/S0104-42302007000600013
   Dhanasekaran R, 2012, HEPATIC MED-EVID RES, V4, P19, DOI 10.2147/HMER.S16316
   OSÓRIO Fernanda Maria Farage, 2013, Arq. Gastroenterol., V50, P97, DOI 10.1590/S0004-28032013000200015
   Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014
   Goncalves Carlos S., 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P165, DOI 10.1590/S0036-46651997000300008
   Grandhi MS, 2016, SURG ONCOL, V25, P74, DOI 10.1016/j.suronc.2016.03.002
   Hartke J, 2017, SEMIN DIAGN PATHOL, V34, P153, DOI 10.1053/j.semdp.2016.12.011
   International Agency for Research on Cancer, 2018, GLOB CANC OBS CANC F
   Kikuchi L, 2017, CLINICS, V72, P454, DOI 10.6061/clinics/2017(08)01
   Kikuchi L, 2013, ANTIVIR THER, V18, P445, DOI 10.3851/IMP2602
   Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Longo L, 2018, DIGEST DIS, V36, P377, DOI 10.1159/000490378
   Mendes EV, 2010, CIENC SAUDE COLETIVA, V15, P2297, DOI 10.1590/S1413-81232010000500005
   Niu ZS, 2016, WORLD J GASTROENTERO, V22, P9069, DOI 10.3748/wjg.v22.i41.9069
   Paranagua-Vezozzo DC, 2014, ANN HEPATOL, V13, P386, DOI 10.1016/S1665-2681(19)30845-2
   Pinero F, 2018, WORLD J GASTROENTERO, V24, P4224, DOI 10.3748/wjg.v24.i37.4224
   Signorelli IV, 2016, CLINICS, V71, P361, DOI 10.6061/clinics/2016(07)01
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Zhang GQ, 2018, EXPERT REV GASTROENT, V12, P515, DOI 10.1080/17474124.2018.1453806
NR 24
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1941-6628
EI 1941-6636
J9 J GASTROINTEST CANC
JI J. Gastrointest. Cancer
DI 10.1007/s12029-020-00508-7
EA SEP 2020
PG 7
WC Oncology; Gastroenterology & Hepatology
SC Oncology; Gastroenterology & Hepatology
GA NN0ED
UT WOS:000568461100002
PM 32918274
OA Other Gold
DA 2020-12-08
ER

PT J
AU Sanduzzi-Zamparelli, M
   Rimola, J
   Montironi, C
   Nunes, V
   Alves, VAF
   Sapena, V
   da Fonseca, LG
   Forner, A
   Carrilho, FJ
   Diaz, A
   Fuster, C
   Ferrer, J
   Fuster, J
   Ayuso, C
   Sole, M
   Bruix, J
   Reig, M
AF Sanduzzi-Zamparelli, Marco
   Rimola, Jordi
   Montironi, Carla
   Nunes, Vinicius
   Alves, Venancio Avancini Ferreira
   Sapena, Victor
   Fonseca, Leonardo Gomes da
   Forner, Alejandro
   Carrilho, Flair Jose
   Diaz, Alba
   Fuster, Carla
   Ferrer, Joana
   Fuster, Josep
   Ayuso, Carmen
   Sole, Manel
   Bruix, Jordi
   Reig, Maria
CA Epithelioid Hemangioendothelioma
TI Hepatic epithelioid hemangioendothelioma: An international multicenter
   study
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Article
DE Liver cancer; Rare tumors; Vascular; Outcome
ID LIVER-TRANSPLANTATION; FOLLOW-UP; RESECTION; PROPOSAL; OUTCOMES
AB Background and aims: Hepatic epithelioid hemangioendothelioma is an ultra-rare hepatic vascular tumor, diagnosed more frequently in females. The knowledge about this tumor derives mainly from small case series with sub-optimal treatment outcomes. The aim of this study is to identify the clinical and radiological issues helpful to develop an international prospective registry.
   Methods: We conducted an international multicentric and retrospective study of patients with hepatic hemangioendothelioma. The clinical, pathological and radiological images collected during follow-up were reviewed. Central radiological revision was performed and 3 patterns of contrast were defined.
   Results: Between 1994 and 2016, 27 patients with hepatic hemangioendothelioma were identified in three institutions but the final diagnosis was hepatic angiosarcoma in one. The majority were females, median age was 38.7-years and 17 patients were asymptomatic at diagnosis. No patient had Two out of ten (20%) patients had surgical specimens with positive macro-vascular invasion and 50% had extrahepatic disease, and the most frequent pattern was the progressive-central-contrast-uptake. After a median follow-up of 6.7-years, the 5- and 10-year survival rates are 91.5% and 51.9%, respectively.
   Conclusions: This multicentric study shows the heterogeneous profile of patients with hepatic hemangioendothelioma, reflecting the need to establish a reference network in order to better characterize these patients and ultimately develop a personalized treatment strategy. (C) 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
C1 [Sanduzzi-Zamparelli, Marco; Sapena, Victor; Forner, Alejandro; Bruix, Jordi; Reig, Maria] Univ Barcelona, Hosp Clin Barcelona, BCLC Grp, Liver Unit,IDIBAPS,CIBERehd, Barcelona, Spain.
   [Rimola, Jordi; Ayuso, Carmen] Univ Barcelona, Hosp Clin Barcelona, BCLC Grp, Radiol Dept,CIBERehd, Barcelona, Catalonia, Spain.
   [Montironi, Carla] Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain.
   [Nunes, Vinicius] Univ Fed Bahia, Salvador Da Bahia, Brazil.
   [Alves, Venancio Avancini Ferreira] Univ Sao Paulo, CICAP Hosp Alemao Oswaldo, Dept Pathol, Sch Med, Sao Paulo, SP, Brazil.
   [Fonseca, Leonardo Gomes da] Univ Sao Paulo, Sch Med, Clin Oncol Inst Canc, Sao Paulo Hosp Clin, Sao Paulo, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Div Clin Gastroenterol & Hepatol, Hosp Clin, Sao Paulo, Brazil.
   [Diaz, Alba; Fuster, Carla; Sole, Manel] Univ Barcelona, BCLC Grp, Dept Pathol, Hosp Clin Barcelona,IDIBAPS, Barcelona, Spain.
   [Ferrer, Joana; Fuster, Josep] Univ Barcelona, Hosp Clin Barcelona, Digest & Metab Dis Inst, BCLC Grp,Liver Surg & Transplant Unit, Barcelona, Spain.
RP Reig, M (corresponding author), Univ Barcelona, Hosp Clin Barcelona, BCLC Grp, Liver Unit,IDIBAPS,CIBERehd, Barcelona, Spain.
EM mreig1@clinic.cat
OI Reig, Maria/0000-0002-5711-9534; Bruix, Jordi/0000-0002-9826-0753
FU Ajuts per a la iniciacioa la recerca 2019 from Societat Catalana de
   Digestologia (SCD); Instituto de Salud Carlos IIIInstituto de Salud
   Carlos III [FI19/041958, PI15/00145, PI18/00768]; ISCIIIInstituto de
   Salud Carlos III [PI13/01229, PI18/00542]; AECC [PI044031]; WCR (AICR)
   [16-0026]
FX MSZ: was supported by "Ajuts per a la iniciacioa la recerca 2019 from
   Societat Catalana de Digestologia (SCD)" and received grant support from
   Instituto de Salud Carlos III (FI19/041958); MR: received grant support
   from Instituto de Salud Carlos III (PI15/00145).; AF: has been supported
   by grants from ISCIII (PI13/01229 and PI18/00542).; JB: received grant
   support from Instituto de Salud Carlos III (PI18/00768), AECC (PI044031)
   and WCR (AICR) 16-0026.; CIBERehd: is funded by the Instituto de Salud
   Carlos III.
CR Calabro L, 2007, J EXP CLIN CANC RES, V26, P145
   Deyrup AT, 2008, AM J SURG PATHOL, V32A, P924, DOI 10.1097/PAS.0b013e31815bf8e6
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Alves VAF, 2019, SEMIN LIVER DIS, V39, P1, DOI 10.1055/s-0038-1676120
   Galvao FHF, 2005, TRANSPL P, V37, P4354, DOI 10.1016/j.transproceed.2005.11.022
   Gan L, 2016, ONCOL LETT, V11, P1699, DOI 10.3892/ol.2016.4149
   ISHAK KG, 1984, HUM PATHOL, V15, P839, DOI 10.1016/S0046-8177(84)80145-8
   Karaman B, 2012, ANN NUCL MED, V26, P440, DOI 10.1007/s12149-012-0592-5
   Kobayashi N, 2016, CASE REP ONCOL, V9, P134, DOI 10.1159/000443986
   Lai Q, 2017, TRANSPLANTATION, V101, P555, DOI 10.1097/TP.0000000000001603
   Lakkis Z, 2013, J HEPATOL, V58, P1254, DOI 10.1016/j.jhep.2013.01.043
   Lau A, 2015, THER ADV MED ONCOL, V7, P229, DOI 10.1177/1758834015582206
   Makhlouf HR, 1999, CANCER, V85, P562, DOI 10.1002/(SICI)1097-0142(19990201)85:3<562::AID-CNCR7>3.0.CO;2-T
   Mehrabi A, 2006, CANCER, V107, P2108, DOI 10.1002/cncr.22225
   Mehrabi A, 2016, ANN MED SURG, V11, P1, DOI 10.1016/j.amsu.2016.03.002
   Rodriguez JA, 2008, J GASTROINTEST SURG, V12, P110, DOI 10.1007/s11605-007-0247-3
   Sangro B, 2012, RARE TUMORS, V4, P106, DOI 10.4081/rt.2012.e34
   Sapisochin G, 2017, NAT REV GASTRO HEPAT, V14, P203, DOI 10.1038/nrgastro.2016.193
   Singh A, 2016, J ONCOL PRACT, V12, P394, DOI 10.1200/JOP.2015.010090
   Studer LL, 2018, ARCH PATHOL LAB MED, V142, P263, DOI 10.5858/arpa.2016-0171-RS
   Uchimura K, 2001, J CLIN GASTROENTEROL, V32, P431, DOI 10.1097/00004836-200105000-00015
   van Rosmalen BV, 2017, BMJ CASE REP, V2017
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD SEP
PY 2020
VL 52
IS 9
BP 1041
EP 1046
DI 10.1016/j.dld.2020.05.003
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NI2SN
UT WOS:000565205600021
PM 32535084
DA 2020-12-08
ER

PT J
AU Terrabuio, DRB
   Haddad, L
   Ducatti, L
   Gouveia, LN
   Rocha-Santos, V
   Ferreira, RMT
   Darce, GF
   Cardoso, AJA
   Carrilho, FJ
   Andraus, W
   Abdala, E
   D'Albuquerque, LAC
AF Terrabuio, Debora Raquel Benedita
   Haddad, Luciana
   Ducatti, Liliana
   Nunes Gouveia, Larissa
   Rocha-Santos, Vinicius
   Ferreira, Renee Mignolo Tanaka
   Darce, George Felipe
   Cardoso, Ana Julia Andrade
   Carrilho, Flair Jose
   Andraus, Wellington
   Abdala, Edson
   D'Albuquerque, Luiz Augusto Carneiro
TI Insights in the approach of long-term liver transplant recipients with
   COVID-19
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Letter; Early Access
C1 [Terrabuio, Debora Raquel Benedita; Ferreira, Renee Mignolo Tanaka; Cardoso, Ana Julia Andrade; Carrilho, Flair Jose] Univ Sao Paulo, Hosp Clin, Div Clin Gastroenterol & Hepatol, Dept Gastroenterol,Sch Med, Sao Paulo, Brazil.
   [Haddad, Luciana; Ducatti, Liliana; Nunes Gouveia, Larissa; Rocha-Santos, Vinicius; Darce, George Felipe; Andraus, Wellington; Abdala, Edson; D'Albuquerque, Luiz Augusto Carneiro] Univ Sao Paulo, Hosp Clin, Div Liver & Gastrointestinal Transplant, Dept Gastroenterol,Sch Med, Sao Paulo, Brazil.
RP Abdala, E (corresponding author), Hosp Clin Sao Paulo, Sch Med, Ave Itaborai,311 Apto 24, BR-04135000 Sao Paulo, SP, Brazil.
EM eabdala@uol.com.br
RI Abdala, Edson/H-5165-2012; Carneiro D'Albuquerque, Luiz
   Augusto/A-8812-2013
OI Abdala, Edson/0000-0003-0765-6654; Carneiro D'Albuquerque, Luiz
   Augusto/0000-0001-7607-7168
CR Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fix OK, 2020, HEPATOLOGY, V72, P287, DOI 10.1002/hep.31281
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Lee BT, 2020, GASTROENTEROLOGY, V159, P1176, DOI 10.1053/j.gastro.2020.05.050
   Negri EM, 2020, PREPRINT, DOI [10.1101/2020.04.15.20067017, DOI 10.1101/2020.04.15.20067017]
   Siordia JA, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104357
NR 7
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13424
DI 10.1111/tid.13424
EA AUG 2020
PG 3
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA MW2PS
UT WOS:000556886200001
PM 32702167
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Nakano, LA
   Cancado, ELR
   Chaves, CE
   Madeira, MCV
   Katayose, JT
   Nabeshima, MA
   Fossaluza, V
   Uhrigshardt, GG
   Zheng, LT
   Pinto, VB
   Carrilho, FJ
   Ono, SK
AF Nakano, Larissa Akeme
   Rachid Cancado, Eduardo Luiz
   Chaves, Cleuber Esteves
   Vaz Madeira, Maria Cristina
   Katayose, Jessica Toshie
   Nabeshima, Mariana Akemi
   Fossaluza, Victor
   Uhrigshardt, Gabriela Guimaraes
   Zheng Liting
   Pinto, Vanusa Barbosa
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI A randomized crossover trial to assess therapeutic efficacy and cost
   reduction of acid ursodeoxycholic manufactured by the university
   hospital for the treatment of primary biliary cholangitis
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Ursodeoxycholic acid; Primary biliary cholangitis; Capsules; Tablets;
   Health care costs; Hospital
ID CIRRHOSIS
AB BackgroundHealth care costs are growing faster than the rest of the global economy, according to the World Health Organization (WHO). Countries' health expenditures include paying for general medicine, diagnostic procedures, hospitalizations and surgeries, as well as medications and prescribed treatment. Primary biliary cholangitis (PBC) is a rare autoimmune liver disease and the first line available treatment is ursodeoxycholic acid (UDCA), however, direct and indirect treatment costs are expensive. Main aim of this trial was to assess if the therapeutic efficacy of UDCA manufactured by the university hospital is equivalent to that of standard UDCA and treatment cost reduction in patients with PBC.MethodsIt is a prospective, interventional, randomized, and crossover study in patients diagnosed with PBC. UDCA 300mg tablets and capsules were developed and manufactured by the university hospital. Thirty patients under treatment with standard UDCA, in stable doses were randomized in sequence A and B, 15 patients in each arm. The groups were treated for 12weeks and after, the UDCA formulation was changed, following for another 12weeks of continuous therapy (tablets and capsules / capsules and tablets). Laboratory tests were performed at time T0 (beginning of treatment), T1 (at the 12week-therapy, before the crossing-over) and T2 (end of treatment). The evaluation was done by comparing the hepatic parameters ALP, GGT, ALT, AST and total bilirubin, also considering the adverse events. The comparison of costs was based on price of the manufactured UDCA and standard UDCA price of the hospital.ResultsHospital reduced 66.1% the PBC treatment costs using manufactured UDCA. There were no differences in the biochemical parameters between sequence (A and B) and tablets or capsules of UDCA formulations applied in the treatment of PBC.ConclusionsThe study showed that there was no significant difference between manufactured UDCA (capsule and tablet) and standard UDCA. Hospital reduced the PBC treatment costs using the manufactured UDCA by the university hospital.Trial registrationClinicalTrials.gov: NCT03489889 retrospectively registered on January 12th, 2018; Ethics Committee approved the study (ID: 1.790.088) on October 25th, 2016.
C1 [Nakano, Larissa Akeme; Rachid Cancado, Eduardo Luiz; Nabeshima, Mariana Akemi; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Hosp Clin, Div Clin Gastroenterol & Hepatol, Dept Gastroenterol,Sch Med, Av Dr Eneas Carvalho Aguiar 255,9th Floor, BR-05403000 Sao Paulo, SP, Brazil.
   [Rachid Cancado, Eduardo Luiz] Univ Sao Paulo, Inst Trop Med, Lab Med Invest LIM 06, Sao Paulo, Brazil.
   [Chaves, Cleuber Esteves; Vaz Madeira, Maria Cristina; Katayose, Jessica Toshie; Pinto, Vanusa Barbosa] Univ Sao Paulo, Div Pharm Hosp Clin, Sch Med, Sao Paulo, Brazil.
   [Fossaluza, Victor; Uhrigshardt, Gabriela Guimaraes; Zheng Liting] Univ Sao Paulo, Inst Math & Stat, Sao Paulo, Brazil.
RP Ono, SK (corresponding author), Univ Sao Paulo, Hosp Clin, Div Clin Gastroenterol & Hepatol, Dept Gastroenterol,Sch Med, Av Dr Eneas Carvalho Aguiar 255,9th Floor, BR-05403000 Sao Paulo, SP, Brazil.
EM suzane.ono@fm.usp.br
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil
   (CAPES)CAPES [001, 1734244]; Brazilian Council for Development of
   Science and Technology (CNPq)National Council for Scientific and
   Technological Development (CNPq) [PQ 308609/2018-2]
FX Not applicable.LAN would like to thank the funding master's scholarship
   provided by the Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior - Brazil (CAPES) - Finance Code 001 (number 1734244). SKO would
   like to thank the Brazilian Council for Development of Science and
   Technology (CNPq) for grant PQ 308609/2018-2. The funders had no role in
   the study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Boonstra K, 2012, J HEPATOL, V56, P1181, DOI 10.1016/j.jhep.2011.10.025
   Dwan K, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4378
   Hirschfield GM, 2017, J HEPATOL, V67, P145, DOI 10.1016/j.jhep.2017.03.022
   Hopf C, 2013, CLIN PHARM DRUG DEV, V2, P231, DOI 10.1002/cpdd.24
   Jessup RL, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024385
   Kulkarni VS, 2016, ESSENTIAL CHEMISTRY FOR FORMULATORS OF SEMISOLID AND LIQUID DOSAGES, P1, DOI 10.1016/C2013-0-18871-X
   Lindor KD, 2019, HEPATOLOGY, V69, P394, DOI 10.1002/hep.30145
   Marin M L, 2001, Rev Hosp Clin Fac Med Sao Paulo, V56, P41
   Nolan SJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159014
   Packeiser PB, 2014, INFARMA, V26, P215
   Pares A, 2006, GASTROENTEROLOGY, V130, P715, DOI 10.1053/j.gastro.2005.12.029
   Piazza C, 2010, EUR MAN MED, P461, DOI 10.1007/978-3-540-68940-9_49
   Poupon R, 2018, OVERVIEW TREATMENT P
   Rodrigues JPO, 2015, URSACOL ACID URSODEO
   Steven P, 2018, DESIGN ANAL CLIN TRI
   Wellek S, 2012, DTSCH ARZTEBL INT, V109, P276, DOI 10.3238/arztebl.2012.0276
NR 16
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD AUG 5
PY 2020
VL 20
IS 1
AR 253
DI 10.1186/s12876-020-01399-5
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NC2SO
UT WOS:000561066500002
PM 32758152
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Andrade, AR
   da Rocha, TRF
   Ortiz-Agostinho, CL
   Nishitokukado, I
   Carlos, AS
   de Azevedo, MFC
   Hashimoto, CL
   Damiao, AOMC
   Carrilho, FJ
   D'Amico, E
   Sipahi, AM
   Leite, AZD
AF Andrade, Adriana Ribas
   Flores da Rocha, Tania Rubia
   Ortiz-Agostinho, Carmen Lucia
   Nishitokukado, Ieda
   Carlos, Alexandre Sousa
   Cardoso de Azevedo, Matheus Freitas
   Hashimoto, Claudio Lioshi
   Moura Cintra Damiao, Aderson Omar
   Carrilho, Flair Jose
   D'Amico, Elbio
   Sipahi, Aytan Miranda
   de Arruda Leite, Andre Zonetti
TI Endoscopic activity, tissue factor and Crohn's disease: findings in
   clinical remission patients
SO THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
LA English
DT Article
DE Crohn's disease; endoscopic activity; tissue factor; thrombosis
ID VON-WILLEBRAND-FACTOR; INFLAMMATORY-BOWEL-DISEASE; THROMBIN GENERATION;
   PROTEASE
AB Background: As Crohn's disease (CD) is associated with a high risk of thromboembolic events (TE), including patients with subclinical inflammation, we aim to evaluate the correlation between the impact of endoscopic activity (EA) in the coagulation profiling of CD patients while in clinical remission. Methods: From 164 consecutive CD patients included in clinical remission [Crohn's disease activity index (CDAI) < 150], 75 were in the EA group [Simplified Endoscopic Score for CD (SES-CD) > 7], 89 were in the endoscopic remission (ER) group (SES-CD <= 2), and 50 were included as healthy controls in the study. Blood samples were analyzed for tissue factor (TF), factor VIII (FVIII), thrombomodulin (TM), ADAMTS-13, von Willebrand factor (VWF), and endogenous thrombin potential (ETP), as well as collecting data regarding risk factors for TE and CD profile. Results: Mean plasma TF activity showed significantly higher levels in the EA group when compared with the ER and control groups (127 pMversus103 pMversus84 pM;p = 0.001), although the VWF:Ag (160%versus168%versus110%;p = 0.001), VWF/ADAMTS-13 (191versus219versus138;p = 0.003), FVIII (150%versus144%versus90%;p = 0.001) and TM (5.13 ng/mlversus4.91 ng/mLversus3.81 ng/ml;p < 0.001) were only increased in CD regardless of EA status when compared with controls. Lastly, ETP with and without TM remained the same in all three groups. Conclusions: CD patients in clinical remission with EA present endothelial lesion inducing TF exposure and subsequent coagulation cascade activation. Recommended thromboprophylaxis for EA outpatient subgroups will require additional investigation in order to be validated.
C1 [Andrade, Adriana Ribas; Flores da Rocha, Tania Rubia; Ortiz-Agostinho, Carmen Lucia; Nishitokukado, Ieda; Carlos, Alexandre Sousa; Cardoso de Azevedo, Matheus Freitas; Hashimoto, Claudio Lioshi; Moura Cintra Damiao, Aderson Omar; Carrilho, Flair Jose; D'Amico, Elbio; Sipahi, Aytan Miranda; de Arruda Leite, Andre Zonetti] Univ Sao Paulo, Sch Med, Lab Gastroenterol Clin & Expt LIM 07, Gastroenterol, Av Dr Arnaldo 455,Sala 4384, BR-01246903 Sao Paulo, Brazil.
   [Andrade, Adriana Ribas; Flores da Rocha, Tania Rubia; Ortiz-Agostinho, Carmen Lucia; Nishitokukado, Ieda; Carlos, Alexandre Sousa; Cardoso de Azevedo, Matheus Freitas; Hashimoto, Claudio Lioshi; Moura Cintra Damiao, Aderson Omar; Carrilho, Flair Jose; D'Amico, Elbio; Sipahi, Aytan Miranda; de Arruda Leite, Andre Zonetti] Univ Sao Paulo, Div Hematol, Coagulat Lab, Sch Med, Av Dr Eneas de Carvalho Aguiar, Sao Paulo, Brazil.
RP Leite, AZD (corresponding author), Univ Sao Paulo, Sch Med, Lab Gastroenterol Clin & Expt LIM 07, Gastroenterol, Av Dr Arnaldo 455,Sala 4384, BR-01246903 Sao Paulo, Brazil.
EM azaleite@gmail.com
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2015/06196-0]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: Grant
   #2015/06196-0, Sao Paulo Research Foundation (FAPESP).
CR Andrade AR, 2018, CLIN TRANSL GASTROEN, V9, DOI 10.1038/s41424-018-0013-8
   Barthet M, 2006, PANCREATOLOGY, V6, P464, DOI 10.1159/000094564
   Bernhard H, 2011, INFLAMM BOWEL DIS, V17, P2333, DOI 10.1002/ibd.21631
   BEST WR, 1976, GASTROENTEROLOGY, V70, P439
   Bryant RV, 2014, J CROHNS COLITIS, V8, P166, DOI 10.1016/j.crohns.2013.09.007
   Bryckaert M, 2015, CELL MOL LIFE SCI, V72, P307, DOI 10.1007/s00018-014-1743-8
   Cibor D, 2017, WORLD J GASTROENTERO, V23, P4796, DOI 10.3748/wjg.v23.i26.4796
   Claus RA, 2009, THROMB HAEMOSTASIS, V101, P239, DOI 10.1160/TH08-03-0161
   EDWARDS RL, 1987, GASTROENTEROLOGY, V92, P329, DOI 10.1016/0016-5085(87)90125-9
   Faioni EM, 2004, CRIT CARE MED, V32, pS266, DOI 10.1097/01.CCM.0000128032.85396.83
   Faye AS, 2020, CLIN GASTROENTEROL H, V18, P1133, DOI 10.1016/j.cgh.2019.07.028
   Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223
   Gao HC, 2017, XENOTRANSPLANTATION, V24, DOI 10.1111/xen.12291
   Geddings JE, 2014, THROMB HAEMOSTASIS, V111, P570, DOI 10.1160/TH13-10-0812
   Harbord M, 2016, J CROHNS COLITIS, V10, P239, DOI 10.1093/ecco-jcc/jjv213
   Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636
   Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958
   Jenkins PV, 2012, BRIT J HAEMATOL, V157, P653, DOI 10.1111/j.1365-2141.2012.09134.x
   Loghmani H, 2018, BLOOD, V132, P148, DOI 10.1182/blood-2017-12-768994
   Lutsey PL, 2009, J THROMB HAEMOST, V7, P1639, DOI 10.1111/j.1538-7836.2009.03561.x
   Mannucci PM, 2004, BRIT J HAEMATOL, V126, P213, DOI 10.1111/j.1365-2141.2004.05009.x
   Meucci G, 1999, SCAND J GASTROENTERO, V34, P287
   Peyrin-Biroulet L, 2014, GUT, V63, P88, DOI 10.1136/gutjnl-2013-304984
   Saibeni S, 2010, THROMB RES, V125, P278, DOI 10.1016/j.thromres.2009.10.012
   Tripodi A, 2016, CLIN CHEM, V62, P699, DOI 10.1373/clinchem.2015.248625
   Undas A, 2010, INFLAMM BOWEL DIS, V16, P1447, DOI 10.1002/ibd.21206
   Zezos P, 2005, WORLD J GASTROENTERO, V11, P7639, DOI 10.3748/wjg.v11.i48.7639
NR 27
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1756-283X
EI 1756-2848
J9 THER ADV GASTROENTER
JI Ther. Adv. Gastroenterol.
PD AUG
PY 2020
VL 13
AR 1756284820939412
DI 10.1177/1756284820939412
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA MZ3VR
UT WOS:000559050500001
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU de Campos, PB
   Oliveira, CP
   Stefano, JT
   Martins, SN
   Chagas, AL
   Herman, P
   D'Albuquerque, LC
   Alvares-da-Silva, MR
   Longatto, A
   Carrilho, FJ
   Alves, VAF
AF de Campos, Priscila B.
   Oliveira, Claudia P.
   Stefano, Jose T.
   Martins-Filho, Sebastiao N.
   Chagas, Aline L.
   Herman, Paulo
   D'Albuquerque, Luiz C.
   Alvares-da-Silva, Mario R.
   Longatto-Filho, Adhemar
   Carrilho, Flair J.
   Alves, Venancio A. F.
TI Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) -
   pathological evidence for a predominance of steatohepatitic inflammatory
   non-proliferative subtype
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE Hepatocellular carcinoma; Non-alcoholic fatty liver disease; Pathology;
   Immunohistochemistry
ID FIBROSIS; CYTOKERATIN-19; EXPRESSION; MANAGEMENT; PROGNOSIS; DIAGNOSIS;
   FEATURES; DRUGS; KI67
AB Objectives. This study evaluated clinical and pathological aspects of patients with hepatocellular carcinoma (HCC) secondary to non-alcoholic fatty liver disease (NAFLD) and related these factors to immunohistochemical markers representative of the proliferative class.
   Methods. We evaluated 35 HCC nodules from 21 patients diagnosed with NAFLD undergoing liver resection (n=12) or liver transplantation (n=8) or both (n=1). Demographic, clinical and biochemical data were compared to histological features and to immunohistochemical reactivity for K19 and Ki-67.
   Results. Cirrhosis was present in 58% of patients. Ages ranged from 50 to 77 years. Sixteen patients (76%) were male and had type 2 diabetes mellitus, 81% had arterial hypertension, and 90% had BMI above 25 kg/m(2). Alpha-fetoprotein levels were normal in 62% of patients. Twenty-five (70%) nodules were diagnosed as "steatohepatitic HCC". Only 32% of the nodules presented high levels of Ki-67 (>10%) and/or K19 (>5%), although 63% were poorly differentiated (G.3/G.4) according to Edmondson & Steiner grading system. K19 positivity (>5%) was associated with higher degree of intratumoral inflammation (G.2/G.3), and with fibrosis, both at the center of the tumor and at the tumor front, whereas Ki-67 positivity (>10%) was associated with ballooning of neoplastic cells and occurred in more than 70% in non-cirrhotic patients.
   Conclusion. NAFLD-related HCC was found in non-cirrhotic patients in 42% of cases, alpha-fetoprotcin level was normal in 63% and "steatohepatitic HCC" was the predominant histological type. Immunoexpression of K19 and/or Ki-67 occurred in 32% of the nodules and were associated with intratumoral inflammation and ballooning, suggesting that HCC in MtS may be preferentially "an inflammatory, non-proliferative subtype of HCC".
C1 [de Campos, Priscila B.; Oliveira, Claudia P.; Carrilho, Flair J.; Alves, Venancio A. F.] Univ Sao Paulo, Med Sch, Sao Paulo, SP, Brazil.
   [Oliveira, Claudia P.; Stefano, Jose T.; Carrilho, Flair J.] Univ Sao Paulo, Hosp Clin HCFMUSP, Sch Med, Lab Clin & Expt Gastroenterol LIM 07,Dept Gastroe, Sao Paulo, SP, Brazil.
   [Martins-Filho, Sebastiao N.; Longatto-Filho, Adhemar; Alves, Venancio A. F.] Univ Sao Paulo, Hosp Clin HCFMUSP, Sch Med, Dept Pathol LIM 14, Sao Paulo, SP, Brazil.
   [Chagas, Aline L.; Herman, Paulo; D'Albuquerque, Luiz C.] Univ Sao Paulo, Hosp Clin HCFMUSP, Sch Med, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Alvares-da-Silva, Mario R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Gastroenterol, Porto Alegre, RS, Brazil.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
RP Oliveira, CP (corresponding author), Univ Sao Paulo, Lab Gastroenterol Clin & Expt LIM 07, Dept Gastroenterol & Hepatol, Hosp Clin HCFMUSP,Fac Med, Av Dr Arnaldo 455 3th Floor 3115, BR-01246903 Sao Paulo, Brazil.
EM cpm@usp.br
RI Alvares-da-Silva, Mario Reis/L-3910-2014
OI Alvares-da-Silva, Mario Reis/0000-0002-5001-246X
FU - [-] Funding Source: Medline
CR Akuta N, 2018, BMC GASTROENTEROL, V18, DOI 10.1186/s12876-018-0900-1
   Alexander J, 2013, J GASTROEN HEPATOL, V28, P848, DOI 10.1111/jgh.12116
   Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046
   Athyros VG, 2017, METABOLISM, V71, P17, DOI 10.1016/j.metabol.2017.02.014
   Bai K, 2017, CLIN LAB, V63, P355, DOI 10.7754/Clin.Lab.2016.160638
   Bruix J, 2016, GASTROENTEROLOGY, V150, P835, DOI 10.1053/j.gastro.2015.12.041
   Bugianesi E, 2007, Clin Liver Dis, V11, P191, DOI 10.1016/j.cld.2007.02.006
   Cao Y, 2017, ONCOL LETT, V13, P4109, DOI 10.3892/ol.2017.5999
   Carulli L, 2013, CURR PHARM DESIGN, V19, P5280
   Chagas AL, 2009, BRAZ J MED BIOL RES, V42, P958, DOI 10.1590/S0100-879X2009005000019
   Cotrim HP, 2016, CLINICS, V71, P281, DOI 10.6061/clinics/2016(05)07
   Duan XY, 2012, HEPATOB PANCREAT DIS, V11, P18, DOI 10.1016/S1499-3872(11)60120-3
   Durnez A, 2006, HISTOPATHOLOGY, V49, P138, DOI 10.1111/j.1365-2559.2006.02468.x
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   Ertle J, 2011, INT J CANCER, V128, P2436, DOI 10.1002/ijc.25797
   Feng JL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151501
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   Guy CD, 2012, HEPATOLOGY, V55, P1711, DOI 10.1002/hep.25559
   Hernandez-Alejandro R, 2012, WORLD J GASTROENTERO, V18, P4145, DOI 10.3748/wjg.v18.i31.4145
   Hoshida Y, 2010, SEMIN LIVER DIS, V30, P35, DOI 10.1055/s-0030-1247131
   Kawada N, 2009, J GASTROENTEROL, V44, P1190, DOI 10.1007/s00535-009-0112-0
   Kikuchi L, 2016, AM J CLIN ONCOL-CANC, V39, P428, DOI 10.1097/COC.0000000000000134
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Kojiro M, 2009, HEPATOLOGY, V49, P658, DOI 10.1002/hep.22709
   Lade A, 2014, CURR OPIN ONCOL, V26, P100, DOI 10.1097/CCO.0000000000000042
   Lee JI, 2012, WORLD J GASTROENTERO, V18, P4751, DOI 10.3748/wjg.v18.i34.4751
   Leung C, 2015, WORLD J GASTROENTERO, V21, P1189, DOI 10.3748/wjg.v21.i4.1189
   Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.19, 10.1038/nrdp.2016.18]
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Mittal S, 2016, CLIN GASTROENTEROL H, V14, P124, DOI 10.1016/j.cgh.2015.07.019
   Nobili V, 2012, HEPATOLOGY, V56, P2142, DOI 10.1002/hep.25742
   Paradis V, 2009, HEPATOLOGY, V49, P851, DOI 10.1002/hep.22734
   Piscaglia F, 2016, HEPATOLOGY, V63, P827, DOI 10.1002/hep.28368
   Salomao M, 2010, AM J SURG PATHOL, V34, P1630, DOI 10.1097/PAS.0b013e3181f31caa
   Shibahara J, 2014, HISTOPATHOLOGY, V64, P951, DOI 10.1111/his.12343
   Wong CR, 2016, WORLD J GASTROENTERO, V22, P8294, DOI 10.3748/wjg.v22.i37.8294
   Yang XR, 2008, CLIN CANCER RES, V14, P3850, DOI 10.1158/1078-0432.CCR-07-4338
   Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061
NR 38
TC 0
Z9 0
U1 1
U2 1
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN
SN 0213-3911
EI 1699-5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD JUL
PY 2020
VL 35
IS 7
BP 729
EP 740
DI 10.14670/HH-18-194
PG 12
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA MQ1CY
UT WOS:000552635700012
PM 31858523
DA 2020-12-08
ER

PT J
AU Kim, V
   van der Wal, T
   Nishi, MY
   Montenegro, LR
   Carrilho, FJ
   Hoshida, Y
   Ono, SK
AF Kim, Vera
   van der Wal, Thijs
   Nishi, Miriam Yumie
   Montenegro, Luciana Ribeiro
   Carrilho, Flair Jose
   Hoshida, Yujin
   Ono, Suzane Kioko
TI Brazilian cohort and genes encoding for drug-metabolizing enzymes and
   drug transporters
SO PHARMACOGENOMICS
LA English
DT Article
DE ADME genes; admixture population; Brazilian; genetic diversity;
   next-generation sequencing; pharmacogenomics
ID IMPORTANT PHARMACOGENE INFORMATION; ATP-BINDING CASSETTE;
   COLORECTAL-CANCER; CLINICAL-IMPLICATIONS; POLYMORPHISMS; ASSOCIATION;
   ABCC2; VARIANTS; POPULATION; GENOTYPES
AB Background & aim: Genetic variability in drug absorption, distribution, metabolism and excretion (ADME) genes contributes to the high heterogeneity of drug responses. The present study investigated polymorphisms of ADME genes frequencies and compared the findings with populations from other continents, available in the 1000 Genome Project (1 KGP) and the Exome Aggregation Consortium (ExAC) databases. Methodology & results: We conducted a study of 100 patients in Brazil and a total of 2003 SNPs were evaluated by targeted next-generation sequencing in 148 genes, including Phase I enzymes (n = 50), Phase II enzymes (n = 38) and drug transporters (n = 60). Overall, the distribution of minor allele frequency (MAF) suggests that the distribution of 2003 SNPs is similar between Brazilian cohort, 1 KGP and ExAC; however, we found moderate SNP allele-frequency divergence between Brazilian cohort and both 1000 KGP and ExAC. These differences were observed in several relevant genes including CYP3A4, NAT2 and SLCO1B1. Conclusion: We concluded that the Brazilian population needs clinical assessment of drug treatment based on individual genotype rather than ethnicity.
C1 [Kim, Vera; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, BR-05403000 Sao Paulo, Brazil.
   [Kim, Vera; van der Wal, Thijs; Hoshida, Yujin] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, Tisch Canc Inst, Div Liver Dis,Dept Med,Liver Canc Program, New York, NY 10029 USA.
   [Hoshida, Yujin] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Simmons Comprehens Canc Ctr, Liver Tumor Transnat Res Program,Div Digest & Liv, Dallas, TX 75390 USA.
   [Nishi, Miriam Yumie; Montenegro, Luciana Ribeiro] Univ Sao Paulo, Fac Med, Hosp Clin, Unidade Endocrinol Desenvolvimento,Disciplina End, BR-05403000 Sao Paulo, Brazil.
RP Ono, SK (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, BR-05403000 Sao Paulo, Brazil.
EM suzane.ono@fm.usp.br
OI Kim, Vera/0000-0003-0840-0247
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES [CAPES
   - 1399290]; Programa de Doutorado Sanduiche [PDSE 88881.132608/2016-01];
   Fundacao de Amparo a pesquisa de Sao PauloFundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [FAPESP 2015/16291-0]; Brazilian Council
   for Development of Science and Technology (CNPq)National Council for
   Scientific and Technological Development (CNPq) [PQ 308609/2018-2]; US
   NIH/NIDDK [R01 DK099558]; European CommissionEuropean CommissionEuropean
   Commission Joint Research Centre [ERCE2014EAdGE671231]; Department of
   DefenseUnited States Department of Defense [W81XWHE16E1E0363]; Cancer
   Prevention and Research Institute of Texas (CPRIT) [RR180016]
FX V Kim would like to thank Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES - 1399290) and Programa de Doutorado Sanduiche no
   Exterior (PDSE 88881.132608/2016-01). SK Ono would like to thank
   Fundacao de Amparo a pesquisa de Sao Paulo (FAPESP 2015/16291-0) and
   Brazilian Council for Development of Science and Technology (CNPq) for
   grant PQ 308609/2018-2. Y Hoshida would like to thank the US NIH/NIDDK
   R01 DK099558, European Commission ERCE2014EAdGE671231, Department of
   Defense W81XWHE16E1E0363 and the Cancer Prevention and Research
   Institute of Texas (CPRIT) RR180016. The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Aarnoudse AJLHJ, 2008, PHARMACOGENET GENOM, V18, P299, DOI 10.1097/FPC.0b013e3282f70458
   Agundez JAG, 2009, EXPERT OPIN DRUG MET, V5, P607, DOI [10.1517/17425250902970998 , 10.1517/17425250902970998]
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Alvarellos ML, 2015, PHARMACOGENET GENOM, V25, P41, DOI 10.1097/FPC.0000000000000100
   An HR, 2012, CLIN EXP PHARMACOL P, V39, P535, DOI 10.1111/j.1440-1681.2012.05713.x
   Barbarino JM, 2014, PHARMACOGENET GENOM, V24, P177, DOI 10.1097/FPC.0000000000000024
   Bonifaz-Pena V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112640
   Brown AMK, 2014, PHARMACOGENOMICS, V15, P1185, DOI [10.2217/PGS.14.81, 10.2217/pgs.14.81]
   Caldwell MD, 2008, BLOOD, V111, P4106, DOI 10.1182/blood-2007-11-122010
   Caronia D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026091
   Choi HD, 2015, PHARMACOGENOMICS, V16, P1879, DOI 10.2217/pgs.15.127
   Chung WH, 2014, JAMA-J AM MED ASSOC, V312, P525, DOI 10.1001/jama.2014.7859
   Ciccacci C, 2010, PHARMACOGENOMICS, V11, P23, DOI 10.2217/PGS.09.142
   Coelho AVC, 2013, J CLIN PHARMACOL, V53, P1286, DOI 10.1002/jcph.165
   Dai D, 2001, PHARMACOGENETICS, V11, P597, DOI 10.1097/00008571-200110000-00006
   Dang MTN, 2005, ANN PHARMACOTHER, V39, P1008, DOI 10.1345/aph.1E566
   de Vos A, 2011, PHARMACOGENOMICS J, V11, P359, DOI 10.1038/tpj.2010.39
   DeGorter MK, 2013, CIRC-CARDIOVASC GENE, V6, P400, DOI 10.1161/CIRCGENETICS.113.000099
   Delser PM, 2013, HUM GENET, V132, P563, DOI 10.1007/s00439-013-1268-5
   DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
   DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
   Dries DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804
   Franke RM, 2011, CLIN PHARMACOL THER, V89, P693, DOI 10.1038/clpt.2011.25
   Fujita K, 2008, BIOL PHARM BULL, V31, P2137, DOI 10.1248/bpb.31.2137
   Haas DW, 2014, J ANTIMICROB CHEMOTH, V69, P2175, DOI 10.1093/jac/dku110
   Haenisch S, 2008, PHARMACOGENET GENOM, V18, P357, DOI 10.1097/FPC.0b013e3282f974b7
   Ho RH, 2007, PHARMACOGENET GENOM, V17, P647, DOI 10.1097/FPC.0b013e3280ef698f
   Hovelson DH, 2017, PHARMACOGENET GENOM, V27, P89, DOI 10.1097/FPC.0000000000000260
   IBGE, 2011, CENS DEM
   Khrunin AV, 2014, PHARMACOGENOMICS, V15, P329, DOI 10.2217/pgs.13.237
   Kim HS, 2013, CIRC-CARDIOVASC GENE, V6, P514, DOI 10.1161/CIRCGENETICS.113.000109
   Kim WJ, 2010, PHARMACOGENET GENOM, V20, P249, DOI 10.1097/FPC.0b013e328338073a
   Kimura M, 1998, THER DRUG MONIT, V20, P243, DOI 10.1097/00007691-199806000-00001
   Kiser JJ, 2008, JAIDS-J ACQ IMM DEF, V47, P298, DOI 10.1097/QAI.0b013e31815e7478
   Lee HK, 2013, PHARMACOGENOMICS, V14, P1283, DOI 10.2217/pgs.13.115
   Lee KH, 2013, CANCER CHEMOTH PHARM, V71, P843, DOI 10.1007/s00280-013-2075-3
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lim HS, 2007, J CLIN ONCOL, V25, P3837, DOI 10.1200/JCO.2007.11.4850
   Lima-Costa MF, 2015, SCI REP-UK, V5, DOI 10.1038/srep09812
   Limdi NA, 2010, BLOOD, V115, P3827, DOI 10.1182/blood-2009-12-255992
   Marciante KD, 2011, PHARMACOGENET GENOM, V21, P280, DOI 10.1097/FPC.0b013e328343dd7d
   McLeod HL, 2010, J CLIN ONCOL, V28, P3227, DOI 10.1200/JCO.2009.21.7943
   Nakamura K, 2002, BIOCHEM BIOPH RES CO, V293, P969, DOI 10.1016/S0006-291X(02)00328-5
   Ortega VE, 2014, J ALLERGY CLIN IMMUN, V133, P16, DOI 10.1016/j.jaci.2013.10.040
   Pasanen MK, 2006, EUR J CLIN PHARMACOL, V62, P409, DOI 10.1007/s00228-006-0123-1
   Qu J, 2012, CNS NEUROSCI THER, V18, P647, DOI 10.1111/j.1755-5949.2012.00336.x
   Ramos E, 2012, PERS MED, V9, P839, DOI 10.2217/PME.12.100
   Rodrigues-Soares F, 2018, PHARMACOGENOMICS J, V18, P749, DOI 10.1038/s41397-018-0015-7
   Rosenberg NA, 2011, HUM BIOL, V83, P659, DOI 10.3378/027.083.0601
   Sim SC, 2013, PHARMACOGENOMICS J, V13, P1, DOI 10.1038/tpj.2012.45
   Sookoian S, 2008, J HEPATOL, V48, P125, DOI 10.1016/j.jhep.2007.08.015
   Stanley LA, 2008, PHARMACOGENOMICS, V9, P1673, DOI 10.2217/14622416.9.11.1673
   Tan A, 2015, BIOINFORMATICS, V31, P2202, DOI 10.1093/bioinformatics/btv112
   Tan SH, 2008, CLIN CANCER RES, V14, P8027, DOI 10.1158/1078-0432.CCR-08-0993
   Tarasova L, 2012, PHARMACOGENET GENOM, V22, P659, DOI 10.1097/FPC.0b013e3283561666
   United States Food and Drug Administration, 2020, TABL PHARM BIOM DRUG
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wang P, 2018, EUR J CLIN PHARMACOL, V74, P433, DOI 10.1007/s00228-017-2395-z
   Whirl-Carrillo M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/clpt.2012.96
   Wu HZ, 2013, PHARMACOGENOMICS, V14, P897, DOI [10.2217/pgs.13.78, 10.2217/PGS.13.78]
   Yamamoto K, 1998, BBA-MOL BASIS DIS, V1406, P267, DOI 10.1016/S0925-4439(98)00013-1
   Yoon YR, 2001, BRIT J CLIN PHARMACO, V51, P277, DOI 10.1046/j.1365-2125.2001.00340.x
   Yu LS, 2013, BIOPHARM DRUG DISPOS, V34, P278, DOI 10.1002/bdd.1842
NR 64
TC 0
Z9 0
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD JUN
PY 2020
VL 21
IS 9
BP 575
EP 586
DI 10.2217/pgs-2020-0013
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ND2VE
UT WOS:000561762000002
PM 32486903
DA 2020-12-08
ER

PT J
AU Nacif, LS
   Gomes, CD
   Paranagua-Vezozzo, D
   Cassenote, AJF
   Pinheiro, RS
   Waisberg, DR
   Rocha-Santos, V
   de Martino, RB
   Arantes, RM
   Ducatti, L
   Haddad, L
   Galvao, F
   Andraus, W
   Carrilho, FJ
   D'Albuquerque, LC
AF Nacif, Lucas Souto
   Gomes, Caroline de Cassia
   Paranagua-Vezozzo, Denise
   Flores Cassenote, Alex Jones
   Pinheiro, Rafael Soares
   Waisberg, Daniel Reis
   Rocha-Santos, Vinicius
   de Martino, Rodrigo Bronze
   Arantes, Rubens Macedo
   Ducatti, Liliana
   Haddad, Luciana
   Galvao, Flavio
   Andraus, Wellington
   Carrilho, Flair Jose
   D'Albuquerque, Luiz Carneiro
TI Liver Elastography in Acute Cellular Rejection After Liver
   Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 16th Brazilian-Transplantation-Society Congress / 18th
   Portuguese-Brazilian Transplant Congress
CY OCT, 2019
CL Campinas, BRAZIL
SP Brazilian Transplantat Soc
ID TRANSIENT ELASTOGRAPHY
C1 [Nacif, Lucas Souto; Gomes, Caroline de Cassia; Paranagua-Vezozzo, Denise; Flores Cassenote, Alex Jones; Pinheiro, Rafael Soares; Waisberg, Daniel Reis; Rocha-Santos, Vinicius; de Martino, Rodrigo Bronze; Arantes, Rubens Macedo; Ducatti, Liliana; Haddad, Luciana; Galvao, Flavio; Andraus, Wellington; Carrilho, Flair Jose; D'Albuquerque, Luiz Carneiro] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Gastrointestinal Transplant Div, Dr Eneas de Carvalho Aguiar 255,9 Andar, BR-05403900 Sao Paulo, Brazil.
RP Nacif, LS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Gastrointestinal Transplant Div, Dr Eneas de Carvalho Aguiar 255,9 Andar, BR-05403900 Sao Paulo, Brazil.
EM lucasnacif@usp.br
RI Nacif, Lucas S./B-2795-2013; D'Albuquerque, Luiz Augusto
   Carneiro/A-8812-2013
OI Nacif, Lucas S./0000-0002-7059-3978; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; GALVAO, FLAVIO/0000-0003-1924-3208
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2017/21491-3]
FX Grant information: Sao Paulo Research Foundation (FAPESP) 2017/21491-3.
CR Choudhary NS, 2017, J CLIN EXP HEPATOL, V7, P358, DOI 10.1016/j.jceh.2017.10.003
   Crespo G, 2016, LIVER TRANSPLANT, V22, P298, DOI 10.1002/lt.24376
   Mikotajczyk-Korniak N, 2016, TRANSPL P, V48, P1725, DOI 10.1016/j.transproceed.2016.01.081
   Mulazzani L, 2019, J HEPATOL, V70, P545, DOI 10.1016/j.jhep.2018.10.012
   Nacif LS, 2018, TRANSPL P, V50, P772, DOI 10.1016/j.transproceed.2018.02.008
   Nacif LS, 2017, ANN TRANSPL, V22, P9, DOI 10.12659/AOT.901010
   Rigamonti C, 2012, LIVER TRANSPLANT, V18, P566, DOI 10.1002/lt.23391
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2020
VL 52
IS 5
BP 1340
EP 1343
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA MA1GP
UT WOS:000541663300031
PM 32217005
DA 2020-12-08
ER

PT J
AU da Fonseca, L
   Carrilho, FJ
AF da Fonseca, Leonardo
   Carrilho, Flair Jose
TI Can thrombotic events be a major concern in hepatocellular carcinoma
   patients under systemic treatment during SARS-Cov-2?
SO LIVER INTERNATIONAL
LA English
DT Letter; Early Access
C1 [da Fonseca, Leonardo; Carrilho, Flair Jose] Univ Sao Paulo, Sao Paulo Clin Liver Canc Grp, Inst Canc Estado Sao Paulo, Hosp Clin Complex,Sch Med, Ave Dr Eneas Carvalho de Aguiar,255 ICHC, BR-05403000 Sao Paulo, SP, Brazil.
RP da Fonseca, L (corresponding author), Univ Sao Paulo, Sao Paulo Clin Liver Canc Grp, Inst Canc Estado Sao Paulo, Hosp Clin Complex,Sch Med, Ave Dr Eneas Carvalho de Aguiar,255 ICHC, BR-05403000 Sao Paulo, SP, Brazil.
EM l.fonseca@fm.usp.br
FU Bayer and Roche Funding Source: Medline
CR Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Qi WX, 2013, INT J CANCER, V132, P2967, DOI 10.1002/ijc.27979
   Sharma R, 2020, LIVER INT, V40, P1823, DOI 10.1111/liv.14517
   Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI [10.1111/jth.14768, 10.1111/jth.14820]
NR 5
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-3223
EI 1478-3231
J9 LIVER INT
JI Liver Int.
DI 10.1111/liv.14545
EA MAY 2020
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LS3YP
UT WOS:000536323600001
PM 32445420
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU da Fonseca, L
   Carrilho, FJ
AF da Fonseca, Leonardo
   Carrilho, Flair Jose
TI Expanding TACTICS trial into a different setting in hepatocellular
   carcinoma
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Liver cancer; Liver transplantation; Transarterial chemobolization;
   Sorafenib
ID LIVER-TRANSPLANTATION; TRANSARTERIAL CHEMOEMBOLIZATION; WAITING-LIST;
   SORAFENIB; PREDICTORS
AB Systemic treatment for hepatocellular carcinoma (HCC) is recommended for patients with advanced stage and for those who progressed on locoregional modalities. The first agent approved for advanced HCC was sorafenib, and it remains one of the cornerstones of systemic treatment. In the past years, immunotherapy has shown promising results and has been incorporated into the treatment armamentarium. The rates of recurrence and progression after locoregional therapies are significant, what highlights the need to explore systemic agents for preventing or delaying these negative outcomes. Recently, sorafenib was shown to benefit patients with unresectable HCC under transarterial chemoembolization (TACE) by delaying tumor progression and prolonging time to vascular invasion and extrahepatic spread. Although this result was reported in patients with intermediate stage, it provides background to test the strategy of combining systemic treatment plus TACE as a bridge therapy to HCC patients awaiting liver transplantation, for which the risk of dropout due to tumor progression impairs the possibility of cure. (c) 2020 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [da Fonseca, Leonardo; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Inst Canc Estado Sao Paulo, Sao Paulo Clin Liver Canc Grp,Hosp Clin Complex, Sao Paulo, Brazil.
RP da Fonseca, L (corresponding author), Ave Dr Eneas Carvalho de Aguiar, BR-05403000 Sao Paulo, SP, Brazil.
EM l.fonseca@fm.usp.br
CR Bruix J, 2017, J HEPATOL, V67, P999, DOI 10.1016/j.jhep.2017.06.026
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
   Frenette CT, 2013, TRANSPL INT, V26, P734, DOI 10.1111/tri.12117
   Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086
   Kudo M, 2019, GUT
   Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007
   Kulik L, 2018, HEPATOLOGY, V67, P381, DOI 10.1002/hep.29485
   Lencioni R, 2016, J HEPATOL, V64, P1090, DOI 10.1016/j.jhep.2016.01.012
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Maddala YK, 2004, LIVER TRANSPLANT, V10, P449, DOI 10.1002/lt.20099
   Majno P, 2005, J HEPATOL, V42, pS134, DOI 10.1016/j.jhep.2004.12.010
   Meyer T, 2017, LANCET GASTROENTEROL, V2, P565, DOI 10.1016/S2468-1253(17)30156-5
   Millonig G, 2007, LIVER TRANSPLANT, V13, P272, DOI 10.1002/lt.21033
   Yao FY, 2003, LIVER TRANSPLANT, V9, P684, DOI 10.1053/jlts.2003.50147
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER ESPANA
PI MADRID
PA CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD MAY-JUN
PY 2020
VL 19
IS 3
BP 230
EP 231
DI 10.1016/j.aohep.2020.02.001
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA MH7DO
UT WOS:000546885200002
PM 32139261
OA Other Gold
DA 2020-12-08
ER

PT J
AU Carrilho, FJ
   Paranagua-Vezozzo, DC
   Chagas, AL
   Alencar, RSDM
   da Fonseca, LG
AF Carrilho, Flair Jose
   Paranagua-Vezozzo, Denise Cerqueira
   Chagas, Aline Lopes
   de Souza Melo Alencar, Regiane Saraiva
   da Fonseca, Leonardo Gomes
TI Epidemiology of Liver Cancer in Latin America: Current and Future Trends
SO SEMINARS IN LIVER DISEASE
LA English
DT Review
DE Latin America; demographics; hepatocellular carcinoma; risk factors
ID HEPATOCELLULAR-CARCINOMA; MULTICENTER COHORT; NONALCOHOLIC
   STEATOHEPATITIS; STAGING SYSTEMS; RISK-FACTORS; HEPATITIS-C; GENOTYPE-F;
   SURVIVAL; DISEASE; TRANSPLANTATION
AB Over 38,000 cases of hepatocellular carcinoma (HCC) are estimated to occur in Latin America annually. The region is characterized by sociocultural heterogeneity and economic disparities, which impose barriers in addressing this major health issue. A significant proportion of patients are still diagnosed in the later stages of the disease, although efforts to implement effective screening programs have been reported by referral centers. While viral hepatitis remains the predominant etiology of liver disease among HCC cases in Latin America, a high prevalence of fatty liver disease in the region is a matter of concern, reflecting the current scenario in many Western countries. In addition, other risk factors such as alcohol, aflatoxin, and early-onset HCC in hepatitis B virus infection contribute to the burden of HCC in Latin America. Interventions to increase screening coverage, expand healthcare access, and implement continuing medical training are key challenges to be overcome.
C1 [Carrilho, Flair Jose; Paranagua-Vezozzo, Denise Cerqueira; Chagas, Aline Lopes; de Souza Melo Alencar, Regiane Saraiva] Univ Sao Paulo, Div Clin Gastroenterol & Hepatol, Sao Paulo Clin Liver Canc Grp, Hosp Clin Complex,Dept Gastroenterol,Sch Med, Av Dr Eneas Carvalho Aguiar,255 ICHC,9th Floor, BR-05403000 Sao Paulo, SP, Brazil.
   [Carrilho, Flair Jose; Paranagua-Vezozzo, Denise Cerqueira; Chagas, Aline Lopes; de Souza Melo Alencar, Regiane Saraiva; da Fonseca, Leonardo Gomes] Univ Sao Paulo, Sao Paulo Clin Liver Canc Grp, Inst Canc Estado Sao Paulo, Hosp Clin Complex,Sch Med, Sao Paulo, Brazil.
RP Carrilho, FJ (corresponding author), Univ Sao Paulo, Div Clin Gastroenterol & Hepatol, Sao Paulo Clin Liver Canc Grp, Hosp Clin Complex,Dept Gastroenterol,Sch Med, Av Dr Eneas Carvalho Aguiar,255 ICHC,9th Floor, BR-05403000 Sao Paulo, SP, Brazil.
EM fjcarril@usp.br
CR Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002
   Andraus Wellington, 2019, Clin Liver Dis (Hoboken), V13, P36, DOI 10.1002/cld.763
   Appel-da-Silva MC, 2016, WORLD J GASTROENTERO, V22, P10219, DOI 10.3748/wjg.v22.i46.10219
   ArauzRuiz P, 1997, J MED VIROL, V51, P305, DOI 10.1002/(SICI)1096-9071(199704)51:4&lt;305::AID-JMV8&gt;3.0.CO;2-9
   Ayuso C, 2018, EUR J RADIOL, V101, P72, DOI 10.1016/j.ejrad.2018.01.025
   Baten J., 2016, HIST GLOBAL EC 1500
   Bertani S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067756
   Bertuccio P, 2017, J HEPATOL, V67, P302, DOI 10.1016/j.jhep.2017.03.011
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1
   Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9
   Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
   Chagas AL, 2019, EUR J GASTROEN HEPAT, V31, P1148, DOI 10.1097/MEG.0000000000001448
   Chan AJ, 2017, CLIN GASTROENTEROL H, V15, P1631, DOI 10.1016/j.cgh.2017.05.015
   Chang MH, 2016, GASTROENTEROLOGY, V151, P472, DOI 10.1053/j.gastro.2016.05.048
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Conti F, 2016, J HEPATOL, V65, P727, DOI 10.1016/j.jhep.2016.06.015
   Cotrim HP, 2016, CLINICS, V71, P281, DOI 10.6061/clinics/2016(05)07
   da Fonseca LG, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5173-0
   Da Fonseca LG, 2015, MOL CLIN ONCOL, V3, P793, DOI 10.3892/mco.2015.536
   Debes JD, 2018, LIVER INT, V38, P136, DOI 10.1111/liv.13502
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Devesa M, 2007, VIRUS RES, V127, P177, DOI 10.1016/j.virusres.2007.01.004
   Di Bisceglie AM, 2005, J HEPATOL, V43, P434, DOI 10.1016/j.jhep.2005.03.019
   Esnaola NF, 2003, ANN SURG, V238, P711, DOI 10.1097/01.sla.0000094436.34556.ac
   European Assoc Study Liver, 2018, J HEPATOL, V69, P461, DOI 10.1016/j.jhep.2018.03.026
   European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
   Fassio E, 2010, ANN HEPATOL, V9, P63, DOI 10.1016/S1665-2681(19)31681-3
   Fitzmaurice C, 2018, JAMA ONCOL, V4, P1553, DOI 10.1001/jamaoncol.2018.2706
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   Forner A, 2010, SEMIN LIVER DIS, V30, P61, DOI 10.1055/s-0030-1247133
   Gabrielli M, 2010, TRANSPL P, V42, P299, DOI 10.1016/j.transproceed.2009.11.034
   Goncalves Carlos S., 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P165, DOI 10.1590/S0036-46651997000300008
   Groopman John D., 2005, Cancer Biomarkers, V1, P5
   Guarino M, 2018, J GASTROEN HEPATOL, V33, P1123, DOI 10.1111/jgh.14013
   Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086
   Hoyos S, 2015, ANN HEPATOL, V14, P58, DOI 10.1016/S1665-2681(19)30801-4
   Kanwal F, 2018, GASTROENTEROLOGY, V155, P1828, DOI 10.1053/j.gastro.2018.08.024
   Kikuchi L, 2017, CLINICS, V72, P454, DOI 10.6061/clinics/2017(08)01
   Kim KM, 2016, LIVER INT, V36, P1490, DOI 10.1111/liv.13107
   LaBrecque DR, 2014, J CLIN GASTROENTEROL, V48, P467, DOI 10.1097/MCG.0000000000000116
   Leathers JS, 2019, J CLIN GASTROENTEROL, V53, P464, DOI 10.1097/MCG.0000000000001085
   Liu Y, 2010, ENVIRON HEALTH PERSP, V118, P818, DOI 10.1289/ehp.0901388
   Liu ZQ, 2019, J HEPATOL, V70, P674, DOI 10.1016/j.jhep.2018.12.001
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   MacLachlan JH, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021410
   Marchio A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30229-8
   Marchio A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114912
   Marrero JA, 2005, HEPATOLOGY, V41, P707, DOI 10.1002/hep.20636
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   Mendez-Sanchez N, 2014, ANN HEPATOL, V13, P412, DOI 10.1016/S1665-2681(19)30876-2
   Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8
   Nogueira JA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-204
   Paranagua-Vezozzo DC, 2014, ANN HEPATOL, V13, P386, DOI 10.1016/S1665-2681(19)30845-2
   Park JW, 2015, LIVER INT, V35, P2155, DOI 10.1111/liv.12818
   Pinero F, 2019, WORLD J GASTROENTERO, V25, P3607, DOI 10.3748/wjg.v25.i27.3607
   Pinero F, 2019, LIVER INT, V39, P1033, DOI 10.1111/liv.14041
   Pinero F, 2018, EUR J GASTROEN HEPAT, V30, P376, DOI 10.1097/MEG.0000000000001049
   Pinero F, 2018, WORLD J HEPATOL, V10, P41, DOI 10.4254/wjh.v10.i1.41
   Pinero F, 2016, LIVER INT, V36, P1657, DOI 10.1111/liv.13159
   Pinero F, 2016, EUR J GASTROEN HEPAT, V28, P421, DOI 10.1097/MEG.0000000000000551
   Pinero F, 2015, EUR J GASTROEN HEPAT, V27, P355, DOI 10.1097/MEG.0000000000000272
   Plymoth A, 2009, CANCER LETT, V286, P15, DOI 10.1016/j.canlet.2009.08.024
   Reig M, 2019, TRANSPLANTATION, V103, P39, DOI 10.1097/TP.0000000000002361
   Reig M, 2017, SEMIN LIVER DIS, V37, P109, DOI 10.1055/s-0037-1601349
   Roblero J, 2018, ANN HEPATOL, V17, P1151
   Ruiz Eloy, 2007, Rev. gastroenterol. Perú, V27, P223
   Ryerson AB, 2016, CANCER-AM CANCER SOC, V122, P1312, DOI 10.1002/cncr.29936
   Salvalaggio PR, 2015, AM J TRANSPLANT, V15, P668, DOI 10.1111/ajt.13011
   Sangiovanni A, 2006, HEPATOLOGY, V43, P1303, DOI 10.1002/hep.21176
   Sapisochin G, 2017, NAT REV GASTRO HEPAT, V14, P203, DOI 10.1038/nrgastro.2016.193
   Tzartzeva K, 2018, GASTROENTEROLOGY, V154, P1706, DOI DOI 10.1053/j.gastro.2018.01.064
   Villanueva A, 2010, ANNU REV MED, V61, P317, DOI 10.1146/annurev.med.080608.100623
   Wild CP, 2010, CARCINOGENESIS, V31, P71, DOI 10.1093/carcin/bgp264
   Yang J D, 2017, CLIN GASTROENTEROL H, V15, P767
   Younossi ZM, 2018, LIVER TRANSPLANT, V24, P166, DOI 10.1002/lt.25003
   Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431
   Zhang BH, 2004, J CANCER RES CLIN, V130, P417, DOI 10.1007/s00432-004-0552-0
   Zhu AX, 2019, LANCET ONCOL, V20, P282, DOI 10.1016/S1470-2045(18)30937-9
NR 79
TC 0
Z9 1
U1 3
U2 3
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0272-8087
EI 1098-8971
J9 SEMIN LIVER DIS
JI Semin. Liver Dis.
PD MAY
PY 2020
VL 40
IS 2
BP 101
EP 110
DI 10.1055/s-0039-3399561
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LL2UB
UT WOS:000531411200001
PM 31711252
DA 2020-12-08
ER

PT J
AU Pi?ero, F
   Boin, I
   Chagas, A
   Qui?onez, E
   Marciano, S
   Vilatob?, M
   Santos, L
   Anders, M
   Duque, SH
   Lima, AS
   Menendez, J
   Padilla, M
   Poniachik, J
   Zapata, R
   Maraschio, M
   Men?ndez, RC
   Mu?oz, L
   Arufe, D
   Figueroa, R
   Mendizabal, M
   Gomez, SH
   Stucchi, R
   Maccali, C
   Sandoval, RV
   Bermudez, C
   McCormack, L
   Var?n, A
   Gadano, A
   Mattera, J
   Rubinstein, F
   Carrilho, F
   Silva, M
AF Pinero, Federico
   Boin, Ilka
   Chagas, Aline
   Quinonez, Emilio
   Marciano, Sebastian
   Vilatoba, Mario
   Santos, Luisa
   Anders, Margarita
   Duque, Sergio Hoyos
   Lima, Agnaldo Soares
   Menendez, Josemaria
   Padilla, Martin
   Poniachik, Jaime
   Zapata, Rodrigo
   Maraschio, Martin
   Menendez, Ricardo Chong
   Munoz, Linda
   Arufe, Diego
   Figueroa, Rodrigo
   Mendizabal, Manuel
   Gomez, Sahara Hurtado
   Stucchi, Raquel
   Maccali, Claudia
   Sandoval, Rodrigo Vergara
   Bermudez, Carla
   McCormack, Lucas
   Varon, Adriana
   Gadano, Adrian
   Mattera, Juan
   Rubinstein, Fernando
   Carrilho, Flair
   Silva, Marcelo
TI Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of
   Higher Wait-List Progression or Posttransplant Recurrence
SO LIVER TRANSPLANTATION
LA English
DT Article
ID HEPATITIS-C; LIVER-TRANSPLANTATION; DROPOUT RATE; THERAPY; STATEMENT
AB The association between direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC) wait-list progression or its recurrence following liver transplantation (LT) remains uncertain. We evaluated the impact of DAAs on HCC wait-list progression and post-LT recurrence. This Latin American multicenter retrospective cohort study included HCC patients listed for LT between 2012 and 2018. Patients were grouped according to etiology of liver disease: hepatitis C virus (HCV) negative, HCV+ never treated with DAAs, and HCV+ treated with DAAs either before or after transplantation. Multivariate competing risks models were conducted for both HCC wait-list progression adjusted by a propensity score matching (pre-LT DAA effect) and for post-LT HCC recurrence (pre- or post-LT DAA effect). From 994 included patients, 50.6% were HCV-, 32.9% were HCV+ never treated with DAAs, and 16.5% were HCV+ treated with DAAs either before (n = 66) or after LT (n = 98). Patients treated with DAAs before LT presented similar cumulative incidence of wait-list tumor progression when compared with those patients who were HCV+ without DAAs (26.2% versus 26.9%; P = 0.47) and a similar HCC-related dropout rate (12.1% [95% CI, 0.4%-8.1%] versus 12.9% [95% CI, 3.8%-27.2%]), adjusted for baseline tumor burden, alpha-fetoprotein values, HCC diagnosis after listing, bridging therapies, and by the probability of having received or not received DAAs through propensity score matching (subhazard ratio [SHR], 0.9; 95% CI, 0.6-1.6; P = 0.95). A lower incidence of posttransplant HCC recurrence among HCV+ patients who were treated with pre- or post-LT DAAs was observed (SHR, 0.7%; 95% CI, 0.2%-4.0%). However, this effect was confounded by the time to DAA initiation after LT. In conclusion, in this multicenter cohort, HCV treatment with DAAs did not appear to be associated with an increased wait-list tumor progression and HCC recurrence after LT.
C1 [Pinero, Federico; Mendizabal, Manuel; Silva, Marcelo] Hosp Univ Austral, Hepatol & Liver Transplant Unit, Ave Presidente Peron 1500,B1629HJ, Buenos Aires, DF, Argentina.
   [Pinero, Federico; Mendizabal, Manuel; Silva, Marcelo] Latin Amer Liver Res Educ & Awareness Network, Pilar, Argentina.
   [Boin, Ilka; Stucchi, Raquel] Univ Estadual Campinas UNICAMP, Hosp Clin, Sao Paulo, Brazil.
   [Chagas, Aline; Maccali, Claudia; Carrilho, Flair] Univ Sao Paulo, Sch Med, Hosp Clin, Sao Paulo, Brazil.
   [Quinonez, Emilio; Sandoval, Rodrigo Vergara; Mattera, Juan] Hosp El Cruce, Florencio Varela, Argentina.
   [Marciano, Sebastian; Bermudez, Carla; Gadano, Adrian] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina.
   [Vilatoba, Mario; Gomez, Sahara Hurtado] Inst Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Santos, Luisa; Varon, Adriana] Fdn Cardioinfantil, Bogota, Colombia.
   [Anders, Margarita; McCormack, Lucas] Hosp Aleman Buenos Aires, Buenos Aires, DF, Argentina.
   [Duque, Sergio Hoyos] Hosp Tobon Uribe, Medellin, Colombia.
   [Duque, Sergio Hoyos] Univ Antioquia, Grp Gastrohepatol, Antioquia, Colombia.
   [Lima, Agnaldo Soares] Hosp Minas Gerais, Belo Horizonte, MG, Brazil.
   [Menendez, Josemaria] Hosp Clin Montevideo, Montevideo, Uruguay.
   [Padilla, Martin] Hosp Guillermo Almenara, Lima, Peru.
   [Poniachik, Jaime] Hosp Univ Chile, Santiago, Chile.
   [Zapata, Rodrigo] Univ Desarrollo, Fac Med, Clin Alemana, Santiago, Chile.
   [Maraschio, Martin] Hosp Privado Cordoba, Cordoba, Argentina.
   [Menendez, Ricardo Chong] Hosp Carlos Andrade Marin, Quito, Ecuador.
   [Munoz, Linda] Hosp Univ Dr Jose E Gonzalez, Monterrey, Mexico.
   [Arufe, Diego] Sanat Sagrado Corazon, Buenos Aires, DF, Argentina.
   [Figueroa, Rodrigo] Sanat Allende, Cordoba, Argentina.
   [Rubinstein, Fernando] Inst Efectividad Clin & Sanitaria, Buenos Aires, DF, Argentina.
RP Pi?ero, F (corresponding author), Hosp Univ Austral, Hepatol & Liver Transplant Unit, Ave Presidente Peron 1500,B1629HJ, Buenos Aires, DF, Argentina.
EM fpinerof@cas.austral.edu.ar
RI Lima, Agnaldo S/F-7452-2011
OI Lima, Agnaldo S/0000-0001-6421-3062; Arufe, Diego/0000-0003-1825-4319;
   Pinero, Federico/0000-0002-9528-2279; PADILLA-MACHACA, PEDRO
   MARTIN/0000-0002-3585-3666
CR Adhoute X, 2018, EUR J GASTROEN HEPAT, V30, P368, DOI 10.1097/MEG.0000000000001082
   ANRS Collaborative Study Grp, 2016, J HEPATOL, V65, P734, DOI 10.1016/j.jhep.2016.05.045
   Cabibbo G, 2017, ALIMENT PHARM THER, V46, P688, DOI 10.1111/apt.14256
   Cabibbo G, 2019, J HEPATOL, V71, P265, DOI 10.1016/j.jhep.2019.03.027
   Calvaruso V, 2018, GASTROENTEROLOGY, V155, P411, DOI 10.1053/j.gastro.2018.04.008
   Conti F, 2016, J HEPATOL, V65, P727, DOI 10.1016/j.jhep.2016.06.015
   Debes JD, 2018, GASTROENTEROLOGY, V154, P515, DOI 10.1053/j.gastro.2017.10.035
   Decaens T, 2011, LIVER INT, V31, P794, DOI 10.1111/j.1478-3231.2010.02425.x
   Dignam JJ, 2012, CLIN CANCER RES, V18, P2301, DOI 10.1158/1078-0432.CCR-11-2097
   Duvoux C, 2012, GASTROENTEROLOGY, V143, P986, DOI 10.1053/j.gastro.2012.05.052
   Emamaullee JA, 2019, CAN J GASTROENTEROL, V2019, DOI 10.1155/2019/2509059
   European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
   Foster GR, 2016, J HEPATOL, V64, P1224, DOI 10.1016/j.jhep.2016.01.029
   Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086
   Huang AC, 2018, HEPATOLOGY, V68, P449, DOI 10.1002/hep.29855
   Ikeda K, 2017, DIGEST DIS SCI, V62, P2932, DOI 10.1007/s10620-017-4739-z
   Kneteman N, 2011, LIVER TRANSPLANT, V17, pS117, DOI 10.1002/lt.22334
   Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132
   Marciano S, 2018, J MED VIROL, V90, P951, DOI 10.1002/jmv.25033
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Mazzaferro V, 2009, LANCET ONCOL, V10, P35, DOI 10.1016/S1470-2045(08)70284-5
   Mehta N, 2013, LIVER TRANSPLANT, V19, P1343, DOI 10.1002/lt.23753
   Mendizabal M, 2019, J VIRAL HEPATITIS, V26, P1284, DOI 10.1111/jvh.13172
   Nagata H, 2017, J HEPATOL, V67, P933, DOI 10.1016/j.jhep.2017.05.028
   Nahon P, 2018, GASTROENTEROLOGY, V155, P1436, DOI 10.1053/j.gastro.2018.07.015
   Pinero F, 2019, LIVER INT, V39, P1033, DOI 10.1111/liv.14041
   Pinero F, 2017, LIVER TRANSPLANT, V23, P1628, DOI 10.1002/lt.24962
   Reig M, 2016, J HEPATOL, V65, P719, DOI 10.1016/j.jhep.2016.04.008
   Reig M, 2013, HEPATOLOGY, V58, P2023, DOI 10.1002/hep.26586
   Ridruejo E, 2019, J VIRAL HEPATITIS, V26, P1200, DOI 10.1111/jvh.13148
   Romano A, 2018, J HEPATOL, V69, P345, DOI 10.1016/j.jhep.2018.03.009
   Singal AG, 2019, GASTROENTEROLOGY, V156, P1215, DOI [10.1053/j.gastro.2018.08.066, 10.1053/j.gastro.2019.01.027]
   Stanaway JD, 2016, LANCET, V388, P1081, DOI 10.1016/S0140-6736(16)30579-7
   Terrault NA, 2017, TRANSPLANTATION, V101, P945, DOI 10.1097/TP.0000000000001708
   Vitale A, 2010, ANN SURG ONCOL, V17, P2290, DOI 10.1245/s10434-010-0993-4
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   Zanetto A, 2017, LIVER TRANSPLANT, V23, P1103, DOI 10.1002/lt.24790
NR 37
TC 2
Z9 2
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAY
PY 2020
VL 26
IS 5
BP 640
EP 650
DI 10.1002/lt.25744
PG 11
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA LE8YU
UT WOS:000527015500005
PM 32133773
DA 2020-12-08
ER

PT J
AU de Fraga, RS
   Van Vaisberg, V
   Mendes, LCA
   Carrilho, FJ
   Ono, SK
AF de Fraga, Raquel Scherer
   Van Vaisberg, Victor
   Mendes, Luiz Claudio Alfaia
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a
   systematic review
SO JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE Chronic hepatitis B; Nucleotide; nucleoside analogues; Adverse events
ID POSITIVE CHRONIC HEPATITIS; TENOFOVIR DISOPROXIL FUMARATE; LONG-TERM
   EFFICACY; PEGYLATED INTERFERON ALPHA-2A; EXTENDED LAMIVUDINE TREATMENT;
   ADEFOVIR DIPIVOXIL THERAPY; SURFACE-ANTIGEN CARRIERS; ORAL ANTIVIRAL
   THERAPY; EARLY VIRAL KINETICS; ONE-YEAR TRIAL
AB Nucleos(t)ide analogues (NAs) are the main drug category used in chronic hepatitis B (CHB) treatment. Despite the fact that NAs have a favourable safety profile, undesired adverse events (AEs) may occur during the treatment of CHB. Given the eminent number of patients currently receiving NAs, even a small risk of any of these toxicities can represent a major medical issue. The main objective of this review was to analyse information available on AEs associated with the use of NAs in published studies. We choose the following MesH terms for this systematic review: chronic hepatitis B, side effects and treatment. All articles published from 1 January 1990 up to 19 February 2018 in MEDLINE of PubMed, EMBASE, the Cochrane Library and LILACS databases were searched. A total of 120 articles were selected for analysis, comprising 6419 patients treated with lamivudine (LAM), 5947 with entecavir (ETV), 3566 with tenofovir disoproxil fumarate (TDF), 3096 with telbivudine (LdT), 1178 with adefovir dipivoxil (ADV) and 876 with tenofovir alafenamide (TAF). The most common AEs in all NAs assessed were abdominal pain/discomfort, nasopharyngitis/upper respiratory tract infections, fatigue, and headache. TAF displays the highest density of AEs per patient treated among NAs (1.14 AE/treated patient). In conclusion, treatment of CHB with NAs is safe, with a low incidence of AEs. Despite the general understanding TAF being safer than TDF, the number of patients treated with TAF still is too small in comparison to other NAs to consolidate an accurate safety profile. PROSPERO Registration No. CRD42018086471
C1 [de Fraga, Raquel Scherer; Van Vaisberg, Victor; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas Carvalho Aguiar,255 ICHC,9th Floor, BR-05403000 Sao Paulo, SP, Brazil.
   [Mendes, Luiz Claudio Alfaia; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Sch Med, Hosp Clin, Div Clin Gastroenterol & Hepatol, Sao Paulo, SP, Brazil.
   [de Fraga, Raquel Scherer] IMED Sch Med, Passo Fundo, RS, Brazil.
RP de Fraga, RS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas Carvalho Aguiar,255 ICHC,9th Floor, BR-05403000 Sao Paulo, SP, Brazil.; de Fraga, RS (corresponding author), IMED Sch Med, Passo Fundo, RS, Brazil.
EM rschfraga@gmail.com
FU Brazilian Council for Development of Science and Technology
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [PQ 308609/2018-2]
FX SKO would like to thank Brazilian Council for Development of Science and
   Technology (CNPq) for Grant PQ 308609/2018-2.
CR Agarwal K, 2015, J HEPATOL, V62, P533, DOI 10.1016/j.jhep.2014.10.035
   Ahn J, 2016, ALIMENT PHARM THER, V43, P134, DOI 10.1111/apt.13440
   Ahn SS, 2014, CLIN MOL HEPATOL, V20, P261, DOI 10.3350/cmh.2014.20.3.261
   Al Ashgar H, 2017, SAUDI J GASTROENTERO, V23, P190, DOI 10.4103/sjg.SJG_541_16
   Ali HY, 2003, SAUDI MED J, V24, P996
   Alsohaibani F, 2015, SAUDI J GASTROENTERO, V21, P295, DOI 10.4103/1319-3767.164189
   An J, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0572-2
   Bedimo R, 2012, AIDS, V26, P825, DOI 10.1097/QAD.0b013e32835192ae
   Berg T, 2014, J HEPATOL, V60, P715, DOI 10.1016/j.jhep.2013.11.024
   Berg T, 2010, GASTROENTEROLOGY, V139, P1207, DOI 10.1053/j.gastro.2010.06.053
   Booth A, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-2
   Buti M, 2016, LANCET GASTROENTEROL, V1, P90, DOI [10.1016/S2468-1253(16)30020-6, 10.1016/S2468-1253(16)30107-8]
   Buti M, 2015, DIGEST DIS SCI, V60, P1457, DOI 10.1007/s10620-014-3486-7
   Buti M, 2012, EUR J GASTROEN HEPAT, V24, P535, DOI 10.1097/MEG.0b013e3283511287
   Chan HLY, 2007, ANN INTERN MED, V147, P745, DOI 10.7326/0003-4819-147-11-200712040-00183
   Chan HLY, 2016, LANCET GASTROENTEROL, V1, P185, DOI 10.1016/S2468-1253(16)30024-3
   Chan HLY, 2014, GASTROENTEROLOGY, V146, P1240, DOI 10.1053/j.gastro.2014.01.044
   Chan HLY, 2005, ANN INTERN MED, V142, P240, DOI 10.7326/0003-4819-142-4-200502150-00006
   Chang TT, 2009, J VIRAL HEPATITIS, V16, P784, DOI 10.1111/j.1365-2893.2009.01142.x
   Chang TT, 2005, GASTROENTEROLOGY, V129, P1198, DOI 10.1053/j.gastro.2005.06.055
   Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285
   Chien RN, 2014, J GASTROEN HEPATOL, V29, P185, DOI 10.1111/jgh.12416
   Da Silva LC, 2001, J GASTROENTEROL, V36, P476, DOI 10.1007/s005350170071
   de Man RA, 2001, HEPATOLOGY, V34, P578, DOI 10.1053/jhep.2001.26815
   Dienstag JL, 2003, HEPATOLOGY, V37, P748, DOI 10.1053/jhep.2003.50117
   DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501
   Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702
   Dienstag JL, 2003, GASTROENTEROLOGY, V124, P105, DOI 10.1053/gast.2003.50013
   Du Jeong In, 2017, Dig Dis Sci, V62, P2908, DOI 10.1007/s10620-017-4737-1
   Du QW, 2013, MED SCI MONITOR, V19, P751, DOI 10.12659/MSM.889443
   European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
   Fontana RJ, 2009, HEPATOLOGY, V49, pS185, DOI 10.1002/hep.22885
   Fung J, 2011, J ANTIMICROB CHEMOTH, V66, P2715, DOI 10.1093/jac/dkr388
   Fung S, 2017, J HEPATOL, V66, P11, DOI 10.1016/j.jhep.2016.08.008
   Fung S, 2014, GASTROENTEROLOGY, V146, P980, DOI 10.1053/j.gastro.2013.12.028
   Gane EJ, 2011, LIVER INT, V31, P676, DOI 10.1111/j.1478-3231.2011.02490.x
   Gill US, 2015, J INFECT DIS, V211, P374, DOI 10.1093/infdis/jiu471
   Gilson RJC, 1999, J VIRAL HEPATITIS, V6, P387, DOI 10.1046/j.1365-2893.1999.00182.x
   Gish RG, 2007, GASTROENTEROLOGY, V133, P1437, DOI 10.1053/j.gastro.2007.08.025
   Gotham D, 2017, CURR OPIN HIV AIDS, V12, P324, DOI 10.1097/COH.0000000000000379
   Guo XH, 2018, INT J ANTIMICROB AG, V52, P201, DOI 10.1016/j.ijantimicag.2018.04.002
   Gwak GY, 2013, HEPATOL INT, V7, P106, DOI 10.1007/s12072-012-9368-1
   Hadziyannis SJ, 2000, HEPATOLOGY, V32, P847, DOI 10.1053/jhep.2000.17915
   Hadziyannis SJ, 2006, GASTROENTEROLOGY, V131, P1743, DOI 10.1053/j.gastro.2006.09.020
   Heo J, 2012, ANTIVIR THER, V17, P1563, DOI 10.3851/IMP2277
   Hill A, 2018, J VIRUS ERAD, V4, P72
   Hongthanakorn C, 2011, HEPATOLOGY, V53, P1854, DOI 10.1002/hep.24318
   Hosaka T, 2013, HEPATOLOGY, V58, P98, DOI 10.1002/hep.26180
   Hou JL, 2015, J VIRAL HEPATITIS, V22, P85, DOI 10.1111/jvh.12313
   Hou JL, 2013, J VIRAL HEPATITIS, V20, P811, DOI 10.1111/jvh.12115
   Hou JL, 2015, ADV THER, V32, P727, DOI 10.1007/s12325-015-0232-2
   Hou JL, 2008, HEPATOLOGY, V47, P447, DOI 10.1002/hep.22075
   Huang MX, 2016, CLIN DRUG INVEST, V36, P471, DOI 10.1007/s40261-016-0392-0
   Huang MX, 2015, INT J CLIN EXP MED, V8, P666
   Imaz A, 2017, EXPERT REV ANTI-INFE, V15, P195, DOI 10.1080/14787210.2017.1286736
   Jia HY, 2015, ANN HEPATOL, V14, P175, DOI 10.1016/S1665-2681(19)30779-3
   Jia JD, 2014, HEPATOL INT, V8, P72, DOI 10.1007/s12072-013-9488-2
   Kamezaki H, 2011, SCAND J GASTROENTERO, V46, P1111, DOI 10.3109/00365521.2011.584898
   Karino Y, 2010, HEPATOL INT, V4, P414, DOI 10.1007/s12072-009-9162-x
   Kayaaslan B, 2017, WORLD J HEPATOL, V9, P227, DOI 10.4254/wjh.v9.i5.227
   Kim HR, 2015, LIVER INT, V35, P860, DOI 10.1111/liv.12605
   Kim HJ, 2010, J GASTROEN HEPATOL, V25, P1374, DOI 10.1111/j.1440-1746.2010.06381.x
   Kim HJ, 2010, LIVER INT, V30, P834, DOI 10.1111/j.1478-3231.2010.02245.x
   Kim HJ, 2015, KOREAN J INTERN MED, V30, P32, DOI 10.3904/kjim.2015.30.1.32
   Kobashi H, 2009, J GASTROEN HEPATOL, V24, P255, DOI 10.1111/j.1440-1746.2008.05593.x
   Koike K, 2018, HEPATOL RES, V48, P59, DOI 10.1111/hepr.12902
   Kwon YJ, 2015, NIGER J CLIN PRACT, V18, P796, DOI 10.4103/1119-3077.163296
   Lai CL, 2007, NEW ENGL J MED, V357, P2576, DOI 10.1056/NEJMoa066422
   Lai CL, 2014, GUT, V63, P996, DOI 10.1136/gutjnl-2013-305138
   Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201
   Lai CL, 2002, GASTROENTEROLOGY, V123, P1831, DOI 10.1053/gast.2002.37058
   Lai CL, 2006, NEW ENGL J MED, V354, P1011, DOI 10.1056/NEJMoa051287
   Lai CL, 2005, GASTROENTEROLOGY, V129, P528, DOI 10.1016/j.gastro.2005.05.053
   Lai CL, 2002, J MED VIROL, V67, P334, DOI 10.1002/jmv.10075
   Lai CL, 1997, HEPATOLOGY, V25, P241, DOI 10.1002/hep.510250144
   Lau GKK, 2005, NEW ENGL J MED, V352, P2682, DOI 10.1056/NEJMoa043470
   Lee KS, 2017, CLIN MOL HEPATOL, V23, P331, DOI 10.3350/cmh.2016.0040
   Leung NWY, 2014, INFECT DIS THER, V3, P191, DOI 10.1007/s40121-014-0039-5
   Leung NWY, 2001, HEPATOLOGY, V33, P1527, DOI 10.1053/jhep.2001.25084
   Li XJ, 2013, CLIN THER, V35, P1546, DOI 10.1016/j.clinthera.2013.07.431
   Li Y, 2013, J VIRAL HEPATITIS, V20, P46, DOI 10.1111/jvh.12063
   Lian JS, 2013, WORLD J GASTROENTERO, V19, P6278, DOI 10.3748/wjg.v19.i37.6278
   Liaw YF, 2000, GASTROENTEROLOGY, V119, P172, DOI 10.1053/gast.2000.8559
   Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364
   Liaw YF, 2009, GASTROENTEROLOGY, V136, P486, DOI 10.1053/j.gastro.2008.10.026
   Lim SG, 2007, ALIMENT PHARM THER, V26, P1419, DOI 10.1111/j.1365-2036.2007.03506.x
   Lim YS, 2016, GUT, V65, P1042, DOI 10.1136/gutjnl-2014-308435
   Lo AOS, 2014, EXPERT REV GASTROENT, V8, P607, DOI 10.1586/17474124.2014.909724
   Lok AS, 2012, GASTROENTEROLOGY, V143, P619, DOI 10.1053/j.gastro.2012.05.037
   Lok ASF, 2016, HEPATOLOGY, V63, P284, DOI 10.1002/hep.28280
   Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190
   Lu DTY, 2000, HEPATOLOGY, V32, P828, DOI 10.1053/jhep.2000.17912
   Lu JJ, 2013, J VIRAL HEPATITIS, V20, P40, DOI 10.1111/jvh.12062
   Luo J, 2013, INT J MED SCI, V10, P427, DOI 10.7150/ijms.5472
   Luo XD, 2017, J VIRAL HEPATITIS, V24, P36, DOI 10.1111/jvh.12790
   Mak LY, 2016, EXPERT OPIN DRUG SAF, V15, P383, DOI 10.1517/14740338.2016.1139573
   Marcellin P, 2004, NEW ENGL J MED, V351, P1206, DOI 10.1056/NEJMoa040431
   Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681
   Marcellin P, 2008, NEW ENGL J MED, V359, P2442, DOI 10.1056/NEJMoa0802878
   Marcellin P, 2008, HEPATOLOGY, V48, P750, DOI 10.1002/hep.22414
   Marcellin P, 2016, DIGEST DIS SCI, V61, P3072, DOI 10.1007/s10620-015-4027-8
   Marcellin P, 2016, GASTROENTEROLOGY, V150, P134, DOI 10.1053/j.gastro.2015.09.043
   Marcellin P, 2015, J HEPATOL, V62, P41, DOI 10.1016/j.jhep.2014.08.021
   Marcellin P, 2013, LANCET, V381, P468, DOI 10.1016/S0140-6736(12)61425-1
   MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743
   Mascolo A, 2017, PHARMACOL RES, V123, P122, DOI 10.1016/j.phrs.2017.07.005
   Mazur Wlodzimierz, 2002, Med Sci Monit, V8, pCR257
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Montazeri G, 2001, IRAN J MED SCI, V26, P1
   Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520
   Ozaras R, 2014, EUR J GASTROEN HEPAT, V26, P774, DOI 10.1097/MEG.0000000000000099
   Pan CQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089789
   Patterson SJ, 2011, GUT, V60, P247, DOI 10.1136/gut.2010.223206
   Perrillo RP, 2011, HEPATOL INT, V5, P654, DOI 10.1007/s12072-010-9228-9
   Pol S, 2012, J VIRAL HEPATITIS, V19, P377, DOI 10.1111/j.1365-2893.2012.01602.x
   Rapti I, 2007, HEPATOLOGY, V45, P307, DOI 10.1002/hep.21534
   Ray AS, 2016, ANTIVIR RES, V125, P63, DOI 10.1016/j.antiviral.2015.11.009
   Ren FY, 2007, WORLD J GASTROENTERO, V13, P4264, DOI 10.3748/wjg.v13.i31.4264
   Ridruejo E, 2014, WORLD J GASTROENTERO, V20, P7169, DOI 10.3748/wjg.v20.i23.7169
   Rizzetto M, 2005, J HEPATOL, V42, P173, DOI 10.1016/j.jhep.2004.10.006
   Rodriguez M, 2017, WORLD J GASTROENTERO, V23, P7459, DOI 10.3748/wjg.v23.i41.7459
   Ruane PJ, 2013, JAIDS-J ACQ IMM DEF, V63, P449, DOI 10.1097/QAI.0b013e3182965d45
   Safadi R, 2011, LIVER INT, V31, P667, DOI 10.1111/j.1478-3231.2010.02360.x
   Santantonio T, 2000, J HEPATOL, V32, P300, DOI 10.1016/S0168-8278(00)80076-8
   Sarin SK, 2016, HEPATOL INT, V10, P1, DOI 10.1007/s12072-015-9675-4
   Sarin SK, 2005, AM J GASTROENTEROL, V100, P2463, DOI 10.1111/j.1572-0241.2005.00247.x
   Schiff ER, 2003, J HEPATOL, V38, P818, DOI 10.1016/S0168-8278(03)00076-X
   Shen HJ, 2016, CELL PHYSIOL BIOCHEM, V40, P370, DOI 10.1159/000452552
   Sherman M, 2006, GASTROENTEROLOGY, V130, P2039, DOI 10.1053/j.gastro.2006.04.007
   Shin SR, 2011, HEPATOL INT, V5, P664, DOI 10.1007/s12072-010-9238-7
   Shindo M, 2009, HEPATOL INT, V3, P445, DOI 10.1007/s12072-009-9135-0
   Suh DJ, 2010, ANTIMICROB AGENTS CH, V54, P1242, DOI 10.1128/AAC.01163-09
   Sun J, 2014, HEPATOLOGY, V59, P1283, DOI 10.1002/hep.26885
   Sung JJY, 2008, J HEPATOL, V48, P728, DOI 10.1016/j.jhep.2007.12.026
   Suzuki F, 2008, J GASTROEN HEPATOL, V23, P1320, DOI 10.1111/j.1440-1746.2008.05455.x
   Tada T, 2018, J GASTROENTEROL, V53, P1196, DOI 10.1007/s00535-018-1467-x
   Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321
   Terrault Norah A, 2018, Clin Liver Dis (Hoboken), V12, P33, DOI 10.1002/cld.728
   Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156
   Vitoria M, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20504
   Wang JC, 2013, EUR REV MED PHARMACO, V17, P1162
   Wang LC, 2011, HEPATOL INT, V5, P671, DOI 10.1007/s12072-010-9243-x
   Wang Z, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-388
   Wolters LMM, 2001, EUR J GASTROEN HEPAT, V13, P1499, DOI 10.1097/00042737-200112000-00016
   Wu IT, 2017, CLIN MICROBIOL INFEC, V23, P464, DOI 10.1016/j.cmi.2017.02.001
   Yang FQ, 2017, WORLD J GASTROENTERO, V23, P306, DOI 10.3748/wjg.v23.i2.306
   Yao FY, 2000, J HEPATOL, V33, P301, DOI 10.1016/S0168-8278(00)80371-2
   Yao GB, 2009, J DIGEST DIS, V10, P131, DOI 10.1111/j.1751-2980.2009.00375.x
   Yao Guang-Bi, 2004, Hepatobiliary Pancreat Dis Int, V3, P188
   Yokosuka O, 2010, J HEPATOL, V52, P791, DOI 10.1016/j.jhep.2009.12.036
   Yuen MF, 2015, J HEPATOL, V62, P526, DOI 10.1016/j.jhep.2014.10.026
   Yuen MF, 2011, J GASTROEN HEPATOL, V26, P138, DOI 10.1111/j.1440-1746.2010.06545.x
   Zhang Y, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.10.024
   Zheng MH, 2010, CLIN THER, V32, P649, DOI 10.1016/j.clinthera.2010.04.001
NR 154
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0944-1174
EI 1435-5922
J9 J GASTROENTEROL
JI J. Gastroenterol.
PD MAY
PY 2020
VL 55
IS 5
BP 496
EP 514
DI 10.1007/s00535-020-01680-0
EA MAR 2020
PG 19
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LI2RA
UT WOS:000520633400001
PM 32185517
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Chagas, AL
   Fonseca, LG
   Coelho, FF
   Saud, LRC
   Abadala, E
   Andraus, W
   Fiore, L
   Moreira, AM
   Menezes, MR
   Carnevale, FC
   Tani, CM
   Alencar, RSSM
   D'Albuquerque, LAC
   Herman, P
   Carrilho, FJ
AF Chagas, Aline Lopes
   Fonseca, Leonardo Gomes
   Coelho, Fabricio Ferreira
   Cunha Saud, Lisa Rodrigues
   Abadala, Edson
   Andraus, Wellington
   Fiore, Lucas
   Moreira, Airton Mota
   Menezes, Marcos Roberto
   Carnevale, Francisco Cesar
   Tani, Claudia Megumi
   Alencar, Regiane S. S. M.
   Carneiro D'Albuquerque, Luiz Augusto
   Herman, Paulo
   Carrilho, Flair Jose
TI Management of Hepatocellular Carcinoma during the COVID-19 Pandemic -
   Sao Paulo Clinicas Liver Cancer Group Multidisciplinary Consensus
   Statement
SO CLINICS
LA English
DT Review
DE Hepatocellular Carcinoma; Hepatocellular Carcinoma/Therapy; COVID-19;
   Clinical Practice Guideline
AB More than 18 million people in 188 countries have been diagnosed as having coronavirus disease (COVID-19), and COVID-19 has been responsible for more than 600,000 deaths worldwide. Brazil is now the second most affected country globally. Faced with this scenario, various public health measures and changes in the daily routines of hospitals were implemented to stop the pandemic. Patients with hepatocellular carcinoma (HCC) are at an increased risk for severe COVID-19 as they present with two major diseases: cancer and concomitant chronic liver disease. The COVID-19 pandemic can significantly impact the management of HCC patients from diagnosis to treatment strategies. These patients need special attention and assistance at this time, especially since treatment for tumors cannot be delayed in most cases. The aim of this guideline was to standardize the management of HCC patients during the COVID-19 pandemic. This document was developed, on the basis of the best evidence available, by a multidisciplinary team from Instituto do Cancer do Estado de Sao Paulo (ICESP), and Instituto Central of the Hospital das Clinicas da Universidade de Sao Paulo (HC-FMUSP), which are members of the Sao Paulo Cli ' nicas Liver Cancer Group.
C1 [Chagas, Aline Lopes; Cunha Saud, Lisa Rodrigues; Tani, Claudia Megumi; Alencar, Regiane S. S. M.; Carrilho, Flair Jose] Univ Sao Paulo, Hosp Clin, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol,Fac Med, Sao Paulo, Brazil.
   [Chagas, Aline Lopes; Fonseca, Leonardo Gomes; Cunha Saud, Lisa Rodrigues; Abadala, Edson; Fiore, Lucas; Moreira, Airton Mota; Menezes, Marcos Roberto; Carnevale, Francisco Cesar; Tani, Claudia Megumi; Alencar, Regiane S. S. M.] Univ Sao Paulo, Hosp Clin, Inst Canc Estado Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Chagas, Aline Lopes; Fonseca, Leonardo Gomes; Coelho, Fabricio Ferreira; Cunha Saud, Lisa Rodrigues; Andraus, Wellington; Fiore, Lucas; Moreira, Airton Mota; Menezes, Marcos Roberto; Carnevale, Francisco Cesar; Tani, Claudia Megumi; Alencar, Regiane S. S. M.; Carneiro D'Albuquerque, Luiz Augusto; Herman, Paulo; Carrilho, Flair Jose] Univ Sao Paulo, Hosp Clin, Fac Med, Sao Paulo Clin Liver Canc Grp, Sao Paulo, Brazil.
   [Coelho, Fabricio Ferreira; Herman, Paulo] Univ Sao Paulo, Hosp Clin, Dept Gastroenterol, Digest Surg Div,Fac Med, Sao Paulo, Brazil.
   [Abadala, Edson; Andraus, Wellington; Carneiro D'Albuquerque, Luiz Augusto] Univ Sao Paulo, Hosp Clin, Dept Gastroenterol, Digest Organs Transplant Div,Fac Med, Sao Paulo, Brazil.
   [Fiore, Lucas; Moreira, Airton Mota; Menezes, Marcos Roberto; Carnevale, Francisco Cesar] Univ Sao Paulo, Dept Radiol & Oncol, Fac Med, Sao Paulo, Brazil.
RP Chagas, AL (corresponding author), Univ Sao Paulo, Hosp Clin, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol,Fac Med, Sao Paulo, Brazil.; Chagas, AL (corresponding author), Univ Sao Paulo, Hosp Clin, Inst Canc Estado Sao Paulo, Fac Med, Sao Paulo, Brazil.; Chagas, AL (corresponding author), Univ Sao Paulo, Hosp Clin, Fac Med, Sao Paulo Clin Liver Canc Grp, Sao Paulo, Brazil.
EM alinelchagas@gmail.com
RI Carneiro D'Albuquerque, Luiz Augusto/A-8812-2013
OI Carneiro D'Albuquerque, Luiz Augusto/0000-0001-7607-7168
CR Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Brandao CE, 2020, NETO JMA NOTA TECNIC
   CHAGAS Aline Lopes, 2020, Arq. Gastroenterol., V57, P1, DOI [10.1590/S0004-2803.202000000-20, 10.1590/s0004-2803.202000000-20]
   Couto CA, 2020, RECOMENDACOES COVID
   COVIDSurg Collaborative, 2020, BRIT J SURG, DOI 10.1002/bjs.11646
   da Fonseca L, 2020, LIVER INT, DOI 10.1111/liv.14545
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Deng GT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02902-w
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086
   Herman P, 2014, J LAPAROENDOSC ADV S, V24, P223, DOI 10.1089/lap.2013.0502
   Iavarone M, 2020, ANN ONCOL, V31, P1084, DOI 10.1016/j.annonc.2020.04.007
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mazzaferro V, 2009, LANCET ONCOL, V10, P35, DOI 10.1016/S1470-2045(08)70284-5
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Ramos Rodrigo Felippe, 2020, Rev Col Bras Cir, V47, pe20202570, DOI 10.1590/0100-6991e-20202570
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 22
TC 0
Z9 0
U1 0
U2 0
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2020
VL 75
AR e2192
DI 10.6061/clinics/2020/e2192
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA ON6TK
UT WOS:000586830500001
PM 33146360
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Moura, DTH
   Proenca, IM
   McCarty, TR
   Sagae, VMT
   Ribeiro, IB
   de Oliveira, GHP
   de Souza, GMV
   Hirsch, BS
   Scatimburgo, MVCV
   Thompson, CC
   Carrilho, FJ
   Cecconello, I
   de Moura, EGH
AF Hourneaux de Moura, Diogo Turiani
   Proenca, Igor Mendonca
   McCarty, Thomas R.
   Takamatsu Sagae, Vitor Massaro
   Ribeiro, Igor Braga
   Peixoto de Oliveira, Guilherme Henrique
   Vieira de Souza, Gabriel Mayo
   Hirsch, Bruno Salomao
   Cury Vieira Scatimburgo, Maria Vitoria
   Thompson, Christopher C.
   Carrilho, Flair Jose
   Cecconello, Ivan
   Hourneaux de Moura, Eduardo Guimaraes
TI Gastrointestinal Manifestations and Associated Health Outcomes of
   COVID-19: A Brazilian Experience From the Largest South American Public
   Hospital
SO CLINICS
LA English
DT Article
DE COVID-19; SARS-CoV-2; Gastrointestinal Symptoms; Prevalence; Pandemic
ID RECEPTOR
AB OBJECTIVES: Brazil has rapidly developed the second-highest number of COVID-19 cases in the world. As such, proper symptom identification, including gastrointestinal manifestations, and relationship to health outcomes remains key. We aimed to assess the prevalence and impact of gastrointestinal symptoms associated with COVID-19 in a large quaternary referral center in South America.
   METHODS: This was a single-center cohort study in a COVID-19 specific hospital in Sao Paulo, Brazil. Consecutive adult patients with laboratory confirmed SARS-CoV-2 were included. Baseline patient history, presenting symptoms, laboratory results, and clinically relevant outcomes were recorded. Regression analyses were performed to determine significant predictors of the gastrointestinal manifestations of COVID-19 and hospitalization outcomes.
   RESULTS: Four-hundred patients with COVID-19 were included. Of these, 33.25% of patients reported gastrointestinal symptom. Diarrhea was the most common gastrointestinal symptom (17.25%). Patients with gastrointestinal symptoms had higher rates of concomitant constitutional symptoms, notably fatigue and myalgia (p <0.05). Gastrointestinal symptoms were also more prevalent among patients on chronic immunosuppressants, ACE/ARB medications, and patient with chronic kidney disease (p <0.05). Laboratory results, length of hospitalization, ICU admission, ICU length of stay, need for mechanical ventilation, vasopressor support, and in-hospital mortality did not differ based upon gastrointestinal symptoms (p> 0.05). Regression analyses showed older age [OR 1.04 (95% CI, 1.02-1.06)], male gender [OR 1.94 (95% CI, 1.12-3.36)], and immunosuppression [OR 2.60 (95% CI, 1.20-5.63)], were associated with increased mortality.
   CONCLUSION: Based upon this Brazilian study, gastrointestinal manifestations of COVID-19 are common but do not appear to impact clinically relevant hospitalization outcomes including the need for ICU admission, mechanical ventilation, or mortality.
C1 [Hourneaux de Moura, Diogo Turiani; Proenca, Igor Mendonca; Takamatsu Sagae, Vitor Massaro; Ribeiro, Igor Braga; Peixoto de Oliveira, Guilherme Henrique; Vieira de Souza, Gabriel Mayo; Hirsch, Bruno Salomao; Cury Vieira Scatimburgo, Maria Vitoria; Carrilho, Flair Jose; Cecconello, Ivan; Hourneaux de Moura, Eduardo Guimaraes] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Hourneaux de Moura, Diogo Turiani; McCarty, Thomas R.; Thompson, Christopher C.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Ribeiro, IB (corresponding author), Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
EM igorbraga1@gmail.com; eduardoghdemoura@gmail.com
RI Ribeiro, Igor Braga/U-2003-2019
OI Ribeiro, Igor Braga/0000-0003-1844-8973
CR Campbell I, 2007, STAT MED, V26, P3661, DOI 10.1002/sim.2832
   Cao C, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03034-x
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301
   Grover A, 2020, EUR HEAR J CARDIOVAS
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Johns Hopkins Universty and Medicine, 2020, COVID 19 DASHBOARD C
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lippi G, 2020, WORLD J EMERG MED, V11, P193, DOI 10.5847/wjem.j.1920-8642.2020.03.013
   Lopes RD, 2020, AM HEART J, V226, P49, DOI 10.1016/j.ahj.2020.05.002
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Parasa S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.11335
   Parohan M, 2019, AGING MALE, V2020, P1
   Franzini TAP, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1989
   Redd WD, 2020, GASTROENTEROLOGY, V159, P765, DOI 10.1053/j.gastro.2020.04.045
   Selcuk M, 2020, CLIN EXP HYPERTENS, V42, P738, DOI 10.1080/10641963.2020.1783549
   Suresh Kumar Vishnu Charan, 2020, BMJ Open Gastroenterol, V7, DOI 10.1136/bmjgast-2020-000417
   von Bartheld CS, 2020, PREVALENCE CHEMOSENS
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, NAMING CORONAVIRUS D
   World Health Organization, 2020, COVID 19 DASHBOARD
   Yu CZ, 2020, AM J PREV MED, V59, P168, DOI 10.1016/j.amepre.2020.05.002
   Zhang H, 2020, GUT, V69, P1010, DOI 10.1136/gutjnl-2020-320953
   Zhang X, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104927
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 0
Z9 0
U1 0
U2 0
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2020
VL 75
AR e2271
DI 10.6061/clinics/2020/e2271
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA ON6UR
UT WOS:000586833800001
PM 33146362
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ono, SK
   Andraus, W
   Terrabuio, DRB
   Cobello, V
   Arai, L
   Ducatti, L
   Haddad, LBD
   D'Albuquerque, LAC
   Carrilho, FJ
AF Ono, Suzane Kioko
   Andraus, Wellington
   Benedita Terrabuio, Debora Raquel
   Cobello-Junior, Vilson
   Arai, Lilian
   Ducatti, Liliana
   de Paiva Haddad, Luciana Bertocco
   Carneiro D'Albuquerque, Luiz Augusto
   Carrilho, Flair Jose
TI Technological Innovation in Outpatient Assistance for Chronic Liver
   Disease and Liver Transplant Patients During the Coronavirus Disease
   Outbreak: A Method to Minimize Transmission
SO CLINICS
LA English
DT Editorial Material
C1 [Ono, Suzane Kioko; Benedita Terrabuio, Debora Raquel; Carrilho, Flair Jose] Univ Sao Paulo, Div Gastroenterol & Hepatol Clin, Hosp Clin HCFMUSP, Fac Med,Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Andraus, Wellington; Ducatti, Liliana; de Paiva Haddad, Luciana Bertocco; Carneiro D'Albuquerque, Luiz Augusto] Univ Sao Paulo, Div Transplante Orgaos Digest, Hosp Clin HCFMUSP, Fac Med,Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Cobello-Junior, Vilson] Univ Sao Paulo, NETI, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Arai, Lilian] Hackmed, Sao Paulo, Brazil.
RP Andraus, W (corresponding author), Univ Sao Paulo, Div Transplante Orgaos Digest, Hosp Clin HCFMUSP, Fac Med,Dept Gastroenterol, Sao Paulo, SP, Brazil.
EM wellingtonandraus@gmail.com
RI D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168
CR American Association for the Study of Liver Diseases, 2020, CLIN INS HEP LIV TRA
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   World Health Organization, 2020, COR DIS COVID 2019 S
NR 3
TC 0
Z9 0
U1 0
U2 0
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2020
VL 75
AR e1946
DI 10.6061/clinics/2020/e1946
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA LV4SR
UT WOS:000538427500001
PM 32490936
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Oba, J
   Deboni, M
   Toma, R
   Sobrado, C
   Azevedo, M
   Carlos, A
   Borba, M
   Damiao, A
   Carrilho, F
   Silva, C
AF Oba, J.
   Deboni, M.
   Toma, R.
   Sobrado, C.
   Azevedo, M.
   Carlos, A.
   Borba, M.
   Damiao, A.
   Carrilho, F.
   Silva, C.
TI Health-related quality of life in adolescents and young adults (AYA)
   with inflammatory bowel disease and its correlations with demographic,
   clinical, laboratory and therapeutic evaluations
SO JOURNAL OF CROHNS & COLITIS
LA English
DT Meeting Abstract
C1 [Oba, J.; Deboni, M.; Toma, R.] Univ Sao Paulo, Fac Med, Hosp Clin, Inst Crianca,Pediat Gastroenterol, Sao Paulo, Brazil.
   [Sobrado, C.; Borba, M.] Univ Sao Paulo, Fac Med, Hosp Clin, Coloproctol, Sao Paulo, Brazil.
   [Azevedo, M.; Carlos, A.; Damiao, A.; Carrilho, F.] Univ Sao Paulo, Fac Med, Hosp Clin, Gastroenterol, Sao Paulo, Brazil.
   [Silva, C.] Univ Sao Paulo, Fac Med, Hosp Clin, Inst Crianca,Adolescent, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1873-9946
EI 1876-4479
J9 J CROHNS COLITIS
JI J. Crohns Colitis
PD JAN
PY 2020
VL 14
SU 1
MA P230
BP S257
EP S258
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA KT1WK
UT WOS:000518803401129
DA 2020-12-08
ER

PT J
AU Rassi, AB
   d'Amico, EA
   Tripodi, A
   da Rocha, TRF
   Migita, BY
   Ferreira, CM
   Carrilho, FJ
   Farias, AQ
AF Rassi, Amanda Bruder
   d'Amico, Elbio Antonio
   Tripodi, Armando
   Flores da Rocha, Tania Rubia
   Migita, Beatriz Yuri
   Ferreira, Caroline Marcondes
   Carrilho, Flair Jose
   Farias, Alberto Queiroz
TI Fresh frozen plasma transfusion in patients with cirrhosis and
   coagulopathy: Effect on conventional coagulation tests and
   thrombomodulin-modified thrombin generation
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Cirrhosis; Thrombin generation; Fresh frozen plasma; Coagulation
ID CRITICALLY-ILL PATIENTS; CHRONIC LIVER-DISEASE; GUIDELINES; PARAMETERS;
   HEPARIN
AB Background & Aims: The efficacy of fresh frozen plasma (FFP) transfusion in enhancing thrombin generation in patients with cirrhosis and impaired conventional coagulation tests has not been sufficiently explored. Thus, we aimed to assess the effect of FFP transfusion on thrombin generation in these patients.
   Methods: Fifty-three consecutive patients receiving a standard dose of FFP to treat bleeding and/or before invasive procedures - if international normalized ratio (INR)/prothrombin time (PT) ratio were >= 1.5 - were prospectively enrolled. The primary endpoint was the amelioration of endogenous thrombin potential (ETP) with thrombomodulin (ETP-TM) after transfusion, which corresponds to the total amount of generated thrombin. INR/PT ratio and activated partial thromboplastin time (aPTT) were also assessed before and after transfusion.
   Results: FFP enhanced ETP-TM by 5.7%, from 973 (731-1,258) to 1,028 (885-1,343 nM x min; p = 0.019). Before transfusion, evidence of normal or high ETP-TM was found in 94% of patients, even in those with bacterial infections. Only 1 (1.9%) patient had ETP-TM values reverting to the normal range after transfusion. Notably, no patients with low ETP-TM had bleeding. The median decrease in ETP-TM was 8.3% and the mean was 12.8% in 18 (34%) patients after transfusion (from 1,225 [1,071-1,537] to 1,124 [812-1,370] nM x min; p <= 0.0001). Similar responses to FFP transfusion were observed in patients with compensated and acute decompensated cirrhosis, acute-on-chronic liver failure, infection or shock. FFP significantly ameliorated INR and aPTT values (p <0.0001), but in a minority of patients the values were reduced to less than the cut-off point of 1.5.
   Conclusions: FFP transfusion enhanced thrombin generation and ameliorated conventional coagulation tests to normal values in a limited number of patients, and slightly decreased thrombin generation in 34% of cases.
   Lay summary: Transfusion of fresh frozen plasma in patients with cirrhosis only slightly improves coagulation test values in a limited number of patients and even appears to worsen them in a third of cases. Transfusion for the purpose of preventing or treating bleeding events could cause inherent risks and costs without clear benefits. (C) 2019 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.
C1 [Rassi, Amanda Bruder; d'Amico, Elbio Antonio; Flores da Rocha, Tania Rubia] Univ Sao Paulo, Div Hematol, Coagulat Lab, Sch Med, Sao Paulo, SP, Brazil.
   [Tripodi, Armando] Fdn IRCCS Ca Granda Osped Maggiore, Hemophilia & Thrombosis Ctr Angelo Bianchi Bonomi, Milan, Italy.
   [Tripodi, Armando] Fdn Luigi Villa, Milan, Italy.
   [Migita, Beatriz Yuri; Ferreira, Caroline Marcondes; Carrilho, Flair Jose; Farias, Alberto Queiroz] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, SP, Brazil.
RP Farias, AQ (corresponding author), Inst Cent Hosp Clin, Gastroenterol, Av Dr Eneas de Carvalho Aguiar 255,9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM alberto.farias@fm.usp.br
RI Farias, Alberto/ABB-1291-2020
OI Farias, Alberto/0000-0002-5572-663X
FU Sao Paulo Research Foundation (FAPESP), BrazilFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2015/00883-5]
FX This study was supported by the Sao Paulo Research Foundation (FAPESP),
   Brazil (Grant number 2015/00883-5). Sponsor had no role in the study
   design, in the collection, analysis, or in the interpretation of date.
CR Amer Soc Anesthesiologists Task Fo, 2006, ANESTHESIOLOGY, V105, P198
   Caldwell Stephen, 2012, Hepatology, V55, P1634, DOI 10.1002/hep.25623
   Carlier L, 2015, THROMB RES, V135, P192, DOI 10.1016/j.thromres.2014.11.001
   Castoldi E, 2011, THROMB RES, V127, pS21, DOI 10.1016/S0049-3848(11)70007-X
   Chandler JB, 2019, J CLIN PATHOL, V72, P177, DOI 10.1136/jclinpath-2018-205438
   da Saude do Brasil M, 2015, GUIA USO HEMOCOMPONE
   Desborough MJR, 2016, LIVER INT, V36, P522, DOI 10.1111/liv.12999
   Drolz A, 2016, HEPATOLOGY, V64, P556, DOI 10.1002/hep.28628
   Giannini EG, 2014, HEPATOLOGY, V60, P1442, DOI 10.1002/hep.27029
   Hall DP, 2012, BRIT J ANAESTH, V109, P919, DOI 10.1093/bja/aes337
   Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636
   HEMKER HC, 1986, THROMB HAEMOSTASIS, V56, P9
   Holland LL, 2006, AM J CLIN PATHOL, V126, P133, DOI 10.1309/NQXHUG7HND78LFFK
   Hyytiainen S, 2003, J THROMB HAEMOST, V1, P1189, DOI 10.1046/j.1538-7836.2003.00243.x
   Lisman T, 2001, GASTROENTEROLOGY, V121, P131, DOI 10.1053/gast.2001.25481
   Lisman T, 2018, LIVER INT, V38, P1988, DOI 10.1111/liv.13882
   Liumbruno GM, 2011, BLOOD TRANSFUS-ITALY, V9, P320, DOI 10.2450/2011.0076-10
   Malloy PC, 2009, J VASC INTERV RADIOL, V20, pS240, DOI 10.1016/j.jvir.2008.11.027
   Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70
   Mannucci PM, 2006, J THROMB HAEMOST, V4, P721, DOI 10.1111/j.1538-7836.2006.01886.x
   Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449
   Montalto P, 2002, J HEPATOL, V37, P463, DOI 10.1016/S0168-8278(02)00208-8
   Moreau R, 2013, GASTROENTEROLOGY, V144, P1426, DOI 10.1053/j.gastro.2013.02.042
   Muller MCA, 2015, J THROMB HAEMOST, V13, P989, DOI 10.1111/jth.12908
   National Institute of Health, FRESH FROZ PLASM INF
   Qi XS, 2015, INTERN EMERG MED, V10, P205, DOI 10.1007/s11739-014-1163-7
   Rockey DC, 2009, HEPATOLOGY, V49, P1017, DOI 10.1002/hep.22742
   Schols SEM, 2008, THROMB HAEMOSTASIS, V99, P64, DOI 10.1160/TH07-07-0438
   Shah NL, 2012, ANN HEPATOL, V11, P686, DOI 10.1016/S1665-2681(19)31443-7
   Szczepiorkowski ZM, 2013, HEMATOL-AM SOC HEMAT, P638, DOI 10.1182/asheducation-2013.1.638
   Tinmouth A, 2013, TRANSFUSION, V53, P2222, DOI 10.1111/trf.12231
   Tripodi A, 2005, HEPATOLOGY, V41, P553, DOI 10.1002/hep.20569
   Tripodi A, 2006, HEPATOLOGY, V44, P440, DOI 10.1002/hep.21266
   Tripodi A, 2016, DIGEST LIVER DIS, V48, P1208, DOI 10.1016/j.dld.2016.06.027
   Tripodi A, 2012, INTERN EMERG MED, V7, P139, DOI 10.1007/s11739-011-0528-4
   Tripodi A, 2009, GASTROENTEROLOGY, V137, P2105, DOI 10.1053/j.gastro.2009.08.045
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Wu H, 2010, CLIN GASTROENTEROL H, V8, P800, DOI 10.1016/j.cgh.2010.05.014
   Yates SG, 2016, TRANSFUSION, V56, P791, DOI 10.1111/trf.13495
   Youngwon N, 2013, BIOMED RES INT, V2013, P1
   Youssef WI, 2003, AM J GASTROENTEROL, V98, P1391, DOI 10.1016/S0002-9270(03)00241-7
   ZIMMON DS, 1974, GUT, V15, P99, DOI 10.1136/gut.15.2.99
NR 42
TC 12
Z9 12
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD JAN
PY 2020
VL 72
IS 1
BP 85
EP 94
DI 10.1016/j.jhep.2019.09.008
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JW4RT
UT WOS:000503041200012
PM 31536747
DA 2020-12-08
ER

PT J
AU Figueiredo-Mello, C
   Casadio, LVB
   Avelino-Silva, VL
   Ho, YL
   Sztajnbok, J
   Joelsons, D
   Antonio, MB
   Pinho, JRR
   Malta, FD
   Gomes-Gouvea, MS
   Salles, APM
   Cora, AP
   Moreira, CHV
   Ribeiro, AF
   Nastri, ACDS
   Malaque, CMS
   Teixeira, RFA
   Borges, LMS
   Gonzalez, MP
   Pereira, LC
   Souza, TNL
   Song, ATW
   D'Albuquerque, LAC
   Abdala, E
   Andraus, W
   de Martino, RB
   Ducatti, L
   Andrade, GM
   Malbouisson, LMS
   de Souza, IM
   Carrilho, FJ
   Sabino, EC
   Levin, AS
AF Figueiredo-Mello, Claudia
   Boas Casadio, Luciana Vilas
   Avelino-Silva, Vivian Lida
   Ho Yeh-Li
   Sztajnbok, Jaques
   Joelsons, Daniel
   Antonio, Marilia Bordignon
   Rebello Pinho, Joao Renato
   Malta, Fernanda de Mello
   Gomes-Gouvea, Michele Soares
   Moreira Salles, Ana Paula
   Cora, Aline Pivetta
   Valente Moreira, Carlos Henrique
   Ribeiro, Ana Freitas
   de Seixas Santos Nastri, Ana Catharina
   Sant'Ana Malaque, Ceila Maria
   Azevedo Teixeira, Ralcyon Francis
   Sansao Borges, Luciana Marques
   Gonzalez, Mario Peribanez
   Pereira Junior, Luiz Carlos
   Lobato Souza, Tamara Newman
   Wan Song, Alice Tung
   Carneiro D'Albuquerque, Luiz Augusto
   Abdala, Edson
   Andraus, Wellington
   de Martino, Rodrigo Bronze
   Ducatti, Liliana
   Andrade, Guilherme Marques
   Se Malbouisson, Luiz Marcelo
   de Souza, Izabel Marcilio
   Carrilho, Flair Jose
   Sabino, Ester Cerdeira
   Levin, Anna S.
TI Efficacy of sofosbuvir as treatment for yellow fever: protocol for a
   randomised controlled trial in Brazil (SOFFA study)
SO BMJ OPEN
LA English
DT Article
AB Introduction An ongoing outbreak of yellow fever (YF) has been reported in Brazil with 1261 confirmed cases and 409 deaths since July 2017. To date, there is no specific treatment available for YF. Recently published papers describing in vitro and animal models suggest a potential effect of antiviral drugs (approved for the treatment of hepatitis virus) against flaviviruses, including YF. The primary aim of this study is to analyse the effect of sofosbuvir on viral kinetics and clinical outcomes among patients presenting with YE This is a multicentre open-label randomised controlled trial with 1:1 individual allocation, stratified by severity and by recruiting centre.
   Methods and analysis Adults with suspected or confirmed YF infection and symptoms lasting up to 15 days are screened. Eligible and consenting patients are randomised to receive oral sofosbuvir 400 mg daily for 10 days or to receive standard clinical care. Viral kinetics are measured daily and the reduction in YF plasma viral load from the sample at inclusion to 72 hours after randomisation will be compared between active and control groups. Clinical outcomes include severity meeting criteria for intensive care support, liver transplantation, in-hospital mortality and mortality within 60 days.
C1 [Figueiredo-Mello, Claudia] Inst Infectol Emilio Ribas, Dept Educ & Res, Sao Paulo, SP, Brazil.
   [Figueiredo-Mello, Claudia; Avelino-Silva, Vivian Lida; Antonio, Marilia Bordignon; Sabino, Ester Cerdeira; Levin, Anna S.] Univ Sao Paulo, Dept Infect & Parasit Dis, Fac Med FMUSP, Sao Paulo, SP, Brazil.
   [Boas Casadio, Luciana Vilas; Ho Yeh-Li; Joelsons, Daniel; de Seixas Santos Nastri, Ana Catharina; Abdala, Edson] Univ Sao Paulo, Dept Infect & Parasit Dis, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Boas Casadio, Luciana Vilas; Rebello Pinho, Joao Renato; Malta, Fernanda de Mello; Gomes-Gouvea, Michele Soares; Moreira Salles, Ana Paula; de Seixas Santos Nastri, Ana Catharina] Univ Sao Paulo, Dept Gastroenterol LIM07, Fac Med FMUSP, Sao Paulo, SP, Brazil.
   [Sztajnbok, Jaques; Sant'Ana Malaque, Ceila Maria] Inst Infectol Emilio Ribas, Div Med, Intens Care Unit, Sao Paulo, SP, Brazil.
   [Cora, Aline Pivetta] Inst Infectol Emilio Ribas, Clin Lab, Sao Paulo, SP, Brazil.
   [Valente Moreira, Carlos Henrique] Inst Infectol Emilio Ribas, Inpatient Unit, Sao Paulo, SP, Brazil.
   [Ribeiro, Ana Freitas] Inst Infectol Emilio Ribas, Epidemiol Serv, Sao Paulo, SP, Brazil.
   [Azevedo Teixeira, Ralcyon Francis] Inst Infectol Emilio Ribas, Med Div, Sao Paulo, SP, Brazil.
   [Sansao Borges, Luciana Marques] Inst Infectol Emilio Ribas, Med Emergency Dept, Sao Paulo, SP, Brazil.
   [Gonzalez, Mario Peribanez] Inst Infectol Emilio Ribas, Outpatients Clin, Sao Paulo, SP, Brazil.
   [Pereira Junior, Luiz Carlos] Inst Infectol Emilio Ribas, Tech Dept, Sao Paulo, SP, Brazil.
   [Lobato Souza, Tamara Newman] Inst Infectol Emilio Ribas, ER & Outpatient Serv, Sao Paulo, SP, Brazil.
   [Wan Song, Alice Tung; Carneiro D'Albuquerque, Luiz Augusto; Andraus, Wellington; de Martino, Rodrigo Bronze; Ducatti, Liliana; Andrade, Guilherme Marques; Se Malbouisson, Luiz Marcelo; Carrilho, Flair Jose] Univ Sao Paulo, Dept Gastroenterol, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Abdala, Edson] Univ Sao Paulo, Infect Dis, Inst Canc Estado Sao Paulo, Sao Paulo, SP, Brazil.
   [de Souza, Izabel Marcilio] Univ Sao Paulo, Epidemiol Surveillance Dept, Hosp Clin, Sao Paulo, SP, Brazil.
RP Figueiredo-Mello, C (corresponding author), Inst Infectol Emilio Ribas, Dept Educ & Res, Sao Paulo, SP, Brazil.; Figueiredo-Mello, C (corresponding author), Univ Sao Paulo, Dept Infect & Parasit Dis, Fac Med FMUSP, Sao Paulo, SP, Brazil.
EM claudiamello@ymail.com
RI Sztajnbok, Jaques/AAN-1793-2020; Levin, Anna S/C-8831-2012; Sztajnbok,
   Jaques/ABE-7055-2020; Casadio, Luciana Vilas Boas/AAF-8371-2019; Abdala,
   Edson/H-5165-2012; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   Avelino-Silva, Vivian/L-2640-2013; Malta, Fernanda/B-1316-2013; Pinho,
   Joao/G-2850-2012; Gouvea, Michele/G-4216-2012
OI Levin, Anna S/0000-0003-2427-8368; Sztajnbok,
   Jaques/0000-0002-3188-8044; Casadio, Luciana Vilas
   Boas/0000-0001-8341-8960; Abdala, Edson/0000-0003-0765-6654;
   D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Avelino-Silva,
   Vivian/0000-0002-6660-3088; Malta, Fernanda/0000-0001-8887-5060; Pinho,
   Joao/0000-0003-3999-0489; Moreira, Carlos Henrique
   Valente/0000-0002-4187-5482; Gouvea, Michele/0000-0001-5932-2360
FU FAPESP, Sao Paulo Foundation for ResearchFundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [2016/01735-2]; Fundacao Faculdade de
   Medicina USP
FX This work was supported by FAPESP, Sao Paulo Foundation for Research
   [grant number 2016/01735-2] and Fundacao Faculdade de Medicina USP. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or in the preparation of the manuscript.
CR Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Colby-Germinario SP, 2017, SCI REPORTS, V7, P1
   de Freitas CS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007072
   Farnik H, 2009, J CHROMATOGR B, V877, P4001, DOI 10.1016/j.jchromb.2009.10.013
   Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Jung BH, 2007, BIOMED CHROMATOGR, V21, P1095, DOI 10.1002/bmc.865
   Mendes EA, 2019, ANN HEPATOL, V18, P816, DOI 10.1016/j.aohep.2019.09.001
   Ministerio da Saude, MON PER SAZ FEBR AM
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   OFCOM, 2014, CREAT BLOCK RAND LIS
   Sacramento CQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40920
NR 13
TC 0
Z9 0
U1 4
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD NOV
PY 2019
VL 9
IS 11
AR e027207
DI 10.1136/bmjopen-2018-027207
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA KK5IG
UT WOS:000512774800019
PM 31772079
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Mendes, EA
   de Pilger, DRB
   Nastri, ACDS
   Malta, FD
   Pascoalino, BD
   D'Albuquerque, LAC
   Balan, A
   Jr, LHGD
   Durigon, EL
   Carrilho, FJ
   Pinho, JRR
AF Mendes, Erica Araujo
   Bairros de Pilger, Denise Regina
   de Seixas Santos Nastri, Ana Catharina
   Malta, Fernanda de Mello
   Pascoalino, Bruno dos Santos
   Carneiro D'Albuquerque, Luiz Augusto
   Balan, Andrea
   Gondim de Freitas Jr, Lucio Holanda
   Durigon, Edison Luis
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Sofosbuvir inhibits yellow fever virus in vitro and in patients with
   acute liver failure
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Acute hepatitis; Flavivirus; YFV; Treatment; Antiviral
ID ZIKA VIRUS; RIBAVIRIN; INTERFERON; INFECTION; OUTBREAK; BRAZIL
AB Introduction and objectives: Direct antiviral agents (DAAs) are very efficient in inhibiting hepatitis C virus and might be used to treat infections caused by other flaviviruses whose worldwide detection has recently increased. The aim of this study was to verify the efficacy of DAAs in inhibiting yellow fever virus (YFV) by using drug repositioning (a methodology applied in the pharmaceutical industry to identify new uses for approved drugs).
   Materials and methods: Three DAAs were evaluated: daclatasvir, sofosbuvir and ledipasvir or their combinations. For in vitro assays, the drugs were diluted in 100% dimethyl sulfoxide. Vaccine strain 17D and a 17D strain expressing the reporter fluorescent protein were used in the assays. A fast and reliable cell-based screening assay using Vero cells or Huh-7 cells (a hepatocyte-derived carcinoma ell line) was carried out. Two patients who acquired yellow fever virus with acute liver failure were treated with sofosbuvir for one week as a compassionate use.
   Results: Using a high-content screening assay, we verified that sofosbuvir presented the best antiviral activity against YFV. Moreover, after an off-label treatment with sofosbuvir, the two female patients diagnosed with yellow fever infection displayed a reduction in blood viremia and an improvement in the course of the disease, which was observed in the laboratory medical parameters related to disease evolution.
   Conclusions: Sofosbuvir may be used as an option for treatment against YFV until other drugs are identified and approved for human use. These results offer insights into the role of nonstructural protein 5 (NS5) in YFV inhibition and suggest that nonstructural proteins may be explored as drug targets for YFV treatment. (C) 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U.
C1 [Mendes, Erica Araujo; Bairros de Pilger, Denise Regina; Pascoalino, Bruno dos Santos; Balan, Andrea; Gondim de Freitas Jr, Lucio Holanda; Durigon, Edison Luis] Univ Sao Paulo, Biomed Sci Inst, Dept Microbiol, Sao Paulo, SP, Brazil.
   [Bairros de Pilger, Denise Regina; Gondim de Freitas Jr, Lucio Holanda] Butantan Inst, Sao Paulo, SP, Brazil.
   [de Seixas Santos Nastri, Ana Catharina] Univ Sao Paulo, Sch Med, Dept Parasit & Infect Dis, Sao Paulo, SP, Brazil.
   [Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
   [Rebello Pinho, Joao Renato] Univ Sao Paulo, Sao Paulo Sch Med, Clin Hosp, Cent Labs Div,LIM 03, Sao Paulo, SP, Brazil.
   [de Seixas Santos Nastri, Ana Catharina; Malta, Fernanda de Mello; Carneiro D'Albuquerque, Luiz Augusto; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Inst Trop Med, Dept Gastroenterol,LIM 07, Sao Paulo, SP, Brazil.
RP Pinho, JRR (corresponding author), Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.; Pinho, JRR (corresponding author), Univ Sao Paulo, Sao Paulo Sch Med, Clin Hosp, Cent Labs Div,LIM 03, Sao Paulo, SP, Brazil.; Pinho, JRR (corresponding author), Univ Sao Paulo, Sch Med, Inst Trop Med, Dept Gastroenterol,LIM 07, Sao Paulo, SP, Brazil.
EM jrrpinho@usp.br
RI Freitas-Junior, Lucio/C-8677-2011; Balan, Andrea/D-1891-2014; Carneiro
   D'Albuquerque, Luiz Augusto/A-8812-2013; Pinho, Joao/G-2850-2012
OI Freitas-Junior, Lucio/0000-0002-8904-7897; Balan,
   Andrea/0000-0001-6199-3198; Carneiro D'Albuquerque, Luiz
   Augusto/0000-0001-7607-7168; Pinho, Joao/0000-0003-3999-0489
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/20045-7]; FAPESP
   (Erica Aradjo Mendes and Bruno dos Santos Pascoalino)Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional para o
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX We thank Professor Amadou Alpha Sall from Institute Pasteur, Senegal,
   and Dr. Laura H. V. G. Gil from the Research Center Aggeu Magalhaes,
   FIOCRUZ, Brazil for providing the YFV used in this study. A. albopictus
   C6/36 cells and the human hepatoma cell line Huh7 were kindly provided
   by Dr. Amilcar Tanuri from Universidade Federal do Rio de Janeiro, Rio
   de Janeiro, Brazil. This work was supported by Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) Grant number 2016/20045-7.
   Scholarship funding was granted by FAPESP (Erica Aradjo Mendes and Bruno
   dos Santos Pascoalino) and Conselho Nacional para o Desenvolvimento
   Cientifico e Tecnologico (CNPq) for Denise Regina Bairros de Pilger.
CR [Anonymous], 2016, WKLY EPIDEMIOL REC, V92, P442
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Best SM, 2017, J VIROL, V91, DOI [10.1128/jvi.01970-16, 10.1128/JVI.01970-16]
   Casadio LVB, 2019, MEM I OSWALDO CRUZ, V114, DOI 10.1590/0074-02760190033
   Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   Caillet-Saguy C, 2014, ANTIVIR RES, V105, P8, DOI 10.1016/j.antiviral.2014.02.006
   Duarte-Neto AN, 2019, HISTOPATHOLOGY, V75, P638, DOI 10.1111/his.13904
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Freitas CS, 2019, PLOS NEGLECT TROP D, V13, pe7072
   Gane EJ, 2013, NEW ENGL J MED, V368, P34, DOI 10.1056/NEJMoa1208953
   Gara N, 2013, CLIN INFECT DIS, V56, P1629, DOI 10.1093/cid/cit074
   Goldani LZ, 2017, BRAZ J INFECT DIS, V21, P123, DOI 10.1016/j.bjid.2017.02.004
   Gorcea CM, 2017, J HOSP INFECT, V95, P214, DOI 10.1016/j.jhin.2016.11.012
   Gritsenko Diana, 2015, P T, V40, P256
   Guedj J, 2014, ANTIVIR THER, V19, P152
   Hosokawa M, 2008, MOLECULES, V13, P412, DOI 10.3390/molecules13020412
   Julander JG, 2007, ANTIVIR RES, V73, P140, DOI 10.1016/j.antiviral.2006.08.008
   Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI [10.1016/S1473-3099(16)30513-8, 10.1016/s1473-3099(16)30513-8]
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lemm JA, 2010, J VIROL, V84, P482, DOI 10.1128/JVI.01360-09
   Leyssen P, 2006, MOL PHARMACOL, V69, P1461, DOI 10.1124/mol.105.020057
   Medina F, 2012, CURR PROTOC MICROBIO
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Neyts J, 1996, ANTIVIR RES, V30, P125, DOI 10.1016/0166-3542(96)89697-5
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   Pascoalino Bruno S, 2016, F1000Res, V5, P2523
   Poordad F, 2016, HEPATOLOGY, V63, P1493, DOI 10.1002/hep.28446
   Reddy KR, 2015, HEPATOLOGY, V15
   Reznik SE, 2016, INT J INFECT DIS, V55, P29
   Sacramento CQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40920
   Sato K, 2018, HEPATOL RES, V48, pE347, DOI 10.1111/hepr.12971
   Zhang JH, 2012, J BIOMOL SCREEN, V1999
NR 34
TC 7
Z9 7
U1 1
U2 3
PU ELSEVIER ESPANA
PI MADRID
PA CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD NOV-DEC
PY 2019
VL 18
IS 6
BP 816
EP 824
DI 10.1016/j.aohep.2019.09.001
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JN5MT
UT WOS:000496943100008
PM 31594756
OA Other Gold
DA 2020-12-08
ER

PT J
AU Pinero, F
   Boin, I
   Chagas, A
   Quinonez, E
   Marciano, S
   Vilatoba, M
   Varon, A
   McCormack, L
   Duque, S
   Lima, AS
   Menendez, J
   Padilla, M
   Poniachik, J
   Zapata, R
   Maraschio, M
   Menende, RC
   Munhoz, L
   Arufe, D
   Figueroa, R
   Campana, AG
   Perales, SR
   Maccali, C
   Sandoval, RV
   Bermudez, C
   Santos, L
   Balmer, M
   Arenas, I
   Gerona, S
   Henriquez, V
   Ginesta, A
   Barrabino, M
   Raffa, P
   Gadano, A
   Mattera, J
   Ataide, EC
   Carrilho, F
   Silva, M
AF Pinero, Federico
   Boin, Ilka
   Chagas, Aline
   Quinonez, Emilio
   Marciano, Sebastian
   Vilatoba, Mario
   Varon, Adriana
   McCormack, Lucas
   Duque, Sergio
   Lima, Agnaldo Soares
   Menendez, Josemaria
   Padilla, Martin
   Poniachik, Jaime
   Zapata, Rodrigo
   Maraschio, Martin
   Menende, Ricardo Chong
   Munhoz, Linda
   Arufe, Diego
   Figueroa, Rodrigo
   Campana, Ariel Gonzalez
   Perales, Simone Reges
   Maccali, Claudia
   Sandoval, Rodrigo Vergara
   Bermudez, Carla
   Santos, Luiza
   Balmer, Matias
   Arenas, Isabel
   Gerona, Solange
   Henriquez, Victor
   Ginesta, Alexandra
   Barrabino, Martin
   Raffa, Pia
   Gadano, Adrian
   Mattera, Juan
   Ataide, Elaine Cristina
   Carrilho, Flair
   Silva, Marcelo
TI LISTING, DROPOUT AND TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN
   LATIN AMERICA: UNEXPECTED AND PREVIOUSLY NOT REPORTED RESULTS
SO TRANSPLANT INTERNATIONAL
LA English
DT Meeting Abstract
C1 [Pinero, Federico; Campana, Ariel Gonzalez; Silva, Marcelo] Hosp Univ Austral, Buenos Aires, DF, Argentina.
   [Boin, Ilka] Univ Estadual Campinas, Campinas, SP, Brazil.
   [Chagas, Aline; Maccali, Claudia; Carrilho, Flair] HC FMUSP, Sao Paulo, Brazil.
   [Quinonez, Emilio; Sandoval, Rodrigo Vergara; Mattera, Juan] Hosp El Cruce, Buenos Aires, DF, Argentina.
   [Marciano, Sebastian; Vilatoba, Mario] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina.
   [Varon, Adriana] Funac Cardio Infantil, Bogota, Colombia.
   [McCormack, Lucas; Balmer, Matias] Hosp Aleman Buenos Aires, Buenos Aires, DF, Argentina.
   [Duque, Sergio] Hosp Tobon Uribe, Medellin, Colombia.
   [Lima, Agnaldo Soares] Santa Casa Belo Horizonte, Belo Horizonte, MG, Brazil.
   [Menendez, Josemaria] Hosp Clin Montevideo, Montevideo, Uruguay.
   [Padilla, Martin] Hosp Guillermo Almenara, Lima, Peru.
   [Poniachik, Jaime] Hosp Univ Chile, Santiago, Chile.
   [Zapata, Rodrigo; Ginesta, Alexandra] Clin Alemana Santiago, Vitacura, Chile.
   [Maraschio, Martin; Barrabino, Martin] Hosp Privado Cordoba, Cordoba, Argentina.
   [Menende, Ricardo Chong; Raffa, Pia] Hosp Carlos Andrade Marin, Quito, Ecuador.
   [Munhoz, Linda] Hosp Univ Dr Jose E Gonzalez, Monterrey, Mexico.
   [Arufe, Diego] Sanatorio Sagrado Corazon, Valladolid, Spain.
   [Figueroa, Rodrigo] Sanatorio Allende Cordoba, Cordoba, Argentina.
   [Perales, Simone Reges; Ataide, Elaine Cristina] Univ Estadual Campinas, HC, Unit Liver Transplantat, Campinas, SP, Brazil.
   [Bermudez, Carla; Gadano, Adrian] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina.
   [Santos, Luiza] Fdn Cardio Infantil Bogota, Bogota, Colombia.
   [Arenas, Isabel] Hosp Tobon Uribe Mendellin, Medellin, Colombia.
   [Gerona, Solange] Hosp Clin Montevideo, Montevideo, Uruguay.
RI Lima, Agnaldo S/F-7452-2011
OI Lima, Agnaldo S/0000-0001-6421-3062
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0934-0874
EI 1432-2277
J9 TRANSPL INT
JI Transpl. Int.
PD OCT
PY 2019
VL 32
SU 2
SI SI
MA LBP029
BP 411
EP 412
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA JF6HK
UT WOS:000491488706026
DA 2020-12-08
ER

PT J
AU Rassi, AB
   D'Amico, EA
   Tripodi, A
   Rocha, TRF
   Migita, B
   Ferreira, CM
   Carrilho, FJ
   Farias, AQ
AF Rassi, Amanda Bruder
   D'Amico, Elbio Antonio
   Tripodi, Armando
   Flores Rocha, Tania Rubia
   Migita, Beatriz
   Ferreira, Caroline Marcondes
   Carrilho, Flair Jose
   Farias, Alberto Q.
TI FRESH FROZEN PLASMA TRANSFUSION IN PATIENTS WITH CIRRHOSIS AND
   COAGULOPATHY: EFFECT ON CONVENTIONAL COAGULATION TESTS AND
   THROMBOMODULIN-MODIFIED THROMBIN GENERATION
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 08-12, 2019
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Rassi, Amanda Bruder] Univ Sao Paulo, Sch Med, Internal Med, Sao Paulo, Brazil.
   [D'Amico, Elbio Antonio] Univ Sao Paulo, Coagulat Lab, Sao Paulo, Brazil.
   [Tripodi, Armando] Univ Milan, Dipartimento Fisiopatol Trapianti, Milan, Italy.
   [Flores Rocha, Tania Rubia] Univ Sao Paulo, Sch Med, Coagulat Lab, Sao Paulo, Brazil.
   [Migita, Beatriz; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, Brazil.
   [Ferreira, Caroline Marcondes] Univ Sao Paulo, Gastroenterol, Sao Paulo, Brazil.
   [Farias, Alberto Q.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Farias, Alberto Q.] Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
RI Farias, Alberto/ABB-1291-2020
OI Farias, Alberto/0000-0002-5572-663X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2019
VL 70
SU 1
MA 400
BP 253A
EP 253A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JB6CZ
UT WOS:000488653500399
DA 2020-12-08
ER

PT J
AU Camargo, CC
   Chagas, A
   Alencar, RSDM
   Tani, CM
   Saud, LRD
   Vezozzo, DP
   Costa, TDA
   Maccali, C
   Pinto, PVA
   Horvat, N
   Carrilho, FJ
AF Camargo, Cinira Cintra
   Chagas, Aline
   De Souza Mel Alencar, Regiane Saraiva
   Tani, Claudia Megumi
   Da Cunha Saud, Lisa Rodrigues
   Vezozzo, Denise Paranagua
   Almeida Costa, Thaisa De Fatima
   Maccali, Claudia
   Alves Pinto, Paulo Victor
   Horvat, Natally
   Carrilho, Flair J.
TI SOCIODEMOGRAPHIC CHARACTERISTICS OF PATIENTS THAT AFFECT THE ADHERENCE
   TO HEPATOCELLULAR CARCINOMA SCREENING
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 08-12, 2019
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Camargo, Cinira Cintra; Chagas, Aline; De Souza Mel Alencar, Regiane Saraiva; Tani, Claudia Megumi; Da Cunha Saud, Lisa Rodrigues; Almeida Costa, Thaisa De Fatima; Maccali, Claudia] Inst Canc Estado Sao Paulo, Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Vezozzo, Denise Paranagua] Hosp Clin Sao Paulo, Fac Med Estado Sao Paulo, Dept Gastroenterol, Div Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Alves Pinto, Paulo Victor; Horvat, Natally] FMUSP, Fac Med Sao Paulo, Inst Radiol, Radiol, Sao Paulo, Brazil.
   [Horvat, Natally] Hosp Sirio Libanes, Radiol, Sao Paulo, Brazil.
   [Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2019
VL 70
SU 1
MA 904
BP 556A
EP 557A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JB6CZ
UT WOS:000488653502054
DA 2020-12-08
ER

PT J
AU Recuero, AM
   Malta, F
   Stefano, JT
   Vezozzo, DP
   Gomes, LG
   Maciel, GAR
   Baracat, E
   Cassenote, AJF
   Pinho, JRR
   Carrilho, FJ
   Oliveira, CPMS
AF Recuero, Amanda Medeiros
   Malta, Fernanda
   Stefano, Jose Tadeu
   Vezozzo, Denise Paranagua
   Gomes, Larissa Garcia
   Rosa Maciel, Gustavo Arantes
   Baracat, Edmund
   Flores Cassenote, Alex Jones
   Pinho, Joao Renato R.
   Carrilho, Flair J.
   Oliveira, Claudia P. M. S.
TI PREVALENCE AND INFLUENCE OF "PATATIN-LIKE PHOSPHOLIPASE DOMAIN
   CONTAINING 3" (PNPLA3) GENE POLYMORPHISM ON SUSCEPTIBILITY TO
   NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH POLYCYSTIC OVARY
   SYNDROME
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 08-12, 2019
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Recuero, Amanda Medeiros] Hosp Clin Univ Sao Paulo, Sch Med, Div Gastroenterol & Hepatol, Sao Paulo, SP, Brazil.
   [Malta, Fernanda] Univ Sao Paulo, Sch Med, Lab Gastroenterol LIM 07, Inst Trop Med, Sao Paulo, SP, Brazil.
   [Stefano, Jose Tadeu] Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, SP, Brazil.
   [Vezozzo, Denise Paranagua; Flores Cassenote, Alex Jones] Hosp Clin Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, SP, Brazil.
   [Gomes, Larissa Garcia] Hosp Clin Univ Sao Paulo, Sch Med, Endocrinol, Sao Paulo, SP, Brazil.
   [Rosa Maciel, Gustavo Arantes; Baracat, Edmund] Hosp Clin Univ Sao Paulo, Sch Med, Gynecol, Sao Paulo, SP, Brazil.
   [Pinho, Joao Renato R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Carrilho, Flair J.; Oliveira, Claudia P. M. S.] Univ Sao Paulo, Sch Med, Div Clin Gastroenterol & Hepatol, Dept Gastroenterol, Sao Paulo, SP, Brazil.
RI Stefano, Jose Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2019
VL 70
SU 1
MA 1803
BP 1088A
EP 1088A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JB6CZ
UT WOS:000488653504076
DA 2020-12-08
ER

PT J
AU Pessoa, MG
   Candolo, ACR
   Zitelli, P
   Singer, JD
   Mazo, D
   Cunha-Silva, M
   Greca, RD
   Oliveira, CPMS
   Lima, RG
   Couto, CA
   Araujo, RC
   Farias, AQ
   Carrilho, FJ
AF Pessoa, Mario G.
   Rocha Candolo, Aline Coelho
   Zitelli, Patricia
   Singer, Julio Da Motta
   Mazo, Daniel
   Cunha-Silva, Marlone
   Greca, Raquel D.
   Oliveira, Claudia P. M. S.
   Lima, Roque G.
   Couto, Claudia A.
   Araujo, Roberta Chaves
   Farias, Alberto Q.
   Carrilho, Flair J.
TI THE IMPORTANCE OF LYSOSOMAL ACID LIPASE DEFICIENCY INVESTIGATION IN THE
   ETIOLOGICAL INVESTIGATION OF CHRONIC CRYPTOGENIC LIVER DISEASES
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 08-12, 2019
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Pessoa, Mario G.] Univ Sao Paulo, Div Gastroenterol & Hepatol, Sch Med, Sao Paulo, Brazil.
   [Rocha Candolo, Aline Coelho; Zitelli, Patricia; Mazo, Daniel; Carrilho, Flair J.] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Div Clin Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Singer, Julio Da Motta] Univ Sao Paulo, Inst Math & Stat, Sao Paulo, Brazil.
   [Mazo, Daniel; Cunha-Silva, Marlone; Greca, Raquel D.] Univ Estadual Campinas, Div Gastroenterol Gastroctr, Campinas, SP, Brazil.
   [Oliveira, Claudia P. M. S.] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Oliveira, Claudia P. M. S.] Univ Sao Paulo, Dept Pathol, Sch Med, Sao Paulo, Brazil.
   [Lima, Roque G.] Univ Sao Paulo, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Couto, Claudia A.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Araujo, Roberta Chaves] Fac Med Ribeirao Preto, Hosp Clin, Div Gastroenterol, Ribeirao Preto, Brazil.
   [Farias, Alberto Q.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Mazo, Daniel FC/D-5631-2015; Couto, Claudia Alves/H-7420-2013; Oliveira,
   Claudia PMS/D-1216-2014; Farias, Alberto/ABB-1291-2020
OI Mazo, Daniel FC/0000-0002-2164-2630; Couto, Claudia
   Alves/0000-0002-9776-4757; Farias, Alberto/0000-0002-5572-663X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2019
VL 70
SU 1
MA 1966
BP 1174A
EP 1175A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JB6CZ
UT WOS:000488653504239
DA 2020-12-08
ER

PT J
AU Shah, ND
   Ventura-Cots, M
   Abraldes, JG
   Alboraie, M
   Alfadhli, A
   Argemi, J
   Badia-Aranda, E
   Arus-Soler, E
   Barritt, AS
   Bessone, F
   Biryukova, M
   Carrilho, FJ
   Fernandez, MC
   Guiridi, ZD
   El Kassas, M
   Eng-Kiong, T
   Farias, AQ
   George, J
   Gui, WF
   Thurairajah, PH
   Hsiang, JC
   Husic-Selimovic, A
   Isakov, V
   Karoney, M
   Kim, W
   Kluwe, J
   Kochhar, R
   Dhaka, N
   Costa, PM
   Pharm, MAN
   Ono, SK
   Reis, D
   Rodil, A
   Domech, CR
   Saez-Royuela, F
   Scheurich, C
   Siow, W
   Sivac-Burina, N
   Traquino, ESD
   Some, F
   Spreckic, S
   Tan, SY
   Vorobioff, J
   Wandera, A
   Wu, PB
   Yacoub, M
   Yang, L
   Yu, YJ
   Zahiragic, N
   Zhang, CQ
   Cortez-Pinto, H
   Bataller, R
AF Shah, Neil D.
   Ventura-Cots, Meritxell
   Abraldes, Juan G.
   Alboraie, Mohamed
   Alfadhli, Ahmad
   Argemi, Josepmaria
   Badia-Aranda, Ester
   Arus-Soler, Enrique
   Barritt, A. Sidney
   Bessone, Fernando
   Biryukova, Marina
   Carrilho, Flair J.
   Castellanos Fernandez, Marlen
   Guiridi, Zaily Dorta
   El Kassas, Mohamed
   Eng-Kiong, Teo
   Farias, Alberto Queiroz
   George, Jacob
   Gui, Wenfang
   Thurairajah, Prem H.
   Hsiang, John Chen
   Husic-Selimovic, Azra
   Isakov, Vasily
   Karoney, Mercy
   Kim, Won
   Kluwe, Johannes
   Kochhar, Rakesh
   Dhaka, Narendra
   Costa, Pedro Marques
   Nabeshima Pharm, Mariana A.
   Ono, Suzane K.
   Reis, Daniela
   Rodil, Agustina
   Ruenes Domech, Caridad
   Saez-Royuela, Federico
   Scheurich, Christoph
   Siow, Way
   Sivac-Burina, Nadja
   dos Santos Traquino, Edna Solange
   Some, Fatma
   Spreckic, Sanjin
   Tan, Shiyun
   Vorobioff, Julio
   Wandera, Andrew
   Wu, Pengbo
   Yacoub, Mohamed
   Yang, Ling
   Yu, Yuanjie
   Zahiragic, Nerma
   Zhang, Chaoqun
   Cortez-Pinto, Helena
   Bataller, Ramon
TI Alcohol-Related Liver Disease Is Rarely Detected at Early Stages
   Compared With Liver Diseases of Other Etiologies Worldwide
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE NAFLD; Mortality; Cirrhosis
ID USE DISORDERS; GUIDELINES; CIRRHOSIS; PREDICTS; WEIGHT; RISK
AB BACKGROUND & AIMS: Despite recent advances in treatment of viral hepatitis, liver-related mortality is high, possibly owing to the large burden of advanced alcohol-related liver disease (ALD). We investigated whether patients with ALD are initially seen at later stages of disease development than patients with hepatitis C virus (HCV) infection or other etiologies.
   METHODS: We performed a cross-sectional study of 3453 consecutive patients with either early or advanced liver disease (1699 patients with early and 1754 with advanced liver disease) seen at 17 tertiary care liver or gastrointestinal units worldwide, from August 2015 through March 2017. We collected anthropometric, etiology, and clinical information, as well as and model for end-stage liver disease scores. We used unconditional logistic regression to estimate the odds ratios for evaluation at late stages of the disease progression.
   RESULTS: Of the patients analyzed, 81% had 1 etiology of liver disease and 17% had 2 etiologies of liver disease. Of patients seen at early stages for a single etiology, 31% had HCV infection, 21% had hepatitis B virus infection, and 17% had nonalcoholic fatty liver disease, whereas only 3.8% had ALD. In contrast, 29% of patients seen for advanced disease had ALD. Patients with ALD were more likely to be seen at specialized centers, with advanced-stage disease, compared with patients with HCV-associated liver disease (odds ratio, 14.1; 95% CI, 10.5-18.9; P < .001). Of patients with 2 etiologies of liver disease, excess alcohol use was associated with 50% of cases. These patients had significantly more visits to health care providers, with more advanced disease, compared with patients without excess alcohol use. The mean model for end-stage liver disease score for patients with advanced ALD (score, 16) was higher than for patients with advanced liver disease not associated with excess alcohol use (score, 13) (P < .01).
   CONCLUSIONS: In a cross-sectional analysis of patients with liver disease worldwide, we found that patients with ALD are seen with more advanced-stage disease than patients with HCV-associated liver disease. Of patients with 2 etiologies of liver disease, excess alcohol use was associated with 50% of cases. Early detection and referral programs are needed for patients with ALD worldwide.
C1 [Shah, Neil D.; Barritt, A. Sidney; Bataller, Ramon] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA.
   [Shah, Neil D.; Barritt, A. Sidney; Bataller, Ramon] Univ N Carolina, Dept Nutr, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA.
   [Ventura-Cots, Meritxell; Argemi, Josepmaria; Bataller, Ramon] Univ Pittsburgh, Dept Med, Pittsburgh Liver Res Ctr, Div Gastroenterol Hepatol & Nutr,Ctr Liver Dis, Pittsburgh, PA USA.
   [Ventura-Cots, Meritxell] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Abraldes, Juan G.] Univ Alberta, CEGIIR, Cirrhosis Care Clin, Div Gastroenterol,Liver Unit, Edmonton, AB, Canada.
   [Alboraie, Mohamed; Alfadhli, Ahmad] Mubarak Al Kabeer Hosp, Haya Al Habeeb Gastroenterol Ctr, Jabriya, Kuwait.
   [Alboraie, Mohamed] Al Azhar Univ, Dept Internal Med, Cairo, Egypt.
   [Argemi, Josepmaria] Clin Univ Navarra, Liver Unit, Pamplona, Spain.
   [Badia-Aranda, Ester; Saez-Royuela, Federico] Hosp Univ Burgos, Liver Unit, Gastroenterol Dept, Burgos, Spain.
   [Arus-Soler, Enrique; Castellanos Fernandez, Marlen; Ruenes Domech, Caridad; dos Santos Traquino, Edna Solange] Inst Gastroenterol, Dept Hepatol, Havana, Cuba.
   [Bessone, Fernando; Vorobioff, Julio] Univ Rosario, Sch Med, Dept Gastroenterol & Hepatol, Rosario, Argentina.
   [Biryukova, Marina; Guiridi, Zaily Dorta; Isakov, Vasily] Fed Res Ctr Nutr Biotechnol & Food Safety, Dept Gastroenterol & Hepatol, Moscow, Russia.
   [Carrilho, Flair J.; Farias, Alberto Queiroz; Nabeshima Pharm, Mariana A.; Ono, Suzane K.; Rodil, Agustina] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [El Kassas, Mohamed] Helwan Univ, Fac Med, Endem Med Dept, Cairo, Egypt.
   [Eng-Kiong, Teo; Thurairajah, Prem H.; Hsiang, John Chen] Changi Gen Hosp, Dept Gastroenterol & Hepatol, Singapore, Singapore.
   [George, Jacob; Siow, Way] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Storr Liver Ctr, Westmead, NSW, Australia.
   [Gui, Wenfang; Yang, Ling] Huazhong Univ Sci & Technol, Union Hosp, Div Gastroenterol, Wuhan, Hubei, Peoples R China.
   [Husic-Selimovic, Azra; Sivac-Burina, Nadja; Spreckic, Sanjin; Zahiragic, Nerma] Univ Hosp Sarajevo, Inst Gastroenterol, Dept Hepatol, Sarajevo, Bosnia & Herceg.
   [Karoney, Mercy; Some, Fatma; Wandera, Andrew] Moi Univ, Coll Hlth Sci, Sch Med, Dept Med, Eldoret, Kenya.
   [Kim, Won] Seoul Natl Univ, Div Gastroenterol & Hepatol, Seoul Metropolitan Govt, Boramae Med Ctr,Dept Internal Med,Coll Med, Seoul, South Korea.
   [Kluwe, Johannes; Scheurich, Christoph] Univ Med Ctr, Dept Gastroenterol & Hepatol, Hamburg, Germany.
   [Kochhar, Rakesh; Dhaka, Narendra] Postgrad Inst Med Educ & Res, Dept Gastroenterol, Chandigarh, India.
   [Costa, Pedro Marques; Reis, Daniela; Cortez-Pinto, Helena] Univ Lisbon, Ctr Hosp Lisboa Norte, Dept Gastrenterol & Hepatol, Lab Nutr,Fac Med, Lisbon, Portugal.
   [Tan, Shiyun; Wu, Pengbo; Yu, Yuanjie; Zhang, Chaoqun] Wuhan Univ, Renmin Hosp, Dept Gastoenterol, Wuhan, Hubei, Peoples R China.
   [Yacoub, Mohamed] Natl Hepatol & Trop Med Res Inst, Hepatol Dept, Cairo, Egypt.
RP Bataller, R (corresponding author), Univ Pittsburgh, Med Ctr, Pittsburgh Liver Res Ctr, Dept Med,Div Gastroenterol Hepatol & Nutr, 200 Lothrop St,BSTW Suite 1116, Pittsburgh, PA 15261 USA.
EM bataller@pitt.edu
RI Cortez-Pinto, Helena/A-3586-2012; Farias, Alberto/ABB-1291-2020; Kassas,
   Mohamed El/AAD-6987-2020; Kim, Won/H-6940-2019; Argemi,
   Josepmaria/AAD-1964-2020; Cortez-Pinto, Helena/AAN-2712-2020;
   /A-4876-2011
OI Farias, Alberto/0000-0002-5572-663X; Kassas, Mohamed
   El/0000-0002-3396-6894; Kim, Won/0000-0002-2926-1007; Argemi,
   Josepmaria/0000-0003-1696-7753; Cortez-Pinto,
   Helena/0000-0002-8537-8744; /0000-0002-4417-8076; Bataller,
   Ramon/0000-0002-1119-7799; Karoney, Mercy/0000-0003-0557-4188;
   Gonzalez-Abraldes, Juan/0000-0003-3421-937X; Badia Aranda,
   Ester/0000-0001-8774-0041; Ventura-Cots, Meritxell/0000-0001-9513-2855
FU National Institute of Alcohol Abuse and AlcoholismUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
   [U01AA021908, U01AA020821]; Spanish Association for the Study of the
   Liver; National Natural Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [NSFC 81570530, 81370550]; NATIONAL
   INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA) [U01AA020821,
   U01AA021908, U01AA021908] Funding Source: NIH RePORTER
FX This study was funded by the National Institute of Alcohol Abuse and
   Alcoholism grants U01AA021908 and U01AA020821, a scholarship grant from
   the Spanish Association for the Study of the Liver (M. V.-C.), and a
   grants NSFC 81570530 and 81370550 from the National Natural Science
   Foundation of China (L. Y.).
CR Addolorato G, 2016, J HEPATOL, V65, P618, DOI 10.1016/j.jhep.2016.04.029
   Banini BA, 2017, AM J GASTROENTEROL, V112, P821, DOI [10.1038/ajg.2017.187, 10.1038/ajg.2017.83]
   Chung RT, 2015, HEPATOLOGY, V62, P932, DOI 10.1002/hep.27950
   de Franchis R, 2015, J HEPATOL, V63, P743, DOI 10.1016/j.jhep.2015.05.022
   GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124
   Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X
   Huang Y, 2014, J HEPATOL, V61, P22, DOI 10.1016/j.jhep.2014.02.031
   Kim WR, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14126
   Mathurin P, 2012, J HEPATOL, V57, P399, DOI 10.1016/j.jhep.2012.04.004
   Ndugga N, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013620
   Rinella ME, 2015, JAMA-J AM MED ASSOC, V313, P2263, DOI 10.1001/jama.2015.5370
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Shoreibah M, 2016, ANN HEPATOL, V15, P183, DOI 10.5604/16652681.1193707
   Stein E, 2016, J HEPATOL, V65, P998, DOI 10.1016/j.jhep.2016.06.018
   Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156
   Thiele M, 2016, GASTROENTEROLOGY, V150, P123, DOI 10.1053/j.gastro.2015.09.040
   Westwood G, 2017, J HEPATOL, V67, P559, DOI 10.1016/j.jhep.2017.04.017
   World Health Organization, 2018, GLOB STAT REP ALC HL
NR 18
TC 11
Z9 11
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD OCT
PY 2019
VL 17
IS 11
BP 2320
EP +
DI 10.1016/j.cgh.2019.01.026
PG 22
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA IY8FL
UT WOS:000486630000033
PM 30708110
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Chagas, AL
   Felga, GEG
   Diniz, MA
   Silva, RF
   Mattos, AA
   Silva, RCMA
   Boin, IFSF
   Garcia, JHP
   Lima, AS
   Coelho, JCU
   Bittencourt, PL
   Alves, VAF
   D'Albuquerque, LAC
   Carrilho, FJ
   Chagas, M
   Kikuchi, LOO
   D'Aibuquerque, LAC
   Carrilho, FJ
   Felga, GEG
   de Almeida, MD
   da Silva, RDMA
   da Silva, RF
   Possato, MB
   Boin, IDSF
   Zanotelli, ML
   Ferreira, GDA
   Coelho, JCU
   Costa, PEG
   Garcia, JHP
   Reichert, P
   Bittencourt, PL
   Baia, CES
   Terrabuio, DRB
   Foinquinos, G
   de Carvalho, SCR
   Pereira, LMMB
   de Moraes, ACP
   Watanabe, ALC
   Lima, AS
   de Mattos, AA
AF Chagas, Aline L.
   Felga, Guilherme E. G.
   Diniz, Marcio A.
   Silva, Renato F.
   Mattos, Angelo A.
   Silva, Rita C. M. A.
   Boin, Ilka F. S. F.
   Garcia, Jose H. P.
   Lima, Agnaldo S.
   Coelho, Julio C. U.
   Bittencourt, Paulo L.
   Alves, Venancio A. F.
   D'Albuquerque, Luiz A. C.
   Carrilho, Flair J.
   Chagas, Mine
   Onishi Kikuchi, Luciana Oba
   Carneiro D'Aibuquerque, Luiz Augusto
   Carrilho, Flair Jose
   Goncalves Felga, Guilherme Eduardo
   de Almeida, Marcio Dias
   Martins Alves da Silva, Rita de Cassia
   da Silva, Renato Ferreira
   Possato, Mariana Bina
   Santana Ferreira Boin, Ilka de Fatima
   Zanotelli, Maria Lucia
   Arantes Ferreira, Gustavo de Sousa
   Uili Coelho, Julio Cezar
   Garcia Costa, Paulo Everton
   Parente Garcia, Jose Huygens
   Reichert, Paulo
   Lisboa Bittencourt, Paulo
   Sandoli Baia, Carlos Eduardo
   Benedita Terrabuio, Debora Raquel
   Foinquinos, Gabriela
   Rampche de Carvalho, Sylene Coutinho
   Moreira Beltrao Pereira, Leila Maria
   Pereira de Moraes, Adriano Claudio
   Conde Watanabe, Andre Luis
   Lima, Agnaldo Soares
   de Mattos, Angelo Alves
CA Brazilian HCC Study Grp
TI Hepatocellular carcinoma recurrence after liver transplantation in a
   Brazilian multicenter study: clinical profile and prognostic factors of
   survival
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
DE hepatocellular carcinoma; liver neoplasms; liver transplantation;
   recurrence; relapse; survival analysis
ID RESECTION; OUTCOMES; MODEL
AB Background Liver transplantation (LT) is the treatment of choice for patients with unresectable early hepatocellular carcinoma (HCC). Post-LT HCC recurrence rates range from 8 to 20% and still impact on overall survival (OS). The aim of our study was to evaluate the impact of HCC recurrence on post-LT survival and analyze prognostic factors among those patients with recurrence. Patients and methods We carried out a national, multicenter, retrospective cohort study in Brazil. Medical records of 1119 LT recipients with HCC were collected. Data from patients with post-LT HCC recurrence were analyzed and correlated with post-relapse survival. Results OS of the 1119 patients included in the study was 63% over 5 years. Post-LT HCC recurrence occurred in 86 (8%) patients. The mean time to recurrence was 12 months. Sites of recurrence were extrahepatic in 55%, hepatic in 27%, and both hepatic and extrahepatic in 18%. Recurrence treatment was performed in 50 (64%) cases, mostly with sorafenib. Post-relapse survival rates were 34% at 1 year and 13% at 5 years. Univariable analysis identified alpha-fetoprotein more than 1000 ng/ml at relapse, recurrence treatment, extrahepatic location, and time to recurrence more than 2 years as prognostic factors. In multivariable analysis, recurrence treatment, extrahepatic location, and time to recurrence more than 2 years were independent predictors of better survival. Conclusion In a large Brazilian cohort of LT recipients with HCC, post-LT HCC recurrence occurred in 8% and impacted significantly on the OS. Patients with early recurrence presented a worse prognosis. However, treatment of recurrence improved outcomes, highlighting the importance of early diagnosis.
C1 [Chagas, Aline L.; Diniz, Marcio A.; D'Albuquerque, Luiz A. C.; Carrilho, Flair J.] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Dept Pathol, Sch Med, Sao Paulo, Brazil.
   [Chagas, Aline L.; Alves, Venancio A. F.; D'Albuquerque, Luiz A. C.; Carrilho, Flair J.] Hosp Israelita Albert Einstein, Sao Paulo Clin Liver Canc Grp, Sao Paulo, Brazil.
   [Felga, Guilherme E. G.; Goncalves Felga, Guilherme Eduardo; de Almeida, Marcio Dias] Hosp Israelita Albert Einstein, Liver Transplantat Unit, Sao Paulo, Brazil.
   [Silva, Renato F.; Silva, Rita C. M. A.] Hosp Base FUNFARME, Fac Med Sao Jose do Rio Preto, Serv Gastroenterol, Sao Jose Do Rio Preto, Brazil.
   [Silva, Renato F.; Silva, Rita C. M. A.] Hosp Base FUNFARME, Fac Med Sao Jose do Rio Preto, Unidade Transplante Figado, Sao Jose Do Rio Preto, Brazil.
   [Mattos, Angelo A.] Fundacao Univ Fed Ciencias Saude Porto Alegre, Dept Gastroenterol, Porto Alegre, RS, Brazil.
   [Boin, Ilka F. S. F.] Univ Estadual Campinas, Unit Liver Transplantat, Campinas, SP, Brazil.
   [Garcia, Jose H. P.] Univ Fed Ceara, Dept Surg & Liver Transplantat, Ceara Unit Liver Transplantat, Fortaleza, Ceara, Brazil.
   [Lima, Agnaldo S.; Lima, Agnaldo Soares] Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil.
   [Coelho, Julio C. U.] Univ Fed Parana, Surg Dept, Curitiba, Parana, Brazil.
   [Bittencourt, Paulo L.] Portuguese Hosp Salvador, Unit Gastroenterol & Hepatol, Salvador, BA, Brazil.
   Cedars Sinai Med Ctr, Biostat & Bioinformat Res Ctr, Los Angeles, CA 90048 USA.
   [Chagas, Aline L.; Onishi Kikuchi, Luciana Oba; Carneiro D'Aibuquerque, Luiz Augusto; Carrilho, Flair Jose] Univ Sao Paulo, Hosp Clin, Sch Med, Dept Gastroenterol,Div Clin Gastroenterol & Hepat, BR-05403000 Sao Paulo, Brazil.
   [Chagas, Aline L.; Onishi Kikuchi, Luciana Oba; Carneiro D'Aibuquerque, Luiz Augusto; Carrilho, Flair Jose] Univ Sao Paulo, Hosp Clin, Sch Med, Dept Gastroenterol,Div Digest Organs Transplantat, Sao Paulo, Brazil.
   [Martins Alves da Silva, Rita de Cassia; da Silva, Renato Ferreira] Hosp Base FUNFARME, Sch Med Sao Jose do Rio Preto, Gastroenterol Div, Sao Jose Do Rio Preto, Brazil.
   [Martins Alves da Silva, Rita de Cassia; da Silva, Renato Ferreira] Hosp Base FUNFARME, Sch Med Sao Jose do Rio Preto, Liver Transplantat Unit, Sao Jose Do Rio Preto, Brazil.
   [Possato, Mariana Bina; Santana Ferreira Boin, Ilka de Fatima] Univ Estadual Campinas, Dept Digest Surg, Campinas, SP, Brazil.
   [Possato, Mariana Bina; Santana Ferreira Boin, Ilka de Fatima] Univ Hosp Campinas, Campinas, SP, Brazil.
   [Zanotelli, Maria Lucia] Santa Casa de Misericordia Porto Alegre, Liver Transplantat Unit, Porto Alegre, RS, Brazil.
   [Arantes Ferreira, Gustavo de Sousa; Uili Coelho, Julio Cezar] Univ Fed Parana, Univ Hosp, Curitiba, Parana, Brazil.
   [Garcia Costa, Paulo Everton; Parente Garcia, Jose Huygens] Univ Fed Ceara, Dept Surg & Liver Transplantat, Liver Transplantat Unit Ceara, Fortaleza, Ceara, Brazil.
   [Reichert, Paulo] Hosp Sao Vicente de Paulo, Passo Fundo, Brazil.
   [Lisboa Bittencourt, Paulo] Hosp Portugues Bahia, Salvador, BA, Brazil.
   [Sandoli Baia, Carlos Eduardo; Benedita Terrabuio, Debora Raquel] Hosp Transplantes Estado Sao Paulo Euryclides Jes, Sao Paulo, Brazil.
   [Foinquinos, Gabriela; Rampche de Carvalho, Sylene Coutinho; Moreira Beltrao Pereira, Leila Maria] Inst Figado Pernambuco, Recife, PE, Brazil.
   [Pereira de Moraes, Adriano Claudio; Conde Watanabe, Andre Luis] Inst Cardiol Dist Fed, Liver Transplantat Unit, Brasilia, DF, Brazil.
   [de Mattos, Angelo Alves] Fed Univ Hlth Sci Porto Alegre, Dept Gastroenterol, Porto Alegre, RS, Brazil.
RP Chagas, AL (corresponding author), Univ Sao Paulo, Hosp Clin, Sch Med, Dept Gastroenterol,Div Clin Gastroenterol & Hepat, BR-05403000 Sao Paulo, Brazil.
EM alinelchages@gmail.com
RI Lima, Agnaldo S/F-7452-2011; D'Albuquerque, Luiz Augusto
   Carneiro/A-8812-2013; BITTENCOURT, PAULO l/I-5817-2014
OI Lima, Agnaldo S/0000-0001-6421-3062; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; BITTENCOURT, PAULO l/0000-0003-0883-4870
CR Adam R, 2012, J HEPATOL, V57, P675, DOI 10.1016/j.jhep.2012.04.015
   Agopian VG, 2015, J AM COLL SURGEONS, V220, P416, DOI 10.1016/j.jamcollsurg.2014.12.025
   Bhoori S, 2014, BEST PRACT RES CL GA, V28, P867, DOI 10.1016/j.bpg.2014.08.001
   BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005
   Bodzin AS, 2017, ANN SURG, V266, P118, DOI 10.1097/SLA.0000000000001894
   Bruix J, 2016, GASTROENTEROLOGY, V150, P835, DOI 10.1053/j.gastro.2015.12.041
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Clavien PA, 2012, LANCET ONCOL, V13, pE11, DOI 10.1016/S1470-2045(11)70175-9
   Cox D. R., 1992, BREAKTHROUGHS STAT, P527, DOI DOI 10.1007/978-1-4612-4380-9_37
   de'Angelis N, 2015, WORLD J GASTROENTERO, V21, P11185, DOI 10.3748/wjg.v21.i39.11185
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fernandez-Sevilla E, 2017, LIVER TRANSPLANT, V23, P440, DOI 10.1002/lt.24742
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   Hollebecque A, 2009, GASTROEN CLIN BIOL, V33, P361, DOI 10.1016/j.gcb.2009.02.036
   Irtan S, 2016, HEPATOB PANCREAT DIS, V15, P147, DOI 10.1016/S1499-3872(16)60069-3
   IWATSUKI S, 1991, ANN SURG, V214, P221, DOI 10.1097/00000658-199109000-00005
   Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   MORENO P, 1995, TRANSPLANT P, V27, P2296
   Na GH, 2016, WORLD J GASTROENTERO, V22, P5790, DOI 10.3748/wjg.v22.i25.5790
   Nagai S, 2015, CLIN TRANSPLANT, V29, P1156, DOI 10.1111/ctr.12644
   Pinero F, 2016, LIVER INT, V36, P1657, DOI 10.1111/liv.13159
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   Rahimi RS, 2015, ANN GASTROENTEROL, V28, P323
   RINGE B, 1991, WORLD J SURG, V15, P270, DOI 10.1007/BF01659064
   Roayaie S, 2004, LIVER TRANSPLANT, V10, P534, DOI 10.1002/lt.20128
   Roberts JP, 2005, LIVER TRANSPLANT, V11, pS45, DOI 10.1002/lt.20605
   Sapisochin G, 2015, ANN SURG ONCOL, V22, P2286, DOI 10.1245/s10434-014-4273-6
   Sapisochin G, 2017, NAT REV GASTRO HEPAT, V14, P203, DOI 10.1038/nrgastro.2016.193
   SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239
   Schwartz M, 2005, J HEPATOL, V43, P584, DOI 10.1016/j.jhep.2005.07.019
   Team RC, 2016, R LANG DEF
   Zimmerman MA, 2008, ARCH SURG-CHICAGO, V143, P182, DOI 10.1001/archsurg.2007.39
NR 33
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0954-691X
EI 1473-5687
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD SEP
PY 2019
VL 31
IS 9
BP 1148
EP 1156
DI 10.1097/MEG.0000000000001448
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JI6BV
UT WOS:000493552900012
PM 31247632
OA Other Gold, Green Published
DA 2020-12-08
ER

PT J
AU Baiges, A
   Turon, F
   Simon-Talero, M
   Tasayco, S
   Bueno, J
   Zekrini, K
   Plessier, A
   Franchi-Abella, S
   Guerin, F
   Mukund, A
   Eapen, CE
   Goel, A
   Shyamkumar, NK
   Coenen, S
   De Gottardi, A
   Majumdar, A
   Onali, S
   Shukla, A
   Carrilho, FJ
   Nacif, L
   Primignani, M
   Tosetti, G
   La Mura, V
   Nevens, F
   Witters, P
   Tripathi, D
   Tellez, L
   Martinez, J
   Alvarez-Navascues, C
   Fraile Lopez, ML
   Procopet, B
   Piscaglia, F
   de Koning, B
   Llop, E
   Romero-Cristobal, M
   Tjwa, E
   Monescillo-Francia, A
   Senzolo, M
   Perez-LaFuente, M
   Segarra, A
   Sarin, SK
   Hernandez-Gea, V
   Patch, D
   Laleman, W
   Hartog, H
   Valla, D
   Genesca, J
   Garcia-Pagan, JC
   Garcia-Criado, A
   Darnell, A
   Belmonte, E
   Ferrusquia-Acosta, J
   Magaz, M
   Vidal-Gonzalez, J
   Horia, S
   Nicoara-Farcau, O
   Joseph, P
   Zachariah, U
   Moses, V
   Mammen, S
   Ahmed, M
   Koshy, G
   Eapen, A
   Sajith, KG
   Vyas, FL
   Raju, RS
   Rymbai, ML
   Arulkumar, S
   Ramachandran, J
   Elias, E
AF Baiges, Anna
   Turon, Fanny
   Simon-Talero, Macarena
   Tasayco, Stephanie
   Bueno, Javier
   Zekrini, Kamal
   Plessier, Aurelie
   Franchi-Abella, Stephanie
   Guerin, Florent
   Mukund, Amar
   Eapen, C. E.
   Goel, Ashish
   Shyamkumar, Nidugala Keshava
   Coenen, Sandra
   De Gottardi, Andrea
   Majumdar, Avik
   Onali, Simona
   Shukla, Akash
   Jose Carrilho, Flair
   Nacif, Lucas
   Primignani, Massimo
   Tosetti, Giulia
   La Mura, Vicenzo
   Nevens, Frederik
   Witters, Peter
   Tripathi, Dhiraj
   Tellez, Luis
   Martinez, Javier
   Alvarez-Navascues, Carmen
   Fraile Lopez, Miguel Lopez
   Procopet, Bogdan
   Piscaglia, Fabio
   de Koning, Barbara
   Llop, Elba
   Romero-Cristobal, Mario
   Tjwa, Eric
   Monescillo-Francia, Alberto
   Senzolo, Marco
   Perez-LaFuente, Mercedes
   Segarra, Antonio
   Sarin, Shiv Kumar
   Hernandez-Gea, Virginia
   Patch, David
   Laleman, Wim
   Hartog, Hermien
   Valla, Dominique
   Genesca, Joan
   Carlos Garcia-Pagan, Juan
   Garcia-Criado, Angeles
   Darnell, Anna
   Belmonte, Ernest
   Ferrusquia-Acosta, Jose
   Magaz, Marta
   Vidal-Gonzalez, Judit
   Horia, Stefanescu
   Nicoara-Farcau, Oana
   Joseph, Philip
   Zachariah, Uday
   Moses, Vinu
   Mammen, Suraj
   Ahmed, Munawwar
   Koshy, George
   Eapen, Anu
   Sajith, K. G.
   Vyas, F. L.
   Raju, R. S.
   Rymbai, Manbha L.
   Arulkumar, S.
   Ramachandran, Jeyamani
   Elias, Elwyn
CA REHEVASC VALDIG EASL Consortium
   Abernethy Grp
TI Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation):
   An International Observational Study
SO HEPATOLOGY
LA English
DT Article
ID CLASSIFICATION; LIVER; HYPERTENSION; MANAGEMENT
AB Congenital extrahepatic portosystemic shunt (CEPS) or Abernethy malformation is a rare condition in which splanchnic venous blood bypasses the liver draining directly into systemic circulation through a congenital shunt. Patients may develop hepatic encephalopathy (HE), pulmonary hypertension (PaHT), or liver tumors, among other complications. However, the actual incidence of such complications is unknown, mainly because of the lack of a protocolized approach to these patients. This study characterizes the clinical manifestations and outcome of a large cohort of CEPS patients with the aim of proposing a guide for their management. This is an observational, multicenter, international study. Sixty-six patients were included; median age at the end of follow-up was 30 years. Nineteen patients (28%) presented HE. Ten-, 20-, and 30-year HE incidence rates were 13%, 24%, and 28%, respectively. No clinical factors predicted HE. Twenty-five patients had benign nodular lesions. Ten patients developed adenomas (median age, 18 years), and another 8 developed HCC (median age, 39 years). Of 10 patients with dyspnea, PaHT was diagnosed in 8 and hepatopulmonary syndrome in 2. Pulmonary complications were only screened for in 19 asymptomatic patients, and PaHT was identified in 2. Six patients underwent liver transplantation for hepatocellular carcinoma or adenoma. Shunt closure was performed in 15 patients with improvement/stability/cure of CEPS manifestations. Conclusion: CEPS patients may develop severe complications. Screening for asymptomatic complications and close surveillance is needed. Shunt closure should be considered both as a therapeutic and prophylactic approach.
C1 [Baiges, Anna; Turon, Fanny; Hernandez-Gea, Virginia; Carlos Garcia-Pagan, Juan] Univ Barcelona, Hosp Clin Barcelona, Barcelona Hepat Hemodynam Lab, Liver Unit,IDIBAPS,CIBERehd, Barcelona, Spain.
   [Simon-Talero, Macarena; Tasayco, Stephanie; Genesca, Joan] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Internal Med, Liver Unit,VHIR,CIBERehd, Barcelona, Spain.
   [Bueno, Javier] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Pediat Surg Dept, Barcelona, Spain.
   [Zekrini, Kamal; Plessier, Aurelie; Valla, Dominique] Hop Beaujon, AP HP, DHU Unity,Pole Malad Appareil Digestif, Ctr Reference Malad Vasculaires Foie,Serv Hepatol, Clichy, France.
   [Franchi-Abella, Stephanie; Guerin, Florent] Hop Bicetre, Grp Hosp Paris Sud GHUPS, Serv Hepatol & Transplantat Hepat & radiol Pediat, Le Kremlin Bicetre, France.
   [Mukund, Amar] Inst Liver & Biliary Sci, Dept Radiol, New Delhi, India.
   [Eapen, C. E.; Goel, Ashish] Christian Med Coll & Hosp, Hepatol Dept, Vellore, Tamil Nadu, India.
   [Shyamkumar, Nidugala Keshava] Christian Med Coll & Hosp, Dept Radiol, Vellore, Tamil Nadu, India.
   [Coenen, Sandra; Hartog, Hermien] Erasmus MC, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
   [De Gottardi, Andrea] Univ Bern, Inselspital, Clin Visceral Surg & Med, Hepatol, Bern, Switzerland.
   [De Gottardi, Andrea] Univ Bern, Dept Clin Res, Bern, Switzerland.
   [Majumdar, Avik; Onali, Simona; Patch, David] Royal Free Hosp, Sheila Sherlock Liver Unit, London, England.
   [Majumdar, Avik; Onali, Simona; Patch, David] Royal Free Hosp, UCL Inst Liver & Digest Hlth, London, England.
   [Majumdar, Avik; Onali, Simona; Patch, David] UCL, London, England.
   [Shukla, Akash] Seth GS Med Coll & KEM Hosp, Dept Gastroenterol, Mumbai, Maharashtra, India.
   [Jose Carrilho, Flair; Nacif, Lucas] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Digest Organ Transplantat Div, Sao Paulo, Brazil.
   [Primignani, Massimo; Tosetti, Giulia; La Mura, Vicenzo] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, AM & A Migliavacca Ctr Liver Dis, Milan, Italy.
   [La Mura, Vicenzo; Laleman, Wim] Osped Maggiore Policlin, UOC Med Gen Emostasi & Trombosi, Fdn IRCCS Ca Granda, Milan, Italy.
   [Nevens, Frederik; Witters, Peter] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium.
   [Tripathi, Dhiraj] Queen Elisabeth Hosp, Liver Unit, Birmingham, W Midlands, England.
   [Tellez, Luis; Martinez, Javier] Univ Alcala De Henares, Hosp Univ Ramon & Cajal, Dept Gastroenterol & Hepatol, IRYCIS,CIBERedh, Madrid, Spain.
   [Alvarez-Navascues, Carmen; Fraile Lopez, Miguel Lopez] HUCA, Aparato Digestivo, Asturias, Spain.
   [Procopet, Bogdan] Univ Med & Pharm Iuliu Hatieganu, Reg Inst Gastroenterol & Hepatol O Fodor, Med Clin 3, Dept Gastroenterol, Cluj Napoca, Romania.
   [Piscaglia, Fabio] Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Unit Internal Med, Bologna, Italy.
   [de Koning, Barbara] Erasmus MC, Sophia Childrens Hosp, Div Pediat Gastroenterol, Rotterdam, Netherlands.
   [Llop, Elba] Univ Autonoma Madrid, Hosp U Puerta de Hierro, Liver Unit, Madrid, Spain.
   [Romero-Cristobal, Mario] Univ Complutense, Digest Dis & Ctr Invest Biomed Red Enfermedades H, Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon,Fac Med, Madrid, Spain.
   [Tjwa, Eric] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands.
   [Monescillo-Francia, Alberto] Complejo Hosp Univ Insular Materno Infant, Digest Dis Dept, Las Palmas Gran Canaria, Spain.
   [Senzolo, Marco] Padua Univ Hosp, Dept Surg Oncol & Gastroenterol, Multivisceral Transplant Unit, Padua, Italy.
   [Perez-LaFuente, Mercedes; Segarra, Antonio] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Intervent Radiol Unit, Barcelona, Spain.
   [Sarin, Shiv Kumar] Inst Liver & Biliary Sci, Dept Hepatol, New Delhi, India.
RP Garcia-Pagan, JC (corresponding author), Hosp Clin Barcelona, Barcelona Hepat Hemodynam Lab, Liver Unit, Villarroel 170, Barcelona 08036, Spain.
EM jcgarcia@clinic.cat
RI Mukund, Amar/AAE-3886-2020; Nacif, Lucas S./B-2795-2013; Procopet,
   Bogdan/AAD-9267-2019; LA MURA, VINCENZO/M-3949-2016; Bueno,
   Javier/N-7804-2018
OI Nacif, Lucas S./0000-0002-7059-3978; Procopet,
   Bogdan/0000-0001-8118-1760; Laleman, Wim/0000-0002-0842-7813; LA MURA,
   VINCENZO/0000-0003-4685-7184; Majumdar, Avik/0000-0003-2975-4327; Bueno,
   Javier/0000-0002-4424-6673
FU Ministry of Education and ScienceMinistry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT) [SAF-2016-75767-R]; Instituto de
   Salud Carlos III, FEDER "Una manera de hacer Europa" [PIE15/00027];
   Instituto de Salud Carlos IIIInstituto de Salud Carlos III; Asociacion
   Espanola para Estudio del Higado (AEEH); European Association for the
   Study of the Liver (EASL); Instituto de Salud Carlos III, SpainInstituto
   de Salud Carlos III [JR17/00029, PI15/00066, PI18/00947]; PFIS from
   Instituto de Salud Carlos III, SpainInstituto de Salud Carlos III
   [FI16/00238]; European Union (ERDF/ESF, "Investing in your
   future")European Union (EU)
FX Supported by the Ministry of Education and Science (SAF-2016-75767-R),
   and Instituto de Salud Carlos III (PIE15/00027), FEDER "Una manera de
   hacer Europa"). The Centro de Investigacion Biomedica en Red de
   Enfermedades Hepaticas y Digestivas (CIBERehd) is funded by the
   Instituto de Salud Carlos III. IDIBAPS CERCA Programme/Generalitat de
   Catalunya, Societat Catalana de Digestologia. REHEVASC is partially
   funded by Asociacion Espanola para Estudio del Higado (AEEH). VALDIG is
   supported by a grant from the European Association for the Study of the
   Liver (EASL). Macarena Simon-Talero is a recipient of a Juan Rodes grant
   (JR17/00029) from Instituto de Salud Carlos III, Spain. Stephanie
   Tasayco is a recipient of a PFIS grant (FI16/00238) from Instituto de
   Salud Carlos III, Spain. Joan Genesca is supported by Instituto de Salud
   Carlos III, Spain (Research Intensification grant, PI15/00066 and
   PI18/00947) and by the European Union (ERDF/ESF, "Investing in your
   future").
CR Akahoshi T, 2000, HEPATO-GASTROENTEROL, V47, P1113
   Amodio P, 2017, METAB BRAIN DIS, V32, P1287, DOI 10.1007/s11011-017-0032-2
   BAEK SM, 1976, ANN SURG, V183, P239, DOI 10.1097/00000658-197603000-00003
   Benedict M, 2017, PEDIATR DEVEL PATHOL, V20, P354, DOI 10.1177/1093526616686458
   Blanc T, 2014, ANN SURG, V260, P188, DOI 10.1097/SLA.0000000000000266
   Chocarro G, 2016, EUR J PEDIATR SURG, V26, P74, DOI 10.1055/s-0035-1566097
   Franchi-Abella S, 2018, ABDOM RADIOL, V43, P2023, DOI 10.1007/s00261-018-1619-8
   Franchi-Abella S, 2010, J PEDIATR GASTR NUTR, V51, P322, DOI 10.1097/MPG.0b013e3181d9cb92
   Francois B, 2017, EUR J PEDIATR, V176, P1613, DOI 10.1007/s00431-017-3013-x
   Fu LJ, 2016, EUR J PEDIATR, V175, P195, DOI 10.1007/s00431-015-2623-4
   Gitzelmann R, 1997, EUR J PEDIATR, V156, P719, DOI 10.1007/s004310050698
   Gong Y, 2015, PEDIATR RADIOL, V45, P1964, DOI 10.1007/s00247-015-3417-6
   Guerin F, 2012, SEMIN PEDIATR SURG, V21, P233, DOI 10.1053/j.sempedsurg.2012.05.006
   Gulsen Z, 2016, SURG RADIOL ANAT, V38, P373, DOI 10.1007/s00276-015-1460-5
   Howard ER, 1997, J PEDIATR SURG, V32, P494, DOI 10.1016/S0022-3468(97)90614-X
   Ikeda S, 1999, J PEDIATR SURG, V34, P1012, DOI 10.1016/S0022-3468(99)90780-7
   Kanazawa H, 2015, J PEDIATR SURG, V50, P688, DOI 10.1016/j.jpedsurg.2015.01.009
   Konstas AA, 2011, EUR J RADIOL, V80, P175, DOI 10.1016/j.ejrad.2009.12.031
   Lautz TB, 2011, J PEDIATR SURG, V46, P308, DOI 10.1016/j.jpedsurg.2010.11.009
   MORGAN G, 1994, J PEDIATR SURG, V29, P1239, DOI 10.1016/0022-3468(94)90812-5
   Morikawa N, 2008, J PEDIATR SURG, V43, DOI 10.1016/j.jpedsurg.2007.11.001
   Murray CP, 2003, PEDIATR RADIOL, V33, P614, DOI 10.1007/s00247-003-1002-x
   Nacif LS, 2015, BMC MED IMAGING, V15, DOI 10.1186/s12880-015-0079-7
   Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485
   Ohno T, 2008, PEDIATRICS, V121, pE892, DOI 10.1542/peds.2006-3411
   Ono H, 1998, ACTA PAEDIATR, V87, P631, DOI 10.1080/080352598750014021
   Sharma R, 2015, HEPATOB PANCREAT DIS, V14, P552, DOI 10.1016/s1499-3872(15)60418-0
   Sokollik C, 2013, J PEDIATR GASTR NUTR, V56, P675, DOI 10.1097/MPG.0b013e31828b3750
   Sorkin T, 2016, HUM PATHOL, V53, P153, DOI 10.1016/j.humpath.2016.02.025
   Stringer MD, 2008, CLIN ANAT, V21, P147, DOI 10.1002/ca.20574
   Uchino T, 1999, J PEDIATR-US, V135, P254, DOI 10.1016/S0022-3476(99)70031-4
   Vicente N, 2015, Cir Pediatr, V28, P67
   Witjes Caroline Dm, 2012, J Med Case Rep, V6, P167, DOI 10.1186/1752-1947-6-167
   Witters P, 2008, J GASTROEN HEPATOL, V23, pE390, DOI 10.1111/j.1440-1746.2007.05156.x
   Yi JE, 2014, J KOREAN MED SCI, V29, P604, DOI 10.3346/jkms.2014.29.4.604
   Yonemitsu H, 2000, ABDOM IMAGING, V25, P572, DOI 10.1007/s002610000044
NR 36
TC 9
Z9 9
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD FEB
PY 2020
VL 71
IS 2
BP 658
EP 669
DI 10.1002/hep.30817
EA AUG 2019
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LP3AA
UT WOS:000482168000001
PM 31211875
OA Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU Torrecilla, S
   Pinyol, R
   Wang, H
   Montironi, C
   Andreu-Oller, C
   Leow, WQ
   Moeini, A
   Oliveira, C
   Alves, VAF
   Lachenmayer, A
   Roessler, S
   Minguez, B
   Schirmacher, P
   Boffetta, P
   Dufour, JF
   Thung, SN
   Uzilov, A
   Carrilho, FJ
   Chang, C
   Sia, D
   Llovet, JM
AF Torrecilla, Sara
   Pinyol, Roser
   Wang, Huan
   Montironi, Carla
   Andreu-Oller, Carmen
   Leow, Wei Qiang
   Moeini, Agrin
   Oliveira, Claudia
   Ferreira Alves, Venancio Avancini
   Lachenmayer, Anja
   Roessler, Stephanie
   Minguez, Beatriz
   Schirmacher, Peter
   Boffetta, Paolo
   Dufour, Jean-Francois
   Thung, Swan N.
   Uzilov, Andrew
   Carrilho, Flair Jose
   Chang, Charissa
   Sia, Daniela
   Llovet, Josep M.
TI Distinctive molecular traits of hepatocellular carcinoma in patients
   with non-alcoholic steatohepatitis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-for-Cancer-Research (AACR)
CY MAR 29-APR 03, 2019
CL Atlanta, GA
SP Amer Assoc Canc Res
C1 [Torrecilla, Sara; Pinyol, Roser; Montironi, Carla; Andreu-Oller, Carmen; Moeini, Agrin; Llovet, Josep M.] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain.
   [Wang, Huan; Uzilov, Andrew] Sema4, New York, NY USA.
   [Leow, Wei Qiang; Boffetta, Paolo; Thung, Swan N.; Chang, Charissa; Sia, Daniela] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
   [Oliveira, Claudia; Ferreira Alves, Venancio Avancini; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Moeini, Agrin; Dufour, Jean-Francois] Univ Bern, Bern Univ Hosp, Bern, Switzerland.
   [Roessler, Stephanie; Schirmacher, Peter] Univ Hosp Heidelberg, Heidelberg, Germany.
   [Minguez, Beatriz] Univ Autonoma Barcelona, CIBERehd, Vall dHebron Inst Res VHIR, Hosp Univ Vall dHebron, Barcelona, Spain.
RI Dufour, Jean Francois Jacques/AAL-9866-2020; Minguez,
   Beatriz/N-4456-2014
OI Dufour, Jean Francois Jacques/0000-0002-8062-1346; Minguez,
   Beatriz/0000-0002-7276-9666
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL
PY 2019
VL 79
IS 13
SU S
MA 461
DI 10.1158/1538-7445.AM2019-461
PG 3
WC Oncology
SC Oncology
GA JA8VR
UT WOS:000488129902127
DA 2020-12-08
ER

PT J
AU Leathers, JS
   Balderramo, D
   Prieto, J
   Diehl, F
   Gonzalez-Ballerga, E
   Ferreiro, MR
   Carrera, E
   Barreyro, F
   Diaz-Ferrer, J
   Singh, D
   Mattos, AZ
   Carrilho, F
   Debes, JD
AF Leathers, James S.
   Balderramo, Domingo
   Prieto, John
   Diehl, Fernando
   Gonzalez-Ballerga, Esteban
   Ferreiro, Melina R.
   Carrera, Enrique
   Barreyro, Fernando
   Diaz-Ferrer, Javier
   Singh, Dupinder
   Mattos, Angelo Z.
   Carrilho, Flair
   Debes, Jose D.
TI Sorafenib for Treatment of Hepatocellular Carcinoma A Survival Analysis
   From the South American Liver Research Network
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE hepatocellular carcinoma; South America; sorafenib; survival
ID PHASE-III; CHILD-PUGH; CLINICAL-PRACTICE; UNITED-STATES; EFFICACY;
   THERAPY; SAFETY; OUTCOMES; CANCER; TRENDS
AB Goals: We aim to describe the efficacy, safety profile, and variables associated with survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib in South America. Background: Sorafenib has been shown to improve survival in patients with advanced HCC. There are few data on sorafenib use for HCC in South America. Study: We performed a retrospective analysis of HCC cases treated with sorafenib from 8 medical centers in 5 South American countries, between January 2010 and June 2017. The primary endpoint was overall survival (OS), which was defined as time from sorafenib initiation to death or last follow-up. Risk factors for decreased OS were assessed using Cox proportional hazard regression and log-rank tests. Results: Of 1336 evaluated patients, 127 were treated with sorafenib and were included in the study. The median age of individuals was 65 years (interquartile range, 55 to 71) and 70% were male individuals. Median OS in all patients was 8 months (interquartile range, 2 to 17). Variables associated with survival on multivariate analysis were platelets >/<250,000 mm(3) (2 vs. 8 mo, P=0.01) and Barcelona Clinic Liver Cancer (BCLC) stage (A/B, 13 vs. C/D, 6 mo; P=0.04). In a subanalysis of patients with BCLC stage C, platelets >/<250,000 mm(3) were also independently associated with survival (2 vs. 5.5 mo, P=0.03). Patients lived longer if they experienced any side effects from sorafenib use (11 vs. 2 mo, P=0.009). Patients who stopped sorafenib because of side effects had shorter survival compared with patients who were able to tolerate side effects and continue treatment (7.5 vs. 13 mo, P=0.01). Conclusions: Pretreatment elevation of platelets and advanced BCLC stage were independently associated with poor survival on sorafenib in a South American cohort.
C1 [Leathers, James S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Balderramo, Domingo; Diehl, Fernando] Inst Univ Ciencias Biomed Cordoba, Hosp Privado Univ Cordoba, Dept Gastroenterol, Cordoba, Argentina.
   [Gonzalez-Ballerga, Esteban; Ferreiro, Melina R.] Hosp Clin Buenos Aires, Dept Gastroenterol, Buenos Aires, DF, Argentina.
   [Barreyro, Fernando] Natl Council Sci & Tech Invest, Posadas, Argentina.
   [Prieto, John] Ctr Enfermedades Hepat & Digest CEHYD, Org Sanitas Colombia, Dept Gastroenterol, Bogota, Colombia.
   [Carrera, Enrique] Hosp Eugenio Espejo, Dept Gastroenterol & Hepatol, Quito, Ecuador.
   [Diaz-Ferrer, Javier] Hosp Nacl Edgardo Rebagliati Martins, HNERM, Dept Gastroenterol, Lima, Peru.
   [Singh, Dupinder; Debes, Jose D.] Univ Minnesota, Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55455 USA.
   [Mattos, Angelo Z.] Pontificia Univ Catolica Rio Grande do Sul, Fed Univ Hlth Sci Porto Alegre, Dept Gastroenterol, Porto Alegre, RS, Brazil.
   [Carrilho, Flair] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
RP Debes, JD (corresponding author), Univ Minnesota, McGuire Translat Res Facil, 2001 6th St,SE Room 3-226, Minneapolis, MN 55455 USA.
EM debes003@umn.edu
RI Debes, Jose/Q-9794-2016; Ford, James/AAQ-4324-2020
OI Ford, James/0000-0003-0311-0718; Balderramo, Domingo/0000-0001-9598-2577
FU Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF);
   Doris Duke International Clinical Research Fellowship Program at the
   University of Minnesota; Robert Wood Johnson FoundationRobert Wood
   Johnson Foundation (RWJF)
FX Supported by the Doris Duke Charitable Foundation through a grant
   supporting the Doris Duke International Clinical Research Fellowship
   Program at the University of Minnesota to J.L., and the Robert Wood
   Johnson Foundation, AFMDP to J.D.D.
CR Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046
   Almeida-Carvalho SR, 2017, ANN HEPATOL, V16, P255, DOI 10.5604/16652681.1231584
   Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753
   Branco F, 2017, ANN HEPATOL, V16, P263, DOI 10.5604/16652681.1231585
   Bruix J, 2017, J HEPATOL, V67, P999, DOI 10.1016/j.jhep.2017.06.026
   Bruix J, 2012, J HEPATOL, V57, P821, DOI 10.1016/j.jhep.2012.06.014
   Carr BI, 2014, INT J BIOL MARKER, V29, pE215, DOI 10.5301/jbm.5000064
   Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
   Chan AJ, 2017, CLIN GASTROENTEROL H, V15, P1631, DOI 10.1016/j.cgh.2017.05.015
   Cheng AL, 2012, EUR J CANCER, V48, P1452, DOI 10.1016/j.ejca.2011.12.006
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Da Fonseca LG, 2015, MOL CLIN ONCOL, V3, P793, DOI 10.3892/mco.2015.536
   Debes JD, 2018, GASTROENTEROLOGY, V154, P515, DOI 10.1053/j.gastro.2017.10.035
   Debes JD, 2018, LIVER INT, V38, P136, DOI 10.1111/liv.13502
   Di Costanzo GG, 2017, TARGET ONCOL, V12, P795, DOI 10.1007/s11523-017-0522-5
   Di Costanzo GG, 2015, FUTURE ONCOL, V11, P943, DOI [10.2217/FON.14.291, 10.2217/fon.14.291]
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Han S, 2018, LIVER TRANSPLANT, V24, P44, DOI 10.1002/lt.24961
   Howlader N, 2012, SEER CANC STAT REV 1
   Jackson R, 2017, J CLIN ONCOL, V35, P622, DOI 10.1200/JCO.2016.69.5197
   Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410
   Kudo M, 2015, LIVER CANCER, V4, P85, DOI 10.1159/000367730
   Kudo M, 2017, ONCOLOGY-BASEL, V93, P135, DOI 10.1159/000481244
   Lee IC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000688
   Li JP, 2014, HEPATO-GASTROENTEROL, V61, P954, DOI 10.5754/hge121205
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Marrero JA, 2016, J HEPATOL, V65, P1140, DOI 10.1016/j.jhep.2016.07.020
   Mehta N, 2013, CLIN GASTROENTEROL H, V11, P572, DOI 10.1016/j.cgh.2012.12.030
   Ogasawara S, 2015, INVEST NEW DRUG, V33, P729, DOI 10.1007/s10637-015-0237-3
   Park JW, 2015, LIVER INT, V35, P2155, DOI 10.1111/liv.12818
   Petrick JL, 2016, INT J CANCER, V139, P1534, DOI 10.1002/ijc.30211
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   Shen A, 2013, J CLIN GASTROENTEROL, V47, P871, DOI 10.1097/MCG.0b013e3182a87cfd
   Spaan M, 2015, J INFECT DIS, V212, P386, DOI 10.1093/infdis/jiv059
   Wong MCS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14513-7
   Zhu AX, 2015, J CLIN ONCOL, V33, P559, DOI 10.1200/JCO.2013.53.7746
NR 37
TC 6
Z9 7
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0192-0790
EI 1539-2031
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD JUL
PY 2019
VL 53
IS 6
BP 464
EP 469
DI 10.1097/MCG.0000000000001085
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ID4UH
UT WOS:000471671300016
PM 29952857
DA 2020-12-08
ER

PT J
AU Mazo, DF
   Malta, FM
   Stefano, JT
   Salles, APM
   Gomes-Gouvea, MS
   Nastri, ACS
   Almeida, JR
   Pinho, JRR
   Carrilho, FJ
   Oliveira, CP
AF Mazo, Daniel F.
   Malta, Fernanda M.
   Stefano, Jose Tadeu
   Salles, Ana Paula M.
   Gomes-Gouvea, Michele S.
   Nastri, Ana Catharina S.
   Almeida, Jazon R.
   Pinho, Joao Renato R.
   Carrilho, Flair J.
   Oliveira, Claudia P.
TI Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver
   fibrosis in an admixed population
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Non-alcoholic fatty liver disease; Single nucleotide polymorphism;
   Patatin-like Phospholipase Domain Containing 3; Transmembrane 6
   Superfamily Member 2; Nonalcoholic steatohepatitis
ID TM6SF2 E167K VARIANT; SUPERFAMILY MEMBER 2; CONFERS SUSCEPTIBILITY;
   GENETIC-VARIATION; DISEASE; I148M; ASSOCIATION; EXPRESSION; PHENOTYPE;
   DIAGNOSIS
AB Introduction and aim: Studies have shown that two polymorphisms were associated with steatosis and progression of non-alcoholic fatty liver disease (NAFLD) in different populations: the Patatin-like Phospholipase Domain Containing 3 (PNPLA3) and Transmembrane 6 Superfamily Member 2 (TM6SF2). However, the frequency and significance of these polymorphisms in an admixed population, i.e., Brazilian, is unknown. Therefore, we aimed to evaluate them in healthy subjects in comparison to patients with NAFLD.
   Material and methods: This was a multicenter cross-sectional study in 248 patients with biopsy-proven NAFLD and in 134 healthy controls from two tertiary centers in Brazil. PNPLA3 (rs738409 c.444C>G) and TM6SF2 (rs58542926 c.449C>T) polymorphisms were evaluated.
   Results: In controls, the frequencies of PNPLA3 CC and CG + GG were 49.25% and 50.74%, respectively; in NAFLD patients, this was 31.05% and 68.88% (p = 0.0044, 95% CI 1.037-2.977). PNPLA3 GG subjects had an increased risk (3.29-fold) of having NAFLD when compared to CC subjects (p = 0.0044,95% CI 1.504-7.225). In patients with nonalcoholic steatohepatitis (NASH), PNPLA3 GG compared to CC was associated with higher AST levels [38.4 +/- 25.3 versus 36.7 +/- 40.1 IU/L, p= 0.0395)] and with the presence of liver fibrosis (>= F2 fibrosis, p = 0.0272). TM6SF2 polymorphisms were not in Hardy-Weinberg equilibrium in our NAFLD group precluding further analysis.
   Conclusion: We demonstrated for the first time that PNPLA3 CG + GG increase the risk of NAFLD among Brazilian subjects. Moreover, PNPLA3 GG was associated with liver enzyme elevation and fibrosis in NASH patients. (C) 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U.
C1 [Mazo, Daniel F.; Stefano, Jose Tadeu; Carrilho, Flair J.; Oliveira, Claudia P.] Univ Sao Paulo, Sch Med FMUSP, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Mazo, Daniel F.; Almeida, Jazon R.] Univ Campinas UNICAMP, Sch Med Sci, Div Gastroenterol, Gastroctr, Campinas, SP, Brazil.
   [Malta, Fernanda M.; Salles, Ana Paula M.; Gomes-Gouvea, Michele S.; Nastri, Ana Catharina S.; Pinho, Joao Renato R.] Univ Sao Paulo, LIM 07, Inst Trop Med, Sao Paulo, Brazil.
RP Mazo, DF (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, Av Dr Eneas de Carvalho Aguiar 255,Inst Cent 9159, BR-05403900 Sao Paulo, Brazil.
EM daniel.mazo@hc.fm.usp.br
RI Stefano, Jose Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014;
   Mazo, Daniel FC/D-5631-2015; Pinho, Joao/G-2850-2012; Malta,
   Fernanda/B-1316-2013
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Mazo, Daniel
   FC/0000-0002-2164-2630; Pinho, Joao/0000-0003-3999-0489; Moreira Salles,
   Ana Paula/0000-0002-4205-9401; Malta, Fernanda/0000-0001-8887-5060
CR Anstee QM, 2015, SEMIN LIVER DIS, V35, P270, DOI 10.1055/s-0035-1562947
   BasuRay S, 2017, HEPATOLOGY, V66, P1111, DOI 10.1002/hep.29273
   Boonvisut S, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0570-y
   BOTSTEIN D, 1980, AM J HUM GENET, V32, P314
   Bruschi FV, 2017, HEPATOLOGY, V65, P1875, DOI 10.1002/hep.29041
   Cavalcante LN, 2015, WORLD J HEPATOL, V7, P1433, DOI 10.4254/wjh.v7.i10.1433
   Pontoriero AC, 2015, BMC GENET, V16, DOI 10.1186/s12863-015-0255-3
   Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367
   Chen LZ, 2015, J CLIN TRANSL HEPATO, V3, P265, DOI 10.14218/JCTH.2015.00023
   Chung GE, 2018, GUT LIVER, V12, P316, DOI 10.5009/gnl17306
   Donati B, 2016, HEPATOLOGY, V63, P787, DOI 10.1002/hep.28370
   Dongiovanni P, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/460190
   Dongiovanni P, 2015, HEPATOLOGY, V61, P506, DOI 10.1002/hep.27490
   Dulai PS, 2017, HEPATOLOGY, V65, P1557, DOI 10.1002/hep.29085
   EASL, 2016, DIABETOLOGIA, V59, P1121, DOI 10.1007/s00125-016-3902-y
   Ehrhardt N, 2017, HUM MOL GENET, V26, P2719, DOI 10.1093/hmg/ddx159
   Eslam M, 2018, J HEPATOL, V68, P268, DOI 10.1016/j.jhep.2017.09.003
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   Huang YC, 2011, J BIOL CHEM, V286, P37085, DOI 10.1074/jbc.M111.290114
   Kantartzis K, 2017, DIABETES METAB, V43, P229, DOI 10.1016/j.diabet.2016.11.006
   Kawamura Y, 2017, INTERNAL MED, V56, P1459, DOI 10.2169/internalmedicine.56.7830
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Kovarova M, 2015, J CLIN ENDOCR METAB, V100, pE1568, DOI 10.1210/jc.2015-2978
   Kozlitina J, 2014, NAT GENET, V46, P352, DOI 10.1038/ng.2901
   Larrieta-Carrasco E, 2018, EXP MOL PATHOL, V104, P50, DOI 10.1016/j.yexmp.2018.01.001
   Lins TC, 2010, AM J HUM BIOL, V22, P187, DOI 10.1002/ajhb.20976
   Liu YL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5309
   Mahdessian H, 2014, P NATL ACAD SCI USA, V111, P8913, DOI 10.1073/pnas.1323785111
   Martinez LA, 2017, ANN HEPATOL, V16, P909, DOI 10.5604/01.3001.0010.5282
   McPherson S, 2017, AM J GASTROENTEROL, V112, P740, DOI 10.1038/ajg.2016.453
   Mondul A, 2015, J NUTR, V145, P1687, DOI 10.3945/jn.115.210633
   Pingitore P, 2016, HUM MOL GENET, V25, P5212, DOI 10.1093/hmg/ddw341
   Pingitore P, 2014, BBA-MOL CELL BIOL L, V1841, P574, DOI 10.1016/j.bbalip.2013.12.006
   Pirazzi C, 2014, HUM MOL GENET, V23, P4077, DOI 10.1093/hmg/ddu121
   Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257
   Salameh H, 2016, J CLIN TRANSL HEPATO, V4, P175, DOI 10.14218/JCTH.2016.00009
   Severson TJ, 2016, WORLD J GASTROENTERO, V22, P6742, DOI 10.3748/wjg.v22.i29.6742
   Sookoian S, 2016, SCI REP-UK, V6, DOI 10.1038/srep27718
   Sookoian S, 2015, HEPATOLOGY, V61, P515, DOI 10.1002/hep.27556
   Sookoian S, 2009, J LIPID RES, V50, P2111, DOI 10.1194/jlr.P900013-JLR200
   Trepo E, 2016, J HEPATOL, V65, P399, DOI 10.1016/j.jhep.2016.03.011
   Uygun A, 2017, EUR J GASTROEN HEPAT, V29, P441, DOI 10.1097/MEG.0000000000000813
   Vasques ACJ, 2008, ARQ BRAS ENDOCRINOL, V52, P32, DOI 10.1590/S0004-27302008000100006
   Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005
   Wang XL, 2015, J HEPATOL, V62, P1438, DOI 10.1016/j.jhep.2015.01.040
   Wong VWS, 2018, J GASTROEN HEPATOL, V33, P70, DOI 10.1111/jgh.13857
   Wood GC, 2017, SCI REP-UK, V7, DOI 10.1038/srep43238
   Wood KL, 2015, BMJ OPEN GASTROENTER, V2, DOI 10.1136/bmjgast-2014-000019
   Xu RF, 2015, SCI REP-UK, V5, DOI 10.1038/srep09284
   Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109
   Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431
   Zhang L, 2015, J GASTROEN HEPATOL, V30, P821, DOI 10.1111/jgh.12889
NR 52
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER ESPANA
PI MADRID
PA CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD MAY-JUN
PY 2019
VL 18
IS 3
BP 466
EP 471
DI 10.1016/j.aohep.2018.10.004
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA IU3DK
UT WOS:000483460600012
PM 31054980
OA Other Gold
DA 2020-12-08
ER

PT J
AU Torrecilla, S
   Pinyol, R
   Wang, H
   Montironi, C
   Andreu-Oller, C
   Leow, WQ
   Moeini, A
   Oliveira, C
   Alves, VAF
   Lachenmayer, A
   Roessler, S
   Minguez, B
   Schirmacher, P
   Boffetta, P
   Dufour, JF
   Thung, SN
   Uzilov, A
   Carrilho, FJ
   Chang, C
   Sia, D
   Llovet, JM
AF Torrecilla, Sara
   Pinyol, Roser
   Wang, Huan
   Montironi, Carla
   Andreu-Oller, Carmen
   Leow, Wei Qiang
   Moeini, Agrin
   Oliveira, Claudia
   Ferreira Alves, Venancio Avancini
   Lachenmayer, Anja
   Roessler, Stephanie
   Minguez, Beatriz
   Schirmacher, Peter
   Boffetta, Paolo
   Dufour, Jean-Francois
   Thung, Swan N.
   Uzilov, Andrew
   Carrilho, Flair Jose
   Chang, Charissa
   Sia, Daniela
   Llovet, Josep M.
TI Molecular fingerprint of hepatocellular carcinoma in patients with
   non-alcoholic steatohepatitis
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 54th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 10-14, 2019
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Torrecilla, Sara; Pinyol, Roser; Montironi, Carla; Andreu-Oller, Carmen; Moeini, Agrin; Llovet, Josep M.] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Hosp Clin, Liver Canc Translat Res Lab, Barcelona, Spain.
   [Wang, Huan; Uzilov, Andrew] Sema4, Stamford, CT USA.
   [Montironi, Carla; Leow, Wei Qiang; Boffetta, Paolo; Thung, Swan N.; Chang, Charissa; Sia, Daniela; Llovet, Josep M.] Icahn Sch Med Mt Sinai, Mt Sinai Liver Canc Program, Dept Hematol Oncol, Tisch Canc Inst,Dept Med,Dept Pathol,Div Liver Di, New York, NY 10029 USA.
   [Leow, Wei Qiang] Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore.
   [Oliveira, Claudia; Ferreira Alves, Venancio Avancini; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol & Pathol, Sao Paulo, Brazil.
   [Lachenmayer, Anja; Dufour, Jean-Francois] Univ Bern, Bern Univ Hosp, Dept Visceral Surg & Med, Bern, Switzerland.
   [Roessler, Stephanie; Schirmacher, Peter] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.
   [Minguez, Beatriz] Univ Autonoma Barcelona, Vall dHebron Inst Res VHIR, Hosp Univ Vall dHebron, Dept Internal Med,CIBERehd,Liver Unit, Barcelona, Spain.
   [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain.
EM torrecilla@idibaps.org
RI Dufour, Jean Francois Jacques/AAL-9866-2020; Minguez,
   Beatriz/N-4456-2014; Oliveira, Claudia PMS/D-1216-2014; Pinyol,
   Roser/AAA-4404-2019
OI Dufour, Jean Francois Jacques/0000-0002-8062-1346; Minguez,
   Beatriz/0000-0002-7276-9666; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2019
VL 70
IS 1
SU 1
MA THU-497
BP E379
EP E379
DI 10.1016/S0618-8278(19)30743-1
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HR9LP
UT WOS:000463481701325
DA 2020-12-08
ER

PT J
AU Zamparelli, MS
   Rimola, J
   Montironi, C
   Nunes, V
   Alves, VAF
   Sapena, V
   Forner, A
   Carrilho, FJ
   Diaz, A
   Fuster, C
   Ferrer, J
   Fuster, J
   Ayuso, C
   Sole, M
   Bruix, J
   Reig, M
AF Sanduzzi Zamparelli, Marco
   Rimola, Jordi
   Montironi, Carla
   Nunes, Vinicius
   Ferreira Alves, Venancio Avancini
   Sapena, Victor
   Forner, Alejandro
   Jose Carrilho, Flair
   Diaz, Alba
   Fuster, Carla
   Ferrer, Joana
   Fuster, Josep
   Ayuso, Carmen
   Sole, Manel
   Bruix, Jordi
   Reig, Maria
TI Hepatic epithelioid hemangioendotelioma: An international multicenter
   study
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 54th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 10-14, 2019
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Sanduzzi Zamparelli, Marco; Sapena, Victor; Forner, Alejandro; Bruix, Jordi; Reig, Maria] Univ Barcelona, Hosp Clin Barcelona, Liver Unit, Barcelona Clin Liver Canc BCLC Grp,CIBERehd,IDIBA, Barcelona, Spain.
   [Rimola, Jordi; Ayuso, Carmen] Univ Barcelona, Hosp Clin Barcelona, Barcelona Clin Liver Canc BCLC Grp, Radiol Dept,IDIBAPS, Barcelona, Spain.
   [Montironi, Carla] Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain.
   [Nunes, Vinicius] Univ Fed Bahia, Salvador Da Bahia, BA, Brazil.
   [Ferreira Alves, Venancio Avancini] Univ Sao Paulo, Hosp Clin, Anat Pathol Div, Sao Paulo, Brazil.
   [Jose Carrilho, Flair] Univ Sao Paulo, Hosp Clin, Div Clin Gastroenterol & Hepatol, Dept Gastroenterol,Sch Med, Sao Paulo, Brazil.
   [Diaz, Alba; Fuster, Carla; Sole, Manel] Univ Barcelona, Hosp Clin, Barcelona Clin Liver Canc BCLC Grp, Dept Pathol,IDIBAPS, Barcelona, Spain.
   [Ferrer, Joana; Fuster, Josep] Univ Barcelona, Hosp Clin, Barcelona Clin Liver Canc BCLC Grp, Liver Surg & Transplant Unit,Digest & Metab Dis I, Barcelona, Spain.
EM mreig1@clinic.cat
RI Sapena, Victor/AAB-1721-2020
OI Sapena, Victor/0000-0003-4379-6486
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2019
VL 70
IS 1
SU 1
MA SAT-483
BP E845
EP E846
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HR9LP
UT WOS:000463481703447
DA 2020-12-08
ER

PT J
AU Martins-Filho, SN
   Alves, VAF
   Wakamatsu, A
   Maeda, M
   Craig, AJ
   Assato, AK
   Villacorta-Martin, C
   D'Avola, D
   Labgaa, I
   Carrilho, FJ
   Thung, SN
   Villanueva, A
AF Martins-Filho, Sebastiao N.
   Alves, Venancio A. F.
   Wakamatsu, Alda
   Maeda, Miho
   Craig, Amanda J.
   Assato, Aline K.
   Villacorta-Martin, Carlos
   D'Avola, Delia
   Labgaa, Ismail
   Carrilho, Flair J.
   Thung, Swan N.
   Villanueva, Augusto
TI A phenotypical map of disseminated hepatocellular carcinoma suggests
   clonal constraints in metastatic sites
SO HISTOPATHOLOGY
LA English
DT Article
DE extra-hepatic metastasis; hepatocellular carcinoma; tumor heterogeneity
ID INTRATUMOR HETEROGENEITY; KERATIN 19; TISSUE MICROARRAYS; CANCER;
   EXPRESSION; GRADE; LIVER; IMMUNOHISTOCHEMISTRY; MUTATIONS; PROGNOSIS
AB Aims Access to tissue in patients with hepatocellular carcinoma (HCC) is limited compared to other malignancies, particularly at advanced stages. This has precluded a thorough characterisation of molecular drivers of HCC dissemination, particularly in relation to distant metastases. Biomarker assessment is restricted to early stages, and paired primary-metastatic comparisons between samples from the same patient are difficult. Methods and results We report the evaluation of 88 patients with HCC who underwent autopsy, including multiregional sampling of primary and metastatic sites totalling 230 nodules analysed. The study included morphological assessment, immunohistochemistry and mutation status of the TERT promoter, the most frequently mutated gene in HCC. We confirm a strong predilection of HCC for lung dissemination, including subclinical micrometastases (unrecognised during imaging and macroscopic examinations) in 30% of patients with disseminated disease. Size of dominant tumour nodule; multinodularity; macrovascular invasion; high histological, nuclear and architectural grades; and cellular crowding were associated with the presence of extrahepatic metastasis. Among the immunohistochemistry markers tested, metastatic nodules had significantly higher K19 and EpCAM expression than primary liver tumours. Morphological and immunohistochemical features showed that metastatic HCC could be traced back to the primary tumour, sometimes to a specific hepatic nodule. Conclusions This study suggests limited heterogeneity in metastatic sites compared to primary tumour sites.
C1 [Martins-Filho, Sebastiao N.; Alves, Venancio A. F.] Univ Sao Paulo, Fac Med FMUSP, Dept Patol, Sao Paulo, Brazil.
   [Martins-Filho, Sebastiao N.] Univ Toronto, Univ Hlth Network, Dept Pathol & Lab Med, Toronto, ON, Canada.
   [Alves, Venancio A. F.; Wakamatsu, Alda; Assato, Aline K.] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Lab Patol Figado LIM 14, Sao Paulo, Brazil.
   [Maeda, Miho; Craig, Amanda J.; Villacorta-Martin, Carlos; Labgaa, Ismail; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Dept Med, Tisch Canc Inst, Liver Canc Res Program,Div Liver Dis, New York, NY 10029 USA.
   [D'Avola, Delia] Clin Univ Navarra, Liver Unit, Ctr Invest Biomed Red Area Temat Enfermedades Hea, Pamplona, Spain.
   [Labgaa, Ismail] Lausanne Univ Hosp CHUV, Dept Visceral Surg, Lausanne, Switzerland.
   [Carrilho, Flair J.] Univ Sao Paulo, Fac Med FMUSP, Dept Gastroenterol, Sao Paulo, Brazil.
   [Thung, Swan N.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA.
   [Villanueva, Augusto] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, Div Hematol & Med Oncol, New York, NY 10029 USA.
RP Alves, VAF (corresponding author), Fac Med FMUSP, Ave Dr Arnaldo 445, BR-01246903 Sao Paulo, SP, Brazil.; Villanueva, A (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,Box 1123,Room 11-70E, New York, NY 10029 USA.
EM venancio@uol.com.br; augusto.villanueva@mssm.edu
RI D'Avola, Delia/AAD-4289-2020
OI D'Avola, Delia/0000-0002-0907-6648; Martins Filho,
   Sebastiao/0000-0002-6123-2601; Labgaa, Ismail/0000-0003-4286-2170;
   Villanueva, Augusto/0000-0003-3585-3727
FU CAPES doctorate grant; Terry Fox Foundation Fellowship Award; Alan
   Hofmann Clinical and Translational Research Award; US Department of
   DefenseUnited States Department of Defense [CA150272P3]; Tisch Cancer
   Institute (Cancer Center Grant) [P30 CA196521]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521, P30CA196521,
   P30CA196521, P30CA196521, P30CA196521, P30CA196521] Funding Source: NIH
   RePORTER
FX S.N.M.F. is supported by the CAPES doctorate grant and the Terry Fox
   Foundation Fellowship Award. A.V. is recipient of the American
   Association for the Study of Liver Diseases Foundation (AASLDF), Alan
   Hofmann Clinical and Translational Research Award, and is supported by
   the US Department of Defense (CA150272P3) and the Tisch Cancer Institute
   (Cancer Center Grant P30 CA196521). We thank Julio Aguirre-Ghiso for
   scientific and technical support for the evaluation of tumor dormancy in
   metastatic sites.
CR Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364
   Akiba J, 2013, AM J SURG PATHOL, V37, P496, DOI 10.1097/PAS.0b013e31827332b0
   Calderaro J, 2017, J HEPATOL, V67, P727, DOI 10.1016/j.jhep.2017.05.014
   DuBay D, 2011, ANN SURG, V253, P166, DOI 10.1097/SLA.0b013e31820508f1
   European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021
   Fatourou E, 2015, EUR J GASTROEN HEPAT, V27, P1094, DOI 10.1097/MEG.0000000000000398
   Felipe-Silva A, 2016, WORLD J GASTROENTERO, V22, P6246, DOI 10.3748/wjg.v22.i27.6246
   Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465
   Friemel J, 2015, CLIN CANCER RES, V21, P1951, DOI 10.1158/1078-0432.CCR-14-0122
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351
   Goyal L, 2017, CANCER DISCOV, V7, P252, DOI 10.1158/2159-8290.CD-16-1000
   Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347
   Han DH, 2013, J GASTROEN HEPATOL, V28, P1384, DOI 10.1111/jgh.12200
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609
   Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
   Higashi Y, 2007, J SURG RES, V139, P68, DOI 10.1016/j.jss.2006.08.038
   Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259
   Jemal A, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx030
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Joseph NM, 2014, MODERN PATHOL, V27, P62, DOI 10.1038/modpathol.2013.114
   Kim H, 2011, HEPATOLOGY, V54, P1707, DOI 10.1002/hep.24559
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377
   Lindstrom LS, 2018, JNCI-J NATL CANCER I, V110, P726, DOI 10.1093/jnci/djx270
   Martins SN, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00193
   Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038
   Nault JC, 2014, HEPATOLOGY, V60, P1983, DOI 10.1002/hep.27372
   Nocito A, 2001, INT J CANCER, V94, P1, DOI 10.1002/ijc.1385
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155
   Roayaie S, 2009, GASTROENTEROLOGY, V137, P850, DOI 10.1053/j.gastro.2009.06.003
   Sapisochin G, 2016, HEPATOLOGY, V64, P2077, DOI 10.1002/hep.28643
   Sasaki K, 2015, WORLD J SURG, V39, P1134, DOI 10.1007/s00268-014-2806-6
   Sasaki K, 2014, WORLD J SURG, V38, P1147, DOI 10.1007/s00268-013-2374-1
   Schulze K, 2016, J HEPATOL, V65, P1031, DOI 10.1016/j.jhep.2016.05.035
   Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007
   Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170
   Torbenson M, 2015, HEPATOLOGY, V61, P431, DOI 10.1002/hep.27545
   Torbenson MS, 2017, GASTROENTEROL CLIN N, V46, P365, DOI 10.1016/j.gtc.2017.01.009
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tsujikawa H, 2016, HUM PATHOL, V50, P24, DOI 10.1016/j.humpath.2015.10.014
   Turajlic S, 2018, CELL, V173, P595, DOI 10.1016/j.cell.2018.03.043
   van Malenstein H, 2012, HEPATOL RES, V42, P990, DOI 10.1111/j.1872-034X.2012.01010.x
   VanderWeele DJ, 2014, CANCER SCI, V105, P1079, DOI 10.1111/cas.12460
   Wong SQ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-23
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
   Yan BC, 2010, AM J SURG PATHOL, V34, P1147, DOI 10.1097/PAS.0b013e3181e5dffa
   Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930
   Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061
NR 50
TC 3
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD APR
PY 2019
VL 74
IS 5
BP 718
EP 730
DI 10.1111/his.13809
PG 13
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA HP7RM
UT WOS:000461886400005
PM 30636011
OA Bronze
DA 2020-12-08
ER

PT J
AU Casadio, LVB
   Salles, APM
   Malta, FD
   Leite, GF
   Ho, YL
   Gomes-Gouvea, MS
   Malbouisson, LMS
   Levin, AS
   Neto, RSD
   Carrilho, FJ
   Nastri, ACSS
   Pinho, JRR
AF Boas Casadio, Luciana Vilas
   Moreira Salles, Ana Paula
   Malta, Fernanda de Mello
   Leite, Gabriel Fialkovitz
   Ho, Yeh-Li
   Gomes-Gouvea, Michele Soares
   Sa Malbouisson, Luiz Marcelo
   Levin, Anna S.
   de Azevedo Neto, Raymundo Soares
   Carrilho, Flair Jose
   Seixas Santos Nastri, Ana Catharina
   Rebello Pinho, Joao Renato
TI Lipase and factor V (but not viral load) are prognostic factors for the
   evolution of severe yellow fever cases
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE yellow fever; lipase; factor v; viral load
ID HAMSTER MESOCRICETUS-AURATUS; ACUTE-PANCREATITIS; VIRUS-INFECTION;
   OUTBREAK; ANGOLA; URINE; CONGO
AB BACKGROUND Despite a highly efficacious vaccine, yellow fever (YF) is still a major threat in developing countries and a cause of outbreaks. In 2018, the Brazilian state of Sao Paulo witnessed a new YF outbreak in areas where the virus has not been detected before.
   OBJECTIVE The aim is to describe the clinical and laboratorial characteristics of severe cases of YF, evaluate viral to determine markers associated with fatal outcome.
   METHODS Acute severe YF cases (n = 62) were admitted to the Intensive Care Unit of a reference hospital and submitted to routine laboratorial evaluation on admission. YFV-RNA was detected in serum and urine by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and then sequenced. Patients were classified in two groups: survival or death.
   FINDINGS In the univariate analysis the following variables were associated with outcome: alanin aminotransferase (ALT), aspartat aminotransferase (AST), AST/ALT ratio, total bilirubin (TB), chronic kidney disease epidemiology collaboration (CKD-EPI), ammonia, lipase, factor V, international normalised ratio (INR), lactate and bicarbonate. Logistic regression model showed two independent variables associated with death: lipase [odds ratio (OR) 1.018, 95% confidence interval (CI) 1.007 to 1.030, p = 0.002], and factor V (OR -0.955, 95% CI 0.929 to 0.982, p = 0.001). The estimated lipase and factor V cut-off values that maximised sensitivity and specificity for death prediction were 147.5 U/L [area under the curve (AUC) = 0.879], and 56.5% (AUC = 0.913).
   MAIN CONCLUSIONS YF acute severe cases show a generalised involvement of different organs (liver, spleen, heart, kidneys, intestines and pancreas), and different parameters were related to outcome. Factor V and lipase are independent variables associated with death, reinforcing the importance of hemorrhagic events due to fulminant liver failure and pointing to pancreatitis as a relevant event in the outcome of the disease.
C1 [Boas Casadio, Luciana Vilas; Moreira Salles, Ana Paula; Malta, Fernanda de Mello; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Seixas Santos Nastri, Ana Catharina; Rebello Pinho, Joao Renato] Univ Sao Paulo, Fac Med Sao Paulo, Inst Med Trop, Dept Gastroenterol,Lab Gastroenterol & Hepatol Tr, LIM 07, Sao Paulo, SP, Brazil.
   [Boas Casadio, Luciana Vilas; Leite, Gabriel Fialkovitz; Ho, Yeh-Li; Levin, Anna S.; Seixas Santos Nastri, Ana Catharina] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, SP, Brazil.
   [Sa Malbouisson, Luiz Marcelo; Levin, Anna S.; Carrilho, Flair Jose] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [de Azevedo Neto, Raymundo Soares] Univ Sao Paulo, Dept Patol, Fac Med, Sao Paulo, SP, Brazil.
   [Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Albert Einstein Med Diagnost, Lab Tecn Especiais, Sao Paulo, SP, Brazil.
RP Casadio, LVB (corresponding author), Univ Sao Paulo, Fac Med Sao Paulo, Inst Med Trop, Dept Gastroenterol,Lab Gastroenterol & Hepatol Tr, LIM 07, Sao Paulo, SP, Brazil.; Casadio, LVB (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, SP, Brazil.
EM lvbcasadio@usp.br
RI Casadio, Luciana Vilas Boas/AAF-8371-2019; Levin, Anna S/C-8831-2012;
   Soares de Azevedo Neto, Raymundo/B-7593-2008; Pinho, Joao/G-2850-2012;
   Malta, Fernanda/B-1316-2013
OI Casadio, Luciana Vilas Boas/0000-0001-8341-8960; Levin, Anna
   S/0000-0003-2427-8368; Soares de Azevedo Neto,
   Raymundo/0000-0003-0660-2371; Pinho, Joao/0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; Moreira Salles, Ana
   Paula/0000-0002-4205-9401
CR Ahmed QA, 2017, TROP DOCT, V47, P92, DOI 10.1177/0049475517699726
   Bae HG, 2005, J CLIN VIROL, V33, P274, DOI 10.1016/j.jcv.2004.12.001
   Barbosa CM, 2018, EMERG INFECT DIS, V24, P176, DOI 10.3201/eid2401.171310
   Barrett Alan D, 2003, Adv Virus Res, V61, P291, DOI 10.1016/S0065-3527(03)61007-9
   Buber Jonathan, 2008, Travel Med Infect Dis, V6, P373, DOI 10.1016/j.tmaid.2008.08.001
   Chen ZH, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.89
   Clements AN, 2017, J VECTOR ECOL, V42, P208, DOI 10.1111/jvec.12261
   Fernandes NCCD, 2017, EMERG INFECT DIS, V23, P2038, DOI 10.3201/eid2312.170685
   Domingo C, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0128-8
   Domingo C, 2012, J CLIN MICROBIOL, V50, P4054, DOI 10.1128/JCM.01799-12
   Gardner CL, 2010, CLIN LAB MED, V30, P237, DOI 10.1016/j.cll.2010.01.001
   Governo do Estado de Sao Paulo/SES/CCD/CVE/DDTVZ-Secretaria de Estado da Saude/Coordenadoria de Controle de Doencas/Centro de Vigilancia Epidemiologica/Divisao de Doencas Transmitidas por Vetores e Zoonoses, 2019, B EPIDEMIOLOGICO FEB
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   HARRISON AK, 1980, EXP MOL PATHOL, V32, P102, DOI 10.1016/0014-4800(80)90047-7
   Jain V, 2014, J GLOB INFECT DIS, V6, P76, DOI 10.4103/0974-777X.132050
   Klitting R, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060291
   Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI [10.1016/S1473-3099(16)30513-8, 10.1016/s1473-3099(16)30513-8]
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Mantel N, 2008, J VIROL METHODS, V151, P40, DOI 10.1016/j.jviromet.2008.03.026
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Monath TP, 2003, ADV VIRUS RES, V60, P343, DOI 10.1016/S0065-3527(03)60009-6
   MONATH TP, 1987, REV INFECT DIS, V9, P165
   MS/ SVS-Ministerio da Saude/ Secretaria de Vigilancia em Saude, 2018, MON PER SAZ FEBR AM
   Nassar E da S, 1995, Rev Inst Med Trop Sao Paulo, V37, P337
   Nunes MRT, 2011, J VIROL METHODS, V174, P29, DOI 10.1016/j.jviromet.2011.02.025
   Oliveira F., 1969, HIST FEBRE AMARELA B
   PERELMAN A, 1974, AM J TROP MED HYG, V23, P1150, DOI 10.4269/ajtmh.1974.23.1150
   Possas C, 2018, MEM I OSWALDO CRUZ, V113, P1, DOI 10.1590/0074-02760170361
   Reusken CBEM, 2017, J CLIN MICROBIOL, V55, P3294, DOI 10.1128/JCM.01113-17
   Rogers DJ, 2006, ADV PARASIT, V62, P181, DOI 10.1016/S0065-308X(05)62006-4
   Seetharam P, 2010, EURASIAN J MED, V42, P151, DOI 10.5152/eajm.2010.41
   Tesh RB, 2001, J INFECT DIS, V183, P1431, DOI 10.1086/320199
   Vicenzi E, 2018, BIOCHEM SOC T, V46, P609, DOI [10.1042/BST20170399, 10.1042/bst20170399]
   Xiao SY, 2001, J INFECT DIS, V183, P1437, DOI 10.1086/320200
NR 36
TC 6
Z9 6
U1 0
U2 0
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2019
VL 114
AR e190033
DI 10.1590/0074-02760190033
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA HZ3UX
UT WOS:000468775000001
PM 31116245
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Terrabuio, DRB
   Diniz, MA
   Falcao, LTD
   Guedes, ALV
   Nakano, LA
   Evangelista, AS
   Lima, FR
   Abrantes-Lemos, CP
   Carrilho, FJ
   Cancado, ELR
AF Benedita Terrabuio, Debora Raquel
   Diniz, Marcio Augusto
   de Moraes Falcao, Lydia Teofilo
   Vilar Guedes, Ana Luiza
   Nakano, Larissa Akeme
   Evangelista, Andreia Silva
   Lima, Fabiana Roberto
   Abrantes-Lemos, Clarice Pires
   Carrilho, Flair Jose
   Rachid Cancado, Eduardo Luiz
TI Chloroquine Is Effective for Maintenance of Remission in Autoimmune
   Hepatitis: Controlled, Double-Blind, Randomized Trial
SO HEPATOLOGY COMMUNICATIONS
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; HYDROXYCHLOROQUINE;
   DIAGNOSIS; THERAPY; SUSCEPTIBILITY; WITHDRAWAL; PHENOTYPES
AB Between 50% and 86% of patients with autoimmune hepatitis (AIH) relapse after immunosuppression withdrawal; long-term immunosuppression is associated with increased risk of neoplasias and infections. Chloroquine diphosphate (CQ) is an immunomodulatory drug that reduces the risk of flares in rheumatologic diseases. Our aims were to investigate the efficacy and safety of CQ for maintenance of biochemical remission of AIH in a double-blind randomized trial and to define a subgroup that obtained a greater benefit from its use. A total of 61 patients with AIH in histologic remission (90.1% AIH type 1 [AIH-1]) were randomized to receive CQ 250 mg/day or placebo for 36 months. Of the 61 patients, 31 received CQ and 30 placebo. At baseline, clinical, laboratory, histologic findings, and human leukocyte antigen (HLA) profile were similar between the two groups. Relapse-free survival was significantly higher in the CQ group compared to the placebo group (59.3% and 19.9%, respectively P = 0.039). For those patients completing 3-year treatment, relapse rates were 41.6% and 0% after CQ and placebo withdrawal, respectively. Factors associated with a higher risk of relapse in multiple Cox regression were placebo use (hazard ratio, 2.4; 95% confidence interval [CI], 1.055.5; P = 0.039) and anti-soluble liver antigen/liver-pancreas (anti-SLA/LP) seropositivity (hazard ratio, 5.4; 95% CI, 1.91-15.3; P = 0.002). Although it was not possible to define a subgroup that obtained a greater benefit from CQ according to anti-SLA/LP reactivity or HLA profile, 100% of patients who were anti-SLA/LP-positive (+) relapsed with placebo compared to 50% with CQ (P = 0.055). In the CQgroup, 54.8% had side effects and 19.3% interrupted the drug regimen. Conclusion: CQ safely reduced the risk of relapse of AIH, but it was not possible to define a subgroup that obtained a greater benefit with CQ use, probably because of sample size.
C1 [Benedita Terrabuio, Debora Raquel; de Moraes Falcao, Lydia Teofilo; Vilar Guedes, Ana Luiza; Nakano, Larissa Akeme; Evangelista, Andreia Silva; Carrilho, Flair Jose; Rachid Cancado, Eduardo Luiz] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hosp Clin,Div Clin Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Diniz, Marcio Augusto] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Biostat & Bioinformat Res Ctr, Los Angeles, CA 90048 USA.
   [Lima, Fabiana Roberto] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   [Abrantes-Lemos, Clarice Pires; Rachid Cancado, Eduardo Luiz] Univ Sao Paulo, Inst Trop Med, Lab Med Invest Immunopathol Schistosomiasis, Sao Paulo, Brazil.
RP Terrabuio, DRB (corresponding author), Univ Sao Paulo, Sch Med, Hosp Clin, Div Clin Gastroenterol & Hepatol, Ave Doutor Eneas de Carvalho Aguiar 255,Room 9159, BR-05403000 Sao Paulo, SP, Brazil.
EM debora.terrabuio@hc.fm.usp.br
OI NAKANO, LARISSA/0000-0002-6838-3306
FU Federico Foundation
FX E.L.R.C received a grant from the Federico Foundation as a stimulus to
   dedicate to this research.
CR ADAMOLEKUN B, 1992, CENT AFR J MED, V38, P350
   Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   ANDERSON TW, 1952, ANN MATH STAT, V23, P193, DOI 10.1214/aoms/1177729437
   Avina-Zubieta JA, 1998, ANN RHEUM DIS, V57, P582, DOI 10.1136/ard.57.10.582
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Chen ZX, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000953
   Costedoat-Chalumeau N, 2015, CLIN REV ALLERG IMMU, V49, P317, DOI 10.1007/s12016-015-8469-8
   CZAJA AJ, 1981, GASTROENTEROLOGY, V80, P687
   Czaja AI, 2009, WORLD J GASTROENTERO, V15, P2314, DOI 10.3748/wjg.15.2314
   Czaja AJ, 2006, LIVER INT, V26, P552, DOI 10.1111/j.1478-3231.2006.01249.x
   da Silva JC, 2013, CLINICS, V68, P766, DOI 10.6061/clinics/2013(06)07
   ESDAILE J, 1991, NEW ENGL J MED, V324, P150
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   Galil SMA, 2015, LUPUS, V24, P638, DOI 10.1177/0961203314561667
   Gayotto LCC, 2000, GED, V19, P137
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   Kanzler S, 2001, J HEPATOL, V34, P354, DOI 10.1016/S0168-8278(00)00095-7
   Levene H., 1960, CONTRIBUTIONS PROBAB, P278
   Liberal R, 2016, REV CLIN ESP, V216, P372, DOI 10.1016/j.rce.2016.04.003
   Lohse AW, 2015, J HEPATOL, V63, P971, DOI 10.1016/j.jhep.2015.06.030
   Manns MP, 2010, HEPATOLOGY, V51, P2193, DOI 10.1002/hep.23584
   Montano-Loza AJ, 2007, LIVER INT, V27, P507, DOI 10.1111/j.1478-3231.2007.01444.x
   Mucenic Marcos, 2005, Arq. Gastroenterol., V42, P249, DOI 10.1590/S0004-28032005000400011
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   National Institutes of Health National Cancer Institute US Department of Health and Human Services, COMM TERM CRIT ADV E
   Ngu JH, 2012, HEPATOLOGY, V55, P522, DOI 10.1002/hep.24743
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Rodriguez-Caruncho C, 2014, ACTAS DERMO-SIFILOGR, V105, P243, DOI [10.1016/j.adengl.2012.10.021, 10.1016/j.ad.2012.10.005]
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   SCHERBEL A L, 1957, Cleve Clin Q, V24, P98
   SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Ugarte-Gil MF, 2018, LUPUS, V27, P536, DOI 10.1177/0961203317728810
   van Gerven NMF, 2013, J HEPATOL, V58, P141, DOI 10.1016/j.jhep.2012.09.009
   Vergani D, 2004, J HEPATOL, V41, P677, DOI 10.1016/j.jhep.2004.08.002
NR 36
TC 3
Z9 4
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2471-254X
J9 HEPATOL COMMUN
JI Hepatol. Commun.
PD JAN
PY 2019
VL 3
IS 1
BP 116
EP 128
DI 10.1002/hep4.1275
PG 13
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HF9SX
UT WOS:000454583900011
PM 30619999
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU da Fonseca, LG
   Marta, GN
   Braghiroli, MIFM
   Chagas, AL
   Carrilho, FJ
   Hoff, PM
   Sabbaga, J
AF da Fonseca, Leonardo Gomes
   Marta, Guilherme Nader
   Freitas Melro Braghiroli, Maria Ignez
   Chagas, Aline Lopes
   Carrilho, Flair Jose
   Hoff, Paulo Marcelo
   Sabbaga, Jorge
TI Safety and efficacy of cytotoxic chemotherapy in hepatocellular
   carcinoma after first-line treatment with sorafenib
SO BMC CANCER
LA English
DT Article
DE Hepatocellular carcinoma; Sorafenib; Cytotoxic chemotherapy; Survival
   rate
ID RANDOMIZED PHASE-III; DOUBLE-BLIND; OXALIPLATIN; DOXORUBICIN; THERAPY;
   PLACEBO; MULTICENTER; GEMCITABINE; SURVIVAL; CANCER
AB BackgroundBefore the targeted therapies era, cytotoxic chemotherapy (CCT) was an option for advanced hepatocellular carcinoma (HCC), even with the lack of supporting evidence. Since the last decade, sorafenib has been established as the first-line therapy. Although new agents are being incorporated, CCT is still considered in regions where new drugs are not available or for patients who progressed through the approved therapies and remain in good clinical condition. We aimed to describe our experience regarding the use of CCT as second-line treatment after sorafenib.MethodsA database of 273 patients was evaluated. Patients that received CCT after sorafenib progression were selected for the analysis. Descriptive statistics was used for categorical and continue variables. Median survival was estimated with Kaplan-Meier curves. Variables were found to be significant if the two-sided p value was 0.05 on multivariate testing using the Cox regression model.ResultsForty-five patients received CCT; 33 (73.3%) had Child-Pugh classification A, and 34 (75.6%) had stage C according to the Barcelona Clinic Liver Cancer (BCLC) staging system. The most used regimen was doxorubicin in 25 patients (55.6%). Median overall survival (OS) was 8.05 months (95% confidence interval [CI] 2.73 - 9.88 months). The 6-month and 1-year survival probability was 52.4% and 27.36%, respectively. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 and disease control with sorafenib was independently associated with better OS in patients treated with CCT. Any-grade toxicities were observed in 82.2% and grade 3-4 in 44.4% of the patients.ConclusionIn accordance with previous studies, CCT had a notable rate of adverse events. The poor prognosis of this cohort suggests that CCT may not alter the natural history of HCC after sorafenib progression.
C1 [da Fonseca, Leonardo Gomes; Marta, Guilherme Nader; Freitas Melro Braghiroli, Maria Ignez; Hoff, Paulo Marcelo; Sabbaga, Jorge] Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, Av Dr Arnaldo 251, BR-01246000 Sao Paulo, Brazil.
   [Chagas, Aline Lopes; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol,Hosp Clin Complex, Sao Paulo Clin Liver Canc Grp,Inst Canc Estado Sa, Sao Paulo, Brazil.
RP da Fonseca, LG (corresponding author), Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, Av Dr Arnaldo 251, BR-01246000 Sao Paulo, Brazil.
EM leogfonseca@hotmail.com
RI Chagas, Aline Lopes/X-2059-2019
CR Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002
   Abou-Alfa GK, 2010, JAMA-J AM MED ASSOC, V304, P2154, DOI 10.1001/jama.2010.1672
   Abou-Alfa GK, 2016, J CLIN ONCOL S, V34
   Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2
   Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297
   International Agency for Research on Cancer, GLOBOCAN 2012 EST CA
   Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410
   Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1
   LAI CL, 1988, CANCER, V62, P479, DOI 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
   Lencioni R, 2017, J HEPATOL, V66, P1166, DOI 10.1016/j.jhep.2017.01.012
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Louafi S, 2007, CANCER-AM CANCER SOC, V109, P1384, DOI 10.1002/cncr.22532
   Patrikidou A, 2014, INVEST NEW DRUG, V32, P1028, DOI 10.1007/s10637-014-0100-y
   Qin SK, 2013, J CLIN ONCOL, V31, P3501, DOI 10.1200/JCO.2012.44.5643
   Yeo W, 2005, JNCI-J NATL CANCER I, V97, P1532, DOI 10.1093/jnci/dji315
   Yothers G, 2011, J CLIN ONCOL, V29, P3768, DOI 10.1200/JCO.2011.36.4539
   Zhu AX, 2015, LANCET ONCOL, V16, P859, DOI 10.1016/S1470-2045(15)00050-9
   Zhu AX, 2015, J CLIN ONCOL, V33, P559, DOI 10.1200/JCO.2013.53.7746
   2018, J HEPATOL, V69, P182, DOI DOI 10.1016/J.JHEP.2018.03.019
NR 24
TC 4
Z9 6
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 13
PY 2018
VL 18
AR 1250
DI 10.1186/s12885-018-5173-0
PG 7
WC Oncology
SC Oncology
GA HE3DA
UT WOS:000453230400003
PM 30545331
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Linhares, LMC
   Oliveira, CP
   Alvares-da-Silva, MR
   Stefano, JT
   Barbeiro, HV
   Barbeiro, DF
   Terrabuio, DRB
   Abdala, E
   Soriano, FG
   Carrilho, FJ
   Farias, AQ
   Siddiqui, MS
   D'Albuquerque, LAC
AF Linhares, L. M. C.
   Oliveira, C. P.
   Alvares-da-Silva, M. R.
   Stefano, J. T.
   Barbeiro, H. V.
   Barbeiro, D. F.
   Terrabuio, D. R. B.
   Abdala, E.
   Soriano, F. G.
   Carrilho, F. J.
   Farias, A. Q.
   Siddiqui, M. S.
   D'Albuquerque, L. A. C.
TI Evolution of Biomarkers of Atherogenic Risk in Liver Transplantation
   Recipients
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID C-REACTIVE PROTEIN; COMPUTED-TOMOGRAPHY; METABOLIC SYNDROME; OUTCOMES;
   QUANTIFICATION; ASSOCIATION; PREDICTION; MORTALITY; DISEASE
AB Background. Cardiovascular disease is a major contributing factor to long-term mortality after liver transplantation (LT).
   Methods. This study evaluated the evolution of atherogenic risk in liver transplant recipients (LTRs). Thirty-six subjects were prospectively enrolled at 12 months and followed for 48 months after liver transplantation. Serum biomarkers of endothelial dysfunction (sICAM-1 and sVCAM-1), chronic inflammation (serum amyloid A), and oxidative stress (myeloperoxidase) were measured at 12 and 48 months after LT. Additionally, at 12 months all patients underwent a cardiac computed tomography (CT) scan and a coronary artery calcium score (CACS).
   Results. The prevalence of risk factors of metabolic syndrome (MS) increased over the course of the study. The patients' sVCAM-1 and sICAM-1 increased from 1.82 +/- 0.44 ng/mL to 9.10 +/- 5.82 ng/mL (P < .001) and 0.23 +/- 0.09 ng/mL to 2.7 +/- 3.3 ng/mL, respectively from month 12 to 48. Serum myeloperoxidase increased from 0.09 +/- 0.07 ng/mL to 3.46 +/- 3.92 ng/mL (P < .001) over the course of the study. Serum amyloid A also increased from 21.4 +/- 40.7 ng/mL at entry to 91.5 +/- 143.6 ng/mL at end of study (P < .001).
   Conclusion. No association between these biomarkers and MS was noted. The cardiac CT revealed mild and moderate disease in 19% and 25% of the cohort, respectively. No association between serum biomarkers and CACS was noted. Serum biomarkers of atherogenic risk increase rapidly in LTRs and precede coronary plaques.
C1 [Linhares, L. M. C.; Oliveira, C. P.; Stefano, J. T.; Terrabuio, D. R. B.; Abdala, E.; Carrilho, F. J.; Farias, A. Q.; D'Albuquerque, L. A. C.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07 LIM 37, Sao Paulo, Brazil.
   [Alvares-da-Silva, M. R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Gastroenterol, Porto Alegre, RS, Brazil.
   [Barbeiro, H. V.; Barbeiro, D. F.; Soriano, F. G.] Univ Sao Paulo, Sch Med, Div Emergency Med LIM 51, Sao Paulo, Brazil.
   [Siddiqui, M. S.] Virginia Commonwealth Univ, Div Gastroenterol & Hepatol, Med Coll Virginia Campus, Richmond, VA 23284 USA.
RP Oliveira, CP (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas Carvalho Aguiar 255,Inst Cent 9159, BR-05403000 Sao Paulo, Brazil.
EM cpm@usp.br
RI Abdala, Edson/H-5165-2012; Farias, Alberto/ABB-1291-2020; Oliveira,
   Claudia PMS/D-1216-2014; Stefano, Jose Tadeu/AAH-5419-2020;
   Alvares-da-Silva, Mario Reis/L-3910-2014; D'ALBUQUERQUE, Luiz Carneiro
   Augusto/I-4011-2012; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   Barbeiro, Hermes V/S-5926-2016; Barbeiro, Hermes V/E-2814-2010; Soriano,
   Francisco/C-3382-2012
OI Abdala, Edson/0000-0003-0765-6654; Farias, Alberto/0000-0002-5572-663X;
   Stefano, Jose Tadeu/0000-0002-0218-1920; Alvares-da-Silva, Mario
   Reis/0000-0002-5001-246X; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Barbeiro, Hermes V/0000-0002-8209-4463;
   Barbeiro, Hermes V/0000-0002-8209-4463; Soriano,
   Francisco/0000-0003-4898-0135
FU Coordination for the Improvement of Higher Education Personnel at the
   University of Sao Paulo
FX This work was supported by a scholarship funded by the Coordination for
   the Improvement of Higher Education Personnel at the University of Sao
   Paulo.
CR Aberg F, 2015, HEPATOLOGY, V61, P668, DOI 10.1002/hep.27538
   AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T
   Baid S, 2001, TRANSPLANTATION, V72, P1066, DOI 10.1097/00007890-200109270-00015
   Bhati C, 2017, TRANSPLANTATION, V101, P1867, DOI 10.1097/TP.0000000000001709
   Bianchi G, 2008, LIVER TRANSPLANT, V14, P1648, DOI 10.1002/lt.21588
   Chhatrala R, 2015, LIVER TRANSPLANT, V21, P623, DOI 10.1002/lt.24100
   Connolly GM, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-23
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Dare AJ, 2014, LIVER TRANSPLANT, V20, P281, DOI 10.1002/lt.23818
   Detrano RC, 2004, AM J CARDIOL, V93, P624, DOI 10.1016/j.amjcard.2003.11.034
   Fussner LA, 2015, LIVER TRANSPLANT, V21, P889, DOI 10.1002/lt.24137
   Greenland P, 2004, JAMA-J AM MED ASSOC, V291, P210, DOI 10.1001/jama.291.2.210
   GRUNDY S. M., 2005, CRITICAL PATHWAYS CA, V4, P198, DOI DOI 10.1097/00132577-200512000-00018
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Idowu MO, 2015, LIVER TRANSPLANT, V21, P1395, DOI 10.1002/lt.24223
   Kosuge M, 2007, CIRC J, V71, P186, DOI 10.1253/circj.71.186
   Laryea M, 2007, LIVER TRANSPLANT, V13, P1109, DOI 10.1002/lt.21126
   Leber AW, 2005, J AM COLL CARDIOL, V46, P147, DOI 10.1016/j.jacc.2005.03.071
   Martin P, 2014, HEPATOLOGY, V59, P1144, DOI 10.1002/hep.26972
   Ogawa H, 1999, AM J CARDIOL, V83, P38, DOI 10.1016/S0002-9149(98)00779-6
   Siddiqui MS, 2016, GASTROENTEROLOGY, V150, P1849, DOI 10.1053/j.gastro.2016.02.077
   Stankovic S, 2012, CLIN LAB, V58, P125
   Watt KDS, 2010, AM J TRANSPLANT, V10, P1420, DOI 10.1111/j.1600-6143.2010.03126.x
   Watt KDS, 2009, GASTROENTEROLOGY, V137, P2010, DOI 10.1053/j.gastro.2009.08.070
   Wawrzynowicz-Syczewska M, 2009, ANN TRANSPL, V14, P45
   Zhang YX, 1999, ATHEROSCLEROSIS, V145, P375, DOI 10.1016/S0021-9150(99)00105-7
NR 26
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2018
VL 50
IS 10
BP 3650
EP 3655
DI 10.1016/j.transproceed.2018.04.030
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA HG4VB
UT WOS:000454972000120
PM 30586839
DA 2020-12-08
ER

PT J
AU Horvat, N
   Rocha, MS
   Chagas, AL
   Oliveira, BC
   Pacheco, MP
   Binotto, MA
   Ikari, NM
   Paranagua-Vezozzo, DC
   Leao, HM
   Vicentini, JRT
   Filho, MRMD
   Jatene, MB
   Carrilho, FJ
   Cerri, GG
AF Horvat, Natally
   Rocha, Manoel Souza
   Chagas, Aline Lopes
   Oliveira, Brunna Clemente
   Pacheco, Mariana Poltronieri
   Binotto, Maria Angelica
   Ikari, Nana Miura
   Paranagua-Vezozzo, Denise Cerqueira
   Leao-Filho, Hilton Muniz
   Terneira Vicentini, Joao Rafael
   Moreira da Silva Filho, Mauricio Ricardo
   Jatene, Marcelo Biscegli
   Carrilho, Flair Jose
   Cerri, Giovanni Guido
TI Multimodality Screening of Hepatic Nodules in Patients With Congenital
   Heart Disease After Fontan Procedure: Role of Ultrasound, ARFI
   Elastography, CT, and MRI
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE CT; Fontan procedure; liver disease; MDCT; MRI; ultrasound
ID HEPATOCELLULAR-CARCINOMA; CARDIAC CIRRHOSIS; LONG-TERM; LIVER;
   CIRCULATION; OPERATION; FIBROSIS; MANAGEMENT; PATHOLOGY; SURVIVAL
AB OBJECTIVE. Currently, there is no consensus in the literature regarding the screening of hepatic nodules in patients who have undergone the Fontan procedure. The objectives of this study are to evaluate in this population the frequency of hepatic nodules at ultrasound (US), CT, and MRI; to measure liver stiffness using acoustic radiation force impulse (ARFI) elastography; and to investigate predictive factors for hepatic nodules.
   SUBJECTS AND METHODS. In this cross-sectional study, 49 patients who underwent the Fontan procedure were prospectively recruited from August 2014 through June 2016. These patients underwent clinical evaluation for hepatic disorders, ARFI elastography, US, CT, and MRI.
   RESULTS. Most of the patients had no symptoms, and hepatic nodules were detected in three of 49 (6.1%) patients at US, 14 of 44 (31.8%) patients at CT, and 19 of 48 (39.6%) patients at MRI. Liver stiffness at ARFI elastography was significantly higher in patients with hepatic nodules than i n patients without such nodules (2.64 +/- 0.81 m/s vs 1.94 +/- 0.49 m/s; p = 0.002) and was a significant predictor of hepatic nodule (AUC, 0.767; p = 0.002). No clinical or laboratory data had any significant correlation with the existence of hepatic nodules, including time since Fontan procedure.
   CONCLUSION. In our study, more than one-third of patients had hepatic nodules at CT or MRI, but US did not detect most hepatic nodules. Liver stiffness at ARFI elastography was significantly higher in patients with hepatic nodules, and it may help guiding which patient should be further imaged with CT or MRI.
C1 [Horvat, Natally; Rocha, Manoel Souza; Oliveira, Brunna Clemente; Leao-Filho, Hilton Muniz; Terneira Vicentini, Joao Rafael; Cerri, Giovanni Guido] Univ Sao Paulo, Fac Med, Hosp Clin, Radiol Dept, Rua Dr Ovidio Pires de Campos,255 Cerqueira Cesar, BR-05403900 Sao Paulo, SP, Brazil.
   [Chagas, Aline Lopes; Pacheco, Mariana Poltronieri; Paranagua-Vezozzo, Denise Cerqueira; Carrilho, Flair Jose] Univ Sao Paulo, Fac Med, Hosp Clin, Hepatol Dept, Sao Paulo, Brazil.
   [Binotto, Maria Angelica; Ikari, Nana Miura; Jatene, Marcelo Biscegli] Univ Sao Paulo, Fac Med, Hosp Clin, Cardiol Dept, Sao Paulo, Brazil.
   [Moreira da Silva Filho, Mauricio Ricardo] Univ Sao Paulo, Med Sch, Sao Paulo, Brazil.
RP Horvat, N (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Radiol Dept, Rua Dr Ovidio Pires de Campos,255 Cerqueira Cesar, BR-05403900 Sao Paulo, SP, Brazil.
EM natallymhorvat@gmail.com
RI Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014; Jatene, Marcelo
   Biscegli/AAZ-6246-2020; Rocha, Manoel S/C-6478-2013; Chagas, Aline
   Lopes/X-2059-2019
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; Jatene, Marcelo
   Biscegli/0000-0002-3465-0533; Rocha, Manoel S/0000-0002-4503-8374;
   POLTRONIERI PACHECO, MARIANA/0000-0002-3932-3195
CR Asrani SK, 2013, NEW ENGL J MED, V368, P1756, DOI 10.1056/NEJMc1214222
   Babaoglu K, 2010, PEDIATR CARDIOL, V31, P861, DOI 10.1007/s00246-010-9685-x
   Baumgartner H, 2010, EUR HEART J, V31, P2915, DOI 10.1093/eurheartj/ehq249
   Bhatt AB, 2015, CIRCULATION, V131, P1884, DOI 10.1161/CIR.0000000000000204
   Bradley Elisa, 2015, Curr Treat Options Cardiovasc Med, V17, P51, DOI 10.1007/s11936-015-0412-z
   Bryant T, 2011, INT J CARDIOL, V151, P268, DOI 10.1016/j.ijcard.2010.05.047
   Bulut OP, 2013, J PEDIATR-US, V163, P201, DOI 10.1016/j.jpeds.2012.12.071
   Camposilvan S, 2008, ANN THORAC SURG, V86, P177, DOI 10.1016/j.athoracsur.2008.03.077
   Daniels CJ, 2017, J AM COLL CARDIOL, V70, P3173, DOI 10.1016/j.jacc.2017.10.045
   Eipel C, 2010, WORLD J GASTROENTERO, V16, P6046, DOI 10.3748/wjg.v16.i48.6046
   Elsayes KM, 2017, RADIOGRAPHICS, V37, P1994, DOI 10.1148/rg.2017170098
   Ewe SH, 2009, CONGENIT HEART DIS, V4, P103, DOI 10.1111/j.1747-0803.2009.00255.x
   FONTAN F, 1971, THORAX, V26, P240, DOI 10.1136/thx.26.3.240
   FONTAN F, 1990, CIRCULATION, V81, P1520, DOI 10.1161/01.CIR.81.5.1520
   Friedrich-Rust M, 2008, J THORAC CARDIOV SUR, V135, P560, DOI 10.1016/j.jtcvs.2007.09.039
   Gewillig M, 2005, HEART, V91, P839, DOI 10.1136/hrt.2004.051789
   Ghaferi AA, 2005, J THORAC CARDIOV SUR, V129, P1348, DOI 10.1016/j.jtcvs.2004.10.005
   Guerin F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125493
   Huppertz A, 2005, RADIOLOGY, V234, P468, DOI 10.1148/radiol.2342040278
   Jacobs JP, 2013, WORLD J PEDIATR CONG, V4, P349, DOI 10.1177/2150135113494228
   Kendall TJ, 2008, J CLIN PATHOL, V61, P504, DOI 10.1136/jcp.2007.052365
   Khairy P, 2008, CIRCULATION, V117, P85, DOI 10.1161/CIRCULATIONAHA.107.738559
   Khairy P, 2007, CIRCULATION, V115, P800, DOI 10.1161/CIRCULATIONAHA.105.592378
   Kiesewetter CH, 2007, HEART, V93, P579, DOI 10.1136/hrt.2006.094516
   Kutty SS, 2014, HEPATOLOGY, V59, P251, DOI 10.1002/hep.26631
   Kwon S, 2015, J GASTROINTEST ONCOL, V6, pE55, DOI 10.3978/j.issn.2078-6891.2015.009
   Melero-Ferrer JL, 2014, WORLD J PEDIATR CONG, V5, P365, DOI 10.1177/2150135114530172
   Maisey NR, 2000, BRIT J CANCER, V83, P287, DOI 10.1054/bjoc.2000.1166
   OH C, 2016, MEDICINE, V95, DOI DOI 10.1097/MD.0000000000004823
   Ono M, 2006, EUR J CARDIO-THORAC, V30, P923, DOI 10.1016/j.ejcts.2006.08.025
   Pellicoro A, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-S1-S26
   Poterucha JT, 2015, MAYO CLIN PROC, V90, P882, DOI 10.1016/j.mayocp.2015.04.020
   Rockey DC, 2009, HEPATOLOGY, V49, P1017, DOI 10.1002/hep.22742
   Rychik J, 2012, PEDIATR CARDIOL, V33, P1001, DOI 10.1007/s00246-012-0315-7
   Seale MK, 2009, RADIOGRAPHICS, V29, P1725, DOI 10.1148/rg.296095515
   Silversides CK, 2010, CAN J CARDIOL, V26, pE98, DOI 10.1016/S0828-282X(10)70356-1
   Surrey LF, 2016, HUM PATHOL, V57, P106, DOI 10.1016/j.humpath.2016.07.006
   Takuma Y, 2016, INTERNAL MED, V55, P3265, DOI 10.2169/internalmedicine.55.6869
   Valla DC, 2018, HEPATOL INT, V12, pS168, DOI 10.1007/s12072-017-9810-5
   Wallihan DB, 2013, PEDIATR RADIOL, V43, P330, DOI 10.1007/s00247-012-2531-y
   Yoo BW, 2014, J THORAC CARDIOV SUR, V148, P1498, DOI 10.1016/j.jtcvs.2014.04.010
NR 41
TC 6
Z9 7
U1 0
U2 4
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD DEC
PY 2018
VL 211
IS 6
BP 1212
EP 1220
DI 10.2214/AJR.18.19762
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA HB3OS
UT WOS:000450961700013
PM 30247977
DA 2020-12-08
ER

PT J
AU Nacif, LS
   Kim, V
   Galvao, F
   Ono, SK
   Pinheiro, RS
   Carrilho, FJ
   D'Albuquerque, LC
AF Nacif, Lucas Souto
   Kim, Vera
   Galvao, Flavio
   Ono, Suzane Kioko
   Pinheiro, Rafael Soares
   Carrilho, Flair Jose
   D'Albuquerque, Luiz Carneiro
TI Translational medical research and liver transplantation: systematic
   review
SO TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Review
DE Liver transplantation (LT); transplantation; systematic review;
   translational medical research
ID ISCHEMIA-REPERFUSION INJURY; ACUTE CELLULAR REJECTION; DONOR LIVER;
   PROTEOMIC ANALYSIS; RAT MODEL; TACROLIMUS; POLYMORPHISMS; PROFILES;
   CYP3A5; VIRUS
AB Translational medicine has become a priority, but there is still a big difference between the arrival of new treatments and investment. Basic science should not be neglected because the translation from basic research is not sustained in the absence of basic research. The purpose of this literature review was to analyze the translational medicine in the liver transplant field: liver ischemia-reperfusion injury (IRI), immunosuppression, clinical and surgical complications, small-for-size syndrome (SFSS), rejection, and ongoing innovations (liver machine, liver preservation, artificial livers, and regenerative medicine). We performed a systematic literature review that were updated in October 2016. The searches were performed in the Cochrane Central Register of Controlled Trials and Review, PubMed/Medline, Embase, and LILACS databases. All the selected studies on the management of translational medical research in liver transplantation (LT) were analyzed. Initially the search found 773 articles. Methodological viewing and analysis of the articles, followed by the application of scientific models, including translational medicine in the liver transplant field. In conclusions, this review demonstrates the application of scientific research with translation medical benefits regarding the LT. The literature has a great tendency, improvements and investments in the study of translational medicine in LT. Innovative studies and technologies from basic science help to clarify clinical doubts. Moreover, evidence increases the importance of scientific research in quality of clinical practice care.
C1 [Nacif, Lucas Souto; Kim, Vera; Galvao, Flavio; Ono, Suzane Kioko; Pinheiro, Rafael Soares; Carrilho, Flair Jose; D'Albuquerque, Luiz Carneiro] Univ Sao Paulo, Disciplina Transplante Figado & Orgaos Aparelho D, Hosp Clin HCFMUSP, Dept Gastroenterol,Fac Med, Sao Paulo, Brazil.
RP Nacif, LS (corresponding author), Rua Dr Eneas de Carvalho Aguiar 255,9o Andar, BR-05403900 Sao Paulo, Brazil.
EM lucasnacif@usp.br
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; D'Albuquerque, Luiz
   Augusto Carneiro/A-8812-2013; Nacif, Lucas S./B-2795-2013
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Nacif, Lucas
   S./0000-0002-7059-3978; GALVAO, FLAVIO/0000-0003-1924-3208
CR Beland K, 2014, J INFECT DIS, V209, P247, DOI 10.1093/infdis/jit423
   Bonaccorsi-Riani E, 2016, AM J TRANSPLANT, V16, P484, DOI 10.1111/ajt.13488
   Chen DW, 2014, DRUG METAB PHARMACOK, V29, P249, DOI 10.2133/dmpk.DMPK-13-RG-095
   Chen DB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077455
   Chen XL, 2011, TRANSPLANTATION, V91, P293, DOI 10.1097/TP.0b013e318204756c
   Cheng J, 2010, EUR SURG RES, V44, P43, DOI 10.1159/000264602
   Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523
   Crettol S, 2008, PHARMACOGENET GENOM, V18, P307, DOI 10.1097/FPC.0b013e3282f7046f
   Cursio R, 2010, HPB, V12, P1, DOI 10.1111/j.1477-2574.2009.00123.x
   Dong J, 2016, AM J TRANSL RES, V8, P2562
   Egawa H, 2012, HEPATOL RES, V42, P895, DOI 10.1111/j.1872-034X.2012.01003.x
   Elens L, 2007, PHARMACOGENET GENOM, V17, P873, DOI 10.1097/FPC.0b013e3282e9a533
   Emadali A, 2006, MOL CELL PROTEOMICS, V5, P1300, DOI 10.1074/mcp.M500393-MCP200
   Fukudo M, 2008, PHARMACOGENET GENOM, V18, P413, DOI 10.1097/FPC.0b013e3282f9ac01
   Gehrau R, 2016, AM J TRANSPLANT, V16, P378
   Goto S, 2014, TRANSPLANTATION, V98, P309
   Hashmi SK, 2015, TRANSPLANT REV-ORLAN, V29, P23, DOI 10.1016/j.trre.2014.01.002
   Hsu LW, 2007, TRANSPL IMMUNOL, V17, P137, DOI 10.1016/j.trim.2006.06.001
   Hsu LW, 2015, HEPATOL RES, V45, P804, DOI 10.1111/hepr.12413
   Iguchi K, 2014, LIVER TRANSPLANT, V20, P838, DOI 10.1002/lt.23884
   Jassem W, 2009, LIVER TRANSPLANT, V15, P1750, DOI 10.1002/lt.21936
   Joshi D, 2013, LIVER TRANSPLANT, V19, P383, DOI 10.1002/lt.23613
   Kristo I, 2011, TRANSPL INT, V24, P912, DOI 10.1111/j.1432-2277.2011.01284.x
   Kurian SM, 2015, AM J TRANSPLANT, V15, P1605, DOI 10.1111/ajt.13145
   Levitsky J, 2013, HEPATOLOGY, V57, P239, DOI 10.1002/hep.25579
   Li J, 2015, CYTOKINE GROWTH F R, V26, P67, DOI 10.1016/j.cytogfr.2014.11.004
   Mankoff S. P., 2004, J TRANSL MED, V2, P14, DOI DOI 10.1186/1479-5876-2-14
   Nacif LS, 2017, ANN TRANSPL, V22, P9, DOI 10.12659/AOT.901010
   Nakano T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037202
   Nakano T, 2010, IMMUNOLOGY, V129, P547, DOI 10.1111/j.1365-2567.2009.03149.x
   Ningappa M, 2016, AM J TRANSPLANT, V16, P497, DOI 10.1111/ajt.13509
   Orlando Giuseppe, 2011, Transpl Int, V24, P223, DOI 10.1111/j.1432-2277.2010.01182.x
   Parikh CR, 2014, HEPATOLOGY, V59, P1242, DOI 10.1002/hep.27031
   Qin JJ, 2016, AM J TRANSL RES, V8, P3364
   Raza A, 2010, LIVER TRANSPLANT, V16, P588, DOI 10.1002/lt.22049
   Selzner N, 2012, TRANSPLANT REV-ORLAN, V26, P115, DOI 10.1016/j.trre.2011.07.003
   Smith HE, 2008, PHARMACOGENET GENOM, V18, P943, DOI 10.1097/FPC.0b013e32830e1e16
   Tapirdamaz O, 2014, PHARMACOGENET GENOM, V24, P427, DOI 10.1097/FPC.0000000000000063
   Taubert R, 2012, AM J TRANSPLANT, V12, P3425, DOI 10.1111/j.1600-6143.2012.04264.x
   Uesugi M, 2014, PHARMACOGENET GENOM, V24, P356, DOI 10.1097/FPC.0000000000000060
   Wei W, 2015, CLIN RES HEPATOL GAS, V39, P340, DOI 10.1016/j.clinre.2014.10.005
   Wu Y, 2009, OMICS, V13, P81, DOI 10.1089/omi.2008.0061
   Xu M, 2014, SHOCK, V42, P65, DOI 10.1097/SHK.0000000000000171
   Yagi S, 2013, AM J TRANSPLANT, V13, P222, DOI 10.1111/j.1600-6143.2012.04310.x
   Zhai Y, 2013, NAT REV GASTRO HEPAT, V10, P79, DOI 10.1038/nrgastro.2012.225
   Zhou ST, 2014, J SURG RES, V187, P297, DOI 10.1016/j.jss.2013.10.024
   Zhuang ZN, 2016, AM J TRANSL RES, V8, P1738
NR 47
TC 1
Z9 2
U1 0
U2 3
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224-476X
EI 2415-1289
J9 TRANSL GASTROENT HEP
JI Transl. Gastroenterol. Hepatol.
PD NOV
PY 2018
VL 3
AR 91
DI 10.21037/tgh.2018.10.14
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HG1SD
UT WOS:000454739200005
PM 30603727
OA Green Published
DA 2020-12-08
ER

PT J
AU Leathers, JS
   Balderramo, D
   Prieto, J
   Diehl, F
   Gonzalez-Ballerga, E
   Ferreiro, MR
   Carrera, E
   Barreyro, F
   Diaz-Ferrer, J
   Singh, D
   Mattos, AZ
   Carrilho, F
   Debes, JD
AF Leathers, James S.
   Balderramo, Domingo
   Prieto, Jhon
   Diehl, Fernando
   Gonzalez-Ballerga, Esteban
   Ferreiro, Melina R.
   Carrera, Enrique
   Barreyro, Fernando
   Diaz-Ferrer, Javier
   Singh, Dupinder
   Mattos, Angelo Z.
   Carrilho, Flair
   Debes, Jose D.
TI PIB: A Score to Select Sorafenib Treatment Candidates for Hepatocellular
   Carcinoma in Resource-Limited Settings
SO HEPATITIS MONTHLY
LA English
DT Article
DE HCC; Hepatocellular Carcinoma; Sorafenib; Score
ID PREDICT
C1 [Leathers, James S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Balderramo, Domingo; Diehl, Fernando] Inst Univ Ciencias Biomed Cordoba, Hosp Privado Univ Cordoba, Dept Gastroenterol, Cordoba, Argentina.
   [Prieto, Jhon] Ctr Enfermedades Hepat & Digest CEHYD, Bogota, Colombia.
   [Gonzalez-Ballerga, Esteban; Ferreiro, Melina R.] Hosp Clin Buenos Aires, Dept Gastroenterol, Buenos Aires, DF, Argentina.
   [Carrera, Enrique] Hosp Eugenio Espejo, Dept Gastroenterol & Hepatol, Quito, Ecuador.
   [Barreyro, Fernando] Consejo Nacl Invest Cient & Tecn, Posadas, Argentina.
   [Diaz-Ferrer, Javier] HNERM, Dept Gastroenterol, Lima, Peru.
   [Singh, Dupinder; Debes, Jose D.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Mattos, Angelo Z.] Fed Univ Hlth Sci Porto Alegre, Porto Alegre, RS, Brazil.
   [Carrilho, Flair] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Leathers, JS (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.; Debes, JD (corresponding author), Univ Minnesota, Dept Med, Hennepin Cty Med Ctr, Box 736 UMHC, Minneapolis, MN 55455 USA.
EM james.leathers@vanderbilt.edu; debes003@umn.edu
RI Ford, James/AAQ-4324-2020
OI Ford, James/0000-0003-0311-0718; Balderramo,
   Domingo/0000-0001-9598-2577; Prieto Ortiz, Jhon
   Edison/0000-0002-8009-5999
FU Doris Duke charitable foundationDoris Duke Charitable Foundation (DDCF);
   Robert Wood Johnson foundationRobert Wood Johnson Foundation (RWJF);
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R21CA215883, R21CA215883] Funding Source: NIH RePORTER
FX Supported in part by the Doris Duke charitable foundation through a
   grant supporting the Doris Duke international clinical research fellows
   program and the Robert Wood Johnson foundation.
CR Debes JD, 2018, LIVER INT, V38, P136, DOI 10.1111/liv.13502
   Di Costanzo GG, 2017, TARGET ONCOL, V12, P795, DOI 10.1007/s11523-017-0522-5
   Edeline J, 2017, EUR J CANCER, V86, P135, DOI 10.1016/j.ejca.2017.08.036
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Leathers JS, 2019, J CLIN GASTROENTEROL, V53, P464, DOI 10.1097/MCG.0000000000001085
   Nakanishi H, 2016, LIVER CANCER, V5, P257, DOI 10.1159/000449337
NR 6
TC 0
Z9 0
U1 0
U2 1
PU KOWSAR PUBL
PI HOENSBROEK
PA PATERSWEG 22,, HOENSBROEK, LIMBURG 6431 GC, NETHERLANDS
SN 1735-143X
EI 1735-3408
J9 HEPAT MON
JI Hepat. Mon.
PD OCT
PY 2018
VL 18
IS 10
AR e82345
DI 10.5812/hepatmon.82345
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GZ8ET
UT WOS:000449720300006
PM 30467514
OA Green Accepted, Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Okada, LSDR
   Oliveira, CP
   Stefano, JT
   Nogueira, MA
   da Silva, IDCG
   Cordeiro, FB
   Alves, VAF
   Torrinhas, RS
   Carrilho, FJ
   Puri, P
   Waitzberg, DL
AF dos Reis Rodrigues Okada, Livia Samara
   Oliveira, Claudia P.
   Stefano, Jose Tadeu
   Nogueira, Monize Aydar
   Cotrim Guerreiro da Silva, Ismael Dale
   Cordeiro, Fernanda Bertucce
   Ferreira Alves, Venancio Avancini
   Torrinhas, Raquel Susana
   Carrilho, Flair Jose
   Puri, Puneet
   Waitzberg, Dan L.
TI Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial
   dysfunction markers in NASH - Proteomic and lipidomic insight
SO CLINICAL NUTRITION
LA English
DT Article
DE Omega-3 PUFA; NASH; Proteomic; Lipidomic; Mitochondrial dysfunction;
   Endoplasmic reticulum stress
ID NONALCOHOLIC FATTY LIVER; ENDOPLASMIC-RETICULUM STRESS; BINDING PROTEIN;
   ENERGY HOMEOSTASIS; HEPATIC STEATOSIS; DISEASE; ACID; STEATOHEPATITIS;
   CELLS; GENE
AB Background & aims: Currently there is no FDA-approved therapy for nonalcoholic steatohepatitis (NASH). Increased n-6/n-3 polyunsaturated fatty acids (PUFA) ratio can induce endoplasmic reticulum (ER) stress and mitochondrial dysfunction that characterize NASH. Our recent study with n-3 PUFA showed improvement in individual histologic parameters like steatosis, ballooning and lobular inflammation. We hypothesized that n-3 PUFA therapy mediated improvement in histologic parameters is modulated by lipidomic and proteomic changes.
   Methods: We therefore evaluated hepatic proteomic and plasma lipidomic profiles before and after n-3 PUFA therapy in subjects with NASH. In a double-blind, randomized, placebo-controlled trial, patients with NASH received 6-month treatment with n-3 PUFA (0.945 g/day [64% alpha-linolenic (ALA), 21% eicosapentaenoic (EPA), and 16% docosahexaenoic (DHA) acids]). Paired liver biopsy and plasma collected before and after-n-3 PUFA therapy were assessed using mass spectrometry and gas chromatography for hepatic proteomics and plasma lipidomics. Data were matched to UniProt and LIPID MAPS database, respectively. Cytoscape software was used to analyze functional pathways. Twenty-seven NASH patients with paired liver histology and plasma before and after n-3 PUFA treatment were studied.
   Results: Treatment with n-3 PUFA significantly increased ALA, EPA, and glycerophospholipids, and decreased arachidonic acid (p < 0.05 for all). Further, proteomic markers of cell matrix, lipid metabolism, ER stress and cellular respiratory pathways were also modulated. Interestingly, these alterations reflected functional changes highly suggestive of decreased cellular lipotoxicity potential; reduced ER proteasome degradation of proteins and induction of chaperones; and a shift in cell energy homeostasis towards mitochondrial beta-oxidation.
   Conclusion: Six-month treatment with omega-3 PUFAs significantly improved hepatic proteomic and plasma lipidomic markers of lipogenesis, endoplasmic reticulum stress and mitochondrial functions in patients with NASH. (C) 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
C1 [dos Reis Rodrigues Okada, Livia Samara; Oliveira, Claudia P.; Stefano, Jose Tadeu; Nogueira, Monize Aydar; Torrinhas, Raquel Susana; Carrilho, Flair Jose; Waitzberg, Dan L.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07 LIM 35, Sao Paulo, Brazil.
   [Cotrim Guerreiro da Silva, Ismael Dale] Sao Paulo Fed Univ, Dept Gynecol, Lab Mol Gynecol, Sao Paulo, SP, Brazil.
   [Ferreira Alves, Venancio Avancini] Univ Sao Paulo, Sch Med, Dept Pathol LIM 14, Sao Paulo, Brazil.
   [Cordeiro, Fernanda Bertucce] Sao Paulo Fed Univ, Dept Surg, Div Urol, Human Reprod Sect, Sao Paulo, Brazil.
   [Puri, Puneet] Virginia Commonwealth Univ, Richmond, VA USA.
RP Oliveira, CP (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas de Carvalho Aguiar 255,Inst Cent 9159, BR-05403000 Sao Paulo, SP, Brazil.; Waitzberg, DL (corresponding author), Univ Sao Paulo, Fac Med, Lab Nutr & Cirurgia Metab Aparelho Digest LIM 35, Av Dr Arnaldo 455,Sala 2108, BR-01246903 Sao Paulo, SP, Brazil.
EM claudia.oliveira220@fm.usp.br; dan@ganep.com.br
RI Torrinhas, Raquel Susana/AAH-4722-2019; Stefano, Jose
   Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014
OI Torrinhas, Raquel Susana/0000-0003-0874-3995; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Cordeiro, Fernanda/0000-0002-5690-9665
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2011/09234-9, 2013/03742-8]
FX This work was supported by the grants from Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (2011/09234-9 and 2013/03742-8).
CR Berlanga A, 2014, CLIN EXP GASTROENTER, V7, P221, DOI 10.2147/CEG.S62831
   Betz C, 2013, P NATL ACAD SCI USA, V110, P12526, DOI 10.1073/pnas.1302455110
   Bravo R, 2013, INT REV CEL MOL BIO, V301, P215, DOI 10.1016/B978-0-12-407704-1.00005-1
   Brunt EM, 2011, HEPATOLOGY, V53, P810, DOI 10.1002/hep.24127
   Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004
   Capanni M, 2006, ALIMENT PHARM THER, V23, P1143, DOI 10.1111/j.1365-2036.2006.02885.x
   Charlton M, 2009, HEPATOLOGY, V49, P1375, DOI 10.1002/hep.22927
   Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200
   Cheng LC, 2015, MOL CELL ENDOCRINOL, V412, P12, DOI 10.1016/j.mce.2015.04.025
   Christoffersen C, 2011, P NATL ACAD SCI USA, V108, P9613, DOI 10.1073/pnas.1103187108
   Dasarathy S, 2015, J CLIN GASTROENTEROL, V49, P137, DOI 10.1097/MCG.0000000000000099
   Guzman C, 2013, BBA-MOL CELL BIOL L, V1831, P803, DOI 10.1016/j.bbalip.2012.12.014
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Jump DB, 2008, CHEM PHYS LIPIDS, V153, P3, DOI 10.1016/j.chemphyslip.2008.02.007
   Kainu V, 2008, J BIOL CHEM, V283, P3676, DOI 10.1074/jbc.M709176200
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Bargut TCL, 2014, LIPIDS, V49, P431, DOI 10.1007/s11745-014-3892-9
   Ma DWL, 2004, FASEB J, V18, P1040, DOI 10.1096/fj.03-1430fje
   Masterton GS, 2010, ALIMENT PHARM THER, V31, P679, DOI 10.1111/j.1365-2036.2010.04230.x
   McPherson S, 2015, J HEPATOL, V62, P1148, DOI 10.1016/j.jhep.2014.11.034
   Muir K, 2013, CANCER RES, V73, P4722, DOI 10.1158/0008-5472.CAN-12-3797
   Nogueira MA, 2016, CLIN NUTR, V35, P578, DOI 10.1016/j.clnu.2015.05.001
   Pais R, 2013, J HEPATOL, V59, P550, DOI 10.1016/j.jhep.2013.04.027
   Parker HM, 2012, J HEPATOL, V56, P944, DOI 10.1016/j.jhep.2011.08.018
   Pfaffenbach KT, 2010, AM J PHYSIOL-ENDOC M, V298, pE1027, DOI 10.1152/ajpendo.00642.2009
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   Puri P, 2007, HEPATOLOGY, V46, P1081, DOI 10.1002/hep.21763
   RUSINOL AE, 1994, J BIOL CHEM, V269, P27494
   Sanyal AJ, 2014, GASTROENTEROLOGY, V147, P377, DOI 10.1053/j.gastro.2014.04.046
   Tang HH, 2010, FEBS LETT, V584, P662, DOI 10.1016/j.febslet.2009.12.051
   Wang D, 2006, ENDOCRINOLOGY, V147, P943, DOI 10.1210/en.2005-0570
   Wang GQ, 2005, HEPATOLOGY, V42, P871, DOI 10.1002/hep.20857
   Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840
   Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200
   Younossi ZM, 2008, OBES SURG, V18, P1430, DOI 10.1007/s11695-008-9506-y
   Younossi ZM, 2010, J PROTEOME RES, V9, P3218, DOI 10.1021/pr100069e
   Zhao JM, 2011, P NATL ACAD SCI USA, V108, P14246, DOI 10.1073/pnas.1018075108
NR 37
TC 16
Z9 17
U1 1
U2 11
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0261-5614
EI 1532-1983
J9 CLIN NUTR
JI Clin. Nutr.
PD OCT
PY 2018
VL 37
IS 5
BP 1474
EP 1484
DI 10.1016/j.clnu.2017.08.031
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA GX2VR
UT WOS:000447578700005
PM 29249532
DA 2020-12-08
ER

PT J
AU Torrecilla, S
   Pinyol, R
   Wei-Qiang, L
   Wang, H
   Moeini, A
   Montironi, C
   Bassaganyas, L
   Andreu-Oller, C
   Oliveira, CPMS
   Alves, VAF
   Lachenmayer, A
   Roessler, S
   Minguez, B
   Schirmacher, P
   Boffetta, P
   Dufour, JF
   Thung, SN
   Uzilov, A
   Carrilho, FJ
   Chang, CY
   Sia, D
   Llovet, JM
AF Torrecilla, Sara
   Pinyol, Roser
   Wei-Qiang, Leow
   Wang, Huan
   Moeini, Agrin
   Montironi, Carla
   Bassaganyas, Laia
   Andreu-Oller, Carmen
   Oliveira, Claudia P. M. S.
   Alves, Venancio A. F.
   Lachenmayer, Anja
   Roessler, Stephanie
   Minguez, Beatriz
   Schirmacher, Peter
   Boffetta, Paolo
   Dufour, Jean-Francois
   Thung, Swan N.
   Uzilov, Andrew
   Carrilho, Flair Jose
   Chang, Charissa Y.
   Sia, Daniela
   Llovet, Josep M.
TI Integrative Molecular Profiling of Non-Alcoholic Steatohepatitis-Related
   Hepatocellular Carcinoma
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Torrecilla, Sara] Univ Barcelona, Liver Canc Translat Res Lab, Barcelona Clin Liver Canc BCLC Grp, Liver Unit,IDIBAPS,Hosp Clin,Ciberehd, Barcelona, Spain.
   [Torrecilla, Sara; Wei-Qiang, Leow; Boffetta, Paolo; Thung, Swan N.; Chang, Charissa Y.] Icahn Sch Med Mt Sinai, Mt Sinai Liver Canc Program, Tisch Canc Inst, Div Liver Dis,Dept Hematol Oncol,Dept Med,Dept Pa, New York, NY 10029 USA.
   [Pinyol, Roser; Moeini, Agrin; Montironi, Carla; Bassaganyas, Laia; Andreu-Oller, Carmen; Llovet, Josep M.] Hosp Clin Barcelona, Idibaps, Liver Unit, Liver Canc Translat Res Lab,Barcelona Clin Liver, Barcelona, Spain.
   [Wei-Qiang, Leow] Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore.
   [Wang, Huan; Uzilov, Andrew] Sema4, Stamford, CT USA.
   [Oliveira, Claudia P. M. S.; Alves, Venancio A. F.; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Oliveira, Claudia P. M. S.; Alves, Venancio A. F.; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   [Lachenmayer, Anja] Univ Bern, Univ Hosp Bern, Dept Visceral Surg & Med, Bern, Switzerland.
   [Roessler, Stephanie; Schirmacher, Peter] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.
   [Minguez, Beatriz] Hosp Valle De Hebron, Liver Unit, Barcelona, Spain.
   [Dufour, Jean-Francois] Bern Univ Hosp, Bern, Switzerland.
   [Sia, Daniela; Llovet, Josep M.] Icahn Sch Med Mt Sinai, Liver Canc Program, Div Liver Dis, New York, NY 10029 USA.
   [Sia, Daniela; Llovet, Josep M.] Icahn Sch Med Mt Sinai, RM Transplant Inst, Tisch Canc Inst, Dept Med, New York, NY 10029 USA.
   [Llovet, Josep M.] ICREA, Barcelona, Spain.
RI Pinyol, Roser/AAA-4404-2019; Dufour, Jean Francois
   Jacques/AAL-9866-2020; Montironi, Carla/AAA-9198-2019; Oliveira, Claudia
   PMS/D-1216-2014; Minguez, Beatriz/N-4456-2014
OI Dufour, Jean Francois Jacques/0000-0002-8062-1346; Minguez,
   Beatriz/0000-0002-7276-9666
FU Bayer PharmaceuticalsBayer AG; Incyte; Blueprint; EisaiEisai Co Ltd;
   Bristol Myers SquibbBristol-Myers Squibb
FX Josep M Llovet - Bayer Pharmaceuticals: Consulting; Bayer
   Pharmaceuticals: Grant/Research Support; Incyte: Grant/Research Support;
   Blueprint: Grant/Research Support; Eisai: Consulting; Eisai:
   Grant/Research Support; Bristol Myers Squibb: Grant/Research Support;
   Bristol Myers Squibb: Advisory Committee or Review Panel; Eli Lilly:
   Advisory Committee or Revie
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 252
BP 155A
EP 156A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020500253
DA 2020-12-08
ER

PT J
AU de Fraga, RS
   Belchior, GM
   Carrilho, FJ
   Ono, SK
AF de Fraga, Raquel Scherer
   Belchior, Gustavo Moreira
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI SIDE Effects of Nucleos(T)Ide Analogues in the Treatment of Chronic
   Hepatitis B: Analysis of Vigiaccess
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [de Fraga, Raquel Scherer] Rua Tiradentes 400 Ap 802, Macapa, AP, Brazil.
   [Belchior, Gustavo Moreira] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 425
BP 253A
EP 253A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020500428
DA 2020-12-08
ER

PT J
AU Nogueira, M
   Lino, A
   Otuyama, L
   Lucena, N
   Dos Santos, GDR
   Ambrosio, V
   Rocha, PA
   Tolentino, R
   Martins, MC
   Pinto, VB
   Carrilho, FJ
   Ono, SK
AF Nogueira, Marcel
   Lino, Ana
   Otuyama, Leonardo
   Lucena, Nayara
   Ribeiro Dos Santos, Graziella D'Agostino
   Ambrosio, Veridiana
   Rocha, Priscilla Alves
   Tolentino, Raphael
   Martins, Maria Cleusa
   Pinto, Vanusa Barbosa
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI Drug-Drug Interactions in the Era of Direct-Acting Antivirals and
   Clinical Outcome of Patients with Chronic Hepatitis C.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Nogueira, Marcel; Lino, Ana; Otuyama, Leonardo; Lucena, Nayara; Ribeiro Dos Santos, Graziella D'Agostino; Ambrosio, Veridiana; Rocha, Priscilla Alves; Tolentino, Raphael; Martins, Maria Cleusa; Pinto, Vanusa Barbosa] Univ Sao Paulo, Sch Med, Pharm, Sao Paulo, Brazil.
   [Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 670
BP 398A
EP 398A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020500684
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Ferreira, CM
   D'Amico, EA
   Souza, EO
   Batista, JM
   Rocha, TRF
   Carrilho, FJ
AF Farias, Alberto Q.
   Ferreira, Caroline Marcondes
   D'Amico, Elbio Antonio
   Souza, Evandro Oliveira
   Batista, Juliana Medeiros
   Flores Rocha, Tania Rubia
   Carrilho, Flair Jose
TI Preservation of Thrombin Generation in Cirrhosis Despite Abnormal
   Results of INR/ Prothrombin Time: Implication for Invasive Procedures
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Farias, Alberto Q.; Batista, Juliana Medeiros] Univ Sao Paulo, Gastroenterol Dept, Sao Paulo, Brazil.
   [Ferreira, Caroline Marcondes; Souza, Evandro Oliveira] Univ Sao Paulo, Gastroenterol, Sao Paulo, Brazil.
   [D'Amico, Elbio Antonio; Flores Rocha, Tania Rubia] Univ Sao Paulo, Coagulat Lab, Sao Paulo, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RI Farias, Alberto/ABB-1291-2020
OI Farias, Alberto/0000-0002-5572-663X
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 811
BP 481A
EP 481A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020501025
DA 2020-12-08
ER

PT J
AU Leathers, J
   Balderramo, D
   Ortiz, JEP
   Diehl, F
   Ballerga, EG
   Ferreiro, M
   Carrera, E
   Barreyro, FJ
   Ferrer, JD
   Singh, D
   Mattos, A
   Carrilho, FJ
   Debes, JD
AF Leathers, James
   Balderramo, Domingo
   Ortiz, Jhon Edison Prieto
   Diehl, Fernando
   Ballerga, Esteban Gonzalez
   Ferreiro, Melina
   Carrera, Enrique
   Barreyro, Fernando J.
   Ferrer, Javier Diaz
   Singh, Dupinder
   Mattos, Angelo
   Carrilho, Flair Jose
   Debes, Jose D.
TI A Simple Score to Select Sorafenib Treatment Candidates: A Report from
   the South American Liver Research Network
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Leathers, James] Vanderbilt Univ, Sch Med, Med, Nashville, TN 37212 USA.
   [Balderramo, Domingo; Diehl, Fernando] Hosp Privado Univ Cordoba, Gastroenterol, Cordoba, Argentina.
   [Ballerga, Esteban Gonzalez; Ferreiro, Melina] Hosp Clin Buenos Aires, Gastroenterol, Buenos Aires, DF, Argentina.
   [Carrera, Enrique] Hosp Eugenio Espejo, Gastroenterol, Quito, Ecuador.
   [Barreyro, Fernando J.] Univ Buenos Aires, Buenos Aires, DF, Argentina.
   [Ferrer, Javier Diaz] Hosp Nacl Edgardo Rebagliati Martins, Gastroenterol, Lima, Peru.
   [Singh, Dupinder; Debes, Jose D.] Univ Minnesota, Minneapolis, MN 55455 USA.
   [Mattos, Angelo] Santa Casa Misericordia Hosp, Porto Alegre, RS, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 917
BP 537A
EP 538A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020501133
DA 2020-12-08
ER

PT J
AU Ximenes, RO
   Helou, CMB
   Souza, HP
   Barbeiro, DF
   Mendes, L
   Martinelli, AC
   Mazo, D
   Alvares-Da-Silva, MR
   Ciarleglio, M
   Deng, YH
   Carrilho, FJ
   Garcia-Tsao, G
   Farias, AQ
AF Ximenes, Rafael Oliveira
   Helou, Claudia Maria B.
   Souza, Heraldo P.
   Barbeiro, Denise F.
   Mendes, Liliana
   Martinelli, Ana C.
   Mazo, Daniel
   Alvares-Da-Silva, Mario R.
   Ciarleglio, Maria
   Deng, Yanhong
   Carrilho, Flair Jose
   Garcia-Tsao, Guadalupe
   Farias, Alberto Q.
TI Early Predictors of AKI Development/Progression in Patients with
   Cirrhosis and Ascites Admitted with a Bacterial Infection
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Ximenes, Rafael Oliveira] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Helou, Claudia Maria B.] Univ Sao Paulo, Nephrol, Sao Paulo, Brazil.
   [Souza, Heraldo P.; Barbeiro, Denise F.] Univ Sao Paulo, Emergency, Sao Paulo, Brazil.
   [Mendes, Liliana] Hosp Base DF, Gastroenterol, Brasilia, DF, Brazil.
   [Martinelli, Ana C.] Fac Med Ribeirao Preto, Gastroenterol & Hepatol, Ribeirao Preto, Brazil.
   [Mazo, Daniel] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Alvares-Da-Silva, Mario R.] Clin Hosp Porto Alegre, Gastroenterol, Porto Alegre, RS, Brazil.
   [Ciarleglio, Maria] Yale, Biostat, New Haven, CT USA.
   [Deng, Yanhong] Yale, Sch Publ Hlth, New Haven, CT USA.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Garcia-Tsao, Guadalupe] Yale Sch Med, Sect Digest Dis, New Haven, CT USA.
   [Farias, Alberto Q.] Univ Sao Paulo, Gastroenterol Dept, Sao Paulo, Brazil.
RI Farias, Alberto/ABB-1291-2020; Garcia-Tsao, Guadalupe/ABF-7374-2020;
   Mazo, Daniel FC/D-5631-2015; Helou, Claudia/J-8868-2012
OI Farias, Alberto/0000-0002-5572-663X; Mazo, Daniel
   FC/0000-0002-2164-2630; Helou, Claudia/0000-0002-2228-6041
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 956
BP 558A
EP 558A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020501171
DA 2020-12-08
ER

PT J
AU Vezozzo, DCP
   Cedro, M
   Recuero, AM
   Margon, JF
   Mischiatti, MN
   Reinoso, G
   Mazo, D
   Gomes, CD
   Franca, JI
   Ono, SK
   Carrilho, FJ
AF Paranagua Vezozzo, Denise Cerqueira
   Cedro, Marconi
   Recuero, Amanda Medeiros
   Margon, Julia Fadini
   Mischiatti, Marilia Nery
   Reinoso, Gleicy
   Mazo, Daniel
   Gomes, Caroline De Cassia
   Franca, Joao Italo
   Ono, Suzane Kioko
   Carrilho, Flair Jose
TI Strong Concordance of New Point Shear Wave S-Shearwave (pSWE) and
   Fibroscan (TE) in HCV Patients.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Paranagua Vezozzo, Denise Cerqueira; Cedro, Marconi; Margon, Julia Fadini; Mischiatti, Marilia Nery; Reinoso, Gleicy] Univ Sao Paulo, Fac Med, Hosp Clin, Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Recuero, Amanda Medeiros] Hosp Clin Sao Paulo, Dept Gastroenterol, Fac Med Estado Sao Paulo, Gastroenterol & Hepatol Div, Sao Paulo, Brazil.
   [Mazo, Daniel; Ono, Suzane Kioko] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Gomes, Caroline De Cassia; Franca, Joao Italo] Univ Sao Paulo, Hosp Clin, Fac Med, Sao Paulo, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Gastroenterol Dept, Sao Paulo, Brazil.
RI Mazo, Daniel FC/D-5631-2015
OI Mazo, Daniel FC/0000-0002-2164-2630
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 1053
BP 614A
EP 614A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020501271
DA 2020-12-08
ER

PT J
AU Zitelli, P
   Gomes-Gouvea, M
   Mazo, D
   Pinho, JRR
   Alves, VAF
   Tanigawa, RY
   Oliveira, CS
   Carrilho, FJ
   Pessoa, MG
AF Zitelli, Patricia
   Gomes-Gouvea, Michele
   Mazo, Daniel
   Pinho, Joo Renato R.
   Alves, Venancio A. F.
   Tanigawa, Ryan Yukimatsu
   Oliveira, Claudia S.
   Carrilho, Flair Jose
   Pessoa, Mario Guimaraes
TI The Impact of HEV Infection on the Disease Severity of Patients with
   Chronic Hepatitis C
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Zitelli, Patricia; Gomes-Gouvea, Michele; Pessoa, Mario Guimaraes] Univ Sao Paulo, Sch Med, Div Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Mazo, Daniel; Pinho, Joo Renato R.; Oliveira, Claudia S.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol LIM 14, Sao Paulo, Brazil.
   [Tanigawa, Ryan Yukimatsu] Univ Sao Paulo, Sao Paulo, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RI Mazo, Daniel FC/D-5631-2015
OI Mazo, Daniel FC/0000-0002-2164-2630
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 1642
BP 935A
EP 935A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020502437
DA 2020-12-08
ER

PT J
AU Malta, F
   Lima, RV
   Salles, APM
   Stefano, JT
   Mazo, D
   Alves, VAF
   Carrilho, FJ
   Pinho, JRR
   Oliveira, CPMS
AF Malta, Fernanda
   Lima, Rodrigo V.
   Salles, Ana Paula M.
   Stefano, Jose Tadeu
   Mazo, Daniel
   Alves, Venancio A. F.
   Carrilho, Flair Jose
   Pinho, Joao Renato R.
   Oliveira, Claudia P. M. S.
TI NON-Invasive Biomarkers to Monitoring LIVER Disease Progression in Nash
   Patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Malta, Fernanda; Lima, Rodrigo V.; Salles, Ana Paula M.; Stefano, Jose Tadeu; Mazo, Daniel; Carrilho, Flair Jose; Pinho, Joao Renato R.; Oliveira, Claudia P. M. S.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol LIM 14, Sao Paulo, Brazil.
RI Oliveira, Claudia PMS/D-1216-2014; Pinho, Joao R. R./G-2850-2012; Mazo,
   Daniel FC/D-5631-2015; Stefano, Jose Tadeu/AAH-5419-2020
OI Pinho, Joao R. R./0000-0003-3999-0489; Mazo, Daniel
   FC/0000-0002-2164-2630; Stefano, Jose Tadeu/0000-0002-0218-1920
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 2297
BP 1300A
EP 1301A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020503527
DA 2020-12-08
ER

PT J
AU Okada, LSRR
   Oliveira, CPMS
   Stefano, JT
   Nogueira, MA
   Cordeiro, FB
   Alves, VAF
   Torrinhas, RS
   Carrilho, FJ
   Waitzberg, DL
AF Reis Rodrigues Okada, Livia Samara
   Oliveira, Claudia P. M. S.
   Stefano, Jose Tadeu
   Nogueira, Monize Aydar
   Cordeiro, Fernanda Bertucce
   Alves, Venancio A. F.
   Torrinhas, Raquel Suzana
   Carrilho, Flair Jose
   Waitzberg, Dan Linetzky
TI Plasma Proteomic Signature in Patients with Nash Treated with OMEGA-3:
   Perspectives of Knowing Mechanism of Action.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Reis Rodrigues Okada, Livia Samara; Oliveira, Claudia P. M. S.; Stefano, Jose Tadeu; Nogueira, Monize Aydar; Torrinhas, Raquel Suzana; Waitzberg, Dan Linetzky] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07 LIM 35, Sao Paulo, Brazil.
   [Cordeiro, Fernanda Bertucce] Sao Paulo Fed Univ, Dept Surg, Div Urol, Human Reprod Sect, Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol LIM 14, Sao Paulo, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RI Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose Tadeu/AAH-5419-2020;
   Torrinhas, Raquel Susana/AAH-4722-2019
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Torrinhas, Raquel
   Susana/0000-0003-0874-3995
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 2308
BP 1306A
EP 1307A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020503538
DA 2020-12-08
ER

PT J
AU Motta, M
   Rocha, TRF
   Migita, BY
   Batista, JM
   D'Amico, EA
   D'Albuquerque, LAC
   Carrilho, FJ
   Farias, AQ
AF Motta, Marina
   Flores Rocha, Tania Rubia
   Migita, Beatriz Yuri
   Batista, Juliana Medeiros
   D'Amico, Elbio Antonio
   Cameiro D'Albuquerque, Lutz Augusto
   Carrilho, Flair Jose
   Farias, Alberto Q.
TI Endogenous Heparinoid Effects during Bacterial Infections in Patients
   with Cirrhosis Do Not Impair Thombin Generation: A Prospective Study
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Motta, Marina; Migita, Beatriz Yuri; Batista, Juliana Medeiros; Carrilho, Flair Jose; Farias, Alberto Q.] Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
   [Flores Rocha, Tania Rubia; D'Amico, Elbio Antonio] Univ Sao Paulo, Coagulat Lab, Sao Paulo, Brazil.
   [Cameiro D'Albuquerque, Lutz Augusto] Univ Sao Paulo, Liver Transplant Dept, Sao Paulo, Brazil.
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; D'Albuquerque, Luiz
   Augusto Carneiro/A-8812-2013; Farias, Alberto/ABB-1291-2020
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Farias,
   Alberto/0000-0002-5572-663X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 2350
BP 1330A
EP 1330A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020503581
DA 2020-12-08
ER

PT J
AU Rabelo, F
   Stefano, JT
   Cavaleiro, AM
   Lima, RVC
   Mazo, DD
   Carrilho, FJ
   Correa-Giannella, ML
   Oliveira, CP
AF Rabelo, Fabiola
   Stefano, Jose Tadeu
   Cavaleiro, Ana Mercedes
   Costa Lima, Rodrigo Vieira
   de Campos Mazo, DanielFerraz
   Carrilho, Flair Jose
   Correa-Giannella, Maria Lucia
   Oliveira, Claudia P.
TI Association between the CYBA and NOX4 genes of NADPH oxidase and its
   relationship with metabolic syndrome in non-alcoholic fatty liver
   disease in Brazilian population
SO HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
LA English
DT Article
DE Non-alcoholic fatty liver disease; Nonalcoholic steatohepatitis; Genetic
   polymorphism; Metabolic syndrome
ID GENOME-WIDE ASSOCIATION; OXIDATIVE STRESS; POLYMORPHISMS;
   STEATOHEPATITIS; VARIANT; NEPHROPATHY; DIAGNOSIS; FIBROSIS
AB Background: Oxidative stress has been implicated in the progression of severe forms of non-alcoholic fatty liver disease (NAFLD). NADPH oxidase produces reactive oxygen species. In the present study, we investigated for the first time two single nucleotide polymorphisms (SNPs) in the regulatory region of genes encoding NADPH oxidase 4 (NOX4) and p22phox (CYBA) in NAFLD.
   Methods: A total of 207 biopsy-proven NAFLD patients [simple steatosis (n =27); nonalcoholic steatohepatitis (NASH) (n =180)] were evaluated. Genomic DNA was extracted from peripheral blood cells, and polymorphisms in CYBA (unregistered) and NOX4 (rs3017887) were determined by direct sequencing of PCR.
   Results: Associations of CYBA-675 T/A with high-density lipoprotein (HDL) (TT vs TA vs AA; P <0.01) and triglycerides (TGL) (TT vs XA; P < 0.01) were observed only in NASH patients. For polymorphisms in the NOX4 gene, NOX4 (rs3017887) CA + AA genotypes was significant associated with alanine aminotransferase (ALT) (CA + AA vs CC; P=0.02). However, there was no association of SNPs in the CYBA and NOX4 genes encoding the NADPH oxidase system proteins and the presence of NASH. Regarding the clinical results, it was observed that the most advanced degrees of fibrosis occurred in patients diagnosed with type 2 diabetes mellitus (66.9% vs 37.5%, P < 0.01) and those who were more obese (32.2 vs 29.0 kg/m(2), P < 0.01). In addition, serum glucose and insulin levels increased significantly in the presence of NASH.
   Conclusions: There were associations between the presence of the allele A in the NOX4 SNP and a higher concentration of ALT in the NAFLD population; between the presence of the AA genotype in the polymorphism of the CYBA-675 T/A CYBA gene and a higher level of TGL and lower HDL in NASH patients. The presence of metabolic syndrome was associated with advanced degrees of fibrosis in NAFLD patients. (C) 2018 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
C1 [Rabelo, Fabiola; Costa Lima, Rodrigo Vieira; Carrilho, Flair Jose; Oliveira, Claudia P.] Univ Sao Paulo, Fac Med FMUSP, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Rabelo, Fabiola; Stefano, Jose Tadeu; Costa Lima, Rodrigo Vieira; de Campos Mazo, DanielFerraz; Carrilho, Flair Jose; Oliveira, Claudia P.] Univ Sao Paulo, Fac Med, LIM07, Hosp Clin HCFMUSP,Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Cavaleiro, Ana Mercedes; Correa-Giannella, Maria Lucia] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP LIM07, Lab Carboidratos & Radioimunensaio,LIM18, Sao Paulo, Brazil.
   [Correa-Giannella, Maria Lucia] Univ Nove Julho UNINOVE, Programa Posgrad Med, Sao Paulo, Brazil.
RP Oliveira, CP (corresponding author), Univ Sao Paulo, Fac Med FMUSP, Dept Gastroenterol, Sao Paulo, SP, Brazil.; Oliveira, CP (corresponding author), Univ Sao Paulo, Fac Med, LIM07, Hosp Clin HCFMUSP,Dept Gastroenterol, Sao Paulo, SP, Brazil.
EM cpm@usp.br
RI Giannella, Maria Lucia/N-3834-2019; Oliveira, Claudia PMS/D-1216-2014;
   Stefano, Jose Tadeu/AAH-5419-2020; Mazo, Daniel FC/D-5631-2015
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Mazo, Daniel
   FC/0000-0002-2164-2630; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [Convenio PROAP 190/2014]
FX This study was supported by the grant from Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) Grant no. Convenio
   PROAP 190/2014.
CR American Diabetes Association, 2017, Diabetes Care, V40, pS11, DOI 10.2337/dc15-S005
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bedard K, 2009, HUM MUTAT, V30, P1123, DOI 10.1002/humu.21029
   Bettaieb A, 2015, GASTROENTEROLOGY, V149, P468, DOI 10.1053/j.gastro.2015.04.009
   Brunt EM, 2009, CLIN LIVER DIS, V13, P533, DOI 10.1016/j.cld.2009.07.008
   Burt AD, 2015, SEMIN LIVER DIS, V35, P207, DOI 10.1055/s-0035-1562942
   Chalasani N, 2012, GASTROENTEROLOGY, V142, P1592, DOI 10.1053/j.gastro.2012.04.001
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Cohen DE, 2013, SEMIN LIVER DIS, V33, P380, DOI 10.1055/s-0033-1358519
   De Minicis S, 2010, HEPATOLOGY, V52, P1420, DOI 10.1002/hep.23804
   de Siqueira ERF, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0136-2
   Hirschhorn JN, 2011, ANNU REV MED, V62, P11, DOI 10.1146/annurev.med.091708.162036
   Hodgkinson AD, 2003, DIABETES CARE, V26, P3111, DOI 10.2337/diacare.26.11.3111
   Jiang JX, 2012, FREE RADICAL BIO MED, V53, P289, DOI 10.1016/j.freeradbiomed.2012.05.007
   Jose GS, 2008, CLIN SCI, V114, P173, DOI 10.1042/CS20070130
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Lan T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129743
   Liang S, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00017
   Lim SC, 2009, DIABETOLOGIA, V52, P1343, DOI 10.1007/s00125-009-1368-x
   Makkonen J, 2009, J HEPATOL, V50, P1035, DOI 10.1016/j.jhep.2008.12.025
   Moreno MU, 2007, J HYPERTENS, V25, P1620, DOI 10.1097/HJH.0b013e3281ac211d
   Oliveira CP, 2015, CLIN RES HEPATOL GAS, V39, pS35, DOI 10.1016/j.clinre.2015.05.014
   Parker HM, 2012, J HEPATOL, V56, P944, DOI 10.1016/j.jhep.2011.08.018
   Patente TA, 2015, GENE, V568, P50, DOI 10.1016/j.gene.2015.05.017
   Quigley EM, 2015, SEMIN LIVER DIS, V35, P262, DOI 10.1055/s-0035-1562946
   Sancho P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045285
   Song HR, 2008, AM J CLIN NUTR, V88, P16
   Sookoian S, 2015, WORLD J GASTROENTERO, V21, P711, DOI 10.3748/wjg.v21.i3.711
   Tariq Z, 2014, LIVER INT, V34, pE180, DOI 10.1111/liv.12523
   Wang C, 2017, BIOMED REP, V7, P95, DOI 10.3892/br.2017.926
   Wu KT, 2016, J CLIN LIPIDOL, V10, P420, DOI 10.1016/j.jacl.2015.12.026
   Zegers D, 2016, CLIN RES HEPATOL GAS, V40, P715, DOI 10.1016/j.clinre.2016.05.004
NR 32
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1499-3872
EI 2352-9377
J9 HEPATOB PANCREAT DIS
JI Hepatob. Pancreatic. Dis. Int.
PD AUG
PY 2018
VL 17
IS 4
BP 330
EP 335
DI 10.1016/j.hbpd.2018.06.005
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GS0OC
UT WOS:000443199800008
PM 30087027
DA 2020-12-08
ER

PT J
AU Silvestre, OM
   Farias, AQ
   Ramos, DS
   Furtado, MS
   Rodrigues, AC
   Ximenes, RO
   Mazo, DFD
   Zitelli, PMY
   Diniz, MA
   Andrade, JL
   Strunz, C
   Friedmann, AA
   Lee, SS
   Carrilho, FJ
   D'Albuquerque, LAC
   Bacal, F
AF Silvestre, Odilson M.
   Farias, Alberto Q.
   Ramos, Danusa S.
   Furtado, Meive S.
   Rodrigues, Ana C.
   Ximenes, Rafael O.
   de Campos Mazo, Daniel F.
   Yoshimura Zitelli, Patricia M.
   Diniz, Marcio A.
   Andrade, Jose L.
   Strunz, Celia
   Friedmann, Antonio A.
   Lee, Samuel S.
   Carrilho, Flair J.
   D'Albuquerque, Luiz A. C.
   Bacal, Fernando
TI beta-Blocker therapy for cirrhotic cardiomyopathy: a
   randomized-controlled trial
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
DE blockers; cardiomyopathy; cirrhosis; cirrhotic cardiomyopathy
ID CONGESTIVE-HEART-FAILURE; STAGE LIVER-DISEASE; METOPROLOL CR/XL;
   INTERVENTION TRIAL; MERIT-HF; STRESS ECHOCARDIOGRAPHY;
   EUROPEAN-ASSOCIATION; PORTAL-HYPERTENSION; AMERICAN-SOCIETY; RATS
AB Background Cirrhotic cardiomyopathy is characterized by an attenuated contractile response to stress. Long-term exposure of beta-adrenergic receptors to persistently high levels of catecholamines has been implicated in its pathogenesis. We hypothesized that beta-blockade with metoprolol could reverse the changes in heart function and morphology in cirrhotic cardiomyopathy.
   Patients and methods In this prospective randomized trial, we included 78 patients aged between 18 and 60 years with abnormal cardiac output response under dobutamine stress echocardiography, without primary cardiac disease or a history of alcohol intake. Patients were assigned randomly to receive metoprolol or placebo for 6 months. The primary endpoint was the improvement in cardiac output response to stress, measured by an increase in the left ventricle stroke volume more than 30%.
   Results Three (7.3%) patients in the metoprolol group and nine (24.3%) patients in the placebo group showed improved stroke volume (P=0.057). Diastolic dysfunction was found in two (4.8%) patients before and in five (15.6%) patients after therapy in the metoprolol group, and in 10 (27%) patients before and nine (31%) patients after therapy in the placebo group (P=0.67). After treatment, no echocardiography parameter of morphology was significantly different between metoprolol or placebo groups. No significant differences were observed in noradrenaline, plasma renin activity, and troponin levels between groups. Cirrhosis-related clinical events, including hospitalizations and mortality, were not significantly different between the two groups. Six months of therapy with beta-blocker did not ameliorate heart function and morphology in patients with cirrhotic cardiomyopathy. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Silvestre, Odilson M.; Strunz, Celia; Bacal, Fernando] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Farias, Alberto Q.; Ramos, Danusa S.; Ximenes, Rafael O.; de Campos Mazo, Daniel F.; Yoshimura Zitelli, Patricia M.; Diniz, Marcio A.; Friedmann, Antonio A.; Carrilho, Flair J.; D'Albuquerque, Luiz A. C.] Univ Sao Paulo, Sch Med, Div Gastroenterol & Hepatol, Dept Gastroenterol, Sao Paulo, Brazil.
   [Furtado, Meive S.; Rodrigues, Ana C.; Andrade, Jose L.] Univ Sao Paulo, Sch Med, Dept Radiol, Sao Paulo, Brazil.
   [Lee, Samuel S.] Univ Calgary, Liver Unit, Calgary, AB, Canada.
RP Farias, AQ (corresponding author), Univ Sao Paulo, Hosp Clin, Ave Doutor Eneas de Carvalho Aguiar 255,Sala 9117, BR-05403000 Sao Paulo, Brazil.
EM albertoqfarias@gmail.com
RI D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013; Mazo, Daniel
   FC/D-5631-2015; Strunz, Celia/G-5562-2011; Ramos, Danusa/H-6276-2012;
   Strunz, Celia Maria Cassaro/L-4117-2019; Farias, Alberto/ABB-1291-2020;
   D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Middlemas,
   Kaci/ABD-2762-2020
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Mazo, Daniel
   FC/0000-0002-2164-2630; Strunz, Celia/0000-0002-9766-1184; Ramos,
   Danusa/0000-0002-6713-5415; Strunz, Celia Maria
   Cassaro/0000-0002-9766-1184; Farias, Alberto/0000-0002-5572-663X; 
FU State of Sao Paulo Research Foundation (FAPESP), Sao Paulo,
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2010/12223-6]
FX The study was funded by the State of Sao Paulo Research Foundation
   (FAPESP grant no. 2010/12223-6), Sao Paulo, Brazil.
CR Abd-El-Aziz TA, 2010, INTERNAL MED, V49, P2547, DOI 10.2169/internalmedicine.49.3520
   Colucci WS, 2007, CIRCULATION, V116, P49, DOI 10.1161/CIRCULATIONAHA.106.666016
   de Franchis R, 2010, J HEPATOL, V53, P762, DOI 10.1016/j.jhep.2010.06.004
   Farias AQ, 2014, HEPATOLOGY, V59, P1043, DOI 10.1002/hep.26643
   Ghali JK, 2009, J CARD FAIL, V15, P310, DOI 10.1016/j.cardfail.2008.11.003
   Giannelli V, 2016, J HEPATOL, V64, pS167, DOI 10.1016/S0168-8278(16)01678-0
   Gines P, 2002, GASTROENTEROLOGY, V123, P1839, DOI 10.1053/gast.2002.37073
   Groenning BA, 2000, J AM COLL CARDIOL, V36, P2072, DOI 10.1016/S0735-1097(00)01006-8
   Henriksen JH, 1998, J HEPATOL, V29, P328, DOI 10.1016/S0168-8278(98)80022-6
   Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295
   Hole T, 2004, ECHOCARDIOGR-J CARD, V21, P215, DOI 10.1111/j.0742-2822.2004.03102.x
   Krag A, 2010, GUT, V59, P105, DOI 10.1136/gut.2009.180570
   Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005
   LEE SS, 1990, HEPATOLOGY, V12, P481, DOI 10.1002/hep.1840120306
   Ma ZH, 1996, HEPATOLOGY, V24, P451
   Ma ZH, 1996, GASTROENTEROLOGY, V110, P1191, DOI 10.1053/gast.1996.v110.pm8613009
   Maack Christoph, 2003, Congest Heart Fail, V9, P263, DOI 10.1111/j.1527-5299.2003.01446.x
   Martell M, 2010, WORLD J HEPATOL, V2, P208, DOI 10.4254/wjh.v2.i6.208
   Mendizabal Victoria E., 2003, Current Vascular Pharmacology, V1, P301, DOI 10.2174/1570161033476583
   Moller S, 2008, GUT, V57, P268, DOI 10.1136/gut.2006.112177
   Moller S, 2011, GUT, V60, P1254, DOI 10.1136/gut.2010.235473
   Nagueh SF, 2009, J AM SOC ECHOCARDIOG, V22, P107, DOI 10.1016/j.echo.2008.11.023
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   Parthenakis FI, 2002, CHEST, V121, P1935, DOI 10.1378/chest.121.6.1935
   PELLIKKA PA, 1995, AM J CARDIOL, V76, P881, DOI 10.1016/S0002-9149(99)80254-9
   PROPST A, 1995, DIGEST DIS SCI, V40, P1805, DOI 10.1007/BF02212706
   Reiberger T, 2013, LIVER INT, V33, P561, DOI 10.1111/liv.12101
   Remme WJ, 2010, CARDIOVASC DRUG THER, V24, P351, DOI 10.1007/s10557-010-6247-7
   Ripoll C, 2008, TRANSPLANTATION, V85, P1766, DOI 10.1097/TP.0b013e318172c936
   Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010
   Ruiz-del-Arbol L, 2005, HEPATOLOGY, V42, P439, DOI 10.1002/hep.20766
   Sicari R, 2009, EUR HEART J, V30, P278, DOI 10.1093/eurheartj/ehn492
   Sigmund M, 1996, EUR J CLIN PHARMACOL, V51, P127, DOI 10.1007/s002280050172
   Silvestre OM, 2013, ANN HEPATOL, V12, P85, DOI 10.1016/S1665-2681(19)31389-4
   Torregrosa M, 2005, J HEPATOL, V42, P68, DOI 10.1016/j.jhep.2004.09.008
   Tripathi D, 2010, EUR J GASTROEN HEPAT, V22, P905, DOI 10.1097/MEG.0b013e3283367a99
   Wikstrand J, 2002, J AM COLL CARDIOL, V40, P491, DOI 10.1016/S0735-1097(02)01970-8
   Zardi EM, 2010, J AM COLL CARDIOL, V56, P539, DOI 10.1016/j.jacc.2009.12.075
NR 38
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0954-691X
EI 1473-5687
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD AUG
PY 2018
VL 30
IS 8
BP 930
EP 937
DI 10.1097/MEG.0000000000001128
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GM9AS
UT WOS:000438533500022
PM 29979644
DA 2020-12-08
ER

PT J
AU Branisso, PPF
   Oliveira, CP
   Leao, HM
   Santos, A
   Lima, FR
   Mancini, M
   Carrilho, FJ
   Rocha, M
   Cercato, C
AF Branisso, Paula P. F.
   Oliveira, Claudia P.
   Leao Filho, Hilton M.
   Santos, Aritania
   Lima, Fabiana R.
   Mancini, Marcio
   Carrilho, Flair Jose
   Rocha, Manoel
   Cercato, Cintia
TI Iron-Overload Evaluation by Noninvasive Methods in Patients with
   Nonalcoholic Fatty Liver Disease, Overweight, and Hyperferritinemia
SO DIABETES
LA English
DT Meeting Abstract
CT 78th Scientific Sessions of the American-Diabetes-Association
CY JUN 22-26, 2018
CL Orlando, FL
SP Amer Diabet Assoc
RI Oliveira, Claudia PMS/D-1216-2014; Santos, Aritania/AAD-3548-2020
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD JUL 1
PY 2018
VL 67
SU 1
DI 10.2337/db18-292-LB
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA HR0NK
UT WOS:000462825101080
DA 2020-12-08
ER

PT J
AU Leathers, J
   Balderramo, D
   Prieto, J
   Diehl, F
   Gonzalez-Ballerga, S
   Ferreiro, M
   Carrera, E
   Barreyro, F
   Diaz-Ferrer, J
   Singh, D
   Mattos, A
   Carrilho, F
   Debes, J
AF Leathers, J.
   Balderramo, D.
   Prieto, J.
   Diehl, F.
   Gonzalez-Ballerga, S.
   Ferreiro, M.
   Carrera, E.
   Barreyro, F.
   Diaz-Ferrer, J.
   Singh, D.
   Mattos, A.
   Carrilho, F.
   Debes, J.
TI PIB, a simple score to select sorafenib treatment candidates for
   viral-associated hepatocellular carcinoma in resource-limited settings
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Leathers, J.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Balderramo, D.; Diehl, F.] Univ Cordoba, Hosp Privado, Cordoba, Argentina.
   [Prieto, J.] Ctr Enfermedades Hepat & Digest CEHYD, Bogota, Colombia.
   [Gonzalez-Ballerga, S.; Ferreiro, M.] Hosp Clin Buenos Aires, Buenos Aires, DF, Argentina.
   [Carrera, E.] Hosp Eugenio Espejo, Quito, Ecuador.
   [Barreyro, F.] Consejo Nacl Invest Cient & Tecn, Posadas, Argentina.
   [Diaz-Ferrer, J.] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru.
   [Singh, D.; Debes, J.] Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
   [Mattos, A.] Pontificia Univ Catolica Rio Grande do Sul, Porto, Portugal.
   [Carrilho, F.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012
FU Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF)
FX J. Leathers Grant/Research support from Doris Duke Charitable
   Foundation, D. Balderramo None Declared, J. Prieto None Declared, F.
   Diehl None Declared, S. Gonzalez-Ballerga None Declared, M. Ferreiro
   None Declared, E. Carrera None Declared, F. Barreyro None Declared, J.
   Diaz-Ferrer None Declared, D. Singh None Declared, A. Mattos None
   Declared, F. Carrilho None Declared, J. Debes None Declared.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P2-031
BP 124
EP 124
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000208
DA 2020-12-08
ER

PT J
AU Felga, G
   Chagas, A
   Almeida, MD
   Alves, VAF
   Carrilho, FJ
AF Felga, G.
   Chagas, A.
   Almeida, M. D.
   Alves, V. A. F.
   Carrilho, F. J.
CA Brazilian HCC Study Grp
TI Dynamic survival analysis of the data from the national survey of
   hepatocellular carcinoma and liver transplantation in Brazil
SO TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY MAY 23-26, 2018
CL Lisbon, PORTUGAL
SP Int Liver Transplantat Soc, European Liver & Intestine Transplant Assoc, Liver Intens Care Grp Europe
C1 [Felga, G.; Almeida, M. D.] Hosp Municipal Vila Santa Catarina, Serv Transplante Figado, Sao Paulo, Brazil.
   [Felga, G.; Chagas, A.; Carrilho, F. J.] Univ Sao Paulo, Gastroenterol, Sao Paulo, Brazil.
   [Alves, V. A. F.] Univ Sao Paulo, Patol, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD MAY
PY 2018
VL 102
SU 5
MA P-224
BP 186
EP 186
PG 1
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA GL1VC
UT WOS:000436897700371
DA 2020-12-08
ER

PT J
AU Nacif, L
   Paranagua-Vezozzo, D
   Gomes, C
   Reinoso, G
   Mischiatti, M
   Andraus, W
   Pinheiro, R
   Arantes, R
   Ono, S
   Carrilho, F
   D'Albuquerque, LC
AF Nacif, L.
   Paranagua-Vezozzo, D.
   Gomes, C.
   Reinoso, G.
   Mischiatti, M.
   Andraus, W.
   Pinheiro, R.
   Arantes, R.
   Ono, S.
   Carrilho, F.
   Carneiro D'Albuquerque, L.
TI Liver transient elastography following liver transplantation
SO TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY MAY 23-26, 2018
CL Lisbon, PORTUGAL
SP Int Liver Transplantat Soc, European Liver & Intestine Transplant Assoc, Liver Intens Care Grp Europe
C1 [Nacif, L.; Paranagua-Vezozzo, D.; Gomes, C.; Reinoso, G.; Mischiatti, M.; Andraus, W.; Pinheiro, R.; Arantes, R.; Ono, S.; Carrilho, F.; Carneiro D'Albuquerque, L.] Univ Sao Paulo, Sao Paulo, Brazil.
RI D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013; Andraus,
   Wellington/G-1860-2012; D'ALBUQUERQUE, Luiz Carneiro
   Augusto/I-4011-2012; Nacif, Lucas S./B-2795-2013; Carrilho, Flair
   J/I-3046-2012
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Andraus,
   Wellington/0000-0002-5162-138X; Nacif, Lucas S./0000-0002-7059-3978; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD MAY
PY 2018
VL 102
SU 5
MA P-370
BP 246
EP 247
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA GL1VC
UT WOS:000436897700512
DA 2020-12-08
ER

PT J
AU Ono, SK
   Bassit, L
   Van Vaisberg, V
   Alves, VAF
   Caldini, EG
   Herman, BD
   Shabman, R
   Fedorova, NB
   Paranagua-Vezozzo, D
   Sampaio, CT
   Lages, RB
   Terrabuio, D
   Andraus, W
   Schinazi, RF
   Carrilho, FJ
AF Ono, Suzane Kioko
   Bassit, Leda
   Van Vaisberg, Victor
   Ferreira Alves, Venancio Avancini
   Caldini, Elia G.
   Herman, Brian D.
   Shabman, Reed
   Fedorova, Nadia B.
   Paranagua-Vezozzo, Denise
   Sampaio, Caroline Torres
   Lages, Rafael Bandeira
   Terrabuio, Debora
   Andraus, Wellington
   Schinazi, Raymond F.
   Carrilho, Flair Jose
TI Acute acalculous cholecystitis during zika virus infection in an
   immunocompromised patient
SO HEPATOLOGY
LA English
DT Editorial Material
C1 [Ono, Suzane Kioko; Van Vaisberg, Victor; Paranagua-Vezozzo, Denise; Sampaio, Caroline Torres; Lages, Rafael Bandeira; Terrabuio, Debora; Andraus, Wellington; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Div Clin Gastroenterol & Hepatol, Dept Gastroenterol,Hosp Clin, Sao Paulo, Brazil.
   [Bassit, Leda; Herman, Brian D.; Schinazi, Raymond F.] Emory Univ, Sch Med, Dept Pediat, Ctr AIDS Res,Lab Biochem Pharmacol, Atlanta, GA USA.
   [Ferreira Alves, Venancio Avancini; Caldini, Elia G.] Univ Sao Paulo, Dept Pathol, Sch Med, Sao Paulo, Brazil.
   [Shabman, Reed; Fedorova, Nadia B.] J Craig Venter Inst, Rockville, MD USA.
RP Ono, SK (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Ave Dr Eneas Carvalho de Aguiar,255 ICHC, BR-05403000 Sao Paulo, Brazil.
EM suzane.ono@fm.usp.br
RI Andraus, Wellington/G-1860-2012; Caldini, Elia G/F-1105-2011;
   Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014
OI Andraus, Wellington/0000-0002-5162-138X; Paranagua-Vezozzo, Denise
   Cerqueira/0000-0002-9606-4935; caldini, elia/0000-0001-5322-3812;
   Vaisberg, Victor/0000-0002-2454-6273
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P30 AI050409, R21 AI129607]; Alves de
   Queiroz Family Fund for Research; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, R21AI129607, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, R21AI129607,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409] Funding Source: NIH RePORTER
FX Supported by NIH sponsored Center for AIDS Research grant P30 AI050409
   (to R.F.S.) and R21 AI129607 (to R.F.S.); Alves de Queiroz Family Fund
   for Research sponsored the Department of Gastroenterology. R.F.S. and
   N.F. report grants from the National Institute of Allergy and Infectious
   Diseases for Zika virus research, outside the submitted work.
CR dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Hakala T, 1997, BRIT J SURG, V84, P1249
   Nimmagadda SS, 2014, J CLIN DIAGN RES, V8, P71, DOI 10.7860/JCDR/2014/6885.3960
   Nogueira ML, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14047
   Poddighe D, 2015, INT J HEPATOL, V2015, DOI 10.1155/2015/459608
   Sarmiento-Ospina A, 2016, LANCET INFECT DIS, V16, P523, DOI 10.1016/S1473-3099(16)30006-8
NR 6
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD MAY
PY 2018
VL 67
IS 5
BP 2051
EP 2054
DI 10.1002/hep.29682
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GD3FF
UT WOS:000430388500038
PM 29171859
OA Bronze, Green Accepted
DA 2020-12-08
ER

PT J
AU Clark, P
   Chua-Anusorn, W
   Oliveira, C
   Rocha, M
   Carrilho, FJ
   Lima, F
   Alves, V
   Oliveira, B
   Filho, HL
AF Clark, P.
   Chua-Anusorn, W.
   Oliveira, C.
   Rocha, M.
   Carrilho, F. J.
   Lima, F.
   Alves, V.
   Oliveira, B.
   Filho, H. L.
TI Noninvasive mapping of fibrosis and inflammation in nonalcoholic fatty
   liver disease: isolating fibrogenesis in the Space of Disse with MRI R2
   multicomponent relaxometry
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress (ILC)
CY APR 11-15, 2018
CL Paris, FRANCE
SP European Assoc Study Liver
C1 [Clark, P.; Chua-Anusorn, W.] MagnePath Pty Ltd, Perth, WA, Australia.
   [Oliveira, C.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Rocha, M.; Oliveira, B.; Filho, H. L.] Univ Sao Paulo, Dept Radiol, Sao Paulo, Brazil.
   [Lima, F.; Alves, V.] Univ Sao Paulo, Dept Pathol, Sao Paulo, Brazil.
EM paul@magnepath.com
RI Lima, Fabiano Guasti/R-7708-2016
OI Lima, Fabiano Guasti/0000-0003-4776-3673
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2018
VL 68
SU 1
MA FRI-425
BP S553
EP S553
DI 10.1016/S0168-8278(18)31363-1
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HO6UT
UT WOS:000461068602330
DA 2020-12-08
ER

PT J
AU Terrabuio, D
   Evangelista, AS
   Guedes, ALV
   Galvao, ARDL
   Carrilho, FJ
   Cancado, E
AF Terrabuio, D.
   Evangelista, A. S.
   Guedes, A. L. V.
   de Moreto Longo Galvao, A. R.
   Carrilho, F. J.
   Cancado, E.
TI Chloroquine in monotherapy is safe and effective for induction of
   remission in anti-SLA/LP positive patients with autoimmune hepatitis
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress (ILC)
CY APR 11-15, 2018
CL Paris, FRANCE
SP European Assoc Study Liver
C1 [Terrabuio, D.; Evangelista, A. S.; Guedes, A. L. V.; de Moreto Longo Galvao, A. R.; Carrilho, F. J.; Cancado, E.] Div Gastroenterol & Hepatol, Gastroenterol, Sao Paulo, Brazil.
EM debora.terrabuio@hc.fm.usp.br
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2018
VL 68
SU 1
MA THU-232
BP S232
EP S233
DI 10.1016/S0168-8278(18)30681-0
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HO6UT
UT WOS:000461068601073
DA 2020-12-08
ER

PT J
AU Duarte, SMB
   Stefano, JT
   Miele, L
   Ponziani, FR
   Souza-Basqueira, M
   Okada, LSRR
   Costa, FGD
   Toda, AK
   Mazo, DFC
   Sabino, EC
   Carrilho, FJ
   Gasbarrini, A
   Oliveira, CP
AF Duarte, S. M. B.
   Stefano, J. T.
   Miele, L.
   Ponziani, F. R.
   Souza-Basqueira, M.
   Okada, L. S. R. R.
   de Barros Costa, F. G.
   Toda, A. K.
   Mazo, D. F. C.
   Sabino, E. C.
   Carrilho, F. J.
   Gasbarrini, A.
   Oliveira, C. P.
TI Gut microbiome composition in lean patients with NASH is associated with
   liver damage independent of caloric intake: A prospective pilot study
SO NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
LA English
DT Article
DE Gut microbiome; NASH; Lean; Obese; Overweight
ID HIGH-FAT DIET; NONALCOHOLIC STEATOHEPATITIS; INTESTINAL MICROBIOTA;
   INFLAMMATORY-BOWEL; DISEASE; OBESITY; HUMANS; CANCER; DYSBIOSIS;
   BUTYRATE
AB Background and Aim: The aim of the study was to compare the gut microbiomes from obese and lean patients with or without NASH to outline phenotypic differences.
   Methods and Results: We performed a cross-sectional pilot study comprising biopsy-proven NASH patients grouped according to BMI. Microbiome DNA was extracted from stool samples, and PCR amplification was performed using primers for the V4 region of the 16S rRNA gene. The amplicons were sequenced using the Ion PGM Torrent platform, and data were analyzed using QIIME software. Macronutrient consumption was analyzed by a 7-day food record. Liver fibrosis >= F2 was associated with increased abundance of Lactobacilli (p = 0.0007). NASH patients showed differences in Faecalibacterium, Ruminococcus, Lactobacillus and Bifidobacterium abundance compared with the control group. Lean NASH patients had a 3-fold lower abundance of Faecalibacterium and Ruminococcus (p = 0.004), obese NASH patients were enriched in Lactobacilli (p = 0.002), and overweight NASH patients had reduced Bifidobacterium (p = 0.018). Moreover, lean NASH patients showed a deficiency in Lactobacillus compared with overweight and obese NASH patients. This group also appeared similar to the control group with regard to gut microbiome alpha diversity. Although there were qualitative differences between lean NASH and overweight/obese NASH, they were not statistically significant (p = 0.618). The study limitations included a small sample size, a food questionnaire that collected only qualitative and semi-quantitative data, and variations in group gender composition that may influence differences in FXR signaling, bile acids metabolism and the composition of gut microbiota.
   Conclusion: Our preliminary finding of a different pathogenetic process in lean NASH patients needs to be confirmed by larger studies, including those with patient populations stratified by sex and dietary habits. (C) 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
C1 [Duarte, S. M. B.; Stefano, J. T.; Okada, L. S. R. R.; de Barros Costa, F. G.; Toda, A. K.; Mazo, D. F. C.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Fac Med FMUSP, Dept Gastroenterol LIM 07, Div Gastroenterol & Hepatol, Sao Paulo, SP, Brazil.
   [Miele, L.; Ponziani, F. R.; Gasbarrini, A.] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, Area Gastroenterol, Div Internal Med Gastroenterol & Hepatol, 8 Largo Gemelli, I-00168 Rome, Italy.
   [Souza-Basqueira, M.; Sabino, E. C.] Univ Sao Paulo, Fac Med FMUSP, Dept Doencas Infecciosas, Sao Paulo, SP, Brazil.
   [Souza-Basqueira, M.; Sabino, E. C.] Univ Sao Paulo, Fac Med FMUSP, Inst Med Trop, Sao Paulo, SP, Brazil.
RP Miele, L (corresponding author), Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, Area Gastroenterol, Div Internal Med Gastroenterol & Hepatol, 8 Largo Gemelli, I-00168 Rome, Italy.; Oliveira, CP (corresponding author), Univ Sao Paulo, Fac Med FMUSP, Dept Gastroenterol LIM 07, Div Gastroenterol & Hepatol,Inst Cent, Ave Dr Eneas de Carvalho Aguiar 255,9159, BR-05403000 Sao Paulo, SP, Brazil.
EM luca.miele@policlinicogemelli.it; claudia.oliveira220@fm.usp.br
RI Mazo, Daniel FC/D-5631-2015; Oliveira, Claudia PMS/D-1216-2014;
   Carrilho, Flair J/I-3046-2012; Sabino, Ester Cerdeira/F-7750-2010;
   Gasbarrini, Antonio/AAB-8487-2019; Miele, Luca/C-2255-2015; Stefano,
   Jose Tadeu/AAH-5419-2020
OI Mazo, Daniel FC/0000-0002-2164-2630; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Miele, Luca/0000-0003-3464-0068; Stefano,
   Jose Tadeu/0000-0002-0218-1920; de Souza Basqueira,
   Marcela/0000-0002-5590-5646
CR Al-Jashamy K, 2010, ASIAN PAC J CANCER P, V11, P1765
   Baba CS, 2006, J GASTROEN HEPATOL, V21, P191, DOI 10.1111/j.1440-1746.2005.04233.x
   Basaranoglu M, 2013, WORLD J GASTROENTERO, V19, P1158, DOI 10.3748/wjg.v19.i8.1158
   Bellentani S, 2008, HEPATOLOGY, V47, P746, DOI 10.1002/hep.22009
   Betrapally NS, 2016, GASTROENTEROLOGY, V150, P1745, DOI 10.1053/j.gastro.2016.02.073
   Boursier J, 2016, CLIN LIVER DIS, V20, P263, DOI 10.1016/j.cld.2015.10.012
   Boursier J, 2016, HEPATOLOGY, V63, P764, DOI 10.1002/hep.28356
   Brahe LK, 2013, OBES REV, V14, P950, DOI 10.1111/obr.12068
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   de Wit N, 2012, AM J PHYSIOL-GASTR L, V303, pG589, DOI 10.1152/ajpgi.00488.2011
   Del Chierico F, 2017, HEPATOLOGY, V65, P451, DOI 10.1002/hep.28572
   Duncan SH, 2009, ENVIRON MICROBIOL, V11, P2112, DOI 10.1111/j.1462-2920.2009.01931.x
   Jiang WW, 2015, SCI REP-UK, V5, DOI 10.1038/srep08096
   Jumpertz R, 2011, AM J CLIN NUTR, V94, P58, DOI 10.3945/ajcn.110.010132
   Larsen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009085
   Leung C, 2016, NAT REV GASTRO HEPAT, V13, P412, DOI 10.1038/nrgastro.2016.85
   Lin H, 2016, SCI REP-UK, V6, DOI 10.1038/srep21618
   Loomba R, 2013, NAT REV GASTRO HEPAT, V10, P686, DOI 10.1038/nrgastro.2013.171
   Macfarlane GT, 2011, J CLIN GASTROENTEROL, V45, pS120, DOI 10.1097/MCG.0b013e31822fecfe
   Machado MV, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040481
   Manti S, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.17641
   Margariti E, 2012, ANN GASTROENTEROL, V25, P45
   Miquel S, 2015, MBIO, V6, DOI 10.1128/mBio.00300-15
   Mosca A, 2017, J HEPATOL, V66, P1031, DOI 10.1016/j.jhep.2016.12.025
   Murphy EF, 2013, GUT, V62, P220, DOI 10.1136/gutjnl-2011-300705
   Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193
   Org E, 2016, GUT MICROBES, V7, P313, DOI 10.1080/19490976.2016.1203502
   Prorok-Hamon M, 2014, GUT, V63, P761, DOI 10.1136/gutjnl-2013-304739
   Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450
   Raman M, 2013, CLIN GASTROENTEROL H, V11, P868, DOI 10.1016/j.cgh.2013.02.015
   Savard C, 2013, HEPATOLOGY, V57, P81, DOI 10.1002/hep.25789
   Schnabl B, 2014, GASTROENTEROLOGY, V146, P1513, DOI 10.1053/j.gastro.2014.01.020
   Scott KP, 2014, FEMS MICROBIOL ECOL, V87, P30, DOI 10.1111/1574-6941.12186
   Sheng LL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01576-9
   Trottier J, 2011, CLIN PHARMACOL THER, V90, P279, DOI 10.1038/clpt.2011.124
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031
   Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X
   Wong RJ, 2014, HEPATOLOGY, V59, P2188, DOI 10.1002/hep.26986
   Wong VWS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062885
   Zhu LX, 2013, HEPATOLOGY, V57, P601, DOI 10.1002/hep.26093
NR 43
TC 28
Z9 29
U1 2
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0939-4753
EI 1590-3729
J9 NUTR METAB CARDIOVAS
JI Nutr. Metab. Carbiovasc. Dis.
PD APR
PY 2018
VL 28
IS 4
BP 369
EP 384
DI 10.1016/j.numecd.2017.10.014
PG 16
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism; Nutrition
   & Dietetics
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism;
   Nutrition & Dietetics
GA FZ5HU
UT WOS:000427623800006
PM 29482963
DA 2020-12-08
ER

PT J
AU Nacif, LS
   Gomes, CDC
   Mischiatti, MN
   Kim, V
   Paranagua-Vezozzo, D
   Reinoso, GL
   Carrilho, FJ
   D'Albuquerque, LC
AF Nacif, L. S.
   Gomes, C. D. C.
   Mischiatti, M. N.
   Kim, V.
   Paranagua-Vezozzo, D.
   Reinoso, G. L.
   Carrilho, F. J.
   D'Albuquerque, L. C.
TI Transient Elastography in Acute Cellular Rejection Following Liver
   Transplantation: Systematic Review
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 15th Brazilian Transplantation Congress / 16th Protuguese-Brazilian
   Transplantation Congress
CY OCT 18-21, 2017
CL Foz do Iguacu, BRAZIL
AB Background. Transient elastography (TE) is a noninvasive technique that measures liver stiffness. When an inflammatory process is present, this is shown by elevated levels of stiffness. Acute cellular rejection (ACR) is a consequence of an inflammatory response directed at endothelial and bile epithelial cells, and it is diagnosed through liver biopsy. This is a systematic review of the viability of TE in ACR following liver transplantation.
   Methods. The Cochrane Library, Embase, and Medline PubMed databases were searched and updated to November 2016. The MESH terms used were "Liver Transplantation," "Graft Rejection," "Elasticity Imaging Techniques" (PubMed), and "Elastography" (Cochrane and Embase).
   Results. Seventy studies were retrieved and selected using the PICO (patient, intervention, comparison or control, outcome) criteria. Three prospective studies were selected to meta-analysis and evaluation. A total of 33 patients with ACR were assessed with TE. One study showed a cutoff point of >7.9 kPa to define graft damage and <5.3 kPa to exclude graft damage (receiver operating characteristic 0.93; P<.001). Another study showed elevated levels of liver stiffness in ACR patients. However, in this study, no cutoff point for ACR was suggested. The final prospective study included 27 patients with ACR at liver biopsy. Cutoff points were defined as TE > 8.5 kPa, moderate to severe ACR, with a specificity of 100% and receiver operating characteristic curve of 0.924. The measurement of TE < 4.2 kPa excludes the possibility of any ACR (P=.02).
   Conclusions. TE may be an important tool for the severity of ACR in patients following liver transplantation. Further studies should be performed to better define the cutoff points and applicability of the exam.
C1 [Nacif, L. S.; Gomes, C. D. C.; D'Albuquerque, L. C.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Gastrointestinal Transplant Div, Sao Paulo, Brazil.
   [Mischiatti, M. N.; Kim, V.; Paranagua-Vezozzo, D.; Reinoso, G. L.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Gastroenterol & Hepatol Div, Sao Paulo, Brazil.
RP Nacif, LS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Gastrointestinal Transplant Div, Sao Paulo, Brazil.
EM lucasnacif@usp.br
RI Nacif, Lucas S./B-2795-2013; D'Albuquerque, Luiz Augusto
   Carneiro/A-8812-2013; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012;
   Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014; Carrilho, Flair
   J/I-3046-2012
OI Nacif, Lucas S./0000-0002-7059-3978; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Paranagua-Vezozzo, Denise
   Cerqueira/0000-0002-9606-4935; 
CR Crespo G, 2016, LIVER TRANSPLANT, V22, P298, DOI 10.1002/lt.24376
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Inoue Y, 2009, TRANSPLANTATION, V88, P103, DOI 10.1097/TP.0b013e3181aacb7f
   Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Martinez SM, 2011, HEPATOLOGY, V53, P325, DOI 10.1002/hep.24013
   Nacif LS, 2017, ANN TRANSPL, V22, P9, DOI 10.12659/AOT.901010
   Rigamonti C, 2012, LIVER TRANSPLANT, V18, P566, DOI 10.1002/lt.23391
   Wells GA, NEWCASTLE OTTAWA SCA
NR 8
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2018
VL 50
IS 3
BP 772
EP 775
DI 10.1016/j.transproceed.2018.02.008
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA GF6RN
UT WOS:000432095300019
PM 29661435
DA 2020-12-08
ER

PT J
AU Martins, SN
   Wakamatsu, A
   Villacorta-Martin, C
   Assato, AK
   Craig, A
   Carrilho, F
   Thung, S
   Villanueva, A
   Alves, V
AF Martins Filho, Sebastiao N.
   Wakamatsu, Alda
   Villacorta-Martin, Carlos
   Assato, Aline K.
   Craig, Amanda
   Carrilho, Flair
   Thung, Swan
   Villanueva, Augusto
   Alves, Venancio
TI Expanding the TMA Method to Investigate Phylogenetic Relationships
   Between Primary and Metastatic Hepatocellular Carcinoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 107th Annual Meeting of the
   United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 17-23, 2018
CL Vancouver, CANADA
SP US & Canadian Acad Pathol
C1 [Martins Filho, Sebastiao N.; Wakamatsu, Alda; Assato, Aline K.; Carrilho, Flair] FMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Villacorta-Martin, Carlos; Craig, Amanda; Villanueva, Augusto] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Thung, Swan] Mt Sinai Med Ctr, New York, NY 10029 USA.
   [Alves, Venancio] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD MAR
PY 2018
VL 31
SU 2
MA 1775
BP 641
EP 641
PG 1
WC Pathology
SC Pathology
GA GB8EQ
UT WOS:000429308604148
DA 2020-12-08
ER

PT J
AU Martins, SN
   Wakamatsu, A
   Villacorta-Martin, C
   Assato, AK
   Craig, A
   Carrilho, F
   Thung, S
   Villanueva, A
   Alves, V
AF Martins Filho, Sebastiao N.
   Wakamatsu, Alda
   Villacorta-Martin, Carlos
   Assato, Aline K.
   Craig, Amanda
   Carrilho, Flair
   Thung, Swan
   Villanueva, Augusto
   Alves, Venancio
TI Expanding the TMA Method to Investigate Phylogenetic Relationships
   Between Primary and Metastatic Hepatocellular Carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 107th Annual Meeting of the
   United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 17-23, 2018
CL Vancouver, CANADA
SP US & Canadian Acad Pathol
C1 [Martins Filho, Sebastiao N.; Wakamatsu, Alda; Assato, Aline K.; Carrilho, Flair] FMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Villacorta-Martin, Carlos; Craig, Amanda; Villanueva, Augusto] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Thung, Swan] Mt Sinai Med Ctr, New York, NY 10029 USA.
   [Alves, Venancio] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD MAR
PY 2018
VL 98
SU 1
MA 1775
BP 641
EP 641
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA HM2ZN
UT WOS:000459341003101
DA 2020-12-08
ER

PT J
AU Nakano, LA
   Katayose, JT
   Abreu, RM
   Mendes, LCA
   Martins, MC
   Pinto, VB
   Carrilho, FJ
   Ono, SK
AF Nakano, Larissa Akeme
   Katayose, Jessica Toshie
   Abreu, Rodrigo Martins
   Alfaia Mendes, Luis Claudio
   Martins, Maria Cleusa
   Pinto, Vanusa Barbosa
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI Assessment of the prevalence of vertical hepatitis B transmission in two
   consecutive generations
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Article
DE Hepatitis B. Infectious Disease Transmission; Vertical. Antiviral Agents
ID PREGNANCY
AB Introduction: Hepatitis B is an important public health problem in the world and one of the forms of contagion would be through vertical transmission. Precose diagnosis allows the adoption of prophylaxis measures, which results in prevention in more than 90% of cases.
   Objective: To describe the prevalences of vertical transmission and compare two generations (mother/patient and patient/child).
   Method: This was a cross-sectional study, which included 101 patients. The interviews were performed through the application of the instrument of data collection and information of the physical file before the medical consultation.
   Results: The mean +/- SD of age was 50.9 +/- 13.1 years, the male gender predominated, with 56.4% of the patients, and the predominance was white, with 43.6%. Vertical transmission between mother and patient occurred in 17.8% and between patient and child, in 7.9%. In all of the eight cases of vertical transmission, the diagnosis was after the birth of children infected with HBV, and in 3/8 (37.5%), there was more than one case of infection by this mechanism per patient, totaling 13 children with the disease.
   Conclusion: There was a reduction in vertical transmission, showing that preventive measures were effective.
C1 [Nakano, Larissa Akeme; Katayose, Jessica Toshie; Martins, Maria Cleusa; Pinto, Vanusa Barbosa] Univ Sao Paulo HC FMUSP, Fac Med, Hosp Clin, Div Pharm, Sao Paulo, SP, Brazil.
   [Abreu, Rodrigo Martins; Alfaia Mendes, Luis Claudio; Carrilho, Flair Jose; Ono, Suzane Kioko] HC FMUSP, Div Dept Gastroenterol & Hepatol, Sao Paulo, SP, Brazil.
RP Nakano, LA (corresponding author), Hosp Clin Sao Paulo, Inst Cent, Av Dr Eneas Carvalho Aguiar 255,9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM larissa.nakano@hc.fm.usp.br
OI NAKANO, LARISSA/0000-0002-6838-3306
CR Abreu RM., 2013, THESIS U SAO PAULO
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica. A B C D E de hepatites para comunicadores, 2005, MIN SAUD SECR VIG SA
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Prevencao e Controle das DST Aids e Hepatites Virais, 2016, B EP HEP VIR
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Prevencao e Controle das DST Aids e Hepatites Virais, 2016, PROT CLIN DIR TER HE
   Cheung KW, 2013, EUR J OBSTET GYN R B, V169, P17, DOI 10.1016/j.ejogrb.2013.02.001
   Dionne-Odom J, 2016, AM J OBSTET GYNECOL, V214, P6, DOI 10.1016/j.ajog.2015.09.100
   Divisao de Imunizacao. Divisao de Hepatites. Centro de Vigilancia Epidemiologica Prof. Alexandre Vranjac, 2006, REV SAUDE PUBL, V40, P1137
   Kim HY, 2013, J CLIN VIROL, V56, P299, DOI 10.1016/j.jcv.2012.11.019
   Ministerio da Saude, 2014, SECR VIG SAUD
   Ministerio da Saude. Secretaria de Atencao a Saude. Departamento de DST AIDS e Hepatites virais, 2015, PROT CLIN DIR TER PR
   Ono-Nita Suzane Kioko, 2004, BMC Fam Pract, V5, P7, DOI 10.1186/1471-2296-5-7
   Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156
   World Health Organization, 2015, GUID PREV CAR TREATM
   Zhuang H, 2016, Zhonghua Gan Zang Bing Za Zhi, V24, P881, DOI 10.3760/cma.j.issn.1007-3418.2016.12.001
NR 14
TC 0
Z9 0
U1 0
U2 2
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
SN 0104-4230
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD FEB
PY 2018
VL 64
IS 2
BP 154
EP 158
DI 10.1590/1806-9282.64.02.154
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA GC0SI
UT WOS:000429487700012
PM 29641674
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Casotti, MO
   Tuan, R
   Gomes, M
   Luna, EJA
   Dias-Neto, E
   Paula, FM
   Pinho, JRR
   Carrilho, FJ
   Gryschek, RCB
   Espirito-Santo, MCC
AF Casotti, Marcia
   Tuan, Roseli
   Gomes, Michele
   Albuquerque Luna, Expedito
   Dias-Neto, Emmanuel
   Paula, Fabiana
   Rebello Pinho, Joao
   Carrilho, Flair
   Borges Gryschek, Ronaldo
   Espirito-Santo, Maria
TI DETECTION OF <it>SCHISTOSOMA MANSONI</it> SPOROCYST STAGE IN
   <it>BIOMPHALARIA GLABRATA</it> MOLLUSK IN EXPERIMENTAL CONDITIONS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 67th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTHM)
CY OCT 28-NOV 01, 2018
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg, Bill & Melinda Gates Fdn, Takeda Pharmaceut Int AG, Novartis Social Business, Celgene Corp, Techlab Inc, Indiana Univ, Sch Med, B EI Resources, Sanofi Pasteur, Welcome, PLOS, Elsevier
C1 [Casotti, Marcia; Gomes, Michele; Dias-Neto, Emmanuel; Paula, Fabiana; Rebello Pinho, Joao; Carrilho, Flair; Borges Gryschek, Ronaldo; Espirito-Santo, Maria] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Tuan, Roseli] Superintendencia Controle Endemias SUCEN, Sao Paulo, Brazil.
   [Albuquerque Luna, Expedito] Univ Sao Paulo, Univ Sao Paulo Fac Med, Inst Med Trop Fac Med, Sao Paulo, Brazil.
RI Dias-Neto, Emmanuel/AAA-6701-2019; Dias-Neto, Emmanuel/A-5869-2008;
   Dias-Neto, Emmanuel/AAE-9147-2020
OI Dias-Neto, Emmanuel/0000-0001-5670-8559; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2018
VL 99
IS 4
SU S
MA 2021
BP 635
EP 635
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA HP0WF
UT WOS:000461386605071
DA 2020-12-08
ER

PT J
AU Cruz-Santos, MD
   Gomes-Gouvea, MS
   Costa-Nunes, JD
   Malta-Romano, C
   Teles-Sousa, M
   Fonseca-Barros, LM
   Carrilho, FJ
   Paiva-Ferreira, AD
   Rebello-Pinho, JR
AF Cruz-Santos, Max D.
   Gomes-Gouvea, Michele S.
   Costa-Nunes, Jomar D.
   Malta-Romano, Camila
   Teles-Sousa, Marinilde
   Fonseca-Barros, Lena M.
   Carrilho, Flair J.
   Paiva-Ferreira, Adalgisa de S.
   Rebello-Pinho, Joao R.
TI High Prevalence of Hepatitis B Subgenotype D4 in Northeast Brazil: an
   Ancient Relic from African Continent?
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE HBV; Genotype; Slave trade; Maranhao
ID VIRUS GENOTYPES; GENETIC DIVERSITY; MOLECULAR EPIDEMIOLOGY; HBV
   INFECTION; CORE MUTANTS; SLAVE-TRADE; MUTATIONS; PRECORE; A1;
   GENOTYPES/SUBGENOTYPES
AB Introduction. Hepatitis B virus (HBV) infection leads to a chronic liver disease that is distributed worldwide. The characterization of HBV into genotypes/subgenotypes is not only a mere procedure for distinguishing different HBV strains around the world because determining their geographic distribution is crucial to understanding their spread across the world. Material and methods. We characterized different HBV genotypes and subgenotypes in five municipalities located in northeastern Maranhao, in the Brazilian north Atlantic coast. 92 HBsAg-positive individuals were submitted to PCR (polymerase chain reaction). Fifty samples were sequenced using automated Sanger sequencing and classified by phylogenetic methods. Results. Subgenotypes D4 and A1 were found in 42 (84%) and eight (16%) samples, respectively. To our knowledge, this is the first study to describe a high frequency of subgenotype D4 in any population. Subgenotype A1 is frequently found across Brazil, but D4 has been rarely detected and only in a few Brazilian states. This study shows the characterization of HBV subgenotypes from a population based study in the state of Maranhao, particularly in populations that do not have frequent contact with populations from other regions of the world. Conclusion. Our findings showed a HBV subgenotype profile that probably reflect the viruses that were brought with the slave trade from Africa to Maranhao. This study also reinforces the need to evaluate the status of HBV dispersion not only in large urban centers, but also in the hinterland, to enable the implementation of effective control and treatment measures.
C1 [Cruz-Santos, Max D.; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Rebello-Pinho, Joao R.] Univ Sao Paulo, Lab Trop Gastroenterol & Hepatol Joao Alves Queir, LIM 07, Sao Paulo Inst Trop Med, Sao Paulo, Brazil.
   [Cruz-Santos, Max D.; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Rebello-Pinho, Joao R.] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Costa-Nunes, Jomar D.; Teles-Sousa, Marinilde; Fonseca-Barros, Lena M.; Paiva-Ferreira, Adalgisa de S.] Univ Fed Maranhao, Ctr Clin Res, Sao Luis, Maranhao, Brazil.
   [Malta-Romano, Camila] Univ Sao Paulo, Lab Virol, LIM 52, Sao Paulo Inst Trop Med, Sao Paulo, SP, Brazil.
   [Malta-Romano, Camila] Univ Sao Paulo, Dept Infect Dis, Sch Med, Sao Paulo, SP, Brazil.
   [Rebello-Pinho, Joao R.] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
   [Cruz-Santos, Max D.; Rebello-Pinho, Joao R.] CNpq Brasil, Brasilia, DF, Brazil.
RP Cruz-Santos, MD (corresponding author), FMUSP, Inst Med Trop, Lab Gastroenterol & Hepatol Trop, Av Dr Eneas Carvalho Aguiar 500, BR-05403000 Sao Paulo, SP, Brazil.
EM maxdiegocs@alumni.usp.br
RI Romano, Camila M/C-8185-2013; Pinho, Joao/G-2850-2012
OI Pinho, Joao/0000-0003-3999-0489
FU Fundacao de Amparo a Pesquisa do Estado do Maranhao - (FAPEMA)
   [PP-SUS-03348/13, PPP-01263/12]; Sao Paulo Research Foundation
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/53946-3]; Brazilian Ministry of Health [1/2013]; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [141138/2012-2]; CNPq
   (Bolsista de Produtividade em Pesquisa do CNPq - Nivel 2)National
   Council for Scientific and Technological Development (CNPq)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado do
   Maranhao - (FAPEMA) [grant: PP-SUS-03348/13 and PPP-01263/12]; Sao Paulo
   Research Foundation (FAPESP) - [grant: 2009/53946-3]; Brazilian Ministry
   of Health [grant: 1/2013]. Max Diego Cruz Santos received a Ph.D.
   fellowship from Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) [grant: 141138/2012-2]. Joao Renato Rebello Pinho
   receives fellowship from CNPq (Bolsista de Produtividade em Pesquisa do
   CNPq - Nivel 2).
CR Alvarado-Mora MV, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-415
   Amponsah-Dacosta E, 2015, J CLIN VIROL, V63, P12, DOI 10.1016/j.jcv.2014.11.032
   Andernach IE, 2009, EMERG INFECT DIS, V15, P1222, DOI 10.3201/eid1508.081642
   Araujo NM, 2011, INFECT GENET EVOL, V11, P1199, DOI 10.1016/j.meegid.2011.04.017
   Baha W, 2012, INFECT GENET EVOL, V12, P1157, DOI 10.1016/j.meegid.2012.04.026
   Banerjee P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109425
   Barros LMF, 2011, VIRUS RES, V160, P333, DOI 10.1016/j.virusres.2011.07.006
   Becker Carlos Eduardo, 2010, Arq. Gastroenterol., V47, P13, DOI 10.1590/S0004-28032010000100003
   Bertolini DA, 2012, INFECT GENET EVOL, V12, P1295, DOI 10.1016/j.meegid.2012.04.009
   Beutels P, 2001, HEALTH ECON, V10, P751, DOI 10.1002/hec.625
   Brichler S, 2013, J GEN VIROL, V94, P2318, DOI 10.1099/vir.0.055459-0
   Carrilho FJ, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-13
   *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P868
   Cooksley WGE, 2010, J VIRAL HEPATITIS, V17, P601, DOI 10.1111/j.1365-2893.2010.01326.x
   Santos MDC, 2016, VIRUS RES, V224, P6, DOI 10.1016/j.virusres.2016.08.003
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Souto FJD, 2016, REV SOC BRAS MED TRO, V49, P11, DOI 10.1590/0037-8682-0176-2015
   Crispim MAE, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-94
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Barros LMF, 2014, INFECT GENET EVOL, V24, P68, DOI 10.1016/j.meegid.2014.03.007
   Ghosh S, 2010, J CLIN MICROBIOL, V48, P4063, DOI 10.1128/JCM.01174-10
   Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
   Gomes-Gouvea MS, 2015, ANTIVIR THER, V20, P387, DOI 10.3851/IMP2938
   Gomes-Gouvea MS, 2014, GASTROENTEROLOGIA
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   Hubschen JM, 2009, J MED VIROL, V81, P435, DOI 10.1002/jmv.21412
   Hundie GB, 2016, J MED VIROL, V88, P1035, DOI 10.1002/jmv.24437
   Huy TTT, 2008, J VIROL, V82, P5657, DOI 10.1128/JVI.02556-07
   IBGE, 2012, CENS DEM 2010 RES GE, P239
   Kitab B, 2011, J INFECTION, V63, P66, DOI 10.1016/j.jinf.2011.05.007
   Kramvis A, 2008, J MED VIROL, V80, P27, DOI 10.1002/jmv.21049
   Kramvis A, 2013, ANTIVIR THER, V18, P513, DOI 10.3851/IMP2657
   Kurbanov F, 2008, J VIROL, V82, P8241, DOI 10.1128/JVI.00793-08
   Kurbanov F, 2010, HEPATOL RES, V40, P14, DOI 10.1111/j.1872-034X.2009.00601.x
   Kwange SO, 2013, VIRUS GENES, V47, P448, DOI 10.1007/s11262-013-0976-1
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lago BV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105317
   Loureiro CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118959
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Martinez AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103545
   Meireles M. C., 2009, OUTROS TEMPOS, V6, P130
   Meldal BHM, 2009, J GEN VIROL, V90, P1622, DOI 10.1099/vir.0.009738-0
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Moura IF, 2013, INFECT GENET EVOL, V14, P195, DOI 10.1016/j.meegid.2012.11.022
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   Orito E, 2001, HEPATOLOGY, V34, P590, DOI 10.1053/jhep.2001.27221
   Osiowy C, 2011, J VIRAL HEPATITIS, V18, pe11, DOI 10.1111/j.1365-2893.2010.01356.x
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
   Perbi A, 2001, SLAVERY SLAVE TRADE, P1
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Roman S, 2014, WORLD J GASTROENTERO, V20, P7181, DOI 10.3748/wjg.v20.i23.7181
   Santos AO, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-315
   Schaefer S, 2007, HEPATOL RES, V37, pS20, DOI 10.1111/j.1872-034X.2007.00099.x
   Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
   Shi WF, 2013, INFECT GENET EVOL, V16, P355, DOI 10.1016/j.meegid.2013.03.021
   Silva D. B. D., 2008, SLAVERY ABOLIT, V29, P477
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Sitnik R, 2010, REV INST MED TROP SP, V52, P119, DOI 10.1590/S0036-46652010000300001
   Tatematsu K, 2009, J VIROL, V83, P10538, DOI 10.1128/JVI.00462-09
   Victoria FD, 2008, BRAZ J INFECT DIS, V12, P27, DOI 10.1590/S1413-86702008000100008
   Zehender G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037198
NR 63
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER ESPANA
PI MADRID
PA CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD JAN-FEB
PY 2018
VL 17
IS 1
BP 54
EP 63
DI 10.5604/01.3001.0010.7535
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HO2LV
UT WOS:000460747500008
OA Other Gold
DA 2020-12-08
ER

PT J
AU Ferreira, AC
   Gomes-Gouvea, MS
   Lisboa-Neto, G
   Mendes-Correa, MCJ
   Picone, CM
   Salles, NA
   Mendrone, A
   Carrilho, FJ
   Pinho, JRR
AF Ferreira, A. C.
   Gomes-Gouvea, Michele Soares
   Lisboa-Neto, G.
   Mendes-Correa, M. C. J.
   Picone, C. M.
   Salles, N. A.
   Mendrone-Junior, A.
   Carrilho, F. J.
   Pinho, J. R. R.
TI Serological and molecular markers of hepatitis E virus infection in
   HIV-infected patients in Brazil
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; E SEROPREVALENCE; HEV INFECTION;
   BLOOD-DONORS; NON-A; NON-B; ANTIBODIES; PREVALENCE; SWINE; CIRRHOSIS
AB In Brazil, the circulation of hepatitis E virus (HEV) has been demonstrated in distinct groups of individuals and some animals, but its prevalence among individuals with human immunodeficiency virus (HIV) infection is unknown. This study aimed to assess the frequency of serological and molecular HEV markers in individuals infected with HIV from So Paulo, Brazil. Serum and plasma samples of 354 HIV-infected patients collected between 2007 and 2013 were included. All samples were tested for anti-HEV IgG and IgM antibodies and HEV RNA. Anti-HEV IgG and IgM antibodies were detected in 10.7% (38/354) and 1.4% (5/354) of the samples, respectively. Both antibodies were detected simultaneously in only two samples. HEV RNA was not detected in any sample. There was no significant correlation of anti-HEV serological status (positivity to anti-HEV IgG and/or IgM) with sex, age, CD4(+) T cell count, HIV viral load, antiretroviral therapy, liver enzyme levels, or coinfection with hepatitis B virus and/or hepatitis C virus. Our study provides serological evidence of past and recent HEV infections in HIV-infected patients from So Paulo, Brazil. However, the occurrence of ongoing HEV infection appears be a rare event in this population.
C1 [Ferreira, A. C.; Gomes-Gouvea, Michele Soares; Carrilho, F. J.; Pinho, J. R. R.] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP,Dept Gastroenterol, Lab Gastroenterol & Hepatol Trop LIM 07,Inst Med, Av Dr Eneas Carvalho Aguiar 500, BR-05403000 Sao Paulo, SP, Brazil.
   [Lisboa-Neto, G.; Mendes-Correa, M. C. J.] Univ Sao Paulo, Hosp Clin HCFMUSP, Dept Doencas Infecciosas & Parasitarias, Lab Virol LIM 52,Inst Med Trop USP, Sao Paulo, SP, Brazil.
   [Picone, C. M.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Dept Doencas Infecciosas & Parasitarias, Sao Paulo, SP, Brazil.
   [Salles, N. A.; Mendrone-Junior, A.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, SP, Brazil.
   [Pinho, J. R. R.] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
RP Gomes-Gouvea, MS (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP,Dept Gastroenterol, Lab Gastroenterol & Hepatol Trop LIM 07,Inst Med, Av Dr Eneas Carvalho Aguiar 500, BR-05403000 Sao Paulo, SP, Brazil.
EM gomesmic@yahoo.com.br
RI Melo Picone, Camila/I-7932-2016; Pinho, Joao R. R./G-2850-2012; Sabino,
   Ester Cerdeira/F-7750-2010; Carrilho, Flair J/I-3046-2012
OI Melo Picone, Camila/0000-0002-2455-5831; Pinho, Joao R.
   R./0000-0003-3999-0489; Sabino, Ester Cerdeira/0000-0003-2623-5126; 
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2012/50504-2]; Alves de Queiroz Family
   Fund for Research; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2012/21588-3]; CAPESCAPES; CNPq (Bolsista de
   Produtividade em Pesquisa do CNPq - Nivel 2)National Council for
   Scientific and Technological Development (CNPq)
FX This study was supported by grant 2012/50504-2 from the Sao Paulo
   Research Foundation (FAPESP) and Alves de Queiroz Family Fund for
   Research. Ariana Carolina Ferreira is a graduate student from the
   Department of Gastroenterology, School of Medicine, University of Sao
   Paulo, Sao Paulo, SP, Brazil, and received a fellowship from FAPESP
   (2012/21588-3) and CAPES. Joao Renato Rebello Pinho and Maria Cassia
   Mendes Correa received a fellowship from CNPq (Bolsista de Produtividade
   em Pesquisa do CNPq - Nivel 2).
CR Assis Sandra Breder, 2002, Rev. Soc. Bras. Med. Trop., V35, P155, DOI 10.1590/S0037-86822002000200005
   BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370
   Balayan MS, 1997, J VIRAL HEPATITIS, V4, P279, DOI 10.1046/j.1365-2893.1997.00050.x
   Bortoliero André Luiz, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P87, DOI 10.1590/S0036-46652006000200006
   Colson P, 2009, J CLIN VIROL, V45, P269, DOI 10.1016/j.jcv.2009.06.002
   Crum-Cianflone NF, 2012, EMERG INFECT DIS, V18, P502, DOI 10.3201/eid1803.111278
   Lana MVD, 2014, TROP ANIM HEALTH PRO, V46, P399, DOI 10.1007/s11250-013-0503-3
   Dalton HR, 2016, DIGEST DIS, V34, P308, DOI 10.1159/000444468
   Dalton HR, 2014, FUTURE MICROBIOL, V9, P1361, DOI 10.2217/fmb.14.89
   Dalton HR, 2009, NEW ENGL J MED, V361, P1025, DOI 10.1056/NEJMc0903778
   de Freitas NR, 2016, MEM I OSWALDO CRUZ, V111, P692, DOI 10.1590/0074-02760160256
   Debes JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160082
   Debes JD, 2016, J CLIN VIROL, V80, P102, DOI 10.1016/j.jcv.2016.05.006
   dos Santos DCM, 2002, MEM I OSWALDO CRUZ, V97, P637, DOI 10.1590/S0074-02762002000500007
   Fainboim H, 1999, J VIRAL HEPATITIS, V6, P53, DOI 10.1046/j.1365-2893.1999.t01-1-6120135.x
   Feldt T, 2013, J CLIN VIROL, V58, P18, DOI 10.1016/j.jcv.2013.05.004
   Geng YS, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.15618
   Gerolami R, 2008, NEW ENGL J MED, V358, P859, DOI 10.1056/NEJMc0708687
   Goncales NSL, 2000, CLIN DIAGN LAB IMMUN, V7, P813, DOI 10.1128/CDLI.7.5.813-816.2000
   Guimaraes FR, 2005, BRAZ J MICROBIOL, V36, P223, DOI 10.1590/S1517-83822005000300004
   Haagsma EB, 2008, LIVER TRANSPLANT, V14, P547, DOI 10.1002/lt.21480
   HARTL J, 2016, VIRUSES-BASEL, V8, DOI DOI 10.3390/V8110299
   Hartl J, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8080211
   Heldt FH, 2016, FOOD ENVIRON VIROL, V8, P200, DOI 10.1007/s12560-016-9243-7
   Hering T, 2014, J MED VIROL, V86, P948, DOI 10.1002/jmv.23915
   Ingiliz P, 2016, CLIN RES HEPATOL GAS, V40, pE23, DOI 10.1016/j.clinre.2016.01.005
   Jothikumar N, 2006, J VIROL METHODS, V131, P65, DOI 10.1016/j.jviromet.2005.07.004
   Kaba M, 2011, J MED VIROL, V83, P1704, DOI 10.1002/jmv.22177
   Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992
   Kamar N, 2014, CLIN MICROBIOL REV, V27, P116, DOI 10.1128/CMR.00057-13
   Kamar N, 2012, LANCET, V379, P2477, DOI 10.1016/S0140-6736(11)61849-7
   Keane FE, 2012, HIV MED, V13, P83, DOI 10.1111/j.1468-1293.2011.00942.x
   Kenfak-Foguena A, 2011, EMERG INFECT DIS, V17, P1074, DOI [10.3201/eid1706.101067, 10.3201/eid/1706.101067]
   Khudyakov Y, 2011, VIRUS RES, V161, P84, DOI 10.1016/j.virusres.2011.06.006
   Koning L, 2013, J HEART LUNG TRANSPL, V32, P78, DOI 10.1016/j.healun.2012.10.008
   Kuniholm MH, 2016, HEPATOLOGY, V63, P712, DOI 10.1002/hep.28384
   Lee GH, 2016, GASTROENTEROLOGY, V150, P355, DOI 10.1053/j.gastro.2015.10.048
   dos Santos DRL, 2009, VET J, V182, P474, DOI 10.1016/j.tvjl.2008.08.001
   Lyra AC, 2005, BRAZ J MED BIOL RES, V38, P767, DOI 10.1590/S0100-879X2005000500015
   Martins RMB, 2014, J CLIN VIROL, V59, P188, DOI 10.1016/j.jcv.2014.01.002
   Maylin S, 2012, J CLIN VIROL, V53, P346, DOI 10.1016/j.jcv.2012.01.001
   Neukam K, 2013, CLIN INFECT DIS, V57, P465, DOI 10.1093/cid/cit224
   Paiva HH, 2007, BRAZ J MICROBIOL, V38, P693, DOI 10.1590/S1517-83822007000400020
   Parana R, 1997, AM J TROP MED HYG, V57, P60, DOI 10.4269/ajtmh.1997.57.60
   Passos-Castilho AM, 2017, BRAZ J INFECT DIS, V21, P535, DOI 10.1016/j.bjid.2017.05.004
   Passos-Castilho AM, 2016, J MED VIROL, V88, P361, DOI 10.1002/jmv.24336
   Passos-Castilho AM, 2014, J CLIN MICROBIOL, V52, P4425, DOI 10.1128/JCM.02286-14
   Pischke S, 2010, LIVER TRANSPLANT, V16, P74, DOI 10.1002/lt.21958
   Politou M, 2015, J MED VIROL, V87, P1517, DOI 10.1002/jmv.24214
   Ramezani A, 2013, INT J STD AIDS, V24, P769, DOI 10.1177/0956462413484457
   Rivero-Juarez A, 2015, J INFECTION, V70, P680, DOI 10.1016/j.jinf.2014.11.010
   Rode OD, 2014, EUR J CLIN MICROBIOL, V33, P2231, DOI 10.1007/s10096-014-2187-7
   Scotto G, 2015, INFECT DIS-NOR, V47, P707, DOI 10.3109/23744235.2015.1049658
   Singh GJ, 2011, HIV MED, V12, P44
   Smith DB, 2014, J GEN VIROL, V95, P2223, DOI 10.1099/vir.0.068429-0
   Souto FJD, 1997, AM J TROP MED HYG, V57, P149, DOI 10.4269/ajtmh.1997.57.149
   de Souza AJS, 2012, COMP IMMUNOL MICROB, V35, P477, DOI 10.1016/j.cimid.2012.04.004
   Tamura A, 2007, HEPATOL RES, V37, P113, DOI 10.1111/j.1872-034X.2007.00024.x
   Trinta KS, 2001, MEM I OSWALDO CRUZ, V96, P25, DOI 10.1590/S0074-02762001000100004
   Vitral CL, 2005, MEM I OSWALDO CRUZ, V100, P117, DOI 10.1590/S0074-02762005000200003
   Wenzel JJ, 2013, J INFECT DIS, V207, P497, DOI 10.1093/infdis/jis688
NR 61
TC 9
Z9 9
U1 0
U2 4
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD JAN
PY 2018
VL 163
IS 1
BP 43
EP 49
DI 10.1007/s00705-017-3562-3
PG 7
WC Virology
SC Virology
GA FS0IC
UT WOS:000419456300005
PM 28965214
DA 2020-12-08
ER

PT J
AU Debes, JD
   Chan, AJ
   Balderramo, D
   Kikuchi, L
   Ballerga, EG
   Prieto, JE
   Tapias, M
   Idrovo, V
   Davalos, MB
   Cairo, F
   Barreyro, FJ
   Paredes, S
   Hernandez, N
   Avendano, K
   Ferrer, JD
   Yang, JD
   Carrera, E
   Garcia, JA
   Mattos, AZ
   Hirsch, BS
   Goncalves, PT
   Carrilho, FJ
   Roberts, LR
AF Debes, Jose D.
   Chan, Aaron J.
   Balderramo, Domingo
   Kikuchi, Luciana
   Gonzalez Ballerga, Esteban
   Prieto, Jhon E.
   Tapias, Monica
   Idrovo, Victor
   Davalos, Milagros B.
   Cairo, Fernando
   Barreyro, Fernando J.
   Paredes, Sebastian
   Hernandez, Nelia
   Avendano, Karla
   Diaz Ferrer, Javier
   Yang, Ju Dong
   Carrera, Enrique
   Garcia, Jairo A.
   Mattos, Angelo Z.
   Hirsch, Bruno S.
   Goncalves, Pablo T.
   Carrilho, Flair J.
   Roberts, Lewis R.
TI Hepatocellular carcinoma in South America: Evaluation of risk factors,
   demographics and therapy
SO LIVER INTERNATIONAL
LA English
DT Article
DE demographics; hepatocellular carcinoma; risk factors; South America
ID TP53 MUTATION; EPIDEMIOLOGY; SURVEILLANCE; PREVENTION; ASSOCIATION;
   PREVALENCE; INFECTION; DIAGNOSIS; CIRRHOSIS; IMPACT
AB Background & AimsHepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Most studies addressing the epidemiology of HCC originate from developed countries. This study reports the preliminary findings of a multinational approach to characterize HCC in South America.
   MethodsWe evaluated 1336 HCC patients seen at 14 centres in six South American countries using a retrospective study design with participating centres completing a template chart of patient characteristics. The diagnosis of HCC was made radiographically or histologically for all cases according to institutional standards. Methodology of surveillance for each centre was following AASLD or EASL recommendations.
   ResultsSixty-eight percent of individuals were male with a median age of 64years at time of diagnosis. The most common risk factor for HCC was hepatitis C infection (HCV, 48%), followed by alcoholic cirrhosis (22%), Hepatitis B infection (HBV, 14%) and NAFLD (9%). We found that among individuals with HBV-related HCC, 38% were diagnosed before age 50. The most commonly provided therapy was transarterial chemoembolization (35% of HCCs) with few individuals being considered for liver transplant (<20%). Only 47% of HCCs were diagnosed during surveillance, and there was no difference in age of diagnosis between those diagnosed incidentally vs by surveillance. Nonetheless, being diagnosed during surveillance was associated with improved overall survival (P=.01).
   ConclusionsOur study represents the largest cohort to date reporting characteristics and outcomes of HCC across South America. We found an important number of HCCs diagnosed outside of surveillance programmes, with associated increased mortality in those patients.
C1 [Debes, Jose D.; Chan, Aaron J.] Univ Minnesota, Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA.
   [Balderramo, Domingo] Hosp Privado Univ Cordoba, Inst Univ Ciencias Biomed Cordoba, Dept Gastroenterol, Cordoba, Argentina.
   [Kikuchi, Luciana; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Gonzalez Ballerga, Esteban] Hosp Clin Buenos Aires, Dept Gastroenterol, Buenos Aires, DF, Argentina.
   [Prieto, Jhon E.] Org Sanitas Colombia, Dept Gastroenterol, CEHYD, Bogota, Colombia.
   [Tapias, Monica; Idrovo, Victor] Hosp Univ Fdn Santa Fe, Dept Gastroenterol, Bogota, Colombia.
   [Tapias, Monica; Idrovo, Victor] Org Sanitas, Bogota, Colombia.
   [Davalos, Milagros B.; Diaz Ferrer, Javier] Hosp Nacl Edgardo Rebagliati Martins, Dept Gastroenterol, Lima, Peru.
   [Cairo, Fernando] Hosp El Cruce, Dept Gastroenterol, Buenos Aires, DF, Argentina.
   [Barreyro, Fernando J.] Consejo Nacl Invest Cient & Tecn, Posadas, Argentina.
   [Paredes, Sebastian] Hosp Presidente Peron, Dept Gastroenterol & Hepatol, Formosa, Argentina.
   [Hernandez, Nelia; Avendano, Karla] Hosp Clin UdelaR, Dept Gastroenterol & Hepatol, Montevideo, Uruguay.
   [Yang, Ju Dong; Roberts, Lewis R.] Mayo Clin, Coll Med, Dept Gastroenterol, Rochester, MN USA.
   [Carrera, Enrique] Hosp Eugenio Espejo, Dept Gastroenterol & Hepatol, Quito, Ecuador.
   [Garcia, Jairo A.] Fdn Lili, Cali, Colombia.
   [Mattos, Angelo Z.; Hirsch, Bruno S.; Goncalves, Pablo T.] HNSC, Dept Gastroenterol, Porto Alegre, RS, Brazil.
RP Debes, JD (corresponding author), Univ Minnesota, Hennepin Cty Med Ctr, Dept Med, Div IDIM,Dept Gastroenterol & Hepatol, Minneapolis, MN 55415 USA.
EM debes003@umn.edu
RI Debes, Jose/Q-9794-2016
OI Prieto Ortiz, Jhon Edison/0000-0002-8009-5999; Balderramo,
   Domingo/0000-0001-9598-2577; Roberts, Lewis/0000-0001-7885-8574
CR Choo SP, 2016, CANCER-AM CANCER SOC, V122, P3430, DOI 10.1002/cncr.30237
   Cucchetti A, 2014, J HEPATOL, V61, P333, DOI 10.1016/j.jhep.2014.03.037
   Edenvik P, 2015, LIVER INT, V35, P1862, DOI 10.1111/liv.12764
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Harris S, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.4_suppl.174
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kudo M, 2016, LIVER INT, V36, P1196, DOI 10.1111/liv.13096
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Lok AS, 2009, GASTROENTEROLOGY, V136, P138, DOI 10.1053/j.gastro.2008.09.014
   Margini C, 2016, LIVER INT, V36, P317, DOI 10.1111/liv.13031
   McGlynn KA, 2015, CLIN LIVER DIS, V19, P223, DOI 10.1016/j.cld.2015.01.001
   Mendez-Sanchez Nahum, 2014, Ann Hepatol, V13 Suppl 1, pS4
   Mourad A, 2014, HEPATOLOGY, V59, P1471, DOI 10.1002/hep.26944
   Nogueira JA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-204
   Nordenstedt H, 2010, DIGEST LIVER DIS, V42, pS206, DOI 10.1016/S1590-8658(10)60507-5
   Park JW, 2015, LIVER INT, V35, P2155, DOI 10.1111/liv.12818
   Ryerson AB, 2016, CANCER-AM CANCER SOC, V122, P1312, DOI 10.1002/cncr.29936
   Salomao M, 2010, AM J SURG PATHOL, V34, P1630, DOI 10.1097/PAS.0b013e3181f31caa
   Sherman M, 2012, HEPATOLOGY, V56, P793, DOI 10.1002/hep.25869
   Singal AG, 2017, GASTROENTEROLOGY, V152, P608, DOI 10.1053/j.gastro.2016.10.042
   Singal AG, 2015, CLIN GASTROENTEROL H, V13, P2140, DOI 10.1016/j.cgh.2015.08.014
   Tholey DM, 2015, GASTROENTEROL CLIN N, V44, P761, DOI 10.1016/j.gtc.2015.07.005
   Turner PC, 2002, J GASTROEN HEPATOL, V17, pS441, DOI 10.1046/j.1440-1746.17.s4.7.x
   Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05
   Wallace MC, 2015, EXPERT REV GASTROENT, V9, P765, DOI 10.1586/17474124.2015.1028363
   Yang JD, 2017, LANCET GASTROENTEROL, V2, P103, DOI 10.1016/S2468-1253(16)30161-3
   Yang JD, 2015, AM J GASTROENTEROL, V110, P1629, DOI 10.1038/ajg.2015.289
   Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431
NR 30
TC 20
Z9 20
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-3223
EI 1478-3231
J9 LIVER INT
JI Liver Int.
PD JAN
PY 2018
VL 38
IS 1
BP 136
EP 143
DI 10.1111/liv.13502
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA FR0BB
UT WOS:000418724800016
PM 28640517
OA Green Published
DA 2020-12-08
ER

PT J
AU Neto, GL
   Malta, FM
   Gomes-Gouvea, MS
   Noble, CF
   Romano, CM
   Pinho, JRR
   Silva, MH
   Leite, AGB
   Piccoli, LZ
   Carrilho, FJ
   Mendes-Correa, MC
AF Neto, Gaspar Lisboa
   Malta, Fernanda M.
   Gomes-Gouvea, Michele S.
   Noble, Caroline F.
   Romano, Camila M.
   Rebello Pinho, Joao R.
   Silva, Mariliza H.
   Leite, Andrea G. B.
   Piccoli, Leonora Z.
   Carrilho, Flair J.
   Mendes-Correa, Maria C.
TI Characterization of clinical predictors of naturally occurring NS3/NS4A
   protease polymorphism in genotype 1 hepatitis C virus mono and HIV
   co-infected patients
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE anti-hepatitis C virus DAA; hepatitis C virus; human immunodeficiency
   virus; mutation; protease inhibitors
ID INTERFERON-FREE; NS3 PROTEASE; RESISTANCE; HCV
AB Spontaneously occurring resistance may impair the success of protease inhibitors based regimens in HCV treatment. This study aimed to evaluate associations between amino acid substitutions in NS3/NS4A domain and clinical features of 247 HCV mono or HCV/HIV co-infected patients. Fourteen samples (5.7%) harbored at least one resistance-associated substitution (RAS). The following RASs were detected in NS3 region: T54S (6-2.4%), V55A (7-2.8%), and Q80R (2-0.8%). S122G occurred in 86.9% of HCV genotype 1b samples with either natural polymorphisms or RASs. Advanced liver fibrosis and HIV co-infection were not related to NS3/NS4A amino acid substitutions.
C1 [Neto, Gaspar Lisboa; Mendes-Correa, Maria C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, SP, Brazil.
   [Neto, Gaspar Lisboa; Romano, Camila M.; Mendes-Correa, Maria C.] Univ Sao Paulo, Sch Med Sao Paulo, Inst Trop Med, Lab Virol LIM 52, Sao Paulo, Brazil.
   [Malta, Fernanda M.; Gomes-Gouvea, Michele S.; Noble, Caroline F.; Rebello Pinho, Joao R.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Inst Trop Med, Lab Trop Gastroenterol & Hepatol LIM 07, Sao Paulo, SP, Brazil.
   [Rebello Pinho, Joao R.] Hosp Israelita Albert Einstein, Albert Einstein Med Diagnost, Sao Paulo, SP, Brazil.
   [Silva, Mariliza H.] Ctr Referencia & Treinamento DST AIDS Estado Sao, Sao Paulo, SP, Brazil.
   [Silva, Mariliza H.] Clin Especialidades, Sao Bernardo Do Campo, SP, Brazil.
   [Leite, Andrea G. B.; Piccoli, Leonora Z.] Ctr Especializado Saude, Caxias Do Sul, RS, Brazil.
RP Neto, GL (corresponding author), Univ Sao Paulo, Sch Med, Inst Trop Med, Lab Virol LIM 52,Dept Infect Dis, Sao Paulo, SP, Brazil.
EM glneto@usp.br
RI Romano, Camila/ABC-2883-2020; Carrilho, Flair J/I-3046-2012; Malta,
   Fernanda/B-1316-2013; Romano, Camila M/C-8185-2013; Pinho, Joao R.
   R./G-2850-2012
OI Romano, Camila/0000-0003-4550-1987; Malta, Fernanda/0000-0001-8887-5060;
   Pinho, Joao R. R./0000-0003-3999-0489
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2011/50633-4]
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Grant number:
   2011/50633-4
CR Patino-Galindo JA, 2016, ANTIMICROB AGENTS CH, V60, P2402, DOI 10.1128/AAC.02776-15
   Applegate TL, 2015, ANTIVIR THER, V20, P199, DOI 10.3851/IMP2821
   Chevaliez S, 2013, J CLIN MICROBIOL, V51, P1078, DOI 10.1128/JCM.02004-12
   Gutierrez JA, 2015, J VIRAL HEPATITIS, V22, P861, DOI 10.1111/jvh.12422
   Halfon P, 2008, AIDS, V22, P1694, DOI 10.1097/QAD.0b013e32830a989b
   Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141
   Lampe E, 2013, ANTIVIR THER, V18, P435, DOI 10.3851/IMP2606
   Li H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019562
   Lontok E, 2015, HEPATOLOGY, V62, P1623, DOI 10.1002/hep.27934
   Nishiya AS, 2015, BRAZ J INFECT DIS, V19, P473, DOI 10.1016/j.bjid.2015.06.010
   Pawlotsky JM, 2016, GASTROENTEROLOGY, V151, P70, DOI 10.1053/j.gastro.2016.04.003
   Peres-da-Silva A, 2010, ARCH VIROL, V155, P807, DOI 10.1007/s00705-010-0642-z
   Ramachandran S, 2011, J VIROL, V85, P6369, DOI 10.1128/JVI.02204-10
   Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
   Santos AF, 2016, SCI REP-UK, V6, DOI 10.1038/srep31780
   Sterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Vermehren J, 2012, BEST PRACT RES CL GA, V26, P487, DOI 10.1016/j.bpg.2012.09.011
   Wyles DL, 2013, J INFECT DIS, V207, pS33, DOI 10.1093/infdis/jis761
   Zeminian LB, 2013, MEM I OSWALDO CRUZ, V108, P13, DOI 10.1590/S0074-02762013000100002
NR 20
TC 1
Z9 1
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2017
VL 89
IS 12
BP 2249
EP 2254
DI 10.1002/jmv.24900
PG 6
WC Virology
SC Virology
GA FJ7IS
UT WOS:000412931100028
PM 28700085
DA 2020-12-08
ER

PT J
AU Barbosa, MED
   Zaninotto, AL
   Mazo, DFD
   Pessoa, MG
   de Oliveira, CPMS
   Carrilho, FJ
   Farias, AQ
AF Dias Barbosa, Mary Ellen
   Zaninotto, Ana Luiza
   de Campos Mazo, Daniel Ferraz
   Pessoa, Mario Guimaraes
   Marques Souza de Oliveira, Claudia Pinto
   Carrilho, Flair Jose
   Farias, Alberto Queiroz
TI Hepatitis C virus eradication improves immediate and delayed episodic
   memory in patients treated with interferon and ribavirin
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Cognition; Memory; Attention; Neuropsychology; Hepatitis C; Depression
ID MAGNETIC-RESONANCE-SPECTROSCOPY; QUALITY-OF-LIFE; INDUCED DEPRESSION;
   PSYCHIATRIC-DISORDERS; COGNITIVE IMPAIRMENT; ANTIVIRAL THERAPY; ALPHA
   THERAPY; PRIME-MD; INFECTION; VULNERABILITY
AB Background: Chronic hepatitis C virus (HCV) infection is associated with impairment of cognitive function and mood disorders. Our aim was to evaluate the impact of sustained virological response (SVR) on cognitive function and mood disorders.
   Method: A prospective exploratory one arm study was conducted. Adult clinically compensated HVC patients were consecutively recruited before treatment with interferon and ribavirin for 24 to 48 weeks, according to HCV genotype. Clinical, neurocognitive and mood assessments using the PRIME-MD and BDI instruments were performed at baseline, right after half of the expected treatment has been reached and 6 months after the end of antiviral treatment. Exclusion criteria were the use of illicit psychotropic substances, mental confusion, hepatic encephalopathy, hepatocellular carcinoma, severe anemia, untreated hypothyroidism, Addison syndrome and major depression before treatment.
   Results: Thirty six patients were enrolled and 21 completed HCV treatment (n = 16 with SVR and n = 5 without). Regardless of the viral clearance at the end of treatment, there was a significant improvement in the immediate verbal episodic memory (p = 0.010), delayed verbal episodic memory (p = 0.007), selective attention (p < 0.001) and phonemic fluency (p = 0.043). Patients with SVR displayed significant improvement in immediate (p = 0.045) and delayed verbal episodic memory (p = 0.040) compared to baseline. The baseline frequency of depression was 9.5%, which rose to 52.4% during treatment, and returned to 9.5% 6 months after the end of treatment, without significant difference between patients with and without SVR. Depressive symptoms were observed in 19.1% before treatment, 62% during (p = 0.016) and 28.6% 6 months after the end of treatment (p = 0.719).
   Conclusions: Eradication of HCV infection improved cognitive performance but did not affect the frequency of depressive symptoms at least in the short range.
C1 [Dias Barbosa, Mary Ellen; Zaninotto, Ana Luiza] Univ Sao Paulo, Sch Med, Clin Hosp, Div Psychol, Ave Dr Eneas Carvalho de Aguiar 255, BR-05403900 Sao Paulo, Brazil.
   [Dias Barbosa, Mary Ellen; de Campos Mazo, Daniel Ferraz; Pessoa, Mario Guimaraes; Marques Souza de Oliveira, Claudia Pinto; Carrilho, Flair Jose; Farias, Alberto Queiroz] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol,Clin Hosp, Ave Dr Eneas Carvalho de Aguiar 255,Sala 9159, BR-05403900 Sao Paulo, Brazil.
   [de Campos Mazo, Daniel Ferraz] Univ Estadual Campinas, Sch Med Sci, Div Gastroenterol, Rua Carlos Chagas 420, BR-13083878 Campinas, SP, Brazil.
   [Dias Barbosa, Mary Ellen] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas Carvalho de Aguiar 255, BR-05403000 Sao Paulo, Brazil.
RP Barbosa, MED (corresponding author), Univ Sao Paulo, Sch Med, Clin Hosp, Div Psychol, Ave Dr Eneas Carvalho de Aguiar 255, BR-05403900 Sao Paulo, Brazil.; Barbosa, MED (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol,Clin Hosp, Ave Dr Eneas Carvalho de Aguiar 255,Sala 9159, BR-05403900 Sao Paulo, Brazil.
EM mary.dias@gmail.com
RI Oliveira, Claudia PMS/D-1216-2014; Mazo, Daniel FC/D-5631-2015; Farias,
   Alberto/ABB-1291-2020; Costa Zaninotto, Ana Luiza/I-4095-2016
OI Mazo, Daniel FC/0000-0002-2164-2630; Farias,
   Alberto/0000-0002-5572-663X; Costa Zaninotto, Ana
   Luiza/0000-0003-0639-0612
FU Capes (Commission for the Improvement of Higher Education Personnel)
FX Thanks to Capes (Commission for the Improvement of Higher Education
   Personnel) for the scholarship during the study for Barbosa ME.
CR Adinolfi LE, 2015, WORLD J GASTROENTERO, V21, P2269, DOI 10.3748/wjg.v21.i8.2269
   Alsop D, 2014, HEPATOLOGY, V60, p221A
   *AM PSYCH ASS, 2002, MAN DIAGN EST TRANST
   Ascione Antonio, 2007, Dig Liver Dis, V39 Suppl 1, pS4, DOI 10.1016/S1590-8658(07)80003-X
   Asnis GM, 2006, J CLIN GASTROENTEROL, V40, P322, DOI 10.1097/01.mcg.0000210099.36500.fe
   Babor T. F., 2001, AUDIT ALCOHOL USE DI
   Bajaj JS, 2007, AM J GASTROENTEROL, V102, P754, DOI 10.1111/j.1572-0241.2007.01048.x
   BEDOSSA P, 1994, HEPATOLOGY, V20, P15
   Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726
   Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014
   BUTLER M, 1991, PROF PSYCHOL-RES PR, V22, P510, DOI 10.1037/0735-7028.22.6.510
   Byrnes V, 2012, J HEPATOL, V56, P549, DOI 10.1016/j.jhep.2011.09.015
   Carta MG, 2012, J AFFECT DISORDERS, V141, P361, DOI 10.1016/j.jad.2012.03.020
   Cattie JE, 2014, J NEUROVIROL, V20, P561, DOI 10.1007/s13365-014-0265-3
   Constant A, 2005, J CLIN PSYCHIAT, V66, P1050, DOI 10.4088/JCP.v66n0814
   Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.0.CO;2-K
   Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297
   Eccles J, 2012, EUR NEUROPSYCHOPHARM, V22, P892, DOI 10.1016/j.euroneuro.2012.03.009
   Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250
   Fialho R, 2017, PSYCHIAT RES, V253, P150, DOI 10.1016/j.psychres.2017.03.049
   Forton DA, 2005, AIDS, V19, pS53, DOI 10.1097/01.aids.0000192071.72948.77
   Forton DM, 2008, J HEPATOL, V49, P316, DOI 10.1016/j.jhep.2008.03.022
   Forton DM, 2002, HEPATOLOGY, V35, P433, DOI 10.1053/jhep.2002.30688
   Forton DM, 2001, LANCET, V358, P38, DOI 10.1016/S0140-6736(00)05270-3
   Fraguas R, 2006, J AFFECT DISORDERS, V91, P11, DOI 10.1016/j.jad.2005.12.003
   Ghany MG, 2011, HEPATOLOGY, V54, P1433, DOI 10.1002/hep.24641
   Gorenstein C, 1998, REV PSIQUIATRIA CLIN, V25, P245
   Hilsabeck RC, 2003, J INT NEUROPSYCH SOC, V9, P847, DOI 10.1017/S1355617703960048
   Hilsabeck RC, 2002, HEPATOLOGY, V35, P440, DOI 10.1053/jhep.2002.31257
   Huang YW, 2013, ANTIVIR THER, V18, P567, DOI 10.3851/IMP2441
   Huckans M, 2015, J PSYCHOSOM RES, V78, P184, DOI 10.1016/j.jpsychores.2014.07.020
   Iriana S, 2017, CLIN LIVER DIS, V21, P535, DOI 10.1016/j.cld.2017.03.008
   Kleefeld F, 2017, NEUROLOGY, V88, P713, DOI 10.1212/WNL.0000000000003575
   Kraus MR, 2013, HEPATOLOGY, V58, P497, DOI 10.1002/hep.26229
   Leutscher PDC, 2010, HEPATOLOGY, V52, P430, DOI 10.1002/hep.23699
   Lezak MD, 2004, NEUROPSYCHOLOGICAL A
   Loftis JM, 2004, J AFFECT DISORDERS, V82, P175, DOI 10.1016/j.jad.2004.04.002
   Marazziti D, 2010, EUR J PHARMACOL, V626, P83, DOI 10.1016/j.ejphar.2009.08.046
   Perry W, 2008, DIGEST DIS SCI, V53, P307, DOI 10.1007/s10620-007-9896-z
   Senzolo M, 2011, WORLD J GASTROENTERO, V17, P3369, DOI 10.3748/wjg.v17.i29.3369
   SPITZER RL, 1995, JAMA-J AM MED ASSOC, V274, P1511, DOI 10.1001/jama.274.19.1511
   Spreen O., 1991, COMPENDIUM NEUROPSYC
   Thames AD, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000059
   Wechsler D., 1998, MANUAL WECHSLER ADUL
   Wedemeyer H, 2015, J VIRAL HEPATITIS, V22, P1, DOI 10.1111/jvh.12371
   Weissenborn K, 2004, J HEPATOL, V41, P845, DOI 10.1016/j.jhep.2004.07.022
   Whale R, 2015, J PSYCHOSOM RES, V79, P640, DOI 10.1016/j.jpsychores.2015.06.003
   Yarlott L, 2017, J ADV RES, V8, P139, DOI 10.1016/j.jare.2016.09.005
   Younossi Z, 2016, GASTROENTEROLOGY, V150, P1599, DOI 10.1053/j.gastro.2016.02.039
NR 49
TC 7
Z9 7
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD NOV 25
PY 2017
VL 17
AR 122
DI 10.1186/s12876-017-0679-5
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA FN6NG
UT WOS:000416131000001
PM 29178838
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Malta, F
   Gaspareto, KV
   Lisboa-Neto, G
   Carrilho, FJ
   Mendes-Correa, MC
   Pinho, JRR
AF Malta, Fernanda
   Gaspareto, Karine Vieira
   Lisboa-Neto, Gaspar
   Carrilho, Flair Jose
   Mendes-Correa, Maria Cassia
   Rebello Pinho, Joao Renato
TI Prevalence of naturally occurring NS5A resistance-associated
   substitutions in patients infected with hepatitis C virus subtype 1a,
   1b, and 3a, co-infected or not with HIV in Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV/HCV coinfection; NS5A; DAA therapy; Resistance-associated
   substitutions
ID REPLICATION COMPLEX INHIBITOR; DIRECT-ACTING ANTIVIRALS; HCV GENOTYPE 1;
   GRAZOPREVIR MK-5172; VARIANTS RESISTANT; ELBASVIR MK-8742; IN-VITRO;
   POLYMORPHISMS; DACLATASVIR; SOFOSBUVIR
AB Background: Non-structural 5A protein (NS5A) resistance-associated substitutions (RASs) have been identified in patients infected with hepatitis C virus (HCV), even prior to exposure to direct-acting antiviral agents (DAAs). Selection for these variants occurs rapidly during treatment and, in some cases, leads to antiviral treatment failure. DAAs are currently the standard of care for hepatitis C treatment in many parts of the world. Nevertheless, in Brazil, the prevalence of pre-existing NS5A RASs is largely unknown. In this study, we evaluated the frequency of naturally occurring NS5A RASs in Brazilian patients infected with HCV as either a monoinfection or coinfection with human immunodeficiency virus (HIV).
   Methods: Direct Sanger sequencing of the NS5A region was performed in 257 DAA-naive patients chronically infected with HCV (156 monoinfected with HCV and 101 coinfected with HIV/HCV).
   Results: The frequencies of specific RASs in monoinfected patients were 14.6% for HCV GT-1a (M28 V and Q30H/R), 6.0% for GT-1b (L31F/V and Y93H), and 22.6% for GT-3a (A30K and Y93H). For HIV/HCV-coinfected patients, the frequencies of RAS were 3.9% for GT-1a (M28 T and Q30H/R), and 11.1% for GT-1b (Y93H); no RASs were found in GT-3a sequences.
   Conclusions: Substitutions that may confer resistance to NS5A inhibitors exist at baseline in Brazilian DAA-naive patients infected with HCV GT-1a, -1b, and -3a. Standardization of RAS definitions is needed to improve resistance analyses and to facilitate comparisons of substitutions reported across studies worldwide. Therapeutic strategies should be optimized to efficiently prevent DAA treatment failure due to selection for RASs, especially in difficult-to-cure patients.
C1 [Malta, Fernanda; Gaspareto, Karine Vieira; Rebello Pinho, Joao Renato] Univ Sao Paulo, Inst Trop Med, LIM 07, Av Dr Eneas Carvalho Aguiar,500 2nd Floor IMT 2, BR-05403000 Sao Paulo, Brazil.
   [Malta, Fernanda; Gaspareto, Karine Vieira; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Lisboa-Neto, Gaspar; Mendes-Correa, Maria Cassia] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Mendes-Correa, Maria Cassia] Univ Sao Paulo, Inst Trop Med, LIM 52, Sao Paulo, Brazil.
   [Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
RP Malta, F (corresponding author), Univ Sao Paulo, Inst Trop Med, LIM 07, Av Dr Eneas Carvalho Aguiar,500 2nd Floor IMT 2, BR-05403000 Sao Paulo, Brazil.; Malta, F (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM femalta@yahoo.com
RI Pinho, Joao R. R./G-2850-2012; Malta, Fernanda/B-1316-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [443,152/2014-4]; Sao Paulo Research Foundation (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/50633-4]; Alves
   de Queiroz Family Fund for Research; CNPq (Bolsista de Produtividade)
FX This study was supported by grant 443,152/2014-4 from CNPq, 2011/50633-4
   from the Sao Paulo Research Foundation (FAPESP) and the Alves de Queiroz
   Family Fund for Research. Joao Renato Rebello Pinho and Maria Cassia
   Mendes Correa received a fellowship from CNPq (Bolsista de
   Produtividade).
CR Asselah T, 2016, LIVER INT, V36, P47, DOI 10.1111/liv.13027
   Bagaglio S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8040091
   Bartels DJ, 2013, J VIROL, V87, P1544, DOI 10.1128/JVI.02294-12
   Boesecke C, 2016, INFECTION, V44, P93, DOI 10.1007/s15010-015-0856-9
   Dietz J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134395
   Feld JJ, 2015, NEW ENGL J MED, V373, P2599, DOI 10.1056/NEJMoa1512610
   Feld Jordan J, 2017, Clin Liver Dis (Hoboken), V9, P115, DOI 10.1002/cld.631
   Foster GR, 2015, NEW ENGL J MED, V373, P2608, DOI 10.1056/NEJMoa1512612
   Fridell RA, 2011, HEPATOLOGY, V54, P1924, DOI 10.1002/hep.24594
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   Hepatitis C, 2015, HEPATOLOGY, V62, P932, DOI [DOI 10.1002/HEP.27950, 10.1002/hep.27950]
   Hernandez D, 2013, J CLIN VIROL, V57, P13, DOI 10.1016/j.jcv.2012.12.020
   Kalaghatgi P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155869
   Karageorgopoulos DE, 2015, WORLD J HEPATOL, V7, P1936, DOI 10.4254/wjh.v7.i15.1936
   Krishnan P, 2016, ANTIMICROB AGENTS CH, V60, P1106, DOI 10.1128/AAC.02606-15
   Krishnan P, 2015, ANTIMICROB AGENTS CH, V59, P979, DOI 10.1128/AAC.04226-14
   Larousse JA, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0318-0
   Lawitz E, 2015, LANCET, V385, P1075, DOI 10.1016/S0140-6736(14)61795-5
   Lawitz EJ, 2012, J HEPATOL, V57, P24, DOI 10.1016/j.jhep.2011.12.029
   Nguyen LT, 2016, ANTIVIR THER, V21, P447, DOI 10.3851/IMP3025
   Liu R, 2015, ANTIMICROB AGENTS CH, V59, P6922, DOI 10.1128/AAC.01390-15
   Lontok E, 2015, HEPATOLOGY, V62, P1623, DOI 10.1002/hep.27934
   Malta FD, 2010, MEM I OSWALDO CRUZ, V105, P92, DOI 10.1590/S0074-02762010000100014
   Mesquita F, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3784-4
   Nakamoto S, 2014, WORLD J GASTROENTERO, V20, P2902, DOI 10.3748/wjg.v20.i11.2902
   Nettles RE, 2011, HEPATOLOGY, V54, P1956, DOI 10.1002/hep.24609
   Paolucci S, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-355
   Pawlotsky JM, 2016, GASTROENTEROLOGY, V151, P70, DOI 10.1053/j.gastro.2016.04.003
   Peres-da-Silva A, 2015, J ANTIMICROB CHEMOTH, V70, P726, DOI 10.1093/jac/dku462
   Platt L, 2016, LANCET INFECT DIS, V16, P797, DOI 10.1016/S1473-3099(15)00485-5
   Plaza Z, 2012, ANTIVIR THER, V17, P921, DOI 10.3851/IMP2091
   Rockstroh JK, 2015, LANCET HIV, V2, pE319, DOI 10.1016/S2352-3018(15)00114-9
   Ross-Thriepland D, 2015, J GEN VIROL, V96, P727, DOI 10.1099/jgv.0.000009
   Sarrazin C, 2016, GASTROENTEROLOGY, V151, P501, DOI 10.1053/j.gastro.2016.06.002
   Sarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011
   Uchida Y, 2016, HEPATOL RES, V46, P1234, DOI 10.1111/hepr.12673
   Wang CF, 2013, ANTIMICROB AGENTS CH, V57, P2054, DOI 10.1128/AAC.02494-12
   Welzel TM, 2017, J HEPATOL, V67, P224, DOI 10.1016/j.jhep.2017.03.014
   Wyles DL, 2015, NEW ENGL J MED, V373, P714, DOI 10.1056/NEJMoa1503153
   Wyles D, 2018, ANTIVIR THER, V23, P229, DOI 10.3851/IMP3181
   Yoshimi S, 2015, J MED VIROL, V87, P1913, DOI 10.1002/jmv.24255
   Zeuzem S, 2015, ANN INTERN MED, V163, P1, DOI 10.7326/M15-0785
NR 42
TC 14
Z9 15
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD NOV 13
PY 2017
VL 17
AR 716
DI 10.1186/s12879-017-2817-7
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA FM4KK
UT WOS:000414985100001
PM 29132303
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Casotti, MO
   Tuan, RT
   Gomes, M
   Dias-Neto, E
   Pinho, JRR
   Paula, FM
   Carrilho, FJCJ
   Luna, EJA
   Gryschek, RCBB
   Espirito-Santo, MC
AF Casotti, Marcia Oliveira
   Tuan, Roseli Tuan
   Gomes, Michele
   Dias-Neto, Emmanuel
   Rebello Pinho, Joao Renato
   Paula, Fabiana Martins
   Carrilho Jose Carrilho, Flair Jose
   Albuquerque Luna, Expedito Jose
   Borges Borges Gryschek, Ronaldo Cesar
   Espirito-Santo, Maria Cristina
TI MOLECULAR CHARACTERIZATION OF THE LARVAL PHASE OF SCHISTOSOMA MANSONI IN
   BIOMPHALARIA GLABRATA MOLLUSKS UNDER EXPERIMENTAL CONDITIONS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 13-16, 2016
CL Atlanta, GA
SP Amer Soc Trop Med & Hygiene, Bill & Melinda Gates Fdn, Takeda Pharamaceut Int AG, ClinicalRM, Techlab Inc, Bayer, Sanofi Pasteur, ACS Infectious Diseases, New England Biolabs
C1 [Casotti, Marcia Oliveira; Tuan, Roseli Tuan] Superintendencia Controle Endemias SUCEN, Sao Paulo, Brazil.
   [Gomes, Michele; Dias-Neto, Emmanuel; Rebello Pinho, Joao Renato; Paula, Fabiana Martins; Carrilho Jose Carrilho, Flair Jose; Borges Borges Gryschek, Ronaldo Cesar; Espirito-Santo, Maria Cristina] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Albuquerque Luna, Expedito Jose] Inst Med Trop, Sao Paulo, Brazil.
   [Espirito-Santo, Maria Cristina] Ctr Univ Fundacao Oswaldo Aranha, Rio De Janeiro, Brazil.
RI Paula, Fabiana/L-8364-2014; Luna, Expedito J A/B-7948-2012; Dias-Neto,
   Emmanuel/AAA-6701-2019; Pinho, Joao R. R./G-2850-2012; Dias-Neto,
   Emmanuel/AAE-9147-2020
OI Paula, Fabiana/0000-0003-3343-0149; Luna, Expedito J
   A/0000-0002-1145-9672; Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2017
VL 95
IS 5
SU S
MA 571
BP 179
EP 179
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FJ6FS
UT WOS:000412851502094
DA 2020-12-08
ER

PT J
AU da Silva-Etto, JMK
   Mattar, R
   Villares-Lopes, CA
   Marques, SB
   Carrilho, FJ
AF Kinoshita da Silva-Etto, Joyce Matie
   Mattar, Rejane
   Villares-Lopes, Cibele Aparecida
   Marques, Sergio Barbosa
   Carrilho, Flair Jose
TI Evaluation of diagnostic accuracy of two rapid stool antigen tests using
   an immunochromatographic assay to detect Helicobacter pylori
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE Helicobacter pylori; Stool antigen test; Immunochromatographic assay
ID BREATH TEST; INFECTION; BRAZIL; ULCER
AB Objectives: The stool antigen assay for H. pylori infection diagnosis with monoclonal antibodies is a simple and recommended technique by the Maastricht V/Florence consensus report. Recently, Pylori K-Set K-1219 (Coris Bioconcept Sprl, Belgium) and HP-F23 (Symbiosys, Brazil) have been made commercially available in Brazil. Thus, the aim of this study was to evaluate the diagnostic accuracies of these two rapid stool antigen tests by immunochromatographic assays (index tests) for the clinical practice.
   Design and methods: A total of 98 patients who underwent upper gastrointestinal endoscopy and 13C-urea breath test entered the study. H. pylori infection status was defined by the combination of the rapid urease test and the C-13-urea breath test (reference standard). Two observers who were aware of H. pylori status performed the reading of index tests. Diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value with 95% confidence intervals, positive likelihood ratio, negative likelihood ratio and kappa index measure of agreement) were determined.
   Results: The index tests where in perfect agreement with the H. pylori status with kappa values of 0.87 for Pylori K-Set K-1219 and 0.92 for HP-F23. The sensitivity of HP-F23 was 97.9% (IC95%: 87.5-100) and specificity was 93.8% (IC95%; 84-97.2). The positive likelihood ratio was 15.8, and the negative likelihood ratio was 0.02. The Pylori K-Set K-1219 had a sensitivity of 87.7% (IC95%: 74.5-94.9) and a specificity of 100% (IC95%: 91.6-100); the positive likelihood ratio was infinity, and the negative likelihood ratio was 0.1. The test line on the cassette device of HP-F23 was stronger than of the Pylori K-Set K-1219.
   Conclusion: The HP-F23 test performed better in clinical practice. Nonetheless, the C-13-urea breath test is more reliable technique. Moreover, caution must be paid to the trace or clear pale test line readings that were observed in false positive and false negative results, leading to incorrect management of the patient.
C1 [Kinoshita da Silva-Etto, Joyce Matie; Mattar, Rejane; Villares-Lopes, Cibele Aparecida; Marques, Sergio Barbosa; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Hosp Clin FMUSP, Dept Gastroenterol,Div Clinical Gastroenterol & H, Sao Paulo, Brazil.
RP Mattar, R (corresponding author), Hosp Clin FMUSP, Div Gastroenterol & Hepatol, Av Dr Eneas de Carvalho Aguiar 255,9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM r.mattar@hc.fm.usp.br
RI Mattar, Rejane/AAO-4842-2020; Carrilho, Flair J/I-3046-2012
OI Mattar, Rejane/0000-0001-7870-8867; 
CR Atkinson N. S. S., 2015, DIG DIS SCI
   Bossuyt PM, 2015, CLIN CHEM, V61, P1446, DOI 10.1373/clinchem.2015.246280
   Calika Z, 2016, BRAZ J MICROBIOL, V47, P167, DOI 10.1016/j.bjm.2015.11.022
   DALLA NORA Magali, 2016, Arq. Gastroenterol., V53, P224, DOI 10.1590/S0004-28032016000400003
   Hamlet A, 1999, SCAND J GASTROENTERO, V34, P367
   da Silva JMK, 2010, REV INST MED TROP SP, V52, P125, DOI 10.1590/S0036-46652010000300002
   Lario S, 2016, CLIN BIOCHEM, V49, P682, DOI 10.1016/j.clinbiochem.2016.01.015
   Malfertheiner P, 2017, Gut, V66, P6, DOI 10.1136/gutjnl-2016-312288
   Marques Sergio B., 2011, Arq. Gastroenterol., V48, P171, DOI 10.1590/S0004-28032011000300003
   Mattar R, 2005, HELICOBACTER, V10, P601, DOI 10.1111/j.1523-5378.2005.00360.x
   MATTAR Rejane, 2014, Arq. Gastroenterol., V51, P133, DOI 10.1590/S0004-28032014000200012
   Patel SK, 2014, WORLD J GASTROENTERO, V20, P12847, DOI 10.3748/wjg.v20.i36.12847
   Ruzsovics A, 2004, ALIMENT PHARM THER, V19, P1137, DOI 10.1111/j.1365-2036.2004.01934.x
NR 13
TC 5
Z9 6
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD NOV
PY 2017
VL 50
IS 16-17
BP 959
EP 962
DI 10.1016/j.clinbiochem.2017.05.005
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA FK3PD
UT WOS:000413397200011
PM 28483407
DA 2020-12-08
ER

PT J
AU Oliveira, CP
   Stefano, JT
   Carrilho, FJ
AF Oliveira, Claudia P.
   Stefano, Jose Tadeu
   Carrilho, Flair Jose
TI Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic
   fatty liver disease (NAFLD): a multicenter prospective study
SO HEPATOBILIARY SURGERY AND NUTRITION
LA English
DT Editorial Material
ID RISK-FACTORS; STEATOHEPATITIS; CIRRHOSIS
C1 [Oliveira, Claudia P.; Stefano, Jose Tadeu; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
RP Oliveira, CP (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
EM cpm@usp.br
RI Stefano, Jose Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
CR Ascha MS, 2010, HEPATOLOGY, V51, P1972, DOI 10.1002/hep.23527
   Bellentani S, 2017, LIVER INT, V37, P81, DOI 10.1111/liv.13299
   Caldwell SH, 2004, GASTROENTEROLOGY, V127, pS97, DOI 10.1053/j.gastro.2004.09.021
   Chagas AL, 2009, BRAZ J MED BIOL RES, V42, P958, DOI 10.1590/S0100-879X2009005000019
   Corey KE, 2017, WORLD J HEPATOL, V9, P385, DOI 10.4254/wjh.v9.i7.385
   Cotrim HP, 2016, CLINICS, V71, P281, DOI 10.6061/clinics/2016(05)07
   Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Ertle J, 2011, INT J CANCER, V128, P2436, DOI 10.1002/ijc.25797
   Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Hashimoto E, 2012, HEPATOL RES, V42, P1, DOI 10.1111/j.1872-034X.2011.00872.x
   Kikuchi L, 2016, AM J CLIN ONCOL-CANC, V39, P428, DOI 10.1097/COC.0000000000000134
   Lazo M, 2013, AM J EPIDEMIOL, V178, P38, DOI 10.1093/aje/kws448
   Malik SM, 2009, CLIN GASTROENTEROL H, V7, P800, DOI 10.1016/j.cgh.2009.02.025
   Piscaglia F, 2016, HEPATOLOGY, V63, P827, DOI 10.1002/hep.28368
   Sanyal AJ, 2006, HEPATOLOGY, V43, P682, DOI 10.1002/hep.21103
   SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149
   White DL, 2012, CLIN GASTROENTEROL H, V10, P1342, DOI 10.1016/j.cgh.2012.10.001
NR 19
TC 2
Z9 3
U1 0
U2 2
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2304-3881
EI 2304-389X
J9 HEPATOL SURG NUTR
JI Hepatol. Surg. Nutr.
PD OCT
PY 2017
VL 6
IS 5
BP 350
EP 352
DI 10.21037/hbsn.2017.06.06
PN 2
PG 3
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Surgery
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Surgery
GA FT9IW
UT WOS:000423466700013
PM 29152487
OA Green Published
DA 2020-12-08
ER

PT J
AU Ragazzo, TG
   Paranagua-Vezozzo, D
   Lima, FR
   Mazo, DFD
   Pessoa, MG
   Oliveira, CP
   Alves, VAF
   Carrilho, FJ
AF Ragazzo, Taisa Grotta
   Paranagua-Vezozzo, Denise
   Lima, Fabiana Roberto
   de Campos Mazo, Daniel Ferraz
   Pessoa, Mario Guimaraes
   Oliveira, Claudia Pinto
   Ferreira Alves, Venancio Avancini
   Carrilho, Flair Jose
TI Accuracy of transient elastography-FibroScan (R), acoustic radiation
   force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test,
   APRI, and the FIB-4 index compared with liver biopsy in patients with
   chronic hepatitis C
SO CLINICS
LA English
DT Article
DE Hepatitis C Chronic; Liver Cirrhosis; Elastography; Biomarkers/Blood;
   Disease Progression; Data Accuracy
ID PLATELET RATIO INDEX; ASPARTATE-AMINOTRANSFERASE; ELASTOGRAPHY
   FIBROSCAN; RISK-FACTORS; STIFFNESS; CIRRHOSIS; METAANALYSIS; COHORT;
   DISCORDANCE; SCORE
AB OBJECTIVES: Although liver biopsy is the gold standard for determining the degree of liver fibrosis, issues regarding its invasiveness and the small amount of liver tissue evaluated can limit its applicability and interpretation in clinical practice. Non-invasive evaluation methods for liver fibrosis can address some of these limitations. The aim of this study was to evaluate the accuracy of transient elastography-FibroScan (R), acoustic radiation force impulse (ARFI), enhanced liver fibrosis (ELF), the aspartate aminotransferase-to-platelet ratio index (APRI), and the FIB-4 index compared with liver biopsy in hepatitis C.
   METHODS: We evaluated chronic hepatitis C patients who were followed at the Division of Clinical Gastroenterology and Hepatology, Hospital das Clinicas, Department of Gastroenterology of University of Sao Paulo School of Medicine, Sao Paulo, Brazil, and who underwent liver biopsy. The accuracy of each method was determined by a receiver operating characteristic (ROC) curve analysis, and fibrosis was classified as significant fibrosis (>= F2), advanced fibrosis (>= F3), or cirrhosis (F4). The Obuchowski method was also used to determine the diagnostic accuracy of each method at the various stages of fibrosis. In total, 107 FibroScan (R), 51 ARFI, 68 ELF, 106 APRI, and 106 FIB-4 analyses were performed.
   RESULTS: A total of 107 patients were included in the study. The areas under the ROC curve (AUROCs) according to fibrosis degree were as follows: significant fibrosis (>= F2): FibroScan (R) : 0.83, FIB-4: 0.76, ELF: 0.70, APRI: 0.69, and ARFI: 0.67; advanced fibrosis (>= F3): FibroScan (R) : 0.85, ELF: 0.82, FIB-4: 0.77, ARFI: 0.74, and APRI: 0.71; and cirrhosis (F4): APRI: 1, FIB-4: 1, FibroScan (R) : 0.99, ARFI: 0.96, and ELF: 0.94. The accuracies of transient elastography, ARFI, ELF, APRI and FIB-4 determined by the Obuchowski method were F0-F1: 0.81, 0.78, 0.44, 0.72 and 0.67, respectively; F1-F2: 0.73, 0.53, 0.62, 0.60, and 0.68, respectively; F2-F3: 0.70, 0.64, 0.77, 0.60, and 0.67, respectively; and F3-F4: 0.98, 0.96, 0.82, 1, and 1, respectively.
   CONCLUSION: Transient elastography remained the most effective method for evaluating all degrees of fibrosis. The accuracy of all methodologies was best at F4.
C1 [Ragazzo, Taisa Grotta; Paranagua-Vezozzo, Denise; de Campos Mazo, Daniel Ferraz; Pessoa, Mario Guimaraes; Oliveira, Claudia Pinto; Carrilho, Flair Jose] Univ Sao Paulo, Div Gastroenterol & Hepatol Clin, Dept Gastroenterol, Hosp Clin HCFMUSP,Fac Med, Sao Paulo, SP, Brazil.
   [Lima, Fabiana Roberto; de Campos Mazo, Daniel Ferraz] Univ Estadual Campinas, Div Gastroenterol, Fac Ciencias Med, Campinas, SP, Brazil.
   [Ferreira Alves, Venancio Avancini] Univ Sao Paulo, Dept Patol, Fac Med FMUSP, Sao Paulo, SP, Brazil.
RP Ragazzo, TG (corresponding author), Univ Sao Paulo, Div Gastroenterol & Hepatol Clin, Dept Gastroenterol, Hosp Clin HCFMUSP,Fac Med, Sao Paulo, SP, Brazil.
EM taisagr@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Mazo, Daniel FC/D-5631-2015;
   Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014; Carrilho, Flair
   J/I-3046-2012
OI Mazo, Daniel FC/0000-0002-2164-2630; Paranagua-Vezozzo, Denise
   Cerqueira/0000-0002-9606-4935; 
CR Al Knawy B, 2007, LIVER INT, V27, P1166, DOI 10.1111/j.1478-3231.2007.01592.x
   Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
   Bamber J, 2013, ULTRASCHALL MED, V34, P169, DOI 10.1055/s-0033-1335205
   BEDOSSA P, 1994, HEPATOLOGY, V20, P15
   Bonder Alan, 2014, Curr Gastroenterol Rep, V16, P372, DOI 10.1007/s11894-014-0372-6
   Bota S, 2015, MED ULTRASON, V17, P200, DOI 10.11152/mu.2013.2066.172.arfi
   Bota S, 2013, LIVER INT, V33, P1138, DOI 10.1111/liv.12240
   Boursier J, 2013, HEPATOLOGY, V57, P1182, DOI 10.1002/hep.25993
   Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706
   Bureau C, 2008, ALIMENT PHARM THER, V27, P1261, DOI 10.1111/j.1365-2036.2008.03701.x
   Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
   Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018
   Castera L, 2008, J HEPATOL, V48, P835, DOI 10.1016/j.jhep.2008.02.008
   Castera L, 2007, GASTROEN CLIN BIOL, V31, P524, DOI 10.1016/S0399-8320(07)89422-X
   Castera L, 2010, HEPATOLOGY, V51, P828, DOI 10.1002/hep.23425
   Crisan D, 2012, HEPAT MON, V12, P177, DOI 10.5812/hepatmon.853
   da Silva RG, 2008, BRAZ J INFECT DIS, V12, P15, DOI 10.1590/S1413-86702008000100005
   de Ledinghen V, 2008, GASTROEN CLIN BIOL, V32, P58, DOI 10.1016/S0399-8320(08)73994-0
   Fagan KJ, 2015, LIVER INT, V35, P1673, DOI 10.1111/liv.12760
   Fierbinteanu-Braticevici C, 2009, WORLD J GASTROENTERO, V15, P5525, DOI 10.3748/wjg.15.5525
   Foucher J, 2006, GUT, V55, P403, DOI 10.1136/gut.2005.069153
   Friedrich-Rust M, 2012, J VIRAL HEPATITIS, V19, pE212, DOI 10.1111/j.1365-2893.2011.01537.x
   Gara N, 2013, CLIN GASTROENTEROL H, V11, P303, DOI 10.1016/j.cgh.2012.10.044
   Guechot J, 2012, CLIN CHEM LAB MED, V50, P693, DOI 10.1515/cclm-2011-0858
   Hong WK, 2013, CLIN MOL HEPATOL, V19, P370, DOI 10.3350/cmh.2013.19.4.370
   Herrero JI, 2014, GASTROENT HEPAT-BARC, V37, P233, DOI 10.1016/j.gastrohep.2013.10.009
   Juarez-Hernandez E, 2015, DIGEST DIS SCI, V60, P2177, DOI 10.1007/s10620-015-3611-2
   Li SM, 2014, WORLD J GASTROENTERO, V20, P9528, DOI 10.3748/wjg.v20.i28.9528
   Liao LY, 2015, ULTRASOUND MED BIOL, V41, P698, DOI 10.1016/j.ultrasmedbio.2014.09.030
   Lichtinghagen R, 2013, J HEPATOL, V59, P1365, DOI 10.1016/j.jhep.2013.07.022
   Martin J, 2015, DIGEST DIS SCI, V60, P1841, DOI 10.1007/s10620-015-3531-1
   Mederacke I, 2009, LIVER INT, V29, P1500, DOI 10.1111/j.1478-3231.2009.02100.x
   Myers RP, 2012, J HEPATOL, V56, P564, DOI 10.1016/j.jhep.2011.10.007
   Myers RP, 2010, LIVER INT, V30, P1471, DOI 10.1111/j.1478-3231.2010.02331.x
   Nadebaum D, 2014, LIV M NOV 7 11 BOST
   Nierhoff J, 2013, EUR RADIOL, V23, P3040, DOI 10.1007/s00330-013-2927-6
   Nishikawa T, 2014, WORLD J GASTROENTERO, V20, P1289, DOI 10.3748/wjg.v20.i5.1289
   Obuchowski NA, 2006, STAT MED, V25, P481, DOI 10.1002/sim.2228
   Obuchowski NA, 2001, STAT MED, V20, P3261, DOI 10.1002/sim.944.abs
   Paranagua-Vezozzo DC, 2014, ANN HEPATOL, V13, P386, DOI 10.1016/S1665-2681(19)30845-2
   Parkes J, 2011, J VIRAL HEPATITIS, V18, P23, DOI 10.1111/j.1365-2893.2009.01263.x
   Parkes J, 2010, GUT, V59, P1245, DOI 10.1136/gut.2009.203166
   Perazzo H, 2015, LIVER INT, V35, P1533, DOI 10.1111/liv.12551
   Petersen JR, 2014, J CLIN GASTROENTEROL, V48, P370, DOI 10.1097/MCG.0b013e3182a87e78
   Pinzani M, 2010, GUT, V59, P1165, DOI 10.1136/gut.2010.214932
   Piscaglia F, 2014, EUR J RADIOL, V83, P450, DOI 10.1016/j.ejrad.2013.06.009
   Poynard Thierry, 2011, Gastroenterol Hepatol (N Y), V7, P445
   Regev A, 2002, AM J GASTROENTEROL, V97, P2614, DOI 10.1111/j.1572-0241.2002.06038.x
   Rosenberg WMC, 2004, GASTROENTEROLOGY, V127, P1704, DOI 10.1053/j.gastro.2004.08.052
   Rustagi Tarun, 2010, Trop Gastroenterol, V31, P199
   Sebastiani G, 2006, WORLD J GASTROENTERO, V12, P3682, DOI 10.3748/wjg.v12.i23.3682
   Serejo F., 2007, J Port Gastrenterol., V14, P8
   Simundic Ana-Maria, 2009, EJIFCC, V19, P203
   Sporea I, 2011, HEPAT MON, V11, P532
   Vallet-Pichard A, 2007, HEPATOLOGY, V46, P32, DOI 10.1002/hep.21669
   Wahl K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051906
   Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346
   WHO, HEP C
   You SC, 2015, WORLD J GASTROENTERO, V21, P1158, DOI 10.3748/wjg.v21.i4.1158
   Ziol M, 2005, HEPATOLOGY, V41, P48, DOI 10.1002/hep.20506
NR 60
TC 10
Z9 11
U1 0
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD OCT
PY 2017
VL 72
IS 9
BP 516
EP 525
DI 10.6061/clinics/2017(09)01
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA FK6XZ
UT WOS:000413649800001
PM 29069254
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Paranagua-Vezozzo, D
   Terrabuio, DR
   Moutinho, RD
   Cancado, EL
   Ono, S
   Salas, V
   Carrilho, F
   Alves, VF
   Cancado, EL
AF Paranagua-Vezozzo, Denise
   Terrabuio, Debora R.
   Moutinho, Renata D.
   Cancado, Eduardo L.
   Ono, Suzane
   Salas, Veronica
   Carrilho, Flair
   Alves, Venancio Ferreira
   Cancado, Eduardo L.
CA Dept Gastroenterology
   Dept Pathology
TI Transient Elastography (TE) And Acoustic Radiation Force Impulse Imaging
   (ARFI) Can Predict Degree Of Advanced Fibrosis For Autoimmune Hepatitis
   In Biochemical Remission
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY OCT 20-24, 2017
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Salas, Veronica; Alves, Venancio Ferreira] Hosp Clin Sao Paulo, Dept Pathol, Sao Paulo, Brazil.
   [Paranagua-Vezozzo, Denise; Terrabuio, Debora R.; Moutinho, Renata D.; Cancado, Eduardo L.; Ono, Suzane; Carrilho, Flair; Cancado, Eduardo L.] Hosp Clin Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2017
VL 66
SU 1
SI SI
MA 331
BP 187A
EP 187A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA FI6GA
UT WOS:000412089800332
DA 2020-12-08
ER

PT J
AU Aznar, AB
   Turon, F
   Simon-Talero, M
   Tasayco, S
   Bueno, J
   Zekrini, K
   Plessier, A
   Coenen, S
   Majumdar, A
   De Gottardi, A
   Shukla, A
   Carrilho, FJ
   Nacif, LS
   Primignani, M
   Nevens, F
   Witters, P
   Procopet, B
   Piscaglia, F
   Alvarez-Navascues, C
   Gonzalez, JM
   Hernandez-Gea, V
   Laleman, W
   Hartog, H
   Valla, DC
   Perez, M
   Genesca, J
   Garcia-Pagan, JC
AF Baiges Aznar, Anna
   Turon, Fanny
   Simon-Talero, Macarena
   Tasayco, Stephanie
   Bueno, Javier
   Zekrini, Kamal
   Plessier, Aurelie
   Coenen, Sandra
   Majumdar, Avik
   De Gottardi, Andrea
   Shukla, Akash
   Carrilho, Flair J.
   Nacif, Lucas S.
   Primignani, Massimo
   Nevens, Frederik
   Witters, Peter
   Procopet, Bogdan
   Piscaglia, Fabio
   Alvarez-Navascues, Carmen
   Martinez Gonzalez, Javier
   Hernandez-Gea, Virginia
   Laleman, Wim
   Hartog, Hermien
   Valla, Dominique C.
   Perez, Mercedes
   Genesca, Joan
   Carlos Garcia-Pagan, Juan
CA REHEVASC
   VALDIG
TI Congenital extrahepatic portosystemic shunts (Abernethy malformation):
   International observational study of clinical manifestations and
   outcome.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY OCT 20-24, 2017
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Baiges Aznar, Anna; Turon, Fanny; Hernandez-Gea, Virginia; Carlos Garcia-Pagan, Juan] Hosp Clin Barcelona, Liver Unit, Hepat Hemodynam Lab, Barcelona, Spain.
   [Simon-Talero, Macarena; Tasayco, Stephanie; Genesca, Joan] Hosp Univ Vall dHebron, Dept Internal Med, Liver Unit, Barcelona, Spain.
   [Bueno, Javier] Hosp Univ Vall dHebron, Pediat Surg Dept, Barcelona, Spain.
   [Zekrini, Kamal; Plessier, Aurelie; Valla, Dominique C.] Hop Beaujon, AP HP, Serv Hepatol, Clichy, France.
   [Coenen, Sandra] Erasmus MC, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
   [Majumdar, Avik] Royal Free Hosp, Sheila Sherlock Liver Unit, London, England.
   [Majumdar, Avik] Royal Free Hosp, UCL Inst Liver & Digest Hlth, London, England.
   [Majumdar, Avik] UCL, London, England.
   [De Gottardi, Andrea] Inselspital Bern, Clin Visceral Surg & Med, Hepatol, Bern, Switzerland.
   [De Gottardi, Andrea] Dept Clin Res, Bern, Switzerland.
   [Shukla, Akash] Seth GS Med Coll & KEM Hosp, Dept Gastroenterol, Bombay, Maharashtra, India.
   [Carrilho, Flair J.; Nacif, Lucas S.] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Digest Organ Transplantat Div, Sao Paulo, Brazil.
   [Primignani, Massimo] IRCCS Ca Granda Maggiore Hosp Fdn, Div Gastroenterol & Hepatol 1, Milan, Italy.
   [Nevens, Frederik; Witters, Peter; Laleman, Wim] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium.
   [Procopet, Bogdan] Univ Med & Pharm, Iuliu Hatieganu Reg Inst Gastroenterol & Hepatol, Dept Gastroenterol, Med Clin 3, Cluj Napoca, Romania.
   [Piscaglia, Fabio] St Orsola Marcello Malpighi Hosp, Dept Med & Surg Sci, Unit Internal Med, Bologna, Italy.
   [Alvarez-Navascues, Carmen] Hosp Univ Cent Asturias, Aparato Digest, Oviedo, Spain.
   [Martinez Gonzalez, Javier] Hosp Univ Ramon & Cajal, Dept Gastroenterol & Hepatol, Madrid, Spain.
   [Hartog, Hermien] Erasmus MC, Dept Surg, Div HPB & Transplant Surg, Rotterdam, Netherlands.
   [Perez, Mercedes] Hosp Univ Vall dHebron, Intervent Radiol Unit, Barcelona, Spain.
RI Nacif, Lucas S./B-2795-2013; Procopet, Bogdan/AAD-9267-2019; Carrilho,
   Flair J/I-3046-2012
OI Nacif, Lucas S./0000-0002-7059-3978; Procopet,
   Bogdan/0000-0001-8118-1760; Laleman, Wim/0000-0002-0842-7813
FU Ferring; RocheRoche Holding; AstellasAstellas Pharmaceuticals;
   NovartisNovartis; Janssen-CilagJohnson & Johnson USAJanssen Biotech Inc;
   AbbvieAbbott Laboratories; GileadGilead Sciences; Esaote; GORE; Exalenz
FX Frederik Nevens - Consulting: MSD, CAF, Intercept, Gore, BMS, Abbvie,
   Novartis, Durect, Janssens-Cilag, Ono Pharma, Promethera Biosciences,
   Gilead; Grant/Research Support: Ferring, Roche, Astellas, Novartis,
   Janssen-Cilag, Abbvie, Gilead; Fabio Piscaglia - Advisory Committees or
   Review Panels: Bayer; Consulting: Eisai; Grant/Research Support: Esaote;
   Speaking and Teaching: Bracco, Meda Pharma; Juan Carlos Garcia-Pagan -
   Consulting: Novartis; Grant/Research Support: GORE, Exalenz
NR 0
TC 0
Z9 0
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2017
VL 66
SU 1
SI SI
MA 482
BP 265A
EP 266A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA FI6GA
UT WOS:000412089800483
DA 2020-12-08
ER

PT J
AU Martins, SN
   Wakamatsu, A
   Villacorta-Martin, C
   Assato, AK
   Craig, AJ
   D'Avola, D
   Carrilho, FJ
   Thung, SN
   Villanueva, A
   Alves, VAF
AF Martins, Sebastiao N.
   Wakamatsu, Alda
   Villacorta-Martin, Carlos
   Assato, Aline K.
   Craig, Amanda J.
   D'Avola, Delia
   Carrilho, Flair J.
   Thung, Swan N.
   Villanueva, Augusto
   Alves, Venancio Avancini F.
TI A phenotypic map of disseminated hepatocellular carcinoma (HCC) shows
   clonal constrains in metastatic sites: a morphological study of 88 HCC
   autopsies.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY OCT 20-24, 2017
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Martins, Sebastiao N.; Villacorta-Martin, Carlos; Craig, Amanda J.; D'Avola, Delia; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Liver Dis, New York, NY 10029 USA.
   [Martins, Sebastiao N.; Wakamatsu, Alda; Assato, Aline K.; Alves, Venancio Avancini F.] Univ Sao Paulo, Pathol, Sao Paulo, Brazil.
   [D'Avola, Delia] Clin Univ Navarra, CIBEREHD, Pamplona, Spain.
   [Carrilho, Flair J.] Univ Sao Paulo, Gastroenterol, Sao Paulo, Brazil.
   [Thung, Swan N.] Icahn Sch Med Mt Sinai, Pathol, New York, NY 10029 USA.
   [Villanueva, Augusto] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA.
RI D'Avola, Delia/AAD-4289-2020; Carrilho, Flair J/I-3046-2012
OI D'Avola, Delia/0000-0002-0907-6648; 
NR 0
TC 0
Z9 0
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2017
VL 66
SU 1
SI SI
MA 1355
BP 727A
EP 727A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA FI6GA
UT WOS:000412089801496
DA 2020-12-08
ER

PT J
AU Campos, PB
   Oliveira, CP
   Stefano, JT
   Chagas, A
   Herman, P
   D'Albuquerque, LC
   Alvares-Da-Silva, MR
   Longatto-Filho, A
   Baltazar, F
   Granja, S
   Carrilho, FJ
   Alves, VAF
AF Campos, Priscila B.
   Oliveira, Claudia P.
   Stefano, Jose Tadeu
   Chagas, Aline
   Herman, Paulo
   D'Albuquerque, Luiz C.
   Alvares-da-Silva, Mario R.
   Longatto-Filho, Adhemar
   Baltazar, Ftima
   Granja, Sara
   Carrilho, Flair J.
   Alves, Venancio Avancini F.
TI Hepatocellular carcinoma in non-alchoolic steatohepatitis (NASH):
   Clinical, histopathological aspects and immunohistochemical of metabolic
   and proliferative related-markers
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY OCT 20-24, 2017
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Campos, Priscila B.; Oliveira, Claudia P.; Stefano, Jose Tadeu; Chagas, Aline; Herman, Paulo; D'Albuquerque, Luiz C.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, Brazil.
   [Alvares-da-Silva, Mario R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Gastroenterol, Porto Alegre, RS, Brazil.
   [Longatto-Filho, Adhemar; Baltazar, Ftima; Granja, Sara] Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Baltazar, Ftima; Granja, Sara] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
   [Longatto-Filho, Adhemar; Alves, Venancio Avancini F.] Univ Sao Paulo, Sch Med, Pathol LIM 14, Sao Paulo, Brazil.
RI Chagas, Aline Lopes/X-2059-2019; Sara, Granja C/T-6442-2018; F,
   Baltazar/A-8720-2010; longatto-filho, adhemar/D-7039-2013; Stefano, Jose
   Tadeu/AAH-5419-2020; Herman, Paulo/J-5457-2013; Longatto-Filho,
   Adhemar/N-3397-2019; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012;
   Carrilho, Flair J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014
OI Sara, Granja C/0000-0001-8717-6751; F, Baltazar/0000-0002-1770-4544;
   longatto-filho, adhemar/0000-0002-5779-9752; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Herman, Paulo/0000-0003-2859-5846;
   Longatto-Filho, Adhemar/0000-0002-5779-9752; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2017
VL 66
SU 1
SI SI
MA 2135
BP 1127A
EP 1128A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA FI6GA
UT WOS:000412089802489
DA 2020-12-08
ER

PT J
AU Mazo, DF
   Malta, F
   Stefano, JT
   Salles, APM
   Gomes-Gouvea, MS
   Nastri, ACS
   Almeida, JRS
   Pinho, JRR
   Carrilho, FJ
   Oliveira, CP
AF Mazo, Daniel F.
   Malta, Fernanda
   Stefano, Jose Tadeu
   Salles, Ana Paula M.
   Gomes-Gouvea, Michele S.
   Nastri, Ana Catharina S.
   Almeida, Jazon Romilson S.
   Pinho, Joao Renato R.
   Carrilho, Flair J.
   Oliveira, Claudia P.
TI PNPLA3 but not TM6SF2 polymorphisms were associated with higher degrees
   of steatosis and liver fibrosis among Brazilian NAFLD patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY OCT 20-24, 2017
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Mazo, Daniel F.; Malta, Fernanda; Stefano, Jose Tadeu; Salles, Ana Paula M.; Gomes-Gouvea, Michele S.; Pinho, Joao Renato R.; Carrilho, Flair J.; Oliveira, Claudia P.] Univ Sao Paulo, Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Mazo, Daniel F.; Almeida, Jazon Romilson S.] Univ Estadual Campinas, Gastroctr, Div Gastroenterol, Sao Paulo, Brazil.
   [Nastri, Ana Catharina S.] Univ Sao Paulo, Infect & Parasit Dis, Sao Paulo, Brazil.
RI Malta, Fernanda/B-1316-2013; Carrilho, Flair J/I-3046-2012; Stefano,
   Jose Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014; Mazo,
   Daniel FC/D-5631-2015; Pinho, Joao R. R./G-2850-2012
OI Malta, Fernanda/0000-0001-8887-5060; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Mazo, Daniel FC/0000-0002-2164-2630; Pinho,
   Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2017
VL 66
SU 1
SI SI
MA 2190
BP 1159A
EP 1159A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA FI6GA
UT WOS:000412089802544
DA 2020-12-08
ER

PT J
AU Shah, ND
   Ventura-Cots, M
   Zhang, C
   Zahiragic, N
   Yu, Y
   Yacoub, MA
   Wu, P
   Wandera, A
   Vorobioff, JD
   Thurairajah, PH
   Tan, S
   Spreckic, S
   Siow, W
   Scheurich, C
   Saez-Royuela, F
   Rodil, A
   Reis, D
   Ono, SK
   Ono, SK
   Teo, EK
   Karoney, MJ
   Fernandez, MIC
   Farias, AQ
   Domech, CR
   Da Costa, PM
   Alfadhli, A
   Yang, L
   Some, F
   Kochhar, R
   Kluwe, J
   Kim, W
   Isakov, V
   Husic-Selimovic, A
   Hsiang, JC
   George, J
   El Kassas, M
   Guridi, ZD
   Carrilho, FJ
   Bessone, F
   Badia, E
   Alboraie, M
   Cortez-Pinto, H
   Bataller, R
AF Shah, Neil D.
   Ventura-Cots, Meritxell
   Zhang, Chaoqun
   Zahiragic, Nerma
   Yu, Yuanjie
   Yacoub, Mohamed A.
   Wu, Pengbo
   Wandera, Andrew
   Vorobioff, Julio D.
   Thurairajah, Prem H.
   Tan, Shiyun
   Spreckic, Sanjin
   Siow, Way
   Scheurich, Christoph
   Saez-Royuela, Federico
   Rodil, Agustina
   Reis, Daniela
   Ono, Suzane K.
   Nabeshima, Mariana A.
   Teo, Eng Kiong
   Karoney, Mercy J.
   Fernandez, Marlen I. Castellanos
   Farias, Alberto Q.
   Domech, Caridad Ruenes
   Da Costa, Pedro Marques
   Alfadhli, Ahmad
   Yang, Ling
   Some, Fatma
   Kochhar, Rakesh
   Kluwe, Johannes
   Kim, Won
   Isakov, Vasily
   Husic-Selimovic, Azra
   Hsiang, John C.
   George, Jacob
   El Kassas, Mohamed
   Guridi, Zaily Dorta
   Carrilho, Flair J.
   Bessone, Fernando
   Badia, Ester
   Alboraie, Mohamed
   Cortez-Pinto, Helena
   Bataller, Ramon
TI Worldwide Lack of Early Referral of Patients with Alcoholic Liver
   Disease: Final Results of the Global Alcoholic Liver Disease Survey
   (GLADIS)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY OCT 20-24, 2017
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Shah, Neil D.] Univ North Carolina Chapel Hill, Gastroenterol & Hepatol, Chapel Hill, NC USA.
   [Ventura-Cots, Meritxell] Hosp Univ Vall dHebron, Vall dHebron Inst Res, Barcelona, Spain.
   [Ventura-Cots, Meritxell] Hosp Univ Vall dHebron, Dept Med, Barcelona, Spain.
   [Zhang, Chaoqun; Yu, Yuanjie; Wu, Pengbo; Tan, Shiyun] Wuhan Univ, Renmin Hosp, Div Gastroenterol, Wuhan, Hubei, Peoples R China.
   [Zahiragic, Nerma; Spreckic, Sanjin; Husic-Selimovic, Azra] Sarajevo Univ, Ctr Clin, Inst Gastroenterol, Dept Hepatol, Sarajevo, Bosnia & Herceg.
   [Yacoub, Mohamed A.; El Kassas, Mohamed] Helwan Univ, Endem Med Dept, Cairo, Egypt.
   [Wandera, Andrew; Karoney, Mercy J.; Some, Fatma] Moi Univ, Dept Med, Eldoret, Kenya.
   [Vorobioff, Julio D.; Rodil, Agustina; Bessone, Fernando] Univ Rosario, Sch Med, Dept Gastroenterol & Hepatol, Rosario, Santa Fe, Argentina.
   [Thurairajah, Prem H.; Hsiang, John C.] Changi Gen Hosp, Dept Gastroenterol & Hepatol, Singapore, Singapore.
   [Siow, Way; Teo, Eng Kiong; George, Jacob] Westmead Millennium Inst, Storr Liver Ctr, Westmead, NSW, Australia.
   [Siow, Way; Teo, Eng Kiong] Westmead Hosp, Westmead, NSW, Australia.
   [Scheurich, Christoph; Kluwe, Johannes] Hamburg Univ, Med Ctr, Dept Gastroenterol, Hamburg, Germany.
   [Saez-Royuela, Federico; Badia, Ester] Univ Hosp Burgos, Liver Unit, Gastroenterol Dept, Burgos, Spain.
   [Reis, Daniela; Da Costa, Pedro Marques; Cortez-Pinto, Helena] Univ Lisbon, Ctr Hosp Lisboa Norte, Lab Nutr, Dept Gastrenterol & Hepatol, Lisbon, Portugal.
   [Ono, Suzane K.; Nabeshima, Mariana A.; Farias, Alberto Q.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Fernandez, Marlen I. Castellanos; Domech, Caridad Ruenes; Guridi, Zaily Dorta] Inst Gastroenterol, Dept Hepatol, Havana, Cuba.
   [Alfadhli, Ahmad; Alboraie, Mohamed] Mubarak Al Kabeer Hosp, Haya Al Habeeb Gastroenterol Ctr, Jabriya, Kuwait.
   [Yang, Ling] Huazhong Univ Sci & Technol, Div Gastroenterol, Wuhan, Hubei, Peoples R China.
   [Kochhar, Rakesh] Postgrad Inst Med Educ & Res, Dept Gastroenterol, Chandigarh, India.
   [Kim, Won] Seoul Natl Univ, Boramae Med Ctr, Div Gastroenterol & Hepatol, Seoul Metropolitan Govt, Seoul, South Korea.
   [Isakov, Vasily] Inst Nutr, Dept Gastroenterol & Hepatol, Moscow, Russia.
   [Alboraie, Mohamed] Al Azhar Univ, Dept Internal Med, Cairo, Egypt.
   [Bataller, Ramon] Univ Pittsburgh, Med Ctr, Pittsburgh Liver Res Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
RI Farias, Alberto/ABB-1291-2020; Cortez-Pinto, Helena/AAN-2712-2020;
   /A-4876-2011; Kassas, Mohamed El/AAD-6987-2020; Kim, Won/H-6940-2019;
   Cortez-Pinto, Helena/A-3586-2012; Carrilho, Flair J/I-3046-2012
OI Farias, Alberto/0000-0002-5572-663X; Cortez-Pinto,
   Helena/0000-0002-8537-8744; /0000-0002-4417-8076; Kassas, Mohamed
   El/0000-0002-3396-6894; Kim, Won/0000-0002-2926-1007; 
FU MSD
FX Jacob George - Advisory Committees or Review Panels: Pharmaxis, BMS,
   MSD, Gilead, Janssen, Abbvie; Grant/Research Support: MSD
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2017
VL 66
SU 1
SI SI
MA 1301
BP 700A
EP 701A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA FI6GA
UT WOS:000412089801442
DA 2020-12-08
ER

PT J
AU Chan, AJ
   Balderramo, D
   Kikuchi, L
   Ballerga, EG
   Prieto, JE
   Tapias, M
   Idrovo, V
   Davalos, MB
   Cairo, F
   Barreyro, FJ
   Paredes, S
   Hernandez, N
   Avendano, K
   Ferrer, JD
   Yang, JD
   Carrera, E
   Mattos, AZ
   Hirsch, BS
   Goncalves, PT
   Carrilho, FJ
   Roberts, LR
   Debes, JD
AF Chan, Aaron J.
   Balderramo, Domingo
   Kikuchi, Luciana
   Gonzalez Ballerga, Esteban
   Prieto, Jhon E.
   Tapias, Monica
   Idrovo, Victor
   Davalos, Milagros B.
   Cairo, Fernando
   Barreyro, Fernando J.
   Paredes, Sebastian
   Hernandez, Nelia
   Avendano, Karla
   Diaz Ferrer, Javier
   Yang, Ju Dong
   Carrera, Enrique
   Mattos, Angelo Z.
   Hirsch, Bruno S.
   Goncalves, Pablo T.
   Carrilho, Flair J.
   Roberts, Lewis R.
   Debes, Jose D.
TI Early Age Hepatocellular Carcinoma Associated With Hepatitis B Infection
   in South America
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Letter
ID GENOTYPES
C1 [Chan, Aaron J.; Debes, Jose D.] Univ Minnesota, Dept Med, 2001 6th St SE, Minneapolis, MN 55455 USA.
   [Balderramo, Domingo] Hosp Privado Univ Cordoba, Inst Univ Ciencias Biomed Cordoba, Dept Gastroenterol, Cordoba, Argentina.
   [Kikuchi, Luciana; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Gonzalez Ballerga, Esteban] Hosp Clin Buenos Aires, Dept Gastroenterol, Buenos Aires, DF, Argentina.
   [Prieto, Jhon E.] Org Sanitas Colombia, Ctr Enfermedades Hepat & Digest, Bogota, Colombia.
   [Tapias, Monica; Idrovo, Victor] Hosp Univ Fundac Santa Fe & Org Sanitas, Bogota, Colombia.
   [Davalos, Milagros B.; Diaz Ferrer, Javier] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru.
   [Cairo, Fernando] Hosp El Cruce, Unidad Hepatol, Buenos Aires, DF, Argentina.
   [Barreyro, Fernando J.] Consejo Nacl Invest Cient & Tecn, Posadas, Argentina.
   [Paredes, Sebastian] Hosp Presidente Peron, Dept Gatroenterol, Formosa, Argentina.
   [Hernandez, Nelia; Avendano, Karla] Univ Republica, Hosp Clin, Montevideo, Uruguay.
   [Yang, Ju Dong; Roberts, Lewis R.] HNSC, Hosp Nossa Senhora Conceicao, Dept Gastroenterol, Porto Alegre, RS, Brazil.
   [Carrera, Enrique] Mayo Clin, Coll Med, Dept Gastroenterol, Rochester, MN USA.
   [Mattos, Angelo Z.; Hirsch, Bruno S.; Goncalves, Pablo T.] HNSC, Dept Gastroenterol, Porto Alegre, RS, Brazil.
RP Debes, JD (corresponding author), Univ Minnesota, Dept Med, 2001 6th St SE, Minneapolis, MN 55455 USA.
EM debes003@umn.edu
RI Carrilho, Flair J/I-3046-2012; Debes, Jose/Q-9794-2016
OI Balderramo, Domingo/0000-0001-9598-2577; Roberts,
   Lewis/0000-0001-7885-8574; Prieto Ortiz, Jhon Edison/0000-0002-8009-5999
CR Alvarado-Mora MV, 2013, ANTIVIR THER, V18, P459, DOI 10.3851/IMP2599
   Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021
   Livingston SE, 2007, J INFECT DIS, V195, P5, DOI 10.1086/509894
   Nogueira JA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-204
   Park JW, 2015, LIVER INT, V35, P2155, DOI 10.1111/liv.12818
   Yang JD, 2015, AM J GASTROENTEROL, V110, P1629, DOI 10.1038/ajg.2015.289
NR 6
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD OCT
PY 2017
VL 15
IS 10
BP 1631
EP 1632
DI 10.1016/j.cgh.2017.05.015
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA FH2RJ
UT WOS:000410988700034
PM 28532694
OA Bronze
DA 2020-12-08
ER

PT J
AU Cardoso, L
   Rodrigues, D
   Gomes, L
   Carrilho, F
AF Cardoso, Luis
   Rodrigues, Dircea
   Gomes, Leonor
   Carrilho, Francisco
TI Short- and long-term mortality after bariatric surgery: A systematic
   review and meta-analysis
SO DIABETES OBESITY & METABOLISM
LA English
DT Review
DE bariatric surgery; meta-analysis; obesity therapy; systematic review
ID Y GASTRIC BYPASS; LAPAROSCOPIC DUODENAL SWITCH; PROSPECTIVE
   RANDOMIZED-TRIAL; BODY-MASS INDEX; QUALITY-OF-LIFE;
   CARDIOVASCULAR-DISEASE; SURGICAL-TREATMENT; MORBID-OBESITY;
   CLINICAL-TRIAL; RISK-FACTORS
AB AimsThe objective of this study was to investigate short- (30days) and long-term (2years) all-cause mortality after bariatric surgery among adult patients with obesity.
   Materials and methodsFor short-term mortality, eligible studies comprised randomized controlled trials (RCTs) reporting perioperative mortality. For long-term mortality, eligible studies comprised RCTs and observational studies comparing mortality between obese patients after bariatric surgery and non-operated controls. Random-effects models using a Bayesian or frequentist approach were used to pool effect estimates of short- and long-term mortality, respectively.
   ResultsShort-term all-cause mortality based on 38 RCTs involving 4030 patients was 0.18% (95% CI, 0.04%-0.38%) and was higher for open surgeries (0.31%; 95% CI, 0.03%-0.97%) and similar in mixed surgeries (0.17%; 95% CI, 0.03%-0.43%) and restrictive surgeries (0.17%; 95% CI, 0.03%-0.45%). For long-term mortality, 12 observational studies involving 27258 operated patients and 97154 non-operated obese controls were included. Of these, 8 studies were eligible for the meta-analysis, which showed a reduction of 41% in all-cause mortality (hazard ratio, 0.59; 95% CI, 0.52-0.67; P<.001). Additionally, operated patients were 0.42 times as likely (95% CI, 0.25-0.72, P<.001) and 0.47 times as likely (95% CI, 0.36-0.63, P<.001) as non-operated obese controls to die from cardiovascular diseases and cancer, respectively.
   ConclusionsBariatric surgery is associated with low short-term mortality and may be associated with long-term reductions in all-cause, cardiovascular and cancer-related mortality.
C1 [Cardoso, Luis; Rodrigues, Dircea; Gomes, Leonor; Carrilho, Francisco] Ctr Hosp, Dept Endocrinol Diabet & Metab, Praceta Prof Mota Pinto, P-3000075 Coimbra, Portugal.
   [Cardoso, Luis; Rodrigues, Dircea; Gomes, Leonor; Carrilho, Francisco] Univ Coimbra, Praceta Prof Mota Pinto, P-3000075 Coimbra, Portugal.
   [Cardoso, Luis; Rodrigues, Dircea; Gomes, Leonor] Univ Coimbra, Fac Med, Coimbra, Portugal.
RP Cardoso, L (corresponding author), Ctr Hosp, Dept Endocrinol Diabet & Metab, Praceta Prof Mota Pinto, P-3000075 Coimbra, Portugal.; Cardoso, L (corresponding author), Univ Coimbra, Praceta Prof Mota Pinto, P-3000075 Coimbra, Portugal.
EM mkcardoso@gmail.com
RI Cardoso, Luis/AAF-6366-2020; Carrilho, Flair J/I-3046-2012; Cardoso,
   Luis/I-2195-2013
OI Cardoso, Luis/0000-0001-9833-7960; Cardoso, Luis/0000-0001-9833-7960;
   Gomes, Leonor/0000-0001-6576-7104; Rodrigues, Dircea/0000-0001-8410-2618
CR Angrisani L, 2015, OBES SURG, V25, P1822, DOI 10.1007/s11695-015-1657-z
   Arterburn DE, 2015, JAMA-J AM MED ASSOC, V313, P62, DOI 10.1001/jama.2014.16968
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benotti P, 2014, ANN SURG, V259, P123, DOI 10.1097/SLA.0b013e31828a0ee4
   Bessler M, 2007, SURG OBES RELAT DIS, V3, P480, DOI 10.1016/j.soard.2007.01.010
   Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12
   Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724
   Buchwald H, 2007, SURGERY, V142, P621, DOI 10.1016/j.surg.2007.07.018
   Busetto L, 2007, SURG OBES RELAT DIS, V3, P496, DOI 10.1016/j.soard.2007.06.003
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Casagrande DS, 2014, OBES SURG, V24, P1499, DOI 10.1007/s11695-014-1276-0
   Chang SH, 2014, JAMA SURG, V149, P275, DOI 10.1001/jamasurg.2013.3654
   Christou NV, 2004, ANN SURG, V240, P416, DOI 10.1097/01.sla.0000137343.63376.19
   Darabi S, 2013, SURG OBES RELAT DIS, V9, P914, DOI 10.1016/j.soard.2013.07.012
   Davidson LE, 2016, JAMA SURG, V151, P631, DOI 10.1001/jamasurg.2015.5501
   Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eliasson B, 2015, LANCET DIABETES ENDO, V3, P847, DOI 10.1016/S2213-8587(15)00334-4
   Finkelstein EA, 2012, AM J PREV MED, V42, P563, DOI 10.1016/j.amepre.2011.10.026
   Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5
   Flum DR, 2004, J AM COLL SURGEONS, V199, P543, DOI 10.1016/j.jamcollsurg.2004.06.014
   Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187
   Food and Agriculture Organisation of the United Nations (FAO) International Fund for Agricultural Development (IFAD) United Nations World Food Programme (WFP), 2013, STAT FOOD INS WORLD
   Guidry CA, 2015, AM J SURG, V209, P463, DOI 10.1016/j.amjsurg.2014.10.009
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968
   Kim J, 2016, SURG OBES RELAT DIS, V12, P453, DOI 10.1016/j.soard.2015.11.021
   Kwok CS, 2014, INT J CARDIOL, V173, P20, DOI 10.1016/j.ijcard.2014.02.026
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Lujan JA, 2004, ANN SURG, V239, P433, DOI 10.1097/01.sla.0000120071.75691.1f
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Maciejewski ML, 2011, JAMA-J AM MED ASSOC, V305, P2419, DOI 10.1001/jama.2011.817
   MACLEAN LD, 1995, OBES SURG, V5, P145, DOI 10.1381/096089295765557917
   MACLEAN LD, 1993, AM J SURG, V165, P155, DOI 10.1016/S0002-9610(05)80420-9
   Maggard MA, 2005, ANN INTERN MED, V142, P547, DOI 10.7326/0003-4819-142-7-200504050-00013
   Marsk R, 2008, ANN SURG, V248, P777, DOI 10.1097/SLA.0b013e318189b0cf
   Mingrone G, 2012, NEW ENGL J MED, V366, P1577, DOI 10.1056/NEJMoa1200111
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI DOI 10.1001/JAMA.289.1.76
   MOLLER H, 1994, EUR J CANCER, V30A, P344, DOI 10.1016/0959-8049(94)90254-2
   Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8
   Nguyen NT, 2010, SURG OBES RELAT DIS, V6, P477, DOI 10.1016/j.soard.2010.03.294
   Nguyen NT, 2003, AM J SURG, V186, P40, DOI 10.1016/S0002-9610(03)00106-5
   Nguyen NT, 2001, ANN SURG, V234, P279, DOI 10.1097/00000658-200109000-00002
   Padwal R, 2011, OBES REV, V12, P602, DOI 10.1111/j.1467-789X.2011.00866.x
   Paluszkiewicz R, 2012, VIDEOSURGERY MINIINV, V7, P225, DOI 10.5114/wiitm.2012.32384
   Peeters A, 2007, ANN SURG, V246, P1028, DOI 10.1097/SLA.0b013e31814a6929
   Pontiroli AE, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0347-z
   Pontiroli AE, 2011, ANN SURG, V253, P484, DOI 10.1097/SLA.0b013e31820d98cb
   Puzziferri N, 2006, ANN SURG, V243, P181, DOI 10.1097/01.sla.0000197381.01214.76
   Risstad H, 2015, JAMA SURG, V150, P352, DOI 10.1001/jamasurg.2014.3579
   Rubino F, 2016, DIABETES CARE, V39, P861, DOI 10.2337/dc16-0236
   Scopinaro N, 1998, OBES SURG, V8, P3, DOI 10.1381/096089298765554971
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.i4086]
   Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254
   Skroubis G, 2006, OBES SURG, V16, P488, DOI 10.1381/096089206776327251
   Smith MD, 2011, OBES SURG, V21, P1687, DOI 10.1007/s11695-011-0497-8
   Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408
   Sovik TT, 2010, BRIT J SURG, V97, P160, DOI 10.1002/bjs.6802
   Sovik TT, 2011, ANN INTERN MED, V155, P281, DOI 10.7326/0003-4819-155-5-201109060-00005
   Sowemimo OA, 2007, SURG OBES RELAT DIS, V3, P73, DOI 10.1016/j.soard.2006.10.017
   Sundbom M, 2004, BRIT J SURG, V91, P418, DOI 10.1002/bjs.4505
   Sutton Alexander J, 2002, Expert Rev Pharmacoecon Outcomes Res, V2, P367, DOI 10.1586/14737167.2.4.367
   Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761
   Tee MC, 2013, SURG ENDOSC, V27, P4449, DOI 10.1007/s00464-013-3127-9
   Telem DA, 2015, SURG ENDOSC, V29, P529, DOI 10.1007/s00464-014-3714-4
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   van Dielen FMH, 2005, OBES SURG, V15, P1292, DOI 10.1381/096089205774512456
   van Mastrigt GAPG, 2006, OBES SURG, V16, P75, DOI 10.1381/096089206775222113
   Wang YF, 2008, OBESITY, V16, P2323, DOI 10.1038/oby.2008.351
   Wells G, 2000, NEWCASTLE OTTAWA SCA
   Westling A, 2001, OBES SURG, V11, P284, DOI 10.1381/096089201321336610
   Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4
   Zhang W, 2005, OBES SURG, V15, P43, DOI 10.1381/0960892052993422
   Zhou X, 2016, OBES SURG, V26, P2590, DOI 10.1007/s11695-016-2144-x
NR 75
TC 48
Z9 48
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
EI 1463-1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD SEP
PY 2017
VL 19
IS 9
BP 1223
EP 1232
DI 10.1111/dom.12922
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA FE5GY
UT WOS:000408241200004
PM 28244626
DA 2020-12-08
ER

PT J
AU Kikuchi, L
   Chagas, AL
   Alencar, RSSM
   Tani, C
   Diniz, MA
   D'Albuquerque, LAC
   Carrilho, FJ
AF Kikuchi, Luciana
   Chagas, Aline Lopes
   Alencar, Regiane S. S. M.
   Tani, Claudia
   Diniz, Marcio A.
   D'Albuquerque, Luiz A. C.
   Carrilho, Flair Jose
TI Adherence to BCLC recommendations for the treatment of hepatocellular
   carcinoma: impact on survival according to stage
SO CLINICS
LA English
DT Article
DE Hepatocellular Carcinoma; Prognosis; Tumor Staging; Guideline Adherence
ID CLINICAL-PRACTICE; MANAGEMENT; GUIDELINES; EXPERIENCE; OUTCOMES
AB OBJECTIVES: This study sought to assess the adherence of newly diagnosed hepatocellular carcinoma patients to the Barcelona Clinic Liver Cancer system treatment guidelines and to examine the impact of adherence on the survival of patients in different stages of the disease.
   METHODS: This study included all patients referred for the treatment of hepatocellular carcinoma between 2010 and 2012. Patients (n=364) were classified according to the Barcelona Clinic Liver Cancer guidelines. Deviations from the recommended guidelines were discussed, and treatment was determined by a multidisciplinary team. The overall survival curves were estimated with the Kaplan-Meier method and were compared using the log-rank test.
   RESULTS: The overall rate of adherence to the guidelines was 52%. The rate of adherence of patients in each scoring group varied as follows: stage 0, 33%; stage A, 45%; stage B, 78%; stage C, 35%; and stage D, 67%. In stage 0/A, adherent patients had a significantly better overall survival than non-adherent patients (hazard ratio=0.19, 95% confidence interval (CI): 0.09-0.42; p<0.001). Among the stage D patients, the overall survival rate was worse in adherent patients than in non-adherent patients (hazard ratio=4.0, 95% CI: 1.67-9.88; p<0.001), whereas no differences were observed in patients in stages B or C.
   CONCLUSIONS: The rate of adherence to the Barcelona Clinic Liver Cancer staging system in clinical practice varies according to clinical disease stage. Adherence to the recommended guidelines positively impacts survival, especially in patients with early-stage disease.
C1 [Kikuchi, Luciana; Chagas, Aline Lopes; Alencar, Regiane S. S. M.; Tani, Claudia; Diniz, Marcio A.; D'Albuquerque, Luiz A. C.; Carrilho, Flair Jose] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP,Dept Gastroenterol, Inst Canc Estado Sao Paulo,Sao Paulo Clin Liver C, Sao Paulo, SP, Brazil.
RP Kikuchi, L (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP,Dept Gastroenterol, Inst Canc Estado Sao Paulo,Sao Paulo Clin Liver C, Sao Paulo, SP, Brazil.
EM lucianakikuchi@usp.br
RI Carrilho, Flair J/I-3046-2012; D'ALBUQUERQUE, Luiz Carneiro
   Augusto/I-4011-2012; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   Chagas, Aline Lopes/X-2059-2019
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; 
FU Alves de Queiroz Family Fund for Research
FX This work was supported by the Alves de Queiroz Family Fund for
   Research.
CR Bolondi L, 2012, SEMIN LIVER DIS, V32, P348, DOI 10.1055/s-0032-1329906
   Borzio M, 2013, FUTURE ONCOL, V9, P283, DOI [10.2217/FON.12.183, 10.2217/fon.12.183]
   Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
   Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Burrel M, 2012, J HEPATOL, V56, P1330, DOI 10.1016/j.jhep.2012.01.008
   D'Avola D, 2011, ANN SURG ONCOL, V18, P1964, DOI 10.1245/s10434-011-1551-4
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   El-Serag HB, 2006, J HEPATOL, V44, P158, DOI 10.1016/j.jhep.2005.10.002
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fomer A, 2014, NAT REV CLIN ONCOL, V11, P525, DOI 10.1038/nrclinonc.2014.122
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Guarino M, 2015, J MED VIROL, V87, P1368, DOI 10.1002/jmv.24187
   Kim BK, 2012, LIVER INT, V32, P1120, DOI 10.1111/j.1478-3231.2012.02811.x
   Kim Sung Eun, 2011, Korean J Hepatol, V17, P113, DOI 10.3350/kjhep.2011.17.2.113
   Leoni S, 2014, DIGEST LIVER DIS, V46, P549, DOI 10.1016/j.dld.2014.02.012
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Piscaglia F, 2013, DIGEST LIVER DIS, V45, P852, DOI 10.1016/j.dld.2013.03.002
   R Development Core Team, 2011, R LANG ENV STAT COMP
   Radu P, 2013, J GASTROINTEST LIVER, V22, P291
   Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006
   Salvalaggio PR, 2014, TRANSPLANTATION, V98, P241, DOI 10.1097/TP.0000000000000198
NR 22
TC 10
Z9 11
U1 0
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD AUG
PY 2017
VL 72
IS 8
BP 454
EP 460
DI 10.6061/clinics/2017(08)01
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA FI2VB
UT WOS:000411803900001
PM 28954003
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Caly, WR
   Abreu, RM
   Bitelman, B
   Carrilho, FJ
   Ono, SK
AF Caly, Wanda Regina
   Abreu, Rodrigo Martins
   Bitelman, Bernardo
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI Clinical Features of Refractory Ascites in Outpatients
SO CLINICS
LA English
DT Article
DE Ascites; Hepatic Encephalopathy; Liver; Liver Cirrhosis; Outpatients
ID INTRAHEPATIC PORTOSYSTEMIC SHUNT; CHRONIC LIVER-DISEASE; SERUM SODIUM;
   HEPATORENAL-SYNDROME; NUTRITIONAL-STATUS; CIRRHOTIC-PATIENTS;
   NONAZOTEMIC CIRRHOSIS; REPEATED PARACENTESIS; PORTAL-HYPERTENSION; ADULT
   PATIENTS
AB OBJECTIVES: To present the clinical features and outcomes of outpatients who suffer from refractory ascites.
   METHODS: This prospective observational study consecutively enrolled patients with cirrhotic ascites who submitted to a clinical evaluation, a sodium restriction diet, biochemical blood tests, 24 hour urine tests and an ascitic fluid analysis. All patients received a multidisciplinary evaluation and diuretic treatment. Patients who did not respond to the diuretic treatment were controlled by therapeutic serial paracentesis, and a transjugular intrahepatic portosystemic shunt was indicated for patients who required therapeutic serial paracentesis up to twice a month.
   RESULTS: The most common etiology of cirrhosis in both groups was alcoholism [49 refractory (R) and 11 non-refractory ascites (NR)]. The majority of patients in the refractory group had Child-Pugh class B cirrhosis (p=0.034). The nutritional assessment showed protein-energy malnutrition in 81.6% of the patients in the R group and 35.5% of the patients in the NR group, while hepatic encephalopathy, hernia, spontaneous bacterial peritonitis, upper digestive hemorrhage and type 2 hepatorenal syndrome were present in 51%, 44.9%, 38.8%, 38.8% and 26.5% of the patients in the R group and 9.1%, 18.2%, 0%, 0% and 0% of the patients in the NR group, respectively (p=0.016, p=0.173, p=0.012, p=0.012, and p=0.100, respectively). Mortality occurred in 28.6% of the patients in the R group and in 9.1% of the patients in the NR group (p=0.262).
   CONCLUSION: Patients with refractory ascites were malnourished, suffered from hernias, had a high prevalence of complications and had a high postoperative death frequency, which was mostly due to infectious processes.
C1 [Caly, Wanda Regina; Abreu, Rodrigo Martins; Bitelman, Bernardo; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Fac Med FMUSP, Div Gastroenterol & Hepatol Clin, Dept Gastroenterol, Sao Paulo, SP, Brazil.
RP Ono, SK (corresponding author), Univ Sao Paulo, Fac Med FMUSP, Div Gastroenterol & Hepatol Clin, Dept Gastroenterol, Sao Paulo, SP, Brazil.
EM skon@usp.br
RI Carrilho, Flair J/I-3046-2012
FU Alves de Queiroz Family Fund
FX Alves de Queiroz Family Fund for Research.
CR Albillos A, 2005, J HEPATOL, V43, P990, DOI 10.1016/j.jhep.2005.06.005
   Altamirano J, 2012, CLIN GASTROENTEROL H, V10, P65, DOI 10.1016/j.cgh.2011.09.011
   Andraus W, 2015, BMC SURG, V15, DOI 10.1186/s12893-015-0052-y
   Angeli P, 2010, GUT, V59, P98, DOI 10.1136/gut.2008.176495
   ARROYO V, 1981, ANN INTERN MED, V94, P198, DOI 10.7326/0003-4819-94-2-198
   Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164
   ARROYO V, 1986, AM J MED, V81, P104, DOI 10.1016/0002-9343(86)90912-5
   ARROYO V, 1983, EUR J CLIN INVEST, V13, P271, DOI 10.1111/j.1365-2362.1983.tb00100.x
   Biggins SW, 2005, HEPATOLOGY, V41, P32, DOI 10.1002/hep.20517
   Bittencourt Paulo Lisboa, 2010, Arq. Gastroenterol., V47, P202, DOI 10.1590/S0004-28032010000200017
   BLACKBURN GL, 1979, MED CLIN N AM, V63, P1103, DOI 10.1016/S0025-7125(16)31663-7
   Boyer TD, 2005, HEPATOLOGY, V41, P386, DOI 10.1002/hep.20559
   D'Amico G, 2005, GASTROENTEROLOGY, V129, P1282, DOI 10.1053/j.gastro.2005.07.031
   Deltenre P, 2005, LIVER INT, V25, P349, DOI 10.1111/j.1478-3231.2005.01095.x
   Durand F, 2005, J HEPATOL, V42, pS100, DOI 10.1016/j.jhep.2004.11.015
   Fasolato S, 2007, HEPATOLOGY, V45, P223, DOI 10.1002/hep.21443
   Gaba R C, 2015, Clin Radiol, V70, pe51, DOI 10.1016/j.crad.2015.02.002
   Garcia-Tsao G, 2006, NAT CLIN PRACT GASTR, V3, P380, DOI 10.1038/ncpgasthep0523
   Gines A, 1996, GASTROENTEROLOGY, V111, P1002, DOI 10.1016/S0016-5085(96)70068-9
   GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124
   Gines P, 2010, J HEPATOL, V53, P397, DOI 10.1016/j.jhep.2010.05.004
   Guevara M, 2010, LIVER INT, V30, P1137, DOI 10.1111/j.1478-3231.2010.02293.x
   Heuman DM, 2004, HEPATOLOGY, V40, P802, DOI 10.1002/hep.20405
   Juakiem W, 2014, CLIN LIVER DIS, V18, P179, DOI 10.1016/j.cld.2013.09.004
   Jung HS, 2009, J VASC INTERV RADIOL, V20, P180, DOI 10.1016/j.jvir.2008.11.005
   Kim WR, 2008, NEW ENGL J MED, V359, P1018, DOI 10.1056/NEJMoa0801209
   LOGUERCIO C, 1990, BRIT J CLIN PRACT, V44, P98
   Londono MC, 2007, GUT, V56, P1283, DOI 10.1136/gut.2006.102764
   Marsman HA, 2007, SURGERY, V142, P372, DOI 10.1016/j.surg.2007.05.006
   MCCULLOUGH AJ, 1992, GASTROENTEROLOGY, V102, P1325
   MERLI M, 1994, NUTRITION, V10, P566
   Moore KP, 2003, HEPATOLOGY, V38, P258, DOI 10.1053/jhep.2003.50315
   MULLER MJ, 1995, J HEPATOL, V23, P31
   POCKROS PJ, 1986, GASTROENTEROLOGY, V90, P1827, DOI 10.1016/0016-5085(86)90249-0
   Rossle M, 2000, NEW ENGL J MED, V342, P1701, DOI 10.1056/NEJM200006083422303
   RUNYON BA, 1994, NEW ENGL J MED, V330, P337, DOI 10.1056/NEJM199402033300508
   Runyon BA, 2013, HEPATOLOGY, V57, P1651, DOI 10.1002/hep.26359
   Runyon BA, 2009, HEPATOLOGY, V49, P2087, DOI 10.1002/hep.22853
   SALERNO F, 1987, J HEPATOL, V5, P102, DOI 10.1016/S0168-8278(87)80067-3
   Salerno F, 2004, HEPATOLOGY, V40, P629, DOI 10.1002/hep.20364
   Salerno F, 2007, GUT, V56, P1310, DOI 10.1136/gut.2006.107789
   Salerno F, 2010, LIVER INT, V30, P937, DOI 10.1111/j.1478-3231.2010.02272.x
   Sam J, 2009, LIVER INT, V29, P1396, DOI 10.1111/j.1478-3231.2009.02077.x
   Santos J, 2003, J HEPATOL, V39, P187, DOI 10.1016/S0168-8278(03)00188-0
   Sanyal AJ, 2003, GASTROENTEROLOGY, V124, P634, DOI 10.1053/gast.2003.50088
   SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532
   Senousy BE, 2009, WORLD J GASTROENTERO, V15, P67, DOI 10.3748/wjg.15.67
   Sorrentino P, 2012, J GASTROEN HEPATOL, V27, P813, DOI 10.1111/j.1440-1746.2011.07043.x
   Teiusanu Adriana, 2012, Maedica (Bucur), V7, P284
NR 49
TC 2
Z9 3
U1 0
U2 3
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD JUL
PY 2017
VL 72
IS 7
BP 405
EP 410
DI 10.6061/clinics/2017(07)03
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA FD2SY
UT WOS:000407386300003
PM 28792999
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Passos, TR
   Santos, FS
   Martins, MC
   Pinto, VB
   Carrilho, FJ
   Ono, SK
AF Passos, Talita Rocha
   Santos, Fabiana Silva
   Martins, Maria Cleusa
   Pinto, Vanusa Barbosa
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI Clinical pharmacology profile of care in Hepatology clinic
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Article
DE hepatitis; drug; polypharmacy; ambulatory care; hematology; omeprazole
ID FATTY LIVER-DISEASE; CHRONIC HEPATITIS-C; NONALCOHOLIC STEATOHEPATITIS;
   INACTIVE HBV; MANAGEMENT; RESISTANCE; CARRIERS
AB Since 2010, the Clinical Gastroenterology and Hepatology Division of the Central Institute of Hospital das Clinicas of the University of Sao Paulo Medical School (HC-FMUSP, in the Portuguese acronym) has been developing specialized electives assistance activities in the Outpatient Specialty Clinic, Secondary Level, in Sao Paulo NGA-63 Varzea do Carmo. The objective of this study was to analyze the pharmacotherapeutic profile of patients. This is a cross-sectional and retrospective study in which patients were seen at the Hepatology sector and the results were submitted to descriptive statistics. During the study period, 492 patients were treated at the clinic, with a mean age of 58.9 years and frequency of 61.2% female and 74.8% living in Sao Paulo. This population was served by various other medical specialties (cardiology and endocrine among others) and the major liver diagnoses were: chronic hepatitis B and C and fatty liver. Comorbidities were also identified, such as diabetes, hypertension and dyslipidemia. Most patients took their medication in the Basic Health Units. We found that 30% of patients use of more than five medications and the most prescribed were omeprazole 208 (42.3%), metformin 132 (26.8%) and losartan 80 (16.3%). Because it is an adult/elderly population, with several comorbidities and polymedication, it is important to be aware of the rational use of medication. The multidisciplinary team is important in applying correct conducts for the safe use of medicines, to reduce the burden on health spending and improving the quality of life of patients.
C1 [Passos, Talita Rocha; Santos, Fabiana Silva] Univ Sao Paulo FMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Martins, Maria Cleusa] Univ Sao Paulo HC FMUSP, Fac Med, Hosp Clin, Inst Cent, Sao Paulo, SP, Brazil.
   [Pinto, Vanusa Barbosa] HC FMUSP, Inst Cent, Sao Paulo, SP, Brazil.
   [Pinto, Vanusa Barbosa] HC FMUSP, Pharmaceut Assistance Div, Sao Paulo, SP, Brazil.
   [Carrilho, Flair Jose] FMUSP, Med Gastroenterol, Sao Paulo, SP, Brazil.
   [Carrilho, Flair Jose; Ono, Suzane Kioko] FMUSP, Gastroenterol Dept, Sao Paulo, SP, Brazil.
   [Passos, Talita Rocha; Santos, Fabiana Silva; Martins, Maria Cleusa; Pinto, Vanusa Barbosa; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, SP, Brazil.
RP Passos, TR (corresponding author), Inst Cent HC, Av Dr Eneas Carvalho Aguiar 255,9 Andar,9159, BR-05403000 Sao Paulo, SP, Brazil.
EM suzane.ono@fm.usp.br
RI Carrilho, Flair J/I-3046-2012
CR Abbasinazari M, 2014, IRAN J PHARM RES, V13, P1221
   Alves MLF, 2015, REV MED MINAS GERAIS, V25, P469
   Armstrong MJ, 2014, HEPATOLOGY, V59, P1174, DOI 10.1002/hep.26717
   Bjerrum L, 1999, BRIT J GEN PRACT, V49, P195
   Bookman ID, 2006, LIVER INT, V26, P566, DOI 10.1111/j.1478-3231.2006.01256.x
   Brasil. Ministerio da Saude, 2013, PROT CLIN DIR TER TR
   Brasil. Ministerio da Saude, 2015, PROT CLIN DIR TER TR
   Brouwer WP, 2016, CLIN GASTROENTEROL H, V14, P1481, DOI 10.1016/j.cgh.2016.01.019
   Brunt EM, 2004, SEMIN LIVER DIS, V24, P3
   Chalasani N, 2012, GASTROENTEROLOGY, V142, P1592, DOI 10.1053/j.gastro.2012.04.001
   Cotta LSF, 2011, INFARMA, V23, P32
   D'Amico Gennaro, 2012, Hepatology, V55, P642, DOI 10.1002/hep.24695
   Hwang Y, 2015, KOREAN J INTERN MED, V30, P792, DOI 10.3904/kjim.2015.30.6.792
   Iida Vivian Helena, 2005, J. Bras. Patol. Med. Lab., V41, P29, DOI 10.1590/S1676-24442005000100008
   Invernizzi F, 2016, LIVER INT, V36, P100, DOI 10.1111/liv.13006
   Jimenez-Perez M, 2016, WORLD J GASTROENTERO, V22, P6573, DOI 10.3748/wjg.v22.i29.6573
   Oliveira JEP, 2015, DIRETRIZES SOC BRASI, P1
   Schwimmer JB, 2009, GASTROENTEROLOGY, V136, P1585, DOI 10.1053/j.gastro.2009.01.050
   Serra CG, 2010, CIENC SAUDE COLETIVA, V15, P3579, DOI 10.1590/S1413-81232010000900033
   [Anonymous], 2007, Arq. Bras. Cardiol., V89, pe24, DOI 10.1590/S0066-782X2007001500012
   Xavier HT, 2013, ARQ BRAS CARDIOL, V101, P1, DOI 10.5935/abc.2013S010
   Yu ML, 2016, EXP THER MED, V12, P1103, DOI 10.3892/etm.2016.3444
   Zipprich A, 2012, Z GASTROENTEROL, V50, P996, DOI 10.1055/s-0031-1299446
NR 23
TC 0
Z9 0
U1 0
U2 2
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
SN 0104-4230
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD MAY
PY 2017
VL 63
IS 5
BP 401
EP 406
DI 10.1590/1806-9282.63.05.401
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA FB2CG
UT WOS:000405950400005
PM 28724036
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Paranagua-Vezozzo, DC
   Andrade, A
   Mazo, DFC
   Nunes, V
   Guedes, AL
   Ragazzo, TG
   Moutinho, R
   Nacif, LS
   Ono, SK
   Alves, VAF
   Carrilho, FJ
AF Paranagua-Vezozzo, Denise C.
   Andrade, Adriana
   Mazo, Daniel F. C.
   Nunes, Vinicius
   Guedes, Ana L.
   Ragazzo, Taisa G.
   Moutinho, Renata
   Nacif, Lucas S.
   Ono, Suzane K.
   Alves, Venancio A. F.
   Carrilho, Flair J.
TI Concordance of non-invasive mechanical and serum tests for liver
   fibrosis evaluation in chronic hepatitis C
SO WORLD JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Elastography; Serum markers; Hepatitis C virus; Liver stiffness; Liver
   biopsy
ID RADIATION FORCE IMPULSE; TRANSIENT ELASTOGRAPHY; DISEASE BURDEN;
   STIFFNESS; ARFI; BIOPSY
AB AIM
   To determine the sensitivity and specificity of liver stiffness measurement (LSM) and serum markers (SM) for liver fibrosis evaluation in chronic hepatitis C.
   METHODS
   Between 2012 and 2014, 81 consecutive hepatitis C virus (HCV) patients had METAVIR score from liver biopsy compared with concurrent results from LSM [transient elastography (TE) [FibroScan (R)/ARFI technology (Virtual Touch (R))] and SM [FIB-4/aspartate aminotransferase-to-platelet ratio index (APRI)]. The diagnostic performance of these tests was assessed using receiver operating characteristic curves. The optimal cut-off levels of each test were chosen to define fibrosis stages F >= 2, F >= 3 and F = 4. The Kappa index set the concordance analysis.
   RESULTS
   Fifty point six percent were female and the median age was 51 years (30-78). Fifty-six patients (70%) were treatment-naive. The optimal cut-off values for predicting F >= 2 stage fibrosis assessed by TE were 6.6 kPa, for acoustic radiation force impulse (ARFI) 1.22 m/s, for APRI 0.75 and for FIB-4 1.47. For F >= 3 TE was 8.9 kPa, ARFI was 1.48 m/s, APRI was 0.75, and FIB-4 was 2. For F = 4, TE was 12.2 kPa, ARFI was 1.77 m/s, APRI was 1.46, and FIB-4 was 3.91. The APRI could not distinguish between F2 and F3, P = 0.92. The negative predictive value for F = 4 for TE and ARFI was 100%. Kappa index values for F >= 3 METAVIR score for TE, ARFI and FIB-4 were 0.687, 0.606 and 0.654, respectively. This demonstrates strong concordance between all three screening methods, and moderate to strong concordance between them and APRI (Kappa index = 0.507).
   CONCLUSION
   Given the costs and accessibility of LSM methods, and the similarity with the outcomes of SM, we suggest that FIB-4 as well as TE and ARFI may be useful indicators of the degree of liver fibrosis. This is of particular importance to developing countries.
C1 [Paranagua-Vezozzo, Denise C.; Andrade, Adriana; Mazo, Daniel F. C.; Nunes, Vinicius; Guedes, Ana L.; Ragazzo, Taisa G.; Moutinho, Renata; Nacif, Lucas S.; Ono, Suzane K.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Div Clin Gastroenterol & Hepatol, Hosp Clin,Dept Gastroenterol, Ave Dr Eneas Carvalho de Aguiar,255,Sala 9159, BR-05403900 Sao Paulo, Brazil.
   [Mazo, Daniel F. C.] Univ Estadual Campinas, Sch Med Sci, Div Gastroenterol, BR-13083970 Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, BR-01246903 Sao Paulo, Brazil.
RP Mazo, DFC (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Gastroenterol & Hepatol, Hosp Clin,Dept Gastroenterol, Ave Dr Eneas Carvalho de Aguiar,255,Sala 9159, BR-05403900 Sao Paulo, Brazil.
EM daniel.mazo@hc.fm.usp.br
RI Mazo, Daniel FC/D-5631-2015; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014; Carrilho, Flair J/I-3046-2012; andrade, adriana
   r/O-3507-2014; Nacif, Lucas S./B-2795-2013
OI Mazo, Daniel FC/0000-0002-2164-2630; Paranagua-Vezozzo, Denise
   Cerqueira/0000-0002-9606-4935; Nacif, Lucas S./0000-0002-7059-3978;
   Ribas Andrade, Adriana/0000-0001-6012-2155
CR Afdhal NH, 2003, HEPATOLOGY, V37, P972, DOI 10.1053/jhep.2003.50223
   [Anonymous], 2015, J HEPATOL, V63, P237, DOI 10.1016/j.jhep.2015.04.006
   Arena U, 2008, HEPATOLOGY, V47, P380, DOI 10.1002/hep.22007
   Bardou-Jacquet E, 2013, WORLD J GASTROENTERO, V19, P516, DOI 10.3748/wjg.v19.i4.516
   Blachier M, 2013, J HEPATOL, V58, P593, DOI 10.1016/j.jhep.2012.12.005
   Bota S, 2013, LIVER INT, V33, P1138, DOI 10.1111/liv.12240
   Bota S, 2011, WORLD J RADIOL, V3, P205, DOI [10.4329/wjr.v3.i8.205, 10.4329/wjr.v3.i7.188]
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, 2015, DEP DST AIDS HEP VIR
   Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018
   Castro R, 2015, INT J HEPATOL, V2015, DOI 10.1155/2015/852968
   Crespo G, 2012, J HEPATOL, V57, P281, DOI 10.1016/j.jhep.2012.03.016
   Dore GJ, 2014, J VIRAL HEPATITIS, V21, P1, DOI 10.1111/jvh.12253
   Frulio N, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-405
   Lin ZH, 2011, HEPATOLOGY, V53, P726, DOI 10.1002/hep.24105
   Piscaglia F, 2014, EUR J RADIOL, V83, P450, DOI 10.1016/j.ejrad.2013.06.009
   Razavi H, 2013, HEPATOLOGY, V57, P2164, DOI 10.1002/hep.26218
   Rizzo L, 2011, AM J GASTROENTEROL, V106, P2112, DOI 10.1038/ajg.2011.341
   Sandrin L, 2003, ULTRASOUND MED BIOL, V29, P1705, DOI 10.1016/j.ultrasmedbio.2003.07.001
   Tsochatzis EA, 2011, J HEPATOL, V54, P650, DOI 10.1016/j.jhep.2010.07.033
   Ziol M, 2005, HEPATOLOGY, V41, P48, DOI 10.1002/hep.20506
NR 20
TC 8
Z9 9
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5182
J9 WORLD J HEPATOL
JI World J. Hepatol.
PD MAR 18
PY 2017
VL 9
IS 8
BP 436
EP 442
DI 10.4254/wjh.v9.i8.436
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EY3SD
UT WOS:000403893100004
PM 28357031
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU De Souza, MMT
   Van Vaisberg, V
   Abreu, RM
   Ferreira, AS
   DaSilvaFerreira, C
   Nasser, PD
   Paschoale, HS
   Carrilho, FJ
   Ono, SK
AF Tavares de Souza, Marcelo Moreira
   Van Vaisberg, Victor
   Abreu, Rodrigo Martins
   Ferreira, Aline Siqueira
   daSilvaFerreira, Camila
   Nasser, Paulo Dominguez
   Paschoale, Helena Scavone
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI UGT1A1*28 relationship with abnormal total bilirubin levels in chronic
   hepatitis C patients Outcomes from a case-control study
SO MEDICINE
LA English
DT Article
DE chronic; Gilbert syndrome; hepatitis C; hyperbilirubinemia
ID UDP-GLUCURONOSYLTRANSFERASE GENE; GILBERTS-SYNDROME; COLORECTAL-CANCER;
   (TA)(8) ALLELE; BREAST-CANCER; UGT1A1; POLYMORPHISMS; PROMOTER;
   ASSOCIATION; IRINOTECAN
AB Gilbert syndrome (GS) is a frequent benign clinical condition, marked by intermittent unconjugated hyperbilirubinemia, mostly due to the polymorphism uridine diphosphate-glucuronosyltransferase 1A1* 28 (UGT1A1* 28). Hyperbilirubinemia has been reported in a GS patient undergoing hepatitis C treatment, and other UGT isoforms polymorphisms have been linked to worse outcomes in viral hepatitis. Yet, little is known to GS contributions' to the liver disease scenario. Our aim was to assess UGT1A1 genotypes' frequency in chronic hepatitis C (CHC) patients and correlate with total bilirubin (TB). This is a case-control study in a large tertiary medical center. Cases were CHC patients confirmed by hepatitis C virus (HCV)-polymerase chain reaction. Exclusion criteria were hepatitis B virus or human immunodeficiency virus (HIV) coinfection. Control were healthy blood donors. UGT1A1 promoter region gene genotyping was performed, and bilirubin serum levels were available for HCV patients. Genotypes and alleles frequencies were similar in case (n= 585; P= 0.101) and control groups (n= 313; P= 0.795). Total bilirubin increase was noticed according to thymine-adenine repeats in genotypes (P < 0.001), and the TB greater than 1mg/dL group had more UGT1A1* 28 subjects than in the group with TB values < 1mg/dL (18.3 vs 5.3; P < 0.001). Bilirubin levels are linked to the studied polymorphisms, and this is the first time that these findings are reported in a chronic liver disease sample. Among patients with increased TB levels, the frequency of UGT1A1* 28 is higher than those with normal TB. Personalized care should be considered to GS, regarding either abnormal bilirubin levels or drug metabolism.
C1 [Tavares de Souza, Marcelo Moreira; Van Vaisberg, Victor; Abreu, Rodrigo Martins; Ferreira, Aline Siqueira; daSilvaFerreira, Camila; Nasser, Paulo Dominguez; Paschoale, Helena Scavone; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo Sch Med, Dept Gastroenterol, Av Dr Eneas Carvalho Aguiar,255 ICHC,9th Floor, BR-05403000 Sao Paulo, SP, Brazil.
RP Ono, SK (corresponding author), Univ Sao Paulo Sch Med, Dept Gastroenterol, Av Dr Eneas Carvalho Aguiar,255 ICHC,9th Floor, BR-05403000 Sao Paulo, SP, Brazil.
EM suzane.ono@fm.usp.br
RI Carrilho, Flair J/I-3046-2012
FU Fundacao de Amparoa Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Alves de Queiroz
   Family Fund
FX The present study was supported by Fundacao de Amparoa Pesquisa do
   Estado de Sao Paulo (FAPESP), Alves de Queiroz Family Fund for
   Researchand Conselho Nacional de Desenvolvimento Cientfico e Tecnolgico
   (CNPq). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abumiya M, 2014, DRUG METAB PHARMACOK, V29, P449, DOI 10.2133/dmpk.DMPK-14-RG-031
   Ando Y, 1998, ANN ONCOL, V9, P845, DOI 10.1023/A:1008438109725
   Astolfi RH, 2011, MED HYPOTHESES, V77, P162, DOI 10.1016/j.mehy.2011.03.047
   Bajro MH, 2012, CANCER GENET-NY, V205, P163, DOI 10.1016/j.cancergen.2012.01.015
   Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170
   Bins S, 2016, PHARMACOGENOMICS, V17, P1483, DOI 10.2217/pgs-2016-0063
   BOCK KW, 1991, CRIT REV BIOCHEM MOL, V26, P129, DOI 10.3109/10409239109081125
   Bosma PJ, 2003, J HEPATOL, V38, P107, DOI 10.1016/S0168-8278(02)00359-8
   BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802
   Costa E, 2006, BLOOD CELL MOL DIS, V36, P91, DOI 10.1016/j.bcmd.2005.09.002
   Culley CL, 2013, ANN PHARMACOTHER, V47, P561, DOI 10.1345/aph.1R550
   Deng G.-J., 2009, USC, V15, P333, DOI DOI 10.1093/HUMUPD/DMP003
   Deterding K, 2009, ANN HEPATOL, V8, P246, DOI 10.1016/S1665-2681(19)31774-0
   Fertrin KY, 2002, AM J MED GENET, V108, P117, DOI 10.1002/ajmg.10209
   Fujita K, 2011, CANCER CHEMOTH PHARM, V67, P237, DOI 10.1007/s00280-010-1445-3
   Gammal RS, 2016, CLIN PHARMACOL THER, V99, P363, DOI 10.1002/cpt.269
   Girard H, 2005, HEPATOLOGY, V42, P448, DOI 10.1002/hep.20770
   Goey AKL, 2016, J CLIN PHARMACOL, V56, P461, DOI 10.1002/jcph.625
   Guillemette C, 2000, CANCER RES, V60, P950
   Innocenti F, 2004, J CLIN ONCOL, V22, P1382, DOI 10.1200/JCO.2004.07.173
   Iolascon A, 1999, HAEMATOLOGICA, V84, P106
   Lankisch TO, 2005, MOL PHARMACOL, V67, P1732, DOI 10.1124/mol.104.007146
   Lin JP, 2006, CIRCULATION, V114, P1476, DOI 10.1161/CIRCULATIONAHA.106.633206
   Lin JP, 2009, ATHEROSCLEROSIS, V206, P228, DOI 10.1016/j.atherosclerosis.2009.02.039
   Liu CY, 2008, CANCER-AM CANCER SOC, V112, P1932, DOI 10.1002/cncr.23370
   Lok AS, 2012, GASTROENTEROLOGY, V143, P619, DOI 10.1053/j.gastro.2012.05.037
   Lubomirov R, 2011, J INFECT DIS, V203, P246, DOI 10.1093/infdis/jiq043
   MACKLON AF, 1979, CLIN PHARMACOKINET, V4, P223, DOI 10.2165/00003088-197904030-00004
   MARTIN JF, 1976, GASTROENTEROLOGY, V70, P385
   Monaghan G, 1996, LANCET, V347, P578, DOI 10.1016/S0140-6736(96)91273-8
   Piratvisuth T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054279
   Premawardhena A, 2003, BLOOD CELL MOL DIS, V31, P98, DOI 10.1016/S1079-9796(03)00071-8
   Souza MMT, 2009, CLIN GASTROENTEROLOG
   Tseng CS, 2005, AM J GASTROENTEROL, V100, P1758, DOI 10.1111/j.1572-0241.2005.41857.x
   Tsezou A, 2000, HAEMATOLOGICA, V85, P319
   Vardhanabhuti S, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv085
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Xiao XG, 2015, ONCOTARGETS THER, V8, P3575, DOI 10.2147/OTT.S95149
   Xu CL, 2016, CANCER CHEMOTH PHARM, V78, P119, DOI 10.1007/s00280-016-3057-z
NR 39
TC 7
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAR
PY 2017
VL 96
IS 11
AR e6306
DI 10.1097/MD.0000000000006306
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA EP8GL
UT WOS:000397613800020
PM 28296739
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Albuquerque, ID
   Sousa, MT
   Santos, MDC
   Nunes, JDC
   Moraes, MJD
   Gomes-Gouvea, MS
   Pinho, JRR
   Carrilho, FJ
   Fonseca, LMB
   Ferreira, ADP
AF Albuquerque, Ingrid de Campos
   Sousa, Marinilde Teles
   Cruz Santos, Max Diego
   Costa Nunes, Jomar Diogo
   Diniz Moraes, Maria Joselia
   Gomes-Gouvea, Michele Soares
   Rebelo Pinho, Joao Renato
   Carrilho, Flair Jose
   Barros Fonseca, Lena Maria
   Paiva Ferreira, Adalgisa de Sousa
TI Mutation in the S Gene a Determinant of the Hepatitis B Virus Associated
   With Concomitant HBsAg and Anti-HBs in a Population in Northeastern
   Brazil
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE hepatitis B; HBsAg; antibody; mutation
ID CHRONICALLY INFECTED PATIENTS; MAJOR HYDROPHILIC REGION;
   SURFACE-ANTIGEN; COEXISTING HBSAG; SEQUENCE-ANALYSIS; CHINESE PATIENTS;
   GENOTYPE C; ANTIBODIES; PREVALENCE; MUTANT
AB Mutations in the a determinant of S gene may develop co-existence of hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HBs) in the serum of infected hepatitis B virus (HBV) individuals. Mutations in this region may change the antigenicity of HBsAg, which in turn, lead to escape of neutralizing action of anti-HBs antibodies. This study identified individuals with concomitant HBsAg and anti-HBs serological markers in individuals of Maranhao, Northeastern Brazil. Samples from a population-based study were evaluated for HBsAg, anti-HBs, and anti-HBc, and those that tested positive for simultaneous HBsAg and anti-HBs were submitted to HBV DNA quantification and S gene characterization by Sanger sequencing. Mutations were investigated in the a determinant located in major hydrophilic region (MHR) of the S gene. Among 3,984 samples analyzed, 92 (2.3%) were positive for HBsAg and three had the atypical HBsAg and anti-HBs-positive profile (3.26%). The frequency of HBsAg and anti-HBs co-existence was similar to previous studies. Only one individual harbored mutation in the S gene a determinant associated with this profile. Little is known about this phenomenon; however, studies as ours may contribute for future enlightenment of this important issue. (C) 2016 Wiley Periodicals, Inc.
C1 [Albuquerque, Ingrid de Campos; Sousa, Marinilde Teles; Costa Nunes, Jomar Diogo] Univ Fed Maranhao, Grad Program Hlth Sci, Sao Luis, Maranhao, Brazil.
   [Cruz Santos, Max Diego; Gomes-Gouvea, Michele Soares; Rebelo Pinho, Joao Renato; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Diniz Moraes, Maria Joselia] Univ Fed Maranhao, Univ Hosp, Maranhao Clin Res Ctr, Sao Luis, Maranhao, Brazil.
   [Barros Fonseca, Lena Maria] Univ Fed Maranhao, Dept Nursing, Sao Luis, Maranhao, Brazil.
   [Paiva Ferreira, Adalgisa de Sousa] Univ Fed Maranhao, Dept Med, Sao Luis, Maranhao, Brazil.
RP Albuquerque, ID (corresponding author), Univ Fed Maranhao, Dept Med, Rua Almirante Tamandare,01 Ctr, BR-65020600 Sao Luis, Maranhao, Brazil.
EM ingrid.c.albuquerque@gmail.com
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012; ferreira,
   adalgisa S P/G-8169-2016
OI Pinho, Joao R. R./0000-0003-3999-0489; 
FU Fundacao de Amparo a Pesquisa do Estado do Maranhao (FAPEMA)
   [PPSUS-03348/13, PPP-01263/12]; Sao Paulo Research Foundation
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/53946-3]; Brazilian Ministry of Health [1/2013]; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [141138/2012-2,
   132135/2014-0]
FX Fundacao de Amparo a Pesquisa do Estado do Maranhao (FAPEMA); Grant
   numbers: PPSUS-03348/13; PPP-01263/12; Grant sponsor: Sao Paulo Research
   Foundation (FAPESP); Grant number: 2009/53946-3; Grant sponsor:
   Brazilian Ministry of Health; Grant number: 1/2013; Grant sponsor:
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   Grant numbers: 141138/2012-2; 132135/2014-0
CR Alavian SM, 2013, J CLIN VIROL, V57, P201, DOI 10.1016/j.jcv.2012.04.027
   Bertolini DA, 2010, REV INST MED TROP SP, V52, P25, DOI 10.1590/S0036-46652010000100004
   Brunetto MR, 2014, J HEPATOL, V60, P473, DOI 10.1016/j.jhep.2013.12.001
   Caligiuri P, 2016, WORLD J GASTROENTERO, V22, P145, DOI 10.3748/wjg.v22.i1.145
   CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A
   Chen Y, 2011, J CLIN VIROL, V52, P198, DOI 10.1016/j.jcv.2011.07.011
   Colson P, 2007, VIROLOGY, V367, P30, DOI 10.1016/j.virol.2007.05.012
   Coppola N, 2015, WORLD J HEPATOL, V7, P2729, DOI 10.4254/wjh.v7.i27.2729
   Cuestas ML, 2006, J CLIN MICROBIOL, V44, P2191, DOI 10.1128/JCM.00057-06
   Ding F, 2016, BRAZ J INFECT DIS, V20, P1, DOI 10.1016/j.bjid.2015.08.014
   Ding F, 2015, J MED VIROL, V87, P2067, DOI 10.1002/jmv.24273
   Souto FJD, 2016, REV SOC BRAS MED TRO, V49, P11, DOI 10.1590/0037-8682-0176-2015
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Barros LMF, 2014, INFECT GENET EVOL, V24, P68, DOI 10.1016/j.meegid.2014.03.007
   Gao S, 2015, WORLD J HEPATOL, V7, P1086, DOI 10.4254/wjh.v7.i8.1086
   Gerlich WH, 2007, CLIN INFECT DIS, V44, P1170, DOI 10.1086/513296
   Gomes-Gouvea MS, 2015, ANTIVIR THER, V20, P387, DOI 10.3851/IMP2938
   Hsu HY, 2013, J INFECT DIS, V207, P1047, DOI 10.1093/infdis/jis943
   Hsu HY, 2010, J INFECT DIS, V201, P1192, DOI 10.1086/651378
   Huang CH, 2012, J HEPATOL, V57, P720, DOI 10.1016/j.jhep.2012.05.009
   Huang XY, 2010, J MED VIROL, V82, P23, DOI 10.1002/jmv.21669
   Jang JS, 2009, J MED VIROL, V81, P1531, DOI 10.1002/jmv.21577
   Komatsu Haruki, 2012, BMC Res Notes, V5, P22, DOI 10.1186/1756-0500-5-22
   Lada O, 2006, J VIROL, V80, P2968, DOI 10.1128/JVI.80.6.2968-2975.2006
   Lazarevic I, 2014, WORLD J GASTROENTERO, V20, P7653, DOI 10.3748/wjg.v20.i24.7653
   Lazarevic I, 2010, J MED VIROL, V82, P1160, DOI 10.1002/jmv.21810
   Li Fanghe, 2009, Front Med China, V3, P277, DOI 10.1007/s11684-009-0047-0
   Liu WW, 2012, ARCH VIROL, V157, P627, DOI 10.1007/s00705-011-1215-5
   Liu Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146980
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Lu HY, 2006, WORLD J GASTROENTERO, V12, P4219, DOI 10.3748/wjg.v12.i26.4219
   Jaramillo CM, 2015, REV CHIL INFECTOL, V32, P190, DOI 10.4067/S0716-10182015000300008
   Mathet VL, 2006, J CLIN MICROBIOL, V44, P3435, DOI 10.1128/JCM.00866-06
   Pancher M, 2015, J CLIN VIROL, V62, P32, DOI 10.1016/j.jcv.2014.11.015
   Pollicino T, 2007, HEPATOLOGY, V45, P277, DOI 10.1002/hep.21529
   Ponde RAA, 2011, EUR J CLIN MICROBIOL, V30, P1325, DOI 10.1007/s10096-011-1240-z
   Pu Z, 2016, J VIRAL HEPATITIS, V23, P286, DOI 10.1111/jvh.12492
   Rahimi R, 2015, HEPAT MON, V15, DOI 10.5812/hepatmon.27120v2
   Sayiner AA, 2007, J CLIN VIROL, V38, P157, DOI 10.1016/j.jcv.2006.12.002
   Shi Y, 2012, J MED VIROL, V84, P1901, DOI 10.1002/jmv.23419
   Sitnik R, 2010, REV INST MED TROP SP, V52, P119, DOI 10.1590/S0036-46652010000300001
   van Dommelen L, 2010, J CLIN VIROL, V47, P293, DOI 10.1016/j.jcv.2009.12.003
   Velu V, 2008, JPN J INFECT DIS, V61, P73
   Wang L, 2010, HEPATOL RES, V40, P1212, DOI 10.1111/j.1872-034X.2010.00723.x
   World Health Organization, HEP B
   World Health Organization, 2015, GUID PREV CAR TREATM
   Yamani LN, 2015, J CLIN MICROBIOL, V53, P3165, DOI 10.1128/JCM.00602-15
   Zaaijer HL, 2008, J VIRAL HEPATITIS, V15, P239, DOI 10.1111/j.1365-2893.2007.00938.x
   Zhang JM, 2007, CLIN INFECT DIS, V44, P1161, DOI 10.1086/513200
   Zhang X, 2015, WORLD J HEPATOL, V7, P1282, DOI 10.4254/wjh.v7.i9.1282
NR 50
TC 2
Z9 2
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2017
VL 89
IS 3
BP 458
EP 462
DI 10.1002/jmv.24653
PG 5
WC Virology
SC Virology
GA EK4JM
UT WOS:000393892900012
PM 27486854
DA 2020-12-08
ER

PT J
AU Branco, F
   Alencar, RSM
   Volt, F
   Sartori, G
   Dode, A
   Kikuchi, L
   Tani, CM
   Chagas, AL
   Pfiffer, T
   Hoff, P
   Carrilho, FJ
   de Mattos, AA
AF Branco, Fernanda
   Alencar, Regiane S. M.
   Volt, Fernanda
   Sartori, Giovana
   Dode, Andressa
   Kikuchi, Luciana
   Tani, Claudia M.
   Chagas, Aline L.
   Pfiffer, Tulio
   Hoff, Paulo
   Carrilho, Flair J.
   de Mattos, Angelo Alves
TI The Impact of Early Dermatologic Events in the Survival of Patients with
   Hepatocellular Carcinoma Treated with Sorafenib
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Hepatocellular carcinoma; Overall survival; Dermatologic adverse events
ID EFFICACY; SAFETY
AB Background and Aims. The presence of dermatologic reaction as an adverse event to sorafenib treatment in patients with unresectable hepatocellular carcinoma has been indicated as a prognostic factor for survival in a recent prospective analysis. To date, this is the only clinical predictor of treatment response , which can be eavaluated earlier in the treatment and, therefore, contribute to a better and more individualized patient management. Material and methods. This retrospective study included 127 patients treated with sorafenib under real-life practice conditions in two hepatology reference centers in Brazil, Demographic data, disease/medical history and time of sorafenib administration as well as adverse events related to the medication were recorded in a database Results. Cirrhosis was present in 94% of patients, 85.6% were child-pugh A, 80.3%BCLC-C,81% had vascular invasion and/or extrahepatic spread and 95% had a performance status 0 to 1. The median duration of treatment was 10.1 months (range: 0.1-47 months). The most common adverse event within the first 60 days of treatment were diarrhea (62.2%) and dermatological reaction (42%). The median overall survival for the cohort was 20 months, and it was higher for patients who developed dermatological reactions within the first 60 days compared to those who did not present this adverse event. Conclusion. This retrospective analysis showed the use of sorafenib in patients selected according to BCLC staging, and it is the first external validation of early dermatologic adverse events as a predictor of overall survival in patients with advanced hepatocellular carcinoma.
C1 [Branco, Fernanda; Volt, Fernanda; Sartori, Giovana; Dode, Andressa; de Mattos, Angelo Alves] Fed Univ Hlth Sci, Irmandade Santa Casa Misericordia Porto Alegre Ho, Dept Hepatol, Pedro Weingartner 46 401 Rio Branco, BR-90430140 Porto Alegre, RS, Brazil.
   [Alencar, Regiane S. M.; Kikuchi, Luciana; Tani, Claudia M.; Chagas, Aline L.; Carrilho, Flair J.] Univ Sao Paulo, Clin Hosp Sch Med, Sao Paulo, Brazil.
   [Alencar, Regiane S. M.; Kikuchi, Luciana; Tani, Claudia M.; Chagas, Aline L.; Carrilho, Flair J.] Univ Sao Paulo, Inst Canc, Sao Paulo Clin Liver Canc Grp, Sao Paulo, Brazil.
   [Pfiffer, Tulio; Hoff, Paulo] Univ Sao Paulo, Sch Med, Oncol, Sao Paulo, Brazil.
RP Branco, F (corresponding author), Fed Univ Hlth Sci, Irmandade Santa Casa Misericordia Porto Alegre Ho, Dept Hepatol, Pedro Weingartner 46 401 Rio Branco, BR-90430140 Porto Alegre, RS, Brazil.
EM fbranco10@gmail.com
RI Carrilho, Flair J/I-3046-2012; Chagas, Aline Lopes/X-2059-2019; Hoff,
   Paulo M. PH/M-7662-2017
OI Hoff, Paulo M. PH/0000-0002-0065-2194; Mattos, Angelo Alves
   de/0000-0003-2417-9765
CR Bruix J, 2016, GASTROENTEROLOGY, V150, P835, DOI 10.1053/j.gastro.2015.12.041
   Bruix J, 2012, J HEPATOL, V57, P821, DOI 10.1016/j.jhep.2012.06.014
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
   Chang YS, 2007, CANCER CHEMOTH PHARM, V59, P561, DOI 10.1007/s00280-006-0393-4
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Cho JY, 2013, LIVER INT, V33, P950, DOI 10.1111/liv.12168
   Di Costanzo GG, 2012, DIGEST LIVER DIS, V44, P788, DOI 10.1016/j.dld.2012.04.001
   Fassio E, 2010, ANN HEPATOL, V9, P63, DOI 10.1016/S1665-2681(19)31681-3
   Gao J, 2012, ASIAN PAC J CANCER P, V13, P743, DOI 10.7314/APJCP.2012.13.3.743
   Kudo M, 2012, DIGEST DIS, V30, P609, DOI 10.1159/000343091
   Lavarone M, 2011, HEPATOLOGY, V54, p896A
   Lencioni R, 2014, INT J CLIN PRACT, V68, P609, DOI 10.1111/ijcp.12352
   Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Otsuka T, 2012, HEPATOL RES, V42, P879, DOI 10.1111/j.1872-034X.2012.00991.x
   Ponziani FR, 2016, LIVER INT, V36, P1033, DOI 10.1111/liv.13052
   Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006
   Reig M, 2014, SEMIN LIVER DIS, V34, P444, DOI 10.1055/s-0034-1394143
   Reig M, 2014, J HEPATOL, V61, P318, DOI 10.1016/j.jhep.2014.03.030
   Vincenzi B, 2010, ONCOLOGIST, V15, P85, DOI 10.1634/theoncologist.2009-0143
   Yada M, 2014, WORLD J GASTROENTERO, V20, P12581, DOI 10.3748/wjg.v20.i35.12581
NR 22
TC 21
Z9 22
U1 1
U2 1
PU MEXICAN ASSOC HEPATOLOGY
PI MEXICO
PA PUNTE DE PIEDRA 150, COLONIA TORIELLO GUERRA, MEXICO, DF CP 14040,
   MEXICO
SN 1665-2681
J9 ANN HEPATOL
PD MAR-APR
PY 2017
VL 16
IS 2
BP 263
EP 268
DI 10.5604/16652681.1231585
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EP0LF
UT WOS:000397078100014
PM 28233750
OA Other Gold
DA 2020-12-08
ER

PT J
AU Carvalho, SCRD
   Vasconcelos, LRS
   Carmo, RF
   Aroucha, DCBL
   Tomitao, MT
   Ribeiro, U
   Pereira, LMMB
   Oliveira, CP
   Carrilho, FJ
AF Carvalho, S. C. R. D.
   Vasconcelos, L. R. S.
   Carmo, R. F.
   Aroucha, D. C. B. L.
   Tomitao, M. T.
   Ribeiro, U., Jr.
   Pereira, L. M. M. B.
   Oliveira, C. P.
   Carrilho, F. J.
TI Polymorphisms in the cyclooxygenase-2 (COX-2) gene, vascular endothelial
   growth factor (VEGF) and methylenetetrahydrofolate reductase (MTHFR)
   gene in patients with hepatocellular carcinoma and hepatitis C virus
   infection
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 52nd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 19-23, 2017
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver
C1 [Carvalho, S. C. R. D.; Tomitao, M. T.; Ribeiro, U., Jr.; Oliveira, C. P.; Carrilho, F. J.] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Carvalho, S. C. R. D.; Aroucha, D. C. B. L.; Pereira, L. M. M. B.] Osvaldo Cruz Univ Hosp UPE, Dept Gastroenterol, Recife, PE, Brazil.
   [Carvalho, S. C. R. D.; Vasconcelos, L. R. S.; Aroucha, D. C. B. L.; Pereira, L. M. M. B.] Inst Liver & Transplantat Pernambuco, Recife, PE, Brazil.
   [Vasconcelos, L. R. S.] Res Ctr Aggeu Magalhaes Fiocruz PE, Recife, PE, Brazil.
   [Carmo, R. F.] Fed Univ Sao Francisco Valley UNIVASF, Petrolina, Brazil.
   [Aroucha, D. C. B. L.; Pereira, L. M. M. B.] Univ Pernambuco, Sch Med, Dept Gastroenterol, Recife, PE, Brazil.
EM sylenerampche@hotmail.com
RI Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012;
   Vasconcelos, Luydson/AAC-4907-2020; Ribeiro, Ulysses/G-5942-2012
OI Vasconcelos, Luydson/0000-0002-1625-3358; Ribeiro,
   Ulysses/0000-0003-1711-7347
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2017
VL 66
IS 1
SU S
MA SAT-076
BP S619
EP S620
DI 10.1016/S0168-8278(17)31682-3
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EU5FI
UT WOS:000401056601525
DA 2020-12-08
ER

PT J
AU Duarte, SM
   Stefano, JT
   Miele, L
   Ponziani, FR
   Souza, M
   Rodrigues, L
   Costa, FG
   Toda, K
   Mazo, DF
   Sabino, EC
   Carrilho, FJ
   Gasbarrini, A
   Oliveira, CP
AF Duarte, S. M.
   Stefano, J. T.
   Miele, L.
   Ponziani, F. R.
   Souza, M.
   Rodrigues, L.
   Costa, F. G.
   Toda, K.
   Mazo, D. F.
   Sabino, E. C.
   Carrilho, F. J.
   Gasbarrini, A.
   Oliveira, C. P.
TI The gut microbiome of lean patients with non-alcoholic steatohepatitis:
   comparison with overweight/obese counterparts and healthy subjects,
   correlation with dietary intake and liver histology
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 52nd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 19-23, 2017
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver
C1 [Duarte, S. M.; Stefano, J. T.; Rodrigues, L.; Costa, F. G.; Toda, K.; Mazo, D. F.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Miele, L.; Ponziani, F. R.; Gasbarrini, A.] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, Div Internal Med Gastroenterol & Hepatol, Rome, Italy.
   [Souza, M.; Sabino, E. C.] Univ Sao Paulo, Sch Med, Infect Dis, Sao Paulo, Brazil.
   [Souza, M.; Sabino, E. C.] Univ Sao Paulo, Sch Med, Inst Trop Med, Sao Paulo, Brazil.
EM cpm@usp.br
RI Carrilho, Flair J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014;
   Gasbarrini, Antonio/AAB-8487-2019; Sabino, Ester Cerdeira/F-7750-2010;
   Mazo, Daniel FC/D-5631-2015; Stefano, Jose Tadeu/AAH-5419-2020
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Mazo, Daniel
   FC/0000-0002-2164-2630; Stefano, Jose Tadeu/0000-0002-0218-1920
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2017
VL 66
IS 1
SU S
MA THU-380
BP S166
EP S167
DI 10.1016/S0168-8278(17)30611-6
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EU5FI
UT WOS:000401056600349
DA 2020-12-08
ER

PT J
AU Linhares, LM
   Oliveira, CP
   Alvares-Da-Silva, MR
   Stefano, JT
   Gebrim, EM
   Barbeiro, HV
   Barbeiro, DF
   Terrabuio, DR
   Abdala, E
   Soriano, FG
   Carrilho, FJ
   Farias, AQ
   Augusto, L
   Albuquerque, CD
AF Linhares, L. M.
   Oliveira, C. P.
   Alvares-Da-Silva, M. R.
   Stefano, J. T.
   Gebrim, E. M.
   Barbeiro, H. V.
   Barbeiro, D. F.
   Terrabuio, D. R.
   Abdala, E.
   Soriano, F. G.
   Carrilho, F. J.
   Farias, A. Q.
   Augusto, L.
   Albuquerque, C. D'
TI Cardiovascular risk and coronary artery calcium score after liver
   transplantation: study at fouth year
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 52nd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 19-23, 2017
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver
C1 [Linhares, L. M.; Oliveira, C. P.; Stefano, J. T.; Terrabuio, D. R.; Carrilho, F. J.; Farias, A. Q.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Alvares-Da-Silva, M. R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Gastroenterol, Porto Alegre, RS, Brazil.
   [Gebrim, E. M.] Univ Sao Paulo, Sch Med, Radiol, Sao Paulo, Brazil.
   [Barbeiro, H. V.; Barbeiro, D. F.; Soriano, F. G.] Univ Sao Paulo, Sch Med, Div Emergency Med LIM 51, Sao Paulo, Brazil.
   [Abdala, E.; Albuquerque, C. D'] Univ Sao Paulo, Sch Med, Gastroenterol LIM 37, Sao Paulo, Brazil.
EM cpm@usp.br
RI Stefano, Jose Tadeu/AAH-5419-2020; Soriano, Francisco/C-3382-2012;
   Farias, Alberto/ABB-1291-2020; Carrilho, Flair J/I-3046-2012; Oliveira,
   Claudia PMS/D-1216-2014; Barbeiro, Hermes V/E-2814-2010; Barbeiro,
   Hermes V/S-5926-2016; Abdala, Edson/H-5165-2012
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Soriano,
   Francisco/0000-0003-4898-0135; Farias, Alberto/0000-0002-5572-663X;
   Barbeiro, Hermes V/0000-0002-8209-4463; Barbeiro, Hermes
   V/0000-0002-8209-4463; Abdala, Edson/0000-0003-0765-6654
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2017
VL 66
IS 1
SU S
MA FRI-492
BP S439
EP S439
DI 10.1016/S0168-8278(17)31249-7
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EU5FI
UT WOS:000401056601092
DA 2020-12-08
ER

PT J
AU Shah, ND
   Cots, MV
   Zhang, C
   Zahiragic, N
   Yu, Y
   Yacoub, M
   Wu, P
   Wandera, A
   Vorobioff, J
   Traquino, ESDS
   Thurairajah, PH
   Tan, S
   Spreckic, S
   Soler, ERA
   Sivac, N
   Siow, W
   Scheurich, C
   Saaez-Royuela, F
   Rodil, A
   Reis, D
   Ono, S
   Nabeshima, M
   Kiong, TE
   Karoney, M
   Gui, W
   Fernaandez, MC
   Farias, A
   Domech, CR
   Costa, PM
   Biryukova, M
   Alfadhli, A
   Yang, L
   Some, F
   Kochhar, R
   Kluwe, J
   Kim, W
   Isakov, V
   Husic-Selimovic, A
   Hsiang, J
   George, J
   El Kassas, M
   Dorta, Z
   Carrilho, FJ
   Bessone, F
   Aranda, EB
   Alboraie, M
   Cortez-Pinto, H
   Bataller, R
AF Shah, N. D.
   Cots, M. V.
   Zhang, C.
   Zahiragic, N.
   Yu, Y.
   Yacoub, M.
   Wu, P.
   Wandera, A.
   Vorobioff, J.
   Traquino, E. S. D. S.
   Thurairajah, P. H.
   Tan, S.
   Spreckic, S.
   Soler, E. R. A.
   Sivac, N.
   Siow, W.
   Scheurich, C.
   Saez-Royuela, F.
   Rodil, A.
   Reis, D.
   Ono, S.
   Nabeshima, M.
   Kiong, T. E.
   Karoney, M.
   Gui, W.
   Fernandez, M. C.
   Farias, A.
   Domech, C. R.
   Costa, P. M.
   Biryukova, M.
   Alfadhli, A.
   Yang, L.
   Some, F.
   Kochhar, R.
   Kluwe, J.
   Kim, W.
   Isakov, V.
   Husic-Selimovic, A.
   Hsiang, J.
   George, J.
   El Kassas, M.
   Dorta, Z.
   Carrilho, F. J.
   Bessone, F.
   Aranda, E. B.
   Alboraie, M.
   Cortez-Pinto, H.
   Bataller, R.
TI Worldwide lack of early referral of patients with alcoholic liver
   disease: results of the global alcoholic liver disease survey (GLADIS)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 52nd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 19-23, 2017
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver
C1 [Shah, N. D.; Bataller, R.] UNC Hosp, Div Gastroenterol & Hepatol, Chapel Hill, NC USA.
   [Cots, M. V.] UNC Hosp, Chapel Hill, NC USA.
   [Cots, M. V.] Hosp Univ Vall dHebron, Barcelona, Spain.
   [Zhang, C.; Yu, Y.; Wu, P.; Tan, S.; Yang, L.] Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China.
   [Zahiragic, N.; Spreckic, S.; Sivac, N.; Husic-Selimovic, A.] Sarajevo Univ, Ctr Clin, Inst Gastroenterol, Sarajevo, Bosnia & Herceg.
   [Yacoub, M.; El Kassas, M.] Helwan Univ, Cairo, Egypt.
   [Wandera, A.; Karoney, M.] Moi Univ, Dept Med, Eldoret, Kenya.
   [Vorobioff, J.; Rodil, A.; Bessone, F.] Univ Rosario, Sch Med, Dept Gastroenterol & Hepatol, Rosario, Santa Fe, Argentina.
   [Traquino, E. S. D. S.; Soler, E. R. A.; Fernandez, M. C.; Domech, C. R.] Inst Gastroenterol, Havana, Cuba.
   [Thurairajah, P. H.; Kiong, T. E.; Hsiang, J.] Changi Gen Hosp, Dept Gastroenterol & Hepatol, Singapore, Singapore.
   [Siow, W.] Westmead Millennium Inst, Storr Liver Ctr, Westmead, NSW, Australia.
   [Siow, W.; George, J.] Westmead Hosp, Westmead, NSW, Australia.
   [Scheurich, C.; Kluwe, J.] Hamburg Univ, Med Ctr, Dept Gastroenterol, Hamburg, Germany.
   [Saez-Royuela, F.] Univ Hosp Burgos, Dept Gastroenterol, Burgos, Spain.
   [Reis, D.; Costa, P. M.; Cortez-Pinto, H.] Univ Lisbon, Dept Gastrenterol & Hepatol, Lisbon, Portugal.
   [Ono, S.; Nabeshima, M.; Farias, A.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Gui, W.; Yang, L.] Huazhong Univ Sci & Technol, Union Hosp, Div Gastroenterol, Wuhan, Peoples R China.
   [Biryukova, M.; Isakov, V.] Inst Nutr, Dept Gastroenterol & Hepatol, Moscow, Russia.
   [Alfadhli, A.] Haya Al Habeeb Gastroenterol Ctr, Jabriya, Kuwait.
   [Some, F.] Moi Univ, Eldoret, Kenya.
   [Kochhar, R.] Postgrad Inst Med Educ & Res, Dept Gastroenterol, Chandigarh, India.
   [Kim, W.] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Div Gastroenterol & Hepatol, Seoul, South Korea.
   [George, J.] Westmead Millennium Inst, Westmead, NSW, Australia.
   [Dorta, Z.] Inst Gastroenterol, Dept Hepatol, Havana, Cuba.
   [Aranda, E. B.] Univ Hosp Burgos, Burgos, Spain.
   [Alboraie, M.] Al Azhar Univ, Cairo, Egypt.
EM neil.shah2@unchealth.unc.edu
RI Kassas, Mohamed El/AAD-6987-2020; /A-4876-2011; Cortez-Pinto,
   Helena/AAN-2712-2020; Carrilho, Flair J/I-3046-2012; Cortez-Pinto,
   Helena/A-3586-2012
OI Kassas, Mohamed El/0000-0002-3396-6894; /0000-0002-4417-8076;
   Cortez-Pinto, Helena/0000-0002-8537-8744; 
NR 0
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2017
VL 66
IS 1
SU S
MA LBP-529
BP S107
EP S108
DI 10.1016/S0168-8278(17)30474-9
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EU5FI
UT WOS:000401056600212
DA 2020-12-08
ER

PT J
AU Filho, HML
   Fabrega, P
   Chua-Anusorn, W
   Oliveira, CP
   Carrilho, FJ
   Lima, F
   Cercato, C
   Clark, P
   Rocha, M
AF Filho, H. M. L.
   Fabrega, P.
   Chua-Anusorn, W.
   Oliveira, C. P.
   Carrilho, F. J.
   Lima, F.
   Cercato, C.
   Clark, P.
   Rocha, M.
TI Hepatic iron overload analysis bymagnetic resonance imaging in a
   non-alcoholic fatty liver disease population
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 52nd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 19-23, 2017
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver
C1 [Filho, H. M. L.; Rocha, M.] Univ Sao Paulo, Sch Med, Dept Radiol, Sao Paulo, Brazil.
   [Fabrega, P.; Cercato, C.] Univ Sao Paulo, Sch Med, Dept Endocrinol, Sao Paulo, Brazil.
   [Chua-Anusorn, W.; Clark, P.] MagnePath, Perth, WA, Australia.
   [Oliveira, C. P.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Lima, F.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
EM hilton.filho@hc.fm.usp.br
RI Carrilho, Flair J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014; Lima,
   Fabiano Guasti/R-7708-2016
OI Lima, Fabiano Guasti/0000-0003-4776-3673
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2017
VL 66
IS 1
SU S
MA THU-502
BP S244
EP S245
DI 10.1016/S0168-8278(17)30794-8
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EU5FI
UT WOS:000401056600531
DA 2020-12-08
ER

PT J
AU Filho, HML
   Chua-Anusorn, W
   Oliveira, CP
   Carrilho, FJ
   Lima, F
   Alves, V
   Clark, P
   Rocha, M
AF Filho, H. M. L.
   Chua-Anusorn, W.
   Oliveira, C. P.
   Carrilho, F. J.
   Lima, F.
   Alves, V.
   Clark, P.
   Rocha, M.
TI Novel mapping of fibrosis and hepatic inflammation in NASH patients with
   dual R2 MRI relaxometry
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 52nd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 19-23, 2017
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver
C1 [Filho, H. M. L.; Rocha, M.] Univ Sao Paulo, Sch Med, Dept Radiol, Sao Paulo, Brazil.
   [Chua-Anusorn, W.; Clark, P.] MagnePath, Perth, WA, Australia.
   [Oliveira, C. P.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Dept Gastroenterolgy, Sao Paulo, Brazil.
   [Lima, F.; Alves, V.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
EM hilton.filho@hc.fm.usp.br
RI Lima, Fabiano Guasti/R-7708-2016; Carrilho, Flair J/I-3046-2012;
   Oliveira, Claudia PMS/D-1216-2014
OI Lima, Fabiano Guasti/0000-0003-4776-3673; 
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2017
VL 66
IS 1
SU S
MA THU-501
BP S243
EP S244
DI 10.1016/S0168-8278(17)30793-6
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EU5FI
UT WOS:000401056600530
DA 2020-12-08
ER

PT J
AU Oliveira, CP
   Cotrim, HP
   Cristina, A
   Siqueira, G
   Salgado, ALA
   Stefano, JT
   Brizolla, P
   Mattos, L
   Martins, AHB
   Andrade, AR
   Sciuto, R
   Freitas, LA
   Alves, VAF
   Carrilho, FJ
   Parise, ER
AF Oliveira, C. P.
   Cotrim, H. P.
   Cristina, A.
   Siqueira, G.
   Salgado, A. L. A.
   Stefano, J. T.
   Brizolla, P.
   Mattos, L.
   Martins, A. H. B.
   Andrade, A. R.
   Sciuto, R.
   Freitas, L. A.
   Alves, V. A. F.
   Carrilho, F. J.
   Parise, E. R.
TI Combination of long term N-Acetylcysteine and Ursodeoxycolic Acid in
   NASH: a multicenter randomized control trial
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 52nd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 19-23, 2017
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver
C1 [Oliveira, C. P.; Stefano, J. T.; Brizolla, P.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Cotrim, H. P.; Cristina, A.; Mattos, L.; Andrade, A. R.; Freitas, L. A.] Univ Fed Bahia, Sch Med, Gastroenterol, Salvador, BA, Brazil.
   [Salgado, A. L. A.; Martins, A. H. B.; Parise, E. R.] Univ Fed Sao Paulo, Gastroenterol, Sao Paulo, Brazil.
   [Sciuto, R.] Sch Med Uruguay UDELAR, Quantitat Methods, Montevideo, Uruguay.
   [Alves, V. A. F.] Univ Sao Paulo, Sch Med, Pathol LIM 14, Sao Paulo, Brazil.
EM cpm@usp.br
RI Stefano, Jose Tadeu/AAH-5419-2020; Carrilho, Flair J/I-3046-2012;
   Oliveira, Claudia PMS/D-1216-2014
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2017
VL 66
IS 1
SU S
MA THU-346
BP S152
EP S153
DI 10.1016/S0168-8278(17)30577-9
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EU5FI
UT WOS:000401056600315
DA 2020-12-08
ER

PT J
AU Toda, KS
   Stefano, JT
   Costa, FB
   Cavaleiro, AM
   Mazo, DF
   Carrilho, FJ
   Correa-Giannella, ML
   Oliveira, CP
AF Toda, K. S.
   Stefano, J. T.
   Costa, F. B.
   Cavaleiro, A. M.
   Mazo, D. F.
   Carrilho, F. J.
   Correa-Giannella, M. L.
   Oliveira, C. P.
TI Influence of UCP3 gene polymorphisms on metabolic syndrome and
   cardiovascular risk in patients with in non-alcoholic fatty liver
   disease
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 52nd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 19-23, 2017
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver
C1 [Toda, K. S.; Stefano, J. T.; Costa, F. B.; Mazo, D. F.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Cavaleiro, A. M.; Correa-Giannella, M. L.] Univ Sao Paulo, Sch Med, Endocrinol LIM 25, Sao Paulo, Brazil.
EM cpm@usp.br
RI Stefano, Jose Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014;
   Giannella, Maria Lucia/N-3834-2019; Carrilho, Flair J/I-3046-2012; Mazo,
   Daniel FC/D-5631-2015
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Mazo, Daniel
   FC/0000-0002-2164-2630
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2017
VL 66
IS 1
SU S
MA THU-381
BP S167
EP S167
DI 10.1016/S0168-8278(17)30612-8
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EU5FI
UT WOS:000401056600350
DA 2020-12-08
ER

PT J
AU Noble, CF
   Malta, F
   Lisboa-Neto, G
   Gomes-Gouvea, MS
   Leite, AGB
   de Castro, VFD
   Santana, RAF
   Carrilho, FJ
   Mendes-Correa, MC
   Pinho, JRR
AF Noble, Caroline Furtado
   Malta, Fernanda
   Lisboa-Neto, Gaspar
   Gomes-Gouvea, Michele Soares
   Batista Leite, Andrea Gurgel
   Duarte de Castro, Vanessa Fusco
   Ferraz Santana, Rubia Anita
   Carrilho, Flair Jose
   Mendes-Correa, Maria Cassia
   Rebello Pinho, Joao Renato
TI Natural occurrence of NS5B inhibitor resistance-associated variants in
   Brazilian patients infected with HCV or HCV and HIV
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID DIRECT-ACTING ANTIVIRALS; CHRONIC HEPATITIS-C; VIRUS POLYMERASE;
   SOFOSBUVIR; RIBAVIRIN; GENOTYPES; EPIDEMIOLOGY; SENSITIVITY; THERAPY
AB Resistance-associated variants (RAVs) represent a challenge to the success of new HCV therapies. The aim of this study was to describe the prevalence of naturally occurring NS5B RAVs in Brazilian direct acting antivirals (DAA)-na < ve patients infected with HCV genotype 1, or co-infected with HIV. Patient enrollment and sample collection were performed between 2011 and 2013. Using Sanger-based sequencing, 244 sequences were obtained. RAVs detected in HCV-1a sequences were V321A (1.6 %), M414V (1.3 %), A421V (21.4-23.7 %), A421G (1.3 %) and Y448H (1.3 %); and in HCV-1b sequences were L159F (16.1 %), C316N (7.1-16.3 %) and A421V (3.2-6.3 %). Understanding the real RAVs scenario in patients is fundamental to establishing the most effective therapeutic strategy and in minimizing the risks for their selection.
C1 [Noble, Caroline Furtado; Malta, Fernanda; Gomes-Gouvea, Michele Soares; Rebello Pinho, Joao Renato] Univ Sao Paulo, Inst Trop Med, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, Ave Dr Eneas Carvalho Aguiar 500,2nd Floor IMT II, BR-05403000 Sao Paulo, SP, Brazil.
   [Noble, Caroline Furtado; Malta, Fernanda; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Lisboa-Neto, Gaspar; Mendes-Correa, Maria Cassia] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, SP, Brazil.
   [Batista Leite, Andrea Gurgel] Ctr Hlth, Caxias Do Sul, RS, Brazil.
   [Duarte de Castro, Vanessa Fusco; Ferraz Santana, Rubia Anita; Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
   [Mendes-Correa, Maria Cassia] Univ Sao Paulo, Inst Trop Med, Virol Lab, LIM 52, Sao Paulo, SP, Brazil.
RP Malta, F (corresponding author), Univ Sao Paulo, Inst Trop Med, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, Ave Dr Eneas Carvalho Aguiar 500,2nd Floor IMT II, BR-05403000 Sao Paulo, SP, Brazil.; Malta, F (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, SP, Brazil.
EM femalta@yahoo.com
RI Pinho, Joao R. R./G-2850-2012; Malta, Fernanda/B-1316-2013; Carrilho,
   Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; 
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2011/506334]; Alves de Queiroz Family Fund
   for Research; CNPq (Bolsista de Produtividade)National Council for
   Scientific and Technological Development (CNPq); CAPEsCAPES
FX This project was supported by grant 2011/506334 Sao Paulo Research
   Foundation (FAPESP) and Alves de Queiroz Family Fund for Research. Joao
   Renato Rebello Pinho and Maria Cassia Mendes Correa receive fellowships
   from CNPq (Bolsista de Produtividade). Caroline Furtado Noble is a
   graduate student from the Department of Gastroenterology at the
   University of Sao Paulo who received a fellowship from CAPEs.
CR Andre-Garnier E, 2016, ANTIVIR THER, V21, P611, DOI 10.3851/IMP3053
   Patino-Galindo JA, 2016, ANTIMICROB AGENTS CH, V60, P2402, DOI 10.1128/AAC.02776-15
   Bartels DJ, 2013, J VIROL, V87, P1544, DOI 10.1128/JVI.02294-12
   Castilho MCB, 2011, MEM I OSWALDO CRUZ, V106, P968, DOI 10.1590/S0074-02762011000800011
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Donaldson EF, 2015, HEPATOLOGY, V61, P56, DOI 10.1002/hep.27375
   Eltahla AA, 2015, VIRUSES-BASEL, V7, P5206, DOI 10.3390/v7102868
   Everson GT, 2016, LIVER INT, V36, P189, DOI 10.1111/liv.12964
   Feld JJ, 2014, SEMIN LIVER DIS, V34, P37, DOI 10.1055/s-0034-1371009
   Franco S, 2013, J CLIN VIROL, V58, P726, DOI 10.1016/j.jcv.2013.09.022
   Gamal N, 2015, DRUG TODAY, V51, P303, DOI 10.1358/dot.2015.51.5.2332992
   Gane EJ, 2013, NEW ENGL J MED, V368, P34, DOI 10.1056/NEJMoa1208953
   Gaudieri S, 2009, HEPATOLOGY, V49, P1069, DOI 10.1002/hep.22773
   Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
   Hajarizadeh B, 2013, NAT REV GASTRO HEPAT, V10, P553, DOI 10.1038/nrgastro.2013.107
   Halfon P, 2012, LIVER INT, V32, P79, DOI 10.1111/j.1478-3231.2011.02716.x
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   Hedskog C, 2015, J VIRAL HEPATITIS, V22, P871, DOI 10.1111/jvh.12405
   Ito J, 2016, HEPATOL RES
   Larousse JA, 2014, J MED VIROL, V86, P1350, DOI 10.1002/jmv.23958
   Lawitz E, 2015, ANN NY ACAD SCI, V1358, P56, DOI 10.1111/nyas.12832
   Lawitz E, 2013, J HEPATOL, V59, P18, DOI 10.1016/j.jhep.2013.02.009
   Legrand-Abravanel F, 2009, ANTIVIR THER, V14, P723
   Nguyen LT, 2016, ANTIVIR THER, V21, P447, DOI 10.3851/IMP3025
   Lontok E, 2015, HEPATOLOGY, V62, P1623, DOI 10.1002/hep.27934
   Ludmerer SW, 2005, ANTIMICROB AGENTS CH, V49, P2059, DOI 10.1128/AAC.49.5.2059-2069.2005
   McQuaid T, 2015, J CLIN TRANSL HEPATO, V3, P27, DOI 10.14218/JCTH.2014.00041
   Morsica G, 2009, JAIDS-J ACQ IMM DEF, V51, P574, DOI 10.1097/QAI.0b013e3181add592
   Pawlotsky JM, 2015, GASTROENTEROLOGY, V148, P468, DOI 10.1053/j.gastro.2015.01.002
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Rockstroh JK, 2015, LIVER INT, V35, P51, DOI 10.1111/liv.12721
   Sulkowski Mark S, 2003, Clin Liver Dis, V7, P179, DOI 10.1016/S1089-3261(02)00074-0
   Svarovskaia ES, 2016, J INFECT DIS, V213, P1240, DOI 10.1093/infdis/jiv564
   Svarovskaia ES, 2014, CLIN INFECT DIS, V59, P1666, DOI 10.1093/cid/ciu697
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Weber R, 2006, ARCH INTERN MED, V166, P1632
NR 36
TC 10
Z9 10
U1 0
U2 4
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD JAN
PY 2017
VL 162
IS 1
BP 165
EP 169
DI 10.1007/s00705-016-3094-2
PG 5
WC Virology
SC Virology
GA EI3IO
UT WOS:000392383900017
PM 27704215
DA 2020-12-08
ER

PT J
AU Medeiros, RP
   Mazo, DF
   Oliveira, CP
   Dodge, JL
   Zitelli, PM
   Lopes, MH
   Carrilho, FJ
   Pinho, JR
   Terrault, N
   Pessoa, MG
AF Medeiros, Roseane P.
   Mazo, Daniel F.
   Oliveira, Claudia P.
   Dodge, Jennifer L.
   Zitelli, Patricia M.
   Lopes, Marta H.
   Carrilho, Flair J.
   Pinho, Joao R.
   Terrault, Norah
   Pessoa, Mario G.
TI Impaired Anti-HBV Vaccine Response In Non-Cirrhotic Chronic HCV Patients
   Is Not Overcome By Double Or Additional (4th) Dosing
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 67th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 11-15, 2016
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Medeiros, Roseane P.; Mazo, Daniel F.; Oliveira, Claudia P.; Zitelli, Patricia M.; Lopes, Marta H.; Carrilho, Flair J.; Pinho, Joao R.; Pessoa, Mario G.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Dodge, Jennifer L.; Terrault, Norah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RI Lopes, Marta H/J-3285-2012; Mazo, Daniel FC/D-5631-2015; Carrilho, Flair
   J/I-3046-2012; Dodge, Jennifer/AAY-2530-2020; Oliveira, Claudia
   PMS/D-1216-2014; Pinho, Joao R. R./G-2850-2012
OI Mazo, Daniel FC/0000-0002-2164-2630; Pinho, Joao R.
   R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2016
VL 64
SU 1
MA 1812
BP 894A
EP 895A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DY9YT
UT WOS:000385493804174
DA 2020-12-08
ER

PT J
AU Ximenes, RO
   Helou, C
   Barbeiro, DF
   Souza, H
   Migita, B
   D'Albuquerque, LC
   Carrilho, FJ
   Farias, AO
AF Ximenes, Rafael O.
   Helou, Claudia
   Barbeiro, Denise F.
   Souza, Heraldo
   Migita, Beatriz
   D'Albuquerque, Luiz C.
   Carrilho, Flair J.
   Farias, Alberto O.
TI Urinary NGAL biomarker predicts non response to therapy with albumin and
   terlipressin in patients with hepatorenal syndrome
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 67th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 11-15, 2016
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Ximenes, Rafael O.; Migita, Beatriz; D'Albuquerque, Luiz C.; Carrilho, Flair J.; Farias, Alberto O.] Hosp Clin FMUSP, Gastroenterol, Goiania, Go, Brazil.
   [Helou, Claudia] Hosp Clin FMUSP, Nephrol, Goiania, Go, Brazil.
   [Helou, Claudia] Univ Sao Paulo, Fac Med, LIM 12, Sao Paulo, Brazil.
   [Barbeiro, Denise F.; Souza, Heraldo] Univ Sao Paulo, Fac Med, LIM 51, Sao Paulo, Brazil.
   [Souza, Heraldo] Hosp Clin FMUSP, Emergency, Sao Paulo, Brazil.
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Carrilho, Flair
   J/I-3046-2012; Helou, Claudia/J-8868-2012
OI Helou, Claudia/0000-0002-2228-6041
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2016
VL 64
SU 1
MA 2080
BP 1035A
EP 1035A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DY9YT
UT WOS:000385493804440
DA 2020-12-08
ER

PT J
AU Chan, AJ
   Balderramo, D
   Kikuchi, L
   Ballerga, EG
   Prieto, J
   Tapias, M
   Idrovo, V
   Davalos, M
   Cairo, F
   Barreyro, F
   Paredes, S
   Hernandez, N
   Avendano, K
   Ferrer, JD
   Yangi, JD
   Carrera, E
   Rodriguez, P
   Hirsch, B
   Mattos, AZ
   Carrilho, FJ
   Roberts, LR
   Debes, J
AF Chan, Aaron J.
   Balderramo, Domingo
   Kikuchi, Luciana
   Ballerga, Esteban Gonzalez
   Prieto, Jhon
   Tapias, Monica
   Idrovo, Victor
   Davalos, Milagros
   Cairo, Fernando
   Barreyro, Fernando
   Paredes, Sebastian
   Hernandez, Nelia
   Avendano, Karla
   Ferrer, Javier Diaz
   Yang, Ju Dong
   Carrera, Enrique
   Rodriguez, Pablo
   Hirsch, Bruno
   Mattos, Angelo Z.
   Carrilho, Flair J.
   Roberts, Lewis R.
   Debes, Jose
TI Hepatitis B and C as Risk Factors for Early Hepatocellular Carcinoma
   Across South America
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 67th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 11-15, 2016
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Chan, Aaron J.; Debes, Jose] Univ Minnesota, St Paul, MN 55108 USA.
   [Balderramo, Domingo] Hosp Privado, Cordoba, Argentina.
   [Kikuchi, Luciana; Carrilho, Flair J.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Ballerga, Esteban Gonzalez] Hosp Clin Buenos Aires, Buenos Aires, DF, Argentina.
   [Prieto, Jhon; Tapias, Monica; Idrovo, Victor] Org Sanitas, Bogota, Colombia.
   [Tapias, Monica; Idrovo, Victor] Hosp Univ Fdn Santa Fe, Bogota, Colombia.
   [Davalos, Milagros; Ferrer, Javier Diaz] HNERM, Lima, Peru.
   [Cairo, Fernando] Hosp El Cruce, Buenos Aires, DF, Argentina.
   [Barreyro, Fernando] Consejo Nacl Invest Cient & Tecn, Posadas, Argentina.
   [Paredes, Sebastian] Hosp Presidente Peron, Formosa, Argentina.
   [Hernandez, Nelia; Avendano, Karla] Univ Republica, Montevideo, Uruguay.
   [Yang, Ju Dong; Roberts, Lewis R.] Mayo Clin, Rochester, MN USA.
   [Carrera, Enrique] Hosp Eugenio Espejo, Quito, Ecuador.
   [Rodriguez, Pablo; Hirsch, Bruno; Mattos, Angelo Z.] HNSC, Porto Alegre, RS, Brazil.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2016
VL 64
SU 1
MA 1341
BP 671A
EP 672A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DY9YT
UT WOS:000385493803148
DA 2020-12-08
ER

PT J
AU Chan, A
   Ballerga, E
   Kikuchi, L
   Prieto, JE
   Tapias, M
   Idrovo, V
   Davalos, M
   Cairo, F
   Barreyro, F
   Paredes, S
   Hirsch, B
   Goncalves, PR
   Hernandez, N
   Avendano, K
   Ferrer, JD
   Yang, JD
   Carrera, E
   Balderramo, D
   Mattos, AZ
   Carrilho, FJ
   Roberts, LR
   Debes, JD
AF Chan, Aaron
   Ballerga, Esteban
   Kikuchi, Luciana
   Edison Prieto, Jhon
   Tapias, Monica
   Idrovo, Victor
   Davalos, Milagros
   Cairo, Fernando
   Barreyro, Fernando
   Paredes, Sebastian
   Hirsch, Bruno
   Goncalves, Pablo Rodrigues
   Hernandez, Nelia
   Avendano, Karla
   Diaz Ferrer, Javier
   Yang, Ju Dong
   Carrera, Enrique
   Balderramo, Domingo
   Mattos, Angelo Z.
   Carrilho, Flair Jose
   Roberts, Lewis R.
   Debes, Jose D.
TI Hepatocellular Carcinoma in South America: Evaluating Factors for
   Curative Therapy and Survival
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 81st Annual Scientific Meeting of the
   American-College-of-Gastroenterology
CY OCT 21-26, 2016
CL Las Vegas, NV
SP Amer Coll Gastroenterol
C1 [Chan, Aaron; Debes, Jose D.] Univ Minnesota, Minneapolis, MN USA.
   [Ballerga, Esteban] Hosp Clin Buenos Aires, Buenos Aires, DF, Argentina.
   [Kikuchi, Luciana; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Edison Prieto, Jhon] Org Sanitas Bogota, Bogota, Distrito Capita, Colombia.
   [Tapias, Monica] Hepatol Clin, Bogota, Distrito Capita, Colombia.
   [Idrovo, Victor; Diaz Ferrer, Javier] HNERM, Lima, Peru.
   [Cairo, Fernando] Hosp El Cruce, Buenos Aires, DF, Argentina.
   [Barreyro, Fernando] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
   [Paredes, Sebastian] Hosp Alta Complejidad Juan Domingo Peron, Formosa, Formosa, Argentina.
   [Hirsch, Bruno; Goncalves, Pablo Rodrigues; Mattos, Angelo Z.] HNSC, Porto Alegre, RS, Brazil.
   [Hernandez, Nelia; Avendano, Karla] Univ Republica, Montevideo, Uruguay.
   [Yang, Ju Dong; Roberts, Lewis R.] Mayo Clin, Coll Med, Rochester, MN USA.
   [Carrera, Enrique] Hosp Eugenio Espejo, Quito, Ecuador.
   [Balderramo, Domingo] Hosp Privado, Cordoba, Argentina.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2016
VL 111
SU 1
MA 900
BP S392
EP S392
DI 10.14309/00000434-201610001-00900
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EN1IV
UT WOS:000395764601332
DA 2020-12-08
ER

PT J
AU Kikuchi, L
   Oliveira, CP
   Alvares-da-Silva, MR
   Tani, CM
   Diniz, MA
   Stefano, JT
   Chagas, AL
   Alencar, RSSM
   Vezozzo, DCP
   Santos, GR
   Campos, PB
   Alves, VAF
   Ratziu, V
   Carrilho, FJ
AF Kikuchi, Luciana
   Oliveira, Claudia P.
   Alvares-da-Silva, Mario R.
   Tani, Claudia M.
   Diniz, Marcio A.
   Stefano, Jose T.
   Chagas, Aline L.
   Alencar, Regiane S. S. M.
   Vezozzo, Denise C. P.
   Santos, Gilmar R.
   Campos, Priscila B.
   Alves, Venancio A. F.
   Ratziu, Vlad
   Carrilho, Flair J.
TI Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease
   Patients Applicability of the BCLC Staging System
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Article
DE nonalcoholic fatty liver disease; hepatocellular carcinoma; BCLC staging
   system; liver cancer; management
ID OUTCOMES
AB Background/Aims: Nonalcoholic fatty liver disease (NAFLD) has emerged as an important cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). The Barcelona Clinic Liver Cancer (BCLC) system is the preferred staging system to evaluate patients with HCC and links prognosis assessment with treatment recommendation. The aim of this retrospective study was to evaluate whether the BCLC staging system and its treatment algorithm are suitable for,patients with HCC arising from NAFLD.
   Methods: Forty-two patients with HCC related to either to NAFLD or cryptogenic cirrhosis were retrieved retrospectively from 2 centers in Brazil. Patients were classified according to BCLC staging system. If the proposed HCC therapy could not be applied, the case was considered to represent deviations from the recommended BCLC guideline. Causes of treatment deviations were investigated.
   Results: There were 4 patients without evidence of cirrhosis according to liver biopsy and/or clinical evaluation. One (2%), 21 (50%), 10 (24%), 5 (12%), and 5 patients (12%) were classified initially to the very early (0), early (A), intermediate (B), advanced (C), and terminal (D) BCLC stages, respectively. Thirty-five patients (83%) were treated according to BCLC recommendations. There were 3 cases (of 5) of protocol deviation in BCLC C patients. The 1- and 2-year overall survival rates were 81% and 66%, respectively.
   Conclusions: The BCLC system is applied in most cases of NAFLD-related HCC cases. Deviation of BCLC is found more frequently in BCLC C stage patients.
C1 [Kikuchi, Luciana; Oliveira, Claudia P.; Tani, Claudia M.; Diniz, Marcio A.; Stefano, Jose T.; Chagas, Aline L.; Alencar, Regiane S. S. M.; Vezozzo, Denise C. P.; Santos, Gilmar R.; Campos, Priscila B.; Alves, Venancio A. F.; Carrilho, Flair J.] Univ Sao Paulo, Sao Paulo Clin Liver Canc Grp, Dept Gastroenterol & Pathol, Hosp Clin,Inst Canc Estado Sao Paulo,Sch Med, Sao Paulo, Brazil.
   [Alvares-da-Silva, Mario R.] Univ Fed Rio Grande do Sul, Div Gastroenterol, Hosp Clin Porto Alegre, Sch Med, Porto Alegre, RS, Brazil.
   [Ratziu, Vlad] Hop La Pitie Salpetriere, Serv Hepatogasteroenterol, Paris, France.
RP Kikuchi, L (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Arnaldo 251,19th Floor,18, BR-01246000 Sao Paulo, Brazil.
EM lucianakikuchi@usp.br
RI Alvares-da-Silva, Mario Reis/L-3910-2014; Stefano, Jose T/H-4792-2013;
   Carrilho, Flair J/I-3046-2012; Chagas, Aline Lopes/X-2059-2019;
   Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014; Stefano, Jose
   Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014
OI Alvares-da-Silva, Mario Reis/0000-0002-5001-246X; Paranagua-Vezozzo,
   Denise Cerqueira/0000-0002-9606-4935; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Diniz, Marcio Augusto/0000-0002-2427-7843
FU Alves de Queiroz Family Fund for Research
FX The authors thank Alves de Queiroz Family Fund for Research for
   financial support and Laboratory of Epidemiology and Statistics of
   Department of Gastroenterology, School of Medicine University of Sao
   Paulo, SP, Brazil.
CR Bruix J, 1996, GASTROENTEROLOGY, V111, P1018, DOI 10.1016/S0016-5085(96)70070-7
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Chen CH, 2009, EUR J CANCER, V45, P1630, DOI 10.1016/j.ejca.2008.12.025
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Cillo U, 2006, J HEPATOL, V44, P723, DOI 10.1016/j.jhep.2005.12.015
   Duan XY, 2012, HEPATOB PANCREAT DIS, V11, P18, DOI 10.1016/S1499-3872(11)60120-3
   El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013
   Ferenci P, 2010, J GASTROINTEST LIVER, V19, P311
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Kawada N, 2009, J GASTROENTEROL, V44, P1190, DOI 10.1007/s00535-009-0112-0
   Kim BK, 2012, LIVER INT, V32, P1120, DOI 10.1111/j.1478-3231.2012.02811.x
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Marrero JA, 2005, HEPATOLOGY, V41, P707, DOI 10.1002/hep.20636
   McCullough Arthur J, 2004, Clin Liver Dis, V8, P521, DOI 10.1016/j.cld.2004.04.004
   Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29
   Reeves H, 2012, J HEPATOL, V56, pS3, DOI 10.1016/S0168-8278(12)60019-1
   Singal AK, 2013, TRANSPLANTATION, V95, P755, DOI 10.1097/TP.0b013e31827afb3a
   Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594
   Villanueva A, 2013, NAT REV GASTRO HEPAT, V10, P34, DOI 10.1038/nrgastro.2012.199
   Wakai T, 2011, J GASTROINTEST SURG, V15, P1450, DOI 10.1007/s11605-011-1540-8
   Yasui K, 2012, HEPATOL RES, V42, P767, DOI 10.1111/j.1872-034X.2012.00986.x
NR 21
TC 9
Z9 9
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3732
EI 1537-453X
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD OCT
PY 2016
VL 39
IS 5
BP 428
EP 432
DI 10.1097/COC.0000000000000134
PG 5
WC Oncology
SC Oncology
GA DY7WH
UT WOS:000385339500002
PM 25268068
OA Green Published
DA 2020-12-08
ER

PT J
AU da Costa, MZG
   Pires, JGL
   Nasser, PD
   Ferreira, CD
   Teixeira, ACD
   Paranagua-Vezozzo, DC
   Guarita, DR
   Carrilho, FJ
   Ono, SK
AF Gouvea da Costa, Marianges Zadrozny
   Lucatelli Pires, Julia Gloria
   Nasser, Paulo Dominguez
   Ferreira, Camila da Silva
   de Sa Teixeira, Ana Cristina
   Paranagua-Vezozzo, Denise Cerqueira
   Guarita, Dulce Reis
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI Frequency of Tabagism and N34S and P55S Mutations of Serine Peptidase
   Inhibitor, Kazal Type 1 (SPINK1) and R254W Mutation of Chymotrypsin C
   (CTRC) in Patients With Chronic Pancreatitis and Controls
SO PANCREAS
LA English
DT Article
DE epidemiology; etiology; chronic pancreatitis; genetics; smoking
ID CIGARETTE-SMOKING; PROTEASE INHIBITOR; RISK-FACTOR; GENE; NATIONWIDE;
   EPIDEMIOLOGY; ASSOCIATION; PREVALENCE; HEREDITARY; CANCER
AB Objective: This study aimed to investigate the association between chronic pancreatitis and smoking or genetic mutations.
   Methods: The study sample comprised 148 patients with chronic pancreatitis, 110 chronic alcoholic subjects without pancreatic disease, and 297 volunteer blood donors.
   Results: Of the patients with chronic pancreatitis, 74% had alcoholic etiology and 26% had idiopathic pancreatitis. The frequency of smoking was 91.4% in patients with alcoholic pancreatitis, higher than 73.3% in alcoholic subjects without pancreatitis (P < 0.01). The difference in smoking frequency was not significant between the patients with idiopathic pancreatitis and blood donors. The N34S mutation of serine peptidase inhibitor, Kazal type 1 (SPINK1) was found in 2.7% of patients with chronic alcoholic pancreatitis, in 5.3% of patients with idiopathic pancreatitis, and in 0.4% of blood donors (P = 0.02). The P55S mutation of SPINK1 was found in 2.7% of patients with alcoholic pancreatitis and in 0.7% of blood donors (P = 0.12). The R254W mutation of chymotrypsin C was found in 0.9% of patients with alcoholic pancreatitis, in 0.9% of chronic alcoholic subjects without pancreatitis, and in 0.4% of blood donors (P = 0.75). In all cases, the mutations were heterozygous.
   Conclusions: Smoking and the N34S mutation of SPINK1 were positively correlated with chronic pancreatitis.
C1 [Gouvea da Costa, Marianges Zadrozny; Lucatelli Pires, Julia Gloria; Nasser, Paulo Dominguez; Ferreira, Camila da Silva; de Sa Teixeira, Ana Cristina; Paranagua-Vezozzo, Denise Cerqueira; Guarita, Dulce Reis; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP da Costa, MZG (corresponding author), 834 Ap 102, BR-88010301 Florianopolis, SC, Brazil.
EM marianges.costa@gmail.com
RI Carrilho, Flair J/I-3046-2012; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Comissao de
   Aperfeicoamento de Pessoal do Nivel Superior (CAPES)CAPES; Alves de
   Queiroz Family Fund for Research
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Comissao de Aperfeicoamento de Pessoal do
   Nivel Superior (CAPES), and the Alves de Queiroz Family Fund for
   Research.
CR Andriulli A, 2010, PANCREAS, V39, P1205, DOI 10.1097/MPA.0b013e3181df27c0
   Aoun E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002003
   Balakrishnan V, 2008, J PANCREAS, V9, P593
   Bang UC, 2014, GASTROENTEROLOGY, V146, P989, DOI 10.1053/j.gastro.2013.12.033
   Bernardino Andrea L Ferreira, 2003, JOP, V4, P169
   Bhatia E, 2002, GASTROENTEROLOGY, V123, P1020, DOI 10.1053/gast.2002.36028
   Boulling A, 2007, EUR J HUM GENET, V15, P936, DOI 10.1038/sj.ejhg.5201873
   Brock C, 2013, WORLD J GASTROENTERO, V19, P7231, DOI 10.3748/wjg.v19.i42.7231
   Catalano MF, 2009, GASTROINTEST ENDOSC, V69, P1251, DOI 10.1016/j.gie.2008.07.043
   Chen JM, 2000, J MED GENET, V37, P67, DOI 10.1136/jmg.37.1.67
   Chiari H., 1896, Z HEILK, V17, P69
   Cote GA, 2011, CLIN GASTROENTEROL H, V9, P266, DOI 10.1016/j.cgh.2010.10.015
   Cunha R M, 1997, Rev Hosp Clin Fac Med Sao Paulo, V52, P306
   Damacena ACP, 2010, CENS DEM
   DANI R, 1990, PANCREAS, V5, P474, DOI 10.1097/00006676-199007000-00016
   Diaconu BL, 2009, J GASTROINTEST LIVER, V18, P143
   Drenth JPH, 2002, GUT, V50, P687, DOI 10.1136/gut.50.5.687
   Etemad B, 2001, GASTROENTEROLOGY, V120, P682, DOI 10.1053/gast.2001.22586
   Ferreira Cda S, 2013, PLOS ONE, V8
   Fortunato F, 2006, AM J PHYSIOL-GASTR L, V290, pG232, DOI 10.1152/ajpgi.00040.2005
   Friedreich N, 1878, CYCLOPOEDIA PRACTICE, pe27
   Frulloni L, 2009, DIGEST LIVER DIS, V41, P311, DOI 10.1016/j.dld.2008.07.316
   Gasiorowska A, 2011, DIGEST DIS SCI, V56, P894, DOI 10.1007/s10620-010-1349-4
   da Costa MZG, 2009, PANCREATOLOGY, V9, P173, DOI 10.1159/000178889
   Hirota M, 2012, PANCREATOLOGY, V12, P79, DOI 10.1016/j.pan.2012.02.005
   Kalinin VN, 2006, WORLD J GASTROENTERO, V12, P5352, DOI 10.3748/wjg.v12.i33.5352
   Kucheriavyi Iu A, 2011, Eksp Klin Gastroenterol, P7
   Laranjeira R, LEVANTAMENTO NACL PA, P1
   Lempinen M, 2005, SCAND J GASTROENTERO, V40, P225, DOI 10.1080/00365520510011560
   Lin Y, 2000, PANCREAS, V21, P109, DOI 10.1097/00006676-200008000-00001
   Masson E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073522
   Rasmussen HH, 2013, WORLD J GASTROENTERO, V19, P7267, DOI 10.3748/wjg.v19.i42.7267
   Rickels MR, 2013, PANCREATOLOGY, V13, P336, DOI 10.1016/j.pan.2013.05.002
   RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124
   Rosendahl J, 2008, NAT GENET, V40, P78, DOI 10.1038/ng.2007.44
   Ryu JK, 2005, DIGESTION, V72, P207, DOI 10.1159/000089414
   Shimosegawa T, 2006, J GASTROENTEROL HE S, V21
   Talamini G, 1996, PANCREAS, V12, P131, DOI 10.1097/00006676-199603000-00004
   Wang YL, 2006, PANCREAS, V32, P351, DOI 10.1097/01.mpa.0000220859.93496.e1
   Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141
   Witt H, 2001, JAMA-J AM MED ASSOC, V285, P2716, DOI 10.1001/jama.285.21.2716-a
   Yadav D, 2007, GASTROENTEROL CLIN N, V36, P219, DOI 10.1016/j.gtc.2007.03.005
   Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068
   Yadav D, 2011, AM J GASTROENTEROL, V106, P2192, DOI 10.1038/ajg.2011.328
   Yadav D, 2010, NAT REV GASTRO HEPAT, V7, P131, DOI 10.1038/nrgastro.2010.6
   Yadav D, 2009, ARCH INTERN MED, V169, P1035, DOI 10.1001/archinternmed.2009.125
   Zhou JY, 2011, J GASTROEN HEPATOL, V26, P1238, DOI 10.1111/j.1440-1746.2011.06791.x
NR 47
TC 2
Z9 2
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD OCT
PY 2016
VL 45
IS 9
BP 1330
EP 1335
DI 10.1097/MPA.0000000000000650
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DX1GA
UT WOS:000384112900018
PM 27253233
DA 2020-12-08
ER

PT J
AU Santos, MDC
   Gomes-Gouvea, MS
   Nunes, JDC
   Barros, LMF
   Carrilho, FJ
   Ferreira, ADP
   Pinho, JRR
AF Cruz Santos, Max Diego
   Gomes-Gouvea, Michele Soares
   Costa Nunes, Jomar Diogo
   Fonseca Barros, Lena Maria
   Carrilho, Flair Jose
   Paiva Ferreira, Adalgisa de Sousa
   Rebello Pinho, Joao Renato
TI The hepatitis delta genotype 8 in Northeast Brazil: The North Atlantic
   slave trade as the potential route for infection
SO VIRUS RESEARCH
LA English
DT Article
DE HDV-8; Slave trade; Maranhao; Brazil
ID B-VIRUS GENOTYPES; GENETIC-VARIABILITY; FULMINANT-HEPATITIS; HIGH
   PREVALENCE; ENDEMIC AREA; AMAZON; AFRICAN; DIVERSITY; EPIDEMIOLOGY;
   SUBGENOTYPES
AB Hepatitis Delta virus (HDV) is not well known, even though HDV and Hepatitis B virus (HBV) co-infection leads to severe forms of acute And chronic liver diseases. HDV is endemic in the Western Amazon region. Recently, the HDV genotype 8 was found in chronic patients followed at the center for liver studies in the Northeast Brazil, Maranhao. Previous studies suggested that this genotype was introduced in Maranhao during the slave trade. The presence of HDV in that study, which was done outside the Amazon region, led us to investigate whether the virus is found infecting individuals in other regions of Maranhao as well. Thus, we screened ninety-two HBsAg positive individuals from five Municipalities of Maranhao for anti-HD antibody and eight were found positive (8.7%). These eight positive individuals were submitted to polymerase chain reaction (PCR) to investigate active HDV infection. Half of Them were positive for a fragment sequence of the delta antigen; their sequence samples were submitted to genotype characterization by phylogenetic analysis. All sequences clustered in a unique branch of the tree separated from the other branch described in Africa. Our study confirmed the presence of HDV-8 in Maranhao. These infected individuals had no evidence of contact with African people. Furthermore, we found individuals infected with HDV-8 in two more different municipalities. More studies like ours are urgent because the co-infection HBV/HDV is more difficult to treat. Identification of the endemic regions and implementation of healthy policies for preventing this infection are urgent in this region. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Cruz Santos, Max Diego; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, Sao Paulo Inst Trop Med, Sch Med, LIM 07, Sao Paulo, SP, Brazil.
   [Cruz Santos, Max Diego; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, LIM 07, Sao Paulo, SP, Brazil.
   [Costa Nunes, Jomar Diogo; Fonseca Barros, Lena Maria; Paiva Ferreira, Adalgisa de Sousa] Univ Fed Maranhao, Univ Hosp, Clin Res Ctr, Sao Luis, Maranhao, Brazil.
   [Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
RP Santos, MDC (corresponding author), FMUSP, Lab Gastroenterol & Hepatol Trop, Inst Med Trop, Av Dr Eneas Carvalho de Aguiar 500, BR-05403000 Sao Paulo, SP, Brazil.
EM maxdiegocs@usp.br
RI Carrilho, Flair J/I-3046-2012; ferreira, adalgisa S P/G-8169-2016;
   Pinho, Joao R. R./G-2850-2012; Gouvea, Michele/G-4216-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Gouvea,
   Michele/0000-0001-5932-2360
FU Fundacao de Amparo a Pesquisa do Estado do Maranhao - (FAPEMA)
   [PPSUS-03348/13, PPP-01263/12]; Sao Paulo Research Foundation
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/53946-3]; Brazilian Ministry of Health [1/2013]; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [141138/2012-2]; CNPq
   (Bolsista de Produtividade em Pesquisa do CNPq - Nivel 2)National
   Council for Scientific and Technological Development (CNPq)
FX The authors thank the State Health Department of Maranhao -
   Epidemiological Surveillance Secretariat; Central Laboratory of Public
   Health- Maranhao (LACEN-MA) as well as the municipal government of all
   participating Municipalities. This work was supported by Fundacao de
   Amparo a Pesquisa do Estado do Maranhao - (FAPEMA) [grant:
   PPSUS-03348/13 and PPP-01263/12]; Sao Paulo Research Foundation (FAPESP)
   - [grant: 2009/53946-3]; Brazilian Ministry of Health [grant: 1/2013].
   Max Diego Cruz Santos received a Ph.D. fellowship from Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq) [grant:
   141138/2012-2]. Joao Renato Rebello Pinho receives fellowship from CNPq
   (Bolsista de Produtividade em Pesquisa do CNPq - Nivel 2).
CR Ahn Joseph, 2014, Gastroenterol Hepatol (N Y), V10, P647
   Alves C, 2013, ADV VIROL, V2013, DOI 10.1155/2013/560105
   Andernach IE, 2014, J CLIN MICROBIOL, V52, P1629, DOI 10.1128/JCM.02297-13
   Andernach IE, 2009, EMERG INFECT DIS, V15, P1222, DOI 10.3201/eid1508.081642
   Barros LMF, 2011, VIRUS RES, V160, P333, DOI 10.1016/j.virusres.2011.07.006
   BENSABATH G, 1987, JAMA-J AM MED ASSOC, V258, P479, DOI 10.1001/jama.1987.03400040077025
   BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007
   Brichler S, 2013, J GEN VIROL, V94, P2318, DOI 10.1099/vir.0.055459-0
   Deny P, 2006, CURR TOP MICROBIOL, V307, P151
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Crispim MAE, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-94
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Barros LMF, 2014, INFECT GENET EVOL, V24, P68, DOI 10.1016/j.meegid.2014.03.007
   Francois-Souquiere S, 2016, INFECT GENET EVOL, V39, P12, DOI 10.1016/j.meegid.2015.12.021
   Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
   Gomes-Gouvea MS, 2015, ANTIVIR THER, V20, P387, DOI 10.3851/IMP2938
   Gomes-Gouvea MS, 2008, ACTA TROP, V106, P149, DOI 10.1016/j.actatropica.2008.02.009
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   Hubschen JM, 2009, J MED VIROL, V81, P435, DOI 10.1002/jmv.21412
   IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990
   Ivaniushina V, 2001, J GEN VIROL, V82, P2709, DOI 10.1099/0022-1317-82-11-2709
   Kramvis A, 2014, INTERVIROLOGY, V57, P141, DOI 10.1159/000360947
   Kwange SO, 2013, VIRUS GENES, V47, P448, DOI 10.1007/s11262-013-0976-1
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Le Gal F, 2006, EMERG INFECT DIS, V12, P1447, DOI 10.3201/eid1209.060112
   Le Gal F, 2012, ARCH VIROL, V157, P647, DOI 10.1007/s00705-011-1212-8
   Loureiro CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118959
   Luna EJA, 2009, VACCINE, V27, P5326, DOI 10.1016/j.vaccine.2009.06.096
   Makuwa M, 2008, J CLIN MICROBIOL, V46, P754, DOI 10.1128/JCM.02142-07
   Makuwa M, 2009, J CLIN MICROBIOL, V47, P2265, DOI 10.1128/JCM.02012-08
   Meireles M. C., 2009, OUTROS TEMPOS, V6, P130
   Mendes-Correa MC, 2011, INT J INFECT DIS, V15, pE828, DOI 10.1016/j.ijid.2011.08.003
   Braga WSM, 2012, REV SOC BRAS MED TRO, V45, P691, DOI 10.1590/S0037-86822012000600007
   Osiowy C, 2011, J VIRAL HEPATITIS, V18, pe11, DOI 10.1111/j.1365-2893.2010.01356.x
   Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
   Perbi A, 2001, SLAVERY SLAVE TRADE, P1
   Radjef N, 2004, J VIROL, V78, P2537, DOI 10.1128/JVI.78.5.2537-2544.2004
   RIZZETTO M, 1977, GUT, V18, P997, DOI 10.1136/gut.18.12.997
   Rizzetto M, 2009, LIVER INT, V29, P140, DOI 10.1111/j.1478-3231.2008.01937.x
   Rizzetto M, 2013, CLIN LIVER DIS, V17, P475, DOI 10.1016/j.cld.2013.05.007
   Rizzetto M, 2012, SEMIN LIVER DIS, V32, P211, DOI 10.1055/s-0032-1323626
   Sakugawa H, 1999, J MED VIROL, V58, P366, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt;366::AID-JMV8&gt;3.0.CO;2-X
   Silva D. B. D., 2008, SLAVERY ABOLIT, V29, P477
   STRAUSS E, 1987, T ROY SOC TROP MED H, V81, P73, DOI 10.1016/0035-9203(87)90288-4
   Sureau C, 2006, CURR TOP MICROBIOL, V307, P113
   Taylor JM, 2014, WORLD J GASTROENTERO, V20, P2971, DOI 10.3748/wjg.v20.i11.2971
   Valente C. V., 2014, CADERNOS PESQUISA, V21, P7
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   Ximenes RAA, 2015, AM J TROP MED HYG, V93, P1341, DOI 10.4269/ajtmh.15-0216
NR 50
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD SEP 15
PY 2016
VL 224
BP 6
EP 11
DI 10.1016/j.virusres.2016.08.003
PG 6
WC Virology
SC Virology
GA DY1KH
UT WOS:000384853400002
PM 27515509
DA 2020-12-08
ER

PT J
AU da Silva, EF
   Mazo, DF
   Oliveira, CP
   Medeiros, RP
   Carrilho, FJ
   Pessoa, MG
AF da Silva, Edvaldo F.
   Mazo, Daniel F.
   Oliveira, Claudia P.
   Medeiros, Roseane P.
   Carrilho, Flair J.
   Pessoa, Mario G.
TI HAV and HBV seroprevalence in 1,000 patients with chronic HCV infection
   in a Tertiary Care Center in Sao Paulo, Brazil
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Chronic Hepatitis C; Hepaclvirus; Hepatitis A; Hepatitis B; Prevalence
ID CHRONIC HEPATITIS-C; CHRONIC LIVER-DISEASE; B-VIRUS-INFECTION; A VIRUS;
   VACCINATION; PREVALENCE; SUPERINFECTION
AB Background. Patients with chronic HCV infection and superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) have higher morbidity and mortality when compared with those without HCV infection. Therefore, HAV and HBV active immunization has become mandatory in this population and hence their serological markers must be determined. The aim of this study was to evaluate the prevalence of serological markers of HAV and HBV infection in patients with chronic HCV. Material and methods: One thousand chronic HCV patients at the University of Sao Paulo School of Medicine were evaluated for the prevalence of serological markers of HAV and HBV infection. Results: Anti-HAV IgG was positive in 92.3% of patients. When stratified by age, anti-HAV IgG was found in 61% of patients between 20-29 years, 70% on patients between 30-39 years, 85% on patients between 40-49 years, 94% on patients between 50-59 years, and in 99% on patients over 60 years of age. Anti-HBc IgG was positive in 244 patients (24%). Stratified by age, in 4.3% of patients between 20-29 years, 17% 30-39 years, 21% 40-49 years, 24% 50-59 years, and in 28% of patients over 60 years. Of the 244 anti-HBc IgG positive patients, 0.8% were HBsAg positive, 8.5% were anti-HBc IgG isolated and 16% were also anti-HBs positive. Conclusions: In conclusion, the prevalence of anti-HAV IgG was similar to the general Brazilian population. However, anti-HBc IgG was higher in our patients, when compared to general population of Western countries, emphasizing the importance of immunization programs for this population.
C1 [da Silva, Edvaldo F.; Mazo, Daniel F.; Oliveira, Claudia P.; Medeiros, Roseane P.; Carrilho, Flair J.; Pessoa, Mario G.] Univ Sao Paulo, Sch Med, Div Gastroenterol & Hepatol, Av Dr Eneas de Carvalho Aguiar 255,Inst Cent 9159, BR-05403000 Sao Paulo, Brazil.
RP Pessoa, MG (corresponding author), Univ Sao Paulo, Sch Med, Div Gastroenterol & Hepatol, Av Dr Eneas de Carvalho Aguiar 255,Inst Cent 9159, BR-05403000 Sao Paulo, Brazil.
EM mgpessoa@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012; Mazo,
   Daniel FC/D-5631-2015
OI Mazo, Daniel FC/0000-0002-2164-2630
FU CAPES (Coordenagao de Aperfeicoamento de Pessoal de Nivel Superior)CAPES
FX E.F.S. received a fellowship from CAPES (Coordenagao de Aperfeicoamento
   de Pessoal de Nivel Superior).
CR ALBERTI A, 1995, J HEPATOL, V22, P38
   Buxton JA, 2008, CAN J INFECT DIS MED, V19, P197, DOI 10.1155/2008/410362
   Chen SL, INT J MED HEPATITI A
   Cho HC, 2011, WORLD J GASTROENTERO, V17, P236, DOI 10.3748/wjg.v17.i2.236
   Ximenes RAD, 2010, CAD SAUDE PUBLICA, V26, P1693, DOI 10.1590/S0102-311X2010000900003
   Mattos Angelo Alves de, 2004, Arq. Gastroenterol., V41, P180, DOI 10.1590/S0004-28032004000300008
   [Departamento de Vigiiiancia Epidemiologica Brazil. Ministry of Health], 2014, INF TECN INTR VAC AD
   Devalle S, 2003, J INFECTION, V47, P125, DOI 10.1016/S0163-4453(03)00061-6
   Redondo MPD, 2009, REV ESP ENFERM DIG, V101, P265, DOI 10.4321/s1130-01082009000400005
   Felsen UR, 2010, J ADDICT DIS, V29, P461, DOI 10.1080/10550887.2010.509281
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   Giannini E, 2003, LIVER INT, V23, P12, DOI 10.1034/j.1600-0676.2003.01742.x
   Idilman R, 2002, AM J GASTROENTEROL, V97, P435, DOI 10.1111/j.1572-0241.2002.05482.x
   Keeffe EB, 2005, AM J MED, V118, P21, DOI 10.1016/j.amjmed.2005.07.013
   Keeffe Emmet B, 2006, Trans Am Clin Climatol Assoc, V117, P227
   Kim MN, 2013, J GASTROENTEROL, V48, P681, DOI 10.1007/s00535-013-0770-9
   Koff RS, 2001, J CLIN GASTROENTEROL, V33, P20, DOI 10.1097/00004836-200107000-00006
   Kramer ES, 2009, DIGEST DIS SCI, V54, P2016, DOI 10.1007/s10620-009-0867-4
   Lau DTY, 2005, AM J MED, V118, P28, DOI 10.1016/j.amjmed.2005.07.014
   Liaw YF, 2002, J GASTROENTEROL, V37, P65, DOI 10.1007/BF02990102
   Liu CJ, 2014, WORLD J GASTROENTERO, V20, P2955, DOI 10.3748/wjg.v20.i11.2955
   Liu Zhihua, 2006, Int J Med Sci, V3, P57
   Menegol D, 2013, BRAZ J MICROBIOL, V44, P1237, DOI 10.1590/S1517-83822014005000013
   Reiss G, 2004, ALIMENT PHARM THER, V19, P715, DOI 10.1111/j.1365-2036.2004.01906.x
   Rowe IA, 2012, HEPATOLOGY, V56, P501, DOI 10.1002/hep.25683
   Saab S, 2005, J VIRAL HEPATITIS, V12, P101, DOI 10.1111/j.1365-2893.2005.00551.x
   Semnani S., 2006, Pakistan Journal of Biological Sciences, V9, P2538, DOI 10.3923/pjbs.2006.2538.2540
   Shim M, 2005, HEPATOLOGY, V42, P688, DOI 10.1002/hep.20830
   Siddiqui F, 2001, AM J GASTROENTEROL, V96, P858, DOI 10.1111/j.1572-0241.2001.03633.x
   Tao YL, 2013, WORLD J GASTROENTERO, V19, P5320, DOI 10.3748/wjg.v19.i32.5320
   Taye Solomon, 2014, BMC Res Notes, V7, P272, DOI 10.1186/1756-0500-7-272
   Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503
   Villar LM, 2009, J GASTROEN HEPATOL, V24, P238, DOI 10.1111/j.1440-1746.2008.05575.x
NR 33
TC 2
Z9 2
U1 0
U2 0
PU MEXICAN ASSOC HEPATOLOGY
PI MEXICO
PA PUNTE DE PIEDRA 150, COLONIA TORIELLO GUERRA, MEXICO, DF CP 14040,
   MEXICO
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD SEP-OCT
PY 2016
VL 15
IS 5
BP 691
EP 695
DI 10.5604/16652681.1212320
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EP0FB
UT WOS:000397061200004
DA 2020-12-08
ER

PT J
AU Mazo, DFD
   Mattar, R
   Stefano, JT
   da Silva-Etto, JMK
   Diniz, MA
   Duarte, SMB
   Rabelo, F
   Lima, RVC
   de Campos, PB
   Carrilho, FJ
   Oliveira, CP
AF de Campos Mazo, Daniel Ferraz
   Mattar, Rejane
   Stefano, Jose Tadeu
   Kinoshita da Silva-Etto, Joyce Matie
   Diniz, Marcio Augusto
   Bezerra Duarte, Sebastiao Mauro
   Rabelo, Fabiola
   Costa Lima, Rodrigo Vieira
   de Campos, Priscila Brizolla
   Carrilho, Flair Jose
   Oliveira, Claudia P.
TI Hypolactasia is associated with insulin resistance in nonalcoholic
   steatohepatitis
SO WORLD JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Lactose intolerance; Genetic polymorphism; Insulin resistance;
   Non-alcoholic fatty liver disease; Nonalcoholic steatohepatitis
ID FATTY LIVER-DISEASE; PROLIFERATOR-ACTIVATED RECEPTOR; LACTASE
   PERSISTENCE GENOTYPE; CONJUGATED LINOLEIC-ACID; ADULT-TYPE HYPOLACTASIA;
   METABOLIC SYNDROME; DAIRY-PRODUCTS; MODEL ASSESSMENT; VACCENIC ACID;
   MILK
AB AIM To assess lactase gene (LCT)-13910C>T polymorphisms in Brazilian non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) patients in comparison with healthy controls.
   METHODS This was a transverse observational clinical study with NAFLD patients who were followed at the Hepatology Outpatient Unit of the Hospital das Clinicas, Sao Paulo, Brazil. The polymorphism of lactase non-persistence/ lactase persistence (LCT-13910C>T) was examined by PCR-restriction fragment length polymorphism technique in 102 liver biopsy-proven NAFLD patients (steatosis in 9 and NASH in 93) and compared to those of 501 unrelated healthy volunteers. Anthropometric, clinical, biochemical and liver histology data were analyzed. Continuous variables were compared using the t or Mann-Whitney tests, and categorical data were compared with the Fisher's exact test. Univariate logistic regression and multivariate logistic regression adjusted for gender and age were performed.
   RESULTS No differences in the LCT-13910 genotype frequencies were noted between the NAFLD patients (66.67% of the patients with steatosis were CC, 33.33% were CT, and none were TT; 55.91% of the patients with NASH were CC, 39.78% were CT, and 4.3% were TT; P = 0.941) and the healthy controls (59.12% were CC, 35.67% were CT, and 5.21% were TT) or between the steatosis and NASH patients. That is, the distribution of the lactase non-persistence/lactase persistence polymorphism (LCT-13910C>T) in the patients with NAFLD was equal to that in the general population. In the NASH patients, the univariate analysis revealed that the lactase nonpersistence (low lactase activity or hypolactasia) phenotype was associated with higher insulin levels (23.47 +/- 15.94 mu U/mL vs 15.8 +/- 8.33 mu U/mL, P = 0.027) and a higher frequency of insulin resistance (91.84% vs 72.22%, P = 0.02) compared with the lactase persistence phenotype. There were no associations between the LCT genotypes and diabetes (P = 0.651), dyslipidaemia (P = 0.328), hypertension (P = 0.507) or liver histology in these patients. Moreover, in the NASH patients, hypolactasia was an independent risk factor for insulin resistance even after adjusting for gender and age [OR = 5.0 (95%CI: 1.35-20; P = 0.017)].
   CONCLUSION The LCT-13910 genotype distribution in Brazilian NAFLD patients was the same as that of the general population, but hypolactasia increased the risk of insulin resistance in the NASH patients.
C1 [de Campos Mazo, Daniel Ferraz; Mattar, Rejane; Stefano, Jose Tadeu; Kinoshita da Silva-Etto, Joyce Matie; Diniz, Marcio Augusto; Bezerra Duarte, Sebastiao Mauro; Rabelo, Fabiola; Costa Lima, Rodrigo Vieira; de Campos, Priscila Brizolla; Carrilho, Flair Jose; Oliveira, Claudia P.] Univ Sao Paulo, Div Gastroenterol & Hepatol, Dept Gastroenterol, Sch Med, LIM 07,Av Dr Eneas de Carvalho Aguiar 255,9 Andar, BR-05403000 Sao Paulo, Brazil.
RP Oliveira, CP (corresponding author), Univ Sao Paulo, Div Gastroenterol & Hepatol, Dept Gastroenterol, Sch Med, LIM 07,Av Dr Eneas de Carvalho Aguiar 255,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM cpm@.usp.br
RI Stefano, Jose Tadeu/AAH-5419-2020; Mazo, Daniel FC/D-5631-2015; Stefano,
   Jose T/H-4792-2013; Oliveira, Claudia PMS/D-1216-2014; Mattar,
   Rejane/AAO-4842-2020
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Mazo, Daniel
   FC/0000-0002-2164-2630; Mattar, Rejane/0000-0001-7870-8867; Diniz,
   Marcio Augusto/0000-0002-2427-7843
CR Almon R, 2007, SCAND J GASTROENTERO, V42, P165, DOI 10.1080/00365520600825257
   Almon R, 2010, EUR J NUTR, V49, P141, DOI 10.1007/s00394-009-0058-2
   Aune D, 2013, AM J CLIN NUTR, V98, P1066, DOI 10.3945/ajcn.113.059030
   Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816
   Belury MA, 2002, NUTR RES, V22, P817, DOI 10.1016/S0271-5317(02)00393-7
   Bettermann K, 2014, INT J MOL SCI, V15, P9924, DOI 10.3390/ijms15069924
   Buning C, 2005, DIGESTION, V71, P245, DOI 10.1159/000087050
   Calton EK, 2014, NUTR RES, V34, P559, DOI 10.1016/j.nutres.2014.06.012
   Chalasani N, 2012, AM J GASTROENTEROL, V107, P811, DOI 10.1038/ajg.2012.128
   Corella D, 2011, OBESITY, V19, P1707, DOI 10.1038/oby.2010.320
   Crichton GE, 2014, NUTR RES, V34, P1036, DOI 10.1016/j.nutres.2014.04.002
   Da Silva MS, 2014, MATURITAS, V77, P221, DOI 10.1016/j.maturitas.2013.12.007
   Donovan SM, 2012, ADV NUTR, V3, p450S, DOI 10.3945/an.112.001859
   Enattah NS, 2007, AM J HUM GENET, V81, P615, DOI 10.1086/520705
   Enattah NS, 2004, EUR J CLIN NUTR, V58, P1319, DOI 10.1038/sj.ejcn.1601971
   Enattah NS, 2002, NAT GENET, V30, P233, DOI 10.1038/ng826
   Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973
   Friedrich DC, 2014, GENET MOL BIOL, V37, P611, DOI [10.1590/S1415-47572014005000012, 10.1590/S1415-47572014000500001]
   Gaggini M, 2013, NUTRIENTS, V5, P1544, DOI 10.3390/nu5051544
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   Hirahatake KM, 2014, METABOLISM, V63, P618, DOI 10.1016/j.metabol.2014.02.009
   Hogenauer C, 2005, EUR J GASTROEN HEPAT, V17, P371
   Hothorn T, 2006, J COMPUT GRAPH STAT, V15, P651, DOI 10.1198/106186006X133933
   Imajo K, 2014, SEMIN IMMUNOPATHOL, V36, P115, DOI 10.1007/s00281-013-0404-6
   Ingram CJE, 2009, HUM GENET, V124, P579, DOI 10.1007/s00439-008-0593-6
   Jacome-Sosa MM, 2014, J NUTR BIOCHEM, V25, P692, DOI 10.1016/j.jnutbio.2014.02.011
   Kalergis Maria, 2013, Front Endocrinol (Lausanne), V4, P90, DOI 10.3389/fendo.2013.00090
   Kettunen J, 2010, HUM MOL GENET, V19, P1129, DOI 10.1093/hmg/ddp561
   Khabarova Y, 2009, WORLD J GASTROENTERO, V15, P1849, DOI 10.3748/wjg.15.1849
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Lamri A, 2013, METABOLISM, V62, P1323, DOI 10.1016/j.metabol.2013.04.006
   Lerchbaum E, 2012, CLIN ENDOCRINOL, V77, P834, DOI 10.1111/j.1365-2265.2012.04334.x
   Madeira IR, 2008, ARQ BRAS ENDOCRINOL, V52, P1466, DOI 10.1590/S0004-27302008000900010
   Maga EA, 2012, APPL ENVIRON MICROB, V78, P6153, DOI 10.1128/AEM.00956-12
   Martins MLB, 2015, NUTRITION, V31, P716, DOI 10.1016/j.nut.2014.12.017
   Mattar R, 2008, CLIN BIOCHEM, V41, P628, DOI 10.1016/j.clinbiochem.2008.01.006
   Mattar R, 2012, CLIN EXP GASTROENTER, V5, P113, DOI 10.2147/CEG.S32368
   Mattar R, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-46
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Miura K, 2014, WORLD J GASTROENTERO, V20, P7381, DOI 10.3748/wjg.v20.i23.7381
   Mouzaki M, 2013, HEPATOLOGY, V58, P120, DOI 10.1002/hep.26319
   Moya-Camarena SY, 1999, BBA-MOL CELL BIOL L, V1436, P331, DOI 10.1016/S0005-2760(98)00121-0
   Mulcare CA, 2004, AM J HUM GENET, V74, P1102, DOI 10.1086/421050
   Nagy D, 2011, AM J PHYS ANTHROPOL, V145, P262, DOI 10.1002/ajpa.21490
   Nascimbeni F, 2013, J HEPATOL, V59, P859, DOI 10.1016/j.jhep.2013.05.044
   Nicklas TA, 2011, AM J CLIN NUTR, V94, P191, DOI 10.3945/ajcn.110.009860
   Paolella G, 2014, WORLD J GASTROENTERO, V20, P15518, DOI 10.3748/wjg.v20.i42.15518
   Parodi PW, 2016, MED HYPOTHESES, V89, P1, DOI 10.1016/j.mehy.2015.12.028
   Peverill W, 2014, INT J MOL SCI, V15, P8591, DOI 10.3390/ijms15058591
   Pfeuffer M, 2007, OBES REV, V8, P109, DOI 10.1111/j.1467-789X.2006.00265.x
   R Core Team, 2014, R LANG ENV STAT COMP
   Ratziu V, 2010, J HEPATOL, V53, P372, DOI 10.1016/j.jhep.2010.04.008
   Samara A, 2013, NUTRITION, V29, P519, DOI 10.1016/j.nut.2012.08.013
   Shin H, 2013, J KOREAN MED SCI, V28, P1482, DOI 10.3346/jkms.2013.28.10.1482
   Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Upton Jeff, 2010, N Z Med J, V123, P123
   Vasques ACJ, 2008, ARQ BRAS ENDOCRINOL, V52, P32, DOI 10.1590/S0004-27302008000100006
   Vassilatou E, 2014, WORLD J GASTROENTERO, V20, P8351, DOI 10.3748/wjg.v20.i26.8351
   Visioli F, 2014, ADV NUTR, V5, P131, DOI 10.3945/an.113.005025
   Wang Y, 2012, MOL NUTR FOOD RES, V56, P1234, DOI 10.1002/mnfr.201100517
   Wong RJ, 2014, WORLD J HEPATOL, V6, P263, DOI 10.4254/wjh.v6.i5.263
   Younossi ZM, 2011, CLIN GASTROENTEROL H, V9, P524, DOI 10.1016/j.cgh.2011.03.020
NR 64
TC 0
Z9 0
U1 0
U2 1
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5182
J9 WORLD J HEPATOL
JI World J. Hepatol.
PD AUG 28
PY 2016
VL 8
IS 24
BP 1019
EP 1027
DI 10.4254/wjh.v8.i24.1019
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VE3YQ
UT WOS:000439246300003
PM 27648154
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Rezende, REF
   Duarte, SMB
   Stefano, JT
   Roschel, H
   Gualano, B
   Pinto, ALD
   Vezozzo, DCP
   Carrilho, FJ
   Oliveira, CP
AF Rezende, Rosamar E. F.
   Duarte, Sebastiao M. B.
   Stefano, Jose T.
   Roschel, Hamilton
   Gualano, Bruno
   Pinto, Ana L. de Sa
   Vezozzo, Denise C. P.
   Carrilho, Flair J.
   Oliveira, Claudia P.
TI Randomized clinical trial: benefits of aerobic physical activity for 24
   weeks in postmenopausal women with nonalcoholic fatty liver disease
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Aerobic physical activity; Nonalcoholic fatty liver disease;
   Postmenopausal women
ID TRANSIENT ELASTOGRAPHY; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE;
   CARDIORESPIRATORY FITNESS; METABOLIC SYNDROME; ALL-CAUSE; EXERCISE;
   SEVERITY; FIBROSIS; OBESE
AB Objective: The aim of the study was to evaluate the effectiveness of aerobic physical activity in reducing the frequency of hepatic steatosis and metabolic and cardiovascular risk in postmenopausal women with nonalcoholic fatty liver disease (NAFLD).
   Methods: Forty sedentary postmenopausal women (mean age 55.3 +/- 8.0 y) with biopsy-proven NAFLD were randomly divided into two groups: an exercising group (19 participants) and a control group (nonexercising, 21 participants). The exercise group underwent a supervised aerobic physical activity program of 120 min/wk for 24 weeks. The anthropometric parameters; body composition; hepatic, lipid, and glycemic profiles; homeostasis model assessment of insulin resistance index; cytokines; transient elastography (FibroScan; liver stiffness/controlled attenuation parameter); and cardiopulmonary exercise test were evaluated at baseline and after 24 weeks of protocol.
   Results: At baseline there were no significant differences in anthropometric, metabolic, and inflammatory parameters-stiffness and liver fat content by FibroScan between the groups. After 24 weeks, we observed a decrease of waist circumference, an increase of high-density lipoprotein cholesterol levels (P < 0.05), and improved cardiopulmonary functional capacity in the exercise group. In addition, the controlled attenuation parameter analysis showed no significant decrease of hepatic steatosis in the exercise group. With regard to the systemic inflammation, there were, however, no significant differences in the cytokines between the groups.
   Conclusions: An aerobic physical activity program of 24 weeks in NAFLD postmenopausal women showed improvement in some variables such as waist circumference, high-density lipoprotein cholesterol, and cardiopulmonary performance that may be beneficial in improving cardiovascular risk factors in this population.
C1 [Rezende, Rosamar E. F.; Stefano, Jose T.; Vezozzo, Denise C. P.; Carrilho, Flair J.; Oliveira, Claudia P.] Univ Sao Paulo, Sch Med, Dept Gastroenteol, Sao Paulo, Brazil.
   [Duarte, Sebastiao M. B.; Roschel, Hamilton; Gualano, Bruno; Pinto, Ana L. de Sa] Univ Sao Paulo, Sch Med, Div Rheumatol, Sao Paulo, Brazil.
RP Rezende, REF (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Gastroenterol, Ave Bandeirantes 3900, BR-14048900 Sao Paulo, Brazil.
EM rosamarrezende@uol.com.br
RI Stefano, Jose T/H-4792-2013; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014; Roschel, Hamilton/D-4353-2012; DUARTE, Sebastiao
   Mauro/B-6075-2017; Oliveira, Claudia PMS/D-1216-2014; Gualano,
   Bruno/ABA-9571-2020; Carrilho, Flair J/I-3046-2012; Gualano,
   Bruno/C-7190-2012; Stefano, Jose Tadeu/AAH-5419-2020
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; Roschel,
   Hamilton/0000-0002-9513-6132; Gualano, Bruno/0000-0001-7100-8681;
   Gualano, Bruno/0000-0001-7100-8681; Stefano, Jose
   Tadeu/0000-0002-0218-1920
FU National Council of Technological and Scientific Development
   (CNPQ)National Council for Scientific and Technological Development
   (CNPq)
FX National Council of Technological and Scientific Development (CNPQ).
CR Adams LA, 2005, DIABETIC MED, V22, P1129, DOI 10.1111/j.1464-5491.2005.01748.x
   Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
   Aldhahi Waleed, 2003, Curr Diab Rep, V3, P293, DOI 10.1007/s11892-003-0020-2
   Angulo P, 2007, ALIMENT PHARM THER, V25, P883, DOI 10.1111/j.1365-2036.2007.03246.x
   Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775
   Duarte SMB, 2014, NUTR HOSP, V29, P94, DOI 10.3305/nh.2014.29.1.7068
   Castera L, 2008, J HEPATOL, V48, P835, DOI 10.1016/j.jhep.2008.02.008
   de Ledinghen V, 2012, LIVER INT, V32, P911, DOI 10.1111/j.1478-3231.2012.02820.x
   de Ledinghen V, 2010, EXPERT REV MED DEVIC, V7, P811, DOI [10.1586/erd.10.46, 10.1586/ERD.10.46]
   Domanski JP, 2012, J CLIN GASTROENTEROL, V46, P427, DOI 10.1097/MCG.0b013e31822fb3f7
   Dowman JK, 2010, QJM-INT J MED, V103, P71, DOI 10.1093/qjmed/hcp158
   Fan JG, 2009, J HEPATOL, V50, P204, DOI 10.1016/j.jhep.2008.10.010
   George AS, 2009, HEPATOLOGY, V50, P68, DOI 10.1002/hep.22940
   Gulati M, 2003, CIRCULATION, V108, P1554, DOI 10.1161/01.CIR.0000091080.57509.E9
   Grobe YG, 2010, ANN HEPATOL, V9, P402, DOI 10.1016/S1665-2681(19)31616-3
   Irwin ML, 2003, JAMA-J AM MED ASSOC, V289, P323, DOI 10.1001/jama.289.3.323
   Johnson NA, 2009, HEPATOLOGY, V50, P1105, DOI 10.1002/hep.23129
   Kelley GA, 2009, PREV MED, V48, P9, DOI 10.1016/j.ypmed.2008.10.010
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Lavie CJ, 2009, AM J MED SCI, V338, P486, DOI 10.1097/MAJ.0b013e3181c61b66
   Lee DC, 2011, CIRCULATION, V124, P2483, DOI 10.1161/CIRCULATIONAHA.111.038422
   Lim S, 2015, INT J CARDIOL, V201, P408, DOI 10.1016/j.ijcard.2015.08.107
   Lyerly GW, 2009, MAYO CLIN PROC, V84, P780, DOI 10.1016/S0025-6196(11)60487-4
   Machado M, 2006, CURR OPIN CLIN NUTR, V9, P637, DOI 10.1097/01.mco.0000241677.40170.17
   Mann S, 2014, SPORTS MED, V44, P211, DOI 10.1007/s40279-013-0110-5
   Manousou P, 2011, LIVER INT, V31, P730, DOI 10.1111/j.1478-3231.2011.02488.x
   Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Newton JL, 2008, GUT, V57, P807, DOI 10.1136/gut.2007.139303
   Pettersson J, 2008, BRIT J CLIN PHARMACO, V65, P253, DOI 10.1111/j.1365-2125.2007.03001.x
   Soares FHR, 2013, WOMEN HEALTH, V53, P298, DOI 10.1080/03630242.2013.782940
   Sanchez-Munoz V, 2013, REV INVEST CLIN, V65, P307
   Sasso M, 2010, ULTRASOUND MED BIOL, V36, P1825, DOI 10.1016/j.ultrasmedbio.2010.07.005
   Simonen P, 2011, J HEPATOL, V54, P153, DOI 10.1016/j.jhep.2010.05.037
   Stepanova M, 2012, CLIN GASTROENTEROL H, V10, P646, DOI 10.1016/j.cgh.2011.12.039
   Suzuki A, 2009, WOMENS HEALTH, V5, P191, DOI 10.2217/17455057.5.2.191
   Troseid M, 2009, METAB SYNDR RELAT D, V7, P579, DOI 10.1089/met.2009.0003
   van der Heijden GJ, 2010, OBESITY, V18, P384, DOI 10.1038/oby.2009.274
   WASSERMAN K, 1973, J APPL PHYSIOL, V35, P236
   Zelber-Sagi S, 2014, WORLD J GASTROENTERO, V20, P4382, DOI 10.3748/wjg.v20.i15.4382
NR 41
TC 12
Z9 13
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072-3714
EI 1530-0374
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD AUG
PY 2016
VL 23
IS 8
BP 876
EP 883
DI 10.1097/GME.0000000000000647
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DS5KF
UT WOS:000380820200011
PM 27458060
DA 2020-12-08
ER

PT J
AU Gaspareto, KV
   Ribeiro, RM
   Malta, FD
   Gomes-Gouvea, MS
   Muto, NH
   Mendes-Correa, MC
   Rozanski, A
   Carrilho, FJ
   Sabino, EC
   Pinho, JRR
AF Gaspareto, Karine Vieira
   Ribeiro, Roberto Marques
   Malta, Fernanda de Mello
   Gomes-Gouvea, Michele Soares
   Muto, Nair Hideko
   Mendes-Correa, Maria Cassia
   Rozanski, Andrei
   Carrilho, Flair Jose
   Sabino, Ester Cerdeira
   Rebello Pinho, Joao Renato
TI HCV inter-subtype 1a/1b recombinant detected by complete-genome
   next-generation sequencing
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID HEPATITIS-C VIRUS; INTERGENOTYPIC RECOMBINANT; GENETIC DIVERSITY; VIRAL
   SEQUENCES; NS3 PROTEASE; DRUG-USERS; GENOTYPE 1; THERAPY; POPULATIONS;
   INFECTION
AB Next-generation sequencing (NGS) provides a practical approach to HCV complete-genome sequencing, detecting low-frequency variants and allowing analysis of viral genetic diversity (quasispecies) in the sample, and so far, it is very useful for identifying preexisting drug-resistant mutants and emerging escape mutations, as well as detecting viral recombinants containing genomic regions from different genotypes and subtypes. The aim of this study was to analyze the complete coding region of hepatitis C virus (HCV) genotype 1 (subtypes 1a and 1b) from patients with chronic infection who were direct-acting antiviral (DAA) na < ve. Next-generation sequencing (Ion Torrent (TM) PGM) was used to determine the sequence of the complete coding region of 100 HCV-monoinfected DAA-na < ve patients (51 and 49 subtypes 1a and 1b, respectively). We report the first description of nearly complete HCV genome sequences of subtype 1a and 1b isolates from a large population of Brazilian patients with chronic hepatitis C, and HCV-1a grouped in two different clades. Using this methodology, an inter-subtype 1a/1b recombinant was identified in this study.
C1 [Gaspareto, Karine Vieira; Malta, Fernanda de Mello; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Inst Trop Med, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, LIM 07, Ave Dr Eneas Carvalho Aguiar 500,2nd Floor IMT 2, BR-05403000 Sao Paulo, SP, Brazil.
   [Gaspareto, Karine Vieira; Malta, Fernanda de Mello; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, SP, Brazil.
   [Gaspareto, Karine Vieira; Rebello Pinho, Joao Renato] Univ Sao Paulo, Grad Program Biotechnol Interunits USP Butantan I, Sao Paulo, Brazil.
   [Ribeiro, Roberto Marques; Sabino, Ester Cerdeira] Univ Sao Paulo, Inst Trop Med, Parasitol Lab, LIM 46, Sao Paulo, SP, Brazil.
   [Ribeiro, Roberto Marques; Mendes-Correa, Maria Cassia; Sabino, Ester Cerdeira] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, SP, Brazil.
   [Muto, Nair Hideko; Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
   [Mendes-Correa, Maria Cassia] Univ Sao Paulo, Inst Trop Med, Virol Lab, LIM 52, Sao Paulo, SP, Brazil.
   [Rozanski, Andrei] Sirio Libanes Hosp, Lab Bioinformat, Sao Paulo, Brazil.
RP Malta, FD (corresponding author), Univ Sao Paulo, Inst Trop Med, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, LIM 07, Ave Dr Eneas Carvalho Aguiar 500,2nd Floor IMT 2, BR-05403000 Sao Paulo, SP, Brazil.; Malta, FD (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, SP, Brazil.
EM femalta@yahoo.com
RI Muto, Nair/P-8363-2017; Malta, Fernanda/B-1316-2013; Pinho, Joao R.
   R./G-2850-2012; Sabino, Ester Cerdeira/F-7750-2010; Carrilho, Flair
   J/I-3046-2012
OI Malta, Fernanda/0000-0001-8887-5060; Pinho, Joao R.
   R./0000-0003-3999-0489; Sabino, Ester Cerdeira/0000-0003-2623-5126;
   Rozanski, Andrei/0000-0001-9082-2240
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [443152/2014-4]; Alves de Queiroz Family Fund for Research; CAPESCAPES
FX This project was supported by grant 443152/2014-4 (CNPq) and Alves de
   Queiroz Family Fund for Research. Karine Vieira Gaspareto is a graduate
   student from Programa de Pos-Graduacao em Biotecnologia, USP, and
   received a fellowship from CAPES. Joao Renato Rebello Pinho, Ester
   Cerdeira Sabino and Maria Cassia Mendes Correa received a fellowship
   from CNPq (Bolsista de Produtividade).
CR Akuta N, 2013, J CLIN MICROBIOL, V51, P2862, DOI 10.1128/JCM.01129-13
   Alavian SM, 2011, J VIRAL HEPATITIS, V18, P821, DOI 10.1111/j.1365-2893.2011.01530.x
   Calado RA, 2011, J MED VIROL, V83, P608, DOI 10.1002/jmv.21955
   Capobianchi MR, 2013, CLIN MICROBIOL INFEC, V19, P15, DOI 10.1111/1469-0691.12056
   Colina R, 2004, J GEN VIROL, V85, P31, DOI 10.1099/vir.0.19472-0
   Cuypers L, 2014, J VIROL METHODS, V209, P126, DOI 10.1016/j.jviromet.2014.09.009
   Du H, 2012, J CLIN VIROL, V54, P207, DOI 10.1016/j.jcv.2012.04.017
   Fan XF, 2010, METHODS MOL BIOL, V630, P139, DOI 10.1007/978-1-60761-629-0_10
   GARSON JA, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92384-T
   Gonzalez-Candelas F, 2011, VIRUSES-BASEL, V3, P2006, DOI 10.3390/v3102006
   Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141
   Hedskog C, 2015, HEPATOLOGY, V61, P471, DOI 10.1002/hep.27361
   Alcantara LCJ, 2009, NUCLEIC ACIDS RES, V37, pW634, DOI 10.1093/nar/gkp455
   Kageyama S, 2006, J MED VIROL, V78, P1423, DOI 10.1002/jmv.20714
   Kalinina O, 2002, J VIROL, V76, P4034, DOI 10.1128/JVI.76.8.4034-4043.2002
   Lampe E, 2013, ANTIVIR THER, V18, P435, DOI 10.3851/IMP2606
   Lauck M, 2012, J VIROL, V86, P3952, DOI 10.1128/JVI.06627-11
   Lee LY, 2012, INT J CLIN PRACT, V66, P342, DOI 10.1111/j.1742-1241.2012.02895.x
   Lee YM, 2010, J MED VIROL, V82, P57, DOI 10.1002/jmv.21658
   Legrand-Abravanel F, 2007, J VIROL, V81, P4357, DOI 10.1128/JVI.02639-06
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Luciani F, 2012, TRENDS BIOTECHNOL, V30, P443, DOI 10.1016/j.tibtech.2012.05.005
   Miura M, 2013, J VIROL, V87, P12541, DOI 10.1128/JVI.00826-13
   Morel V, 2016, INFECT GENET EVOL, V40, P374, DOI 10.1016/j.meegid.2015.09.030
   Moreno P, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-203
   Ninomiya M, 2012, J CLIN MICROBIOL, V50, P857, DOI 10.1128/JCM.05715-11
   Peres-da-Silva A, 2012, MEM I OSWALDO CRUZ, V107, P254, DOI 10.1590/S0074-02762012000200016
   Plauzolles A, 2013, SCI WORLD J, DOI 10.1155/2013/673240
   Prosperi MCF, 2013, SCI REP-UK, V3, DOI 10.1038/srep02837
   Ross RS, 2008, EVOL BIOINFORM, V4, P249
   Shi WF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041997
   Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744
   Svarovskaia ES, 2012, J CLIN MICROBIOL, V50, P3267, DOI 10.1128/JCM.00838-12
   Timm J, 2007, WORLD J GASTROENTERO, V13, P4808, DOI 10.3748/wjg.v13.i36.4808
   Wyles DL, 2014, J VIRAL HEPATITIS, V21, P229, DOI 10.1111/jvh.12230
   Xu CH, 2012, ARCH VIROL, V157, P2153, DOI 10.1007/s00705-012-1390-z
   Yang PL, 2011, CURR OPIN VIROL, V1, P607, DOI 10.1016/j.coviro.2011.10.019
   Yun AB, 1996, J MED VIROL, V49, P155, DOI 10.1002/(SICI)1096-9071(199607)49:3<155::AID-JMV1>3.0.CO;2-3
NR 38
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD AUG
PY 2016
VL 161
IS 8
BP 2161
EP 2168
DI 10.1007/s00705-016-2889-5
PG 8
WC Virology
SC Virology
GA DR8FZ
UT WOS:000380135100009
PM 27194536
DA 2020-12-08
ER

PT J
AU Nastri, ACDS
   Malta, FD
   Diniz, MA
   Yoshino, A
   Abe-Sandes, K
   dos Santos, SEB
   Lyra, AD
   Carrilho, FJ
   Pinho, JRR
AF de Seixas Santos Nastri, Ana Catharina
   Malta, Fernanda de Mello
   Diniz, Marcio Augusto
   Yoshino, Alessandra
   Abe-Sandes, Kiyoko
   Batista dos Santos, Sidney Emanuel
   Lyra, Andre de Castro
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus
   infection in a population from southeastern Brazil
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID TREATMENT-NAIVE PATIENTS; GENETIC-VARIATION; IL28B; ANCESTRY; PHASE;
   HCV; SUBSTRUCTURE; SOFOSBUVIR; CLEARANCE; RIBAVIRIN
AB Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated complications such as liver cirrhosis and hepatocellular carcinoma (HCC). Viral and host factors are known to be predictors for antiviral therapy. Host factors that are predictors of sustained viral response (SVR) were discovered by genome-wide association studies (GWAS), including single-nucleotide polymorphisms (SNPs) in or near the interferon lambda gene (rs8099917, rs12979860 and rs368234815). The aim of the present study was to verify the genotype frequencies of SNPs rs8099917, rs12979860 and rs368234815 and to evaluate the association between SNPs and the outcome of HCV infection, taking into account the population ancestry. In this study, there was an association of the three polymorphisms with both clinical outcome and response to treatment with PEG-IFN and RBV. The polymorphisms rs12979860 and rs368234815 were associated with increased sensitivity (97.7 %, 95 % CI 87.2-100, and 93.3 %, 95 % CI 81.3-98.3; respectively) and with a greater predictive value of a positive response to treatment. In multivariable analysis adjusted by gender, age and ancestry, the haplotype G/T/Delta G was related to non-response to treatment (OR = 21.09, 95 % CI 5.33-83.51; p < 0.001) and to a higher chance of developing chronic infection (OR = 5.46, 95 % CI 2.06-14.46; p = 0.001) when compared to the haplotype T/C/TT. These findings may help to adjust our treatment policies for HCV infection based on greater certainty in studies with populations with such genetic characteristics, as well as allowing us to get to know the genetic profile of our population for these polymorphisms.
C1 [de Seixas Santos Nastri, Ana Catharina; Yoshino, Alessandra] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [de Seixas Santos Nastri, Ana Catharina; Malta, Fernanda de Mello; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Malta, Fernanda de Mello; Rebello Pinho, Joao Renato] Univ Sao Paulo, Inst Trop Med, LIM 07, Av Dr Encas Carvalho Aguiar 500,2nd Floor IMT 2, Sao Paulo, SP, Brazil.
   [Diniz, Marcio Augusto] Cedars Sinai Med Ctr, Samuel Oschin Canc Inst, Los Angeles, CA 90048 USA.
   [Abe-Sandes, Kiyoko] Fed Univ Bahia UFBA, Hlth Sci Inst ICS, Immunol Lab, Salvador, BA, Brazil.
   [Batista dos Santos, Sidney Emanuel] Fed Univ Bahia UFBA, Dept Med, Salvador, BA, Brazil.
   [Lyra, Andre de Castro] Fed Univ Para UFPA, Human Genet & Med Lab, Belem, Para, Brazil.
   [Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
RP Malta, FD (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.; Malta, FD (corresponding author), Univ Sao Paulo, Inst Trop Med, LIM 07, Av Dr Encas Carvalho Aguiar 500,2nd Floor IMT 2, Sao Paulo, SP, Brazil.
EM femalta@yahoo.com
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; Malta,
   Fernanda/B-1316-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; Diniz, Marcio Augusto/0000-0002-2427-7843
FU FapespFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2010/10.549-1]; Alves de Queiroz Family Fund for Research; CNPq
   (Bolsista de Produtividade em Pesquisa do CNPq - Nivel 2)National
   Council for Scientific and Technological Development (CNPq)
FX This Project was supported by grant 2010/10.549-1 (Fapesp) and the Alves
   de Queiroz Family Fund for Research. Joao Renato Rebello Pinho is the
   recipient of a fellowship from CNPq (Bolsista de Produtividade em
   Pesquisa do CNPq - Nivel 2).
CR Akamatsu S, 2015, J HEPATOL, V63, P554, DOI 10.1016/j.jhep.2015.03.033
   Cavalcante LN, 2012, LIVER INT, V32, P476, DOI 10.1111/j.1478-3231.2011.02653.x
   Esser C, 2005, J INVEST DERMATOL, V124, P1082, DOI 10.1111/j.0022-202X.2005.23709.x
   Gane EJ, 2014, ANTIMICROB AGENTS CH, V58, P1136, DOI 10.1128/AAC.01515-13
   Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
   Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
   Hamming OJ, 2013, EMBO J, V32, P3055, DOI 10.1038/emboj.2013.232
   HOLM S, 1979, SCAND J STAT, V6, P65
   IBGE, 2015, EST POV
   Jouvin-Marche E, 2014, J INFECT DIS, V209, P1907, DOI 10.1093/infdis/jiu016
   Kowdley KV, 2013, LANCET, V381, P2100, DOI 10.1016/S0140-6736(13)60247-0
   Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811
   Lawitz EJ, 2012, J HEPATOL, V57, P24, DOI 10.1016/j.jhep.2011.12.029
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Manns MP, 2015, J VIRAL HEPATITIS, V22, P366, DOI 10.1111/jvh.12346
   Manns M, 2011, ANTIVIR THER, V16, P1021, DOI 10.3851/IMP1894
   Nelson DR, 2015, HEPATOLOGY, V61, P1127, DOI 10.1002/hep.27726
   O'Brien TR, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv057
   O'Brien TR, 2015, J HEPATOL, V63, P1103, DOI 10.1016/j.jhep.2015.06.035
   Olmedo DB, 2015, J MED VIROL, V87, P1702, DOI 10.1002/jmv.24227
   Prokunina-Olsson L, 2013, NAT GENET, V45, P164, DOI 10.1038/ng.2521
   Ramos JA, 2012, MEM I OSWALDO CRUZ, V107, P888, DOI 10.1590/S0074-02762012000700008
   Razavi H, 2014, J VIRAL HEPATITIS, V21, P34, DOI 10.1111/jvh.12248
   Santos NPC, 2010, HUM MUTAT, V31, P184, DOI 10.1002/humu.21159
   Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447
   Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449
   Terczynska-Dyla E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6699
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Tian C, 2008, HUM MOL GENET, V17, pR143, DOI 10.1093/hmg/ddn268
   Wack A, 2015, NAT IMMUNOL, V16, P802, DOI 10.1038/ni.3212
NR 30
TC 7
Z9 7
U1 0
U2 5
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD JUN
PY 2016
VL 161
IS 6
BP 1477
EP 1484
DI 10.1007/s00705-016-2809-8
PG 8
WC Virology
SC Virology
GA DM5QQ
UT WOS:000376405500006
PM 26973228
DA 2020-12-08
ER

PT J
AU Nogueira, MA
   Oliveira, CP
   Alves, VAF
   Stefano, JT
   Rodrigues, LSD
   Torrinhas, RS
   Cogliati, B
   Barbeiro, H
   Carrilho, FJ
   Waitzberg, DL
AF Nogueira, Monize Aydar
   Oliveira, Claudia Pinto
   Ferreira Alves, Venancio Avancini
   Stefano, Jose Tadeu
   dos Reis Rodrigues, Livia Samara
   Torrinhas, Raquel Susana
   Cogliati, Bruno
   Barbeiro, Hermes
   Carrilho, Flair Jose
   Waitzberg, Dan Linetzky
TI Omega-3 polyunsaturated fatty acids in treating non-alcoholic
   steatohepatitis: A randomized, double-blind, placebo-controlled trial
SO CLINICAL NUTRITION
LA English
DT Article
DE Alpha-linolenic acid; Eicosapentaenoic acid; Docosahexaenoic acid;
   Flaxseed oil; Fish oil; Nonalcoholic steatohepatitis
ID CONTROLLED CLINICAL-TRIAL; LIVER-DISEASE; METABOLIC SYNDROME; HEPATIC
   STEATOSIS; FISH-OIL; PLASMA; OMEGA-3-FATTY-ACIDS; SUPPLEMENTATION;
   FLAXSEED; MANAGEMENT
AB Background: & aims: Few clinical trials have addressed the potential benefits of omega-3 polyunsaturated fatty acids (PUFAs) on non-alcoholic steatohepatitis (NASH). We evaluated the effects of supplementation with omega-3 PUFAs from flaxseed and fish oils in patients with biopsy-proven NASH.
   Methods: Patients received three capsules daily, each containing 0315 g of omega-3 PUFAs (64% alpha-linolenic [ALA], 16% eicosapentaenoic [EPA], and 21% docosahexaenoic [DHA] acids; n-3 group, n = 27) or mineral oil (placebo group, n = 23). Liver biopsies were evaluated histopathologically by the NASH activity score (NAS). Plasma levels of omega-3 PUFAs were assessed as a marker of intake at baseline and after 6 months of treatment. Secondary endpoints included changes in plasma biochemical markers of lipid metabolism, inflammation, and liver function at baseline and after 3 and 6 months of treatment.
   Results: At baseline, NAS was comparable between the groups (p = 0.98). After intervention with omega 3 PUFAs, plasma ALA and EPA levels increased (p <= 0.05). However in the placebo group, we also observed increased EPA and DHA (p <= 0.05), suggesting an off-protocol intake of PUFAs. NAS improvement/stabilization was correlated with increased ALA in the n-3 group (p = 0.02) and with increased EPA (p = 0.04) and DHA (p = 0.05) in the placebo group. Triglycerides were reduced after 3 months in the n-3 group compared to baseline (p = 0.01).
   Conclusions: In NASH patients, the supplementation of omega-3 PUFA from flaxseed and fish oils significantly impacts on plasma lipid profile of patients with NASH. Plasma increase of these PUFAs was associated with better liver histology. (C) 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
C1 [Nogueira, Monize Aydar; Oliveira, Claudia Pinto; Stefano, Jose Tadeu; Cogliati, Bruno; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Clin Div Clin Gastroenterol & Hepatol LIM 07, Sao Paulo, Brazil.
   [Ferreira Alves, Venancio Avancini] Univ Sao Paulo, Sch Med, Dept Pathol LIM 14, Sao Paulo, Brazil.
   [dos Reis Rodrigues, Livia Samara; Torrinhas, Raquel Susana; Waitzberg, Dan Linetzky] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Surg Div LIM 35, Sao Paulo, Brazil.
   [Barbeiro, Hermes] Univ Sao Paulo, Sch Med, Dept Emergency LIM 51, Sao Paulo, Brazil.
RP Waitzberg, DL (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Surg Div LIM 35, Sao Paulo, Brazil.
EM dan@ganep.com.br
RI Stefano, Jose T/H-4792-2013; Torrinhas, Raquel Susana/AAH-4722-2019;
   Stefano, Jose Tadeu/AAH-5419-2020; Carrilho, Flair J/I-3046-2012;
   Barbeiro, Hermes V/S-5926-2016; Cogliati, Bruno/E-9956-2012; Barbeiro,
   Hermes V/E-2814-2010; Oliveira, Claudia PMS/D-1216-2014
OI Torrinhas, Raquel Susana/0000-0003-0874-3995; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Barbeiro, Hermes V/0000-0002-8209-4463;
   Cogliati, Bruno/0000-0002-1388-7240; Barbeiro, Hermes
   V/0000-0002-8209-4463; 
FU Department of Gastroenterology, School of Medicine, University of Sao
   Paulo, Brazil [LIM-07]
FX This study was funded by the Department of Gastroenterology (LIM-07),
   School of Medicine, University of Sao Paulo, Brazil. Omega-3 and placebo
   capsules were provided by Amway (USA). The authors have no conflicts of
   interest to disclose.
CR Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012
   Alwayn IPJ, 2005, TRANSPLANTATION, V79, P606, DOI 10.1097/01.TP.0000150023.86487.44
   Araya J, 2004, CLIN SCI, V106, P635, DOI 10.1042/CS20030326
   Argo CK, 2015, J HEPATOL, V62, P190, DOI 10.1016/j.jhep.2014.08.036
   Berlanga A, 2014, CLIN EXP GASTROENTER, V7, P221, DOI 10.2147/CEG.S62831
   Bloedon LT, 2008, J AM COLL NUTR, V27, P65, DOI 10.1080/07315724.2008.10719676
   Capanni M, 2006, ALIMENT PHARM THER, V23, P1143, DOI 10.1111/j.1365-2036.2006.02885.x
   Dasarathy S, 2015, J CLIN GASTROENTEROL, V49, P137, DOI 10.1097/MCG.0000000000000099
   Dewell A, 2011, J NUTR, V141, P2166, DOI 10.3945/jn.111.142240
   Fukumitsu S, 2013, CYTOTECHNOLOGY, V65, P899, DOI 10.1007/s10616-012-9510-x
   Harper CR, 2006, J NUTR, V136, P83
   Iverson SJ, 2001, LIPIDS, V36, P1283, DOI 10.1007/s11745-001-0843-0
   Janczyk W, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-85
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158
   Masterton GS, 2010, ALIMENT PHARM THER, V31, P679, DOI 10.1111/j.1365-2036.2010.04230.x
   Torrinhas RSMD, 2013, CLIN NUTR, V32, P503, DOI 10.1016/j.clnu.2012.12.008
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   McClain CJ, 2004, ALCOHOL, V34, P67, DOI 10.1016/j.alcohol.2004.07.007
   *NAT CHOL ED PROGR, 2001, NIH PUBL
   Nobili V, 2013, NUTR METAB CARDIOVAS, V23, P1066, DOI 10.1016/j.numecd.2012.10.010
   Pan A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001148
   Parker HM, 2012, J HEPATOL, V56, P944, DOI 10.1016/j.jhep.2011.08.018
   Sanyal AJ, 2014, GASTROENTEROLOGY, V147, P377, DOI 10.1053/j.gastro.2014.04.046
   Scorletti E, 2013, ANNU REV NUTR, V33, P231, DOI 10.1146/annurev-nutr-071812-161230
   Scorletti E, 2014, HEPATOLOGY, V60, P1211, DOI 10.1002/hep.27289
   Shirai N, 2005, ANAL BIOCHEM, V343, P48, DOI 10.1016/j.ab.2005.04.037
   Spadaro L, 2008, DIGEST LIVER DIS, V40, P194, DOI 10.1016/j.dld.2007.10.003
   Tanaka N, 2008, J CLIN GASTROENTEROL, V42, P413, DOI 10.1097/MCG.0b013e31815591aa
   Wu HY, 2010, J NUTR, V140, P1937, DOI 10.3945/jn.110.126300
   Zelber-Sagi S, 2011, WORLD J GASTROENTERO, V17, P3377, DOI 10.3748/wjg.v17.i29.3377
   Zhu FS, 2008, WORLD J GASTROENTERO, V14, P6395, DOI 10.3748/wjg.14.6395
NR 32
TC 52
Z9 53
U1 2
U2 37
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0261-5614
EI 1532-1983
J9 CLIN NUTR
JI Clin. Nutr.
PD JUN
PY 2016
VL 35
IS 3
BP 578
EP 586
DI 10.1016/j.clnu.2015.05.001
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DN1GQ
UT WOS:000376814700004
PM 26047766
DA 2020-12-08
ER

PT J
AU Loureiro, R
   Dias, MV
   Becho, J
   Santos, M
   Carrilho, F
   Costa, P
   Cruz, J
   Fidalgo, C
   Roxo, F
   Palos, A
AF Loureiro, R.
   Dias, M. V.
   Becho, J.
   Santos, M.
   Carrilho, F.
   Costa, P.
   Cruz, J.
   Fidalgo, C.
   Roxo, F.
   Palos, A.
TI Autoimmune meningoencephalitis with two possible etiologic factors: HCV
   infection and anti-NMDA receptor antibodies
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
C1 [Loureiro, R.; Dias, M. V.; Becho, J.; Palos, A.] Hosp Dist Santarem, Neurol, Santarem, Portugal.
   [Santos, M.; Costa, P.; Cruz, J.; Fidalgo, C.] Hosp Dist Santarem, Intens Care Unit, Santarem, Portugal.
   [Carrilho, F.] Hosp Dist Santarem, Santarem, Portugal.
   [Roxo, F.] Hosp Dist Santarem, Internal Med, Santarem, Portugal.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD JUN
PY 2016
VL 23
SU 2
SI SI
MA P22195
BP 585
EP 585
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA VC1UO
UT WOS:000431634202441
DA 2020-12-08
ER

PT J
AU Moreira, JP
   Malta, FD
   Diniz, MA
   Kikuchi, L
   Chagas, AL
   Lima, LDB
   Gomes-Gouvea, MS
   de Castro, VFD
   Santana, RAF
   Sumita, NM
   Vezozzo, DCP
   Carrilho, FJ
   Pinho, JRR
AF Moreira, Joao Paulo
   Malta, Fernanda de Mello
   Diniz, Marcio Augusto
   Kikuchi, Luciana
   Chagas, Aline Lopes
   Botelho Lima, Livia de Souza
   Gomes-Gouvea, Michele Soares
   Duarte de Castro, Vanessa Fusco
   Ferraz Santana, Rubia Anita
   Sumita, Nairo Massakazu
   Paranagua Vezozzo, Denise Cerqueira
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Interferon lambda and hepatitis C virus core protein polymorphisms
   associated with liver cancer
SO VIROLOGY
LA English
DT Article
DE Hepatitis C virus; Chronic hepatitis; Mutation; Infection; Oncogenesis;
   Immune responses
ID RIBAVIRIN COMBINATION THERAPY; AMINO-ACID SUBSTITUTIONS;
   HEPATOCELLULAR-CARCINOMA; PREDICTIVE FACTORS; GENETIC-VARIATION;
   GENOTYPE 1B; IL28B; REGION; CLEARANCE; DISEASE
AB Background: Hepatitis C virus (HCV) infection is often persistent and gradually advances from chronic hepatitis to liver cirrhosis and hepatocellular carcinoma (HCC). Worldwide, hepatocellular carcinoma is the fifth most common neoplasm.
   Method of study: the Interferon lambda (IFNL) polymorphisms genotypes (rs8099917, rs12979860 and rs12980275) and the presence of mutations in HCV core protein were analyzed in 59 patients with HCC, and also in 50 cirrhotic patients (without HCC).
   Results: the rs12980275-AG genotype was associated with HCC on age-adjusted analysis (OR 2.42, 95% CI 1.03-5.69, P=0.043). Core substitutions R70Q and L91M were mainly found in genotype 1b isolates. Furthermore, a borderline level of statistical significance association was found among the presence of amino acid Glutamine (Q) in the position 70 and IFNL3 genotype AG (P=0.054).
   Conclusions: the screening of these polymorphisms and functional studies would be useful in clinical practice for identifying groups at high risk of HCC development. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Moreira, Joao Paulo; Malta, Fernanda de Mello; Botelho Lima, Livia de Souza; Gomes-Gouvea, Michele Soares; Rebello Pinho, Joao Renato] Univ Sao Paulo, Inst Trop Med, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, LIM 07, BR-05403000 Sao Paulo, SP, Brazil.
   [Moreira, Joao Paulo; Malta, Fernanda de Mello; Diniz, Marcio Augusto; Kikuchi, Luciana; Chagas, Aline Lopes; Botelho Lima, Livia de Souza; Gomes-Gouvea, Michele Soares; Paranagua Vezozzo, Denise Cerqueira; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, SP, Brazil.
   [Diniz, Marcio Augusto] Cedars Sinai Med Ctr, Samuel Oschin Canc Inst, Los Angeles, CA 90048 USA.
   [Duarte de Castro, Vanessa Fusco; Ferraz Santana, Rubia Anita; Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Sumita, Nairo Massakazu] Univ Sao Paulo, Cent Lab, Div Hosp Clin, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
RP Malta, FD (corresponding author), Univ Sao Paulo, Inst Trop Med, Av Dr Eneas Carvalho Aguiar 500,2nd Floor IMT-2, BR-05403000 Sao Paulo, SP, Brazil.
EM femalta@yahoo.com
RI Pinho, Joao R. R./G-2850-2012; Chagas, Aline Lopes/X-2059-2019; Malta,
   Fernanda/B-1316-2013; Moreira, Joao Paulo/M-9185-2013; Ibrahim, Essam
   H./G-1960-2018; Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014;
   Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; Ibrahim, Essam H./0000-0003-0130-2257;
   Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; Diniz, Marcio
   Augusto/0000-0002-2427-7843
FU FapespFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2011/50562-0]; Alves de Queiroz Family Fund for Research; CAPESCAPES;
   CNPq (Bolsista de Produtividade em Pesquisa do CNPq - Nivel 2)National
   Council for Scientific and Technological Development (CNPq)
FX This Project was supported by grant 2011/50562-0 (Fapesp) and Alves de
   Queiroz Family Fund for Research. Joao Paulo Moreira is a graduate
   student from Programa de Pos-Graduacao Ciencias em Gastroenterologia,
   FMUSP and receives a fellowship from CAPES. Joao Renato Rebello Pinho
   receive fellowship from CNPq (Bolsista de Produtividade em Pesquisa do
   CNPq - Nivel 2).
CR Akuta N, 2006, J MED VIROL, V78, P83, DOI 10.1002/jmv.20507
   Akuta N, 2007, HEPATOLOGY, V46, P1357, DOI 10.1002/hep.21836
   Akuta N, 2007, J HEPATOL, V46, P403, DOI 10.1016/j.jhep.2006.09.019
   ANDERSON TW, 1952, ANN MATH STAT, V23, P193, DOI 10.1214/aoms/1177729437
   Araujo OC, 2014, J MED VIROL, V86, P217, DOI 10.1002/jmv.23837
   Banerjee A, 2010, VIRUSES-BASEL, V2, P2108, DOI 10.3390/v2092108
   Bosetti C, 2014, BEST PRACT RES CL GA, V28, P753, DOI 10.1016/j.bpg.2014.08.007
   Cavalcante LN, 2012, LIVER INT, V32, P476, DOI 10.1111/j.1478-3231.2011.02653.x
   Chang KC, 2015, CLIN GASTROENTEROL H, V13, P1017, DOI 10.1016/j.cgh.2014.10.035
   Chen CCM, 2011, IEEE ACM T COMPUT BI, V8, P1580, DOI 10.1109/TCBB.2011.46
   Chen RF, 2007, ONCOL REP, V17, P105
   El-Shamy A, 2013, HEPATOLOGY, V58, P555, DOI 10.1002/hep.26205
   EMIGH TH, 1980, BIOMETRICS, V36, P627, DOI 10.2307/2556115
   Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
   Kang SM, 2009, CANCER LETT, V279, P230, DOI 10.1016/j.canlet.2009.02.003
   Kelly C, 2011, GUT, V60, P1284, DOI 10.1136/gut.2010.222976
   Kikuchi L, 2013, ANTIVIR THER, V18, P445, DOI 10.3851/IMP2602
   Kobayashi M, 2010, J MED VIROL, V82, P41, DOI 10.1002/jmv.21629
   Lin MV, 2015, ANNU REV PATHOL-MECH, V10, P345, DOI 10.1146/annurev-pathol-012414-040323
   Miura M, 2013, J VIROL, V87, P12541, DOI 10.1128/JVI.00826-13
   Miura M, 2012, HEPATOL INT, V6, P386, DOI 10.1007/s12072-011-9307-6
   Nakamoto S, 2010, J HEPATOL, V52, P72, DOI 10.1016/j.jhep.2009.10.001
   Prokunina-Olsson L, 2013, NAT GENET, V45, P164, DOI 10.1038/ng.2521
   Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295
   Ren S, 2012, CANCER IMMUNOL IMMUN, V61, P1433, DOI 10.1007/s00262-012-1203-y
   Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
   Spengler U, 2007, CLIN SCI, V112, P141, DOI 10.1042/CS20060171
   STUYVER L, 1995, VIRUS RES, V38, P137, DOI 10.1016/0168-1702(95)00052-R
   Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449
   Team R. C., 2014, R LANG ENV STAT COMP
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Thomas E, 2012, GASTROENTEROLOGY, V142, P978, DOI 10.1053/j.gastro.2011.12.055
   Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05
   WHO, 1999, WEEKLY EPIDEMIOLOGIC, V72, P341
   Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100
   Yeom SK, 2015, WORLD J HEPATOL, V7, P2069, DOI 10.4254/wjh.v7.i17.2069
NR 38
TC 4
Z9 4
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN
PY 2016
VL 493
BP 136
EP 141
DI 10.1016/j.virol.2016.03.008
PG 6
WC Virology
SC Virology
GA DL7MH
UT WOS:000375824300013
PM 27035616
OA Bronze
DA 2020-12-08
ER

PT J
AU Chan, AJ
   Ballerga, EG
   Kikuchi, L
   Prieto, JE
   Tapias, M
   Idrovo, V
   Davalos, MB
   Cairo, F
   Barreyro, FJ
   Paredes, S
   Hernandez, N
   Avendano, K
   Ferrer, JD
   Yang, JD
   Carrera, E
   Balderramo, D
   Mattos, A
   Hirsch, BS
   Goncalves, PT
   Carrilho, FJ
   Roberts, L
   Debes, JD
AF Chan, Aaron J.
   Ballerga, Esteban Gonzalez
   Kikuchi, Luciana
   Prieto, Jhon E.
   Tapias, Monica
   Idrovo, Victor
   Davalos, Milagros B.
   Cairo, Fernando
   Barreyro, Fernando J.
   Paredes, Sebastian
   Hernandez, Nelia
   Avendano, Karla
   Ferrer, Javier Diaz
   Yang, Ju Dong
   Carrera, Enrique
   Balderramo, Domingo
   Mattos, Angelo
   Hirsch, Bruno S.
   Goncalves, Pablo T.
   Carrilho, Flair J.
   Roberts, Lewis
   Debes, Jose D.
TI Hepatocellular Carcinoma in South America: Predominance of Hepatitis C
   Etiology and Late Diagnosis
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 57th Annual Meeting and Residents Fellow Conference of the
   Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / 52nd Annual Meeting
   on Digestive Disease Week (DDW) / Meeting of the
   American-Gastroenterological-Association (AGA)
CY MAY 21-24, 2016
CL San Diego, CA
SP Soc Surg Alimentary Tract, Amer Gastroenterol Assoc
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2016
VL 150
IS 4
SU 1
MA Mo1495
BP S1130
EP S1130
DI 10.1016/S0016-5085(16)33817-3
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EH4ZZ
UT WOS:000391783700318
DA 2020-12-08
ER

PT J
AU Oliveira, KG
   Malta, FM
   Nastri, ACSS
   Widman, A
   Faria, PL
   Santana, RAF
   Alves, VAF
   Carrilho, FJ
   Pinho, JRR
AF Oliveira, Ketti G.
   Malta, Fernanda M.
   Nastri, Ana C. S. S.
   Widman, Azzo
   Faria, Paola L.
   Santana, Rubia A. F.
   Alves, Venancio A. F.
   Carrilho, Flair J.
   Pinho, Joao R. R.
TI Increased hepatic expression of miRNA-122 in patients infected with HCV
   genotype 3
SO MEDICAL MICROBIOLOGY AND IMMUNOLOGY
LA English
DT Article
DE Hepatic expression; Lipid metabolism; miR-122; HCV infection
ID GENE-EXPRESSION; MIR-122; PROTEIN; LIVER; STEATOSIS; MICRORNAS;
   METABOLISM; SECRETION; MODEL
AB Hepatitis C virus (HCV) infection affects approximately 3 % of the world population. HCV targets hepatic tissue, and most infected patients develop a chronic infection. Currently, studies have demonstrated an association between HCV-RNA replication and miR-122, the most abundant microRNA in the liver. Our aim was to evaluate liver and serum expression of miR-122 in patients infected with HCV genotypes 1 and 3, and to identify possible associations between miR-122 expression and lipid profiles, HCV viral load, apolipoproteins and liver enzymes. MicroRNAs were isolated from blood and liver tissue, and miR-122 expression was quantified by real-time PCR. HCV viral load was quantified by real-time PCR and HCV genotype, and serum biomarkers were obtained from medical report. The levels of miR-122 were higher in liver than those in blood from individuals infected with HCV genotypes 1 and 3 (p < 0.0001). The tissue levels of miR-122 were higher in subjects infected with HCV genotype 3 (6.22-fold, p < 0.001). A positive correlation was observed between the blood and hepatic levels of miR-122 in patients infected with HCV genotype 1 (r = 0.302, p = 0.026); in these patients, an inverse correlation was observed between serum apolipoprotein A-II (ApoA-II) levels and the blood (r = -0.330; p = 0.014) and hepatic (r = -0.311; p = 0.020) levels of miR-122. In patients infected with HCV genotype 3, there was a positive correlation between the hepatic miR-122 and the high-density lipoprotein-HDL (r = 0.412, p = 0.036) and insulin (r = 0.478, p = 0.044). Lipid metabolism proteins and miR-122 expression levels have different relations in HCV-3- and HCV-1-infected patients.
C1 [Oliveira, Ketti G.; Malta, Fernanda M.; Widman, Azzo; Faria, Paola L.; Carrilho, Flair J.; Pinho, Joao R. R.] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Malta, Fernanda M.; Faria, Paola L.; Pinho, Joao R. R.] Univ Sao Paulo, Inst Trop Med, Av Dr Eneas Carvalho Aguiar,500-2 Andar IMT II, BR-05403000 Sao Paulo, SP, Brazil.
   [Oliveira, Ketti G.; Santana, Rubia A. F.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Nastri, Ana C. S. S.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RP Malta, FM (corresponding author), Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.; Malta, FM (corresponding author), Univ Sao Paulo, Inst Trop Med, Av Dr Eneas Carvalho Aguiar,500-2 Andar IMT II, BR-05403000 Sao Paulo, SP, Brazil.
EM femalta@yahoo.com
RI Malta, Fernanda/B-1316-2013; Pinho, Joao R. R./G-2850-2012; Carrilho,
   Flair J/I-3046-2012
OI Malta, Fernanda/0000-0001-8887-5060; Pinho, Joao R.
   R./0000-0003-3999-0489; 
FU CNPq (Bolsistade Produtividade em Pesquisa do CNPq-Nivel 2)
FX FAPESP Sao Paulo Research Foundation(2012/50332-7 and 2012/15706-3) and
   Alves de Queiroz Family Fundfor Research. Joao R. R. Pinho receives
   fellowship from CNPq (Bolsistade Produtividade em Pesquisa do CNPq-Nivel
   2).
CR Abid K, 2005, J HEPATOL, V42, P744, DOI 10.1016/j.jhep.2004.12.034
   Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Bostjancic E, 2015, J VIRAL HEPATITIS, V22, P146, DOI 10.1111/jvh.12266
   Cermelli S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023937
   Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066
   Cheng JC, 2012, CELL MOL LIFE SCI, V69, P2621, DOI 10.1007/s00018-012-0940-6
   Cheung O, 2008, HEPATOLOGY, V48, P1810, DOI 10.1002/hep.22569
   Douam F, 2015, PROG MOL BIOL TRANSL, V129, P63, DOI 10.1016/bs.pmbts.2014.10.003
   Erson AE, 2008, CLIN GENET, V74, P296, DOI 10.1111/j.1399-0004.2008.01076.x
   Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005
   Fukuhara T, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004534
   Gastaminza P, 2008, J VIROL, V82, P2120, DOI 10.1128/JVI.02053-07
   Girard M, 2008, J HEPATOL, V48, P648, DOI 10.1016/j.jhep.2008.01.019
   Horie T, 2014, J ATHEROSCLER THROMB, V21, P17
   Hou WH, 2010, HEPATOLOGY, V51, P1494, DOI 10.1002/hep.23401
   Hourioux C, 2007, GUT, V56, P1302, DOI 10.1136/gut.2006.108647
   Hsu SH, 2012, J CLIN INVEST, V122, P2871, DOI 10.1172/JCI63539
   Jackel-Cram C, 2010, J GEN VIROL, V91, P1388, DOI 10.1099/vir.0.017418-0
   Jiang JY, 2009, J VIROL, V83, P12680, DOI 10.1128/JVI.01476-09
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Morita K, 2011, LIVER INT, V31, P474, DOI 10.1111/j.1478-3231.2010.02433.x
   Murakami Y, 2009, J HEPATOL, V50, P453, DOI 10.1016/j.jhep.2008.06.010
   Pazienza V, 2009, LIVER INT, V29, P661, DOI 10.1111/j.1478-3231.2008.01866.x
   Piodi A, 2008, HEPATOLOGY, V48, P16, DOI 10.1002/hep.22288
   Rubbia-Brandt L, 2000, J HEPATOL, V33, P106, DOI 10.1016/S0168-8278(00)80166-X
   Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429
   Schaefer EAK, 2013, SEMIN LIVER DIS, V33, P358, DOI 10.1055/s-0033-1358524
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Shibata C, 2013, BIOCHEM BIOPH RES CO, V438, P230, DOI 10.1016/j.bbrc.2013.07.064
   Thomas DL, 2013, TOP ANTIVIR MED, V21, P152
   Tsai WC, 2012, J CLIN INVEST, V122, P2884, DOI 10.1172/JCI63455
NR 33
TC 6
Z9 7
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0300-8584
EI 1432-1831
J9 MED MICROBIOL IMMUN
JI Med. Microbiol. Immunol.
PD APR
PY 2016
VL 205
IS 2
BP 111
EP 117
DI 10.1007/s00430-015-0431-0
PG 7
WC Immunology; Microbiology
SC Immunology; Microbiology
GA DG6DA
UT WOS:000372171200002
PM 26272127
DA 2020-12-08
ER

PT J
AU Abreu, RM
   Ferreira, CD
   Ferreira, AS
   Remor, E
   Nasser, PD
   Carrilho, FJ
   Ono, SK
AF Abreu, Rodrigo Martins
   Ferreira, Camila da Silva
   Ferreira, Aline Siqueira
   Remor, Eduardo
   Nasser, Paulo Dominguez
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI Assessment of Adherence to Prescribed Therapy in Patients with Chronic
   Hepatitis B
SO INFECTIOUS DISEASES AND THERAPY
LA English
DT Article
DE Assessment tool; Chronic disease; Hepatitis B; Patient adherence;
   Questionnaire
ID SELF-RATING INSTRUMENTS; PSYCHOMETRIC PROPERTIES; ANTIRETROVIRAL
   THERAPY; ANTIVIRAL TREATMENT; VIRUS INFECTION; MEDICATION; MANAGEMENT;
   VALIDITY
AB Evidence shows that treatment for hepatitis B virus (HBV) can suppress viral load. Among the factors directly linked to therapeutic success is adherence to the treatment. Several instruments to assess adherence are available, but they are not validated for use in chronic hepatitis B. The purpose of this paper was to adapt and validate the "Assessment of Adherence to Antiretroviral Therapy Questionnaire-HIV" (CEAT-VIH) for patients with chronic hepatitis B (referred to herein as CEAT-HBV).
   The validity of the adapted questionnaire evidence was established through concurrent, criterion, and construct validities.
   We found negative and significant correlation between the domain "degree of compliance to antiviral therapy" assessed by CEAT-HBV and the Morisky test (r = -0.62, P < 0.001) and between the domain "barriers to adherence" and HBV viral load (r = -0.42, P < 0.001). In terms of the construct's discriminative capacity, scores greater than or equal to 80 detected antiviral therapy success, which are necessary for the prediction of an undetectable HBV viral load. Thus, a cutoff value of 80.5 was set with a value of 81% for sensitivity and 67% for specificity.
   The CEAT-HBV identified 43% (n = 79) non-adherent patients and was shown to be a useful tool in clinical practice.
C1 [Abreu, Rodrigo Martins; Ferreira, Camila da Silva; Ferreira, Aline Siqueira; Nasser, Paulo Dominguez; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Remor, Eduardo] Univ Autonoma Madrid, Fac Psychol, Madrid, Spain.
RP Ono, SK (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, Sao Paulo, Brazil.
EM skon@usp.br
RI Remor, Eduardo/B-7133-2011; Carrilho, Flair J/I-3046-2012
OI Remor, Eduardo/0000-0002-5393-8700; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Alves de Queiroz Family Fund for Research
FX This research was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and Alves de Queiroz Family Fund for
   Research. All named authors meet the International Committee of Medical
   Journal Editors (ICMJE) criteria for authorship for this manuscript,
   take responsibility for the integrity of the work as a whole, and have
   given final approval for the version to be published.
CR Abreu RM, 2013, QUESTIONNAIRE VALIDA
   [Anonymous], 2010, PROT CLIN DIR TER TR
   Ayoub WS, 2011, ALIMENT PHARM THER, V34, P1145, DOI 10.1111/j.1365-2036.2011.04869.x
   Brasil. Ministerio da Saude, 2008, REC TER ANT AD INF P
   Chotiyaputta W, 2012, J VIRAL HEPATITIS, V19, P205, DOI 10.1111/j.1365-2893.2011.01494.x
   Chotiyaputta W, 2011, J HEPATOL, V54, P12, DOI 10.1016/j.jhep.2010.06.016
   CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/h0040957
   Dima AL, 2013, PSYCHOL HEALTH MED, V18, P343, DOI 10.1080/13548506.2012.722648
   Garcia-Llana H, 2013, PSICOTHEMA, V25, P79, DOI 10.7334/psicothema2012.96
   Ha NB, 2011, DIGEST DIS SCI, V56, P2423, DOI 10.1007/s10620-011-1610-5
   HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757
   Hilleret MN, 2011, J HEPATOL, V55, P1468, DOI 10.1016/j.jhep.2011.04.006
   Hoofnagle JH, 2006, NEW ENGL J MED, V354, P1074, DOI 10.1056/NEJMe058309
   KANE M, 1995, VACCINE, V13, pS47
   Keeffe EB, 2006, CLIN GASTROENTEROL H, V4, P936, DOI 10.1016/j.cgh.2006.05.016
   Kim V, 2016, J VIRAL HEPATITIS, V23, P154, DOI 10.1111/jvh.12418
   Koschack J, 2010, J CLIN EPIDEMIOL, V63, P299, DOI 10.1016/j.jclinepi.2009.06.011
   Lacey L, 2004, J GASTROEN HEPATOL, V19, pS10, DOI 10.1111/j.1440-1746.2003.03392.x
   Lieveld FI, 2013, ANN HEPATOL, V12, P380, DOI 10.1016/S1665-2681(19)31000-2
   Locarnini S, 2004, ANTIVIR THER, V9, P679
   Mao HF, 2002, STROKE, V33, P1022, DOI 10.1161/01.STR.0000012516.63191.C5
   MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007
   Ono SK, 2001, J CLIN INVEST, V107, P449, DOI 10.1172/JCI11100
   Ono-Nita SK, 1999, J CLIN INVEST, V103, P1635, DOI 10.1172/JCI5882
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Remor E, 2002, PSICOTHEMA, V14, P262
   Remor E, 2007, REV SAUDE PUBL, V41, P685, DOI [10.1590/S0034-89102006005000043, 10.1590/s0034-89102007000500001]
   Remor E, 2013, PATIENT, V6, P61, DOI 10.1007/s40271-013-0009-0
   Sogni P, 2012, ANTIVIR THER, V17, P395, DOI 10.3851/IMP1944
   Tauil MD, 2012, CAD SAUDE PUBLICA, V28, P472, DOI 10.1590/S0102-311X2012000300007
   Voils CI, 2011, J CLIN EPIDEMIOL, V64, P1
   Voils CI, 2011, J CLIN EPIDEMIOL, V64, P340, DOI 10.1016/j.jclinepi.2009.11.022
   Zoulim F, 2011, NAT REV GASTRO HEPAT, V8, P366, DOI 10.1038/nrgastro.2011.104
NR 33
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 2193-8229
EI 2193-6382
J9 INFECT DIS THER
JI Infect. Dis. Ther.
PD MAR
PY 2016
VL 5
IS 1
BP 53
EP 64
DI 10.1007/s40121-015-0101-y
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA EL0LQ
UT WOS:000394314300005
PM 26757720
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Kim, V
   Abreu, RM
   Nakagawa, DM
   Baldassare, RM
   Carrilho, FJ
   Ono, SK
AF Kim, V.
   Abreu, R. M.
   Nakagawa, D. M.
   Baldassare, R. M.
   Carrilho, F. J.
   Ono, S. K.
TI Pegylated interferon alfa for chronic hepatitis B: systematic review and
   meta-analysis
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Review
DE chronic hepatitis B; meta-analysis; pegylated interferon alfa;
   randomized controlled trials
ID LAMIVUDINE COMBINATION THERAPY; PEGINTERFERON ALPHA-2A; ADEFOVIR
   DIPIVOXIL; CONTROLLED-TRIAL; DISEASE BURDEN; HBEAG; MONOTHERAPY;
   EFFICACY; HBSAG; ENTECAVIR
AB Conventional interferon alfa and nucleos(t)ide analogues, such as lamivudine, are frequently used for chronic hepatitis B (CHB) treatment, but are associated with adverse effects and viral resistance. Here we performed a systematic review and meta-analysis evaluating all studies of pegylated interferon alfa (PEG-IFN) treatment in hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients with CHB. We searched electronic databases - PubMed, EMBASE, Cochrane Library and LILACS - for randomized controlled trials evaluating PEG-IFN therapy between 1999 and September 2014. Virological response was the primary outcome. We identified 14 studies involving 2829 patients. Our analysis revealed that PEG-IFN+lamivudine combination therapy produced better virological and biochemical responses than PEG-IFN monotherapy in HBeAg-positive and HBeAg-negative patients at the end of treatment. PEG-IFN+adefovir dipivoxil achieved better seroconversion rate than PEG-IFN in HBeAg-positive patients at the end of treatment. The present findings demonstrated a beneficial response rate following PEG-IFN combination therapy with nucelos(t)ides among HBeAg-positive and HBeAg-negative patients with CHB. Further trials are needed to investigate simultaneous and sequential therapy strategies.
C1 [Kim, V.; Abreu, R. M.; Nakagawa, D. M.; Baldassare, R. M.; Carrilho, F. J.; Ono, S. K.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, Av Dr Eneas Carvalho de Aguiar,255,ICHC,9th Floor, BR-05403000 Sao Paulo, Brazil.
RP Ono, SK (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Clin Gastroenterol & Hepatol, Av Dr Eneas Carvalho de Aguiar,255,ICHC,9th Floor, BR-05403000 Sao Paulo, Brazil.
EM skon@usp.br
RI Carrilho, Flair J/I-3046-2012
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [576631/2008-6]; Alves de Queiroz Family Fund for Research
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq No. 576631/2008-6) and Alves de Queiroz
   Family Fund for Research. The authors would like to thank the other
   investigators of the study group: Fernanda Rocha Barbosa (University of
   Sao Paulo School of Medicine) and Helena Scavone Paschoale (University
   of Sao Paulo School of Medicine).
CR Boglione L, 2013, J VIRAL HEPATITIS, V20, pe11, DOI 10.1111/jvh.12018
   Cao ZH, 2013, J DIGEST DIS, V14, P446, DOI 10.1111/1751-2980.12065
   Chen CC, 2012, J VIRAL HEPATITIS, V19, P161, DOI 10.1111/j.1365-2893.2011.01469.x
   Cooksley WGE, 2003, J VIRAL HEPATITIS, V10, P298, DOI 10.1046/j.1365-2893.2003.00450.x
   Deng Zhenzhen, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P1193, DOI 10.3969/j.issn.1672-7347.2013.12.001
   Feld J, 2003, HEPATOLOGY, V38, P545, DOI 10.1053/jhep.2003.50389
   Fung SK, 2004, J VIRAL HEPATITIS, V11, P432, DOI 10.1111/j.1365-2893.2004.00556.x
   Goldstein ST, 2005, INT J EPIDEMIOL, V34, P1329, DOI 10.1093/ije/dyi206
   Hadziyannis SJ, 2000, HEPATOLOGY, V32, P847, DOI 10.1053/jhep.2000.17915
   Hadziyannis SJ, 2005, NEW ENGL J MED, V352, P2673, DOI 10.1056/NEJMoa042957
   Hadziyannis SJ, 2012, GASTROENTEROLOGY, V143, P629, DOI 10.1053/j.gastro.2012.05.039
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Huang Z, 2013, J VIRAL HEPATITIS, V20, P52, DOI 10.1111/jvh.12064
   Huang ZL, 2013, EUR J GASTROEN HEPAT, V25, P1165, DOI 10.1097/MEG.0b013e3283612e95
   Janssen HLA, 2005, LANCET, V365, P123, DOI 10.1016/S0140-6736(05)17701-0
   Kaymakoglu S, 2007, ANTIMICROB AGENTS CH, V51, P3020, DOI 10.1128/AAC.00088-07
   Kioko Ono-Nita Suzane, 2001, Curr Infect Dis Rep, V3, P137
   Lacey L, 2004, J GASTROEN HEPATOL, V19, pS10, DOI 10.1111/j.1440-1746.2003.03392.x
   Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201
   Lai CL, 2003, CLIN INFECT DIS, V36, P687, DOI 10.1086/368083
   Lampertico P, 2003, HEPATOLOGY, V37, P756, DOI 10.1053/jhep.2003.50148
   Lampertico P, 2013, GUT, V62, P290, DOI 10.1136/gutjnl-2011-301430
   Lau GKK, 2005, NEW ENGL J MED, V352, P2682, DOI 10.1056/NEJMoa043470
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Levrero M, 2009, J HEPATOL, V51, P581, DOI 10.1016/j.jhep.2009.05.022
   Liaw YF, 1999, HEPATOLOGY, V30, P567, DOI 10.1002/hep.510300221
   LIAW YF, 1994, J HEPATOL, V20, P175, DOI 10.1016/S0168-8278(05)80055-8
   Liaw YF, 2013, HEPATOLOGY, V58, P1856, DOI 10.1002/hep.26358
   Liu YH, 2014, J HUAZHONG U SCI-MED, V34, P542, DOI 10.1007/s11596-014-1312-2
   LOK ASF, 1992, GASTROENTEROLOGY, V102, P2091, DOI 10.1016/0016-5085(92)90337-X
   Manesis EK, 2007, ANTIVIR THER, V12, P73
   Marcellin P, 2004, NEW ENGL J MED, V351, P1206, DOI 10.1056/NEJMoa040431
   Marcellin P, 2014, HEPATOLOGY, V60, p294A
   Marcellin P, 2009, J HEPATOL, V50, P227, DOI 10.1016/j.jhep.2008.10.001
   Moucari R, 2011, J VIRAL HEPATITIS, V18, P580, DOI 10.1111/j.1365-2893.2010.01332.x
   Moucari R, 2009, HEPATOLOGY, V49, P1151, DOI 10.1002/hep.22744
   Ning Q, 2014, J HEPATOL, V61, P777, DOI 10.1016/j.jhep.2014.05.044
   Papadopoulos VP, 2009, MED SCI MONITOR, V15, pCR56
   Papatheodoridis G, 2012, J HEPATOL, V57, P167, DOI 10.1016/j.jhep.2012.02.010
   Piccolo P, 2013, ANTIVIR THER, V18, P57, DOI 10.3851/IMP2281
   Piccolo P, 2009, ANTIVIR THER, V14, P1165, DOI 10.3851/IMP1466
   Rijckborst V, 2011, ALIMENT PHARM THER, V33, P501, DOI 10.1111/j.1365-2036.2010.04555.x
   Shi Y, 2010, HEPATOB PANCREAT DIS, V9, P462
   Suh DJ, 2013, ANTIVIR THER, V18, P765, DOI 10.3851/IMP2664
   Wang YD, 2012, HEPATO-GASTROENTEROL, V59, P680, DOI 10.5754/hge12183
   Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018
   World Health Organization, 2014, HEP B
   Xie Q, 2014, CLIN INFECT DIS, V59, P1714, DOI 10.1093/cid/ciu702
   Zhao H, 2007, CLIN INFECT DIS, V44, P541, DOI 10.1086/511042
NR 51
TC 15
Z9 17
U1 1
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD MAR
PY 2016
VL 23
IS 3
BP 154
EP 169
DI 10.1111/jvh.12418
PG 16
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA DC4AD
UT WOS:000369161000001
PM 25967226
OA Other Gold, Green Published
DA 2020-12-08
ER

PT J
AU Carone, L
   Oliveira, CP
   Alvares-da-Silva, MR
   Stefano, JT
   Terrabuio, DRB
   Abdala, E
   Carrilho, FJ
   Farias, AQ
   D'Albuquerque, LAC
AF Carone, L.
   Oliveira, C. P.
   Alvares-da-Silva, M. R.
   Stefano, J. T.
   Terrabuio, D. R. B.
   Abdala, E.
   Carrilho, F. J.
   Farias, A. Q.
   D'Albuquerque, L. A. C.
TI CORONARY ARTERY CALCIUM SCORE AND FRAMINGHAM SCORE IN EVALUATION OF
   CARDIOVASCULAR RISK AFTER LIVER TRANSPLANTATION
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT EASL International Liver Congress
CY APR 13-17, 2016
CL Barcelona, SPAIN
SP EASL
C1 [Carone, L.; Oliveira, C. P.; Stefano, J. T.; Terrabuio, D. R. B.; Abdala, E.; Carrilho, F. J.; Farias, A. Q.; D'Albuquerque, L. A. C.] Univ Sao Paulo, Sch Med, Gastroenterol Hepatologiy & Liver Transplantat, Sao Paulo, Brazil.
   [Alvares-da-Silva, M. R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Gastroenterol, Porto Alegre, RS, Brazil.
EM cpm@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Farias, Alberto/ABB-1291-2020;
   Stefano, Jose Tadeu/AAH-5419-2020; Carrilho, Flair J/I-3046-2012;
   D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Abdala,
   Edson/H-5165-2012
OI Farias, Alberto/0000-0002-5572-663X; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Abdala, Edson/0000-0003-0765-6654
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2016
VL 64
SU 2
MA FRI-443
BP S534
EP S534
DI 10.1016/S0168-8278(16)00948-X
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ER3RR
UT WOS:000398715800133
DA 2020-12-08
ER

PT J
AU de Campos, PB
   Oliveira, CP
   Kikuchi, L
   Stefano, JT
   Chagas, AL
   Herman, P
   D'albuquerque, LC
   da Silva, MRA
   Carrilho, FJ
   Alves, VAF
AF de Campos, P. B.
   Oliveira, C. P.
   Kikuchi, L.
   Stefano, J. T.
   Chagas, A. L.
   Herman, P.
   D'albuquerque, L. C.
   Alvares da Silva, M. R.
   Carrilho, F. J.
   Alves, V. A. F.
TI HEPATOCELLULAR CARCINOMA IN NON-ALCHOOLIC STEATOHEPATITIS -
   HISTOPATHOLOGICAL ASPECTS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT EASL International Liver Congress
CY APR 13-17, 2016
CL Barcelona, SPAIN
SP EASL
C1 [de Campos, P. B.; Oliveira, C. P.; Kikuchi, L.; Stefano, J. T.; Chagas, A. L.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Herman, P.; D'albuquerque, L. C.] Univ Sao Paulo, Sch Med, Div Liver & Gastrointestinal Transplant LIM 37, Dept Gastroenterol, Sao Paulo, Brazil.
   [Alvares da Silva, M. R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Gastroenterol, Porto Alegre, RS, Brazil.
   [Alves, V. A. F.] Univ Sao Paulo, Sch Med, Pathol LIM 14, Sao Paulo, Brazil.
EM cpm@usp.br
RI Chagas, Aline Lopes/X-2059-2019; Stefano, Jose Tadeu/AAH-5419-2020;
   D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Carrilho, Flair
   J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014; Herman,
   Paulo/J-5457-2013
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Herman,
   Paulo/0000-0003-2859-5846
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2016
VL 64
SU 2
MA FRI-287
BP S477
EP S477
DI 10.1016/S0168-8278(16)00809-6
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ER3QE
UT WOS:000398711700802
DA 2020-12-08
ER

PT J
AU Pessoa, MG
   Porto, R
   Mazo, D
   Oliveira, CP
   Terrault, N
   Dodge, J
   Zitelli, PM
   Pinho, JR
   Lopes, M
   Carrilho, FJ
AF Pessoa, M. G.
   Porto, R.
   Mazo, D.
   Oliveira, C. P.
   Terrault, N.
   Dodge, J.
   Zitelli, P. M.
   Pinho, J. R.
   Lopes, M.
   Carrilho, F. J.
TI IMPAIRED ANTI-HBV VACCINE RESPONSE IN NON-CIRRHOTIC CHRONIC HCV PATIENTS
   IS NOT OVERCOME BY DOUBLE DOSE REGIMEN: A RANDOMIZED CONTROL TRIAL
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT EASL International Liver Congress
CY APR 13-17, 2016
CL Barcelona, SPAIN
SP EASL
C1 [Pessoa, M. G.; Porto, R.; Mazo, D.; Oliveira, C. P.; Zitelli, P. M.; Pinho, J. R.; Lopes, M.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Terrault, N.; Dodge, J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
EM mgpessoa@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Pinho, Joao R. R./G-2850-2012; Lopes,
   Marta H/J-3285-2012; Carrilho, Flair J/I-3046-2012; Dodge,
   Jennifer/AAY-2530-2020; Mazo, Daniel FC/D-5631-2015
OI Pinho, Joao R. R./0000-0003-3999-0489; Mazo, Daniel
   FC/0000-0002-2164-2630
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2016
VL 64
SU 2
MA FRI-191
BP S623
EP S624
DI 10.1016/S0168-8278(16)01159-4
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ER3RR
UT WOS:000398715800344
DA 2020-12-08
ER

PT J
AU Terrabuio, DR
   Falcao, LTD
   Ono, SK
   Diniz, MA
   Carrilho, FJ
   Cancado, E
AF Terrabuio, D. R.
   Falcao, L. T. De Moraes
   Ono, S. K.
   Diniz, M. A.
   Carrilho, F. J.
   Cancado, E.
TI ALLOPURINOL IS SAFE AND EFFECTIVE TO ACHIEVE BIOCHEMICAL AND
   HISTOLOGICAL REMISSION IN PATIENTS WITH AUTOIMMUNE HEPATITIS WITH
   INCOMPLETE THERAPEUTIC RESPONSE
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT EASL International Liver Congress
CY APR 13-17, 2016
CL Barcelona, SPAIN
SP EASL
C1 [Terrabuio, D. R.; Falcao, L. T. De Moraes; Ono, S. K.; Diniz, M. A.; Carrilho, F. J.; Cancado, E.] Univ Sao Paulo, Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Cancado, E.] Univ Sao Paulo, Inst Trop Med, Lab Med Invest 6, Sao Paulo, Brazil.
EM edulrc@uol.com.br
RI Cancado, Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012
OI Cancado, Eduardo/0000-0002-9309-1524; 
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2016
VL 64
SU 2
MA FRI-377
BP S435
EP S435
DI 10.1016/S0168-8278(16)00712-1
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ER3QE
UT WOS:000398711700706
DA 2020-12-08
ER

PT J
AU Ximenes, RO
   Helou, C
   Diniz, M
   Barbeiro, D
   Souza, H
   D'Albuquerque, LA
   Carrilho, F
   Farias, A
AF Ximenes, R. O.
   Helou, C.
   Diniz, M.
   Barbeiro, D.
   Souza, H.
   D'Albuquerque, L. A.
   Carrilho, F.
   Farias, A.
TI URINARY BIOMARKER NGAL IN PATIENTS WITH CIRRHOSIS AND BACTERIAL
   INFECTIONS: ACCURACY STUDY IN ACUTE KIDNEY INJURY PREDICTION DEFINED BY
   KDIGO CRITERIA
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT EASL International Liver Congress
CY APR 13-17, 2016
CL Barcelona, SPAIN
SP EASL
C1 [Ximenes, R. O.; Diniz, M.; D'Albuquerque, L. A.; Carrilho, F.; Farias, A.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Helou, C.] Univ Sao Paulo, Sch Med, Dept Nephrol, Sao Paulo, SP, Brazil.
   [Helou, C.] Univ Sao Paulo, Sch Med, LIM 12, Sao Paulo, SP, Brazil.
   [Barbeiro, D.; Souza, H.] Univ Sao Paulo, Sch Med, Emergency Derpartment, Sao Paulo, SP, Brazil.
EM rximenes@gmail.com
RI D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013; Helou,
   Claudia/J-8868-2012; Carrilho, Flair J/I-3046-2012; Farias,
   Alberto/ABB-1291-2020; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Helou,
   Claudia/0000-0002-2228-6041; Farias, Alberto/0000-0002-5572-663X; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2016
VL 64
SU 2
MA SAT-032
BP S665
EP S665
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ER3RR
UT WOS:000398715800440
DA 2020-12-08
ER

PT J
AU Ximenes, RO
   Helou, C
   Diniz, M
   Barbeiro, D
   Souza, H
   D'Albuquerque, LA
   Carrilho, F
   Farias, A
AF Ximenes, R. O.
   Helou, C.
   Diniz, M.
   Barbeiro, D.
   Souza, H.
   D'Albuquerque, L. A.
   Carrilho, F.
   Farias, A.
TI URINARY BIOMARKER NGAL IN PATIENTS WITH HEPATORENAL SYNDROME: ACCURACY
   STUDY IN PREDICTION OF NO RESPONSE TO THERAPY WITH ALBUMIN AND
   TERLIPRESSIN
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT EASL International Liver Congress
CY APR 13-17, 2016
CL Barcelona, SPAIN
SP EASL
C1 [Ximenes, R. O.; Diniz, M.; D'Albuquerque, L. A.; Carrilho, F.; Farias, A.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Helou, C.] Univ Sao Paulo, Sch Med, Dept Nephrol, Sao Paulo, SP, Brazil.
   [Helou, C.] Univ Sao Paulo, Sch Med, LIM 12, Sao Paulo, SP, Brazil.
   [Barbeiro, D.; Souza, H.] Univ Sao Paulo, Sch Med, Emergency Derpartment, Sao Paulo, SP, Brazil.
EM rximenes@gmail.com
RI Helou, Claudia/J-8868-2012; D'Albuquerque, Luiz Augusto
   Carneiro/A-8812-2013; Farias, Alberto/ABB-1291-2020; D'ALBUQUERQUE, Luiz
   Carneiro Augusto/I-4011-2012; Carrilho, Flair J/I-3046-2012
OI Helou, Claudia/0000-0002-2228-6041; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Farias, Alberto/0000-0002-5572-663X; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2016
VL 64
SU 2
MA SAT-033
BP S665
EP S666
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ER3RR
UT WOS:000398715800441
DA 2020-12-08
ER

PT J
AU Cotrim, HP
   Oliveira, CP
   Coelho, HSM
   Alvares-Da-Silva, MR
   Nabuco, L
   Parise, ER
   Ivantes, C
   Martinelli, ALC
   Galizzi-Filho, J
   Carrilho, FJ
AF Cotrim, Helma P.
   Oliveira, Claudia P.
   Coelho, Henrique Sergio M.
   Alvares-da-Silva, Mario R.
   Nabuco, Leticia
   Parise, Edison Roberto
   Ivantes, Claudia
   Martinelli, Ana L. C.
   Galizzi-Filho, Joao
   Carrilho, Flair J.
CA SBH Brazilian HCC-NASH Survey
TI Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian
   survey
SO CLINICS
LA English
DT Article
DE Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis;
   Hepatocellular Carcinoma; Fatty Liver
ID TRENDS; DNA
AB OBJECTIVE: The majority of cases of hepatocellular carcinoma have been reported in individuals with cirrhosis due to chronic viral hepatitis and alcoholism, but recently, the prevalence has become increasingly related to nonalcoholic steatohepatitis around the world. The study aimed to evaluate the clinical and histophatological characteristics of hepatocellular carcinoma in Brazilians' patients with nonalcoholic steatohepatitis at the present time.
   METHODS: Members of the Brazilian Society of Hepatology were invited to complete a survey regarding patients with hepatocellular carcinoma related to nonalcoholic steatohepatitis. Patients with a history of alcohol intake (420 g/day) and other liver diseases were excluded. Hepatocellular carcinoma diagnosis was performed by liver biopsy or imaging methods according to the American Association for the Study of Liver Diseases' 2011 guidelines.
   RESULTS: The survey included 110 patients with a diagnosis of hepatocellular carcinoma and nonalcoholic fatty liver disease from nine hepatology units in six Brazilian states (Bahia, Minas Gerais, Rio de Janeiro, Sao Paulo, Parana and Rio Grande do Sul). The mean age was 67 +/- 11 years old, and 65.5% were male. Obesity was observed in 52.7% of the cases; diabetes, in 73.6%; dyslipidemia, in 41.0%; arterial hypertension, in 60%; and metabolic syndrome, in 57.2%. Steatohepatitis without fibrosis was observed in 3.8% of cases; steatohepatitis with fibrosis (grades 1-3), in 27%; and cirrhosis, in 61.5%. Histological diagnosis of hepatocellular carcinoma was performed in 47.2% of the patients, with hepatocellular carcinoma without cirrhosis accounting for 7.7%. In total, 58 patients with cirrhosis had their diagnosis by ultrasound confirmed by computed tomography or magnetic resonance imaging. Of these, 55% had 1 nodule; 17%, 2 nodules; and 28%, >= 3 nodules.
   CONCLUSIONS: Nonalcoholic steatohepatitis is a relevant risk factor associated with hepatocellular carcinoma in patients with and without cirrhosis in Brazil. In this survey, hepatocellular carcinoma was observed in elevated numbers of patients with steatohepatitis without cirrhosis.
C1 [Cotrim, Helma P.] Univ Fed Bahia, Dept Med, Serv Gastrohepatol, Salvador, BA, Brazil.
   [Oliveira, Claudia P.; Parise, Edison Roberto; Carrilho, Flair J.] Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Coelho, Henrique Sergio M.] Univ Fed Rio de Janeiro, Dept Clin Med, Rio De Janeiro, RJ, Brazil.
   [Alvares-da-Silva, Mario R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Dept Med Interna, Serv Gastroenterol, Porto Alegre, RS, Brazil.
   [Nabuco, Leticia] Hosp Fed Servidores Estado, Serv Clin Med, Setor Hepatol, Rio De Janeiro, RJ, Brazil.
   [Ivantes, Claudia] Hosp Nossa Senhora Gracas, Serv Gastroenterol Hepatol Transplante Hepat, Curitiba, PR, Brazil.
   [Martinelli, Ana L. C.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Div Gastroenterol, Ribeirao Preto, SP, Brazil.
   [Galizzi-Filho, Joao] Univ Fed Minas Gerais, Dept Clin Med, Belo Horizonte, MG, Brazil.
   [SBH Brazilian HCC-NASH Survey] NAFLD HCC Survey SBH, Sao Paulo, SP, Brazil.
RP Cotrim, HP (corresponding author), Univ Fed Bahia, Dept Med, Serv Gastrohepatol, Salvador, BA, Brazil.
EM helmacotrim@gmail.com
RI Oliveira, Claudia PMS/D-1216-2014; Alvares-da-Silva, Mario
   Reis/L-3910-2014; Ramalho, Leandra/A-3983-2010; D'Albuquerque, Luiz
   Augusto Carneiro/A-8812-2013; Carrilho, Flair J/I-3046-2012; Coelho,
   Henrique Sergio Moraes/AAB-3973-2019; D'ALBUQUERQUE, Luiz Carneiro
   Augusto/I-4011-2012
OI Alvares-da-Silva, Mario Reis/0000-0002-5001-246X; Ramalho,
   Leandra/0000-0002-3486-5294; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; PARISE, EDISON ROBERTO/0000-0003-4890-9259
FU Sociedade Brasileira de Hepatologia/SBH (Brazilian Society of
   Hepatology)
FX Sociedade Brasileira de Hepatologia/SBH (Brazilian Society of
   Hepatology).
CR Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168
   Cauchy F, 2013, BRIT J SURG, V100, P113, DOI 10.1002/bjs.8963
   Chagas AL, 2009, BRAZ J MED BIOL RES, V42, P958, DOI 10.1590/S0100-879X2009005000019
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Cotrim HP, 2000, AM J GASTROENTEROL, V95, P3018, DOI 10.1016/S0002-9270(00)02034-7
   Dongiovanni P, 2014, WORLD J GASTROENTERO, V20, P12945, DOI 10.3748/wjg.v20.i36.12945
   El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013
   Flores A, 2014, CLIN MED INSIGHTS-ON, V8, P71, DOI 10.4137/CMO.S9926
   Hu WW, 2002, CARCINOGENESIS, V23, P1781, DOI 10.1093/carcin/23.11.1781
   KASAI H, 1989, CANCER RES, V49, P2603
   Kikuchi L, 2014, AM J CLIN ONCOL
   Kim H, 2004, J HEPATOL, V40, P298, DOI 10.1016/j.jhep.2003.10.023
   Kirstein MM, 2014, DIGEST DIS, V32, P545, DOI 10.1159/000360499
   Leclercq IA, 2000, HEPATOLOGY, V32, p302A
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Paranagua-Vezozzo DC, 2014, ANN HEPATOL, V13, P386, DOI 10.1016/S1665-2681(19)30845-2
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Reeves H, 2012, J HEPATOL, V56, pS3, DOI 10.1016/S0168-8278(12)60019-1
   Roskams T, 2003, AM J PATHOL, V163, P1301, DOI 10.1016/S0002-9440(10)63489-X
   Wakai T, 2011, J GASTROINTEST SURG, V15, P1450, DOI 10.1007/s11605-011-1540-8
   Yan SQ, 2001, CANCER RES, V61, P5016
   Yasui K, 2012, HEPATOL RES, V42, P767, DOI 10.1111/j.1872-034X.2012.00986.x
NR 24
TC 10
Z9 13
U1 0
U2 4
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2016
VL 71
IS 5
BP 281
EP 284
DI 10.6061/clinics/2016(05)07
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DQ2NM
UT WOS:000379039100007
PM 27276398
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Gaspareto, KV
   Ribeiro, RM
   Malta, FD
   Gomes-Gouvea, MS
   Muto, NH
   Romano, CM
   Mendes-Correa, MC
   Carrilho, FJ
   Sabino, EC
   Pinho, JRR
AF Gaspareto, Karine V.
   Ribeiro, Roberto M.
   Malta, Fernanda de Mello
   Gomes-Gouvea, Michele S.
   Muto, Nair H.
   Romano, Camila M.
   Mendes-Correa, Maria C.
   Carrilho, Flair J.
   Sabino, Ester C.
   Pinho, Joao R. Rebello
TI Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion
   Torrent sequencing platform
SO ANTIVIRAL THERAPY
LA English
DT Article
ID HEPATITIS-C VIRUS; DIRECT-ACTING ANTIVIRALS; PEGYLATED INTERFERON;
   GENOTYPE-1 INFECTION; COMBINATION THERAPY; PLUS RIBAVIRIN; BASE-LINE;
   INHIBITOR; MUTATIONS; POLYMERASE
AB Background: As a result of increased understanding of the HCV life cycle, a new generation of drugs known as direct-acting antivirals (DAAs) was developed and is constantly being improved. At baseline, HCV variants resistant to DAA therapy may pre-exist, increasing the likelihood of treatment failure. The aim of this study was to investigate the presence of resistance-associated variants (RAVs) in treatment-naive patients infected with HCV subtypes 1a and 1b.
   Methods: Next-generation sequencing was used to assess the frequencies of NS3-4A, NS5A and NS5B RAVs in 100 HCV monoinfected DAA-naive patients (HCV-1a: n= 51; HCV-1b: n= 49).
   Results: Complete HCV sequence information was obtained for most samples. RAVs were detected in the NS3-4A (T54S, V55A, Q80K and R155K), NS5A (Q30H/R, H58P and Y93C/H/N) and NS5B (A421V) regions in 10%, 22% and 8%, respectively, of patients infected with HCV subtype-1a. Among the patients infected with HCV subtype-1b, mutations in the NS3-4A (F43I, T54S, Q80H, D168E and M175L), NS5A (L28M, R30Q, L31M, Q54H, A92T and Y93H) and NS5B (L159F, C316N, A421V and S556G) regions were observed in 12%, 53% and 31% of patients, respectively.
   Conclusions: High-throughput DNA sequencing allows an easier and more complete analysis of DAA RAVs, including mutations that represent only a minor variant of the whole viral population. RAVs to the three different classes of DAAs were found in our population. The characterization of their profile in the circulating virus is relevant to determine the better treatment option for infected individuals or to guide the implementation of treatment policies.
C1 [Gaspareto, Karine V.; Malta, Fernanda de Mello; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Pinho, Joao R. Rebello] Univ Sao Paulo, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, Inst Trop Med, Sch Med,LIM 07, Sao Paulo, Brazil.
   [Gaspareto, Karine V.; Malta, Fernanda de Mello; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Pinho, Joao R. Rebello] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Gaspareto, Karine V.; Pinho, Joao R. Rebello] Univ Sao Paulo, Grad Program Biotechnol Interunits USP Butantan I, Sao Paulo, Brazil.
   [Ribeiro, Roberto M.; Sabino, Ester C.] Univ Sao Paulo, Lab Parasitol, LIM 46, Inst Trop Med,Sch Med, Sao Paulo, Brazil.
   [Ribeiro, Roberto M.; Romano, Camila M.; Mendes-Correa, Maria C.; Sabino, Ester C.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Muto, Nair H.; Pinho, Joao R. Rebello] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Romano, Camila M.; Mendes-Correa, Maria C.] Univ Sao Paulo, Sch Med, Lab Virol, LIM 52,Inst Trop Med, Sao Paulo, Brazil.
RP Gaspareto, KV (corresponding author), Univ Sao Paulo, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, Inst Trop Med, Sch Med,LIM 07, Sao Paulo, Brazil.; Gaspareto, KV (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.; Gaspareto, KV (corresponding author), Univ Sao Paulo, Grad Program Biotechnol Interunits USP Butantan I, Sao Paulo, Brazil.
EM karine.gaspareto@usp.br
RI Carrilho, Flair J/I-3046-2012; Romano, Camila/ABC-2883-2020; Romano,
   Camila M/C-8185-2013; Sabino, Ester Cerdeira/F-7750-2010; Pinho, Joao R.
   R./G-2850-2012; Muto, Nair/P-8363-2017; Malta, Fernanda/B-1316-2013
OI Romano, Camila/0000-0003-4550-1987; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Pinho, Joao R. R./0000-0003-3999-0489;
   Malta, Fernanda/0000-0001-8887-5060
FU CAPESCAPES; CNPq (Bolsista de Produtividade em Pesquisa); CNPqNational
   Council for Scientific and Technological Development (CNPq)
   [443152/2014-4]
FX KVG is a graduate student from Programa de Pos-Graduacao Interunidades
   em Biotecnologia, USP and receives a PhD fellowship from CAPES. ECS,
   JRRP and MCM-C receive fellowship from CNPq (Bolsista de Produtividade
   em Pesquisa). This study was funded by CNPq 443152/2014-4.
CR Applegate TL, 2015, ANTIVIR THER, V20, P199, DOI 10.3851/IMP2821
   Bartels DJ, 2013, J VIROL, V87, P1544, DOI 10.1128/JVI.02294-12
   Capobianchi MR, 2013, CLIN MICROBIOL INFEC, V19, P15, DOI 10.1111/1469-0691.12056
   Chulanov V, 2014, 65 ANN M AM ASS STUD
   Cuypers L, 2015, VIRUSES-BASEL, V7, P5018, DOI 10.3390/v7092857
   Di Maio VC, 2014, ANTIMICROB AGENTS CH, V58, P2781, DOI 10.1128/AAC.02386-13
   Dietz J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134395
   Donaldson EF, 2015, HEPATOLOGY, V61, P56, DOI 10.1002/hep.27375
   Feld JJ, 2015, NEW ENGL J MED, V373, P2599, DOI 10.1056/NEJMoa1512610
   Flamm SL, 2013, CLIN GASTROENTEROL H, V11, P81, DOI 10.1016/j.cgh.2012.10.006
   Forns X, 2015, J HEPATOL, V63, P564, DOI 10.1016/j.jhep.2015.04.009
   Foster GR, 2015, NEW ENGL J MED, V373, P2608, DOI 10.1056/NEJMoa1512612
   Fourati S, 2015, VIRUSES-BASEL, V7, P6346, DOI 10.3390/v7122941
   Fridell RA, 2011, HEPATOLOGY, V54, P1924, DOI 10.1002/hep.24594
   Gane EJ, 2010, LANCET, V376, P1467, DOI 10.1016/S0140-6736(10)61384-0
   GARSON JA, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92384-T
   Hoffmann L, 2015, BBA CLIN, V3, P146, DOI 10.1016/j.bbacli.2015.01.004
   Jacobson I, 2013, J HEPATOL, V58, pS574, DOI 10.1016/S0168-8278(13)61424-5
   Kieffer TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034372
   Larousse JA, 2014, J MED VIROL, V86, P1350, DOI 10.1002/jmv.23958
   Lenz O, 2013, HEPATOLOGY, V58, p743A
   Lisboa-Neto G, 2014, ANTIVIR THER, V20, P281, DOI DOI 10.3851/IMP2873
   Loman NJ, 2012, NAT BIOTECHNOL, V30, P434, DOI 10.1038/nbt.2198
   Margeridon-Thermet S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105569
   Paolucci S, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-355
   Pawlotsky JM, 2016, GASTROENTEROLOGY, V151, P70, DOI 10.1053/j.gastro.2016.04.003
   Pawlotsky JM, 2015, J HEPATOL, V63, P199, DOI 10.1016/j.jhep.2015.03.025
   Pawlotsky JM, 2014, GASTROENTEROLOGY, V146, P1176, DOI 10.1053/j.gastro.2014.03.003
   Perry CM, 2012, DRUGS, V72, P619, DOI 10.2165/11208370-000000000-00000
   Pol S, 2015, HEPATOLOGY, V62, P129, DOI 10.1002/hep.27836
   Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494
   Qi HF, 2015, CURR OPIN VIROL, V14, P62, DOI 10.1016/j.coviro.2015.08.005
   Ribeiro RM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002881
   Roelandt P, 2012, J HEPATOL, V57, P246, DOI 10.1016/j.jhep.2012.03.030
   Rothberg JM, 2011, NATURE, V475, P348, DOI 10.1038/nature10242
   Sarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011
   Sarrazin C, 2015, ANTIVIR RES, V116, P10, DOI 10.1016/j.antiviral.2015.01.003
   Sarrazin C, 2014, HEPATOLOGY, V60, p1128A
   Solund C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113034
   Uchida Y, 2016, J GASTROENTEROL, V51, P260, DOI 10.1007/s00535-015-1106-8
   Vandamme AM, 2011, AIDS REV, V13, P77
   Vermehren J, 2011, CLIN MICROBIOL INFEC, V17, P122, DOI 10.1111/j.1469-0691.2010.03430.x
   Yoshimi S, 2015, J MED VIROL, V87, P1913, DOI 10.1002/jmv.24255
   Zeuzem S, 2012, HEPATOLOGY, V55, P749, DOI 10.1002/hep.24744
NR 44
TC 7
Z9 8
U1 0
U2 9
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2016
VL 21
IS 8
BP 653
EP 660
DI 10.3851/IMP3057
PG 8
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA EN6BP
UT WOS:000396089800002
PM 27314166
DA 2020-12-08
ER

PT J
AU Passos-Castilho, AM
   Carvalho, VM
   Cardozo, KHM
   Kikuchi, L
   Chagas, AL
   Gomes-Gouvea, MS
   Malta, F
   Nastri, ACDS
   Pinho, JRR
   Carrilho, FJ
   Granato, CFH
AF Passos-Castilho, Ana Maria
   Carvalho, Valdemir Melechco
   Morais Cardozo, Karina Helena
   Kikuchi, Luciana
   Chagas, Aline Lopes
   Gomes-Gouvea, Michele Soares
   Malta, Fernanda
   de Seixas-Santos Nastri, Ana Catharina
   Rebello Pinho, Joao Renato
   Carrilho, Flair Jose
   Hernandes Granato, Celso Francisco
TI Serum lipidomic profiling as a useful tool for screening potential
   biomarkers of hepatitis B-related hepatocellular carcinoma by
   ultraperformance liquid chromatography-mass spectrometry
SO BMC CANCER
LA English
DT Article
DE Biomarker; Hepatocellular carcinoma; Hepatitis B; Lipidomics; UPLC-MS;
   Diagnosis
ID EPIDEMIOLOGIC ASPECTS; PLASMA; VIRUS; LIVER
AB Background: Chronic hepatitis B (CHB) virus infection is a major cause of hepatocellular carcinoma (HCC), as late diagnosis is the main factor for the poor survival of patients. There is an urgent need for accurate biomarkers for early diagnosis of HCC. The aim of the study was to explore the serum lipidome profiles of hepatitis B-related HCC to identify potential diagnostic biomarkers.
   Methods: An ultraperformance liquid chromatography mass spectrometry (UPLC-MS) lipidomic method was used to characterize serum profiles from HCC (n = 32), liver cirrhosis (LC) (n = 30), CHB (n = 25), and healthy subjects (n = 34). Patients were diagnosed by clinical laboratory and imaging evidence and all presented with CHB while healthy controls had normal liver function and no infectious diseases.
   Results: The UPLC-MS-based serum lipidomic profile provided more accurate diagnosis for LC patients than conventional alpha-fetoprotein (AFP) detection. HCC patients were discriminated from LC with 78 % sensitivity and 64 % specificity. In comparison, AFP showed sensitivity and specificity of 38 % and 93 %, respectively. HCC was differentiated from CHB with 100 % sensitivity and specificity using the UPLC-MS approach. Identified lipids comprised glycerophosphocolines, glycerophosphoserines and glycerophosphoinositols.
   Conclusions: UPLC-MS lipid profiling proved to be an efficient and convenient tool for diagnosis and screening of HCC in a high-risk population.
C1 [Passos-Castilho, Ana Maria; Hernandes Granato, Celso Francisco] Univ Fed Sao Paulo, Div Infect Dis, BR-04039032 Sao Paulo, SP, Brazil.
   [Carvalho, Valdemir Melechco; Morais Cardozo, Karina Helena; Hernandes Granato, Celso Francisco] Fleury Grp, Sao Paulo, SP, Brazil.
   [Kikuchi, Luciana; Chagas, Aline Lopes; Gomes-Gouvea, Michele Soares; Malta, Fernanda; Rebello Pinho, Joao Renato; Carrilho, Flair Jose] Hosp Clin Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo Clin Liver Canc Grp, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [de Seixas-Santos Nastri, Ana Catharina] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, SP, Brazil.
RP Passos-Castilho, AM (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, 781 Pedro Toledo St,15th Floor, BR-04039032 Sao Paulo, SP, Brazil.
EM anampassos@gmail.com
RI Pinho, Joao R. R./G-2850-2012; Chagas, Aline Lopes/X-2059-2019; Malta,
   Fernanda/B-1316-2013; Carrilho, Flair J/I-3046-2012; Carvalho, Valdemir
   M/C-5816-2008; Cardozo, Karina Helena M/Q-2829-2017; Passos-Castilho,
   Ana Maria/J-3512-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; Carvalho, Valdemir M/0000-0002-9816-8615;
   Cardozo, Karina Helena M/0000-0002-0333-794X; Passos-Castilho, Ana
   Maria/0000-0002-4814-5191
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/03701-0]; Fleury
   SA Group
FX The Fleury SA Group supported this work and AMPC received a doctorate
   scholarship from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo -
   FAPESP (no. 2013/03701-0). The funding agencies did not interfere in the
   scientific aspects of the study.
CR BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bolondi L, 2003, J HEPATOL, V39, P1076, DOI 10.1016/S0168-8278(03)00349-0
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
   Diamond DL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000719
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Hu CX, 2009, J CHROMATOGR B, V877, P2836, DOI 10.1016/j.jchromb.2009.01.038
   Jia LW, 2008, METABOLOMICS, V4, P183, DOI 10.1007/s11306-008-0110-x
   Kikuchi L, 2013, ANTIVIR THER, V18, P445, DOI 10.3851/IMP2602
   Kim CK, 2001, J ULTRAS MED, V20, P99
   Kimhofer T, 2015, BRIT J CANCER, V112, P1141, DOI 10.1038/bjc.2015.38
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   McGlynn KA, 2015, CLIN LIVER DIS, V19, P223, DOI 10.1016/j.cld.2015.01.001
   Oehler N, 2014, HEPATOLOGY, V60, P1483, DOI 10.1002/hep.27159
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Patterson AD, 2011, CANCER RES, V71, P6590, DOI 10.1158/0008-5472.CAN-11-0885
   Singal A, 2009, ALIMENT PHARM THER, V30, P37, DOI 10.1111/j.1365-2036.2009.04014.x
   Sullentrop F, 2002, NMR BIOMED, V15, P60, DOI 10.1002/nbm.758
   Wang BH, 2012, J PROTEOME RES, V11, P1217, DOI 10.1021/pr2009252
   Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776
   Zhou LN, 2012, ANAL BIOANAL CHEM, V403, P203, DOI 10.1007/s00216-012-5782-4
NR 22
TC 7
Z9 9
U1 1
U2 28
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 18
PY 2015
VL 15
AR 985
DI 10.1186/s12885-015-1995-1
PG 9
WC Oncology
SC Oncology
GA CZ1YG
UT WOS:000366901300003
PM 26680993
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Costa, COPC
   Carrilho, FJ
   Nunes, VS
   Sipahi, AM
   Rodrigues, M
AF Prospero Cavalcante Costa, Camila Ortiz
   Carrilho, Flair Jose
   Nunes, Valeria Sutti
   Sipahi, Aytan Miranda
   Rodrigues, Maraci
TI A snapshot of the nutritional status of Crohn's disease among
   adolescents in Brazil: a prospective cross-sectional study
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Crohn's disease; Adolescence; Nutritional assessment
ID INFLAMMATORY-BOWEL-DISEASE; GROWTH FAILURE; PEDIATRIC-PATIENTS;
   BODY-COMPOSITION; CHILDREN; DEFICIENCY; IRON
AB Background: The relationship between nutrition and Crohn's disease (CD) is complex and involves several therapeutic possibilities including: nutrition treatment for malnourished patients, optimization of growth and development, prevention of osteoporosis, first-line therapy for active disease, and maintenance of disease remission. In children and adolescents with CD, malnutrition is a common problem that adversely affects the prognosis. In at-risk adolescent CD patients, it is important to assess body composition, food intake, energy expenditure, nutrient balance and serum levels of nutrients before planning interventions for this population. The aim of this study was to provide a snapshot of the nutritional status of adolescents with CD in Brazil.
   Methods: We prospectively selected 22 patients with mildly to moderately active CD, 29 patients with inactive CD and 35 controls (first-degree relatives of and in the same age bracket as the CD patients). The age range of participants was between 13.2 and 19.4 years old. We collected anthropometric data including weight, height, and body mass index (BMI), which were expressed as Z scores: weight-for-age, height-for-age and BMI-for-age, respectively, as well as using bioimpedance to determine body composition and assessing the Tanner stage. We also assessed macronutrients and micronutrients (serum levels and dietary intake of both). We used the chi-square test to determine whether any of the studied variables were associated with inactive or active CD. The level of significance was set at 5 % (p < 0.05). We have written informed parental consent for participation for any minors and written informed consent for any participants that were adults.
   Results: The mean values for lean body mass, Tanner stage, height-for-age Z score and BMI-for-age Z score were lower in the active CD group than in the inactive CD and control groups (p < 0.05 for both). Compared with the controls, the CD patients showed significant differences in terms of the quality of dietary intake (particularly in caloric intake, dietary protein intake, dietary fiber intake, and micronutrient intake), which were reflected in the serum levels of nutrients, mainly vitamins A and E (p < 0.05).
   Conclusions: Adolescents with CD (including those with mildly to moderately active or inactive disease) have a nutritional risk, which makes it important to conduct nutritional assessments in such patients.
C1 [Prospero Cavalcante Costa, Camila Ortiz; Carrilho, Flair Jose; Sipahi, Aytan Miranda; Rodrigues, Maraci] Univ Sao Paulo, Sch Med, Hosp Clin, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Nunes, Valeria Sutti] Univ Sao Paulo, Sch Med, Hosp Clin, Endocrinol & Metab Div,Lipids Lab LIM 10, BR-05403000 Sao Paulo, Brazil.
RP Rodrigues, M (corresponding author), Univ Sao Paulo, Sch Med, Hosp Clin, Dept Gastroenterol, Av Dr Eneas de Carvalho Aguiar 255, BR-05403000 Sao Paulo, Brazil.
EM maraci@uol.com.br
RI Nunes, Valeria S./G-4778-2012; Sipahi, Aytan Miranda/O-7768-2019;
   Carrilho, Flair J/I-3046-2012
OI Nunes, Valeria S./0000-0002-6769-5412; Sipahi, Aytan
   Miranda/0000-0002-9686-1627; Maria dos Santos,
   Fabiana/0000-0003-1785-7388; RODRIGUES, MARACI/0000-0002-1571-5282
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo
   Research Foundation)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)
FX The study was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP, Sao Paulo Research Foundation).
CR Bousvaros A, 1998, J PEDIATR GASTR NUTR, V26, P129, DOI 10.1097/00005176-199802000-00002
   Branen L, 1999, J NUTR EDUC, V31, P304, DOI 10.1016/S0022-3182(99)70483-8
   Burnham JM, 2004, J BONE MINER RES, V19, P1961, DOI 10.1359/JBMR.040908
   de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497
   El-Matary W, 2015, ACTA PAEDIATR, V104, P827, DOI 10.1111/apa.13026
   GASCHE C, 1994, DIGEST DIS SCI, V39, P1930, DOI 10.1007/BF02088127
   Green TJ, 1998, CAN J GASTROENTEROL, V12, P544, DOI 10.1155/1998/928706
   Harris JA, 1999, BIOMETRIC STUDY BASA
   Heuschkel R, 2008, INFLAMM BOWEL DIS, V14, P839, DOI 10.1002/ibd.20378
   HOFFBRAND AV, 1968, BMJ-BRIT MED J, V2, P71, DOI 10.1136/bmj.2.5597.71
   HYAMS JS, 1991, J PEDIATR GASTR NUTR, V12, P439, DOI 10.1097/00005176-199105000-00005
   Kleinman RE, 2004, J PEDIATR GASTR NUTR, V39, P15, DOI 10.1097/00005176-200407000-00005
   KUROKI F, 1993, DIGEST DIS SCI, V38, P1614, DOI 10.1007/BF01303168
   Levine A, 2014, J PEDIATR GASTR NUTR, V58, P795, DOI 10.1097/MPG.0000000000000239
   Levine A, 2011, INFLAMM BOWEL DIS, V17, P1314, DOI 10.1002/ibd.21493
   MARKOWITZ J, 1993, J PEDIATR GASTR NUTR, V16, P373, DOI 10.1097/00005176-199305000-00005
   MOTIL KJ, 1993, GASTROENTEROLOGY, V105, P681, DOI 10.1016/0016-5085(93)90883-E
   Oldenburg B, 2001, ALIMENT PHARM THER, V15, P429, DOI 10.1046/j.1365-2036.2001.00930.x
   Sauer CG, 2009, GASTROENTEROL CLIN N, V38, P611, DOI 10.1016/j.gtc.2009.07.010
   Stephens M, 2001, Semin Gastrointest Dis, V12, P253
   Tanner JM, 1962, GROWTH ADOLESCENCE G
   THOMAS AG, 1993, J PEDIATR GASTR NUTR, V17, P75, DOI 10.1097/00005176-199307000-00011
   Thoyu M, 2007, INFLAMM BOWEL DIS, V13, P1121, DOI 10.1002/ibd.20149
   Trumbo P, 2002, J AM DIET ASSOC, V102, P1621, DOI 10.1016/S0002-8223(02)90346-9
   Woodrow G, 2007, PERITON DIALYSIS INT, V27, pS245
   World Health Organization (WHO), 2003, WHO TECHN REP SER, V916
NR 26
TC 6
Z9 6
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD DEC 8
PY 2015
VL 15
AR 172
DI 10.1186/s12876-015-0403-2
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CX8HL
UT WOS:000365943200001
PM 26642931
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Vaisberg, VV
   Kim, V
   Ono, SK
   Mendes, LC
   Carrilho, FJ
AF Vaisberg, V. V.
   Kim, V
   Ono, S. K.
   Mendes, L. C.
   Carrilho, F. J.
TI COMPARISON OF CHRONIC HEPATITIS C TREATMENT EFFICACY IN RANDOMIZED
   CONTROLLED TRIALS AND REAL-LIFE STUDIES - INFLUENCE OF STUDY DESIGN IN
   THE SUSTAINED VIROLOGICAL RESPONSE: A SYSTEMATIC REVIEW OF PUBLISHED
   LITERATURE
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Vaisberg, V. V.; Kim, V; Ono, S. K.; Mendes, L. C.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD NOV
PY 2015
VL 18
IS 7
MA PRM17
BP A815
EP A815
DI 10.1016/j.jval.2015.09.226
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA V46CD
UT WOS:000209861400542
PM 26534345
OA Bronze
DA 2020-12-08
ER

PT J
AU Passos-Castilho, AM
   Ferraz, ML
   Carvalho, VM
   Cardozo, KH
   Kikuchi, L
   Chagas, A
   Pinho, JRR
   Gomes-Gouvea, MS
   Malta, F
   Carrilho, FJ
   Granato, C
AF Passos-Castilho, Ana Maria
   Ferraz, Maria Lucia
   Carvalho, Valdemir M.
   Cardozo, Karina H.
   Kikuchi, Luciana
   Chagas, Aline
   Pinho, Joao Renato R.
   Gomes-Gouvea, Michele S.
   Malta, Fernanda
   Carrilho, Flair J.
   Granato, Celso
TI Serum Lipidomic Profiling for Screening Potential Biomarkers of Liver
   Cirrhosis among Patients with Chronic Hepatitis C
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 13-17, 2015
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Passos-Castilho, Ana Maria; Granato, Celso] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Ferraz, Maria Lucia] Univ Fed Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
   [Carvalho, Valdemir M.; Cardozo, Karina H.; Granato, Celso] Fleury SA Grp, Sao Paulo, Brazil.
   [Kikuchi, Luciana; Chagas, Aline; Pinho, Joao Renato R.; Gomes-Gouvea, Michele S.; Malta, Fernanda; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RI Chagas, Aline Lopes/X-2059-2019; Pinho, Joao R. R./G-2850-2012;
   Carrilho, Flair J/I-3046-2012; Malta, Fernanda/B-1316-2013; Carvalho,
   Valdemir M/C-5816-2008
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; Carvalho, Valdemir M/0000-0002-9816-8615
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2015
VL 62
SU 1
SI SI
MA 48
BP 232A
EP 232A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB2YA
UT WOS:000368375400049
DA 2020-12-08
ER

PT J
AU Rodrigues, L
   Oliveira, CP
   Stefano, JT
   Nogueira, MA
   Silva, ID
   Lo Turco, EG
   Alves, VAF
   Carrilho, FJ
   Puri, P
   Waitzberg, D
AF Rodrigues, Livia
   Oliveira, Claudia P.
   Stefano, Jose Tadeu
   Nogueira, Monize A.
   Silva, Ismael D.
   Lo Turco, Edson G.
   Alves, Venancio Avancini F.
   Carrilho, Flair J.
   Puri, Puneet
   Waitzberg, Dan
TI Omega-3 fatty acids improve proteomic and lipidomic markers of
   endoplasmic reticulum (ER) stress and mitochondrial dysfunction in a
   randomized controlled trial in subjects with Nonalcoholic
   Steatohepatitis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 13-17, 2015
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Rodrigues, Livia; Oliveira, Claudia P.; Stefano, Jose Tadeu; Nogueira, Monize A.; Carrilho, Flair J.; Waitzberg, Dan] Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, Brazil.
   [Silva, Ismael D.] Univ Fed Sao Paulo, Gynecol, Sao Paulo, Brazil.
   [Lo Turco, Edson G.] Univ Fed Sao Paulo, Surg Urol, Sao Paulo, Brazil.
   [Alves, Venancio Avancini F.] Univ Sao Paulo, Sch Med, Patol, Sao Paulo, Brazil.
   [Puri, Puneet] Virginia Commonwealth Univ, Gastroenterol Hepatol & Nutr, Richmond, VA USA.
RI Stefano, Jose Tadeu/AAH-5419-2020; Carrilho, Flair J/I-3046-2012;
   Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose T/H-4792-2013
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2015
VL 62
SU 1
SI SI
MA 240
BP 333A
EP 333A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB2YA
UT WOS:000368375401125
DA 2020-12-08
ER

PT J
AU Chagas, A
   Kikuchi, L
   Felga, G
   Mattos, AA
   Silva, RF
   da Silva, RDM
   Branco, F
   Almeida, MD
   Boin, IF
   Garcia, JH
   D'Albuquerque, LC
   Carrilho, FJ
AF Chagas, Aline
   Kikuchi, Luciana
   Felga, Guilherme
   Mattos, Angelo A.
   Silva, Renato F.
   da Silva, Rita de Cassia M.
   Branco, Fernanda
   Almeida, Marcio D.
   Boin, Ilka F.
   Garcia, Jose H.
   D'Albuquerque, Luiz C.
   Carrilho, Flair J.
TI Multicentric Study of Liver Transplantation in patients with
   Hepatocellular Carcinoma in Brazil- Preliminary data of 913 patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 13-17, 2015
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Chagas, Aline; Kikuchi, Luciana; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Chagas, Aline; Kikuchi, Luciana; D'Albuquerque, Luiz C.; Carrilho, Flair J.] Sao Paulo Clin, Liver Canc Grp, Sao Paulo, Brazil.
   [Felga, Guilherme; Almeida, Marcio D.] Hosp Israelita Albert Einstein, Liver Transplant, Sao Paulo, Brazil.
   [Mattos, Angelo A.] Fundacao Univ Fed Ciencias Saude Porto Alegre, Dept Gastroenterol, Porto Alegre, RS, Brazil.
   [Silva, Renato F.; da Silva, Rita de Cassia M.] Hosp Base FUNFARME, Fac Med Sao Jose do Rio Preto, Serv Gastroenterol, Sao Jose Do Rio Preto, Brazil.
   [Silva, Renato F.; da Silva, Rita de Cassia M.] Hosp Base FUNFARME, Fac Med Sao Jose do Rio Preto, Unidade Transplante Figado, Sao Jose Do Rio Preto, Brazil.
   [Branco, Fernanda] Santa Casa Misericordia Porto Alegre, Dept Gastroenterol, Porto Alegre, RS, Brazil.
   [Boin, Ilka F.] Univ Estadual Campinas, Dept Digest Surg, Campinas, SP, Brazil.
   [Garcia, Jose H.] Univ Fed Ceara, Dept Surg & Liver Transplantat, Fortaleza, Ceara, Brazil.
   [D'Albuquerque, Luiz C.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Boin,
   Ilka/M-7184-2019; Carrilho, Flair J/I-3046-2012; Chagas, Aline
   Lopes/X-2059-2019; Alves da Silva, Rita de Cassia/A-3404-2019; Boin,
   Ilka FSF/C-7811-2009
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2015
VL 62
SU 1
SI SI
MA 469
BP 445A
EP 446A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB2YA
UT WOS:000368375401352
DA 2020-12-08
ER

PT J
AU Medeiros, RP
   Lopes, M
   Mazo, DF
   Oliveira, CP
   Zitteli, PM
   Pinho, JRR
   Carrilho, FJ
   Pessoa, MG
AF Medeiros, Roseane P.
   Lopes, Marta
   Mazo, Daniel F.
   Oliveira, Claudia P.
   Zitteli, Patricia M.
   Pinho, Joao Renato R.
   Carrilho, Flair J.
   Pessoa, Mario G.
TI The Antibody response to hepatitis B virus vaccination is not influenced
   by the hepatitis C virus viral load in patients with chronic hepatitis C
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 13-17, 2015
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Medeiros, Roseane P.; Lopes, Marta; Mazo, Daniel F.; Oliveira, Claudia P.; Zitteli, Patricia M.; Pinho, Joao Renato R.; Carrilho, Flair J.; Pessoa, Mario G.] Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, Brazil.
RI Mazo, Daniel FC/D-5631-2015; Pinho, Joao R. R./G-2850-2012; Carrilho,
   Flair J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014
OI Mazo, Daniel FC/0000-0002-2164-2630; Pinho, Joao R.
   R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2015
VL 62
SU 1
SI SI
MA 1033
BP 713A
EP 713A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB2YA
UT WOS:000368375402356
DA 2020-12-08
ER

PT J
AU Abreu, RM
   Bassit, LC
   Tao, SJ
   Jiang, Y
   Paranagua-Vezozzo, D
   Schinazi, RF
   Carrilho, FJ
   Ono, SK
AF Abreu, Rodrigo M.
   Bassit, Leda C.
   Tao, Sijia
   Jiang, Yong
   Paranagua-Vezozzo, Denise
   Schinazi, Raymond F.
   Carrilho, Flair J.
   Ono, Suzane K.
TI Four years real-life experience with antiviral adherence in chronic
   hepatitis B infection in a tertiary university hospital
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 13-17, 2015
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Abreu, Rodrigo M.; Paranagua-Vezozzo, Denise; Carrilho, Flair J.; Ono, Suzane K.] Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, Brazil.
   [Abreu, Rodrigo M.] Univ Sao Paulo, Sch Med, Clin Hosp, Div Pharm, Sao Paulo, Brazil.
   [Bassit, Leda C.; Tao, Sijia; Jiang, Yong; Schinazi, Raymond F.] Emory Univ, Sch Med, Pediat, Sao Paulo, Brazil.
   [Bassit, Leda C.; Tao, Sijia; Jiang, Yong; Schinazi, Raymond F.] Vet Affairs Med Ctr, Sao Paulo, Brazil.
RI Schinazi, Raymond F/B-6777-2017; Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2015
VL 62
SU 1
SI SI
MA 1544
BP 963A
EP 963A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB2YA
UT WOS:000368375403336
DA 2020-12-08
ER

PT J
AU Oliveira, CP
   Stefano, JT
   Ribeiro, RM
   Duarte, SM
   Rodrigues, L
   Campos, PB
   Costa, FG
   Mazo, DF
   Carrilho, FJ
   Sabino, EC
AF Oliveira, Claudia P.
   Stefano, Jose Tadeu
   Ribeiro, Roberto M.
   Duarte, Sebastiao M.
   Rodrigues, Livia
   Campos, Priscila B.
   Costa, Fernando G.
   Mazo, Daniel F.
   Carrilho, Flair J.
   Sabino, Ester C.
TI Molecular Characterization of the Fecal Microbiome in Brazilian Obese
   NASH patients compared to lean healthy controls.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 13-17, 2015
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Oliveira, Claudia P.; Stefano, Jose Tadeu; Duarte, Sebastiao M.; Rodrigues, Livia; Campos, Priscila B.; Costa, Fernando G.; Mazo, Daniel F.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, Brazil.
   [Ribeiro, Roberto M.; Sabino, Ester C.] Univ Sao Paulo, Sch Med, Inst Trop Med, Sao Paulo, Brazil.
RI Sabino, Ester Cerdeira/F-7750-2010; Stefano, Jose Tadeu/AAH-5419-2020;
   Stefano, Jose T/H-4792-2013; Oliveira, Claudia PMS/D-1216-2014; Mazo,
   Daniel FC/D-5631-2015; Carrilho, Flair J/I-3046-2012; DUARTE, Sebastiao
   Mauro/B-6075-2017
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Mazo, Daniel FC/0000-0002-2164-2630; 
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2015
VL 62
SU 1
SI SI
MA 2221
BP 1290A
EP 1291A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB2YA
UT WOS:000368375404462
DA 2020-12-08
ER

PT J
AU Toda, KS
   Kikuchi, L
   Chagas, AL
   Tanigawa, RY
   Paranagua-Vezozzo, DC
   Pfiffer, T
   Rocha, MD
   Alves, VAF
   Carrilho, FJ
AF Toda, Karla Sawada
   Kikuchi, Luciana
   Chagas, Aline Lopes
   Tanigawa, Ryan Yukimatsu
   Paranagua-Vezozzo, Denise Cerqueira
   Pfiffer, Tulio
   Rocha, Manoel de Souza
   Ferreira Alves, Venancio Avancini
   Carrilho, Flair Jose
TI Hepatocellular Carcinoma Related to Schistosoma mansoni Infection: Case
   Series and Literature Review
SO JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
LA English
DT Review
DE Schistosoma mansoni; Schistosomiasis; Hepatocellular carcinoma
AB Background and Aims: Schistosomiasis is a major chronic disease of humans in endemic regions, and infected individuals may develop a spectrumof pathology, including hepatic fibrosis, hepatosplenomegaly, and portal hypertension. Hepatocellular carcinoma (HCC) is considered the fifth most common cancer in the world, and there is limited and controversial evidence suggesting that Schistosoma mansoni infection may be a possible risk factor for HCC. The aim of this study was to report a case series of patients with HCC and S. mansoni infection and to conduct a literature review on the topic. Methods: From January 2002 to January 2015, an institutional database was screened retrospectively to identify patients with HCC and S. mansoni infection at a single center in the Department of Gastroenterology of University of Sao Paulo School of Medicine and Hospital das Clinicas, Brazil. Results: Seven cases were included. The mean age of patients was 62.1 +/- 10.3 years; six (85.7%) were male and one (14.3%) was female. All cases had positive epidemiology, coming from endemic areas of S. mansoni infection in Brazil, and four (57.1%) had previous complications (upper gastrointestinal bleeding) related toportal hypertension or surgery intervention (splenectomy) performed more than 10 years before the HCC diagnosis. Nontumoral portal vein thrombosis was identified in five (71.4%) patients. All patients had negative serology for HCV, and four (57.1%) had positivity of HBVcore antibodies without evidence of viral replication. According to BCLC staging, one (14.3%) patient was BCLC A and received TACE instead of RFA because HCC size was >30 mm; three (42.8%) BCLC B patients received sorafenib instead of local regional treatment due to the presence of nontumoral TPV. During follow-up, all patients developed tumoral progression and died. Conclusions: It remains unclear if S. mansoni infection alone has carcinogenic potential. The available literature indicates that S. Mansoni, in the presence of HBV and HCV infections, likely acts as a cofactor for the hepatic lesion and potentiates injury. (C) 2015 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved.
C1 [Toda, Karla Sawada; Kikuchi, Luciana; Chagas, Aline Lopes; Tanigawa, Ryan Yukimatsu; Paranagua-Vezozzo, Denise Cerqueira; Pfiffer, Tulio; Rocha, Manoel de Souza; Ferreira Alves, Venancio Avancini; Carrilho, Flair Jose] Hosp Clin Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo Clin Liver Canc Grp, Sao Paulo, Brazil.
   [Toda, Karla Sawada; Kikuchi, Luciana; Chagas, Aline Lopes; Paranagua-Vezozzo, Denise Cerqueira] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas de Carvalho Aguiar 255, BR-05403000 Sao Paulo, SP, Brazil.
   [Tanigawa, Ryan Yukimatsu; Ferreira Alves, Venancio Avancini] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   [Pfiffer, Tulio] Univ Sao Paulo, Sch Med, Dept Oncol, Sao Paulo, Brazil.
   [Rocha, Manoel de Souza] Univ Sao Paulo, Sch Med, Dept Radiol, Sao Paulo, Brazil.
RP Carrilho, FJ (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas de Carvalho Aguiar 255, BR-05403000 Sao Paulo, SP, Brazil.
EM fjcarril@usp.br
RI Chagas, Aline Lopes/X-2059-2019; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935
CR Abdel-Rahim AY, 2001, DIGEST DIS, V19, P288, DOI 10.1159/000050695
   ABE K, 1993, J MED PRIMATOL, V22, P237
   Andrade ZA, 2009, PARASITE IMMUNOL, V31, P656, DOI 10.1111/j.1365-3024.2009.01157.x
   Bahgat MM, 2014, J CLIN TRANSL HEPATO, V2, P134, DOI 10.14218/JCTH.2013.00028
   Batista-Neto J, 2013, ABCD-ARQ BRAS CIR DI, V26, P49, DOI 10.1590/S0102-67202013000100011
   Bhandarkar DS, 2011, INDIAN J SURG, V73, P324, DOI 10.1007/s12262-011-0331-5
   Brazilian Ministry of Health, 2012, PLAN INT AC ESTR EL
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Cillo U, 2006, J HEPATOL, V44, P723, DOI 10.1016/j.jhep.2005.12.015
   Davis A., 1996, Manson's tropical diseases., P1413
   El-Tonsy MM, 2013, ACTA TROP, V128, P542, DOI 10.1016/j.actatropica.2013.07.024
   Evangelista-Neto J, 2012, ABCD-ARQ BRAS CIR DI, V25, P41, DOI 10.1590/S0102-67202012000100010
   GENTILE JM, 1994, MUTAT RES, V305, P315, DOI 10.1016/0027-5107(94)90251-8
   Guerin F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125493
   Hams E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00089
   Kakizoe Y, 1985, Kurume Med J, V32, P169, DOI 10.2739/kurumemedj.32.169
   Kamal S, 2000, LIVER, V20, P281, DOI 10.1034/j.1600-0676.2000.020004281.x
   Khurana S, 2005, Indian J Med Microbiol, V23, P74
   Makoissi Fabio Ferrari, 2009, Arquivos de Gastroenterologia, V46, P50
   Martins-Melo FR, 2014, INT J PARASITOL, V44, P1055, DOI 10.1016/j.ijpara.2014.07.009
   Palumbo E, 2007, INFECT DIS CLIN PRAC, V15, P145, DOI 10.1097/01.idc.0000269904.90155.ce
   Paranagua-Vezozzo DC, 2014, ANN HEPATOL, V13, P386, DOI 10.1016/S1665-2681(19)30845-2
   Shaker Y, 2014, J CLIN TRANSL HEPATO, V2, P212, DOI 10.14218/JCTH.2014.00018
   Stickland GT., 2006, HEPATOLOGY, V43, P915, DOI [10.1002/hep.21173, DOI 10.1002/HEP.21173]
NR 24
TC 10
Z9 11
U1 0
U2 1
PU XIA & HE PUBLISHING INC
PI SUGAR LAND
PA 14090 SOUTHWEST FREEWAY, STE 300, SUGAR LAND, TX 77478 USA
SN 2225-0719
EI 2310-8819
J9 J CLIN TRANSL HEPATO
JI J. Clin. Transl. Hepatol.
PD OCT-DEC
PY 2015
VL 3
IS 4
BP 260
EP 264
DI 10.14218/JCTH.2015.00027
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VH2JA
UT WOS:000451344300004
PM 26807381
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Nacif, LS
   Paranagua-Vezozzo, DC
   Galvao, FHF
   Rocha, MS
   Andraus, W
   Carrilho, FJ
   D'Albuquerque, LC
AF Nacif, Lucas Souto
   Paranagua-Vezozzo, Denise Cerqueira
   Ferreira Galvao, Flavio Henrique
   Rocha, Manoel S.
   Andraus, Wellington
   Carrilho, Flair Jose
   D'Albuquerque, Luiz Carneiro
TI Significance of CT scan and color Doppler duplex ultrasound in the
   assessment of Abernethy malformation
SO BMC MEDICAL IMAGING
LA English
DT Article
DE Abernethy malformation; Liver surgery; Liver transplantation; Abdominal
   imaging
ID SHUNTS
AB Background: Abernethy malformation is a rare congenital vascular abnormality in which the portal vein bypasses the liver and drains directly into the inferior vena cava. Diagnosis is complex and requires good quality imaging methods to identify details in systemic and portal circulation in order to establish diagnostic confirmation and treatment strategy. In this study we highlight the significance of the use of CT scans and Color Doppler Duplex Ultrasound for the diagnosis, treatment and evolution assessment in two adults with Abernethy malformation.
   Case presentation: The diagnosis and the treatment of two patients with Abernethy malformation by CT scan and Color Doppler Duplex Ultrasound is described. One patient was submitted to liver transplantation due to chronic liver disease and multiple nodules diagnosed as adenoma. The other patient had normal liver function and a mild neurological and psychomotor dysfunction, therefore we adopted clinical treatment and close liver parenchyma evaluation and nodule surveillance, using an imaging approach involving intercalating CT scan and Color Doppler Duplex Ultrasound every 6 months. We highlight some important direct and indirect findings of non-invasive imaging methods.
   Conclusion: Abernethy malformation requires meticulous image diagnosis to improve treatment and avoid iatrogenic procedures. CT scans and Color Doppler Duplex Ultrasound are both efficient methods for diagnosis, treatment planning and evolution assessment of patients with Abernethy malformation.
C1 [Nacif, Lucas Souto; Paranagua-Vezozzo, Denise Cerqueira; Ferreira Galvao, Flavio Henrique; Rocha, Manoel S.; Andraus, Wellington; Carrilho, Flair Jose; D'Albuquerque, Luiz Carneiro] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Gastrointestinal Transplant Div, BR-05403900 Sao Paulo, Brazil.
RP Nacif, LS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Gastrointestinal Transplant Div, Rua Dr Eneas Carvalho Aguiar, BR-05403900 Sao Paulo, Brazil.
EM lucasnacif@usp.br
RI Carrilho, Flair J/I-3046-2012; Galvao, Flavio Henrique
   Ferreira/D-3487-2017; Andraus, Wellington/G-1860-2012; Nacif, Lucas
   S./B-2795-2013; Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014; Rocha,
   Manoel S/C-6478-2013; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012
OI Galvao, Flavio Henrique Ferreira/0000-0003-1924-3208; Andraus,
   Wellington/0000-0002-5162-138X; Nacif, Lucas S./0000-0002-7059-3978;
   Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; Rocha, Manoel
   S/0000-0002-4503-8374; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; 
FU Alves de Queiroz Family Found for Research
FX The study was supported in part by Alves de Queiroz Family Found for
   Research and special acknowledgement to the figure illustrator of the
   Gastrointestinal Department Marcos Antonio Rezter.
CR Badea R, 2012, J GASTROEN HEPATOL, V27, P1875, DOI 10.1111/j.1440-1746.2012.07226.x
   Hao YB, 2015, ONCOL LETT, V9, P695, DOI 10.3892/ol.2014.2767
   Howard ER, 1997, J PEDIATR SURG, V32, P494, DOI 10.1016/S0022-3468(97)90614-X
   Lisovsky M, 2011, AM J SURG PATHOL, V35, P1381, DOI 10.1097/PAS.0b013e3182230ce4
   Loomba RS, J PEDIAT SURG
   MORGAN G, 1994, J PEDIATR SURG, V29, P1239, DOI 10.1016/0022-3468(94)90812-5
   Schaeffer DF, 2013, HUM PATHOL, V44, P432, DOI 10.1016/j.humpath.2012.08.018
   Van Beers BE, 2015, J HEPATOL, V62, P690, DOI 10.1016/j.jhep.2014.10.014
NR 8
TC 6
Z9 6
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2342
J9 BMC MED IMAGING
JI BMC Med. Imag.
PD SEP 18
PY 2015
VL 15
AR 37
DI 10.1186/s12880-015-0079-7
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CR6EI
UT WOS:000361435800001
PM 26385342
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Cavalcante, LN
   Stefano, JT
   Machado, MV
   Mazo, DF
   Rabelo, F
   Sandes, KA
   Carrilho, FJ
   Cortez-Pinto, H
   Lyra, AC
   de Oliveira, CP
AF Cavalcante, Lourianne Nascimento
   Stefano, Jose Tadeu
   Machado, Mariana, V
   Mazo, Daniel F.
   Rabelo, Fabiola
   Sandes, Kiyoko Abe
   Carrilho, Flair Jose
   Cortez-Pinto, Helena
   Lyra, Andre Castro
   de Oliveira, Claudia P.
TI Genetic ancestry analysis in non-alcoholic fatty liver disease patients
   from Brazil and Portugal
SO WORLD JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Ancestry; Nonalcoholic fatty liver disease; Simple steatosis;
   Nonalcoholic steatohepatitis; Admixed population
AB AIM: To study the association between genetic ancestry, non-alcoholic fatty liver disease (NAFLD) metabolic characteristics in two cohorts of patients, from Brazil and Portugal.
   METHODS: We included 131 subjects from Brazil [(n = 45 with simple steatosis (S. Steatosis) and n = 86 with nonalcoholic steatohepatitis (NASH)] and 90 patients from Portugal (n = 66, S. Steatosis; n = 24, NASH). All patients had biopsy-proven NAFLD. In histologic evaluation NAFLD activity score was used to assess histology and more than 5 points defined NASH in this study. Patients were divided into two groups according to histology diagnosis: simple steatosis or non-alcoholic statohepatitis. Genetic ancestry was assessed using real-time polymerase chain reaction. Seven ancestry informative markers (AT3-I/D, LPL, Sb19.3, APO, FY-Null, PV92, and CKMM) with the greatest ethnicgeographical differential frequencies (>= 48%) were used to define genetic ancestry. Data were analyzed using R PROJECTS software. Ancestry allele frequencies between groups were analyzed by GENEPOP online and the estimation of genetic ancestry contribution was evaluated by ADMIX-95 software. The 5% alpha-error was considered as significant (P < 0.05).
   RESULTS: In the Brazilian sample, NASH was significantly more frequent among the elderly patients with diabetes (NASH 56 +/- 1.1 years old vs S. Steatosis 51 +/- 1.5 years old, P = 3.7 x 10(-9)), dyslipidemia (NASH 63% vs S. Steatosis 37%, P = 0.009), higher fasting glucose levels (NASH 124 +/- 5.2 vs S. Steatosis 106 +/- 5.3, P = 0.001) and Homeostatic Model of Assessment index > 2.5 [NASH 5.3 (70.8%) vs S. Steatosis 4.6 (29.2%) P = 0.04]. In the Portuguese study population, dyslipidemia was present in all patients with NASH (P = 0.03) and hypertension was present in a larger percentage of subjects in the S. Steatosis group (P = 0.003, respectively). The genetic ancestry contribution among Brazilian and Portuguese individuals with NASH was similar to those with S. Steatosis from each cohort (Brazilian cohort: P = 0.75; Portuguese cohort: P = 0.97). Nonetheless, the genetic ancestry contribution of the Brazilian and Portuguese population were different, and a greater European and Amerindian ancestry contribution was detected in the Portuguese population while a higher African genetic ancestry contribution was observed in Brazilian population of both NASH and S. Steatosis groups.
   CONCLUSION: There was no difference between the genetic ancestry contribution among Brazilian and Portuguese individuals with NASH and S. Steatosis from each cohort.
C1 [Cavalcante, Lourianne Nascimento; Lyra, Andre Castro] Hosp Sao Rafael, Gastrohepatol Dept, Av Sao Rafael 2152, BR-41253190 Salvador, BA, Brazil.
   [Stefano, Jose Tadeu; Mazo, Daniel F.; Rabelo, Fabiola; Carrilho, Flair Jose; de Oliveira, Claudia P.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Gastroenterol & Hepatol, BR-05469000 Sao Paulo, SP, Brazil.
   [Machado, Mariana, V; Cortez-Pinto, Helena] Santa Maria Univ, Dept Gastroenterol, Lab Nutr, Univ Hosp, P-1649035 Lisbon, Portugal.
   [Sandes, Kiyoko Abe] Univ Bahia State, Life Sci Dept, BR-41253190 Salvador, BA, Brazil.
   [Lyra, Andre Castro] Univ Fed Bahia, Fac Med, BR-41253190 Salvador, BA, Brazil.
RP Cavalcante, LN (corresponding author), Hosp Sao Rafael, Gastrohepatol Dept, Av Sao Rafael 2152, BR-41253190 Salvador, BA, Brazil.
EM lourianne@gmail.com
RI Oliveira, Claudia PMS/D-1216-2014; Cortez-Pinto, Helena/AAN-2712-2020;
   Stefano, Jose Tadeu/AAH-5419-2020; Mazo, Daniel FC/D-5631-2015;
   Cortez-Pinto, Helena/A-3586-2012
OI Cortez-Pinto, Helena/0000-0002-8537-8744; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Mazo, Daniel FC/0000-0002-2164-2630; 
CR Arnaiz-Villena A, 2013, MOL BIOL REP, V40, P1819, DOI 10.1007/s11033-012-2236-1
   BATZER MA, 1994, P NATL ACAD SCI USA, V91, P12288, DOI 10.1073/pnas.91.25.12288
   Cardena MMSG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062005
   CHAKRABORTY R, 1985, GENETIC MICRODIFFERE, P171
   Dongiovanni P, 2013, CURR PHARM DESIGN, V19, P5219, DOI 10.2174/13816128113199990381
   Salgado Ana Lúcia Farias de Azevedo, 2010, Arq. Gastroenterol., V47, P165, DOI 10.1590/S0004-28032010000200009
   Fridman C, 2014, INT J LEGAL MED, V128, P589, DOI 10.1007/s00414-014-1023-z
   Hidalgo G, 2014, AM J HUM BIOL, V26, P710, DOI 10.1002/ajhb.22567
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Leite TKM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027162
   Lins TC, 2010, AM J HUM BIOL, V22, P187, DOI 10.1002/ajhb.20976
   Manta FSN, 2013, ANN HUM BIOL, V40, P94, DOI 10.3109/03014460.2012.742138
   Palmer ND, 2013, HEPATOLOGY, V58, P966, DOI 10.1002/hep.26440
   Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Shriver MD, 1997, AM J HUM GENET, V60, P957
   Younossi ZM, 2011, HEPATOLOGY, V53, P1874, DOI 10.1002/hep.24268
NR 18
TC 4
Z9 4
U1 0
U2 2
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5182
J9 WORLD J HEPATOL
JI World J. Hepatol.
PD JUN 8
PY 2015
VL 7
IS 10
BP 1433
EP 1438
DI 10.4254/wjh.v7.i10.1433
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VE3RO
UT WOS:000439195700015
PM 26052389
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Pereira, IVA
   Torres, MM
   Bida, PM
   Coelho, AMM
   Xerfan, MP
   Cogliati, B
   Barbeiro, DF
   Mazo, DFC
   Kubrusly, MS
   D'Albuquerque, LAC
   Souza, HP
   Carrilho, FJ
   Oliveira, CP
AF Stefano, J. T.
   Pereira, I. V. A.
   Torres, M. M.
   Bida, P. M.
   Coelho, A. M. M.
   Xerfan, M. P.
   Cogliati, B.
   Barbeiro, D. F.
   Mazo, D. F. C.
   Kubrusly, M. S.
   D'Albuquerque, L. A. C.
   Souza, H. P.
   Carrilho, F. J.
   Oliveira, C. P.
TI Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis
   (NASH) rodent model
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE NASH; Fibrosis; Mitochondrial dysfunction; Sorafenib
ID MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; HEPATIC-FIBROSIS; SPECIAL
   EMPHASIS; PATHOGENESIS; FIBROGENESIS; EXPRESSION; MMPS
AB Liver fibrosis occurring as an outcome of non-alcoholic steatohepatitis (NASH) can precede the development of cirrhosis. We investigated the effects of sorafenib in preventing liver fibrosis in a rodent model of NASH. Adult Sprague-Dawley rats were fed a choline-deficient high-fat diet and exposed to diethylnitrosamine for 6 weeks. The NASH group (n=10) received vehicle and the sorafenib group (n=10) received 2.5 mg.kg(-1).day(-1) by gavage. A control group (n=4) received only standard diet and vehicle. Following treatment, animals were sacrificed and liver tissue was collected for histologic examination, mRNA isolation, and analysis of mitochondrial function. Genes related to fibrosis (MMP9, TIMP1, TIMP2), oxidative stress (HSP60, HSP90, GST), and mitochondrial biogenesis (PGC1 alpha) were evaluated by real-time quantitative polymerase chain reaction (RT-qPCR). Liver mitochondrial oxidation activity was measured by a polarographic method, and cytokines by enzyme-linked immunosorbent assay (ELISA). Sorafenib treatment restored mitochondrial function and reduced collagen deposition by nearly 63% compared to the NASH group. Sorafenib upregulated PGC1 alpha and MMP9 and reduced TIMP1 and TIMP2 mRNA and IL-6 and IL-10 protein expression. There were no differences in HSP60, HSP90 and GST expression. Sorafenib modulated PGC1 alpha expression, improved mitochondrial respiration and prevented collagen deposition. It may, therefore, be useful in the treatment of liver fibrosis in NASH.
C1 [Stefano, J. T.; Pereira, I. V. A.; Torres, M. M.; Bida, P. M.; Xerfan, M. P.; Mazo, D. F. C.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Fac Med, Disciplina Gastroenterol Clin LIM 07, Sao Paulo, SP, Brazil.
   [Coelho, A. M. M.; Kubrusly, M. S.; D'Albuquerque, L. A. C.] Univ Sao Paulo, Fac Med, Disciplina Transplante Orgaos Aparelho Digest LIM, Sao Paulo, SP, Brazil.
   [Barbeiro, D. F.; Souza, H. P.] Univ Sao Paulo, Fac Med, Disciplina Emergencias Clin LIM 51, Sao Paulo, SP, Brazil.
   [Cogliati, B.] Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Patol, Sao Paulo, SP, Brazil.
RP Oliveira, CP (corresponding author), Univ Sao Paulo, Fac Med, Disciplina Gastroenterol Clin LIM 07, Sao Paulo, SP, Brazil.
EM cpm@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Mazo, Daniel FC/D-5631-2015;
   Carrilho, Flair J/I-3046-2012; Stefano, Jose Tadeu/AAH-5419-2020;
   Stefano, Jose T/H-4792-2013; Kubrusly, Marcia S/N-3943-2014; Souza,
   Heraldo P/C-2498-2012; Cogliati, Bruno/E-9956-2012; D'ALBUQUERQUE, Luiz
   Carneiro Augusto/I-4011-2012; Veloso Alves Pereira, Isabel/N-4616-2014
OI Mazo, Daniel FC/0000-0002-2164-2630; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Kubrusly, Marcia S/0000-0003-3258-5632;
   Cogliati, Bruno/0000-0002-1388-7240; XERFAN CORSO, MARIANA
   P./0000-0002-5864-2300; Veloso Alves Pereira, Isabel/0000-0002-3439-1658
FU Alves de Queiroz Family Fund for Research; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX We wish to thank Bayer (R) HealthCare Pharmaceuticals for providing
   sorafenib, and the Alves de Queiroz Family Fund for Research and CNPq
   for financial support.
CR Ahmad A, 2012, SAUDI J GASTROENTERO, V18, P155, DOI 10.4103/1319-3767.96445
   Bataller R, 2005, ANTIOXID REDOX SIGN, V7, P1346, DOI 10.1089/ars.2005.7.1346
   Begriche K, 2006, MITOCHONDRION, V6, P1, DOI 10.1016/j.mito.2005.10.004
   Bonis PAL, 2001, NEW ENGL J MED, V344, P452, DOI 10.1056/NEJM200102083440610
   Caldwell SH, 1999, J HEPATOL, V31, P430, DOI 10.1016/S0168-8278(99)80033-6
   Coelho A M, 1998, Rev Hosp Clin Fac Med Sao Paulo, V53, P104
   Cogliati Bruno, 2010, Arq. Gastroenterol., V47, P79, DOI 10.1590/S0004-28032010000100014
   Cortez-Pinto H, 1999, JAMA-J AM MED ASSOC, V282, P1659, DOI 10.1001/jama.282.17.1659
   Coulon S, 2012, CYTOKINE, V59, P442, DOI 10.1016/j.cyto.2012.05.001
   Das SK, 2011, INDIAN J CLIN BIOCHE, V26, P202, DOI 10.1007/s12291-011-0121-7
   de Lima VM, 2008, J HEPATOL, V49, P1055, DOI 10.1016/j.jhep.2008.07.024
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Grattagliano I, 2008, EUR J CLIN INVEST, V38, P523, DOI 10.1111/j.1365-2362.2008.01963.x
   Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003
   Hennenberg M, 2011, LAB INVEST, V91, P241, DOI 10.1038/labinvest.2010.148
   Hong F, 2013, DIGEST DIS SCI, V58, P257, DOI 10.1007/s10620-012-2325-y
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mejias M, 2009, HEPATOLOGY, V49, P1245, DOI 10.1002/hep.22758
   Oliveira CPMS, 2006, BRAZ J MED BIOL RES, V39, P189, DOI 10.1590/S0100-879X2006000200004
   Perez-Carreras M, 2003, HEPATOLOGY, V38, P999, DOI 10.1053/jhep.2003.50398
   Pessayre D, 2007, J GASTROEN HEPATOL, V22, pS20, DOI 10.1111/j.1440-1746.2006.04640.x
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Roderfeld M, 2007, Z GASTROENTEROL, V45, P25, DOI 10.1055/s-2006-927388
   Roderfeld M, 2006, FASEB J, V20, P444, DOI 10.1096/fj.05-4828com
   Rolo AP, 2012, FREE RADICAL BIO MED, V52, P59, DOI 10.1016/j.freeradbiomed.2011.10.003
   Sanyal A J, 2001, Indian J Gastroenterol, V20, P215
   Serviddio G, 2008, MOL ASPECTS MED, V29, P22, DOI 10.1016/j.mam.2007.09.014
   Serviddio G, 2011, EXPERT REV GASTROENT, V5, P233, DOI [10.1586/egh.11.11, 10.1586/EGH.11.11]
   Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008
   Ueberham E, 2003, HEPATOLOGY, V37, P1067, DOI 10.1053/jhep.2003.50196
   Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000
   Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x
   Wang Y, 2010, J HEPATOL, V53, P132, DOI 10.1016/j.jhep.2010.02.027
   Yang YY, 2014, LIVER INT, V34, P521, DOI 10.1111/liv.12299
NR 35
TC 12
Z9 12
U1 0
U2 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD MAY
PY 2015
VL 48
IS 5
BP 408
EP 414
DI 10.1590/1414-431X20143962
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA CH6ZU
UT WOS:000354186100005
PM 25714891
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Passos-Castilho, AM
   Carvalho, VM
   Cardozo, KHM
   Kikuchi, L
   Chagas, A
   Pinho, JR
   Gomes-Gouvea, MS
   Malta, F
   Carrilho, FJ
   Granato, CFH
AF Passos-Castilho, A. M.
   Carvalho, V. M.
   Cardozo, K. H. M.
   Kikuchi, L.
   Chagas, A.
   Pinho, J. R.
   Gomes-Gouvea, M. S.
   Malta, F.
   Carrilho, F. J.
   Granato, C. F. H.
TI SERUM LIPIDOMIC PROFILING FOR SCREENING POTENTIAL BIOMARKERS OF
   HEPATOCELLULAR CARCINOMA BY ULTRAPERFORMANCE LIQUID CHROMATOGRAPHY-MASS
   SPECTROMETRY
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 50th International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 22-26, 2015
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Passos-Castilho, A. M.; Granato, C. F. H.] Univ Fed Sao Paulo, Dept Med, Div Infect Dis, Sao Paulo, Brazil.
   [Carvalho, V. M.; Cardozo, K. H. M.; Granato, C. F. H.] Univ Sao Paulo, Sch Med, Fleury SA Grp, Sao Paulo, Brazil.
   [Kikuchi, L.; Chagas, A.; Pinho, J. R.; Gomes-Gouvea, M. S.; Malta, F.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM anampassos@gmail.com
RI Pinho, Joao R. R./G-2850-2012; Cardozo, Karina Helena M/Q-2829-2017;
   Carrilho, Flair J/I-3046-2012; Malta, Fernanda/B-1316-2013; Carvalho,
   Valdemir M/C-5816-2008; Chagas, Aline Lopes/X-2059-2019
OI Pinho, Joao R. R./0000-0003-3999-0489; Cardozo, Karina Helena
   M/0000-0002-0333-794X; Malta, Fernanda/0000-0001-8887-5060; Carvalho,
   Valdemir M/0000-0002-9816-8615; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2015
VL 62
SU 2
MA O049
BP S216
EP S216
DI 10.1016/S0168-8278(15)30063-5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CS3IZ
UT WOS:000361967600062
DA 2020-12-08
ER

PT J
AU Duarte, SM
   Rezende, RE
   Stefano, JT
   Perandini, LA
   Dassouki, T
   Sa-Pinto, AL
   Roschel, H
   Gualano, B
   Carrilho, FJ
   Oliveira, CP
AF Duarte, S. M.
   Rezende, R. E.
   Stefano, J. T.
   Perandini, L. A.
   Dassouki, T.
   Sa-Pinto, A. L.
   Roschel, H.
   Gualano, B.
   Carrilho, F. J.
   Oliveira, C. P.
TI IMPAIRED AEROBIC CAPACITY AND CARDIAC AUTONOMIC CONTROL IN SEDENTARY
   POSTMENOPAUSAL WOMEN WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 50th International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 22-26, 2015
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Duarte, S. M.; Rezende, R. E.; Stefano, J. T.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Perandini, L. A.; Dassouki, T.; Sa-Pinto, A. L.; Roschel, H.; Gualano, B.] Univ Sao Paulo, Sch Med, Reumatol, Sao Paulo, Brazil.
EM cpm@usp.br
RI Stefano, Jose Tadeu/AAH-5419-2020; Gualano, Bruno/ABA-9571-2020;
   Stefano, Jose T/H-4792-2013; Oliveira, Claudia PMS/D-1216-2014;
   Perandini, Luiz Augusto/N-1186-2019; DUARTE, Sebastiao
   Mauro/B-6075-2017; Gualano, Bruno/C-7190-2012; Roschel,
   Hamilton/D-4353-2012; Carrilho, Flair J/I-3046-2012
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Gualano,
   Bruno/0000-0001-7100-8681; Perandini, Luiz Augusto/0000-0001-8767-251X;
   Gualano, Bruno/0000-0001-7100-8681; Roschel,
   Hamilton/0000-0002-9513-6132; 
NR 0
TC 1
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2015
VL 62
SU 2
MA P1028
BP S733
EP S733
DI 10.1016/S0168-8278(15)31228-9
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5EL
UT WOS:000362830900221
DA 2020-12-08
ER

PT J
AU Neto, GL
   Noble, C
   Pinho, JRR
   Malta, FM
   Gomes-Gouvea, MS
   Alvarado-Mora, MV
   Silva, MH
   Leite, AG
   Piccoli, LZ
   Carrilho, FJ
   Mendes-Correa, MC
AF Lisboa Neto, G.
   Noble, C.
   Pinho, J. R. R.
   Malta, F. M.
   Gomes-Gouvea, M. S.
   Alvarado-Mora, M. V.
   Silva, M. H.
   Leite, A. G.
   Piccoli, L. Z.
   Carrilho, F. J.
   Mendes-Correa, M. C.
TI CHARACTERIZATION OF CLINICAL PREDICTORS OF NATURALLY OCCURRING NS3/NS4A
   PROTEASE POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS INFECTED PATIENTS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 50th International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 22-26, 2015
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Lisboa Neto, G.; Mendes-Correa, M. C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Noble, C.; Pinho, J. R. R.; Malta, F. M.; Gomes-Gouvea, M. S.; Alvarado-Mora, M. V.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Inst Trop Med, Dept Gastroenterol,LIM 07, Sao Paulo, Brazil.
   [Silva, M. H.] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Leite, A. G.; Piccoli, L. Z.] Ctr Especializado Saude, Caxias Do Sul, Brazil.
EM glneto@gmail.com
RI Carrilho, Flair J/I-3046-2012; Malta, Fernanda/B-1316-2013; Pinho, Joao
   R. R./G-2850-2012
OI Malta, Fernanda/0000-0001-8887-5060; Pinho, Joao R.
   R./0000-0003-3999-0489
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2015
VL 62
SU 2
MA P0911
BP S686
EP S686
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5EL
UT WOS:000362830900107
DA 2020-12-08
ER

PT J
AU Pessoa, MG
   Medeiros, RP
   Lopes, M
   Mazo, D
   Oliveira, CP
   Zitelli, PM
   Pinho, JR
   Carrilho, FJ
AF Pessoa, M. G.
   Medeiros, R. P.
   Lopes, M.
   Mazo, D.
   Oliveira, C. P.
   Zitelli, P. M.
   Pinho, J. R.
   Carrilho, F. J.
TI IMPAIRED ANTI-HBV VACCINE RESPONSE IN NON-CIRRHOTIC CHRONIC HCV PATIENTS
   COMPARED TO HEALTHY CONTROLS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 50th International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 22-26, 2015
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Pessoa, M. G.; Medeiros, R. P.; Lopes, M.; Mazo, D.; Oliveira, C. P.; Zitelli, P. M.; Pinho, J. R.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, Brazil.
EM mgpessoa@usp.br
RI Lopes, Marta H/J-3285-2012; Carrilho, Flair J/I-3046-2012; Oliveira,
   Claudia PMS/D-1216-2014; Pinho, Joao R. R./G-2850-2012; Mazo, Daniel
   FC/D-5631-2015
OI Pinho, Joao R. R./0000-0003-3999-0489; Mazo, Daniel
   FC/0000-0002-2164-2630
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2015
VL 62
SU 2
MA P0548
BP S520
EP S521
DI 10.1016/S0168-8278(15)30755-8
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5EJ
UT WOS:000362830600265
DA 2020-12-08
ER

PT J
AU Rezende, RE
   Duarte, SM
   Stefano, JT
   Perandini, LA
   Dassouki, T
   Sa-Pinto, AL
   Roschel, H
   Gualano, B
   Vezozzo, DC
   Carrilho, FJ
   Oliveira, CP
AF Rezende, R. E.
   Duarte, S. M.
   Stefano, J. T.
   Perandini, L. A.
   Dassouki, T.
   Sa-Pinto, A. L.
   Roschel, H.
   Gualano, B.
   Vezozzo, D. C.
   Carrilho, F. J.
   Oliveira, C. P.
TI IMPACT OF AEROBIC EXERCISE IN POSTMENOPAUSAL WOMEN WITH NONALCOHOLIC
   FATTY LIVER DISEASE: A 24 WEEKS RANDOMIZED CLINICAL TRIAL
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 50th International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 22-26, 2015
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Rezende, R. E.; Duarte, S. M.; Stefano, J. T.; Vezozzo, D. C.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Perandini, L. A.; Dassouki, T.; Sa-Pinto, A. L.; Roschel, H.; Gualano, B.] Univ Sao Paulo, Sch Med, Rheumatol, Sao Paulo, Brazil.
EM cpm@usp.br
RI Carrilho, Flair J/I-3046-2012; Gualano, Bruno/ABA-9571-2020; Gualano,
   Bruno/C-7190-2012; Perandini, Luiz Augusto/N-1186-2019; Stefano, Jose
   Tadeu/AAH-5419-2020; DUARTE, Sebastiao Mauro/B-6075-2017; Roschel,
   Hamilton/D-4353-2012; Stefano, Jose T/H-4792-2013; Oliveira, Claudia
   PMS/D-1216-2014
OI Gualano, Bruno/0000-0001-7100-8681; Gualano, Bruno/0000-0001-7100-8681;
   Perandini, Luiz Augusto/0000-0001-8767-251X; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Roschel, Hamilton/0000-0002-9513-6132; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2015
VL 62
SU 2
MA P1004
BP S724
EP S724
DI 10.1016/S0168-8278(15)31205-8
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5EL
UT WOS:000362830900198
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Torres, MM
   Pereira, IVA
   Jimenez, D
   Muntanelli, B
   Malta, FM
   Cogliati, B
   Pinho, JRR
   Carrilho, FJ
   Oliveira, CP
AF Stefano, J. T.
   Torres, M. M.
   Pereira, I. V. A.
   Jimenez, D.
   Muntanelli, B.
   Malta, F. M.
   Cogliati, B.
   Pinho, J. R. R.
   Carrilho, F. J.
   Oliveira, C. P.
TI THE COMBINATION OF PROBIOTICS AND PREBIOTICS SUPPLEMENTATION IMPROVES
   LIPID METABOLISM, NAFLD AND OBESITY IN OB/OB MICE
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 50th International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 22-26, 2015
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Stefano, J. T.; Torres, M. M.; Pereira, I. V. A.; Jimenez, D.; Muntanelli, B.; Malta, F. M.; Pinho, J. R. R.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Cogliati, B.] Univ Sao Paulo, Vet Med, Sao Paulo, Brazil.
EM cpm@usp.br
RI Carrilho, Flair J/I-3046-2012; Stefano, Jose T/H-4792-2013; Oliveira,
   Claudia PMS/D-1216-2014; Stefano, Jose Tadeu/AAH-5419-2020; Pinho, Joao
   R. R./G-2850-2012; Malta, Fernanda/B-1316-2013
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Pinho, Joao R.
   R./0000-0003-3999-0489; Malta, Fernanda/0000-0001-8887-5060
NR 0
TC 1
Z9 1
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2015
VL 62
SU 2
MA P0922
BP S691
EP S691
DI 10.1016/S0168-8278(15)31125-9
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5EL
UT WOS:000362830900118
DA 2020-12-08
ER

PT J
AU Cornella, H
   Alsinet, C
   Sayols, S
   Zhang, ZY
   Hao, K
   Cabellos, L
   Hoshida, Y
   Villanueva, A
   Thung, S
   Ward, SC
   Rodriguez-Carunchio, L
   Vila-Casadess, M
   Imbeaud, S
   Lachenmayer, A
   Quaglia, A
   Nagorney, DM
   Minguez, B
   Carrilho, F
   Lachenmayer, A
   Quaglia, A
   Nagorney, DM
   Minguez, B
   Carrilho, F
   Roberts, LR
   Waxman, S
   Mazzaferro, V
   Schwartz, M
   Esteller, M
   Heaton, ND
   Zucman-Rossi, J
   Llovet, JM
AF Cornella, Helena
   Alsinet, Clara
   Sayols, Sergi
   Zhang, Zhongyang
   Hao, Ke
   Cabellos, Laia
   Hoshida, Yujin
   Villanueva, Augusto
   Thung, Swan
   Ward, Stephen C.
   Rodriguez-Carunchio, Leonardo
   Vila-Casadess, Maria
   Imbeaud, Sandrine
   Lachenmayer, Anja
   Quaglia, Alberto
   Nagorney, David M.
   Minguez, Beatriz
   Carrilho, Flair
   Lachenmayer, Anja
   Quaglia, Alberto
   Nagorney, David M.
   Minguez, Beatriz
   Carrilho, Flair
   Roberts, Lewis R.
   Waxman, Samuel
   Mazzaferro, Vincenzo
   Schwartz, Myron
   Esteller, Manel
   Heaton, Nigel D.
   Zucman-Rossi, Jessica
   Llovet, Josep M.
TI Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma
SO GASTROENTEROLOGY
LA English
DT Article
DE Molecular Classification; Genomic Profiling; Outcome; Targeted Therapies
ID CIRCULAR BINARY SEGMENTATION; GENE-EXPRESSION SIGNATURE; COPY-NUMBER
   ALTERATION; CLINICOPATHOLOGICAL FEATURES; MOLECULAR CLASSIFICATION;
   DIFFERENTIAL-DIAGNOSIS; LIVER; CANCER; DISCOVERY; HEPATOCYTES
AB BACKGROUND & AIMS: Fibrolamellar hepatocellular carcinoma (FLC) is a rare primary hepatic cancer that develops in children and young adults without cirrhosis. Little is known about its pathogenesis, and it can be treated only with surgery. We performed an integrative genomic analysis of a large series of patients with FLC to identify associated genetic factors. METHODS: By using 78 clinically annotated FLC samples, we performed whole-transcriptome (n = 58), single-nucleotide polymorphism array (n = 41), and next-generation sequencing (n = 48) analyses; we also assessed the prevalence of the DNAJB1-PRKACA fusion transcript associated with this cancer (n = 73). We performed class discovery using non-negative matrix factorization, and functional annotation using gene-set enrichment analyses, nearest template prediction, ingenuity pathway analyses, and immunohistochemistry. The genomic identification of significant targets in a cancer algorithm was used to identify chromosomal aberrations, MuTect and VarScan2 were used to identify somatic mutations, and the random survival forest was used to determine patient prognoses. Findings were validated in an independent cohort. RESULTS: Unsupervised gene expression clustering showed 3 robust molecular classes of tumors: the proliferation class (51% of samples) had altered expression of genes that regulate proliferation and mammalian target of rapamycin signaling activation; the inflammation class (26% of samples) had altered expression of genes that regulate inflammation and cytokine enriched production; and the unannotated class (23% of samples) had a gene expression signature that was not associated previously with liver tumors. Expression of genes that regulate neuroendocrine function, as well as histologic markers of cholangiocytes and hepatocytes, were detected in all 3 classes. FLCs had few copy number variations; the most frequent were focal amplification at 8q24.3 (in 12.5% of samples), and deletions at 19p13 (in 28% of samples) and 22q13.32 (in 25% of samples). The DNAJB1-PRKACA fusion transcript was detected in 79% of samples. FLC samples also contained mutations in cancer-related genes such as BRCA2 (in 4.2% of samples), which are uncommon in liver neoplasms. However, FLCs did not contain mutations most commonly detected in liver cancers. We identified an 8-gene signature that predicted survival of patients with FLC. CONCLUSIONS: In a genomic analysis of 78 FLC samples, we identified 3 classes based on gene expression profiles. FLCs contain mutations and chromosomal aberrations not previously associated with liver cancer, and almost 80% contain the DNAJB1-PRKACA fusion transcript. By using this information, we identified a gene signature that is associated with patient survival time.
C1 [Cornella, Helena; Alsinet, Clara; Rodriguez-Carunchio, Leonardo; Llovet, Josep M.] Univ Barcelona, Hosp Clin,Liver Unit, CIBERehd,Barcelona Clin Liver Canc Grp,HCC Transl, Inst Invest Biomed August Pi i Sunyer,Dept Pathol, Barcelona 08036, Spain.
   [Vila-Casadess, Maria] Univ Barcelona, Hosp Clin,Liver Unit, CIBERehd, Inst Invest Biomed August Pi i Sunyer,Bioinformat, Barcelona 08036, Spain.
   [Sayols, Sergi; Esteller, Manel] Bellvitge Biomed Res Inst, Canc Epigenet & Biol Programme, Barcelona, Catalonia, Spain.
   [Zhang, Zhongyang; Hao, Ke; Cabellos, Laia; Hoshida, Yujin; Villanueva, Augusto; Thung, Swan; Ward, Stephen C.; Waxman, Samuel; Schwartz, Myron; Llovet, Josep M.] Icahn Sch Med Mt Sinai, Recanati Miller Transplantat Inst, Tisch Canc Inst, Div Liver Dis,Liver Canc Program, New York, NY USA.
   [Imbeaud, Sandrine; Zucman-Rossi, Jessica] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Dept Pathol, New York, NY USA.
   [Imbeaud, Sandrine; Zucman-Rossi, Jessica] IUH, Inserm, Genom Fonct Tumeurs Solides, UMR 1162, Paris, France.
   [Lachenmayer, Anja] Univ Paris 05, Sorbonne Paris Cite, Fac Med, Labex Immunooncol, Paris, France.
   [Quaglia, Alberto] Univ Hosp Dusseldorf, Dept Gen Visceral & Pediat Surg, Dusseldorf, Germany.
   [Nagorney, David M.; Roberts, Lewis R.] Kings Coll Hosp London, Inst Liver Studies, Div Transplant Immunol & Mucosal Biol, London, England.
   [Minguez, Beatriz] Mayo Clin, Div Gastroenterol & Hepatol, Div Gastroenterol & Gen Surg, Rochester, MN USA.
   [Carrilho, Flair] Hosp Valle De Hebron, Liver Unit, Barcelona, Catalonia, Spain.
   [Mazzaferro, Vincenzo] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Esteller, Manel; Llovet, Josep M.] NCI, Gastrointestinal Surg & Liver Transplantat Unit, Milan, Italy.
   [Esteller, Manel; Llovet, Josep M.] Inst Catalana Recerca Estudis Avancats, Barcelona, Catalonia, Spain.
RP Llovet, JM (corresponding author), Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi i Sunyer,Liver Unit, Barcelona Clin Liver Canc Grp,HCC Translat Res La, Villarroel 170, Barcelona 08036, Spain.
EM jmllovet@clinic.cat
RI Mazzaferro, Vincenzo/AAL-4707-2020; Cabellos, Laia/L-4629-2017; Hoshida,
   Yujin/R-7513-2019; Minguez, Beatriz/N-4456-2014; Vila Casadesus,
   Maria/J-8207-2016; Heaton, Nigel/AAK-8363-2020; Llovet, Josep
   M/D-4340-2014; Esteller, Manel/L-5956-2014; zucman-rossi,
   Jessica/B-5098-2009; Mazzaferro, Vincenzo/C-2726-2017; Carrilho, Flair
   J/I-3046-2012; Imbeaud, Sandrine/P-8780-2017
OI Minguez, Beatriz/0000-0002-7276-9666; Vila Casadesus,
   Maria/0000-0001-6597-7953; Llovet, Josep M/0000-0003-0547-2667;
   Esteller, Manel/0000-0003-4490-6093; zucman-rossi,
   Jessica/0000-0002-5687-0334; Mazzaferro, Vincenzo/0000-0002-4013-8085;
   Villanueva, Augusto/0000-0003-3585-3727; Roberts,
   Lewis/0000-0001-7885-8574; Imbeaud, Sandrine/0000-0001-8439-6732;
   Sayols, Sergi/0000-0002-3877-4170
FU US National Institute of Diabetes and Digestive and Kidney
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [1R01DK076986, R01 DK099558]; Samuel
   Waxman Cancer Research Foundation; Spanish National Health Institute
   [SAF-2013-41027]; Asociacion Espanola Contra el Cancer; European
   CommissionEuropean CommissionEuropean Commission Joint Research Centre
   [259744]; Instituto de Salud Carlos IIIInstituto de Salud Carlos III
   [ISCIII/FIS FI10/00143]; Spanish Ministry of EducationSpanish Government
   [FPU12/05138]; Innate/Adaptive Immune Interactions in Gut Inflammation
   (National Institutes of Health/National Institute of Diabetes and
   Digestive and Kidney Diseases) [P01/DK072201]; Cellex
   FoundationFoundation CELLEX; Botin Foundation; Health Department of the
   Catalan Government (Generalitat de Catalunya)Generalitat de Catalunya;
   Science Department of the Catalan Government (Generalitat de Catalunya);
   US National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); Mayo Clinic Center for Cell Signaling in
   Gastroenterology [R01CA165076]; Mayo Clinic Center for Cell Signaling in
   Gastroenterology (National Institute of Diabetes and Digestive and
   Kidney Diseases) [P30DK084567]; INCa (PAIR-CHC, NoFLIC project); Italian
   Association for Cancer ResearchAssociazione Italiana per la Ricerca sul
   Cancro (AIRC); INT-Milano; Alves de Queiroz Family Fund for Research
   from Brazil; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA165076, R01CA165076, R01CA165076,
   R01CA165076, R01CA165076, R01CA165076, R01CA165076, R01CA165076,
   R01CA165076, R01CA165076, R01CA165076, R01CA165076] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [P01DK072201, P30DK084567,
   P01DK072201, P01DK072201, P01DK072201, P01DK072201, P30DK084567,
   P01DK072201, P01DK072201, P01DK072201, P30DK084567, P01DK072201,
   P30DK084567, P01DK072201, R01DK076986, P01DK072201, P30DK084567,
   P01DK072201, P01DK072201, P30DK084567, P01DK072201, P30DK084567,
   P30DK084567, P01DK072201, P01DK072201, P01DK072201, P01DK072201,
   P01DK072201, R01DK099558, P01DK072201, P30DK084567, P01DK072201,
   P01DK072201, R01DK099558, P30DK084567, P01DK072201, P30DK084567,
   P30DK084567, P30DK084567, P30DK084567, P30DK084567, P01DK072201,
   P01DK072201, P30DK084567, P01DK072201, P01DK072201, P30DK084567,
   P01DK072201, P30DK084567, P01DK072201, P01DK072201, P01DK072201,
   P01DK072201, P30DK084567, P01DK072201, P30DK084567, P30DK084567,
   P30DK084567, P01DK072201, P30DK084567, P01DK072201, P30DK084567,
   P30DK084567, P01DK072201, P01DK072201, P01DK072201, P01DK072201,
   P30DK084567, P30DK084567, P01DK072201, P01DK072201, P01DK072201,
   P01DK072201, R01DK099558, R01DK076986, R01DK076986, P30DK084567,
   P30DK084567, R01DK076986, P01DK072201, P30DK084567, P01DK072201,
   P01DK072201, P30DK084567, P30DK084567, P01DK072201, P01DK072201,
   P01DK072201, P30DK084567, P01DK072201, P30DK084567, P30DK084567,
   R01DK099558, P01DK072201, P30DK084567, P01DK072201, P01DK072201,
   P01DK072201, P01DK072201, P30DK084567, P01DK072201, P30DK084567,
   P30DK084567, P01DK072201, P01DK072201, P01DK072201, P01DK072201,
   P30DK084567, P01DK072201, P30DK084567, R01DK076986, P30DK084567,
   P01DK072201, P01DK072201, P30DK084567, P30DK084567, P01DK072201,
   P01DK072201, P30DK084567, P30DK084567, P30DK084567, P30DK084567,
   P01DK072201, P30DK084567, P01DK072201, P30DK084567, P01DK072201,
   P30DK084567, P01DK072201, P30DK084567] Funding Source: NIH RePORTER;
   ICREAICREA Funding Source: Custom
FX Supported by grants from the US National Institute of Diabetes and
   Digestive and Kidney Diseases (1R01DK076986), the Samuel Waxman Cancer
   Research Foundation, the Spanish National Health Institute
   (SAF-2013-41027), the Asociacion Espanola Contra el Cancer, and the
   European Commission Framework Programme 7 (Heptromic, proposal number
   259744) (J.M.L.); by a fellowship from the Instituto de Salud Carlos III
   (ISCIII/FIS FI10/00143 to H.C.); by the US National Institute of
   Diabetes and Digestive and Kidney Diseases (R01 DK099558 to Y.H.); by
   the Spanish Ministry of Education (FPU12/05138 to M.V.C.); by the
   Innate/Adaptive Immune Interactions in Gut Inflammation (National
   Institutes of Health/National Institute of Diabetes and Digestive and
   Kidney Diseases P01/DK072201 to S.C.W.); by Cellex Foundation, Botin
   Foundation, and the Health and Science Departments of the Catalan
   Government (Generalitat de Catalunya) (M.E.); by a grant from the US
   National Cancer Institute and supported by the Mayo Clinic Center for
   Cell Signaling in Gastroenterology (R01CA165076 and National Institute
   of Diabetes and Digestive and Kidney Diseases P30DK084567) (L.R.R.); by
   a grant from INCa (PAIR-CHC, NoFLIC project) (J.Z.R.); by the Italian
   Association for Cancer Research and the INT-Milano Institutional Funds
   (5x1000 on Hepato-Oncology) (V.M.); and by a grant from the Alves de
   Queiroz Family Fund for Research from Brazil (F.C.).
CR BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bhat M, 2013, HEPATOLOGY, V58, P810, DOI 10.1002/hep.26323
   Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467
   Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101
   Buckley AF, 2006, HUM PATHOL, V37, P410, DOI 10.1016/j.humpath.2005.12.009
   Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283
   de Stahl TD, 2005, GENE CHROMOSOME CANC, V44, P161, DOI 10.1002/gcc.20226
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Deshpande AJ, 2013, BLOOD, V121, P2533, DOI 10.1182/blood-2012-11-465120
   EDMONDSON HA, 1956, AMA J DIS CHILD, V91, P168, DOI 10.1001/archpedi.1956.02060020170015
   El-Serag HB, 2004, HEPATOLOGY, V39, P798, DOI 10.1002/hep.20096
   Frey BJ, 2007, SCIENCE, V315, P972, DOI 10.1126/science.1136800
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Heider A, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-75
   Honeyman JN, 2014, SCIENCE, V343, P1010, DOI 10.1126/science.1249484
   Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525
   Hoshida Y, 2013, GASTROENTEROLOGY, V144, P1024, DOI 10.1053/j.gastro.2013.01.021
   Hoshida Y, 2010, SEMIN LIVER DIS, V30, P35, DOI 10.1055/s-0030-1247131
   Hsu YC, 2009, CLIN CANCER RES, V15, P7309, DOI 10.1158/1078-0432.CCR-09-1572
   Ishwaran Hemant, 2011, Statistical Analysis and Data Mining, V4, P115, DOI 10.1002/sam.10103
   Kakar S, 2005, MODERN PATHOL, V18, P1417, DOI 10.1038/modpathol.3800449
   Kannangai R, 2007, HUM PATHOL, V38, P639, DOI 10.1016/j.humpath.2006.07.019
   Kauskot A, 2013, BLOOD, V121, P5208, DOI 10.1182/blood-2012-10-462887
   Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Liu YF, 2007, ONCOL REP, V18, P943
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Malouf GG, 2014, HEPATOLOGY, V59, P2228, DOI 10.1002/hep.27018
   Mavros MN, 2012, J AM COLL SURGEONS, V215, P820, DOI 10.1016/j.jamcollsurg.2012.08.001
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41
   Montero-Conde C, 2008, ONCOGENE, V27, P1554, DOI 10.1038/sj.onc.1210792
   Moser JM, 2002, NAT IMMUNOL, V3, P189, DOI 10.1038/ni757
   Nault JC, 2013, GASTROENTEROLOGY, V145, P176, DOI 10.1053/j.gastro.2013.03.051
   Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008
   Patonai A, 2013, PATHOL ONCOL RES, V19, P63, DOI 10.1007/s12253-012-9558-0
   Peiffer DA, 2006, GENOME RES, V16, P1136, DOI 10.1101/gr.5402306
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941
   Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Schonherr C, 2010, ONCOGENE, V29, P2817, DOI 10.1038/onc.2010.27
   Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889
   Sia D, 2013, GASTROENTEROLOGY, V144, P829, DOI 10.1053/j.gastro.2013.01.001
   Staaf J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r136
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Swoboda RK, 2007, CANCER RES, V67, P3555, DOI 10.1158/0008-5472.CAN-06-2763
   Torbenson M, 2007, ADV ANAT PATHOL, V14, P217, DOI 10.1097/PAP.0b013e3180504913
   Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646
   Villanueva A PA, 2015, HEPATOLOGY
   Villanueva A, 2014, NAT REV CLIN ONCOL, V11, P73, DOI [10.1038/nrclinonc.2013.243, 10.1038/nrclinonc.2013.227]
   Ward SC, 2011, SEMIN LIVER DIS, V31, P61, DOI 10.1055/s-0031-1272835
   Ward SC, 2010, MODERN PATHOL, V23, P1180, DOI 10.1038/modpathol.2010.105
   WENNERBERG AE, 1993, AM J PATHOL, V143, P1050
   Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97
   Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103
   Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622
NR 61
TC 56
Z9 57
U1 0
U2 37
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2015
VL 148
IS 4
BP 806
EP U231
DI 10.1053/j.gastro.2014.12.028
PG 23
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CE2IJ
UT WOS:000351639000027
PM 25557953
OA Green Accepted
DA 2020-12-08
ER

PT J
AU de Siqueira, ERF
   Pereira, LB
   Stefano, JT
   Patente, T
   Cavaleiro, AM
   Vasconcelos, LRS
   Carmo, RF
   Pereira, LMMB
   Carrilho, FJ
   Correa-Giannella, ML
   Oliveira, CP
AF Forte de Siqueira, Erika Rabelo
   Pereira, Luciano Beltrao
   Stefano, Jose Tadeu
   Patente, Thiago
   Cavaleiro, Ana Mercedes
   Silva Vasconcelos, Luydson Richardson
   Carmo, Rodrigo Feliciano
   Moreira Beltrao Pereira, Leila Maria
   Carrilho, Flair Jose
   Correa-Giannella, Maria Lucia
   Oliveira, Claudia P.
TI Association of a variant in the regulatory region of NADPH oxidase 4
   gene and metabolic syndrome in patients with chronic hepatitis C
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE Hepatitis C; NADPH oxidase 4 polymorphisms; Metabolic syndrome
ID OXIDATIVE STRESS; HEPATOCELLULAR-CARCINOMA; VIRUS-INFECTION; PROTEIN;
   DISEASE; PLASMA; HEALTH; RISK
AB Background: Given the important contribution of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system to the generation of reactive oxygen species induced by hepatitis C virus (HCV), we investigated two single nucleotide polymorphisms (SNPs) in the putative regulatory region of the genes encoding NADPH oxidase 4 catalytic subunit (NOX4) and its regulatory subunit p22phox (CYBA) and their relation with metabolic and histological variables in patients with HCV.
   Methods: One hundred seventy eight naive HCV patients (49.3% male; 65% HCV genotype 1) with positive HCV RNA were genotyped using specific primers and fluorescent-labeled probes for SNPs rs3017887 in NOX4 and -675 T -> A in CYBA.
   Results: No association was found between the genotype frequencies of NOX4 and CYBA SNPs and inflammation scores or fibrosis stages in the overall population. The presence of the CA + AA genotypes of the NOX4 SNP was nominally associated with a lower alanine aminotransferase (ALT) concentration in the male population (CA + AA = 72.23 +/- 6.34 U/L versus CC = 100.22 +/- 9.85; mean +/- SEM; P = 0.05). The TT genotype of the CYBA SNP was also nominally associated with a lower ALT concentration in the male population (TT = 84.01 +/- 6.77 U/L versus TA + AA = 109.67 +/- 18.37 U/L; mean +/- SEM; P = 0.047). The minor A-allele of the NOX4 SNP was inversely associated with the frequency of metabolic syndrome (MS) in the male population (odds ratio (OR): 0.15; 95% confidence interval (CI): 0.03 to 0.79; P = 0.025).
   Conclusions: The results suggest that the evaluated NOX4 and CYBA SNPs are not direct genetic determinants of fibrosis in HCV patients, but nevertheless NOX4 rs3017887 SNP could indirectly influence fibrosis susceptibility due to its inverse association with MS in male patients.
C1 [Forte de Siqueira, Erika Rabelo; Pereira, Luciano Beltrao; Stefano, Jose Tadeu] Univ Sao Paulo, Sch Med, Dept Gastroenterol, LIM 07, BR-1246903 Sao Paulo, Brazil.
   [Patente, Thiago; Cavaleiro, Ana Mercedes; Correa-Giannella, Maria Lucia] Univ Sao Paulo, Sch Med, Lab Cellular & Mol Endocrinol, LIM 25, BR-1246903 Sao Paulo, SP, Brazil.
   [Forte de Siqueira, Erika Rabelo; Pereira, Luciano Beltrao; Moreira Beltrao Pereira, Leila Maria] Univ Pernambuco, Sch Med, Dept Gastroenterol, BR-1235 Pernambuco, Brazil.
   [Forte de Siqueira, Erika Rabelo; Pereira, Luciano Beltrao; Silva Vasconcelos, Luydson Richardson; Moreira Beltrao Pereira, Leila Maria] Liver Inst Pernambuco, BR-282 Recife, PE, Brazil.
   [Carmo, Rodrigo Feliciano] Fed Univ Sao Francisco Valley, Coll Pharmaceut Sci, Petrolina, PE, Brazil.
   [Correa-Giannella, Maria Lucia] Univ Sao Paulo, Sch Med, NUCEL NETCEM, Cell & Mol Therapy Ctr, BR-1246903 Sao Paulo, SP, Brazil.
RP Oliveira, CP (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, LIM 07, Av Dr Arnaldo 455,3 Andar 3115, BR-1246903 Sao Paulo, Brazil.
EM cpm@usp.br
RI Stefano, Jose Tadeu/AAH-5419-2020; Carmo, Rodrigo Feliciano
   do/V-9795-2017; Vasconcelos, Luydson/AAC-4907-2020; Stefano, Jose
   T/H-4792-2013; Giannella, Maria Lucia/N-3834-2019; Carrilho, Flair
   J/I-3046-2012; Patente, Thiago A/G-1698-2017; Oliveira, Claudia
   PMS/D-1216-2014
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Carmo, Rodrigo Feliciano
   do/0000-0001-9601-6995; Vasconcelos, Luydson/0000-0002-1625-3358;
   Patente, Thiago A/0000-0001-9333-869X; Silva, Richardson Augusto Rosendo
   da/0000-0001-6290-9365; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
CR Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Bureau C, 2001, J BIOL CHEM, V276, P23077, DOI 10.1074/jbc.M100698200
   Cave AC, 2006, ANTIOXID REDOX SIGN, V8, P691, DOI 10.1089/ars.2006.8.691
   Choi J, 2014, FREE RADICAL BIO MED, V72, P267, DOI 10.1016/j.freeradbiomed.2014.04.020
   de Mochel NSR, 2010, HEPATOLOGY, V52, P47, DOI 10.1002/hep.23671
   Elnakish MT, 2013, J PATHOL, V231, P290, DOI 10.1002/path.4255
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298
   Grundy SM, 2004, ARTERIOSCL THROM VAS, V24, pE19, DOI 10.1161/01.ATV.0000112379.88385.67
   Guichard C, 2008, BIOCHEM SOC T, V36, P920, DOI 10.1042/BST0360920
   Kawaguchi Y, 2014, WORLD J GASTROENTERO, V20, P2888, DOI 10.3748/wjg.v20.i11.2888
   Lavanchy D, 2008, BEST PRACT RES CL GA, V22, P991, DOI 10.1016/j.bpg.2008.11.002
   Li QS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004163
   Lim SC, 2009, DIABETOLOGIA, V52, P1343, DOI 10.1007/s00125-009-1368-x
   Loguercio C, 2003, FREE RADICAL BIO MED, V34, P1, DOI 10.1016/S0891-5849(02)01167-X
   Meaney MJ, 2010, CHILD DEV, V81, P41, DOI 10.1111/j.1467-8624.2009.01381.x
   Monteiro MB, 2013, FREE RADICAL RES, V47, P804, DOI 10.3109/10715762.2013.828347
   Moreno MU, 2007, J HYPERTENS, V25, P1620, DOI 10.1097/HJH.0b013e3281ac211d
   Moriya K, 2001, CANCER RES, V61, P4365
   Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Stuyver L, 1996, J CLIN MICROBIOL, V34, P2259, DOI 10.1128/JCM.34.9.2259-2266.1996
   Yu L, 2012, MOL BIOL REP, V39, P6641, DOI 10.1007/s11033-012-1469-3
NR 23
TC 4
Z9 4
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD MAR 28
PY 2015
VL 20
AR 45
DI 10.1186/s40001-015-0136-2
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CE8FV
UT WOS:000352078000001
PM 25888935
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Chagas, AL
   Kikuchi, L
   Herman, P
   Alencar, RSSM
   Tani, CM
   Diniz, MA
   Pugliese, V
   Rocha, MD
   D'Albuquerque, LAC
   Carrilho, FJ
   Alves, VAF
AF Chagas, Aline Lopes
   Kikuchi, Luciana
   Herman, Paulo
   Alencar, Regiane S. S. M.
   Tani, Claudia M.
   Diniz, Marcio Augusto
   Pugliese, Vincenzo
   Rocha, Manoel de Souza
   Carneiro D'Albuquerque, Luiz Augusto
   Carrilho, Flair Jose
   Alves, Venancio A. F.
TI Clinical and pathological evaluation of fibrolamellar hepatocellular
   carcinoma: a single center study of 21 cases
SO CLINICS
LA English
DT Article
DE Fibrolamellar hepatocellular carcinoma; Liver cancer; Liver neoplasms;
   Hepatocellular carcinoma (fibrolamellar variant)
ID HEPATIC CARCINOMA; FIBROUS STROMA; LIVER; TRANSPLANTATION; PREGNANCY;
   CHILDHOOD; DIAGNOSIS; PROGNOSIS; RESECTION; SURVIVAL
AB OBJECTIVES: Fibrolamellar hepatocellular carcinoma is a rare primary malignant liver tumor that differs from conventional hepatocellular carcinoma in several aspects. The aim of this study was to describe the clinical, surgical and histopathological features of fibrolamellar hepatocellular carcinoma and to analyze the factors associated with survival.
   METHODS: We identified 21 patients with histopathologically diagnosed fibrolamellar hepatocellular carcinoma over a 22-year period. Clinical information was collected from medical records and biopsies, and surgical specimens were reviewed.
   RESULTS: The median age at diagnosis was 20 years. Most patients were female (67%) and did not have associated chronic liver disease. Most patients had a single nodule, and the median tumor size was 120 mm. Vascular invasion was present in 31% of patients, and extra-hepatic metastases were present in 53%. Fourteen patients underwent surgery as the first-line therapy, three received chemotherapy, and four received palliative care. Eighteen patients had "pure fibrolamellar hepatocellular carcinoma,'' whereas three had a distinct area of conventional hepatocellular carcinoma and were classified as having "mixed fibrolamellar hepatocellular carcinoma.'' The median overall survival was 36 months. The presence of "mixed fibrolamellar hepatocellular carcinoma'' and macrovascular invasion were predictors of poor survival. Vascular invasion was associated with an increased risk of recurrence in patients who underwent surgery.
   CONCLUSION: Fibrolamellar hepatocellular carcinoma was more common in young female patients without chronic liver disease. Surgery was the first therapeutic option to achieve disease control, even in advanced cases. Vascular invasion was a risk factor for tumor recurrence. The presence of macrovascular invasion and areas of conventional hepatocellular carcinoma were directly related to poor survival.
C1 [Chagas, Aline Lopes; Kikuchi, Luciana; Herman, Paulo; Alencar, Regiane S. S. M.; Tani, Claudia M.; Diniz, Marcio Augusto; Pugliese, Vincenzo; Rocha, Manoel de Souza; Carneiro D'Albuquerque, Luiz Augusto; Carrilho, Flair Jose; Alves, Venancio A. F.] Sao Paulo Clin Liver Canc Grp, Sao Paulo, Brazil.
   [Chagas, Aline Lopes; Kikuchi, Luciana; Herman, Paulo; Alencar, Regiane S. S. M.; Tani, Claudia M.; Diniz, Marcio Augusto; Pugliese, Vincenzo; Carneiro D'Albuquerque, Luiz Augusto; Carrilho, Flair Jose] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   [Rocha, Manoel de Souza] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Radiol, BR-05508 Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Pathol, BR-05508 Sao Paulo, Brazil.
   [Chagas, Aline Lopes; Kikuchi, Luciana; Alencar, Regiane S. S. M.; Tani, Claudia M.] Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, BR-05508 Sao Paulo, Brazil.
RP Chagas, AL (corresponding author), Sao Paulo Clin Liver Canc Grp, Sao Paulo, Brazil.
EM alinelchagas@gmail.com
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Rocha, Manoel
   S/C-6478-2013; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013; Herman,
   Paulo/J-5457-2013; Chagas, Aline Lopes/X-2059-2019; Carrilho, Flair
   J/I-3046-2012
OI Rocha, Manoel S/0000-0002-4503-8374; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Herman, Paulo/0000-0003-2859-5846; Diniz,
   Marcio Augusto/0000-0002-2427-7843
FU Alves de Queiroz Family Fund
FX The authors would like to thank the Alves de Queiroz Family Fund for
   Research for the support of our continued work and the Laboratory of
   Epidemiology and Statistics of Department of Gastroenterology, School of
   Medicine - University of Sao Paulo, SP, Brazil for their permanent
   assistance.
CR Arista-Nasr Julian, 2002, Pathology and Oncology Research, V8, P133
   BERMAN MM, 1980, CANCER, V46, P1448, DOI 10.1002/1097-0142(19800915)46:6<1448::AID-CNCR2820460626>3.0.CO;2-J
   Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
   CRAIG JR, 1980, CANCER, V46, P372, DOI 10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S
   Dahan MH, 2002, J REPROD MED, V47, P47
   EDMONDSON HA, 1956, AMA J DIS CHILD, V91, P168, DOI 10.1001/archpedi.1956.02060020170015
   El-Gazzaz G, 2000, Transpl Int, V13 Suppl 1, pS406, DOI 10.1007/s001470050372
   El-Serag HB, 2004, HEPATOLOGY, V39, P798, DOI 10.1002/hep.20096
   GEMER O, 1994, ARCH GYNECOL OBSTET, V255, P211, DOI 10.1007/BF02335087
   Hemming A W, 1997, J Gastrointest Surg, V1, P342, DOI 10.1016/S1091-255X(97)80055-8
   Kakar S, 2005, MODERN PATHOL, V18, P1417, DOI 10.1038/modpathol.3800449
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   LACK EE, 1983, CANCER, V52, P1510, DOI 10.1002/1097-0142(19831015)52:8<1510::AID-CNCR2820520830>3.0.CO;2-7
   Liu S, 2009, AM J GASTROENTEROL, V104, P2617, DOI 10.1038/ajg.2009.440
   Malouf G, 2009, J CLIN PATHOL, V62, P519, DOI 10.1136/jcp.2008.062620
   Malouf GG, 2012, CANCER-AM CANCER SOC, V118, P4981, DOI 10.1002/cncr.27520
   Maniaci V, 2009, EJSO-EUR J SURG ONC, V35, P617, DOI 10.1016/j.ejso.2008.12.009
   McLarney JK, 1999, RADIOGRAPHICS, V19, P453, DOI 10.1148/radiographics.19.2.g99mr09453
   Moreno-Luna LE, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-142
   NAGORNEY DM, 1985, AM J SURG, V149, P113, DOI 10.1016/S0002-9610(85)80019-2
   Paranagua-Vezozzo DC, 2014, ANN HEPATOL, V13, P386, DOI 10.1016/S1665-2681(19)30845-2
   Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8
   Pinna AD, 1997, HEPATOLOGY, V26, P877
   R Core Team, 2013, R LANG ENV STAT COMP
   RINGE B, 1992, SURG GYNECOL OBSTET, V175, P299
   SILVA H, 1988, REV MED CHILE, V116, P153
   Sobin LH, 2010, CANCER-AM CANCER SOC, V116, P5336, DOI 10.1002/cncr.25537
   STEVENS WR, 1995, AM J ROENTGENOL, V164, P1153, DOI 10.2214/ajr.164.5.7717223
   Stipa F, 2006, CANCER-AM CANCER SOC, V106, P1331, DOI 10.1002/cncr.21703
   Toberson M, 2007, ADV ANAT PATHOL, V14, P217
   WETZEL WJ, 1983, SOUTHERN MED J, V76, P796, DOI 10.1097/00007611-198306000-00028
NR 31
TC 13
Z9 14
U1 0
U2 9
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD MAR
PY 2015
VL 70
IS 3
BP 207
EP 213
DI 10.6061/clinics/2015(03)10
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI6HZ
UT WOS:000354860900010
PM 26017653
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Zhu, AX
   Rosmorduc, O
   Evans, TRJ
   Ross, PJ
   Santoro, A
   Carrilho, FJ
   Bruix, J
   Qin, SK
   Thuluvath, PJ
   Llovet, JM
   Leberre, MA
   Jensen, M
   Meinhardt, G
   Kang, YK
AF Zhu, Andrew X.
   Rosmorduc, Olivier
   Evans, T. R. Jeffry
   Ross, Paul J.
   Santoro, Armando
   Carrilho, Flair Jose
   Bruix, Jordi
   Qin, Shukui
   Thuluvath, Paul J.
   Llovet, Josep M.
   Leberre, Marie-Aude
   Jensen, Markus
   Meinhardt, Gerold
   Kang, Yoon-Koo
TI SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
   of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular
   Carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; TARGETED THERAPY; CLINICAL-TRIALS; ACTIVATION;
   BRIVANIB; EGFR
AB Purpose
   To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial.
   Patients and Methods
   Patients with advanced HCC and underlying Child-Pugh class A cirrhosis, who were naive to systemic treatment (N = 720), were randomly assigned to sorafenib plus either erlotinib (n = 362) or placebo (n = 358). The primary end point was overall survival (OS).
   Results
   Median OS was similar in the sorafenib plus erlotinib and sorafenib plus placebo groups (9.5 v 8.5 months, respectively; hazard ratio [HR], 0.929; P = .408), as was median time to progression (3.2 v 4.0 months, respectively; HR, 1.135; P = .18). In the sorafenib/erlotinib arm versus the sorafenib/placebo arm, the overall response rate trended higher (6.6% v 3.9%, respectively; P = .102), whereas the disease control rate was significantly lower (43.9% v 52.5%, respectively; P = .021). The median durations of treatment with sorafenib were 86 days in the sorafenib/erlotinib arm and 123 days in the sorafenib/placebo arm. In the sorafenib/erlotinib and sorafenib/placebo arms, the rates of treatment-emergent serious AEs (58.0% v 54.6%, respectively) and drug-related serious AEs (21.0% v 22.8%, respectively) were similar. AEs matched the known safety profiles of both agents, but rates of rash/desquamation, anorexia, and diarrhea were higher in the sorafenib/erlotinib arm, whereas rates of alopecia and hand-foot skin reaction were higher in the sorafenib/placebo arm. Withdrawal rates for AEs during cycles 1 to 3 were higher in the sorafenib/erlotinib arm.
   Conclusion
   Adding erlotinib to sorafenib did not improve survival in patients with advanced HCC. (C) 2014 by American Society of Clinical Oncology
C1 [Zhu, Andrew X.; Rosmorduc, Olivier; Evans, T. R. Jeffry; Ross, Paul J.; Santoro, Armando; Carrilho, Flair Jose; Bruix, Jordi; Qin, Shukui; Thuluvath, Paul J.; Llovet, Josep M.; Leberre, Marie-Aude; Jensen, Markus; Meinhardt, Gerold; Kang, Yoon-Koo] Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Andrew X Zhu, Boston, MA USA.
   [Zhu, Andrew X.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA.
   [Rosmorduc, Olivier] Hop St Antoine, Serv Hepatol, F-75571 Paris, France.
   [Leberre, Marie-Aude] Bayer HealthCare Pharmaceut, Loos, France.
   [Evans, T. R. Jeffry] Univ Glasgow, Inst Canc Sci, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.
   [Ross, Paul J.] Kings Coll Hosp London, London, England.
   [Santoro, Armando] Humanitas Canc Ctr, Milan, Italy.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Bruix, Jordi; Llovet, Josep M.] Hosp Clin Barcelona, Barcelona Clin Liver Canc Grp, Inst Invest Biomed August Pi I Sunyer, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain.
   [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Catalonia, Spain.
   [Qin, Shukui] Nanjing Bayi Hosp, Peoples Liberat Army Canc Ctr, Nanjing, Jiangsu, Peoples R China.
   [Thuluvath, Paul J.] Mercy Med Ctr, Inst Digest Hlth & Liver Dis, Baltimore, MD USA.
   [Llovet, Josep M.] Mt Sinai Sch Med, Mt Sinai Liver Canc Program, New York, NY USA.
   [Jensen, Markus] Bayer Vital GmbH, Leverkusen, Germany.
   [Meinhardt, Gerold] Bayer HealthCare Pharmaceut, Montville, NJ USA.
   [Kang, Yoon-Koo] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea.
RP Zhu, AX (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, 55 Fruit St,LH POB 232, Boston, MA 02114 USA.
EM azhu@partners.org
RI Carrilho, Flair J/I-3046-2012; Santoro, Armando/J-9594-2018; Llovet,
   Josep M/D-4340-2014
OI Santoro, Armando/0000-0003-1709-9492; Llovet, Josep
   M/0000-0003-0547-2667; Bruix, Jordi/0000-0002-9826-0753
FU NovartisNovartis; BayerBayer AG; Onyx; Daiichi SankyoDaiichi Sankyo
   Company Limited; ArQule; Boehringer-IngelheimBoehringer Ingelheim; Bayer
   PharmaceuticalsBayer AG; Cancer Research UKCancer Research UK [11650]
   Funding Source: researchfish; Versus ArthritisVersus Arthritis [20409]
   Funding Source: researchfish; ICREAICREA Funding Source: Custom
FX Andrew X. Zhu, Novartis, Bayer, Onyx; Flair Jose Carrilho, Bayer; Jordi
   Bruix, Daiichi Sankyo, ArQule, Bayer; Paul J. Thuluvath, Bayer; Josep M.
   Llovet, Boehringer-Ingelheim, Bayer Pharmaceuticals; Yoon-Koo Kang,
   Bayer, Novartis
CR Astellas Pharma US Genentech, 2012, TARC ERL TABL OR PRE
   Bassullu N, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.7492
   Bayer HealthCare Pharmaceuticals, 2012, NEX TABL OR PRESCR I
   Berasain C, 2012, DIGEST DIS, V30, P524, DOI 10.1159/000341705
   Blivet-Van Eggelpoel MJ, 2012, J HEPATOL, V57, P108, DOI 10.1016/j.jhep.2012.02.019
   Cainap C, 2013, J CLIN ONCOL, V31, DOI 10.1200/jco.2013.31.4_suppl.249
   Cheng AL, 2013, J CLIN ONCOL, V31, P4067, DOI 10.1200/JCO.2012.45.8372
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Duran I, 2007, CLIN CANCER RES, V13, P4849, DOI 10.1158/1078-0432.CCR-07-0382
   Ezzoukhry Z, 2012, INT J CANCER, V131, P2961, DOI 10.1002/ijc.27604
   Hughes AN, 2009, J CLIN ONCOL, V27, P1220, DOI 10.1200/JCO.2008.19.3995
   Iyer R, 2010, EXPERT OPIN PHARMACO, V11, P311, DOI 10.1517/14656560903551283
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115
   Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410
   Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007
   Lacouture ME, 2008, ONCOLOGIST, V13, P1001, DOI 10.1634/theoncologist.2008-0131
   Lencioni R, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.4_suppl.lba154
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
   Llovet JM, 2013, J CLIN ONCOL, V31, P3509, DOI 10.1200/JCO.2012.47.3009
   National Comprehensive Cancer Network, 2013, NCCN GUID VERS 2 201
   Philip PA, 2005, J CLIN ONCOL, V23, P6657, DOI 10.1200/JCO.2005.14.696
   Pitarch G, 2008, ACTAS DERMO-SIFILOGR, V99, P54
   Steins M, 2010, RECENT RESULTS CANC, V184, P21, DOI 10.1007/978-3-642-01222-8_2
   Tazi EM, 2011, N AM J MED SCI, V3, P167, DOI 10.4297/najms.2011.3167
   Thomas MB, 2007, CANCER-AM CANCER SOC, V110, P1059, DOI 10.1002/cncr.22886
   Thomas MB, 2010, J CLIN ONCOL, V28, P3994, DOI 10.1200/JCO.2010.28.7805
   Waller LL, 2010, LUNG CANCER, V67, P12, DOI 10.1016/j.lungcan.2009.08.014
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Zhu AX, 2012, SEMIN ONCOL, V39, P493, DOI 10.1053/j.seminoncol.2012.05.014
NR 30
TC 267
Z9 278
U1 3
U2 39
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2015
VL 33
IS 6
BP 559
EP 566
DI 10.1200/JCO.2013.53.7746
PG 8
WC Oncology
SC Oncology
GA CF4MS
UT WOS:000352523800009
PM 25547503
OA Green Published
DA 2020-12-08
ER

PT J
AU Espirito-Santo, MCC
   Alvarado-Mora, MV
   Pinto, PLS
   Sanchez, MCA
   Dias-Neto, E
   Castilho, VLP
   Goncalves, EMD
   Chieffi, PP
   Luna, EJD
   Pinho, JRR
   Carrilho, FJ
   Gryschek, RCB
AF Carvalho Espirito-Santo, Maria Cristina
   Alvarado-Mora, Monica Viviana
   Silva Pinto, Pedro Luiz
   Arroyo Sanchez, Maria Carmen
   Dias-Neto, Emmanuel
   Pagliusi Castilho, Vera Lucia
   do Nascimento Goncalves, Elenice Messias
   Chieffi, Pedro Paulo
   de Albuquerque Luna, Expedito Jose
   Rebello Pinho, Joao Renato
   Carrilho, Flair Jose
   Borges Gryschek, Ronaldo Cesar
TI Comparative Study of the Accuracy of Different Techniques for the
   Laboratory Diagnosis of Schistosomiasis Mansoni in Areas of Low
   Endemicity in Barra Mansa City, Rio de Janeiro State, Brazil
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; CIRCULATING ANTIGENS CAA;
   LOW-TRANSMISSION AREAS; EGG COUNT VARIATION; KATO-KATZ; STOOL SAMPLES;
   THICK-SMEAR; QUANTITATIVE DIAGNOSIS; BANANAL STATE
AB Schistosomiasis constitutes a major public health problem, with an estimated 200 million people infected worldwide. Many areas of Brazil show low endemicity of schistosomiasis, and the current standard parasitological techniques are not sufficiently sensitive to detect the low-level helminth infections common in areas of low endemicity (ALEs). This study compared the Kato-Katz (KK); Hoffman, Pons, and Janer (HH); enzyme-linked immunosorbent assay-(ELISA-) IgG and ELISA-IgM; indirect immunofluorescence technique (IFT-IgM); and qPCR techniques for schistosomiasis detection in serum and fecal samples, using the circumoval precipitin test (COPT) as reference. An epidemiological survey was conducted in a randomized sample of residents from five neighborhoods of Barra Mansa, RJ, with 610 fecal and 612 serum samples. ELISA-IgM(21.4%) showed the highest positivity and HH and KK techniques were the least sensitive (0.8%). All techniques except qPCR-serum showed high accuracy (82-95.5%), differed significantly from COPT in positivity (P < 0.05), and showed poor agreement with COPT. Medium agreement was seen with ELISA-IgG (Kappa = 0.377) and IFA (Kappa = 0.347). Parasitological techniques showed much lower positivity rates than those by other techniques. We suggest the possibility of using a combination of laboratory tools for the diagnosis of schistosomiasis in ALEs.
C1 [Carvalho Espirito-Santo, Maria Cristina; Carrilho, Flair Jose; Borges Gryschek, Ronaldo Cesar] Univ Sao Paulo, Dept Infect & Parasit Dis, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
   [Carvalho Espirito-Santo, Maria Cristina; Carrilho, Flair Jose; Borges Gryschek, Ronaldo Cesar] Univ Sao Paulo, Lab Immunopathol Schistosomiasis LIM 06, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
   [Carvalho Espirito-Santo, Maria Cristina] Univ Ctr Volta Redonda, BR-27240560 Volta Redonda, RJ, Brazil.
   [Alvarado-Mora, Monica Viviana; Rebello Pinho, Joao Renato] Univ Sao Paulo, Dept Gastroenterol, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
   [Alvarado-Mora, Monica Viviana; Rebello Pinho, Joao Renato] Univ Sao Paulo, Lab Trop Gastroenterol & Hepatol, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
   [Silva Pinto, Pedro Luiz] Adolfo Lutz Inst, Dept Enteroparasites, Parasitol & Mycol Serv, BR-01246902 Sao Paulo, Brazil.
   [Arroyo Sanchez, Maria Carmen] Univ Sao Paulo, Lab Seroepidemiol & Immunobiol, Inst Trop Med, BR-05403000 Sao Paulo, SP, Brazil.
   [Dias-Neto, Emmanuel] AC Camargo Canc Ctr, Lab Med Genom, BR-01509010 Sao Paulo, SP, Brazil.
   [Dias-Neto, Emmanuel] Univ Sao Paulo, Inst Psychiat LIM 27, Sao Paulo Med Sch, BR-01246903 Sao Paulo, SP, Brazil.
   [Pagliusi Castilho, Vera Lucia; do Nascimento Goncalves, Elenice Messias] Univ Sao Paulo, Sect Parasitol, Cent Lab Div Hosp Clin, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
   [Chieffi, Pedro Paulo] Santa Casa Med Sch, BR-01221020 Sao Paulo, SP, Brazil.
   [Chieffi, Pedro Paulo; de Albuquerque Luna, Expedito Jose] Univ Sao Paulo, Inst Trop Med, BR-05403000 Sao Paulo, SP, Brazil.
RP Espirito-Santo, MCC (corresponding author), Univ Sao Paulo, Dept Infect & Parasit Dis, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
EM cristinasanto@usp.br
RI Carrilho, Flair J/I-3046-2012; Dias-Neto, Emmanuel/AAE-9147-2020; Luna,
   Expedito J A/B-7948-2012; Dias-Neto, Emmanuel/A-5869-2008; Pinto, Pedro
   Luiz LS Silva/B-5225-2016; Pinho, Joao R. R./G-2850-2012; Dias-Neto,
   Emmanuel/AAA-6701-2019
OI Luna, Expedito J A/0000-0002-1145-9672; Dias-Neto,
   Emmanuel/0000-0001-5670-8559; Pinto, Pedro Luiz LS
   Silva/0000-0002-3727-596X; Pinho, Joao R. R./0000-0003-3999-0489; Arroyo
   Sanchez, Maria Carmen/0000-0003-4055-5556
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [07/53457-7, 08/50461-6, 10/52615-0]
FX This study was supported by the Sao Paulo Research Foundation (Grants
   07/53457-7, 08/50461-6, and 10/52615-0). The authors would also like to
   thank Ms. Maria Cristina Conceicao de Mello (LIM-06-FMUSP) for her
   excellent technical assistance concerning the maintenance of the S.
   mansoni biological cycle. Emmanuel Dias-Neto and Joao Renato Rebello
   Pinho are research fellows of the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq). Finally, they would like to thank Dr.
   Wilton Neri and staff of the Municipal Health Department of Barra Mansa,
   Rio de Janeiro, Brazil.
CR Oliveira LMA, 2010, DIAGN MICR INFEC DIS, V68, P416, DOI 10.1016/j.diagmicrobio.2010.07.016
   Altman DG, 1991, PRACTICAL STAT MED R
   BARRETO ML, 1990, T ROY SOC TROP MED H, V84, P554, DOI 10.1016/0035-9203(90)90037-F
   Bergquist NR, 2002, TRENDS PARASITOL, V18, P309, DOI 10.1016/S1471-4922(02)02301-2
   Carneiro TR, 2012, REV SOC BRAS MED TRO, V45, P510, DOI 10.1590/S0037-86822012000400019
   do Espirito-Santo MCC, 2012, REV INST MED TROP SP, V54, P245, DOI 10.1590/S0036-46652012000500002
   Espirito-Santo MCC, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0558-4
   CHEEVER AW, 1968, AM J TROP MED HYG, V17, P38, DOI 10.4269/ajtmh.1968.17.38
   Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Cnops L, 2012, TROP MED INT HEALTH, V17, P1208, DOI 10.1111/j.1365-3156.2012.03060.x
   Coelho PMZ, 2009, MEM I OSWALDO CRUZ, V104, P720, DOI 10.1590/S0074-02762009000500010
   COKER CM, 1957, AM J TROP MED HYG, V6, P390
   CORREAOLIVEIRA R, 1988, AM J TROP MED HYG, V38, P348, DOI 10.4269/ajtmh.1988.38.348
   de Noya BA, 2007, ACTA TROP, V103, P41, DOI 10.1016/j.actatropica.2007.04.018
   de Noya BA, 2000, EXP PARASITOL, V95, P106, DOI 10.1006/expr.2000.4515
   de Noya BA, 2006, MEM I OSWALDO CRUZ, V101, P29, DOI 10.1590/S0074-02762006000900006
   de Oliveira EJ, 2005, MEM I OSWALDO CRUZ, V100, P421, DOI 10.1590/S0074-02762005000400013
   DEELDER AM, 1976, EXP PARASITOL, V40, P189, DOI 10.1016/0014-4894(76)90081-3
   DEELDER AM, 1989, AM J TROP MED HYG, V40, P50, DOI 10.4269/ajtmh.1989.40.50
   Demerdash Z, 2013, KOREAN J PARASITOL, V51, P93, DOI 10.3347/kjp.2013.51.1.93
   DENOYA BA, 1992, MEM I OSWALDO CRUZ, V87, P227, DOI 10.1590/S0074-02761992000800035
   DEVLAS SJ, 1992, PARASITOL TODAY, V8, P274, DOI 10.1016/0169-4758(92)90144-Q
   DRESDEN MH, 1981, J PARASITOL, V67, P450, DOI 10.2307/3280573
   Ebrahim A, 1997, AM J TROP MED HYG, V57, P706, DOI 10.4269/ajtmh.1997.57.706
   Engels D, 1997, AM J TROP MED HYG, V57, P571, DOI 10.4269/ajtmh.1997.57.571
   Enk MJ, 2008, ACTA TROP, V108, P222, DOI 10.1016/j.actatropica.2008.09.016
   Espirito-Santo MCC, 2014, EUR J CLIN MICROBIOL, V33, P2275, DOI 10.1007/s10096-014-2196-6
   Gomes LI, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000664
   Goncalves MML, 2006, ACTA TROP, V100, P24, DOI 10.1016/j.actatropica.2006.09.004
   Gryseels B, 1996, PARASITOL TODAY, V12, P115, DOI 10.1016/0169-4758(96)80671-5
   HAMBURGER J, 1991, MOL BIOCHEM PARASIT, V44, P73, DOI 10.1016/0166-6851(91)90222-R
   [Health Surveillance Secretariat Department of Analysis of Health Situations Mortality Information System Ministry of Health], 2012, MORT INF SYST DEATHS
   HILLYER GV, 1979, AM J TROP MED HYG, V28, P661, DOI 10.4269/ajtmh.1979.28.661
   Hoffman W. A., 1934, Puerto Rico Journal of Public Health & Tropical Medicine, V9, P283
   Kanamura H Y, 1998, Rev Inst Med Trop Sao Paulo, V40, P225, DOI 10.1590/S0036-46651998000400004
   Kanamura Herminia Yohko, 1998, Revista do Instituto de Medicina Tropical de Sao Paulo, V40, P85, DOI 10.1590/S0036-46651998000200004
   Kato K., 1954, JAPAN J PARASITOL, V3, P35
   Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397
   KLOETZEL K., 1959, Revista do Instituto de Medicina Tropical de Sao Paulo, V1, P129
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARTIN LK, 1968, AM J TROP MED HYG, V17, P382, DOI 10.4269/ajtmh.1968.17.382
   Municipal Health Secretariat and Epidemiology Coordination Office, 2008, DOC TAK SINANNET 07
   NASH TE, 1974, AM J TROP MED HYG, V23, P1085, DOI 10.4269/ajtmh.1974.23.1085
   NASH TE, 1978, AM J TROP MED HYG, V27, P938
   Noya O, 2002, MEM I OSWALDO CRUZ, V97, P167, DOI 10.1590/S0074-02762002000900032
   OLIVERGONZALEZ J, 1954, J INFECT DIS, V95, P86, DOI 10.1093/infdis/95.1.86
   OLIVERGONZALEZ J, 1955, AM J TROP MED HYG, V4, P443, DOI 10.4269/ajtmh.1955.4.443
   PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7
   Pinto PL, 1995, REV PATOL TROP, V23, P264
   POLMAN K, 1995, AM J TROP MED HYG, V53, P152, DOI 10.4269/ajtmh.1995.53.152
   Pontes LA, 2003, AM J TROP MED HYG, V68, P652, DOI 10.4269/ajtmh.2003.68.652
   Pontes LA, 2002, AM J TROP MED HYG, V66, P157, DOI 10.4269/ajtmh.2002.66.157
   Pordeus LC, 2008, EPIDEMIOL SERV SAUDE, V17, P163
   Ruiz J. M., 1952, Memorias do Instituto Butantan, V24, P63
   RUIZTIBEN E, 1979, AM J TROP MED HYG, V28, P230, DOI 10.4269/ajtmh.1979.28.230
   SENTERFIT LB, 1958, AM J HYG, V68, P148, DOI 10.1093/oxfordjournals.aje.a119959
   SILVA RM, 1992, REV BRAS PAT CLIN, V28, P39
   SLEIGH A, 1982, T ROY SOC TROP MED H, V76, P403, DOI 10.1016/0035-9203(82)90201-2
   Spencer L, 1991, G E N, V45, P77
   State Department of Health and Civil Defense and Government of the State of Rio de Janeiro, 2009, HLTH INF BOOKL STAT
   Teixeira CF, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000073
   Teles HMS, 2002, MEM I OSWALDO CRUZ, V97, P181, DOI 10.1590/S0074-02762002000900035
   ten Hove RJ, 2008, T ROY SOC TROP MED H, V102, P179, DOI 10.1016/j.trstmh.2007.10.011
   van Lieshout L, 2000, ACTA TROP, V77, P69, DOI 10.1016/S0001-706X(00)00115-7
   VANLIESHOUT L, 1995, ACTA TROP, V59, P19, DOI 10.1016/0001-706X(94)00084-E
   Wang W, 2012, ASIAN PAC J TROP MED, V5, P15, DOI 10.1016/S1995-7645(11)60238-1
   WHO, 2009, WHO EL SCHIST LOW TR
   WHO, 2014, SCHISTOSOMIASIS
   Wichmann D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-55
   Wichmann D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000422
   World Health Organization, 2002, WHO TECHN REP SER, V912
   Zacharias F, 2002, MEM I OSWALDO CRUZ, V97, P19, DOI 10.1590/S0074-02762002000900005
   Zhang YY, 2009, ACTA TROP, V112, P16, DOI 10.1016/j.actatropica.2009.05.020
   Zhou L, 2011, ACTA TROP, V120, P88, DOI 10.1016/j.actatropica.2011.06.006
   Zhu YC, 2005, ACTA TROP, V96, P130, DOI 10.1016/j.actatropica.2005.07.007
   Zhu YC, 2002, J IMMUNOL METHODS, V266, P1, DOI 10.1016/S0022-1759(02)00086-8
NR 77
TC 9
Z9 9
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 135689
DI 10.1155/2015/135689
PG 16
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CT9BQ
UT WOS:000363111200001
PM 26504777
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Evangelista, FS
   Muller, CR
   Stefano, JT
   Torres, MM
   Muntanelli, BR
   Simon, D
   Alvares-da-Silva, MR
   Pereira, IV
   Cogliati, B
   Carrilho, FJ
   Oliveira, CP
AF Evangelista, Fabiana S.
   Muller, Cynthia R.
   Stefano, Jose T.
   Torres, Mariana M.
   Muntanelli, Bruna R.
   Simon, Daniel
   Alvares-da-Silva, Mario R.
   Pereira, Isabel V.
   Cogliati, Bruno
   Carrilho, Flair J.
   Oliveira, Claudia P.
TI Physical training improves body weight and energy balance but does not
   protect against hepatic steatosis in obese mice
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Obesity; energy balance; liver steatosis; gene expression;
   leptin-deficient mice
ID ADIPOSE-TISSUE INFLAMMATION; FAT DIET; INSULIN SENSITIVITY; AEROBIC
   EXERCISE; PREVENTS; LEPTIN; METABOLISM; MUSCLE; ADIPONECTIN; LIPOLYSIS
AB This study sought to determine the role of physical training (PT) on body weight (BW), energy balance, histological markers of nonalcoholic fatty liver disease (NAFLD) and metabolic gene expression in the liver of ob/ob mice. Adult male ob/ob mice were assigned into groups sedentary (S; n = 8) and trained (T; n = 9). PT consisted in running sessions of 60 min at 60% of maximal speed conducted five days per week for eight weeks. BW of S group was higher from the 4th to 8th week of PT compared to their own BW at the beginning of the experiment. PT decreased daily food intake and increased resting oxygen consumption and energy expenditure in T group. No difference was observed in respiratory exchange ratio, but the rates of carbohydrate and lipids oxidation, and maximal running capacity were greater in T than S group. Both groups showed liver steatosis but not inflammation. PT increased CPT1a and SREBP1c mRNA expression in T group, but did not change MTP, PPAR-alpha, PPAR-gamma, and NFKB mRNA expression. In conclusion, PT prevented body weight gain in ob/ob mice by inducing negative energy balance and increased physical exercise tolerance. However, PT did not change inflammatory gene expression and failed to prevent liver steatosis possible due to an upregulation in the expression of SREBP1c transcription factor. These findings reveal that PT has positive effect on body weight control but not in the liver steatosis in a leptin deficiency condition.
C1 [Evangelista, Fabiana S.] Univ Sao Paulo, Sch Arts Sci & Humanities, BR-03828000 Sao Paulo, SP, Brazil.
   [Muller, Cynthia R.] Univ Sao Paulo, Fac Med, Expt Pathophysiol Dept, BR-03828000 Sao Paulo, SP, Brazil.
   [Stefano, Jose T.; Torres, Mariana M.; Muntanelli, Bruna R.; Pereira, Isabel V.; Cogliati, Bruno; Carrilho, Flair J.; Oliveira, Claudia P.] Univ Sao Paulo, Fac Med, Gastroenterol Dept LIM 07, BR-03828000 Sao Paulo, SP, Brazil.
   [Simon, Daniel] Luterana Univ Brazil ULBRA, Mol & Cellular Biol Appl Hlth Dept, Canoas, RS, Brazil.
   [Alvares-da-Silva, Mario R.] Univ Fed Rio Grande do Sul, Clin Hosp Porto Alegre, Div Gastroenterol, Porto Alegre, RS, Brazil.
RP Evangelista, FS (corresponding author), Univ Sao Paulo, Sch Arts Sci & Humanities, Ave Arlindo Bettio,1000 Ermelino Mattarazzo, BR-03828000 Sao Paulo, SP, Brazil.
EM fabiana_evangelista@yahoo.com.br
RI Stefano, Jose T/H-4792-2013; Carrilho, Flair J/I-3046-2012; Oliveira,
   Claudia PMS/D-1216-2014; Alvares-da-Silva, Mario Reis/L-3910-2014;
   Stefano, Jose Tadeu/AAH-5419-2020; Simon, Daniel/A-9087-2011; Cogliati,
   Bruno/E-9956-2012
OI Alvares-da-Silva, Mario Reis/0000-0002-5001-246X; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Simon, Daniel/0000-0003-1122-8468; Cogliati,
   Bruno/0000-0002-1388-7240; Evangelista, Fabiana/0000-0002-8103-6923;
   Rodrigues Muller, Cynthia/0000-0003-4698-8168
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2013/06020-3]
FX This study was supported by grants from the Sao Paulo Research
   Foundation (FAPESP) number 2013/06020-3.
CR Baicy K, 2007, P NATL ACAD SCI USA, V104, P18276, DOI 10.1073/pnas.0706481104
   Bradley RL, 2008, AM J PHYSIOL-ENDOC M, V295, pE586, DOI 10.1152/ajpendo.00309.2007
   Broderick TL, 2014, REGUL PEPTIDES, V188, P52, DOI 10.1016/j.regpep.2013.12.005
   Cintra DE, 2012, LIFE SCI, V10, P1016
   Dastmalchi M, 2007, ARTHRIT RHEUM-ARTHR, V57, P1303, DOI 10.1002/art.22996
   De Souza CT, 2010, J PHYSIOL-LONDON, V588, P2239, DOI 10.1113/jphysiol.2009.183996
   Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7
   Eguchi R, 2008, REV BRAS MED ESPORTE, V14, P182, DOI 10.1590/S1517-86922008000300004
   Ferreira JCB, 2007, CLIN EXP PHARMACOL P, V34, P760, DOI 10.1111/j.1440-1681.2007.04635.x
   FRAYN KN, 1983, J APPL PHYSIOL, V55, P628
   Fu L, 2012, METABOLISM, V61, P146, DOI 10.1016/j.metabol.2011.06.017
   Gaidhu MP, 2010, AM J PHYSIOL-CELL PH, V298, pC961, DOI 10.1152/ajpcell.00547.2009
   George AS, 2009, HEPATOLOGY, V50, P68, DOI 10.1002/hep.22940
   Gollisch KSC, 2009, AM J PHYSIOL-ENDOC M, V297, pE495, DOI 10.1152/ajpendo.90424.2008
   Goncalves IO, 2014, MITOCHONDRION, V15, P40, DOI 10.1016/j.mito.2014.03.012
   Higa TS, 2014, LIFE SCI, V103, P41, DOI 10.1016/j.lfs.2014.02.039
   Higa TS, 2012, BRAZ J MED BIOL RES, V45, P988, DOI 10.1590/S0100-879X2012007500097
   Jankiewicz-Wika J, 2011, ENDOKRYNOL POL, V62, P109
   Jiang L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006884
   Jocken JWE, 2008, PHYSIOL BEHAV, V94, P219, DOI 10.1016/j.physbeh.2008.01.002
   Jun HJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044345, 10.1371/annotation/eff6e471-306a-41bd-88e3-13857af094af]
   Kelley GA, 2001, J GERONTOL A-BIOL, V56, pM298, DOI 10.1093/gerona/56.5.M298
   Kim HJ, 2004, EUR J APPL PHYSIOL, V93, P353, DOI 10.1007/s00421-004-1214-2
   Larter CZ, 2008, J GASTROEN HEPATOL, V23, P1635, DOI 10.1111/j.1440-1746.2008.05543.x
   Leick L, 2009, PHYSL ENDOCRINOL MET, V297, p92 
   Ljbicic V, 2010, BIOCHIM BIOPHYS ACTA, V1800, P223
   Malin SK, 2012, DIABETES OBES METAB, V14, P835, DOI 10.1111/j.1463-1326.2012.01608.x
   Malloy VL, 2013, METABOLISM, V62, P1651, DOI 10.1016/j.metabol.2013.06.012
   Mazzucatto F, 2014, INT J CLIN EXP MED, V7, P2000
   McGee SL, 2010, CLIN SCI, V118, P507, DOI 10.1042/CS20090533
   Misra A, 2010, J AM COLL NUTR, V29, p289S, DOI 10.1080/07315724.2010.10719844
   Morton GJ, 2011, AM J PHYSIOL-ENDOC M, V300, pE392, DOI 10.1152/ajpendo.00546.2010
   Muller MJ, 2009, EUR J CLIN NUTR, V63, P1045, DOI 10.1038/ejcn.2009.55
   Nassis GP, 2005, METABOLISM, V54, P1472, DOI 10.1016/j.metabol.2005.05.013
   Oliva J, 2012, EXP MOL PATHOL, V93, P26, DOI 10.1016/j.yexmp.2012.03.006
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pons S, 2013, J MOL CELL CARDIOL, V54, P82, DOI 10.1016/j.yjmcc.2012.11.010
   Postic C, 2008, DIABETES METAB, V34, P643, DOI 10.1016/S1262-3636(08)74599-3
   Rector RS, 2008, J PHYSIOL-LONDON, V586, P4241, DOI 10.1113/jphysiol.2008.156745
   Ribeiro AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023364
   Ross R, 2009, NAT REV ENDOCRINOL, V5, P319, DOI 10.1038/nrendo.2009.78
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Sahin-Efe A, 2012, METABOLISM, V61, P1659, DOI 10.1016/j.metabol.2012.09.001
   Sakurai T, 2010, ACTA PHYSIOL, V200, P325, DOI [10.1111/j.1748-1716.2010.02159.x, 10.1111/j.1748-1708.2010.02159.x]
   Schultz A, 2012, EXP TOXICOL PATHOL, V64, P273, DOI 10.1016/j.etp.2010.08.019
   Song MK, 2012, EXP THER MED, V3, P707, DOI 10.3892/etm.2012.462
   Swift DL, 2014, PROG CARDIOVASC DIS, V56, P441, DOI 10.1016/j.pcad.2013.09.012
   Vieira VJ, 2009, AM J PHYSIOL-ENDOC M, V296, pE1164, DOI 10.1152/ajpendo.00054.2009
   Zeng Q, 2007, LIFE SCI, V80, P454, DOI 10.1016/j.lfs.2006.09.031
NR 49
TC 6
Z9 6
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 7
BP 10911
EP 10919
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CR7UR
UT WOS:000361557500072
PM 26379885
DA 2020-12-08
ER

PT J
AU Lisboa-Neto, G
   Noble, CF
   Pinho, JRR
   Malta, FM
   Gomes-Gouvea, MS
   Alvarado-Mora, MV
   da Silva, MH
   Leite, AGB
   Piccoli, LZ
   Rodrigues, FK
   Carrilho, FJ
   Mendes-Correa, MC
AF Lisboa-Neto, Gaspar
   Noble, Caroline F.
   Rebello Pinho, Joao R.
   Malta, Fernanda M.
   Gomes-Gouvea, Michele S.
   Alvarado-Mora, Monica V.
   da Silva, Mariliza H.
   Leite, Andrea G. B.
   Piccoli, Leonora Z.
   Rodrigues, Flaviane K.
   Carrilho, Flair J.
   Mendes-Correa, Maria C.
TI Resistance mutations are rare among protease inhibitor treatment-naive
   hepatitis C genotype-1 patients with or without HIV coinfection
SO ANTIVIRAL THERAPY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NS3 PROTEASE; HCV; INFECTION; THERAPY;
   BRAZIL; VARIABILITY; ANTIVIRALS; RIBAVIRIN; VARIANTS
AB Background: HCV has a high replication rate and a lack of proofreading activity, leading to a greatly diverse viral population. This diversity may lead to emergence of resistant strains in direct-acting antiviral therapy. The frequency of naturally occurring HCV protease inhibitor (PI) mutations has been addressed in many countries, but there are few data on the prevalence of these mutations in Brazilian patients.
   Methods: We evaluated the sequence of HCV NS3 protease gene in 247 patients (135 HCV-monoinfected and 112 HIV-HCV-coinfected patients). HCV RNA was extracted from plasma and a fragment of 765 base pairs from the NS3 region was amplified and sequenced with Sanger-based technology.
   Results: HIV-HCV-coinfected patients were more likely to be older than 40 years and have an HCV subtype-1a infection. Overall, 21.9% of patients had at least one amino acid substitution in the NS3 region; 14 patients (5.7%) harboured at least one resistance mutation (T54S, V55A, Q80R) and the Q80K mutation was not found in our case series. There was no difference between monoinfected and coinfected patients regarding the frequency of natural polymorphisms and resistance mutations.
   Conclusions: Baseline HCV NS3 amino acid substitutions identified herein are considered mostly natural polymorphisms with no clinical impact on PI-based therapy. The identified resistance mutations may be associated with low-level resistance to PIs in vitro. Q80K substitution seems to be a rare event in Brazil. HIV coinfection was not associated with a greater frequency of such substitutions in the studied sample.
C1 [Lisboa-Neto, Gaspar; Mendes-Correa, Maria C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, SP, Brazil.
   [Noble, Caroline F.; Rebello Pinho, Joao R.; Malta, Fernanda M.; Gomes-Gouvea, Michele S.; Alvarado-Mora, Monica V.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, LIM 07,Inst Trop Med,Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Rebello Pinho, Joao R.] Hosp Israelita Albert Einstein, Albert Einstein Med Diagnost, Sao Paulo, SP, Brazil.
   [da Silva, Mariliza H.] Ctr Referencia & Treinamento DST AIDS Estado Sao, Sao Paulo, SP, Brazil.
   [da Silva, Mariliza H.] Clin Especialidades, Sao Bernardo Do Campo, SP, Brazil.
   [Leite, Andrea G. B.; Piccoli, Leonora Z.] Ctr Especializado Saude, Caxias Do Sul, RS, Brazil.
   [Rodrigues, Flaviane K.; Mendes-Correa, Maria C.] ABC Fdn Med Sch, Infect Dis Res Unit, Santo Andre, SP, Brazil.
RP Pinho, JRR (corresponding author), Univ Sao Paulo, Sch Med, Lab Trop Gastroenterol & Hepatol Joao Alves de Qu, LIM 07,Inst Trop Med,Dept Gastroenterol, Sao Paulo, SP, Brazil.
EM jrrpinho@usp.br
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012; Malta,
   Fernanda/B-1316-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2011/50633-4]; Alves de Queiroz Family
   Fund for Research; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2010/50081-9, 2009/53306-4, 2008/50461-6]; Fundacao
   Faculdade de Medicina de Sao Paulo; CAPESCAPES; CNPq (Bolsista de
   Produtividade em Pesquisa do CNPq - Nivel 2)National Council for
   Scientific and Technological Development (CNPq)
FX This Project was supported by grant 2011/50633-4 from the Sao Paulo
   Research Foundation (FAPESP) and the Alves de Queiroz Family Fund for
   Research. GL-N is a graduate student in the Department of Infectious
   Diseases at the University of Sao Paulo. FMM, MSG-G and MVA-M were
   graduate students from the Department of Gastroenterology at the
   University of Sao Paulo and received fellowships from FAPESP
   (2010/50081-9, 2009/53306-4 and 2008/50461-6) and from Fundacao
   Faculdade de Medicina de Sao Paulo. CFN is a graduate student from the
   Department of Gastroenterology at the University of Sao Paulo who
   received a fellowship from CAPES. JRRP and MCM-C received fellowships
   from CNPq (Bolsista de Produtividade em Pesquisa do CNPq - Nivel 2).
CR Guirao AA, 2006, ENFERM INFEC MICR CL, V24, P264, DOI 10.1016/S0213-005X(06)73773-9
   Barnard RJO, 2013, VIROLOGY, V444, P329, DOI 10.1016/j.virol.2013.06.029
   Bartels DJ, 2013, J VIROL, V87, P1544, DOI 10.1128/JVI.02294-12
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Campiotto S, 2002, 12 INT C VIR PAR 27
   Chevaliez S, 2013, J CLIN MICROBIOL, V51, P1078, DOI 10.1128/JCM.02004-12
   de Oliveira SB, 2014, CAD SAUDE PUBLICA, V30, P433, DOI 10.1590/0102-311X00010413
   Gaudieri S, 2009, HEPATOLOGY, V49, P1069, DOI 10.1002/hep.22773
   Halfon P, 2008, AIDS, V22, P1694, DOI 10.1097/QAD.0b013e32830a989b
   Hoffmann L, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-57
   Kim AY, 2005, BLOOD, V105, P1170, DOI 10.1182/blood-2004-06-2336
   Kuntzen T, 2008, HEPATOLOGY, V48, P1769, DOI 10.1002/hep.22549
   Lenz O, 2010, ANTIMICROB AGENTS CH, V54, P1878, DOI 10.1128/AAC.01452-09
   Lin L, 2006, EUR J GASTROEN HEPAT, V18, P1311, DOI 10.1097/01.meg.0000243881.09820.09
   Maasoumy B, 2012, BEST PRACT RES CL GA, V26, P401, DOI 10.1016/j.bpg.2012.09.009
   Mani N, 2012, ANN FORUM COLLAB HIV, V14, P1
   Mendes-Correa MC, 2008, INT J STD AIDS, V19, P595, DOI 10.1258/ijsa.2007.007183
   Morsica G, 2009, JAIDS-J ACQ IMM DEF, V51, P106, DOI 10.1097/QAI.0b013e3181a02fda
   Nakano T, 2004, J INFECT DIS, V190, P1098, DOI 10.1086/422606
   Nishiya AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086413
   Olysio (simeprevir), OL SIM PRESCR INF 20
   Paolucci S, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-245
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Peres-da-Silva A, 2010, ARCH VIROL, V155, P807, DOI 10.1007/s00705-010-0642-z
   Rallon NI, 2012, JAIDS-J ACQ IMM DEF, V60, P117, DOI 10.1097/QAI.0b013e31824f5506
   Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
   Sarrazin C, 2012, J HEPATOL, V56, pS88, DOI 10.1016/S0168-8278(12)60010-5
   Soriano V, 2012, INFECT DIS CLIN N AM, V26, P931, DOI 10.1016/j.idc.2012.08.004
   Trevino A, 2011, ANTIVIR THER, V16, P413, DOI 10.3851/IMP1760
   Trimoulet P, 2011, HIV MED, V12, P506, DOI 10.1111/j.1468-1293.2011.00913.x
   Vermehren J, 2012, BEST PRACT RES CL GA, V26, P487, DOI 10.1016/j.bpg.2012.09.011
   Vicenti I, 2012, J ANTIMICROB CHEMOTH, V67, P984, DOI 10.1093/jac/dkr581
   Victrelis (boceprevir), VICTR BOC PRESCR INF
   Wegzyn CM, 2012, CURR OPIN PHARMACOL, V12, P556, DOI 10.1016/j.coph.2012.06.005
   Welsch C, 2012, GUT, V61, P36, DOI 10.1136/gutjnl-2012-302144
   Wyles DL, 2013, J INFECT DIS, V207, pS33, DOI 10.1093/infdis/jis761
   Zeminian LB, 2013, MEM I OSWALDO CRUZ, V108, P13, DOI 10.1590/S0074-02762013000100002
NR 37
TC 12
Z9 12
U1 0
U2 5
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2015
VL 20
IS 3
BP 281
EP 287
DI 10.3851/IMP2873
PG 7
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA CP5GP
UT WOS:000359909600004
PM 25279715
DA 2020-12-08
ER

PT J
AU Gomes-Gouvea, MS
   Ferreira, AC
   Teixeira, R
   Andrade, JR
   Ferreira, ASP
   Barros, LMF
   Rezende, REF
   Nastri, ACSS
   Leite, AGB
   Piccoli, LZ
   Galvan, J
   Conde, SRSS
   Soares, MCP
   Kliemann, DA
   Bertolini, DA
   Kunyoshi, ASO
   Lyra, AC
   Oikawa, MK
   de Araujo, LV
   Carrilho, FJ
   Mendes-Correa, MCJ
   Pinho, JRR
AF Gomes-Gouvea, Michele S.
   Ferreira, Ariana C.
   Teixeira, Rosangela
   Andrade, Jose R.
   Ferreira, Adalgisa S. P.
   Barros, Lena M. F.
   Rezende, Rosamar E. F.
   Santos Nastri, Ana C. S.
   Leite, Andrea G. B.
   Piccoli, Leonora Z.
   Galvan, Josiane
   Conde, Simone R. S. S.
   Soares, Manoel C. P.
   Kliemann, Dimas A.
   Bertolini, Dennis A.
   Kunyoshi, Aline S. O.
   Lyra, Andre C.
   Oikawa, Marcio K.
   de Araujo, Luciano V.
   Carrilho, Flair J.
   Mendes-Correa, Maria C. J.
   Rebello Pinho, Joao R.
TI HBV carrying drug-resistance mutations in chronically infected
   treatment-naive patients
SO ANTIVIRAL THERAPY
LA English
DT Article
ID HEPATITIS-B-VIRUS; REVERSE-TRANSCRIPTASE SEQUENCES;
   LAMIVUDINE-RESISTANCE; ADEFOVIR DIPIVOXIL; MOLECULAR CHARACTERIZATION;
   REDUCED ANTIGENICITY; ANTIVIRAL THERAPY; POLYMERASE GENE; S GENE;
   MUTANTS
AB Background: Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also alter the hepatitis B surface (HBs) protein and in some cases reduce binding to HBs antibodies. The spread of NA-resistant HBV may impact the efficacy of antiviral treatment and hepatitis B immunization programmes. In this study, we used direct sequencing to assess the occurrence of HBV carrying known mutations that confer NA resistance in the largest cohort of treatment-naive patients with chronic hepatitis B (CHB) to date.
   Methods: HBV DNA samples isolated from 702 patients were sequenced and the RT region subjected to mutational analysis.
   Results: There was high genetic variability among the HBV samples analysed: A1 (63.7%), D3 (14.5%), A2 (3.3%), A3 (0.1%), B1 (0.1%), B2 (0.1%), C2 (0.9%), D1 (0.9%), D2 (4.6%), D4 (5.1%), D unclassified sub-genotype (0.7%), E (0.6%), F2a (4.6%), F4 (0.4%) and G (0.4%). HBV strains harbouring mutations conferring NA resistance alone or combined with compensatory mutations were identified in 1.6% (11/702) of the patients.
   Conclusions: HBV strains harbouring resistance mutations can comprise the major population of HBV quasispecies in treatment-naive patients. In Brazil, there is a very low frequency of untreated patients who are infected with these strains. These findings suggest that the spread and natural selection of drug-resistant HBV is an uncommon event and/or most of these strains remain unstable in the absence of NA selective pressure.
C1 [Gomes-Gouvea, Michele S.; Ferreira, Ariana C.; Santos Nastri, Ana C. S.; Carrilho, Flair J.; Rebello Pinho, Joao R.] Univ Sao Paulo, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Gomes-Gouvea, Michele S.; Ferreira, Ariana C.; Santos Nastri, Ana C. S.; Carrilho, Flair J.; Rebello Pinho, Joao R.] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Teixeira, Rosangela; Andrade, Jose R.] Univ Fed Minas Gerais, Sch Med, Dept Internal Med, Belo Horizonte, MG, Brazil.
   [Ferreira, Adalgisa S. P.; Barros, Lena M. F.] Univ Fed Maranhao, Clin Res Ctr, Sao Luis, Maranhao, Brazil.
   [Rezende, Rosamar E. F.] Municipal Secretary Hlth, Sao Paulo, Brazil.
   [Santos Nastri, Ana C. S.; Mendes-Correa, Maria C. J.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Conde, Simone R. S. S.] Fundacao Santa Casa Misericordia Para, Belem, Para, Brazil.
   [Soares, Manoel C. P.] Inst Evandro Chagas, Serv Hepatol, Ananindeua, Para, Brazil.
   [Kliemann, Dimas A.] Hosp Nossa Senhora da Conceicao, Serv Infectol, Porto Alegre, RS, Brazil.
   [Bertolini, Dennis A.; Kunyoshi, Aline S. O.] Univ Estadual Maringa, Lab Imunol Clin, Dept Anal Clin & Biomed, Maringa, Parana, Brazil.
   [Lyra, Andre C.] Univ Fed Bahia, Dept Med, Div Gastroenterol & Hepatol, BR-41170290 Salvador, BA, Brazil.
   [Oikawa, Marcio K.] Univ Fed ABC, Ctr Matemat Comp & Cognicao, Sao Paulo, Brazil.
   [de Araujo, Luciano V.] Univ Sao Paulo, Escola Artes Ciencias & Humanidades, Sao Paulo, Brazil.
RP Gomes-Gouvea, MS (corresponding author), Univ Sao Paulo, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, Sao Paulo, Brazil.
EM gomesmic@yahoo.com.br
RI Kliemann, Dimas A/J-9513-2017; Bertolini, Dennis/ABG-1427-2020;
   ferreira, adalgisa S P/G-8169-2016; Pinho, Joao R. R./G-2850-2012;
   Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
FU FAPESP (Sao Paulo Research Foundation)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2010/50081-9, 2010/51208-2]; Alves de
   Queiroz Family Fund
FX This work was supported by FAPESP (Sao Paulo Research Foundation):
   2010/50081-9 and 2010/51208-2 and Alves de Queiroz Family Fund for
   Research.
CR Estevez MA, 2013, ENFERM INFEC MICR CL, V31, P520, DOI 10.1016/j.eimc.2013.02.014
   Amini-Bavil-Olyaee S, 2009, J HEPATOL, V51, P647, DOI 10.1016/j.jhep.2009.04.022
   Bartholorneusz A, 2006, SEMIN LIVER DIS, V26, P162, DOI 10.1055/s-2006-939758
   Borroto-Esoda K, 2007, J HEPATOL, V47, P492, DOI 10.1016/j.jhep.2007.06.011
   Bottecchia M, 2008, J ANTIMICROB CHEMOTH, V62, P626, DOI 10.1093/jac/dkn207
   Curtis M, 2007, J INFECT DIS, V196, P1483, DOI 10.1086/522521
   De Maddalena C, 2007, VIROLOGY, V365, P113, DOI 10.1016/j.virol.2007.03.015
   Delaney WE, 2003, J VIROL, V77, P11833, DOI 10.1128/JVI.77.21.11833-11841.2003
   Mello FCD, 2012, MEM I OSWALDO CRUZ, V107, P317, DOI 10.1590/S0074-02762012000300005
   Han Y, 2009, J GASTROEN HEPATOL, V24, P1417, DOI 10.1111/j.1440-1746.2009.05864.x
   Ismail AM, 2012, INTERVIROLOGY, V55, P36, DOI 10.1159/000323521
   Jardi R, 2007, J VIRAL HEPATITIS, V14, P835, DOI 10.1111/j.1365-2893.2007.00877.x
   Kamili S, 2009, HEPATOLOGY, V49, P1483, DOI 10.1002/hep.22796
   Karatayli E, 2012, J CLIN VIROL, V53, P130, DOI 10.1016/j.jcv.2011.10.011
   Khudyakov Y, 2010, ANTIVIR THER, V15, P505, DOI 10.3851/IMP1515
   Lee YS, 2012, J GASTROEN HEPATOL, V27, P300, DOI 10.1111/j.1440-1746.2011.06853.x
   Li XG, 2012, J MED VIROL, V84, P207, DOI 10.1002/jmv.23182
   Liu BM, 2010, ANTIVIR RES, V85, P512, DOI 10.1016/j.antiviral.2009.12.006
   Liu LJ, 2010, J VIRAL HEPATITIS, V17, P66, DOI 10.1111/j.1365-2893.2010.01273.x
   Lok AS, 2007, HEPATOLOGY, V46, P254, DOI 10.1002/hep.21698
   Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190
   Mantovani N, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-320
   Margeridon-Thermet S, 2013, ANTIMICROB AGENTS CH, V57, P343, DOI 10.1128/AAC.01601-12
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Mello FCA, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-96
   Ministerio da Saude Departamento de DST, 2011, VIR HEP BRAZ STAT AC
   Ministerio da Saude Departamento de DST Aids e Hepatites Virais, 2011, CLIN PROT THER GUID
   Mohebbi SR, 2012, J MED VIROL, V84, P414, DOI 10.1002/jmv.23200
   Morando F, 2013, J MED VIROL, V85, P210, DOI 10.1002/jmv.23448
   Nguyen MH, 2009, ALIMENT PHARM THER, V30, P1150, DOI 10.1111/j.1365-2036.2009.04151.x
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Pollicino T, 2009, ANTIVIR THER, V14, P649
   Qin B, 2013, CHINESE SCI BULL, V58, P1760, DOI 10.1007/s11434-013-5770-x
   Salpini R, 2011, ANTIVIR RES, V92, P382, DOI 10.1016/j.antiviral.2011.08.013
   Sayan M, 2011, INT J INFECT DIS, V15, pE722, DOI 10.1016/j.ijid.2011.05.019
   Sayan M, 2010, INT J INFECT DIS, V14, pE136, DOI 10.1016/j.ijid.2009.11.039
   Sayan M, 2010, J VIRAL HEPATITIS, V17, P23, DOI 10.1111/j.1365-2893.2009.01149.x
   Schildgen O, 2010, J CLIN MICROBIOL, V48, P631, DOI 10.1128/JCM.01073-09
   Selabe SG, 2007, J MED VIROL, V79, P1650, DOI 10.1002/jmv.20974
   Sheldon J, 2006, J VIRAL HEPATITIS, V13, P427, DOI 10.1111/j.1365-2893.2005.00713.x
   Singla B, 2013, J MED VIROL, V85, P1155, DOI 10.1002/jmv.23608
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Sitnik R, 2010, REV INST MED TROP SP, V52, P119, DOI 10.1590/S0036-46652010000300001
   Te Helen S, 2010, Clin Liver Dis, V14, P1, DOI 10.1016/j.cld.2009.11.009
   Tenney DJ, 2004, ANTIMICROB AGENTS CH, V48, P3498, DOI 10.1128/AAC.48.9.3498-3507.2004
   Thio CL, 2013, AIDS, V27, P191, DOI 10.1097/QAD.0b013e32835a9984
   Torresi J, 2002, VIROLOGY, V293, P305, DOI 10.1006/viro.2001.1246
   Trevino A, 2009, AIDS RES HUM RETROV, V25, P1273, DOI 10.1089/aid.2009.0119
   Xu ZH, 2010, J CLIN VIROL, V48, P270, DOI 10.1016/j.jcv.2010.05.010
   Yeh CT, 2010, ANTIVIR THER, V15, P471, DOI 10.3851/IMP1552
   Zheng JX, 2012, LIVER INT, V32, P1535, DOI 10.1111/j.1478-3231.2012.02859.x
   Zoulim F, 2009, GASTROENTEROLOGY, V137, P1593, DOI 10.1053/j.gastro.2009.08.063
NR 52
TC 23
Z9 24
U1 0
U2 12
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2015
VL 20
IS 4
BP 387
EP 395
DI 10.3851/IMP2938
PG 9
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA CP5HG
UT WOS:000359911300004
PM 25624410
DA 2020-12-08
ER

PT J
AU Evangelista, AS
   Nakhle, MC
   de Araujo, TF
   Abrantes-Lemos, CP
   Deguti, MM
   Carrilho, FJ
   Cancado, ELR
AF Evangelista, Andreia Silva
   Nakhle, Maria Cristina
   de Araujo, Thiago Ferreira
   Abrantes-Lemos, Clarice Pires
   Deguti, Marta Mitiko
   Carrilho, Flair Jose
   Rachid Cancado, Eduardo Luiz
TI HFE Genotyping in Patients with Elevated Serum Iron Indices and Liver
   Diseases
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID HEREDITARY HEMOCHROMATOSIS; NONINVASIVE PREDICTION; CLINICAL EXPRESSION;
   C282Y MUTATION; GENE-MUTATIONS; POPULATION; DIAGNOSIS; ORIGIN;
   EPIDEMIOLOGY; HOMOZYGOTES
AB Iron abnormalities in chronic liver disease may be the result of genetic diseases or secondary factors. The present study aimed to identify subjects with HFE-HH in order to describe the frequency of clinical manifestations, identify risk factors for iron elevation, and compare the iron profile of HFE-HH to other genotypes in liver disease patients. A total of 108 individuals with hepatic disease, transferrin saturation (TS) > 45%, and serum ferritin (SF) > 350 ng/mL were tested for HFE mutations. Two groups were characterized: C282Y/C282Y or C282Y/H63D genotypes (n = 16) were the HFE hereditary hemochromatosis (HFE-HH) group; and C282Y and H63D single heterozygotes, the H63D/H63D genotype, and wild-type were considered group 2 (n = 92). Nonalcoholic liver disease, alcoholism, and chronic hepatitis C were detected more frequently in group 2, whereas arthropathy, hepatocarcinoma, diabetes, and osteoporosis rates were significantly higher in the HFE-HH group. TS > 82%, SF > 2685 ng/mL, and serum iron > 178 mu g/dL were the cutoffs for diagnosis of HFE-HH in patients with liver disease. Thus, in non-Caucasian populations with chronic liver disease, HFE-HH diagnosis is more predictable in those with iron levels higher than those proposed in current guidelines for the general population.
C1 [Evangelista, Andreia Silva; Deguti, Marta Mitiko; Carrilho, Flair Jose; Rachid Cancado, Eduardo Luiz] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Nakhle, Maria Cristina; de Araujo, Thiago Ferreira; Abrantes-Lemos, Clarice Pires; Deguti, Marta Mitiko; Carrilho, Flair Jose; Rachid Cancado, Eduardo Luiz] Univ Sao Paulo, Inst Trop Med, Lab Med Invest LIM 06, BR-05403000 Sao Paulo, Brazil.
RP Evangelista, AS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Ave Dr Eneas de Carvalho Aguiar 255, BR-05403000 Sao Paulo, Brazil.
EM andreia1179@yahoo.com.br
RI Cancado, Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012; Araujo,
   Thiago/E-2624-2016
OI Cancado, Eduardo/0000-0002-9309-1524; Araujo, Thiago/0000-0001-8423-256X
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/53946-3]; Alves de Queiroz Family Fund for research for research
FX This work received financial support from FAPESP (2009/53946-3) and the
   Alves de Queiroz Family Fund for research. The authors thank Marcio
   Augusto Diniz and Guilherme E. G. Felga for assistance with the
   preparation of the submitted paper.
CR Agostinho MF, 1999, BLOOD CELL MOL DIS, V25, P324, DOI 10.1006/bcmd.1999.0260
   Allen KJ, 2008, NEW ENGL J MED, V358, P221, DOI 10.1056/NEJMoa073286
   Allen KJ, 2010, HEPATOLOGY, V52, P925, DOI 10.1002/hep.23786
   Andersen RV, 2004, BLOOD, V103, P2914, DOI 10.1182/blood-2003-10-3564
   Bacon BR, 2011, HEPATOLOGY, V54, P328, DOI 10.1002/hep.24330
   Barbosa KVBD, 2005, J CLIN GASTROENTEROL, V39, P430, DOI 10.1097/01.mcg.0000159218.85537.e5
   Beaton M, 2002, HEPATOLOGY, V36, P673, DOI 10.1053/jhep.2002.35343
   Bittencourt PL, 2009, CLINICS, V64, P837, DOI 10.1590/S1807-59322009000900003
   Brissot Pierre, 2006, Hematology Am Soc Hematol Educ Program, P36
   Cherfane CE, 2013, AM J MED, V126, P1010, DOI 10.1016/j.amjmed.2013.07.013
   Dever JB, 2010, DIGEST DIS SCI, V55, P803, DOI 10.1007/s10620-009-1080-1
   Elmberg M, 2003, GASTROENTEROLOGY, V125, P1733, DOI 10.1053/j.gastro.2003.09.035
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   Gleeson F, 2004, EUR J GASTROEN HEPAT, V16, P859, DOI 10.1097/00042737-200409000-00008
   Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3
   Harrison SA, 2005, MED CLIN N AM, V89, P391, DOI 10.1016/j.mcna.2004.08.005
   Hearnshaw S, 2006, WORLD J GASTROENTERO, V12, P5866, DOI 10.3748/wjg.v12.i36.5866
   Lucotte G, 2003, BLOOD CELL MOL DIS, V31, P262, DOI 10.1016/S1079-9796(03)00133-5
   Lucotte G, 1998, BLOOD CELL MOL DIS, V24, P433, DOI 10.1006/bcmd.1998.0212
   Matthes T, 2004, BLOOD, V104, P2181, DOI 10.1182/blood-2004-01-0332
   Moodie SJ, 2002, EUR J GASTROEN HEPAT, V14, P223, DOI 10.1097/00042737-200203000-00004
   Morrison ED, 2003, ANN INTERN MED, V138, P627, DOI 10.7326/0003-4819-138-8-200304150-00008
   Nichols L, 2006, AM J CLIN PATHOL, V125, P236, DOI 10.1309/BVCBNKUYH7C1UM71Y
   NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004
   Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002
   Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573
   Pietrangelo A, 2010, GASTROENTEROLOGY, V139, P393, DOI 10.1053/j.gastro.2010.06.013
   Pietrangelo A, 2010, J HEPATOL, V53, P3, DOI 10.1016/j.jhep.2010.03.001
   Poullis A, 2003, ANN CLIN BIOCHEM, V40, P521, DOI 10.1258/000456303322326434
   Poullis A, 2002, LANCET, V360, P411, DOI 10.1016/S0140-6736(02)09581-8
   Santos PCJL, 2011, BLOOD CELL MOL DIS, V46, P302, DOI 10.1016/j.bcmd.2011.02.008
NR 31
TC 7
Z9 7
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 164671
DI 10.1155/2015/164671
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CA3BI
UT WOS:000348780500001
PM 25654085
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Herman, P
   Chagas, AL
   Perini, MV
   Coelho, FF
   Fonseca, GM
   Alves, VAF
   Carrilho, FJ
   Cecconello, I
AF Herman, Paulo
   Chagas, Aline Lopes
   Perini, Marcos Vinicius
   Coelho, Fabricio Ferreira
   Fonseca, Gilton Marques
   Ferreira Alves, Venancio Avancini
   Carrilho, Flair Jose
   Cecconello, Ivan
TI Surgical treatment of fibrolamellar hepatocellular carcinoma: an
   underestimated malignant tumor?
SO HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
LA English
DT Article
DE fibrolamellar hepatocellular carcinoma; hepatectomy; hepatocellular
   carcinoma; lymph node excision; survival
ID CLINICOPATHOLOGICAL FEATURES; LIVER-TRANSPLANTATION; BINDING-CAPACITY;
   PROGNOSIS; SURVIVAL; THERAPY; VARIANT
AB BACKGROUND: Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare disease with an indolent behavior. Its prognosis is better than that of patients with hepatocellular carcinoma. The authors present their experience with resection of FLHCC.
   METHODS: Twenty-one patients with FLHCC were treated at our institution between 1990 and 2012. Of these patients, 14 were subjected to resection of the tumor. Patient demographics, medical history, results of imaging studies and laboratory tests, surgical data, and pathologic findings were evaluated.
   RESULTS: The median age of the patients at the diagnosis of the tumor was 20 years and 14 patients were female. None of the patients had tumor-associated chronic liver disease or cirrhosis. The mean tumor size was 12.8 cm (range 6-19) and 18 patients had a single liver nodule. Fourteen patients were subjected to hepatectomy and six of them had lymph node metastases resected. Pathologic evaluation revealed that 5 (35.7%) patients had major vascular invasion. Tumor recurrence was seen in 8 patients (66.7%), during a follow-up. The median survival time for patients who were subjected to resection was 36 months. The 5-year overall survival rate and disease free survival rate were 28.0% and 8.5%, respectively. Univariate analysis showed that vascular invasion was the only variable associated with the disease free survival rate.
   CONCLUSIONS: Despite an aggressive treatment, patients with FLHCC presented unexpected low survival rates. It seems that an underestimated malignant behavior is attributed to this disease, and that the forms of adjuvant treatment should be urgently evaluated.
C1 [Herman, Paulo; Chagas, Aline Lopes; Perini, Marcos Vinicius; Coelho, Fabricio Ferreira; Fonseca, Gilton Marques; Carrilho, Flair Jose; Cecconello, Ivan] Univ Sao Paulo, Digest Surg Div, Dept Gastroenterol, Sch Med,Inst Cent, BR-05403900 Sao Paulo, SP, Brazil.
   [Ferreira Alves, Venancio Avancini] Univ Sao Paulo, Dept Pathol, Sch Med, Inst Cent, BR-05403900 Sao Paulo, SP, Brazil.
RP Herman, P (corresponding author), Univ Sao Paulo, Digest Surg Div, Dept Gastroenterol, Sch Med,Inst Cent, Ave Doutor Eneas Carvalho Aguiar 255,9 Andar, BR-05403900 Sao Paulo, SP, Brazil.
EM pherman@uol.com.br
RI Fonseca, Gilton M/J-4073-2014; Coelho, Fabricio Ferreira/AAZ-7531-2020;
   Perini, Marcos/D-4616-2019; Herman, Paulo/J-5457-2013; Carrilho, Flair
   J/I-3046-2012; Chagas, Aline Lopes/X-2059-2019; Cecconello,
   Ivan/A-3918-2013; Coelho, Fabricio F/G-9912-2012
OI Fonseca, Gilton M/0000-0002-7260-0799; Coelho, Fabricio
   Ferreira/0000-0002-5290-8286; Perini, Marcos/0000-0002-0165-1564;
   Herman, Paulo/0000-0003-2859-5846; Cecconello, Ivan/0000-0002-3535-4170;
   Coelho, Fabricio F/0000-0002-5290-8286
CR Ang Celina S, 2013, Gastrointest Cancer Res, V6, P3
   BERMAN MM, 1980, CANCER, V46, P1448, DOI 10.1002/1097-0142(19800915)46:6<1448::AID-CNCR2820460626>3.0.CO;2-J
   CRAIG JR, 1980, CANCER, V46, P372, DOI 10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S
   EDMONDSON HA, 1956, AMA J DIS CHILD, V91, P168, DOI 10.1001/archpedi.1956.02060020170015
   El-Serag HB, 2004, HEPATOLOGY, V39, P798, DOI 10.1002/hep.20096
   Ichikawa T, 2000, RADIOLOGY, V217, P145, DOI 10.1148/radiology.217.1.r00se46145
   Ichikawa T, 1999, RADIOLOGY, V213, P352, DOI 10.1148/radiology.213.2.r99nv31352
   Kakar S, 2005, MODERN PATHOL, V18, P1417, DOI 10.1038/modpathol.3800449
   Kanai T, 2004, JPN J CLIN ONCOL, V34, P346, DOI 10.1093/jjco/hyh050
   KANE RA, 1987, CT-J COMPUT TOMOGR, V11, P27
   Kaseb AO, 2013, ONCOLOGY-BASEL, V85, P197, DOI 10.1159/000354698
   Liu S, 2009, AM J GASTROENTEROL, V104, P2617, DOI 10.1038/ajg.2009.440
   Maniaci V, 2009, EJSO-EUR J SURG ONC, V35, P617, DOI 10.1016/j.ejso.2008.12.009
   Martinez Isla A, 1997, REV ESP ENFERM DIG, V89, P699
   Mavros MN, 2012, J AM COLL SURGEONS, V215, P820, DOI 10.1016/j.jamcollsurg.2012.08.001
   Mayo SC, 2014, J AM COLL SURGEONS, V218, P196, DOI 10.1016/j.jamcollsurg.2013.10.011
   McLarney JK, 1999, RADIOGRAPHICS, V19, P453, DOI 10.1148/radiographics.19.2.g99mr09453
   MCPEAKE JR, 1993, J HEPATOL, V18, P226, DOI 10.1016/S0168-8278(05)80250-8
   Meriggi F, 2007, ANN ITAL CHIR, V78, P53
   OGRADY JG, 1988, ANN SURG, V207, P373, DOI 10.1097/00000658-198804000-00002
   PARADINAS FJ, 1982, BRIT MED J, V285, P840, DOI 10.1136/bmj.285.6345.840
   PENN I, 1991, SURGERY, V110, P726
   Pinna AD, 1997, HEPATOLOGY, V26, P877
   RINGE B, 1992, SURG GYNECOL OBSTET, V175, P299
   STEVENS WR, 1995, AM J ROENTGENOL, V164, P1153, DOI 10.2214/ajr.164.5.7717223
   Stipa F, 2006, CANCER-AM CANCER SOC, V106, P1331, DOI 10.1002/cncr.21703
   Torbenson M, 2007, ADV ANAT PATHOL, V14, P217, DOI 10.1097/PAP.0b013e3180504913
   Ward SC, 2011, SEMIN LIVER DIS, V31, P61, DOI 10.1055/s-0031-1272835
   Wojcicki M, 2012, J PANCREAS, V13, P529, DOI 10.6092/1590-8577/839
NR 29
TC 5
Z9 5
U1 0
U2 7
PU ZHEJIANG UNIV SCH MEDICINE
PI HANGZHOU
PA FIRST AFFILIATED HOSPITAL, 79 QINGCHUN ROAD, HANGZHOU, 310003, PEOPLES R
   CHINA
SN 1499-3872
J9 HEPATOB PANCREAT DIS
JI Hepatob. Pancreatic. Dis. Int.
PD DEC 15
PY 2014
VL 13
IS 6
BP 618
EP 621
DI 10.1016/S1499-3872(14)60294-0
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AW4AI
UT WOS:000346223600007
PM 25475864
DA 2020-12-08
ER

PT J
AU Silva, MF
   Carrilho, FJ
   Paranagua-Vezozzo, DC
   Campos, LT
   Nacif, LS
   Diniz, MA
   Farias, AQ
   Alves, VAF
   D'Alburquerque, LAC
   Ono, SK
AF Silva, Mauricio F.
   Carrilho, Flair J.
   Paranagua-Vezozzo, Denise C.
   Campos, Luciana T.
   Nacif, Lucas S.
   Diniz, Marcio A.
   Farias, Alberto Q.
   Alves, Venancio A. F.
   D'Alburquerque, Luis A. C.
   Ono, Suzane K.
TI m-RECIST at 1 month and Child A are survival predictors after
   percutaneous ethanol injection of hepatocellular carcinoma
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Liver cancer; Percutaneous ablation; Radiological response; Curative
   treatment; Clinical decision-making
ID ACETIC-ACID INJECTION; RADIOFREQUENCY THERMAL ABLATION; RISK-FACTORS;
   PROGNOSIS; CIRRHOSIS; TRIALS
AB Background and aims. Percutaneous ethanol injection (PEI) is a well-established therapeutic option in patients with cirrhosis and hepatocellular carcinoma (HCC). The modified-Response Evaluation Criteria in Solid Tumors (m-RECIST) are an important tool for the assessment of HCC response to therapy. The aim was to evaluate whether HCC response according to the m-RECIST criteria could be an effective predictor of Long-term survival in Barcelona Clinic Liver Cancer (BCLC) stage 0 and A HCC patients undergoing PEI. Material and methods. 79 patients were followed-up for median time of 26.8 months. HCC diagnosis was based on the,current guidelines of the American Association for Study of the Liver Diseases (AASLD) and European Association for Study of the Liver (EASL). Patient survival was calculated from the first PEI session to the end of the follow-up. Results. The 1-, 3-, and 5-year overall survival rates were 79, 48 and 37%, respectively. In the multivariate analysis, Child-Pugh-Turcotte (CPT) (p = 0.022) and the response to m-RECIST criteria (p = 0.016) were associated with patient survival. CPT A patients who achieved Complete Response (CR) 1 month after PEI presented a 5-year survival rate of 55%. By contrast, the worst scenario, the group with CPT B but without CR had a 5-year survival rate of 9%, while the group with either CPT A or CR as a survival predictor had a 5-year survival rate of 31%. In conclusion, in BCLC stage 0 and A HCC-patients, m-RECIST at 1 month and Child A may predict survival rates after PEI.
C1 [Carrilho, Flair J.; Paranagua-Vezozzo, Denise C.; Nacif, Lucas S.; Farias, Alberto Q.; Alves, Venancio A. F.; D'Alburquerque, Luis A. C.; Ono, Suzane K.] Univ Sao Paulo, Sch Med, Sao Paulo Clin Liver Canc Grp, Sao Paulo, Brazil.
   [Silva, Mauricio F.; Carrilho, Flair J.; Paranagua-Vezozzo, Denise C.; Campos, Luciana T.; Nacif, Lucas S.; Diniz, Marcio A.; Farias, Alberto Q.; D'Alburquerque, Luis A. C.; Ono, Suzane K.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Silva, Mauricio F.] Santa Casa Gen Hosp, Liver Transplant Unit, Porto Alegre, RS, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RP Paranagua-Vezozzo, DC (corresponding author), Av Dr Eneas Carvalho de Aguiar,255 ICHC,9th Floor, BR-05403000 Sao Paulo, Brazil.
EM denise.vezozzo@hc.fm.usp.br
RI Nacif, Lucas S./B-2795-2013; Farias, Alberto/ABB-1291-2020;
   Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014; Carrilho, Flair
   J/I-3046-2012
OI Nacif, Lucas S./0000-0002-7059-3978; Farias,
   Alberto/0000-0002-5572-663X; Paranagua-Vezozzo, Denise
   Cerqueira/0000-0002-9606-4935; Diniz, Marcio Augusto/0000-0002-2427-7843
FU Alves de Queiroz Family Fund
FX The study was supported in part by Alves de Queiroz Family Fund for
   Research.
CR Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Brunello F, 2008, SCAND J GASTROENTERO, V43, P727, DOI 10.1080/00365520701885481
   Cho YK, 2009, HEPATOLOGY, V49, P453, DOI 10.1002/hep.22648
   Germani G, 2010, J HEPATOL, V52, P380, DOI 10.1016/j.jhep.2009.12.004
   Huo TI, 2003, SCAND J GASTROENTERO, V38, P770, DOI 10.1080/00365520310003048
   Khan KN, 2000, J HEPATOL, V32, P269, DOI 10.1016/S0168-8278(00)80072-0
   Kikuchi L, 2014, WORLD J GASTROENTERO, V20, P1585, DOI 10.3748/wjg.v20.i6.1585
   Kikuchi L, 2013, ANTIVIR THER, V18, P445, DOI 10.3851/IMP2602
   Kuang M, 2009, RADIOLOGY, V253, P552, DOI 10.1148/radiol.2532082021
   LENCIONI R, 1995, CANCER, V76, P1737, DOI 10.1002/1097-0142(19951115)76:10<1737::AID-CNCR2820761010>3.0.CO;2-P
   Lencioni RA, 2003, RADIOLOGY, V228, P235, DOI 10.1148/radiol.2281020718
   Lencioni R, 2010, HEPATOLOGY, V52, P762, DOI 10.1002/hep.23725
   Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132
   Lin SM, 2005, GUT, V54, P1151, DOI 10.1136/gut.2004.045203
   Lin SM, 2004, GASTROENTEROLOGY, V127, P1714, DOI 10.1053/j.gastro.2004.09.003
   LIVRAGHI T, 1992, CANCER, V69, P925, DOI 10.1002/1097-0142(19920215)69:4<925::AID-CNCR2820690415>3.0.CO;2-G
   Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629
   Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Marrero JA, 2005, HEPATOLOGY, V41, P707, DOI 10.1002/hep.20636
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Ohnishi K, 1998, HEPATOLOGY, V27, P67, DOI 10.1002/hep.510270112
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731
   Sala M, 2004, HEPATOLOGY, V40, P1352, DOI 10.1002/hep.20465
   Sherman M, 2010, ONCOLOGY-BASEL, V78, P7, DOI 10.1159/000315223
   Shiina S, 2005, GASTROENTEROLOGY, V129, P122, DOI 10.1053/j.gastro.2005.04.009
   Villa E, 2000, HEPATOLOGY, V32, P233, DOI 10.1053/jhep.2000.9603
NR 29
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER ESPANA
PI MADRID
PA CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD NOV-DEC
PY 2014
VL 13
IS 6
BP 796
EP 802
DI 10.1016/S1665-2681(19)30982-2
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AX6FG
UT WOS:000347018000010
PM 25332266
OA Other Gold
DA 2020-12-08
ER

PT J
AU Espirito-Santo, MCC
   Alvarado-Mora, MV
   Dias-Neto, E
   Botelho-Lima, LS
   Moreira, JP
   Amorim, M
   Pinto, PLS
   Heath, AR
   Castilho, VLP
   Goncalves, EMD
   Luna, EJD
   Carrilho, FJ
   Pinho, JRR
   Gryschek, RCB
AF Carvalho Espirito-Santo, Maria Cristina
   Alvarado-Mora, Monica Viviana
   Dias-Neto, Emmanuel
   Botelho-Lima, Livia Souza
   Moreira, Joao Paulo
   Amorim, Maria
   Silva Pinto, Pedro Luiz
   Heath, Ashley R.
   Pagliusi Castilho, Vera Lucia
   do Nascimento Goncalves, Elenice Messias
   de Albuquerque Luna, Expedito Jose
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
   Borges Gryschek, Ronaldo Cesar
TI Evaluation of real-time PCR assay to detect Schistosoma mansoni
   infections in a low endemic setting
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Schistosomiasis mansoni; TaqMan (R) Real-Time PCR system; Laboratory
   diagnosis; Low endemicity areas; Brazil/epidemiology
ID POLYMERASE-CHAIN-REACTION; RIBOSOMAL-RNA GENES; KATO-KATZ; STOOL
   SAMPLES; LOW TRANSMISSION; DNA; DIAGNOSIS; INTENSITY; AREAS; SENSITIVITY
AB Background: Schistosomiasis constitutes a major public health problem, and 200 million people are estimated to be infected with schistosomiasis worldwide. In Brazil, schistosomiasis has been reported in 19 states, showing areas of high and medium endemicity and a wide range of areas of low endemicity (ALE). Barra Mansa in Rio de Janeiro state has an estimated prevalence of 1%. ALE represent a new challenge for the helminth control because about 75% of infected individuals are asymptomatic and infections occur with a low parasite load (<100 eggs per gram of feces), causing a decrease in sensitivity of stool parasitological techniques, which are a reference for the laboratory diagnosis of this helminth. The objective of this study was to evaluate the performance of a TaqMan quantitative polymerase chain reaction (qPCR) technique in serum and feces DNA samples using the techniques of Kato-Katz (KK), Hoffman, Pons and Janer (HH) as references, during an epidemiological survey using fecal samples and sera from randomized residents from an ALE.
   Methods: A cross-sectional study conducted from April to December 2011 using a probabilistic sampling that collected 572 fecal and serum samples. The laboratory diagnostic techniques used were: KK, HH and qPCR ( feces and serum).
   Results: We obtained the following results using the different diagnostic techniques: KK and HH, 0.9% (n = 5); qPCR-feces, 9.6% (n = 55); and qPCR-serum, 1.4% (n = 8). The qPCR-feces presented the highest positivity, whereas the techniques of HH and KK were the least sensitive to detect infections (0.8%). Compared to HH and KK, qPCR-feces showed a statistically significant difference in positivity (p < 0.05), although with poor agreement.
   Conclusion: The positivity rate presented by the qPCR approach was far higher than that obtained by parasitological techniques. The lack of adequate surveillance in ALE of schistosomiasis indicates a high possibility of these areas being actually of medium and high endemicity. This study presents a control perspective, pointing to the possibility of using combined laboratory tools in the diagnosis of schistosomiasis in ALE.
C1 [Carvalho Espirito-Santo, Maria Cristina; Borges Gryschek, Ronaldo Cesar] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Alvarado-Mora, Monica Viviana; Botelho-Lima, Livia Souza; Moreira, Joao Paulo; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Lab Trop Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Dias-Neto, Emmanuel; Amorim, Maria] AC Camargo Canc Ctr, Lab Med Genom, Sao Paulo, Brazil.
   [Silva Pinto, Pedro Luiz] Adolfo Lutz Inst, Parasitol & Mycol Serv, Dept Enteroparasites, Sao Paulo, Brazil.
   [de Albuquerque Luna, Expedito Jose] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Pagliusi Castilho, Vera Lucia; do Nascimento Goncalves, Elenice Messias] Univ Sao Paulo, Sch Med, Hosp Clin, Cent Lab Div,Parasitol Sect, Sao Paulo, Brazil.
   [Heath, Ashley R.] Sigma Custom Prod, The Woodlands, TX 77380 USA.
   [Dias-Neto, Emmanuel] Univ Sao Paulo, Alzira Denise Hertzog Silva LIM Inst27, Neurosci Lab, Sao Paulo, Brazil.
   [Dias-Neto, Emmanuel] Univ Sao Paulo, Dept Psychiat, Sao Paulo, Brazil.
   [Carvalho Espirito-Santo, Maria Cristina] Univ Ctr Volta Redonda, Volta Redonda, RJ, Brazil.
RP Espirito-Santo, MCC (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, LIM 06, Sao Paulo, Brazil.
EM cristinasanto@usp.br
RI Dias-Neto, Emmanuel/A-5869-2008; Luna, Expedito J A/B-7948-2012;
   Dias-Neto, Emmanuel/AAA-6701-2019; Pinto, Pedro Luiz LS
   Silva/B-5225-2016; Dias-Neto, Emmanuel/AAE-9147-2020; Moreira, Joao
   Paulo/M-9185-2013; Carrilho, Flair J/I-3046-2012; de Amorim, Maria
   Galli/K-8259-2016; Pinho, Joao R. R./G-2850-2012
OI Dias-Neto, Emmanuel/0000-0001-5670-8559; Luna, Expedito J
   A/0000-0002-1145-9672; Pinto, Pedro Luiz LS Silva/0000-0002-3727-596X;
   de Amorim, Maria Galli/0000-0002-1910-8770; Pinho, Joao R.
   R./0000-0003-3999-0489
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [07/53457-7, 08/50461-6, 10/52615-0]
FX This study was supported by the Sao Paulo Research Foundation (grants:
   07/53457-7, 08/50461-6, and 10/52615-0). We would like to thank Dr.
   Luciana Inacia Gomes and Dr. Ana Rabello, from the Laboratory of
   Clinical Research of the Rene Rachou Research Institute - Fiocruz, Belo
   Horizonte, Brazil, for their assistance during the standardization
   process. We would also like to thank Ms. Magali Orban, from the
   Parasitology Section of the Central Laboratory Division, Clinics
   Hospital, School of Medicine of the University of Sao Paulo, for her
   technical assistance in conducting the parasitological analysis of fecal
   samples and Ms. Maria Cristina Conceicao de Mello (LIM-06-FMUSP) for her
   excellent technical assistance concerning the maintenance of the S.
   mansoni biological cycle. EDN and JRRP are research fellows of the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq).
   Finally, we would like to thank Dr. Witon Neri and staff of the
   Municipal Health Department of Barra Mansa, Rio de Janeiro, Brazil.
CR Oliveira LMA, 2010, DIAGN MICR INFEC DIS, V68, P416, DOI 10.1016/j.diagmicrobio.2010.07.016
   Bergquist NR, 2002, TRENDS PARASITOL, V18, P309, DOI 10.1016/S1471-4922(02)02301-2
   Brasil. Ministerio da Saude, 1976, CONS DES SOC
   Brasil. Ministerio da Saude. Secretaria de Vigilancia a Saude: Sistema de Informacao do Programa de Controle da Esquistossomose, 2012, SIST INF PROGR CONTR
   Carneiro TR, 2012, REV SOC BRAS MED TRO, V45, P510, DOI 10.1590/S0037-86822012000400019
   do Espirito-Santo MCC, 2012, REV INST MED TROP SP, V54, P245, DOI 10.1590/S0036-46652012000500002
   Espirito-Santo MCC, 2014, EXP PARASITOL, V143, P83, DOI 10.1016/j.exppara.2014.05.013
   Cavalcanti MG, 2013, TRENDS PARASITOL, V29, P75, DOI 10.1016/j.pt.2012.11.003
   Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Cnops L, 2012, TROP MED INT HEALTH, V17, P1208, DOI 10.1111/j.1365-3156.2012.03060.x
   de Janeiro R, 2009, SECRETARIA ESTADO SA
   de Noya BA, 2006, MEM I OSWALDO CRUZ, V101, P29, DOI 10.1590/S0074-02762006000900006
   Gomes ALD, 2006, MEM I OSWALDO CRUZ, V101, P133, DOI 10.1590/S0074-02762006000900021
   Doenhoff MJ, 2004, TRENDS PARASITOL, V20, P35, DOI 10.1016/j.pt.2003.10.019
   Ebrahim A, 1997, AM J TROP MED HYG, V57, P706, DOI 10.4269/ajtmh.1997.57.706
   Engels D, 1996, AM J TROP MED HYG, V54, P319, DOI 10.4269/ajtmh.1996.54.319
   Enk MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038947
   Enk MJ, 2008, ACTA TROP, V108, P222, DOI 10.1016/j.actatropica.2008.09.016
   Espirito-Santo MCC, 2011, 47 CONGR SOC BRAS ME, V85, P41
   Espirito-Santo MCC, 2012, 18 INT C TROP MED MA, VII, P662
   Gomes LI, 2009, MEM I OSWALDO CRUZ, V104, P1194, DOI 10.1590/S0074-02762009000800021
   HAMBURGER J, 1991, MOL BIOCHEM PARASIT, V44, P73, DOI 10.1016/0166-6851(91)90222-R
   Kato K., 1954, JAPAN J PARASITOL, V3, P35
   Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397
   Kirkwood B. R., 2003, ESSENTIAL MED STAT
   Pontes LA, 2003, AM J TROP MED HYG, V68, P652, DOI 10.4269/ajtmh.2003.68.652
   Pontes LA, 2002, AM J TROP MED HYG, V66, P157, DOI 10.4269/ajtmh.2002.66.157
   Pordeus LC, 2008, EPIDEMIOL SERV SAUDE, V17, P163
   Rio de Janeiro, 2008, SINANNET07052008
   RUIZTIBEN E, 1979, AM J TROP MED HYG, V28, P230, DOI 10.4269/ajtmh.1979.28.230
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SIMPSON AJG, 1984, EUR J BIOCHEM, V139, P41, DOI 10.1111/j.1432-1033.1984.tb07973.x
   Sorgho H, 2005, ACTA TROP, V93, P169, DOI 10.1016/j.actatropica.2004.10.006
   SPOTILA LD, 1991, MOL BIOCHEM PARASIT, V48, P117, DOI 10.1016/0166-6851(91)90172-3
   TEESDALE CH, 1985, T ROY SOC TROP MED H, V79, P369, DOI 10.1016/0035-9203(85)90384-0
   Teles HMS, 2001, THESIS U ESTADUAL CA
   ten Hove RJ, 2008, T ROY SOC TROP MED H, V102, P179, DOI 10.1016/j.trstmh.2007.10.011
   VANKEULEN H, 1985, MOL BIOCHEM PARASIT, V15, P215, DOI 10.1016/0166-6851(85)90121-5
   WHO, 2000, REP INF CONS SCHIST
   Wichmann D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-55
   Wichmann D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000422
   Zhang YY, 2009, ACTA TROP, V112, P16, DOI 10.1016/j.actatropica.2009.05.020
   Zhou L, 2011, ACTA TROP, V120, P88, DOI 10.1016/j.actatropica.2011.06.006
NR 44
TC 21
Z9 23
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD OCT 23
PY 2014
VL 14
AR 558
DI 10.1186/s12879-014-0558-4
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AR8NH
UT WOS:000343831200001
PM 25338651
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Silvestre, OM
   Bacal, F
   Ramos, DS
   Tarasoutchi, F
   Acorsi, TD
   Fernandes, F
   Lemos, PA
   Carrilho, FJ
   D'Albuquerque, LAC
   Farias, AQ
AF Silvestre, Odilson Marcos
   Bacal, Fernando
   Ramos, Danusa Souza
   Tarasoutchi, Flavio
   Acorsi, Tarso D.
   Fernandes, Fabio
   Lemos, Pedro A.
   Carrilho, Flair Jose
   D'Albuquerque, Luiz A. C.
   Farias, Alberto Queiroz
TI Transcatheter Aortic Valve Implantation as Rescue Therapy for Liver
   Transplant Candidates With Aortic Valve Stenosis
SO LIVER TRANSPLANTATION
LA English
DT Letter
ID SURGERY
C1 [Silvestre, Odilson Marcos; Bacal, Fernando; Tarasoutchi, Flavio; Acorsi, Tarso D.; Fernandes, Fabio; Lemos, Pedro A.] Univ Sao Paulo, Sch Med, Dept Cardiol, BR-05403000 Sao Paulo, Brazil.
   [Ramos, Danusa Souza; Carrilho, Flair Jose; D'Albuquerque, Luiz A. C.; Farias, Alberto Queiroz] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
RP Silvestre, OM (corresponding author), Univ Sao Paulo, Sch Med, Dept Cardiol, 255 Dr Eneas de Carvalho Aguiar Ave,Sala 9117, BR-05403000 Sao Paulo, Brazil.
EM odilsonsilvestre@yahoo.com.br
RI Fernandes, Fabio/D-5994-2012; D'ALBUQUERQUE, Luiz Carneiro
   Augusto/I-4011-2012; Farias, Alberto/ABB-1291-2020; Tarasoutchi,
   F/I-2458-2013; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013; Lemos,
   Pedro A./G-5758-2013; Ramos, Danusa/H-6276-2012; Bacal,
   Fernando/H-7952-2012; Carrilho, Flair J/I-3046-2012
OI Fernandes, Fabio/0000-0002-9323-8805; Farias,
   Alberto/0000-0002-5572-663X; Tarasoutchi, F/0000-0002-9964-3289;
   D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Lemos, Pedro
   A./0000-0002-6782-750X; Ramos, Danusa/0000-0002-6713-5415; 
CR Genereux P, 2012, EUR HEART J, V33, P2388, DOI 10.1093/eurheartj/ehs220
   Global Observatory on Donation and Transplantation World Health Organization, ORG DON TRANSPL ACT
   Kertai MD, 2004, AM J MED, V116, P8, DOI 10.1016/j.amjmed.2003.07.012
   LIEBERMAN EB, 1995, J AM COLL CARDIOL, V26, P1522, DOI 10.1016/0735-1097(95)00363-0
   Makkar RR, 2012, NEW ENGL J MED, V366, P1696, DOI 10.1056/NEJMoa1202277
   Thielmann M, 2010, EUR J CARDIO-THORAC, V38, P592, DOI 10.1016/j.ejcts.2010.02.042
NR 6
TC 7
Z9 7
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD OCT
PY 2014
VL 20
IS 10
BP 1277
EP 1279
DI 10.1002/lt.23941
PG 3
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AQ7PR
UT WOS:000343012000017
PM 24962070
OA Bronze
DA 2020-12-08
ER

PT J
AU de Carvalho, IMVG
   Alves, R
   de Souza, PAVM
   da Silva, EF
   Mazo, D
   Carrilho, FJ
   Queiroz, ATL
   Pessoa, MG
AF de Carvalho, Isabel M. V. G.
   Alves, Rafael
   Vasconcelos-Medeiros de Souza, Polyana A.
   da Silva, Edvaldo F.
   Mazo, Daniel
   Carrilho, Flair J.
   Queiroz, Artur T. L.
   Pessoa, Mario G.
TI Protease Inhibitor Resistance Mutations in Untreated Brazilian Patients
   Infected with HCV: Novel Insights about Targeted Genotyping Approaches
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HCV; hepatitis C; protease inhibitors; resistance; genotyping
ID HEPATITIS-C-VIRUS; SEQUENCE ALIGNMENT; NS3/4A PROTEASE; NS3-4A PROTEASE;
   IN-VITRO; RIBAVIRIN; BOCEPREVIR; TELAPREVIR; VARIANTS; THERAPY
AB Several new direct-acting antiviral (DAA) drugs are being developed or are already approved for the treatment of chronic hepatitis C virus (HCV) infection. HCV variants presenting drug-resistant phenotypes were observed both in vitro and during clinical trials. The aim of this study was to characterize amino acid changes at positions previously associated with resistance in the NS3 protease in untreated Brazilian patients infected with HCV genotypes 1a and 1b. Plasma samples from 171 untreated Brazilian patients infected with HCV were obtained from the Department of Gastroenterology of Clinics Hospital (HCFMUSP) in Sao Paulo, Brazil. Nested PCR and Sanger sequencing were used to obtain genetic information on the NS3 protein. Bioinformatics was used to confirm subtype information and analyze frequencies of resistance mutations. The results from the genotype analysis using non-NS3 targeted methods were at variance with those obtained from the NS3 protease phylogenetic analyses. It was found that 7.4% of patients infected with HCV genotype 1a showed the resistance-associated mutations V36L, T54S, Q80K, and R155K, while 5.1% of patients infected with HCV genotype 1b had the resistance-associated mutations V36L, Q41R, T54S, and D168S. Notably, codons at positions 80 and 155 differed between samples from Brazilian patient used in this study and global isolates. The present study demonstrates that genotyping methods targeting the NS3 protein showed a difference of results when compared to mainstream methodologies (INNO-LiPA and polymerase sequencing). The resistance mutations present in untreated patients infected with HCV and codon composition bias by geographical location warrant closer examination. (C) 2014 Wiley Periodicals, Inc.
C1 [de Carvalho, Isabel M. V. G.; Vasconcelos-Medeiros de Souza, Polyana A.] Butantan Inst, Sao Paulo, Brazil.
   [de Carvalho, Isabel M. V. G.; Alves, Rafael] Univ Fed Sao Paulo, Appl Mol Hepatol Lab LHeMA, Hepatitis Sect, Div Gastroenterol, Sao Paulo, Brazil.
   [da Silva, Edvaldo F.; Mazo, Daniel; Carrilho, Flair J.; Pessoa, Mario G.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Queiroz, Artur T. L.] Goncalo Moniz Res Ctr FIOCRUZ, Immunoparasitol Lab, Salvador, BA, Brazil.
RP Queiroz, ATL (corresponding author), Rua Waldemar Falcao 121, Salvador, BA, Brazil.
EM artur.queiroz@bahia.fiocruz.br
RI Carrilho, Flair J/I-3046-2012; de carvalho-Mello, Isabel Maria V
   G/D-3641-2012; Mazo, Daniel FC/D-5631-2015; Alves da Silva,
   Rafael/H-1105-2012
OI Mazo, Daniel FC/0000-0002-2164-2630; Alves da Silva,
   Rafael/0000-0003-3473-9412; de Queiroz, Artur Trancoso
   Lopo/0000-0003-4908-9993
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/14277-9, 2012/18168-2]; CAPES (Brazil)CAPES
FX Grant sponsor: FAPESP; Grant numbers: 2009/14277-9; 2012/18168-2; Grant
   sponsor: CAPES (Brazil).
CR Alves R, 2013, J VIRAL HEPATITIS, V20, P414, DOI 10.1111/jvh.12051
   Bae A, 2010, ANTIMICROB AGENTS CH, V54, P5288, DOI 10.1128/AAC.00777-10
   Bartels DJ, 2008, J INFECT DIS, V198, P800, DOI 10.1086/591141
   Beerenwinkel N, 2011, CURR OPIN VIROL, V1, P413, DOI 10.1016/j.coviro.2011.07.008
   Cento V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039652
   Chary A, 2010, REV RECENT CLIN TRIA, V5, P158, DOI 10.2174/157488710792007293
   Chen ZY, 2002, J CLIN MICROBIOL, V40, P3127, DOI 10.1128/JCM.40.9.3127-3134.2002
   Colson P, 2011, J INFECT DIS, V203, P1341, DOI 10.1093/infdis/jir021
   Courcambeck J, 2006, ANTIVIR THER, V11, P847
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339
   Flint M, 2009, ANTIMICROB AGENTS CH, V53, P401, DOI 10.1128/AAC.01081-08
   Fonseca-Coronado S, 2012, J CLIN MICROBIOL, V50, P281, DOI 10.1128/JCM.05842-11
   Gao M, 2010, NATURE, V465, P96, DOI 10.1038/nature08960
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   Gottwein JM, 2009, HEPATOLOGY, V49, P364, DOI 10.1002/hep.22673
   Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259
   Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   Hoffmann L, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-57
   Kim AY, 2008, EXPERT REV ANTI-INFE, V6, P463, DOI 10.1586/14787210.6.4.463
   Kowdley KV, 2005, J CLIN GASTROENTEROL, V39, pS3, DOI 10.1097/01.mcg.0000145494.76305.11
   Lampe E, 2013, ANTIVIR THER, V18, P435, DOI 10.3851/IMP2606
   Larrat S, 2013, J CLIN MICROBIOL, V51, P2815, DOI 10.1128/JCM.00586-13
   Le Pogam S, 2010, J INFECT DIS, V202, P1510, DOI 10.1086/656774
   Lemke CT, 2011, J BIOL CHEM, V286, P11434, DOI 10.1074/jbc.M110.211417
   Lenz O, 2010, ANTIMICROB AGENTS CH, V54, P1878, DOI 10.1128/AAC.01452-09
   Liapakis AM, 2012, LIVER INT, V32, P17, DOI 10.1111/j.1478-3231.2011.02708.x
   Lin C, 2005, J BIOL CHEM, V280, P36784, DOI 10.1074/jbc.M506462200
   Macalalad AR, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002417
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   McCown MF, 2009, ANTIMICROB AGENTS CH, V53, P2129, DOI 10.1128/AAC.01598-08
   Ninomiya M, 2012, J CLIN MICROBIOL, V50, P857, DOI 10.1128/JCM.05715-11
   Paolucci S, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-245
   Peres-da-Silva A, 2010, ARCH VIROL, V155, P807, DOI 10.1007/s00705-010-0642-z
   Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321
   Qureshi Saleem, 2009, J Ayub Med Coll Abbottabad, V21, P10
   Salloum S, 2010, ANTIVIR RES, V87, P272, DOI 10.1016/j.antiviral.2010.05.006
   Shimakami T, 2011, GASTROENTEROLOGY, V140, P667, DOI 10.1053/j.gastro.2010.10.056
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Susser S, 2009, HEPATOLOGY, V50, P1709, DOI 10.1002/hep.23192
   Thibeault D, 2004, J VIROL, V78, P7352, DOI 10.1128/JVI.78.14.7352-7359.2004
   Thompson AJV, 2009, J VIRAL HEPATITIS, V16, P377, DOI 10.1111/j.1365-2893.2009.01124.x
   Tong X, 2008, ANTIVIR RES, V77, P177, DOI 10.1016/j.antiviral.2007.11.010
   Verbeeck J, 2008, J CLIN MICROBIOL, V46, P1901, DOI 10.1128/JCM.02390-07
   Vermehren J, 2012, J VIRAL HEPATITIS, V19, P120, DOI 10.1111/j.1365-2893.2011.01449.x
   Vermehren J, 2011, CLIN MICROBIOL INFEC, V17, P122, DOI 10.1111/j.1469-0691.2010.03430.x
   Welsch C, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r16
NR 52
TC 13
Z9 13
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2014
VL 86
IS 10
BP 1714
EP 1721
DI 10.1002/jmv.24015
PG 8
WC Virology
SC Virology
GA AN4EN
UT WOS:000340540500011
PM 25042789
OA Green Published
DA 2020-12-08
ER

PT J
AU Nassar, AP
   Farias, AQ
   d' Albuquerque, LAC
   Carrilho, FJ
   Malbouisson, LMS
AF Nassar Junior, Antonio Paulo
   Farias, Alberto Queiroz
   Carneiro d' Albuquerque, Luiz Augusto
   Carrilho, Flair Jose
   Sa Malbouisson, Luiz Marcelo
TI Terlipressin versus Norepinephrine in the Treatment of Hepatorenal
   Syndrome: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID CONTROLLED-TRIAL; NORADRENALINE; PILOT; CIRRHOSIS; ALBUMIN; PREDICTORS;
   DIAGNOSIS; SURVIVAL
AB Background: Hepatorenal syndrome (HRS) is a severe and progressive functional renal failure occurring in patients with cirrhosis and ascites. Terlipressin is recognized as an effective treatment of HRS, but it is expensive and not widely available. Norepinephrine could be an effective alternative. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of norepinephrine compared to terlipressin in the management of HRS.
   Methods: We searched the Medline, Embase, Scopus, CENTRAL, Lilacs and Scielo databases for randomized trials of norepinephrine and terlipressin in the treatment of HRS up to January 2014. Two reviewers collected data and assessed the outcomes and risk of bias. The primary outcome was the reversal of HRS. Secondary outcomes were mortality, recurrence of HRS and adverse events.
   Results: Four studies comprising 154 patients were included. All trials were considered to be at overall high risk of bias. There was no difference in the reversal of HRS (RR = 0.97, 95% CI = 0.76 to 1.23), mortality at 30 days (RR = 0.89, 95% CI = 0.68 to 1.17) and recurrence of HRS (RR = 0.72; 95% CI = 0.36 to 1.45) between norepinephrine and terlipressin. Adverse events were less common with norepinephrine (RR = 0.36, 95% CI = 0.15 to 0.83).
   Conclusions: Norepinephrine seems to be an attractive alternative to terlipressin in the treatment of HRS and is associated with less adverse events. However, these findings are based on data extracted from only four small studies.
C1 [Nassar Junior, Antonio Paulo; Sa Malbouisson, Luiz Marcelo] Univ Sao Paulo, Dept Gastroenterol, Intens Care Unit, Sao Paulo, Brazil.
   [Farias, Alberto Queiroz; Carrilho, Flair Jose] Univ Sao Paulo, Dept Gastroenterol, Discipline Gastroenterol, Sao Paulo, Brazil.
   [Carneiro d' Albuquerque, Luiz Augusto] Univ Sao Paulo, Dept Gastroenterol, Liver & Gastrointestinal Transplant Div, Sao Paulo, Brazil.
RP Nassar, AP (corresponding author), Univ Sao Paulo, Dept Gastroenterol, Intens Care Unit, Sao Paulo, Brazil.
EM paulo_nassar@yahoo.com.br
RI Nassar, Antonio P/I-5508-2015; D'Albuquerque, Luiz Augusto
   Carneiro/A-8812-2013; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012;
   Carrilho, Flair J/I-3046-2012; Farias, Alberto/ABB-1291-2020;
   Malbouisson, Luiz Marcelo/F-4819-2012
OI Nassar, Antonio P/0000-0002-0522-7445; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Farias, Alberto/0000-0002-5572-663X;
   Malbouisson, Luiz Marcelo/0000-0002-3261-5603
CR Alessandria C, 2007, J HEPATOL, V47, P499, DOI 10.1016/j.jhep.2007.04.010
   Angeli P, 2012, J HEPATOL, V57, P1135, DOI 10.1016/j.jhep.2012.06.024
   Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164
   Arroyo V, 2011, NAT REV NEPHROL, V7, P517, DOI 10.1038/nrneph.2011.96
   de Carvalho GC, 2012, ANN HEPATOL, V11, P90
   Dobre M, 2011, INT UROL NEPHROL, V43, P175, DOI 10.1007/s11255-010-9725-8
   Duvoux C, 2002, HEPATOLOGY, V36, P374, DOI 10.1053/jhep.2002.34343
   Ghosh S, 2013, LIVER INT, V33, P1187, DOI 10.1111/liv.12179
   GINES A, 1993, GASTROENTEROLOGY, V105, P229, DOI 10.1016/0016-5085(93)90031-7
   Gluud LL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005162.pub3
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hiremath SB, 2013, INDIAN J PHARMACOL, V45, P54, DOI 10.4103/0253-7613.106436
   Kiszka-Kanowitz M, 2004, SCAND J GASTROENTERO, V39, P486, DOI 10.1080/00365520310008728
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Martin-Llahi M, 2008, GASTROENTEROLOGY, V134, P1352, DOI 10.1053/j.gastro.2008.02.024
   Narahara Y, 2009, J GASTROEN HEPATOL, V24, P1791, DOI 10.1111/j.1440-1746.2009.05873.x
   Nazar A, 2010, HEPATOLOGY, V51, P219, DOI 10.1002/hep.23283
   Salerno F, 2007, GUT, V56, P1310, DOI 10.1136/gut.2006.107789
   Salerno F, 2011, J HEPATOL, V55, P1241, DOI 10.1016/j.jhep.2011.03.012
   Sanyal AJ, 2008, GASTROENTEROLOGY, V134, P1360, DOI 10.1053/j.gastro.2008.02.014
   Sharma P, 2008, AM J GASTROENTEROL, V103, P1689, DOI 10.1111/j.1572-0241.2008.01828.x
   Singh V, 2012, J HEPATOL, V56, P1293, DOI 10.1016/j.jhep.2012.01.012
   Wallace BC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-80
NR 23
TC 51
Z9 53
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2014
VL 9
IS 9
AR e107466
DI 10.1371/journal.pone.0107466
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ3IF
UT WOS:000342684500103
PM 25203311
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Sanches, L
   da Silva, LB
   de Lima, SD
   Pereira, OA
   Carrilho, FJ
   Nogueira, JD
AF Sanches, Luciana
   da Silva, Ludymilla B.
   de Lima, Suzy D.
   Pereira, Osvaldo A.
   Carrilho, Flair J.
   Nogueira, Jose de S.
TI Energy storage in the biomass and air of the canopy of Vochysia
   divergens Pohl
SO REVISTA BRASILEIRA DE ENGENHARIA AGRICOLA E AMBIENTAL
LA Portuguese
DT Article
DE wetland; energy balance; flooding; Pantanal; seasonality
ID HEAT-STORAGE; BALANCE CLOSURE; FOREST; FLUXES
AB The variation of the storage energy in the biomass and in the air of the canopy can be estimated by measuring biomass and air temperature and biomass distribution being a significant component of energy balance. Nevertheless, accurate estimates of this component of energy balance are difficult to obtain and usually neglected in the calculations, especially in analysis of long periods. To understand the energy balance in the forest, this study estimated the energy stored in biomass using micrometeorological data in a forest monodominant Vochysia divergens Pohl in Pantanal in 2007. The energy stored in the biomass and in the air of the canopy (S) was higher in rainy season than in dry season, however, the difference between maximum and minimum values was higher during the dry season. The values of S in V. divergens forest in Pantanal in 2007 were similar to storage energy in the other tropical forests.
C1 [Sanches, Luciana; de Lima, Suzy D.] Univ Fed Mato Grosso, Dept Engn Sanit & Ambiental, Cuiaba, MT, Brazil.
   [da Silva, Ludymilla B.; Pereira, Osvaldo A.; Carrilho, Flair J.; Nogueira, Jose de S.] Univ Fed Mato Grosso, Inst Fis, Programa Posgrad Fis Ambiental, Cuiaba, MT, Brazil.
RP da Silva, LB (corresponding author), Univ Fed Mato Grosso, Inst Fis, Programa Posgrad Fis Ambiental, Cuiaba, MT, Brazil.
EM lsanches@ufmt.br; ludymillab@gmail.com; suzydarley@hotmail.com;
   osvaldo_fu@yahoo.com.br; flasosa@msn.com; nogueira@ufmt.br
RI de Souza Nogueira, Jose/N-6229-2018
OI de Souza Nogueira, Jose/0000-0003-2504-7924
CR Arieira Julia, 2006, Acta Bot. Bras., V20, P569, DOI 10.1590/S0102-33062006000300007
   Barr AG, 2006, AGR FOREST METEOROL, V140, P322, DOI 10.1016/j.agrformet.2006.08.007
   Bidlake W. R., 1996, EVAPOTRANSPIRATION A
   Curado L. F. A., 2014, Atmospheric and Climate Sciences, V4, P219, DOI 10.4236/acs.2014.42025
   Michiles AAD, 2008, AGR FOREST METEOROL, V148, P917, DOI 10.1016/j.agrformet.2008.01.001
   GALVAO JAC, 2000, REV BRAS METEOROL, V15, P25
   German ER, 2000, REGIONAL EVALUATION
   Girard P., 2011, PANTANAL ECOLOGY BIO, P103
   GOUDRIAAN J, 1988, AGR FOREST METEOROL, V43, P155, DOI 10.1016/0168-1923(88)90089-5
   Harris MB, 2005, CONSERV BIOL, V19, P714, DOI 10.1111/j.1523-1739.2005.00708.x
   Huxman TE, 2005, ECOLOGY, V86, P308, DOI 10.1890/03-0583
   Junk WJ, 2005, ECOL ENG, V24, P391, DOI 10.1016/j.ecoleng.2004.11.012
   MCCAUGHEY JH, 1988, AGR FOREST METEOROL, V44, P1, DOI 10.1016/0168-1923(88)90029-9
   McCaughey JH, 1997, J GEOPHYS RES-ATMOS, V102, P28997, DOI 10.1029/97JD00239
   Meesters AGCA, 1996, AGR FOREST METEOROL, V78, P181, DOI 10.1016/0168-1923(95)02251-1
   Mesquita Francisco Luiz Leitão de, 2013, Rev. bras. meteorol., V28, P65, DOI 10.1590/S0102-77862013000100007
   Monsi M., 1953, JAPANESE J BOTANY, V14, P22, DOI DOI 10.1093/AOB/MCI052
   MOORE CJ, 1986, AGR FOREST METEOROL, V38, P147, DOI 10.1016/0168-1923(86)90055-9
   Nunes da Cunha C, 2004, APPL VEG SCI, V7, P103, DOI DOI 10.1658/1402-2001(2004)007[0103:YCIWLD]2.0.CO;2
   Oliphant AJ, 2004, AGR FOREST METEOROL, V126, P185, DOI 10.1016/j.agrformet.2004.07.003
   Pinto OB, 2011, INT J BIOMETEOROL, V55, P109, DOI 10.1007/s00484-010-0317-1
   Roupsard O, 2006, AGR FOREST METEOROL, V139, P252, DOI 10.1016/j.agrformet.2006.07.006
   Sanches L., 2010, REV BRAS METEOROL, V25, P287
   Sanches L, 2011, WETLANDS, V31, P1215, DOI 10.1007/s13157-011-0233-0
   Schwerdtfeger J., 2014, HYDROL EARTH SYST SC, V11, P4017
   Scott RL, 2006, HYDROL PROCESS, V20, P3227, DOI 10.1002/hyp.6329
   Shoemaker W. B., 2005, WATER RESOURCE, V41, P1
   TANNER C. B., 1960, SOIL SCI SOC AMER PROC, V24, P1
   Vourlitis G, 2010, ECOSYSTEM FUNCTION G, P97, DOI DOI 10.1201/B10275-8
   Wilson K, 2002, AGR FOREST METEOROL, V113, P223, DOI 10.1016/S0168-1923(02)00109-0
NR 30
TC 0
Z9 1
U1 1
U2 9
PU UNIV FEDERAL CAMPINA GRANDE
PI CAMPINA GRANDE PB
PA RUA APRIGIO VELOSO 882, BODO CONGO, CAMPINA GRANDE PB, 58109 090, BRAZIL
SN 1415-4366
EI 1807-1929
J9 REV BRAS ENG AGR AMB
JI Rev. Bras. Eng. Agric. Ambient.
PD SEP
PY 2014
VL 18
IS 9
BP 955
EP 962
DI 10.1590/1807-1929/agriambi.v18n09p955-962
PG 8
WC Agricultural Engineering
SC Agriculture
GA AY5KS
UT WOS:000347611600012
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Espirito-Santo, MCC
   Alvarado-Mora, MV
   Pinto, PLS
   de Brito, T
   Botelho-Lima, L
   Heath, AR
   Amorim, MG
   Dias-Neto, E
   Chieffi, PP
   Pinho, JRR
   Carrilho, FJ
   Luna, EJA
   Gryschek, RCB
AF Carvalho Espirito-Santo, Maria Cristina
   Alvarado-Mora, Monica Viviana
   Silva Pinto, Pedro Luiz
   de Brito, Thales
   Botelho-Lima, Livia
   Heath, Ashley Richard
   Amorim, Maria Galli
   Dias-Neto, Emmanuel
   Chieffi, Pedro Paulo
   Rebello Pinho, Joao Renato
   Carrilho, Flair Jose
   Albuquerque Luna, Expedito Jose
   Borges Gryschek, Ronaldo Cesar
TI Detection of Schistosoma mansoni infection by TaqMan (R) Real-Time PCR
   in a hamster model
SO EXPERIMENTAL PARASITOLOGY
LA English
DT Article
DE S. mansoni; TaqMan (R) Real-Time PCR system; Circumoval precipitin test;
   Kato-Katz method; Histopathology
ID FILTERED URINE; DNA FRAGMENTS; DIAGNOSIS; EGGS; HAEMATOBIUM; EXTRACTION;
   FECES; TESTS; ELISA; SERUM
AB An experimental study in hamsters was performed to evaluate the capability for detecting Schistosoma mansoni DNA in serum and fecal samples during the pre and post-egg-laying periods of infection using TaqMan (R) Real-Time PCR system (qPCR), was compared with the circumoval precipitin test (COPT) and the Kato-Katz technique, especially among individuals with low parasitic burden. Twenty-four hamsters were infected with cercariae. Three hamsters were sacrificed per week under anesthesia, from 7 days post infection (DPI) up to 56 DPI. A serum sample and a pool of feces were collected from each hamster. The presence of S. mansoni eggs in fecal samples was evaluated by Kato-Katz method and in the hamsters gut-by histopathology. Detection of S. mansoni DNA was performed using qPCR and S. mansoni antibody using COPT. The first detection of eggs in feces by Kato-Katz method and S. mansoni DNA in feces by qPCR occurred 49 DPI. Nevertheless, S. mansoni DNA was detected in serum samples from 14 up to 56 DPI. COPT was positive at 35 DPI. The results not only confirm the reliability of S. mansoni DNA detection by qPCR, but also demonstrate that serum is a trustworthy source of DNA in the pre patent infection period. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Carvalho Espirito-Santo, Maria Cristina; de Brito, Thales; Borges Gryschek, Ronaldo Cesar] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, BR-05508 Sao Paulo, Brazil.
   [Carvalho Espirito-Santo, Maria Cristina; de Brito, Thales; Borges Gryschek, Ronaldo Cesar] Univ Sao Paulo, Fac Med, Lab Med Invest 6, BR-05508 Sao Paulo, Brazil.
   [Alvarado-Mora, Monica Viviana; Botelho-Lima, Livia; Rebello Pinho, Joao Renato; Carrilho, Flair Jose] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Lab Trop Gastroenterol & Hepatol, BR-05508 Sao Paulo, Brazil.
   [Silva Pinto, Pedro Luiz] Inst Adolfo Lutz Secretaria Estado Saude Sao Paul, Dept Enteroparasites, Ctr Parasitol & Mycol, Sao Paulo, Brazil.
   [Chieffi, Pedro Paulo] Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
   [de Brito, Thales; Chieffi, Pedro Paulo; Albuquerque Luna, Expedito Jose] Univ Sao Paulo, Inst Med Trop Sao Paulo, BR-05508 Sao Paulo, Brazil.
   [Amorim, Maria Galli; Dias-Neto, Emmanuel] Hosp AC Camargo Fund Antonio Prudente, Ctr Int Res & Educ CIPE, Lab Med Genom, Sao Paulo, Brazil.
   [Heath, Ashley Richard] Sigma Life Sci, The Woodlands, TX USA.
   [Dias-Neto, Emmanuel] Univ Sao Paulo, Fac Med, Dept & Inst Psychiat, Lab Neurociencies LIM 27, BR-05508 Sao Paulo, Brazil.
RP Espirito-Santo, MCC (corresponding author), Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, BR-05508 Sao Paulo, Brazil.
EM cristinasanto@usp.br
RI Carrilho, Flair J/I-3046-2012; Pinto, Pedro Luiz LS Silva/B-5225-2016;
   Luna, Expedito J A/B-7948-2012; Dias-Neto, Emmanuel/A-5869-2008; De
   Brito, Thales/L-2865-2017; Dias-Neto, Emmanuel/AAE-9147-2020; Pinho,
   Joao R. R./G-2850-2012; Dias-Neto, Emmanuel/AAA-6701-2019; de Amorim,
   Maria Galli/K-8259-2016
OI Pinto, Pedro Luiz LS Silva/0000-0002-3727-596X; Luna, Expedito J
   A/0000-0002-1145-9672; Dias-Neto, Emmanuel/0000-0001-5670-8559; De
   Brito, Thales/0000-0003-1106-7254; Pinho, Joao R.
   R./0000-0003-3999-0489; de Amorim, Maria Galli/0000-0002-1910-8770
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [07/53457-7, 08/50461-6, 10/52615-0]
FX This study was supported by the Sao Paulo Research Foundation under
   processes 07/53457-7, 08/50461-6 and 10/52615-0. We would like to thank
   Dra. Luciana Inacia Gomes and Dra. Ana Rabello, from the Laboratorio de
   Pesquisas Clinicas (Laboratory of Clinical Research) of the Instituto de
   Pesquisas Rene Rachou - Fiocruz, Belo Horizonte, Brazil, for their
   assistance during the standardization process. Finally, we would like to
   thank Miss Maria Cristina Conceicao de Mello from LIM-06-FMUSP for her
   excellent technical assistance concerning the S. mansoni biological
   cycle.
CR Barreto M L, 1978, Trans R Soc Trop Med Hyg, V72, P181, DOI 10.1016/0035-9203(78)90056-1
   Bergquist NR, 2002, TRENDS PARASITOL, V18, P309, DOI 10.1016/S1471-4922(02)02301-2
   Berhe N, 2004, ACTA TROP, V92, P205, DOI 10.1016/j.actatropica.2004.06.011
   Blanchard Tom J, 2004, Travel Med Infect Dis, V2, P5, DOI 10.1016/j.tmaid.2004.02.011
   do Espirito-Santo MCC, 2012, REV INST MED TROP SP, V54, P245, DOI 10.1590/S0036-46652012000500002
   Cheever AW, 2002, MEM I OSWALDO CRUZ, V97, P917, DOI 10.1590/S0074-02762002000700002
   CHEEVER AW, 1968, AM J TROP MED HYG, V17, P38, DOI 10.4269/ajtmh.1968.17.38
   Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   de Noya BA, 2006, MEM I OSWALDO CRUZ, V101, P29, DOI 10.1590/S0074-02762006000900006
   DOENHOFF MJ, 1993, T ROY SOC TROP MED H, V87, P42, DOI 10.1016/0035-9203(93)90415-M
   DRESDEN MH, 1981, J PARASITOL, V67, P450, DOI 10.2307/3280573
   Engels D, 1996, AM J TROP MED HYG, V54, P319, DOI 10.4269/ajtmh.1996.54.319
   FELDMEIER H, 1983, ZBL BAKT-INT J MED M, V255, P413, DOI 10.1016/S0174-3031(83)80185-1
   Gryseels B, 2012, INFECT DIS CLIN N AM, V26, P383, DOI 10.1016/j.idc.2012.03.004
   HAMBURGER J, 1991, MOL BIOCHEM PARASIT, V44, P73, DOI 10.1016/0166-6851(91)90222-R
   Hussein HM, 2012, PARASITOL RES, V111, P475, DOI 10.1007/s00436-012-2822-0
   Ibironke O, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001464
   Ibironke OA, 2011, AM J TROP MED HYG, V84, P998, DOI 10.4269/ajtmh.2011.10-0691
   Karanja DMS, 1997, AM J TROP MED HYG, V56, P515, DOI 10.4269/ajtmh.1997.56.515
   Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397
   King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4
   Lambertucci JR, 2010, MEM I OSWALDO CRUZ, V105, P422, DOI 10.1590/S0074-02762010000400012
   Lodh N, 2013, AM J TROP MED HYG, V89, P46, DOI 10.4269/ajtmh.13-0104
   LONG GW, 1980, AM J TROP MED HYG, V29, P1241, DOI 10.4269/ajtmh.1980.29.1241
   Ministry of Health Brazil, 2012, INF SYST DIS SAUD 20
   Noya O, 2002, MEM I OSWALDO CRUZ, V97, P167, DOI 10.1590/S0074-02762002000900032
   OLIVERGONZALEZ J, 1954, J INFECT DIS, V95, P86, DOI 10.1093/infdis/95.1.86
   Patz JA, 2000, INT J PARASITOL, V30, P1395, DOI 10.1016/S0020-7519(00)00141-7
   Pinto PL, 1995, REV PATOL TROP, V23, P264
   Pontes LA, 2002, AM J TROP MED HYG, V66, P157, DOI 10.4269/ajtmh.2002.66.157
   Rabello ALT, 1997, CLIN INFECT DIS, V24, P304, DOI 10.1093/clinids/24.3.304
   Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396
   RUIZTIBEN E, 1979, AM J TROP MED HYG, V28, P230, DOI 10.4269/ajtmh.1979.28.230
   Sadek SM, 2008, PUJ, V1, P31
   Spencer L, 1991, G E N, V45, P77
   STEINER JJ, 1995, NUCLEIC ACIDS RES, V23, P2569, DOI 10.1093/nar/23.13.2569-a
   Teles HMS, 2002, MEM I OSWALDO CRUZ, V97, P181, DOI 10.1590/S0074-02762002000900035
   vanEtten L, 1997, T ROY SOC TROP MED H, V91, P154, DOI 10.1016/S0035-9203(97)90204-2
   WARREN KS, 1975, AM J PATHOL, V80, P279
   Wichmann D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-55
   Wichmann D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000422
   World Health Organization, 2002, TDR REF GROUP SCHIST
   Ye XP, 1998, ANN TROP MED PARASIT, V92, P181, DOI 10.1080/00034989860021
   Zhou L, 2011, ACTA TROP, V120, P88, DOI 10.1016/j.actatropica.2011.06.006
NR 45
TC 8
Z9 10
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4894
EI 1090-2449
J9 EXP PARASITOL
JI Exp. Parasitol.
PD AUG
PY 2014
VL 143
BP 83
EP 89
DI 10.1016/j.exppara.2014.05.013
PG 7
WC Parasitology
SC Parasitology
GA AM0LM
UT WOS:000339537100013
PM 24858959
DA 2020-12-08
ER

PT J
AU Alvares-da-Silva, MR
   de Oliveira, CPMS
   Stefano, JT
   Barbeiro, HV
   Barbeiro, D
   Soriano, FG
   Farias, AQ
   Carrilho, FJ
   D'Albuquerque, LAC
AF Alvares-da-Silva, Mario Reis
   Marques Souza de Oliveira, Claudia Pinto
   Stefano, Jose Tadeu
   Barbeiro, Hermes V.
   Barbeiro, Denise
   Soriano, Francisco G.
   Farias, Alberto Queiroz
   Carrilho, Flair Jose
   Carneiro D'Albuquerque, Luiz Augusto
TI Pro-atherosclerotic markers and cardiovascular risk factors one year
   after liver transplantation
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Cell adhesion molecules; Endothelial biomarkers; Cardiovascular disease;
   Nonalcoholic steatohepatitis; Metabolic syndrome
ID METABOLIC SYNDROME; ADHESION MOLECULES; HEPATITIS-C; EVENTS;
   ASSOCIATION; ADIPONECTIN; PREDICTION; MANAGEMENT; CYTOKINES
AB AIM: To investigate pro-atherosclerotic markers (endothelial dysfunction and inflammation) in patients one year after liver transplantation.
   METHODS: Forty-four consecutive liver transplant (LT) outpatients who were admitted between August 2009 and July 2010, were followed-up by for 1 year, exhibited no evidences of infection or rejection, all of them underwent tacrolimus-based immunosuppressive regimens were consecutively enrolled. Inflammatory cytokines (TNF alpha, IFN gamma, IL-8, and IL-10), endothelial biomarkers (sVCAM-1, sICAM-1, MPO, adiponectin, PAI-1, SAP, SAA, E-selectin, and MMP-9), high sensitive C-reactive protein, and Framingham risk score (FRS) were assessed. The anthropometric data, aminotransferases, metabolic syndrome features, glucose and lipid profiles, and insulin resistance data were also collected. The LT recipients were compared to 22 biopsy-proven non-alcoholic steatohepatitis (NASH) patients and 20 healthy controls (non-obese, non-diabetics, and non-dyslipidemic).
   RESULTS: The LT recipients had significantly younger ages and lower body mass indices, aminotransferases, fasting glucose and insulin levels, glucose homeostasis model and metabolic syndrome features than the NASH patients. Classic cardiovascular risk markers, such as Hs-CRP and FRS [2.0 (1.0-8.75)], were lower in the LT patients compared to those observed in the NASH patients (P = 0.009). In contrast, the LT recipients and NASH patients had similar inflammatory and endothelial serum markers compared to the controls (pg/mL): lower IL-10 levels (32.3 and 32.3 vs 62.5, respectively, P = 0.019) and higher IFN gamma (626.1 and 411.9 vs 67.9, respectively, P < 0.001), E-selectin (48.5 and 90.03 vs 35.7, respectively, P < 0.001), sVCAM-1 (1820.6 and 1692.4 vs 1167.2, respectively, P < 0.001), and sICAM-1 (230.3 and 259.7 vs 152.9, respectively, P = 0.015) levels.
   CONCLUSION: Non-obese LT recipients have similar pro-atherosclerotic serum profiles after a short 1-year follow-up period compared to NASH patients, suggesting a high risk of atherosclerosis in this population. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Alvares-da-Silva, Mario Reis; Carneiro D'Albuquerque, Luiz Augusto] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Liver & Gastrointestinal Transplant LIM 37, BR-05508070 Sao Paulo, Brazil.
   [Alvares-da-Silva, Mario Reis] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Gastroenterol, BR-90035903 Porto Alegre, RS, Brazil.
   [Marques Souza de Oliveira, Claudia Pinto; Stefano, Jose Tadeu; Farias, Alberto Queiroz; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508070 Sao Paulo, Brazil.
   [Barbeiro, Hermes V.; Barbeiro, Denise; Soriano, Francisco G.] Univ Sao Paulo, Sch Med, Div Emergency Med LIM 51, BR-05508070 Sao Paulo, Brazil.
RP Alvares-da-Silva, MR (corresponding author), Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Gastroenterol, Rua Ramiro Barcellos 2350,Sala 2033, BR-90035903 Porto Alegre, RS, Brazil.
EM marioreis@live.com
RI Farias, Alberto/ABB-1291-2020; Stefano, Jose Tadeu/AAH-5419-2020;
   D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Barbeiro, Hermes
   V/E-2814-2010; Alvares-da-Silva, Mario Reis/L-3910-2014; Oliveira,
   Claudia PMS/D-1216-2014; Soriano, Francisco/C-3382-2012; Carrilho, Flair
   J/I-3046-2012; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   Stefano, Jose T/H-4792-2013; Barbeiro, Hermes V/S-5926-2016
OI Farias, Alberto/0000-0002-5572-663X; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Barbeiro, Hermes V/0000-0002-8209-4463;
   Alvares-da-Silva, Mario Reis/0000-0002-5001-246X; Soriano,
   Francisco/0000-0003-4898-0135; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Barbeiro, Hermes V/0000-0002-8209-4463
FU Department of Gastroenterology LIM-37/LIM07, School of Medicine,
   University of Sao Paulo, Brazil
FX Supported by Department of Gastroenterology LIM-37/LIM07, School of
   Medicine, University of Sao Paulo, Brazil
CR Aharinejad S, 2007, EUR J CARDIO-THORAC, V32, P48, DOI 10.1016/j.ejcts.2007.04.007
   Albeldawi M, 2012, LIVER TRANSPLANT, V18, P370, DOI 10.1002/lt.22468
   Brogren H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026762
   Buechler C, 2011, WORLD J GASTROENTERO, V17, P2801, DOI 10.3748/wjg.v17.i23.2801
   Calan M, 2011, INTERNAL MED, V50, P1529, DOI 10.2169/internalmedicine.50.4297
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Coss E, 2011, LIVER TRANSPLANT, V17, P23, DOI 10.1002/lt.22140
   DEE GW, 1995, CLIN TRANSPLANT, V9, P463
   Desai S, 2010, LIVER INT, V30, P948, DOI 10.1111/j.1478-3231.2010.02274.x
   Elias-Miro M, 2011, LIVER TRANSPLANT, V17, P993, DOI 10.1002/lt.22358
   Estep JM, 2009, OBES SURG, V19, P617, DOI 10.1007/s11695-009-9814-x
   Fouad TR, 2009, TRANSPLANTATION, V87, P763, DOI 10.1097/TP.0b013e318198d734
   Grundy SM, 2004, ARTERIOSCL THROM VAS, V24, pE19, DOI 10.1161/01.ATV.0000112379.88385.67
   Hanouneh IA, 2008, LIVER TRANSPLANT, V14, P1287, DOI 10.1002/lt.21524
   Jarrar MH, 2008, ALIMENT PHARM THER, V27, P412, DOI 10.1111/j.1365-2036.2007.03586.x
   Kannel WB, 2005, LIPIDS, V40, P1215, DOI 10.1007/s11745-005-1488-8
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Laish I, 2011, LIVER TRANSPLANT, V17, P15, DOI 10.1002/lt.22198
   Lauer MS, 2010, J AM COLL CARDIOL, V56, P106, DOI 10.1016/j.jacc.2010.01.059
   de Oliveira CPMS, 2013, EXPERT REV GASTROENT, V7, P361, DOI [10.1586/EGH.13.19, 10.1586/egh.13.19]
   Matsudo Sandra Mahecha, 2003, Rev Panam Salud Publica, V14, P265, DOI 10.1590/S1020-49892003000900007
   Migita K, 2006, LIFE SCI, V78, P2510, DOI 10.1016/j.lfs.2005.10.003
   Mueller AR, 1996, TRANSPLANTATION, V62, P1118, DOI 10.1097/00007890-199610270-00017
   Oliveira CPMS, 2013, INT J CARDIOL, V164, P221, DOI 10.1016/j.ijcard.2011.07.016
   Pagadala M, 2009, LIVER TRANSPLANT, V15, P1662, DOI 10.1002/lt.21952
   Rabelo F, 2010, OBES SURG, V20, P906, DOI 10.1007/s11695-010-0181-4
   Raval Z, 2011, J AM COLL CARDIOL, V58, P223, DOI 10.1016/j.jacc.2011.03.026
   Ridker PM, 2007, J AM COLL CARDIOL, V49, P2129, DOI 10.1016/j.jacc.2007.02.052
   Stravitz RT, 2011, CLIN LIVER DIS, V15, P821, DOI 10.1016/j.cld.2011.08.007
   Watt KDS, 2010, J HEPATOL, V53, P199, DOI 10.1016/j.jhep.2010.01.040
   Wiest R, 2011, CYTOKINE, V53, P178, DOI 10.1016/j.cyto.2010.06.013
   Yajnik CS, 2013, INT J CARDIOL, V165, P255, DOI 10.1016/j.ijcard.2011.08.053
NR 32
TC 7
Z9 8
U1 0
U2 5
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUL 14
PY 2014
VL 20
IS 26
BP 8667
EP 8673
DI 10.3748/wjg.v20.i26.8667
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AL8LF
UT WOS:000339389500033
PM 25024624
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Lugao, RD
   Motta, MP
   de Azevedo, MFC
   de Lima, RGR
   Abrantes, FD
   Abdala, E
   Carrilho, FJ
   Mazo, DFD
AF Lugao, Renata dos Santos
   Motta, Marina Pamponet
   Cardoso de Azevedo, Matheus Freitas
   Rezende de Lima, Roque Gabriel
   Abrantes, Flavia de Azevedo
   Abdala, Edson
   Carrilho, Flair Jose
   de Campos Mazo, Daniel Ferraz
TI Immune thrombocytopenic purpura induced by intestinal tuberculosis in a
   liver transplant recipient
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Immune thrombocytopenic purpura; Tuberculosis; Liver transplant;
   Thrombocytopenia; Intestinal tuberculosis
ID PULMONARY TUBERCULOSIS; ADULTS
AB A variety of clinical manifestations are associated directly or indirectly with tuberculosis. Among them, haematological abnormalities can be found in both the pulmonary and extrapulmonary forms of the disease. We report a case of immune thrombocytopenic purpura (ITP) associated with intestinal tuberculosis in a liver transplant recipient. The initial management of thrombocytopenia, with steroids and intravenous immunoglobulin, was not successful, and the lack of tuberculosis symptoms hampered a proper diagnostic evaluation. After the diagnosis of intestinal tuberculosis and the initiation of specific treatment, a progressive increase in the platelet count was observed. The mechanism of ITP associated with tuberculosis has not yet been well elucidated, but this condition should be considered in cases of ITP that are unresponsive to steroids and intravenous immunoglobulin, especially in immunocompromised patients and those from endemic areas. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Lugao, Renata dos Santos; Motta, Marina Pamponet; Cardoso de Azevedo, Matheus Freitas; Rezende de Lima, Roque Gabriel; Carrilho, Flair Jose; de Campos Mazo, Daniel Ferraz] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch,Clin Div, BR-05403000 Sao Paulo, Brazil.
   [Abrantes, Flavia de Azevedo; Abdala, Edson] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Gastrointestinal Transplant Div, BR-05403000 Sao Paulo, Brazil.
   [Abrantes, Flavia de Azevedo; Abdala, Edson] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, BR-05403000 Sao Paulo, Brazil.
RP Mazo, DFD (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch,Clin Div, Av Dr Eneas de Carvalho Aguiar 255,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM daniel.mazo@hc.fm.usp.br
RI Abdala, Edson/H-5165-2012; Mazo, Daniel FC/D-5631-2015; Carrilho, Flair
   J/I-3046-2012
OI Abdala, Edson/0000-0003-0765-6654; Mazo, Daniel FC/0000-0002-2164-2630; 
CR Almadi MA, 2009, AM J GASTROENTEROL, V104, P1003, DOI 10.1038/ajg.2008.162
   AlMajed SA, 1995, ACTA HAEMATOL-BASEL, V94, P135, DOI 10.1159/000203995
   BOOTS RJ, 1992, THORAX, V47, P396, DOI 10.1136/thx.47.5.396
   Bussel JB, 2009, SEMIN HEMATOL, V46, pS44, DOI 10.1053/j.seminhematol.2008.12.003
   Donoghue HD, 2009, CURR OPIN INFECT DIS, V22, P490, DOI 10.1097/QCO.0b013e3283306712
   George JN, 2012, AM J HEMATOL, V87, pS12, DOI 10.1002/ajh.23132
   Ghobrial MW, 2001, AM J HEMATOL, V67, P139, DOI 10.1002/ajh.1093
   GLASSER RM, 1970, ARCH INTERN MED, V125, P691, DOI 10.1001/archinte.125.4.691
   Heikal NM, 2013, AM J HEMATOL, V88, P818, DOI 10.1002/ajh.23503
   HernandezMaraver D, 1996, ACTA HAEMATOL-BASEL, V96, P266, DOI 10.1159/000203802
   JURAK SS, 1983, CLIN PEDIATR, V22, P318, DOI 10.1177/000992288302200416
   Kalra A, 2010, CASE REP MED, DOI 10.1155/2010/946278
   Olave M T, 1999, Sangre (Barc), V44, P495
   Ozkalemkas Fahir, 2004, Ann Clin Microbiol Antimicrob, V3, P16, DOI 10.1186/1476-0711-3-16
   Psaila B, 2007, HEMATOL ONCOL CLIN N, V21, P743, DOI 10.1016/j.hoc.2007.06.007
   Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503
   Sato S, 2004, GASTROINTEST ENDOSC, V59, P362, DOI 10.1016/S0016-5107(03)02716-0
   Tabarsi P, 2010, BRAZ J INFECT DIS, V14, P639, DOI 10.1590/S1413-86702010000600017
   Tsuro K, 2006, INTERNAL MED, V45, P739, DOI 10.2169/internalmedicine.45.1639
   Ursavas A, 2010, J INFECT CHEMOTHER, V16, P42, DOI 10.1007/s10156-009-0003-6
NR 20
TC 2
Z9 2
U1 0
U2 2
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUL 7
PY 2014
VL 20
IS 25
BP 8304
EP 8308
DI 10.3748/wjg.v20.i25.8304
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AK6EM
UT WOS:000338520900041
PM 25009408
OA Other Gold, Green Published
DA 2020-12-08
ER

PT J
AU Paranagua-Vezozzo, DC
   Ono, SK
   Alvarado-Mora, MV
   Farias, AQ
   Cunha-Silva, M
   Franca, JID
   Alves, VAF
   Sherman, M
   Carrilho, FJ
AF Paranagua-Vezozzo, Denise C.
   Ono, Suzane K.
   Alvarado-Mora, Monica V.
   Farias, Alberto Q.
   Cunha-Silva, Marlone
   Franca, Joao I. D.
   Alves, Venancio A. F.
   Sherman, Morris
   Carrilho, Flair Jose
TI Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year
   cohort
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Ultrasonography; Milan criteria; Risk factors; Hepatocellular carcinoma;
   Surveillance
ID HEPATOCELLULAR-CARCINOMA; LIVER-TRANSPLANTATION; CIRRHOSIS; SURVIVAL;
   SURVEILLANCE; JAPAN
AB Background and aim. The lack of information about hepatocellular carcinoma (HCC) in Brazil weakens health policy in preventing deaths from the illness. The aim of this study was to establish the cumulative incidence and the risk factors for hepatocellular carcinoma development in patients under a surveillance program. Material and methods. 884 patients with compensated cirrhosis were prospectively followed up for at least five years, from August 1998 until August 2008, with at least one annual ultrasonography liver examination and serum alpha fetoprotein (AFP) measurement. Results. Among 884 patients, 72 (8.1%) developed a tumor with a median follow up of 21.4 months. In the hepatocellular carcinoma group, hepatitis C virus infection was the major etiological factor (65.3%), 56.9% (41/72) were male and the mean average age was 57 +/- 10 years. The annual incidence of hepatocellular carcinoma was 2.9%. 79.2% (57/72) of HCCs were detected within Milan Criteria, and the mean survival time was 52.3 months, significantly higher than for those outside Milan, with a mean time of 40.6 months (p = 0.0003). Conclusion. The annual incidence of HCC among this large series of Brazilian cirrhotic patients was around 2.9% with a detection rate of 8.1%, or a cumulative incidence rate over five years of 14.3%. The three variables related to HCC risk were low serum albumin [HR: 0.518 (0.46-0.78)], high AFP > 20 ng/mL [HR: 3.16 (1.86-5.38)], and ethnicity (Brazilian-East Asian descendants vs. other mixed Brazilian ethnicities) [HR: 2.86 (1.48-5.53)].
C1 [Paranagua-Vezozzo, Denise C.; Ono, Suzane K.; Alvarado-Mora, Monica V.; Farias, Alberto Q.; Alves, Venancio A. F.; Carrilho, Flair Jose] Sao Paulo Clin Liver Canc Grp, Sao Paulo, Brazil.
   [Paranagua-Vezozzo, Denise C.; Ono, Suzane K.; Alvarado-Mora, Monica V.; Farias, Alberto Q.; Cunha-Silva, Marlone; Franca, Joao I. D.; Carrilho, Flair Jose] Univ Sao Paulo, Dept Gastroenterol, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Dept Pathol, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Sherman, Morris] Univ Toronto, Dept Gastroenterol, Toronto, ON, Canada.
   [Sherman, Morris] Univ Hlth Network, Toronto, ON, Canada.
RP Paranagua-Vezozzo, DC (corresponding author), Univ Sao Paulo, Hepatol Branch, Dept Gastroenterol, Sch Med, Av Dr Eneas de Carvalho Aguiar 255, BR-05403000 Sao Paulo, Brazil.
EM denise.vezozzo@hc.fm.usp.br
RI Carrilho, Flair J/I-3046-2012; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014; Farias, Alberto/ABB-1291-2020
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; Farias,
   Alberto/0000-0002-5572-663X; Cunha-Silva, Marlone/0000-0002-4424-6606
FU Alves de Queiroz Family Fund for Research
FX The study was supported in part by Alves de Queiroz Family Fund for
   Research.
CR Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
   Chagas AL, 2009, BRAZ J MED BIOL RES, V42, P958, DOI 10.1590/S0100-879X2009005000019
   Coelho GR, 2009, TRANSPL P, V41, P1740, DOI 10.1016/j.transproceed.2009.01.104
   Colombo M., 1995, VIRAL HEPATITIS REV, V1, P65
   Davila JA, 2010, HEPATOLOGY, V52, P132, DOI 10.1002/hep.23615
   El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807
   El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001
   Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014
   Goncalves CS, 1997, REV INST MED TROP SP, V39, P165
   Jan CF, 2005, J GASTROEN HEPATOL, V20, P521, DOI 10.1111/j.1440-1746.2005.03602.x
   Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172
   Kikuchi LOO, 2009, J CLIN GASTROENTEROL, V43, P191, DOI 10.1097/MCG.0b013e31817ff199
   Kudo M, 2011, DIGEST DIS, V29, P339, DOI 10.1159/000327577
   Lee E, 2013, CLIN GASTROENTEROL H, V11, P437, DOI 10.1016/j.cgh.2012.11.029
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Michitaka K, 2010, J GASTROENTEROL, V45, P86, DOI 10.1007/s00535-009-0128-5
   Ripoll C, 2009, J HEPATOL, V50, P923, DOI 10.1016/j.jhep.2009.01.014
   Sangiovanni A, 2004, GASTROENTEROLOGY, V126, P1005, DOI 10.1053/j.gastro.2003.12.049
   Singal A, 2009, ALIMENT PHARM THER, V30, P37, DOI 10.1111/j.1365-2036.2009.04014.x
   Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05
   Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100
NR 23
TC 27
Z9 32
U1 0
U2 7
PU MEXICAN ASSOC HEPATOLOGY
PI MEXICO
PA PUNTE DE PIEDRA 150, COLONIA TORIELLO GUERRA, MEXICO, DF CP 14040,
   MEXICO
SN 1665-2681
J9 ANN HEPATOL
PD JUL-AUG
PY 2014
VL 13
IS 4
BP 386
EP 393
DI 10.1016/S1665-2681(19)30845-2
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AO6MX
UT WOS:000341467300008
PM 24927609
OA Other Gold
DA 2020-12-08
ER

PT J
AU Haddad, L
   Ducatti, L
   Malbouisson, LM
   Macedo, E
   Ohnishi, L
   Lima, C
   Andraus, W
   Carrilho, FJ
   D'Albuquerque, LAC
AF Haddad, Luciana
   Ducatti, Liliana
   Malbouisson, Luiz Marcelo
   Macedo, Etienne
   Ohnishi, Luis
   Lima, Camila
   Andraus, Wellington
   Carrilho, Flair Jose
   Carneiro D'Albuquerque, Luiz Augusto
TI Renal Insufficiency Leads To Increased Mortality in Post-Liver
   Transplantation.
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY JUN 04-07, 2014
CL London, ENGLAND
SP ILTS, ELITA, LICAGE
C1 [Haddad, Luciana; Ducatti, Liliana; Malbouisson, Luiz Marcelo; Macedo, Etienne; Ohnishi, Luis; Lima, Camila; Andraus, Wellington; Carrilho, Flair Jose; Carneiro D'Albuquerque, Luiz Augusto] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Andraus, Wellington/G-1860-2012; D'ALBUQUERQUE, Luiz Carneiro
   Augusto/I-4011-2012; Carrilho, Flair J/I-3046-2012; Haddad,
   Luciana/S-2436-2019; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013
OI Andraus, Wellington/0000-0002-5162-138X; Haddad,
   Luciana/0000-0003-0202-9037; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2014
VL 20
SU 1
MA P-478
BP S300
EP S300
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AM6FU
UT WOS:000339959602345
DA 2020-12-08
ER

PT J
AU Nacif, LS
   Vezozzo, DCP
   Matsuda, A
   Andraus, W
   Pinheiro, RS
   Ono, SK
   Carrilho, FJ
   D'Albuquerque, LC
AF Nacif, Lucas S.
   Vezozzo, Denise C. P.
   Matsuda, Alina
   Andraus, Wellington
   Pinheiro, Rafael S.
   Ono, Suzane K.
   Carrilho, Flair J.
   D'Albuquerque, Luiz C.
TI Diagnostic Accuracy of Elastography, Alfa Fetoprotein and Ultrasound
   Findings in Screening for Hepatocellular Carcinoma in Patients on Liver-
   Transplant Waiting List
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY JUN 04-07, 2014
CL London, ENGLAND
SP ILTS, ELITA, LICAGE
C1 [Nacif, Lucas S.; Vezozzo, Denise C. P.; Matsuda, Alina; Andraus, Wellington; Pinheiro, Rafael S.; Ono, Suzane K.; Carrilho, Flair J.; D'Albuquerque, Luiz C.] Gastroenterol Liver & Gastrointestinal Transplant, Sao Paulo, Brazil.
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Carrilho, Flair
   J/I-3046-2012; Andraus, Wellington/G-1860-2012; Nacif, Lucas
   S./B-2795-2013
OI Andraus, Wellington/0000-0002-5162-138X; Nacif, Lucas
   S./0000-0002-7059-3978
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2014
VL 20
SU 1
MA P-109
BP S184
EP S184
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AM6FU
UT WOS:000339959601258
DA 2020-12-08
ER

PT J
AU Silvestre, OM
   Bacal, F
   Ximenes, RO
   Carrilho, FJ
   D'Albuquerque, LAC
   Farias, AQ
AF Silvestre, Odilson Marcos
   Bacal, Fernando
   Ximenes, Rafael Oliveira
   Carrilho, Flair Jose
   Carneiro D'Albuquerque, Luiz Augusto
   Farias, Alberto Queiroz
TI Cardiohepatic Interactions - from Humoral Theory to Organ
   Transplantation
SO ARQUIVOS BRASILEIROS DE CARDIOLOGIA
LA English
DT Editorial Material
DE Heart failure; Hypertension, portal; Hepatic insufficiency; Liver
   diseases; Liver cirrhosis / complications
ID HEART-FAILURE; LIVER-DISEASE
C1 [Silvestre, Odilson Marcos; Bacal, Fernando] Univ Sao Paulo, Fac Med, Hosp Clin, Inst Coracao, Sao Paulo, Brazil.
   [Ximenes, Rafael Oliveira; Carrilho, Flair Jose; Carneiro D'Albuquerque, Luiz Augusto; Farias, Alberto Queiroz] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil.
RP Silvestre, OM (corresponding author), Ave Dr Eneas de Carvalho Aguiar 255,Sala 9117, BR-05403000 Sao Paulo, Brazil.
EM odilsonsilvestre@cardiol.br
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Farias,
   Alberto/ABB-1291-2020; Carrilho, Flair J/I-3046-2012; D'Albuquerque,
   Luiz Augusto Carneiro/A-8812-2013; Bacal, Fernando/H-7952-2012
OI Farias, Alberto/0000-0002-5572-663X; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; 
CR Farias AQ, 2014, HEPATOLOGY, V59, P1043, DOI 10.1002/hep.26643
   Gelow JM, 2010, CIRC-HEART FAIL, V3, P59, DOI 10.1161/CIRCHEARTFAILURE.109.872556
   Ocel JJ, 2004, MAYO CLIN PROC, V79, P492, DOI 10.4065/79.4.492
   Poelzl G, 2012, EUR J CLIN INVEST, V42, P153, DOI 10.1111/j.1365-2362.2011.02573.x
   Ruiz-del-Arbol L, 2005, HEPATOLOGY, V42, P439, DOI 10.1002/hep.20766
   Seeto RK, 2000, AM J MED, V109, P109, DOI 10.1016/S0002-9343(00)00461-7
   Silvestre OM, 2013, ANN HEPATOL, V12, P85, DOI 10.1016/S1665-2681(19)31389-4
   Zardi EM, 2010, J AM COLL CARDIOL, V56, P539, DOI 10.1016/j.jacc.2009.12.075
NR 8
TC 0
Z9 0
U1 0
U2 4
PU ARQUIVOS BRASILEIROS CARDIOLOGIA
PI RIO DE JANEIRO
PA AVENIDA MARECHAL CAMARA 160-330 CENTRO, RIO DE JANEIRO, RJ 20 020-907,
   BRAZIL
SN 0066-782X
J9 ARQ BRAS CARDIOL
JI Arq. Bras. Cardiol.
PD JUN
PY 2014
VL 102
IS 6
BP E65
EP E67
DI 10.5935/abc.20140079
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AL3FL
UT WOS:000339011700003
PM 25004427
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Barros, LMF
   Gomes-Gouvea, MS
   Kramvis, A
   Mendes-Correa, MCJ
   dos Santos, A
   Souza, LAB
   Santos, MDC
   Carrilho, FJ
   Domicini, AD
   Pinho, JRR
   Ferreira, ADP
AF Fonseca Barros, Lena Maria
   Gomes-Gouvea, Michele Soares
   Kramvis, Anna
   Jacintho Mendes-Correa, Maria Cassia
   dos Santos, Alexsandro
   Barros Souza, Leticia Alana
   Cruz Santos, Max Diego
   Carrilho, Flair Jose
   Domicini, Arnaldo de Jesus
   Rebello Pinho, Joao Renato
   Paiva Ferreira, Adalgisa de Souza
TI High prevalence of hepatitis B virus subgenotypes A1 and D4 in Maranhao
   state, Northeast Brazil
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Phylogenetics; Subgenotype A1; Subgenotype D4; Slave trade; Maranhao;
   Brazil
ID MOLECULAR CHARACTERIZATION; GENETIC DIVERSITY; PREGNANT-WOMEN;
   GENOTYPE-F; INFECTION; AFRICAN; HBV; POPULATION; MUTATIONS; PRECORE
AB In this study, we determined the prevalence of HBV subgenotypes in Maranhao state, located in northeastern Brazil, where the population is heterogeneous, with a high proportion of African descendants. HBV was detected in 119 of 133 (89.5%) chronic hepatitis B patients, including 103 (86.5%) who were HBeAg-negative. Using phylogenetic analysis of the S/Polymerase region of HBV DNA, subgenotype A1 was found to be the most prevalent (67%), followed by genotype D (28%; subgenotype D4 was detected in 24%, D3 in 3%, and D2 in 1%). Genotype F, clustering with subgenotype F2a, was found in six (5%) patients. The topology of the phylogenetic tree showed that HBV/A1 sequences did not cluster together, suggesting that more than one strain was introduced into Maranhao. On the other hand, HBV/D4 sequences formed a monophyletic cluster, suggesting a single entry of this strain in this population. This study showed that HBV/A1 was the only subgenotype of HBV/A present in the population from Maranhao and indicated that in this region HBV/A1 was not restricted to an Afro-descendant community where it was previously reported, but is widely distributed among general population of HBV chronic carriers.
   Unexpectedly, we found a high frequency of HBV subgenotype D4. Together with previously reported data on the distribution of HBV/D4 in the world, these findings suggest that this subgenotype was more prevalent in the African continent in the past and may have been introduced in Maranhao by means of the slave trade during the late XVIII century, when the largest number of African slaves arrived to this region. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Fonseca Barros, Lena Maria; dos Santos, Alexsandro; Barros Souza, Leticia Alana; Cruz Santos, Max Diego; Domicini, Arnaldo de Jesus; Paiva Ferreira, Adalgisa de Souza] Univ Fed Maranhao, Sao Luis, Maranhao, Brazil.
   [Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Lab Gastroenterol & Hepatol, Sao Paulo Inst Trop Med, Sao Paulo, Brazil.
   [Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Kramvis, Anna] Univ Witwatersrand, Sch Clin Med, Dept Internal Med, Hepatitis Virus Div Res Programme, Johannesburg, South Africa.
   [Jacintho Mendes-Correa, Maria Cassia] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
RP Gomes-Gouvea, MS (corresponding author), FMUSP, Inst Trop Med, Lab Gastroenterol & Hepatol Trop, Av Dr Eneas Carvalho de Aguiar 500, BR-05403000 Sao Paulo, Brazil.
EM gomesmic@yahoo.com.br
RI Carrilho, Flair J/I-3046-2012; Santos, Alexsandro dos/M-1969-2019;
   ferreira, adalgisa S P/G-8169-2016; correa, maria cassia
   mendes/A-6779-2013; Santos, Alexsandro/F-4717-2017; Pinho, Joao R.
   R./G-2850-2012
OI Santos, Alexsandro dos/0000-0003-3863-3869; Santos,
   Alexsandro/0000-0003-3863-3869; Pinho, Joao R. R./0000-0003-3999-0489;
   Kramvis, Anna/0000-0001-6006-3765
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2010/50081-9, 2010/51208-2]; Fundacao de
   Amparo a Pesquisa do Estado do Maranhao - FAPEMA [APP2009/00950];
   Secretaria de Sa de do Estado do Maranhao Departamento de Vigil ncia
   Epidemiologica
FX This work was supported by Sao Paulo Research Foundation (FAPESP) -
   grant 2010/50081-9 and 2010/51208-2; Fundacao de Amparo a Pesquisa do
   Estado do Maranhao - FAPEMA (APP2009/00950) and Secretaria de Sa de do
   Estado do Maranhao Departamento de Vigil ncia Epidemiologica.
CR Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Alvarado-Mora MV, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-415
   Andernach IE, 2009, EMERG INFECT DIS, V15, P1222, DOI 10.3201/eid1508.081642
   Araujo NM, 2011, INFECT GENET EVOL, V11, P1199, DOI 10.1016/j.meegid.2011.04.017
   Araujo NM, 2004, ARCH VIROL, V149, P1383, DOI 10.1007/s00705-003-0269-4
   Barros LMF, 2011, VIRUS RES, V160, P333, DOI 10.1016/j.virusres.2011.07.006
   Bertolini DA, 2006, BRAZ J MED BIOL RES, V39, P1083, DOI 10.1590/S0100-879X2006000800011
   Bertolini DA, 2012, INFECT GENET EVOL, V12, P1295, DOI 10.1016/j.meegid.2012.04.009
   Brichler S, 2013, J GEN VIROL, V94, P2318, DOI 10.1099/vir.0.055459-0
   Cooksley WGE, 2010, J VIRAL HEPATITIS, V17, P601, DOI 10.1111/j.1365-2893.2010.01326.x
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   El Khouri Marcelo, 2010, Arq. Gastroenterol., V47, P35, DOI 10.1590/S0004-28032010000100007
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
   Hudjashov G, 2007, P NATL ACAD SCI USA, V104, P8726, DOI 10.1073/pnas.0702928104
   Hubschen JM, 2009, J MED VIROL, V81, P435, DOI 10.1002/jmv.21412
   Klein H.S., 1986, SLAVERY PLANTATION E, P123
   Kramvis A, 2005, J VIRAL HEPATITIS, V12, P456, DOI 10.1111/j.1365-2893.2005.00624.x
   Kramvis A, 2008, J MED VIROL, V80, P27, DOI 10.1002/jmv.21049
   Kramvis A, 2013, ANTIVIR THER, V18, P513, DOI 10.3851/IMP2657
   Kurbanov F, 2010, HEPATOL RES, V40, P14, DOI 10.1111/j.1872-034X.2009.00601.x
   Lin CL, 2011, J GASTROEN HEPATOL, V26, P123, DOI 10.1111/j.1440-1746.2010.06541.x
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Braga WSM, 2012, REV SOC BRAS MED TRO, V45, P13, DOI 10.1590/S0037-86822012000100004
   Motta-Castro A, 2008, ARCH VIROL, V153, P2197, DOI 10.1007/s00705-008-0237-0
   Moura IF, 2013, INFECT GENET EVOL, V14, P195, DOI 10.1016/j.meegid.2012.11.022
   Nakano T, 2001, J GEN VIROL, V82, P359, DOI 10.1099/0022-1317-82-2-359
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   Osiowy C, 2011, J VIRAL HEPATITIS, V18, pe11, DOI 10.1111/j.1365-2893.2010.01356.x
   Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Pezzano SC, 2011, CLIN MICROBIOL INFEC, V17, P223, DOI 10.1111/j.1469-0691.2010.03283.x
   Santos AO, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-315
   Schaefer S, 2007, HEPATOL RES, V37, pS20, DOI 10.1111/j.1872-034X.2007.00099.x
   Silva D. B. D., 2008, SLAVERY ABOLIT, V29, P477
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Sitnik R, 2010, REV INST MED TROP SP, V52, P119, DOI 10.1590/S0036-46652010000300001
   Souto FJD, 1999, GASTROENTEROL ENDOSC, V18, P143
   Souto Francisco José Dutra, 2004, Rev. Soc. Bras. Med. Trop., V37, P63, DOI 10.1590/S0037-86822004000700010
   Souza MT, 2012, BRAZ J INFECT DIS, V16, P517, DOI 10.1016/j.bjid.2012.07.008
   Venegas M, 2008, ARCH VIROL, V153, P2129, DOI 10.1007/s00705-008-0231-6
   Victoria FD, 2008, BRAZ J INFECT DIS, V12, P27, DOI 10.1590/S1413-86702008000100008
   World Health Organization (WHO), 2002, GLOB AL RESP
   Yousif M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-328
   Yousif M, 2013, HEPATOL RES, V43, P355, DOI 10.1111/j.1872-034X.2012.01090.x
NR 47
TC 19
Z9 20
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUN
PY 2014
VL 24
BP 68
EP 75
DI 10.1016/j.meegid.2014.03.007
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA AG4GG
UT WOS:000335376800007
PM 24642137
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Silvestre, OM
   Garcia-Tsao, G
   Seguro, LFBD
   Mazo, DFD
   Bacal, F
   Andrade, JL
   Goncalves, LL
   Strunz, C
   Ramos, DS
   Polli, D
   Pugliese, V
   Rodrigues, ACT
   Furtado, MS
   Carrilho, FJ
   D'Albuquerque, LAC
AF Farias, Alberto Q.
   Silvestre, Odilson M.
   Garcia-Tsao, Guadalupe
   da Costa Seguro, Luis F. B.
   de Campos Mazo, Daniel F.
   Bacal, Fernando
   Andrade, Jose L.
   Goncalves, Luciana L.
   Strunz, Celia
   Ramos, Danusa S.
   Polli, Demerson
   Pugliese, Vincenzo
   Rodrigues, Ana C. T.
   Furtado, Meive S.
   Carrilho, Flair J.
   D'Albuquerque, Luiz A. C.
TI Serum B-type natriuretic peptide in the initial workup of patients with
   new onset ascites: A diagnostic accuracy study (vol 59, pg 1043. 2014)
SO HEPATOLOGY
LA English
DT Correction
RI Carrilho, Flair J/I-3046-2012; D'Albuquerque, Luiz Augusto
   Carneiro/A-8812-2013; Mazo, Daniel FC/D-5631-2015; Garcia-Tsao,
   Guadalupe/ABF-7374-2020; Farias, Alberto/ABB-1291-2020; Bacal,
   Fernando/H-7952-2012; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012;
   Ramos, Danusa/H-6276-2012
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Mazo, Daniel
   FC/0000-0002-2164-2630; Farias, Alberto/0000-0002-5572-663X; Ramos,
   Danusa/0000-0002-6713-5415
CR Farias AQ, 2014, HEPATOLOGY, V59, P1043, DOI 10.1002/hep.26643
NR 1
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD MAY
PY 2014
VL 59
IS 5
BP 2058
EP 2058
DI 10.1002/hep.27144
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AI9TA
UT WOS:000337278400051
OA Bronze
DA 2020-12-08
ER

PT J
AU Cavalcante, LN
   Stefano, JT
   Machado, M
   Rabelo, F
   Mazo, DC
   Angelo, ALD
   Abe-Sandes, K
   Lyra, LGC
   Carrilho, FJ
   Cortez-Pinto, H
   Lyra, AC
   Oliveira, CP
AF Cavalcante, L. N.
   Stefano, J. T.
   Machado, M.
   Rabelo, F.
   Mazo, D. C.
   Angelo, A. L. D.
   Abe-Sandes, K.
   Lyra, L. G. C.
   Carrilho, F. J.
   Cortez-Pinto, H.
   Lyra, A. C.
   Oliveira, C. P.
TI GENETIC ANCESTRY CHARACTERIZATION IN NAFLD PATIENTS FROM BRAZIL AND
   PORTUGAL
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Cavalcante, L. N.; Angelo, A. L. D.; Abe-Sandes, K.; Lyra, L. G. C.; Lyra, A. C.] San Rafael Hosp, Gastroenterol & Hepatol, Salvador, BA, Brazil.
   [Stefano, J. T.; Rabelo, F.; Mazo, D. C.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Clin Div,LIM 07, Sao Paulo, Brazil.
   [Machado, M.; Cortez-Pinto, H.] Univ Lisbon, Gastroenterol, P-1699 Lisbon, Portugal.
EM cpm@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose T/H-4792-2013;
   Cortez-Pinto, Helena/AAN-2712-2020; Carrilho, Flair J/I-3046-2012;
   Cortez-Pinto, Helena/A-3586-2012; Mazo, Daniel FC/D-5631-2015; Stefano,
   Jose Tadeu/AAH-5419-2020
OI Cortez-Pinto, Helena/0000-0002-8537-8744; Mazo, Daniel
   FC/0000-0002-2164-2630; Stefano, Jose Tadeu/0000-0002-0218-1920
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P797
BP S336
EP S336
DI 10.1016/S0168-8278(14)60958-2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5DT
UT WOS:000362828600214
DA 2020-12-08
ER

PT J
AU Nastri, AC
   Malta, F
   Faria, PL
   Oliveira, K
   Carrilho, F
   Pinho, JR
AF Nastri, A. C.
   Malta, F.
   Faria, P. L.
   Oliveira, K.
   Carrilho, F.
   Pinho, J. R.
TI COMBINATION OF IFNL4 AND IFNL3 HAPLOTYPES IMPROVES PREDICTION OF
   RESPONSE TO INTERFERON THERAPIES IN PATIENTS FROM AN ADMIXED POPULATION
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Nastri, A. C.] FMUSP, Infect & Parasit Dis, Sao Paulo, Brazil.
   [Malta, F.; Faria, P. L.; Oliveira, K.; Carrilho, F.; Pinho, J. R.] FMUSP, Gastroenterol, Sao Paulo, Brazil.
EM femalta@yahoo.com
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012; Malta,
   Fernanda/B-1316-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P1213
BP S493
EP S493
DI 10.1016/S0168-8278(14)61373-8
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5DT
UT WOS:000362828600629
DA 2020-12-08
ER

PT J
AU Oliveira, K
   Malta, F
   Nastri, AC
   Faria, P
   Widman, A
   Carrilho, F
   Pinho, JR
AF Oliveira, K.
   Malta, F.
   Nastri, A. C.
   Faria, P.
   Widman, A.
   Carrilho, F.
   Pinho, J. R.
TI HEPATIC EXPRESSION OF miRNA AND miR-33a TARGET GENES IN CHRONIC HCV
   INFECTION
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Oliveira, K.; Malta, F.; Faria, P.; Widman, A.; Carrilho, F.; Pinho, J. R.] FMUSP, Gastroenterol, Sao Paulo, Brazil.
   [Nastri, A. C.] FMUSP, Infect & Parasit Dis, Sao Paulo, Brazil.
EM femalta@yahoo.com
RI Malta, Fernanda/B-1316-2013; Pinho, Joao R. R./G-2850-2012; Carrilho,
   Flair J/I-3046-2012
OI Malta, Fernanda/0000-0001-8887-5060; Pinho, Joao R.
   R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P787
BP S333
EP S333
DI 10.1016/S0168-8278(14)60948-X
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5DT
UT WOS:000362828600204
DA 2020-12-08
ER

PT J
AU Rabelo, F
   Stefano, JT
   Lima, RV
   Seixas, M
   Patente, T
   Vanni, D
   Cavaleiro, AM
   Mazo, DC
   Carrilho, FJ
   Correa-Giannella, ML
   Oliveira, C
AF Rabelo, F.
   Stefano, J. T.
   Lima, R. V.
   Seixas, M.
   Patente, T.
   Vanni, D.
   Cavaleiro, A. M.
   Mazo, D. C.
   Carrilho, F. J.
   Correa-Giannella, M. L.
   Oliveira, C.
TI NADPH OXIDASE (NOX 4) AND P22PHOX GENE POLYMORPHISMS ARE ASSOCIATED WITH
   HUMAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Rabelo, F.; Stefano, J. T.; Lima, R. V.; Seixas, M.; Vanni, D.; Mazo, D. C.; Carrilho, F. J.; Oliveira, C.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Clin Div,LIM 07, Sao Paulo, Brazil.
   [Patente, T.; Cavaleiro, A. M.; Correa-Giannella, M. L.] Univ Sao Paulo, Sch Med, Lab Cellular & Mol Endocrinol LIM 25, Sao Paulo, Brazil.
EM cpm@usp.br
RI Carrilho, Flair J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014;
   Giannella, Maria Lucia/N-3834-2019; Mazo, Daniel FC/D-5631-2015;
   Stefano, Jose Tadeu/AAH-5419-2020; Stefano, Jose T/H-4792-2013
OI Mazo, Daniel FC/0000-0002-2164-2630; Stefano, Jose
   Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P796
BP S335
EP S335
DI 10.1016/S0168-8278(14)60957-0
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5DT
UT WOS:000362828600213
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Torres, MM
   Pereira, IVA
   Cogliati, B
   de Oliveira, MG
   Chammas, C
   Carrilho, FJ
   Oliveira, CP
AF Stefano, J. T.
   Torres, M. M.
   Pereira, I. V. A.
   Cogliati, B.
   de Oliveira, M. G.
   Chammas, C.
   Carrilho, F. J.
   Oliveira, C. P.
TI INTRATUMORAL INJECTION OF S-NITROSO-N-ACETYLCYSTEINE (SNAC) IN A RODENT
   MODEL OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR
   CARCINOMA (HCC)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Stefano, J. T.; Torres, M. M.; Pereira, I. V. A.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Hepatol Branch LIM 07, Clin Div, Div Gastroenterol,Sch Med, Sao Paulo, Brazil.
   [Cogliati, B.] Univ Sao Paulo, Dept Pathol, Sch Vet Med & Anim Sci, Sao Paulo, Brazil.
   [de Oliveira, M. G.] Univ Estadual Campinas, Inst Chem, Sao Paulo, Brazil.
   [Chammas, C.] Univ Sao Paulo, Sch Med, Dept Radiol, Sao Paulo, Brazil.
EM jstefano@usp.br
RI de Oliveira, Marcelo Ganzarolli/B-4709-2013; Stefano, Jose
   T/H-4792-2013; Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair
   J/I-3046-2012; Stefano, Jose Tadeu/AAH-5419-2020
OI de Oliveira, Marcelo Ganzarolli/0000-0002-9371-9975; Stefano, Jose
   Tadeu/0000-0002-0218-1920
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P262
BP S152
EP S152
DI 10.1016/S0168-8278(14)60424-4
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CS3HB
UT WOS:000361961700423
DA 2020-12-08
ER

PT J
AU Terrabuio, DRB
   Diniz, MA
   Abrantes-Lemos, CP
   Mello, ES
   Carrilho, FJ
   Cancado, E
   Souza, FG
AF Terrabuio, D. R. B.
   Diniz, M. A.
   Abrantes-Lemos, C. P.
   Mello, E. S.
   Carrilho, F. J.
   Cancado, E.
   Souza, F. G.
TI CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS ESPECIALLY
   IN PATIENTS WITH REACTIVITY TO ANTI-SLA
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Terrabuio, D. R. B.; Diniz, M. A.; Carrilho, F. J.; Cancado, E.; Souza, F. G.] Univ Sao Paulo, Sch Med, Gastroenterol, Sao Paulo, Brazil.
   [Abrantes-Lemos, C. P.; Cancado, E.] Univ Sao Paulo, Inst Trop Med, LIM 06, Sao Paulo, Brazil.
   [Mello, E. S.] Univ Sao Paulo, Sch Med, Clin Pathol, Sao Paulo, Brazil.
EM edulrc@uol.com.br
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016
OI Cancado, Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P360
BP S187
EP S187
DI 10.1016/S0168-8278(14)60522-5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CS3HB
UT WOS:000361961700521
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Silvestre, OM
   Garcia-Tsao, G
   Seguro, LFBD
   Mazo, DFD
   Bacal, F
   Andrade, JL
   Goncalves, LL
   Strunz, C
   Ramos, DS
   Polli, D
   Pugliese, V
   Rodrigues, ACT
   Furtado, MS
   Carrilho, FJ
   D'Albuquerque, LAC
AF Farias, Alberto Q.
   Silvestre, Odilson M.
   Garcia-Tsao, Guadalupe
   da Costa Seguro, Luis F. B.
   de Campos Mazo, Daniel F.
   Bacal, Fernando
   Andrade, Jose L.
   Goncalves, Luciana L.
   Strunz, Celia
   Ramos, Danusa S.
   Polli, Demerson
   Pugliese, Vincenzo
   Rodrigues, Ana C. T.
   Furtado, Meive S.
   Carrilho, Flair J.
   D'Albuquerque, Luiz A. C.
TI Serum B-Type Natriuretic Peptide in the Initial Workup of Patients With
   New Onset Ascites: A Diagnostic Accuracy Study
SO HEPATOLOGY
LA English
DT Article
ID CHRONIC HEART-FAILURE; EMERGENCY DIAGNOSIS; PLEURAL FLUID; LIVER SIEVE;
   ECHOCARDIOGRAPHY; MANAGEMENT; CIRRHOSIS; DISEASE; RECOMMENDATIONS;
   DYSFUNCTION
AB Heart failure (HF) is, after cirrhosis, the second-most common cause of ascites. Serum B-type natriuretic peptide (BNP) plays an important role in the diagnosis of HF. Therefore, we hypothesized that BNP would be useful in the differential diagnosis of ascites. Consecutive patients with new onset ascites were prospectively enrolled in this cross-sectional study. All patients had measurements of serum-ascites albumin gradient (SAAG), total protein concentration in ascitic fluid, serum, and ascites BNP. We enrolled 218 consecutive patients with ascites resulting from HF (n = 44), cirrhosis (n = 162), peritoneal disease (n = 10), and constrictive pericarditis (n = 2). Compared to SAAG and/or total protein concentration in ascites, the test that best discriminated HF-related ascites from other causes of ascites was serum BNP. A cutoff of >364 pg/mL (sensitivity 98%, specificity 99%, and diagnostic accuracy 99%) had the highest positive likelihood ratio (168.1); that is, it was the best to rule in HF-related ascites. Conversely, a cutoff 182 pg/mL had the lowest negative likelihood ratio (0.0) and was the best to rule out HF-related ascites. These findings were confirmed in a 60-patient validation cohort. Conclusions: Serum BNP is more accurate than ascites analyses in the diagnosis of HF-related ascites. The workup of patients with new onset ascites could be streamlined by obtaining serum BNP as an initial test and could forego the need for diagnostic paracentesis, particularly in cases where the cause of ascites is uncertain and/or could be the result of HF. (Hepatology 2014;59:1043-1051)
C1 [Farias, Alberto Q.; de Campos Mazo, Daniel F.; Ramos, Danusa S.; Pugliese, Vincenzo; Carrilho, Flair J.; D'Albuquerque, Luiz A. C.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Silvestre, Odilson M.; da Costa Seguro, Luis F. B.; Bacal, Fernando; Strunz, Celia] Univ Sao Paulo, Inst Heart, Sch Med, Sao Paulo, Brazil.
   [Garcia-Tsao, Guadalupe] Yale Univ, Sect Digest Dis, West Haven, CT USA.
   [Garcia-Tsao, Guadalupe] VA CT Healthcare Syst, West Haven, CT USA.
   [Andrade, Jose L.; Rodrigues, Ana C. T.; Furtado, Meive S.] Univ Sao Paulo, Sch Med, Inst Radiol, Sao Paulo, Brazil.
   [Goncalves, Luciana L.] Univ Fed Espirito Santo, Vitoria, ES, Brazil.
   [Polli, Demerson] Univ Brasilia, Dept Stat, Brasilia, DF, Brazil.
RP Farias, AQ (corresponding author), Hosp Clin USP, Ave Doutor Eneas de Carvalho Aguiar 255,Sala 911, BR-05403000 Sao Paulo, Brazil.
EM albertofarias@terra.com.br
RI Farias, Alberto/ABB-1291-2020; Strunz, Celia Maria Cassaro/L-4117-2019;
   Carrilho, Flair J/I-3046-2012; Strunz, Celia/G-5562-2011; D'ALBUQUERQUE,
   Luiz Carneiro Augusto/I-4011-2012; Ramos, Danusa/H-6276-2012; Bacal,
   Fernando/H-7952-2012; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   Mazo, Daniel FC/D-5631-2015; Garcia-Tsao, Guadalupe/ABF-7374-2020;
   Polli, Demerson/D-1212-2013
OI Farias, Alberto/0000-0002-5572-663X; Strunz, Celia Maria
   Cassaro/0000-0002-9766-1184; Strunz, Celia/0000-0002-9766-1184; Ramos,
   Danusa/0000-0002-6713-5415; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Mazo, Daniel FC/0000-0002-2164-2630;
   Polli, Demerson/0000-0002-5904-2315
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; Sao Paulo
   Research Foundation)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2011/09484-5]
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP; Sao Paulo Research Foundation; grant no.:
   2011/09484-5).
CR Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010
   CARLSON KJ, 1985, J CHRON DIS, V38, P733, DOI 10.1016/0021-9681(85)90115-8
   Christou L, 2007, SCAND J GASTROENTERO, V42, P1102, DOI 10.1080/00365520701272433
   Daniels LB, 2007, J AM COLL CARDIOL, V50, P2357, DOI 10.1016/j.jacc.2007.09.021
   Davis RC, 2002, BRIT MED J, V325, P1156, DOI 10.1136/bmj.325.7373.1156
   de Lemos JA, 2003, LANCET, V362, P316, DOI 10.1016/S0140-6736(03)13976-1
   Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309
   FRASER R, 1995, HEPATOLOGY, V21, P863, DOI 10.1016/0270-9139(95)90542-1
   Garcia-Tsao G, 2012, ZAKIM BOYERS HEPATOL, P283
   Henriksen JH, 2003, GUT, V52, P1511, DOI 10.1136/gut.52.10.1511
   HENRIKSEN JH, 1984, LIVER, V4, P221
   Jessup M, 2009, CIRCULATION, V119, P1977, DOI 10.1161/CIRCULATIONAHA.109.192064
   Kolditz M, 2006, EUR RESPIR J, V28, P144, DOI 10.1183/09031936.06.00113205
   Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005
   Maisel A, 2008, EUR J HEART FAIL, V10, P824, DOI 10.1016/j.ejheart.2008.07.014
   Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233
   Maisel AS, 2003, J AM COLL CARDIOL, V41, P2010, DOI 10.1016/S0735-1097(03)00405-4
   Mant J, 2009, HEALTH TECHNOL ASSES, V13, pIX, DOI 10.3310/hta13320
   Mant J, 2011, ANN INTERN MED, V155, P252, DOI 10.7326/0003-4819-155-4-201108160-00009
   Manzano-Fernandez Sergio, 2010, Congest Heart Fail, V16, P214, DOI 10.1111/j.1751-7133.2010.00153.x
   McCullough PA, 2003, AM J KIDNEY DIS, V41, P571, DOI 10.1053/ajkd.2003.50118
   MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601
   Mueller C, 2004, NEW ENGL J MED, V350, P647, DOI 10.1056/NEJMoa031681
   Nagueh SF, 2009, J AM SOC ECHOCARDIOG, V22, P107, DOI 10.1016/j.echo.2008.11.023
   Porcel JM, 2009, CHEST, V136, P671, DOI 10.1378/chest.09-0270
   REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896
   RIEDER H, 1992, J HEPATOL, V15, P237, DOI 10.1016/0168-8278(92)90042-N
   RUNYON BA, 1992, ANN INTERN MED, V117, P215, DOI 10.7326/0003-4819-117-3-215
   Runyon BA, 2009, HEPATOLOGY, V49, P2087, DOI 10.1002/hep.22853
   Sheer Todd A, 2010, J Clin Gastroenterol, V44, pe23, DOI 10.1097/MCG.0b013e318198113b
   STEVENSON LW, 1989, JAMA-J AM MED ASSOC, V261, P884, DOI 10.1001/jama.261.6.884
   Suttner Stefan W, 2004, Curr Opin Crit Care, V10, P336, DOI 10.1097/01.ccx.0000135513.26376.4f
   The Criteria Committee of the New York Heart Association, 1994, NOM CRIT DIAGN DIS H, P253, DOI DOI 10.3378/027.083.0506
   Tomcsanyi J, 2004, EUR J HEART FAIL, V6, P753, DOI 10.1016/j.ejheart.2003.11.017
   WHEELDON NM, 1993, Q J MED, V86, P17
   WISSE E, 1985, HEPATOLOGY, V5, P683, DOI 10.1002/hep.1840050427
   Yildiz R, 2005, J GASTROEN HEPATOL, V20, P1115, DOI 10.1111/j.1440-1746.2005.03906.x
   Zardi EM, 2010, J AM COLL CARDIOL, V56, P539, DOI 10.1016/j.jacc.2009.12.075
NR 38
TC 14
Z9 14
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD MAR
PY 2014
VL 59
IS 3
BP 1043
EP 1051
DI 10.1002/hep.26643
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AB4VH
UT WOS:000331787500033
PM 23907731
OA Bronze
DA 2020-12-08
ER

PT J
AU Kikuchi, L
   Menezes, M
   Chagas, AL
   Tani, CM
   Alencar, RSSM
   Diniz, MA
   Alves, VAF
   D'Albuquerque, LAC
   Carrilho, FJ
AF Kikuchi, Luciana
   Menezes, Marcos
   Chagas, Aline L.
   Tani, Claudia M.
   Alencar, Regiane S. S. M.
   Diniz, Marcio A.
   Alves, Venancio A. F.
   Carneiro D'Albuquerque, Luiz Augusto
   Carrilho, Flair Jose
TI Percutaneous radiofrequency ablation for early hepatocellular carcinoma:
   Risk factors for survival
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Hepatocellular carcinoma; Radiofrequency ablation; Overall survival;
   Disease-free survival
ID PROGNOSTIC-FACTORS; TRANSARTERIAL CHEMOEMBOLIZATION; ETHANOL INJECTION;
   METAANALYSIS; CIRRHOSIS; MULTICENTER; RESECTION; CRITERIA; CANCER; EASL
AB AIM: To evaluate outcomes of radiofrequency ablation (RFA) therapy for early hepatocellular carcinoma (HCC) and identify survival-and recurrence-related factors.
   METHODS: Consecutive patients diagnosed with early HCC by computed tomography (CT) or magnetic resonance imaging (MRI) (single nodule of <= 5 cm, or multi-(up to 3) nodules of <= 3 cm each) and who underwent RFA treatment with curative intent between January 2010 and August 2011 at the Instituto do Cancer do Estado de Sao Paulo, Brazil were enrolled in the study. RFA of the liver tumors (with 1.0 cm ablative margin) was carried out under CT-fluoro scan and ultrasonic image guidance of the percutaneous ablation probes. Procedure-related complications were recorded. At 1-mo post-RFA and 3-mo intervals thereafter, CT and MRI were performed to assess outcomes of complete response (absence of enhancing tissue at the tumor site) or incomplete response (enhancing tissue remaining at the tumor site). Overall survival and disease-free survival rates were estimated by the Kaplan-Meier method and compared by the log rank test or simple Cox regression. The effect of risk factors on survival was assessed by the Cox proportional hazard model.
   RESULTS: A total of 38 RFA sessions were performed during the study period on 34 patients (age in years: mean, 63 and range, 49-84). The mean follow-up time was 22 mo (range, 1-33). The study population showed predominance of male sex (76%), less severe liver disease (Child-Pugh A, n = 26; Child-Pugh B, n = 8), and single tumor (65%). The maximum tumor diameters ranged from 10 to 50 mm (median, 26 mm). The initial (immediately post-procedure) rate of RFA-induced complete tumor necrosis was 90%. The probability of achieving complete response was significantly greater in patients with a single nodule (vs patients with multi-nodules, P = 0.04). Two patients experienced major complications, including acute pulmonary edema (resolved with intervention) and intestinal perforation (led to death). The 1- and 2-year overall survival rates were 82% and 71%, respectively. Sex, tumor size, initial response, and recurrence status influenced survival, but did not reach the threshold of statistical significance. Child-Pugh class and the model for end-stage liver disease score were identified as predictors of survival by simple Cox regression, but only Child-Pugh class showed a statistically significant association to survival in multiple Cox regression analysis (HR = 15; 95% CI: 3-76 mo; P = 0.001). The 1- and 2-year cumulative disease-free survival rates were 65% and 36%, respectively.
   CONCLUSION: RFA is an effective therapy for local tumor control of early HCC, and patients with preserved liver function are the best candidates. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
C1 [Kikuchi, Luciana; Chagas, Aline L.; Tani, Claudia M.; Alencar, Regiane S. S. M.; Diniz, Marcio A.; Carneiro D'Albuquerque, Luiz Augusto; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hosp Clin,Sao Paulo Clin Liver Canc Grp,Inst Canc, BR-01246000 Sao Paulo, Brazil.
   [Menezes, Marcos] Univ Sao Paulo, Sch Med, Dept Radiol, Hosp Clin,Sao Paulo Clin Liver Canc Grp,Inst Canc, BR-01246000 Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, Hosp Clin,Sao Paulo Clin Liver Canc Grp,Inst Canc, BR-01246000 Sao Paulo, Brazil.
RP Kikuchi, L (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hosp Clin,Sao Paulo Clin Liver Canc Grp,Inst Canc, 255 Arnaldo Ave, BR-01246000 Sao Paulo, Brazil.
EM lucianakikuchi@usp.br
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Carrilho, Flair
   J/I-3046-2012; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013; Chagas,
   Aline Lopes/X-2059-2019
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Diniz, Marcio
   Augusto/0000-0002-2427-7843
FU Alves de Queiroz Family Fund for Research
FX Supported by Alves de Queiroz Family Fund for Research
CR Borie F, 2008, J SURG ONCOL, V98, P505, DOI 10.1002/jso.21159
   Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011
   Bouza C, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-31
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Duan CY, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-190
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Gillmore R, 2011, J HEPATOL, V55, P1309, DOI 10.1016/j.jhep.2011.03.007
   Kaibori M, 2013, WORLD J SURG, V37, P820, DOI 10.1007/s00268-013-1902-3
   Kikuchi L, 2013, ANTIVIR THER, V18, P445, DOI 10.3851/IMP2602
   Kim JH, 2011, ANN SURG ONCOL, V18, P1624, DOI 10.1245/s10434-011-1673-8
   Koike Y, 2000, HEPATOLOGY, V32, P1216, DOI 10.1053/jhep.2000.20237
   Lausen B, 1994, CONTR STAT, P483
   Lencioni R, 2005, RADIOLOGY, V234, P961, DOI 10.1148/radiol.2343040350
   Lencioni R, 2010, HEPATOLOGY, V52, P762, DOI 10.1002/hep.23725
   Livraghi T, 2003, RADIOLOGY, V226, P441, DOI 10.1148/radiol.2262012198
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Mazzaferro V, 2004, ANN SURG, V240, P900, DOI 10.1097/01.sla.0000143301.56154.95
   Minagawa M, 2003, ANN SURG, V238, P703, DOI 10.1097/01.sla.0000094549.11754.e6
   N'Kontchou G, 2009, HEPATOLOGY, V50, P1475, DOI 10.1002/hep.23181
   Ni JY, 2013, WORLD J GASTROENTERO, V19, P3872, DOI 10.3748/wjg.v19.i24.3872
   Orlando A, 2009, AM J GASTROENTEROL, V104, P514, DOI 10.1038/ajg.2008.80
   Peng ZW, 2012, RADIOLOGY, V262, P689, DOI 10.1148/radiol.11110637
   Piscaglia F, 2013, DIGEST LIVER DIS, V45, P852, DOI 10.1016/j.dld.2013.03.002
   Pompili M, 2013, J HEPATOL, V59, P89, DOI 10.1016/j.jhep.2013.03.009
   Sala M, 2004, HEPATOLOGY, V40, P1352, DOI 10.1002/hep.20465
   Shiina S, 2012, AM J GASTROENTEROL, V107, P569, DOI 10.1038/ajg.2011.425
   Takahashi S, 2007, ONCOLOGY-BASEL, V72, P98, DOI 10.1159/000111714
   Tateishi R, 2005, CANCER-AM CANCER SOC, V103, P1201, DOI 10.1002/cncr.20892
   Yan K, 2008, EUR J RADIOL, V67, P336, DOI 10.1016/j.ejrad.2007.07.007
NR 29
TC 14
Z9 17
U1 0
U2 9
PU BAISHIDENG PUBL GRP CO LTD
PI WANCHAI
PA ROOM 1701, 17-F, HENAN BUILDING, NO. 90, JAFFE RD, WANCHAI, HONG KONG
   100025, PEOPLES R CHINA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD FEB 14
PY 2014
VL 20
IS 6
BP 1585
EP 1593
DI 10.3748/wjg.v20.i6.1585
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AB2HH
UT WOS:000331613300019
PM 24587635
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Couto, CA
   Bittencourt, PL
   Porta, G
   Abrantes-Lemos, CP
   Carrilho, FJ
   Guardia, BD
   Cancado, ELR
AF Couto, Claudia A.
   Bittencourt, Paulo L.
   Porta, Gilda
   Abrantes-Lemos, Clarice P.
   Carrilho, Flair J.
   Guardia, Bianca D.
   Cancado, Eduardo L. R.
TI Antismooth Muscle and Antiactin Antibodies Are Indirect Markers of
   Histological and Biochemical Activity of Autoimmune Hepatitis
SO HEPATOLOGY
LA English
DT Article
ID SOLUBLE LIVER ANTIGEN; SERUM AUTOANTIBODIES; F-ACTIN; TYPE-1; DIAGNOSIS;
   CLASSIFICATION; HETEROGENEITY; CHILDHOOD
AB Reactivity and titers of autoantibodies vary during the course of autoimmune hepatitis (AIH), and some autoantibodies have been associated with disease activity and adverse outcomes after treatment. The aim of this study was to assess the autoantibody behavior in AIH and its significance as predictors of biochemical and histological remission. A total of 117 patients with AIH (mean age 18.6 [4-69] years) were evaluated and tested for autoantibodies at disease onset and successively (mean 3.2 [2-6] times) after a mean follow-up evaluation of 70 [20-185] months. Antismooth muscle (ASMA), antiliver kidney microsome type 1 (anti-LKM1), antiliver cytosol type 1 (anti-LC1), antimitochondrial, antinuclear (ANA), and antiactin antibodies (AAA) were determined at disease onset and 379 other times during the follow-up evaluation through indirect immunofluorescence in rodent tissues, HEp-2 cells, and human fibroblasts. Anti-SLA/LP were assessed 45 times in the follow-up evaluation of 19 patients using enzyme-linked immunosorbent assay (ELISA). Upon admission, AIH types 1 and 2 were observed in 95 and 17 patients, respectively. Five subjects had AIH with anti-SLA/LP as the sole markers. Patients initially negative for AAA did not develop these antibodies thereafter. ANA were detected de novo in six and three subjects with AIH types 1 and 2, respectively. After treatment, only ASMA (>1:80) and AAA (>1:40) were significantly associated with biochemical (76.9% and 79.8%) and histological features (100% and 100%) of disease activity (P<0.001). Conclusion: With the exception of ANA, the autoantibody profile does not markedly vary in the course of AIH. The persistence of high titers of ASMA and/or AAA in patients with AIH is associated with disease activity. (Hepatology 2014;59:592-600)
C1 [Couto, Claudia A.] Univ Fed Minas Gerais, Sch Med, Dept Internal Med, Belo Horizonte, MG, Brazil.
   [Couto, Claudia A.] Univ Fed Minas Gerais, Univ Hosp, Alfa Inst Gastroenterol, Belo Horizonte, MG, Brazil.
   [Bittencourt, Paulo L.] Portuguese Hosp, Unit Gastroenterol & Hepatol, Salvador, BA, Brazil.
   [Porta, Gilda] Univ Sao Paulo, Sch Med, Children Inst, Sao Paulo, Brazil.
   [Abrantes-Lemos, Clarice P.; Cancado, Eduardo L. R.] Univ Sao Paulo, Inst Trop Med, Lab Med Invest LIM 06, Sao Paulo, Brazil.
   [Carrilho, Flair J.; Guardia, Bianca D.; Cancado, Eduardo L. R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Cancado, ELR (corresponding author), Rua Alves Guimaraes 1133-102, BR-0510002 Sao Paulo, Brazil.
EM eduardocancado@usp.br
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016; Couto,
   Claudia Alves/H-7420-2013; BITTENCOURT, PAULO l/I-5817-2014
OI Cancado, Eduardo/0000-0002-9309-1524; Couto, Claudia
   Alves/0000-0002-9776-4757; BITTENCOURT, PAULO l/0000-0003-0883-4870
FU CNPq (Research Council of Brazil); Alves de Queiroz Family Research
   Fund; Federico Foundation
FX Supported by CNPq (Research Council of Brazil), Alves de Queiroz Family
   Research Fund, and Federico Foundation.
CR Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
   Baeres M, 2002, GUT, V51, P259, DOI 10.1136/gut.51.2.259
   Ballot E, 2000, J HEPATOL, V33, P208, DOI 10.1016/S0168-8278(00)80361-X
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Cancado ELR, 2001, J AUTOIMMUN, V17, P223, DOI 10.1006/jaut.2001.0540
   Cassani F, 1997, HEPATOLOGY, V26, P561, DOI 10.1002/hep.510260305
   Czaja AJ, 1996, HEPATOLOGY, V24, P1068
   Czaja AJ, 1999, J HEPATOL, V30, P394, DOI 10.1016/S0168-8278(99)80096-8
   Czaja AJ, 2002, HEPATOLOGY, V36, P479, DOI 10.1053/jhep.2002.34944
   Czaja AJ, 2002, J HEPATOL, V37, P302, DOI 10.1016/S0168-8278(02)00182-4
   Czaja AJ, 2002, AM J GASTROENTEROL, V97, P413
   DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
   Gayotto LCC, 2000, GED, V19, P137
   Granito A, 2006, J CLIN PATHOL, V59, P280, DOI 10.1136/jcp.2005.027367
   Gregorio GV, 2001, HEPATOLOGY, V33, P544, DOI 10.1053/jhep.2001.22131
   Gregorio GV, 2002, AUTOIMMUNITY, V35, P515, DOI 10.1080/0891693021000056721
   HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
   JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435
   Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   Ma Y, 2002, HEPATOLOGY, V35, P658, DOI 10.1053/jhep.2002.32092
   MANNS M, 1987, LANCET, V1, P292
   Manns MP, 2010, HEPATOLOGY, V51, P2193, DOI 10.1002/hep.23584
   Mehendiratta V, 2009, CLIN GASTROENTEROL H, V7, P98, DOI 10.1016/j.cgh.2008.08.043
   Miyake Y, 2009, HEPATOL RES, V39, P241, DOI 10.1111/j.1872-034X.2008.00454.x
   Muratori L, 1998, GUT, V42, P721, DOI 10.1136/gut.42.5.721
   NORBERG R, 1979, EUR J BIOCHEM, V100, P575, DOI 10.1111/j.1432-1033.1979.tb04204.x
   Vergani D, 2004, J HEPATOL, V41, P677, DOI 10.1016/j.jhep.2004.08.002
   Vuppalanchi R, 2012, HEPATOL INT, V6, P379, DOI 10.1007/s12072-011-9277-8
NR 30
TC 47
Z9 58
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD FEB
PY 2014
VL 59
IS 2
BP 592
EP 600
DI 10.1002/hep.26666
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 298FT
UT WOS:000330310300025
PM 23929663
OA Bronze
DA 2020-12-08
ER

PT J
AU Linhares, LM
   Alvares-da-Silva, MR
   Oliveira, CP
   Stefano, JT
   Gebrim, EM
   Carrilho, FJ
   D'Albuquerque, LC
AF Linhares, Livia M.
   Alvares-da-Silva, Mario R.
   Oliveira, Claudia P.
   Stefano, Jose Tadeu
   Gebrim, Eloisa M.
   Carrilho, Flair J.
   D'Albuquerque, Luiz C.
TI Coronary artery calcium score in evaluating cardiovascular risk 1 and 4
   years after liver transplant
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 07-11, 2014
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Linhares, Livia M.; Oliveira, Claudia P.; Stefano, Jose Tadeu; Carrilho, Flair J.; D'Albuquerque, Luiz C.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Gebrim, Eloisa M.] Univ Sao Paulo, Sch Med, Dept Radiol, Sao Paulo, Brazil.
   [Alvares-da-Silva, Mario R.] Univ Fed Rio Grande do Sul, Sch Med, Div Gastroenterol, Porto Alegre, RS, Brazil.
RI Stefano, Jose Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014;
   Stefano, Jose T/H-4792-2013; D'ALBUQUERQUE, Luiz Carneiro
   Augusto/I-4011-2012; Carrilho, Flair J/I-3046-2012
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PY 2014
VL 60
SU 1
SI SI
MA 542
BP 464A
EP 464A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AS8EW
UT WOS:000344483802039
DA 2020-12-08
ER

PT J
AU Kikuchi, L
   Oliveira, CP
   Carrilho, FJ
AF Kikuchi, Luciana
   Oliveira, Claudia P.
   Carrilho, Flair J.
TI Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID NATURAL-HISTORY; DIABETES INCREASES; RISK-FACTORS; STEATOHEPATITIS;
   CIRRHOSIS; OBESITY; CANCER; COHORT; GENE; MICE
AB Hepatocellular carcinoma (HCC) incidence is increasing worldwide in recent years. Most HCC cases develop in the presence of advanced chronic liver disease related to chronic hepatitis C virus (HCV) infection, chronic hepatitis B (HBV) infection, and alcohol abuse. Approximately 15-50% of HCC cases are classified as idiopathic, suggesting that other risk factors are responsible for its rising incidence. Recent studies suggest that nonalcoholic fatty liver disease (NAFLD) can be associated with these "idiopathic" cases. NAFLD progresses slowly and can develop into liver cirrhosis, liver failure, and HCC. In the last few years, NAFLD has received more attention because of its high prevalence worldwide.
C1 [Kikuchi, Luciana; Oliveira, Claudia P.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Inst Canc Estado Sao Paulo, Sao Paulo Clin Liver Canc Grp,Hosp Clin,Dept Gast, BR-05403000 Sao Paulo, Brazil.
RP Oliveira, CP (corresponding author), Univ Sao Paulo, Sch Med, Inst Canc Estado Sao Paulo, Sao Paulo Clin Liver Canc Grp,Hosp Clin,Dept Gast, Ave Dr Eneas de Carvalho Aguiar 255, BR-05403000 Sao Paulo, Brazil.
EM cpm@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012
FU Alves de Queiroz Family Fund for Research
FX The authors would like to thank Alves de Queiroz Family Fund for
   Research for their support of our continued work.
CR Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014
   Ascha MS, 2010, HEPATOLOGY, V51, P1972, DOI 10.1002/hep.23527
   Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
   Bugianesi E, 2007, Clin Liver Dis, V11, P191, DOI 10.1016/j.cld.2007.02.006
   Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003
   Chagas AL, 2009, BRAZ J MED BIOL RES, V42, P958, DOI 10.1590/S0100-879X2009005000019
   Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167
   de Lima VM, 2008, J HEPATOL, V49, P1055, DOI 10.1016/j.jhep.2008.07.024
   El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065
   El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013
   Harrison SA, 2003, AM J GASTROENTEROL, V98, P2042, DOI 10.1016/S0002-9270(03)00622-1
   Hashimoto E, 2009, J GASTROENTEROL, V44, P89, DOI 10.1007/s00535-008-2262-x
   Hoshida Y, 2012, CURR CANCER DRUG TAR, V12, P1129
   Hu WW, 2002, CARCINOGENESIS, V23, P1781, DOI 10.1093/carcin/23.11.1781
   *IARC, 2002, IARC HDB CANC PREV
   Kahn CR, 1995, ENDOCRINOLOGY, P1373
   KASAI H, 1989, CANCER RES, V49, P2603
   Kim H, 2004, J HEPATOL, V40, P298, DOI 10.1016/j.jhep.2003.10.023
   Kodama K, 2013, ALCOHOL CLIN EXP RES, V37, pE247, DOI 10.1111/j.1530-0277.2012.01900.x
   Kubrusly MS, 2010, HISTOL HISTOPATHOL, V25, P1123, DOI 10.14670/HH-25.1123
   Leclerq I. A., 2000, HEPATOLOGY, V32
   Li Xiao, 2005, Hepatobiliary Pancreat Dis Int, V4, P427
   Marrero JA, 2002, HEPATOLOGY, V36, P1349, DOI 10.1053/jhep.2002.36939
   McCullough Arthur J, 2004, Clin Liver Dis, V8, P521, DOI 10.1016/j.cld.2004.04.004
   Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76
   Nair S, 2002, HEPATOLOGY, V36, P150, DOI 10.1053/jhep.2002.33713
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Pitot HC, 2001, LANCET, V358, P859, DOI 10.1016/S0140-6736(01)06038-X
   Roskams T, 2003, AM J PATHOL, V163, P1301, DOI 10.1016/S0002-9440(10)63489-X
   Sato W, 2006, HEPATOL RES, V34, P256, DOI 10.1016/j.hepres.2006.01.003
   Stefano JT, 2011, LIVER INT, V31, P377, DOI 10.1111/j.1478-3231.2010.02370.x
   Wideroff L, 1997, J NATL CANCER I, V89, P1360, DOI 10.1093/jnci/89.18.1360
   Yan SQ, 2001, CANCER RES, V61, P5016
   Zumoff B, 1988, Acta Med Scand Suppl, V723, P153
NR 36
TC 29
Z9 33
U1 0
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 106247
DI 10.1155/2014/106247
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AD5MQ
UT WOS:000333297600001
PM 24738043
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Duarte, SMB
   Faintuch, J
   Stefano, JT
   de Oliveira, MBS
   Mazo, DFD
   Rabelo, F
   Vanni, D
   Nogueira, MA
   Carrilho, FJ
   de Oliveira, CPMS
AF Bezerra Duarte, Sebastiao Mauro
   Faintuch, Joel
   Stefano, Jose Tadeu
   Sobral de Oliveira, Maria Beatriz
   de Campos Mazo, Daniel Ferraz
   Rabelo, Fabiola
   Vanni, Denise
   Nogueira, Monize Aydar
   Carrilho, Flair Jose
   Marques Souza de Oliveira, Claudia Pinto
TI Hypocaloric high-protein diet improves clinical and biochemical markers
   in patients with nonalcoholic fatty liver disease (NAFLD)
SO NUTRICION HOSPITALARIA
LA English
DT Article
DE NAFLD; Hypocaloric diet; Hyperproteic diet; Liver enzymes; Weight loss
ID WEIGHT-LOSS; INSULIN-RESISTANCE; METABOLIC SYNDROME; STEATOHEPATITIS;
   GLUCOSE; TRANSAMINASES; CARBOHYDRATE; ASSOCIATION; HOMEOSTASIS;
   MANAGEMENT
AB Objective: To investigate the role of hypocaloric high-protein diet, a prospective clinical study was conducted in NAFLD patients.
   Research methods and procedures: Pre-versus post-interventional data were analyzed in 48 stable NAFLD patients (submitted to a hypocaloric high-protein diet during 75 days. Variables included anthropometrics (body mass index/ BMI and waist circumference/WC), whole-body and segmental bioimpedance analysis and biochemical tests. Diet compliance was assessed by interviews every two weeks.
   Results: BMI, WC and body fat mass remained relatively stable (-1.3%, -1.8% and -2.5% respectively, no significance). HDL- cholesterol increased (P < 0.05) whereas total, LDL and VLDL cholesterol, triglycerides, aspartate aminotransferase/AST, gamma glutamyltransferase/GGT, alkaline phosphatase/AP, fasting blood glucose and glycated hemoglobin/HbA1c decreased (P < 0.05). When patients were stratified according to increase (22/48, 45.8%) and decrease (21/48, 43.8%) of BMI, association between weight decrease and liver benefit could be elicited in such circumstances for ALT, AP and AST/ALT ratio. No change could be demonstrated in patients who gained weight. Multivariate assessment confirmed that waist circumference, ferritin, triacylglycerol, and markers of glucose homeostasis were the most relevant associated with liver enzymes.
   Discussion: Ours results are consistent with the literature of calorie restriction in the management of NAFLD. Changes in lifestyle and weight loss are recommended for NAFLD patients. European guidelines also support this recommendation.
   Conclusion: This is the first study that demonstrated that a high protein, hypocaloric diet were associated with improvement of lipid profile, glucose homeostasis and liver enzymes in NAFLD independent on BMI decrease or body fat mass reduction.
C1 [Bezerra Duarte, Sebastiao Mauro; Stefano, Jose Tadeu; Sobral de Oliveira, Maria Beatriz; de Campos Mazo, Daniel Ferraz; Rabelo, Fabiola; Vanni, Denise; Nogueira, Monize Aydar; Carrilho, Flair Jose; Marques Souza de Oliveira, Claudia Pinto] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Clin Div,Hepatol Branch LIM 07, BR-05403000 Sao Paulo, Brazil.
   [Faintuch, Joel] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
RP de Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas de Carvalho Aguiar,255 Inst Cent,9159, BR-05403000 Sao Paulo, Brazil.
EM cpm@usp.br
RI Carrilho, Flair J/I-3046-2012; Mazo, Daniel FC/D-5631-2015; Oliveira,
   Claudia PMS/D-1216-2014; Stefano, Jose Tadeu/AAH-5419-2020; DUARTE,
   Sebastiao Mauro/B-6075-2017; Stefano, Jose T/H-4792-2013
OI Mazo, Daniel FC/0000-0002-2164-2630; Stefano, Jose
   Tadeu/0000-0002-0218-1920; 
CR Angulo P, 2007, NUTR REV, V65, pS57, DOI [10.1111/j.1753-4887.2007.tb00329.x, 10.1301/nr.2007.jun.S57-S63]
   Bortolotti M, 2011, CLIN NUTR, V30, P494, DOI 10.1016/j.clnu.2011.01.006
   Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466
   Burza MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060495
   Catalano D, 2008, LIVER INT, V28, P1280, DOI 10.1111/j.1478-3231.2008.01742.x
   Cave M, 2007, J NUTR BIOCHEM, V18, P184, DOI 10.1016/j.jnutbio.2006.12.006
   Chalasani N, 2012, GASTROENTEROLOGY, V142, P1592, DOI 10.1053/j.gastro.2012.04.001
   Clifton PM, 2008, AM J CLIN NUTR, V87, P23
   de Luis DA, 2008, DIABETES RES CLIN PR, V79, P74, DOI 10.1016/j.diabres.2007.07.015
   de Luis DA, 2010, NUTR HOSP, V25, P730, DOI 10.3305/nh.2010.25.5.4643
   de Wit NJW, 2012, J HEPATOL, V57, P1370, DOI 10.1016/j.jhep.2012.07.003
   Dixon JB, 2006, OBES SURG, V16, P1278, DOI 10.1381/096089206778663805
   Ellrott Thomas, 2013, MMW Fortschr Med, V155, P49
   George AS, 2009, J GASTROEN HEPATOL, V24, P399, DOI 10.1111/j.1440-1746.2008.05694.x
   Grundy SM, 2004, ARTERIOSCL THROM VAS, V24, pE19, DOI 10.1161/01.ATV.0000112379.88385.67
   Haufe S, 2011, HEPATOLOGY, V53, P1504, DOI 10.1002/hep.24242
   Haukeland JW, 2005, SCAND J GASTROENTERO, V40, P1469, DOI 10.1080/00365520500264953
   Huang MA, 2005, AM J GASTROENTEROL, V100, P1072, DOI 10.1111/j.1572-0241.2005.41334.x
   Kang HL, 2006, AM J GASTROENTEROL, V101, P2247, DOI 10.1111/j.1572-0241.2006.00719.x
   LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158
   Maersk M, 2012, AM J CLIN NUTR, V95, P283, DOI 10.3945/ajcn.111.022533
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   McCarthy EM, 2012, J ACAD NUTR DIET, V112, P401, DOI 10.1016/j.jada.2011.10.007
   Oliveira LPM, 2012, NUTR HOSP, V27, P991, DOI 10.3305/nh.2012.27.4.5833
   Peng LJ, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003619.pub3
   Ratziu V, 2010, J HEPATOL, V53, P372, DOI 10.1016/j.jhep.2010.04.008
   Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748
   Scaglioni F, 2012, CLIN RES HEPATOL GAS
   Schugar RC, 2012, CURR OPIN CLIN NUTR, V15, P374, DOI 10.1097/MCO.0b013e3283547157
   Schwarz J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047303
   Shapiro JR, 2012, PREV MED, V55, P412, DOI 10.1016/j.ypmed.2012.08.011
   Utzschneider KM, 2006, J CLIN ENDOCR METAB, V91, P4753, DOI 10.1210/jc.2006-0587
   Utzschneider KM, 2013, BRIT J NUTR, V109, P1096, DOI 10.1017/S0007114512002966
   Vilar L, 2008, NUTRITION, V24, P1097, DOI 10.1016/j.nut.2008.05.017
   Wycherley TP, 2013, EUR J NUTR, V52, P317, DOI 10.1007/s00394-012-0338-0
   Yasutake K, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/859697
   Zivkovic AM, 2007, AM J CLIN NUTR, V86, P285
NR 37
TC 21
Z9 23
U1 0
U2 6
PU ARAN EDICIONES, S L
PI MADRID
PA C/ CASTELLO, 128, 1O, MADRID, 28006, SPAIN
SN 0212-1611
EI 1699-5198
J9 NUTR HOSP
JI Nutr. Hosp.
PD JAN
PY 2014
VL 29
IS 1
BP 94
EP 101
DI 10.3305/nh.2014.29.1.7068
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AA8IV
UT WOS:000331340100013
PM 24483967
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Gouveia, S
   Gomes, L
   Ribeiro, C
   Carrilho, F
AF Gouveia, Sofia
   Gomes, Leonor
   Ribeiro, Cristina
   Carrilho, Francisco
TI Screening for autoimmune polyglandular syndrome in a cohort of patients
   with type 1 diabetes mellitus
SO ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA
LA Portuguese
DT Article
DE Autoimmune polyendocrinopathies; type 1 diabetes mellitus; Addison
   disease; thyroiditis; gastritis; celiac disease
ID DISEASE; POLYENDOCRINOPATHY; AUTOANTIBODIES; DIAGNOSIS
AB Objective: To characterize a cohort of patients with type 1 diabetes mellitus (T1DM) on the presence of other autoimmune disorders that could establish the diagnosis of autoimmune polyglandular syndrome (APS). Subjects and methods: We included 151 patients with T1DM. The following clinical parameters were analyzed: gender, current age, disease duration, previous history of autoimmune disorders, and familial history for diabetes mellitus. Each patient was analyzed to detect autoimmune markers of thyroiditis, adrenocortical insufficiency, gastritis, and celiac disease, as well as possible associated dysfunctions. Results: A cohort with 51.7% males, average current age of 33.4 +/- 13 years and disease duration of 14.4 +/- 9.6 years was analyzed. Previous history of autoimmunity was found in 2%, and familial history for diabetes mellitus in 31.1% of the cohort. Frequency of autoimmune markers was 24% for thyroiditis, 9.4% for adrenocortical insufficiency, 17.2% for gastritis, and 2% for celiac disease. APS was diagnosed on 25.2% of the patients. APS and autoimmune thyroiditis risk was higher in females. Disease duration correlated directly with gastric autoantibodies, and inversely with positive islet cell, glutamic acid decarboxylase, and tyrosine phosphatase antibodies. We noticed a correlation between autoimmune markers for thyroiditis and gastritis, as well as between celiac disease and adrenocortical insufficiency. Conclusion: Considering APS prevalence and prognosis, the need for APS screening in patients with T1DM is emphasized. Early diagnosis of other autoimmune disorders will enable us to adjust each patient treatment and follow-up.
C1 [Gouveia, Sofia; Gomes, Leonor; Ribeiro, Cristina; Carrilho, Francisco] Hosp Univ Coimbra, Ctr Hosp, Serv Endocrinol Diabet & Metab, P-3000075 Coimbra, Portugal.
   [Gouveia, Sofia; Gomes, Leonor; Ribeiro, Cristina; Carrilho, Francisco] Univ Coimbra, EPE, P-3000075 Coimbra, Portugal.
RP Gouveia, S (corresponding author), Hosp Univ Coimbra, Ctr Hosp, Serv Endocrinol Diabet & Metab, P-3000075 Coimbra, Portugal.
EM sofiamgouveia@gmail.com
RI Carrilho, Flair J/I-3046-2012
OI Gomes, Leonor/0000-0001-6576-7104
CR Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011
   [Anonymous], 2011, GLOBAL IDF ISPAD GUI, P123
   Barker JM, 2006, J CLIN ENDOCR METAB, V91, P1210, DOI 10.1210/jc.2005-1679
   Betterle C, 2002, ENDOCR REV, V23, P327, DOI 10.1210/er.23.3.327
   Coco G, 2006, J CLIN ENDOCR METAB, V91, P1637, DOI 10.1210/jc.2005-0860
   Falorni A, 2002, ENDOCRIN METAB CLIN, V31, P369, DOI 10.1016/S0889-8529(01)00010-X
   Masharani U., 2011, GREENSPANS BASIC CLI, P573
   Michels AW, 2009, J INTERN MED, V265, P530, DOI 10.1111/j.1365-2796.2009.02091.x
   Owen CJ, 2009, ENDOCRIN METAB CLIN, V38, P419, DOI 10.1016/j.ecl.2009.01.007
   Queiroz MS, 2008, ARQ BRAS ENDOCRINOL, V52, P198, DOI 10.1590/S0004-27302008000200007
   Robles DT, 2002, ENDOCRIN METAB CLIN, V31, P353, DOI 10.1016/S0889-8529(01)00015-9
   Schatz DA, 2002, ENDOCRIN METAB CLIN, V31, P339, DOI 10.1016/S0889-8529(01)00012-3
   Triolo TM, 2011, DIABETES CARE, V34, P1211, DOI 10.2337/dc10-1756
   Van den Driessche A, 2009, NETH J MED, V67, P376
   van der Windt DAWM, 2010, JAMA-J AM MED ASSOC, V303, P1738, DOI 10.1001/jama.2010.549
   Warncke K, 2010, DIABETES CARE, V33, P2010, DOI 10.2337/dc10-0404
NR 16
TC 2
Z9 2
U1 0
U2 2
PU SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
PI RIO DE JANEIRO, RJ
PA RUA HUMAITA, 85 CJ 501, RIO DE JANEIRO, RJ, 22261-000, BRAZIL
SN 0004-2730
EI 1677-9487
J9 ARQ BRAS ENDOCRINOL
JI Arq. Bras. Endocrinol. Metabol.
PD DEC
PY 2013
VL 57
IS 9
BP 733
EP 738
DI 10.1590/S0004-27302013000900010
PG 6
GA 286FV
UT WOS:000329452700010
PM 24402020
OA Other Gold
DA 2020-12-08
ER

PT J
AU Malta, FM
   Bruno, FR
   Carvalho, KI
   Nastri, ACSS
   Kalil, J
   Carrilho, FJ
   Kallas, EG
   Pinho, JRR
AF Malta, F. M.
   Bruno, F. R.
   Carvalho, K. I.
   Nastri, A. C. S. S.
   Kalil, J.
   Carrilho, F. J.
   Kallas, E. G.
   Pinho, J. R. R.
TI HCV Viremia Drives an Increment of CD86 Expression by Myeloid Dendritic
   Cells
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE hepatitis C virus; innate immunity; dendritic cell; chronic infection;
   CD86
ID HEPATITIS-C VIRUS; GENETIC-VARIATION; FUNCTIONAL-CAPACITY;
   IMMUNE-RESPONSES; INFECTION; INNATE; IL28B; ASSOCIATION; MATURATION;
   CLEARANCE
AB The host immune response, including innate and adaptive immunity, plays a critical role in determining the outcome of viral infection. Nevertheless, little is known about the exact reasons for the failure of the host immune system in controlling hepatitis C virus (HCV) infection. Impairment of dendritic cells (DCs) function is probably one of the mechanisms responsible for immune evasion of HCV. In this study, the frequency and phenotype of DCs subsets were analyzed in three groups: HCV-infected individuals who developed viral persistence (1), HCV-infected individuals who spontaneously cleared the virus (2) and HCV-seronegative uninfected subjects (3). The results showed that the frequency of DCs subsets was not statistically significant between groups. Plasmacytoid DCs circulating exhibited an immature phenotype characterized by low expression of CD86. On the other hand, CD86 expression in myeloid DCs was significantly higher in chronic infected individuals compared to healthy controls (P=0.037). A positive correlation was observed between CD86(+) myeloid DC (mDC) and HCV viral load (r=0.4121, P=0.0263). These results suggest that HCV did not have an inhibitory effect on mDC maturation and the HCV viremia drives the increase of CD86 expression in mDC. The regulation of DCs maturation and migration lies at the level of intracellular signaling. HCV can activate or block intracellular signaling pathways and alter DC function. In conclusion, the present study suggests that imbalance of DC maturation by the virus represents a mechanism of evasion of the immune system despite the fact that HCV viremia appears to exert a stimulatory effect on cell-surface immune phenotype. J Med. Virol. 85:1919-1924, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Malta, F. M.; Nastri, A. C. S. S.; Carrilho, F. J.; Pinho, J. R. R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Bruno, F. R.; Carvalho, K. I.; Kalil, J.; Kallas, E. G.] Univ Sao Paulo, Clin Immunol & Allergy Branch, Dept Internal Med, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Carvalho, K. I.; Pinho, J. R. R.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Nastri, A. C. S. S.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, BR-05403000 Sao Paulo, Brazil.
RP Malta, FM (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Eneas Carvalho Aguiar,500-2 Andar IMT II, BR-05403000 Sao Paulo, Brazil.
EM femalta@yahoo.com
RI Pinho, Joao R. R./G-2850-2012; Carvalho, Karina IL/J-6789-2012; Malta,
   Fernanda/B-1316-2013; Carrilho, Flair J/I-3046-2012; KALIL,
   JORGE/C-8029-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Carvalho, Karina
   IL/0000-0002-7763-8139; Malta, Fernanda/0000-0001-8887-5060; KALIL,
   JORGE/0000-0001-8415-4274; Kallas, Esper/0000-0003-2026-6925
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [09/53.270-0, 09/53.306-4.]; FFM; HC-FMUSP; Alves de Queiroz Family
   Fund; Tropical Medicine Institute of Sao Paulo
FX Grant sponsor: FAPESP; Grant numbers: 09/53.270-0, 09/53.306-4.; Grant
   sponsor: FFM; Grant sponsor: HC-FMUSP; Grant sponsor: Alves de Queiroz
   Family Fund; Grant sponsor: Tropical Medicine Institute of Sao Paulo
CR Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802
   Auffermann-Gratzinger S, 2001, BLOOD, V97, P3171, DOI 10.1182/blood.V97.10.3171
   Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Barchet W, 2005, SEMIN IMMUNOL, V17, P253, DOI 10.1016/j.smim.2005.05.008
   Barnes E, 2008, J VIRAL HEPATITIS, V15, P219, DOI 10.1111/j.1365-2893.2007.00934.x
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Della Bella S, 2007, IMMUNOLOGY, V121, P283, DOI 10.1111/j.1365-2567.2007.02577.x
   Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
   Harrison RJ, 2010, CLIN EXP IMMUNOL, V161, P306, DOI 10.1111/j.1365-2249.2010.04169.x
   Jo J, 2011, J GEN VIROL, V92, P477, DOI 10.1099/vir.0.027987-0
   Kanto T, 2004, J INFECT DIS, V190, P1919, DOI 10.1086/425425
   Kanto T, 1999, J IMMUNOL, V162, P5584
   Landi A, 2011, J VIRAL HEPATITIS, V18, P700, DOI 10.1111/j.1365-2893.2010.01357.x
   LARSEN CP, 1994, J IMMUNOL, V152, P5208
   Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499
   Longman RS, 2005, J INFECT DIS, V192, P497, DOI 10.1086/431523
   Longman RS, 2004, BLOOD, V103, P1026, DOI 10.1182/blood-2003-04-1339
   Mazzoni A, 2004, J LEUKOCYTE BIOL, V75, P721, DOI 10.1189/jlb.1003482
   Pachiadakis I, 2009, CLIN IMMUNOL, V131, P415, DOI 10.1016/j.clim.2009.02.001
   Pachiadakis L, 2005, LANCET INFECT DIS, V5, P296, DOI 10.1016/S1473-3099(05)70114-6
   Piccioli D, 2005, J HEPATOL, V42, P61, DOI 10.1016/j.jhep.2004.09.014
   Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4
   Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056
   Rehermann B, 2000, SEMIN LIVER DIS, V20, P127, DOI 10.1055/s-2000-9946
   Rehermann B, 2000, CURR TOP MICROBIOL, V242, P299
   Rehermann B, 2009, J CLIN INVEST, V119, P1745, DOI 10.1172/JCI39133
   Reizis B, 2011, NAT REV IMMUNOL, V11, P558, DOI 10.1038/nri3027
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   Ryan EJ, 2011, J VIRAL HEPATITIS, V18, P601, DOI 10.1111/j.1365-2893.2011.01453.x
   Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17
   Sun JR, 2001, J VIROL, V75, P11992, DOI 10.1128/JVI.75.24.11992-11998.2001
   Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Wu L, 2007, IMMUNITY, V26, P741, DOI 10.1016/j.immuni.2007.06.006
NR 36
TC 5
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2013
VL 85
IS 11
BP 1919
EP 1924
DI 10.1002/jmv.23692
PG 6
WC Virology
SC Virology
GA 282UG
UT WOS:000329198500008
PM 23926073
DA 2020-12-08
ER

PT J
AU Ferreira, CD
   Abreu, RM
   da Silva, MC
   Ferreira, AS
   Nasser, PD
   Carrilho, FJ
   Ono, SK
AF Ferreira, Camila da Silva
   Abreu, Rodrigo Martins
   da Silva, Marlone Cunha
   Ferreira, Aline Siqueira
   Nasser, Paulo Dominguez
   Carrilho, Flair Jose
   Ono, Suzane Kioko
TI A Fast and Cost-Effective Method for Identifying a Polymorphism of
   Interleukin 28B Related to Hepatitis C
SO PLOS ONE
LA English
DT Article
ID GENETIC-VARIATION; VIRUS-INFECTION; IL28B; VARIANTS
AB Approximately 170 million people are chronic carriers of hepatitis C virus (HCV). Patients with chronic hepatitis C are currently treated with pegylated interferon and ribavirin (PEG-IFN/RBV). A genome-wide association with PEG-IFN/RBV treatment response and a single nucleotide polymorphism (rs12979860) has been identified near the interleukin 28B gene that encodes interferon-lambda-3. In this paper, we describe an innovative, fast, and low-cost multiplex polymerase chain reaction with confronting two-pair primers that detects the rs12979860 polymorphism. The assay is internally controlled and does not require the use of restriction endonucleases or special equipment. Moreover, the assay decreases costs, being about 40% cheaper than direct sequencing methods.
C1 [Ferreira, Camila da Silva; Abreu, Rodrigo Martins; da Silva, Marlone Cunha; Nasser, Paulo Dominguez; Carrilho, Flair Jose; Ono, Suzane Kioko] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Ferreira, Aline Siqueira] Univ Fed Juiz de Fora, Dept Parasitol Microbiol & Immunol, Inst Biol Sci, Juiz De Fora, MG, Brazil.
RP Ono, SK (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM skon@usp.br
RI Carrilho, Flair J/I-3046-2012
OI Cunha-Silva, Marlone/0000-0002-4424-6606
FU Alves de Queiroz Family Foundation
FX The work was supported by the Alves de Queiroz Family Foundation. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Montes-Cano MA, 2010, HEPATOLOGY, V52, P33, DOI 10.1002/hep.23624
   Bacon BR, 2007, AM J MANAG CARE, V13, pS319
   Chevaliez S, 2011, GASTROENTEROLOGY, V141, P119, DOI 10.1053/j.gastro.2011.03.039
   Craxi A, 2011, J HEPATOL, V55, P245, DOI 10.1016/j.jhep.2011.02.023
   Cyr DD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021854
   Doehring A, 2010, ANTIVIR THER, V15, P1099, DOI 10.3851/IMP1689
   Eurich D, 2011, LIVER TRANSPLANT, V17, P289, DOI 10.1002/lt.22235
   Galmozzi E, 2011, J VIRAL HEPATITIS, V18, P628, DOI 10.1111/j.1365-2893.2010.01349.x
   Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
   Ghany MG, 2011, HEPATOLOGY, V54, P1433, DOI 10.1002/hep.24641
   da Costa MZG, 2009, PANCREATOLOGY, V9, P173, DOI 10.1159/000178889
   Hamajima N, 2000, JPN J CANCER RES, V91, P865, DOI 10.1111/j.1349-7006.2000.tb01026.x
   McCarthy JJ, 2010, GASTROENTEROLOGY, V138, P2307, DOI 10.1053/j.gastro.2010.02.009
   Ministerio da Saude, 2011, PROT CLIN DIR TER HE
   Nakatani SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010150
   Ono-Nita Suzane Kioko, 2006, Arq. Gastroenterol., V43, P71, DOI 10.1590/S0004-28032006000200001
   Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease, 1998, CTR DIS CONTROL PREV, V47, P1
   Reynolds JM, 2012, PLOS ONE, V7, P271, DOI 10.1371/journal.pone.0029983
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Urban T, 2012, HEPATOLOGY, V56, P361, DOI 10.1002/hep.25794
NR 20
TC 4
Z9 4
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 22
PY 2013
VL 8
IS 10
AR e78142
DI 10.1371/journal.pone.0078142
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239OF
UT WOS:000326034500062
PM 24167602
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Vanni, DS
   Oliveira, CP
   Mazo, DF
   Rabelo, F
   Stefano, JT
   Carrilho, FJ
AF Vanni, Denise S.
   Oliveira, Claudia P.
   Mazo, Daniel F.
   Rabelo, Fabiola
   Stefano, Jose Tadeu
   Carrilho, Flair J.
TI Comparison between Results of Hepatic Transient Elastography (fibroscan
   (R)) and Controlled Attenuation Parameter (cap (TM)) versus Liver Biopsy
   in NAFLD Patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Vanni, Denise S.; Oliveira, Claudia P.; Mazo, Daniel F.; Rabelo, Fabiola; Stefano, Jose Tadeu; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Mazo, Daniel FC/D-5631-2015; Stefano,
   Jose Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014; Stefano,
   Jose T/H-4792-2013
OI Mazo, Daniel FC/0000-0002-2164-2630; Stefano, Jose
   Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 660
BP 523A
EP 523A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202264
DA 2020-12-08
ER

PT J
AU Faria, P
   Malta, F
   Nastri, ACS
   Oliveira, KG
   Carrilho, FJ
   Pinho, JR
AF Faria, Paola
   Malta, Fernanda
   Nastri, Ana Catharina S.
   Oliveira, Ketti G.
   Carrilho, Flair J.
   Pinho, Joao R.
TI Single-nucleotide polymorphisms (SNPs) in IL18BP and IFN-gamma genes as
   biomarker candidates for spontaneous HCV clearance prediction
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Faria, Paola; Malta, Fernanda; Nastri, Ana Catharina S.; Oliveira, Ketti G.; Carrilho, Flair J.; Pinho, Joao R.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Pinho, Joao R.] Hosp Israelita Albert Einstein, Albert Einstein Med Diagnost, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012; Malta,
   Fernanda/B-1316-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1589
BP 974A
EP 975A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204372
DA 2020-12-08
ER

PT J
AU Gomes-Gouvea, MS
   Ferreira, AC
   Feitoza, B
   Pessoa, MG
   Abdala, E
   Terrabuio, DR
   Moraes, AC
   Bonazzi, PR
   D'Albuquerque, LC
   Carrilho, FJ
   Pinho, JR
AF Gomes-Gouvea, Michele S.
   Ferreira, Ariana C.
   Feitoza, Bruna
   Pessoa, Mario G.
   Abdala, Edson
   Terrabuio, Deborah R.
   Moraes, Adriano C.
   Bonazzi, Patricia R.
   D'Albuquerque, Luiz C.
   Carrilho, Flair J.
   Pinho, Joao R.
TI Evidence of Hepatitis E Virus Infection in Liver Transplant Recipients
   from Brazil
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Gomes-Gouvea, Michele S.; Ferreira, Ariana C.; Feitoza, Bruna; Pessoa, Mario G.; Terrabuio, Deborah R.; Moraes, Adriano C.; D'Albuquerque, Luiz C.; Carrilho, Flair J.; Pinho, Joao R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Abdala, Edson; Bonazzi, Patricia R.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
RI Abdala, Edson/H-5165-2012; Carrilho, Flair J/I-3046-2012; Pinho, Joao R.
   R./G-2850-2012; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012
OI Abdala, Edson/0000-0003-0765-6654; Pinho, Joao R.
   R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1754
BP 1052A
EP 1052A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205104
DA 2020-12-08
ER

PT J
AU Gonzalez, MP
   Klautau, GB
   Mendes-Correa, MC
   Mazo, DFC
   Nogueira, RS
   Carrilho, FJ
   Pessoa, MG
AF Gonzalez, Mario P.
   Klautau, Giselle B.
   Mendes-Correa, Maria Cassia
   Mazo, Daniel F. C.
   Nogueira, Roberta S.
   Carrilho, Flair J.
   Pessoa, Mario G.
TI Hepatic Steatosis and Insulin Resistance are associated to Vitamin D
   Deficiency (VDD) in Hepatitis C monoinfection and HIV/HCV coinfection
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Gonzalez, Mario P.; Klautau, Giselle B.] Inst Infectol Emilio Ribas, Outpatients Clin, Sao Paulo, Brazil.
   [Mendes-Correa, Maria Cassia] Univ Sao Paulo, Parasitary & Infect Dis Div, Sao Paulo, Brazil.
   [Gonzalez, Mario P.; Mazo, Daniel F. C.; Carrilho, Flair J.; Pessoa, Mario G.] Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
   [Nogueira, Roberta S.] Ctr Referncia & Treinamento DST Aids, Outpatients Clin, Sao Paulo, Brazil.
RI correa, maria cassia mendes/A-6779-2013; Mazo, Daniel FC/D-5631-2015;
   Carrilho, Flair J/I-3046-2012
OI Mazo, Daniel FC/0000-0002-2164-2630; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2271
BP 1306A
EP 1307A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206223
DA 2020-12-08
ER

PT J
AU Poynard, T
   Munteanu, M
   Colombo, M
   Bruix, J
   Schiff, E
   Terg, R
   Flamm, S
   Moreno-Otero, R
   Carrilho, F
   Schmidt, W
   Berg, T
   Mcgarrity, T
   Heathcote, EJ
   Goncales, F
   Diago, M
   Craxi, A
   Silva, M
   Boparai, N
   Griffel, L
   Burroughs, M
   Brass, C
   Albrecht, J
AF Poynard, Thierry
   Munteanu, Mona
   Colombo, Massimo
   Bruix, Jordi
   Schiff, Eugene
   Terg, Ruben
   Flamm, Steven
   Moreno-Otero, Ricardo
   Carrilho, Flair
   Schmidt, Warren
   Berg, Thomas
   Mcgarrity, Thomas
   Heathcote, E. Jenny
   Goncales, Fernando
   Diago, Moises
   Craxi, Antonio
   Silva, Marcelo
   Boparai, Navdeep
   Griffel, Louis
   Burroughs, Margaret
   Brass, Clifford
   Albrecht, Janice
TI FibroTest is an independent predictor of virologic response in chronic
   hepatitis C patients retreated with pegylated interferon alfa-2b and
   ribavirin in the EPIC3 program (vol 54, pg 227, 2011)
SO JOURNAL OF HEPATOLOGY
LA English
DT Correction
C1 [Poynard, Thierry; Munteanu, Mona] APHP UPMC Liver Ctr, Paris, France.
   [Colombo, Massimo] Univ Milan, Fdn IRCCS Maggiore Hosp, Div Gastroenterol 1, Milan, Italy.
   [Bruix, Jordi] Univ Barcelona, Hosp Clin, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Liver Unit, Barcelona, Spain.
   [Schiff, Eugene] Univ Miami, Sch Med, Miami, FL USA.
   [Terg, Ruben] Hosp Municipal Gastroenterol Dr Bonorino, Buenos Aires, Argentina.
   [Flamm, Steven] Northwestern Univ, Chicago, IL 60611 USA.
   [Moreno-Otero, Ricardo] Hospital Univ Princesa, Madrid, Spain.
   [Moreno-Otero, Ricardo] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Carrilho, Flair] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Schmidt, Warren] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
   [Berg, Thomas] Univ Med Berlin, Campus Virchow Klinikum, Charite, Berlin, Germany.
   [Mcgarrity, Thomas] Milton S Hershey Med Ctr, Hershey, PA USA.
   [Heathcote, E. Jenny] Univ Hlth Network, Toronto, ON, Canada.
   [Goncales, Fernando] Univ Estadual Campinas, Dept Med Clin, Fac Med Sci, Campinas, SP, Brazil.
   [Diago, Moises] Hosp Gen Univ Valencia, Valencia, Spain.
   [Craxi, Antonio] Univ Palermo, GI & Liver Unit, DIBIMIS, Palermo, Italy.
   [Silva, Marcelo] Hosp Univ Austral, Pilar, Argentina.
   [Boparai, Navdeep; Griffel, Louis; Burroughs, Margaret; Brass, Clifford; Albrecht, Janice] Schering Plough Res Inst, Kenilworth, NJ USA.
RP Poynard, T (corresponding author), Hop La Pitie Salpetriere, Serv Hepatol, 47-83 Blvd Hop, F-75651 Paris, France.
EM tpoynard@teaser.fr
RI Carrilho, Flair J/I-3046-2012; DIAGO, MOISES/AAH-5364-2019; Craxi,
   Antonio/K-9529-2016
OI Craxi, Antonio/0000-0002-4480-9544; Bruix, Jordi/0000-0002-9826-0753;
   Poynard, Thierry/0000-0002-2050-640X; Berg, Thomas/0000-0003-0003-6241;
   schmidt, Warren/0000-0003-2893-6014
CR Poynard T, 2011, J HEPATOL, V54, P227, DOI 10.1016/j.jhep.2010.06.038
NR 1
TC 0
Z9 0
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD OCT
PY 2013
VL 59
IS 4
BP 914
EP 914
DI 10.1016/j.jhep.2013.07.006
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 218ZY
UT WOS:000324473700041
DA 2020-12-08
ER

PT J
AU Silvestre, OM
   Farias, AQ
   Ramos, DS
   Zitelli, PMY
   Furtado, MS
   Andrade, JL
   Ximenes, RO
   Carrilho, FJ
   D'Albuquerque, LAC
   Bacal, F
AF Silvestre, O. M.
   Farias, A. Q.
   Ramos, D. S.
   Zitelli, P. M. Y.
   Furtado, M. S.
   Andrade, J. L.
   Ximenes, R. O.
   Carrilho, F. J.
   D'Albuquerque, L. A. C.
   Bacal, F.
TI Clinical predictors of primary cardiopathies in liver transplantation
   candidates
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 31-SEP 04, 2013
CL Amsterdam, NETHERLANDS
SP European Soc Cardiol
C1 [Silvestre, O. M.; Farias, A. Q.; Ramos, D. S.; Zitelli, P. M. Y.; Furtado, M. S.; Andrade, J. L.; Ximenes, R. O.; Carrilho, F. J.; D'Albuquerque, L. A. C.; Bacal, F.] Univ Sao Paulo, BR-09500900 Sao Paulo, Brazil.
RI Bacal, Fernando/H-7952-2012; Farias, Alberto/ABB-1291-2020; Carrilho,
   Flair J/I-3046-2012; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012
OI Farias, Alberto/0000-0002-5572-663X; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2013
VL 34
SU 1
BP 304
EP 304
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 262OH
UT WOS:000327744602018
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Silvestre, OM
   Bacal, F
   Garcia-Tsao, G
   Seguro, LFBC
   Mazo, DFC
   Andrade, JL
   Furtado, MS
   Carrilho, FJ
   D'Albuquerque, LAC
AF Farias, A. Q.
   Silvestre, O. M.
   Bacal, F.
   Garcia-Tsao, G.
   Seguro, L. F. B. C.
   Mazo, D. F. C.
   Andrade, J. L.
   Furtado, M. S.
   Carrilho, F. J.
   D'Albuquerque, L. A. C.
CA BNP Ascites Study Grp
TI Serum B-type natriuretic peptide is more accurate than ascites analyses
   in the diagnosis of ascites related to heart failure
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 31-SEP 04, 2013
CL Amsterdam, NETHERLANDS
SP European Soc Cardiol
C1 [Farias, A. Q.; Silvestre, O. M.; Bacal, F.; Seguro, L. F. B. C.; Mazo, D. F. C.; Andrade, J. L.; Furtado, M. S.; Carrilho, F. J.; D'Albuquerque, L. A. C.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Garcia-Tsao, G.] Yale Univ, West Haven, CT USA.
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Bacal,
   Fernando/H-7952-2012; Carrilho, Flair J/I-3046-2012; Garcia-Tsao,
   Guadalupe/ABF-7374-2020; Mazo, Daniel FC/D-5631-2015; D'Albuquerque,
   Luiz Augusto Carneiro/A-8812-2013; Farias, Alberto/ABB-1291-2020
OI Mazo, Daniel FC/0000-0002-2164-2630; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Farias, Alberto/0000-0002-5572-663X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2013
VL 34
SU 1
BP 781
EP 781
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 262OH
UT WOS:000327744604605
DA 2020-12-08
ER

PT J
AU Alves, R
   Queiroz, ATL
   Pessoa, MG
   da Silva, EF
   Mazo, DFC
   Carrilho, FJ
   Carvalho, RJ
   de Carvalho, IMVG
AF Alves, R.
   Queiroz, A. T. L.
   Pessoa, M. G.
   da Silva, E. F.
   Mazo, D. F. C.
   Carrilho, F. J.
   Carvalho-Filho, R. J.
   de Carvalho, I. M. V. G.
TI The presence of resistance mutations to protease and polymerase
   inhibitors in Hepatitis C virus sequences from the Los Alamos databank
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
DE direct-acting antiviral agents; hepatitis C virus; polymerase; protease;
   resistance mutations
ID NS3/4A PROTEASE; IN-VITRO; COMBINATION THERAPY; CROSS-RESISTANCE; PLUS
   RIBAVIRIN; HCV; BOCEPREVIR; TELAPREVIR; MECHANISMS; SELECTION
AB Several new direct-acting antiviral (DAA) drugs are in development for chronic hepatitis C viral (HCV) infection, and NS3-NS4A serine protease and the NS5B RNA-dependent RNA polymerase have been the major targets. HCV variants displaying drug-resistant phenotypes have been observed both in vitro and during clinical trials. Our aim was to characterize amino acid changes at positions previously associated with resistance in protease (NS3) and polymerase (NS5B) regions from treatment-naive HCV patients infected with genotypes 1a, 1b and 3a. All 1383 NS3 protease sequences (genotype 1a=680, 1b=498 and 3a=205) and 806 NS5B polymerase sequences (genotypes 1a=471, 1b=329, 3a=6) were collected from Los Alamos databank. Genotype 3a protease sequences showed the typical low-level resistance mutation V36L. NS3 sequences from other genotypes presented mutations on positions 36, 39, 41, 43, 54, 80, 109, 155 and 168 in a frequency lower than 2%, except for the mutation Q80R found in 35% of genotype 1a isolates. Polymerase sequences from genotype 3a patients showed five typical mutations: L419I, I424V, I482L, V499A and S556G. Two positions presented high polymorphism in the NS5B region from genotype 1a (V499A) and genotype 1b (C316N) subjects. Our results demonstrated a natural profile of genotype 3a that can be associated with the pre-existence of HCV variants resistant to first-generation protease inhibitors and to non-nucleoside polymerase inhibitors. Likewise, genotype 1b isolates and genotype 1a sequences exhibited pre-existing mutations associated with resistance to Palm II and Thumb I polymerase inhibitors, respectively.
C1 [Alves, R.; Carvalho-Filho, R. J.; de Carvalho, I. M. V. G.] Univ Fed Sao Paulo, Div Gastroenterol, Setor Hepatites, Lab Hepatol Mol Aplicada, Sao Paulo, Brazil.
   [Queiroz, A. T. L.] CPqGM FIOCRUZ, Lab Imunoparasitol, Salvador, BA, Brazil.
   [Pessoa, M. G.; da Silva, E. F.; Mazo, D. F. C.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [de Carvalho, I. M. V. G.] Inst Butantan, Sao Paulo, Brazil.
RP Pessoa, MG (corresponding author), Av Dr Eneas Carvalho de Aguiar 255 9 Sala 9117, BR-05403900 Sao Paulo, Brazil.
EM mgpessoa@usp.br
RI Carrilho, Flair J/I-3046-2012; Mazo, Daniel FC/D-5631-2015; Alves da
   SIlva, Rafael/H-1105-2012; Carvalho-Filho, Roberto J. J./D-2222-2012;
   Queiroz, Artur/F-6083-2014; de carvalho-Mello, Isabel Maria V
   G/D-3641-2012
OI Mazo, Daniel FC/0000-0002-2164-2630; Alves da SIlva,
   Rafael/0000-0003-3473-9412; Carvalho-Filho, Roberto J.
   J./0000-0002-7136-7171; de Queiroz, Artur Trancoso
   Lopo/0000-0003-4908-9993; Carvalho-Filho, Roberto/0000-0002-9795-5705
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/14277-9-2010/19054-5]; Capes/Escola de Altos Estudos
FX This manuscript was fully supported by the Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP- 2009/14277-9-2010/19054-5) and
   Capes/Escola de Altos Estudos.
CR Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482
   Bae A, 2010, ANTIMICROB AGENTS CH, V54, P5288, DOI 10.1128/AAC.00777-10
   Beaulieu PL, 2010, IDRUGS, V13, P938
   Beerenwinkel N, 2011, CURR OPIN VIROL, V1, P413, DOI 10.1016/j.coviro.2011.07.008
   Cento V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039652
   Chen ZY, 2002, J CLIN MICROBIOL, V40, P3127, DOI 10.1128/JCM.40.9.3127-3134.2002
   Courcambeck J, 2006, ANTIVIR THER, V11, P847
   Cubero M, 2008, VIROLOGY, V370, P237, DOI 10.1016/j.virol.2007.10.006
   Dahl G, 2007, ANTIVIR THER, V12, P733
   Flint M, 2009, ANTIMICROB AGENTS CH, V53, P401, DOI 10.1128/AAC.01081-08
   Fridell RA, 2010, ANTIMICROB AGENTS CH, V54, P3641, DOI 10.1128/AAC.00556-10
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Gane EJ, 2010, LANCET, V376, P1467, DOI 10.1016/S0140-6736(10)61384-0
   Gottwein JM, 2009, HEPATOLOGY, V49, P364, DOI 10.1002/hep.22673
   Guedj J, 2012, HEPATOLOGY, V55, P1030, DOI 10.1002/hep.24788
   Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912
   Kim AY, 2008, EXPERT REV ANTI-INFE, V6, P463, DOI 10.1586/14787210.6.4.463
   KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549
   Kukolj G, 2005, J BIOL CHEM, V280, P39260, DOI 10.1074/jbc.M506407200
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Legrand-Abravanel F, 2010, EXPERT OPIN INV DRUG, V19, P963, DOI 10.1517/13543784.2010.500285
   Lemke CT, 2011, J BIOL CHEM, V286, P11434, DOI 10.1074/jbc.M110.211417
   Lenz O, 2010, ANTIMICROB AGENTS CH, V54, P1878, DOI 10.1128/AAC.01452-09
   Lin C, 2005, J BIOL CHEM, V280, P36784, DOI 10.1074/jbc.M506462200
   Liu-Young G, 2008, AIDS PATIENT CARE ST, V22, P449, DOI 10.1089/apc.2007.0199
   Lopez-Labrador FX, 2008, ANTIVIR THER, V13, P481
   Macalalad AR, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002417
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Mello IMVGC, 2009, J VIRAL HEPATITIS, V16, P732, DOI 10.1111/j.1365-2893.2009.01125.x
   Ohara E, 2011, J HEPATOL, V54, P872, DOI 10.1016/j.jhep.2010.08.033
   Ohno T, 1997, J CLIN MICROBIOL, V35, P201, DOI 10.1128/JCM.35.1.201-207.1997
   Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494
   Qureshi Saleem, 2009, J Ayub Med Coll Abbottabad, V21, P10
   Reesink HW, 2006, GASTROENTEROLOGY, V131, P997, DOI 10.1053/j.gastro.2006.07.013
   Salloum S, 2010, ANTIVIR RES, V87, P272, DOI 10.1016/j.antiviral.2010.05.006
   Shimakami T, 2011, GASTROENTEROLOGY, V140, P667, DOI 10.1053/j.gastro.2010.10.056
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Susser S, 2009, HEPATOLOGY, V50, P1709, DOI 10.1002/hep.23192
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Thibeault D, 2004, J VIROL, V78, P7352, DOI 10.1128/JVI.78.14.7352-7359.2004
   Tong X, 2008, ANTIVIR RES, V77, P177, DOI 10.1016/j.antiviral.2007.11.010
   Valdar WSJ, 2002, PROTEINS, V48, P227, DOI 10.1002/prot.10146
   Vanwolleghem T, 2007, GASTROENTEROLOGY, V133, P1144, DOI 10.1053/j.gastro.2007.07.007
   Vermehren J, 2012, J VIRAL HEPATITIS, V19, P120, DOI 10.1111/j.1365-2893.2011.01449.x
   Vermehren J, 2011, CLIN MICROBIOL INFEC, V17, P122, DOI 10.1111/j.1469-0691.2010.03430.x
   Welsch C, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r16
   Wyles David L, 2010, Top HIV Med, V18, P132
   Yang WG, 2008, ANTIMICROB AGENTS CH, V52, P2043, DOI 10.1128/AAC.01548-07
   Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086
   Zhou Y, 2008, ANTIMICROB AGENTS CH, V52, P110, DOI 10.1128/AAC.00863-07
NR 53
TC 38
Z9 38
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2013
VL 20
IS 6
BP 414
EP 421
DI 10.1111/jvh.12051
PG 8
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA 140EU
UT WOS:000318638000006
PM 23647958
OA Green Published
DA 2020-12-08
ER

PT J
AU Oliveira, CPMS
   Kappel, CR
   Siqueira, ER
   Lima, VMR
   Stefano, JT
   Michalczuk, MT
   Marini, SS
   Barbeiro, HV
   Soriano, FG
   Carrilho, FJ
   Pereira, LMMB
   Alvares-da-Silva, MR
AF Oliveira, C. P. M. S.
   Kappel, C. R.
   Siqueira, E. R.
   Lima, V. M. R.
   Stefano, J. T.
   Michalczuk, M. T.
   Marini, S. S.
   Barbeiro, H. V.
   Soriano, F. G.
   Carrilho, F. J.
   Pereira, L. M. M. B.
   Alvares-da-Silva, M. R.
TI Effects of Hepatitis C virus on cardiovascular risk in infected
   patients: A comparative study
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Hepatitis C virus; Cardiovascular risk; Framingham Score;
   Pro-inflammatory cytokines
ID INSULIN-RESISTANCE; CELLS; ATHEROSCLEROSIS; ASSOCIATION; EXPRESSION;
   STEATOSIS; DISEASE; INTERLEUKIN-10; SEROPOSITIVITY; CHOLESTEROL
AB The role of hepatitis C virus (HCV) in the pathogenesis of atherosclerosis and cardiovascular events is unclear. The aim of this study was to evaluate the direct effect of HCV on cardiovascular risk and correlate it with pro and anti-inflammatory cytokines in patients with HCV. HCV monoinfected patients, genotype 1, naive, non-obese (BMI<30) and non-diabetics were included and compared to controls (blood donors). Patients with prior diagnosis of cardiovascular diseases, hypertension, chronic renal failure, cancer and chronic use of lipid-lowering drugs or immunosuppressants were excluded. Age, BMI, systolic blood pressure (SBP) and diastolic (DBP), fasting glucose and lipid levels were determined. Serum cytokines (IL-6, IL-10 and TNF-alpha) and Framingham score were also evaluated. 62 HCV patients, 34 (54.8%) were males and none of them was smoking. The Framingham scores (median and 25th and 75th percentiles) were 12% (6.5-14%), showing an intermediate cardiovascular risk in patients with HCV. There was significant direct correlation between Framingham and total cholesterol (p=0.043) and DBP (p=0.007). HDL-C (p=0.002) was inversely correlated with the Framingham score. HCV patients had higher levels of proinflammatory cytokines (IL-6 and TNF-alpha) compared to controls (p<0.0001) and the relation of proinflammatory/anti-inflammatory TNF-alpha/IL10 and IL-6/IL10 were higher in HCV patients (p<0.01). The Framingham score was directly correlated to IL-6 and TNF-alpha, but differences were not statistically significant. Patients with HCV monoinfected, nonobese, naive and non diabetic have an intermediate cardiovascular risk, as measured by the Framingham score and high levels of proinflammatory cytokines (IL-6 and TNF). (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Oliveira, C. P. M. S.; Lima, V. M. R.; Stefano, J. T.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM07, Sao Paulo, Brazil.
   [Kappel, C. R.; Michalczuk, M. T.; Marini, S. S.; Alvares-da-Silva, M. R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Sch Med, Div Gastroenterol, Porto Alegre, RS, Brazil.
   [Siqueira, E. R.; Pereira, L. M. M. B.] Liver Inst Pernambuco, Recife, PE, Brazil.
   [Barbeiro, H. V.; Soriano, F. G.] Univ Sao Paulo, Sch Med, Dept Emergency LIM51, Sao Paulo, Brazil.
RP Alvares-da-Silva, MR (corresponding author), Hosp Clin Porto Alegre, Rua Ramiro Barcelos,2330 Sala 2033, BR-90035903 Porto Alegre, RS, Brazil.
EM mras@terra.com.br
RI Stefano, Jose T/H-4792-2013; Carrilho, Flair J/I-3046-2012; Soriano,
   Francisco/C-3382-2012; Stefano, Jose Tadeu/AAH-5419-2020;
   Alvares-da-Silva, Mario Reis/L-3910-2014; Pereira, Lexley
   Pinto/T-2547-2019; Barbeiro, Hermes V/E-2814-2010; Barbeiro, Hermes
   V/S-5926-2016; Michalczuk, Matheus Truccolo/V-5906-2019
OI Soriano, Francisco/0000-0003-4898-0135; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Alvares-da-Silva, Mario
   Reis/0000-0002-5001-246X; Barbeiro, Hermes V/0000-0002-8209-4463;
   Barbeiro, Hermes V/0000-0002-8209-4463; 
CR Abbas Z, 2003, J Pak Med Assoc, V53, P59
   ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259
   ANDERSON C, 1991, NATURE, V353, P289, DOI 10.1038/353289a0
   ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356
   Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004
   Boddi Maria, 2007, Dig Liver Dis, V39 Suppl 1, pS55
   Brown PMJ, 2001, CLIN BIOCHEM, V34, P167, DOI 10.1016/S0009-9120(01)00210-7
   Chen Y, 2007, AM J PHYSIOL-RENAL, V293, pF680, DOI 10.1152/ajprenal.00209.2007
   Clement S, 2009, VIRUSES-BASEL, V1, P126, DOI 10.3390/v1020126
   Corey KE, 2009, HEPATOLOGY, V50, P1030, DOI 10.1002/hep.23219
   Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1
   Fartoux L, 2005, GUT, V54, P1003, DOI 10.1136/gut.2004.050302
   Fernandez-Real JM, 1999, DIABETOLOGIA, V42, P1367, DOI 10.1007/s001250051451
   FIORENTINO DF, 1991, J IMMUNOL, V146, P3444
   Floris-Moore M, 2007, AIDS PATIENT CARE ST, V21, P479, DOI 10.1089/apc.2006.0150
   Freiberg MS, 2007, AIDS, V21, P193, DOI 10.1097/QAD.0b013e3280118a0d
   Fukui M, 2003, JAMA-J AM MED ASSOC, V289, P1245, DOI 10.1001/jama.289.10.1245-b
   Grundy SM, 2004, CIRCULATION, V109, P551, DOI 10.1161/01.CIR.0000112379.88385.67
   Guiltinan AM, 2008, AM J EPIDEMIOL, V167, P743, DOI 10.1093/aje/kwm370
   Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220
   Ishizaka N, 2002, LANCET, V359, P133, DOI 10.1016/S0140-6736(02)07339-7
   Lecube A, 2006, DIABETES CARE, V29, P1096, DOI 10.2337/dc05-2509
   Llorente L, 1996, J HEPATOL, V24, P555, DOI 10.1016/S0168-8278(96)80140-1
   Maggi G, 1996, ITAL J GASTROENTEROL, V28, P436
   MALEFYT RD, 1991, J EXP MED, V174, P1209
   MALEFYT RD, 1991, J EXP MED, V174, P915
   Marzouk D, 2007, GUT, V56, P1105, DOI 10.1136/gut.2006.091983
   Milner KL, 2010, GASTROENTEROLOGY, V138, P932, DOI 10.1053/j.gastro.2009.11.050
   Mostafa A, 2010, GUT, V59, P1135, DOI 10.1136/gut.2009.202317
   Negro F, 2009, J VIRAL HEPATITIS, V16, P681, DOI 10.1111/j.1365-2893.2009.01186.x
   Persico M, 2007, HEPATOLOGY, V46, P1009, DOI 10.1002/hep.21782
   Ruan XZ, 2003, J AM SOC NEPHROL, V14, P593, DOI 10.1097/01.ASN.0000050414.52908.DA
   Syed GH, 2010, TRENDS ENDOCRIN MET, V21, P33, DOI 10.1016/j.tem.2009.07.005
   Tsui JI, 2009, J CARD FAIL, V15, P451, DOI 10.1016/j.cardfail.2008.12.003
   Tsuruma T, 1998, CELL IMMUNOL, V184, P121, DOI 10.1006/cimm.1998.1266
   Vassalle C, 2004, HEART, V90, P565, DOI 10.1136/hrt.2003.018937
   Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545
   Yue FY, 1997, INT J CANCER, V71, P630, DOI 10.1002/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.3.CO;2-H
   Zeller JC, 1999, J IMMUNOL, V163, P3684
NR 39
TC 58
Z9 59
U1 0
U2 22
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD APR 5
PY 2013
VL 164
IS 2
BP 221
EP 226
DI 10.1016/j.ijcard.2011.07.016
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 112NO
UT WOS:000316599200018
PM 21784542
DA 2020-12-08
ER

PT J
AU Gonzalez, MP
   Klautau, GB
   Mazo, DF
   Nogueira, RS
   Mendes-Correa, MCJ
   Carrilho, FJ
   Pessoa, MG
AF Gonzalez, M. P.
   Klautau, G. B.
   Mazo, D. F.
   Nogueira, R. S.
   Mendes-Correa, M. C. J.
   Carrilho, F. J.
   Pessoa, M. G.
TI INSULIN RESISTANCE AND HIGH CHOLESTEROL LEVELS ARE ASSOCIATED WITH
   VITAMIN D DEFICIENCY IN HCV, HIV AND HIV/HCV COINFECTED PATIENTS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Gonzalez, M. P.] Univ Sao Paulo, Hepatitis & HIV Outpatients Clin, Inst Infectol Emilio Ribas, Sao Paulo, Brazil.
   [Klautau, G. B.] Univ Sao Paulo, HIV Outpatients Clin, Inst Infectol Emilio Ribas, Sao Paulo, Brazil.
   [Mazo, D. F.; Carrilho, F. J.; Pessoa, M. G.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Nogueira, R. S.] Univ Sao Paulo, HIV Aids Outpatients Clin, Ctr Referencia & Treinamento HIV Aids, Sao Paulo, Brazil.
   [Mendes-Correa, M. C. J.] Univ Sao Paulo, Sch Med, Div Infect Dis, Sao Paulo, Brazil.
EM mpgonzalez@terra.com.br
RI Mazo, Daniel FC/D-5631-2015; Carrilho, Flair J/I-3046-2012; correa,
   maria cassia mendes/A-6779-2013
OI Mazo, Daniel FC/0000-0002-2164-2630; 
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 459
BP S187
EP S188
DI 10.1016/S0168-8278(13)60461-4
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000460
DA 2020-12-08
ER

PT J
AU Nogueira, MA
   Alves, VAF
   Stefano, JT
   Rodrigues, L
   Carrilho, FJ
   Waitzberg, D
   Oliveira, CP
AF Nogueira, M. A.
   Alves, V. A. F.
   Stefano, J. T.
   Rodrigues, L.
   Carrilho, F. J.
   Waitzberg, D.
   Oliveira, C. P.
TI EFFECTS OF omega-3 POLYUNSATURATED FATTY ACIDS (PUFA) FROM FISH AND
   FLAXSEED OILS ON NONALCOHOLIC STEATOHEPATITIS (NASH)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Nogueira, M. A.; Stefano, J. T.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Sch Med, Clin Div, Hepatol Branch LIM 07, Sao Paulo, Brazil.
   [Alves, V. A. F.] Univ Sao Paulo, Sch Med, Pathol LIM 14, Sao Paulo, Brazil.
   [Rodrigues, L.; Waitzberg, D.] Univ Sao Paulo, Sch Med, Surg Div LIM 35, Sao Paulo, Brazil.
EM cpm@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose T/H-4792-2013;
   Carrilho, Flair J/I-3046-2012; Stefano, Jose Tadeu/AAH-5419-2020
OI Stefano, Jose Tadeu/0000-0002-0218-1920
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 1353
BP S544
EP S544
DI 10.1016/S0168-8278(13)61352-5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983001611
DA 2020-12-08
ER

PT J
AU Silva, MF
   Sapisochin, G
   Strasser, SI
   Hewa-Geeganage, S
   Chen, J
   Wigg, AJ
   Jones, R
   Saraiva, R
   Kikuchi, L
   Carrilho, F
   Fontes, PRO
   Charco, R
AF Silva, M. F.
   Sapisochin, G.
   Strasser, S. I.
   Hewa-Geeganage, S.
   Chen, J.
   Wigg, A. J.
   Jones, R.
   Saraiva, R.
   Kikuchi, L.
   Carrilho, F.
   Fontes, P. R. O.
   Charco, R.
TI Liver resection and transplantation offer similar 5-year survival for
   Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5 cm: A
   multicenter, exploratory analysis
SO EJSO
LA English
DT Article
DE Hepatocellular carcinoma; Liver resection; Liver transplantation
ID EARLY HEPATOCELLULAR-CARCINOMA; CLASS-A PATIENTS; HEPATIC RESECTION;
   PORTAL-HYPERTENSION; MILAN CRITERIA; CIRRHOSIS; OUTCOMES; TUMORS
AB Background and aim: The current guideline of the American Association for the Study of Liver Diseases recommends liver resection for Child-Pugh-Turcotte A patients with a single hepatocellular carcinoma, total serum bilirubin <= 1 mg/dL and absence of significant portal hypertension. This subset of patients would have a long-term survival comparable to transplantation. The main aim of this study is to evaluate the survival rates in patients with a single nodule <= 5 cm following resection.
   Methods: Medical records of 105 Child-Pugh-Turcotte A patients who underwent liver resection between 1997 and 2009 were analyzed in 3 countries.
   Results: One, 3-, and 5-year survival rate was 97%, 83%, and 66%, respectively, and no variable that can be assessed prior to liver resection predicted survival probabilities.
   Conclusions: Liver resection offers 5-year survival similar to transplantation for Child-Pugh-Turcotte A patients with hepatocellular carcinoma and a single nodule up to 5 cm, independently of any patient baseline characteristics. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Silva, M. F.] Flinders Univ S Australia, Dept Gastroenterol, Adelaide, SA 5001, Australia.
   [Silva, M. F.; Fontes, P. R. O.] Santa Casa Gen Hosp, Dept HBP Surg & Transplantat, BR-90450090 Porto Alegre, RS, Brazil.
   [Silva, M. F.; Fontes, P. R. O.] Univ Fed Ciencias Saude, Postgrad Course Hepatol, Porto Alegre, RS, Brazil.
   [Sapisochin, G.; Charco, R.] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept HBP Surg & Transplantat, Barcelona, Spain.
   [Strasser, S. I.; Hewa-Geeganage, S.] Royal Prince Alfred Hosp, Liver Transplant Unit, Sydney, NSW, Australia.
   [Chen, J.; Wigg, A. J.] Flinders Med Ctr, Liver Transplant Unit, Adelaide, SA, Australia.
   [Jones, R.] Austin Hosp, Liver Transplant Unit, Melbourne, Vic 3084, Australia.
   [Saraiva, R.; Kikuchi, L.; Carrilho, F.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Silva, MF (corresponding author), Santa Casa Gen Hosp, Dept HBP Surg & Transplantat, Barao Uba 299-402, BR-90450090 Porto Alegre, RS, Brazil.
EM mauriciosilva11@yahoo.com.br
RI Saraiva, Roberto/A-7387-2014; Carrilho, Flair J/I-3046-2012
OI Saraiva, Roberto/0000-0002-2263-4261; Charco, Ramon/0000-0001-9709-6288
CR Abdel-Wahab M, 2010, LANGENBECK ARCH SURG, V395, P625, DOI 10.1007/s00423-010-0643-0
   Boleslawski E, 2012, BRIT J SURG, V99, P855, DOI 10.1002/bjs.8753
   Bruix J, 1996, GASTROENTEROLOGY, V111, P1018, DOI 10.1016/S0016-5085(96)70070-7
   Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Capussotti L, 2006, WORLD J SURG, V30, P992, DOI 10.1007/s00268-005-0524-9
   Chiappa A, 2000, EUR J SURG ONCOL, V26, P387, DOI 10.1053/ejso.1999.0904
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   Ercolani G, 2003, ANN SURG, V237, P536, DOI 10.1097/00000658-200304000-00016
   Ferrero A, 2005, WORLD J SURG, V29, P1101, DOI 10.1007/s00268-005-7768-2
   Germani G, 2011, LIVER TRANSPLANT, V17, pS58, DOI 10.1002/lt.22336
   Grazi GL, 2001, ANN SURG, V234, P71, DOI 10.1097/00000658-200107000-00011
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Huang ZY, 2011, LANGENBECK ARCH SURG, V396, P193, DOI 10.1007/s00423-010-0700-8
   Ishizawa T, 2008, GASTROENTEROLOGY, V134, P1908, DOI 10.1053/j.gastro.2008.02.091
   Lee KK, 2010, J SURG ONCOL, V101, P47, DOI 10.1002/jso.21415
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629
   Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
   Margarit C, 2005, LIVER TRANSPLANT, V11, P1242, DOI 10.1002/lt.20398
   Mazzaferro V, 2007, LIVER TRANSPLANT, V13, pS44, DOI 10.1002/lt.21330
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Park YK, 2009, TRANSPL P, V41, P1691, DOI 10.1016/j.transproceed.2008.07.146
   Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731
   Pawlik TM, 2009, J GASTROINTEST SURG, V13, P1026, DOI 10.1007/s11605-008-0779-1
   Poon RTP, 2002, ANN SURG, V236, P602, DOI 10.1097/00000658-200211000-00010
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   Santambrogio R, 2009, ANN SURG ONCOL, V16, P3289, DOI 10.1245/s10434-009-0678-z
   Sapisochin G, ANN SURG ON IN PRESS
   Sapisochin G, 2010, WORLD J SURG, V34, P2146, DOI 10.1007/s00268-010-0583-4
   Sherman M, 2010, ONCOLOGY-BASEL, V78, P7, DOI 10.1159/000315223
   Sun Hui-Chuan, 2005, Hepatobiliary Pancreat Dis Int, V4, P370
   Taura K, 2007, SURGERY, V142, P685, DOI 10.1016/j.surg.2007.05.009
   Tremosini S, 2010, DIGEST LIVER DIS, V42, pS242, DOI 10.1016/S1590-8658(10)60512-9
   Vauthey JN, 2002, J CLIN ONCOL, V20, P1527, DOI 10.1200/JCO.20.6.1527
   Weels GA, NEWCASTTLE OTTAWA SC
   Wu CC, 2005, BRIT J SURG, V92, P348, DOI 10.1002/bjs.4838
   Yamamoto J, 2001, HEPATOLOGY, V34, P707, DOI 10.1053/jhep.2001.27950
   Zhou JA, 2010, J CANCER RES CLIN, V136, P1453, DOI 10.1007/s00432-010-0802-2
NR 39
TC 22
Z9 24
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0748-7983
EI 1532-2157
J9 EJSO-EUR J SURG ONC
JI EJSO
PD APR
PY 2013
VL 39
IS 4
BP 386
EP 395
DI 10.1016/j.ejso.2012.12.011
PG 10
WC Oncology; Surgery
SC Oncology; Surgery
GA 111HG
UT WOS:000316511800012
PM 23375469
DA 2020-12-08
ER

PT J
AU Moura, IF
   Lopes, EP
   Alvarado-Mora, MV
   Pinho, JR
   Carrilho, FJ
AF Moura, Izolda Fernandes
   Lopes, Edmundo Pessoa
   Alvarado-Mora, Monica Viviana
   Pinho, Joao Renato
   Carrilho, Flair Jose
TI Phylogenetic analysis and subgenotypic distribution of the hepatitis B
   virus in Recife, Brazil
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE HBV genotype; HBV subgenotype; Phylogenetic analysis; Bayesian analysis;
   Hepatitis B virus
ID HBV GENOTYPES; MOLECULAR CHARACTERIZATION; INFECTED PATIENTS;
   EPIDEMIOLOGY; AFRICA; RELEVANCE; COMMUNITY; SUBTYPES; A1
AB The analysis of the genomes of the hepatitis B virus in human hosts identifies phylogenetic variants called viral genotypes. Indeed, clinical and epidemiological observations suggest that differences in viral genotypes lead to distinct biological and clinical behaviors. The aim of this study was to evaluate the subgenotypic distribution and to conduct a phylogenetic analysis by Bayesian method of the hepatitis B virus (HBV) in patients from Recife, Brazil. From July 2009 to December 2010, 60 HBV infected patients were examined, 39 (65%) were males, whose mean age was 50 years old. 33 (55%) were genotyped by obtaining and amplifying a 1306 bp fragment comprising part of the DNA polymerase and the surface antigen of the HBV. The sequencing was performed on an ABI 3500 Automatic Sequencer and the consensus sequences were obtained by aligning both the sequenced strands (clockwise and anti-clockwise) using SEQUENCHER software. Phylogenetic analysis was conducted using the Markov Chain Monte Carlo simulation implemented by Bayesian evolutionary method by sampling trees. The following subgenotypic distribution was observed: A1 (79%), F2a (12%), A2 (6%) and F4 (3%) as was that those identified as subgenotype A1 were in the same cluster in the phylogenetic tree. In this study, the majority of patients presented the A1 subgenotype from the same viral strain. As per the distribution in the phylogenetic tree by Bayesian method, possibly this subgenotype was in the genetic make-up of Africans brought in centuries past to Brazil as slaves. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Moura, Izolda Fernandes] Univ Fed Pernambuco, Hosp Clin, Cent Lab, Recife, PE, Brazil.
   [Lopes, Edmundo Pessoa] Univ Fed Pernambuco, Dept Internal Med, Div Gastroenterol, Recife, PE, Brazil.
   [Alvarado-Mora, Monica Viviana; Pinho, Joao Renato; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Lab Gastroenterol & Hepatol, Sao Paulo Inst Trop Med, BR-05508 Sao Paulo, Brazil.
   [Alvarado-Mora, Monica Viviana; Pinho, Joao Renato; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
RP Lopes, EP (corresponding author), Rua Irma Maria Davi,154 Ap3201, BR-52061070 Recife, PE, Brazil.
EM epalopes@uol.com.br
RI Carrilho, Flair J/I-3046-2012; Lopes, Edmundo/R-5159-2017; Pinho, Joao
   R. R./G-2850-2012
OI Lopes, Edmundo/0000-0002-3470-1564; Pinho, Joao R.
   R./0000-0003-3999-0489
CR Alcalde R, 2009, REV INST MED TROP SP, V51, P269, DOI 10.1590/S0036-46652009000500006
   Almeida Delvone, 2006, Braz J Infect Dis, V10, P317
   Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
   Alvarado-Mora MV, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-415
   Andernach IE, 2009, EMERG INFECT DIS, V15, P1222, DOI 10.3201/eid1508.081642
   Dias ALB, 2012, REV SOC BRAS MED TRO, V45, P9, DOI 10.1590/S0037-86822012000100003
   Becker Carlos Eduardo, 2010, Arq. Gastroenterol., V47, P13, DOI 10.1590/S0004-28032010000100003
   Bertolini D.A., 2012, INFECT GENET EVOL
   Ribeiro NRC, 2006, LIVER INT, V26, P636, DOI 10.1111/j.1478-3231.2006.01280.x
   Cao GW, 2009, WORLD J GASTROENTERO, V15, P5761, DOI 10.3748/wjg.15.5761
   Carrilho FJ, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-13
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Mello FCD, 2012, MEM I OSWALDO CRUZ, V107, P317, DOI 10.1590/S0074-02762012000300005
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Kim BK, 2011, ANTIVIR THER, V16, P1169, DOI 10.3851/IMP1982
   Kimbi GC, 2004, J GEN VIROL, V85, P1211, DOI 10.1099/vir.0.19749-0
   Kramvis A, 2007, HEPATOL RES, V37, pS9, DOI 10.1111/j.1872-034X.2007.00098.x
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Matos MAD, 2009, T ROY SOC TROP MED H, V103, P899, DOI 10.1016/j.trstmh.2009.01.013
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Motta-Castro A, 2008, ARCH VIROL, V153, P2197, DOI 10.1007/s00705-008-0237-0
   Palumbo E, 2007, BRAZ J INFECT DIS, V11, P311, DOI 10.1590/S1413-86702007000300002
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Raimondi S, 2010, J HEPATOL, V52, P441, DOI 10.1016/j.jhep.2009.12.014
   Santos AO, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-315
   Scheiblauer H, 2010, VOX SANG, V98, P403, DOI 10.1111/j.1423-0410.2009.01272.x
   Tanwar Sudeep, 2012, Curr Gastroenterol Rep, V14, P37, DOI 10.1007/s11894-011-0233-5
   Teles SA, 1999, ARTIF ORGANS, V23, P1074, DOI 10.1046/j.1525-1594.1999.06310.x
   Tonetto PA, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-149
   Valente F, 2010, MEM I OSWALDO CRUZ, V105, P970, DOI 10.1590/S0074-02762010000800004
   Wang Ge, 2010, J BIOMEDICAL IMAGING, V2010, P1, DOI DOI 10.1016/J.JHAZMAT.2010.08.103.20855153
NR 33
TC 15
Z9 15
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD MAR
PY 2013
VL 14
BP 195
EP 199
DI 10.1016/j.meegid.2012.11.022
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 115WE
UT WOS:000316841800025
PM 23268113
DA 2020-12-08
ER

PT J
AU Poynard, T
   Bruix, J
   Schiff, ER
   Diago, M
   Berg, T
   Moreno-Otero, R
   Lyra, AC
   Carrilho, F
   Griffel, LH
   Boparai, N
   Jiang, RY
   Burroughs, M
   Brass, CA
   Albrecht, JK
AF Poynard, Thierry
   Bruix, Jordi
   Schiff, Eugene R.
   Diago, Moises
   Berg, Thomas
   Moreno-Otero, Ricardo
   Lyra, Andre C.
   Carrilho, Flair
   Griffel, Louis H.
   Boparai, Navdeep
   Jiang, Ruiyun
   Burroughs, Margaret
   Brass, Clifford A.
   Albrecht, Janice K.
TI Improved inflammatory activity with peginterferon alfa-2b maintenance
   therapy in non-cirrhotic prior non-responders: A randomized study
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Fibrosis; Biomarkers; Hepatitis C; Liver; FibroTest
ID CHRONIC HEPATITIS-C; LIVER FIBROSIS; FIBROTEST; PROGRESSION; BIOMARKERS;
   DIAGNOSIS; ACTITEST
AB Background 82 Aims: Therapeutic options for patients failing hepatitis C retreatment are limited. EPIC3 included a prospective trial assessing long-term peginterferon alfa-2b (PegIFN alpha-2b) maintenance therapy in patients with METAVIR fibrosis scores (MFS) of F2 or F3 who previously failed hepatitis C retreatment.
   Methods: Patients with F2/F3 MFS who failed retreatment were randomized to PegIFN alpha-2b (0.5 mu g/kg/week, n = 270) or observation (n = 270) for 36 months. Blinded liver biopsies obtained before retreatment and after maintenance therapy were evaluated using MFS and activity scores, and confirmatory testing was performed using FibroTest and ActiTest.
   Results: In total, 348 patients had paired biopsies: 192 patients had missing post-treatment biopsies and were considered as having no change in fibrosis/activity scores. In total, 16% of patients receiving PegIFN alpha-2b and 11% of observation patients had improvement in MFS (p = 0.32). More PegIFN alpha-2b than observation patients had improvement in activity score (20% vs. 9%; p <0.001). Among patients treated for >2.5 years, improvement in MFS or activity score was more common with PegIFN alpha-2b than observation (21% vs. 14%, p = 0.08 and 26% vs. 10%, p <0.001). FibroTest and ActiTest evaluations indicated significant benefit associated with PegIFN alpha-2b in terms of reduced fibrosis progression and improved activity score. The safety profile of PegIFN alpha-2b was similar to previous studies.
   Conclusions: PegIFN alpha-2b did not significantly improve MFS estimated by biopsy compared with observation; however, activity scores were significantly improved and MFS trended toward increased improvement with treatment durations >2.5 years. Both FibroTest and ActiTest were significantly improved during maintenance therapy. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
C1 [Poynard, Thierry] APHP UPMC Paris Liver Ctr, Serv Hepatogastroenterol, Paris, France.
   [Bruix, Jordi] Univ Barcelona, Hosp Clin, Liver Unit, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain.
   [Schiff, Eugene R.] Univ Miami, Miller Sch Med, Ctr Liver Dis, Miami, FL 33136 USA.
   [Diago, Moises] Hosp Gen Univ Valencia, Valencia, Spain.
   [Berg, Thomas] Univ Klinikum Leipzig, Sekt Hepatol, Klin & Poliklin Gastroenterol & Rheumatol, Leipzig, Germany.
   [Moreno-Otero, Ricardo] Hosp Univ la Princesa IIS IP, Madrid, Spain.
   [Moreno-Otero, Ricardo] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Lyra, Andre C.] Hosp Sao Rafael, Salvador, BA, Brazil.
   [Lyra, Andre C.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Carrilho, Flair] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Griffel, Louis H.; Boparai, Navdeep; Jiang, Ruiyun; Burroughs, Margaret; Brass, Clifford A.; Albrecht, Janice K.] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA.
RP Poynard, T (corresponding author), Hop La Pitie Salpetriere, Serv Hepatol, 47-83 Blvd Hop, F-75651 Paris 13, France.
EM tpoynard@teaser.fr
RI DIAGO, MOISES/AAH-5364-2019; Carrilho, Flair J/I-3046-2012; Poynard,
   Thierry/C-1355-2010; Chaparro, Maria/I-2500-2016
OI Poynard, Thierry/0000-0002-3726-7230; Chaparro,
   Maria/0000-0002-9275-4242; Bruix, Jordi/0000-0002-9826-0753; Berg,
   Thomas/0000-0003-0003-6241; Poynard, Thierry/0000-0002-2050-640X
FU Merck & Co., Inc., Whitehouse Station, NJ, USAMerck & Company;
   BayerBayer AG; AbbottAbbott Laboratories; Anadys; BMSBristol-Myers
   Squibb; GileadGilead Sciences; MerckMerck & Company; Medtronics;
   Novelos; Orasure; RocheRoche Holding; VertexVertex Pharmaceuticals;
   Pharmasset; Merck Sharp Dohme Corp.Merck & Company
FX These studies were supported by Schering-Plough Corporation, now Merck &
   Co., Inc., Whitehouse Station, NJ, USA. This research received no
   specific grant from any funding agency in the public, commercial, or
   not-for-profit sectors.; T. Poynard is on a speakers bureau for Merck
   Sharp & Dohme Corp. and has stock ownership or equity in BioPredictive.
   J. Bruix has been a consultant for Bayer, Biocompatible, BMS, Glaxo,
   Kowa, Novartis, ArQule; has advisory arrangements with Bayer,
   Biocompatible, BMS; is on a speakers bureau for Bayer; and has received
   research and unrestricted grants from Bayer. E.R. Schiff has been a
   consultant for Gilead and Merck; has advisory arrangements with
   Bristol-Myers-Squibb, Gilead, and Vertex; and has received research
   grants from Abbott, Anadys, BMS, Gilead, Merck, Medtronics, Novelos,
   Orasure, Roche, Vertex, and Pharmasset. M. Diago has nothing to
   disclose. T. Berg is on a speakers bureau for Merck Sharp & Dohme
   Corp./Schering Plough. R. Moreno-Otero has nothing to disclose. AC Lyra
   is an investigator for the study. F. Carrilho has nothing to disclose.
   L.H. Griffel has stock ownership in and is a former employee of Merck
   Sharp & Dohme Corp. N. Boparai is a former employee of Merck Sharp &
   Dohme Corp. R. Jiang is an employee of Merck Sharp & Dohme Corp. M.
   Burroughs has stock ownership in and is an employee of Merck Sharp &
   Dohme Corp. C.A. Brass has stock ownership in and is a former employee
   of Merck Sharp & Dohme Corp. J.K. Albrecht is a former employee of Merck
   Sharp & Dohme Corp.; Medical writing and editorial assistance was
   provided by T. Ibbotson, PhD, and Santo D'Angelo, PhD, MS, of ApotheCom.
   This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of
   Merck & Co., Inc., Whitehouse Station, NJ, USA.
CR Afdhal NH, 2008, 43 ANN M EUR ASS STU
   Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482
   Bruix J, 2011, GASTROENTEROLOGY, V140, P1990, DOI 10.1053/j.gastro.2011.03.010
   Di Bisceglie AM, 2008, NEW ENGL J MED, V359, P2429, DOI 10.1056/NEJMoa0707615
   Dienstag JL, 2011, HEPATOLOGY, V54, P396, DOI 10.1002/hep.24370
   Ellis EL, 2012, J HEPATOL, V56, P1171, DOI 10.1016/j.jhep.2011.09.024
   Halfon P, 2008, GASTROEN CLIN BIOL, V32, P22, DOI 10.1016/S0399-8320(08)73991-5
   Imbert-Bismut F, 2005, ANN BIOL CLIN-PARIS, V63, P305
   Imbert-Bismut F, 2004, CLIN CHEM LAB MED, V42, P323, DOI 10.1515/CCLM.2004.058
   Manning DS, 2008, GASTROENTEROLOGY, V134, P1670, DOI 10.1053/j.gastro.2008.03.001
   McHutchison JG, 2010, NEW ENGL J MED, V362, P1292, DOI 10.1056/NEJMoa0908014
   Ngo Y, 2006, CLIN CHEM, V52, P1887, DOI 10.1373/clinchem.2006.070961
   Patel K, 2011, WORLD J GASTROENTERO, V17, P4581, DOI 10.3748/wjg.v17.i41.4581
   Poynard T, 2002, GASTROENTEROLOGY, V122, P1303, DOI 10.1053/gast.2002.33023
   Poynard Thierry, 2004, Comp Hepatol, V3, P8, DOI 10.1186/1476-5926-3-8
   Poynard T, 2012, J HEPATOL, V57, P541, DOI 10.1016/j.jhep.2012.04.025
   Poynard T, 2012, CLIN GASTROENTEROL H, V10, P657, DOI 10.1016/j.cgh.2012.01.023
   Poynard T, 2011, J HEPATOL, V54, P227, DOI 10.1016/j.jhep.2010.06.038
   Poynard T, 2010, ANTIVIR THER, V15, P617, DOI 10.3851/IMP1570
   Poynard T, 2009, GASTROENTEROLOGY, V136, P1618, DOI 10.1053/j.gastro.2009.01.039
   Snyder N, 2006, J CLIN GASTROENTEROL, V40, P535, DOI 10.1097/00004836-200607000-00013
   Vergniol J, 2011, GASTROENTEROLOGY, V140, P1970, DOI 10.1053/j.gastro.2011.02.058
NR 22
TC 5
Z9 5
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD MAR
PY 2013
VL 58
IS 3
BP 452
EP 459
DI 10.1016/j.jhep.2012.11.001
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 106TK
UT WOS:000316167400009
PM 23159770
DA 2020-12-08
ER

PT J
AU Vezozzo, DCP
   Mendes-Correa, MC
   Cunha-Silva, M
   Alvarado-Mora, MV
   Franca, JID
   Sebba, JL
   Nicodemo, AC
   Oliveira, CPMS
   Carrilho, FJ
AF Paranagua Vezozzo, Denise Cerqueira
   Mendes-Correa, Maria Cassia
   Cunha-Silva, Marlone
   Viviana Alvarado-Mora, Monica
   Dias Franca, Joao Italo
   Sebba, Jose Luiz
   Nicodemo, Antonio Carlos
   Oliveira, Claudia P. M. S.
   Carrilho, Flair Jose
TI Strong correlation by ultrasonography of hepatomegaly and the presence
   of co-infection in HIV/HCV cirrhotic patients
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Ultrasonography; HIV/HCV co-infection; Hepatomegaly; Liver size;
   Cirrhosis
ID CHRONIC HEPATITIS-C; HUMAN-IMMUNODEFICIENCY-VIRUS; LIVER FIBROSIS;
   ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; RISK-FACTORS; HIV;
   ULTRASOUND; AIDS; PROGRESSION
AB Objectives: Progression of hepatic fibrosis is accelerated in patients co-infected with human immunodeficiency virus and hepatitis C virus compared to hepatitis C virus mono-infected patients. This study aimed to compare ultrasound features and selected clinical and biochemical variables between patients with human immunodeficiency virus/hepatitis C virus co-infection (n = 16) versus hepatitis C virus mono-infection (n = 16).
   Methods: Each patient underwent abdominal ultrasound, and a specific evaluation was performed in order to detect findings consistent with chronic liver disease. Characterization of spleen size, liver structural pattern, diameter of the portal, spleen, and mesenteric veins was based on classical ultrasound parameters. Propensity score was used for control of selection bias and performed using binary logistic regression to generate a score for each patient. The Fisher and Mann-Whitney tests were used to evaluate categorical variables and continuous variables, respectively.
   Results: On univariate analysis right hepatic lobe size was larger in human immunodeficiency virus/hepatitis C virus patients (157.06 +/- 17.56 mm) compared to hepatitis C virus mono-infected patients (134.94 +/- 16.95 mm) (p = 0.0011). The left hepatic lobe was also significantly larger in human immunodeficiency virus/hepatitis C virus patients (115.88 +/- 22.69 mm) versus hepatitis C virus mono-infected patients (95.06 +/- 24.18 mm) (p = 0.0177). Also, there was a strong correlation between hepatomegaly and co-infection (p = 0.005).
   Conclusion: Human immunodeficiency virus infection was the primary variable influencing liver enlargement in this population. Hepatomegaly on ultrasound was more common among cirrhotic human immunodeficiency virus/hepatitis C virus co-infected patients than among cirrhotic hepatitis C virus mono-infected patients. This aspect is very important in the management of human immunodeficiency virus/hepatitis C virus co-infected patients, because screening for hepatocellular carcinoma is necessary in this population. (C) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Paranagua Vezozzo, Denise Cerqueira; Cunha-Silva, Marlone; Viviana Alvarado-Mora, Monica; Dias Franca, Joao Italo; Sebba, Jose Luiz; Oliveira, Claudia P. M. S.; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Mendes-Correa, Maria Cassia; Nicodemo, Antonio Carlos] Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-05403000 Sao Paulo, Brazil.
RP Vezozzo, DCP (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, Av Dr Eneas de Carvalho Aguiar 255, BR-05403000 Sao Paulo, Brazil.
EM denise.paranagua@gmail.com
RI correa, maria cassia mendes/A-6779-2013; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014; Carrilho, Flair J/I-3046-2012; Oliveira, Claudia
   PMS/D-1216-2014
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; Cunha-Silva,
   Marlone/0000-0002-4424-6606
FU Alves de Queiroz Family Fund
FX We are deeply indebted to the Alves de Queiroz Family Fund for the
   continuous sponsoring support.
CR Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432
   Allory Y, 2000, HUM PATHOL, V31, P69, DOI 10.1016/S0046-8177(00)80201-4
   Amorosa V, 2005, JAIDS-J ACQ IMM DEF, V39, P557
   ASTAGNEAU P, 1990, ANN MED INTERNE, V141, P459
   Barreiro P, 2006, CLIN INFECT DIS, V42, P1032, DOI 10.1086/501021
   Bjornsson E, 2007, ARCH MED RES, V38, P621, DOI 10.1016/j.arcmed.2006.09.001
   Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179
   Cholet F, 2003, GASTROEN CLIN BIOL, V28, P272
   GOSINK BB, 1981, J CLIN ULTRASOUND, V9, P37, DOI 10.1002/jcu.1870090110
   Gotzberger M, 2006, Praxis (Bern 1994), V95, P183
   HISLOP WS, 1983, Q J MED, V52, P232
   Kratzer W, 2003, J ULTRAS MED, V22, P1155, DOI 10.7863/jum.2003.22.11.1155
   Lesi OA, 2009, J NATL MED ASSOC, V101, P151, DOI 10.1016/S0027-9684(15)30828-2
   Lizardi-Cervera Javier, 2005, Ann Hepatol, V4, P188
   Mallon PWG, 2007, CURR OPIN HIV AIDS, V2, P282, DOI 10.1097/COH.0b013e3281e72ca0
   Martin-Carbonero L, 2004, CLIN INFECT DIS, V38, P128, DOI 10.1086/380130
   Martinez-Sierra C, 2003, CLIN INFECT DIS, V36, P491, DOI 10.1086/367643
   Matsutani S, 1987, PORTAL HYPERTENSION, P197
   Meier JM, 2007, SEMIN NUCL MED, V37, P154, DOI 10.1053/j.semnuclmed.2007.02.001
   Mendes-Correa MCJ, 2005, AM J TROP MED HYG, V72, P762
   Monto A, 2006, AM J GASTROENTEROL, V101, P1509, DOI 10.1111/j.1572-0241.2006.00613.x
   Neau D, 2007, JAIDS-J ACQ IMM DEF, V45, P168, DOI 10.1097/QAI.0b013e318042e1db
   Palmentieri B, 2006, DIGEST LIVER DIS, V38, P485, DOI 10.1016/j.dld.2006.03.021
   PIETRI H, 1988, J ULTRAS MED, V7, P189
   Richard P, 1985, J Radiol, V66, P503
   SAPIRA JD, 1979, ARCH INTERN MED, V139, P971, DOI 10.1001/archinte.139.9.971
   Serfaty L, 1997, HEPATOLOGY, V26, P776, DOI 10.1002/hep.510260334
   Simonovsky V, 1999, BRIT J RADIOL, V72, P29, DOI 10.1259/bjr.72.853.10341686
   Soriano V, 2007, AIDS, V21, P1073, DOI 10.1097/QAD.0b013e3281084e4d
   Sulkowski MS, 2000, CLIN INFECT DIS, V30, pS77, DOI 10.1086/313842
   Tien Phyllis C, 2002, Semin Gastrointest Dis, V13, P47
   Tshibwabwa ET, 2000, ABDOM IMAGING, V25, P290, DOI 10.1007/s002610000035
   Wigg AJ, 2001, GUT, V48, P206, DOI 10.1136/gut.48.2.206
   ZOLI M, 1995, AM J GASTROENTEROL, V90, P1428
NR 34
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2013
VL 17
IS 2
BP 150
EP 155
DI 10.1016/j.bjid.2012.09.009
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 141RD
UT WOS:000318743300006
PM 23453412
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Silva, MF
   Strasser, SI
   Carrilho, FJ
AF Silva, Mauricio F.
   Strasser, Simone I.
   Carrilho, Flair J.
TI Is hepatic venous pressure gradient assessment required before liver
   resection in patients with cirrhosis and hepatocellular carcinoma?
SO CLINICS
LA English
DT Editorial Material
C1 [Silva, Mauricio F.] Santa Casa Gen Hosp, Dept Liver Transplantat, Porto Alegre, RS, Brazil.
   [Strasser, Simone I.] Royal Prince Alfred Hosp, AW Morrow Gastroenterol & Liver Ctr, Sydney, NSW, Australia.
   [Carrilho, Flair J.] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Silva, MF (corresponding author), Santa Casa Gen Hosp, Dept Liver Transplantat, Porto Alegre, RS, Brazil.
EM mauriciosilva11@yahoo.com.br
RI Carrilho, Flair J/I-3046-2012
CR Boleslawski E, 2012, BRIT J SURG, V99, P855, DOI 10.1002/bjs.8753
   Bruix J, 1996, GASTROENTEROLOGY, V111, P1018, DOI 10.1016/S0016-5085(96)70070-7
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Germani G, 2011, LIVER TRANSPLANT, V17, pS58, DOI 10.1002/lt.22336
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629
   Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Simpson KJ, 1995, BAILLIERE CLIN GASTR, V9, P639, DOI 10.1016/0950-3528(95)90054-3
   Tremosini S, 2010, DIGEST LIVER DIS, V42, pS242, DOI 10.1016/S1590-8658(10)60512-9
NR 10
TC 0
Z9 0
U1 0
U2 0
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
J9 CLINICS
JI Clinics
PY 2013
VL 68
IS 4
BP 437
EP 440
DI 10.6061/clinics/2013(04)01
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 158VO
UT WOS:000320002000001
PM 23778344
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Silvestre, OM
   Bacal, F
   Ramos, DD
   Andrade, JL
   Furtado, M
   Pugliese, V
   Belleti, E
   Andraus, W
   Carrilho, FJ
   D'Albuquerque, LAC
   Farias, AQ
AF Silvestre, Odilson Marcos
   Bacal, Fernando
   Ramos, Danusa de Souza
   Andrade, Jose L.
   Furtado, Meive
   Pugliese, Vincenzo
   Belleti, Elisangela
   Andraus, Wellington
   Carrilho, Flair Jose
   Carneiro D'Albuquerque, Luiz Augusto
   Farias, Alberto Queiroz
TI Impact of the severity of end-stage liver disease in cardiac structure
   and function
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Cirrhosis; Cardiac remodeling; Liver transplantation; MELD score;
   Cirrhotic cardiomyopathy
ID LEFT ATRIAL VOLUME; CIRRHOTIC CARDIOMYOPATHY; HYPERDYNAMIC CIRCULATION;
   HEPATOPULMONARY SYNDROME; ARTERIAL VASODILATION; CLINICAL-IMPLICATIONS;
   HEPATORENAL-SYNDROME; REFRACTORY ASCITES; AMERICAN-SOCIETY;
   HEART-FAILURE
AB Background. The impact of end-stage liver disease (ESLD) in cardiac remodeling of patients with cirrhosis is unknown. Our aim was to correlate the severity of ESLD with morphologic and functional heart changes. Material and methods. 184 patients underwent a protocol providing data on the severity of ESLD and undergoing echocardiography to assess the diameters of the left atrium and right ventricle; the systolic and diastolic diameters of the left ventricle, interventricular septum, and posterior wall of the left ventricle; systolic pulmonary artery pressure; ejection fraction; and diastolic function. Severity of ESLD was assessed by the Model for End-Stage Liver Disease (MELD) score. Results. Left-atrial diameter (r = 0.323; IC 95% 0.190-0.455; p < 0.001), left-ventricular diastolic diameter (r = 0.177; IC 95% 0.033-0.320; p = 0.01) and systolic pulmonary artery pressure (r = 0.185; IC 95% 0.036-0.335; p = 0.02) significantly correlated with MELD score. Patients with MELD 16 had significantly higher left-atrial diameter and systolic pulmonary artery pressure, compared with patients with MELD scores < 16 points. Conclusions. Changes in cardiac structure and function correlate with the severity of ESLD.
C1 [Ramos, Danusa de Souza; Pugliese, Vincenzo; Belleti, Elisangela; Andraus, Wellington; Carrilho, Flair Jose; Carneiro D'Albuquerque, Luiz Augusto; Farias, Alberto Queiroz] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   [Silvestre, Odilson Marcos; Bacal, Fernando] Univ Sao Paulo, Sch Med, Inst Heart, BR-05508 Sao Paulo, Brazil.
   [Andrade, Jose L.; Furtado, Meive] Univ Sao Paulo, Sch Med, Inst Radiol, BR-05508 Sao Paulo, Brazil.
RP Farias, AQ (corresponding author), Univ Sao Paulo, Hosp Clin, Av Dr Eneas de Carvalho Aguiar 255,Sala 9117, BR-05403000 Sao Paulo, Brazil.
EM albertofarias@terra.com.br
RI Bacal, Fernando/H-7952-2012; Carrilho, Flair J/I-3046-2012; Farias,
   Alberto Q/H-7873-2013; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012;
   Farias, Alberto/ABB-1291-2020; D'Albuquerque, Luiz Augusto
   Carneiro/A-8812-2013; Andraus, Wellington/G-1860-2012
OI Farias, Alberto/0000-0002-5572-663X; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Andraus, Wellington/0000-0002-5162-138X
FU Department of Gastroenterology of the University of Sao Paulo
FX This study was supported by the Department of Gastroenterology of the
   University of Sao Paulo.
CR Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164
   BENJAMIN EJ, 1995, CIRCULATION, V92, P835, DOI 10.1161/01.CIR.92.4.835
   BRAVERMAN AC, 1995, CHEST, V107, P1467, DOI 10.1378/chest.107.5.1467
   Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0
   De BK, 2003, J HEPATOL, V39, P315, DOI 10.1016/S0168-8278(03)00271-X
   Douglas PS, 2009, J AM SOC ECHOCARDIOG, V22, P755, DOI 10.1016/j.echo.2009.05.020
   Fouad TR, 2009, TRANSPLANTATION, V87, P763, DOI 10.1097/TP.0b013e318198d734
   Freeman RB, 2002, LIVER TRANSPLANT, V8, P851, DOI 10.1053/jlts.2002.35927
   Gines P, 2002, GASTROENTEROLOGY, V123, P1839, DOI 10.1053/gast.2002.37073
   Gottdiener JS, 2006, AM J CARDIOL, V97, P83, DOI 10.1016/j.amjcard.2005.07.126
   HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421
   Huo TI, 2008, LIVER INT, V28, P606, DOI 10.1111/j.1478-3231.2008.01727.x
   Krowka MJ, 2004, LIVER TRANSPLANT, V10, P174, DOI 10.1002/lt.20016
   Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005
   Lapa M, 2009, CIRCULATION, V119, P1518, DOI 10.1161/CIRCULATIONAHA.108.803221
   LEWIS FW, 1992, GASTROENTEROLOGY, V102, P1024, DOI 10.1016/0016-5085(92)90192-2
   Ma ZH, 1996, HEPATOLOGY, V24, P451
   Malinchoc M, 2000, HEPATOLOGY, V31, P864, DOI 10.1053/he.2000.5852
   Merion RM, 2004, LIVER TRANSPLANT, V10, pS69, DOI 10.1002/lt.20265
   Moller S, 2008, GUT, V57, P268, DOI 10.1136/gut.2006.112177
   Moller S, 2002, HEART, V87, P9, DOI 10.1136/heart.87.1.9
   Moller S, 2011, GUT, V60, P1254, DOI 10.1136/gut.2010.235473
   Nagueh SF, 2009, J AM SOC ECHOCARDIOG, V22, P107, DOI 10.1016/j.echo.2008.11.023
   PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161
   Pozzi M, 1997, HEPATOLOGY, V26, P1131
   Rabie RN, 2009, AM J GASTROENTEROL, V104, P2458, DOI 10.1038/ajg.2009.321
   Ripoll C, 2008, TRANSPLANTATION, V85, P1766, DOI 10.1097/TP.0b013e318172c936
   Rodriguez-Roisin R, 2004, EUR RESPIR J, V24, P861, DOI 10.1183/09031936.04.00010904
   Ruiz-del-Arbol L, 2005, HEPATOLOGY, V42, P439, DOI 10.1002/hep.20766
   Safadi A, 2009, CIRCULATION, V120, P1189, DOI 10.1161/CIRCULATIONAHA.108.847178
   SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532
   Snowden CP, 2000, LIVER TRANSPLANT, V6, P466, DOI 10.1053/jlts.2000.7580
   Valeriano V, 2000, AM J GASTROENTEROL, V95, P3200
   Wong F, 1999, CLIN SCI, V97, P259, DOI 10.1042/CS19990026
   Zamirian M, 2007, AM J GASTROENTEROL, V102, P1392, DOI 10.1111/j.1572-0241.2007.01228.x
   Zardi EM, 2010, J AM COLL CARDIOL, V56, P539, DOI 10.1016/j.jacc.2009.12.075
NR 36
TC 17
Z9 20
U1 0
U2 2
PU MEXICAN ASSOC HEPATOLOGY
PI MEXICO
PA PUNTE DE PIEDRA 150, COLONIA TORIELLO GUERRA, MEXICO, DF CP 14040,
   MEXICO
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD JAN-FEB
PY 2013
VL 12
IS 1
BP 85
EP 91
DI 10.1016/S1665-2681(19)31389-4
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 145PU
UT WOS:000319030100011
PM 23293198
OA Other Gold
DA 2020-12-08
ER

PT J
AU Kikuchi, L
   Chagas, AL
   Alencar, RSSM
   Paranagua-Vezozzo, DC
   Carrilho, FJ
AF Kikuchi, Luciana
   Chagas, Aline L.
   Alencar, Regiane S. S. M.
   Paranagua-Vezozzo, Denise C.
   Carrilho, Flair J.
TI Clinical and epidemiological aspects of hepatocellular carcinoma in
   Brazil
SO ANTIVIRAL THERAPY
LA English
DT Review
AB The global hepatocellular carcinoma (HCC) incidence is widely variable, depending on geographic region and the prevalence of major risk factors. In Brazil, two large multicentre retrospective studies were performed to investigate clinical and epidemiological aspects of HCC. In the first study, performed in 1997, HCC was found in cirrhotic livers in 71% of cases. Chronic alcoholism was present in 36% of cases, chronic hepatitis B in 35% and hepatitis C in 25%. In a 2010 survey, cirrhosis was present in 98% of cases and HCV was the main aetiology (54%). Differences in HBV prevalence were found among regions. Selection of HCC treatment depends on tumour burden, liver function and performance status. Liver transplantation ( LT) is the best available curative treatment for HCC in its early stage and with compromised liver function. After modifications in priority policy, the number of patients with early HCC submitted for LT has increased in the past 5 years in Brazil. Chemoembolization is the most common initial HCC therapy in early and intermediate stages of HCC in Brazil.
C1 [Kikuchi, Luciana; Chagas, Aline L.; Alencar, Regiane S. S. M.; Paranagua-Vezozzo, Denise C.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo Clin Liver Canc Grp,Hosp Clin,Inst Canc, Sao Paulo, Brazil.
RP Carrilho, FJ (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo Clin Liver Canc Grp,Hosp Clin,Inst Canc, Sao Paulo, Brazil.
EM fjcarril@usp.br
RI Chagas, Aline Lopes/X-2059-2019; Carrilho, Flair J/I-3046-2012;
   Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935
CR Alves RC, 2001, ANN HEPATOL, V10, P21
   Brazilian Association of Organ Transplantation, 2010, BRAZ TRANSPL REG 15
   Brazilian Health Ministry, 2003, NAT IMM PROGR
   Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
   Bruix J, 1996, GASTROENTEROLOGY, V111, P1018, DOI 10.1016/S0016-5085(96)70070-7
   Cancer Research UK, LIV CANC INC STAT
   Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
   Cella LTC, 2009, THESIS U SAO PAULO S
   Chagas AL, 2009, BRAZ J MED BIOL RES, V42, P958, DOI 10.1590/S0100-879X2009005000019
   Chang MH, 2009, JNCI-J NATL CANCER I, V101, P1348, DOI 10.1093/jnci/djp288
   Da Silva L C, 2005, Gastroenterol Hepatol, V28, P30
   El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013
   El-Serag HB, HEPATOCELLULAR CARCI
   Fay OH, 2009, VACCINE S1, V8, pS100
   Gomaa AI, 2008, WORLD J GASTROENTERO, V14, P4300, DOI 10.3748/wjg.14.4300
   Goncalves Carlos S., 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P165, DOI 10.1590/S0036-46651997000300008
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Nogueira JA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-204
   Orlando A, 2009, AM J GASTROENTEROL, V104, P514, DOI 10.1038/ajg.2008.80
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Sherman M, 2010, ONCOLOGY-BASEL, V78, P7, DOI 10.1159/000315223
   Teixeira AC, 2010, TRANSPL P, V42, P502, DOI 10.1016/j.transproceed.2010.01.045
   Freitas Alexandre Coutinho Teixeira de, 2010, Arq. Gastroenterol., V47, P233, DOI 10.1590/S0004-28032010000300004
NR 24
TC 12
Z9 12
U1 0
U2 5
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2013
VL 18
IS 3
BP 445
EP 449
DI 10.3851/IMP2602
PN B
PG 5
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA AG2FM
UT WOS:000335231500004
PM 23793796
OA Green Published
DA 2020-12-08
ER

PT J
AU Mazo, DFC
   de Oliveira, MG
   Pereira, IVA
   Cogliati, B
   Stefano, JT
   de Souza, GFP
   Rabelo, F
   Lima, FR
   Alves, VAF
   Carrilho, FJ
   de Oliveira, CPMS
AF Mazo, Daniel F. C.
   de Oliveira, Marcelo G.
   Pereira, Isabel V. A.
   Cogliati, Bruno
   Stefano, Jose T.
   de Souza, Gabriela F. P.
   Rabelo, Fabiola
   Lima, Fabiana R.
   Alves, Venancio A. Ferreira
   Carrilho, Flair J.
   de Oliveira, Claudia P. M. S.
TI S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental
   nonalcoholic steatohepatitis
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE nitric oxide; S-nitroso-N-acetylcysteine; fibrogenesis; NASH;
   diethylnitrosamine
ID NITRIC-OXIDE; SPECIAL EMPHASIS; EXPRESSION; MECHANISMS; CIRRHOSIS;
   PROLIFERATION; EPIDEMIOLOGY; PEROXIDATION; INHIBITION; RESOLUTION
AB S-Nitroso-N-acetylcysteine (SNAC) is a water soluble primary S-nitrosothiol capable of transferring and releasing nitric oxide and inducing several biochemical activities, including modulation of hepatic stellate cell activation. In this study, we evaluated the antifibrotic activity of SNAC in an animal model of nonalcoholic steatohepatitis (NASH) induced in Sprague-Dawley rats fed with a choline-deficient, high trans fat diet and exposed to diethylnitrosamine for 8 weeks. The rats were divided into three groups: SNAC, which received oral SNAC solution daily; NASH, which received the vehicle; and control, which received standard diet and vehicle. Genes related to fibrosis (matrix metalloproteinases [MMP]-13, -9, and -2), transforming growth factor beta-1 [TGF beta-1], collagen-1 alpha, and tissue inhibitors of metalloproteinase [TIMP-1 and -2] and oxidative stress (heat-shock proteins [HSP]-60 and -90) were evaluated. SNAC led to a 34.4% reduction in the collagen occupied area associated with upregulation of MMP-13 and -9 and downregulation of HSP-60, TIMP-2, TGF beta-1, and collagen-1 alpha. These results indicate that oral SNAC administration may represent a potential antifibrotic treatment for NASH.
C1 [Mazo, Daniel F. C.; Pereira, Isabel V. A.; Stefano, Jose T.; Rabelo, Fabiola; Carrilho, Flair J.; de Oliveira, Claudia P. M. S.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch LIM 07,Clin Div, Sao Paulo, Brazil.
   [de Oliveira, Marcelo G.; de Souza, Gabriela F. P.] Univ Estadual Campinas, UNICAMP, Inst Chem, BR-13083970 Campinas, SP, Brazil.
   [Cogliati, Bruno] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Pathol, Sao Paulo, Brazil.
   [Lima, Fabiana R.; Alves, Venancio A. Ferreira] Univ Sao Paulo, Sch Med, Dept Pathol LIMI4, Sao Paulo, Brazil.
RP de Oliveira, MG (corresponding author), Univ Estadual Campinas, UNICAMP, Inst Chem, CP 6154, BR-13083970 Campinas, SP, Brazil.
EM mgo@iqm.unicamp.br; cpm@usp.br
RI Mazo, Daniel FC/D-5631-2015; Carrilho, Flair J/I-3046-2012; Stefano,
   Jose T/H-4792-2013; Oliveira, Claudia PMS/D-1216-2014; de Oliveira,
   Marcelo Ganzarolli/B-4709-2013; Stefano, Jose Tadeu/AAH-5419-2020;
   Cogliati, Bruno/E-9956-2012; de souza, Gabriela/G-3508-2016; de souza,
   gabriela/N-4225-2015; Veloso Alves Pereira, Isabel/N-4616-2014
OI Mazo, Daniel FC/0000-0002-2164-2630; de Oliveira, Marcelo
   Ganzarolli/0000-0002-9371-9975; Stefano, Jose Tadeu/0000-0002-0218-1920;
   Cogliati, Bruno/0000-0002-1388-7240; de souza,
   gabriela/0000-0002-2792-9683; Veloso Alves Pereira,
   Isabel/0000-0002-3439-1658
FU FAPESP - Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [08/56157-7,
   08/52454-7, 11/50514-5]; Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico, CNPqNational Council for Scientific and Technological
   Development (CNPq) [309390/2011-7, 482646/2010-1]
FX This study was supported by grants from FAPESP - Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (project #08/56157-7). DFCM and GFPS
   received a fellowship from FAPESP (projects #08/52454-7 and #11/50514-5,
   respectively). MGO acknowledges financial support from Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico, CNPq (projects
   #309390/2011-7 and 482646/2010-1). We would like to thank Heraldo
   Possolo de Souza and Francisco Garcia Soriano for technical support and
   Fabio Marra for critically reading the manuscript.
CR Aitio ML, 2006, BRIT J CLIN PHARMACO, V61, P5, DOI 10.1111/j.1365-2125.2005.02523.x
   Argo CK, 2009, CLIN LIVER DIS, V13, P511, DOI 10.1016/j.cld.2009.07.005
   Baumgardner JN, 2008, J NUTR, V138, P1872
   Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552
   Byrne CD, 2009, CLIN SCI, V116, P539, DOI 10.1042/CS20080253
   Cogliati Bruno, 2010, Arq. Gastroenterol., V47, P79, DOI 10.1590/S0004-28032010000100014
   de Lima VM, 2008, J HEPATOL, V49, P1055, DOI 10.1016/j.jhep.2008.07.024
   de Oliveira CPMS, 2008, J AM COLL NUTR, V27, P299, DOI 10.1080/07315724.2008.10719703
   de Oliveira CPMS, 2006, WORLD J GASTROENTERO, V12, P1905, DOI 10.3748/wjg.v12.i12.1905
   de Oliveira MG, 2002, J PHYS CHEM A, V106, P8963, DOI 10.1021/jp025756u
   Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327
   Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003
   Galicia-Moreno M, 2009, EUR J GASTROEN HEPAT, V21, P908, DOI 10.1097/MEG.0b013e32831f1f3a
   Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7
   Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003
   Hernandez-Gea V, 2011, ANNU REV PATHOL-MECH, V6, P425, DOI 10.1146/annurev-pathol-011110-130246
   Ignarro LJ, 2002, CIRC RES, V90, P21, DOI 10.1161/hh0102.102330
   Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018
   Issa R, 2002, FASEB J, V16, P47, DOI 10.1096/fj.02-0494fje
   Issa R, 2004, GASTROENTEROLOGY, V126, P1795, DOI 10.1053/j.gastro.2004.03.009
   JAMES J, 1990, LIVER, V10, P1
   Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443
   Lewis JR, 2010, DIGEST DIS SCI, V55, P560, DOI 10.1007/s10620-009-1081-0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   de Oliveira CPMS, 2006, J HEPATOL, V45, P725, DOI 10.1016/j.jhep.2006.05.017
   Martinez V, 2002, J PHARMACOL EXP THER, V301, P611, DOI 10.1124/jpet.301.2.611
   Okazaki Isao, 2001, Keio Journal of Medicine, V50, P58
   Oliveira CPMS, 2007, BIOCHEM PHARMACOL, V74, P290, DOI 10.1016/j.bcp.2007.04.013
   Ramachandran P, 2009, ANN HEPATOL, V8, P283, DOI 10.1016/S1665-2681(19)31740-5
   Ricardo KFS, 2002, NITRIC OXIDE-BIOL CH, V7, P57, DOI 10.1016/S1089-8603(02)00009-5
   Roderfeld M, 2007, Z GASTROENTEROL, V45, P25, DOI 10.1055/s-2006-927388
   Roderfeld M, 2006, FASEB J, V20, P444, DOI 10.1096/fj.05-4828com
   RUBBO H, 1994, J BIOL CHEM, V269, P26066
   Sherman M, 2010, SEMIN LIVER DIS, V30, P3, DOI 10.1055/s-0030-1247128
   Simplicio FI, 2010, J BRAZIL CHEM SOC, V21, P1885, DOI 10.1590/S0103-50532010001000013
   Stefano JT, 2011, NITRIC OXIDE-BIOL CH, V25, P360, DOI 10.1016/j.niox.2011.07.001
   Timerghazin QK, 2007, ORG LETT, V9, P3049, DOI 10.1021/ol0711016
   Ueberham E, 2003, HEPATOLOGY, V37, P1067, DOI 10.1053/jhep.2003.50196
   Vercelino R, 2010, J MOL MED, V88, P401, DOI 10.1007/s00109-009-0577-6
   Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200
   Williams DLH, 2003, ORG BIOMOL CHEM, V1, P441, DOI 10.1039/b209748f
   Zhou XY, 2004, J BIOL CHEM, V279, P23996, DOI 10.1074/jbc.M311668200
NR 42
TC 15
Z9 15
U1 0
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2013
VL 7
BP 553
EP 563
DI 10.2147/DDDT.S43930
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 172EM
UT WOS:000320982800001
PM 23843692
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Mazo, DF
   De Oliveira, MG
   Pereira, IV
   Cogliati, B
   Stefano, JT
   De, SGF
   Rabelo, F
   Lima, FR
   Alves, VAF
   Carrilho, FJ
   de Oliveira, CP
AF Mazo, D. F.
   De Oliveira, M. G.
   Pereira, I., V
   Cogliati, B.
   Stefano, J. T.
   de Souza, G. F.
   Rabelo, F.
   Lima, F. R.
   Ferreira Alves, V. A.
   Carrilho, F. J.
   de Oliveira, C. P.
TI S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental
   nonalcoholic steatohepatitis (vol 7, pg 553, 2013)
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Correction
RI de Oliveira, Marcelo Ganzarolli/B-4709-2013; Carrilho, Flair
   J/I-3046-2012; Stefano, Jose T/H-4792-2013; Oliveira, Claudia
   PMS/D-1216-2014; Stefano, Jose Tadeu/AAH-5419-2020; Mazo, Daniel
   FC/D-5631-2015
OI de Oliveira, Marcelo Ganzarolli/0000-0002-9371-9975; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Mazo, Daniel FC/0000-0002-2164-2630
CR Mazo DFC, 2013, DRUG DES DEV THER, V7, P553, DOI 10.2147/DDDT.S43930
NR 1
TC 0
Z9 0
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2013
VL 7
BP 971
EP 972
DI 10.2147/DDDT.S52000
PG 2
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 215RO
UT WOS:000324228200001
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-08
ER

PT J
AU Alvarado-Mora, MV
   Romano, CM
   Gomes-Gouvea, MS
   Gutierrez, MF
   Carrilho, FJ
   Pinho, JRR
AF Alvarado-Mora, Monica V.
   Romano, Camila M.
   Gomes-Gouvea, Michele S.
   Gutierrez, Maria F.
   Carrilho, Flair J.
   Pinho, Joao R. R.
TI Phylogenetic analysis of complete genome sequences of hepatitis B virus
   from an Afro-Colombian community: presence of HBV F3/A1 recombinant
   strain
SO VIROLOGY JOURNAL
LA English
DT Article
DE Hepatitis B virus; Subgenotype A1; Genotype E; Subgenotype D3; Bayesian
   analysis; Recombinant subgenotype F3/A1; Colombia
ID MOLECULAR CHARACTERIZATION; GENETIC DIVERSITY; GENOTYPE-A; SUBGENOTYPE;
   EPIDEMIOLOGY; AMERINDIANS; INFECTIONS; AMAZONAS; REGION
AB Background: Hepatitis B virus (HBV) infection is one of the most prevalent viral infections in humans and represents a serious public health problem. In Colombia, our group reported recently the presence of subgenotypes F3, A2 and genotype G in Bogota. The aim of this study was to characterize the HBV genotypes circulating in Quibdo, the largest Afro-descendant community in Colombia. Sixty HBsAg-positive samples were studied. A fragment of 1306 bp (S/POL) was amplified by nested PCR. Positive samples to S/POL fragment were submitted to PCR amplification of the HBV complete genome.
   Findings: The distribution of HBV genotypes was: A1 (52.17%), E (39.13%), D3 (4.3%) and F3/A1 (4.3%). An HBV recombinant strain subgenotype F3/A1 was found for the first time.
   Conclusions: This study is the first analysis of complete HBV genome sequences from Afro-Colombian population. It was found an important presence of HBV/A1 and HBV/E genotypes. A new recombinant strain of HBV genotype F3/A1 was reported in this population. This fact may be correlated with the introduction of these genotypes in the times of slavery.
C1 [Alvarado-Mora, Monica V.; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Pinho, Joao R. R.] Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Alvarado-Mora, Monica V.; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Pinho, Joao R. R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Romano, Camila M.] Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Dept Infect & Parasit Dis LIMHC, Sao Paulo, Brazil.
   [Gutierrez, Maria F.] Pontificia Javeriana Univ, Dept Microbiol, Virol Lab, Bogota, Colombia.
RP Alvarado-Mora, MV (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Gutierrez, Maria/AAF-2966-2019; Romano, Camila M/C-8185-2013; Pinho,
   Joao R. R./G-2850-2012; Alvarado-Mora, Monica/I-3180-2012; Carrilho,
   Flair J/I-3046-2012; Romano, Camila/ABC-2883-2020
OI Pinho, Joao R. R./0000-0003-3999-0489; Romano,
   Camila/0000-0003-4550-1987
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo -
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2007/53457-7/2011/50562-0, 2008/50461-6]; HCFMUSP; FFM
FX This study was previously presented as a poster in 2011 in the 62nd
   annual meeting of the American association for the study of liver
   diseases in San Francisco, United States of America. This work has been
   supported by CNPq and by Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo - FAPESP 2007/53457-7/2011/50562-0 and 2008/50461-6, HCFMUSP and
   FFM.
CR Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
   Alvarado-Mora MV, 2011, PLOS ONE, V6
   Andernach IE, 2009, EMERG INFECT DIS, V15, P1222, DOI 10.3201/eid1508.081642
   Mbayed VA, 2009, ARCH VIROL, V154, P525, DOI 10.1007/s00705-009-0328-6
   ARBOLEDA M, 1995, T ROY SOC TROP MED H, V89, P481, DOI 10.1016/0035-9203(95)90074-8
   Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Duarte MC, 2010, TROP MED INT HEALTH, V15, P924, DOI 10.1111/j.1365-3156.2010.02560.x
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   FAY OH, 1990, VACCINE, V8, pS100, DOI 10.1016/0264-410X(90)90228-E
   Gomes-Gouvea MS, 2005, CHARACTERIZATION COM, P130
   Hannoun C, 2005, J GEN VIROL, V86, P2163, DOI 10.1099/vir.0.80972-0
   Hubschen JM, 2011, CLIN MICROBIOL INFEC, V17, P88, DOI 10.1111/j.1469-0691.2010.03205.x
   Kramvis A, 2002, J GEN VIROL, V83, P835, DOI 10.1099/0022-1317-83-4-835
   Kramvis A, 2007, HEPATOL RES, V37, pS27, DOI 10.1111/j.1872-034X.2007.00100.x
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   Motta-Castro ARC, 2005, J MED VIROL, V77, P188, DOI 10.1002/jmv.20435
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   Olinger CM, 2006, J GEN VIROL, V87, P1163, DOI 10.1099/vir.0.81614-0
   Pourkarim MR, 2010, J CLIN VIROL, V47, P93, DOI 10.1016/j.jcv.2009.09.032
   Purdy MA, 2008, J GEN VIROL, V89, P1179, DOI 10.1099/vir.0.83392-0
   Simmonds P, 2005, J VIROL, V79, P15467, DOI 10.1128/JVI.79.24.15467-15476.2005
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Sugauchi F, 2002, J VIROL, V76, P5985, DOI 10.1128/JVI.76.12.5985-5992.2002
   Tanaka J, 2000, VACCINE, V18, pS17, DOI 10.1016/S0264-410X(99)00455-7
   Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297
NR 28
TC 9
Z9 9
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD OCT 24
PY 2012
VL 9
AR 244
DI 10.1186/1743-422X-9-244
PG 7
WC Virology
SC Virology
GA 037SL
UT WOS:000311126700001
PM 23092209
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Gomes-Gouvea, MS
   Mendes-Correa, MC
   Ferreira, AC
   Teixeira, R
   Andrade, JR
   Barros, LMF
   Ferreira, AS
   Rezende, RF
   Nastri, ACS
   Leite, AG
   Piccoli, LZ
   Galvan, J
   Conde, SRS
   Soares, MC
   Carrilho, FJ
   Pinho, JR
AF Gomes-Gouvea, Michele S.
   Mendes-Correa, Maria Cassia
   Ferreira, Ariana C.
   Teixeira, Rosangela
   Andrade, Jose R.
   Barros, Lena Maria F.
   Ferreira, Adalgisa S.
   Rezende, Rosamar F.
   Nastri, Ana Catharina S.
   Leite, Andrea G.
   Piccoli, Leonora Z.
   Galvan, Josiane
   Conde, Simone Regina S.
   Soares, Manoel C.
   Carrilho, Flair J.
   Pinho, Joao R.
TI HBV resistance frequency in nucleos(t)ide analogue-untreated patients
   from different Brazilian regions
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Gomes-Gouvea, Michele S.; Ferreira, Ariana C.; Nastri, Ana Catharina S.; Carrilho, Flair J.; Pinho, Joao R.] Univ Sao Paulo, Sch Med, Inst Trop Med, Sao Paulo, Brazil.
   [Mendes-Correa, Maria Cassia; Nastri, Ana Catharina S.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Mendes-Correa, Maria Cassia] ABC Med Sch, Infect Dis Res Unit, Santo Andre, Brazil.
   [Teixeira, Rosangela; Andrade, Jose R.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Barros, Lena Maria F.; Ferreira, Adalgisa S.] Univ Fed Maranhao, Sao Luis, Brazil.
   [Rezende, Rosamar F.] Municipal Secretary Hlth, Ribeirao Preto, Brazil.
   [Leite, Andrea G.; Piccoli, Leonora Z.; Galvan, Josiane] Ctr Especializado Saude Caxias do Sul, Serv Municipal Infectol, Caxias Do Sul, Brazil.
   [Conde, Simone Regina S.] Santa Casa de Misericordia Para, Belem, Para, Brazil.
   [Soares, Manoel C.] Inst Evandro Chagas, Secao Hepatol, Belem, Para, Brazil.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; Oliveira,
   Claudia PMS/D-1216-2014; correa, maria cassia mendes/A-6779-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 916
BP 636A
EP 636A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602295
DA 2020-12-08
ER

PT J
AU Silva, EF
   Mazo, DF
   Oliveira, CP
   Medeiros, RP
   Carrilho, FJ
   Pessoa, MG
AF Silva, Edvaldo F.
   Mazo, Daniel F.
   Oliveira, Claudia P.
   Medeiros, Roseane P.
   Carrilho, Flair J.
   Pessoa, Mario G.
TI Hepatitis A and B Seroprevalence in 1000 Patients with Chronic HCV
   Infection on a Tertiary Care Center in Brazil
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Silva, Edvaldo F.; Mazo, Daniel F.; Oliveira, Claudia P.; Medeiros, Roseane P.; Carrilho, Flair J.; Pessoa, Mario G.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012; Mazo,
   Daniel FC/D-5631-2015
OI Mazo, Daniel FC/0000-0002-2164-2630
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 934
BP 645A
EP 645A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602313
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Pereira, IV
   Coelho, AMM
   Xerfan, MP
   Barbeiro, DF
   Torres, MM
   Bida, PM
   Mazo, DF
   Cogliati, B
   Souza, HP
   D'Albuquerque, LC
   Carrilho, FJ
   Oliveira, CP
AF Stefano, Jose Tadeu
   Pereira, Isabel V.
   Coelho, Ana Maria M.
   Xerfan, Mariana P.
   Barbeiro, Denise F.
   Torres, Mariana Maciel
   Bida, Patricia Martins
   Mazo, Daniel F.
   Cogliati, Bruno
   Souza, Heraldo Possolo
   D'Albuquerque, Luiz C.
   Carrilho, Flair J.
   Oliveira, Claudia P.
TI Sorafenib improves liver mitochondrial dysfunction attenuating liver
   fibrosis in non-alcoholic steatohepatitis (NASH) model
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Stefano, Jose Tadeu; Pereira, Isabel V.; Xerfan, Mariana P.; Torres, Mariana Maciel; Bida, Patricia Martins; Mazo, Daniel F.; Carrilho, Flair J.; Oliveira, Claudia P.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Coelho, Ana Maria M.; D'Albuquerque, Luiz C.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 37, Sao Paulo, Brazil.
   [Barbeiro, Denise F.; Souza, Heraldo Possolo] Univ Sao Paulo, Sch Med, Emergency Med Div LIM 51, Sao Paulo, Brazil.
   [Cogliati, Bruno] Univ Sao Paulo, Sch Vet Med & Anim Sci, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Mazo, Daniel FC/D-5631-2015; Stefano,
   Jose T/H-4792-2013; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   Coelho, Ana/E-5605-2013; D'ALBUQUERQUE, Luiz Carneiro
   Augusto/I-4011-2012; Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose
   Tadeu/AAH-5419-2020
OI Mazo, Daniel FC/0000-0002-2164-2630; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Coelho, Ana/0000-0002-0606-6532; Stefano,
   Jose Tadeu/0000-0002-0218-1920
NR 0
TC 0
Z9 0
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1430
BP 864A
EP 864A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603029
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Silvestre, OM
   Garcia-Tsao, G
   Seguro, L
   Mazo, DF
   Bacal, F
   Andrade, JL
   Goncalves, LL
   Carrilho, FJ
   D'Albu-Querque, LC
AF Farias, Alberto Q.
   Silvestre, Odilson M.
   Garcia-Tsao, Guadalupe
   Seguro, Luis
   Mazo, Daniel F.
   BAcal, Fernando
   Andrade, Jose L.
   Goncalves, Luciana L.
   Carrilho, Flair J.
   D'Albu-Querque, Luiz C.
TI Serum B-type natriuretic peptide is more accurate than ascites analyses
   in the diagnosis of heart failure-related ascites
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
RI Bacal, Fernando/H-7952-2012; Garcia-Tsao, Guadalupe/ABF-7374-2020;
   Carrilho, Flair J/I-3046-2012; Mazo, Daniel FC/D-5631-2015; Farias,
   Alberto/ABB-1291-2020
OI Mazo, Daniel FC/0000-0002-2164-2630; Farias, Alberto/0000-0002-5572-663X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1576
BP 930A
EP 930A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603174
DA 2020-12-08
ER

PT J
AU Silvestre, OM
   Bacal, F
   Ramos, D
   Belleti, E
   Andrade, JL
   Pugliese, V
   Andraus, W
   Furtado, M
   Carrilho, FJ
   D'Albuquerque, LC
   Farias, AQ
AF Silvestre, Odilson M.
   BAcal, Fernando
   Ramos, Danusa
   Belleti, Elisangela
   Andrade, Jose L.
   Pugliese, Vincenzo
   Andraus, Wellington
   Furtado, Meive
   Carrilho, Flair J.
   D'Albuquerque, Luiz C.
   Farias, Alberto Q.
TI Impact of the severity of end-stage liver disease in cardiac remodeling
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Silvestre, Odilson M.; BAcal, Fernando; Ramos, Danusa; Belleti, Elisangela; Andrade, Jose L.; Pugliese, Vincenzo; Andraus, Wellington; Furtado, Meive; Carrilho, Flair J.; D'Albuquerque, Luiz C.; Farias, Alberto Q.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Farias, Alberto/ABB-1291-2020
OI Farias, Alberto/0000-0002-5572-663X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1609
BP 944A
EP 944A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603207
DA 2020-12-08
ER

PT J
AU Alvarado-Mora, MV
   Moura, IM
   Botelho-Lima, LS
   Azevedo, RS
   Lopes, E
   Carrilho, FJ
   Pinho, JRR
AF Alvarado-Mora, Monica V.
   Moura, Izolda M.
   Botelho-Lima, Livia S.
   Azevedo, Raymundo S.
   Lopes, Edmundo
   Carrilho, Flair J.
   Pinho, Joao R. R.
TI Distribution and molecular characterization of hepatitis C virus (HCV)
   genotypes in patients with chronic infection from Pernambuco State,
   Brazil
SO VIRUS RESEARCH
LA English
DT Article
DE Hepatitis C virus; Subtype 1b; Pernambuco; Phylogenetic analysis; NS5B
   region
ID HEPATOCELLULAR-CARCINOMA; BLOOD-DONORS; NS5B REGION; EPIDEMIOLOGY;
   SEQUENCE; FRANCE
AB Hepatitis C virus (HCV) is a public health problem throughout the world and 3% of the world population is infected with this virus. It is estimated that 3-4 millions individuals are being infected every year. It has been estimated that around 1.5% of Brazilian population is anti-HCV positive and the Northeast region showed the highest prevalence in Brazil. The aim of this study was to characterize HCV genotypes circulating in Pernambuco State (PE), Brazil, located in the Northeast region of the country. This study included 85 anti-HCV positive patients followed up between 2004 and 2011. For genotyping, a 380bp fragment of HCV RNA in the NS5B region was amplified by nested PCR. Phylogenetic analysis was conducted using Bayesian Markov chain Monte Carlo simulation (MCMC) using BEAST v.1.5.3. From 85 samples, 63 (74.1%) positive to NS5B fragment were successfully sequenced. Subtype 1b was the most prevalent in this population (42-66.7%), followed by 3a (16-25.4%), 1a (4-6.3%) and 2b (1-1.6%). Twelve (63.1%) and seven (36.9%) patients with HCV and schistosomiasis were infected with subtypes 1b and 3a, respectively. Brazil is a large country with many different population backgrounds; a large variation in the frequencies of HCV genotypes is predictable throughout its territory. This study reports HCV genotypes from Pernambuco State where subtype 1b was found to be the most prevalent. Phylogenetic analysis suggests the presence of the different HCV strains circulating within this population. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Alvarado-Mora, Monica V.] Univ Sao Paulo, Fac Med, Depto Gastroenterol, Lab Trop Gastroenterol & Hepatol,Sch Med, Sao Paulo, Brazil.
   [Moura, Izolda M.] Fed Univ Pernambuco UFPE, Clin Hosp, Cent Lab, Recife, PE, Brazil.
   [Azevedo, Raymundo S.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   [Lopes, Edmundo] Fed Univ Pernambuco UFPE, Dept Clin Med, Recife, PE, Brazil.
RP Alvarado-Mora, MV (corresponding author), Univ Sao Paulo, Fac Med, Depto Gastroenterol, Lab Trop Gastroenterol & Hepatol,Sch Med, Av Dr Eneas de Carvalho Aguiar 500,2 Andar,Predio, Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Lopes, Edmundo/R-5159-2017; Azevedo, Raymundo S/B-7593-2008; Carrilho,
   Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; Alvarado-Mora,
   Monica/I-3180-2012
OI Lopes, Edmundo/0000-0002-3470-1564; Azevedo, Raymundo
   S/0000-0003-0660-2371; Pinho, Joao R. R./0000-0003-3999-0489; 
FU FFM; HCFMUSP; CNPqNational Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   - FAPESP, Sao Paulo, SP, BrazilFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2008/50461-6, 2011/50562-0]
FX FFM, HCFMUSP, CNPq and Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo - FAPESP (2008/50461-6 and 2011/50562-0), Sao Paulo, SP, Brazil
   supported this work.
CR Alencar RSM, 2008, BRAZ J MED BIOL RES, V41, P235, DOI 10.1590/S0100-879X2006005000197
   Mora MVA, 2010, J MED VIROL, V82, P1889, DOI 10.1002/jmv.21908
   Aquino Renata Telles Rudge de, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P313
   Bourliere M, 2002, J VIRAL HEPATITIS, V9, P62, DOI 10.1046/j.1365-2893.2002.00319.x
   Calvaruso V, 2012, LIVER INT, V32, P2, DOI 10.1111/j.1478-3231.2011.02703.x
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Cantaloube JF, 2006, J CLIN MICROBIOL, V44, P2051, DOI 10.1128/JCM.02463-05
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   Carvalho Priscila Diniz de, 2011, Cad. Saúde Pública, V27, P2095, DOI 10.1590/S0102-311X2011001100003
   Mello LD, 2007, REV SOC BRAS MED TRO, V40, P290, DOI 10.1590/S0037-86822007000300008
   de Souza V.S., 2008, REV PARAENSE MED, V22
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Duailibi Lígia Bonacim, 2008, Cad. Saúde Pública, V24, ps545, DOI 10.1590/S0102-311X2008001600007
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Ishii K, 1999, HEPATOLOGY, V29, P1227, DOI 10.1002/hep.510290448
   Jimenez-Mendez R, 2010, ANN HEPATOL, V9, P33, DOI 10.1016/S1665-2681(19)31676-X
   Kershenobich D, 2011, LIVER INT, V31, P18, DOI 10.1111/j.1478-3231.2011.02538.x
   KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409
   Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Lole KS, 2003, J CLIN MICROBIOL, V41, P5240, DOI 10.1128/JCM.41.11.5240-5244.2003
   Martial J, 2004, J CLIN MICROBIOL, V42, P784, DOI 10.1128/JCM.42.2.784-791.2004
   McHutchison JG, 2004, AM J MANAG CARE, V10, pS20
   Mendez-Sanchez N, 2010, ANN HEPATOL, V9, pS27, DOI 10.1016/S1665-2681(19)31719-3
   Pawlotsky JM, 2003, ANTIVIR RES, V59, P1, DOI 10.1016/S0166-3542(03)00088-3
   PAWLOTSKY JM, 1995, J INFECT DIS, V171, P1607, DOI 10.1093/infdis/171.6.1607
   de Carvalho FHP, 2009, REV SAUDE PUBL, V43, P133, DOI 10.1590/S0034-89102009000100017
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Silva Luciana, 1995, Arquivos de Gastroenterologia, V32, P168
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Soza A, 2010, ANN HEPATOL, V9, pS30, DOI 10.1016/S1665-2681(19)31720-X
   Suzuki T, 2007, ADV DRUG DELIVER REV, V59, P1200, DOI 10.1016/j.addr.2007.04.014
   SVS, 2005, PROGR VIG CONTR ESQ
   Te Helen S, 2010, Clin Liver Dis, V14, P1, DOI 10.1016/j.cld.2009.11.009
   Toledo Jr. Antonio C., 2005, Braz J Infect Dis, V9, P374, DOI 10.1590/S1413-86702005000500004
   Veras KN, 2009, BRAZ J INFECT DIS, V13, P125, DOI 10.1590/S1413-86702009000200011
   Vieira DS, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-165
   Zhou ST, 2010, JAIDS-J ACQ IMM DEF, V54, P191, DOI 10.1097/QAI.0b013e3181c99226
NR 43
TC 3
Z9 3
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD OCT
PY 2012
VL 169
IS 1
BP 8
EP 12
DI 10.1016/j.virusres.2012.06.023
PG 5
WC Virology
SC Virology
GA 037VE
UT WOS:000311133800002
PM 22766449
DA 2020-12-08
ER

PT J
AU Bertolini, DA
   Gomes-Gouvea, MS
   de Carvalho-Mello, IMVG
   Saraceni, CP
   Sitnik, R
   Grazziotin, FG
   Laurino, JP
   Fagundes, NJR
   Carrilho, FJ
   Pinho, JRR
AF Bertolini, Dennis Armando
   Gomes-Gouvea, Michele Soares
   Vicente Guedes de Carvalho-Mello, Isabel Maria
   Saraceni, Claudia Patara
   Sitnik, Roberta
   Grazziotin, Felipe Gobbi
   Laurino, Jomar Pereira
   Rosa Fagundes, Nelson Jurandi
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Hepatitis B virus genotypes from European origin explains the high
   endemicity found in some areas from southern Brazil (vol 12, pg 1295,
   2012)
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Correction
C1 [Bertolini, Dennis Armando] Univ Estadual Maringa, Lab Imunol Clin, Dept Anal Clin & Biomed, Maringa, Parana, Brazil.
   [Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, BR-05508 Sao Paulo, Brazil.
   [Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   [Vicente Guedes de Carvalho-Mello, Isabel Maria] Inst Butantan, Lab Imunol Viral, Sao Paulo, Brazil.
   [Saraceni, Claudia Patara] Adolfo Lutz Inst, Serv Virol, Sao Paulo, Brazil.
   [Sitnik, Roberta; Rebello Pinho, Joao Renato] Hosp Israelite Albert Einstein, Dept Patol Clin, Sao Paulo, Brazil.
   [Grazziotin, Felipe Gobbi; Rosa Fagundes, Nelson Jurandi] Pontificia Univ Catolica Rio Grande do Sul, Lab Biol Genom & Mol, Porto Alegre, RS, Brazil.
   [Rosa Fagundes, Nelson Jurandi] Univ Fed Rio Grande do Sul, Dept Genet, Porto Alegre, RS, Brazil.
   [Laurino, Jomar Pereira] Univ Caxias Sul, Inst Biotecnol, Caxias Do Sul, RS, Brazil.
RP Bertolini, DA (corresponding author), Univ Estadual Maringa, Lab Imunol Clin, Dept Anal Clin & Biomed, Maringa, Parana, Brazil.
EM dabertolini@uem.br
RI Bertolini, Dennis/ABG-1427-2020; Sitnik, Roberta/N-4740-2017;
   Grazziotin, Felipe G/D-7525-2015; Carrilho, Flair J/I-3046-2012;
   Fagundes, Nelson JR/F-7490-2014; Pinho, Joao R. R./G-2850-2012
OI Sitnik, Roberta/0000-0002-6243-8118; Grazziotin, Felipe
   G/0000-0001-9896-9722; Fagundes, Nelson JR/0000-0003-0456-0323; Pinho,
   Joao R. R./0000-0003-3999-0489
CR Bertolini DA, 2012, INFECT GENET EVOL, V12, P1295, DOI 10.1016/j.meegid.2012.04.009
NR 1
TC 0
Z9 1
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD OCT
PY 2012
VL 12
IS 7
BP 1586
EP 1586
DI 10.1016/j.meegid.2012.06.004
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 024MZ
UT WOS:000310114600034
DA 2020-12-08
ER

PT J
AU do Espirito-Santo, MCC
   Alvarado-Mora, MV
   Pinto, PLS
   Carrilho, FJ
   Pinho, JRR
   Gryschek, RCB
AF Carvalho do Espirito-Santo, Maria Cristina
   Alvarado-Mora, Monica Viviana
   Silva Pinto, Pedro Luiz
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
   Borges Gryschek, Ronaldo Cesar
TI TWO SEQUENTIAL PCR AMPLIFICATIONS FOR DETECTION OF Schistosoma mansoni
   IN STOOL SAMPLES WITH LOW PARASITE LOAD
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE S. mansoni; PCR reamplification; Eggs; Human feces; Diagnosis
ID DNA; EXTRACTION; INFECTION; FECES
AB Schistosomiasis constitutes a major public health problem, with an estimated 200 million individuals infected worldwide and 700 million people living in risk areas. In Brazil there are areas of high, medium and low endemicity. Studies have shown that in endemic areas with a low prevalence of Schistosoma infection the sensitivity of parasitological methods is clearly reduced. Consequently diagnosis is often impeded due to the presence of false-negative results. The aim of this study is to present the PCR reamplification (Re-PCR) protocol for the detection of Schistosoma mansoni in samples with low parasite load (with less than 100 eggs per gram (epg) of feces). Three methods were used for the lysis of the envelopes of the S. mansoni eggs and two techniques of DNA extraction were carried out. Extracted DNA was quantified, and the results suggested that the extraction technique, which mixed glass beads with a guanidine isothiocyanate/phenol/chloroform (GT) solution, produced good results. PCR reamplification was conducted and detection sensitivity was found to be five eggs per 500 mg of artificially marked feces. The results achieved using these methods suggest that they are potentially viable for the detection of Schistosoma infection with low parasite load.
C1 [Carvalho do Espirito-Santo, Maria Cristina; Borges Gryschek, Ronaldo Cesar] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Alvarado-Mora, Monica Viviana; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Lab Gastroenterol & Hepatol, Inst Trop Med,Dept Gastroenterol, Sao Paulo, Brazil.
   [Silva Pinto, Pedro Luiz] Adolfo Lutz Inst, Enteroparasitosis Sect, Parasitol & Mycol Div, Sao Paulo, Brazil.
RP do Espirito-Santo, MCC (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
EM cristinasanto@usp.br; monica.viviana@usp.br; pedro.luiz44@terra.com.br;
   fjcarril@usp.br; jrrpinho@usp.br; rcbgry@usp.br
RI Alvarado-Mora, Monica/I-3180-2012; Pinto, Pedro Luiz LS
   Silva/B-5225-2016; Pinho, Joao R. R./G-2850-2012; Carrilho, Flair
   J/I-3046-2012
OI Pinto, Pedro Luiz LS Silva/0000-0002-3727-596X; Pinho, Joao R.
   R./0000-0003-3999-0489; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [07/53457-7, 08/50461-6,
   10/52615-0]
FX This study was funded by the Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo, processes 07/53457-7, 08/50461-6 and 10/52615-0. We thank Dr.
   Luciana Inacia Gomes, from Laboratorio de Pesquisas Clinicas (Laboratory
   of Clinical Research), Instituto de Pesquisas Rene Rachou-Fiocruz - Belo
   Horizonte, Brazil, for her advice on the standardization process.
   Finally, we thank Miss Maria Cristina Conceicao de Mello from LIM-06
   FMUSP for her technical support in the biological cycle of S. mansoni.
CR Oliveira LMA, 2010, DIAGN MICR INFEC DIS, V68, P416, DOI 10.1016/j.diagmicrobio.2010.07.016
   Brasil. Ministerio da Saude, 2010, DOENC INF PAR GUIA B, P169
   Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Colley DG, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000032
   da Silva AJ, 1999, MOL DIAGN, V4, P57, DOI 10.1016/S1084-8592(99)80050-2
   Doenhoff MJ, 1998, PARASITOL TODAY, V14, P105, DOI 10.1016/S0169-4758(97)01204-0
   DRESDEN MH, 1981, J PARASITOL, V67, P450, DOI 10.2307/3280573
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Gomes LI, 2009, MEM I OSWALDO CRUZ, V104, P1194, DOI 10.1590/S0074-02762009000800021
   Gomes LI, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000664
   Musso O, 1996, J VIROL METHODS, V56, P125, DOI 10.1016/0166-0934(95)01892-1
   Pinto PL, 1995, REV PATOL TROP, V23, P264
   Pontes LA, 2002, AM J TROP MED HYG, V66, P157, DOI 10.4269/ajtmh.2002.66.157
   Rey L, 2002, BASES PARASITOLOGIA, P153
   RUIZTIBEN E, 1979, AM J TROP MED HYG, V28, P230, DOI 10.4269/ajtmh.1979.28.230
   Teles HMS, 2001, THESIS UNICAMP CAMPI
NR 18
TC 7
Z9 7
U1 0
U2 10
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD SEP-OCT
PY 2012
VL 54
IS 5
BP 245
EP 248
DI 10.1590/S0036-46652012000500002
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 005NE
UT WOS:000308756300002
PM 22983286
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Bertolini, DA
   Gomes-Gouvea, MS
   de Carvalho-Mello, IMVG
   Saraceni, CP
   Sitnik, R
   Grazziotin, FG
   Laurindo, JP
   Fagundes, NJR
   Carrilho, FJ
   Pinho, JRR
AF Bertolini, Dennis Armando
   Gomes-Gouvea, Michele Soares
   Vicente Guedes de Carvalho-Mello, Isabel Maria
   Saraceni, Claudia Patara
   Sitnik, Roberta
   Grazziotin, Felipe Gobbi
   Laurindo, Jomar Pereira
   Rosa Fagundes, Nelson Jurandi
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Hepatitis B virus genotypes from European origin explains the high
   endemicity found in some areas from southern Brazil
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Hepatitis B virus; Genotypes; Genotype D; Migration; Brazil; Europe
ID MOLECULAR EPIDEMIOLOGY; GENETIC DIVERSITY; PREGNANT-WOMEN; RISK-FACTORS;
   MUTATIONS; SUBGENOTYPES; INFECTIONS; PREVALENCE; STRAINS; PRECORE
AB Southern Brazil is considered an area of low Hepatitis B endemicity, but some areas of higher endemicity have been described in the Southwest of Parana and Santa Catarina states. The aim of this study was to evaluate viral genotypes circulating throughout Parana state. PCR amplification and partial sequencing of the S gene was carried out in 228 samples from HBsAg positive candidate blood donors. Samples have been collected in seven different counties (Cascavel, Curitiba, Foz do Iguacu, Francisco Beltrao, Matinga Londrina and Paranagua). The most common HBV genotype in Parana state was D (82.9%; 189/228), followed by A (14.1%; 32/228). Genotypes F (1.3%; 3/228), C (1.3%; 3/228) and H (0.4%; 1/228) were also found. Distribution of genotypes was different in the studied counties, but genotype D was the most frequent in all of them. In Francisco Beltrao, all studied samples belonged to genotype D. The high prevalence of HBV genotype Din South of Brazil is explained by the intense migration of settlers from Europeans countries. Subgenotypes A1 and A2 were identified circulating in all cities where HBV/A was found. As observed in other areas of Brazil, HBV/A1 is more frequent than the HBV/A2 in Parana state and its presence was significantly larger in black and mulatto individuals. Genotype C was found only in individuals with Asian ancestry from Londrina and Maringa. Most HBV/F sequences identified in this study were classified as subgenotype F2a that was previously described in Brazil. The sole case of subgenotype F4 was from Foz do Iguacu city, near to Northern Argentina, where F4 is highly prevalent. The single genotype H sample was from Curitiba. This is the first case of this genotype described in Brazil. Further studies should be carried out to determine if more genotype H samples can be found in other populations from Brazil. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Bertolini, Dennis Armando] Univ Estadual Maringa, Dept Anal Clin & Biomed, Lab Imunol Clin, Maringa, Parana, Brazil.
   [Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, Sch Med, BR-05508 Sao Paulo, Brazil.
   [Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   [Vicente Guedes de Carvalho-Mello, Isabel Maria] Inst Butantan, Lab Imunol Viral, Sao Paulo, Brazil.
   [Saraceni, Claudia Patara] Adolfo Lutz Inst, Serv Virol, Sao Paulo, Brazil.
   [Sitnik, Roberta; Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Dept Patol Clin, Sao Paulo, Brazil.
   [Grazziotin, Felipe Gobbi; Rosa Fagundes, Nelson Jurandi] Pontificia Univ Catolica Rio Grande do Sul, Lab Biol Genom & Mol, Porto Alegre, RS, Brazil.
   [Rosa Fagundes, Nelson Jurandi] Univ Fed Rio Grande do Sul, Dept Genet, Porto Alegre, RS, Brazil.
   [Laurindo, Jomar Pereira] Univ Caxias Sul, Inst Biotechnol, Caxias do Sul, RS, Brazil.
RP Bertolini, DA (corresponding author), Univ Estadual Maringa, Dept Clin Analyses, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM dabertolini@uem.br
RI Bertolini, Dennis/ABG-1427-2020; Sitnik, Roberta/N-4740-2017; Carrilho,
   Flair J/I-3046-2012; de carvalho-Mello, Isabel Maria V G/D-3641-2012;
   Pinho, Joao R. R./G-2850-2012; Grazziotin, Felipe G/D-7525-2015;
   Fagundes, Nelson JR/F-7490-2014
OI Sitnik, Roberta/0000-0002-6243-8118; Pinho, Joao R.
   R./0000-0003-3999-0489; Grazziotin, Felipe G/0000-0001-9896-9722;
   Fagundes, Nelson JR/0000-0003-0456-0323
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo,
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [FAPESP 99/09551-0, FAPESP 2010/50081-9]
FX This work had the financial support of the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and from the
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 99/09551-0,
   FAPESP 2010/50081-9), Brazil. This study is dedicated to all patients
   and health professionals of the Parana state, the City and state Health
   Secretaries and the Hemocentros (Blood Banks).
CR Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Alvarado-Esquivel C, 2006, WORLD J GASTROENTERO, V12, P6540, DOI 10.3748/wjg.v12.i40.6540
   Alvarado-Mora MV, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-415
   [Anonymous], 2007, BRAS 500 AN POV
   Arankalle VA, 2003, J GEN VIROL, V84, P1915, DOI 10.1099/vir.0.18943-0
   Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   Becker Carlos Eduardo, 2010, Arq. Gastroenterol., V47, P13, DOI 10.1590/S0004-28032010000100003
   Bertolini DA, 2006, BRAZ J MED BIOL RES, V39, P1083, DOI 10.1590/S0100-879X2006000800011
   Ribeiro NRC, 2006, LIVER INT, V26, P636, DOI 10.1111/j.1478-3231.2006.01280.x
   Carrilho FJ, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-13
   Carvalho S.P., 1995, REV BRAS ANAL CLIN, V27, P77
   Chandra PK, 2009, J VIRAL HEPATITIS, V16, P749, DOI 10.1111/j.1365-2893.2009.01129.x
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Clemente CM, 2009, J GASTROENTEROL, V44, P568, DOI 10.1007/s00535-009-0044-8
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Di Lello FA, 2009, J MED VIROL, V81, P1887, DOI 10.1002/jmv.21607
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Flichman D, 2009, J CLIN MICROBIOL, V47, P4191, DOI 10.1128/JCM.01337-09
   Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
   Gomes-Gouvea MS, 2008, ACTA TROP, V106, P149, DOI 10.1016/j.actatropica.2008.02.009
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   Huy TTT, 2008, J VIROL, V82, P5657, DOI 10.1128/JVI.02556-07
   Huy TTT, 2004, PEDIATR INT, V46, P223, DOI 10.1046/j.1442-200x.2004.01867.x
   Kramvis A, 2008, J MED VIROL, V80, P27, DOI 10.1002/jmv.21049
   Kramvis A, 2007, HEPATOL RES, V37, pS27, DOI 10.1111/j.1872-034X.2007.00100.x
   Kurbanov F, 2010, HEPATOL RES, V40, P14, DOI 10.1111/j.1872-034X.2009.00601.x
   Lazier, 1997, ANAL HIST POSSE TERR
   Lin CL, 2011, J GASTROEN HEPATOL, V26, P123, DOI 10.1111/j.1440-1746.2010.06541.x
   Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Mendes-Correa MC, 2010, J MED VIROL, V82, P1481, DOI 10.1002/jmv.21845
   Motta-Castro A, 2008, ARCH VIROL, V153, P2197, DOI 10.1007/s00705-008-0237-0
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   NORDER H, 1993, J GEN VIROL, V74, P1341, DOI 10.1099/0022-1317-74-7-1341
   Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
   Leone FGPY, 2008, J CLIN VIROL, V42, P381, DOI 10.1016/j.jcv.2008.01.018
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Reis LMW, 2011, J MED VIROL, V83, P2103, DOI 10.1002/jmv.22246
   Sanchez LV, 2007, INTERVIROLOGY, V50, P9, DOI 10.1159/000096307
   Santos AO, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-315
   Schaefer S, 2007, HEPATOL RES, V37, pS20, DOI 10.1111/j.1872-034X.2007.00099.x
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Souto FJD, 1999, GASTROENTEROL ENDOSC, V18, P143
   Souto Francisco José Dutra, 2004, Rev. Soc. Bras. Med. Trop., V37, P63, DOI 10.1590/S0037-86822004000700010
   STROFFOLINI T, 1988, PUBLIC HEALTH, V102, P329, DOI 10.1016/S0033-3506(88)80102-1
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Tatematsu K, 2009, J VIROL, V83, P10538, DOI 10.1128/JVI.00462-09
   Thedja MD, 2011, ARCH VIROL, V156, P855, DOI 10.1007/s00705-011-0926-y
   Vieth S, 2002, VIRUS GENES, V24, P153, DOI 10.1023/A:1014572600432
   Wiegand J, 2008, ANTIVIR THER, V13, P211
NR 50
TC 32
Z9 32
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD AUG
PY 2012
VL 12
IS 6
BP 1295
EP 1304
DI 10.1016/j.meegid.2012.04.009
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 969DA
UT WOS:000306034700018
PM 22538208
DA 2020-12-08
ER

PT J
AU Fylyk, SN
   Tobaru, A
   Mestieri, LH
   Farias, AQ
   Carrilho, FJ
   D'Albuquerque, LAC
   De Moura, EG
   Sakai, P
AF Fylyk, Sonia N.
   Tobaru, Andre
   Mestieri, Luiz H.
   Farias, Alberto Q.
   Carrilho, Flair J.
   D'Albuquerque, Luiz Augusto C.
   De Moura, Eduardo G.
   Sakai, Paulo
TI Evaluation of the Small Intestine by Video Capsule Endoscopy in Patients
   Candidates for Liver Transplantation
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Meeting Abstract
CT Digestive Disease Week (DDW)
CY MAY 19-22, 2012
CL San Diego, CA
C1 [Fylyk, Sonia N.; Tobaru, Andre; Mestieri, Luiz H.; De Moura, Eduardo G.; Sakai, Paulo] Univ Sao Paulo, Sch Med, Gastrointestinal Endoscopy Unit, Sao Paulo, Brazil.
RI D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013; D'ALBUQUERQUE, Luiz
   Carneiro Augusto/I-4011-2012; Carrilho, Flair J/I-3046-2012; de Moura,
   Eduardo Guimaraes Hourneaux/D-3885-2018
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; de Moura,
   Eduardo Guimaraes Hourneaux/0000-0002-8023-3722
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD APR
PY 2012
VL 75
IS 4
SU S
BP 268
EP 268
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 946CU
UT WOS:000304328001278
DA 2020-12-08
ER

PT J
AU Carvalho, CF
   Chammas, MC
   Cogliatti, B
   Stefano, JT
   Carrilho, FJ
   Oliveira, CPMS
AF Carvalho, C. F.
   Chammas, M. C.
   Cogliatti, B.
   Stefano, J. T.
   Carrilho, F. J.
   Oliveira, C. P. M. S.
TI ELASTOGRAPHY AND CONTRAST-ENHANCED ULTRASONOGRAPHY IMPROVES EARLY
   DETECTION OF HEPATOCELLULAR CARCINOMA IN AN EXPERIMENTAL MODEL OF
   NON-ALCOHOLIC STEATOHEPATITIS (NASH)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 47th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 18-22, 2012
CL Barcelona, SPAIN
SP European Assoc Study Liver (EASL)
C1 [Carvalho, C. F.; Chammas, M. C.] Univ Sao Paulo, Sch Med, Inst Radiol, Sao Paulo, Brazil.
   [Cogliatti, B.] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Pathol, Sao Paulo, Brazil.
   [Stefano, J. T.; Carrilho, F. J.; Oliveira, C. P. M. S.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
EM cpm@usp.br
RI Carvalho, C/M-6912-2019; Carrilho, Flair J/I-3046-2012; Stefano, Jose
   T/H-4792-2013; Chammas, Maria Cristina/M-1960-2017; Stefano, Jose
   Tadeu/AAH-5419-2020; Oliveira, Claudia PMS/D-1216-2014
OI Chammas, Maria Cristina/0000-0001-7041-3079; Stefano, Jose
   Tadeu/0000-0002-0218-1920; 
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2012
VL 56
SU 2
MA 1252
BP S495
EP S495
DI 10.1016/S0168-8278(12)61264-1
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 931TD
UT WOS:000303241302359
DA 2020-12-08
ER

PT J
AU Chagas, AL
   Kikuchi, L
   Freitas, NS
   Santos, ACB
   Alencar, RSSM
   Tani, CM
   Moreira, AM
   Rocha, MS
   D'Albuquerque, LAC
   Carnevale, FC
   Carrilho, FJ
AF Chagas, A. L.
   Kikuchi, L.
   Freitas, N. S.
   Santos, A. C. B.
   Alencar, R. S. S. M.
   Tani, C. M.
   Moreira, A. M.
   Rocha, M. S.
   D'Albuquerque, L. A. C.
   Carnevale, F. C.
   Carrilho, F. J.
TI TUMOR RESPONSE EVALUATION ACCORDING TO MRECIST CRITERIA IN PATIENTS WITH
   HEPATOCELLULAR CARCINOMA TREATED WITH TACE-DRUG ELUTING BEADS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 47th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 18-22, 2012
CL Barcelona, SPAIN
SP European Assoc Study Liver (EASL)
C1 [Chagas, A. L.; Kikuchi, L.; Alencar, R. S. S. M.; Tani, C. M.; Moreira, A. M.] Univ Sao Paulo, Sch Med, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil.
EM alinelchagas@gmail.com
RI D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013; Carnevale,
   Francisco/I-6135-2015; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012;
   Chagas, Aline Lopes/X-2059-2019; Rocha, Manoel S/C-6478-2013; Carrilho,
   Flair J/I-3046-2012
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Rocha, Manoel
   S/0000-0002-4503-8374; 
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2012
VL 56
SU 2
MA 997
BP S390
EP S390
DI 10.1016/S0168-8278(12)61009-5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 931TD
UT WOS:000303241302104
DA 2020-12-08
ER

PT J
AU Gonzalez, MP
   Klautau, GB
   Prestes, DP
   Mendes-Correa, MC
   Mazo, DF
   Carrilho, FJ
   Pessoa, MG
AF Gonzalez, M. P.
   Klautau, G. B.
   Prestes, D. P.
   Mendes-Correa, M. C.
   Mazo, D. F.
   Carrilho, F. J.
   Pessoa, M. G.
TI VITAMIN D AND CHOLESTEROL SERUM LEVELS ARE INVERSELY ASSOCIATED IN HCV,
   HIV AND HIV/HCV COINFECTED PATIENTS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 47th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 18-22, 2012
CL Barcelona, SPAIN
SP European Assoc Study Liver (EASL)
C1 [Klautau, G. B.] Univ Sao Paulo, Ambulatorio HIV AIDS, Inst Infectol Emilio Ribas, Sao Paulo, Brazil.
   [Mendes-Correa, M. C.] Univ Sao Paulo, Div Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
   [Mazo, D. F.; Carrilho, F. J.; Pessoa, M. G.] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM mpgonzalez@terra.com.br
RI Carrilho, Flair J/I-3046-2012; Mazo, Daniel FC/D-5631-2015; correa,
   maria cassia mendes/A-6779-2013
OI Mazo, Daniel FC/0000-0002-2164-2630; 
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2012
VL 56
SU 2
MA 141
BP S62
EP S62
DI 10.1016/S0168-8278(12)60154-8
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 931TD
UT WOS:000303241300141
DA 2020-12-08
ER

PT J
AU Vieira, J
   Oliveira, PV
   Juliano, V
   Warde, KRJ
   Deguti, MM
   Barbosa, ER
   Carrilho, FJ
   Cancado, ELR
AF Vieira, Jakeliny
   Oliveira, Pedro Vitoriano
   Juliano, Vara
   Jorge Warde, Karim Repsold
   Deguti, Marta Mitiko
   Barbosa, Egberto Reis
   Carrilho, Flair Jose
   Rachid Cancado, Eduardo Luiz
TI Urinary copper excretion before and after oral intake of D-penicillamine
   in parents of patients with Wilson's disease
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Article
DE ATP7B heterozygotes; Cupriuresis; Hepatolenticular degeneration
ID LIVER-DISEASE; DIAGNOSIS; CHALLENGE; CHILDREN; HETEROZYGOTES;
   CERULOPLASMIN; REEVALUATION; EXPERIENCE; METABOLISM
AB Background: Urinary copper excretion higher than 100 mu g/24 h is useful for diagnosing Wilson's disease. D-Penicillamine challenge test may produce higher levels than 1400 mu g/24 h, allowing for better diagnostic accuracy. This study investigated whether heterozygotes reach this value and compared copper serum levels, ceruloplasmin, and urinary copper excretion before and after administering D-penicillamine to the parents of Wilson's disease patients.
   Methods: Fifty parents of adult patients were enrolled to obtain copper serum levels and ceruloplasmin along with 24-h urinary copper excretion before and after administering 1 g D-penicillamine.
   Results: Serum ceruloplasmin and copper levels were significantly lower in fathers than in mothers (mean 21.8 x 27.8 mg%; 71.4 x 88.0 mu g%; p <= 0.001). The mean of basal 24-h urinary copper excretion was higher in fathers (26.2 x 18.7 mu g/24 h, p = 0.01), but did not differ between the genders after D-penicillamine (521.7 x 525.3, range 31.6-1085.1 mu g/24 h, p = 0.8).
   Conclusions: The mean values of serum copper, ceruloplasmin, and basal urinary copper excretion were different between males and females. The current diagnostic threshold of 24-h urinary copper excretion after D-penicillamine was not reached by heterozygotes. The increased urinary copper excretion after D-penicillamine challenge was much higher than fivefold the upper limit of normal urinary copper excretion in the majority of heterozygotes and should not be taken into account when diagnosing Wilson's disease. (C) 2011 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
C1 [Vieira, Jakeliny; Jorge Warde, Karim Repsold; Deguti, Marta Mitiko; Carrilho, Flair Jose; Rachid Cancado, Eduardo Luiz] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   [Barbosa, Egberto Reis] Univ Sao Paulo, Sch Med, Dept Neurol, BR-05508 Sao Paulo, Brazil.
   [Oliveira, Pedro Vitoriano] Univ Sao Paulo, Inst Chem, BR-05508 Sao Paulo, Brazil.
   [Juliano, Vara] Santo Amaro Sch Med, Discipline Publ Hlth, Sao Paulo, Brazil.
   [Rachid Cancado, Eduardo Luiz] Univ Sao Paulo, Inst Trop Med, Lab Med Invest LIM 06, BR-05508 Sao Paulo, Brazil.
RP Cancado, ELR (corresponding author), Rua Alves Guimaraes 1133-102, BR-05410002 Sao Paulo, Brazil.
EM edulrc@uol.com.br
RI Cancado, Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012; Barbosa,
   Egberto R/G-7763-2012; Oliveira, Pedro Vitoriano/C-6283-2014
OI Cancado, Eduardo/0000-0002-9309-1524; Juliano, Yara/0000-0003-2894-0208;
   Reis Barbosa, Egberto/0000-0002-6996-9130
FU Department of Gastroenterology of Faculty of Medicine; Institute of
   Chemistry of University of Sao Paulo
FX The study was funded by the Department of Gastroenterology of Faculty of
   Medicine and Institute of Chemistry of University of Sao Paulo through
   their own funding sources.
CR Ala A, 2007, LANCET, V369, P397, DOI 10.1016/S0140-6736(07)60196-2
   Cauza E, 1997, J HEPATOL, V27, P358, DOI 10.1016/S0168-8278(97)80182-1
   DACOSTA CM, 1992, HEPATOLOGY, V15, P609, DOI 10.1002/hep.1840150410
   Deguti MM, 2004, HUM MUTAT, V23, P398, DOI 10.1002/humu.9227
   Demirkiran M, 1996, NEUROLOGY, V46, P1040, DOI 10.1212/WNL.46.4.1040
   Dhawan A, 2005, LIVER TRANSPLANT, V11, P441, DOI 10.1002/lt.20352
   Eden A, 1940, BIOCHEM J, V34, P1202, DOI 10.1042/bj0341202
   Ferenci P, 2003, LIVER INT, V23, P139, DOI 10.1034/j.1600-0676.2003.00824.x
   Foruny JR, 2008, SCAND J GASTROENTERO, V43, P597, DOI 10.1080/00365520701847044
   FROMMER DJ, 1981, DIGESTION, V21, P169, DOI 10.1159/000198559
   Gollan John L., 1998, Journal of Hepatology, V28, P28, DOI 10.1016/S0168-8278(98)80373-5
   Gow PJ, 2000, GUT, V46, P415, DOI 10.1136/gut.46.3.415
   LARUSSO NF, 1976, GASTROENTEROLOGY, V70, P653
   LEU M, 1972, AM J MED SCI, V263, P19, DOI 10.1097/00000441-197201000-00003
   Mak CM, 2008, CRIT REV CL LAB SCI, V45, P263, DOI 10.1080/10408360801991055 
   MCCALL JT, 1967, AM J MED SCI, V254, P13, DOI 10.1097/00000441-196707000-00002
   Mendez MA, 2004, ENVIRON HEALTH PERSP, V112, P1654, DOI 10.1289/ehp.7134
   Muller T, 2007, J HEPATOL, V47, P270, DOI 10.1016/j.jhep.2007.03.011
   Nicastro E, 2010, HEPATOLOGY, V52, P1948, DOI 10.1002/hep.23910
   Oliveira PV, 2001, FRESEN J ANAL CHEM, V371, P909, DOI 10.1007/s002160101060
   Roberts EA, 2008, HEPATOLOGY, V47, P2089, DOI 10.1002/hep.22261
   Scheinberg I. Herbert, 1996, American Journal of Clinical Nutrition, V63, p842S
   SPECTOR H, 1971, CLIN CHIM ACTA, V31, P5, DOI 10.1016/0009-8981(71)90355-X
   Steindl P, 1997, GASTROENTEROLOGY, V113, P212, DOI 10.1016/S0016-5085(97)70097-0
   TU JB, 1967, METABOLISM, V16, P507, DOI 10.1016/0026-0495(67)90079-0
NR 25
TC 4
Z9 4
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1590-8658
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD APR
PY 2012
VL 44
IS 4
BP 323
EP 327
DI 10.1016/j.dld.2011.11.001
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 919OX
UT WOS:000302338800010
PM 22169274
DA 2020-12-08
ER

PT J
AU Silvestre, OM
   Bacal, F
   Farias, AQ
   Andrade, JL
   Furtado, M
   Pugliese, V
   Andraus, W
   Ramos, DS
   Belleti, E
   Albuquerque, LAC
   Carrilho, FJ
AF Silvestre, O. M.
   Bacal, F.
   Farias, A. Q.
   Andrade, J. L.
   Furtado, M.
   Pugliese, V.
   Andraus, W.
   Ramos, D. S.
   Belleti, E.
   Albuquerque, L. A. C.
   Carrilho, F. J.
TI Impact of the Severity of End-Stage Liver Disease in Cardiac Remodeling
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 32nd Annual Meeting and Scientific Sessions of the
   International-Society-for-Heart-and-Lung-Transplantation/Meeting of the
   ISHLT Academy - Core Competencies in Mechanical Circulatory Support
CY APR 17-21, 2012
CL Prague, CZECH REPUBLIC
SP Int Soc Heart & Lung Transplantat (ISHLT), Int Soc Heart & Lung Transplantat Acad (ISHLT)
C1 [Silvestre, O. M.; Bacal, F.; Farias, A. Q.; Andrade, J. L.; Furtado, M.; Pugliese, V.; Andraus, W.; Ramos, D. S.; Belleti, E.; Albuquerque, L. A. C.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Bacal, Fernando/H-7952-2012;
   D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013; Andraus,
   Wellington/G-1860-2012; Ramos, Danusa/H-6276-2012; Farias,
   Alberto/ABB-1291-2020; D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Andraus,
   Wellington/0000-0002-5162-138X; Ramos, Danusa/0000-0002-6713-5415;
   Farias, Alberto/0000-0002-5572-663X; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2012
VL 31
IS 4
SU S
MA 429
BP S152
EP S152
DI 10.1016/j.healun.2012.01.439
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA 917VY
UT WOS:000302207900429
DA 2020-12-08
ER

PT J
AU Lauck, M
   Alvarado-Mora, MV
   Becker, EA
   Bhattacharya, D
   Striker, R
   Hughes, AL
   Carrilho, FJ
   O'Connor, DH
   Pinho, JRR
AF Lauck, Michael
   Alvarado-Mora, Monica V.
   Becker, Ericka A.
   Bhattacharya, Dipankar
   Striker, Rob
   Hughes, Austin L.
   Carrilho, Flair J.
   O'Connor, David H.
   Rebello Pinho, Joao R.
TI Analysis of Hepatitis C Virus Intrahost Diversity across the Coding
   Region by Ultradeep Pyrosequencing
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RESISTANCE MUTATIONS; SELECTION PRESSURE; PROTEASE; HCV; VARIANTS;
   REPLICATION; BOCEPREVIR; INHIBITORS; POPULATION; TELAPREVIR
AB Hepatitis C virus (HCV) is the leading cause of liver disease worldwide. In this study, we analyzed four treatment-naive patients infected with subtype 1a and performed Roche/454 pyrosequencing across the coding region. We report the presence of low-level drug resistance mutations that would most likely have been missed using conventional sequencing methods. The approach described here is broadly applicable to studies of viral diversity and could help to improve the efficacy of direct-acting antiviral agents (DAA) in the treatment of HCV-infected patients.
C1 [Lauck, Michael; Becker, Ericka A.; O'Connor, David H.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53703 USA.
   [Alvarado-Mora, Monica V.; Carrilho, Flair J.; Rebello Pinho, Joao R.] Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Lab Trop Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Alvarado-Mora, Monica V.; Carrilho, Flair J.; Rebello Pinho, Joao R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Striker, Rob] WS Middleton Mem Vet Assoc Hosp, Madison, WI USA.
   [Bhattacharya, Dipankar; Striker, Rob] Univ Wisconsin, Dept Med, Madison, WI USA.
   [Bhattacharya, Dipankar; Striker, Rob] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA.
   [Hughes, Austin L.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.
RP Alvarado-Mora, MV (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53703 USA.
EM monica.viviana@usp.br
RI Pinho, Joao R. R./G-2850-2012; Alvarado-Mora, Monica/I-3180-2012;
   Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; o'connor,
   david/0000-0003-2139-470X; Striker, Rob/0000-0002-0454-895X
FU National Center for Research Resources (NCRR), National Institutes of
   Health (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [P51 RR000167]; Clinical Science Research and
   Development Service [I01CX000117]; NIHUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [R01
   AI077376-01, GM43940]; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [FAPESP 2007/53457-7, 2008/50461-6]; University of Wisconsin School of
   Medicine and Public Health through Wisconsin Center for Infectious
   Disease (WisCID); Research and Facilities Improvement Program
   [RR15459-01, RR020141-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, C06RR020141, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, C06RR020141, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, C06RR020141, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, C06RR020141, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, C06RR020141, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, C06RR015459, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, C06RR020141, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI077376, R01AI077376,
   R01AI077376, R01AI077376, R01AI077376, R01AI077376, R01AI077376,
   R01AI077376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940] Funding
   Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs
   [I01CX000117, I01CX000117, I01CX000117] Funding Source: NIH RePORTER
FX This publication was made possible by grant P51 RR000167 from the
   National Center for Research Resources (NCRR), a component of the
   National Institutes of Health (NIH), to the Wisconsin National Primate
   Research Center, University of Wisconsin-Madison; by VA merit award
   I01CX000117 from the Clinical Science Research and Development Service
   to R. S.; by NIH grant R01 AI077376-01 to D.H.O.; by NIH grant GM43940
   to A. L. H.; and by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   grants FAPESP 2007/53457-7 and 2008/50461-6 to M.V.A.-M. and J.R.R.P.
   Additional funding was provided by the University of Wisconsin School of
   Medicine and Public Health from The Wisconsin Partnership Program
   through the Wisconsin Center for Infectious Disease (WisCID). This
   research was conducted in part at a facility constructed with support
   from Research and Facilities Improvement Program grants RR15459-01 and
   RR020141-01.
CR Bae A, 2010, ANTIMICROB AGENTS CH, V54, P5288, DOI 10.1128/AAC.00777-10
   Bartels DJ, 2008, J INFECT DIS, V198, P800, DOI 10.1086/591141
   Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631
   Bimber BN, 2010, J VIROL, V84, P12087, DOI 10.1128/JVI.01378-10
   Bimber BN, 2009, J VIROL, V83, P8247, DOI 10.1128/JVI.00897-09
   Butt AA, 2012, CLIN INFECT DIS, V54, P96, DOI 10.1093/cid/cir774
   Coelmont L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013687
   FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205
   Figlerowicz M, 2010, ARCH VIROL, V155, P1977, DOI 10.1007/s00705-010-0789-7
   Fridell RA, 2011, J VIROL, V85, P7312, DOI 10.1128/JVI.00253-11
   GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H
   Gaudieri S, 2009, HEPATOLOGY, V49, P1069, DOI 10.1002/hep.22773
   Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011
   Hiraga N, 2011, HEPATOLOGY, V54, P781, DOI 10.1002/hep.24460
   JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002
   Kukolj G, 2005, J BIOL CHEM, V280, P39260, DOI 10.1074/jbc.M506407200
   Kuntzen T, 2008, HEPATOLOGY, V48, P1769, DOI 10.1002/hep.22549
   KUROSAKI M, 1993, HEPATOLOGY, V18, P1293, DOI 10.1002/hep.1840180602
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Li H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019562
   MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992
   Pawlotsky JM, 2006, CURR TOP MICROBIOL, V299, P261
   Pickett BE, 2011, J VIRAL HEPATITIS, V18, P608, DOI 10.1111/j.1365-2893.2010.01342.x
   Qiu P, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp251
   Rong LB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000544
   Schlutter J, 2011, NATURE, V474, pS5, DOI 10.1038/474S5a
   Simen BB, 2009, J INFECT DIS, V199, P693, DOI 10.1086/596736
   Soriano V, 2011, J ANTIMICROB CHEMOTH, V66, P1673, DOI 10.1093/jac/dkr215
   Susser S, 2009, HEPATOLOGY, V50, P1709, DOI 10.1002/hep.23192
   Suzuki T, 2007, J GASTROENTEROL, V42, P411, DOI 10.1007/s00535-007-2030-3
   Trevino A, 2011, ANTIVIR THER, V16, P413, DOI 10.3851/IMP1760
   Verbinnen T, 2010, J VIROL, V84, P11124, DOI 10.1128/JVI.01217-10
   Vierling JM, 2010, HEPATOLOGY, V52, p702A
   Wang GP, 2010, J VIROL, V84, P6218, DOI 10.1128/JVI.02271-09
   Welch JS, 2011, HEMATOL-AM SOC HEMAT, P30, DOI 10.1182/asheducation-2011.1.30
   Zwickl D. J., 2006, THESIS U TEXAS AUSTI
NR 36
TC 39
Z9 39
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD APR
PY 2012
VL 86
IS 7
BP 3952
EP 3960
DI 10.1128/JVI.06627-11
PG 9
WC Virology
SC Virology
GA 906TV
UT WOS:000301371500051
PM 22278255
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Alvares-da-Silva, MR
   Oliveira, C
   Stefano, JT
   Okamatsu, E
   Barbeiro, H
   Barbeiro, DF
   Soriano, F
   Farias, AQ
   Carrilho, FJ
   D'Albuquerque, LAC
AF Alvares-da-Silva, M. R.
   Oliveira, C.
   Stefano, J. T.
   Okamatsu, E.
   Barbeiro, H.
   Barbeiro, D. F.
   Soriano, F.
   Farias, A. Q.
   Carrilho, F. J.
   D'Albuquerque, L. A. C.
TI CONVENTIONAL AND NOVEL CARDIOVASCULAR RISK FACTORS IN LIVER TRANSPLANT
   RECIPIENTS (LTR)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 47th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 18-22, 2012
CL Barcelona, SPAIN
SP European Assoc Study Liver (EASL)
C1 [Alvares-da-Silva, M. R.; Oliveira, C.; Stefano, J. T.; Okamatsu, E.; Barbeiro, H.; Barbeiro, D. F.; Soriano, F.; Farias, A. Q.; Carrilho, F. J.; D'Albuquerque, L. A. C.] Univ Sao Paulo, Sao Paulo, Brazil.
EM mras@terra.com.br
RI Barbeiro, Hermes V/E-2814-2010; Soriano, Francisco/C-3382-2012; Stefano,
   Jose T/H-4792-2013; Stefano, Jose Tadeu/AAH-5419-2020; D'Albuquerque,
   Luiz Augusto Carneiro/A-8812-2013; Farias, Alberto/ABB-1291-2020;
   D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Carrilho, Flair
   J/I-3046-2012; Barbeiro, Hermes V/S-5926-2016
OI Barbeiro, Hermes V/0000-0002-8209-4463; Soriano,
   Francisco/0000-0003-4898-0135; Stefano, Jose Tadeu/0000-0002-0218-1920;
   D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Farias,
   Alberto/0000-0002-5572-663X; Barbeiro, Hermes V/0000-0002-8209-4463
NR 0
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2012
VL 56
SU 2
MA 173
BP S75
EP S76
DI 10.1016/S0168-8278(12)60186-X
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 931TD
UT WOS:000303241300173
DA 2020-12-08
ER

PT J
AU Vassiliadis, E
   Oliveira, CP
   Alvares-da-Silva, MR
   Zhang, C
   Carrilho, FJ
   Stefano, JT
   Rabelo, F
   Pereira, L
   Kappel, CR
   Henriksen, K
   Veidal, SS
   Vainer, B
   Duffin, KL
   Christiansen, C
   Leeming, DJ
   Karsdal, M
AF Vassiliadis, E.
   Oliveira, C. P.
   Alvares-da-Silva, M. R.
   Zhang, C.
   Carrilho, F. J.
   Stefano, J. T.
   Rabelo, F.
   Pereira, L.
   Kappel, C. R.
   Henriksen, K.
   Veidal, Skovgard S.
   Vainer, B.
   Duffin, K. L.
   Christiansen, C.
   Leeming, D. J.
   Karsdal, M.
TI Citrullination and MMP degradation of vimentin, a key event in fibrosis
   and tissue destruction
SO APMIS
LA English
DT Meeting Abstract
C1 [Vassiliadis, E.; Zhang, C.; Henriksen, K.; Veidal, Skovgard S.; Christiansen, C.; Leeming, D. J.; Karsdal, M.] Nord Biosci, Copenhagen, Denmark.
   [Vassiliadis, E.; Veidal, Skovgard S.] Univ So Denmark, Dept Endocrinol, Odense, Denmark.
   [Zhang, C.] Tech Univ Denmark, Dept Syst Biol, DK-2800 Lyngby, Denmark.
   [Vainer, B.] Copenhagen Univ Hosp, Rigshosp, Dept Pathol, Copenhagen, Denmark.
   [Duffin, K. L.] Eli Lilly & Co, Greenfield, IN USA.
   [Oliveira, C. P.; Carrilho, F. J.; Stefano, J. T.; Rabelo, F.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Alvares-da-Silva, M. R.; Kappel, C. R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Allegre, Div Gastroenterol, Porto Alegre, RS, Brazil.
   [Pereira, L.] Inst Figado Pernambuco, Pernambuco, Brazil.
RI Alvares-da-Silva, Mario Reis/L-3910-2014; Stefano, Jose T/H-4792-2013;
   Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012;
   Stefano, Jose Tadeu/AAH-5419-2020; Vassiliadis, Efstathios/ABC-8546-2020
OI Alvares-da-Silva, Mario Reis/0000-0002-5001-246X; Stefano, Jose
   Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
J9 APMIS
JI APMIS
PD MAR
PY 2012
VL 120
SU 134
SI SI
BP 10
EP 10
PG 1
WC Immunology; Microbiology; Pathology
SC Immunology; Microbiology; Pathology
GA 095TZ
UT WOS:000315358900023
DA 2020-12-08
ER

PT J
AU Vassiliadis, E
   Oliveira, CP
   Alvares-da-Silva, MR
   Zhang, C
   Carrilho, FJ
   Stefano, JT
   Rabelo, F
   Pereira, L
   Kappel, CR
   Henriksen, K
   Veidal, SS
   Vainer, B
   Duffin, KL
   Christiansen, C
   Leeming, DJ
   Karsdal, M
AF Vassiliadis, Efstathios
   Oliveira, Claudia P.
   Alvares-da-Silva, Mario R.
   Zhang, Chen
   Carrilho, Flair J.
   Stefano, Jose T.
   Rabelo, Fabiola
   Pereira, Leila
   Kappel, Camila R.
   Henriksen, Kim
   Veidal, Sanne Skovgard
   Vainer, Ben
   Duffin, Kevin L.
   Christiansen, Claus
   Leeming, Diana J.
   Karsdal, Morten
TI Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in
   liver fibrosis related pathology
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Biomarker; citrulline; hepatitis C; NAFLD
ID HEPATIC STELLATE CELLS; MYELIN BASIC-PROTEIN; RHEUMATOID-ARTHRITIS;
   INTERMEDIATE FILAMENTS; MATRIX; AUTOANTIBODIES; DEIMINATION;
   INVOLVEMENT; EXPRESSION; APOPTOSIS
AB Aim: To investigate whether increased levels of vimentin citrullinated peptides identified by MS in articular cartilage can be measured in pathologies other than rheumatoid arthritis and be utilised for diagnostic purposes. Methods: A monoclonal antibody against the sequence RLRSSVPGV-citrulline (VICM) was developed and evaluated in a carbon tetrachloride (CCl4) (n=52 + 28 controls) rat model of liver fibrosis and two clinical cohorts of adult patients with hepatitis C (HCV) (n=92) and non-alcoholic fatty liver disease (NAFLD) (n=62), and compared to healthy controls. Results: In CCl4-treated rats, mean systemic VICM levels increased 31% at week 12 (176 ng/mL, P<0.001), 41.7% at weeks 16 (190 ng/mL, P<0.001), 49.2% at weeks 20 (200 ng/ml, P<0.001), compared to controls (134 ng/mL). VICM levels correlated with total hepatic collagen determined by Sirius red staining of rat livers (r=0.75, P<0.05). In the HCV cohort, when stratified according to the METAVIR F score, VICM levels were 63% higher in F0 (632 ng/mL +/- 75, p<0.05), 54% in F1 (597 ng/mL +/- 41.3, p<0.05) and 62% in F2 (628 ng/mL +/- 59, p<0.05) all compared to controls. In the NAFLD cohort, VICM levels were 20.6% higher in F0 (339 +/- 12 ng/mL, P<0.05), 23.8% in F1 (348 +/- 12 ng/mL, P<0.05) and 28.8% in F2 (362 +/- 25 P<0.05). Conclusion: We demonstrated increased serological levels of citrullinated and MMP degraded vimentin in an animal model of liver fibrosis and in early fibrosis associated with HCV and NAFLD patients. These data suggest that citrullinated and MMP degraded proteins are also present in liver fibrosis.
C1 [Vassiliadis, Efstathios; Henriksen, Kim; Veidal, Sanne Skovgard; Christiansen, Claus; Leeming, Diana J.; Karsdal, Morten] Nord Biosci, Assay Dev, Copenhagen, Denmark.
   [Vassiliadis, Efstathios; Veidal, Sanne Skovgard] Univ Southern Denmark, Dept Endocrinol, Odense, Denmark.
   [Zhang, Chen] Tech Univ Denmark, Dept Syst Biol, DK-2800 Lyngby, Denmark.
   [Vainer, Ben] Copenhagen Univ Hosp, Rigshosp, Dept Pathol, Copenhagen, Denmark.
   [Duffin, Kevin L.] Eli Lilly & Co, Greenfield, IN USA.
   [Oliveira, Claudia P.; Carrilho, Flair J.; Stefano, Jose T.; Rabelo, Fabiola] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Alvares-da-Silva, Mario R.; Kappel, Camila R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Allegre, Div Gastroenterol, Porto Alegre, RS, Brazil.
   [Pereira, Leila] Inst Figado Pernambuco, Pernambuco, Brazil.
RP Vassiliadis, E (corresponding author), Nord Biosci AS, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.
EM eva@nordicbioscience.com
RI Carrilho, Flair J/I-3046-2012; Stefano, Jose Tadeu/AAH-5419-2020;
   Alvares-da-Silva, Mario Reis/L-3910-2014; Stefano, Jose T/H-4792-2013;
   Oliveira, Claudia PMS/D-1216-2014; Vassiliadis,
   Efstathios/ABC-8546-2020; Vassiliadis, Efstathios/E-5450-2011
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Alvares-da-Silva, Mario
   Reis/0000-0002-5001-246X; 
CR Abdeen S, 2011, HEPATIC MED-EVID RES, V3, P13, DOI 10.2147/HMER.S17039
   Adair-Kirk TL, 2008, INT J BIOCHEM CELL B, V40, P1101, DOI 10.1016/j.biocel.2007.12.005
   Amalinei C, 2010, ROM J MORPHOL EMBRYO, V51, P215
   Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245
   Asaga H, 1998, BIOCHEM BIOPH RES CO, V243, P641, DOI 10.1006/bbrc.1998.8148
   Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048
   Benes P, 2006, DIFFERENTIATION, V74, P265, DOI 10.1111/j.1432-0436.2006.00077.x
   Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552
   Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6
   Copple BL, 2010, COMPREHENSIVE TOXICOLOGY, VOL 9: HEPATIC TOXICOLOGY, 2ND EDITION, P263
   Ehrlich A, 2004, J AM ACAD DERMATOL, V50, P533, DOI 10.1016/j.jaad.2003.09.018
   Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906
   Evans Robert M., 1994, Trends in Cell Biology, V4, P149, DOI 10.1016/0962-8924(94)90189-9
   Geerts A, 2001, HEPATOLOGY, V33, P177, DOI 10.1053/jhep.2001.21045
   GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818
   Girbal-Neuhauser E, 1999, J IMMUNOL, V162, P585
   Goeb V, 2009, JOINT BONE SPINE, V76, P343, DOI 10.1016/j.jbspin.2008.12.006
   Goldbach-Mansky R, 2000, ARTHRITIS RES, V2, P145, DOI 10.1186/ar79
   Goldbach-Mansky R, 2000, ARTHRITIS RES, V2, P236, DOI 10.1186/ar93
   Gyorgy B, 2006, INT J BIOCHEM CELL B, V38, P1662, DOI 10.1016/j.biocel.2006.03.008
   Harauz G, 2004, MICRON, V35, P503, DOI 10.1016/j.micron.2004.04.005
   Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003
   HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X
   Holm A, 2006, ANAL BIOCHEM, V352, P68, DOI 10.1016/j.ab.2006.02.007
   Ishida-Yamamoto A, 2000, J INVEST DERMATOL, V114, P701, DOI 10.1046/j.1523-1747.2000.00936.x
   Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040
   Karsdal MA, 2010, CLIN BIOCHEM, V43, P793, DOI 10.1016/j.clinbiochem.2010.03.015
   Lutteri L, 2007, CLIN CHIM ACTA, V386, P76, DOI 10.1016/j.cca.2007.08.002
   Marcelletti JF, 2003, CLIN APPL IMMUNOL RE, V4, P109
   Mastronardi FG, 1996, J CLIN INVEST, V97, P349, DOI 10.1172/JCI118422
   McGraw WT, 1999, INFECT IMMUN, V67, P3248, DOI 10.1128/IAI.67.7.3248-3256.1999
   McInroy L, 2007, BIOCHEM BIOPH RES CO, V360, P109, DOI 10.1016/j.bbrc.2007.06.036
   Meri S, 2001, BIOMOL ENG, V18, P213, DOI 10.1016/S1389-0344(01)00106-X
   Miyata E, 2008, BLOOD, V111, P2427, DOI 10.1182/blood-2007-07-101261
   Muller K, 2001, ATHEROSCLEROSIS, V156, P133, DOI 10.1016/S0021-9150(00)00641-9
   NIENHUIS RL, 1964, ANN RHEUM DIS, V23, P302, DOI 10.1136/ard.23.4.302
   Nijenhuis S, 2004, CLIN CHIM ACTA, V350, P17, DOI 10.1016/j.cccn.2004.07.016
   Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316
   Schuppan D, 2001, SEMIN LIVER DIS, V21, P351, DOI 10.1055/s-2001-17556
   Sghiri R, 2010, JOINT BONE SPINE, V77, P279, DOI 10.1016/j.jbspin.2010.02.007
   Shigeki TA, 2006, CLIN CHIM ACTA, V364, P33, DOI 10.1016/j.cca.2005.06.014
   Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5
   Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709
   van Gaalen F, 2005, J IMMUNOL, V175, P5575, DOI 10.4049/jimmunol.175.9.5575
   Veidal SS, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-5
   Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357
   Vossenaar ER, 2004, CLIN APPL IMMUNOL RE, V4, P239, DOI [DOI 10.1016/j.cair.2003.11.001, DOI 10.1016/J.CAIR.2003.11.001]
   Zhao LN, 2007, J MOL HISTOL, V38, P53, DOI 10.1007/s10735-007-9078-5
   Zhen EY, 2008, ARTHRITIS RHEUM-US, V58, P2420, DOI 10.1002/art.23654
NR 49
TC 37
Z9 39
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2012
VL 4
IS 4
BP 403
EP 414
PG 12
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA 135HW
UT WOS:000318280200004
PM 23145208
DA 2020-12-08
ER

PT J
AU Siqueira, ERF
   Oliveira, CPMS
   Correa-Giannella, ML
   Stefano, JT
   Cavaleiro, AM
   Fortes, MAHZ
   Muniz, MTC
   Silva, FS
   Pereira, LMMB
   Carrilho, FJ
AF Siqueira, E. R. F.
   Oliveira, C. P. M. S.
   Correa-Giannella, M. L.
   Stefano, J. T.
   Cavaleiro, A. M.
   Fortes, M. A. H. Z.
   Muniz, M. T. C.
   Silva, F. S.
   Pereira, L. M. M. B.
   Carrilho, F. J.
TI MTP-493G/T gene polymorphism is associated with steatosis in hepatitis
   C-infected patients
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Hepatitis C; Steatosis; Fibrosis; Microsomal transfer protein
ID TRIGLYCERIDE TRANSFER PROTEIN; DENSITY-LIPOPROTEIN RECEPTOR; FATTY
   LIVER-DISEASE; VIRUS CORE PROTEIN; INSULIN-RESISTANCE; OXIDATIVE STRESS;
   LIPID DROPLET; GENOTYPE; PATHOGENESIS; HEPATOCYTES
AB The reduction of hepatic microsomal transfer protein (MTP) activity results in fatty liver, worsening hepatic steatosis and fibrosis in chronic hepatitis C (CHC). The G allele of the MTP gene promoter, -493G/T, has been associated with lower transcriptional activity than the T allele. We investigated this association with metabolic and histological variables in patients with CHC. A total of 174 untreated patients with CHC were genotyped for MTP -493G/T by direct sequencing using PCR. All patients were negative for markers of Wilson's disease, hemochromatosis and autoimmune diseases and had current and past daily alcohol intake lower than 100 g/week. The sample distribution was in Hardy-Weinberg equilibrium. Among subjects with genotype 1, 56.8% of the patients with fibrosis grade 3+4 presented at least one G allele versus 34.3% of the patients with fibrosis grade 1+2 (OR = 1.8; 95%CI = 1.3-2.3). Logistic regression analysis with steatosis as the dependent variable identified genotypes GG+GT as independent protective factors against steatosis (OR = 0.4, 95%CI = 0.2-0.8; P = 0.01). The results suggest that the presence of the G allele of MTP -493G/T associated with lower hepatic MTP expression protects against steatosis in our CHC patients.
C1 [Siqueira, E. R. F.; Oliveira, C. P. M. S.; Stefano, J. T.; Carrilho, F. J.] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Correa-Giannella, M. L.; Cavaleiro, A. M.; Fortes, M. A. H. Z.] Univ Sao Paulo, Fac Med, Lab Endocrinol Celular & Mol, Sao Paulo, Brazil.
   [Siqueira, E. R. F.; Muniz, M. T. C.; Silva, F. S.] Univ Pernambuco, Dept Bioquim, Fac Med, Recife, PE, Brazil.
   [Siqueira, E. R. F.; Pereira, L. M. M. B.] Univ Pernambuco, Dept Gastroenterol, Fac Med, Recife, PE, Brazil.
   [Pereira, L. M. M. B.] Inst Figado Pernambuco, Recife, PE, Brazil.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Dept Gastroenterol LIM 07, FM, Av Dr Arnaldo 455,3 Andar, BR-01246903 Sao Paulo, Brazil.
EM cpm@usp.br
RI Carrilho, Flair J/I-3046-2012; da Silva, Filipe Santana/C-3255-2011;
   Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose T/H-4792-2013;
   Giannella, Maria Lucia/N-3834-2019; Fortes, Maria Angela HZ/K-4422-2013;
   Stefano, Jose Tadeu/AAH-5419-2020
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446; Santana da Silva, Filipe/0000-0002-6803-1407
FU CAPESCAPES
FX Research supported by CAPES.
CR Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432
   Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766
   ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259
   Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002
   Asselah T, 2006, GUT, V55, P123, DOI 10.1136/gut.2005.069757
   Asselah T, 2003, GUT, V52, P1638, DOI 10.1136/gut.52.11.1638
   Bernard S, 2000, DIABETOLOGIA, V43, P995, DOI 10.1007/s001250051481
   Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785
   Boulant S, 2008, TRAFFIC, V9, P1268, DOI 10.1111/j.1600-0854.2008.00767.x
   Clement S, 2009, VIRUSES-BASEL, V1, P126, DOI 10.3390/v1020126
   Corey KE, 2009, HEPATOLOGY, V50, P1030, DOI 10.1002/hep.23219
   Domitrovich AM, 2005, J BIOL CHEM, V280, P39802, DOI 10.1074/jbc.M510391200
   Salgado Ana Lúcia Farias de Azevedo, 2010, Arq. Gastroenterol., V47, P165, DOI 10.1590/S0004-28032010000200009
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gambino R, 2007, HEPATOLOGY, V45, P1097, DOI 10.1002/hep.21631
   GROBHOLZ R, 1993, CANCER RES, V53, P4204
   Guo JS, 2007, SEMIN LIVER DIS, V27, P413, DOI 10.1055/s-2007-991517
   Hui JM, 2002, J GASTROEN HEPATOL, V17, P873, DOI 10.1046/j.1440-1746.2002.02813.x
   Karpe F, 1998, ARTERIOSCL THROM VAS, V18, P756, DOI 10.1161/01.ATV.18.5.756
   Kumar D, 2002, HEPATOLOGY, V36, P1266, DOI 10.1053/jhep.2002.36370
   Mirandola S, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-13
   Mirandola S, 2009, LIVER INT, V29, P557, DOI 10.1111/j.1478-3231.2008.01892.x
   Miyanari Y, 2007, NAT CELL BIOL, V9, P1089, DOI 10.1038/ncb1631
   Molina S, 2007, J HEPATOL, V46, P411, DOI 10.1016/j.jhep.2006.09.024
   Moradpour D, 2005, EUR J GASTROEN HEPAT, V17, P477, DOI 10.1097/00042737-200505000-00002
   Namikawa C, 2004, J HEPATOL, V40, P781, DOI 10.1016/j.jhep.2004.01.028
   Negro F, 2010, GUT, V59, P1279, DOI 10.1136/gut.2009.192732
   Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13
   Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983
   Petit JM, 2006, MOL GENET METAB, V88, P196, DOI 10.1016/j.ymgme.2005.12.006
   Poynard T, 2003, HEPATOLOGY, V38, P75, DOI 10.1053/jhep.2003.50267
   Richardson MM, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.032557
   Romero-Gomez M, 2003, AM J GASTROENTEROL, V98, P1135, DOI [10.1016/S0002-9270(03)00185-0, 10.1111/j.1572-0241.2003.07450.x]
   Rubbia-Brandt L, 2004, GUT, V53, P406, DOI 10.1136/gut.2003.018770
   Rubbia-Brandt L, 2000, J HEPATOL, V33, P106, DOI 10.1016/S0168-8278(00)80166-X
   Schreuder TCMA, 2008, WORLD J GASTROENTERO, V14, P2474, DOI 10.3748/wjg.14.2474
   Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225
   Syed GH, 2010, TRENDS ENDOCRIN MET, V21, P33, DOI 10.1016/j.tem.2009.07.005
   Zampino R, 2008, J VIRAL HEPATITIS, V15, P740, DOI 10.1111/j.1365-2893.2008.00994.x
   Zoulim F, 2003, REV MED VIROL, V13, P57, DOI 10.1002/rmv.371
NR 40
TC 10
Z9 13
U1 0
U2 3
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JAN
PY 2012
VL 45
IS 1
BP 72
EP 77
DI 10.1590/S0100-879X2011007500160
PG 6
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 875RU
UT WOS:000299053200012
PM 22147193
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Feitosa, F
   Carlos, A
   Nogueira, JG
   Kishi, H
   Hashimoto, C
   Carrilho, F
   Damiao, A
AF Feitosa, Flavio
   Carlos, Alexandre
   Nogueira, Jose Guilherme
   Kishi, Humberto
   Hashimoto, Claudio
   Carrilho, Flair
   Damiao, Aderson
TI Narrow-band imaging and chromoendoscopy for the detecion of colonic
   dysplasia in inflammatory bowel disease: a prospective and randomized
   study
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Meeting Abstract
C1 [Feitosa, Flavio; Carlos, Alexandre; Nogueira, Jose Guilherme; Hashimoto, Claudio; Carrilho, Flair; Damiao, Aderson] HCFMUSP, Dept Gastroenterol, Sao Paulo, Brazil.
   [Kishi, Humberto] HCFMUSP, Dept Pathol, Sao Paulo, Brazil.
RI Feitosa, Flavio/AAR-4582-2020; Carrilho, Flair J/I-3046-2012
CR Herszenyi L, 2007, DIGEST DIS, V25, P267, DOI 10.1159/000103898
   Sano Y, 2005, DIGEST ENDOSC, V17, pS43, DOI DOI 10.1111/J.1443-1661.2005.00511.X
NR 2
TC 9
Z9 9
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1078-0998
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD DEC
PY 2011
VL 17
SU 2
BP S14
EP S15
DI 10.1097/00054725-201112002-00045
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 857RB
UT WOS:000297735300046
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Cogliati, B
   Santos, F
   Lima, VMR
   Mazo, DC
   Matte, U
   Alvares-Da-Silva, MR
   Silveira, TR
   Carrilho, FJ
   Oliveira, CPMS
AF Stefano, J. T.
   Cogliati, B.
   Santos, F.
   Lima, V. M. R.
   Mazo, D. C.
   Matte, U.
   Alvares-da-Silva, M. R.
   Silveira, T. R.
   Carrilho, F. J.
   Oliveira, C. P. M. S.
TI S-Nitroso-N-acetylcysteine induces de-differentiation of activated
   hepatic stellate cells and promotes antifibrotic effects in vitro
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Article
DE S-Nitroso-N-acetylcysteine; Fibrogenesis; Hepatic stellate cells
ID NITRIC-OXIDE SYNTHASE; CHRONIC LIVER-DISEASE; TGF-BETA; OXIDATIVE
   STRESS; GENE-EXPRESSION; COLLAGEN GENE; NONALCOHOLIC STEATOHEPATITIS;
   MATRIX METALLOPROTEINASE-13; FIBROSIS; RAT
AB Nitric oxide (NO) has been shown to act as a potent antifibrogenic agent by decreasing myofibroblast differentiation. S-Nitroso-N-acetylcysteine (SNAC), a NO donor, attenuates liver fibrosis in rats, but the cellular and molecular mechanisms on liver myofibroblast-like phenotype still remain unknown. Here, we investigate the antifibrotic effects of SNAC on hepatic stellate cells, the major fibrogenic cell type in the liver. A murine GRX cell line was incubated with SNAC (100 mu M) or vehicle (control group) for 72 h. Cell viability was measured by MTT colorimetric assay and the conversion of myofibroblast into quiescent fat-storing cell phenotype was evaluated by Oil-Red-O staining. TGF beta-1, TIMP-1, and MMP-13 levels were measure in the supernatant by ELISA. Profibrogenic- and fibrolytic-related gene expression was quantified using real-time qPCR. SNAC induced phenotype conversion of myofibroblast-like phenotype into quiescent cells. SNAC decreased gene and protein expression of TGF beta-1 and MMP-2 compared to control groups. Besides, SNAC down-regulated profibrogenic molecules and up-regulated MMP-13 gene expression, which plays a key role in the degradation of interstitial collagen in liver fibrosis. In conclusion, these findings demonstrate that SNAC efficiently can modulate the activation and functionality of murine hepatic stellate cells and could be considered as an antifibrotic treatment to human liver fibrosis. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Stefano, J. T.; Cogliati, B.; Lima, V. M. R.; Mazo, D. C.; Carrilho, F. J.; Oliveira, C. P. M. S.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, BR-01246903 Sao Paulo, Brazil.
   [Santos, F.; Matte, U.; Alvares-da-Silva, M. R.; Silveira, T. R.] Univ Fed Rio Grande do Sul, Dept Internal Med & Pediat, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Arnaldo 455,Floor 3,3115, BR-01246903 Sao Paulo, Brazil.
EM cpm@usp.br
RI Da Silveira Matte umatte, Ursula/U-3912-2019; Stefano, Jose
   T/H-4792-2013; oliveira, Fernanda/W-2879-2019; Silveira,
   Themis/H-4286-2016; Stefano, Jose Tadeu/AAH-5419-2020; Carrilho, Flair
   J/I-3046-2012; de Oliveira, Fernanda/W-2819-2019; Cogliati,
   Bruno/E-9956-2012; Oliveira, Claudia PMS/D-1216-2014; Alvares-da-Silva,
   Mario Reis/L-3910-2014; Mazo, Daniel FC/D-5631-2015; Matte,
   Ursula/J-4589-2012
OI Da Silveira Matte umatte, Ursula/0000-0003-4977-6662; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Cogliati, Bruno/0000-0002-1388-7240;
   Alvares-da-Silva, Mario Reis/0000-0002-5001-246X; Mazo, Daniel
   FC/0000-0002-2164-2630; 
FU FAPESP - Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [08/56157-7]
FX We thank Dr. Marcelo G. de Oliveira and Gabriela F. de Souza (Institute
   of Chemistry, State University of Campinas - UNICAMP, Campinas, SP,
   Brazil) for provided the S-nitroso-N-acetylcysteine (SNAC). This study
   was supported by Grants from FAPESP - Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (08/56157-7).
CR Anania FA, 2001, FREE RADICAL BIO MED, V30, P846, DOI 10.1016/S0891-5849(01)00470-1
   Arias M, 2002, CELL GROWTH DIFFER, V13, P265
   Arkenau HT, 2002, Z GASTROENTEROL, V40, P907, DOI 10.1055/s-2002-35413
   Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245
   Baroni GS, 1998, HEPATOLOGY, V27, P720
   Bolkenius U, 2004, BIOCHEM BIOPH RES CO, V325, P1264, DOI 10.1016/j.bbrc.2004.10.164
   Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006
   Campbell JS, 2005, P NATL ACAD SCI USA, V102, P3389, DOI 10.1073/pnas.0409722102
   Chatziantoniou C, 1998, J CLIN INVEST, V101, P2780, DOI 10.1172/JCI2132
   de Lima VM, 2008, J HEPATOL, V49, P1055, DOI 10.1016/j.jhep.2008.07.024
   de Oliveira CPMS, 2008, J AM COLL NUTR, V27, P299, DOI 10.1080/07315724.2008.10719703
   de Oliveira CPMS, 2006, WORLD J GASTROENTERO, V12, P1905, DOI 10.3748/wjg.v12.i12.1905
   Death AK, 2002, J AM COLL CARDIOL, V39, P1943, DOI 10.1016/S0735-1097(02)01907-1
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Douglass A, 2008, J HEPATOL, V49, P88, DOI 10.1016/j.jhep.2008.01.032
   El-Sherif AM, 2008, HEPATOL INT, V2, P341, DOI 10.1007/s12072-008-9077-y
   Failli P, 2000, GASTROENTEROLOGY, V119, P479, DOI 10.1053/gast.2000.9354
   Fallowfield JA, 2007, J IMMUNOL, V178, P5288, DOI 10.4049/jimmunol.178.8.5288
   Ferrini M, 2001, NEUROENDOCRINOLOGY, V74, P1, DOI 10.1159/000054665
   Ferrini M, 2001, BIOL REPROD, V64, P974, DOI 10.1095/biolreprod64.3.974
   Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003
   Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007
   Friedman SL, 2003, J HEPATOL, V38, pS38, DOI 10.1016/S0168-8278(02)00429-4
   George J, 1999, P NATL ACAD SCI USA, V96, P12719, DOI 10.1073/pnas.96.22.12719
   Giustarini D, 2003, CLIN CHIM ACTA, V330, P85, DOI 10.1016/S0009-8981(03)00046-9
   Gnainsky Y, 2007, CELL TISSUE RES, V328, P153, DOI 10.1007/s00441-006-0330-1
   Greenwel P, 2000, HEPATOLOGY, V31, P109, DOI 10.1002/hep.510310118
   Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner
   Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315
   Guimaraes ELM, 2006, LIVER INT, V26, P477, DOI 10.1111/j.1478-3231.2006.01245.x
   Guo JS, 2007, SEMIN LIVER DIS, V27, P413, DOI 10.1055/s-2007-991517
   Guyot C, 2006, INT J BIOCHEM CELL B, V38, P135, DOI 10.1016/j.biocel.2005.08.021
   Harrison SA, 2003, AM J GASTROENTEROL, V98, P2485, DOI 10.1111/j.1572-0241.2003.08699.x
   HOU J, 1995, J CLIN INVEST, V96, P2469, DOI 10.1172/JCI118305
   Iredale JP, 1997, INT J BIOCHEM CELL B, V29, P43, DOI 10.1016/S1357-2725(96)00118-5
   Ishibashi H, 2007, SEMIN LIVER DIS, V27, P214, DOI 10.1055/s-2007-979472
   Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512
   Kawada N, 1996, BIOCHEM BIOPH RES CO, V229, P238, DOI 10.1006/bbrc.1996.1786
   Kim KY, 2001, J BIOL CHEM, V276, P40591, DOI 10.1074/jbc.M100975200
   Kinkel AD, 2004, CYTOTECHNOLOGY, V46, P49, DOI 10.1007/s10616-004-3903-4
   KIRKALI G, 2000, TURK J MED SCI, V30, P511
   Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5
   Krischel V, 1998, J INVEST DERMATOL, V111, P286, DOI 10.1046/j.1523-1747.1998.00268.x
   Langer DA, 2008, HEPATOLOGY, V47, P1983, DOI 10.1002/hep.22285
   Lee KS, 2001, YONSEI MED J, V42, P1
   Li D., 2003, EXTRACELLULAR MATRIX, p155 178
   Li JR, 1999, AM J PHYSIOL-GASTR L, V276, pG1069, DOI 10.1152/ajpgi.1999.276.5.G1069
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lukivskaya O, 2008, EUR J CLIN INVEST, V38, P317, DOI 10.1111/j.1365-2362.2008.01941.x
   de Oliveira CPMS, 2006, J HEPATOL, V45, P725, DOI 10.1016/j.jhep.2006.05.017
   Melgert BN, 2001, HEPATOLOGY, V34, P719, DOI 10.1053/jhep.2001.27805
   Modol T, 2011, BIOCHEM PHARMACOL, V81, P451, DOI 10.1016/j.bcp.2010.10.017
   Muriel P, 2009, HEPATOL INT, V3, P526, DOI 10.1007/s12072-009-9158-6
   Novo E, 2006, GUT, V55, P1174, DOI 10.1136/gut.2005.082701
   O'Shaughnessy MC, 2000, BIOCHEM BIOPH RES CO, V277, P604, DOI 10.1006/bbrc.2000.3714
   Peunova N, 2001, J NEUROSCI, V21, P8809, DOI 10.1523/JNEUROSCI.21-22-08809.2001
   Rizvi MAD, 1997, J MOL CELL CARDIOL, V29, P1779, DOI 10.1006/jmcc.1996.0480
   Rodriguez-Martin E, 2000, NEUROPHARMACOLOGY, V39, P2090, DOI 10.1016/S0028-3908(00)00049-6
   Schaefer B, 2003, AM J PATHOL, V162, P1771, DOI 10.1016/S0002-9440(10)64312-X
   Schuppan D, 2009, GASTROEN CLIN BIOL, V33, P949, DOI 10.1016/j.gcb.2009.07.021
   Schuppan D, 2008, LANCET, V371, P838, DOI 10.1016/S0140-6736(08)60383-9
   Ueno T., 2003, EXTRACELLULAR MATRIX, P89
   Urtasun R, 2007, REV ESP ENFERM DIG, V99, P223, DOI 10.4321/s1130-01082007000400007
   Vercelino R, 2010, J MOL MED, V88, P401, DOI 10.1007/s00109-009-0577-6
   Vicente CP, 1997, MOL CELL BIOCHEM, V168, P31, DOI 10.1023/A:1006845808305
   Wright MC, 2001, GASTROENTEROLOGY, V121, P685, DOI 10.1053/gast.2001.27188
   Yoshiji H, 2002, HEPATOLOGY, V36, P850, DOI 10.1053/jhep.2002.35625
NR 67
TC 8
Z9 8
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
EI 1089-8611
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD OCT 30
PY 2011
VL 25
IS 3
BP 360
EP 365
DI 10.1016/j.niox.2011.07.001
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 837FZ
UT WOS:000296177800016
PM 21820071
DA 2020-12-08
ER

PT J
AU Nakatani, SM
   Santos, CA
   Riediger, IN
   Krieger, MA
   Duarte, CAB
   Debur, MD
   Carrilho, FJ
   Ono, SK
AF Nakatani, Sueli M.
   Santos, Carlos A.
   Riediger, Irina N.
   Krieger, Marco A.
   Duarte, Cesar A. B.
   Debur, Maria do Carmo
   Carrilho, Flair J.
   Ono, Suzane K.
TI Comparative performance evaluation of hepatitis C virus genotyping based
   on the 5 ' untranslated region versus partial sequencing of the NS5B
   region of brazilian patients with chronic hepatitis C
SO VIROLOGY JOURNAL
LA English
DT Article
DE HCV; genotyping; NS5B region; 5 ' UTR
ID MAJOR GENOTYPES; ASSAY; NOMENCLATURE; SUBTYPES; SYSTEM
AB Background: Genotyping of hepatitis C virus (HCV) has become an essential tool for prognosis and prediction of treatment duration. The aim of this study was to compare two HCV genotyping methods: reverse hybridization line probe assay (LiPA v.1) and partial sequencing of the NS5B region.
   Methods: Plasma of 171 patients with chronic hepatitis C were screened using both a commercial method (LiPA HCV Versant, Siemens, Tarrytown, NY, USA) and different primers targeting the NS5B region for PCR amplification and sequencing analysis.
   Results: Comparison of the HCV genotyping methods showed no difference in the classification at the genotype level. However, a total of 82/171 samples (47.9%) including misclassification, non-subtypable, discrepant and inconclusive results were not classified by LiPA at the subtype level but could be discriminated by NS5B sequencing. Of these samples, 34 samples of genotype 1a and 6 samples of genotype 1b were classified at the subtype level using sequencing of NS5B.
   Conclusions: Sequence analysis of NS5B for genotyping HCV provides precise genotype and subtype identification and an accurate epidemiological representation of circulating viral strains.
C1 [Nakatani, Sueli M.; Carrilho, Flair J.; Ono, Suzane K.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Nakatani, Sueli M.; Riediger, Irina N.; Debur, Maria do Carmo] LACEN PR, Lab Cent Estado Parana, Sao Jose Dos Pinhais, Parana, Brazil.
   [Santos, Carlos A.] Ctr Genomas, Sao Paulo, Brazil.
   [Krieger, Marco A.; Duarte, Cesar A. B.] ICC FioCruz, Curitiba, Parana, Brazil.
RP Ono, SK (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM skon@usp.br
RI Ono, Suzane/I-3107-2012; Publica, Inct Saude/J-9544-2013; Krieger,
   Marco/AAE-8611-2020; Carrilho, Flair J/I-3046-2012; P, CM/B-1358-2013
FU Secretaria de Saude do Estado do Parana; Fundacao AraucariaFundacao
   Araucaria; Alves de Queiroz Family Fund for Research
FX These investigations were supported in part by grants from Secretaria de
   Saude do Estado do Parana, Fundacao Araucaria and Alves de Queiroz
   Family Fund for Research. We are indebted to Dr. Hermes Pedreira da
   Silva Filho (CPqGM/Fiocruz-Bahia), who performed the phylogenetic
   analyses in this study and to Dr. Alexandre Dias Tavares Costa
   (Instituto Carlos Chagas) for carefully reviewing this article.
CR ANDONOV A, 1995, J CLIN MICROBIOL, V33, P254, DOI 10.1128/JCM.33.1.254-256.1995
   Buckton AJ, 2006, J CLIN MICROBIOL, V44, P2779, DOI 10.1128/JCM.01638-05
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Cantaloube JF, 2006, J CLIN MICROBIOL, V44, P2051, DOI 10.1128/JCM.02463-05
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Corbet S, 2003, J CLIN MICROBIOL, V41, P1091, DOI 10.1128/JCM.41.3.1091-1100.2003
   DAVIDSON F, 1995, J GEN VIROL, V76, P1197, DOI 10.1099/0022-1317-76-5-1197
   HALL TA, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.5598/IMAFUNGUS.2011.02.02.06
   Holland PV, 1996, J CLIN MICROBIOL, V34, P2372, DOI 10.1128/JCM.34.10.2372-2378.1996
   KUSSER W, 2006, CSH PROTOCOLS
   Laperche S, 2005, J CLIN MICROBIOL, V43, P733, DOI 10.1128/JCM.43.2.733-739.2005
   Murphy DG, 2007, J CLIN MICROBIOL, V45, P1102, DOI 10.1128/JCM.02366-06
   NAKATANI SM, 2005, PLOS ONE, V5
   Nolte FS, 2003, J CLIN MICROBIOL, V41, P1558, DOI 10.1128/JCM.41.4.1558-1564.2003
   Quarleri JF, 2003, J CLIN MICROBIOL, V41, P2727, DOI 10.1128/JCM.41.6.2727-2733.2003
   Schroter M, 2002, J CLIN MICROBIOL, V40, P2046, DOI 10.1128/JCM.40.6.2046-2050.2002
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391
   SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7
   SMITH DB, 1995, J GEN VIROL, V76, P1749, DOI 10.1099/0022-1317-76-7-1749
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   WANG JT, 1992, J CLIN MICROBIOL, V30, P750, DOI 10.1128/JCM.30.3.750-753.1992
NR 22
TC 17
Z9 17
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD OCT 3
PY 2011
VL 8
AR 459
DI 10.1186/1743-422X-8-459
PG 5
WC Virology
SC Virology
GA 846AC
UT WOS:000296868600001
PM 21967749
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Nasser, PD
   Cancado, ELR
   Abreu, RM
   Chocair, PR
   Pacheco-Neto, M
   Alves, AN
   Ferreira, C
   Fortini, AS
   Paschoale, HS
   Carrilho, FJ
   Ono, SK
AF Nasser, Paulo D.
   Cancado, Eduardo Luiz R.
   Abreu, Rodrigo M.
   Chocair, Pedro Renato
   Pacheco-Neto, Maurilio
   Alves, Atecla N.
   Ferreira, Camila
   Fortini, Alexandre S.
   Paschoale, Helena S.
   Carrilho, Flair J.
   Ono, Suzane K.
TI TPMT GENOTYPING AND AZATHIOPRINE METABOLITES DOSAGE IN PATIENTS WITH
   AUTOIMMUNE HEPATITIS AND TRANSPLANTED KIDNEY
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 04-08, 2011
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Nasser, Paulo D.; Cancado, Eduardo Luiz R.; Abreu, Rodrigo M.; Chocair, Pedro Renato; Pacheco-Neto, Maurilio; Alves, Atecla N.; Ferreira, Camila; Fortini, Alexandre S.; Paschoale, Helena S.; Carrilho, Flair J.; Ono, Suzane K.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Ono, Suzane/I-3107-2012; Cancado, Eduardo/K-1861-2016; Carrilho, Flair
   J/I-3046-2012
OI Cancado, Eduardo/0000-0002-9309-1524; 
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2011
VL 54
SU 1
BP 524A
EP 524A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 829KG
UT WOS:000295578002332
DA 2020-12-08
ER

PT J
AU Vassiliadis, E
   Oliveira, CP
   Alvares-da-Silva, MR
   Siqueira, ERF
   Stefano, JT
   Pereira, L
   Carrilho, FJ
   Zhang, C
   Larsen, DV
   Chen, XL
   Zheng, QL
   Leeming, DJ
   Karsdal, MA
AF Vassiliadis, Efstathios
   Oliveira, Claudia P.
   Alvares-da-Silva, Mario R.
   Siqueira, Erika Rabelo F.
   Stefano, Jose Tadeu
   Pereira, Leila
   Carrilho, Flair J.
   Zhang, Chen
   Larsen, Dorthe V.
   Chen, Xiaoliang
   Zheng, Qinlong
   Leeming, Diana J.
   Karsdal, Morten A.
TI AN MMP DEGRADED AND CITRULLINATED VIMENTIN FRAGMENT IS A NOVEL LIVER
   FIBROSIS BIOMARKER IN CHRONIC HEPATITIS C AND NON-ALCOHOLIC FATTY LIVER
   DISEASE
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 04-08, 2011
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Vassiliadis, Efstathios; Zhang, Chen; Larsen, Dorthe V.; Chen, Xiaoliang; Zheng, Qinlong; Leeming, Diana J.; Karsdal, Morten A.] Nord Biosci, Copenhagen, Denmark.
   [Vassiliadis, Efstathios] Univ So Denmark, Odense, Denmark.
   [Oliveira, Claudia P.; Siqueira, Erika Rabelo F.; Stefano, Jose Tadeu] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Alvares-da-Silva, Mario R.; Carrilho, Flair J.] Univ Fed Rtio Grande Sul, Dept Gastroenterol, Sao Paulo, Brazil.
   [Pereira, Leila] Liver Inst Pernambuco, Recife, PE, Brazil.
RI Vassiliadis, Efstathios/ABC-8546-2020; ZHENG, Qin/T-2925-2019; Stefano,
   Jose Tadeu/AAH-5419-2020; Carrilho, Flair J/I-3046-2012; Stefano, Jose
   T/H-4792-2013; Oliveira, Claudia PMS/D-1216-2014
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2011
VL 54
SU 1
BP 561A
EP 562A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 829KG
UT WOS:000295578002408
DA 2020-12-08
ER

PT J
AU Silva, MF
   Sapisochin, G
   Strasser, SI
   Hewa-Geeganage, S
   Chen, J
   Wigg, AJ
   Alencar, RS
   Jones, RM
   Kikuchi, L
   Carrilho, FJ
   Fontes, PR
   Charco, R
AF Silva, Mauricio F.
   Sapisochin, Gonzalo
   Strasser, Simone I.
   Hewa-Geeganage, Shanika
   Chen, John
   Wigg, Alan J.
   Alencar, Regiane S.
   Jones, Robert M.
   Kikuchi, Luciana
   Carrilho, Flair J.
   Fontes, Paulo R.
   Charco, Ramon
TI LIVER RESECTION FOR HEPATOCELLULAR CARCINOMA: A MULTICENTER EVALUATION
   OF THE AASLD AND EASL GUIDELINES RECOMMENDATION
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 04-08, 2011
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Silva, Mauricio F.; Fontes, Paulo R.] Santa Casa Gen Hosp, Dept HBP Surg & Transplantat, Porto Alegre, RS, Brazil.
   [Silva, Mauricio F.] Flinders Univ S Australia, Dept Gastroenterol, Adelaide, SA, Australia.
   [Sapisochin, Gonzalo; Charco, Ramon] Hosp Univ Vall Hebron, Dept HBP Surg & Transplantat, Barcelona, Spain.
   [Strasser, Simone I.; Hewa-Geeganage, Shanika] Royal Prince Alfred Hosp, Liver Transplant Unit, Sydney, NSW, Australia.
   [Chen, John; Wigg, Alan J.] Flinders Med Ctr, Liver Transplant Unit, Adalaide, NSW, Australia.
   [Jones, Robert M.] Austin Hosp, Liver Transplant Unit, Melbourne, Vic 3084, Australia.
   [Alencar, Regiane S.; Kikuchi, Luciana; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Fontes, Paulo R.] Univ Fed Ciencias Saude, Postgrad Course Hepatol, Porto Alegre, RS, Brazil.
RI Charco, Ramon/H-8522-2012; Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2011
VL 54
SU 1
BP 676A
EP 676A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 829KG
UT WOS:000295578002647
DA 2020-12-08
ER

PT J
AU Alvarado-Mora, MV
   Romano, CM
   Gomes-Gouvea, M
   Gutierrez, MF
   Carrilho, FJ
   Pinho, JR
AF Alvarado-Mora, Monica V.
   Romano, Camila M.
   Gomes-Gouvea, Michele
   Gutierrez, Maria F.
   Carrilho, Flair J.
   Pinho, Joao R.
TI PHYLOGENETIC ANALYSIS OF COMPLETE GENOME SEQUENCES OF HEPATITIS B VIRUS
   FROM AFRO-COLOMBIAN COMMUNITY: PRESENCE OF HBV F3/A1 RECOMBINANT STRAIN
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 04-08, 2011
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Romano, Camila M.] Univ Sao Paulo, Infect & Parasit Dis LIMHC, Sao Paulo, Brazil.
   [Gutierrez, Maria F.] Pontificia Javeriana Univ, Bogota, Colombia.
RI Alvarado-Mora, Monica/I-3180-2012; Pinho, Joao R. R./G-2850-2012;
   Gutierrez, Maria/AAF-2966-2019; Carrilho, Flair J/I-3046-2012; Romano,
   Camila M/C-8185-2013; Romano, Camila/ABC-2883-2020
OI Pinho, Joao R. R./0000-0003-3999-0489; Romano,
   Camila/0000-0003-4550-1987
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2011
VL 54
SU 1
BP 886A
EP 886A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 829KG
UT WOS:000295578003332
DA 2020-12-08
ER

PT J
AU Pereira, IV
   Stefano, JT
   Halla, N
   Xerfan, MP
   Mazo, DF
   Lima, FR
   Alves, VAF
   Carrilho, FJ
   Oliveira, CP
AF Pereira, Isabel V.
   Stefano, Jose Tadeu
   Halla, Nathalia
   Xerfan, Mariana P.
   Mazo, Daniel F.
   Lima, Fabiana R.
   Alves, Venancio Avancini F.
   Carrilho, Flair J.
   Oliveira, Claudia P.
TI SORAFENIB INCREASES TISSUE INHIBITOR OF METALLOPROTEINASE-2 (TIMP-2) AND
   ATTENUATES LIVER FIBROSIS IN A RODENT MODEL OF NON ALCOHOLIC
   STEATOHEPATITIS (NASH): A NOVEL ANTI-ANGIOGENIC EFFECT?
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 04-08, 2011
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Pereira, Isabel V.; Stefano, Jose Tadeu; Halla, Nathalia; Xerfan, Mariana P.; Mazo, Daniel F.; Lima, Fabiana R.; Alves, Venancio Avancini F.; Carrilho, Flair J.; Oliveira, Claudia P.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Mazo, Daniel FC/D-5631-2015; Stefano,
   Jose T/H-4792-2013; Stefano, Jose Tadeu/AAH-5419-2020; Oliveira, Claudia
   PMS/D-1216-2014
OI Mazo, Daniel FC/0000-0002-2164-2630; Stefano, Jose
   Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2011
VL 54
SU 1
BP 1161A
EP 1161A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 829KG
UT WOS:000295578004157
DA 2020-12-08
ER

PT J
AU Leeming, DJ
   Oliveira, CP
   Veidal, SS
   Alvares-Da-Silva, MR
   Stefano, JT
   Rabelo, F
   Carrilho, FJ
   Vassiliadis, E
   Karsdal, MA
AF Leeming, Diana J.
   Oliveira, Claudia P.
   Veidal, Sanne S.
   Alvares-da-Silva, Mario R.
   Stefano, Jose Tadeu
   Rabelo, Fabiola
   Carrilho, Flair J.
   Vassiliadis, Efstathios
   Karsdal, Morten A.
TI SEROLOGICAL TYPE III AND VI COLLAGEN DEGRADATION FRAGMENTS INCREASE WITH
   FIBROSIS SEVERITY IN NON ALCOHOLIC FATTY LIVER DISEASE (NFALD) PATIENTS
   AND IN A PRECLINICAL LIVER FIBROSIS MODEL
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 04-08, 2011
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Leeming, Diana J.; Veidal, Sanne S.; Vassiliadis, Efstathios; Karsdal, Morten A.] Nord Biosci, Fibrosis Biol & Biomarkers, Herlev, Denmark.
   [Oliveira, Claudia P.; Stefano, Jose Tadeu; Rabelo, Fabiola; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Alvares-da-Silva, Mario R.] Univ Fed Rtio Grande Sul, Sch Med, Div Gastroenterol, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
RI Carrilho, Flair J/I-3046-2012; Vassiliadis, Efstathios/ABC-8546-2020;
   Stefano, Jose T/H-4792-2013; Stefano, Jose Tadeu/AAH-5419-2020;
   Oliveira, Claudia PMS/D-1216-2014
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2011
VL 54
SU 1
BP 1227A
EP 1228A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 829KG
UT WOS:000295578004300
DA 2020-12-08
ER

PT J
AU Siqueira, ERF
   Oliveira, CP
   Correa-Giannella, ML
   Stefano, JT
   Cavaleiro, AM
   Fortes, MAZ
   Muniz, MT
   Silva, FS
   Pereira, L
   Carrilho, FJ
AF Siqueira, Erika Rabelo F.
   Oliveira, Claudia P.
   Correa-Giannella, Maria Lucia
   Stefano, Jose Tadeu
   Cavaleiro, Ana Mercedes
   Fortes, Maria Angela Z.
   Muniz, Maria T.
   Silva, Filipe S.
   Pereira, Leila
   Carrilho, Flair J.
TI STEATOSIS IN CHRONIC HEPATITIS C: THE ROLE OF METHYLENETETRAHYDROFOLATE
   REDUCTASE (MTHFR) C677T POLIMORPHYSM AND MICROSOMAL TRIGLYCERIDE
   TRANSFER PROTEIN (MTP)-493G/T POLYMORPHISM
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 04-08, 2011
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Siqueira, Erika Rabelo F.; Oliveira, Claudia P.; Correa-Giannella, Maria Lucia; Stefano, Jose Tadeu; Cavaleiro, Ana Mercedes; Fortes, Maria Angela Z.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Siqueira, Erika Rabelo F.; Muniz, Maria T.; Silva, Filipe S.; Pereira, Leila] Univ Fed Pernambuco, Sch Med, Recife, PE, Brazil.
RI Stefano, Jose Tadeu/AAH-5419-2020; Fortes, Maria Angela HZ/K-4422-2013;
   Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose T/H-4792-2013;
   Carrilho, Flair J/I-3046-2012; Giannella, Maria Lucia/N-3834-2019
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2011
VL 54
SU 1
BP 1329A
EP 1329A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 829KG
UT WOS:000295578004524
DA 2020-12-08
ER

PT J
AU Alvares-da-Silva, MR
   Oliveira, CP
   Stefano, JT
   Okamatsu, EB
   Lima, VM
   Barbeiro, HV
   Barbeiro, DF
   Soriano, FG
   Farias, AQ
   Carrilho, FJ
   DAlbuquerque, LC
AF Alvares-da-Silva, Mario R.
   Oliveira, Claudia P.
   Stefano, Jose Tadeu
   Okamatsu, Elisangela B.
   Lima, Vicencia M.
   Barbeiro, Hermes V.
   Barbeiro, Denise F.
   Soriano, Francisco G.
   Farias, Alberto Q.
   Carrilho, Flair J.
   DAlbuquerque, Luiz C.
TI INCREASED CARDIOVASCULAR RISK AND SYSTEMIC INFLAMMATION IN LIVER
   TRANSPLANTATION: AN EMERGING DISEASE IN LIVER TRANSPLANT RECIPIENTS
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 04-08, 2011
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Alvares-da-Silva, Mario R.; DAlbuquerque, Luiz C.] Univ Sao Paulo, Sch Med, Liver Transplant Unit, Sao Paulo, Brazil.
   [Oliveira, Claudia P.; Stefano, Jose Tadeu; Okamatsu, Elisangela B.; Lima, Vicencia M.; Farias, Alberto Q.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RI Stefano, Jose Tadeu/AAH-5419-2020; Farias, Alberto/ABB-1291-2020;
   Stefano, Jose T/H-4792-2013; Barbeiro, Hermes V/S-5926-2016; Carrilho,
   Flair J/I-3046-2012; Soriano, Francisco/C-3382-2012; D'ALBUQUERQUE, Luiz
   Carneiro Augusto/I-4011-2012; Barbeiro, Hermes V/E-2814-2010; Oliveira,
   Claudia PMS/D-1216-2014
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Farias,
   Alberto/0000-0002-5572-663X; Barbeiro, Hermes V/0000-0002-8209-4463;
   Soriano, Francisco/0000-0003-4898-0135; Barbeiro, Hermes
   V/0000-0002-8209-4463; 
NR 0
TC 0
Z9 0
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2011
VL 54
SU 1
BP 635A
EP 635A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 829KG
UT WOS:000295578002557
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Oliveira, CP
   Carrilho, FJ
   Alves, VAF
AF Stefano, Jose T.
   Oliveira, Claudia P.
   Carrilho, Flair J.
   Alves, Venancio A. F.
TI Survivin expression patterns could reflect different roles in
   hepatocarcinogenesis, especially in non-alcoholic fatty liver
   disease-related hepatocellular carcinoma
SO LIVER INTERNATIONAL
LA English
DT Letter
C1 [Stefano, Jose T.; Oliveira, Claudia P.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RP Stefano, JT (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RI Stefano, Jose Tadeu/AAH-5419-2020; Stefano, Jose T/H-4792-2013;
   Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
FU Grants-in-Aid for Scientific ResearchMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [21790280] Funding Source: KAKEN
CR Panera N, 2011, LIVER INT, V31, P1416, DOI 10.1111/j.1478-3231.2011.02533.x
   Stefano JT, 2011, LIVER INT, V31, P377, DOI 10.1111/j.1478-3231.2010.02370.x
NR 2
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1478-3223
J9 LIVER INT
JI Liver Int.
PD OCT
PY 2011
VL 31
IS 9
BP 1417
EP 1417
DI 10.1111/j.1478-3231.2011.02567.x
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 819JZ
UT WOS:000294822500024
DA 2020-12-08
ER

PT J
AU Venegas, M
   Alvarado-Mora, MV
   Villanueva, RA
   Pinho, JRR
   Carrilho, FJ
   Locarnini, S
   Yuen, L
   Brahm, J
AF Venegas, Mauricio
   Alvarado-Mora, Monica V.
   Villanueva, Rodrigo A.
   Rebello Pinho, Joao R.
   Carrilho, Flair J.
   Locarnini, Stephen
   Yuen, Lilly
   Brahm, Javier
TI Phylogenetic Analysis of Hepatitis B Virus Genotype F Complete Genome
   Sequences From Chilean Patients With Chronic Infection
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HBV subgenotype F1b; resistance mutations; Santiago; Chile
ID LAMIVUDINE THERAPY; SURFACE-ANTIGEN; CORE PROMOTER; MUTATIONS;
   DIVERSITY; MUTANTS; REPLICATION; RELATEDNESS; AMERINDIANS; SUBGENOTYPE
AB Molecular epidemiological data concerning the hepatitis B virus (HBV) in Chile are not known completely. Since the HBV genotype F is the most prevalent in the country, the goal of this study was to obtain full HBV genome sequences from patients infected chronically in order to determine their subgenotypes and the occurrence of resistance-associated mutations. Twenty-one serum samples from antiviral drug-naive patients with chronic hepatitis B were subjected to full-length PCR amplification, and both strands of the whole genomes were fully sequenced. Phylogenetic analyses were performed along with reference sequences available from GenBank (n = 290). The sequences were aligned using Clustal X and edited in the SE-AL software. Bayesian phylogenetic analyses were conducted by Markov Chain Monte Carlo simulations (MCMC) for 10 million generations in order to obtain the substitution tree using BEAST. The sequences were also analyzed for the presence of primary drug resistance mutations using CodonCode Aligner Software. The phylogenetic analyses indicated that all sequences were found to be the HBV subgenotype F1b, clustered into four different groups, suggesting that diverse lineages of this subgenotype may be circulating within this population of Chilean patients. J. Med. Virol. 83: 1530-1536, 2011. (C) 2011 Wiley-Liss, Inc.
C1 [Venegas, Mauricio; Brahm, Javier] Univ Chile, Clin Hosp, Dept Med, Gastroenterol Sect, Santiago, Chile.
   [Alvarado-Mora, Monica V.; Rebello Pinho, Joao R.; Carrilho, Flair J.] Univ Sao Paulo, Sao Paulo Inst Trop Med, Lab Trop Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Alvarado-Mora, Monica V.; Rebello Pinho, Joao R.; Carrilho, Flair J.] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Villanueva, Rodrigo A.] Fac Med, Inst Biomed Sci, Virol Program, Lab Hepatitis Viruses, Santiago, Chile.
   [Locarnini, Stephen; Yuen, Lilly] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia.
RP Venegas, M (corresponding author), Univ Chile, Clin Hosp, Dept Med, Gastroenterol Sect, Santiago, Chile.
EM mvenegas@redclinicauchile.cl
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012;
   Alvarado-Mora, Monica/I-3180-2012; Venegas, Mauricio/I-6420-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Venegas,
   Mauricio/0000-0001-7379-6108; Yuen, Lilly/0000-0003-2934-0167
FU University of Chile Clinical Hospital [OAIC 362/09]; Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [07/53457-7, 08/50461-6]; CNPq in
   BrazilNational Council for Scientific and Technological Development
   (CNPq)
FX Grant sponsor: University of Chile Clinical Hospital, (to Dr Mauricio
   Venegas); Grant number: OAIC 362/09; Grant sponsor: Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo FAPESP; Grant numbers: 07/53457-7;
   08/50461-6; Grant sponsor: CNPq in Brazil.
CR Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   Baumert TF, 1998, J VIROL, V72, P6785, DOI 10.1128/JVI.72.8.6785-6795.1998
   Blitz L, 1998, J CLIN MICROBIOL, V36, P648, DOI 10.1128/JCM.36.3.648-651.1998
   Delaney WE, 2003, J VIROL, V77, P11833, DOI 10.1128/JVI.77.21.11833-11841.2003
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Di Lello FA, 2009, J MED VIROL, V81, P1887, DOI 10.1002/jmv.21607
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   GUNTHER S, 1995, J VIROL, V69, P5437
   Huy TTT, 2006, J MED VIROL, V78, P178, DOI 10.1002/jmv.20525
   Mahtab MA, 2008, HEPATOB PANCREAT DIS, V7, P457
   McMahon BJ, 2009, HEPATOL INT, V3, P334, DOI 10.1007/s12072-008-9112-z
   NORDER H, 1994, VIROLOGY, V198, P489, DOI 10.1006/viro.1994.1060
   OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575
   Parekh S, 2003, J VIROL, V77, P6601, DOI 10.1128/JVI.77.12.6601-6612.2003
   Pereira A, 2008, REV MED CHILE, V136, P725, DOI [/S0034-98872008000600006, 10.4067/S0034-98872008000600006]
   Poordad Fred, 2010, Curr Gastroenterol Rep, V12, P62, DOI 10.1007/s11894-009-0088-1
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Santos AO, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-315
   Shaw T, 2006, J HEPATOL, V44, P593, DOI 10.1016/j.jhep.2006.01.001
   Sheldon J, 2005, ANTIVIR THER, V10, P727
   Shepard CW, 2006, EPIDEMIOL REV, V28, P112, DOI 10.1093/epirev/mxj009
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Sloan RD, 2008, ANTIVIR THER, V13, P439
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   TIOLLAIS P, 1981, SCIENCE, V213, P406, DOI 10.1126/science.6264599
   Torresi J, 2002, VIROLOGY, V293, P305, DOI 10.1006/viro.2001.1246
   van Bommel F, 2010, HEPATOLOGY, V51, P73, DOI 10.1002/hep.23246
   Venegas M, 2008, ARCH VIROL, V153, P2129, DOI 10.1007/s00705-008-0231-6
   Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297
   Yuen LKW, 2007, ANTIVIR RES, V75, P64, DOI 10.1016/j.antiviral.2006.11.014
   Zoulim F, 2009, GASTROENTEROLOGY, V137, P1593, DOI 10.1053/j.gastro.2009.08.063
NR 33
TC 16
Z9 16
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2011
VL 83
IS 9
BP 1530
EP 1536
DI 10.1002/jmv.22129
PG 7
WC Virology
SC Virology
GA 790OW
UT WOS:000292600100006
PM 21739442
DA 2020-12-08
ER

PT J
AU Alvarado-Mora, MV
   Botelho, L
   Gomes-Gouvea, MS
   de Souza, VF
   Nascimento, MC
   Pannuti, CS
   Carrilho, FJ
   Pinho, JRR
AF Alvarado-Mora, Monica V.
   Botelho, Livia
   Gomes-Gouvea, Michele S.
   de Souza, Vanda F.
   Nascimento, Maria C.
   Pannuti, Claudio S.
   Carrilho, Flair J.
   Pinho, Joao R. R.
TI Detection of Hepatitis B virus subgenotype A1 in a Quilombo community
   from Maranhao, Brazil
SO VIROLOGY JOURNAL
LA English
DT Article
DE Hepatitis B virus; Genotype A1; Quilombo community; Maranhao state;
   Brazil; Bayesian Analysis
ID MOLECULAR CHARACTERIZATION; GENOTYPE; EPIDEMIOLOGY; INFECTION
AB Background: The Brazilian population is mainly descendant from European colonizers, Africans and Native Americans. Some Afro-descendants lived in small isolated communities since the slavery period. The epidemiological status of HBV infection in Quilombos communities from northeast of Brazil remains unknown. The aim of this study was to characterize the HBV genotypes circulating inside a Quilombo isolated community from Maranhao State, Brazil.
   Methods: Seventy-two samples from Frechal Quilombo community at Maranhao were collected. All serum samples were screened by enzyme-linked immunosorbent assays for the presence of hepatitis B surface antigen ( HBsAg). HBsAg positive samples were submitted to DNA extraction and a fragment of 1306 bp partially comprising HBsAg and polymerase coding regions (S/POL) was amplified by nested PCR and its nucleotide sequence was determined. Viral isolates were genotyped by phylogenetic analysis using reference sequences from each genotype obtained from GenBank (n = 320). Sequences were aligned using Muscle software and edited in the SE-AL software. Bayesian phylogenetic analyses were conducted using Markov Chain Monte Carlo (MCMC) method to obtain the MCC tree using BEAST v.1.5.3.
   Results: Of the 72 individuals, 9 (12.5%) were HBsAg-positive and 4 of them were successfully sequenced for the 1306 bp fragment. All these samples were genotype A1 and grouped together with other sequences reported from Brazil.
   Conclusions: The present study represents the first report on the HBV genotypes characterization of this community in the Maranhao state in Brazil where a high HBsAg frequency was found. In this study, we reported a high frequency of HBV infection and the exclusive presence of subgenotype A1 in an Afro-descendent community in the Maranhao State, Brazil.
C1 [Alvarado-Mora, Monica V.; Botelho, Livia; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Pinho, Joao R. R.] Univ Sao Paulo, Lab Trop Gastroenterol & Hepatol, Sao Paulo Inst Trop Med, Sch Med, Sao Paulo, Brazil.
   [Alvarado-Mora, Monica V.; Botelho, Livia; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Pinho, Joao R. R.] Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [de Souza, Vanda F.; Nascimento, Maria C.; Pannuti, Claudio S.] Univ Sao Paulo, Virol Lab, Sao Paulo Inst Trop Med, Dept Infect & Parasit Dis,Sch Med, Sao Paulo, Brazil.
RP Alvarado-Mora, MV (corresponding author), Univ Sao Paulo, Lab Trop Gastroenterol & Hepatol, Sao Paulo Inst Trop Med, Sch Med, Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Carrilho, Flair J/I-3046-2012; Alvarado-Mora, Monica/I-3180-2012;
   Pannuti, Claudio/B-7649-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2007/53457-7,
   2008/50461-6]; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX We are deeply indebted to Maria Claudia Nascimento and Laura Sumita for
   provide the samples for this study. This work has been supported by
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP
   2007/53457-7 and 2008/50461-6 and CNPq.
CR ALENCASTRO LF, 2000, SAO PAULO COMPANHIA, P9
   Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Araujo NM, 2004, ARCH VIROL, V149, P1383, DOI 10.1007/s00705-003-0269-4
   Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   Bottecchia M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-11
   Bowyer SM, 1997, J GEN VIROL, V78, P1719, DOI 10.1099/0022-1317-78-7-1719
   Ribeiro NRC, 2006, LIVER INT, V26, P636, DOI 10.1111/j.1478-3231.2006.01280.x
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Hannoun C, 2000, J GEN VIROL, V81, P2267, DOI 10.1099/0022-1317-81-9-2267
   Kimbi GC, 2004, J GEN VIROL, V85, P1211, DOI 10.1099/vir.0.19749-0
   Kramvis A, 2007, HEPATOL RES, V37, pS27, DOI 10.1111/j.1872-034X.2007.00100.x
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Magnius LO, 1995, INTERVIROLOGY, V38, P24, DOI 10.1159/000150411
   Matos MAD, 2009, T ROY SOC TROP MED H, V103, P899, DOI 10.1016/j.trstmh.2009.01.013
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Motta-Castro A, 2008, ARCH VIROL, V153, P2197, DOI 10.1007/s00705-008-0237-0
   Motta-Castro ARC, 2005, J MED VIROL, V77, P188, DOI 10.1002/jmv.20435
   Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Pourkarim MR, 2011, CLIN MICROBIOL INFEC, V17, P947, DOI 10.1111/j.1469-0691.2010.03374.x
   Quintero A, 2002, ARCH VIROL, V147, P1829, DOI 10.1007/s00705-002-0842-2
   Ribeiro D., 1995, POVO BRASILEIRO FORM
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Santos AO, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-315
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   *WHO, 2011, HEP B FACT SHEET 204
   Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297
   2008, RAPOPORT DELEGATION, P2
NR 33
TC 12
Z9 12
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD AUG 25
PY 2011
VL 8
AR 415
DI 10.1186/1743-422X-8-415
PG 6
WC Virology
SC Virology
GA 826GO
UT WOS:000295341500001
PM 21867526
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Siqueira, ERF
   Oliveira, CPMS
   Muniz, MTC
   Silva, F
   Pereira, LMMB
   Carrilho, FJ
AF Siqueira, Erika R. F.
   Oliveira, Claudia P. M. S.
   Muniz, Maria T. C.
   Silva, Filipe
   Pereira, Leila M. M. B.
   Carrilho, Flair J.
TI Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and high
   plasma homocysteine in chronic hepatitis C (CHC) infected patients from
   the Northeast of Brazil
SO NUTRITION JOURNAL
LA English
DT Article
DE Hepatitis C; MTHFR; Genotype 1; Steatosis; Homocysteine
ID LOW-DENSITY-LIPOPROTEIN; ENDOPLASMIC-RETICULUM STRESS; RISK-FACTOR;
   VASCULAR-DISEASE; LIVER STEATOSIS; COMMON MUTATION;
   HYPERHOMOCYSTEINEMIA; VIRUS; GENE; MECHANISMS
AB Background/Aim: Hyperhomocysteinemia due to Methylenetetrahydrofolate Reductase (MTHFR) gene, in particular the C677T (Ala222Val) polymorphism were recently associated to steatosis and fibrosis. We analyzed the frequency of MTHFR gene in a cross-sectional study of patients affected by Chronic Hepatitis C (CHC) from Northeast of Brazil.
   Method: One hundred seven-four untreated patients with CHC were genotyped for the C677T MTHFR. Genomic DNA was extracted from peripheral blood cells and the C677T MTHFR polymorphism was identified by PCR-RFLP. The homocysteine (Hcy) levels were determined by chemiluminescence method. All patients were negative for markers of Wilson's disease, hemochromatosis and autoimmune diseases and have current and past daily alcohol intake less than 100 g/week.
   Results: Among subjects infected with CHC genotype non-1 the frequency of MTHFR genotypes TT was 9.8% versus 4.4% genotype 1 (p = 0.01). Nevertheless, association was found between the MTHFR genotype TT x CT/CC polymorphism and the degree of steatosis and fibrosis in both hepatitis C genotype (p < 0.05). A significant difference was found on plasma Hcy levels in patients with steatosis regardless of HCV genotype (p = 0.03).
   Conclusion: Our results indicate that plasma Hcy levels is highly prevalent in subjects with chronic hepatits C with steatosis regardless of HCV genotype and vitamin deficiency. The presence of genotype TT of MTHFR C677T polymorphism was more common in CHC genotype non-1 infected patient regardless of histopathological classification and genotype TT+CT frequencies were significant in the presence of fibrosis grade 1+2 and of steatosis in CHC infected patients from the northeast of Brazil regardless of HCV genotype. The genetic susceptibility of MTHFR C677T polymorphism should be confirmed in a large population.
C1 [Siqueira, Erika R. F.; Oliveira, Claudia P. M. S.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, BR-01246903 Sao Paulo, Brazil.
   [Siqueira, Erika R. F.; Pereira, Leila M. M. B.] Univ Pernambuco, Sch Med, Dept Gastroenterol, BR-50100010 Pernambuco, Brazil.
   [Muniz, Maria T. C.; Silva, Filipe] Univ Pernambuco, Sch Med, Dept Biochem, BR-50100010 Pernambuco, Brazil.
   [Siqueira, Erika R. F.; Pereira, Leila M. M. B.] Liver Inst Pernambuco, BR-50100130 Pernambuco, Brazil.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM cpm@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012; da
   Silva, Filipe Santana/C-3255-2011
OI cartaxo muniz, maria tereza/0000-0001-9498-5223; Santana da Silva,
   Filipe/0000-0002-6803-1407
FU CAPES (Centro de Aperfeicoamento de Pessoal do Ensino Superior)CAPES
FX The authors acknowledge the CAPES (Centro de Aperfeicoamento de Pessoal
   do Ensino Superior) that supported this study.
CR Adinolfi LE, 2005, HEPATOLOGY, V41, P995, DOI 10.1002/hep.20664
   Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766
   Almawi WY, 2004, J THROMB THROMBOLYS, V17, P199, DOI 10.1023/B:THRO.0000040489.86029.27
   Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002
   Andreassi MG, 2003, HUM GENET, V112, P171, DOI 10.1007/s00439-002-0859-3
   BORGIA G, 2008, LIVER INT, P248
   Bostom AG, 1997, KIDNEY INT, V52, P10, DOI 10.1038/ki.1997.298
   Castera L, 2004, GUT, V53, P420, DOI 10.1136/gut.2002.009936
   Cattaneo M, 1999, THROMB HAEMOSTASIS, V81, P165
   CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701
   Couto Fábio David, 2004, Cad. Saúde Pública, V20, P529, DOI 10.1590/S0102-311X2004000200021
   da Silva VC, 2006, ARQ NEURO-PSIQUIAT, V64, P941, DOI 10.1590/S0004-282X2006000600010
   Dayal S, 2002, ARTERIOSCL THROM VAS, V22, P1996, DOI 10.1161/01.ATV.0000041629.92741.DC
   den Heijer M, 1998, THROMB HAEMOSTASIS, V80, P874
   Eskes TKAB, 1998, NUTR REV, V56, P236, DOI 10.1111/j.1753-4887.1998.tb01755.x
   FINKELSTEIN JD, 1988, J BIOL CHEM, V263, P11750
   Fiore G, 1996, EUR J GASTROEN HEPAT, V8, P125, DOI 10.1097/00042737-199602000-00006
   FRIEDEWALD WT, 1992, CLIN CHEM, V21, P1983
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Garcia-Tevijano ER, 2001, HYPERTENSION, V38, P1217, DOI 10.1161/hy1101.099499
   GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195
   Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775
   Grundy SM, 2004, CIRCULATION, V109, P551, DOI 10.1161/01.CIR.0000112379.88385.67
   Hayden MR, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-4
   Hezode C, 2004, J VIRAL HEPATITIS, V11, P455, DOI 10.1111/j.1365-2893.2004.00528.x
   Jee SH, 2000, ATHEROSCLEROSIS, V153, P161, DOI 10.1016/S0021-9150(00)00389-0
   Ji C, 2003, GASTROENTEROLOGY, V124, P1488, DOI 10.1016/S0016-5085(03)00276-2
   KANG SS, 1988, AM J HUM GENET, V43, P414
   Lehmann M, 1999, DEMENT GERIATR COGN, V10, P12, DOI 10.1159/000017092
   Lonardo A, 2004, GASTROENTEROLOGY, V126, P586, DOI 10.1053/j.gastro.2003.11.020
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Mindicino H J, 2002, Clin Lab, V48, P493
   Molina S, 2007, J HEPATOL, V46, P411, DOI 10.1016/j.jhep.2006.09.024
   Morita H, 1997, CIRCULATION, V95, P2032, DOI 10.1161/01.CIR.95.8.2032
   Negro F, 2009, LIVER INT, V29, P26, DOI 10.1111/j.1478-3231.2008.01950.x
   Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213
   Patton HM, 2004, J HEPATOL, V40, P484, DOI 10.1016/j.jhep.2003.11.004
   Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31
   Rozen R, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P259
   Rubbia-Brandt L, 2004, GUT, V53, P406, DOI 10.1136/gut.2003.018770
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   TONIUTTO P, 2007, LIVER INT, P273
   Torres L, 1999, BBA-MOL BASIS DIS, V1455, P12, DOI 10.1016/S0925-4439(99)00049-6
   Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012
   van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825
   Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596
   YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271
NR 47
TC 3
Z9 3
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2891
J9 NUTR J
JI Nutr. J.
PD AUG 19
PY 2011
VL 10
AR 86
DI 10.1186/1475-2891-10-86
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 819TV
UT WOS:000294854500001
PM 21854603
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Alvarado-Mora, MV
   Romano, CM
   Gomes-Gouvea, MS
   Gutierrez, MF
   Carrilho, FJ
   Pinho, JRR
AF Alvarado-Mora, Monica Viviana
   Romano, Camila Malta
   Gomes-Gouvea, Michele Soares
   Fernanda Gutierrez, Maria
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Dynamics of Hepatitis D (delta) virus genotype 3 in the Amazon region of
   South America
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Hepatitis Delta; Genotype 3; South America; Bayesian Inference; Dynamics
ID LABREA BLACK FEVER; B-VIRUS; FULMINANT-HEPATITIS; PHYLOGENETIC ANALYSIS;
   GENERAL-POPULATION; GENETIC DIVERSITY; YUCPA INDIANS; ENDEMIC AREA;
   INFECTION; EPIDEMIOLOGY
AB Hepatitis delta virus (HDV) is widely distributed and associated with fulminant hepatitis epidemics in areas with high prevalence of HBV. Several studies performed in the 1980s showed data on HDV infection in South America, but there are no studies on the viral dynamics of this virus. The aim of this study was to conduct an evolutionary analysis of hepatitis delta genotype 3 (HDV/3) prevalent in South America: estimate its nucleotide substitution rate, determine the time of most recent ancestor (TMRCA) and characterize the epidemic history and evolutionary dynamics. Furthermore, we characterized the presence of HBV/HDV infection in seven samples collected from patients who died due to fulminant hepatitis from Amazon region in Colombia and included them in the evolutionary analysis. This is the first study reporting HBV and HDV sequences from the Amazon region of Colombia. Of the seven Colombian patients, five were positive for HBV-DNA and HDV-RNA. Of them, two samples were successfully sequenced for HBV (subgenotypes F3 and Fib) and the five samples HDV positive were classified as HDV/3. By using all HDV/3 available reference sequences with sampling dates (n = 36), we estimated the HDV/3 substitution rate in 1.07 x 10(-3) substitutions per site per year (s/s/y), which resulted in a time to the most recent common ancestor (TMRCA) of 85 years. Also, it was determined that HDV/3 spread exponentially from early 1950s to the 1970s in South America. This work discusses for the first time the viral dynamics for the HDV/3 circulating in South America. We suggest that the measures implemented to control HBV transmission resulted in the control of HDV/3 spreading in South America, especially after the important raise in this infection associated with a huge mortality during the 1950s up to the 1970s. The differences found among HDV/3 and the other HDV genotypes concerning its diversity raises the hypothesis of a different origin and/or a different transmission route. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Alvarado-Mora, Monica Viviana] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Alvarado-Mora, Monica Viviana; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Romano, Camila Malta] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis LIMHC, Inst Trop Med Sao Paulo, Sao Paulo, Brazil.
   [Fernanda Gutierrez, Maria] Pontificia Javeriana Univ, Dept Microbiol, Virol Lab, Bogota, Colombia.
RP Alvarado-Mora, MV (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sch Med, Av Dr Eneas de Carvalho Aguiar,500 Segundo Andar,, Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012; Romano,
   Camila/ABC-2883-2020; Gutierrez, Maria/AAF-2966-2019; Alvarado-Mora,
   Monica/I-3180-2012; Romano, Camila M/C-8185-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Romano,
   Camila/0000-0003-4550-1987; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo -
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2007/53457-7, 2008/50461-6]; Pontificia Universidad Javeriana, Bogota,
   Colombia
FX This study was previously presented as a poster in 2010 in the EASL
   monothematic conference on Delta Hepatitis, Istanbul, Turkey. We thank
   the collaboration of the Amazon Public Health Laboratory of Leticia,
   Amazonas, especially Dra. Luz Mila Murcia Montano, coordinator of the
   Amazon Public Health, for providing the samples for the study. This work
   has been supported by CNPq, Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo - FAPESP 2007/53457-7 and 2008/50461-6, CNPq and Pontificia
   Universidad Javeriana, Bogota, Colombia.
CR Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
   Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   BENSABATH G, 1983, REV I MED TROP, V25, P182
   BENSABATH G, 1987, JAMA-J AM MED ASSOC, V258, P479, DOI 10.1001/jama.1987.03400040077025
   Blitz L, 1998, J CLIN MICROBIOL, V36, P648, DOI 10.1128/JCM.36.3.648-651.1998
   Bonino F, 1987, Prog Clin Biol Res, V234, P145
   Braga W.S.M., 1998, REV SOC BRASILEIR S1, V31, P31
   Braga Wornei Silva Miranda, 2004, Rev. Soc. Bras. Med. Trop., V37, P9, DOI 10.1590/S0037-86822004000700002
   BUITRAGO B, 1986, HEPATOLOGY, V6, P1285, DOI 10.1002/hep.1840060610
   CASEY JL, 1993, P NATL ACAD SCI USA, V90, P9016, DOI 10.1073/pnas.90.19.9016
   CHAO YC, 1990, VIROLOGY, V178, P384
   CHAO YC, 1994, J MED VIROL, V43, P397, DOI 10.1002/jmv.1890430414
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   de la Hoz F, 2005, TROP MED INT HEALTH, V10, P322, DOI 10.1111/j.1365-3156.2005.01399.x
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Devesa M, 2004, J MED VIROL, V72, P377, DOI 10.1002/jmv.20015
   Devesa M, 2007, VIRUS RES, V127, P177, DOI 10.1016/j.virusres.2007.01.004
   DIAS LB, 1985, REV I MED TROP, V27, P242, DOI 10.1590/S0036-46651985000500003
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Erhardt A, 2006, LIVER INT, V26, P805, DOI 10.1111/j.1478-3231.2006.01279.x
   Espinal C. A., 1998, Biomedica, V18, P216
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   FAN W, 2010, VIRUS GENES
   Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
   HADLER SC, 1992, AM J EPIDEMIOL, V136, P1507, DOI 10.1093/oxfordjournals.aje.a116472
   Hadziyannis SJ, 1997, J GASTROEN HEPATOL, V12, P289, DOI 10.1111/j.1440-1746.1997.tb00424.x
   HADZIYANNIS SJ, 1991, PROG CLIN BIOL RES, V364, P51
   HADZIYANNIS SJ, 2011, J HEPATOL IN PRESS, DOI DOI 10.1016/JJHEP.2010.12.030
   IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990
   Ivaniushina V, 2001, J GEN VIROL, V82, P2709, DOI 10.1099/0022-1317-82-11-2709
   Kramvis A, 2008, J MED VIROL, V80, P27, DOI 10.1002/jmv.21049
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lavanchy D, 2005, J CLIN VIROL, V34, pS1, DOI 10.1016/S1386-6532(05)00384-7
   Le Gal F, 2006, EMERG INFECT DIS, V12, P1447, DOI 10.3201/eid1209.060112
   LEE CM, 1992, VIROLOGY, V188, P265, DOI 10.1016/0042-6822(92)90756-F
   LIAW YF, 1990, J INFECT DIS, V162, P1170, DOI 10.1093/infdis/162.5.1170
   Livingston SE, 2007, J INFECT DIS, V195, P5, DOI 10.1086/509894
   LJUNGGREN KE, 1985, HEPATOLOGY, V5, P299, DOI 10.1002/hep.1840050225
   MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0
   Nakano T, 2001, J GEN VIROL, V82, P2183, DOI 10.1099/0022-1317-82-9-2183
   Niro GA, 1999, J HEPATOL, V30, P564, DOI 10.1016/S0168-8278(99)80185-8
   Niro GA, 2006, HEPATOLOGY, V44, P713, DOI 10.1002/hep.21296
   Pascarella S, 2011, LIVER INT, V31, P7, DOI 10.1111/j.1478-3231.2010.02320.x
   Popper H, 1983, Prog Clin Biol Res, V143, P397
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   PRIETO F, 2003, BIOMEDICA, V8, P2
   Quintero A, 2001, J MED VIROL, V64, P356, DOI 10.1002/jmv.1058
   RIZZETTO M, 1990, J HEPATOL, V11, pS145, DOI 10.1016/0168-8278(90)90183-R
   RIZZETTO M, 1986, J HEPATOL, V3, pS229, DOI 10.1016/S0168-8278(86)80125-8
   Rizzetto M, 2000, ACTA GASTRO-ENT BELG, V63, P221
   Romano CM, 2008, J MOL EVOL, V66, P292, DOI 10.1007/s00239-008-9087-3
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011170
   Sakugawa H, 1999, J MED VIROL, V58, P366, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt;366::AID-JMV8&gt;3.0.CO;2-X
   Santos AO, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-315
   Shakil AO, 1997, VIROLOGY, V234, P160, DOI 10.1006/viro.1997.8644
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Tambini G., 1998, Biomedica, V18, P169
   Taylor J, 2010, FUTURE MICROBIOL, V5, P393, DOI [10.2217/fmb.10.15, 10.2217/FMB.10.15]
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   Watanabe H, 2003, J GEN VIROL, V84, P3275, DOI 10.1099/vir.0.19499-0
   Wedemeyer H, 2010, NAT REV GASTRO HEPAT, V7, P31, DOI 10.1038/nrgastro.2009.205
   Wu JC, 1995, HEPATOLOGY, V22, P1656, DOI 10.1016/0270-9139(95)90187-6
   Wu JC, 1998, J GEN VIROL, V79, P1105, DOI 10.1099/0022-1317-79-5-1105
   Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297
   Zehender G, 2008, VIROLOGY, V380, P84, DOI 10.1016/j.virol.2008.07.009
   Zhang YY, 1996, J CLIN MICROBIOL, V34, P3023, DOI 10.1128/JCM.34.12.3023-3030.1996
   Zhou Y, 2007, J MOL EVOL, V65, P197, DOI 10.1007/s00239-007-0054-1
NR 70
TC 27
Z9 28
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD AUG
PY 2011
VL 11
IS 6
BP 1462
EP 1468
DI 10.1016/j.meegid.2011.05.020
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 806JV
UT WOS:000293804600039
PM 21645647
DA 2020-12-08
ER

PT J
AU Alvarado-Mora, MV
   Botelho, L
   Nishiya, A
   Neto, RA
   Gomes-Gouvea, MS
   Gutierrez, MF
   Carrilho, FJ
   Pinho, JRR
AF Alvarado-Mora, Monica V.
   Botelho, Livia
   Nishiya, Anna
   Neto, Raymundo A.
   Gomes-Gouvea, Michele S.
   Gutierrez, Maria F.
   Carrilho, Flair J.
   Pinho, Joao R. R.
TI Frequency and genotypic distribution of GB virus C (GBV-C) among
   Colombian population with Hepatitis B (HBV) or Hepatitis C (HCV)
   infection
SO VIROLOGY JOURNAL
LA English
DT Article
ID C/HEPATITIS-G-VIRUS; BLOOD-DONORS; HIGH PREVALENCE; MOLECULAR
   CHARACTERIZATION; HEMODIALYSIS-PATIENTS; PHYLOGENETIC ANALYSIS;
   LIVER-DISEASE; C/HGV MARKERS; REGION; RECIPIENTS
AB Background: GB virus C (GBV-C) is an enveloped positive-sense ssRNA virus belonging to the Flaviviridae family. Studies on the genetic variability of the GBV-C reveals the existence of six genotypes: genotype 1 predominates in West Africa, genotype 2 in Europe and America, genotype 3 in Asia, genotype 4 in Southwest Asia, genotype 5 in South Africa and genotype 6 in Indonesia. The aim of this study was to determine the frequency and genotypic distribution of GBV-C in the Colombian population.
   Methods: Two groups were analyzed: i) 408 Colombian blood donors infected with HCV (n = 250) and HBV (n = 158) from Bogota and ii) 99 indigenous people with HBV infection from Leticia, Amazonas. A fragment of 344 bp from the 5' untranslated region (5' UTR) was amplified by nested RT PCR. Viral sequences were genotyped by phylogenetic analysis using reference sequences from each genotype obtained from GenBank (n = 160). Bayesian phylogenetic analyses were conducted using Markov chain Monte Carlo (MCMC) approach to obtain the MCC tree using BEAST v. 1.5.3.
   Results: Among blood donors, from 158 HBsAg positive samples, eight 5.06% (n = 8) were positive for GBV-C and from 250 anti-HCV positive samples, 3.2%(n = 8) were positive for GBV-C. Also, 7.7% (n = 7) GBV-C positive samples were found among indigenous people from Leticia. A phylogenetic analysis revealed the presence of the following GBV-C genotypes among blood donors: 2a (41.6%), 1 (33.3%), 3 (16.6%) and 2b (8.3%). All genotype 1 sequences were found in co-infection with HBV and 4/5 sequences genotype 2a were found in co-infection with HCV. All sequences from indigenous people from Leticia were classified as genotype 3. The presence of GBV-C infection was not correlated with the sex (p = 0.43), age (p = 0.38) or origin (p = 0.17).
   Conclusions: It was found a high frequency of GBV-C genotype 1 and 2 in blood donors. The presence of genotype 3 in indigenous population was previously reported from Santa Marta region in Colombia and in native people from Venezuela and Bolivia. This fact may be correlated to the ancient movements of Asian people to South America a long time ago.
C1 [Alvarado-Mora, Monica V.; Botelho, Livia; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Pinho, Joao R. R.] Univ Sao Paulo, Lab Gastroenterol & Hepatol, Sao Paulo Inst Trop Med, Sao Paulo, Brazil.
   [Alvarado-Mora, Monica V.; Botelho, Livia; Gomes-Gouvea, Michele S.; Carrilho, Flair J.; Pinho, Joao R. R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Nishiya, Anna] Sao Paulo Blood Bank, Sao Paulo, Brazil.
   [Neto, Raymundo A.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   [Gutierrez, Maria F.] Pontificia Javeriana Univ, Virol Lab, Dept Microbiol, Bogota, Colombia.
RP Alvarado-Mora, MV (corresponding author), Univ Sao Paulo, Lab Gastroenterol & Hepatol, Sao Paulo Inst Trop Med, Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Nishiya, Anna/Q-8156-2016; Carrilho, Flair J/I-3046-2012; Alvarado-Mora,
   Monica/I-3180-2012; Gutierrez, Maria/AAF-2966-2019; Pinho, Joao R.
   R./G-2850-2012; Soares de Azevedo Neto, Raymundo/B-7593-2008
OI Pinho, Joao R. R./0000-0003-3999-0489; Soares de Azevedo Neto,
   Raymundo/0000-0003-0660-2371
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo-FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2007/53457-7, 2008/50461-6]; Pontificia Universidad Javeriana,
   Bogota, Colombia
FX This work has been supported by CNPq, Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo-FAPESP 2007/53457-7 and 2008/50461-6 and Pontificia
   Universidad Javeriana, Bogota, Colombia. We thank Banco Nacional de
   Sangre de la Cruz Roja Colombiana for their kind provision of blood
   donor samples for this study.
CR Alter HJ, 1997, TRANSFUSION, V37, P569, DOI 10.1046/j.1537-2995.1997.37697335149.x
   Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Mora MVA, 2010, J MED VIROL, V82, P1889, DOI 10.1002/jmv.21908
   Barusruk Sahapat, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P289
   Berzsenyi MD, 2005, J CLIN VIROL, V33, P257, DOI 10.1016/j.jcv.2005.04.002
   Bjorkman P, 2001, VOX SANG, V81, P148, DOI 10.1046/j.1423-0410.2001.00098.x
   Bouchardeau F, 2000, TRANSFUSION, V40, P875, DOI 10.1046/j.1537-2995.2000.40070875.x
   Casteling A, 1998, J MED VIROL, V55, P103, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;103::AID-JMV4&gt;3.0.CO;2-6
   CAVALLISFORZA LL, 1991, SCI AM, V265, P72, DOI 10.1038/scientificamerican1191-104
   Cesaire R, 1999, J MED VIROL, V59, P160, DOI 10.1002/(SICI)1096-9071(199910)59:2&lt;160::AID-JMV6&gt;3.0.CO;2-Y
   Dawson GJ, 1996, J MED VIROL, V50, P97, DOI 10.1002/(SICI)1096-9071(199609)50:1&lt;97::AID-JMV16&gt;3.0.CO;2-V
   DiBisceglie AM, 1996, ANN INTERN MED, V125, P772, DOI 10.7326/0003-4819-125-9-199611010-00013
   Ding X, 1999, VIRUS GENES, V19, P51, DOI 10.1023/A:1008188623062
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   El-Zayadi AR, 1999, J VIROL METHODS, V80, P53, DOI 10.1016/S0166-0934(99)00036-1
   Feucht HH, 1997, J CLIN MICROBIOL, V35, P767, DOI 10.1128/JCM.35.3.767-768.1997
   Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4
   Giret MTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018407
   GonzalezPerez MA, 1997, J MED VIROL, V52, P149, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;149::AID-JMV5&gt;3.0.CO;2-3
   Hanci SY, 2008, MIKROBIYOL BUL, V42, P617
   Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X
   Katayama K, 1998, ARCH VIROL, V143, P1063, DOI 10.1007/s007050050356
   Konomi N, 1999, J CLIN MICROBIOL, V37, P3291, DOI 10.1128/JCM.37.10.3291-3295.1999
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lampe E, 1998, CLIN DIAGN VIROL, V9, P1, DOI 10.1016/S0928-0197(97)10017-4
   Laskus T, 1997, J VIROL, V71, P7804, DOI 10.1128/JVI.71.10.7804-7806.1997
   Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A
   Levi José Eduardo, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P75, DOI 10.1590/S0036-46652003000200004
   Ling BH, 1998, WORLD J GASTROENTERO, V4, P489, DOI 10.3748/wjg.v4.i6.489
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Loureiro CL, 2002, J MED VIROL, V68, P357, DOI 10.1002/jmv.10211
   Lyra AC, 2005, BRAZ J MED BIOL RES, V38, P767, DOI 10.1590/S0100-879X2005000500015
   Moaven LD, 1996, MED J AUSTRALIA, V165, P369, DOI 10.5694/j.1326-5377.1996.tb125019.x
   Muerhoff AS, 2006, J MED VIROL, V78, P105, DOI 10.1002/jmv.20510
   Muerhoff AS, 1996, J HEPATOL, V25, P379, DOI 10.1016/S0168-8278(96)80125-5
   Muerhoff AS, 1997, J VIROL, V71, P6501, DOI 10.1128/JVI.71.9.6501-6508.1997
   Mukaide M, 1997, FEBS LETT, V407, P51, DOI 10.1016/S0014-5793(97)00136-1
   Naito H, 1999, J CLIN MICROBIOL, V37, P1217, DOI 10.1128/JCM.37.4.1217-1220.1999
   Naito H, 2001, J VIROL METHODS, V91, P3, DOI 10.1016/S0166-0934(00)00207-X
   Okamoto H, 1997, J GEN VIROL, V78, P737, DOI 10.1099/0022-1317-78-4-737
   Oubina JR, 1999, VIRUS RES, V65, P121, DOI 10.1016/S0168-1702(99)00109-4
   Pinho JRR, 1999, J CLIN MICROBIOL, V37, P1634, DOI 10.1128/JCM.37.5.1634-1637.1999
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Ramezani A, 2008, INT J INFECT DIS, V12, P57, DOI 10.1016/j.ijid.2007.04.010
   Ramos R, 2004, MEM I OSWALDO CRUZ, V99, P639, DOI 10.1590/S0074-02762004000600019
   Ribeiro-dos-Santos G, 2002, EUR J CLIN MICROBIOL, V21, P438, DOI 10.1007/s10096-002-0752-y
   Seifried C, 2004, TRANSFUSION, V44, P268, DOI 10.1111/j.1537-2995.2004.00665.x
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Smith DB, 1997, J GEN VIROL, V78, P1533, DOI 10.1099/0022-1317-78-7-1533
   Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0
   Suzuki Y, 1999, J MOL EVOL, V48, P383, DOI 10.1007/PL00006482
   Tanaka E, 1996, ANN INTERN MED, V125, P740, DOI 10.7326/0003-4819-125-9-199611010-00007
   Tanaka Y, 1998, AM J TROP MED HYG, V59, P462, DOI 10.4269/ajtmh.1998.59.462
   Thomas DL, 1997, J INFECT DIS, V176, P586, DOI 10.1086/514078
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tillmann HL, 2001, ANTIVIR RES, V52, P83, DOI 10.1016/S0166-3542(01)00172-3
   Tucker TJ, 1999, J MED VIROL, V59, P52, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;52::AID-JMV9&gt;3.0.CO;2-D
   Wiwanitkit V, 2006, J PEDIAT INF DIS-GER, V1, P83
   ZANINOVIC V, 1994, AIDS RES HUM RETROV, V10, P97, DOI 10.1089/aid.1994.10.97
   Zhu WF, 2003, WORLD J GASTROENTERO, V9, P1739, DOI 10.3748/wjg.v9.i8.1739
NR 60
TC 9
Z9 10
U1 1
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD JUL 11
PY 2011
VL 8
AR 345
DI 10.1186/1743-422X-8-345
PG 7
WC Virology
SC Virology
GA 796UV
UT WOS:000293079500001
PM 21745373
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU da Costa, MZG
   Guarita, DR
   Ono-Nita, SK
   Paranagua-Vezozzo, DC
   Felga, GEG
   Pedroso, MRA
   de Souza, MMT
   Nasser, PD
   Ferreira, CD
   Carrilho, FJ
AF Gouvea da Costa, Marianges Zadrozny
   Guarita, Dulce Reis
   Ono-Nita, Suzane Kioko
   Paranagua-Vezozzo, Denise Cerqueira
   Goncalves Felga, Guilherme Eduardo
   Arcon Pedroso, Martha Regina
   Tavares de Souza, Marcelo Moreira
   Nasser, Paulo Dominguez
   Ferreira, Camila da Silva
   Carrilho, Flair Jose
TI Genetic Risk for Alcoholic Chronic Pancreatitis
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Review
DE pancreatic diseases; alcoholism; genetics; cationic trypsinogen; cystic
   fibrosis transmembrane conductance regulator; serine protease inhibitor
   kazal type 1; chymotrypsin C
ID CATIONIC TRYPSINOGEN PRSS1; GLUTATHIONE-S-TRANSFERASE; CYSTIC-FIBROSIS
   GENE; SERINE-PROTEASE INHIBITOR; HEREDITARY PANCREATITIS; CFTR GENE;
   MUTATION ANALYSIS; GERMLINE MUTATIONS; JAPANESE PATIENTS; KAZAL TYPE-1
AB In recent years many studies have examined the genetic predisposition to pancreatic diseases. Pancreatic disease of an alcoholic etiology was determined to be a multi-factorial disease, where environmental factors interact with the genetic profile of the individual. In this review we discuss the main results from studies examining the frequency of genetic mutations in alcoholic chronic pancreatitis.
C1 [Gouvea da Costa, Marianges Zadrozny; Guarita, Dulce Reis; Ono-Nita, Suzane Kioko; Paranagua-Vezozzo, Denise Cerqueira; Goncalves Felga, Guilherme Eduardo; Arcon Pedroso, Martha Regina; Tavares de Souza, Marcelo Moreira; Nasser, Paulo Dominguez; Ferreira, Camila da Silva; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
RP da Costa, MZG (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
EM marianges.costa@gmail.com; d.guarita@uol.com.br; skonita@gmail.com;
   denise.paranagua@gmail.com; uilherme.felga@gmail.com;
   marthapedroso@yahoo.com.br; marcelo_lim07@yahoo.com.br;
   pdnasser@gmail.com; camila.fr@usp.br; fjcarrilho@hcnet.usp.br
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012;
   Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935
CR [Anonymous], 1981, Scand J Gastroenterol, V16, P305
   Aoun E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002003
   Apte MV, 2003, BEST PRACT RES CL GA, V17, P593, DOI 10.1016/S1521-6918(03)00050-7
   Arduino C, 1999, CLIN GENET, V56, P400
   Behrman SW, 2007, SURG CLIN N AM, V87, P1309, DOI 10.1016/j.suc.2007.09.001
   Bendicho MT, 2005, PANCREAS, V30, P333, DOI 10.1097/01.mpa.0000161809.24284.33
   Bernardino Andrea L Ferreira, 2003, JOP, V4, P169
   Braganza JM, 1998, DIGESTION, V59, P1, DOI 10.1159/000051438
   Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561
   Casals T, 2004, PANCREAS, V28, P374, DOI 10.1097/00006676-200405000-00004
   Chandak GR, 2004, GUT, V53, P723, DOI 10.1136/gut.2003.026526
   Chang MC, 2009, PANCREATOLOGY, V9, P287, DOI 10.1159/000199437
   Chen JM, 2000, J MED GENET, V37, P67, DOI 10.1136/jmg.37.1.67
   Chiari H., 1896, Z HEILK, V17, P69
   Cichoz-Lach H, 2006, ALCOHOL ALCOHOLISM, V41, P14, DOI 10.1093/alcalc/agh225
   DANI R, 1990, PANCREAS, V5, P474, DOI 10.1097/00006676-199007000-00016
   Drenth JPH, 2002, GUT, V50, P687, DOI 10.1136/gut.50.5.687
   Etemad B, 2001, GASTROENTEROLOGY, V120, P682, DOI 10.1053/gast.2001.22586
   Ferec C, 1999, J MED GENET, V36, P228
   Fujiki K, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.014456
   Gaia E, 2002, DIGEST DIS SCI, V47, P2416, DOI 10.1023/A:1020579119691
   Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498
   da Costa MZG, 2009, PANCREATOLOGY, V9, P173, DOI 10.1159/000178889
   Haber PS, 1999, ALCOHOL CLIN EXP RES, V23, P509, DOI 10.1111/j.1530-0277.1999.tb04145.x
   Hanck C, 2003, BEST PRACT RES CL GA, V17, P613, DOI 10.1016/S1521-6918(03)00048-9
   Hayakawa Tetsuo, 2002, J Hepatobiliary Pancreat Surg, V9, P669, DOI 10.1007/s005340200092
   Howell WM, 2005, J CLIN PATHOL, V58, P595, DOI 10.1136/jcp.2004.020842
   Kimura S, 2000, DIGEST DIS SCI, V45, P2007, DOI 10.1023/A:1005500210281
   Kimura S, 2000, DIGEST DIS SCI, V45, P2013, DOI 10.1023/A:1005650902961
   Laranjeira R., 2007, 1 LEVANTAMENTO NACL, P1
   Le Marechal C, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-19
   Lee KH, 2005, DIGEST DIS SCI, V50, P1852, DOI 10.1007/s10620-005-2950-9
   Lin Y, 2000, J GASTROENTEROL, V35, P136, DOI 10.1007/s005350050026
   Lucrezio L, 2008, Minerva Med, V99, P391
   Malats N, 2001, GUT, V48, P70, DOI 10.1136/gut.48.1.70
   Mariani A, 2008, WORLD J GASTROENTERO, V14, P995, DOI 10.3748/wjg.14.995
   Monaghan KG, 2000, AM J MED GENET, V94, P120, DOI 10.1002/1096-8628(20000911)94:2<120::AID-AJMG4>3.0.CO;2-N
   Muddana V, 2008, WORLD J GASTROENTERO, V14, P4486, DOI 10.3748/wjg.14.4486
   Naruse S, 2004, PANCREAS, V28, pE80, DOI 10.1097/00006676-200404000-00029
   Nisevic I, 2008, CELL BIOCHEM FUNCT, V26, P659, DOI 10.1002/cbf.1487
   Ockenga J, 2003, GASTROENTEROLOGY, V124, P1802, DOI 10.1016/S0016-5085(03)00294-4
   Osterreicher CH, 2007, MUTAGENESIS, V22, P305, DOI 10.1093/mutage/gem017
   Pandol SJ, 2007, PANCREATOLOGY, V7, P105, DOI 10.1159/000104235
   Perri F, 2003, EUR J HUM GENET, V11, P687, DOI 10.1038/sj.ejhg.5201035
   Pezzilli R, 2003, PANCREAS, V27, P332, DOI 10.1097/00006676-200311000-00011
   Pfutzer R, 2002, GUT, V50, P271, DOI 10.1136/gut.50.2.271
   Rebours V, 2009, GUT, V58, P97, DOI 10.1136/gut.2008.149179
   Rebours V, 2008, AM J GASTROENTEROL, V103, P111, DOI 10.1111/j.1572-0241.2007.01597.x
   Rosendahl J, 2008, NAT GENET, V40, P78, DOI 10.1038/ng.2007.44
   Rosendahl J, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-1
   Schneider A, 2004, J GASTROENTEROL, V39, P783, DOI 10.1007/s00535-004-1389-7
   Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001
   Shimosegawa T, 2008, J GASTROEN HEPATOL, V23, pS82, DOI 10.1111/j.1440-1746.2007.05291.x
   Simon P, 2002, J BIOL CHEM, V277, P5404, DOI 10.1074/jbc.M108073200
   Sobczynska-Tomaszewska A, 2006, J PEDIATR GASTR NUTR, V43, P299, DOI 10.1097/01.mpg.0000232570.48773.df
   Talar-Wojnarowska R, 2009, DIGEST DIS SCI, V54, P683, DOI 10.1007/s10620-008-0390-z
   Teich N, 2004, HUM MUTAT, V23, P22, DOI 10.1002/humu.10285
   Teich N, 2002, SCAND J GASTROENTERO, V37, P360, DOI 10.1080/003655202317284291
   Teich N, 1998, HUM MUTAT, V12, P39, DOI 10.1002/(SICI)1098-1004(1998)12:1<39::AID-HUMU6>3.0.CO;2-P
   Teich N, 2008, BEST PRACT RES CL GA, V22, P115, DOI 10.1016/j.bpg.2007.10.019
   Truninger K, 2001, AM J GASTROENTEROL, V96, P2657
   Verlaan M, 2003, AM J MED GENET A, V120A, P34, DOI 10.1002/ajmg.a.20010
   Weiss FU, 2006, ENDOCRIN METAB CLIN, V35, P289, DOI 10.1016/j.ecl.2006.02.001
   Whitcomb DC, 2007, CELL MOL LIFE SCI, V64, P1763, DOI 10.1007/s00018-007-7055-5
   Whitcomb DC, 2006, J GASTROEN HEPATOL, V21, pS52, DOI 10.1111/j.1440-1746.2006.04583.x
   Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141
   Whitcomb DC, 2000, MED CLIN N AM, V84, P531, DOI 10.1016/S0025-7125(05)70238-8
   Whitcomb DC, 2003, PANCREAS, V27, P321, DOI 10.1097/00006676-200311000-00009
   Witt H, 2002, J PEDIATR GASTR NUTR, V34, P125, DOI 10.1097/00005176-200202000-00006
   Witt H, 1999, GASTROENTEROLOGY, V117, P7, DOI 10.1016/S0016-5085(99)70543-3
   Yadav D, 2007, GASTROENTEROL CLIN N, V36, P219, DOI 10.1016/j.gtc.2007.03.005
   Yadav D, 2010, NAT REV GASTRO HEPAT, V7, P131, DOI 10.1038/nrgastro.2010.6
   Zoller H, 2007, WIEN KLIN WOCHENSCHR, V119, P527, DOI 10.1007/s00508-007-0849-5
NR 73
TC 12
Z9 12
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-7827
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUL
PY 2011
VL 8
IS 7
BP 2747
EP 2757
DI 10.3390/ijerph8072747
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 796QS
UT WOS:000293067300011
PM 21845156
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Alvarado-Mora, MV
   Santana, RAF
   Sitnik, R
   Ferreira, PRA
   Mangueira, CLP
   Carrilho, FJ
   Pinho, JRR
AF Alvarado-Mora, Monica Viviana
   Ferraz Santana, Rubia Anita
   Sitnik, Roberta
   Abrao Ferreira, Paulo Roberto
   Pitangueira Mangueira, Cristovao Luis
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Full-length genomic sequence of hepatitis B virus genotype C2 isolated
   from a native Brazilian patient
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE hepatitis B virus; genotype C2; China; bayesian analyses; complete
   genome; Brazilian patient
ID HEPATOCELLULAR-CARCINOMA; PHYLOGENETIC RELATEDNESS;
   GEOGRAPHIC-DISTRIBUTION; CORE PROMOTER; INFECTION; PRECORE; MUTANTS;
   AMERICA; CHINA
AB The hepatitis B virus (HBV) is among the leading causes of chronic hepatitis, cirrhosis and hepatocellular carcinoma. In Brazil, genotype A is the most frequent, followed by genotypes D and F. Genotypes B and C are found in Brazil exclusively among Asian patients and their descendants. The aim of this study was to sequence the entire HBV genome of a Caucasian patient infected with HBV/C2 and to infer the origin of the virus based on sequencing analysis. The sequence of this Brazilian isolate was grouped with four other sequences described in China. The sequence of this patient is the first complete genome of HBV/C2 reported in Brazil.
C1 [Alvarado-Mora, Monica Viviana; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Fac Med, Inst Trop Med, Lab Gastroenterol & Hepatol Trop,Dept Gastroenter, BR-05403000 Sao Paulo, Brazil.
   [Ferraz Santana, Rubia Anita; Sitnik, Roberta; Pitangueira Mangueira, Cristovao Luis; Rebello Pinho, Joao Renato] Hosp Israelita Albert Einstein, Dept Patol Clin, Sao Paulo, Brazil.
   [Abrao Ferreira, Paulo Roberto] Univ Fed Sao Paulo, Sao Paulo, Brazil.
RP Alvarado-Mora, MV (corresponding author), Univ Sao Paulo, Fac Med, Inst Trop Med, Lab Gastroenterol & Hepatol Trop,Dept Gastroenter, Av Dr Eneas de Carvalho Aguiar 500,Predio IMT2 2, BR-05403000 Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; Mangueira,
   Cristovao Luis/D-1779-2013; Sitnik, Roberta/N-4740-2017; Abrao Ferreira,
   Paulo Roberto/A-5703-2016; Alvarado-Mora, Monica/I-3180-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Sitnik,
   Roberta/0000-0002-6243-8118; Abrao Ferreira, Paulo
   Roberto/0000-0003-4858-2778; Mangueira, Cristovao/0000-0002-4227-3723
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2007/53457-7, 2008/50461-6]; CNPqNational Council for Scientific and
   Technological Development (CNPq); IIRS/HIAE
FX Financial support: FAPESP (2007/53457-7, 2008/50461-6), CNPq, IIRS/HIAE
CR Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   Bottecchia M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-11
   Chan HLY, 2005, J INFECT DIS, V191, P2022, DOI 10.1086/430324
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Chu CJ, 2002, GASTROENTEROLOGY, V122, P1756, DOI 10.1053/gast.2002.33588
   da Silva Luiz Caetano, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P189
   DANE DS, 1970, LANCET, V1, P695
   de Oliveira CM, 2008, ARCH VIROL, V153, P823, DOI 10.1007/s00705-008-0053-6
   Devesa M, 2007, VIRUS RES, V127, P177, DOI 10.1016/j.virusres.2007.01.004
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   GOMESGOUVEA MS, 2005, CHARACTERIZATION COM
   Grimm D, 2011, HEPATOL INT, V5, P644, DOI 10.1007/s12072-011-9261-3
   GUNTHER S, 1995, J VIROL, V69, P5437
   Kramvis A, 2008, J MED VIROL, V80, P27, DOI 10.1002/jmv.21049
   Kramvis A, 2007, HEPATOL RES, V37, pS9, DOI 10.1111/j.1872-034X.2007.00098.x
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Mulyanto, 2010, ARCH VIROL, V155, P705, DOI 10.1007/s00705-010-0628-x
   Mulyanto, 2009, ARCH VIROL, V154, P1047, DOI 10.1007/s00705-009-0406-9
   Ni YH, 2004, GASTROENTEROLOGY, V127, P1733, DOI 10.1053/j.gastro.2004.09.048
   NORDER H, 1994, VIROLOGY, V198, P489, DOI 10.1006/viro.1994.1060
   Orito E, 2001, HEPATOLOGY, V34, P590, DOI 10.1053/jhep.2001.27221
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Santos AO, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-315
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   TAKAHASHI K, 1995, J GEN VIROL, V76, P3159, DOI 10.1099/0022-1317-76-12-3159
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tonetto PA, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-149
   Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297
   Yu MW, 2005, JNCI-J NATL CANCER I, V97, P265, DOI 10.1093/jnci/dji043
   Zeng G, 2005, J VIRAL HEPATITIS, V12, P609, DOI 10.1111/j.1365-2893.2005.00657.x
   Zhu CT, 2009, HEPATOB PANCREAT DIS, V8, P397
NR 34
TC 2
Z9 2
U1 0
U2 4
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JUN
PY 2011
VL 106
IS 4
BP 495
EP 498
DI 10.1590/S0074-02762011000400017
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 787UN
UT WOS:000292402300017
PM 21739039
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Alvarado-Mora, MV
   Fernandez, MFG
   Gomes-Gouvea, MS
   Neto, RSD
   Carrilho, FJ
   Pinho, JRR
AF Alvarado-Mora, Monica Viviana
   Gutierrez Fernandez, Maria Fernanda
   Gomes-Gouvea, Michele Soares
   de Azevedo Neto, Raymundo Soares
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Hepatitis B (HBV), Hepatitis C (HCV) and Hepatitis Delta (HDV) Viruses
   in the Colombian Population-How Is the Epidemiological Situation?
SO PLOS ONE
LA English
DT Article
ID LATIN-AMERICA; SOUTH-AMERICA; MOLECULAR CHARACTERIZATION; SANTA-MARTA;
   GENOTYPE-I; INFECTION; DISEASE; VENEZUELA; SEQUENCE; INDIANS
AB Background: Viral hepatitis B, C and delta still remain a serious problem worldwide. In Colombia, data from 1980s described that HBV and HDV infection are important causes of hepatitis, but little is known about HCV infection. The aim of this study was to determine the currently frequency of HBV, HCV and HDV in four different Colombian regions.
   Methodology/Principal Findings: This study was conducted in 697 habitants from 4 Colombian departments: Amazonas, Choco, Magdalena and San Andres Islands. Epidemiological data were obtained from an interview applied to each individual aiming to evaluate risk factors related to HBV, HCV or HDV infections. All samples were tested for HBsAg, anti-HBc, anti-HBs and anti-HCV markers. Samples that were positive to HBsAg and/or anti-HBc were tested to anti-HDV. Concerning the geographical origin of the samples, the three HBV markers showed a statistically significant difference: HBsAg (p = 0.033) and anti-HBc (p < 0.001) were more frequent in Amazonas and Magdalena departments. Isolated anti-HBs (a marker of previous vaccination) frequencies were: Choco (53.26%), Amazonas (32.88%), Magdalena (17.0%) and San Andres (15.33%) p < 0.001. Prevalence of anti-HBc increased with age; HBsAg varied from 1.97 to 8.39% (p = 0.033). Amazonas department showed the highest frequency for anti-HCV marker (5.68%), while the lowest frequency was found in San Andres Island (0.66%). Anti-HDV was found in 9 (5.20%) out of 173 anti-HBc and/or HBsAg positive samples, 8 of them from the Amazonas region and 1 from them Magdalena department.
   Conclusions/Significance: In conclusion, HBV, HCV and HDV infections are detected throughout Colombia in frequency levels that would place some areas as hyperendemic for HBV, especially those found in Amazonas and Magdalena departments. Novel strategies to increase HBV immunization in the rural population and to strengthen HCV surveillance are reinforced by these results.
C1 [Alvarado-Mora, Monica Viviana; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Gutierrez Fernandez, Maria Fernanda] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Gutierrez Fernandez, Maria Fernanda] Pontificia Javeriana Univ, Dept Microbiol, Virol Lab, Bogota, Colombia.
   [de Azevedo Neto, Raymundo Soares] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RP Alvarado-Mora, MV (corresponding author), Univ Sao Paulo, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Pinho, Joao R. R./G-2850-2012; Azevedo, Raymundo S/B-7593-2008;
   Carrilho, Flair J/I-3046-2012; Alvarado-Mora, Monica/I-3180-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Azevedo, Raymundo
   S/0000-0003-0660-2371; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2007/53457-7,
   2008/50461-6]; CNPqNational Council for Scientific and Technological
   Development (CNPq); Sao Paulo, SP, Brazil; Pontificia Universidad
   Javeriana, Bogota, Colombia
FX This work has been supported by Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo - FAPESP 2007/53457-7 and 2008/50461-6 and CNPq, Sao Paulo,
   SP, Brazil and by Pontificia Universidad Javeriana, Bogota, Colombia.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Mora MVA, 2010, J MED VIROL, V82, P1889, DOI 10.1002/jmv.21908
   Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
   Beltran Mauricio, 2005, J Clin Virol, V34 Suppl 2, pS33, DOI 10.1016/S1386-6532(05)80032-0
   Bensabath G, 1987, Bull Pan Am Health Organ, V21, P16
   Bostan N, 2010, CRIT REV MICROBIOL, V36, P91, DOI 10.3109/10408410903357455
   BUITRAGO B, 1986, HEPATOLOGY, V6, P1292, DOI 10.1002/hep.1840060611
   Buitrago B, 1991, BIOMEDICA, V11, P5
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   CASEY JL, 1993, P NATL ACAD SCI USA, V90, P9016, DOI 10.1073/pnas.90.19.9016
   CHAO YC, 1990, VIROLOGY, V178, P384
   de la Hoz F, 1992, BIOMEDICA, V12, P5
   Echevarría José M., 2003, Cad. Saúde Pública, V19, P1583, DOI 10.1590/S0102-311X2003000600003
   Espinal C. A., 1998, Biomedica, V18, P216
   FAY OH, 1990, VACCINE, V8, pS100, DOI 10.1016/0264-410X(90)90228-E
   Gaeta GB, 2000, HEPATOLOGY, V32, P824, DOI 10.1053/jhep.2000.17711
   GAYOTTO LCD, 1991, PROG CLIN BIOL RES, V364, P123
   Gish RG, 2006, J VIRAL HEPATITIS, V13, P787, DOI 10.1111/j.1365-2893.2006.00787.x
   Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
   HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339
   LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Le Gal F, 2006, EMERG INFECT DIS, V12, P1447, DOI 10.3201/eid1209.060112
   LJUNGGREN KE, 1985, HEPATOLOGY, V5, P299, DOI 10.1002/hep.1840050225
   MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0
   Martinez M, 1991, BIOMEDICA, V11, P20
   Ministerio de Salud, 1996, MAN NORM TECN ADM PR
   Ministerio de Salud, 2002, B EP SEM SIT HEP B C
   Pasquier C, 2005, J MED VIROL, V77, P390, DOI 10.1002/jmv.20468
   PRIETO F, 2003, BIOMEDICA, V8, P2
   Quintero A, 2001, J MED VIROL, V64, P356, DOI 10.1002/jmv.1058
   Radjef N, 2004, J VIROL, V78, P2537, DOI 10.1128/JVI.78.5.2537-2544.2004
   Ramsey GH, 1931, FEVER JAUNDICE PROVI
   REEVES WC, 1975, AM J TROP MED HYG, V24, P873, DOI 10.4269/ajtmh.1975.24.873
   Sakugawa H, 1999, J MED VIROL, V58, P366, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt;366::AID-JMV8&gt;3.0.CO;2-X
   Schmunis GA, 1998, EMERG INFECT DIS, V4, P5, DOI 10.3201/eid0401.980102
   Schmunis GA, 2005, CLIN MICROBIOL REV, V18, P12, DOI 10.1128/CMR.18.1.12-29.2005
   Shakil AO, 1997, VIROLOGY, V234, P160, DOI 10.1006/viro.1997.8644
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Slusarczyk J, 2000, VACCINE, V18, pS4, DOI 10.1016/S0264-410X(99)00451-X
   Soza A, 2010, ANN HEPATOL, V9, pS30, DOI 10.1016/S1665-2681(19)31720-X
   Tanaka J, 2000, VACCINE, V18, pS17, DOI 10.1016/S0264-410X(99)00455-7
   Te H. S., 2010, CLIN LIVER DIS, V14, pvii, DOI DOI 10.1016/J.CLD.2009.11.009]
   Te Helen S, 2010, Clin Liver Dis, V14, P1, DOI 10.1016/j.cld.2009.11.009
   Torres JR, 1996, GUT, V38, pS48, DOI 10.1136/gut.38.Suppl_2.S48
   WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0
   Watanabe H, 2003, J GEN VIROL, V84, P3275, DOI 10.1099/vir.0.19499-0
   World Health Organization, 2001, HEP DELT, P18
   Wu JC, 1998, J GEN VIROL, V79, P1105, DOI 10.1099/0022-1317-79-5-1105
   Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297
NR 50
TC 29
Z9 33
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2011
VL 6
IS 4
AR e18888
DI 10.1371/journal.pone.0018888
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 756OZ
UT WOS:000290024700033
PM 21559488
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Vieira, DS
   Alvarado-Mora, MV
   Botelho, L
   Carrilho, FJ
   Pinho, JRR
   Salcedo, JM
AF Vieira, Deusilene S.
   Alvarado-Mora, Monica V.
   Botelho, Livia
   Carrilho, Flair J.
   Pinho, Joao R. R.
   Salcedo, Juan M.
TI Distribution of hepatitis c virus (hcv) genotypes in patients with
   chronic infection from Rondonia, Brazil
SO VIROLOGY JOURNAL
LA English
DT Article
ID BLOOD-DONORS; SEQUENCE; PROTEIN; STATE
AB Background: Hepatitis C virus (HCV) is an important human pathogen affecting around 3% of the human population. In Brazil, it is estimated that there are approximately 2 to 3 million HCV chronic carriers. There are few reports of HCV prevalence in Rondonia State (RO), but it was estimated in 9.7% from 1999 to 2005. The aim of this study was to characterize HCV genotypes in 58 chronic HCV infected patients from Porto Velho, Rondonia (RO), Brazil.
   Methods: A fragment of 380 bp of NS5B region was amplified by nested PCR for genotyping analysis. Viral sequences were characterized by phylogenetic analysis using reference sequences obtained from the GenBank (n = 173). Sequences were aligned using Muscle software and edited in the SE-AL software. Phylogenetic analyses were conducted using Bayesian Markov chain Monte Carlo simulation (MCMC) to obtain the MCC tree using BEAST v. 1.5.3.
   Results: From 58 anti-HCV positive samples, 22 were positive to the NS5B fragment and successfully sequenced. Genotype 1b was the most prevalent in this population (50%), followed by 1a (27.2%), 2b (13.6%) and 3a (9.0%).
   Conclusions: This study is the first report of HCV genotypes from Rondonia State and subtype 1b was found to be the most prevalent. This subtype is mostly found among people who have a previous history of blood transfusion but more detailed studies with a larger number of patients are necessary to understand the HCV dynamics in the population of Rondonia State, Brazil.
C1 [Alvarado-Mora, Monica V.; Botelho, Livia; Carrilho, Flair J.; Pinho, Joao R. R.] Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Lab Trop Gastroenterol & Hepatol, BR-05508 Sao Paulo, Brazil.
   [Alvarado-Mora, Monica V.; Botelho, Livia; Carrilho, Flair J.; Pinho, Joao R. R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   [Vieira, Deusilene S.; Salcedo, Juan M.] Fiocruz Noroeste Porto Velho, Oswaldo Cruz Fdn, Porto Velho, RO, Brazil.
RP Alvarado-Mora, MV (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Lab Trop Gastroenterol & Hepatol, BR-05508 Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Pinho, Joao R. R./G-2850-2012; Alvarado-Mora, Monica/I-3180-2012;
   DALLACQUA, DEUSILENE/ABA-3597-2020; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
FU Oswaldo Cruz Foundation; Fiocruz Noroeste; CNPqNational Council for
   Scientific and Technological Development (CNPq); Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo - FAPESP, Sao Paulo, SP, BrazilFundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2007/53457-7,
   2008/50461-6]
FX Oswaldo Cruz Foundation, Fiocruz Noroeste, CNPq and Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo - FAPESP (2007/53457-7 and
   2008/50461-6), Sao Paulo, SP, Brazil supported this work.
CR Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505
   Mora MVA, 2010, J MED VIROL, V82, P1889, DOI 10.1002/jmv.21908
   Bassit Leda, 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P183, DOI 10.1590/S0036-46651999000300010
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Cantaloube JF, 2006, J CLIN MICROBIOL, V44, P2051, DOI 10.1128/JCM.02463-05
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   Cavlek TV, 2009, J MED VIROL, V81, P1348, DOI 10.1002/jmv.21530
   Diament D, 2007, BRAZ J INFECT DIS, V11, P6, DOI 10.1590/S1413-86702007000700002
   Drexler JF, 2009, PLOS MED, V6, P210, DOI 10.1371/journal.pmed.1000031
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Ferrari J O, 1999, Rev Soc Bras Med Trop, V32, P299, DOI 10.1590/S0037-86821999000300013
   Focaccia R., 2004, Braz J Infect Dis, V8, P348, DOI 10.1590/S1413-86702004000500003
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   Freitas NR, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-205
   Germano FN, 2010, INT J STD AIDS, V21, P466, DOI 10.1258/ijsa.2009.009089
   Germer JJ, 2001, MAYO CLIN PROC, V76, P911
   Ishii K, 1999, HEPATOLOGY, V29, P1227, DOI 10.1002/hep.510290448
   KATSURAGAWA, 2010, REV PANAMAZ SAUDE, V1, P91
   Kurbanov F, 2003, J MED VIROL, V69, P367, DOI 10.1002/jmv.10298
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lampe E, 2010, INFECT GENET EVOL, V10, P886, DOI 10.1016/j.meegid.2010.05.010
   Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35
   Lopes CLR, 2009, REV SAUDE PUBL, V43
   MAERTENS G, 1997, MOL MED VIRAL HEPATI, P182
   Martins RMB, 1998, MEM I OSWALDO CRUZ, V93, P299, DOI 10.1590/S0074-02761998000300004
   McHutchison JG, 2004, AM J MANAG CARE, V10, pS20
   Oliveira GC, 1999, TRANSFUSION, V39, P1194, DOI 10.1046/j.1537-2995.1999.39111194.x
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P279, DOI 10.1590/S0100-879X1999000300005
   Pawlotsky JM, 2003, ANTIVIR RES, V59, P1, DOI 10.1016/S0166-3542(03)00088-3
   PAWLOTSKY JM, 1995, J INFECT DIS, V171, P1607, DOI 10.1093/infdis/171.6.1607
   Penin F, 2004, J BIOL CHEM, V279, P40835, DOI 10.1074/jbc.M404761200
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
   Santos AO, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-315
   Silva Giovanni Faria, 2005, Braz J Infect Dis, V9, P142, DOI 10.1590/S1413-86702005000200004
   SILVA MB, MEM I OSWALDO CRUZ, V105, P299
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   Veras KN, 2009, BRAZ J INFECT DIS, V13, P125, DOI 10.1590/S1413-86702009000200011
   Zarife MAS, 2006, T ROY SOC TROP MED H, V100, P663, DOI 10.1016/j.trstmh.2005.09.009
NR 44
TC 8
Z9 8
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD APR 12
PY 2011
VL 8
AR 165
DI 10.1186/1743-422X-8-165
PG 5
WC Virology
SC Virology
GA 754WI
UT WOS:000289888100001
PM 21486472
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Stefano, JT
   de Oliveira, CPMS
   Correa-Giannella, ML
   Soares, IC
   Kubrusly, MS
   Bellodi-Privato, M
   de Mello, ES
   de Lima, VMR
   Carrilho, FJ
   Alves, VAF
AF Stefano, Jose T.
   de Oliveira, Claudia P. M. S.
   Correa-Giannella, Maria L.
   Soares, Ibere C.
   Kubrusly, Marcia S.
   Bellodi-Privato, Marta
   de Mello, Evandro S.
   de Lima, Vicencia M. R.
   Carrilho, Flair J.
   Alves, Venancio A. F.
TI Decreased immunoexpression of survivin could be a potential marker in
   human non-alcoholic fatty liver disease progression?
SO LIVER INTERNATIONAL
LA English
DT Article
DE HCC; immunohistochemistry; NAFLD; NASH; survivin
ID HEPATIC GENE-EXPRESSION; WILD-TYPE P53; HEPATOCELLULAR-CARCINOMA;
   CRYPTOGENIC CIRRHOSIS; HEPATOCYTE APOPTOSIS; MAMMALIAN TARGET;
   NATURAL-HISTORY; STEATOHEPATITIS; CANCER; RECURRENCE
AB Background/aim
   Regulation of apoptosis in non-alcoholic fatty liver disease (NAFLD) has been a theme of growing debate. Although no other study assessed the role of survivin in NAFLD, its expression has been reported in hepatic carcinogenesis because of other aetiological factors with relevant discrepancies. The aim of this study was to assess the pattern of survivin immunoexpression by tissue microarray along the whole spectrum of NAFLD, including non-alcoholic steatohepatitis (NASH)-related hepatocelular carcinoma (HCC).
   Methods
   Liver biopsies from 56 patients with NAFLD were evaluated: 18 with steatosis, 21 non-cirrhotic NASH, 10 NASH-related cirrhosis, seven NASH-related HCC, as compared with 71 HCC related to other causes and with 12 normal livers.
   Results
   Survivin immunoexpression in NAFLD was restricted to cytoplasm and was found to be progressively lower in advanced stages, including cirrhosis and HCC: steatosis vs NASH-related cirrhosis (P=0.0243); steatosis vs NASH-related HCC (P=0.0010); NASH vs NASH-related cirrhosis (P=0.0318); and NASH vs NASH-related HCC (P=0.0007), thus suggesting a deregulation of apoptosis from NAFLD towards HCC. Interestingly, survivin immunoreactivity in NASH-related HCC was also found to be significantly lower than in HCC related to other causes (P < 0.05). Remarkably, nuclear staining for survivin was not detected in any case of NAFLD, contrasting to its presence in all other cases of HCC.
   Conclusions
   Survivin immunoexpression in NASH-related HCC is herein originally found substantially different than in HCC related to other causes, thus requiring further studies to elucidate the role of survivin in human NAFLD progression.
C1 [Stefano, Jose T.; de Oliveira, Claudia P. M. S.; Kubrusly, Marcia S.; de Lima, Vicencia M. R.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07 & 37, Sao Paulo, Brazil.
   [Correa-Giannella, Maria L.] Univ Sao Paulo, Sch Med, Lab Cellular & Mol Endocrinol LIM 25, Sao Paulo, Brazil.
   [Soares, Ibere C.; Bellodi-Privato, Marta; de Mello, Evandro S.; Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol LIM 14, Sao Paulo, Brazil.
RP de Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Arnaldo 455,Room 3115 Cerqueira Cesar, Sao Paulo, Brazil.
EM cpm@usp.br
RI Stefano, Jose T/H-4792-2013; Kubrusly, Marcia S/N-3943-2014; Stefano,
   Jose Tadeu/AAH-5419-2020; Giannella, Maria Lucia/N-3834-2019; Oliveira,
   Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012
OI Kubrusly, Marcia S/0000-0003-3258-5632; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
FU FAPESP - Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [05/55167-0,
   04/09932-4]; CNPq - Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq) [477655-2006-8]; Brazilian Ministry of Health
   [25000.219551/2007-51]
FX We thank Dr Ariel E. Feldstein (Department of Pediatric Gastroenterology
   and Cell Biology, Cleveland Clinic, OH, USA) for his suggestions in
   preparing this manuscript. The quality of immunohistochemistry reactions
   provided by Alda Wakamatsu, MSc, LIM-14, University of Sao Paulo &
   Instituto Adolfo Lutz, is also acknowledged. This study was supported by
   grants from FAPESP - Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (05/55167-0 and 04/09932-4), CNPq - Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (477655-2006-8) and from the
   Brazilian Ministry of Health (25000.219551/2007-51).
CR Altieri DC, 2006, CURR OPIN CELL BIOL, V18, P609, DOI 10.1016/j.ceb.2006.08.015
   Augello C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-125
   Baranova A, 2007, OBES SURG, V17, P1111, DOI 10.1007/s11695-007-9187-y
   Browning JD, 2004, AM J GASTROENTEROL, V99, P292, DOI 10.1111/j.1572-0241.2004.04059.x
   Bullock RE, 2004, J HEPATOL, V41, P685, DOI 10.1016/j.jhep.2004.05.008
   Caldwell SH, 2002, AM J GASTROENTEROL, V97, P1496, DOI 10.1016/S0002-9270(02)04151-5
   Canbay Ali, 2005, Turk J Gastroenterol, V16, P1
   Chagas AL, 2009, BRAZ J MED BIOL RES, V42, P958, DOI 10.1590/S0100-879X2009005000019
   Chau GY, 2007, HISTOPATHOLOGY, V51, P204, DOI 10.1111/j.1365-2559.2007.02738.x
   Chiappini F, 2006, LAB INVEST, V86, P154, DOI 10.1038/labinvest.3700374
   Clark JM, 2006, J CLIN GASTROENTEROL, V40, pS5
   Cohen C, 2003, MODERN PATHOL, V16, P574, DOI 10.1097/01.MP.0000073868.31297.B0
   Cotrim HP, 2000, AM J GASTROENTEROL, V95, P3018, DOI 10.1016/S0002-9270(00)02034-7
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7
   Fields AC, 2004, MODERN PATHOL, V17, P1378, DOI 10.1038/modpathol.3800203
   Guo R, 2010, BIOMED PHARMACOTHER, V64, P249, DOI 10.1016/j.biopha.2009.06.007
   Hai S, 2006, SURG TODAY, V36, P390, DOI 10.1007/s00595-005-3167-4
   Herberger B, 2007, CLIN CANCER RES, V13, P4795, DOI 10.1158/1078-0432.CCR-07-0738
   Hirohashi S, 2000, TUMORS DIGESTIVE SYS, P159
   Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200
   Hussain SP, 2007, ONCOGENE, V26, P2166, DOI 10.1038/sj.onc.1210279
   Iannaccone R, 2007, RADIOLOGY, V243, P422, DOI 10.1148/radiol.2432051244
   Ichikawa T, 2006, J GASTROEN HEPATOL, V21, P1865, DOI 10.1111/j.1440-1746.2006.04282.x
   Johnson ME, 2004, VET PATHOL, V41, P599, DOI 10.1354/vp.41-6-599
   Kannangai Rajesh, 2005, Int J Gastrointest Cancer, V35, P53, DOI 10.1385/IJGC:35:1:053
   KAWAKITA N, 1992, AM J PATHOL, V140, P513
   Kawasaki H, 1998, CANCER RES, V58, P5071
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Koike H, 2008, UROLOGY, V72, P1229, DOI 10.1016/j.urology.2007.12.064
   Kojiro M, 2009, HEPATOLOGY, V49, P658, DOI 10.1002/hep.22709
   Kubo S, 2000, CANCER-AM CANCER SOC, V88, P1016, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1016::AID-CNCR10>3.0.CO;2-V
   Kubrusly MS, 2010, HISTOL HISTOPATHOL, V25, P1123, DOI 10.14670/HH-25.1123
   Li FZ, 2005, INT J CANCER, V114, P509, DOI 10.1002/ijc.20768
   Lu CD, 1998, CANCER RES, V58, P1808
   McCullough AJ, 2006, J CLIN GASTROENTEROL, V40, pS17
   Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353
   Montorsi M, 2007, HEPATO-GASTROENTEROL, V54, P2040
   Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100
   Nassar A, 2008, APPL IMMUNOHISTO M M, V16, P221, DOI 10.1097/PAI.0b013e3180c317bc
   Nogueira JA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-204
   Okada T, 2003, FEBS LETT, V555, P583, DOI 10.1016/S0014-5793(03)01345-0
   Piras F, 2007, HISTOPATHOLOGY, V50, P835, DOI 10.1111/j.1365-2559.2007.02695.x
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   Ribeiro PS, 2004, AM J GASTROENTEROL, V99, P1708, DOI 10.1111/j.1572-0241.2004.40009.x
   Rubio A, 2007, J HEPATOL, V46, P708, DOI 10.1016/j.jhep.2006.10.021
   Sarela AI, 2002, BRIT J CANCER, V86, P886, DOI 10.1038/sj.bjc.6600133
   Shimada M, 2002, J HEPATOL, V37, P154, DOI 10.1016/S0168-8278(02)00099-5
   Sreekumar R, 2003, HEPATOLOGY, V38, P244, DOI 10.1053/jhep.2003.50290
   STEFANO JT, 2008, IDENTIFICATION COMMO, P28
   Struben VMD, 2000, AM J MED, V108, P9, DOI 10.1016/S0002-9343(99)00315-0
   Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614
   Willner IR, 2001, AM J GASTROENTEROL, V96, P2957
   Younossi ZM, 2005, HEPATOLOGY, V42, P665, DOI 10.1002/hep.20838
   Younossi ZM, 2005, LIVER INT, V25, P760, DOI 10.1111/j.1478-3231.2005.01117.x
   Zhu H, 2005, WORLD J GASTROENTERO, V11, P3855
NR 57
TC 10
Z9 11
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1478-3223
J9 LIVER INT
JI Liver Int.
PD MAR
PY 2011
VL 31
IS 3
BP 377
EP 385
DI 10.1111/j.1478-3231.2010.02370.x
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 714VK
UT WOS:000286836900015
PM 21108736
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Bellodi-Privato, M
   Cogliati, B
   Souza, GF
   Oliveira, MG
   Silva, TC
   Lima, VM
   Oliveira, ER
   D'Albuquerque, LA
   Carrilho, FJ
   Oliveira, CP
AF Stefano, J. T.
   Bellodi-Privato, M.
   Cogliati, B.
   Souza, G. F.
   Oliveira, M. G.
   Silva, T. C.
   Lima, V. M.
   Oliveira, E. R.
   D'Albuquerque, L. A.
   Carrilho, F. J.
   Oliveira, C. P.
TI DOWNREGULATION OF CYCLIN-CDK COMPLEX BY S-NITROSO-N-ACETYLCYSTEINE
   (SNAC) IN HUMAN HEPATOCELLULAR CANCER CELLS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY 2011
CL Berlin, GERMANY
SP European Assoc Study Liver (EASL)
C1 [Stefano, J. T.; Cogliati, B.; Lima, V. M.; D'Albuquerque, L. A.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07 & 37, Sao Paulo, Brazil.
   [Bellodi-Privato, M.] Univ Sao Paulo, Sch Med, Pathol LIM 14, Sao Paulo, Brazil.
   [Souza, G. F.; Oliveira, M. G.] State Univ Campinas UNICAMP, Inst Chem, Campinas, Brazil.
   [Silva, T. C.] Univ Sao Paulo, Sch Vet Med & Anim Sci, Sao Paulo, Brazil.
   [Oliveira, E. R.] Univ Sao Paulo, Lab Cellular & Mol Endocrinol LIM 25, Sao Paulo, Brazil.
EM jstefano@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose T/H-4792-2013;
   D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Stefano, Jose
   Tadeu/AAH-5419-2020; de Oliveira, Marcelo Ganzarolli/B-4709-2013;
   Carrilho, Flair J/I-3046-2012; D'Albuquerque, Luiz Augusto
   Carneiro/A-8812-2013
OI Stefano, Jose Tadeu/0000-0002-0218-1920; de Oliveira, Marcelo
   Ganzarolli/0000-0002-9371-9975; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD MAR
PY 2011
VL 54
SU 1
MA 254
BP S104
EP S105
DI 10.1016/S0168-8278(11)60256-0
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 856GC
UT WOS:000297625600255
DA 2020-12-08
ER

PT J
AU Poynard, T
   Munteanu, M
   Colombo, M
   Bruix, J
   Schiff, E
   Terg, R
   Flamm, S
   Moreno-Otero, R
   Carrilho, F
   Schmidt, W
   Berg, T
   Mcgarrity, T
   Heathcote, EJ
   Goncales, F
   Diago, M
   Craxi, A
   Silva, M
   Boparai, N
   Griffel, L
   Burroughs, M
   Brass, C
   Albrecht, J
AF Poynard, Thierry
   Munteanu, Mona
   Colombo, Massimo
   Bruix, Jordi
   Schiff, Eugene
   Terg, Ruben
   Flamm, Steven
   Moreno-Otero, Ricardo
   Carrilho, Flair
   Schmidt, Warren
   Berg, Thomas
   Mcgarrity, Thomas
   Heathcote, E. Jenny
   Goncales, Fernando
   Diago, Moises
   Craxi, Antonio
   Silva, Marcelo
   Boparai, Navdeep
   Griffel, Louis
   Burroughs, Margaret
   Brass, Clifford
   Albrecht, Janice
TI FibroTest is an independent predictor of virologic response in chronic
   hepatitis C patients retreated with pegylated interferon alfa-2b and
   ribavirin in the EPIC3 program
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Hepatitis C; Non-responder; Relapser; Cirrhosis; Fibrosis; Biomarkers,
   Treatment failure; Early virologic response
ID OPERATING CHARACTERISTIC CURVES; LIVER FIBROSIS MARKERS; BIOCHEMICAL
   MARKERS; NONINVASIVE BIOMARKERS; DIAGNOSTIC EVALUATION; THERAPY;
   VARIABILITY; COMBINATION; PEGINTERFERON; ACTITEST
AB Background & Aims: EPIC-3 is a prospective, international study that has demonstrated the efficacy of PEG-IFN alfa-2b plus weight-based ribavirin in patients with chronic hepatitis C and significant fibrosis who previously failed any interferon-alfa/ribavirin therapy. The aim of the present study was to assess FibroTest (FT), a validated non-invasive marker of fibrosis in treatment-naive patients, as a possible alternative to biopsy as the baseline predictor of subsequent early virologic (EVR) and sustained virologic response (SVR) in previously treated patients.
   Methods: Of 2312 patients enrolled, 1459 had an available baseline FT, biopsy, and complete data. Uni- (UV) and multi-variable (MV) analyses were performed using FT and biopsy.
   Results: Baseline characteristics were similar as in the overall population; METAVIR stage: 28% F2, 29% F3, and 43% F4, previous relapsers 29%, previous PEG-IFN regimen 41%, high baseline viral load (BVL) 64%. 506 patients (35%) had undetectable HCV-RNA at TW12 (TW12neg), with 58% achieving SVR. The accuracy of FT was similar to that in naive patients: AUROC curve for the diagnosis of F4 vs F2 = 0.80 (p<0.00001). Five baseline factors were associated (p<0.001) with SVR in UV and MV analyses (odds ratio: UV/MV): fibrosis stage estimated using FT (4.5/5.9) or biopsy (1.5/1.6), genotype 2/3 (4.5/5.1), BVL (1.5/1.3), prior relapse (1.6/1.6), previous treatment with non-PEG-IFN (2.6/2.0). These same factors were associated (p <= 0.001) with EVR. Among patients TW12neg, two independent factors remained highly predictive of SVR by MV analysis (p <= 0.001): genotype 2/3 (odds ratio = 2.9), fibrosis estimated with FT (4.3) or by biopsy (1.5).
   Conclusions: FibroTest at baseline is a possible non-invasive alternative to biopsy for the prediction of EVR at 12 weeks and SVR, in patients with previous failures and advanced fibrosis, retreated with PEG-IFN alfa-2b and ribavirin. (C) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
C1 [Poynard, Thierry; Munteanu, Mona] APHP UPMC Liver Ctr, Paris, France.
   [Colombo, Massimo] Univ Milan, Div Gastroenterol 1, Fdn IRCCS, Maggiore Hosp, Milan, Italy.
   [Bruix, Jordi] Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Hosp Clin, Barcelona, Spain.
   [Schiff, Eugene] Univ Miami, Sch Med, Miami, FL USA.
   [Terg, Ruben] Hosp Municipal Gastroenterol Dr Bonorino Udaondo, Buenos Aires, Argentina.
   [Flamm, Steven] Northwestern Univ, Chicago, IL 60611 USA.
   [Moreno-Otero, Ricardo] Hosp Univ Princesa, Madrid, Spain.
   [Moreno-Otero, Ricardo] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Carrilho, Flair] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Schmidt, Warren] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
   [Berg, Thomas] Univ Med Berlin, Charite, Campus Virchow Klinikum, Berlin, Germany.
   [Mcgarrity, Thomas] Milton S Hershey Med Ctr, Hershey, PA USA.
   [Goncales, Fernando] Univ Estadual Campinas, Dept Clin Med, Fac Med Sci, Campinas, Brazil.
   [Diago, Moises] Univ Valencia, Gen Hosp, Valencia, Spain.
   [Heathcote, E. Jenny] Univ Hlth Network, Toronto, ON, Canada.
   [Craxi, Antonio] Univ Palermo, GI & Liver Unit, DIBIMIS, Palermo, Italy.
   [Silva, Marcelo] Hosp Univ Austral, Pilar, Argentina.
   [Boparai, Navdeep; Griffel, Louis; Burroughs, Margaret; Brass, Clifford; Albrecht, Janice] Schering Plough Res Inst, Kenilworth, NJ USA.
RP Poynard, T (corresponding author), Hop La Pitie Salpetriere, Serv Hepatol, 47-83 Blvd Hop, F-75651 Paris 13, France.
EM tpoynard@teaser.fr
RI Poynard, Thierry/C-1355-2010; DIAGO, MOISES/AAH-5364-2019; Carrilho,
   Flair J/I-3046-2012; Craxi, Antonio/K-9529-2016
OI Poynard, Thierry/0000-0002-3726-7230; Craxi,
   Antonio/0000-0002-4480-9544; Poynard, Thierry/0000-0002-2050-640X;
   Bruix, Jordi/0000-0002-9826-0753; Berg, Thomas/0000-0003-0003-6241;
   schmidt, Warren/0000-0003-2893-6014
FU Schering-PloughMerck & CompanySchering Plough Corporation; RocheRoche
   Holding; Valeant; Schering-Plough Research InstituteMerck & Company;
   Veterans AffairsUS Department of Veterans Affairs [I01BX000159,
   I01BX000159, I01BX000159, I01BX000159, I01BX000159, I01BX000159,
   I01BX000159, I01BX000159, I01BX000159, I01BX000159] Funding Source: NIH
   RePORTER
FX T. Poynard, M. Colombo, S. Flamm, T. Berg, E. Schiff, E.J. Heathcote, A.
   Craxi, M. Silva, and W. Schmidt are members of the Speakers Bureau for
   Schering-Plough; A. Craxi, E.J. Heathcote, and W. Schmidt are members of
   the Speakers Bureau for Roche; T. Poynard, M. Colombo, E. Schiff, M.
   Diago, S. Flamm, T. Berg, A. Craxi, M. Silva, E.J. Heathcote, and F.
   Goncales receive research support from Schering-Plough; A. Craxi and
   E.J. Heathcote receive research support from Roche; S. Flamm receives
   research support from Valeant and serves on the Speakers Bureau for
   Novartis; M. Colombo, E. Schiff, A. Craxi, J. Bruix, and E.J. Heathcote
   are consultants for Schering-Plough; A. Craxi and E.J. Heathcote are
   consultants for Roche; L Griffel, M. Burroughs, C. Brass, J.K. Albrecht,
   and N. Boparai are employees of Schering-Plough Research Institute and
   stockholders of Schering-Plough; R. Moreno-Otero, F. Carrilho, R. Terg,
   and T. McGarrity have nothing to disclose. Thierry Poynard is the
   inventor of FibroTest-ActiTest-SteatoTest with a capital interest in
   Biopredictive, the company marketing the tests. The patents belong to
   "Assistance Publique Hopitaux de Paris" a public organization. Mona
   Munteanu is a full-time employee of Biopredictive.; Schering-Plough
   Research Institute fully supported the study except for the FibroTest
   algorithm supported by Biopredictive.
CR Afdhal NH, 2008, J HEPATOL, V48, pS4, DOI 10.1016/S0168-8278(08)60005-7
   [Anonymous], 2002, NIH Consens State Sci Statements, V19, P1
   Bedossa P, 2003, HEPATOLOGY, V38, p337A
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Brissot Pierre, 2006, Hematology Am Soc Hematol Educ Program, P36
   Bruix J, 2009, J HEPATOL, V50, pS22, DOI 10.1016/S0168-8278(09)60051-9
   d'Arondel C, 2006, J VIRAL HEPATITIS, V13, P182, DOI 10.1111/j.1365-2893.2005.00668.x
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Di Bisceglie AM, 2008, NEW ENGL J MED, V359, P2429, DOI 10.1056/NEJMoa0707615
   Fontaine H, 2007, GASTROEN CLIN BIOL, V31, P504, DOI 10.1016/S0399-8320(07)89420-6
   Halfon P, 2008, GASTROEN CLIN BIOL, V32, P22, DOI 10.1016/S0399-8320(08)73991-5
   Hintze J.L., 2007, NCSS 2007 USER GUIDE
   Imbert-Bismut F, 2005, ANN BIOL CLIN-PARIS, V63, P305
   Imbert-Bismut F, 2004, CLIN CHEM LAB MED, V42, P323, DOI 10.1515/CCLM.2004.058
   La Haute Autorite de Sante (HAS) in France, HAS REC MAN CHRON HE
   Lambert J, 2008, CLIN CHEM, V54, P1372, DOI 10.1373/clinchem.2007.097923
   Manning DS, 2008, GASTROENTEROLOGY, V134, P1670, DOI 10.1053/j.gastro.2008.03.001
   Naveau S, 2009, HEPATOLOGY, V49, P97, DOI 10.1002/hep.22576
   Ngo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002573
   Ngo Y, 2006, CLIN CHEM, V52, P1887, DOI 10.1373/clinchem.2006.070961
   Patel K, 2009, J VIRAL HEPATITIS, V16, P178, DOI 10.1111/j.1365-2893.2008.01062.x
   Poynard T, 2003, HEPATOLOGY, V38, P75, DOI 10.1053/jhep.2003.50267
   Poynard T, 2008, GASTROEN CLIN BIOL, V32, P8, DOI 10.1016/S0399-8320(08)73990-3
   Poynard T, 2007, ALIMENT PHARM THER, V25, P733, DOI 10.1111/j.1365-2036.2007.03252.x
   Poynard T, 2004, CLIN CHEM, V50, P1344, DOI 10.1373/clinchem.2004.032227
   Poynard T, 2003, HEPATOLOGY, V38, P481, DOI 10.1053/jhep.2003.50319
   Poynard T, 2010, GASTROEN CLIN BIOL, V34, P388, DOI 10.1016/j.gcb.2010.05.001
   Poynard T, 2002, J VIRAL HEPATITIS, V9, P128, DOI 10.1046/j.1365-2893.2002.00341.x
   Poynard T, 2000, HEPATOLOGY, V31, P211, DOI 10.1002/hep.510310131
   Poynard T, 2007, CLIN CHEM, V53, P1615, DOI 10.1373/clinchem.2007.085795
   Poynard Thierry, 2004, Comp Hepatol, V3, P8, DOI 10.1186/1476-5926-3-8
   Poynard T, 2009, NEW ENGL J MED, V360, P1152
   Poynard T, 2009, GASTROENTEROLOGY, V136, P1618, DOI 10.1053/j.gastro.2009.01.039
   Ratziu V, 2005, J HEPATOL, V42, P12, DOI 10.1016/j.jhep.2004.11.027
   Veldt BJ, 2007, ANN INTERN MED, V147, P677, DOI 10.7326/0003-4819-147-10-200711200-00003
   ZHOU X, 2002, STAT METHODS DIAGNOS, P235
NR 36
TC 16
Z9 16
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD FEB
PY 2011
VL 54
IS 2
BP 227
EP 235
DI 10.1016/j.jhep.2010.06.038
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 717TN
UT WOS:000287070400008
PM 21056496
OA Green Published
DA 2020-12-08
ER

PT J
AU Vieira, A
   Santos, J
   Gomes, L
   Moreira, A
   Alves, M
   Gouveia, S
   Saraiva, J
   Costa, G
   Carrilho, F
   Carvalheiro, M
AF Vieira, A.
   Santos, J.
   Gomes, L.
   Moreira, A.
   Alves, M.
   Gouveia, S.
   Saraiva, J.
   Costa, G.
   Carrilho, F.
   Carvalheiro, M.
TI Pancreatic Neuroendocrine Tumors: Experience of Endocrinology Department
   of the University Hospital of Coimbra
SO NEUROENDOCRINOLOGY
LA English
DT Meeting Abstract
CT 8th Annual ENETS Conference for the Diagnosis and Treatment of
   Neuroendocine Tumor Disease
CY MAR 09-11, 2011
CL Lisbon, PORTUGAL
C1 [Vieira, A.; Santos, J.; Gomes, L.; Moreira, A.; Alves, M.; Gouveia, S.; Saraiva, J.; Costa, G.; Carrilho, F.; Carvalheiro, M.] Coimbras Univ Hosp, EPE, Coimbra, Portugal.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0028-3835
J9 NEUROENDOCRINOLOGY
JI Neuroendocrinology
PY 2011
VL 94
SU 1
BP 49
EP 49
PG 1
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 856KM
UT WOS:000297638900159
DA 2020-12-08
ER

PT J
AU Mattar, R
   Monteiro, M
   Silva, JM
   Carrilho, F
AF Mattar, Rejane
   Monteiro, Maria
   Silva, Joyce Matie
   Carrilho, Flair
TI LCT-22018G > A single nucleotide polymorphism is a better predictor of
   adult-type hypolactasia/lactase persistence in Japanese-Brazilians than
   LCT-13910C > T (vol 65, 1399, 2010)
SO CLINICS
LA English
DT Correction
RI Carrilho, Flair J/I-3046-2012; Mattar, Rejane/K-3883-2012; Mattar,
   Rejane/AAO-4842-2020
OI Mattar, Rejane/0000-0001-7870-8867
CR Mattar R, 2010, CLINICS, V65, P1399, DOI 10.1590/S1807-59322010001200030
NR 1
TC 0
Z9 0
U1 0
U2 4
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
J9 CLINICS
JI Clinics
PY 2011
VL 66
IS 2
BP 365
EP 365
DI 10.1590/S1807-59322011000200032
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 748BO
UT WOS:000289365200032
OA DOAJ Gold, Green Accepted
DA 2020-12-08
ER

PT J
AU Mora, MVA
   Romano, CM
   Gomes-Gouvea, MS
   Gutierrez, MF
   Botelho, L
   Carrilho, FJ
   Pinho, JRR
AF Alvarado Mora, Monica Viviana
   Romano, Camila Malta
   Gomes-Gouvea, Michele Soares
   Fernanda Gutierrez, Maria
   Botelho, Livia
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Molecular characterization of the Hepatitis B virus genotypes in
   Colombia: A Bayesian inference on the genotype F
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Hepatitis B virus; Genotype G; Genotype A2; Genotype F; Bayesian
   analysis; Colombia
ID HEPATOCELLULAR-CARCINOMA; PHYLOGENETIC ANALYSIS; GENETIC DIVERSITY;
   COMPLETE GENOMES; HBV GENOTYPE; WEST-AFRICA; EPIDEMIOLOGY; SUBGENOTYPE;
   SEQUENCES; SUBTYPES
AB Hepatitis B is a worldwide health problem affecting about 2 billion people and more than 350 million are chronic carriers of the virus. Nine HBV genotypes (A to I) have been described. The geographical distribution of HBV genotypes is not completely understood due to the limited number of samples from some parts of the world. One such example is Colombia, in which few studies have described the HBV genotypes. In this study, we characterized HBV genotypes in 143 HBsAg-positive volunteer blood donors from Colombia. A fragment of 1306 bp partially comprising HBsAg and the DNA polymerase coding regions (S/POL) was amplified and sequenced. Bayesian phylogenetic analyses were conducted using the Markov Chain Monte Carlo (MCMC) approach to obtain the maximum clade credibility (MCC) tree using BEAST v.1.5.3. Of all samples, 68 were positive and 52 were successfully sequenced. Genotype F was the most prevalent in this population (77%) - subgenotypes F3 (75%) and Fib (2%). Genotype G (7.7%) and subgenotype A2 (15.3%) were also found. Genotype G sequence analysis suggests distinct introductions of this genotype in the country. Furthermore, we estimated the time of the most recent common ancestor (TMRCA) for each HBV/F subgenotype and also for Colombian F3 sequences using two different datasets: (i) 77 sequences comprising 1306 bp of S/POL region and (ii) 283 sequences comprising 681 bp of S/POL region. We also used two other previously estimated evolutionary rates: (i) 2.60 x 10(-4) s/s/y and (ii) 1.5 x 10(-5) s/s/y. Here we report the HBV genotypes circulating in Colombia and estimated the TMRCA for the four different subgenotypes of genotype F. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Alvarado Mora, Monica Viviana] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   [Alvarado Mora, Monica Viviana; Gomes-Gouvea, Michele Soares; Botelho, Livia; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Lab Gastroenterol & Hepatol, Sao Paulo Inst Trop Med, Sch Med, Sao Paulo, Brazil.
   [Romano, Camila Malta] Univ Sao Paulo, Dept Infect & Parasit Dis LIMHC, Sao Paulo Inst Trop Med, Sch Med, Sao Paulo, Brazil.
   [Fernanda Gutierrez, Maria] Pontificia Javeriana Univ, Dept Microbiol, Virol Lab, Bogota, Colombia.
RP Mora, MVA (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sch Med, Av Dr Eneas de Carvalho Aguiar,500 Segundo Andar,, Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Alvarado-Mora, Monica/I-3180-2012; Carrilho, Flair J/I-3046-2012;
   Romano, Camila M/C-8185-2013; Romano, Camila/ABC-2883-2020; Pinho, Joao
   R. R./G-2850-2012; FHV, Inct/K-2346-2013; Gutierrez, Maria/AAF-2966-2019
OI Romano, Camila/0000-0003-4550-1987; Pinho, Joao R.
   R./0000-0003-3999-0489; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo -
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2007/53457-7, 2008/50461-6]; Pontificia Universidad Javeriana, Bogota,
   Colombia
FX This work has been supported by CNPq, Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo - FAPESP 2007/53457-7 and 2008/50461-6 and
   Pontificia Universidad Javeriana, Bogota, Colombia. We thank Banco
   Nacional de Sangre de la Cruz Roja Colombiana for their kind provision
   of blood donor samples for this study.
CR Alestig E, 2001, ARCH VIROL, V146, P2321, DOI 10.1007/s007050170005
   Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
   Alvarado-Esquivel C, 2006, WORLD J GASTROENTERO, V12, P6540, DOI 10.3748/wjg.v12.i40.6540
   Andernach IE, 2009, EMERG INFECT DIS, V15, P1222, DOI 10.3201/eid1508.081642
   Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   BHAT RA, 1990, HEPATOLOGY, V11, P271, DOI 10.1002/hep.1840110218
   Bottecchia M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-11
   Bowyer SM, 1997, J GEN VIROL, V78, P1719, DOI 10.1099/0022-1317-78-7-1719
   Campos Rodolfo H, 2005, J Clin Virol, V34 Suppl 2, pS8, DOI 10.1016/S1386-6532(05)80028-9
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Chu CJ, 2003, GASTROENTEROLOGY, V125, P444, DOI 10.1016/S0016-5085(03)00895-3
   Chudy M, 2006, HEPATOLOGY, V44, P99, DOI 10.1002/hep.21220
   De Maddalena C, 2007, VIROLOGY, V365, P113, DOI 10.1016/j.virol.2007.03.015
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Devesa M, 2004, J MED VIROL, V72, P377, DOI 10.1002/jmv.20015
   Di Lello FA, 2009, J MED VIROL, V81, P1887, DOI 10.1002/jmv.21607
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Echevarria JM, 2005, J MED VIROL, V76, P176, DOI 10.1002/jmv.20341
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Flichman D, 2009, J CLIN MICROBIOL, V47, P4191, DOI 10.1128/JCM.01337-09
   Fung SK, 2004, HEPATOLOGY, V40, P790, DOI 10.1002/hep.20455
   Hannoun C, 2005, J GEN VIROL, V86, P2163, DOI 10.1099/vir.0.80972-0
   HUBSCHEN JM, 2010, CLIN MICROBIOL INFEC, DOI DOI 10.1111/J.1469-0691.2010.03205.X/ABSTRACT
   Huy TTT, 2006, J MED VIROL, V78, P178, DOI 10.1002/jmv.20525
   Jardi R, 2008, J HEPATOL, V49, P695, DOI 10.1016/j.jhep.2008.03.030
   Kato H, 2002, J VIROL, V76, P6131, DOI 10.1128/JVI.76.12.6131-6137.2002
   Kato H, 2005, WORLD J GASTROENTERO, V11, P6295, DOI 10.3748/wjg.v11.i40.6295
   Kramvis A, 2007, HEPATOL RES, V37, pS9, DOI 10.1111/j.1872-034X.2007.00098.x
   Kumar S, 2008, BRIEF BIOINFORM, V9, P299, DOI 10.1093/bib/bbn017
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lacombe K, 2006, AIDS, V20, P419, DOI 10.1097/01.aids.0000200537.86984.0e
   Langer BCA, 1997, J VIRAL HEPATITIS, V4, P339, DOI 10.1046/j.1365-2893.1997.00063.x
   Lindh M, 2005, J CLIN VIROL, V34, P315, DOI 10.1016/j.jcv.2005.10.002
   Livingston SE, 2007, J INFECT DIS, V195, P5, DOI 10.1086/509894
   Magnius LO, 1995, INTERVIROLOGY, V38, P24, DOI 10.1159/000150411
   Mahtab MA, 2008, HEPATOB PANCREAT DIS, V7, P457
   McMahon BJ, 2009, HEPATOL INT, V3, P334, DOI 10.1007/s12072-008-9112-z
   Nakano T, 2001, J GEN VIROL, V82, P359, DOI 10.1099/0022-1317-82-2-359
   NAUMANN H, 1993, J GEN VIROL, V74, P1627, DOI 10.1099/0022-1317-74-8-1627
   Norder H, 2003, J GEN VIROL, V84, P2083, DOI 10.1099/vir.0.19034-0
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   NORDER H, 1994, VIROLOGY, V198, P489, DOI 10.1006/viro.1994.1060
   OKAMOTO H, 1987, JPN J EXP MED, V57, P231
   Olinger CM, 2006, J GEN VIROL, V87, P1163, DOI 10.1099/vir.0.81614-0
   ORITO E, 1989, P NATL ACAD SCI USA, V86, P7059, DOI 10.1073/pnas.86.18.7059
   Osiowy C, 2003, J CLIN MICROBIOL, V41, P5473, DOI 10.1128/JCM.41.12.5473-5477.2003
   Pas SD, 2008, J CLIN MICROBIOL, V46, P1268, DOI 10.1128/JCM.01519-07
   Perez-Olmeda M, 2003, AIDS RES HUM RETROV, V19, P657, DOI 10.1089/088922203322280874
   PINEIRO Y, 2003, VIRUS GENES, V27, P103
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Pourkarim MR, 2010, J CLIN VIROL, V47, P93, DOI 10.1016/j.jcv.2009.09.032
   Sanchez LV, 2007, INTERVIROLOGY, V50, P9, DOI 10.1159/000096307
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Shibayama T, 2005, J MED VIROL, V76, P24, DOI 10.1002/jmv.20319
   Simmonds P, 2005, J VIROL, V79, P15467, DOI 10.1128/JVI.79.24.15467-15476.2005
   Singh J, 2009, INTERVIROLOGY, V52, P235, DOI 10.1159/000227279
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Sloan RD, 2009, J CLIN VIROL, V44, P157, DOI 10.1016/j.jcv.2008.11.010
   Suwannakarn K, 2005, J GEN VIROL, V86, P3027, DOI 10.1099/vir.0.81241-0
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Toan NL, 2006, HEPATOLOGY, V43, P1375, DOI 10.1002/hep.21188
   van Steenbergen JE, 2002, J MED VIROL, V66, P159, DOI 10.1002/jmv.2125
   Vieth S, 2002, VIRUS GENES, V24, P153, DOI 10.1023/A:1014572600432
   von Meltzer M, 2008, VIRUS GENES, V37, P225, DOI 10.1007/s11262-008-0261-x
   Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297
   Zhou Y, 2007, J MOL EVOL, V65, P197, DOI 10.1007/s00239-007-0054-1
NR 66
TC 38
Z9 39
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JAN
PY 2011
VL 11
IS 1
BP 103
EP 108
DI 10.1016/j.meegid.2010.10.003
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 711AT
UT WOS:000286558800014
PM 20951841
DA 2020-12-08
ER

PT J
AU Santos, AO
   Alvarado-Mora, MV
   Botelho, L
   Vieira, DS
   Pinho, JRR
   Carrilho, FJ
   Honda, ER
   Salcedo, JM
AF Santos, Alcione O.
   Alvarado-Mora, Monica V.
   Botelho, Livia
   Vieira, Deusilene S.
   Rebello Pinho, Joao R.
   Carrilho, Flair J.
   Honda, Eduardo R.
   Salcedo, Juan M.
TI Characterization of Hepatitis B virus (HBV) genotypes in patients from
   Rondonia, Brazil
SO VIROLOGY JOURNAL
LA English
DT Article
ID MOLECULAR EPIDEMIOLOGY; GENETIC DIVERSITY; SURFACE-ANTIGEN; SUBGENOTYPE;
   SEQUENCE; STRAINS; INFECTION; PRECORE; AFRICA; GENOME
AB Background: Hepatitis B virus (HBV) can be classified into nine genotypes (A-I) defined by sequence divergence of more than 8% based on the complete genome. This study aims to identify the genotypic distribution of HBV in 40 HBsAg-positive patients from Rondonia, Brazil. A fragment of 1306 bp partially comprising surface and polymerase overlapping genes was amplified by PCR. Amplified DNA was purified and sequenced. Amplified DNA was purified and sequenced on an ABI PRISM (R) 377 Automatic Sequencer (Applied Biosystems, Foster City, CA, USA). The obtained sequences were aligned with reference sequences obtained from the GenBank using Clustal X software and then edited with Se-Al software. Phylogenetic analyses were conducted by the Markov Chain Monte Carlo (MCMC) approach using BEAST v.1.5.3.
   Results: The subgenotypes distribution was A1 (37.1%), D3 (22.8%), F2a (20.0%), D4 (17.1%) and D2 (2.8%).
   Conclusions: These results for the first HBV genotypic characterization in Rondonia state are consistent with other studies in Brazil, showing the presence of several HBV genotypes that reflects the mixed origin of the population, involving descendants from Native Americans, Europeans, and Africans.
C1 [Alvarado-Mora, Monica V.; Botelho, Livia; Rebello Pinho, Joao R.; Carrilho, Flair J.] Univ Sao Paulo, Lab Gastroenterol & Hepatol, Sao Paulo Inst Trop Med, Sch Med, Sao Paulo, Brazil.
   [Alvarado-Mora, Monica V.; Botelho, Livia; Rebello Pinho, Joao R.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Santos, Alcione O.; Vieira, Deusilene S.; Honda, Eduardo R.; Salcedo, Juan M.] CEPEM Trop Pathol Res Inst IPEPATRO, Res Ctr Trop Med, Porto Velho, RO, Brazil.
RP Alvarado-Mora, MV (corresponding author), Univ Sao Paulo, Lab Gastroenterol & Hepatol, Sao Paulo Inst Trop Med, Sch Med, Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI DALLACQUA, DEUSILENE/ABA-3597-2020; Pinho, Joao R. R./G-2850-2012;
   Carrilho, Flair J/I-3046-2012; Alvarado-Mora, Monica/I-3180-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
FU IPEPATRO; CEPEM; CNPqNational Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   - FAPESP, Sao Paulo, SP, BrazilFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2007/53457-7, 2008/50461-60]
FX This work was supported by IPEPATRO, CEPEM, CNPq and Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo - FAPESP (2007/53457-7 and
   2008/50461-60), Sao Paulo, SP, Brazil.
CR Alcalde R, 2009, REV INST MED TROP SP, V51, P269, DOI 10.1590/S0036-46652009000500006
   Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
   Alves-Silva J, 2000, AM J HUM GENET, V67, P444, DOI 10.1086/303004
   Andernach IE, 2009, EMERG INFECT DIS, V15, P1222, DOI 10.3201/eid1508.081642
   Araujo NM, 2004, ARCH VIROL, V149, P1383, DOI 10.1007/s00705-003-0269-4
   BECKER CE, ARQ GASTROENTEROL, V47, P13
   Bertolini DA, 2010, REV INST MED TROP SP, V52, P25, DOI 10.1590/S0036-46652010000100004
   Blitz L, 1998, J CLIN MICROBIOL, V36, P648, DOI 10.1128/JCM.36.3.648-651.1998
   Bottecchia M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-11
   Bowyer SM, 1997, J GEN VIROL, V78, P1719, DOI 10.1099/0022-1317-78-7-1719
   Carrilho FJ, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-13
   Chandra PK, 2009, J VIRAL HEPATITIS, V16, P749, DOI 10.1111/j.1365-2893.2009.01129.x
   Chu CJ, 2003, GASTROENTEROLOGY, V125, P444, DOI 10.1016/S0016-5085(03)00895-3
   Dal Molin G, 2006, J MED VIROL, V78, P734, DOI 10.1002/jmv.20616
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Echevarria JM, 2006, J MED VIROL, V78, pS36, DOI 10.1002/jmv.20605
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Gish RG, 2006, J VIRAL HEPATITIS, V13, P787, DOI 10.1111/j.1365-2893.2006.00787.x
   Hannoun C, 2005, J GEN VIROL, V86, P2163, DOI 10.1099/vir.0.80972-0
   HUBSCHEN JM, 2010, CLIN MICROBIOL INFEC
   IBGE, 2000, CENS DEM
   Jutavijittum Prapan, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P674
   Kato H, 2005, WORLD J GASTROENTERO, V11, P6295, DOI 10.3748/wjg.v11.i40.6295
   KATSURAGAWA, 2010, REV PANAMAZ SAUDE, V1, P91
   Kramvis A, 2005, J MED VIROL, V77, P47, DOI 10.1002/jmv.20412
   Kramvis A, 2007, HEPATOL RES, V37, pS9, DOI 10.1111/j.1872-034X.2007.00098.x
   Kurbanov F, 2005, J GEN VIROL, V86, P2047, DOI 10.1099/vir.0.80922-0
   Kurbanov F, 2010, HEPATOL RES, V40, P14, DOI 10.1111/j.1872-034X.2009.00601.x
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Magnius LO, 1995, INTERVIROLOGY, V38, P24, DOI 10.1159/000150411
   Mahtab MA, 2008, HEPATOB PANCREAT DIS, V7, P457
   Makuwa M, 2005, J CLIN VIROL, V34, pS83, DOI 10.1016/S1386-6532(05)80016-2
   MARQUESE RD, 2006, NOVOS ESTUD, V74, P107
   Mbayed VA, 1998, J CLIN MICROBIOL, V36, P3362, DOI 10.1128/JCM.36.11.3362-3365.1998
   McMahon BJ, 2009, HEPATOLOGY, V49, pS45, DOI 10.1002/hep.22898
   Medici MC, 2006, NEW MICROBIOL, V29, P63
   Meldal BHM, 2009, J GEN VIROL, V90, P1622, DOI 10.1099/vir.0.009738-0
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Mendes-Correa MC, 2010, J MED VIROL, V82, P1481, DOI 10.1002/jmv.21845
   MORA MVA, INFECT GENETICS EVOL
   Moraes MTB, 1996, ARCH VIROL, V141, P1767, DOI 10.1007/BF01718299
   Motta-Castro ARC, 2005, J MED VIROL, V77, P188, DOI 10.1002/jmv.20435
   Motta-Castro ARC, 2003, MEM I OSWALDO CRUZ, V98, P13, DOI 10.1590/S0074-02762003000100002
   Mulders MN, 2004, J INFECT DIS, V190, P400, DOI 10.1086/421502
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   NORDER H, 1992, J GEN VIROL, V73, P1201, DOI 10.1099/0022-1317-73-5-1201
   OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575
   Olinger CM, 2008, EMERG INFECT DIS, V14, P1777, DOI 10.3201/eid1411.080437
   Olinger CM, 2006, J GEN VIROL, V87, P1163, DOI 10.1099/vir.0.81614-0
   Osiowy C, 2008, J GEN VIROL, V89, P3009, DOI 10.1099/vir.0.2008/005124-0
   Owada T, 2006, J VIRAL HEPATITIS, V13, P11, DOI 10.1111/j.1365-2893.2005.00648.x
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Pourkarim MR, 2009, J CLIN VIROL, V46, P61, DOI 10.1016/j.jcv.2009.06.015
   Quintero A, 2002, ARCH VIROL, V147, P1829, DOI 10.1007/s00705-002-0842-2
   Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573
   Rezende REF, 2005, J CLIN VIROL, V32, P53, DOI 10.1016/j.jcv.2004.08.001
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schaefer S, 2007, WORLD J GASTROENTERO, V13, P14, DOI 10.3748/wjg.v13.i1.14
   Singh J, 2009, INTERVIROLOGY, V52, P235, DOI 10.1159/000227279
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Tallo T, 2008, J GEN VIROL, V89, P1829, DOI 10.1099/vir.0.83660-0
   Teles SA, 2002, J MED VIROL, V68, P41, DOI 10.1002/jmv.10168
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Utama A, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-128
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   von Meltzer M, 2008, VIRUS GENES, V37, P225, DOI 10.1007/s11262-008-0261-x
   Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297
NR 70
TC 40
Z9 40
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD NOV 12
PY 2010
VL 7
AR 315
DI 10.1186/1743-422X-7-315
PG 7
WC Virology
SC Virology
GA 689FM
UT WOS:000284912700001
PM 21073730
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Mora, MVA
   Romano, CM
   Gomes-Gouvea, MS
   Gutierrez, MF
   Carrilho, FJ
   Pinho, JRR
AF Alvarado Mora, Monica Viviana
   Romano, Camila Malta
   Gomes-Gouvea, Michele Soares
   Fernanda Gutierrez, Maria
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Molecular Characterization, Distribution, and Dynamics of Hepatitis C
   Virus Genotypes in Blood Donors in Colombia
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE hepatitis C virus; genotype 1b; blood donors; Colombia; Bayesian
   analysis
ID SEQUENCE-ANALYSIS; CENTRAL BRAZIL; RISK-FACTORS; NS5B REGION; INFECTION;
   HCV; EPIDEMIOLOGY; PCR; DIVERSITY; COUNTRIES
AB Hepatitis C virus (HCV) is a frequent cause of acute and chronic hepatitis and a leading cause for cirrhosis of the liver and hepatocellular carcinoma. HCV is classified in six major genotypes and more than 70 subtypes. In Colombian blood banks, serum samples were tested for anti-HCV antibodies using a third-generation ELISA. The aim of this study was to characterize the viral sequences in plasma of 184 volunteer blood donors who attended the "Banco Nacional de Sangre de la Cruz Roja Colombiana,'' Bogota, Colombia. Three different HCV genomic regions were amplified by nested PCR. The first of these was a segment of 180 bp of the 5'UTR region to confirm the previous diagnosis by ELISA. From those that were positive to the 5'UTR region, two further segments were amplified for genotyping and subtyping by phylogenetic analysis: a segment of 380 bp from the NS5B region; and a segment of 391 bp from the E1 region. The distribution of HCV subtypes was: 1b (82.8%), 1a (5.7%), 2a (5.7%), 2b (2.8%), and 3a (2.8%). By applying Bayesian Markov chain Monte Carlo simulation, it was estimated that HCV-1b was introduced into Bogota around 1950. Also, this subtype spread at an exponential rate between about 1970 to about 1990, after which transmission of HCV was reduced by anti-HCV testing of this population. Among Colombian blood donors, HCV genotype 1b is the most frequent genotype, especially in large urban conglomerates such as Bogota, as is the case in other South American countries. J. Med. Virol. 82: 1889-1898, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Alvarado Mora, Monica Viviana; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Fac Med, Dept Gastroenterol,Lab Gastroenterol Hepatol, Sao Paulo Inst Trop Med,Sch Med, Sao Paulo, Brazil.
   [Romano, Camila Malta] Univ Sao Paulo, Sao Paulo Inst Trop Med, Virol Lab, Dept Infect & Parasit Dis,Sch Med, Sao Paulo, Brazil.
   [Fernanda Gutierrez, Maria] Pontificia Javeriana Univ, Virol Lab, Dept Microbiol, Bogota, Colombia.
RP Mora, MVA (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol,Lab Gastroenterol Hepatol, Sao Paulo Inst Trop Med,Sch Med, Av Dr Eneas Carvalho Aguiar,500 2 Andar,Predio IM, Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Gutierrez, Maria/AAF-2966-2019; Pinho, Joao R. R./G-2850-2012; Carrilho,
   Flair J/I-3046-2012; Alvarado-Mora, Monica/I-3180-2012; Romano,
   Camila/ABC-2883-2020; Romano, Camila M/C-8185-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Romano,
   Camila/0000-0003-4550-1987; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2007/53457-7,
   2008/50461-6]; Pontificia Universidad Javeriana, Bogota, Colombia
FX Grant sponsor: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); Grant numbers: 2007/53457-7, 2008/50461-6; Grant sponsor:
   Pontificia Universidad Javeriana, Bogota, Colombia.
CR AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901
   Amorim RMS, 2004, MEM I OSWALDO CRUZ, V99, P895, DOI 10.1590/S0074-02762004000800019
   Andrade AFB, 2006, MEM I OSWALDO CRUZ, V101, P673, DOI 10.1590/S0074-02762006000600016
   Beltran Mauricio, 2005, J Clin Virol, V34 Suppl 2, pS33, DOI 10.1016/S1386-6532(05)80032-0
   BOOTH JCL, 2001, GUT               S1, V49, P1
   BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234
   Cantaloube JF, 2006, J CLIN MICROBIOL, V44, P2051, DOI 10.1128/JCM.02463-05
   Dal Molin G, 2002, J MED VIROL, V68, P352, DOI 10.1002/jmv.10210
   Di Lello F, 2008, J MED VIROL, V80, P619, DOI 10.1002/jmv.21112
   Di Lello FA, 2009, J MED VIROL, V81, P1887, DOI 10.1002/jmv.21607
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Echevarría José M., 2003, Cad. Saúde Pública, V19, P1583, DOI 10.1590/S0102-311X2003000600003
   Elghouzzi MH, 2000, VOX SANG, V79, P138, DOI 10.1159/000031231
   ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8
   Espirito-Santo MP, 2007, BRAZ J MED BIOL RES, V40, P545, DOI 10.1590/S0100-879X2007000400013
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Ferraro D, 2008, J MED VIROL, V80, P1723, DOI 10.1002/jmv.21276
   Furione M, 1999, J CLIN VIROL, V13, P121, DOI 10.1016/S1386-6532(99)00036-0
   Garcia-Montalvo BM, 2007, TRANSFUSION MED, V17, P488, DOI 10.1111/j.1365-3148.2007.00796.x
   GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W
   GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H
   Guadagnino V, 1997, HEPATOLOGY, V26, P1006, DOI 10.1002/hep.510260431
   Halfon P, 1997, J MED VIROL, V52, P391, DOI 10.1002/(SICI)1096-9071(199708)52:4&lt;391::AID-JMV8&gt;3.0.CO;2-X
   Ishii K, 1999, HEPATOLOGY, V29, P1227, DOI 10.1002/hep.510290448
   Katsoulidou A, 2006, J VIRAL HEPATITIS, V13, P19, DOI 10.1111/j.1365-2893.2005.00649.x
   Kurbanov F, 2003, J MED VIROL, V69, P367, DOI 10.1002/jmv.10298
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Liu PP, 2008, AIDS RES HUM RETROV, V24, P1, DOI 10.1089/aid.2007.0144
   MAERTENS G, 1997, MOL MED VIRAL HEPATI, P182
   Martell M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh088
   Martins RMB, 1998, MEM I OSWALDO CRUZ, V93, P299, DOI 10.1590/S0074-02761998000300004
   Munoz G, 1998, REV MED CHILE, V126, P1035
   Nakano T, 2004, J INFECT DIS, V190, P1098, DOI 10.1086/422606
   NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001
   Pasquier C, 2005, J MED VIROL, V77, P390, DOI 10.1002/jmv.20468
   Pawlotsky JM, 2003, ANTIVIR RES, V59, P1, DOI 10.1016/S0166-3542(03)00088-3
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   ROMANO CM, 2010, PLOS ONE IN PRESS
   Ross RS, 2000, J MED VIROL, V60, P122, DOI 10.1002/(SICI)1096-9071(200002)60:2&lt;122::AID-JMV3&gt;3.0.CO;2-#
   Salemi M, 2002, J MOL EVOL, V54, P62, DOI 10.1007/s00239-001-0018-9
   Sanchez JL, 2000, AM J TROP MED HYG, V63, P242, DOI 10.4269/ajtmh.2000.63.242
   Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
   Schmunis GA, 2005, CLIN MICROBIOL REV, V18, P12, DOI 10.1128/CMR.18.1.12-29.2005
   Schmunis GA, 2001, AM J TROP MED HYG, V65, P924, DOI 10.4269/ajtmh.2001.65.924
   SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391
   Smith DB, 1997, J GEN VIROL, V78, P321, DOI 10.1099/0022-1317-78-2-321
   Soza Alejandro, 2004, Ann Hepatol, V3, P146
   Spada E, 1998, RES VIROLOGY, V149, P209, DOI 10.1016/S0923-2516(98)80002-2
   Suzuki T, 2007, J GASTROENTEROL, V42, P411, DOI 10.1007/s00535-007-2030-3
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   *WHO, 1991, CREAT COMM GROUND WO, P13
   Zwickl D. J., 2006, GENETIC ALGORITHM AP
   1996, EPIDEMIOL B, V19, P12
NR 54
TC 16
Z9 17
U1 1
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2010
VL 82
IS 11
BP 1889
EP 1898
DI 10.1002/jmv.21908
PG 10
WC Virology
SC Virology
GA 655RJ
UT WOS:000282266900011
PM 20872715
DA 2020-12-08
ER

PT J
AU Galvao, FHF
   Farias, AQ
   Pompeu, E
   Waisberg, DR
   Teixeira, ARF
   de Mello, ES
   Costa, ACL
   Galvao, RD
   Santos, VR
   Chaib, E
   Carrilho, FJ
   D'Albuquerque, LAC
AF Ferreira Galvao, Flavio Henrique
   Farias, Alberto Queiroz
   Pompeu, Eduardo
   Waisberg, Daniel Reis
   Franchi Teixeira, Antonio Roberto
   de Mello, Evandro Sobroza
   Lino Costa, Anderson Costa
   Galvao, Raoni de Castro
   Santos, Vinicius Rocha
   Chaib, Eleazar
   Carrilho, Flair Jose
   D'Albuquerque, Luiz Augusto Carneiro
TI Endoscopic features in a model of multivisceral xenotransplantation
SO XENOTRANSPLANTATION
LA English
DT Article
DE endoscopy; experimental animal model; intestine; stomach;
   xenotransplantation
ID TRANSPLANTATION
AB Introduction:
   Xenotransplantation and multivisceral transplantation are advanced therapeutic methods that still require a scientific basis. There are no experimental models of multivisceral transplantation available, particularly not the monitoring by endoscopy. Here, we describe the endoscopic features in a model of multivisceral xenotransplantation.
   Methods:
   The distal esophagus, stomach, intestine, colon, liver, pancreas, and the kidneys with a common vascular pedicle were harvested from rabbits and implanted in swine (group I, n = 9) or in rabbits (group II, n = 4). Endoscopy was performed in the stomach, jejunum, and ascending colon at four consecutive time points (immediate after surgery and 10, 90, and 180 min after reperfusion). Lesions were macroscopically graded as mild, moderate, and severe. Biopsies were taken following sacrifice at 180 min after reperfusion.
   Results:
   In group I, the stomach, jejunum, and colon manifested a progression of lesions with predominance of mild lesions after 10 min, mild to moderate lesions after 90 min, and moderate to severe lesions after 180 min. In animals from group II, endoscopy showed normal features at all time points after reperfusion. Histopathologic analysis confirmed the diagnosis of hyperacute rejection in group I. Grafts from group II animals presented normal or mild ischemic/reperfusion injury.
   Conclusion:
   All animals subjected to multivisceral xenotransplantation showed a progression of endoscopic lesions with time after transplantation, while animals subjected to allotransplantation showed no aberrations in endoscopy. We conclude that endoscopy is a useful tool in the assessment of hyperacute rejection of a xenograft.
C1 [Ferreira Galvao, Flavio Henrique; Farias, Alberto Queiroz; Waisberg, Daniel Reis; Franchi Teixeira, Antonio Roberto; de Mello, Evandro Sobroza; Lino Costa, Anderson Costa; Santos, Vinicius Rocha; Chaib, Eleazar; Carrilho, Flair Jose; D'Albuquerque, Luiz Augusto Carneiro] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Pompeu, Eduardo] Univ Sao Paulo, Sch Med, Anim Facil, Sao Paulo, Brazil.
   [Galvao, Raoni de Castro] Santa Casa Sch Med, Sao Paulo, Brazil.
RP Galvao, FHF (corresponding author), Rua Dona Antonia de Queiroz 551,Apt 31, Sao Paulo, Brazil.
EM fgalvao@usp.br
RI D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Farias, Alberto
   Q/H-7873-2013; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   Carrilho, Flair J/I-3046-2012; Waisberg, Daniel/AAD-9783-2019; Galvao,
   Flavio Henrique Ferreira/D-3487-2017; Rocha-Santos,
   Vinicius/H-2984-2017; Farias, Alberto/ABB-1291-2020; Rocha-Santos,
   Vinicius/O-9759-2018
OI D'Albuquerque, Luiz Augusto Carneiro/0000-0001-7607-7168; Waisberg,
   Daniel/0000-0003-4284-0633; Galvao, Flavio Henrique
   Ferreira/0000-0003-1924-3208; Rocha-Santos,
   Vinicius/0000-0002-2643-6094; Farias, Alberto/0000-0002-5572-663X; 
CR Galvao FHF, 2005, TRANSPLANTATION, V80, P1522, DOI 10.1097/01.tp.0000184448.86704.c8
   Galvao FH, 2008, XENOTRANSPLANTATION, V15, P184, DOI 10.1111/j.1399-3089.2008.00470.x
   Llanos JC, 2006, TRANSPL P, V38, P1855, DOI 10.1016/j.transproceed.2006.06.085
   Pierson RN, 2009, XENOTRANSPLANTATION, V16, P263, DOI 10.1111/j.1399-3089.2009.00534.x
   Starzl T E, 1960, Surg Forum, V11, P28
   Tector AJ, 1998, XENOTRANSPLANTATION, V5, P257, DOI 10.1111/j.1399-3089.1998.tb00036.x
   Tzakis AG, 2005, ANN SURG, V242, P480, DOI 10.1097/01.sla..0000183347.61361.7a
   Yang YG, 2007, NAT REV IMMUNOL, V7, P519, DOI 10.1038/nri2099
   Yedidag EN, 1996, TRANSPLANTATION, V62, P1385, DOI 10.1097/00007890-199611270-00002
NR 9
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0908-665X
J9 XENOTRANSPLANTATION
JI Xenotransplantation
PD NOV-DEC
PY 2010
VL 17
IS 6
BP 423
EP 428
DI 10.1111/j.1399-3089.2010.00609.x
PG 6
WC Medicine, Research & Experimental; Transplantation
SC Research & Experimental Medicine; Transplantation
GA 695RL
UT WOS:000285390200005
PM 21192494
DA 2020-12-08
ER

PT J
AU Alvarado-Mora, MV
   Romano, CM
   Botelho, L
   Gomes-Gouvea, M
   Gutierrez, MF
   Carrilho, FJ
   Pinho, JR
AF Alvarado-Mora, Monica V.
   Romano, Camila M.
   Botelho, Livia
   Gomes-Gouvea, Michele
   Gutierrez, Maria F.
   Carrilho, Flair J.
   Pinho, Joao R.
TI MOLECULAR CHARACTERIZATION OF THE HEPATITIS B VIRUS GENOTYPES
   CIRCULATING IN COLOMBIA: AN INFERENCE OF THE GENOTYPE F GEOGRAPHICAL
   DISTRIBUTION
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Alvarado-Mora, Monica V.; Romano, Camila M.; Botelho, Livia; Gomes-Gouvea, Michele; Carrilho, Flair J.; Pinho, Joao R.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Gutierrez, Maria F.] Pontificia Javeriana Univ, Bogota, Colombia.
RI Alvarado-Mora, Monica/I-3180-2012; Romano, Camila/ABC-2883-2020;
   Carrilho, Flair J/I-3046-2012; Gutierrez, Maria/AAF-2966-2019; Pinho,
   Joao R. R./G-2850-2012; Romano, Camila M/C-8185-2013
OI Romano, Camila/0000-0003-4550-1987; Pinho, Joao R.
   R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 742
BP 674A
EP 674A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775601061
DA 2020-12-08
ER

PT J
AU Venegas, M
   Alvarado-Mora, MV
   Villanueva, RA
   Pinho, JR
   Carrilho, FJ
   Brahm, J
AF Venegas, Mauricio
   Alvarado-Mora, Monica V.
   Villanueva, Rodrigo A.
   Pinho, Joao R.
   Carrilho, Flair J.
   Brahm, Javier
TI PHYLOGENETIC ANALYSIS OF COMPLETE GENOME SEQUENCES OF HEPATITIS B VIRUS
   GENOTYPE F OF CHILEAN PATIENTS WITH CHRONIC INFECTION
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Venegas, Mauricio; Brahm, Javier] Univ Chile, Hosp Clin, Santiago, Chile.
   [Alvarado-Mora, Monica V.; Pinho, Joao R.; Carrilho, Flair J.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Villanueva, Rodrigo A.] Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Virol, Santiago 7, Chile.
RI Venegas, Mauricio/I-6420-2012; Alvarado-Mora, Monica/I-3180-2012;
   Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Venegas, Mauricio/0000-0001-7379-6108; Pinho, Joao R.
   R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 755
BP 681A
EP 681A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775601074
DA 2020-12-08
ER

PT J
AU Poynard, T
   Munteanu, M
   Bruix, J
   Schiff, ER
   Diago, M
   Berg, T
   Moreno-Otero, R
   Lyra, LG
   Carrilho, FJ
   Boparai, N
   Griffel, LH
   Burroughs, M
   Brass, CA
   Albrecht, JK
AF Poynard, Thierry
   Munteanu, Mona
   Bruix, Jordi
   Schiff, Eugene R.
   Diago, Moises
   Berg, Thomas
   Moreno-Otero, Ricardo
   Lyra, Luiz G.
   Carrilho, Flair J.
   Boparai, Navdeep
   Griffel, Louis H.
   Burroughs, Margaret
   Brass, Clifford A.
   Albrecht, Janice K.
TI IMPACT OF PEGINTRON (PEG) MAINTENANCE THERAPY (MT) ON FIBROSIS
   BIOMARKERS (FIBROTEST[FT]/FIBROSURE) IN PRIOR NONRESPONDERS WITH METAVIR
   FIBROSIS SCORES (MFS) OF F2/F3: FINAL RESULTS FROM THE EPIC3 PROGRAM
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Poynard, Thierry] UPMC Paris Liver Ctr, APHP, Paris, France.
   [Munteanu, Mona] Biopredictive, Paris, France.
   [Bruix, Jordi] Univ Barcelona, Hosp Clin, Barcelona, Spain.
   [Schiff, Eugene R.] Univ Miami, Sch Med, Miami, FL USA.
   [Diago, Moises] Hosp Gen Univ Valencia, Valencia, Spain.
   [Berg, Thomas] Univ Klinikum Leipzig, Leipzig, Germany.
   [Moreno-Otero, Ricardo] Inst Salud Carlos III, Madrid, Spain.
   [Lyra, Luiz G.] Hosp Sao Rafael, Salvador, BA, Brazil.
   [Carrilho, Flair J.] Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
   [Boparai, Navdeep; Griffel, Louis H.; Burroughs, Margaret; Brass, Clifford A.; Albrecht, Janice K.] Now Merck & Co, Schering Plough Corp, Whitehouse Stn, NJ USA.
RI DIAGO, MOISES/AAH-5364-2019; Carrilho, Flair J/I-3046-2012; Poynard,
   Thierry/C-1355-2010
OI Poynard, Thierry/0000-0002-3726-7230
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 817
BP 713A
EP 713A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775601137
DA 2020-12-08
ER

PT J
AU Kappel, CR
   Siqueira, ERF
   Lima, VM
   Stefano, JT
   Michalczuk, MT
   Marini, SS
   Barbeiro, HV
   Soriano, FG
   Pereira, L
   Oliveira, CP
   Carrilho, FJ
   Alvares-Da-Silva, MR
AF Kappel, Camila R.
   Siqueira, Erika Rabelo F.
   Lima, Vicencia M.
   Stefano, Jose Tadeu
   Michalczuk, Matheus T.
   Marini, Stela S.
   Barbeiro, Hermes V.
   Soriano, Francisco G.
   Pereira, Leila
   Oliveira, Claudia P.
   Carrilho, Flair J.
   Alvares-da-Silva, Mario R.
TI INCREASED CARDIOVASCULAR RISK IN PATIENTS WITH HEPATITIS C: ASSESSMENT
   BY FRAMINGHAM SCORE AND SERUM INFLAMMATORY MARKERS
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Kappel, Camila R.; Michalczuk, Matheus T.; Marini, Stela S.; Alvares-da-Silva, Mario R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
   [Lima, Vicencia M.; Stefano, Jose Tadeu; Barbeiro, Hermes V.; Soriano, Francisco G.; Oliveira, Claudia P.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Siqueira, Erika Rabelo F.; Pereira, Leila] Inst Figado Pernambuco, Recife, PE, Brazil.
RI Oliveira, Claudia PMS/D-1216-2014; Soriano, Francisco/C-3382-2012;
   Stefano, Jose Tadeu/AAH-5419-2020; Barbeiro, Hermes/S-5926-2016
OI Soriano, Francisco/0000-0003-4898-0135; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Barbeiro, Hermes/0000-0002-8209-4463
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 777
BP 691A
EP 691A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775601096
DA 2020-12-08
ER

PT J
AU Mazo, DF
   Pereira, IV
   Lima, VM
   Stefano, JT
   Oliveira, FD
   Cogliati, B
   de Souza, GF
   Uribe, C
   Matte, U
   Alvares-da-Silva, MR
   Silveira, TR
   Carrilho, FJ
   de Oliveira, MG
   Oliveira, CP
AF Mazo, Daniel F.
   Pereira, Isabel V.
   Lima, Vicencia M.
   Stefano, Jose Tadeu
   Oliveira, Fernanda D.
   Cogliati, Bruno
   de Souza, Gabriela F.
   Uribe, Carolina
   Matte, Ursula
   Alvares-da-Silva, Mario R.
   Silveira, Themis R.
   Carrilho, Flair J.
   de Oliveira, Marcelo G.
   Oliveira, Claudia P.
TI S-NITROSO-N-ACETYLCYSTEINE (SNAC), A NITRIC OXIDE DONOR, MODULATED
   HEPATIC STELLATE CELLS (HSCS) ACTIVITY AND HAS ANTIFIBROGENIC PROPERTIES
   IN EXPERIMENTAL NONALCOHOLIC STEATOHEPATITIS (NASH)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Mazo, Daniel F.; Pereira, Isabel V.; Lima, Vicencia M.; Stefano, Jose Tadeu; Carrilho, Flair J.; Oliveira, Claudia P.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [de Souza, Gabriela F.; de Oliveira, Marcelo G.] State Univ Campinas UNICAMP, Inst Chem, Campinas, SP, Brazil.
   [Oliveira, Fernanda D.; Uribe, Carolina; Matte, Ursula; Alvares-da-Silva, Mario R.; Silveira, Themis R.] Univ Fed Rio Grande do Sul, Dept Internal Med & Pediat, Porto Alegre, RS, Brazil.
   [Cogliati, Bruno] Univ Sao Paulo, Dept Pathol, Sch Vet Med & Anim Sci, Sao Paulo, Brazil.
RI Stefano, Jose T/H-4792-2013; Silveira, Themis/H-4286-2016; Matte,
   Ursula/J-4589-2012; de Oliveira, Marcelo Ganzarolli/B-4709-2013; Da
   Silveira Matte umatte, Ursula/U-3912-2019; Stefano, Jose
   Tadeu/AAH-5419-2020; Alvares-da-Silva, Mario Reis/L-3910-2014; Mazo,
   Daniel FC/D-5631-2015; Oliveira, Claudia PMS/D-1216-2014; Carrilho,
   Flair J/I-3046-2012
OI de Oliveira, Marcelo Ganzarolli/0000-0002-9371-9975; Da Silveira Matte
   umatte, Ursula/0000-0003-4977-6662; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Alvares-da-Silva, Mario
   Reis/0000-0002-5001-246X; Mazo, Daniel FC/0000-0002-2164-2630; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 1528
BP 1052A
EP 1052A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775602148
DA 2020-12-08
ER

PT J
AU Paschoale, HS
   Barbosa, FR
   Nita, ME
   Carrilho, FJ
   Ono-Nita, SK
AF Paschoale, Helena S.
   Barbosa, Fernanda R.
   Nita, Marcelo E.
   Carrilho, Flair J.
   Ono-Nita, Suzane Kioko
TI Clinical trials profile: Professionals and sites
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Clinical trial; Professionals; Clinical research
AB Clinical trial is considered a breakthrough method in medicine and essential to the development of new drugs. Clinical trials that comply with international and national regulations require an appropriate infrastructure and team qualification. The goal of this study was to evaluate clinical trial groups in Brazil: professional qualification, site structure regulatory knowledge and Good Clinical Practice (GCP) adherence. This is a transversal study with investigators (PI) and sub investigator (SI). PI and SI data were initially identified from Curriculum Lattes from National Advice of Scientific and Technological Development. The study participants were submitted to a questionnaire, which was composed of qualitative and quantitative questions. A hundred PI and SI were interviewed. The most representative Brazilian regions were Southeast (68%) and South (18%). The main institutions involved were HCFMUSP complex and UNIFESP among others institutions. Academic graduation is observed in 86% of them and the higher degree is Doctorate (62%). 91% had GCP knowledge although only 74% had formal training. About the team, all of them are multidisciplinary with majority of nurses and pharmaceuticals. 88% had GCP knowledge although only 77% had formal training. 36%, 60% and 44% of clinical trials were in phase II,III and IV. In conclusion, researchers have appropriate skills and knowledge to perform clinical studies however there is still a need for training. The centers where the researchers work, have trained staff and adequate infrastructure for conducting clinical trials phase II,III and IV. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Paschoale, Helena S.; Barbosa, Fernanda R.; Nita, Marcelo E.; Carrilho, Flair J.; Ono-Nita, Suzane Kioko] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
RP Ono-Nita, SK (corresponding author), Av Dr Eneas Carvalho de Aguiar 255,ICHC 9th Floor, BR-05403000 Sao Paulo, Brazil.
EM skon@usp.br
RI Ono, Suzane/I-3107-2012; Carrilho, Flair J/I-3046-2012
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq)
FX We thank Claudia Arruda for helping the execution of this study. We had
   financial support from Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq).
CR ARBIT HM, 2006, MANAGEMENT SERIES MA, P30
   BORFITZ D, 2001, CTR WATCH, V8, P3
   Csillag C, 1999, Rev Assoc Med Bras (1992), V45, P152
   Dainesi SM, 2007, REV BRAS PSIQUIATR, V29, P283, DOI 10.1590/S1516-44462006005000049
   Friedman L. M., 1998, FUNDAMENTALS CLIN TR
   Glancszpigel D., 2003, APPL CLIN TRIALS, P38
   Lader EW, 2004, CIRCULATION, V109, P2672, DOI 10.1161/01.CIR.0000128702.16441.75
   MARQUES SP, 2003, CADERNOS MED FARMA 2, V2, P10
   *MERC MAN CONS, 2008, AR NEXT PROF ZON PHA
   NETO FM, 2002, INTERFACE, V1, P27
   Nishioka AS, 2006, REV ASSOC MED BRAS, V52, P60, DOI 10.1590/S0104-42302006000100025
   NOBRE MRC, 2004, REV ASSOC MED BRAS, V50, P1
   Quental Cristiane, 2006, Rev. bras. epidemiol., V9, P408, DOI 10.1590/S1415-790X2006000400002
   Rodrigues DG, 2007, J INVEST MED, V55, P223, DOI 10.2310/6650.2007.00007
   Stober M., 2003, APPL CLIN TRIALS SEP, P24
   ZAGO MA, 2004, CIENC SAUDE COLETIVA, V9, P363
NR 16
TC 1
Z9 2
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD SEP
PY 2010
VL 31
IS 5
BP 438
EP 442
DI 10.1016/j.cct.2010.06.002
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 657CX
UT WOS:000282391000012
PM 20601160
DA 2020-12-08
ER

PT J
AU Rabelo, F
   Oliveira, CPMS
   Faintuch, J
   Mazo, DFC
   Lima, VMR
   Stefano, JT
   Barbeiro, HV
   Soriano, FG
   Alves, VAF
   Carrilho, FJ
AF Rabelo, Fabiola
   Oliveira, Claudia P. M. S.
   Faintuch, Joel
   Mazo, Daniel F. C.
   Lima, Vicencia M. R.
   Stefano, Jose Tadeu
   Barbeiro, Hermes V.
   Soriano, Francisco G.
   Ferreira Alves, Venancio A.
   Carrilho, Flair J.
TI Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis
SO OBESITY SURGERY
LA English
DT Article
DE Obesity; Diabetes; Steatosis; Steatohepatitis; NASH; IL-6; IL-10;
   TNF-alpha; Inflammation; Anti-inflammatory cytokines
ID CIRCULATING INTERLEUKIN-6 LEVELS; MORBIDLY OBESE-PATIENTS; FATTY
   LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS; BARIATRIC SURGERY;
   PENTOXIFYLLINE; CIRRHOSIS; SEVERITY; FIBROSIS; ALPHA
AB Fatty liver disease is a problem in both bariatric patients and in patients with moderate obesity. Tumor necrosis factor (TNF)-alpha has been frequently measured in nonalcoholic steatohepatitis (NASH) with or without diabetes, but less is known about interleukin (IL)-6 and IL-10.
   Moderately obese patients (n = 80) with histologically proven steatosis (n = 29) and NASH (n = 51) were recruited. Serum levels of cytokines were documented along with clinical information. The aim was to identify the correlates of such biomolecules in a stable population.
   Diabetes tended to be more associated with NASH (52.5% instead of 41.4%, P = 0.015), with no difference of age, gender, or body mass index regarding steatosis. For the entire population, cytokine changes were not significant, including TNF-alpha and IL-6. In diabetics only, all markers tended to diminish with NASH, especially IL-10 (P = 0.000). IL-10 correlated with homeostatic model assessment index (P = 0.000) and other variables of glucose homeostasis in diabetes, thus representing a major marker of the disease.
   (1) Generally inconsistent changes in pro- and anti-inflammatory cytokines occurred when NASH was globally compared to steatosis. (2) In contrast, downregulation of IL-6 and IL-10 was perceived in diabetics with NASH. (3) Arterial hypertension did not play a role in these circumstances. (4) IL-10 maintained strong correlations with glucose metabolism indices. (5) TNF-alpha could not be incriminated for progressive liver damage, as values failed to increase in NASH. (6) Investigations of IL-10 and other counterregulatory cytokines are lacking in this context and deserve further studies.
C1 [Rabelo, Fabiola; Oliveira, Claudia P. M. S.; Faintuch, Joel; Mazo, Daniel F. C.; Lima, Vicencia M. R.; Stefano, Jose Tadeu; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Barbeiro, Hermes V.; Soriano, Francisco G.] Univ Sao Paulo, Sch Med, Dept Emergency, Sao Paulo, Brazil.
   [Ferreira Alves, Venancio A.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM cpm@usp.br
RI Mazo, Daniel FC/D-5631-2015; Carrilho, Flair J/I-3046-2012; Oliveira,
   Claudia PMS/D-1216-2014; Stefano, Jose T/H-4792-2013; Barbeiro, Hermes
   V/E-2814-2010; Soriano, Francisco/C-3382-2012; Stefano, Jose
   Tadeu/AAH-5419-2020; Barbeiro, Hermes V/S-5926-2016
OI Mazo, Daniel FC/0000-0002-2164-2630; Barbeiro, Hermes
   V/0000-0002-8209-4463; Soriano, Francisco/0000-0003-4898-0135; Stefano,
   Jose Tadeu/0000-0002-0218-1920; Barbeiro, Hermes V/0000-0002-8209-4463
CR Abiru S, 2006, LIVER INT, V26, P39, DOI 10.1111/j.1478-3231.2005.01191.x
   Bahcecioglu IH, 2005, HEPATO-GASTROENTEROL, V52, P1549
   Chagas AL, 2009, BRAZ J MED BIOL RES, V42, P958, DOI 10.1590/S0100-879X2009005000019
   de Lalla C, 2004, J IMMUNOL, V173, P1417, DOI 10.4049/jimmunol.173.2.1417
   Dogru T, 2008, AM J GASTROENTEROL, V103, P3217, DOI 10.1111/j.1572-0241.2008.02161_17.x
   Elinav E, 2006, J PATHOL, V208, P74, DOI 10.1002/path.1869
   Estep JM, 2009, OBES SURG, V19, P617, DOI 10.1007/s11695-009-9814-x
   Floreani A, 2008, AM J GASTROENTEROL, V103, P1959, DOI 10.1111/j.1572-0241.2008.01888.x
   Grundy SM, 2004, CIRCULATION, V109, P551, DOI 10.1161/01.CIR.0000112379.88385.67
   Hong EG, 2009, DIABETES, V58, P2525, DOI 10.2337/db08-1261
   ISAACS A, 1962, P ROY SOC MED, V55, P725, DOI 10.1177/003591576205500901
   Jarrar MH, 2008, ALIMENT PHARM THER, V27, P412, DOI 10.1111/j.1365-2036.2007.03586.x
   Kashyap SR, 2009, OBESITY, V17, P1696, DOI 10.1038/oby.2009.89
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Lee YM, 2008, HEPATOL INT, V2, P196, DOI 10.1007/s12072-008-9058-1
   Mathurin P, 2009, GASTROENTEROLOGY, V137, P532, DOI 10.1053/j.gastro.2009.04.052
   Mummadi RR, 2008, CLIN GASTROENTEROL H, V6, P1396, DOI 10.1016/j.cgh.2008.08.012
   Naveau S, 2005, GASTROEN CLIN BIOL, V29, P269, DOI 10.1016/S0399-8320(05)80760-2
   Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052
   Peng XD, 2009, BIOCHEM BIOPH RES CO, V388, P31, DOI 10.1016/j.bbrc.2009.07.099
   Rosenson RS, 2009, CARDIOVASC DRUG THER, V23, P289, DOI 10.1007/s10557-009-6185-4
   Salgado W, 2009, OBES SURG, V19, P867, DOI 10.1007/s11695-009-9851-5
   Satapathy SK, 2004, AM J GASTROENTEROL, V99, P1946, DOI 10.1111/j.1572-0241.2004.40220.x
   Tarantino G, 2008, CLIN INVEST MED, V31, pE24
   Wieckowska A, 2008, AM J GASTROENTEROL, V103, P1372, DOI 10.1111/j.1572-0241.2007.01774.x
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Yamaguchi K, 2007, HEPATOLOGY, V45, P1366, DOI 10.1002/hep.21655
   Yoneda M, 2007, J GASTROENTEROL, V42, P573, DOI 10.1007/s00535-007-2060-x
   Younossi ZM, 2008, OBES SURG, V18, P1430, DOI 10.1007/s11695-008-9506-y
NR 29
TC 17
Z9 18
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0960-8923
EI 1708-0428
J9 OBES SURG
JI Obes. Surg.
PD JUL
PY 2010
VL 20
IS 7
BP 906
EP 912
DI 10.1007/s11695-010-0181-4
PG 7
WC Surgery
SC Surgery
GA 608ZK
UT WOS:000278624300013
PM 20454933
DA 2020-12-08
ER

PT J
AU Balbinot, SS
   Sakai, P
   Ribeiro, U
   Balbinot, RA
   Safatle-Ribeiro, AV
   Navarro-Rodriguez, T
   Alves, VA
   Soares, IC
   Carrilho, FJ
AF Balbinot, Silvana S.
   Sakai, Paulo
   Ribeiro, Ulysses
   Balbinot, Raul A.
   Safatle-Ribeiro, Adriana V.
   Navarro-Rodriguez, Tomas
   Alves, Venancio A.
   Soares, Ibere C.
   Carrilho, Flair J.
TI Comparative Study of Immunoexpression of Junctional Proteins (Claudin 1,
   3 and 4), Cyclooxygenase-2 and Inflammatory Infiltrate in Patients With
   Erosive and Non-Erosive Gastroesophageal Reflux Disease
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
RI Ribeiro, Ulysses/G-5942-2012
OI Ribeiro, Ulysses/0000-0003-1711-7347
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2010
VL 138
IS 5
SU 1
MA T1114
BP S491
EP S491
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VI3RT
UT WOS:000475844802429
DA 2020-12-08
ER

PT J
AU Sa, CC
   Ferreira, CS
   Ono-Nita, SK
   Carrilho, FJ
   Moraes, JP
   Vecchia, VD
   Barbuti, RC
   Eisig, JN
   Navarro-Rodriguez, T
AF Sa, Claudia C.
   Ferreira, Camila S.
   Ono-Nita, Suzane K.
   Carrilho, Flair J.
   Moraes-Filho, Joaquim P.
   Vecchia, Vanise D.
   Barbuti, Ricardo C.
   Eisig, Jaime N.
   Navarro-Rodriguez, Tomas
TI High Rate of Fast Omeprazole Metabolizers in Patients With Persistent
   Gastroesophageal Reflux Disease
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
RI Barbuti, Ricardo/AAK-5495-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2010
VL 138
IS 5
SU 1
MA W1122
BP S656
EP S656
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VI3RT
UT WOS:000475844803248
DA 2020-12-08
ER

PT J
AU Ussui, VM
   Hashimoto, CL
   Rocha, TD
   Mazo, DF
   Moraes-Filho, JP
   Carrilho, FJ
AF Ussui, Vivian M.
   Hashimoto, Claudio L.
   Rocha, Tarciso D.
   Mazo, Daniel F.
   Moraes-Filho, Joaquim P.
   Carrilho, Flair J.
TI Elastic Ligature: Promising Method in the Treatment of Hemorrhagic
   Gastric Angiodysplasia
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Meeting Abstract
CT Digestive Disease Week/111th Annual Meeting of the
   American-Gastroenterological-Association
CY MAY 01-06, 2010
CL New Orleans, LA
SP Amer Gastroenterol Assoc
RI Mazo, Daniel FC/D-5631-2015; Carrilho, Flair J/I-3046-2012
OI Mazo, Daniel FC/0000-0002-2164-2630; 
NR 0
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD APR
PY 2010
VL 71
IS 5
BP AB360
EP AB360
DI 10.1016/j.gie.2010.03.976
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 583WJ
UT WOS:000276710401502
DA 2020-12-08
ER

PT J
AU Vieira, MC
   Borges, LV
   Ussui, VM
   Silva, JGN
   Carrilho, FJ
   Hashimoto, CL
AF Vieira, Manoel C.
   Borges, Luana V.
   Ussui, Vivian M.
   Nogueira Silva, Jose Guilherme
   Carrilho, Flair J.
   Hashimoto, Claudio L.
TI Evaluation of Colon Preparation Methods Prior to a Colonoscopy: A
   Prospective, Randomized, Comparative Study Among a Low Volume
   Polyethylene Glycol Plus Bisacodyl Solution and a Mannitol Plus
   Bisacodyl Solution
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Meeting Abstract
CT Digestive Disease Week/111th Annual Meeting of the
   American-Gastroenterological-Association
CY MAY 01-06, 2010
CL New Orleans, LA
SP Amer Gastroenterol Assoc
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD APR
PY 2010
VL 71
IS 5
BP AB270
EP AB270
DI 10.1016/j.gie.2010.03.623
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 583WJ
UT WOS:000276710401150
DA 2020-12-08
ER

PT J
AU Artifon, ELD
   Lopasso, FP
   Moura, GB
   Fernandes, FAMH
   Sakai, P
   Carrilho, FJ
   Caldini, ETEG
   Silva, ODCE
AF de Almeida Artifon, Everson Luiz
   Lopasso, Fabio Pinatel
   Moura, Gustavo Brazuna
   Mardiros Herbella Fernandes, Fernando Augusto
   Sakai, Paulo
   Carrilho, Flair Jose
   Espin Garcia Caldini, Elia Tamaso
   de Castro e Silva Junior, Orlando
TI Effects of plastic stenting in commom bile duct of rats. A quantitative
   reaction analysis using collagen and elastin morphometry
SO ACTA CIRURGICA BRASILEIRA
LA English
DT Article
DE Prostheses and Implants; Collagen; Elastin; Common Bile Duct; Rats
ID BILIARY-TRACT; ENDOPROSTHESIS; CHOLANGITIS
AB Purpose: To evaluate the effects of biliary stenting in rats through analysis of collagen and elastin deposition in the bile ducts. Methods: Twenty male rats underwent midline laparotomy, duodenotomy and transampullary stenting of the common bile duct with a 22Fr plastic stent. Animals were randomized in 4 groups, with 5 components in each: (I) control, (II) biliary stenting for 7 days, (III) biliary stenting for 14 days, and (IV) biliary stenting for 30 days. Sections of the common bile duct were stained using Hematoxylin Eosin; Sirius Red to quantitate the amount of collagen present; and Weigert's Resorcin-fuchsin to quantitate the amount of elastin present. Results: The percentage of area stained for collagen was 13.4; 21.5; 29.5 and 32.8, for groups I to IV, respectively. The percentage of area stained for elastin fibers was 7.0; 5.2; 4.0 and 2.9, for groups I to IV, respectively. Collagen/Elastin ratio was 2.4; 5.1; 11.0 and 14.4 for groups I to IV, respectively. Conclusions: The biliary stenting leads to collagen and elastin deposition in the bile ducts; and collagen deposition and collagen/elastin ratio are proportional to the period of stenting.
C1 [de Almeida Artifon, Everson Luiz; Lopasso, Fabio Pinatel; Moura, Gustavo Brazuna; Sakai, Paulo; Carrilho, Flair Jose] Univ Sao Paulo, Dept Gastroenterol, Fac Med, BR-09500900 Sao Paulo, Brazil.
   [Mardiros Herbella Fernandes, Fernando Augusto] Sao Paulo Fed Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Espin Garcia Caldini, Elia Tamaso] Univ Sao Paulo, Dept Pathol, Fac Med, BR-09500900 Sao Paulo, Brazil.
   [de Castro e Silva Junior, Orlando] Univ Sao Paulo, Dept Anat & Surg, Fac Med Ribeirao Preto, BR-09500900 Sao Paulo, Brazil.
RP Artifon, ELD (corresponding author), Rua Guimaraes Passos 260-121, BR-04107030 Sao Paulo, Brazil.
EM eartifon@hotmail.com
RI Carrilho, Flair J/I-3046-2012; Castro e Silva, Orlando/D-4646-2013
OI Castro e Silva, Orlando/0000-0003-3912-0096; caldini,
   elia/0000-0001-5322-3812
CR CARRASCO CH, 1985, AM J ROENTGENOL, V145, P1279, DOI 10.2214/ajr.145.6.1279
   COSTAMAGNA G, 1989, Rays (Rome), V14, P115
   COX JL, 1978, SURG GYNECOL OBSTET, V146, P233
   DEITCH EA, 1990, AM J SURG, V159, P79, DOI 10.1016/S0002-9610(05)80610-5
   DIAZ SG, 1996, LYON CHIR, V62, P229
   Dunkin BJ, 2000, SURG LAPARO ENDO PER, V10, P275, DOI 10.1097/00019509-200010000-00003
   GOLDMAN LD, 1983, AM J SURG, V145, P450, DOI 10.1016/0002-9610(83)90038-7
   HABER MH, 1962, J PATHOL BACTERIOL, V84, P413, DOI 10.1002/path.1700840215
   HUANG T, 1969, ARCH SURG-CHICAGO, V98, P629
   HUIBREGTSE K, 1986, GASTROINTEST ENDOSC, V32, P334, DOI 10.1016/S0016-5107(86)71878-6
   JAMES J, 1990, SEMIN LIVER DIS, V10, P91, DOI 10.1055/s-2008-1040461
   KARSTEN TM, 1992, SURGERY, V111, P562
   KARSTEN TM, 1994, J AM COLL SURGEONS, V178, P343
   Laukkarinen J, 2007, GASTROINTEST ENDOSC, V65, P1063, DOI 10.1016/j.gie.2006.11.059
   RAPER SE, 1989, SURGERY, V105, P352
   REIGHLEY MRB, 1976, BRIT J SURG, V63, P258
   SHERMAN S, 1993, GASTROINTEST ENDOSC, V39, P658, DOI 10.1016/S0016-5107(93)70218-7
   Wagholikar Gajanan D, 2003, Indian J Gastroenterol, V22, P166
NR 18
TC 1
Z9 1
U1 1
U2 4
PU ACTA CIRURGICA BRASILEIRA
PI SAO PAULO
PA ALAMEDA RIO CLARO, 179-41, SAO PAULO, SP 01332-010, BRAZIL
SN 0102-8650
J9 ACTA CIR BRAS
JI Acta Cir. Bras.
PD MAR-APR
PY 2010
VL 25
IS 2
BP 153
EP 157
DI 10.1590/S0102-86502010000200006
PG 5
WC Surgery
SC Surgery
GA 572JK
UT WOS:000275827400006
PM 20305881
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Moreira, R
   Figueiredo, GM
   Ximenez, R
   Montarroyos, U
   Braga, C
   Cardoso, MR
   Coral, G
   Carrilho, F
   Stein, A
   Marion, Z
   Spina, A
   Cardoso, A
   Moriya, Y
   Alves, A
   Correa, EBD
   Theme-Filha, M
   Muzzillo, D
   Vidor, AC
   Nogueira, CV
   Pinto, ME
   Barone, AA
   Ferreira, L
   Pereira, L
AF Moreira, R.
   Figueiredo, G. M.
   Ximenez, R.
   Montarroyos, U.
   Braga, C.
   Cardoso, M. R.
   Coral, G.
   Carrilho, F.
   Stein, A.
   Marion, Z.
   Spina, A.
   Cardoso, A.
   Moriya, Y.
   Alves, A.
   Correa, E. B. D.
   Theme-Filha, M.
   Muzzillo, D.
   Vidor, A. C.
   Nogueira, C. V.
   Pinto, M. E.
   Barone, A. A.
   Ferreira, L.
   Pereira, L.
TI Population-based seroprevalence of hepatitis C virus infection in the
   South and Southeast regions of Brazil
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Moreira, R.; Spina, A.] Inst Adolfo Lutz Registro, Sao Paulo, Brazil.
   [Figueiredo, G. M.] Secretaria Estado Saude Sao Paulo, Sao Paulo, Brazil.
   [Ximenez, R.; Montarroyos, U.; Braga, C.; Pereira, L.] Univ Estadual Pernambuco, Recife, PE, Brazil.
   [Cardoso, M. R.; Carrilho, F.; Barone, A. A.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Coral, G.; Stein, A.; Alves, A.] Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Marion, Z.] LACEN Porto Alegre, Porto Alegre, RS, Brazil.
   [Cardoso, A.] LACEN Santa Catarina, Florianopolis, SC, Brazil.
   [Moriya, Y.] LACEN Parana, Curitiba, Parana, Brazil.
   [Correa, E. B. D.] Univ Fed Florianopolis, Florianopolis, SC, Brazil.
   [Theme-Filha, M.] Escola Nacl Saude Publica, Rio De Janeiro, Brazil.
   [Muzzillo, D.] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil.
   [Vidor, A. C.] Secretaria Muncipal Saude Florianopolis, Florianopolis, SC, Brazil.
   [Nogueira, C. V.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Pinto, M. E.] Univ Fed Ciencias Med, Porto Alegre, RS, Brazil.
   [Barone, A. A.] Secretaria Municipal Saude Curitiba, Curitiba, Parana, Brazil.
RI Braga, Maria Cynthia/A-8204-2013; Figueiredo, Gerusa M/B-6660-2014;
   Montarroyos, Ulisses/AAJ-7527-2020; Carrilho, Flair J/I-3046-2012;
   Moreira, Regina C/B-1488-2016; Cardoso, Maria Regina A/J-7280-2012;
   Barone, Antonio A/C-5531-2013
OI Braga, Maria Cynthia/0000-0002-7862-6455; Figueiredo, Gerusa
   M/0000-0001-9657-9675; Moreira, Regina C/0000-0002-8208-8776; Barone,
   Antonio A/0000-0001-9895-3886
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAR
PY 2010
VL 14
SU 1
BP E274
EP E274
DI 10.1016/j.ijid.2010.02.2095
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 578MQ
UT WOS:000276298201184
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU de Carvalho-Mello, IMVG
   Medeiros, JE
   Gomes-Gouvea, MS
   Malta, FD
   de Queiroz, ATL
   Pinho, JRR
   Carrilho, FJ
AF Vicente Guedes de Carvalho-Mello, Isabel Maria
   Medeiros Filho, Jose Eymard
   Gomes-Gouvea, Michele Soares
   Malta, Fernanda de Mello
   Lopo de Queiroz, Artur Trancoso
   Rebello Pinho, Joao Renato
   Carrilho, Flair Jose
TI Molecular evidence of horizontal transmission of hepatitis C virus
   within couples
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID SEXUALLY-TRANSMITTED-DISEASES; INTRAFAMILIAL TRANSMISSION; INTRASPOUSAL
   TRANSMISSION; RISK-FACTOR; INFECTION; CONFIDENCE; DIVERSITY; SPREAD
AB Hepatitis C virus (HCV) transmission has decreased with the adoption of universal blood donor screening and social policies to reduce the risk of infection in intravenous drug users, but remains a worldwide health problem. The objective of this study was to evaluate the phylogenetic relationships among sequences from different HCV genomic regions from sexual partners of infected patients. Nine couples with a stable relationship and without other risk factors for HCV infection and 42 control patients were selected, and the NS3 and NS5B regions were analysed. Phylogenetic analysis showed that viruses from five of the couples had a common origin, clustering in the same monophyletic group, with bootstrap values greater than 70. For the other couples, monophyletic groups were observed, but without bootstrap support. Thus, using two different viral genome regions, a common source of infection was observed in both members of five couples. These data strongly support HCV transmission within couples.
C1 [Vicente Guedes de Carvalho-Mello, Isabel Maria] Inst Butantan, Lab Imunol Viral, BR-05503900 Sao Paulo, Brazil.
   [Vicente Guedes de Carvalho-Mello, Isabel Maria; Medeiros Filho, Jose Eymard; Gomes-Gouvea, Michele Soares; Malta, Fernanda de Mello; Rebello Pinho, Joao Renato; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Lopo de Queiroz, Artur Trancoso] Univ Sao Paulo, Inst Biociencias, BR-05508090 Sao Paulo, Brazil.
RP de Carvalho-Mello, IMVG (corresponding author), Inst Butantan, Lab Imunol Viral, Av Vital Brasil 1500, BR-05503900 Sao Paulo, Brazil.
EM imvgcmello@butantan.gov.br
RI Carrilho, Flair J/I-3046-2012; de carvalho-Mello, Isabel Maria V
   G/D-3641-2012; Pinho, Joao R. R./G-2850-2012; Queiroz,
   Artur/F-6083-2014; Malta, Fernanda/B-1316-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; de Queiroz, Artur Trancoso
   Lopo/0000-0003-4908-9993
FU Alves de Queiroz Family Fund for Research; Instituto Adolfo Lutz;
   Instituto Butantan
FX This work was supported by the Alves de Queiroz Family Fund for
   Research, Instituto Adolfo Lutz and Instituto Butantan.
CR AKAHANE Y, 1994, ANN INTERN MED, V120, P748, DOI 10.7326/0003-4819-120-9-199405010-00005
   Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802
   Alter MJ, 2002, HEPATOLOGY, V36, pS93, DOI 10.1053/jhep.2002.36389
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Caporaso N, 1998, J VIRAL HEPATITIS, V5, P67, DOI 10.1046/j.1365-2893.1998.00085.x
   Cavalheiro ND, 2009, REV SOC BRAS MED TRO, V42, P239, DOI 10.1590/S0037-86822009000300001
   Cavalheiro Norma de Paula, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P86, DOI 10.1590/S0036-46652004000200016
   CHAYAMA K, 1995, J HEPATOL, V22, P431, DOI 10.1016/0168-8278(95)80106-5
   Chevaliez S, 2007, WORLD J GASTROENTERO, V13, P2461, DOI 10.3748/wjg.v13.i17.2461
   Chiaramonte M, 1996, J HEPATOL, V24, P129, DOI 10.1016/S0168-8278(96)80020-1
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Filippini P, 2001, SEX TRANSM DIS, V28, P725, DOI 10.1097/00007435-200112000-00010
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   HONDA M, 1993, HEPATOLOGY, V17, P971, DOI 10.1016/0270-9139(93)90109-Z
   KAO JH, 1992, J INFECT DIS, V166, P900, DOI 10.1093/infdis/166.4.900
   Keiserman DR, 2003, AM J GASTROENTEROL, V98, P878, DOI [10.1016/S0002-9270(03)00004-2, 10.1111/j.1572-0241.2003.07340.x]
   Leitner T, 2000, AIDS REV, V2, P241
   LLIBRE JM, 1992, Q J MED, V82, P149
   Mastromatteo AM, 2001, HEPATO-GASTROENTEROL, V48, P193
   McCormack GP, 2002, REV MED VIROL, V12, P221, DOI 10.1002/rmv.355
   Mohamed MK, 2005, HEPATOLOGY, V42, P683, DOI 10.1002/hep.20811
   NAKASHIMA K, 1992, AM J EPIDEMIOL, V136, P1132, DOI 10.1093/oxfordjournals.aje.a116579
   Ndimbie OK, 1996, GENITOURIN MED, V72, P213
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Ross RS, 1999, FORENSIC SCI INT, V100, P69, DOI 10.1016/S0379-0738(98)00200-X
   Salemi M, 2002, J MOL EVOL, V54, P62, DOI 10.1007/s00239-001-0018-9
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   Simmonds P, 1996, J GEN VIROL, V77, P3013, DOI 10.1099/0022-1317-77-12-3013
   Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815
   Swofford D.L., 2002, PAUP PHYLOGENETIC AN
   Terrault NA, 2002, HEPATOLOGY, V36, pS99, DOI 10.1053/jhep.2002.36797
   THOMAS DL, 1995, J INFECT DIS, V171, P768, DOI 10.1093/infdis/171.4.768
   Zharkikh A, 1995, MOL PHYLOGENET EVOL, V4, P44, DOI 10.1006/mpev.1995.1005
NR 37
TC 11
Z9 11
U1 0
U2 0
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD MAR
PY 2010
VL 91
BP 691
EP 696
DI 10.1099/vir.0.015594-0
PN 3
PG 6
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 569HM
UT WOS:000275587200012
PM 19889924
OA Bronze
DA 2020-12-08
ER

PT J
AU Chang, TT
   Lai, CL
   Yoon, SK
   Lee, SS
   Coelho, HSM
   Carrilho, FJ
   Poordad, F
   Halota, W
   Horsmans, Y
   Tsai, N
   Zhang, H
   Tenney, DJ
   Tamez, R
   Iloeje, U
AF Chang, Ting-Tsung
   Lai, Ching-Lung
   Yoon, Seung Kew
   Lee, Samuel S.
   Coelho, Henrique Sergio M.
   Carrilho, Flair Jose
   Poordad, Fred
   Halota, Waldemar
   Horsmans, Yves
   Tsai, Naoky
   Zhang, Hui
   Tenney, Daniel J.
   Tamez, Ricardo
   Iloeje, Uchenna
TI Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e
   Antigen-Positive Chronic Hepatitis B
SO HEPATOLOGY
LA English
DT Article
ID TENOFOVIR DISOPROXIL FUMARATE; NUCLEOSIDE-NAIVE PATIENTS; ADEFOVIR
   DIPIVOXIL; HEPATOCELLULAR-CARCINOMA; PEGINTERFERON ALPHA-2A; RESISTANCE;
   LAMIVUDINE; RISK; TELBIVUDINE; MANAGEMENT
AB Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from ETV-022 subsequently enrolled in study ETV-901. We present the results after up to 5 years (240 weeks) of continuous entecavir therapy. The entecavir long-term cohort consists of patients who received >= 1 year of entecavir 0.5 mg in ETV-022 and then entered ETV-901 with a treatment gap <= 35 days. In ETV-901 the entecavir dose was 1.0 mg daily. For patients with samples available at Year 5, proportions with hepatitis B virus (HBV) DNA <300 copies/mL, normal alanine aminotransferase (ALT) levels, HBeAg loss, and HBeAg seroconversion were determined. In all, 146 patients met criteria for inclusion in the entecavir long-term cohort. At Year 5, 94% (88/94) had HBV DNA <300 copies/mL and 80% (78/98) had normal ALT levels. In addition to patients who achieved serologic responses during study ETV-022, 23% (33/141) achieved HBeAg seroconversion and 1.4% (2/145) lost hepatitis B surface antigen (HBsAg) during study ETV-901. Through 5 years, entecavir resistance emerged in one patient. The safety profile of entecavir was consistent with previous reports. Conclusion: Extended therapy with entecavir through 5 years maintained or increased rates of HBV DNA suppression and ALT normalization. Additional patients also achieved HBeAg loss and seroconversion. Entecavir provides sustained viral suppression with minimal resistance during long-term treatment of HBeAg-positive CHB. (HEPATOLOGY 2010;51:422-430.)
C1 [Chang, Ting-Tsung] Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan.
   [Lai, Ching-Lung] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Yoon, Seung Kew] Catholic Univ Korea, Kangnam St Mary Hosp, Seoul, South Korea.
   [Lee, Samuel S.] Univ Calgary, Foothills Prov Gen Hosp, Calgary, AB, Canada.
   [Coelho, Henrique Sergio M.] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
   [Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Poordad, Fred] Cedars Sinai Med Ctr, Dept Hepatol & Liver Transplantat, Los Angeles, CA 90048 USA.
   [Halota, Waldemar] Nicholas Copernicus Univ, Dept Infect Dis & Hepatol, Bydgoszcz, Poland.
   [Horsmans, Yves] Clin St Luc, Dept Gastroenterol & Hepatol, Brussels, Belgium.
   [Tsai, Naoky] Univ Hawaii, Honolulu, HI 96822 USA.
   [Zhang, Hui; Tenney, Daniel J.; Iloeje, Uchenna] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA.
   [Tamez, Ricardo] Bristol Myers Squibb Co, Res & Dev, Princeton, NJ USA.
RP Chang, TT (corresponding author), 138 Sheng Li Rd, Tainan 70428, Taiwan.
EM ttchang@mail.ncku.edu.tw
RI Coelho, Henrique Sergio Moraes/AAB-3973-2019; Lai, Ching
   Lung/C-4298-2009; Carrilho, Flair J/I-3046-2012
OI Lai, Ching-Lung/0000-0002-5927-2436
FU Bristol-Myers SquibbBristol-Myers Squibb
FX The study was sponsored by Bristol-Myers Squibb. The sponsor designed
   the study in collaboration with expert hepatologists. The sponsor also
   collected the data, monitored study conduct, performed the statistical
   analyses, and coordinated writing of the article with all authors.
CR Chang TT, 2004, J GASTROEN HEPATOL, V19, P1276, DOI 10.1111/j.1440-1746.2004.03428.x
   Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285
   Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65
   Colonno RJ, 2007, J HEPATOL, V46, pS294, DOI 10.1016/S0168-8278(07)62379-4
   Colonno RJ, 2006, HEPATOLOGY, V44, P1656, DOI 10.1002/hep.21422
   Cooksley WGE, 2003, J VIRAL HEPATITIS, V10, P298, DOI 10.1046/j.1365-2893.2003.00450.x
   Gish RG, 2007, GASTROENTEROLOGY, V133, P1437, DOI 10.1053/j.gastro.2007.08.025
   Heathcote EJ, 2008, HEPATOLOGY, V48, p376A
   Iloeje U, 2007, HEPATOLOGY, V46, p640A
   Iloeje UH, 2006, GASTROENTEROLOGY, V130, P678, DOI 10.1053/j.gastro.2005.11.016
   Keeffe EB, 2008, CLIN GASTROENTEROL H, V6, P1315, DOI 10.1016/j.cgh.2008.08.021
   Lai CL, 2007, NEW ENGL J MED, V357, P2576, DOI 10.1056/NEJMoa066422
   Lai CL, 2006, HEPATOLOGY, V44, p222A
   Lai CL, 2003, LANCET, V362, P2089, DOI 10.1016/S0140-6736(03)15108-2
   Lau GKK, 2005, NEW ENGL J MED, V352, P2682, DOI 10.1056/NEJMoa043470
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Liaw YF, 2008, HEPATOL INT, V2, P263, DOI 10.1007/s12072-008-9080-3
   Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513
   Marcellin P, 2008, NEW ENGL J MED, V359, P2442, DOI 10.1056/NEJMoa0802878
   Marcellin P, 2008, HEPATOLOGY, V48, P750, DOI 10.1002/hep.22414
   Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202
   Snow-Lampart A, 2008, HEPATOLOGY, V48, p745A
   TAKEHARA T, 2008, HEPATOL INT, V2, pS311
   Tenney DJ, 2007, ANTIMICROB AGENTS CH, V51, P902, DOI 10.1128/AAC.00833-06
   Tenney DJ, 2009, HEPATOLOGY, V49, P1503, DOI 10.1002/hep.22841
   Yuen MF, 2005, GUT, V54, P1610, DOI 10.1136/gut.2005.065136
NR 26
TC 401
Z9 423
U1 2
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD FEB
PY 2010
VL 51
IS 2
BP 422
EP 430
DI 10.1002/hep.23327
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 550ME
UT WOS:000274131200011
PM 20049753
DA 2020-12-08
ER

PT J
AU Oliveira, CPMS
   Stefano, JT
   Cavaleiro, AM
   Fortes, MAHZ
   Vieira, SM
   Lima, VMR
   Santos, TE
   Santos, VN
   Salgado, ALFD
   Parise, ER
   Alves, VAF
   Carrilho, FJ
   Correa-Giannella, ML
AF Marques Souza Oliveira, Claudia Pinto
   Stefano, Jose Tadeu
   Cavaleiro, Ana Mercedes
   Henriques Zanella Fortes, Maria Angela
   Vieira, Suzana Maria
   Rodrigues Lima, Vicencia Mara
   Santos, Telma Eugenio
   Santos, Virginia Nascimento
   Farias de Azevedo Salgado, Ana Lucia
   Parise, Edson Roberto
   Ferreira Alves, Venancio Avancini
   Carrilho, Flair Jose
   Correa-Giannella, Maria Lucia
TI Association of polymorphisms of glutamate-cystein ligase and microsomal
   triglyceride transfer protein genes in non-alcoholic fatty liver disease
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE fatty liver; genetic susceptibility; genetic polymorphisms; microsomal
   TG transfer protein; lipid metabolism; glutamate-cystein ligase;
   glutathione; oxidative stress
ID LIPID-PEROXIDATION; DYSFUNCTION; NAFLD
AB Background and Aims: Although the metabolic risk factors for non-alcoholic fatty liver disease (NAFLD) progression have been recognized, the role of genetic susceptibility remains a field to be explored. The aim of this study was to examine the frequency of two polymorphisms in Brazilian patients with biopsy-proven simple steatosis or non-alcoholic steatohepatitis (NASH): -493 G/T in the MTP gene, which codes the protein responsible for transferring triglycerides to nascent apolipoprotein B, and -129 C/T in the GCLC gene, which codes the catalytic subunit of glutamate-cystein ligase in the formation of glutathione.
   Methods: One hundred and thirty-one biopsy-proven NAFLD patients (n = 45, simple steatosis; n = 86, NASH) and 141 unrelated healthy volunteers were evaluated. Genomic DNA was extracted from peripheral blood cells, and the -129 C/T polymorphism of the GCLC gene was determined by restriction fragment length polymorphism (RFLP). The -493 G/T polymorphism of the MTP gene was determined by direct sequencing of the polymerase chain reaction products.
   Results: The presence of at least one T allele in the -129 C/T polymorphism of the GCLC gene was independently associated with NASH (odds ratio 12.14, 95% confidence interval 2.01-73.35; P = 0.007), whereas, the presence of at least one G allele in the -493 G/T polymorphism of the MTP gene differed slightly between biopsy-proven NASH and simple steatosis.
   Conclusion: This difference clearly warrants further investigation in larger samples. These two polymorphisms could represent an additional factor for consideration in evaluating the risk of NAFLD progression. Further studies involving a larger population are necessary to confirm this notion.
C1 [Marques Souza Oliveira, Claudia Pinto; Stefano, Jose Tadeu; Rodrigues Lima, Vicencia Mara; Santos, Telma Eugenio; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Ferreira Alves, Venancio Avancini] Univ Sao Paulo, Sch Med, Dept Pathol, BR-05403000 Sao Paulo, Brazil.
   [Cavaleiro, Ana Mercedes; Henriques Zanella Fortes, Maria Angela; Vieira, Suzana Maria; Correa-Giannella, Maria Lucia] Univ Sao Paulo, Sch Med, Div Endocrinol, Lab Cellular & Mol Endocrinol, BR-05403000 Sao Paulo, Brazil.
   [Santos, Virginia Nascimento; Farias de Azevedo Salgado, Ana Lucia; Parise, Edson Roberto] Univ Fed Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas Carvalho Aguiar 255,Inst Cent 9159, BR-05403000 Sao Paulo, Brazil.
EM cpm@usp.br
RI Stefano, Jose T/H-4792-2013; Fortes, Maria Angela HZ/K-4422-2013;
   Carrilho, Flair J/I-3046-2012; Stefano, Jose Tadeu/AAH-5419-2020;
   Giannella, Maria Lucia/N-3834-2019; Oliveira, Claudia PMS/D-1216-2014
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
CR Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012
   Begriche K, 2006, MITOCHONDRION, V6, P1, DOI 10.1016/j.mito.2005.10.004
   Bernard S, 2000, DIABETOLOGIA, V43, P995, DOI 10.1007/s001250051481
   Bugianesi E, 2007, Clin Liver Dis, V11, P191, DOI 10.1016/j.cld.2007.02.006
   de Alwis NMW, 2007, SEMIN LIVER DIS, V27, P44, DOI 10.1055/s-2006-960170
   Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327
   FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7
   Garcia-Ruiz C, 2006, J GASTROEN HEPATOL, V21, pS3, DOI 10.1111/j.1440-1746.2006.04570.x
   Hensley K, 2000, CARCINOGENESIS, V21, P983, DOI 10.1093/carcin/21.5.983
   Karpe F, 1998, ARTERIOSCL THROM VAS, V18, P756, DOI 10.1161/01.ATV.18.5.756
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Koide S, 2003, J AM COLL CARDIOL, V41, P539, DOI 10.1016/S0735-1097(02)02866-8
   Marchesini G, 2005, CURR OPIN LIPIDOL, V16, P421, DOI 10.1097/01.mol.0000174153.53683.f2
   Marra F, 2008, TRENDS MOL MED, V14, P72, DOI 10.1016/j.molmed.2007.12.003
   Namikawa C, 2004, J HEPATOL, V40, P781, DOI 10.1016/j.jhep.2004.01.028
   Oliveira CPMS, 2005, OBES SURG, V15, P502, DOI 10.1381/0960892053723493
   Oliveira CPMS, 2002, J CELL MOL MED, V6, P399, DOI 10.1111/j.1582-4934.2002.tb00518.x
   PARTIN JS, 1974, GASTROENTEROLOGY, V67, P107
   Perlemuter G, 2002, FASEB J, V16, P185, DOI 10.1096/fj.01-0396com
   Pessayre D, 2002, AM J PHYSIOL-GASTR L, V282, pG193, DOI 10.1152/ajpgi.00426.2001
   Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256
   Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3
   Yesilova Z, 2005, AM J GASTROENTEROL, V100, P850, DOI 10.1111/j.1572-0241.2005.41500.x
NR 23
TC 48
Z9 51
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD FEB
PY 2010
VL 25
IS 2
BP 357
EP 361
DI 10.1111/j.1440-1746.2009.06001.x
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 551CX
UT WOS:000274184500024
PM 19817962
DA 2020-12-08
ER

PT J
AU Mora, MVA
   Romano, CM
   Gomes-Gouvea, MS
   Gutierrez, MF
   Carrilho, FJ
   Pinho, JRR
AF Alvarado Mora, Monica Viviana
   Romano, Camila Malta
   Gomes-Gouvea, Michele Scares
   Gutierrez, Maria Fernanda
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Molecular epidemiology and genetic diversity of hepatitis B virus
   genotype E in an isolated Afro-Colombian community
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID WEST-AFRICA; PHYLOGENETIC RELATEDNESS; COMPLETE GENOME; HBV-GENOTYPES;
   BLOOD-DONORS; S-GENE; VARIABILITY; INFECTION; EVOLUTION; SEQUENCE
AB Hepatitis B virus (HBV) infection is a significant public health concern with 350 million chronic carriers worldwide. Eight HBV genotypes (A-H) have been described so far. Genotype E (HBV/E) is widely distributed in West Africa and has rarely been found in other continents, except for a few cases in individuals with an African background. In this study, we characterized HBV genotypes in Quibdo, Colombia, by partial S/P gene sequencing, and found, for the first time, HBV/E circulating in nine Afro-Colombian patients who had no recent contact with Africa. The presence of HBV/E in this community as a monophyletic group suggests that it was a result of a recent introduction by some Afro-descendent contact or, alternatively, that the virus came with slaves brought to Colombia. By using sequences with sampling dates, we estimated the substitution rate to be about 3.2x10(-4) substitutions per site per year, which resulted in a time to the most recent common ancestor (TMRCA) of 29 years. In parallel, we also estimated the TMRCA for HBV/E by using two previously estimated substitution rates (7.7x10(-4) and 1.5x10(-5) substitutions per site per year). The TMRCA was around 35 years under the higher rate and 1500 years under the slower rate. In sum, this work reports for the first time the presence of an exclusively African HBV genotype circulating in South America. We also discuss the time of the entry of this virus into America based on different substitution rates estimated for HBV.
C1 [Alvarado Mora, Monica Viviana; Gomes-Gouvea, Michele Scares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, BR-05508 Sao Paulo, Brazil.
   [Alvarado Mora, Monica Viviana; Gomes-Gouvea, Michele Scares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   [Romano, Camila Malta] Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Dept Infect & Parasit Dis,Lab Virol, BR-05508 Sao Paulo, Brazil.
   [Gutierrez, Maria Fernanda] Pontificia Javeriana Univ Bogota, Dept Microbiol, Virol Lab, Bogota, Colombia.
RP Mora, MVA (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, BR-05508 Sao Paulo, Brazil.
EM monica.viviana@usp.br
RI Carrilho, Flair J/I-3046-2012; Romano, Camila M/C-8185-2013; Romano,
   Camila/ABC-2883-2020; Alvarado-Mora, Monica/I-3180-2012; Pinho, Joao R.
   R./G-2850-2012; Gutierrez, Maria/AAF-2966-2019
OI Romano, Camila/0000-0003-4550-1987; Pinho, Joao R.
   R./0000-0003-3999-0489; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2007/53457-7,
   2008/50461-60]; Sao Paulo, SP, Brazil; Pontificia Universidad Javeriana,
   Bogota, Colombia
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP; 2007/53457-7 and 2008/50461-60), Sao Paulo, SP,
   Brazil, and by Pontificia Universidad Javeriana, Bogota, Colombia, We
   thank the Laboratorio de Salud Publica, Quibdo, Colombia, for kindly
   providing the samples for this study.
CR Andernach IE, 2009, REV MED VIROL, V19, P231, DOI 10.1002/rmv.618
   Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   Bekondi C, 2007, J CLIN VIROL, V40, P31, DOI 10.1016/j.jcv.2007.05.009
   Bowyer SM, 1997, J GEN VIROL, V78, P1719, DOI 10.1099/0022-1317-78-7-1719
   Candotti D, 2006, J VIRAL HEPATITIS, V13, P715, DOI 10.1111/j.1365-2893.2006.00741.x
   Cardoso GL, 2006, AM J HUM BIOL, V18, P93, DOI 10.1002/ajhb.20467
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159
   Cuellar-Ambrosi F, 2000, HEMOGLOBIN, V24, P221, DOI 10.3109/03630260008997529
   Cunha L, 2007, J MED VIROL, V79, P1832, DOI 10.1002/jmv.21010
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Dumpis U, 2001, J MED VIROL, V65, P664, DOI 10.1002/jmv.2088
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
   Halfon P, 2006, J VIRAL HEPATITIS, V13, P329, DOI 10.1111/j.1365-2893.2005.00692.x
   Hannoun C, 2005, J GEN VIROL, V86, P2163, DOI 10.1099/vir.0.80972-0
   Hubschen JM, 2008, J CLIN VIROL, V43, P376, DOI 10.1016/j.jcv.2008.08.018
   Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889
   Kato H, 2004, J MED VIROL, V73, P516, DOI 10.1002/jmv.20120
   Kramvis A, 2005, J MED VIROL, V77, P47, DOI 10.1002/jmv.20412
   Kramvis A, 2007, HEPATOL RES, V37, pS9, DOI 10.1111/j.1872-034X.2007.00098.x
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Liu HF, 2001, J PEDIATR GASTR NUTR, V32, P274, DOI 10.1097/00005176-200103000-00008
   Maddison D. R., 2003, MACCLADE 4 ANAL PHYL
   Magnius LO, 1995, INTERVIROLOGY, V38, P24, DOI 10.1159/000150411
   Martin DP, 2009, METHODS MOL BIOL, V537, P185, DOI 10.1007/978-1-59745-251-9_9
   Mathet VL, 2006, J CLIN MICROBIOL, V44, P3435, DOI 10.1128/JCM.00866-06
   Motta-Castro A, 2008, ARCH VIROL, V153, P2197, DOI 10.1007/s00705-008-0237-0
   Motta-Castro ARC, 2005, J MED VIROL, V77, P188, DOI 10.1002/jmv.20435
   Mulders MN, 2004, J INFECT DIS, V190, P400, DOI 10.1086/421502
   NORDER H, 1992, J GEN VIROL, V73, P1201, DOI 10.1099/0022-1317-73-5-1201
   Odemuyiwa SO, 2001, J MED VIROL, V65, P463, DOI 10.1002/jmv.2058
   OKAMOTO H, 1987, JPN J EXP MED, V57, P231
   Olinger CM, 2006, J GEN VIROL, V87, P1163, DOI 10.1099/vir.0.81614-0
   Osiowy C, 2006, J VIROL, V80, P10307, DOI 10.1128/JVI.00996-06
   Palumbo Emilio, 2007, Arq. Gastroenterol., V44, P54, DOI 10.1590/S0004-28032007000100012
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Pult I, 2001, J VIROL, V75, P9623, DOI 10.1128/JVI.75.20.9623-9632.2001
   Quintero A, 2002, ARCH VIROL, V147, P1829, DOI 10.1007/s00705-002-0842-2
   Rodas C, 2003, HUM BIOL, V75, P13, DOI 10.1353/hub.2003.0026
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467
   Simmonds P, 2005, J VIROL, V79, P15467, DOI 10.1128/JVI.79.24.15467-15476.2005
   Sitnik R, 2007, BRAZ J MED BIOL RES, V40, P1689, DOI 10.1590/S0100-879X2007001200013
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Suzuki S, 2003, J MED VIROL, V69, P459, DOI 10.1002/jmv.10331
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Toro C, 2006, J MED VIROL, V78, P1599, DOI 10.1002/jmv.20744
   van Steenbergen JE, 2002, J MED VIROL, V66, P159, DOI 10.1002/jmv.2125
   Vray M, 2006, J MED VIROL, V78, P329, DOI 10.1002/jmv.20544
   Zaaijer HL, 2008, J VIRAL HEPATITIS, V15, P239, DOI 10.1111/j.1365-2893.2007.00938.x
   Zhou Y, 2007, J MOL EVOL, V65, P197, DOI 10.1007/s00239-007-0054-1
   Zwickl D. J., 2006, THESIS U TEXAS AUSTI
NR 53
TC 31
Z9 32
U1 0
U2 1
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD FEB
PY 2010
VL 91
BP 501
EP 508
DI 10.1099/vir.0.015958-0
PN 2
PG 8
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 559FA
UT WOS:000274806600021
PM 19846674
OA Bronze
DA 2020-12-08
ER

PT J
AU Malta, FD
   de Medeiros, JEM
   de Azevedo, RS
   Goncalves, L
   da Silva, LC
   Carrilho, FJ
   Pinho, JRR
AF Malta, Fernanda de Mello
   Moraes de Medeiros-Filho, Jose Eymard
   de Azevedo, Raymundo Soares
   Goncalves, Luzia
   da Silva, Luiz Caetano
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian
   patients with chronic hepatitis
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE E2protein; hepatitis C virus; interferon sensitivity determining region;
   NS5A protein; PKR-eIF2a phosphorylation homology domain
ID C VIRUS NS5A; NONSTRUCTURAL 5A PROTEIN; PHOSPHORYLATION HOMOLOGY DOMAIN;
   SENSITIVITY-DETERMINING REGION; AMINO-ACID-SEQUENCE; INTERFERON
   SENSITIVITY; RIBAVIRIN THERAPY; MUTATIONAL ANALYSES; TREATMENT RESPONSE;
   ANTIVIRAL THERAPY
AB Hepatitis C virus (HCV) is a major cause of liver disease throughout the world. The NS5A and E2 proteins of HCV genotype 1 were reported to inhibit the double-stranded (ds) RNA-dependent protein kinase (PKR), which is involved in the cellular antiviral response induced by interferon (IFN). The response to IFN therapy is quite different between genotypes, with response rates among patients infected with types 2 and 3 that are two-three-fold higher than in patients infected with type 1. Interestingly, a significant percentage of HCV genotype 3-infected patients do not respond to treatment at all. The aim of this paper was to analyse the sequences of fragments of the E2 and NS5A regions from 33 outpatients infected with genotype 3a, including patients that have responded (SVR) or not responded (NR) to treatment. HCV RNA was extracted and amplified with specific primers for the NS5A and E2 regions and the PCR products were then sequenced. The sequences obtained covered amino acids (aa) 636-708 in E2 and in NS5A [including the IFN sensitivity determining region (ISDR), PKR-binding domain and extended V3 region)]. In the E2 and NS5A regions, we did observe aa changes among patients, but these changes were not statistically significant between the SVR and NR groups. In conclusion, our results suggest that the ISDR domain is not predictive of treatment success in patients infected with HCV genotype 3a.
C1 [Malta, Fernanda de Mello; Moraes de Medeiros-Filho, Jose Eymard; da Silva, Luiz Caetano; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Fac Med, Inst Trop Med,Dept Gastroenterol, Lab Gastroenterol & Hepatol Trop, BR-05403000 Sao Paulo, Brazil.
   [de Azevedo, Raymundo Soares] Univ Sao Paulo, Fac Med, Dept Patol, BR-05403000 Sao Paulo, Brazil.
   [Goncalves, Luzia] Univ Nova Lisboa, Inst Higiene & Med Trop, Unidade Epidemiol & Bioestatist, P-1200 Lisbon, Portugal.
RP Malta, FD (corresponding author), Univ Sao Paulo, Fac Med, Inst Trop Med,Dept Gastroenterol, Lab Gastroenterol & Hepatol Trop, Av Dr Eneas Carvalho Aguiar, BR-05403000 Sao Paulo, Brazil.
EM femalta@yahoo.com
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; Goncalves,
   Luzia/J-6649-2012; Malta, Fernanda/B-1316-2013; Azevedo, Raymundo
   S/B-7593-2008
OI Pinho, Joao R. R./0000-0003-3999-0489; Goncalves,
   Luzia/0000-0002-9710-1945; Malta, Fernanda/0000-0001-8887-5060; Azevedo,
   Raymundo S/0000-0003-0660-2371
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [00/11457-1]; Alves de Queiroz Family Fund
FX FAPESP (00/11457-1), Alves de Queiroz Family Fund for Research
CR Appel N, 2006, J BIOL CHEM, V281, P9833, DOI 10.1074/jbc.R500026200
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Berg T, 2000, HEPATOLOGY, V32, P1386, DOI 10.1053/jhep.2000.20527
   Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200
   Castelain S, 2002, J INFECT DIS, V185, P573, DOI 10.1086/339051
   Chayama K, 2000, HEPATOLOGY, V32, P1138, DOI 10.1053/jhep.2000.19364
   Cochrane A, 2000, J INFECT DIS, V182, P1515, DOI 10.1086/315886
   de Rueda PM, 2008, J VIROL, V82, P6644, DOI 10.1128/JVI.02231-07
   Duverlie G, 1998, J GEN VIROL, V79, P1373, DOI 10.1099/0022-1317-79-6-1373
   Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203
   ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025
   Francois C, 2000, J VIROL, V74, P5587, DOI 10.1128/JVI.74.12.5587-5596.2000
   Gale M, 2005, NATURE, V436, P939, DOI 10.1038/nature04078
   Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208
   Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157
   Gerotto M, 2000, GASTROENTEROLOGY, V119, P1649, DOI 10.1053/gast.2000.20230
   Goyal A, 2007, MED MICROBIOL IMMUN, V196, P11, DOI 10.1007/s00430-006-0024-z
   Hofmann WP, 2005, J CLIN VIROL, V32, P86, DOI 10.1016/j.jcv.2004.08.004
   Huang LY, 2005, J BIOL CHEM, V280, P36417, DOI 10.1074/jbc.M508175200
   Hung CH, 2003, J VIRAL HEPATITIS, V10, P87, DOI 10.1046/j.1365-2893.2003.00414.x
   Kohashi T, 2006, J VIRAL HEPATITIS, V13, P582, DOI 10.1111/j.1365-2893.2006.00739.x
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Lo SY, 2001, VIRUS RES, V75, P107, DOI 10.1016/S0168-1702(01)00224-6
   Macdonald A, 2004, J GEN VIROL, V85, P2485, DOI 10.1099/vir.0.80204-0
   Murphy MD, 2002, DIGEST DIS SCI, V47, P1195, DOI 10.1023/A:1015349924116
   Nousbaum JB, 2000, J VIROL, V74, P9028, DOI 10.1128/JVI.74.19.9028-9038.2000
   Pascu M, 2004, GUT, V53, P1345, DOI 10.1136/gut.2003.031336
   Penin F, 2004, J BIOL CHEM, V279, P40835, DOI 10.1074/jbc.M404761200
   Podevin P, 2001, HEPATOLOGY, V33, P1503, DOI 10.1053/jhep.2001.24749
   Polyak SJ, 1999, HEPATOLOGY, V29, P1262, DOI 10.1002/hep.510290438
   Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4
   Puig-Basagoiti F, 2005, J GEN VIROL, V86, P1067, DOI 10.1099/vir.0.80526-0
   Saito T, 2003, AM J GASTROENTEROL, V98, P1377, DOI 10.1111/j.1572-0241.2003.07469.x
   Saiz JC, 1998, J INFECT DIS, V177, P839, DOI 10.1086/515243
   Sarrazin C, 2002, J VIROL, V76, P11079, DOI 10.1128/JVI.76.21.11079-11090.2002
   Sarrazin C, 2000, J INFECT DIS, V181, P432, DOI 10.1086/315263
   Sarrazin C, 2000, HEPATOLOGY, V31, P1360, DOI 10.1053/jhep.2000.7987
   Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885
   Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Ukai K, 2006, WORLD J GASTROENTERO, V12, P3722, DOI 10.3748/wjg.v12.i23.3722
   Veillon P, 2007, WORLD J GASTROENTERO, V13, P1195, DOI 10.3748/wjg.v13.i8.1195
NR 42
TC 6
Z9 7
U1 0
U2 4
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2010
VL 105
IS 1
BP 92
EP 98
DI 10.1590/S0074-02762010000100014
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 565WF
UT WOS:000275325500014
PM 20209336
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Moreira, RC
   Deguti, MM
   Lemos, MF
   Saraceni, CP
   Oba, IT
   Spina, AMM
   Nescimento-Lima, AS
   Fares, J
   Azevedo, RS
   Gomes-Gouvea, MS
   Carrilho, FJ
   Pinho, JRR
AF Moreira, Regina Celia
   Deguti, Marta Mitiko
   Lemos, Marcilio Figueiredo
   Saraceni, Claudia Patara
   Oba, Isabel Takano
   Miranda Spina, Angela Maria
   Nescimento-Lima, Alessandra Stilhano
   Fares, Jorge
   Azevedo, Raymundo Soares
   Gomes-Gouvea, Michele Soares
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI HBV markers in haemodialysis Brazilian patients: a prospective 12-month
   follow-up
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE haemodialysis; hepatitis B; screening
ID B-VIRUS INFECTION; HEPATITIS-B
AB The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV) among haemodialysis (HD) subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from Sao Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR) in each of the prospective subjects (n = 123) during one year. Additionally, all samples (n = 1,476) were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc), hepatitis B surface antigen ( HBsAg) and HBV DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8% (17/45) of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units.
C1 [Moreira, Regina Celia; Lemos, Marcilio Figueiredo; Saraceni, Claudia Patara; Oba, Isabel Takano; Miranda Spina, Angela Maria] Adolfo Lutz Inst, Serv Virol, BR-01246902 Sao Paulo, Brazil.
   [Deguti, Marta Mitiko; Nescimento-Lima, Alessandra Stilhano; Gomes-Gouvea, Michele Soares; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Fac Med, Dept Gastroenterol, LIM 07, Sao Paulo, Brazil.
   [Azevedo, Raymundo Soares] Univ Sao Paulo, Fac Med, Dept Patol, LIM 01, Sao Paulo, Brazil.
   [Fares, Jorge] Univ Sao Paulo, Fac Med, Ctr Hemodialise, Sao Paulo, Brazil.
RP Moreira, RC (corresponding author), Adolfo Lutz Inst, Serv Virol, Av Dr Arnaldo 355, BR-01246902 Sao Paulo, Brazil.
EM regina.moreira7@gmail.com
RI Azevedo, Raymundo S/B-7593-2008; Moreira, Regina C/B-1488-2016; Pinho,
   Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Azevedo, Raymundo S/0000-0003-0660-2371; Moreira, Regina
   C/0000-0002-8208-8776; Pinho, Joao R. R./0000-0003-3999-0489; 
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [01/11405-4]
FX FAPESP (01/11405-4)
CR ALBUQUERQUE ACC, 2009, VIRUS REV RES, V14, P1
   Carrilho FJ, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-13
   Elwell Rowland J, 2003, Nephrol Nurs J, V30, P310
   Fabrizi F, 2008, J VIRAL HEPATITIS, V15, P917, DOI 10.1111/j.1365-2893.2008.01039.x
   Fabrizi F, 2008, INT J ARTIF ORGANS, V31, P386
   Fabrizi F, 2008, SEMIN DIALYSIS, V21, P440, DOI 10.1111/j.1525-139X.2008.00437.x
   Ferreira RC, 2006, MEM I OSWALDO CRUZ, V101, P689, DOI 10.1590/S0074-02762006000600019
   Janzen L, 1996, J AM SOC NEPHROL, V7, P1228
   KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989
   Ly D, 2002, AM J GASTROENTEROL, V97, P138, DOI 10.1111/j.1572-0241.2002.05437.x
   *SBN BRAS, 2009, PROP EL REG TECN PRO
   Souza KP, 2003, MEM I OSWALDO CRUZ, V98, P599, DOI 10.1590/S0074-02762003000500003
   Tseng GY, 2008, RENAL FAILURE, V30, P1000, DOI 10.1080/08860220802406377
   [Anonymous], 2001, MMWR Recomm Rep, V50, P1
NR 14
TC 8
Z9 8
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2010
VL 105
IS 1
BP 107
EP 108
DI 10.1590/S0074-02762010000100017
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 565WF
UT WOS:000275325500017
PM 20209339
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Dalcanale, L
   Oliveira, CPMS
   Faintuch, J
   Nogueira, MA
   Rondo, P
   Lima, VMR
   Mendonca, S
   Pajecki, D
   Mancini, M
   Carrilho, FJ
AF Dalcanale, Lorenca
   Oliveira, Claudia P. M. S.
   Faintuch, Joel
   Nogueira, Monize A.
   Rondo, Patricia
   Lima, Vicencia M. R.
   Mendonca, Simone
   Pajecki, Denis
   Mancini, Marcio
   Carrilho, Flair J.
TI Long-Term Nutritional Outcome After Gastric Bypass
SO OBESITY SURGERY
LA English
DT Article
DE Obesity; Weight loss; Weight regain; Gastric bypass; Bariatric surgery;
   Follow-up; Gastrointestinal symptoms; Vitamin supplement; Anemia;
   Malnutrition; Long-term outcome
ID MORBIDLY OBESE-PATIENTS; DEFICIENCIES; MORTALITY; SURGERY; VITAMIN; FORM
AB Weight loss and nutritional status 5 or more years after Roux-en-Y gastric bypass was prospectively documented. The hypothesis was that even after clinical adaptation, imbalances might still occur.
   Seventy-five consecutive patients (age 49.3 +/- 10.6 years, 89.3% females) were recruited 83.4 +/- 14.3 months after the intervention. Weight loss and nutritional abnormalities were registered.
   Body mass index (BMI) was 56.5 +/- 10.0 preoperatively, 29.4 +/- 6. 2 by 24 months and 34.4 +/- 14.6 when last seen. Major current deficit occurred for magnesium (32.1% of the patients), hemoglobin (50.8%), iron (29.8%), ferritin (36.0%), zinc (40.5%), vitamin B-12 (61.8%), vitamin D-3 (60.5%), and beta-carotene (56.8%). Low preoperative measurements had already been unveiled for iron, transferrin, zinc, and vitamin B-12. Total drug consumption tended to decrease after operation, and present findings correlated with excess weight loss (EWL). Also presence of diabetes and BMI value were predictors of long-term EWL, along with biochemical profile by 2 years. Multivitamin supplementation and gastrointestinal complaints partially correlated with nutritional results.
   (1) Good initial weight loss with moderate late regain, anemia, and multiple nutrient deficits was the common pattern. (2) Massive weight loss, frequent vomiting, dumping syndrome, and women in reproductive age were risk factors for hemoglobin or vitamin deficits, whereas superobesity, diabetes, and use of multiple drugs were associated with EWL result. (3) Most laboratory tests became stable by 2 years and along with BMI correlated with late EWL. (4) Two-year nutritional investigation is especially recommended because of its long-term predictive value.
C1 [Dalcanale, Lorenca] Dept Gastroenterol, BR-05405900 Sao Paulo, Brazil.
   [Dalcanale, Lorenca; Oliveira, Claudia P. M. S.; Lima, Vicencia M. R.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Clin Div, Dept Gastroenterol, Sao Paulo, Brazil.
   [Faintuch, Joel; Nogueira, Monize A.; Pajecki, Denis] Univ Sao Paulo, Sch Med, Div Surg, Dept Gastroenterol, Sao Paulo, Brazil.
   [Rondo, Patricia; Mendonca, Simone] Univ Sao Paulo, Sch Med, Sch Publ Hlth, Dept Nutr, Sao Paulo, Brazil.
   [Mancini, Marcio] Univ Sao Paulo, Sch Med, Dept Endocrinol, Sao Paulo, Brazil.
RP Dalcanale, L (corresponding author), Dept Gastroenterol, Ave Eneias C Aguiar 255,ICHC,9th Floor, BR-05405900 Sao Paulo, Brazil.
EM adal19@hotmail.com
RI Pajecki, Denis/E-4931-2014; Oliveira, Claudia PMS/D-1216-2014; de
   carvalho rondo, Patricia Rondo;/E-1936-2015; Carrilho, Flair
   J/I-3046-2012
OI Pajecki, Denis/0000-0002-0898-9285; de carvalho rondo, Patricia
   Rondo;/0000-0002-8308-6393; 
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [05/53831-0]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [300392/2008-7]
FX This investigation was conducted by a multidisciplinary clinical and
   nutritional team with patients originally registered at the Obesity
   Surgery Service. The valuable help of Alessandra Rascovski, Alfredo
   Halpern, and Arthur B. Garrido Jr is appreciated. Financial grants were
   received from FAPESP 05/53831-0 and CNPq 300392/2008-7. The authors
   declare no conflict of interest.
CR Aills L, 2008, SURG OBES RELAT DIS, V4, pS73, DOI 10.1016/j.soard.2008.03.002
   Brolin R E, 1998, J Gastrointest Surg, V2, P436, DOI 10.1016/S1091-255X(98)80034-6
   Brolin RE, 1999, OBES SURG, V9, P150, DOI 10.1381/096089299765553395
   Christou NV, 2004, ANN SURG, V240, P416, DOI 10.1097/01.sla.0000137343.63376.19
   Claudio L, 2002, OBES SURG, V12, P328, DOI 10.1381/096089202321088093
   Faintuch J, 2004, OBES SURG, V14, P175, DOI 10.1381/096089204322857528
   Folope V, 2007, GASTROEN CLIN BIOL, V31, P369, DOI 10.1016/S0399-8320(07)89395-X
   Goldner WS, 2009, OBES SURG, V19, P173, DOI 10.1007/s11695-008-9680-y
   Granado-Lorencio F, 2009, OBES SURG, V19, P879, DOI 10.1007/s11695-008-9476-0
   Higa KD, 2000, ARCH SURG-CHICAGO, V135, P1029, DOI 10.1001/archsurg.135.9.1029
   Ishida RK, 2007, OBES SURG, V17, P752, DOI 10.1007/s11695-007-9139-6
   Johansson HE, 2009, OBES SURG, V19, P1250, DOI 10.1007/s11695-008-9536-5
   Kaidar-Person O, 2008, OBES SURG, V18, P1028, DOI 10.1007/s11695-007-9350-5
   Kaidar-Person O, 2008, OBES SURG, V18, P870, DOI 10.1007/s11695-007-9349-y
   KUSHNER FR, 2006, CURR OPIN ENDOCRINOL, V13, P405
   Pajecki D, 2007, OBES SURG, V17, P601, DOI 10.1007/s11695-007-9104-4
   PORIES WJ, 1995, ANN SURG, V222, P339, DOI 10.1097/00000658-199509000-00011
   Ritz P, 2009, OBES SURG, V19, P840, DOI 10.1007/s11695-008-9627-3
   Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254
   World Health Organization, 1998, WHONUTNCD981
NR 20
TC 101
Z9 106
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0960-8923
EI 1708-0428
J9 OBES SURG
JI Obes. Surg.
PD FEB
PY 2010
VL 20
IS 2
BP 181
EP 187
DI 10.1007/s11695-009-9916-5
PG 7
WC Surgery
SC Surgery
GA 551LV
UT WOS:000274212000008
PM 19705207
DA 2020-12-08
ER

PT J
AU Abrantes-Lemos, CP
   Nakhle, MC
   Damiao, AOMC
   Sipahi, AM
   Carrilho, FJ
   Cancado, ELR
AF Abrantes-Lemos, Clarice Pires
   Nakhle, Maria Cristina
   Mourao Cintra Damiao, Aderson Omar
   Sipahi, Aytan Miranda
   Carrilho, Flair Jose
   Cancado, Eduardo Luiz R.
TI Performance of Two Commercial ELISAs for Detecting IgA Anti-Human and
   Anti-Guinea Pig Tissue Transglutaminase Antibodies
SO CLINICAL LABORATORY
LA English
DT Article
DE celiac disease; tissue transglutaminase; anti-tissue transglutaminase
   antibodies; anti-endomysial antibodies; gluten-free diet
ID DIAGNOSE CELIAC-DISEASE; GLUTEN-FREE DIET; CHILDREN; POPULATIONS;
   PREVALENCE; TESTS; ASSAY
AB Background: Sensitivity and specificity of anti-human tissue transglutaminase antibodies (anti-htTGA) seem to be superior to those of anti-tissue transglutaminase of guinea pig (anti-gptTGA) for screening patients with celiac disease (CD), but there are still controversies. The aim of this study was to evaluate the performance of two INOVA ELISA kits to detect IgA anti-htTGA and anti-gptTGA in patients with and without CD.
   Methods: The study groups were comprised of 49 anti-endomysial antibody (EMA)-positive untreated-CD, and 123 controls (EMA-negative treated CD, EMA-negative chronic diarrhea, autoimmune hepatitis, inflammatory bowel disease and healthy people).
   Results: The agreement between the two ELISAs was statistically significant in all study groups and there was no significant difference between them (92.7% agreement; kappa=0.70; kappa p=0.001; McNemar p=1). All patients with serum reactivity of more than 100 units had histologic diagnosis of CD. In seven of 10 patients with treated-CD who had control biopsies, villous atrophy was still present in four who tested positive by both kits. Two of three celiacs with histologic remission tested positive for both anti-tTGA.
   Conclusions: the anti-gptTGA and anti-htTGA determination were equally efficient in identifying patients with untreated-CD with high titers of EMA. Whatever the anti-tTGA ELISA used, the reactivity above 100 units was always related to active CD diagnosed by histologic alterations in intestinal biopsies. The anti-tTGA reactivity by both kits was not only similar in determining histologic activity in the follow-up of CD after a gluten free diet, but also in identifying positive sera from the control groups, regardless if CD has been confirmed by duodenal biopsies. (Clin. Lab. 2010;56:29-35)
C1 [Abrantes-Lemos, Clarice Pires; Nakhle, Maria Cristina; Cancado, Eduardo Luiz R.] Univ Sao Paulo, Lab Immunopathol Schistosomiasis LIM 06, Lab Trop Gastroenterol & Hepatol, Inst Trop Med,Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Mourao Cintra Damiao, Aderson Omar; Sipahi, Aytan Miranda; Carrilho, Flair Jose; Cancado, Eduardo Luiz R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
RP Cancado, ELR (corresponding author), Univ Sao Paulo, Lab Immunopathol Schistosomiasis LIM 06, Lab Trop Gastroenterol & Hepatol, Inst Trop Med,Sch Med, 2O Andar Av Dr Eneas Carvalho Aguiar 500, BR-05403000 Sao Paulo, Brazil.
EM edulrc@uol.com.br
RI Cancado, Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012; Sipahi,
   Aytan Miranda/O-7768-2019
OI Cancado, Eduardo/0000-0002-9309-1524; Sipahi, Aytan
   Miranda/0000-0002-9686-1627; Maria dos Santos,
   Fabiana/0000-0003-1785-7388
FU Alves-Queiroz Foundation
FX Clarice Pires Abrantes-Lemos was partially supported by a scholarship of
   Alves de Queiroz Family Fund for Research instead of the Alves-Queiroz
   Foundation.
CR Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   Barker CC, 2005, PEDIATRICS, V115, P1341, DOI 10.1542/peds.2004-1392
   Cancado ELR, 2001, J AUTOIMMUN, V17, P223, DOI 10.1006/jaut.2001.0540
   Carroccio A, 2001, GUT, V49, P506, DOI 10.1136/gut.49.4.506
   Di Domenico M R, 2002, Pediatr Med Chir, V24, P208
   Di Tola M, 2004, CLIN CHEM LAB MED, V42, P1092, DOI 10.1515/CCLM.2004.225
   Fabiani E, 2004, DIGEST LIVER DIS, V36, P671, DOI 10.1016/j.dld.2004.05.008
   Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600
   Hansson T, 2000, J PEDIATR GASTR NUTR, V30, P379, DOI 10.1097/00005176-200004000-00006
   Hill ID, 2005, GASTROENTEROLOGY, V128, pS25, DOI 10.1053/j.gastro.2005.02.012
   Hill ID, 2005, J PEDIATR GASTR NUTR, V40, P1, DOI 10.1097/00005176-200501000-00001
   Kaukinen K, 2002, EUR J GASTROEN HEPAT, V14, P311, DOI 10.1097/00042737-200203000-00017
   Korponay-Szabo IR, 1999, J PEDIATR GASTR NUTR, V28, P26, DOI 10.1097/00005176-199901000-00008
   Lagerqvist C, 2001, J INTERN MED, V250, P241, DOI 10.1046/j.1365-2796.2001.00891.x
   Leeds JS, 2007, SCAND J GASTROENTERO, V42, P1214, DOI 10.1080/00365520701365112
   Leon F, 2001, SCAND J GASTROENTERO, V36, P849, DOI 10.1080/003655201750313388
   Lewis NR, 2006, ALIMENT PHARM THER, V24, P47, DOI 10.1111/j.1365-2036.2006.02967.x
   Maki M, 1997, GUT, V41, P565, DOI 10.1136/gut.41.4.565
   Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019
   Rostom A, 2005, GASTROENTEROLOGY, V128, pS38, DOI 10.1053/j.gastro.2005.02.028
   Rubio-Tapia A, 2008, LIVER INT, V28, P467, DOI 10.1111/j.1478-3231.2008.01681.x
   Salmi TT, 2006, GUT, V55, P1746, DOI 10.1136/gut.2005.071514
   Sblattero D, 2000, AM J GASTROENTEROL, V95, P1253
   Vahedi K, 2003, AM J GASTROENTEROL, V98, P1079, DOI 10.1111/j.1572-0241.2003.07284.x
   WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909
   Wong RCW, 2002, J CLIN PATHOL, V55, P488, DOI 10.1136/jcp.55.7.488
   Zintzaras E, 2006, CLIN VACCINE IMMUNOL, V13, P187, DOI 10.1128/CVI.13.2.187-192.2006
NR 27
TC 2
Z9 2
U1 0
U2 3
PU CLIN LAB PUBL
PI HEIDELBERG
PA IM BREITSPIEL 15, HEIDELBERG, D-69126, GERMANY
SN 1433-6510
J9 CLIN LAB
JI Clin. Lab.
PY 2010
VL 56
IS 1-2
BP 29
EP 35
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 572SH
UT WOS:000275852800004
PM 20380357
DA 2020-12-08
ER

PT J
AU Carrilho, FJ
   Kikuchi, L
   Branco, F
   Goncalves, CS
   de Mattos, AA
AF Carrilho, Flair Jose
   Kikuchi, Luciana
   Branco, Fernanda
   Goncalves, Carlos Sandoval
   de Mattos, Angelo Aves
CA Brazilian HCC Study Grp
TI Clinical and epidemiological aspects of hepatocellular carcinoma in
   Brazil
SO CLINICS
LA English
DT Article
DE Hepatocellular carcinoma; Epidemiology; Liver cancer; Brazil; Treatment
ID RISK-FACTORS; INFECTION; CIRRHOSIS; DISEASE
AB OBJECTIVES: We performed a national survey to update hepatocellular carcinoma (HCC) epidemiology in Brazil and determined the clinical and epidemiological profiles of patients with HCC in different Brazilian regions.
   METHODS: Data from 29 centers included 1,405 patients diagnosed with HCC from 2004 to 2009.
   RESULTS: The median age was 59 (1-92 years old; 78% male). At diagnosis, females were older than males (median age: 62 vs. 59 years old respectively; p<0.0001). Ninety-eight percent of the patients had cirrhosis (1279/1308). Hepatitis C virus was the main etiology (54%), followed by hepatitis B virus (16%) and alcohol (14%). In Southeastern and Southern Brazil, hepatitis C virus accounted for over 55% of cases. In the Northeast and North, hepatitis C virus accounted for less than 50%, and hepatitis B virus accounted for 22-25% of cases; hepatitis B was more prevalent in the Northern than in the Southern regions. Some 43%, 35%, and 22% of patients were in early, intermediate, and advanced stages respectively. Initial therapies for HCC included chemoembolization or embolization (36%), percutaneous ablation (13%), liver resection (7%), and sorafenib (1%). Liver transplantation was performed in 242 patients (19%), but it was the initial therapy for only 56 patients (4%).
   CONCLUSION: The epidemiology, classification, and therapy selection for HCC varied among Brazilian regions. Hepatitis C infection was the most common etiology of liver cirrhosis; chemoembolization was the most common therapy employed. Liver cirrhosis was the main risk factor for HCC development in Brazil.
C1 [Carrilho, Flair Jose; Kikuchi, Luciana] Univ Sao Paulo, Dept Gastroenterol, Fac Med, Sao Paulo, Brazil.
   [Branco, Fernanda] Univ Fed Ciencias Saude Porto Alegre, Porto Alegre, RS, Brazil.
   [Goncalves, Carlos Sandoval; Brazilian HCC Study Grp] Univ Fed Espirito Santo, Ctr Biomed, Nucleo Doencas Infecciosas, Vitoria, ES, Brazil.
   [de Mattos, Angelo Aves] Fundacao Fac Fed Ciencias Med Porto Alegre, Porto Alegre, RS, Brazil.
RP Carrilho, FJ (corresponding author), Univ Sao Paulo, Dept Gastroenterol, Fac Med, Sao Paulo, Brazil.
EM fjcarril@usp.br
RI Carrilho, Flair J/I-3046-2012
CR Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
   Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168
   Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020
   El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013
   Fassio Eduardo, 2009, Acta Gastroenterol Latinoam, V39, P47
   Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014
   Goncalves Carlos S., 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P165, DOI 10.1590/S0036-46651997000300008
   Hellerbrand C, 2001, DIGEST DIS, V19, P345, DOI 10.1159/000050702
   Kao JH, 2005, LIVER INT, V25, P696, DOI 10.1111/j.1478-3231.2005.01139.x
   Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001
   Parana R, 2005, J CLIN VIROL, V34, pS130, DOI 10.1016/S1386-6532(05)80022-8
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Sangiovanni A, 2004, GASTROENTEROLOGY, V126, P1005, DOI 10.1053/j.gastro.2003.12.049
   Trevisani F, 2001, J HEPATOL, V34, P570, DOI 10.1016/S0168-8278(00)00053-2
NR 15
TC 47
Z9 57
U1 0
U2 3
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
J9 CLINICS
JI Clinics
PY 2010
VL 65
IS 12
BP 1285
EP 1290
DI 10.1590/S1807-59322010001200010
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 736KK
UT WOS:000288493400010
PM 21340216
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Mattar, R
   Monteiro, MMPMD
   da Silva, JMSPJMK
   Carrilho, FCPFJ
AF Mattar, Rejane
   Maria do Socorro Monteiro, Maria Monteiro Para
   Matie Kinoshita da Silva, Joyce Matie Silva Para Joyce
   Flair Jose Carrilho, Flair Carrilho Para
TI LCT-22018G > A single nucleotide polymorphism is a better predictor of
   adult-type hypolactasia/lactase persistence in Japanese-Brazilians than
   LCT-13910C > T
SO CLINICS
LA English
DT Editorial Material
ID LACTOSE-INTOLERANCE; C/T-13910
C1 [Mattar, Rejane; Maria do Socorro Monteiro, Maria Monteiro Para; Matie Kinoshita da Silva, Joyce Matie Silva Para Joyce; Flair Jose Carrilho, Flair Carrilho Para] Univ Sao Paulo, Fac Med, Hosp Clin, BR-05403000 Sao Paulo, Brazil.
RP Mattar, R (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Av Dr Eneas de Carvalho Aguiar 255,9 Andar Sala 9, BR-05403000 Sao Paulo, Brazil.
EM rmattar@hcnet.usp.br
RI Mattar, Rejane/AAO-4842-2020; Mattar, Rejane/K-3883-2012; Carrilho,
   Flair J/I-3046-2012
OI Mattar, Rejane/0000-0001-7870-8867; 
CR Bernardes-Silva CF, 2007, CLIN CHIM ACTA, V386, P7, DOI 10.1016/j.cca.2007.07.012
   Buning C, 2003, SCAND J GASTROENTERO, V38, P538, DOI 10.1080/00365520310000555
   Enattah NS, 2002, NAT GENET, V30, P233, DOI 10.1038/ng826
   KONDO T, 1994, J GASTROENTEROL, V29, P715, DOI 10.1007/BF02349276
   Mattar R, 2008, CLIN BIOCHEM, V41, P628, DOI 10.1016/j.clinbiochem.2008.01.006
   Mattar R, 2010, REV ASSOC MED BRAS, V56, P230, DOI 10.1590/S0104-42302010000200025
   Mattar R, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-46
   NOSE O, 1979, ARCH DIS CHILD, V54, P436, DOI 10.1136/adc.54.6.436
   Seva-Pereira A, 1982, Arq Gastroenterol, V19, P133
   Xu LD, 2010, SCAND J GASTROENTERO, V45, P168, DOI 10.3109/00365520903414176
NR 10
TC 15
Z9 18
U1 0
U2 1
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
J9 CLINICS
JI Clinics
PY 2010
VL 65
IS 12
BP 1399
EP 1400
DI 10.1590/S1807-59322010001200030
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 736KK
UT WOS:000288493400030
PM 21340236
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Almeida, TMB
   Leitao, RMC
   Carrilho, FJ
   Sonohara, S
AF de Almeida, Terezinha M. B.
   Leitao, Regina Maria C.
   Carrilho, Flair J.
   Sonohara, Shigueko
TI Micronuclei formation in liver fibrosis samples from patients infected
   by hepatitis C virus
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE micronuclei; hepatocytes; chronic hepatitis C; fibrosis progression;
   HCV-patients
ID DAMAGE; CELLS
AB Genetic research on fibrosis outset and its progression in chronic hepatitis (CH) by hepatitis C virus (HCV) are limited. The lack of cytogenetic data led us to investigate the presence of micronuclei (MNi), as a sign of genomic damage. Hepatocytes of hepatic parenchyma from 62 cases diagnosed with CH associated with HCV and displaying different degrees of fibrosis (F1-F4) were analyzed. These data were compared to 15 cases without fibrosis (F0). Twelve healthy liver parenchyma samples were included as control. All samples were obtained from paraffin-embedded archival material. Micronucleated hepatocytes (MN-Heps) were analyzed through Feulgen/Fastgreen staining. Results showed that the rates of MN-Heps in the F4 group were statistically significant (p < 0.05) and higher than those in the control group. Like results were also obtained on comparing F4 with F0, F1, F2 and F3 cases. Conversely, differences were not significant (p > 0.05) on comparing F0, F1, F2, F3, one against the other, as well as individual versus control. Although chromosomal losses in CH were detected, it was shown that liver parenchyma with fibrosis in the initial stages (F1-F3) cannot be considered cytogenetically abnormal.
C1 [de Almeida, Terezinha M. B.; Sonohara, Shigueko] Univ Sao Paulo, Dept Radiol & Oncol, Fac Med, Disciplina Oncol, BR-01246903 Sao Paulo, Brazil.
   [Leitao, Regina Maria C.] Lab Anat Pat Diagnost, Sao Paulo, Brazil.
   [Carrilho, Flair J.] Univ Sao Paulo, Dept Gastroenterol, Fac Med, Disciplina Gastroenterol Clin Hepatol, BR-01246903 Sao Paulo, Brazil.
RP Sonohara, S (corresponding author), Univ Sao Paulo, Dept Radiol, Fac Med, Av Dr Arnaldo 455,4 Andar,Sala 4121, BR-01246903 Sao Paulo, Brazil.
EM shigueko@lim24.fm.usp.br
RI Carrilho, Flair J/I-3046-2012
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Sense Industria e
   Comercio Ltda.; Centro de Estudos em Gastroenterologia - Agostinho
   Betarello; Alves de Queiroz Family Fund for Research
FX This work was supported by grants from the Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP), Sense Industria e Comercio Ltda.,
   Centro de Estudos em Gastroenterologia - Agostinho Betarello, and the
   Alves de Queiroz Family Fund for Research. We are grateful to Helena
   Khouri for English language revision, Joao Italo Dias Fran a for the
   revision of statistical analyses and Maria Cristina Granero Grandal for
   figure editing.
CR Baek KH, 2006, J MOL BIOL, V359, P22, DOI 10.1016/j.jmb.2006.03.020
   BEDOSSA P, 1994, HEPATOLOGY, V20, P15
   But DYK, 2008, WORLD J GASTROENTERO, V14, P1652, DOI 10.3748/wjg.14.1652
   CALLEA F, 1991, DIGEST DIS SCI, V36, P1287, DOI 10.1007/BF01307524
   Canonero R, 1997, MUTAGENESIS, V12, P35, DOI 10.1093/mutage/12.1.35
   Choi J, 2006, AM J PHYSIOL-GASTR L, V290, pG847, DOI 10.1152/ajpgi.00522.2005
   de Almeida TMB, 2004, CANCER GENET CYTOGEN, V150, P16, DOI 10.1016/j.cancergencyto.2003.08.001
   Donato MF, 2001, HEPATOLOGY, V34, P523, DOI 10.1053/jhep.2001.26820
   Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8
   Fimognari C, 1997, MUTAGENESIS, V12, P91, DOI 10.1093/mutage/12.2.91
   Guido M, 2008, ANTICANCER RES, V28, P2507
   HEDDLE JA, 1991, ENVIRON MOL MUTAGEN, V18, P277, DOI 10.1002/em.2850180414
   Hind O, 2002, J GASTROENTEROL, V37, P883, DOI 10.1007/s005350200149
   Kim Eun Ji, 2009, Proceedings of the American Association for Cancer Research Annual Meeting, V50, P752
   Kitamura T, 1998, J GASTROEN HEPATOL, V13, pS96
   KIYOSAWA K, 2002, HEPATOL RES, V24, P40
   Livezey KW, 2002, MUTAT RES-FUND MOL M, V505, P63, DOI 10.1016/S0027-5107(02)00140-9
   *ONL R DEV TEAM, 2009, R LANG ENV STAT COMP
   Saeki A, 2002, CANCER-AM CANCER SOC, V94, P2047, DOI 10.1002/cncr.10448
   Sanyal R, 1997, MUTAGENESIS, V12, P297, DOI 10.1093/mutage/12.4.297
   Seronello S, 2007, FREE RADICAL BIO MED, V43, P869, DOI 10.1016/j.freeradbiomed.2007.05.036
   Thomson BJ, 2005, CLIN MICROBIOL INFEC, V11, P86, DOI 10.1111/j.1469-0691.2004.01061.x
   WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341
NR 23
TC 3
Z9 3
U1 0
U2 2
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 1415-4757
EI 1678-4685
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PY 2010
VL 33
IS 3
BP 418
EP 421
DI 10.1590/S1415-47572010005000061
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 651FX
UT WOS:000281913300003
PM 21637406
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Kikuchi, L
   Nunez, M
   Barreiro, P
   Nelson, M
   Vispo, ME
   Page, E
   Puoti, M
   Fox, R
   Sherman, M
   Carrilho, F
   Brau, N
AF Kikuchi, L.
   Nunez, M.
   Barreiro, P.
   Nelson, M.
   Vispo, M. E.
   Page, E.
   Puoti, M.
   Fox, R.
   Sherman, M.
   Carrilho, F.
   Braeu, N.
TI IMPACT OF SCREENING FOR HEPATOCELLULAR CARCINOMA (HCC) IN
   HIV/HCV-COINFECTED PATIENTS ON STAGING, THERAPY AND SURVIVAL
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 14-18, 2010
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Kikuchi, L.; Carrilho, F.] Univ Sao Paulo, Liver Canc HIV Study Grp, Sao Paulo, Brazil.
   [Nunez, M.] Wake Forest Univ, Winston Salem, NC 27109 USA.
   [Barreiro, P.; Vispo, M. E.] Hosp Carlos III, Madrid, Spain.
   [Nelson, M.; Page, E.] Chelsea & Westminster Hosp, London, England.
   [Puoti, M.] Univ Brescia, Brescia, Italy.
   [Fox, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Sherman, M.] Univ Toronto, Toronto, ON, Canada.
   [Braeu, N.] Bronx Vet Affairs Med Ctr, Bronx, NY USA.
   [Braeu, N.] Mt Sinai Sch Med, Div Infect Dis & Liver Dis, New York, NY USA.
EM lu1912@gmail.com
RI Puoti, Massimo/AAA-6580-2020; Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2010
VL 52
SU 1
BP S412
EP S412
DI 10.1016/S0168-8278(10)61066-5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587UE
UT WOS:000277018002265
DA 2020-12-08
ER

PT J
AU Oliveira, CP
   Lima, VM
   Rabelo, F
   Stefano, JT
   Faintuch, J
   Mazo, DC
   Nogueira, MA
   Cunha-Silva, M
   De Lima, RG
   Carrilho, FJ
AF Oliveira, C. P.
   Lima, V. M.
   Rabelo, F.
   Stefano, J. T.
   Faintuch, J.
   Mazo, D. C.
   Nogueira, M. A.
   Cunha-Silva, M.
   De Lima, R. G.
   Carrilho, F. J.
TI HYPOTHYROIDISM AND GLUCOSE HOMEOSTASIS MARKERS IN NAFLD PATIENTS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 14-18, 2010
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Oliveira, C. P.; Lima, V. M.; Rabelo, F.; Stefano, J. T.; Faintuch, J.; Mazo, D. C.; Nogueira, M. A.; Cunha-Silva, M.; De Lima, R. G.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
EM cpm@usp.br
RI Carrilho, Flair J/I-3046-2012; Mazo, Daniel FC/D-5631-2015; Stefano,
   Jose Tadeu/AAH-5419-2020; Stefano, Jose T/H-4792-2013; Oliveira, Claudia
   PMS/D-1216-2014
OI Mazo, Daniel FC/0000-0002-2164-2630; Stefano, Jose
   Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2010
VL 52
SU 1
BP S151
EP S151
DI 10.1016/S0168-8278(10)60366-2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587UE
UT WOS:000277018000365
DA 2020-12-08
ER

PT J
AU Poynard, T
   Bruix, J
   Schiff, E
   Diago, M
   Berg, T
   Moreno-Otero, R
   Lyra, LG
   Carrilho, FJ
   Boparai, N
   Griffel, L
   Burroughs, M
   Brass, C
   Albrecht, JK
AF Poynard, T.
   Bruix, J.
   Schiff, E.
   Diago, M.
   Berg, T.
   Moreno-Otero, R.
   Lyra, L. G.
   Carrilho, F. J.
   Boparai, N.
   Griffel, L.
   Burroughs, M.
   Brass, C.
   Albrecht, J. K.
TI IMPROVED INFLAMMATORY ACTIVITY WITH LOW-DOSE PEGINTRON (PEG) MAINTENANCE
   THERAPY IN PRIOR NONRESPONDERS WITH METAVIR FIBROSIS SCORES (MFS) OF
   F2/F3: FINAL RESULTS FROM THE EPIC3 PROGRAM
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 14-18, 2010
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Poynard, T.] UPMC, AP HP, Ctr Liver, Serv Hepatogastroenterol, Paris, France.
   [Bruix, J.] Univ Barcelona, Hosp Clin, Liver Unit, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain.
   [Schiff, E.] Univ Miami, Sch Med, Miami, FL USA.
   [Diago, M.] Hosp Gen Univ Valencia, Valencia, Spain.
   [Berg, T.] Univ Med Berlin, Campus Virchow Klinikum, Charite, Berlin, Germany.
   [Moreno-Otero, R.] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Moreno-Otero, R.] Hosp Univ Princesa, Madrid, Spain.
   [Lyra, L. G.] Hosp Sao Rafael, Salvador, BA, Brazil.
   [Carrilho, F. J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Boparai, N.; Griffel, L.; Burroughs, M.; Brass, C.; Albrecht, J. K.] Schering Plough Corp, Whitehouse Stn, NJ USA.
EM tpoynard@teaser.fr
RI Poynard, Thierry/C-1355-2010; DIAGO, MOISES/AAH-5364-2019; Carrilho,
   Flair J/I-3046-2012
OI Poynard, Thierry/0000-0002-3726-7230; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2010
VL 52
SU 1
BP S469
EP S470
DI 10.1016/S0168-8278(10)61205-6
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587UE
UT WOS:000277018002404
DA 2020-12-08
ER

PT J
AU Siqueira, ER
   Oliveira, CM
   Stefano, TJ
   Cavaleiro, AM
   Fortes, M
   Muniz, MT
   Silva, KA
   Silva, FS
   Correa-Gianella, ML
   Pereira, LM
   Carrilho, FJ
AF Siqueira, E. R.
   Oliveira, C. M.
   Stefano, T. J.
   Cavaleiro, A. M.
   Fortes, M.
   Muniz, M. T.
   Silva, K. A.
   Silva, F. S.
   Correa-Gianella, M. L.
   Pereira, L. M.
   Carrilho, F. J.
TI MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP)-493 G/T POLYMORPHISM IS
   ASSOCIATED WITH FIBROSIS IN CHRONIC HEPATITIS C (CHC) GENOTYPE 1
   INFECTED PATIENTS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 14-18, 2010
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Siqueira, E. R.] Univ Sao Paulo, Recife, PE, Brazil.
   [Oliveira, C. M.; Stefano, T. J.; Cavaleiro, A. M.; Fortes, M.; Correa-Gianella, M. L.; Carrilho, F. J.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Muniz, M. T.; Silva, K. A.; Silva, F. S.] Univ Pernambuco, Recife, PE, Brazil.
   [Pereira, L. M.] Liver Inst Pernambuco, Recife, PE, Brazil.
EM erfs@usp.br
RI Fortes, Maria Angela HZ/K-4422-2013; Siqueira, E.R./B-5490-2013;
   Carrilho, Flair J/I-3046-2012
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2010
VL 52
SU 1
BP S418
EP S418
DI 10.1016/S0168-8278(10)61082-3
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587UE
UT WOS:000277018002281
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Cogliati, B
   Oliveira, FS
   Lima, VM
   de Souza, GF
   Uribe, C
   de Oliveira, MG
   Matte, U
   Dagli, MLZ
   Alvares-da-Silva, MR
   Silveira, TR
   Carrilho, FJ
   Oliveira, CP
AF Stefano, J. T.
   Cogliati, B.
   Oliveira, F. S.
   Lima, V. M.
   de Souza, G. F.
   Uribe, C.
   de Oliveira, M. G.
   Matte, U.
   Dagli, M. L. Z.
   Alvares-da-Silva, M. R.
   Silveira, T. R.
   Carrilho, F. J.
   Oliveira, C. P.
TI S-NITROSO-N-ACETYLCYSTEINE (SNAC), A NITRIC OXIDE DONOR, MODULATED
   HEPATIC STELLATE CELLS (HSCS) ACTIVITY: A NEW ANTIFIBROGENIC AGENT
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 14-18, 2010
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Alvares-da-Silva, M. R.] Univ Fed Rio Grande do Sul, Dept Internal Med, Porto Alegre, RS, Brazil.
   [de Souza, G. F.; de Oliveira, M. G.] State Univ Campinas UNICAMP, Inst Chem, Campinas, SP, Brazil.
   [Oliveira, F. S.; Uribe, C.; Matte, U.; Silveira, T. R.] Univ Fed Rio Grande do Sul, Dept Internal Med & Pediat, Porto Alegre, RS, Brazil.
   [Cogliati, B.; Dagli, M. L. Z.] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Pathol, Sao Paulo, Brazil.
   [Stefano, J. T.; Lima, V. M.; Carrilho, F. J.; Oliveira, C. P.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
EM jstefano@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Dagli, Maria/C-5809-2012; Stefano,
   Jose Tadeu/AAH-5419-2020; Stefano, Jose T/H-4792-2013; Carrilho, Flair
   J/I-3046-2012; Silveira, Themis/H-4286-2016; de Oliveira, Marcelo
   Ganzarolli/B-4709-2013; Da Silveira Matte umatte, Ursula/U-3912-2019;
   Matte, Ursula/J-4589-2012; de Oliveira, Fernanda/W-2819-2019
OI Dagli, Maria/0000-0001-7031-6711; Stefano, Jose
   Tadeu/0000-0002-0218-1920; de Oliveira, Marcelo
   Ganzarolli/0000-0002-9371-9975; Da Silveira Matte umatte,
   Ursula/0000-0003-4977-6662; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2010
VL 52
SU 1
BP S381
EP S382
DI 10.1016/S0168-8278(10)60989-0
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587UE
UT WOS:000277018002188
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Pereira, IVA
   Fatobene, G
   Giannella-Neto, D
   Carrilho, FJ
   Correa-Giannella, ML
AF Stefano, J. T.
   Pereira, I. V. A.
   Fatobene, G.
   Giannella-Neto, D.
   Carrilho, F. J.
   Correa-Giannella, M. L.
TI ANALYSIS OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS IN
   HCV-INDUCED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 14-18, 2010
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Stefano, J. T.; Pereira, I. V. A.; Fatobene, G.; Giannella-Neto, D.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Correa-Giannella, M. L.] Univ Sao Paulo, Sch Med, Endocrinol LIM 25, Sao Paulo, Brazil.
EM jstefano@usp.br
RI Carrilho, Flair J/I-3046-2012; Stefano, Jose T/H-4792-2013; Stefano,
   Jose Tadeu/AAH-5419-2020; Giannella, Maria Lucia/N-3834-2019;
   Giannella-Neto, Daniel/B-1475-2008
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2010
VL 52
SU 1
BP S261
EP S261
DI 10.1016/S0168-8278(10)60672-1
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587UE
UT WOS:000277018001296
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Kassab, F
   da Rocha, ECV
   Bomfim, VD
   Vezozzo, DCP
   Bittencourt, PL
   Carrilho, FJ
AF Farias, Alberto Queiroz
   Kassab, Fabio
   Vieira da Rocha, Evandra Cristina
   Bomfim, Valdinelia dos Santos
   Paranagua Vezozzo, Denise Cerqueira
   Bittencourt, Paulo Lisboa
   Carrilho, Flair Jose
TI Propranolol reduces variceal pressure and wall tension in
   schistosomiasis presinusoidal portal hypertension
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE portal hypertension; propranolol; schistosomiasis
ID PRIMARY PROPHYLAXIS; ESOPHAGEAL-VARICES; ULTRASOUND; CIRRHOSIS; THERAPY;
   HEMODYNAMICS; HEMORRHAGE; GAUGE; LIVER; RISK
AB Background and Aim:
   Although prophylaxis with beta-blockers has been shown to decrease variceal pressure and wall tension in cirrhotic patients, this has not been demonstrated in non-cirrhotic portal hypertension caused by Schistosoma mansoni infection.
   Methods:
   Thirteen patients without history of previous gastrointestinal bleeding were included. All of them had high-risk esophageal varices at endoscopy. An endoscopic gauge and a high-frequency endoscopic ultrasonography miniprobe were used to assess transmural variceal pressure and wall tension before and after achieving beta-blockade with propranolol.
   Results:
   Baseline variceal pressure decreased from 13.3 +/- 3.5 to 8.2 +/- 2.0 mmHg (P < 0.0001) and wall tension from 500.2 +/- 279.8 to 274.0 +/- 108.3 mg.mm-1. The overall effect of propranolol on decreasing variceal pressure and wall tension expressed in percentage change in relation to baseline values was 35.7 +/- 18.4% and 35.9 +/- 26.7%, respectively (P = 0.9993).
   Conclusion:
   Propranolol significantly reduced variceal pressure and wall tension in schistosomiasis.
C1 [Farias, Alberto Queiroz; Kassab, Fabio; Vieira da Rocha, Evandra Cristina; Bomfim, Valdinelia dos Santos; Paranagua Vezozzo, Denise Cerqueira; Bittencourt, Paulo Lisboa; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
RP Farias, AQ (corresponding author), Serv Gastroenterol Clin, Av Dr Eneas de Carvalho Aguiar 255, BR-9159 Sala, Brazil.
EM albertofarias@terra.com.br
RI Carrilho, Flair J/I-3046-2012; Farias, Alberto Q/H-7873-2013;
   BITTENCOURT, PAULO l/I-5817-2014; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014; Farias, Alberto/ABB-1291-2020
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; Paranagua-Vezozzo, Denise
   Cerqueira/0000-0002-9606-4935; Farias, Alberto/0000-0002-5572-663X
FU Alves de Queiroz Family Fund for Research
FX The authors are grateful to Dr Jose Eymard Medeiros-Filho for his
   technical assistance with the Varipress system and comments. Statement
   of interests: The study was funded in part by a grant from the Alves de
   Queiroz Family Fund for Research.
CR BOSCH J, 1986, HEPATOLOGY, V6, P667, DOI 10.1002/hep.1840060421
   Brett BT, 2001, EUR J GASTROEN HEPAT, V13, P349, DOI 10.1097/00042737-200104000-00008
   El Atti EA, 1999, GUT, V45, P618, DOI 10.1136/gut.45.4.618
   ELTOURABI H, 1994, ANN TROP MED PARASIT, V88, P493
   Escorsell A, 1997, GASTROENTEROLOGY, V113, P1640, DOI 10.1053/gast.1997.v113.pm9352867
   FEU F, 1995, LANCET, V346, P1056, DOI 10.1016/S0140-6736(95)91740-3
   Fevery J, 2000, J GASTROEN HEPATOL, V15, P842, DOI 10.1046/j.1440-1746.2000.02211.x
   GARCIATSAO G, 1985, HEPATOLOGY, V5, P419, DOI 10.1002/hep.1840050313
   Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3
   HOMEIDA MMA, 1987, BRIT J CLIN PHARMACO, V24, P393, DOI 10.1111/j.1365-2125.1987.tb03187.x
   IDEZUKI Y, 1995, WORLD J SURG, V19, P420, DOI 10.1007/BF00299178
   JENKINS JM, 1992, ACTA TROP, V51, P45
   Khuroo MS, 2005, ALIMENT PHARM THER, V21, P347, DOI 10.1111/j.1365-2036.2005.02346.x
   Mies S, 1997, DIGEST DIS SCI, V42, P751, DOI 10.1023/A:1018803911915
   MORIYASU F, 1986, AJR, V146, P753
   Nevens F, 1996, J HEPATOL, V24, P66, DOI 10.1016/S0168-8278(96)80188-7
   Richter J, 2001, MEM I OSWALDO CRUZ, V96, P151, DOI 10.1590/S0074-02762001000900023
   RIGAU J, 1989, GASTROENTEROLOGY, V96, P873
   SARIN SK, 1987, GUT, V28, P260, DOI 10.1136/gut.28.3.260
   Talwalkar JA, 2004, AM J MED, V116, P759, DOI 10.1016/j.amjmed.2004.03.006
   Tripathi D, 2001, ALIMENT PHARM THER, V15, P291, DOI 10.1046/j.1365-2036.2001.00920.x
   Vezozzo DCP, 2006, DIGEST DIS SCI, V51, P1413, DOI 10.1007/s10620-005-9020-1
   WHO Expert Committee, 2002, WHO TECH REP SER, V912, P1
NR 23
TC 16
Z9 19
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD DEC
PY 2009
VL 24
IS 12
BP 1852
EP 1856
DI 10.1111/j.1440-1746.2009.05912.x
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 525BS
UT WOS:000272188700011
PM 19686417
OA Bronze
DA 2020-12-08
ER

PT J
AU Gomes-Gouvea, MS
   Soares, MCP
   Bensabath, G
   de Carvalho-Mello, IMVG
   Brito, EMF
   Souza, OSC
   Queiroz, ATL
   Carrilho, FJ
   Pinho, JRR
AF Gomes-Gouvea, M. S.
   Soares, M. C. P.
   Bensabath, G.
   de Carvalho-Mello, I. M. V. G.
   Brito, E. M. F.
   Souza, O. S. C.
   Queiroz, A. T. L.
   Carrilho, F. J.
   Pinho, J. R. R.
TI Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of
   fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon
   region
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID NORTHERN SOUTH-AMERICA; YUCPA INDIANS; SURFACE-ANTIGEN; SANTA-MARTA;
   INFECTION; BASIN; VENEZUELA; HDV; PREVALENCE
AB The genotypes of hepatitis B (HBV) and delta (HDV) viruses circulating among fulminant hepatitis cases from the western Amazon Basin of Brazil were characterized in this study. HBV and HDV isolates were obtained from liver samples from 14 patients who developed fulminant hepatitis and died during 1978-1989. HBV DNA and HDV RNA were detected in all samples. Phylogenetic analyses of HDV sequences showed that they all clustered with previously characterized sequences of HDV genotype 3 (HDV-3). HBV genotypes F, A and D were found in 50.0, 28.6 and 21.4% of cases, respectively. These results confirm the predominance of HDV-3 in South America and its association with the severe form of hepatitis, and the finding of the co-infection of HDV-3 with different genotypes of HBV suggests that the association between HDV-3 and HBV-F is not necessarily causally related to a more severe clinical course of infection.
C1 [Gomes-Gouvea, M. S.; de Carvalho-Mello, I. M. V. G.; Carrilho, F. J.; Pinho, J. R. R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Lab Trop Hepatol & Gastroenterol,Trop Med Inst, BR-05403000 Sao Paulo, Brazil.
   [Gomes-Gouvea, M. S.; Soares, M. C. P.; Bensabath, G.; Brito, E. M. F.; Souza, O. S. C.] Inst Evandro Chagas, Secao Hepatol, BR-66090000 Belem, Para, Brazil.
   [de Carvalho-Mello, I. M. V. G.] Inst Butantan, Lab Imunol Viral, BR-05503900 Sao Paulo, Brazil.
   [Queiroz, A. T. L.] Univ Sao Paulo, Inst Biociencias, BR-05508900 Sao Paulo, Brazil.
RP Gomes-Gouvea, MS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Lab Trop Hepatol & Gastroenterol,Trop Med Inst, Av Dr Eneas Carvalho de Aguiar 500, BR-05403000 Sao Paulo, Brazil.
EM gomesmic@yahoo.com.br
RI Pinho, Joao R. R./G-2850-2012; Queiroz, Artur/F-6083-2014; Carrilho,
   Flair J/I-3046-2012; FHV, Inct/K-2346-2013; de carvalho-Mello, Isabel
   Maria V G/D-3641-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; de Queiroz, Artur Trancoso
   Lopo/0000-0003-4908-9993
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [00/11457-1]; Instituto Evandro Chagas/SVS/MS-INCT/CNPqNational Council
   for Scientific and Technological Development (CNPq); Alves de Queiroz
   Family
FX This work was supported by FAPESP (no. 00/11457-1), Instituto Evandro
   Chagas/SVS/MS-INCT/CNPq, and Alves de Queiroz Family Fund for Research.
CR BENSABATH G, 1983, REV I MED TROP, V25, P182
   BENSABATH G, 1987, JAMA-J AM MED ASSOC, V258, P479, DOI 10.1001/jama.1987.03400040077025
   Braga W S, 2001, Rev Soc Bras Med Trop, V34, P349, DOI 10.1590/S0037-86822001000400007
   BUITRAGO B, 1986, HEPATOLOGY, V6, P1285, DOI 10.1002/hep.1840060610
   Casey JL, 1996, J INFECT DIS, V174, P920, DOI 10.1093/infdis/174.5.920
   CASEY JL, 1993, P NATL ACAD SCI USA, V90, P9016, DOI 10.1073/pnas.90.19.9016
   Casey JL, 1996, CLIN LAB MED, V16, P451, DOI 10.1016/S0272-2712(18)30279-8
   Da Silva LC, 2001, J GASTROENTEROL, V36, P476, DOI 10.1007/s005350170071
   FONSECA JCF, 1988, T ROY SOC TROP MED H, V82, P469, DOI 10.1016/0035-9203(88)90166-6
   Gomes-Gouvea MS, 2008, ACTA TROP, V106, P149, DOI 10.1016/j.actatropica.2008.02.009
   HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339
   Hsu SC, 2002, HEPATOLOGY, V35, P665, DOI 10.1053/jhep.2002.31777
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lesbordes J L, 1987, Prog Clin Biol Res, V234, P451
   LJUNGGREN KE, 1985, HEPATOLOGY, V5, P299, DOI 10.1002/hep.1840050225
   Manock SR, 2000, AM J TROP MED HYG, V63, P209, DOI 10.4269/ajtmh.2000.63.209
   Nakano T, 2001, J GEN VIROL, V82, P2183, DOI 10.1099/0022-1317-82-9-2183
   Nakano T, 2001, J GEN VIROL, V82, P359, DOI 10.1099/0022-1317-82-2-359
   Parana R, 2006, AM J TROP MED HYG, V75, P475, DOI 10.4269/ajtmh.2006.75.475
   POPPER H, 1983, HEPATOLOGY, V3, P906
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Quintero A, 2001, J MED VIROL, V64, P356, DOI 10.1002/jmv.1058
   RIZZETTO M, 1991, J HEPATOL, V13, pS116, DOI 10.1016/0168-8278(91)90040-I
   Shih HH, 2008, J VIROL, V82, P2250, DOI 10.1128/JVI.02155-07
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   SJOGREN MH, 1991, PROG CLIN BIOL RES, V364, P97
   SMEDILE A, 1982, LANCET, V2, P945, DOI 10.1016/S0140-6736(82)90156-8
   Swofford D.L., 2002, PAUP PHYLOGENETIC AN
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   TORRES JR, 1991, REV INFECT DIS, V13, P52
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   Victoria FD, 2008, BRAZ J INFECT DIS, V12, P27, DOI 10.1590/S1413-86702008000100008
NR 32
TC 54
Z9 55
U1 0
U2 5
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD NOV
PY 2009
VL 90
BP 2638
EP 2643
DI 10.1099/vir.0.013615-0
PN 11
PG 6
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 515BF
UT WOS:000271440500008
PM 19605587
OA Bronze
DA 2020-12-08
ER

PT J
AU Mattar, R
   Monteiro, MS
   Villares, CA
   Santos, AF
   Silva, JMK
   Carrilho, FJ
AF Mattar, Rejane
   Monteiro, Maria S.
   Villares, Cibele A.
   Santos, Anibal F.
   Silva, Joyce M. K.
   Carrilho, Flair J.
TI Frequency of LCT-13910C > T single nucleotide polymorphism associated
   with adult-type hypolactasia/lactase persistence among Brazilians of
   different ethnic groups
SO NUTRITION JOURNAL
LA English
DT Article
ID LACTASE GENE; DIGESTION; UPSTREAM; DNA
AB Background: Adult-type hypolactasia, the physiological decline of lactase some time after weaning, was previously associated with the LCT -13910C>T polymorphism worldwide except in Africa. Lactase non-persistence is the most common phenotype in humans, except in northwestern Europe with its long history of pastoralism and milking. We had previously shown association of LCT -13910C>T polymorphism with adult-type hypolactasia in Brazilians; thus, we assessed its frequency among different Brazilian ethnic groups.
   Methods: We investigated the ethnicity-related frequency of this polymorphism in 567 Brazilians [mean age, 42.1 +/- 16.8 years; 157 (27.7%) men]; 399 (70.4%) White, 50 (8.8%) Black, 65 (11.5%) Brown, and 53 (9.3%) Japanese-Brazilian. DNA was extracted from leukocytes; LCT -13910C>T polymorphism was analyzed by PCR-restriction fragment length polymorphism.
   Results: Prevalence of the CC genotype associated with hypolactasia was similar (57%) among White and Brown groups; however, prevalence was higher among Blacks (80%) and those of Japanese descent (100%). Only 2 (4%) Blacks had TT genotype, and 8 (16%) had the CT genotype. Assuming an association between CC genotype and hypolactasia, and CT and TT genotypes with lactase persistence, 356 (62.8%) individuals had hypolactasia and 211 (37.2%) had lactase persistence. The White and Brown groups had the same hypolactasia prevalence (similar to 57%); nevertheless, was 80% among Black individuals and 100% among Japanese-Brazilians (P < 0.01).
   Conclusion: The lactase persistence allele, LCT -13910T, was found in about 43% of both White and Brown and 20% of the Black Brazilians, but was absent among all Japanese Brazilians studied.
C1 [Mattar, Rejane; Monteiro, Maria S.; Villares, Cibele A.; Santos, Anibal F.; Silva, Joyce M. K.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Mattar, R (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM rejane-mattar@ig.com.br; mmont@hcnet.usp.br; cibele.villares@ig.com.br;
   anibal2007@ig.com.br; jomatie@gmail.com; fjcarril@usp.br
RI Mattar, Rejane/AAO-4842-2020; Mattar, Rejane/K-3883-2012; Carrilho,
   Flair J/I-3046-2012
OI Mattar, Rejane/0000-0001-7870-8867; 
FU CAPES (Coordenacao de aperfeicoamento de pessoal de nivel
   superior)CAPES; Fundacao Faculdade de Medicina; Alves Queiroz Family
   Fund for Research; CAPESCAPES
FX The molecular genetic studies were partially supported by CAPES
   (Coordenacao de aperfeicoamento de pessoal de nivel superior) and
   Fundacao Faculdade de Medicina. Publication charges and English revision
   will be supported by Alves Queiroz Family Fund for Research and CAPES.
CR Enattah NS, 2002, NAT GENET, V30, P233, DOI 10.1038/ng826
   Goncalves VF, 2008, HUM HERED, V65, P23, DOI 10.1159/000106059
   Ingram CJE, 2009, HUM GENET, V124, P579, DOI 10.1007/s00439-008-0593-6
   Mattar R, 2008, CLIN BIOCHEM, V41, P628, DOI 10.1016/j.clinbiochem.2008.01.006
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mulcare CA, 2004, AM J HUM GENET, V74, P1102, DOI 10.1086/421050
   Olds LC, 2003, HUM MOL GENET, V12, P2333, DOI 10.1093/hmg/ddg244
   Robayo-Torres CC, 2006, CLIN GASTROENTEROL H, V4, P276, DOI 10.1016/j.cgh.2005.12.023
   Seva-Pereira A, 1982, Arq Gastroenterol, V19, P133
   Tishkoff SA, 2007, NAT GENET, V39, P31, DOI 10.1038/ng1946
   Wang YX, 1998, GASTROENTEROLOGY, V114, P1230, DOI 10.1016/S0016-5085(98)70429-9
NR 11
TC 27
Z9 30
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2891
J9 NUTR J
JI Nutr. J.
PD OCT 2
PY 2009
VL 8
AR 46
DI 10.1186/1475-2891-8-46
PG 3
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 508YM
UT WOS:000270975200001
PM 19799794
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Chagas, AL
   Kikuchi, LOO
   Oliveira, CPMS
   Vezozzo, DCP
   Mello, ES
   Oliveira, AC
   Cella, LC
   Herman, P
   Bachella, T
   Caldwell, SH
   Alves, VAF
   Carrilho, FJ
AF Chagas, A. L.
   Kikuchi, L. O. O.
   Oliveira, C. P. M. S.
   Vezozzo, D. C. P.
   Mello, E. S.
   Oliveira, A. C.
   Cella, L. C.
   Herman, P.
   Bachella, T.
   Caldwell, S. H.
   Alves, V. A. F.
   Carrilho, F. J.
TI Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in
   cirrhotic and non-cirrhotic patients?
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Hepatocellular carcinoma; Liver cancer; Fatty liver; Steatohepatitis;
   Cirrhosis
ID FATTY LIVER-DISEASE; CRYPTOGENIC CIRRHOSIS; ADULTS; RISK
AB Non-alcoholic steatohepatitis (NASH) has been associated with hepatocellular carcinoma (HCC) often arising in histologically advanced disease when steatohepatitis is not active (cryptogenic cirrhosis). Our objective was to characterize patients with HCC and active, histologically defined steatohepatitis. Among 394 patients with HCC detected by ultrasound imaging over 8 years and staged by the Barcelona Clinic Liver Cancer (BCLC) criteria, we identified 7 cases (1.7%) with HCC occurring in the setting of active biopsy-proven NASH. All were negative for other liver diseases such as hepatitis C, hepatitis B, autoimmune hepatitis, Wilson disease, and hemochromatosis. The patients (4 males and 3 females, age 63 +/- 13 years) were either overweight (4) or obese (3); 57% were diabetic and 28.5% had dyslipidemia. Cirrhosis was present in 6 of 7 patients, but 1 patient had well-differentiated HCC in the setting of NASH without cirrhosis (fibrosis stage 1) based on repeated liver biopsies, the absence of portal hypertension by clinical and radiographic evaluations and by direct surgical inspection. Among the cirrhotic patients, 71.4% were clinically staged as Child A and 14.2% as Child B. Tumor size ranged from 1.0 to 5.2 cm and 5 of 7 patients were classified as early stage; 46% of all nodules were hyper-echoic and 57% were <3 cm. HCC was well differentiated in 1/6 and moderately differentiated in 5/6. Alpha-fetoprotein was <100 ng/mL in all patients. HCC in patients with active steatohepatitis is often multifocal, may precede clinically advanced disease and occurs without diagnostic levels of alpha-fetoprotein. Importantly, HCC may occur in NASH in the absence of cirrhosis. More aggressive screening of NASH patients may be warranted.
C1 [Chagas, A. L.; Kikuchi, L. O. O.; Oliveira, C. P. M. S.; Vezozzo, D. C. P.; Oliveira, A. C.; Cella, L. C.; Herman, P.; Bachella, T.; Carrilho, F. J.] Univ Sao Paulo, Fac Med, Dept Gastroenterol LIM 07 37, BR-01246903 Sao Paulo, Brazil.
   [Mello, E. S.; Alves, V. A. F.] Univ Sao Paulo, Fac Med, Dept Patol LIM 14, BR-01246903 Sao Paulo, Brazil.
   [Caldwell, S. H.] Univ Virginia, Dept Gastroenterol & Hepatol, Charlottesville, VA USA.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol, Av Dr Arnaldo 455,3 Andar,Sala 3117, BR-01246903 Sao Paulo, Brazil.
EM cpml@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012;
   Herman, Paulo/J-5457-2013; Chagas, Aline Lopes/X-2059-2019;
   Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014
OI Herman, Paulo/0000-0003-2859-5846; Paranagua-Vezozzo, Denise
   Cerqueira/0000-0002-9606-4935
FU NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK067629, P30DK067629, P30DK067629,
   P30DK067629, P30DK067629, P30DK067629, P30DK067629, P30DK067629,
   P30DK067629, P30DK067629, P30DK067629, P30DK067629, P30DK067629,
   P30DK067629, P30DK067629, P30DK067629, P30DK067629, P30DK067629,
   P30DK067629, P30DK067629, P30DK067629, P30DK067629, P30DK067629] Funding
   Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30
   DK067629] Funding Source: Medline
CR Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012
   Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1
   Brunt EM, 2004, SEMIN LIVER DIS, V24, P3
   Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168
   Bugianesi Elisabetta, 2007, Curr Diab Rep, V7, P175, DOI 10.1007/s11892-007-0029-z
   Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Clark JM, 2006, J CLIN GASTROENTEROL, V40, pS5
   Cuadrado A, 2005, OBES SURG, V15, P442, DOI 10.1381/0960892053576596
   Dam-Larsen S, 2004, GUT, V53, P750, DOI 10.1136/gut.2003.019984
   Hai S, 2006, SURG TODAY, V36, P390, DOI 10.1007/s00595-005-3167-4
   Iannaccone R, 2007, RADIOLOGY, V243, P422, DOI 10.1148/radiol.2432051244
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Marrero JA, 2002, HEPATOLOGY, V36, P1349, DOI 10.1053/jhep.2002.36939
   Ong J, 2001, LIVER TRANSPLANT, V7, P797, DOI 10.1053/jlts.2001.24644
   Shimada M, 2002, J HEPATOL, V37, P154, DOI 10.1016/S0168-8278(02)00099-5
NR 16
TC 44
Z9 49
U1 0
U2 7
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD OCT
PY 2009
VL 42
IS 10
BP 958
EP 962
DI 10.1590/S0100-879X2009005000019
PG 5
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 499OO
UT WOS:000270233400014
PM 19787150
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Poynard, T
   Munteanu, M
   Colombo, M
   Bruix, J
   Schiff, ER
   Terg, R
   Flamm, SL
   Moreno-Otero, R
   Carrilho, FJ
   Schmidt, WN
   Berg, T
   McGarrity, TJ
   Heathcote, EJ
   Goncales, FL
   Diago, M
   Craxi, A
   Silva, MO
   Bedossa, P
   Boparai, N
   Griffel, LH
   Burroughs, M
   Brass, CA
   Albrecht, JK
AF Poynard, Thierry
   Munteanu, Mona
   Colombo, Massimo
   Bruix, Jordi
   Schiff, Eugene R.
   Terg, Ruben
   Flamm, Steven L.
   Moreno-Otero, Ricardo
   Carrilho, Flair J.
   Schmidt, Warren N.
   Berg, Thomas
   McGarrity, Thomas J.
   Heathcote, E. Jenny
   Goncales, Fernando L.
   Diago, Moises
   Craxi, Antonio
   Silva, Marcelo O.
   Bedossa, Pierre
   Boparai, Navdeep
   Griffel, Louis H.
   Burroughs, Margaret
   Brass, Clifford A.
   Albrecht, Janice K.
TI IMPACT OF PEGINTRON MAINTENANCE THERAPY ON BIOMARKERS (FIBROTEST
   [FT]-ACTITEST [AT]) IN CIRRHOTIC (METAVIR F4) HCV PRIOR NON-RESPONDERS:
   RESULTS FROM THE EPIC3 CIRRHOSIS MAINTENANCE TRIAL
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 30-NOV 03, 2009
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Poynard, Thierry; Munteanu, Mona] UPMC, APHP, Ctr Liver, Paris, France.
   [Colombo, Massimo] Univ Milan, Fdn IRCCS Maggiore Hosp, Div Gastroenterol 1, Milan, Italy.
   [Bruix, Jordi] Univ Barcelona, Liver Unit,Hosp Clin, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain.
   [Schiff, Eugene R.] Univ Miami, Sch Med, Miami, FL USA.
   [Terg, Ruben] Hosp Municipal Gastroenterol Dr Bonorino Udaondo, Buenos Aires, Argentina.
   [Flamm, Steven L.] Northwestern Univ, Chicago, IL 60611 USA.
   [Moreno-Otero, Ricardo] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Moreno-Otero, Ricardo] Hosp Univ Princesa, Madrid, Spain.
   [Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Schmidt, Warren N.] Univ Iowa, Hosp & Clin, Iowa City, IA USA.
   [Berg, Thomas] Univ Med, Charite Campus Virchow Klinikum, Berlin, Germany.
   [McGarrity, Thomas J.] Milton S Hershey Med Ctr, Hershey, PA USA.
   [Heathcote, E. Jenny] Univ Hlth Network, Toronto, ON, Canada.
   [Goncales, Fernando L.] Univ Estadual Campinas, Dept Clin Med, Fac Med Sci, Campinas, SP, Brazil.
   [Diago, Moises] Univ Valencia, Gen Hosp, Valencia, Spain.
   [Craxi, Antonio] Univ Palermo, GI, Palermo, Italy.
   [Craxi, Antonio] Univ Palermo, Liver Unit, DIBIMIS, Palermo, Italy.
   [Silva, Marcelo O.] Hosp Univ Austral, Pilar, Argentina.
   [Bedossa, Pierre] Hop Beaujon, Clichy, France.
   [Boparai, Navdeep; Griffel, Louis H.; Burroughs, Margaret; Brass, Clifford A.; Albrecht, Janice K.] Schering Plough Res Inst, Kenilworth, NJ USA.
RI Poynard, Thierry/C-1355-2010; DIAGO, MOISES/AAH-5364-2019; Carrilho,
   Flair J/I-3046-2012
OI Poynard, Thierry/0000-0002-3726-7230; 
NR 0
TC 1
Z9 1
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2009
VL 50
IS 4
MA 865
BP 711A
EP 711A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 502JV
UT WOS:000270456000864
DA 2020-12-08
ER

PT J
AU Baldassare, RM
   Paranagua-Vezozzo, DC
   Carrilho, FJ
   Ono-Nita, SK
AF Baldassare, R. M.
   Paranagua-Vezozzo, D. C.
   Carrilho, F. J.
   Ono-Nita, S. K.
TI FOCUS OF SERBIAN OF CLINICAL HEPATOLOGY, HOSPITAL DAS CLINICAS - FMUSP:
   CHALLENGES AND OPPORTUNITIES
SO VALUE IN HEALTH
LA Portuguese
DT Meeting Abstract
C1 [Baldassare, R. M.; Paranagua-Vezozzo, D. C.; Carrilho, F. J.; Ono-Nita, S. K.] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil.
RI Ono, Suzane/I-3107-2012; Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD OCT
PY 2009
VL 12
IS 7
BP A528
EP A528
DI 10.1016/S1098-3015(10)75508-X
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 495GH
UT WOS:000269878101432
OA Bronze
DA 2020-12-08
ER

PT J
AU Nabeshima, MA
   Ferreira, R
   Cipriano, SL
   Carrilho, FJ
   Ono-Nita, SK
AF Nabeshima, M. A.
   Ferreira, R.
   Cipriano, S. L.
   Carrilho, F. J.
   Ono-Nita, S. K.
TI CHRONIC HEPATITIS C VIRUS (HCV) TREATMENT COSTS IN THE TERTIARY
   REFERENCE HOSPITAL DAS CLiNICAS-UNIVERSITY OF SaO PAULO SCHOOL OF
   MEDICINE (HC-FMUSP)
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Nabeshima, M. A.; Ferreira, R.; Cipriano, S. L.; Carrilho, F. J.; Ono-Nita, S. K.] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil.
RI Ono, Suzane/I-3107-2012; Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD OCT
PY 2009
VL 12
IS 7
BP A508
EP A508
DI 10.1016/S1098-3015(10)75406-1
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 495GH
UT WOS:000269878101330
OA Bronze
DA 2020-12-08
ER

PT J
AU Da Rocha, ECV
   D'Amico, EA
   Caldwell, SH
   Da Rocha, TRF
   Silva, CSSSE
   Bomfim, VD
   Felga, G
   Barbosa, WF
   Kassab, F
   Polli, DA
   Carrilho, FJ
   Farias, AQ
AF Vieira Da Rocha, Evandra Cristina
   D'Amico, Elbio Antonio
   Caldwell, Stephen Hugh
   Flores Da Rocha, Tania Rubia
   Solon Soares E Silva, Cristina Simoes
   Bomfim, Valdinelia Dos Santos
   Felga, Guilherme
   Barbosa, Walnei Fernandes
   Kassab, Fabio
   Polli, Demerson Andre
   Carrilho, Flair Jose
   Farias, Alberto Queiroz
TI A Prospective Study of Conventional and Expanded Coagulation Indices in
   Predicting Ulcer Bleeding After Variceal Band Ligation
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
ID INTERNATIONAL NORMALIZED RATIO; VON-WILLEBRAND-FACTOR; LIVER-DISEASE;
   HEPATOCELLULAR-CARCINOMA; PORTAL-HYPERTENSION; THROMBIN GENERATION;
   PRIMARY PROPHYLAXIS; CIRRHOSIS; HEMOSTASIS; ABNORMALITIES
AB BACKGROUND & AIMS: There is controversy over whether coagulation status predicts bleeding caused by ulceration after esophageal varices band ligation (EVL). METHODS: EVL was performed for primary (n = 45) or secondary (n = 105) prophylaxis in 150 patients with cirrhosis (Child A, n = 74, 49%; Child B, n = 42, 28%; Child C, n = 34, 23%). International normalized ratio (INR) and platelet counts were assessed in all. In 92 patients, levels of factor V, fibrinogen, D-dimer, protein C and protein S, von Willebrand factor, and thromboelastography (TEG) were assessed. Platelet count < 50 x 10(3)/mm(3) and INR > 1.5 were considered high-risk cutoff for bleeding. Conversely, platelet count >= 50 x 10(3)/mm(3) with INR <= 1.5 were safe cutoffs. RESULTS: Overall, 11 patients (7.3%) had post-EVL ulcer bleeding. Bleeding occurred in S patients with Child A/B (4.3%) and 6 patients with Child C (17%) (P = .0174 for Child A/B versus Child C). Eight patients with bleeding were among the 110 below the cutoff for INR and platelet count, whereas only 3 of the patients with bleeding were among the 40 patients with purported high-risk values (P = 1.0). Among the 92 patients with expanded coagulation tests, bleeding occurred in S. There was no difference in any of the coagulation parameters, including overall TEG patterns, between patients who did and did nor bleed. CONCLUSIONS: Post-EVL ulcer bleeding was associated with Child C status but not with conventional or expanded coagulation indices in cirrhotic patients without renal failure or infection undergoing elective EVL. These results call into question the common use of prophylactic procoagulants in the elective setting.
C1 [Farias, Alberto Queiroz] Univ Sao Paulo, Hosp Clin, Fac Med, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Caldwell, Stephen Hugh] Univ Virginia, Charlottesville, VA USA.
RP Farias, AQ (corresponding author), Univ Sao Paulo, Hosp Clin, Fac Med, Sch Med, Av Dr Eneas Carvalho Agular 255,Sala 9159, BR-05403000 Sao Paulo, Brazil.
EM albertofarias@terra.com.br
RI Carrilho, Flair J/I-3046-2012; Farias, Alberto Q/H-7873-2013; Farias,
   Alberto/ABB-1291-2020; Polli, Demerson/D-1212-2013
OI Farias, Alberto/0000-0002-5572-663X; Polli, Demerson/0000-0002-5904-2315
FU NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK067629, P30DK067629, P30DK067629,
   P30DK067629, P30DK067629, P30DK067629, P30DK067629, P30DK067629,
   P30DK067629, P30DK067629, P30DK067629, P30DK067629, P30DK067629,
   P30DK067629, P30DK067629, P30DK067629, P30DK067629, P30DK067629,
   P30DK067629, P30DK067629, P30DK067629, P30DK067629, P30DK067629] Funding
   Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30
   DK067629] Funding Source: Medline
CR Adams M, 2007, SEMIN THROMB HEMOST, V33, P226, DOI 10.1055/s-2007-971808
   Bellest L, 2007, HEPATOLOGY, V46, P528, DOI 10.1002/hep.21680
   Bosch J, 2004, GASTROENTEROLOGY, V127, P1123, DOI 10.1053/j.gastro.2004.07.015
   Caldwell SH, 2006, HEPATOLOGY, V44, P1039, DOI 10.1002/hep.21303
   Corran P, 1999, WHO TECH REP SER, V889, P1
   D'Amico G, 2003, HEPATOLOGY, V38, P599, DOI 10.1053/jhep.2003.50385
   DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1016/0270-9139(95)90388-7
   de Franchis R, 2005, J HEPATOL, V43, P167, DOI 10.1016/j.jhep.2005.05.009
   DEFRANCHIS R, 1988, NEW ENGL J MED, V319, P983
   Favaloro EJ, 2007, HAEMATOLOGICA, V92, P292, DOI 10.3324/haematol.11231
   Ferro D, 1996, HEPATOLOGY, V23, P1377, DOI 10.1002/hep.510230613
   Garcia-Tsao G, 2008, HEPATOLOGY, V48, P2064, DOI 10.1002/hep.22605
   Hu KQ, 2001, AM J GASTROENTEROL, V96, P1581
   Imperiale TF, 2001, HEPATOLOGY, V33, P802, DOI 10.1053/jhep.2001.23054
   Lisman T, 2006, HEPATOLOGY, V44, P53, DOI 10.1002/hep.21231
   Lisman T, 2002, J HEPATOL, V37, P280, DOI 10.1016/S0168-8278(02)00199-X
   Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122
   Mannucci PM, 2001, BLOOD, V98, P2730, DOI 10.1182/blood.V98.9.2730
   Marti-Carvajal AJ, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004887.pub2
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Montalto P, 2002, J HEPATOL, V37, P463, DOI 10.1016/S0168-8278(02)00208-8
   Norberto L, 2007, LIVER TRANSPLANT, V13, P1272, DOI 10.1002/lt.21083
   Salooja N, 2001, BLOOD COAGUL FIBRIN, V12, P327, DOI 10.1097/00001721-200107000-00001
   Spadaro A, 2008, WORLD J GASTROENTERO, V14, P1549, DOI 10.3748/wjg.14.1549
   Tripodi A, 2007, ALIMENT PHARM THERAP, V26, P141, DOI 10.1111/j.1365-2036.2007.03369.x
   Tripodi A, 2005, HEPATOLOGY, V41, P553, DOI 10.1002/hep.20569
   Tripodi A, 2007, HEPATOLOGY, V46, P520, DOI 10.1002/hep.21732
   Tripodi A, 2007, J HEPATOL, V46, P727, DOI 10.1016/j.jhep.2007.01.015
   Tripodi A, 2006, HEPATOLOGY, V44, P440, DOI 10.1002/hep.21266
   Wadhawan M, 2006, DIGEST DIS SCI, V51, P2264, DOI 10.1007/s10620-006-9310-2
   Yang MT, 2007, HEPATO-GASTROENTEROL, V54, P1705
NR 31
TC 46
Z9 47
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD SEP
PY 2009
VL 7
IS 9
BP 988
EP 993
DI 10.1016/j.cgh.2009.04.019
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 502GJ
UT WOS:000270443700016
PM 19410018
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   da Nova, ML
   Ono-Nita, SK
   Pinho, JRR
   Sitnik, R
   dos Santos, VA
   Carrilho, FJ
AF Da Silva, Luiz Caetano
   da Nova, Maria Luiza
   Ono-Nita, Suzane Kioko
   Rebello Pinho, Joao Renato
   Sitnik, Roberta
   dos Santos, Vera Aparecida
   Carrilho, Flair Jose
TI SIMULTANEOUS QUANTITATION OF SERUM HBV DNA AND HBeAg CAN DISTINGUISH
   BETWEEN SLOW AND FAST VIRAL RESPONSES TO ANTIVIRAL THERAPY IN PATIENTS
   WITH CHRONIC HEPATITIS B
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Hepatitis B; Serological markers; Treatment response; Treatment
   follow-up
ID POLYMERASE-CHAIN-REACTION; VIRUS-DNA; LAMIVUDINE THERAPY; E-ANTIGEN;
   MANAGEMENT; INFECTION; WORKSHOP; EFFICACY; DECLINE; PRECORE
AB Background: The quantitation of serum HBeAg is not commonly used to monitor viral response to therapy in chronic hepatitis B. Methods: In this study, 21 patients receiving varying therapies were followed and their viral response monitored by concomitant viral load and HBeAg quantitation in order to study the meaning and the kinetics of both parameters. Results: It was possible to distinguish between three different patterns of viral response. The first was characterized by a simultaneous decrease in serum HBV DNA and HBeAg. The second pattern was characterized by a decrease in serum HBeAg but persistent detection of HBV DNA. The third pattern was characterized by undetectable HBV DNA with persistent HBeAg positivity, which points to a non-response (Pattern III-B) except when HBeAg levels showed a slow but steady drop, characterizing a "slow responder" patient (Pattern III-A). Conclusions: The first pattern is compatible with a viral response. A long-term HBeAg seropositivity with a slow and persistent decrease (Pattern III-A) is also compatible with a viral response and calls for a prolongation of anti-viral treatment.
C1 [Da Silva, Luiz Caetano; da Nova, Maria Luiza; Ono-Nita, Suzane Kioko; Rebello Pinho, Joao Renato; Sitnik, Roberta; dos Santos, Vera Aparecida; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, BR-05508 Sao Paulo, Brazil.
RP Da Silva, LC (corresponding author), IMT2,Av Dr Eneas de Carvalho Aguiar 500, BR-05403000 Sao Paulo, Brazil.
EM lucadasi@bol.com.br; marialuizanova@gmail.com; skon@usp.br;
   jrrpinho@usp.br; rositnik@hotmail.com; vera@usp.br; fjcarril@usp.br
RI Pinho, Joao R. R./G-2850-2012; Sitnik, Roberta/N-4740-2017; Carrilho,
   Flair J/I-3046-2012; Ono, Suzane/I-3107-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Sitnik,
   Roberta/0000-0002-6243-8118; 
CR Alberti A, 2003, HEPATOLOGY, V38, P18, DOI 10.1053/jhep.2003.50280
   Buti M, 2007, ALIMENT PHARM THER, V26, P705, DOI 10.1111/j.1365-2036.2007.03419.x
   Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285
   Conjeevaram HS, 2003, J HEPATOL, V38, pS90, DOI 10.1016/S0168-8278(02)00431-2
   Corden S, 2003, J CLIN VIROL, V27, P52, DOI 10.1016/S1386-6532(02)00127-0
   Da Silva LC, 2002, HEPATOLOGY, V36, p638A
   Da Silva LC, 2001, J GASTROENTEROL, V36, P476, DOI 10.1007/s005350170071
   da Silva Luiz Caetano, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P189
   DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501
   Fried MW, 2008, HEPATOLOGY, V47, P428, DOI 10.1002/hep.22065
   Fung SK, 2004, CLIN GASTROENTEROL H, V2, P839, DOI 10.1016/S1542-3565(04)00386-6
   Heijtink RA, 1997, J MED VIROL, V53, P282, DOI 10.1002/(SICI)1096-9071(199711)53:3<282::AID-JMV18>3.3.CO;2-S
   Heijtink RA, 2000, J VIRAL HEPATITIS, V7, P382
   Ho SKN, 2003, J MED MICROBIOL, V52, P397, DOI 10.1099/jmm.0.05071-0
   Honkoop P, 1998, J VIRAL HEPATITIS, V5, P307, DOI 10.1046/j.1365-2893.1998.00121.x
   Jardi R, 2001, J VIRAL HEPATITIS, V8, P465, DOI 10.1046/j.1365-2893.2001.00322.x
   KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989
   KANEKO S, 1990, GASTROENTEROLOGY, V99, P799
   Keeffe EB, 2004, CLIN GASTROENTEROL H, V2, P87, DOI 10.1016/S1542-3565(03)00312-4
   Keeffe EB, 2007, CLIN GASTROENTEROL H, V5, P890, DOI 10.1016/j.cgh.2007.05.004
   Kimura T, 2005, J BIOL CHEM, V280, P21713, DOI 10.1074/jbc.M501564200
   Lewin SR, 2001, HEPATOLOGY, V34, P1012, DOI 10.1053/jhep.2001.28509
   Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513
   Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839
   Lok ASF, 2004, HEPATOLOGY, V39, P857, DOI 10.1002/hep.20110
   Neumann AU, 2005, HEPATOLOGY, V42, P249, DOI 10.1002/hep.20831
   Park NH, 2005, J VIRAL HEPATITIS, V12, P216, DOI 10.1111/j.1365-2893.2005.00602.x
   PERRILLO R, 1993, HEPATOLOGY, V18, P1306, DOI 10.1016/0270-9139(93)90216-A
   Rokuhara A, 2003, J VIRAL HEPATITIS, V10, P324, DOI 10.1046/j.1365-2893.2003.00437.x
   Shaw T, 2002, GASTROENTEROLOGY, V123, P2135, DOI 10.1053/gast.2002.37288
   Shin JW, 2006, WORLD J GASTROENTERO, V12, P6693, DOI 10.3748/wjg.v12.i41.6693
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   ter Borg MJ, 2006, HEPATOLOGY, V44, P721, DOI 10.1002/hep.21302
   Wong DKH, 2007, J CLIN MICROBIOL, V45, P3942, DOI 10.1128/JCM.00366-07
   Yotsuyanagi H, 1998, HEPATOLOGY, V27, P1377, DOI 10.1002/hep.510270526
NR 35
TC 10
Z9 10
U1 0
U2 1
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD SEP-OCT
PY 2009
VL 51
IS 5
BP 261
EP 268
DI 10.1590/S0036-46652009000500005
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 528PN
UT WOS:000272458800006
PM 19893978
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Nogueira, JA
   Ono-Nita, SK
   Nita, ME
   de Souza, MMT
   do Carmo, EP
   Mello, ES
   Scapulatempo, C
   Paranagua-Vezozzo, DC
   Carrilho, FJ
   Alves, VAF
AF Nogueira, Jeronimo A.
   Ono-Nita, Suzane K.
   Nita, Marcelo E.
   de Souza, Marcelo M. T.
   do Carmo, Eliane P.
   Mello, Evandro S.
   Scapulatempo, Cristovan
   Paranagua-Vezozzo, Denise C.
   Carrilho, Flair J.
   Alves, Venancio A. F.
TI 249 TP53 mutation has high prevalence and is correlated with larger and
   poorly differentiated HCC in Brazilian patients
SO BMC CANCER
LA English
DT Article
ID HEPATITIS-B-VIRUS; HEPATOCELLULAR-CARCINOMA; P53 GENE; AFLATOXIN
   EXPOSURE; EPIDEMIOLOGY; PROTEIN; PATHOGENESIS; ACTIVATION; EXPRESSION;
   SPECTRUM
AB Background: Ser-249 TP53 mutation (249(Ser)) is a molecular evidence for aflatoxin-related carcinogenesis in Hepatocellular Carcinoma (HCC) and it is frequent in some African and Asian regions, but it is unusual in Western countries. HBV has been claimed to add a synergic effect on genesis of this particular mutation with aflatoxin. The aim of this study was to investigate the frequency of 249Ser mutation in HCC from patients in Brazil.
   Methods: We studied 74 HCC formalin fixed paraffin blocks samples of patients whom underwent surgical resection in Brazil. 249Ser mutation was analyzed by RFLP and DNA sequencing. HBV DNA presence was determined by Real-Time PCR.
   Results: 249Ser mutation was found in 21/74 (28%) samples while HBV DNA was detected in 13/74 (16%). 249Ser mutation was detected in 21/74 samples by RFLP assay, of which 14 were confirmed by 249Ser mutant-specific PCR, and 12 by nucleic acid sequencing. All HCC cases with p53-249ser mutation displayed also wild-type p53 sequences. Poorly differentiated HCC was more likely to have 249Ser mutation (OR = 2.415, 95% CI = 1.001 - 5.824, p = 0.05). The mean size of 249Ser HCC tumor was 9.4 cm versus 5.5 cm on wild type HCC (p = 0.012). HBV DNA detection was not related to 249Ser mutation.
   Conclusion: Our results indicate that 249Ser mutation is a HCC important factor of carcinogenesis in Brazil and it is associated to large and poorly differentiated tumors.
C1 [Nogueira, Jeronimo A.; Ono-Nita, Suzane K.; Nita, Marcelo E.; de Souza, Marcelo M. T.; do Carmo, Eliane P.; Paranagua-Vezozzo, Denise C.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Mello, Evandro S.; Scapulatempo, Cristovan; Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RP Ono-Nita, SK (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM jeronimo_nogueira@yahoo.com.br; skon@usp.br; menita@usp.br;
   marcelo_lim07@yahoo.com.br; elianepcarmo@gmail.com;
   esmello@netpint.com.br; cristovamscapula@uol.com.br;
   denisecpv@uol.com.br; fjcarril@usp.br; venancio@uol.com.br
RI Carrilho, Flair J/I-3046-2012; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014; Ono, Suzane/I-3107-2012
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935;
   Scapulatempo-Neto, Cristovam/0000-0002-8920-6579
FU Alves de Queiroz Family Fund; FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)
FX We thank Helena Scavone Paschoale, Claudia Arruda and Alda Wakamatsu for
   helping the execution of this study. We had financial support from Alves
   de Queiroz Family Fund for Research and FAPESP.
CR Alves Venâncio Avancini Ferreira, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P25, DOI 10.1590/S0036-46652004000100005
   Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117
   BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0
   COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258
   Denissenko MF, 1999, MUTAT RES-FUND MOL M, V425, P205, DOI 10.1016/S0027-5107(99)00038-X
   El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   FORRESTER K, 1995, ONCOGENE, V10, P2103
   Garcia S, 2006, MYCOPATHOLOGIA, V162, P255, DOI 10.1007/s11046-006-0058-1
   Guengerich FP, 1998, MUTAT RES-FUND MOL M, V402, P121, DOI 10.1016/S0027-5107(97)00289-3
   GUNTHER S, 1995, J VIROL, V69, P5437
   Hoque A, 1999, NUTR CANCER, V35, P27, DOI 10.1207/S1532791427-33
   HOSONO S, 1993, ONCOGENE, V8, P491
   HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0
   Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101
   KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0
   Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   KUBICKA S, 1995, J HEPATOL, V23, P412, DOI 10.1016/0168-8278(95)80199-5
   LEHMAN TA, 1991, CANCER RES, V51, P4090
   Lunn RM, 1997, CANCER RES, V57, P3471
   NG IOL, 1994, ONCOGENE, V9, P985
   NITA Marcelo Eidi, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P39, DOI 10.1590/S0036-46652002000100007
   ODA T, 1992, CANCER RES, V52, P6358
   OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U
   PONCHEL F, 1994, CANCER RES, V54, P2064
   PUISIEUX A, 1991, CANCER RES, V51, P6185
   Qu JH, 2005, WORLD J GASTROENTERO, V11, P6212, DOI 10.3748/wjg.v11.i39.6212
   Robins H, 2005, 25 YEARS OF P53 RESEARCH, P1, DOI 10.1007/1-4020-2922-5_1
   Rocken C, 2001, DIGEST DIS, V19, P269, DOI 10.1159/000050693
   SABINO M, 1989, FOOD ADDIT CONTAM, V6, P327, DOI 10.1080/02652038909373787
   Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535
   Soini Y, 1996, CARCINOGENESIS, V17, P1007, DOI 10.1093/carcin/17.5.1007
   Strosnider H, 2006, ENVIRON HEALTH PERSP, V114, P1898, DOI 10.1289/ehp.9302
   Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996
   Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428
   Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
   Tiemersma EW, 2001, CANCER EPIDEM BIOMAR, V10, P785
   VOLKMANN M, 1994, ONCOGENE, V9, P195
   WANG XW, 1995, CANCER RES, V55, P6012
NR 39
TC 24
Z9 27
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 26
PY 2009
VL 9
AR 204
DI 10.1186/1471-2407-9-204
PG 8
WC Oncology
SC Oncology
GA 477DC
UT WOS:000268496900001
PM 19558663
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Lemos, MC
   Coutinho, E
   Gomes, L
   Bastos, M
   Fagulha, A
   Barros, L
   Carrilho, F
   Geraldes, E
   Regateiro, FJ
   Carvalheiro, M
AF Lemos, M. C.
   Coutinho, E.
   Gomes, L.
   Bastos, M.
   Fagulha, A.
   Barros, L.
   Carrilho, F.
   Geraldes, E.
   Regateiro, F. J.
   Carvalheiro, M.
TI The CTLA4+49 A/G polymorphism is not associated with susceptibility to
   type 1 diabetes mellitus in the Portuguese population
SO INTERNATIONAL JOURNAL OF IMMUNOGENETICS
LA English
DT Article
ID GENE; GENOTYPE; SIGNAL
AB CTLA4 genetic polymorphisms have been associated with type 1 diabetes. We genotyped 207 patients and 249 controls for the most frequently investigated polymorphism of the CTLA4 gene (+49A/G (rs231775)). No significant differences were observed, suggesting that this polymorphism is not strongly associated with type 1 diabetes in the Portuguese population.
C1 [Lemos, M. C.] Univ Beira Interior, Fac Hlth Sci, CICS, Hlth Sci Res Ctr, P-6200506 Covilha, Portugal.
   [Lemos, M. C.; Coutinho, E.; Regateiro, F. J.] Univ Coimbra, Fac Med, Med Genet Serv, Coimbra, Portugal.
   [Lemos, M. C.; Gomes, L.; Bastos, M.; Fagulha, A.; Barros, L.; Carrilho, F.; Geraldes, E.; Carvalheiro, M.] Univ Hosp Coimbra, Endocrinol Diabet & Metab Serv, Coimbra, Portugal.
RP Lemos, MC (corresponding author), Univ Beira Interior, Fac Hlth Sci, CICS, Hlth Sci Res Ctr, P-6200506 Covilha, Portugal.
EM mclemos@fcsaude.ubi.pt
RI Carrilho, Flair J/I-3046-2012; Lemos, Manuel/D-9861-2013; Coutinho,
   Eduarda/I-5845-2015
OI Lemos, Manuel/0000-0001-9326-8900; Gomes, Leonor/0000-0001-6576-7104;
   Regateiro, Fernando/0000-0003-2619-8871; Coutinho,
   Eduarda/0000-0002-9923-2164
FU 'Bolsa Dr M. M. Almeida Ruas - Sociedade Portuguesa de Diabetologia/Novo
   Nordisk, em Diabete
FX This work was supported by 'Bolsa Dr M. M. Almeida Ruas - Sociedade
   Portuguesa de Diabetologia/Novo Nordisk, em Diabetes (2003)'.
CR Ahmedov G, 2006, PEDIATR DIABETES, V7, P88, DOI 10.1111/j.1399-543X.2006.00152.x
   Anjos S, 2002, J BIOL CHEM, V277, P46478, DOI 10.1074/jbc.M206894200
   Caputo M, 2005, AUTOIMMUNITY, V38, P277, DOI 10.1080/08916930500158203
   Donner H, 1997, J CLIN ENDOCR METAB, V82, P143, DOI 10.1210/jc.82.1.143
   Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197-2456(97)00074-3
   Gough SCL, 2005, IMMUNOL REV, V204, P102, DOI 10.1111/j.0105-2896.2005.00249.x
   Hauache OM, 2005, DIS MARKERS, V21, P139, DOI 10.1155/2005/684123
   Kavvoura FK, 2005, AM J EPIDEMIOL, V162, P3, DOI 10.1093/aje/kwi165
   Marron MP, 1997, HUM MOL GENET, V6, P1275, DOI 10.1093/hmg/6.8.1275
   Maurer M, 2002, IMMUNOGENETICS, V54, P1, DOI 10.1007/s00251-002-0429-9
   Mayans S, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-3
   Mojtahedi Z, 2005, DIABETES RES CLIN PR, V68, P111, DOI 10.1016/j.diabres.2004.08.008
   Muro M, 2008, TRANSPL IMMUNOL, V18, P246, DOI 10.1016/j.trim.2007.07.003
   Perez-Garcia A, 2007, BLOOD, V110, P461, DOI 10.1182/blood-2007-01-069781
   Schneider H, 2006, SCIENCE, V313, P1972, DOI 10.1126/science.1131078
   Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621
   Zalloua P, 2004, HUM IMMUNOL, V65, P719, DOI 10.1016/j.humimm.2004.04.007
NR 17
TC 17
Z9 17
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-3121
EI 1744-313X
J9 INT J IMMUNOGENET
JI Int. J. Immunogenet.
PD JUN
PY 2009
VL 36
IS 3
BP 193
EP 195
DI 10.1111/j.1744-313X.2009.00844.x
PG 3
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 445SJ
UT WOS:000266071500010
PM 19490216
DA 2020-12-08
ER

PT J
AU Clemente, CM
   Carrilho, FJ
   Pinho, JRR
   Ono-Nita, SK
   Da Silva, LC
   Moreira, RC
   Lemos, MF
   Mello, IMVGD
AF Clemente, Cintia Mendes
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
   Ono-Nita, Suzane Kioko
   Da Silva, Luiz Caetano
   Moreira, Regina Celia
   Lemos, Marcilio Figueiredo
   Guedes de Carvalho Mello, Isabel Maria Vicente
TI A phylogenetic study of hepatitis B virus in chronically infected
   Brazilian patients of Western and Asian descent
SO JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Hepatitis B; Disease transmission; Genotype; Phylogeny; Family
ID HBV INFECTION; TRANSMISSION; GENOTYPES; SEQUENCE; PRECORE; FAMILIES;
   MUTANTS
AB Hepatitis B virus (HBV) causes one of the most important chronic viral infections worldwide. HBV is classified into eight genotypes whose epidemiology varies geographically. In Brazil, genotypes A, D, and F are more frequent, while in East Asia, genotypes B and C predominate. Several studies showed that immigrants retain the HBV infection pattern of their ancestral country.
   To identify HBV genotypes infecting chronic carriers in Brazilian families of Western and Asian descent by Hepatitis B surface antigen gene sequencing and analyze the route of viral transmission by phylogenetic analysis of viral sequences.
   Eighty-seven people chronically infected with HBV were separated into two groups: Western descent (27) and Asian descent (60). Surface and pre-core/core genes were amplified from serum HBV-DNA and sequences were subjected to phylogenetic analysis.
   HBV genotype A was found in 74% of Western subjects, while genotype C was found in 94% of Asian patients. Thirty-eight percent of Western families were infected with HBV with similar pre-core/core sequences, while only 25% of Asian families showed similarity in these sequences.
   Phylogenetical analysis of pre-core/core HBV gene suggested intra-familial transmission of HBV in 38% of Western families and 25% of Asian families. Analysis of HBsAg gene sequences helped to define the HBV genotype but did not allow inferring route of transmission as its sequences showed a smaller phylogenetic signal than pre-core/core sequences. Chronic HBV carriers of Asian descent born in or living in Brazil were infected with the same HBV genotype predominant in their ancestral country.
C1 [Clemente, Cintia Mendes; Carrilho, Flair Jose; Rebello Pinho, Joao Renato; Ono-Nita, Suzane Kioko; Da Silva, Luiz Caetano; Guedes de Carvalho Mello, Isabel Maria Vicente] Univ Sao Paulo, Dept Gastroenterol, Fac Med, BR-01246902 Sao Paulo, Brazil.
   [Rebello Pinho, Joao Renato] Univ Sao Paulo, Lab Hepatol & Gastroenterol Trop, Inst Trop Med, BR-05403000 Sao Paulo, Brazil.
   [Moreira, Regina Celia; Lemos, Marcilio Figueiredo] Inst Adolfo Lutz Registro, Serv Virol, BR-01246902 Sao Paulo, Brazil.
   [Guedes de Carvalho Mello, Isabel Maria Vicente] Inst Butantan, Lab Immunol Viral, BR-05503900 Sao Paulo, Brazil.
RP Clemente, CM (corresponding author), Univ Sao Paulo, Dept Gastroenterol, Fac Med, Ave Doutor Arnaldo 455, BR-01246902 Sao Paulo, Brazil.
EM cintiamclemente@uol.com.br; fjcarril@usp.br; jrrpinho@usp.br;
   skon@usp.br; lucadasi@bol.com.br; rmoreira@ial.sp.gov.br;
   mflemos@ial.sp.gov.br; imvgcmello@butantan.gov.br
RI Moreira, Regina C/B-1488-2016; Pinho, Joao R. R./G-2850-2012; Ono,
   Suzane/I-3107-2012; Carrilho, Flair J/I-3046-2012
OI Moreira, Regina C/0000-0002-8208-8776; Pinho, Joao R.
   R./0000-0003-3999-0489; 
FU FAPESP-Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [00/00998/1,
   0011457/1]; Alves de Queiroz Family Fund
FX FAPESP-Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Grants
   00/00998/1 and 0011457/1 Viral Genetic Diversity Network) and Alves de
   Queiroz Family Fund for Research.
CR ALARKA US, 1994, HEPATOLOGY, V19, P1366
   Cacciola I, 2002, J HEPATOL, V36, P426, DOI 10.1016/S0168-8278(01)00295-1
   Carrilho FJ, 2005, BRAZ J MED BIOL RES, V38, P1399, DOI 10.1590/S0100-879X2005000900015
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   Chu CJ, 2003, GASTROENTEROLOGY, V125, P444, DOI 10.1016/S0016-5085(03)00895-3
   Dumpis U, 2001, J HEPATOL, V35, P99, DOI 10.1016/S0168-8278(01)00064-2
   Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2
   Hall T, 2004, BIOEDIT VERSION 6 0
   KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989
   Kann M, 2005, VIRAL HEPATITIS, 3RD EDITION, P149
   Khan A, 2008, VIRUS RES, V132, P174, DOI 10.1016/j.virusres.2007.12.005
   Kidd-Ljunggren K, 2002, J GEN VIROL, V83, P1267, DOI 10.1099/0022-1317-83-6-1267
   Lavanchy D, 2005, VIRAL HEPATITIS, 3RD EDITION, P181, DOI 10.1002/9780470987131.ch11
   Lin CL, 2005, CLIN INFECT DIS, V41, P1576, DOI 10.1086/497837
   Martinson FEA, 1998, AM J EPIDEMIOL, V147, P478, DOI 10.1093/oxfordjournals.aje.a009474
   Ono-Nita Suzane Kioko, 2004, BMC Fam Pract, V5, P7, DOI 10.1186/1471-2296-5-7
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Santantonio T, 1997, J HEPATOL, V26, P221, DOI 10.1016/S0168-8278(97)80034-7
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815
   Sugauchi F, 2000, CLIN INFECT DIS, V31, P1195, DOI 10.1086/317428
   Swofford D.L., 2002, PAUP PHYLOGENETIC AN
   TAKAHASHI K, 1995, J GEN VIROL, V76, P3159, DOI 10.1099/0022-1317-76-12-3159
   THOMAS HC, 1994, GASTROENTEROL CLIN N, V23, P499
   Zampino R, 2002, J HEPATOL, V36, P248, DOI 10.1016/S0168-8278(01)00253-7
   ZHONG M, 1996, CHUNG HUA I HSUEH TS, V76, P194
NR 26
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0944-1174
EI 1435-5922
J9 J GASTROENTEROL
JI J. Gastroenterol.
PD JUN
PY 2009
VL 44
IS 6
BP 568
EP 576
DI 10.1007/s00535-009-0044-8
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 457JP
UT WOS:000266924600008
PM 19370306
DA 2020-12-08
ER

PT J
AU Rossi-Aguiar, VPS
   Navarro-Rodriguez, T
   Mattar, R
   Peres, MPSD
   Barbuti, RC
   Silva, FM
   Carrilho, FJ
   Eisig, JN
AF Silva Rossi-Aguiar, V. P.
   Navarro-Rodriguez, T.
   Mattar, R.
   Siqueira de Melo Peres, M. P.
   Barbuti, R. Correa
   Silva, F. M.
   Carrilho, F. J.
   Eisig, J. N.
TI Oral cavity is not a reservoir for Helicobacter pylori in infected
   patients with functional dyspepsia
SO ORAL MICROBIOLOGY AND IMMUNOLOGY
LA English
DT Article
DE dyspepsia; Helicobacter pylori; oral cavity
ID POLYMERASE-CHAIN-REACTION; ERADICATION THERAPY; HIGH PREVALENCE;
   PERIODONTITIS PATIENTS; DUODENAL-ULCER; DENTAL PLAQUE; SALIVA; PCR;
   GASTRITIS; ABSENCE
AB Helicobacter pylori infection is very prevalent in Brazil, infecting almost 65% of the population. The aim of this study was to evaluate the presence of this bacterium in the oral cavity of patients with functional dyspepsia (epigastric pain syndrome), establish the main sites of infection in the mouth, and assess the frequency of cagA and vacA genotypes of oral H. pylori.
   All 43 outpatients with epigastric pain syndrome, who entered the study, were submitted to upper gastrointestinal endoscopy to rule out organic diseases. Helicobacter pylori infection in the stomach was confirmed by a rapid urease test and urea breath tests. Samples of saliva, the tongue dorsum and supragingival dental plaque were collected from the oral cavity of each subject and subgingival dental plaque samples were collected from the patients with periodontitis; H. pylori infection was verified by polymerase chain reaction using primers that amplify the DNA sequence of a species-specific antigen present in all H. pylori strains; primers that amplify a region of urease gene, and primers for cagA and vacA (m1, m2, s1a, s1b, s2) genotyping.
   Thirty patients harbored H. pylori in the stomach, but it was not possible to detect H. pylori in any oral samples using P1/P2 and Urease A/B. The genotype cagA was also negative in all samples and vacA genotype could not be characterized (s-m-).
   The oral cavity may not be a reservoir for H. pylori in patients with epigastric pain syndrome, the bacterium being detected exclusively in the stomach.
C1 [Silva Rossi-Aguiar, V. P.; Navarro-Rodriguez, T.; Mattar, R.; Barbuti, R. Correa; Silva, F. M.; Carrilho, F. J.; Eisig, J. N.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Clin Gastroenterol Div, Sao Paulo, Brazil.
   [Siqueira de Melo Peres, M. P.] Univ Sao Paulo, Sch Med, Dept Dent, Sao Paulo, Brazil.
RP Rossi-Aguiar, VPS (corresponding author), Rua Prof Joao Marinho 95, BR-04007010 Sao Paulo, Brazil.
EM fopvan@yahoo.com
RI Barbuti, Ricardo/H-6277-2015; Rodriguez, TOMAS NAVARRO/I-3170-2012;
   Mattar, Rejane/AAO-4842-2020; Barbuti, Ricardo/AAK-5495-2020; Carrilho,
   Flair J/I-3046-2012; Mattar, Rejane/K-3883-2012
OI Rodriguez, TOMAS NAVARRO/0000-0002-3458-699X; Mattar,
   Rejane/0000-0001-7870-8867; 
CR Adler I, 2005, HELICOBACTER, V10, P312, DOI 10.1111/j.1523-5378.2005.00322.x
   Aiba Y, 1998, AM J GASTROENTEROL, V93, P2097, DOI 10.1111/j.1572-0241.1998.00600.x
   Allaker RP, 2002, J MED MICROBIOL, V51, P312, DOI 10.1099/0022-1317-51-4-312
   Amieva MR, 2008, GASTROENTEROLOGY, V134, P306, DOI 10.1053/j.gastro.2007.11.009
   ASIKAINEN S, 1994, ORAL MICROBIOL IMMUN, V9, P318, DOI 10.1111/j.1399-302X.1994.tb00079.x
   ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771
   Bonamico M, 2004, HELICOBACTER, V9, P69, DOI 10.1111/j.1083-4389.2004.00192.x
   COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791
   Czesnikiewicz-Guzik M, 2005, J Physiol Pharmacol, V56 Suppl 6, P77
   Czesnikiewicz-Guzik M, 2007, J CLIN GASTROENTEROL, V41, P145, DOI 10.1097/01.mcg.0000225654.85060.3d
   Dowsett SA, 1999, J CLIN MICROBIOL, V37, P2456, DOI 10.1128/JCM.37.8.2456-2460.1999
   Dowsett SA, 2003, CRIT REV ORAL BIOL M, V14, P226, DOI 10.1177/154411130301400307
   Drossman Douglas A, 2006, Chin J Dig Dis, V7, P181, DOI 10.1111/j.1443-9573.2006.00265.x
   Eisig JN, 2006, HELICOBACTER, V11, P431, DOI 10.1111/j.1523-5378.2006.00434.x
   FERGUSON DA, 1993, J CLIN MICROBIOL, V31, P2802, DOI 10.1128/JCM.31.10.2802-2804.1993
   Gebara ECE, 2006, J CLIN PERIODONTOL, V33, P329, DOI 10.1111/j.1600-051X.2006.00915.x
   Gebara ECE, 2004, ORAL MICROBIOL IMMUN, V19, P277, DOI 10.1111/j.1399-302X.2004.00153.x
   HAMMAR M, 1992, J CLIN MICROBIOL, V30, P54, DOI 10.1128/JCM.30.1.54-58.1992
   Kignel S, 2005, ORAL DIS, V11, P17, DOI 10.1111/j.1601-0825.2004.01043.x
   LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991
   LI C, 1995, J CLIN PATHOL, V48, P662, DOI 10.1136/jcp.48.7.662
   Loster BW, 2006, J PHYSIOL PHARMACOL, V57, P91
   MAPSTONE NP, 1993, J CLIN PATHOL, V46, P540, DOI 10.1136/jcp.46.6.540
   Martinez-Gomis J, 2006, ORAL MICROBIOL IMMUN, V21, P407, DOI 10.1111/j.1399-302X.2006.00295.x
   Mattar R, 2005, HELICOBACTER, V10, P601, DOI 10.1111/j.1523-5378.2005.00360.x
   Mattar R, 2007, J MED MICROBIOL, V56, P9, DOI 10.1099/jmm.0.46824-0
   Mattar Rejane, 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P3, DOI 10.1590/S0036-46651999000100002
   MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870
   Miyabayashi H, 2000, HELICOBACTER, V5, P30, DOI 10.1046/j.1523-5378.2000.00004.x
   NGUYEN AMH, 1995, ORAL SURG ORAL MED O, V79, P705, DOI 10.1016/S1079-2104(05)80304-X
   Nguyen TN, 1999, HELICOBACTER, V4, P185, DOI 10.1046/j.1523-5378.1999.99294.x
   Okuda K, 2003, J PERIODONTOL, V74, P123, DOI 10.1902/jop.2003.74.1.123
   Okuda K, 2000, MICROBIOL IMMUNOL, V44, P385, DOI 10.1111/j.1348-0421.2000.tb02510.x
   Olivier BJ, 2006, J CLIN MICROBIOL, V44, P635, DOI 10.1128/JCM.44.2.635-636.2006
   Ozdemir A, 2001, QUINTESSENCE INT, V32, P131
   Shi RH, 2008, HELICOBACTER, V13, P157, DOI 10.1111/j.1523-5378.2008.00586.x
   Shimoyama T, 2000, J Oral Sci, V42, P225
   Siavoshi F, 2005, HELICOBACTER, V10, P318, DOI 10.1111/j.1523-5378.2005.00319.x
   Song O, 2000, J MED MICROBIOL, V49, P349, DOI 10.1099/0022-1317-49-4-349
   Song QS, 2000, DIGEST DIS SCI, V45, P2162, DOI 10.1023/A:1026636519241
   Souto R, 2008, J PERIODONTOL, V79, P97, DOI [10.1902/jop.2008.070241, 10.1902/jop.2008.070241 ]
   Tack J, 2006, GASTROENTEROLOGY, V130, P1466, DOI 10.1053/j.gastro.2005.11.059
   Teoman I, 2007, CLIN ORAL INVEST, V11, P201, DOI 10.1007/s00784-007-0104-5
   Umeda M, 2003, J PERIODONTOL, V74, P129, DOI 10.1902/jop.2003.74.1.129
   Zaterka S, 2007, HELICOBACTER, V12, P82, DOI 10.1111/j.1523-5378.2007.00474.x
NR 45
TC 21
Z9 22
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0055
J9 ORAL MICROBIOL IMMUN
JI Oral Microbiol. Immunol.
PD JUN
PY 2009
VL 24
IS 3
BP 255
EP 259
DI 10.1111/j.1399-302X.2008.00491.x
PG 5
WC Dentistry, Oral Surgery & Medicine; Immunology; Microbiology
SC Dentistry, Oral Surgery & Medicine; Immunology; Microbiology
GA 433FN
UT WOS:000265189800013
PM 19416457
DA 2020-12-08
ER

PT J
AU Poynard, T
   Colombo, M
   Bruix, J
   Schiff, E
   Terg, R
   Flamm, S
   Moreno-Otero, R
   Carrilho, F
   Schmidt, W
   Berg, T
   McGarrity, T
   Heathcote, EJ
   Goncales, F
   Diago, M
   Craxi, A
   Silva, M
   Bedossa, P
   Mukhopadhyay, P
   Griffel, L
   Burroughs, M
   Brass, C
   Albrecht, J
AF Poynard, Thierry
   Colombo, Massimo
   Bruix, Jordi
   Schiff, Eugene
   Terg, Ruben
   Flamm, Steven
   Moreno-Otero, Ricardo
   Carrilho, Flair
   Schmidt, Warren
   Berg, Thomas
   McGarrity, Thomas
   Heathcote, E. Jenny
   Goncales, Fernando
   Diago, Moises
   Craxi, Antonio
   Silva, Marcelo
   Bedossa, Pierre
   Mukhopadhyay, Pabak
   Griffel, Louis
   Burroughs, Margaret
   Brass, Clifford
   Albrecht, Janice
CA Epic Study Grp
TI Peginterferon alfa-2b and Ribavirin: Effective in Patients With
   Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
SO GASTROENTEROLOGY
LA English
DT Article; Proceedings Paper
CT 43rd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 23-27, 2008
CL Milan, ITALY
SP European Assoc Study Liver
ID SUSTAINED VIROLOGICAL RESPONSE; PLUS RIBAVIRIN; RANDOMIZED-TRIAL;
   NONRESPONDER PATIENTS; COMBINATION THERAPY; TREATMENT DURATION;
   VIRUS-INFECTION; RETREATMENT; FIBROSIS; REGIMEN
AB Background & Aims: Treatment with peginterferon alfa and ribavirin produces a sustained virologic response (SVR) in approximately 60% of hepatitis C virus (HCV)-infected patients. Alternate options are needed for patients who relapse or do not respond to therapy. Methods: This prospective, international, multicenter, open-label study evaluated efficacy and safety of peginterferon alfa-2b (1.5 mu g/kg/wk) plus weight-based ribavirin (800-1400 mg/day) in 2333 chronic HCV-infected patients with significant fibrosis/cirrhosis whose previous interferon alfa/ribavirin therapy failed. Patients with undetectable HCV-RNA at treatment week (TW) 12 received 48 weeks of therapy; patients with detectable HCV-RNA at TW12 could enter maintenance studies at TW18; 188 patients with low/detectable HCV-RNA at TW12 continued therapy at the investigator's request. Results: Overall, 22% of the patients attained SVR (56% with undetectable HCV-RNA and 12% with low/detectable HCV-RNA at TW12). SVR was better in relapsers (38%) than nonresponders (14%), regardless of previous treatment, and in patients previously treated with interferon-alfa/ribavirin (25%) than peginterferon alfa-ribavirin (17%). Predictors of response in patients with undetectable HCV-RNA at TW12 were genotype (2/3 vs 1, respectively; odds ratio [OR] 2.4; P < .0001), fibrosis score (F2 vs F4; OR, 2.2; F3 vs F4; OR, 1.7; P < .0001), and baseline viral load (<= 600,000 vs >600,000 IU/mL; OR, 1.4; P = .0223). These factors plus previous treatment and response were overall predictors of SVR. Safety was similar among fibrosis groups. Conclusions: Peginterferon alfa-2b plus weight-based ribavirin is effective and safe in patients who failed interferon alfa/ribavirin therapy. Genotype, baseline viral load, and fibrosis stage were predictors of response.
C1 [Poynard, Thierry] Univ Paris 06, Hop La Pitie Salpetriere, Ctr Liver, Serv Hepatol, F-75651 Paris 13, France.
   [Colombo, Massimo] Univ Milan, Fdn IRCCS Maggiore Hosp, Div Gastroenterol 1, Milan, Italy.
   [Bruix, Jordi] Univ Barcelona, Hosp Clin, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Liver Unit, Barcelona, Spain.
   [Schiff, Eugene] Univ Miami, Sch Med, Miami, FL USA.
   [Terg, Ruben] Hosp Municipal Gastroenterol Dr Bonorino Udaondo, Buenos Aires, Argentina.
   [Flamm, Steven] Northwestern Univ, Chicago, IL 60611 USA.
   [Moreno-Otero, Ricardo] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Moreno-Otero, Ricardo] Hosp Univ Princesa, Madrid, Spain.
   [Carrilho, Flair] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Schmidt, Warren] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
   [Berg, Thomas] Charite Univ Med Berlin, D-13353 Berlin, Germany.
   [McGarrity, Thomas] Milton S Hershey Med Ctr, Hershey, PA USA.
   [Heathcote, E. Jenny] Univ Hlth Network, Toronto, ON, Canada.
   [Goncales, Fernando] Univ Estadual Campinas, Fac Med Sci, Dept Clin Med, Campinas, SP, Brazil.
   [Diago, Moises] Univ Valencia, Gen Hosp, Valencia, Spain.
   [Craxi, Antonio] Univ Palermo, DIBIMIS, GI & Liver Unit, Palermo, Italy.
   [Silva, Marcelo] Hosp Univ Austral, Pilar, Argentina.
   [Bedossa, Pierre] Hop Beaujon, Clichy, France.
   [Mukhopadhyay, Pabak; Griffel, Louis; Burroughs, Margaret; Brass, Clifford; Albrecht, Janice] Schering Plough Res Inst, Kenilworth, NJ USA.
RP Poynard, T (corresponding author), Univ Paris 06, Hop La Pitie Salpetriere, Ctr Liver, Serv Hepatol, 47-83 Blvd Hop, F-75651 Paris 13, France.
EM tpoynard@teaser.fr
RI Carvalho, Armando/P-6134-2018; Poynard, Thierry/C-1355-2010; Leggett,
   Barbara A/D-3579-2011; Carrilho, Flair J/I-3046-2012; Peltekian, Kevork
   M/D-1083-2010; DIAGO, MOISES/AAH-5364-2019; Carvalho,
   Armando/H-4510-2016; Craxi, Antonio/K-9529-2016
OI Carvalho, Armando/0000-0003-2455-8781; Poynard,
   Thierry/0000-0002-3726-7230; Peltekian, Kevork M/0000-0002-9560-5576;
   Carvalho, Armando/0000-0003-2455-8781; Craxi,
   Antonio/0000-0002-4480-9544; Bruix, Jordi/0000-0002-9826-0753; Berg,
   Thomas/0000-0003-0003-6241; Leggett, Barbara/0000-0003-2062-7380;
   schmidt, Warren/0000-0003-2893-6014; Poynard,
   Thierry/0000-0002-2050-640X; Bedossa, Pierre/0000-0002-8487-7322
CR AFDHAL NH, 2008, 43 ANN M EUR ASS STU, P12908
   Basso M, 2007, DIGEST LIVER DIS, V39, P47, DOI 10.1016/j.dld.2006.08.007
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Berg T, 2006, GASTROENTEROLOGY, V130, P1086, DOI 10.1053/j.gastro.2006.02.015
   Bruno S, 2007, HEPATOLOGY, V45, P579, DOI 10.1002/hep.21492
   Cornberg M, 2006, J HEPATOL, V44, P291, DOI 10.1016/j.jhep.2005.10.021
   Di Bisceglie AM, 2008, NEW ENGL J MED, V359, P2429, DOI 10.1056/NEJMoa0707615
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Jacobson IM, 2005, AM J GASTROENTEROL, V100, P2453, DOI 10.1111/j.1572-0241.2005.00282.x
   Jacobson IM, 2007, HEPATOLOGY, V46, P971, DOI 10.1002/hep.21932
   Krawitt EL, 2005, J HEPATOL, V43, P243, DOI 10.1016/j.jhep.2005.03.015
   Mangia A, 2008, HEPATOLOGY, V47, P43, DOI 10.1002/hep.22061
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Marcellin P, 2007, J HEPATOL, V47, P580, DOI 10.1016/j.jhep.2007.07.015
   Moucari R, 2007, J HEPATOL, V46, P596, DOI 10.1016/j.jhep.2006.10.016
   Parise E., 2006, Braz J Infect Dis, V10, P11, DOI 10.1590/S1413-86702006000100003
   Pearlman BL, 2007, HEPATOLOGY, V46, P1688, DOI 10.1002/hep.21919
   Poynard T, 2000, HEPATOLOGY, V31, P211, DOI 10.1002/hep.510310131
   Sagir A, 2007, LIVER INT, V27, P954, DOI 10.1111/j.1478-3231.2007.01508.x
   Sanchez-Tapias JM, 2006, GASTROENTEROLOGY, V131, P451, DOI 10.1053/j.gastro.2006.05.016
   Sherman M, 2006, GUT, V55, P1631, DOI 10.1136/gut.2005.083113
   Shiffman Mitchell L, 2004, Rev Gastroenterol Disord, V4 Suppl 1, pS22
   Shiffman ML, 2004, GASTROENTEROLOGY, V126, P1015, DOI 10.1053/j.gastro.2004.01.014
   Shiratori Y, 2000, ANN INTERN MED, V132, P517, DOI 10.7326/0003-4819-132-7-200004040-00002
   Sobesky R, 1999, GASTROENTEROLOGY, V116, P378, DOI 10.1016/S0016-5085(99)70135-6
   Taliani G, 2006, GASTROENTEROLOGY, V130, P1098, DOI 10.1053/j.gastro.2006.02.016
   Veldt BJ, 2007, ANN INTERN MED, V147, P677, DOI 10.7326/0003-4819-147-10-200711200-00003
   Veldt BJ, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-24
NR 28
TC 182
Z9 186
U1 0
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2009
VL 136
IS 5
BP 1618
EP 1628
DI 10.1053/j.gastro.2009.01.039
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 440WQ
UT WOS:000265730800025
PM 19208349
DA 2020-12-08
ER

PT J
AU Navarro-Rodriguez, T
   Barbuti, RC
   Damiao, AO
   Moraes, JP
   Silva, FM
   Carrilho, FJ
   Eisig, JN
AF Navarro-Rodriguez, Tomas
   Barbuti, Ricardo C.
   Damiao, Aderson O.
   Moraes-Filho, Joaquim P.
   Silva, Fernando M.
   Carrilho, Flair J.
   Eisig, Jaime N.
TI Association of a Probiotic to a Helicobacter pylori Eradication Scheme
   Does Not Increase Eradication Rate Neither Decreases the Adverse Events.
   a Prospective, Randomized, Double-Blind Placebo Controlled Study
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Digestive Disease Week/110th Annual Meeting of the
   American-Gastroenterological-Association
CY MAY 30-JUN 04, 2009
CL Chicago, IL
SP Amer Gastroenterol Assoc
RI Rodriguez, TOMAS NAVARRO/I-3170-2012; Barbuti, Ricardo/AAK-5495-2020;
   Barbuti, Ricardo/H-6277-2015; Carrilho, Flair J/I-3046-2012
OI Rodriguez, TOMAS NAVARRO/0000-0002-3458-699X; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2009
VL 136
IS 5
SU 1
BP A346
EP A346
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 565GI
UT WOS:000275277201701
DA 2020-12-08
ER

PT J
AU Sa, CC
   Moraes, JP
   Eisig, JN
   Werneck-Silva, AL
   Barbuti, RC
   Kishi, HS
   Carrilho, FJ
   Navarro-Rodriguez, T
AF Sa, Claudia C.
   Moraes-Filho, Joaquim P.
   Eisig, Jaime N.
   Werneck-Silva, Ana Luiza
   Barbuti, Ricardo C.
   Kishi, Humberto S.
   Carrilho, Flair J.
   Navarro-Rodriguez, Tomas
TI Low Prevalence of Eosinophilic Esophagitis in Patients with Refractory
   Gastroesophageal Reflux Disease. a Prospective Study
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Digestive Disease Week/110th Annual Meeting of the
   American-Gastroenterological-Association
CY MAY 30-JUN 04, 2009
CL Chicago, IL
SP Amer Gastroenterol Assoc
RI Barbuti, Ricardo/H-6277-2015; Rodriguez, TOMAS NAVARRO/I-3170-2012;
   Carrilho, Flair J/I-3046-2012; Barbuti, Ricardo/AAK-5495-2020; Silva,
   Ana Luiza/S-4239-2019
OI Rodriguez, TOMAS NAVARRO/0000-0002-3458-699X; 
NR 0
TC 4
Z9 4
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2009
VL 136
IS 5
SU 1
BP A282
EP A282
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 565GI
UT WOS:000275277201399
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Oliveira, CP
   Soares, IC
   Correa-Giannella, ML
   Kubrusly, MS
   Bellodi-Privato, M
   Lima, VM
   Bachella, T
   Alves, VA
   Carrilho, FJ
AF Stefano, Jose T.
   Oliveira, Claudia P.
   Soares, Ibere C.
   Correa-Giannella, Maria Lucia
   Kubrusly, Marcia S.
   Bellodi-Privato, Marta
   Lima, Vicencia M.
   Bachella, Telesforo
   Alves, Venancio A.
   Carrilho, Flair J.
TI Downregulation of Survivin Could Be a Potential Marker in Human
   Nonalcoholic Fatty Liver Disease (NAFLD) Progression?
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Digestive Disease Week/110th Annual Meeting of the
   American-Gastroenterological-Association
CY MAY 30-JUN 04, 2009
CL Chicago, IL
SP Amer Gastroenterol Assoc
RI Carrilho, Flair J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014;
   Stefano, Jose Tadeu/AAH-5419-2020; Kubrusly, Marcia S/N-3943-2014;
   Giannella, Maria Lucia/N-3834-2019; Stefano, Jose T/H-4792-2013
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Kubrusly, Marcia
   S/0000-0003-3258-5632; Correa-Giannella, Maria Lucia/0000-0003-3655-4446
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2009
VL 136
IS 5
SU 1
BP A804
EP A804
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 565GI
UT WOS:000275277204044
DA 2020-12-08
ER

PT J
AU Terrabuio, DRB
   Abrantes-Lemos, CP
   Carrilho, FJ
   Cancado, ELR
AF Terrabuio, Debora Raquel B.
   Abrantes-Lemos, Clarice Pires
   Carrilho, Flair Jose
   Cancado, Eduardo Luiz R.
TI Follow-up of Pregnant Women With Autoimmune Hepatitis The Disease
   Behavior Along With Maternal and Fetal Outcomes
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE autoimmune hepatitis; autoimmune disease; pregnancy; azathioprine;
   miscarriage; congenital malformation
ID LIVER-DISEASE; AZATHIOPRINE; COHORT; 6-MERCAPTOPURINE; MERCAPTOPURINE;
   MANAGEMENT; REMISSION; ABORTION; IMURAN; BRAZIL
AB Goals: To assess maternal and fetal outcomes and clinical management of pregnancy in patients with autoimmune hepatitis (AIH).
   Background: There is a paucity of information about maternal and fetal outcomes, and AIH activity during pregnancy and in the postpartum period. There is no consensus about the administration of azathioprine during pregnancy and breastfeeding.
   Study: Retrospective analysis of 54 pregnancies (3 still in progress) in 39 AIH patients.
   Results: The median age at conception was 24 years, and 68.4% of women had liver cirrhosis. Before conception and in early pregnancy, azathioprine and prednisone were administered in 48.1%, but treatment regimen vas usually changed further to 20 mg/d prednisone and 20.4%, were off treatment. There were 36 livebirths, and fetal loss rates were 29.4% (13 miscarriages, 1 stillbirth, and 1 ectopic pregnancy). Preterm birth rate was 11.8%. In 2 cases, there was acute fetal distress; and in 2 others congenital malformations (3.9%). The rate of serious maternal complication was 7.8%, with no deaths. There were no flares in 41.2% pregnancies, but aminotransferase elevations occurred in 54.9%, 31.4% of which were true AIH relapses, only registered in the postpartum period.
   Conclusions: Despite the high fetal miscarriage rate, pregnancy in AIH was safe. Patients needed careful monitoring, especially in the postpartum period because of relapses. There was no evidence of a cause and effect relationship among azathioprine administration and premature births and congenital abnormalities, but more studies are necessary. Higher doses of prednisone may be an alternative option for those who prefer azathioprine withdrawal during pregnancy.
C1 [Abrantes-Lemos, Clarice Pires; Cancado, Eduardo Luiz R.] Univ Sao Paulo, Sch Med, Inst Trop Med, Lab Med Invest Immunopathol Schistosomiasis, BR-05403000 Sao Paulo, Brazil.
   [Terrabuio, Debora Raquel B.; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
RP Cancado, ELR (corresponding author), Univ Sao Paulo, Sch Med, Inst Trop Med, Lab Med Invest Immunopathol Schistosomiasis, 20 Andar Av Dr Eneas de Carvalho Aguiar 500, BR-05403000 Sao Paulo, Brazil.
EM edulrc@uol.com.br
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016
OI Cancado, Eduardo/0000-0002-9309-1524
CR Aagaard-Tillery KM, 2006, SEMIN FETAL NEONAT M, V11, P279, DOI 10.1016/j.siny.2006.04.003
   Ahman E, 2002, REPROD HEALTH MATTER, V10, P13, DOI 10.1016/S0968-8080(02)00012-5
   Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   Aragão Vânia Maria de Farias, 2004, Cad. Saúde Pública, V20, P57, DOI 10.1590/S0102-311X2004000100019
   Benjaminov FS, 2004, AM J GASTROENTEROL, V99, P2479, DOI 10.1111/j.1572-0241.2004.30231.x
   BEST RG, ANENCEPHALY 2007
   Buchel E, 2002, AM J GASTROENTEROL, V97, P3160
   Candia L, 2005, SEMIN ARTHRITIS RHEU, V35, P49, DOI 10.1016/j.semarthrit.2005.03.002
   Chambers CD, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1977
   CHAN GLC, 1990, J CLIN PHARMACOL, V30, P358, DOI 10.1002/j.1552-4604.1990.tb03606.x
   Colle I, 1999, LIVER, V19, P55, DOI 10.1111/j.1478-3231.1999.tb00010.x
   de Boer NKH, 2006, AM J GASTROENTEROL, V101, P1390, DOI 10.1111/j.1572-0241.2006.00538.x
   Elsing Christoph, 2007, Indian J Gastroenterol, V26, P104
   Francella A, 2003, GASTROENTEROLOGY, V124, P9, DOI 10.1053/gast.2003.50014
   Garcia-Tsao G, 2006, CURR OPIN GASTROEN, V22, P254
   GILBERTBARNESS E, 1997, POTTERS PATHOLOGY FE
   GITHENS JH, 1965, J PEDIATR-US, V66, P959, DOI 10.1016/S0022-3476(65)80071-3
   Golding A, 2007, RHEUM DIS CLIN N AM, V33, P319, DOI 10.1016/j.rdc.2007.01.001
   Goldstein LH, 2007, BIRTH DEFECTS RES A, V79, P696, DOI 10.1002/bdra.20399
   GROSS A, 1977, OBSTET GYNECOL, V50, P713
   Guedes AC, 2000, REPROD HEALTH MATTER, V8, P66, DOI 10.1016/S0968-8080(00)90188-5
   Heneghan MA, 2001, GUT, V48, P97, DOI 10.1136/gut.48.1.97
   Kallen K, 1997, INT J EPIDEMIOL, V26, P571, DOI 10.1093/ije/26.3.571
   Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
   Langagergaard V, 2007, ALIMENT PHARM THER, V25, P73, DOI 10.1111/j.1365-2036.2006.03162.x
   LEE WM, 1992, GASTROENTEROL CLIN N, V21, P889
   Levine AB, 2000, OBSTET GYNECOL, V95, P1033, DOI 10.1016/S0029-7844(00)00817-6
   Lopez-Mendez Eric, 2006, Ann Hepatol, V5, P219
   Martins I R, 1991, Cad Saude Publica, V7, P251
   McFarlane Ian G, 2002, Clin Liver Dis, V6, P605, DOI 10.1016/S1089-3261(02)00019-3
   MEEHAN RT, 1987, J RHEUMATOL, V14, P252
   MEGAN EB, 2007, RHEUM DIS CLIN N AM, V33, P237
   Mezzomo CLS, 2007, CAD SAUDE PUBLICA, V23, P2716, DOI 10.1590/S0102-311X2007001100019
   MISHRA P C, 1989, Indian Pediatrics, V26, P32
   Muratori P, 2002, DIGEST LIVER DIS, V34, P608, DOI 10.1016/S1590-8658(02)80098-6
   Norgard B, 2003, ALIMENT PHARM THER, V17, P827, DOI 10.1046/j.1365-2036.2003.01537.x
   NORONHA L., 2003, J BRAS PATOL MED LAB, V39, P237
   Prime E, 2000, ECONTENT, V23, P24
   Sau A, 2007, BJOG-INT J OBSTET GY, V114, P498, DOI 10.1111/j.1471-0528.2006.01232.x
   Schramm C, 2006, AM J GASTROENTEROL, V101, P556, DOI 10.1111/j.1572-0241.2006.00479.x
   STEVEN MM, 1979, Q J MED, V48, P519
   Thiele Dwain L, 2005, Clin Liver Dis, V9, P635, DOI 10.1016/j.cld.2005.07.004
   Uribe Misael, 2006, Ann Hepatol, V5, P187
   VILLE Y, 1993, AM J OBSTET GYNECOL, V168, P896, DOI 10.1016/S0002-9378(12)90841-8
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
   Werner M, 2007, SCAND J GASTROENTERO, V42, P986, DOI 10.1080/00365520601155266
   WHELTON MJ, 1968, LANCET, V2, P995
   Wilder RL, 1998, ANN NY ACAD SCI, V840, P45, DOI 10.1111/j.1749-6632.1998.tb09547.x
   Yip L, 2006, CLIN DERMATOL, V24, P84, DOI 10.1016/j.clindermatol.2005.10.022
NR 49
TC 49
Z9 53
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0192-0790
EI 1539-2031
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD APR
PY 2009
VL 43
IS 4
BP 350
EP 356
DI 10.1097/MCG.0b013e318176b8c5
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 439MM
UT WOS:000265631200011
PM 19077726
DA 2020-12-08
ER

PT J
AU Kikuchi, LOO
   Paranagua-Vezozzo, DC
   Chagas, AL
   Mello, ES
   Alves, VAF
   Farias, AQ
   Pietrobon, R
   Carrilho, FJ
AF Kikuchi, Luciana O. O.
   Paranagua-Vezozzo, Denise C.
   Chagas, Aline L.
   Mello, Evandro S.
   Alves, Venancio A. F.
   Farias, Alberto Q.
   Pietrobon, Ricardo
   Carrilho, Flair J.
TI Nodules Less Than 20 mm and Vascular Invasion are Predictors of Survival
   in Small Hepatocellular Carcinoma
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE small hepatocellular carcinoma; survival; mortality; vascular invasion
ID PERCUTANEOUS ETHANOL INJECTION; LIVER-TRANSPLANTATION;
   PROGNOSTIC-FACTORS; HEPATIC RESECTION; NATURAL-HISTORY; CIRRHOSIS;
   CLASSIFICATION; CANCER; MODEL
AB Background: The aims of this study were to analyze the overall survival of patients with cirrhosis and small hepatocellular carcinoma (HCC) and identify independent pretreatment predictors of survival in Brazil.
   Methods: Between 1998 and 2003, 74 patients with cirrhosis and small HCC were evaluated. Predictors of survival were identified using the Kaplan-Meier survival curves and the Cox model.
   Results: The overall survival rates were 80%, 41%, and 17% at 12, 36, and 60 months, respectively. The mean length of follow-up after HCC diagnosis was 23 months (median 22 mo, range: I to 86 mo) for the entire group. Univariate analysis showed that model for endstage liver disease (MELD) score (P = 0.016), Child-Pugh classification (P = 0.007), alpha-fetoprotein level (P = 0.006), number of nodules (P = 0.041), tumor diameter (P = 0.009), and vascular invasion (P < 0.0001) were significant predictors Of Survival. Cox regression analysis identified vascular invasion (relative risk = 14.60, confidence interval 95% = 3.3-64.56, P < 0.001) and tumor size > 20 mm (relative risk = 2.14, confidence interval 95% = 1.07-4.2, P = 0.030) as independent predictors of decreased survival. Treatment of HCC was related to increased overall survival.
   Conclusions: Identification of HCC smaller than 20 mm is associated with longer survival. Presence of vascular invasion, even in small tumors, maybe associated with poor prognosis. Treatment of small tumors Of LIP to 20 mm diameter is related to increased survival.
C1 [Kikuchi, Luciana O. O.; Paranagua-Vezozzo, Denise C.; Chagas, Aline L.; Farias, Alberto Q.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Mello, Evandro S.; Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, BR-05403000 Sao Paulo, Brazil.
   [Pietrobon, Ricardo] Duke Univ Med, Ctr Excellence Surg Outcome, Dept Surg, Durham, NC USA.
RP Kikuchi, LOO (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, 255,Dr Eneas C Aguiar Ave,Room 9159, BR-05403000 Sao Paulo, Brazil.
EM lucianakikuchi29@gmail.com
RI Chagas, Aline Lopes/X-2059-2019; Carrilho, Flair J/I-3046-2012; Farias,
   Alberto/ABB-1291-2020; Farias, Alberto Q/H-7873-2013; Paranagua-Vezozzo,
   Denise Cerqueira/N-7270-2014
OI Farias, Alberto/0000-0002-5572-663X; Paranagua-Vezozzo, Denise
   Cerqueira/0000-0002-9606-4935; Pietrobon, Ricardo/0000-0003-2996-2193
FU Alvez de Queiroz Family Fund for Research
FX Alvez de Queiroz Family Fund for Research for partial financial support.
CR BARBARA L, 1992, HEPATOLOGY, V16, P132, DOI 10.1002/hep.1840160122
   Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3
   Daniele B, 2003, J CLIN GASTROENTEROL, V36, P63, DOI 10.1097/00004836-200301000-00017
   Ebara M, 2005, J HEPATOL, V43, P458, DOI 10.1016/j.jhep.2005.03.033
   EBARA M, 1986, GASTROENTEROLOGY, V90, P289, DOI 10.1016/0016-5085(86)90923-6
   El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001
   Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014
   Goncalves Carlos S., 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P165, DOI 10.1590/S0036-46651997000300008
   Ikai I, 2004, CANCER-AM CANCER SOC, V101, P796, DOI 10.1002/cncr.20426
   Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172
   Kojiro Masamichi, 2004, Liver Transpl, V10, pS3, DOI 10.1002/lt.20042
   Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122
   Llovet JM, 1998, HEPATOLOGY, V27, P1572, DOI 10.1002/hep.510270616
   Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629
   Manghisi G, 1998, HEPATOLOGY, V28, P751
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Paranagua-Vezozzo DC, 2006, HEPATOLOGY, V44, p504A
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Poon RTP, 2003, ANN SURG, V237, P376, DOI 10.1097/00000658-200303000-00012
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   Sala M, 2004, HEPATOLOGY, V40, P1352, DOI 10.1002/hep.20465
   Tateishi R, 2005, GUT, V54, P419, DOI 10.1136/gut.2003.035055
NR 22
TC 28
Z9 30
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD FEB
PY 2009
VL 43
IS 2
BP 191
EP 195
DI 10.1097/MCG.0b013e31817ff199
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 399HA
UT WOS:000262789800017
PM 19142170
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Marin, MLC
   Couto, CA
   Cancado, ELR
   Carrilho, FJ
   Goldberg, AC
AF Bittencourt, Paulo Lisboa
   Carnevale Marin, Maria Lucia
   Couto, Claudia Alves
   Rachid Cancado, Eduardo Luiz
   Carrilho, Flair Jose
   Goldberg, Anna Carla
TI ANALYSIS OF HFE AND NON-HFE GENE MUTATIONS IN BRAZILIAN PATIENTS WITH
   HEMOCHROMATOSIS
SO CLINICS
LA English
DT Article
DE Hereditary hemochromatosis; Iron overload; HFE mutations; Gene
   mutations; Brazil
ID TRANSFERRIN RECEPTOR-2 TFR2; IRON OVERLOAD; HEREDITARY HEMOCHROMATOSIS;
   H63D HOMOZYGOTES; PROBANDS; C282Y
AB BACKGROUND: Approximately one-half of Brazilian patients with hereditary hemochromatosis (HH) are neither homozygous for the C282Y mutation nor compound heterozygous for the H63D and C282Y mutations that are associated with HH in Caucasians. Other mutations have been described in the HFE gene as well as in genes involved in iron metabolism, such as transferrin receptor 2 (TfR2) and ferroportin 1 (SCL40A1).
   AIMS: To evaluate the role of HFE, TfR2 and SCL40A1 mutations in Brazilian subjects with HH.
   PATIENTS AND METHODS: Nineteen male subjects (median age 42 [range: 20-72] years) with HH were evaluated using the Haemochromatosis StripAssay A (R). This assay is capable of detecting twelve HFE mutations, which are V53M, V59M, H63D, H63H, S65C, Q127H, P160delC, E168Q, E168X, W169X, C282Y and Q283, four TfR2 mutations, which are E60X, M172K, Y250X, AVAQ594-597del, and two SCL40A1 mutations, which are N144H and V162del.
   RESULTS: In our cohort, nine (47%) patients were homozygous for the C282Y mutation, two (11%) were heterozygous for the H63D mutation, and one each (5%) was either heterozygous for C282Y or compound heterozygous for C282Y and H63D. No other mutations in the HFE, TfR2 or SCL40A1 genes were observed in the studied patients.
   CONCLUSIONS: One-third of Brazilian subjects with the classical phenotype of HH do not carry HFE or other mutations that are currently associated with the disease in Caucasians. This observation suggests a role for other yet unknown mutations in the aforementioned genes or in other genes involved in iron homeostasis in the pathogenesis of HH in Brazil.
C1 [Bittencourt, Paulo Lisboa; Rachid Cancado, Eduardo Luiz; Carrilho, Flair Jose] Portuguese Hosp, Salvador, BA, Brazil.
   [Bittencourt, Paulo Lisboa] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Carnevale Marin, Maria Lucia] Univ Sao Paulo, Fac Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   [Couto, Claudia Alves] Univ Fed Minas Gerais, Minas Gerais, Brazil.
   [Goldberg, Anna Carla] Inst Israelita Ensino & Pesquisa Albert Einstein, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Portuguese Hosp, Salvador, BA, Brazil.
EM plbbr@uol.com.br
RI Goldberg, Anna Carla/H-8594-2014; Carrilho, Flair J/I-3046-2012;
   BITTENCOURT, PAULO l/I-5817-2014; Cancado, Eduardo/K-1861-2016; Couto,
   Claudia Alves/H-7420-2013
OI Goldberg, Anna Carla/0000-0003-2600-7940; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Cancado, Eduardo/0000-0002-9309-1524; Couto,
   Claudia Alves/0000-0002-9776-4757
FU Sao Paulo Research Foundation (FAPESB)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [0553/05, 01/09850-0]; Alves de Queiroz
   Family Fund for Research
FX This study was in part supported by the Sao Paulo Research Foundation
   (FAPESB), grants number 0553/05 and 01/09850-0 and Alves de Queiroz
   Family Fund for Research.
CR Agostinho MF, 1999, BLOOD CELL MOL DIS, V25, P324, DOI 10.1006/bcmd.1999.0260
   Aguilar-Martinez P, 2001, GUT, V48, P836, DOI 10.1136/gut.48.6.836
   Aguilar-Martinez P, 2001, BLOOD CELL MOL DIS, V27, P290, DOI 10.1006/bcmd.2001.0382
   Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1
   Barton EH, 2001, BLOOD CELL MOL DIS, V27, P279, DOI 10.1006/bcmd.2001.0380
   Barton JC, 2007, BLOOD CELL MOL DIS, V39, P206, DOI 10.1016/j.bcmd.2007.03.008
   Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129
   Bittencourt PL, 2007, SAO PAULO MED J, V125, P65, DOI 10.1590/S1516-31802007000100014
   Bittencourt PL, 2002, BRAZ J MED BIOL RES, V35, P329, DOI 10.1590/S0100-879X2002000300007
   Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534
   Camaschella C, 1999, HEPATOLOGY, V29, P1563, DOI 10.1002/hep.510290509
   Cançado Rodolfo Delfini, 2006, Sao Paulo Med. J., V124, P55, DOI 10.1590/S1516-31802006000200002
   de Diego C, 2007, EUR J HAEMATOL, V78, P66, DOI 10.1111/j.1600-0609.2006.00775.x
   Fleming Robert E, 2004, Clin Liver Dis, V8, P755, DOI 10.1016/j.cld.2004.06.004
   Gordeuk VR, 2003, BLOOD CELL MOL DIS, V31, P299, DOI 10.1016/S1079-9796(03)00164-5
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Hayashi H, 2006, INTERNAL MED, V45, P1107, DOI 10.2169/internalmedicine.45.1876
   Holmstrom P, 2002, GUT, V51, P723, DOI 10.1136/gut.51.5.723
   Le Gac G, 2003, BLOOD CELL MOL DIS, V30, P231, DOI 10.1016/S1079-9796(03)00036-6
   Mattman A, 2002, BLOOD, V100, P1075, DOI 10.1182/blood-2002-01-0133
   Mcnamara L, 2005, J GASTROEN HEPATOL, V20, P1855, DOI 10.1111/j.1440-1746.2005.03930.x
   McNamara L, 1998, BRIT J HAEMATOL, V102, P1176
   Monaghan KG, 1998, AM J HEMATOL, V58, P213, DOI 10.1002/(SICI)1096-8652(199807)58:3<213::AID-AJH9>3.0.CO;2-U
   Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505
   PEREIRA AC, 2003, HUM BIOL, V73, P145
   Pietrangelo A, 2004, HEPATOLOGY, V39, P21, DOI 10.1002/hep.20007
   Pointon JJ, 2000, GENET TEST, V4, P151, DOI 10.1089/10906570050114867
   Roetto A, 2001, BLOOD, V97, P2555, DOI 10.1182/blood.V97.9.2555
   Salvioni A, 2003, HAEMATOLOGICA, V88, P250
   Siah Chiang W, 2006, Clin Biochem Rev, V27, P5
   Tavill AS, 2001, HEPATOLOGY, V33, P1321, DOI 10.1053/jhep.2001.24783
NR 31
TC 10
Z9 10
U1 0
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2009
VL 64
IS 9
BP 837
EP 841
DI 10.1590/S1807-59322009000900003
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 499OL
UT WOS:000270232700003
PM 19759876
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU da Costa, MZG
   Guarita, DR
   Ono-Nita, SK
   Nogueira, JD
   Nita, ME
   Paranagua-Vezozzo, DC
   de Souza, MT
   do Carmo, EP
   Teixeira, ACD
   Carrilho, FJ
AF Gouvea da Costa, Marianges Zadrozny
   Guarita, Dulce Reis
   Ono-Nita, Suzane Kioko
   Nogueira, Jeronimo de Alencar
   Nita, Marcelo Eidi
   Paranagua-Vezozzo, Denise Cerqueira
   de Souza, Marcelo Tavares
   do Carmo, Eliane Pereira
   de Sa Teixeira, Ana Cristina
   Carrilho, Flair Jose
TI CFTR Polymorphisms in Patients with Alcoholic Chronic Pancreatitis
SO PANCREATOLOGY
LA English
DT Article
DE Pancreatitis/genetics; Cystic fibrosis transmembrane conductance
   regulator; Polymorphisms; Alcoholism
ID CYSTIC-FIBROSIS GENE; SERINE-PROTEASE INHIBITOR; JAPANESE MALE
   ALCOHOLICS; TYPE-1 SPINK1 GENE; MUTATION ANALYSIS; KAZAL TYPE-1;
   DISEASE; CANCER; ASSOCIATION; MANAGEMENT
AB Introduction: Pancreas susceptibility to alcohol is variable and only 5-10% of chronic alcohol abusers develop chronic pancreatitis; the role of genetic factors in this process is unknown. The CFTR gene encodes a protein that acts on epithelial cells and plays a key role in normal exocrine pancreatic function. Methods: This study investigated the frequency of polymorphisms in intron 8 of the CFTR gene in patients with alcoholic chronic pancreatitis. Three groups of patients were studied: group A-68 adult alcoholics with a diagnosis of chronic pancreatitis; group B-68 adult alcoholics without pancreatic disease or liver cirrhosis and group C-104 healthy nonalcoholic adults. Results: T5/T7 genotype was more frequent in group A (11.8%) than in group B (2.9%) (p = 0.0481), and there was no statistical difference when groups A and C (5.8%) were compared (p = 0.1317). The haplotype combination (TG) 10-T7/(TG) 11-T7 was more frequent in groups B (23.5%) and C (20.2%) than in group A (7.3%) (p = 0.0080 and 0.0162). Conclusion: There are differences when these three groups are compared and individuals with T5/T7 genotype might have a greater risk of developing chronic pancreatitis when they become chronic alcoholics. Copyright (C) 2008 S. Karger AG, Basel and IAP
C1 [Gouvea da Costa, Marianges Zadrozny; Guarita, Dulce Reis; Ono-Nita, Suzane Kioko; Nogueira, Jeronimo de Alencar; Nita, Marcelo Eidi; Paranagua-Vezozzo, Denise Cerqueira; de Souza, Marcelo Tavares; do Carmo, Eliane Pereira; de Sa Teixeira, Ana Cristina; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
RP da Costa, MZG (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Eneas Carvalho de Aguiar 255,Room 9159, BR-05403000 Sao Paulo, Brazil.
EM marianges@hotmail.com
RI Carrilho, Flair J/I-3046-2012; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014; Ono, Suzane/I-3107-2012
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; 
FU Funda ao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Alves de Queiroz
   Family Fund for Research
FX This work was supported by grants from Funda ao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) and the Alves de Queiroz Family Fund for
   Research.
CR Ammann RW, 2006, SWISS MED WKLY, V136, P166
   Bendicho MT, 2005, PANCREAS, V30, P333, DOI 10.1097/01.mpa.0000161809.24284.33
   Bernardino Andrea L Ferreira, 2003, JOP, V4, P169
   Bruno MJ, 2001, SCAND J GASTROENTERO, V36, P103, DOI 10.1080/003655201753265532
   Burton PR, 2005, LANCET, V366, P941, DOI 10.1016/S0140-6736(05)67322-9
   Buscail L, 2003, GASTROEN CLIN BIOL, V27, P391
   Casals T, 2004, PANCREAS, V28, P374, DOI 10.1097/00006676-200405000-00004
   Cichoz-Lach H, 2006, ALCOHOL ALCOHOLISM, V41, P14, DOI 10.1093/alcalc/agh225
   Cohn JA, 2004, GASTROENTEROL CLIN N, V33, P817, DOI 10.1016/j.gtc.2004.07.008
   Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639
   Fujiki K, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.014456
   Gaia E, 2002, DIGEST DIS SCI, V47, P2416, DOI 10.1023/A:1020579119691
   GAIA E, 2004, J PANCREAS, V6, P521
   Haber PS, 1999, ALCOHOL CLIN EXP RES, V23, P509, DOI 10.1111/j.1530-0277.1999.tb04145.x
   HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503
   Howes N, 2005, CLIN LAB MED, V25, P39, DOI 10.1016/j.cll.2004.12.004
   Kimura S, 2000, DIGEST DIS SCI, V45, P2007, DOI 10.1023/A:1005500210281
   Kume K, 2005, PANCREATOLOGY, V5, P354, DOI 10.1159/000086535
   Lee KH, 2005, DIGEST DIS SCI, V50, P1852, DOI 10.1007/s10620-005-2950-9
   Lempinen M, 2005, SCAND J GASTROENTERO, V40, P225, DOI 10.1080/00365520510011560
   Lyon E, 2003, ARCH PATHOL LAB MED, V127, P1133
   Malats N, 2001, GUT, V48, P70, DOI 10.1136/gut.48.1.70
   MARQUES ACP, 2002, PROJETO DIRETRIZES, P1
   Monaghan KG, 2000, AM J MED GENET, V94, P120, DOI 10.1002/1096-8628(20000911)94:2<120::AID-AJMG4>3.0.CO;2-N
   MOTT CB, 2004, CONDUTAS GASTROENTER, P632
   Nakamura Y, 2005, PANCREAS, V31, P225, DOI 10.1097/01.mpa.0000175180.70539.b6
   Nakamura Y, 2004, INTERNAL MED, V43, P1131, DOI 10.2169/internalmedicine.43.1131
   Ockenga J, 2003, GASTROENTEROLOGY, V124, P1802, DOI 10.1016/S0016-5085(03)00294-4
   Perri F, 2003, EUR J HUM GENET, V11, P687, DOI 10.1038/sj.ejhg.5201035
   Pezzilli R, 2003, PANCREAS, V27, P332, DOI 10.1097/00006676-200311000-00011
   Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001
   Teich N, 2004, MED SCI MONITOR, V10, pRA325
   Tukiainen E, 2005, PANCREAS, V30, P239, DOI 10.1097/01.mpa.0000157479.84036.ed
   Vantyghem MC, 2005, ANN ENDOCRINOL-PARIS, V66, P347, DOI 10.1016/S0003-4266(05)81792-5
   Verlaan M, 2003, AM J MED GENET A, V120A, P34, DOI 10.1002/ajmg.a.20010
   Whitcomb DC, 2004, GUT, V53, P1710, DOI 10.1136/gut.2003.015511
   Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141
   Witt H, 2000, NAT GENET, V25, P213, DOI 10.1038/76088
   Witt H, 2001, JAMA-J AM MED ASSOC, V285, P2716, DOI 10.1001/jama.285.21.2716-a
   Witt H, 2003, GUT, V52, pII31, DOI 10.1136/gut.52.suppl_2.ii31
NR 40
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1424-3903
EI 1424-3911
J9 PANCREATOLOGY
JI Pancreatology
PY 2009
VL 9
IS 1-2
BP 173
EP 181
DI 10.1159/000178889
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 428SM
UT WOS:000264870000022
PM 19077469
DA 2020-12-08
ER

PT J
AU de Lima, VM
   Oliveira, CPMS
   Alves, VAF
   Charnmas, MC
   Oliveira, EP
   Stefano, JT
   de Mello, ES
   Cerri, GG
   Carrilho, FJ
   Caldwell, SH
AF de Lima, Vicencia M. R.
   Oliveira, Claudia P. M. S.
   Alves, Venancio A. F.
   Charnmas, Maria Cristina
   Oliveira, Ellen Pierre
   Stefano, Jose Tadeu
   de Mello, Evandro Sobroza
   Cerri, Giovanni Guido
   Carrilho, Flair Jose
   Caldwell, Stephen H.
TI A rodent model of NASH with cirrhosis, oval cell proliferation and
   hepatocellular carcinoma
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Hepatocellular carcinoma; Fatty liver; NAFLD; NASH; Cirrhosis; Animal
   model
ID FATTY LIVER-DISEASE; PTEN-DEFICIENT MICE; HEPATITIS-C-VIRUS;
   ACID-DEFINED DIET; HEN-SHI-KO; NONALCOHOLIC STEATOHEPATITIS;
   CYTOKERATIN-19 EXPRESSION; LIPID-PEROXIDATION; DIABETES-MELLITUS;
   RISK-FACTOR
AB Background/Aims: Hepatocellular carcinoma (HCC) is a well recognized complication of advanced NASH (non-alcoholic steatohepatitis). We sought to produce a rat model of NASH, cirrhosis and HCC.
   Methods: Adult Sprague-Dawley rats, weighing 250-300 g, were fed a choline-deficient, high trans-fat diet and exposed to DEN in drinking water. After 16 weeks, the animals underwent liver ultrasound (US), sacrifice and assessment by microscopy, immunohistochemistry and transmission electron microscopy (TEM).
   Results: US revealed steatosis and focal lesions in 6 of 7. All had steatohepatitis defined as inflammation, advanced fibrosis and ballooning with Mallory-Denk bodies (MDB) with frank cirrhosis in 6. Areas of more severe injury were associated with anti-CK19 positive ductular reaction. HCC, present in all, were macro-trabecullar or solid with polyhedral cells with foci of steatosis and ballooned cells. CK19 was positive in single or solid nests of oval cells and in neoplastic hepatocytes. TEM showed ballooning with small droplet fat, dilated endoplasmic reticulum and MDB in non-neoplastic hepatocytes and small droplet steatosis in some cancer cells.
   Conclusions: This model replicated many features of NASH including steatohepatitis with ballooning, fibrosis, cirrhosis and hepatocellular carcinoma. Oval cell proliferation was evident and the presence anti-CK 19 positivity in the cancer suggests oval cell origin of the malignancy. (C) 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
C1 [de Lima, Vicencia M. R.; Oliveira, Claudia P. M. S.; Oliveira, Ellen Pierre; Stefano, Jose Tadeu; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Alves, Venancio A. F.; de Mello, Evandro Sobroza] Univ Sao Paulo, Sch Med, Dept Pathol, BR-05403000 Sao Paulo, Brazil.
   [Charnmas, Maria Cristina; Cerri, Giovanni Guido] Univ Sao Paulo, Sch Med, Dept Radiol, BR-05403000 Sao Paulo, Brazil.
   [Caldwell, Stephen H.] Univ Virginia, Hlth Sci Ctr, GI Hepatol Div, Charlottesville, VA USA.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Av Dr Eneas Carvalho Agiuiar 255,Inst Cent 9159, BR-05403000 Sao Paulo, Brazil.
EM cpm@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose Tadeu/AAH-5419-2020;
   Stefano, Jose T/H-4792-2013; Carrilho, Flair J/I-3046-2012
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
FU Alves Queiroz Family Fund for Research in Sao Paulo; The University of
   Virginia Cancer Center, Commonwealth Cancer Foundation; Mr. Jack P
   Chambers
FX This study wits Supported by the Alves Queiroz Family Fund for Research
   in Sao Paulo, by The University of Virginia Cancer Center, Commonwealth
   Cancer Foundation for Research and by the generous Support of Mr. Jack P
   Chambers.
CR Albano E, 2005, GUT, V54, P987, DOI 10.1136/gut.2004.057968
   Anstee QM, 2006, INT J EXP PATHOL, V87, P1, DOI 10.1111/j.0959-9673.2006.00465.x
   Baumgardner JN, 2008, AM J PHYSIOL-GASTR L, V294, pG27, DOI 10.1152/ajpgi.00296.2007
   Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011
   Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
   CALDWELL SH, 2007, NONALCOHOLIC STEATOH
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   de Oliveira CPMS, 2006, WORLD J GASTROENTERO, V12, P1905, DOI 10.3748/wjg.v12.i12.1905
   Ding SJ, 2004, MOL CELL PROTEOMICS, V3, P73, DOI 10.1074/mcp.M300094-MCP200
   Durnez A, 2006, HISTOPATHOLOGY, V49, P138, DOI 10.1111/j.1365-2559.2006.02468.x
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   El-Serag HB, 2001, AM J GASTROENTEROL, V96, P2462, DOI 10.1111/j.1572-0241.2001.04054.x
   ELSERAG HB, 1999, NEW ENGL J MED, V19, P221
   Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014
   Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925-4773(02)00338-6
   Fausto N, 2004, HEPATOLOGY, V39, P1477, DOI 10.1002/hep.20214
   GANS JH, 1976, P SOC EXP BIOL MED, V153, P116
   GARCEA R, 1984, CELL BIOCHEM FUNCT, V2, P177, DOI 10.1002/cbf.290020312
   HALLIWELL B, 1989, FREE RADICAL BIO MED, P44
   HE XY, 1994, PATHOLOGY, V26, P154, DOI 10.1080/00313029400169401
   Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513
   HSIA CC, 1992, HEPATOLOGY, V16, P1327, DOI 10.1002/hep.1840160604
   Kim WR, 2005, GASTROENTEROLOGY, V129, P486, DOI 10.1053/j.gastro.2005.05.001
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Kojiro M, 2006, PATHOLOGY HEPATOCELL, P77
   Lagiou P, 2000, J NATL CANCER I, V92, P1096, DOI 10.1093/jnci/92.13.1096
   Leandro G, 2006, GASTROENTEROLOGY, V130, P1636, DOI 10.1053/j.gastro.2006.03.014
   Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377
   Li Xiao, 2005, Hepatobiliary Pancreat Dis Int, V4, P427
   Libbrecht L, 2006, SEMIN LIVER DIS, V26, P328, DOI 10.1055/s-2006-951600
   MOLLER H, 1994, EUR J CANCER, V30A, P344, DOI 10.1016/0959-8049(94)90254-2
   MULCAHY LS, 1983, MOL PHARMACOL, V24, P329
   Nair S, 2002, HEPATOLOGY, V36, P150, DOI 10.1053/jhep.2002.33713
   Newell P, 2008, J HEPATOL, V48, P858, DOI 10.1016/j.jhep.2008.01.008
   Niedernhofer LJ, 2003, J BIOL CHEM, V278, P31426, DOI 10.1074/jbc.M212549200
   Oliveira CPMS, 2006, BRAZ J MED BIOL RES, V39, P189, DOI 10.1590/S0100-879X2006000200004
   Oliveira CPMS, 2002, J CELL MOL MED, V6, P399, DOI 10.1111/j.1582-4934.2002.tb00518.x
   Onishi M, 2007, BIOCHEM BIOPH RES CO, V362, P183, DOI 10.1016/j.bbrc.2007.07.175
   Pekow JR, 2007, CANCER-AM CANCER SOC, V109, P2490, DOI 10.1002/cncr.22701
   Powell EE, 2005, GASTROENTEROLOGY, V129, P1937, DOI 10.1053/j.gastro.2005.09.015
   Powell EE, 2005, HEPATOLOGY, V42, P5, DOI 10.1002/hep.20750
   Richardson MM, 2007, GASTROENTEROLOGY, V133, P80, DOI 10.1053/j.gastro.2007.05.012
   de Lima VMR, 2007, LIVER INT, V27, P227, DOI 10.1111/j.1478-3231.2006.01405.x
   Roskams TA, 2004, HEPATOLOGY, V39, P1739, DOI 10.1002/hep.20130
   Sato W, 2006, HEPATOL RES, V34, P256, DOI 10.1016/j.hepres.2006.01.003
   Savransky V, 2007, AM J PHYSIOL-GASTR L, V293, pG871, DOI 10.1152/ajpgi.00145.2007
   SELL S, 1981, GANN, V72, P479
   Shimizu K, 2007, CANCER SCI, V98, P1318, DOI 10.1111/j.1349-7006.2007.00564.x
   Smith PGJ, 1996, HEPATOLOGY, V23, P145, DOI 10.1002/hep.510230120
   Stefano JT, 2007, DIGEST DIS SCI, V52, P3448, DOI 10.1007/s10620-007-9810-8
   Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100
   Takuma Y, 2007, LIVER INT, V27, P620, DOI 10.1111/j.1478-3231.2007.01462.x
   Tanaka A, 2007, WORLD J GASTROENTERO, V13, P5180, DOI 10.3748/wjg.v13.i39.5180
   Theise ND, 2002, LEUKEMIA, V16, P542, DOI 10.1038/sj.leu.2402445
   TRAVIS CC, 1991, TOXICOL APPL PHARM, V109, P289, DOI 10.1016/0041-008X(91)90176-F
   Turlin B, 2002, J HEPATOL, V37, P620, DOI 10.1016/S0168-8278(02)00249-0
   Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x
   VANEYKEN P, 1988, HUM PATHOL, V19, P562, DOI 10.1016/S0046-8177(88)80205-3
   Watanabe S, 2005, HEPATOL RES, V33, P161, DOI 10.1016/j.hepres.2005.09.026
   Wideroff L, 1997, J NATL CANCER I, V89, P1360, DOI 10.1093/jnci/89.18.1360
   Wu PC, 1999, J HEPATOL, V31, P965
   Zhao WD, 2005, J CANCER RES CLIN, V131, P597, DOI 10.1007/s00432-005-0684-x
NR 62
TC 59
Z9 60
U1 0
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD DEC
PY 2008
VL 49
IS 6
BP 1055
EP 1061
DI 10.1016/j.jhep.2008.07.024
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 383XV
UT WOS:000261708600021
PM 18929425
DA 2020-12-08
ER

PT J
AU Vilar, L
   Oliveira, CPMS
   Faintuch, J
   Mello, ES
   Nogueira, MA
   Santos, TE
   Alves, VAF
   Carrilho, FJ
AF Vilar, Lisis
   Oliveira, Claudia P. M. S.
   Faintuch, Joel
   Mello, Evandro S.
   Nogueira, Monize A.
   Santos, Telma E.
   Alves, Venancio A. F.
   Carrilho, Flair J.
TI High-fat diet: A trigger of non-alcoholic steatohepatitis? Preliminary
   findings in obese subjects
SO NUTRITION
LA English
DT Article
DE High-fat diet; Non-alcoholic fatty liver disease; Non-alcoholic
   steatohepatitis; Obesity; Anthropometric measurements; Visceral fat
ID INSULIN-RESISTANCE; LIVER-DISEASE
AB Objective: We correlated dietary profile and markers of visceral and somatic obesities in nonalcoholic fatty liver disease.
   Methods: Patients with histologically proven fatty infiltration of the liver (n = 25, 52 +/- 11 y of age, 64% women) underwent abdominal computed tomography, bioelectrical impedance, and anthropometric measurements. Insulin resistance was evaluated (homeostasis model assessment) and dietary intake of macronutrients was estimated by 24-h recall. Main outcome measurements were correlation of carbohydrate and fat ingestion with liver histology.
   Results: Metabolic syndrome was present in 72% of the population, and increased waist circumference and low high-density lipoprotein cholesterol occurred in 66%. Total body fat (bioimpedance) and dietary intake of lipids were higher in patients with non-alcoholic steatohepatitis (P < 0.05), but not in diabetic subjects who exhibited more steatosis than non-alcoholic steatohepatitis. Waist circumference exhibited a good correlation with homeostasis model assessment, total energy intake, and ingestion of specific fatty acids. Body mass index correlated well with somatic and visceral adiposities.
   Conclusion: Energy intake and visceral adiposity were predisposing factors for fatty liver disease. Lipid input correlated with non-alcoholic steatohepatitis in the entire group and after stratification for diabetes. These findings suggest that lipid intake may play a greater role in non-alcoholic steatohepatitis than hitherto suspected. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Oliveira, Claudia P. M. S.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Hosp Clin Sao Paulo, Sao Paulo, Brazil.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
EM faintuch@net.ipen.br
RI Carrilho, Flair J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014
CR Ahima RS, 2007, GASTROENTEROLOGY, V132, P444, DOI 10.1053/j.gastro.2006.11.048
   Allison DB, 1998, INT J EAT DISORDER, V24, P275, DOI 10.1002/(SICI)1098-108X(199811)24:3&lt;275::AID-EAT5&gt;3.0.CO;2-J
   Arsov T, 2006, BIOCHEM BIOPH RES CO, V342, P1152, DOI 10.1016/j.bbrc.2006.02.032
   Cave M, 2007, J NUTR BIOCHEM, V18, P184, DOI 10.1016/j.jnutbio.2006.12.006
   Cortez-Pinto H, 2006, CLIN NUTR, V25, P816, DOI 10.1016/j.clnu.2006.01.027
   de Piano A, 2007, J PEDIATR GASTR NUTR, V44, P446, DOI 10.1097/MPG.0b013e31803815d9
   George J, 2008, MOL PHARMACEUT, V5, P49, DOI 10.1021/mp700110z
   Gupte P, 2004, J GASTROEN HEPATOL, V19, P854, DOI 10.1111/j.1440-1746.2004.03312.x
   Haukeland JW, 2005, SCAND J GASTROENTERO, V40, P1469, DOI 10.1080/00365520500264953
   Hirooka M, 2005, INTERNAL MED, V44, P794, DOI 10.2169/internalmedicine.44.794
   Jaskiewicz K, 2008, DIGEST DIS SCI, V53, P785, DOI 10.1007/s10620-007-9942-x
   Kennedy ET, 1999, J AM COLL NUTR, V18, P207, DOI 10.1080/07315724.1999.10718853
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Lear SA, 2007, OBESITY, V15, P2817, DOI 10.1038/oby.2007.334
   Lee GS, 2007, J LIPID RES, V48, P1885, DOI 10.1194/jlr.M700181-JLR200
   Machado M, 2006, J HEPATOL, V45, P600, DOI 10.1016/j.jhep.2006.06.013
   Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
   McClain CJ, 2007, HEPATOLOGY, V45, P1343, DOI 10.1002/hep.21788
   Milagro FI, 2006, OBESITY, V14, P1118, DOI 10.1038/oby.2006.128
   Musso G, 2003, HEPATOLOGY, V37, P909, DOI 10.1053/jhep.2003.50132
   Solga S, 2004, DIGEST DIS SCI, V49, P1578, DOI 10.1023/B:DDAS.0000043367.69470.b7
   Sung KC, 2007, DIABETES CARE, V30, P2113, DOI 10.2337/dc07-0512
NR 22
TC 36
Z9 37
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD NOV-DEC
PY 2008
VL 24
IS 11-12
BP 1097
EP 1102
DI 10.1016/j.nut.2008.05.017
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 372VS
UT WOS:000260930700006
PM 18640006
DA 2020-12-08
ER

PT J
AU Siqueira, ERF
   Oliveira, CP
   Correa-Giannella, ML
   Stefano, JT
   Cavaleiro, AM
   Fortes, MAZ
   Muniz, MTC
   Silva, KA
   Silva, FS
   Pereira, LB
   Carrilho, FJ
AF Siqueira, Erika R. F.
   Oliveira, Claudia P.
   Correa-Giannella, Maria Luia
   Stefano, Jose Tadeu
   Cavaleiro, Ana Mercedes
   Fortes, Maria Angela Z.
   Muniz, Maria Tereza C.
   Silva, Karina A.
   Silva, Filipe S.
   Pereira, Leila B.
   Carrilho, Flair J.
TI MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP)-493 G/T POLYMORPHISM IS
   ASSOCIATED WITH INSULIN RESISTANCE IN CHRONIC HEPATITIS C (CHC) GENOTYPE
   1 INFECTION
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 31-NOV 04, 2008
CL San Francisco, CA
SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr
C1 [Siqueira, Erika R. F.; Oliveira, Claudia P.; Stefano, Jose Tadeu; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   [Correa-Giannella, Maria Luia; Cavaleiro, Ana Mercedes; Fortes, Maria Angela Z.] Lab Cellular & Mol Endocrinol LIM 25, Div Endocrinol, Sao Paulo, Brazil.
   [Muniz, Maria Tereza C.; Silva, Karina A.; Silva, Filipe S.; Pereira, Leila B.] Univ Pernambuco, Dept Gastroenterol, Sch Med, Pernambuco, Brazil.
   [Muniz, Maria Tereza C.; Silva, Karina A.; Silva, Filipe S.; Pereira, Leila B.] Univ Pernambuco, Dept Biochem, Sch Med, Pernambuco, Brazil.
   [Siqueira, Erika R. F.; Pereira, Leila B.] Univ Pernambuco, Inst Liver, Sch Med, Recife, PE, Brazil.
RI Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose Tadeu/AAH-5419-2020;
   Stefano, Jose T/H-4792-2013; Carrilho, Flair J/I-3046-2012; Giannella,
   Maria Lucia/N-3834-2019; Fortes, Maria Angela HZ/K-4422-2013
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
NR 0
TC 0
Z9 0
U1 0
U2 4
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2008
VL 48
IS 4
SU S
MA 1084
BP 791A
EP 791A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 356CX
UT WOS:000259757401466
DA 2020-12-08
ER

PT J
AU Lima, VM
   Oliveira, CP
   Barbeiro, DF
   Stefano, JT
   Veloso, I
   Barbeiro, HV
   Caldwell, SH
   Alyes, VAF
   Soriano, FG
   Souza, HP
   Carrilho, FJ
AF Lima, Vicencia M.
   Oliveira, Claudia P.
   Barbeiro, Denise F.
   Stefano, Jose Tadeu
   Veloso, Isabel
   Barbeiro, Hermes V.
   Caldwell, Stephen H.
   Alyes, Venancio Avancini F.
   Soriano, Francisco G.
   Souza, Heraldo P.
   Carrilho, Flair J.
TI HEPATIC GENE EXPRESSION OF HEAT SHOCK PROTEINS (HSP) AND PPAR- ALPHA IN
   EXPERIMENTAL MODEL OF CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN
   NONOALCOHOLIC FATTY LIVER DISEASE (NAFLD)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 31-NOV 04, 2008
CL San Francisco, CA
SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr
C1 [Lima, Vicencia M.; Oliveira, Claudia P.; Stefano, Jose Tadeu; Veloso, Isabel; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Gastroenterol LIM07, Sao Paulo, Brazil.
   [Alyes, Venancio Avancini F.] Univ Sao Paulo, Sch Med, Pathol LIM14, Sao Paulo, Brazil.
   [Caldwell, Stephen H.] Univ Virginia, Hlth Sci Ctr, GI Hepatol Div, Charlottesville, VA USA.
RI Barbeiro, Hermes V/E-2814-2010; Barbeiro, Hermes V/S-5926-2016; Stefano,
   Jose T/H-4792-2013; Stefano, Jose Tadeu/AAH-5419-2020; Soriano,
   Francisco/C-3382-2012; Oliveira, Claudia PMS/D-1216-2014; Carrilho,
   Flair J/I-3046-2012
OI Barbeiro, Hermes V/0000-0002-8209-4463; Barbeiro, Hermes
   V/0000-0002-8209-4463; Stefano, Jose Tadeu/0000-0002-0218-1920; Soriano,
   Francisco/0000-0003-4898-0135; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2008
VL 48
IS 4
SU S
MA 1201
BP 843A
EP 843A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 356CX
UT WOS:000259757401582
DA 2020-12-08
ER

PT J
AU Souza, MM
   Ono-Nita, SK
   Ferreira, CS
   Zanini, C
   Paschoale, HS
   Nasser, PD
   Carmo, EP
   Nita, ME
   Carrilho, FJ
AF Souza, Marcelo M.
   Ono-Nita, Suzane K.
   Ferreira, Camilo S.
   Zanini, Cinthia
   Paschoale, Helena S.
   Nasser, Paulo D.
   Carmo, Eliane P.
   Nita, Marcelo E.
   Carrilho, Flair J.
TI HIPERBILIRUBINEMIA IN PATIENTS WITH CHRONIC HEPATITIS C MAY BE DUE TO
   UGT1A1 PROMOTER POLYMORPHISMS
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 31-NOV 04, 2008
CL San Francisco, CA
SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr
C1 [Souza, Marcelo M.; Ono-Nita, Suzane K.; Ferreira, Camilo S.; Zanini, Cinthia; Paschoale, Helena S.; Nasser, Paulo D.; Carmo, Eliane P.; Nita, Marcelo E.; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Gastroenterol Hepatol Branch, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2008
VL 48
IS 4
SU S
MA 1934
BP 1175A
EP 1175A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 356CX
UT WOS:000259757402610
DA 2020-12-08
ER

PT J
AU Artifon, ELA
   Sakai, P
   Ishioka, S
   Marques, SB
   Lino, AS
   Cunha, JEM
   Jukemura, J
   Cecconello, I
   Carrilho, FJ
   Opitz, E
   Kumar, A
AF Artifon, Everson L. A.
   Sakai, Paulo
   Ishioka, Shinichi
   Marques, Sergio B.
   Lino, Andre S.
   Cunha, Jose E. M.
   Jukemura, Jose
   Cecconello, Ivan
   Carrilho, Flair J.
   Opitz, Eduardo
   Kumar, Atul
TI Endoscopic sphincterotomy before deployment of covered metal stent is
   associated with greater complication rate - A prospective randomized
   control trial
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE endoscopic sphincterotomy; obstructive jaundice; stent
ID MALIGNANT BILIARY OBSTRUCTION; COMMON BILE-DUCT; MANAGEMENT; PALLIATION;
   BYPASS; VATER
AB Objective: Endoscopic sphincterotomy (ES) may facilitate insertion of self expandable metal stent (SEMS) and also help avert the development of pancreatitis from stent-related occlusion of the pancreatic duct. On the other hand, ES is also independently associated with pancreatitis, bleeding, and perforation. We evaluated whether ES before SEMS placement was associated with a greater likelihood of stent migration and other complications in patients with malignant obstruction of the distal common bile duct.
   Methods: Seventy-four patients with unresectable distal bile duct obstruction were prospectively randomized to biliary stenting following ES (group 1) and without ES (group 2). Main outcome measures included overall procedure complications rates including stent migration, stent occlusion, oxygen desaturation, bleeding, perforation, and pancreatitis.
   Results: Covered SEMS were successfully deployed in all patients in both groups. Stent migration occurred in 6 patients (16%) in group 1 and 1 patient (3%) in group 2, P = 0.075. Overall, complications occurred in 18 patients in group 1 and 4 patients in group 2, P = 0.006. There was no pancreatitis in either group.
   Conclusions: Deployment of covered SEMS without prior ES in patients with distal common bile duct obstruction owing to pancreatic cancer is feasible and prevents the development of complications such as stent migration, bleeding, and perforation.
C1 [Kumar, Atul] Northport VA Med Ctr, Northport, NY 11790 USA.
   SUNY Stony Brook, Northport, NY USA.
RP Kumar, A (corresponding author), Northport VA Med Ctr, 79 Middleville Rd, Northport, NY 11790 USA.
EM atul.kumar2@va.gov
RI Carrilho, Flair J/I-3046-2012; Jukemura, Jose/H-6232-2012; Cecconello,
   Ivan/A-3918-2013; da Cunha, Jose Eduardo Monteiro/D-9698-2012
OI Jukemura, Jose/0000-0002-3943-7088; Cecconello,
   Ivan/0000-0002-3535-4170; 
CR Artifon EL, 2005, GASTROINTEST ENDOSC, V61, pAB187, DOI 10.1016/S0016-5107(05)01022-9
   Bethge N, 1996, GASTROINTEST ENDOSC, V43, P596, DOI 10.1016/S0016-5107(96)81592-6
   CLASSEN M, 1974, DEUT MED WOCHENSCHR, V99, P496, DOI 10.1055/s-0028-1107790
   COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2
   Di Giorgio P, 2004, WORLD J GASTROENTERO, V10, P1212
   Freeman ML, 1996, NEW ENGL J MED, V335, P909, DOI 10.1056/NEJM199609263351301
   GILBERT DA, 1992, GASTROINTEST ENDOSC, V38, P750
   Hausegger KA, 1998, AM J ROENTGENOL, V170, P403, DOI 10.2214/ajr.170.2.9456954
   Isayama H, 2002, GASTROINTEST ENDOSC, V55, P366, DOI 10.1067/mge.2002.121876
   Isayama H, 2004, GUT, V53, P729, DOI 10.1136/gut.2003.018945
   KAWAI K, 1974, GASTROINTEST ENDOSC, V20, P148, DOI 10.1016/S0016-5107(74)73914-1
   KNYRIM K, 1993, ENDOSCOPY, V25, P207, DOI 10.1055/s-2007-1010294
   Miyayama S, 1997, J VASC INTERV RADIOL, V8, P641, DOI 10.1016/S1051-0443(97)70624-9
   Nakai Y, 2005, GASTROINTEST ENDOSC, V62, P742, DOI 10.1016/j.gie.2005.06.030
   Rabenstein T, 1998, ENDOSCOPY, V30, pA194, DOI 10.1055/s-2007-1001439
   RAIJMAN W, 2002, WHERE ARE WE GOING W
   SAITO H, 1994, NIPPON ACTA RADIOL, V4, P180
   Santos Y, 2003, REC RES DEV MICROBIO, V7, P175
   SHEPHERD HA, 1988, BRIT J SURG, V75, P1166, DOI 10.1002/bjs.1800751207
   SMITH AC, 1994, LANCET, V344, P1655, DOI 10.1016/S0140-6736(94)90455-3
   Thurnher SA, 1996, CARDIOVASC INTER RAD, V19, P10, DOI 10.1007/s002709900002
   Wamsteker EJ, 2003, GASTROINTEST ENDOSC, V58, P792, DOI 10.1016/S0016-5107(03)02024-8
NR 22
TC 45
Z9 50
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0192-0790
EI 1539-2031
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD AUG
PY 2008
VL 42
IS 7
BP 815
EP 819
DI 10.1097/MCG.0b013e31803dcd8a
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 336UJ
UT WOS:000258389800010
PM 18285718
DA 2020-12-08
ER

PT J
AU Gomes-Gouvea, MS
   Soares, MDP
   Mello, IMVG
   Brito, EMF
   Moia, LDMP
   Bensabath, G
   Nunes, HM
   Carrilho, FJ
   Pinho, JRR
AF Gomes-Gouvea, Michele Soares
   Pereira Soares, Manoel do Carmo
   Vicente Guedes de Carvalho Mello, Isabel Maria
   Figueiredo Brito, Elisabete Maria
   Maues Pereira Moia, Lizomar de Jesus
   Bensabath, Gilberta
   Nunes, Heloisa Marceliano
   Carrilho, Flair Jose
   Rebello Pinho, Joao Renato
TI Hepatitis D and B virus genotypes in chronically infected patients from
   the Eastern Amazon Basin
SO ACTA TROPICA
LA English
DT Article
DE HDV; HBV; genotypes; Amazon; Brazil
ID WESTERN BRAZILIAN AMAZON; NORTHERN SOUTH-AMERICA; DELTA-VIRUS;
   PHYLOGENETIC ANALYSIS; CLINICAL-SIGNIFICANCE; FULMINANT-HEPATITIS; YUCPA
   INDIANS; ENDEMIC AREA; SANTA-MARTA; PREVALENCE
AB Hepatitis D virus (HDV) is a defective hepatotropic virus whose infectivity is dependent on hepatitis B virus (HBV). HDV super- or co-infiection leads to an increased risk of fulminant hepatitis or progression to severe chronic liver disease in HBV infected patients. The Brazilian Amazon Basin has been reported to be endemic for HBV and HDV, especially in the Western Amazon Basin. In this region, HDV infection is frequently associated with acute fulminant hepatitis with characteristic histologic features. HDV is classified into seven major clades (HDV-1 to HDV-7) and HBV is subdivided into eight genotypes (A-H). HDV and HBV genotypes have been shown to have a distinct geographic distribution. The aim of this study was to determine the HBV and HDV genotypes harbored by chronically infected patients from the Eastern Amazon Basin, Brazil. We studied 17 serum samples from HBV and HDV chronically infected patients admitted to a large public hospital (Santa Casa de Misericordia) at Belem, state of Para, Brazil, between 1994 and 2002. HDV-3 and HBV genotype A (subtype adw2) have been identified in all cases, in contrast to previous studies from other regions of the Amazon, where HBV genotype F has been found co-infecting patients that harbored HDV-3. The HDV-3/HBV-A co-infection suggests that there is not a specific interaction between HBV and HDV genotypes, and co-infection might merely reflect the most frequent genotypes found in a particular geographic area. The analysis of the carboxy-terminal region of the large hepatitis D antigen (L-HDAg), which interacts with the hepatitis B surface antigen (HBsAg) and is essential for HDV assembly, showed some diversity between the different isolates from the Eastern Amazon. This diversity is not observed among HDV-3 sequences from other South American regions. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Gomes-Gouvea, Michele Soares; Vicente Guedes de Carvalho Mello, Isabel Maria; Carrilho, Flair Jose; Rebello Pinho, Joao Renato] Univ Sao Paulo, Lab Gastroenterol & Hepatol Trop, Inst Trop Med, Dept Gastroenterol,Sch Med,FMUSP, BR-05403000 Sao Paulo, Brazil.
   [Pereira Soares, Manoel do Carmo; Figueiredo Brito, Elisabete Maria; Bensabath, Gilberta; Nunes, Heloisa Marceliano] Inst Evandro Chagas, Secao Hepatol, BR-66090000 Belem, Para, Brazil.
   [Vicente Guedes de Carvalho Mello, Isabel Maria] Inst Butantan, Lab Imunol Viral, BR-05503900 Sao Paulo, Brazil.
   [Maues Pereira Moia, Lizomar de Jesus] Fundacao Santa Casa Misericordia Para, BR-66050380 Belem, Para, Brazil.
RP Gomes-Gouvea, MS (corresponding author), Univ Sao Paulo, Lab Gastroenterol & Hepatol Trop, Inst Trop Med, Dept Gastroenterol,Sch Med,FMUSP, Av Dr Eneas Carvalho de Aguiar 500, BR-05403000 Sao Paulo, Brazil.
EM gomesmic@yahoo.com.br
RI Pinho, Joao R. R./G-2850-2012; de carvalho-Mello, Isabel Maria V
   G/D-3641-2012; FHV, Inct/K-2346-2013; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
CR BENSABATH G, 1987, JAMA-J AM MED ASSOC, V258, P479, DOI 10.1001/jama.1987.03400040077025
   BUITRAGO B, 1986, HEPATOLOGY, V6, P1285, DOI 10.1002/hep.1840060610
   Casey JL, 1996, J INFECT DIS, V174, P920, DOI 10.1093/infdis/174.5.920
   CASEY JL, 1993, P NATL ACAD SCI USA, V90, P9016, DOI 10.1073/pnas.90.19.9016
   Casey JL, 1996, CLIN LAB MED, V16, P451, DOI 10.1016/S0272-2712(18)30279-8
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159
   Conde Simone Regina Souza da Silva, 2004, Rev. Soc. Bras. Med. Trop., V37, P33, DOI 10.1590/S0037-86822004000700005
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   Guettouche T, 2005, ANTIVIR THER, V10, P593
   HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339
   IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990
   Ivaniushina V, 2001, J GEN VIROL, V82, P2709, DOI 10.1099/0022-1317-82-11-2709
   KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989
   Karayiannis P, 1998, REV MED VIROL, V8, P13, DOI 10.1002/(SICI)1099-1654(199801/03)8:1&lt;13::AID-RMV208&gt;3.0.CO;2-L
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lee CM, 1996, J MED VIROL, V49, P145, DOI 10.1002/(SICI)1096-9071(199606)49:2&lt;145::AID-JMV12&gt;3.0.CO;2-D
   LJUNGGREN KE, 1985, HEPATOLOGY, V5, P299, DOI 10.1002/hep.1840050225
   Manock SR, 2000, AM J TROP MED HYG, V63, P209, DOI 10.4269/ajtmh.2000.63.209
   Nakano T, 2001, J GEN VIROL, V82, P2183, DOI 10.1099/0022-1317-82-9-2183
   Parana R, 2006, AM J TROP MED HYG, V75, P475, DOI 10.4269/ajtmh.2006.75.475
   POPPER H, 1983, HEPATOLOGY, V3, P906
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Quintero A, 2001, J MED VIROL, V64, P356, DOI 10.1002/jmv.1058
   Radjef N, 2004, J VIROL, V78, P2537, DOI 10.1128/JVI.78.5.2537-2544.2004
   Sakugawa H, 1999, J MED VIROL, V58, P366, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt;366::AID-JMV8&gt;3.0.CO;2-X
   Santos E O, 1995, Cad Saude Publica, V11, P212
   Shakil AO, 1997, VIROLOGY, V234, P160, DOI 10.1006/viro.1997.8644
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   SJOGREN MH, 1991, PROG CLIN BIOL RES, V364, P97
   SMEDILE A, 1982, LANCET, V2, P945, DOI 10.1016/S0140-6736(82)90156-8
   Swofford D.L., 2002, PAUP PHYLOGENETIC AN
   TAKAHASHI K, 1995, J GEN VIROL, V76, P3159, DOI 10.1099/0022-1317-76-12-3159
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   Wu JC, 1998, J GEN VIROL, V79, P1105, DOI 10.1099/0022-1317-79-5-1105
   Zhang YY, 1996, J CLIN MICROBIOL, V34, P3023, DOI 10.1128/JCM.34.12.3023-3030.1996
NR 39
TC 25
Z9 25
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD JUN
PY 2008
VL 106
IS 3
BP 149
EP 155
DI 10.1016/j.actatropica.2008.02.009
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 317GB
UT WOS:000257006900002
PM 18420172
DA 2020-12-08
ER

PT J
AU Mattar, R
   Monteiro, MD
   Villares, CA
   dos Santos, AF
   Carrilho, FJ
AF Mattar, Rejane
   Monteiro, Maria do Socorro
   Villares, Cibele Aparecida
   dos Santos, Anibal Ferreira
   Carrilho, Flair Jose
TI Single nucleotide polymorphism C/T-13910, located upstream of the
   lactase gene, associated with adult-type hypolactasia: Validation for
   clinical practice
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE hypolactasia; lactase persistence; lactose malabsorption; single
   nucleotide polymorphism; hydrogen breath test
ID LACTOSE-INTOLERANCE; PERSISTENCE; DNA; DIAGNOSIS; ELEMENT; TESTS
AB Objectives: To validate C/T-13910 polymorphism associated with primary hypolactasia for clinical practice.
   Design and methods: Lactose breath test and PCR-RFLP for the C/T-13910 polymorphism were performed.
   Results: Twenty-seven of 28 patients with genotype CC had positive breath tests, all twenty-two patients with genotypes CT or TT had negative breath tests. Agreement of tests was high (p<0.0001; Kappa Index 0.96).
   Conclusion: C/T-13910 polymorphism detection may be a new tool for primary hypolactasia diagnosis. (C) 2008 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Mattar, Rejane; Monteiro, Maria do Socorro; Villares, Cibele Aparecida; dos Santos, Anibal Ferreira; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, SP, Brazil.
RP Mattar, R (corresponding author), Hosp Clin Sao Paulo, Serv Gastroenterol, Av Dr Eneas Carvalho Aguiar 255,9 Andar,Sala 9159, BR-05403000 Sao Paulo, SP, Brazil.
EM rmattar@hcnet.usp.br
RI Mattar, Rejane/K-3883-2012; Carrilho, Flair J/I-3046-2012; Mattar,
   Rejane/AAO-4842-2020
OI Mattar, Rejane/0000-0001-7870-8867
CR BERNARDESSILVA CF, 2007, CLIN CHIM ACTA
   Bodlaj G, 2006, CLIN CHEM, V52, P148, DOI 10.1373/clinchem.2005.057240
   Buning C, 2005, DIGESTION, V71, P245, DOI 10.1159/000087050
   Enattah NS, 2002, NAT GENET, V30, P233, DOI 10.1038/ng826
   Hogenauer C, 2005, EUR J GASTROEN HEPAT, V17, P371
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mulcare CA, 2004, AM J HUM GENET, V74, P1102, DOI 10.1086/421050
   Olds LC, 2003, HUM MOL GENET, V12, P2333, DOI 10.1093/hmg/ddg244
   Poulter M, 2003, ANN HUM GENET, V67, P298, DOI 10.1046/j.1469-1809.2003.00048.x
   Ridefelt P, 2005, SCAND J GASTROENTERO, V40, P822, DOI 10.1080/00365520510015764
   Robayo-Torres CC, 2006, CLIN GASTROENTEROL H, V4, P276, DOI 10.1016/j.cgh.2005.12.023
   Romagnuolo J, 2002, AM J GASTROENTEROL, V97, P1113, DOI 10.1111/j.1572-0241.2002.05664.x
   Szilagyi A, 2007, CLIN GASTROENTEROL H, V5, P192, DOI 10.1016/j.cgh.2006.06.009
NR 13
TC 28
Z9 30
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD MAY
PY 2008
VL 41
IS 7-8
BP 628
EP 630
DI 10.1016/j.clinbiochem.2008.01.006
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 292JM
UT WOS:000255262300031
PM 18237552
DA 2020-12-08
ER

PT J
AU Mendes, LSC
   Nita, ME
   Ono-Nita, SK
   Mello, ES
   da Silva, LC
   Alves, VAF
   Carrilho, FJ
AF Mendes, Liliana S. C.
   Nita, Marcelo E.
   Ono-Nita, Suzane K.
   Mello, Evandro S.
   da Silva, Luiz Caetano
   Alves, Venancio A. F.
   Carrilho, Flair J.
TI Prognostic factors for progression of liver structural lesions in
   chronic hepatitis C patients
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE hepatitis C; histology; fibrosis; interferons; disease progression
ID INTERFERON-ALPHA; FIBROSIS PROGRESSION; VIRUS GENOTYPES;
   NATURAL-HISTORY; PLATELET COUNT; STEATOSIS; INFECTION; IMPACT; INDEX
AB AIM: To evaluate the epidemiological, clinical, laboratory and histological variables capable of predicting the progression of hepatic structural disturbances in chronic hepatitis C patients during the time interval between two liver biopsies.
   METHODS: Clinical charts of 112 chronic hepatitis C patients were retrospectively analyzed, whereas liver biopsies were revised. Immunohistochemical detection of interferon receptor was based on the Envision-Peroxidase System.
   RESULTS: In the multivariate analysis, the variables in the age at first biopsy, ALT levels, presence of lymphoid aggregates and siderosis were the determinants of the best model for predicting the severity of the disease. The direct progression rate of hepatic structural lesions was significantly higher in untreated patients, intermediate in treated non-responders and lower in treated responders to antiviral therapy (non-treated vs responders, 0.22 +/- 0.50 vs -0.15 +/- 0.46, P = 0.0053). Immuno-expression of interferon receptor is not a relevant factor.
   CONCLUSION: The best predictors of the progression of fibrosis are age at the first liver biopsy, extent of ALT elevation, inflammation at liver histology and hepatic siderosis. Antiviral treatment is effective in preventing the progression of liver structural lesions in chronic hepatitis C patients. (C) 2008 WJG. All rights reserved.
C1 [Mendes, Liliana S. C.; Nita, Marcelo E.; Ono-Nita, Suzane K.; da Silva, Luiz Caetano; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, BR-04537040 Sao Paulo, Brazil.
   [Mello, Evandro S.; Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, BR-04537040 Sao Paulo, Brazil.
RP Carrilho, FJ (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, R Silva Correia,153 Ap 41, BR-04537040 Sao Paulo, Brazil.
EM fjcarril@usp.br
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012
CR Adinolfi LE, 2000, EUR J GASTROEN HEPAT, V12, P299, DOI 10.1097/00042737-200012030-00007
   Albanis Efsevia, 2006, Clin Liver Dis, V10, P821, DOI 10.1016/j.cld.2006.08.027
   Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505
   [Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117
   BEDOSSA P, 1994, HEPATOLOGY, V20, P15
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   Delladetsima JK, 1996, J HEPATOL, V24, P27, DOI 10.1016/S0168-8278(96)80182-6
   El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   Friedman Scott L., 1999, American Journal of Medicine, V107, p27S
   Ghany MG, 2003, GASTROENTEROLOGY, V124, P97, DOI 10.1053/gast.2003.50018
   Giannini E, 2001, EUR J GASTROEN HEPAT, V13, P1355, DOI 10.1097/00042737-200111000-00015
   Koda M, 2007, HEPATOLOGY, V45, P297, DOI 10.1002/hep.21520
   Krug LP, 1996, BRAZ J MED BIOL RES, V29, P1629
   Mathurin P, 1998, HEPATOLOGY, V27, P868, DOI 10.1002/hep.510270333
   Myers RP, 2001, J VIRAL HEPATITIS, V8, P249, DOI 10.1046/j.1365-2893.2001.00288.x
   Ohta T, 2006, ACTA MED OKAYAMA, V60, P77
   Poynard T, 2000, HEPATOLOGY, V32, P1131, DOI 10.1053/jhep.2000.19347
   Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8
   Poynard T, 1997, EUR CYTOKINE NETW, V8, P319
   Poynard T, 2000, SEMIN LIVER DIS, V20, P47, DOI 10.1055/s-2000-9258
   Poynard T, 1997, J VIRAL HEPATITIS, V4, P199, DOI 10.1046/j.1365-2893.1997.00141.x
   Pradat P, 2002, HEPATOLOGY, V36, P973, DOI 10.1053/jhep.2002.35530
   Rubbia-Brandt L, 2000, J HEPATOL, V33, P106, DOI 10.1016/S0168-8278(00)80166-X
   Rumi MG, 2002, J VIRAL HEPATITIS, V9, P71, DOI 10.1046/j.1365-2893.2002.00328.x
   Sobesky R, 1999, GASTROENTEROLOGY, V116, P378, DOI 10.1016/S0016-5085(99)70135-6
   Tassopoulos NC, 1998, HEPATO-GASTROENTEROL, V45, P1678
   Verbaan H, 1998, J VIRAL HEPATITIS, V5, P43, DOI 10.1046/j.1365-2893.1998.00082.x
   Westin J, 2002, J HEPATOL, V37, P837, DOI 10.1016/S0168-8278(02)00299-4
   Wiley TE, 2002, AM J GASTROENTEROL, V97, P700, DOI 10.1111/j.1572-0241.2002.05555.x
   Wright TL, 2002, HEPATOLOGY, V36, pS185, DOI 10.1053/jhep.2002.36812
   Wyatt J, 2004, J CLIN PATHOL, V57, P402, DOI 10.1136/jcp.2003.009357
   Yatsuhashi H, 1999, J HEPATOL, V30, P995, DOI 10.1016/S0168-8278(99)80252-9
NR 34
TC 7
Z9 8
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD APR 28
PY 2008
VL 14
IS 16
BP 2522
EP 2528
DI 10.3748/wjg.14.2522
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 295TN
UT WOS:000255496900008
PM 18442199
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU de Oliveira, CPMS
   de Lima, VMR
   Simplicio, FI
   Soriano, FG
   de Mello, ES
   de Souza, HP
   Alves, VAF
   Laurindo, FRM
   Carrilho, FJ
   de Oliveira, MG
AF de Oliveira, Claudia P. M. S.
   de Lima, Vicencia M. R.
   Simplicio, Fernanda I.
   Soriano, Francisco G.
   de Mello, Evandro S.
   de Souza, Heraldo P.
   Alves, Venancio A. F.
   Laurindo, Francisco R. M.
   Carrilho, Flair J.
   de Oliveira, Marcelo G.
TI Prevention and reversion of nonalcoholic steatohepatitis in ob/ob mice
   by S-nitroso-N-acetylcysteine treatment
SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
LA English
DT Article
DE NASH; oxidative stress; S-nitroso-N-acetylcysteine; nitric oxide
ID LOW-DENSITY-LIPOPROTEIN; FATTY LIVER-DISEASE; NITRIC-OXIDE;
   LIPID-PEROXIDATION; HEPATIC STEATOSIS; NATURAL-HISTORY; RATS;
   PEROXYNITRITE; LIPOGENESIS; OXIDATION
AB Objective: To evaluate the role oral administration of S-nitroso-N-acetylcysteine (SNAC), a NO donor drug, in the prevention and reversion of NASH in two different animal models.
   Methods: NASH was induced in male ob/ob mice by methionine-choline deficient (MCD) and high-fat (H) diets. Two animal groups received or not SNAC orally for four weeks since the beginning of the treatment. Two other groups were submitted to MCD and H diets for 60 days receiving SNAC only from the 31(st) to the 60(th) day.
   Results: SNAC administration inhibited the development of NASH in all groups, leading to a marked decrease in macro and microvacuolar steatosis and in hepatic lipid peroxidation in the MCD group. SNAC treatment reversed the development of NASH in animals treated for 60 days with MCD or H diets, which received SNAC only from the 31(st) to the 60(th) day.
   Conclusions: Oral administration of SNAC markedly inhibited and reversed NASH induced by MCD and H diets in ob/ob mice.
C1 [de Oliveira, Claudia P. M. S.] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Inst Cent,Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Soriano, Francisco G.; de Souza, Heraldo P.] Univ Sao Paulo, Sch Med, Dept Emergency, BR-05403000 Sao Paulo, Brazil.
   [de Mello, Evandro S.; Alves, Venancio A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, BR-05403000 Sao Paulo, Brazil.
   [de Souza, Heraldo P.; Laurindo, Francisco R. M.] Univ Sao Paulo, Sch Med, Inst Heart, BR-05403000 Sao Paulo, Brazil.
   [Simplicio, Fernanda I.; de Oliveira, Marcelo G.] State Univ Campinas UNICAMP, Inst Chem, Campinas, SP, Brazil.
RP de Oliveira, CPMS (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol, Inst Cent,Sch Med, 9 Andar,Sala 9159,Av Dr Eneas de Carvalho Aguiar, BR-05403000 Sao Paulo, Brazil.
EM cpm@usp.br
RI Souza, Heraldo P/C-2498-2012; Carrilho, Flair J/I-3046-2012; de
   Oliveira, Marcelo Ganzarolli/B-4709-2013; Laurindo, Francisco
   R/J-6575-2015; Soriano, Francisco/C-3382-2012; Oliveira, Claudia
   PMS/D-1216-2014
OI de Oliveira, Marcelo Ganzarolli/0000-0002-9371-9975; Soriano,
   Francisco/0000-0003-4898-0135; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2004/04483-7]; Alves
   de Queiroz Family Fund Research; CNPqNational Council for Scientific and
   Technological Development (CNPq) [140702/2003-2]
FX This study was supported in part by Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Grant 2004/04483-7 and Alves de Queiroz
   Family Fund Research. FIS holds a graduate studentship from Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq, Grant
   140702/2003-2.
CR Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445
   Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927
   Clemens MG, 1999, HEPATOLOGY, V30, P1, DOI 10.1002/hep.510300148
   de Oliveira CPMS, 2006, WORLD J GASTROENTERO, V12, P1905, DOI 10.3748/wjg.v12.i12.1905
   de Oliveira MG, 2002, J PHYS CHEM A, V106, P8963, DOI 10.1021/jp025756u
   DEOLIVEIRA CPM, 2002, J CELL MOL MED, V6, P399
   Ewing JF, 1998, FREE RADICAL BIO MED, V25, P621, DOI 10.1016/S0891-5849(98)00083-5
   Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926
   Garcia-Monzon C, 2000, J HEPATOL, V32, P331, DOI 10.1016/S0168-8278(00)80080-X
   Giustarini D, 2003, CLIN CHIM ACTA, V330, P85, DOI 10.1016/S0009-8981(03)00046-9
   Grattagliano I, 2000, J NUTR, V130, P2131
   Hogg N, 1999, BBA-BIOENERGETICS, V1411, P378, DOI 10.1016/S0005-2728(99)00027-4
   Jaworski K, 2001, EUR J PHARMACOL, V425, P11, DOI 10.1016/S0014-2999(01)01166-9
   Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932
   Laurent A, 2004, HEPATOLOGY, V39, P1277, DOI 10.1002/hep.20177
   Letteron P, 1996, J HEPATOL, V24, P200, DOI 10.1016/S0168-8278(96)80030-4
   de Oliveira CPMS, 2006, J HEPATOL, V45, P725, DOI 10.1016/j.jhep.2006.05.017
   McCullough AJ, 2002, J CLIN GASTROENTEROL, V34, P255, DOI 10.1097/00004836-200203000-00013
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   ROBERTSON G, 2001, AM J PHYSIOL-GASTR L, V28, pG1135
   Roediger WE, 2004, IUBMB LIFE, V56, P35, DOI 10.1080/15216540310001649822
   Roediger WEW, 2001, NITRIC OXIDE-BIOL CH, V5, P83, DOI 10.1006/niox.2001.0336
   Rubbo H, 2002, BIOL CHEM, V383, P547, DOI 10.1515/BC.2002.055
   Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q
   SANTOS KFR, 2002, NITRIC OXIDE-BIOL CH, V7, P57
   Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028
   STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928
   STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603
   Violi F, 1999, DIABETES-METAB RES, V15, P283, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<283::AID-DMRR42>3.0.CO;2-U
   WILLUMSEN N, 1993, LIPIDS, V28, P683, DOI 10.1007/BF02535987
   Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829
NR 31
TC 25
Z9 25
U1 0
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0731-5724
EI 1541-1087
J9 J AM COLL NUTR
JI J. Am. Coll. Nutr.
PD APR
PY 2008
VL 27
IS 2
BP 299
EP 305
DI 10.1080/07315724.2008.10719703
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 339VH
UT WOS:000258604900014
PM 18689562
DA 2020-12-08
ER

PT J
AU Alencar, RSM
   Gomes, MMS
   Sitnik, R
   Pinho, JRR
   Malta, FM
   Mello, IMVGC
   Mello, ES
   Bacchella, T
   Machado, MCC
   Alves, VAF
   Carrilho, FJ
AF Alencar, R. S. M.
   Gomes, M. M. S.
   Sitnik, R.
   Pinho, J. R. R.
   Malta, F. M.
   Mello, I. M. V. G. C.
   Mello, E. S.
   Bacchella, T.
   Machado, M. C. C.
   Alves, V. A. F.
   Carrilho, F. J.
TI Low occurrence of occult hepatitis B virus infection and high frequency
   of hepatitis C virus genotype 3 in hepatocellular carcinoma in Brazil
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hepatitis c virus; occult hepatitis B; hepatocellular carcinoma; HCV
   genotypes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SURFACE-ANTIGEN; HBV INFECTION;
   LIVER-DISEASE; CLINICAL-IMPLICATIONS; DNA; PREVALENCE; SERUM; HCV;
   CIRRHOSIS
AB Occult hepatitis B virus (HBV) infection has been reported among patients with hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC). Our aim was to evaluate the presence of occult HBV infection in patients with HCV-related liver cirrhosis (LC) with or without HCC in Sao Paulo, Brazil. Serum and liver tissue samples from 50 hepatitis B surface antigen-negative patients with HCV-related LC who underwent liver transplantation at the University of Sao Paulo School of Medicine Hospital from 1993 to 2004 were divided into groups with LC only (N = 33) and with LC plus HCC ( N = 17). HBV DNA was assayed for serum and paraffin-embedded liver tissue (tumoral and non-tumoral) using real time PCR and only 1 case with HCC had HBV DNA-positive serum. All liver samples were negative. HCV genotype 3 was detected in 17/39 (43.7%) cases. In conclusion, using a sensitive real time PCR directed to detect HBV variants circulating in Brazil, occult hepatitis B infection was not found among HCV-positive cirrhotic patients and was rarely found among HCV-positive HCC patients. These results are probably related to the low prevalence of HBV infection in our population. Furthermore, we have also shown that HCV genotype 3 is frequently found in Brazilian cirrhotic patients, particularly when they also have HCC. More studies involving a large number of cases should be carried out to confirm these data and to further characterize Brazilian HCV genotype isolates to elucidate genetic features that might be related to its carcinogenic potential.
C1 [Gomes, M. M. S.; Pinho, J. R. R.; Malta, F. M.; Mello, I. M. V. G. C.] Univ Sao Paulo, Inst Trop Med, Lab Gastroenterol & Hepatol Trop, BR-05508000 Sao Paulo, Brazil.
   [Alencar, R. S. M.; Gomes, M. M. S.; Pinho, J. R. R.; Malta, F. M.; Bacchella, T.; Machado, M. C. C.; Carrilho, F. J.] Univ Sao Paulo, Fac Med, Dept Gastroenterol, BR-05508000 Sao Paulo, Brazil.
   [Mello, E. S.; Alves, V. A. F.] Univ Sao Paulo, Fac Med, Dept Patol, BR-05508000 Sao Paulo, Brazil.
   [Sitnik, R.; Pinho, J. R. R.] Hosp Israelita Albert Einstein, Dept Patol Clin, Sao Paulo, Brazil.
   [Mello, I. M. V. G. C.] Inst Butantan, Lab Imunol Viral, Sao Paulo, Brazil.
RP Pinho, JRR (corresponding author), Univ Sao Paulo, Inst Trop Med, Lab Gastroenterol & Hepatol Trop, Av Dr Eneas C Aguiar 470, BR-05508000 Sao Paulo, Brazil.
EM jrrpinho@usp.br
RI Sitnik, Roberta/N-4740-2017; Malta, Fernanda/B-1316-2013; Carrilho,
   Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Sitnik, Roberta/0000-0002-6243-8118; Malta,
   Fernanda/0000-0001-8887-5060; Pinho, Joao R. R./0000-0003-3999-0489
CR Allain JP, 2004, TRANSFUS CLIN BIOL, V11, P18, DOI 10.1016/j.tracli.2003.11.007
   Anzola M, 2004, J VIRAL HEPATITIS, V11, P383, DOI 10.1111/j.1365-2893.2004.00521.x
   Brechot C, 2001, HEPATOLOGY, V34, P194, DOI 10.1053/jhep.2001.25172
   Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
   Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104
   Cacciola I, 2000, HEPATOLOGY, V31, P507, DOI 10.1002/hep.510310235
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Dakhama A, 1996, J HISTOCHEM CYTOCHEM, V44, P1205, DOI 10.1177/44.10.8813086
   De Maria N, 2000, AM J GASTROENTEROL, V95, P3529, DOI 10.1016/S0002-9270(00)02164-X
   Ding X, 2003, JPN J INFECT DIS, V56, P12
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   Fabris P, 2004, J CLIN VIROL, V29, P160, DOI 10.1016/S1386-6532(03)00117-3
   Fattovich G, 2001, J VIRAL HEPATITIS, V8, P206, DOI 10.1046/j.1365-2893.2001.00291.x
   Giannini E, 2003, LIVER INT, V23, P12, DOI 10.1034/j.1600-0676.2003.01742.x
   Goncales FL, 2003, CLIN DIAGN LAB IMMUN, V10, P718, DOI 10.1128/CDLI.10.4.718-720.2003
   Hou JL, 2001, HEPATOLOGY, V34, P1027, DOI 10.1053/jhep.2001.28708
   Hu KQ, 2002, J VIRAL HEPATITIS, V9, P243, DOI 10.1046/j.1365-2893.2002.00344.x
   INFANTERIVARD C, 1987, HEPATOLOGY, V7, P660, DOI 10.1002/hep.1840070408
   Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172
   Kao JH, 2002, J CLIN MICROBIOL, V40, P4068, DOI [10.1128/JCM.40.11.4068-4071.2002, 10.1128/JCM.40.8.3047-3049.2002]
   KHRISTOVA M, 2000, ANTIVIR THER S, V5, pB22
   Lee CM, 2006, T ROY SOC TROP MED H, V100, P767, DOI 10.1016/j.trstmh.2005.10.008
   LopezLabrador FX, 1997, J HEPATOL, V27, P959, DOI 10.1016/S0168-8278(97)80137-7
   Murakami Y, 2004, J MED VIROL, V72, P203, DOI 10.1002/jmv.10547
   Ohba K, 2004, SURG TODAY, V34, P842, DOI 10.1007/s00595-004-2818-1
   Pinho J. R. R., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P515
   Rodriguez-Inigo E, 2003, J MED VIROL, V70, P571, DOI 10.1002/jmv.10432
   RUMI MG, 1990, BLOOD, V75, P1654
   Santos EA, 2003, EUR J CLIN MICROBIOL, V22, P92, DOI 10.1007/s10096-002-0868-0
   Shiota G, 2000, J MED VIROL, V62, P151, DOI 10.1002/1096-9071(200010)62:2&lt;151::AID-JMV5&gt;3.0.CO;2-N
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Souza LO, 2004, BRAZ J MED BIOL RES, V37, P1665, DOI 10.1590/S0100-879X2004001100011
   *SPSS, 2006, COMP PROGR VERS 12 0
   Squadrito G, 2002, AM J GASTROENTEROL, V97, P1518, DOI 10.1111/j.1572-0241.2002.05707.x
   Tamori A, 2003, J MED VIROL, V71, P492, DOI 10.1002/jmv.10514
   Tamori A, 2003, J MED VIROL, V69, P475, DOI 10.1002/jmv.10334
   Trevisani F, 2001, J HEPATOL, V34, P570, DOI 10.1016/S0168-8278(00)00053-2
   Yotsuyanagi H, 2001, TRANSFUSION, V41, P1093, DOI 10.1046/j.1537-2995.2001.41091093.x
NR 40
TC 13
Z9 13
U1 0
U2 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD MAR
PY 2008
VL 41
IS 3
BP 235
EP 240
DI 10.1590/S0100-879X2006005000197
PG 6
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 272TG
UT WOS:000253882200010
PM 18097499
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Farias, AQ
   Porta, G
   Cancado, ELR
   Miura, I
   Pugliese, R
   Kalil, J
   Goldberg, AC
   Carrilho, FJ
AF Bittencourt, Paulo Lisboa
   Farias, Alberto Queiroz
   Porta, Gilda
   Cancado, Eduardo L. R.
   Miura, Irene
   Pugliese, Renata
   Kalil, Jorge
   Goldberg, Anna C.
   Carrilho, Flair J.
TI Frequency of concurrent autoimmune disorders in patients with autoimmune
   hepatitis - Effect of age, gender, and genetic background
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE autoimmune hepatitis; autoimmune diseases; autoantibodies; HLA antigens;
   CTLA-4; TNF-alpha
ID CHRONIC ACTIVE HEPATITIS; TYPE-1; HLA; SUSCEPTIBILITY; POLYMORPHISMS;
   HETEROGENEITY; DISTINCTIONS; ASSOCIATION; ANTIGEN; BRAZIL
AB Background: Concurrent autoimmune disorders (CAIDs) have been shown to occur in 22% to 34% of the patients with autoimmune hepatitis (AIH). Their presence has been linked to female gender, older age, and to certain HLA antigens, namely HLA-A11. DRB1*04, and DRB4*01.
   Aims: To assess the frequency and nature of CAID in Brazilian patients with AIH types 1 (AIH-1) and 2 (AIH-2) and to investigate the influence of age, gender, and genetic background in their occurrence.
   Patients and Methods: The presence and nature of CAID was studied in 143 patients [117 females, median age 11 (1.3 to 69)] with AIH-1 (n = 125) and AIH-2 (n = 28). HLA typing and tumor necrosis factor a gene promoter and exon I cytotoxic T lymphocyte associated antigen 4 (CTLA-4) gene polymorphisms were determined by polymerase chain reaction-based techniques.
   Results: The frequency of CAID was similar in patients with AIH-1 (14%) and AIH-2 (18%), but their nature was shown to vary. Arthritis was seen in half of the patients (n = 8) with CAID and AIH-1 and in none of those with AIH-2. Subjects with AIH-1 and CAID were shown to be older [24 (1.3 to 6 1) vs. 11 (1.3 to 69) y P = 0.02] and to have more often circulating antinuclear antibody (76% vs. 40%, P = 0.008) and less frequently antiactin antibodies (33% vs. 75%, P = 0.008) when compared with their counterparts without CAID. No particular HLA-DR and DQ alleles, as well as tumor necrosis factor a and CTLA-4 genotypes, were associated with CAID.
   Conclusions: The nature, but not the frequency, of CAID was shown to vary in AIH-1 and AIH-2. In subjects with AIH-1, CAID was linked to older subjects and to the presence of antinuclear antibody. No predisposition to CAID was associated to HLA-DRB1*04 or DDB4*01 alleles. The observed lower frequency of CAID could be attributed to the lower age of disease onset in Brazilians and to differences in HLA-encoded susceptibility to AIH-1 observed in South America.
C1 Univ Sao Paulo, Inst Chem,Dept Gastroenterol, Sch Med,Liver Unit,Childrens Inst, Inst Heart,Lab Immunol, Sao Paulo, Brazil.
   Portuguese Hosp Salvador, Salvador, BA, Brazil.
RP Bittencourt, PL (corresponding author), Rua Clementino Fraga 220,Apto 1901, Salvador, BA, Brazil.
EM plbbr@uol.com.br
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016;
   BITTENCOURT, PAULO l/I-5817-2014; Farias, Alberto Q/H-7873-2013;
   Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; Farias,
   Alberto/ABB-1291-2020
OI Cancado, Eduardo/0000-0002-9309-1524; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; Farias, Alberto/0000-0002-5572-663X
CR ABUAF N, 1992, HEPATOLOGY, V16, P892, DOI 10.1002/hep.1840160407
   Agarwal K, 2000, HEPATOLOGY, V31, P49, DOI 10.1002/hep.510310110
   Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bittencourt PL, 2003, AM J GASTROENTEROL, V98, P1616, DOI 10.1016/S0002-9270(03)00307-1
   Bittencourt PL, 2001, J HEPATOL, V35, P24, DOI 10.1016/S0168-8278(01)00072-1
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   Cookson S, 1999, HEPATOLOGY, V30, P851, DOI 10.1002/hep.510300412
   CORDONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   Czaja AJ, 1997, AM J GASTROENTEROL, V92, P2197
   Czaja AJ, 2005, HEPATOLOGY, V41, P207, DOI 10.1002/hep.20539
   CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1502, DOI 10.1016/0016-5085(93)90157-8
   Czaja AJ, 2002, AM J GASTROENTEROL, V97, P2051
   Czaja AJ, 2002, J HEPATOL, V37, P302, DOI 10.1016/S0168-8278(02)00182-4
   Czaja AJ, 2000, IMMUNOL REV, V174, P250, DOI 10.1034/j.1600-0528.2002.017401.x
   CZAJA AJ, 1993, HEPATOLOGY, V18, P816, DOI 10.1002/hep.1840180411
   Djilali-Saiah I, 2004, J HEPATOL, V40, P904, DOI 10.1016/j.jhep.2004.02.023
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81
   Goldberg AC, 1998, GENET MOL BIOL, V21, P301, DOI 10.1590/S1415-47571998000300001
   Goldberg AC, 2001, HUM IMMUNOL, V62, P165, DOI 10.1016/S0198-8859(00)00234-2
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
   Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   MA X, 2001, WORLD J GASTROENTERO, V7, P1
   Manns MP, 2006, HEPATOLOGY, V43, pS132, DOI 10.1002/hep.21059
   MARCOS Y, 1994, HEPATOLOGY, V19, P1371, DOI 10.1016/0270-9139(94)90230-5
   Nishioka M, 2000, FALK SYMP, V114, P69
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   ONJI M, 1993, GASTROENTEROL JPN, V28, P134
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
NR 38
TC 35
Z9 39
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0192-0790
EI 1539-2031
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD MAR
PY 2008
VL 42
IS 3
BP 300
EP 305
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 270GN
UT WOS:000253709100014
PM 18223493
DA 2020-12-08
ER

PT J
AU de Oliveira, CPMS
   Stefano, JT
   de Siqueira, ERF
   Silva, LS
   Mazo, DFD
   Lima, VMR
   Furuya, CK
   Mello, ES
   Souza, FG
   Rabello, F
   Santos, TE
   Nogueira, MA
   Caldwell, SH
   Alves, VAF
   Carrilho, FJ
AF Marques Souza de Oliveira, Claudia Pinto
   Stefano, Jose Tadeu
   Forte de Siqueira, Erika Rabelo
   Silva, Leonardo Soares
   de Campos Mazo, Daniel Ferraz
   Rodrigues Lima, Vicencia Mara
   Furuya, Carlos Kioshi
   Mello, Evandro Sobroza
   Souza, Fabricio G.
   Rabello, Fabiola
   Santos, Telma Eugenio
   Nogueira, Monize Aydar
   Caldwell, Stephen H.
   Ferreira Alves, Venancio Avancini
   Carrilho, Flair Jose
TI Combination of N-acetylcysteine and metformin improves histological
   steatosis and fibrosis in patients with non-alcoholic steatohepatitis
SO HEPATOLOGY RESEARCH
LA English
DT Article
DE metformin; N-acetylcysteine; non-alcoholic steatohepatitis; oxidative
   stress
ID CRYPTOGENIC CIRRHOSIS; INSULIN-RESISTANCE; VITAMIN-E; INFLAMMATION;
   MEDIATOR; OBESE
AB Aim: There is no proven medical therapy for the treatment of non-alcoholic steatohepatitis (NASH). Oxidative stress and insulin resistance are the mechanisms that seem to be mostly involved in its pathogenesis. The aim of our study was to evaluate the efficacy of N-acetylcysteine (NAC) in combination with metformin (MTF) in improving the aminotransferases and histological parameters (steatosis, inflammation, hepatocellular ballooning, and fibrosis) after 12 months of treatment.
   Methods: Twenty consecutive patients (mean age 53 +/- 2 years [36-68] and body mass index [BMI] 29 [25-35]) with biopsy-proven NASH were enrolled in the study. NAC (1.2 g/day) and MTF (850-1000 mg/day) were given orally for 12 months. All patients underwent evaluation of serum aminotransferases, fasting lipid profile and serum glucose, anthropometric parameters, and nutritional status at 0 and 12 months. A low calorie diet was prescribed for all patients.
   Results: Serum alanine aminotransferase, high-density lipoprotein, insulin, and glucose concentrations and thehomeostasis model assessment-insulin resistance (HOMA-IR) index were reduced significantly at the end of study (P < 0.05). The BMI declined, but without statistical significance. Aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, cholesterol, and triglycerides levels were not altered with the treatment. Liver steatosis and fibrosis decreased (P < 0.05), but no improvement was noted in lobular inflammation or hepatocellular ballooning. The NASH activity score was significantly improved after treatment.
   Conclusion: Based on the biochemical and histological evidence in this pilot study, NAC in combination with MTF appears to ameliorate several aspects of NASH, including fibrosis. Further studies of this form of combination therapy are warranted to assess its potential efficacy.
C1 [Marques Souza de Oliveira, Claudia Pinto; Stefano, Jose Tadeu; Forte de Siqueira, Erika Rabelo; Silva, Leonardo Soares; de Campos Mazo, Daniel Ferraz; Rodrigues Lima, Vicencia Mara; Furuya, Carlos Kioshi; Souza, Fabricio G.; Rabello, Fabiola; Santos, Telma Eugenio; Nogueira, Monize Aydar; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-01246903 Sao Paulo, Brazil.
   [Mello, Evandro Sobroza; Ferreira Alves, Venancio Avancini] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   [Caldwell, Stephen H.] Univ Virginia, Dept Gastroenterol & Hepatol, Charlottesville, VA USA.
RP de Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Ave Dr Arnaldo 455,3 Andar,3117, BR-01246903 Sao Paulo, Brazil.
EM cpm@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Stefano, Jose Tadeu/AAH-5419-2020;
   Stefano, Jose T/H-4792-2013; Mazo, Daniel FC/D-5631-2015; Carrilho,
   Flair J/I-3046-2012
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Mazo, Daniel
   FC/0000-0002-2164-2630; 
CR Ailhaud G, 2002, CURR OPIN CLIN NUTR, V5, P385, DOI 10.1097/00075197-200207000-00006
   Brunt EM, 2004, SEMIN LIVER DIS, V24, P3
   Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168
   Bugianesi E, 2005, AM J GASTROENTEROL, V100, P1082, DOI 10.1111/j.1572-0241.2005.41583.x
   Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347
   Caldwell SH, 2002, AM J GASTROENTEROL, V97, P2058, DOI 10.1111/j.1572-0241.2002.05922.x
   Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927
   Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1111/j.1572-0241.2003.07486.x
   Clarke D, 2006, PERS INDIV DIFFER, V40, P5, DOI 10.1016/j.paid.2005.05.008
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Cotgreave I A, 1997, Adv Pharmacol, V38, P205
   De Rosa SC, 2000, EUR J CLIN INVEST, V30, P915, DOI 10.1046/j.1365-2362.2000.00736.x
   den Boer M, 2004, ARTERIOSCL THROM VAS, V24, P644, DOI 10.1161/01.ATV.0000116217.57583.6e
   Garg R, 2003, CURR DRUG TARGETS, V4, P487, DOI 10.2174/1389450033490920
   Gillissen A, 1998, RESP MED, V92, P609, DOI 10.1016/S0954-6111(98)90506-6
   Grundy SM, 2004, CIRCULATION, V109, P551, DOI 10.1161/01.CIR.0000112379.88385.67
   Gulbahar O, 2000, GASTROENTEROLOGY, V118, pA1444, DOI 10.1016/S0016-5085(00)81671-6
   Harrison SA, 2004, ALIMENT PHARM THERAP, V20, P623, DOI 10.1111/j.1365-2036.2004.02153.x
   Jansen PLM, 2004, NETH J MED, V62, P217
   Kawanaka M, 2004, HEPATOL RES, V29, P39, DOI 10.1016/j.hepres.2004.02.002
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Kooby DA, 2003, J GASTROINTEST SURG, V7, P1034, DOI 10.1016/j.gassur.2003.09.012
   Lindor KD, 2004, HEPATOLOGY, V39, P770, DOI 10.1002/hep.20092
   Marchesini G, 2001, LANCET, V358, P893, DOI 10.1016/S0140-6736(01)06042-1
   MARCHESINI G, 2005, FATTY LIVER DIS NASH, P55
   McCullough AJ, 2006, J CLIN GASTROENTEROL, V40, pS17
   Mehta K, 2002, NUTR REV, V60, P289, DOI 10.1301/002966402320387224
   Nair S, 2004, ALIMENT PHARM THERAP, V20, P23, DOI 10.1111/j.1365-2036.2004.02025.x
   Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193
   Oliveira CP, 2005, GASTROENTEROLOGY, V128, pA769
   Ong J, 2001, LIVER TRANSPLANT, V7, P797, DOI 10.1053/jlts.2001.24644
   PAMUK GE, 2003, J GASTROEN HEPATOL, V18, P1214
   Pessayre D, 2002, AM J PHYSIOL-GASTR L, V282, pG193, DOI 10.1152/ajpgi.00426.2001
   Ramesh S, 2005, J HEPATOL, V42, pS2, DOI 10.1016/j.jhep.2004.11.022
   Rota C, 2002, ANTIOXID REDOX SIGN, V4, P221, DOI 10.1089/152308602753625988
   Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256
   Sochman J, 2002, J AM COLL CARDIOL, V39, P1422, DOI 10.1016/S0735-1097(02)01797-7
   Suzuki A, 2006, LIVER INT, V26, P1209, DOI 10.1111/j.1478-3231.2006.01362.x
   Tripathy D, 2003, DIABETES, V52, P2882, DOI 10.2337/diabetes.52.12.2882
   Uesugi T, 2002, J IMMUNOL, V168, P2963, DOI 10.4049/jimmunol.168.6.2963
   Uygun A, 2004, ALIMENT PHARM THER, V19, P537, DOI 10.1111/j.1365-2036.2004.01888.x
   Uygun A, 2000, AM J GASTROENTEROL, V95, P3584
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
NR 43
TC 76
Z9 78
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1386-6346
EI 1872-034X
J9 HEPATOL RES
JI Hepatol. Res.
PD FEB
PY 2008
VL 38
IS 2
BP 159
EP 165
DI 10.1111/j.1872-034X.2007.00215.x
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 249WH
UT WOS:000252260500006
PM 18197877
DA 2020-12-08
ER

PT J
AU Lemos, MC
   Fagulha, A
   Coutinho, E
   Gomes, L
   Bastos, M
   Barros, L
   Carrilho, F
   Geraldes, E
   Regateiro, FJ
   Carvatheiro, M
AF Lemos, Manuel C.
   Fagulha, Ana
   Coutinho, Eduarda
   Gomes, Leonor
   Bastos, Margarida
   Barros, Luisa
   Carrilho, Francisco
   Geraldes, Elizabete
   Regateiro, Fernando J.
   Carvatheiro, Manuela
TI Lack of association of vitamin D receptor gene polymorphisms with
   susceptibility to type 1 diabetes mellitus in the Portuguese population
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE vitamin D receptor; VDR; single nucleotide polymorphism; SNP; type 1
   diabetes mellitus; genetic susceptibility
ID BONE-MINERAL DENSITY; FOKI POLYMORPHISM; RISK; COMBINATIONS; GENOTYPE;
   ONSET
AB The vitamin D receptor (VDR) gene is a candidate gene for susceptibility to autoimmune disorders. Association studies of VDR polymorphisms and risk of type 1 diabetes often produced conflicting results in different ethnic backgrounds. The aim of this study was to test for association between common VDR polymorphisms and the genetic susceptibility to type I diabetes in the Portuguese population. We genotyped 207 patients with type 1 diabetes and 249 controls for the FokI T>C (rs10735810), BsmI A>G (rs1544410), Apal G>T (rs7975232), and Taql C>T (rs731236) single nucleotide polymorphisms by polymerase chain reaction and restriction fragment Length polymorphism analysis. The distribution of VDR genotype, allele, and haplotype frequencies did not differ significantly between patients and controls. These data suggest that the single nucleotide polymorphisms of the VDR gene are unlikely to contribute significantly to type 1 diabetes susceptibility in the Portuguese population. (C) 2008 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Lemos, Manuel C.] Univ Beira Interior, Fac Hlth Sci, Hlth Sci Res Ctr CICS, P-6200506 Covilha, Portugal.
   [Lemos, Manuel C.; Fagulha, Ana; Gomes, Leonor; Bastos, Margarida; Barros, Luisa; Carrilho, Francisco; Geraldes, Elizabete; Carvatheiro, Manuela] Univ Hosp Coimbra, Endocrinol Diabet & Metab Serv, P-3000075 Coimbra, Portugal.
   [Lemos, Manuel C.; Coutinho, Eduarda; Regateiro, Fernando J.] Univ Coimbra, Fac Med, Gen Med Serv, P-3004504 Coimbra, Portugal.
RP Lemos, MC (corresponding author), Univ Beira Interior, Fac Hlth Sci, Hlth Sci Res Ctr CICS, P-6200506 Covilha, Portugal.
EM mclemos@fcsaude.ubi.pt
RI Carrilho, Flair J/I-3046-2012; Lemos, Manuel/D-9861-2013; Atwa, Hoda
   Ahmed/E-6199-2019; Coutinho, Eduarda/I-5845-2015
OI Lemos, Manuel/0000-0001-9326-8900; Atwa, Hoda Ahmed/0000-0003-0890-4058;
   Regateiro, Fernando/0000-0003-2619-8871; Coutinho,
   Eduarda/0000-0002-9923-2164; Gomes, Leonor/0000-0001-6576-7104
CR Arai H, 1997, J BONE MINER RES, V12, P915, DOI 10.1359/jbmr.1997.12.6.915
   ArnaizVillena A, 1997, IMMUNOGENETICS, V47, P37, DOI 10.1007/s002510050324
   Audi L, 2004, DIABETIC MED, V21, P393, DOI 10.1111/j.1464-5491.2004.01126.x
   Chang TJ, 2000, CLIN ENDOCRINOL, V52, P575, DOI 10.1046/j.1365-2265.2000.00985.x
   Crofts LA, 1998, P NATL ACAD SCI USA, V95, P10529, DOI 10.1073/pnas.95.18.10529
   Dahlquist G, 1999, DIABETOLOGIA, V42, P51, DOI 10.1007/s001250051112
   Fassbender WJ, 2002, HORM METAB RES, V34, P330, DOI 10.1055/s-2002-33262
   Fronczak CM, 2003, DIABETES CARE, V26, P3237, DOI 10.2337/diacare.26.12.3237
   Garcia D, 2007, DIABETES RES CLIN PR, V77, P134, DOI 10.1016/j.diabres.2006.10.018
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Guja C, 2002, J CELL MOL MED, V6, P75, DOI 10.1111/j.1582-4934.2002.tb00312.x
   Guo SW, 2006, AM J EPIDEMIOL, V164, P711, DOI 10.1093/aje/kwj278
   Gyorffy B, 2002, EUR J ENDOCRINOL, V147, P803, DOI 10.1530/eje.0.1470803
   Hauache OM, 1998, OSTEOPOROSIS INT, V8, P204, DOI 10.1007/s001980050055
   Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1
   Karvonen M, 2000, DIABETES CARE, V23, P1516, DOI 10.2337/diacare.23.10.1516
   Koeleman BPC, 2002, LANCET, V359, P1246, DOI 10.1016/S0140-6736(02)08228-4
   Lin WY, 2006, J CLIN LAB ANAL, V20, P109, DOI 10.1002/jcla.20110
   MATHIEU C, 1994, DIABETOLOGIA, V37, P552, DOI 10.1007/BF00403372
   McDermott MF, 1997, DIABETOLOGIA, V40, P971, DOI 10.1007/s001250050776
   Motohashi Y, 2003, J CLIN ENDOCR METAB, V88, P3137, DOI 10.1210/jc.2002-021881
   Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004-0002
   Nejentsev S, 2004, DIABETES, V53, P2709, DOI 10.2337/diabetes.53.10.2709
   Pani MA, 2002, EUR J ENDOCRINOL, V147, P635, DOI 10.1530/eje.0.1470635
   Pani MA, 2000, DIABETES, V49, P504, DOI 10.2337/diabetes.49.3.504
   Ramos-Lopez E, 2006, ANN NY ACAD SCI, V1079, P327, DOI 10.1196/annals.1375.050
   San-Pedro JI, 2005, AUTOIMMUNITY, V38, P439, DOI 10.1080/08916930500288455
   Skrabic V, 2003, DIABETES RES CLIN PR, V59, P31, DOI 10.1016/S0168-8227(02)00195-X
   Turpeinen H, 2003, EUR J ENDOCRINOL, V149, P591, DOI 10.1530/eje.0.1490591
   Valdivielso JM, 2006, CLIN CHIM ACTA, V371, P1, DOI 10.1016/j.cca.2006.02.016
   van Etten E, 2007, EUR J IMMUNOL, V37, P395, DOI 10.1002/eji.200636043
   Yokota I, 2002, DIABETES CARE, V25, P1244, DOI 10.2337/diacare.25.7.1244
   Zemunik T, 2005, J MOL DIAGN, V7, P600, DOI 10.1016/S1525-1578(10)60593-4
NR 33
TC 46
Z9 50
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0198-8859
EI 1879-1166
J9 HUM IMMUNOL
JI Hum. Immunol.
PD FEB
PY 2008
VL 69
IS 2
BP 134
EP 138
DI 10.1016/j.humimm.2008.01.008
PG 5
WC Immunology
SC Immunology
GA 285PZ
UT WOS:000254790000011
PM 18361940
OA Green Published
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Oliveira, CPMS
   Correa-Giannella, ML
   Kubrusly, MS
   Bellodi-Privato, M
   Caldwell, SH
   Alves, VAF
   Carrilho, FJ
AF Stefano, J. T.
   Oliveira, C. P. M. S.
   Correa-Giannella, M. L.
   Kubrusly, M. S.
   Bellodi-Privato, M.
   Caldwell, S. H.
   Alves, V. A. F.
   Carrilho, F. J.
TI Molecular profiles in human nonalcoholic steatohepatitis (NASH)-related
   hepatocellular carcinoma (HCC) assessed by whole genome bioarray
   hybridization
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 43rd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 23-27, 2008
CL Milan, ITALY
SP European Assoc Study Liver
C1 [Stefano, J. T.; Oliveira, C. P. M. S.; Kubrusly, M. S.; Bellodi-Privato, M.; Carrilho, F. J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Correa-Giannella, M. L.] Univ Sao Paulo, Sch Med, Div Endocrinol, Lab Cellular & Mol Endocrinol LIM 25, Sao Paulo, Brazil.
   [Alves, V. A. F.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   [Caldwell, S. H.] Univ Virginia, Dept Gastroenterol, Charlottesville, VA USA.
   [Caldwell, S. H.] Univ Virginia, Dept Hepatol, Charlottesville, VA USA.
EM jstefano@usp.br
RI Kubrusly, Marcia S/N-3943-2014; Oliveira, Claudia PMS/D-1216-2014;
   Giannella, Maria Lucia/N-3834-2019; Stefano, Jose T/H-4792-2013;
   Stefano, Jose Tadeu/AAH-5419-2020; Carrilho, Flair J/I-3046-2012
OI Kubrusly, Marcia S/0000-0003-3258-5632; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2008
VL 48
SU 2
MA 972
BP S363
EP S363
DI 10.1016/S0168-8278(08)60974-5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 312PL
UT WOS:000256683201463
DA 2020-12-08
ER

PT J
AU Tani, CM
   Abrantes-Lemos, CR
   Nakhle, MC
   Preuhs-Filho, G
   Rodrigues, H
   Deguti, MM
   Kalil, J
   Carrilho, FJ
   Cancado, EL
AF Tani, C. M.
   Abrantes-Lemos, C. R.
   Nakhle, M. C.
   Preuhs-Filho, G.
   Rodrigues, H.
   Deguti, M. M.
   Kalil, J.
   Carrilho, F. J.
   Cancado, E. L.
TI Analysis of classe IIHLA in patients with chronic hepatitis C with
   characteristics of autoimmune hepatitis
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 43rd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 23-27, 2008
CL Milan, ITALY
SP European Assoc Study Liver
C1 [Tani, C. M.; Deguti, M. M.; Carrilho, F. J.; Cancado, E. L.] Univ Sao Paulo, Dept Gastroenterol, Hepatol Branch, Hosp Clin,Sch Med, Sao Paulo, Brazil.
   [Abrantes-Lemos, C. R.; Nakhle, M. C.; Cancado, E. L.] Univ Sao Paulo, Sch Med, LIM 06, Sao Paulo, Brazil.
   [Preuhs-Filho, G.; Rodrigues, H.; Kalil, J.] Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
EM marta.deguti@uol.com.br
RI KALIL, JORGE/C-8029-2012; Carrilho, Flair J/I-3046-2012; Cancado,
   Eduardo/K-1861-2016
OI KALIL, JORGE/0000-0001-8415-4274; Cancado, Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2008
VL 48
SU 2
MA 859
BP S322
EP S323
DI 10.1016/S0168-8278(08)60861-2
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 312PL
UT WOS:000256683201350
DA 2020-12-08
ER

PT J
AU Franca, PHC
   Coelho, HSM
   Brandao, CE
   Segadas, JA
   Quintaes, RF
   Carrilho, FJ
   Ono-Nita, S
   Mattos, AA
   Tovo, C
   Gouvea, VS
   Sablon, E
   Vanderborght, BOM
AF Franca, P. H. C.
   Coelho, H. S. M.
   Brandao, C. E.
   Segadas, J. A.
   Quintaes, R. F.
   Carrilho, F. J.
   Ono-Nita, S.
   Mattos, A. A.
   Tovo, C.
   Gouvea, V. S.
   Sablon, E.
   Vanderborght, B. O. M.
TI The emergence of YMDD mutants precedes biochemical flare by 19 weeks in
   lamivudine-treated chronic hepatitis B patients: an opportunity for
   therapy reevaluation
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hepatitis B; antiviral therapy; lamivudine; drug resistance; YMDD
   variants; hepatitis B virus
ID LONG-TERM LAMIVUDINE; MONITORING DRUG-RESISTANCE; INNO-LIPA HBV;
   ADEFOVIR DIPIVOXIL; VIRUS GENOTYPES; FOLLOW-UP; MUTATIONS; PRECORE;
   IDENTIFICATION; ENTECAVIR
AB Given the loss of therapeutic efficacy associated with the development of resistance to lamivudine (LMV) and the availability of new alternative treatments for chronic hepatitis B patients, early detection of viral genotypic resistance could allow the clinician to consider therapy modification before viral breakthrough and biochemical relapse occur. To this end, 28 LMV-treated patients (44 +/- 12 years; 24 men), on their first therapy schedule, were monitored monthly at four Brazilian centers for the emergence of drug resistance using the reverse hybridization-based INNO-LiPA HBV DR assay and occasionally sequencing (two cases). Positive viral responses (HBV DNA clearance) after 6, 12, and 18 months of therapy were achieved by 57, 68, and 53% of patients, while biochemical responses (serum alanine aminotransferase normalization) were observed in 82, 82, and 53% of cases. All viral breakthrough cases (N = 8) were related to the emergence of YMDD variants observed in 7, 21, and 35% of patients at 6, 12, and 18 months, respectively. The emergence of these variants was not associated with viral genotype, HBeAg expression status, or pretreatment serum alanine aminotransferase levels. The detection of resistance-associated mutations was observed before the corresponding biochemical flare (41 +/- 14 and 60 +/- 15 weeks) in the same individuals. Then, if highly sensitive LMV drug resistance testing is carried out at frequent and regular intervals, the relatively long period ( 19 +/- 2 weeks) between the emergence of viral resistance and the onset of biochemical relapse can provide clinicians with ample time to reevaluate drug therapy.
C1 [Franca, P. H. C.] Univ Regiao, Dept Med, BR-89201972 Joinville, SC, Brazil.
   [Franca, P. H. C.; Gouvea, V. S.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Virol, BR-21941 Rio De Janeiro, RJ, Brazil.
   [Coelho, H. S. M.; Segadas, J. A.; Quintaes, R. F.; Vanderborght, B. O. M.] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Dept Gastroenterol, BR-21941 Rio De Janeiro, RJ, Brazil.
   [Brandao, C. E.] Univ Fed Rio de Janeiro, Hosp Univ Gaffree Guinle, Dept Gastroenterol, Rio De Janeiro, RJ, Brazil.
   [Carrilho, F. J.; Ono-Nita, S.] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   [Mattos, A. A.] Fundacao Fac Fed Ciencias Med Porto Alegre, Dept Med Interne, Porto Alegre, RS, Brazil.
   [Sablon, E.; Vanderborght, B. O. M.] Innogenet NV, Ghent, Belgium.
RP Franca, PHC (corresponding author), Univ Regiao, Dept Med, Univille Caxia Postal 246, BR-89201972 Joinville, SC, Brazil.
EM phfranca@terra.com.br
RI Carrilho, Flair J/I-3046-2012; Vanderborght, Bram/A-1599-2008; Coelho,
   Henrique Sergio Moraes/AAB-3973-2019; Franca, Paulo HC/C-3134-2019
OI Vanderborght, Bram/0000-0003-4881-9341; Franca, Paulo
   HC/0000-0002-1750-9132
CR Akuta N, 2003, J HEPATOL, V38, P315, DOI 10.1016/S0168-8278(02)00410-5
   Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628
   Araujo NM, 2004, ARCH VIROL, V149, P1383, DOI 10.1007/s00705-003-0269-4
   Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285
   Ciancio A, 2004, HEPATOLOGY, V39, P64, DOI 10.1002/hep.20019
   da Silva Luiz Caetano, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P189
   Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702
   Fung SK, 2004, NAT CLIN PRACT GASTR, V1, P90, DOI 10.1038/ncpgasthep0056
   Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087
   Hadziyannis SJ, 2000, HEPATOLOGY, V32, P847, DOI 10.1053/jhep.2000.17915
   Hadziyannis SJ, 2003, NEW ENGL J MED, V348, P800, DOI 10.1056/NEJMoa021812
   HALL TA, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.5598/IMAFUNGUS.2011.02.02.06
   Hussain M, 2003, J CLIN MICROBIOL, V41, P3699, DOI 10.1128/JCM.41.8.3699-3705.2003
   Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201
   Lai CL, 2003, LANCET, V362, P2089, DOI 10.1016/S0140-6736(03)15108-2
   Lai CL, 2006, NEW ENGL J MED, V354, P1011, DOI 10.1056/NEJMoa051287
   Lai CL, 2003, CLIN INFECT DIS, V36, P687, DOI 10.1086/368083
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Liaw YF, 1999, HEPATOLOGY, V30, P567, DOI 10.1002/hep.510300221
   Lok ASF, 2003, GASTROENTEROLOGY, V125, P1714, DOI 10.1053/j.gastro.2003.09.033
   Lok ASF, 2004, HEPATOLOGY, V39, P857, DOI 10.1002/hep.20110
   Lok ASF, 2002, J CLIN MICROBIOL, V40, P3729, DOI 10.1128/JCM.40.10.3729-3734.2002
   Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681
   Matsuda M, 2004, J MED VIROL, V74, P361, DOI 10.1002/jmv.20185
   Moskovitz DN, 2005, J VIRAL HEPATITIS, V12, P398, DOI 10.1111/j.1365-2893.2005.00613.x
   Natsuizaka M, 2005, J VIRAL HEPATITIS, V12, P154, DOI 10.1111/j.1365-2893.2005.00559.x
   Nogales M C, 2004, Gastroenterol Hepatol, V27, P515, DOI 10.1157/13068136
   Ono SK, 2001, J CLIN INVEST, V107, P449, DOI 10.1172/JCI11100
   Osiowy C, 2003, J CLIN MICROBIOL, V41, P5473, DOI 10.1128/JCM.41.12.5473-5477.2003
   Pallier C, 2006, J VIROL, V80, P643, DOI 10.1128/JVI.80.2.643-653.2006
   Papatheodoridis GV, 2002, HEPATOLOGY, V36, P219, DOI 10.1053/jhep.2002.33894
   Sablon Erwin, 2005, Int J Med Sci, V2, P8
   *SBH, 2005, GED S1, V24, pS1
   Schalm SW, 2000, GUT, V46, P562, DOI 10.1136/gut.46.4.562
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Stuyver L, 2000, J CLIN MICROBIOL, V38, P702, DOI 10.1128/JCM.38.2.702-707.2000
   Sun J, 2005, J MED VIROL, V75, P391, DOI 10.1002/jmv.20281
   Tong Shuping, 2005, Int J Med Sci, V2, P2
   *WHO, FACT SHEET 204
   Yuen MF, 2004, J CLIN MICROBIOL, V42, P3932, DOI 10.1128/JCM.42.9.3932-3936.2004
NR 40
TC 2
Z9 2
U1 0
U2 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD DEC
PY 2007
VL 40
IS 12
BP 1605
EP 1614
DI 10.1590/S0100-879X2006005000169
PG 10
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 258BR
UT WOS:000252843900003
PM 17713642
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Stefano, JT
   de Oliveira, CPMS
   Correa-Giannella, ML
   de Lima, VMR
   de Sa, SV
   de Oliveira, EP
   de Mello, ES
   Giannella, D
   Alves, VAF
   Carrilho, FJ
AF Stefano, Jose Tadeu
   de Oliveira, Claudia Pinto Marques Souza
   Correa-Giannella, Maria Lucia
   de Lima, Vicencia Mara Rodrigues
   de Sa, Sandra Valeria
   de Oliveira, Ellen Pierre
   de Mello, Evandro Sobroza
   Giannella-Neto, Daniel
   Alves, Venancio Avancini Ferreira
   Carrilho, Flair Jose
TI Nonalcoholic steatohepatitis (NASH) in OB/OB mice treated with yo jyo
   hen shi ko (YHK): Effects on peroxisome proliferator-activated receptors
   (PPARs) and microsomal triglyceride transfer protein (MTP)
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE nonalcoholic steatohepatitis; methionine/choline-deficient diet;
   peroxisome proliferator-activated receptors; microsomal triglyceride
   transfer protein; yo jyo hen shi ho; reverse transcription-quantitative
   polymerase chain reaction
ID INSULIN-RESISTANCE; CHOLINE-DEFICIENT; NATURAL-HISTORY; GENE-EXPRESSION;
   LIVER STEATOSIS; HIGH-FAT; ALPHA; PPAR-GAMMA-2; K-17.22; GAMMA
AB YHK has antioxidant properties, has a hypoglycemic effect, and may reduce plasma lipid levels. In this study, we examined the hepatic expression of PPAR-alpha and -gamma and MTP in ob/ob mice receiving or not receiving YHK. Ob/ob mice were assigned to receive oral YHK (20 mg/kg/day) fed solution (methionine/choline-deficient [MCD] diet + YHK group) or vehicle (MCD group) by gavage for 4 weeks. Liver fragments were collected for histologic examination and mRNA isolation. PPAR-alpha and -gamma and MTP gene expression was examined by RT-qPCR. YHK treatment was associated with NASH prevention, weight loss, and reduction of visceral fat and of serum concentrations of aminotransferases in comparison to the MCD group. YHK promoted an increment in PPAR-alpha and MTP and a decrement in PPAR-gamma mRNA contents. These findings suggest that modulation of PPAR-alpha and -gamma and MTP RNA expression may be implicated in the protective effect of YHK in experimental NASH, limiting hepatocyte lipid accumulation.
C1 Univ Sao Paulo, Sch Med, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol LIM 14, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Lab Cellular & Mol Endocrinol LIM 25, Sao Paulo, Brazil.
RP Stefano, JT (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Eneas Carvalho Aguiar 255,Inst Cent 9159, BR-05403000 Sao Paulo, Brazil.
EM jstefano@usp.br
RI Stefano, Jose Tadeu/AAH-5419-2020; Carrilho, Flair J/I-3046-2012;
   Giannella, Maria Lucia/N-3834-2019; Stefano, Jose T/H-4792-2013;
   Giannella-Neto, Daniel/B-1475-2008; Oliveira, Claudia PMS/D-1216-2014
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
CR Ameen C, 2005, J BIOL CHEM, V280, P1224, DOI 10.1074/jbc.M412107200
   Armanini D, 2002, EXP CLIN ENDOCR DIAB, V110, P257, DOI 10.1055/s-2002-34587
   BENNETT AJ, 1995, BIOCHEM BIOPH RES CO, V212, P473, DOI 10.1006/bbrc.1995.1994
   Caldwell SH, 2006, J CLIN GASTROENTEROL, V40, pS61
   Chande N, 2006, DIGEST DIS SCI, V51, P1183, DOI 10.1007/s10620-006-8030-y
   Choi SB, 2002, BIOSCI BIOTECH BIOCH, V66, P2036, DOI 10.1271/bbb.66.2036
   Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2
   Edvardsson U, 2006, BIOCHEM BIOPH RES CO, V340, P111, DOI 10.1016/j.bbrc.2005.12.008
   Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926
   Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973
   GHOSHAL AK, 1970, EXP MOL PATHOL, V12, P31, DOI 10.1016/0014-4800(70)90072-9
   GHOSHAL AK, 1993, LAB INVEST, V68, P255
   Hensley K, 2000, CARCINOGENESIS, V21, P983, DOI 10.1093/carcin/21.5.983
   Hui JM, 2003, J GASTROEN HEPATOL, V18, P1115, DOI 10.1046/j.1440-1746.2003.03170.x
   Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1
   Inoue M, 2005, BIOCHEM BIOPH RES CO, V336, P215, DOI 10.1016/j.bbrc.2005.08.070
   Ip E, 2003, HEPATOLOGY, V38, P123, DOI 10.1053/jhep.2003.50307
   Jefferies H, 2003, ANZ J SURG, V73, P517, DOI 10.1046/j.1445-1433.2003.02682.x
   Jeon SM, 2004, J MED FOOD, V7, P358, DOI 10.1089/1096620041938687
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932
   Larter CZ, 2006, J HEPATOL, V44, P253, DOI 10.1016/j.jhep.2005.11.030
   Lee MK, 2005, DIABETES RES CLIN PR, V67, P22, DOI 10.1016/j.diabres.2004.05.013
   LEE SST, 1995, MOL CELL BIOL, V15, P3012
   Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marotta F, 2004, J HEPATOL, V40, P97, DOI 10.1016/S0168-8278(04)90317-0
   Marotta F, 2001, BIOMED RES-TOKYO, V22, P167, DOI 10.2220/biomedres.22.167
   Marotta F, 2001, BIOMED RES-TOKYO, V22, P221, DOI 10.2220/biomedres.22.221
   MAROTTA F, 2001, J PANCREAS S5, V2, P350
   Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223
   Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021
   Mirandola S, 2006, GASTROENTEROLOGY, V130, P1661, DOI 10.1053/j.gastro.2006.02.035
   Negro F, 2006, WORLD J GASTROENTERO, V12, P6756, DOI 10.3748/wjg.v12.i42.6756
   OSHIMA Y, 1987, J NAT PROD, V50, P188, DOI 10.1021/np50050a010
   Park SA, 2006, J ETHNOPHARMACOL, V107, P412, DOI 10.1016/j.jep.2006.03.034
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Phillips C, 2002, ATHEROSCLEROSIS, V160, P355, DOI 10.1016/S0021-9150(01)00721-3
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   de Lima VMR, 2007, LIVER INT, V27, P227, DOI 10.1111/j.1478-3231.2006.01405.x
   Rozen S, 2000, Methods Mol Biol, V132, P365
   RUSHMORE TH, 1984, CANCER LETT, V24, P251, DOI 10.1016/0304-3835(84)90020-X
   Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004
   Siebler J, 2006, WORLD J GASTROENTERO, V12, P2161
   SOTANIEMI EA, 1995, DIABETES CARE, V18, P1373, DOI 10.2337/diacare.18.10.1373
   STEINEGER HH, 1994, EUR J BIOCHEM, V225, P967, DOI 10.1111/j.1432-1033.1994.0967b.x
   Tanaka Naoki, 2006, Nihon Rinsho, V64, P1089
   Tanaka Tomohiro, 2005, Nihon Rinsho, V63, P700
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X
   Uto H, 2005, HEPATOL RES, V32, P235, DOI 10.1016/j.hepres.2005.05.008
   WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P3155, DOI 10.1210/jc.80.11.3155
   White DA, 1998, BRIT J NUTR, V80, P219, DOI 10.1017/S0007114598001263
   Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200
NR 53
TC 15
Z9 17
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD DEC
PY 2007
VL 52
IS 12
BP 3448
EP 3454
DI 10.1007/s10620-007-9810-8
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 229EI
UT WOS:000250785400033
PM 17394061
DA 2020-12-08
ER

PT J
AU Oliveira, CP
   Luna, AMC
   Stefano, JT
   Santos, TE
   Vieira, SM
   De Lima, VMR
   Fortes, MAHZ
   Alves, VAF
   Carrilho, FJ
AF Oliveira, Claudia P.
   Luna, Ana Mercedes C.
   Stefano, Jose T.
   Santos, Telma E.
   Vieira, Suzana M.
   De Lima, Vicencia M. Rodrigues
   Fortes, Maria Angela H. Z.
   Alves, Venancio A. F.
   Carrilho, Flair J.
TI Study of a polymorphism in the glutamatecysteine ligase (GCLC) gene in
   nonalcholic fatty liver disease
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 58th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 02-06, 2007
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Sch Med, LIM 07, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, LIM 25, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, LIM 14, Sao Paulo, Brazil.
RI Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012;
   Fortes, Maria Angela HZ/K-4422-2013; Stefano, Jose Tadeu/AAH-5419-2020;
   Stefano, Jose T/H-4792-2013
OI Stefano, Jose Tadeu/0000-0002-0218-1920; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2007
VL 46
IS 4
SU S
MA 1130
BP 740A
EP 740A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 216WT
UT WOS:000249910401393
DA 2020-12-08
ER

PT J
AU Gomes-Gouvea, MS
   Soares, MP
   Mello, IM
   Brito, EF
   Moia, LP
   Bensabath, G
   Nunes, HM
   Carrilho, FJ
   Pinho, JR
AF Gomes-Gouvea, Michele S.
   Soares, Manoel P.
   Mello, Isabel M.
   Brito, Elizabethe F.
   Moia, Lizomar P.
   Bensabath, Gilberta
   Nunes, Heloisa M.
   Carrilho, Flair J.
   Pinho, Joao R.
TI Hepatitis D (HDV) and B (HBV) viruses genotypes in chronic liver disease
   patients from eastern Amazon Basin
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 58th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 02-06, 2007
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 Inst Med Trop USP, Dept Gastroenterol, Fac Med, Sao Paulo, Brazil.
   Inst Evandro Chagas, Secao Hepatol, Belem, Para, Brazil.
   Inst Butantan, Lab Imunol Viral, Sao Paulo, Brazil.
   Fdn Santa Casa Misericordia Para, Programa Hepatopatias Cronicas, Belem, Para, Brazil.
RI de carvalho-Mello, Isabel Maria V G/D-3641-2012; Carrilho, Flair
   J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2007
VL 46
IS 4
SU S
MA 1477
BP 899A
EP 899A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 216WT
UT WOS:000249910401750
DA 2020-12-08
ER

PT J
AU Lemos, MC
   Carrilho, F
   Rodrigues, F
   Coutinho, E
   Gomes, L
   Carvalheiro, M
   Regateiro, FJ
AF Lemos, Manuel C.
   Carrilho, Francisco
   Rodrigues, Fernando
   Coutinho, Eduarda
   Gomes, Leonor
   Carvalheiro, Manuela
   Regateiro, Fernando J.
TI Genetic polymorphism of CYP2D6 influences susceptibility to papillary
   thyroid cancer
SO CLINICAL ENDOCRINOLOGY
LA English
DT Article
ID S-TRANSFERASE POLYMORPHISMS; METABOLIZING-ENZYMES; GSTM1; NAT2; RISK;
   FREQUENCIES; CARCINOMAS; LOCUS
AB Objectives Xenobiotic-metabolizing enzymes are widely polymorphic and confer interindividual variation in the ability to detoxify carcinogens or to activate pro-carcinogens. A common polymorphism of cytochrome P450 2D6 (CYP2D6) results in lack of enzyme activity and has been associated with an altered susceptibility to several cancers. The aim of this study was to investigate the association between the CYP2D6 poor metaboliser genotype and the risk of papillary thyroid cancer (PTC).
   Design Retrospective case-control study.
   Patients One hundred and eighty-seven patients with PTC and 256 controls.
   Measurements Genotyping was performed by PCR and restriction enzyme analysis to detect the presence of the common CYP2D6*4 poor metaboliser allele.
   Results The frequency of individuals with the homozygous poor metaboliser genotype was lower in the patient group [1.6 vs. 5.5%, P = 0.037, OR = 0.28 (95% CI 0.09-0.93)]. The CYP2D6*4 allele frequency was also lower in the patient group [13.4 vs. 21.7%, P = 0.002, OR = 0.56 (95% CI 0.39-0.80)].
   Conclusions The results suggest that the poor metaboliser genotype is associated with a protective effect against PTC. This could be explained by a possible role of CYP2D6 on the metabolic activation of putative environmental chemical thyroid carcinogens or by linkage to another cancer-causing gene. Further research may allow the identification of metabolic risk factors and contribute towards understanding the molecular mechanisms involved in thyroid carcinogenesis.
C1 Univ Beira Interior, Fac Ciencias Saude, Ctr Invest Ciencias Saude, P-6200506 Covilha, Portugal.
   Hosp Univ Coimbra, Serv Endocrinol Diabet & Metab, Coimbra, Portugal.
   Univ Coimbra, Fac Med, Serv Genet Med, Coimbra, Portugal.
   Inst Portugues Oncol Coimbra Francisco Gentil, Serv Endocrinol, Coimbra, Portugal.
RP Lemos, MC (corresponding author), Univ Beira Interior, Fac Ciencias Saude, Ctr Invest Ciencias Saude, P-6200506 Covilha, Portugal.
EM mclemos@fcsaude.ubi.pt
RI Carrilho, Flair J/I-3046-2012; Lemos, Manuel/D-9861-2013; Coutinho,
   Eduarda/I-5845-2015
OI Lemos, Manuel/0000-0001-9326-8900; Gomes, Leonor/0000-0001-6576-7104;
   Regateiro, Fernando/0000-0003-2619-8871; BANDRES MOYA,
   FERNANDO/0000-0002-4675-8226; Rodrigues, Fernando/0000-0002-4913-3889;
   Coutinho, Eduarda/0000-0002-9923-2164
CR Agundez JAG, 2004, CURR DRUG METAB, V5, P211, DOI 10.2174/1389200043335621
   Agundez JAG, 1997, AGE AGEING, V26, P147, DOI 10.1093/ageing/26.2.147
   Al-Brahim N, 2006, ARCH PATHOL LAB MED, V130, P1057
   Autrup H, 2000, MUTAT RES-GEN TOX EN, V464, P65, DOI 10.1016/S1383-5718(99)00167-9
   Fleming ID, 1997, AJCC CANC STAGING MA
   Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239
   Gaspar J, 2004, CANCER GENET CYTOGEN, V151, P60, DOI 10.1016/j.cancergencyto.2003.09.018
   GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0
   Guengerich FP, 2000, CARCINOGENESIS, V21, P345, DOI 10.1093/carcin/21.3.345
   Hard GC, 1998, ENVIRON HEALTH PERSP, V106, P427, DOI 10.2307/3434174
   Ho T, 2006, ARCH OTOLARYNGOL, V132, P756, DOI 10.1001/archotol.132.7.756
   Ingelman-Sundberg M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/sj.tpj.6500285
   Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010
   Kirsch-Volders M, 2006, CANCER EPIDEM BIOMAR, V15, P1038, DOI 10.1158/1055-9965.EPI-05-0487
   Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836
   Lemos MC, 1998, PHARMACOGENETICS, V8, P561, DOI 10.1097/00008571-199812000-00013
   Lemos MC, 1999, CARCINOGENESIS, V20, P1225, DOI 10.1093/carcin/20.7.1225
   Morari EC, 2002, CANCER EPIDEM BIOMAR, V11, P1485
   Muiras ML, 1998, HUM GENET, V102, P526, DOI 10.1007/s004390050735
   Rostami-Hodjegan A, 1998, PHARMACOGENETICS, V8, P227, DOI 10.1097/00008571-199806000-00005
   Sobin LH, 1997, UICC TNM CLASSIFICAT
   Sobrinho-Simoes M, 2005, VIRCHOWS ARCH, V447, P787, DOI 10.1007/s00428-005-0065-5
   Wilkinson GR, 2005, NEW ENGL J MED, V352, P2211, DOI 10.1056/NEJMra032424
NR 23
TC 11
Z9 13
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0300-0664
J9 CLIN ENDOCRINOL
JI Clin. Endocrinol.
PD AUG
PY 2007
VL 67
IS 2
BP 180
EP 183
DI 10.1111/j.1365-2265.2007.02858.x
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 197BH
UT WOS:000248527600004
PM 17547692
OA Green Published
DA 2020-12-08
ER

PT J
AU Kikuchi, L
   Vezozzo, D
   Chagas, A
   Mello, E
   Farias, A
   Pietrobon, R
   Carrilho, F
   Alves, V
AF Kikuchi, Luciana
   Vezozzo, Denise
   Chagas, Aline
   Mello, Evandro
   Farias, Alberto
   Pietrobon, Ricardo
   Carrilho, Flair
   Alves, Venancio
TI Impact of tumor size and vascular invasion on survival of patients with
   small hepatocellular carcinoma
SO VIRCHOWS ARCHIV
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0945-6317
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD AUG
PY 2007
VL 451
IS 2
BP 378
EP 378
PG 1
WC Pathology
SC Pathology
GA 210KH
UT WOS:000249454600807
DA 2020-12-08
ER

PT J
AU Oliveira, CPMS
   Alves, VAF
   Lima, VMR
   Stefano, JT
   Debbas, V
   Sa, SV
   Wakamatsu, A
   Correa-Giannella, ML
   de Mello, ES
   Havaki, S
   Tiniakos, DG
   Marinos, E
   de Oliveira, MG
   Giannella-Neto, D
   Laurindo, FR
   Caldwell, S
   Carrilho, FJ
AF Oliveira, Claudia P. M. S.
   Alves, Venancio A. F.
   Lima, Vicencia M. R.
   Stefano, Jose Tadeu
   Debbas, Victor
   Sa, Sandra Valeria
   Wakamatsu, Alda
   Correa-Giannella, Maria Lucia
   de Mello, Evandro Sobroza
   Havaki, Sofia
   Tiniakos, Dina G.
   Marinos, Evangelos
   de Oliveira, Marcelo G.
   Giannella-Neto, Daniel
   Laurindo, Francisco R.
   Caldwell, Stephen
   Carrilho, Flair J.
TI Modulation of hepatic microsomal triglyceride transfer protein (MTP)
   induced by S-nitroso-N-acetylcysteine in ob/ob mice
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE NAFLD; NASH; MCD diet; MTP; S-nitroso-N-acetylcysteine; SNAC
ID FATTY LIVER-DISEASE; APOLIPOPROTEIN-B; INSULIN-RESISTANCE;
   NATURAL-HISTORY; STEATOHEPATITIS; STEATOSIS; BINDING; INHIBITION;
   MECHANISM; MODELS
AB We evaluated the effects of a potent NO donor, S-nitroso-N-acetylcysteine (SNAC), on microsomal triglyceride transfer protein (MTP) expression in ob/ob mice. NAFLD was induced in male ob/ob mice using a methionine-choline deficient diet (MCD) concomitantly with oral SNAC fed solution (n = 5) or vehicle (control; n = 5) by gavage daily for 4 weeks. Livers were collected for histology and for assessing MTP by RT-qPCR, Western blot, immunohistochemistry and immunogold electron microscopy analyses. Histological analysis showed diffuse macro and microvesicular steatosis, moderate hepatocellular ballooning and moderate inflammatory infiltrate in ob/ob mice fed the MCD diet. With SNAC, mice showed a marked reduction in liver steatosis (p < 0.01), in parenchymal inflammation (p = 0.02) and in MTP protein immunoexpression in zone III (p = 0.05). Moreover, SNAC caused reduction of MTP protein in Western blot analysis (p < 0.05). In contrast, MTP mRNA content was significantly higher (p < 0.05) in mice receiving SNAC. Immuno-electron microscopy showed MTP localized in the rough endoplasmic reticulum of hepatocytes in both treated and untreated groups. However with SNAC treatment, MTP was also observed surrounding fat globules. Histological improvement mediated by a nitric oxide donor is associated with significantly altered expression and distribution of MTP in this animal model of fatty liver disease. Further studies are in progress to examine possible mechanisms and to develop SNAC as a possible therapy for human fatty liver disease. (C) 2007 Elsevier Inc. All rights reserved.
C1 Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Lab Cellular & Mol Biol Endocrinol, LIM 25, Sao Paulo, Brazil.
   Natl & Kapodistrian Univ Athens, Sch Med, Lab Histol & Embryol, Athens, Greece.
   Univ Estadual Campinas, Inst Chem, Campinas, Brazil.
   Univ Virginia, Dept Gastroenterol & Hepatol, Charlottesville, VA USA.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol, Av Dr Arnaldo,455, Sao Paulo, Brazil.
EM cpm@usp.br
RI Giannella-Neto, Daniel/B-1475-2008; Oliveira, Claudia PMS/D-1216-2014;
   Carrilho, Flair J/I-3046-2012; Laurindo, Francisco R/J-6575-2015;
   Stefano, Jose T/H-4792-2013; de Oliveira, Marcelo
   Ganzarolli/B-4709-2013; Debbas, Victor/J-9475-2012; Stefano, Jose
   Tadeu/AAH-5419-2020; Tiniakos, Dina G/AAA-5708-2020; Giannella, Maria
   Lucia/N-3834-2019
OI de Oliveira, Marcelo Ganzarolli/0000-0002-9371-9975; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
CR Aggarwal Dimple, 2005, BMC Cardiovasc Disord, V5, P30, DOI 10.1186/1471-2261-5-30
   Anstee QM, 2006, INT J EXP PATHOL, V87, P1, DOI 10.1111/j.0959-9673.2006.00465.x
   Bakillah A, 2001, J BIOL CHEM, V276, P31466, DOI 10.1074/jbc.M100390200
   Bakillah A, 2000, BIOCHEMISTRY-US, V39, P4892, DOI 10.1021/bi9924009
   Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927
   Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2
   de Oliveira CPMS, 2006, WORLD J GASTROENTERO, V12, P1905, DOI 10.3748/wjg.v12.i12.1905
   de Oliveira MG, 2002, J PHYS CHEM A, V106, P8963, DOI 10.1021/jp025756u
   Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926
   GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6
   Havaki S, 2006, ULTRASTRUCT PATHOL, V30, P177, DOI 10.1080/01913120600689806
   Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a
   Inoue M, 2005, BIOCHEM BIOPH RES CO, V336, P215, DOI 10.1016/j.bbrc.2005.08.070
   Ip E, 2003, HEPATOLOGY, V38, P123, DOI 10.1053/jhep.2003.50307
   ISII M, 2004, P NATL ACAD SCI USA, V14, P2819
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932
   Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533
   Larter CZ, 2006, J HEPATOL, V44, P253, DOI 10.1016/j.jhep.2005.11.030
   Letteron P, 2003, HEPATOLOGY, V38, P133, DOI 10.1053/jhep.2003.50309
   Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049
   Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5
   McCullough AJ, 2006, J CLIN GASTROENTEROL, V40, pS17
   Mirandola S, 2006, GASTROENTEROLOGY, V130, P1661, DOI 10.1053/j.gastro.2006.02.035
   OLIVEIRA CPM, 2006, J HEPATOL, V45, P725
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Phillips C, 2002, ATHEROSCLEROSIS, V160, P355, DOI 10.1016/S0021-9150(01)00721-3
   POLAK JM, 1997, INTRO IMMUNOCYTOCHEM, P81
   Potter JJ, 2003, J HEPATOL, V38, P281, DOI 10.1016/S0168-8278(02)00414-2
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Shelness GS, 1999, J NUTR, V129, p456S, DOI 10.1093/jn/129.2.456S
   SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109
   Sliskovic I, 2005, J BIOL CHEM, V280, P8733, DOI 10.1074/jbc.M408080200
   Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3
   Zafrani ES, 2004, VIRCHOWS ARCH, V444, P3, DOI 10.1007/s00428-003-0943-7
NR 36
TC 10
Z9 11
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JUL 15
PY 2007
VL 74
IS 2
BP 290
EP 297
DI 10.1016/j.bcp.2007.04.013
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 191VS
UT WOS:000248160700011
PM 17524368
DA 2020-12-08
ER

PT J
AU Alencar, RSSM
   Pinho, JRR
   Carrilho, FJ
   Mello, IMVGC
   Mello, ES
   Alves, VAF
   Malta, FM
   Gomes, MMS
   Sitnik, R
AF Alencar, Regiane S. S. M.
   Pinho, Joao Renato R.
   Carrilho, Flair J.
   Mello, Ivete M. V. G. C.
   Mello, Evandro S.
   Alves, Venancio A. F.
   Malta, F. M.
   Gomes, Michelle M. S.
   Sitnik, R.
TI Occurrence of occult hepatitis B virus infection in hepatitis C
   cirrhotic liver explants with or without hepatocellular carcinoma.
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th Annual Congress of the International-Liver-Transplantation-Society
CY JUN 20-23, 2007
CL Rio de Janeiro, BRAZIL
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Sitnik, Roberta/N-4740-2017; Carrilho,
   Flair J/I-3046-2012; Malta, Fernanda/B-1316-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Sitnik,
   Roberta/0000-0002-6243-8118; Malta, Fernanda/0000-0001-8887-5060
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2007
VL 13
IS 6
SU 1
MA 524
BP S213
EP S213
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 176KU
UT WOS:000247084700523
DA 2020-12-08
ER

PT J
AU Bacchella, T
   Figueira, E
   Barros, M
   Cury, R
   Abdala, E
   Bonazzi, P
   Medeiros, P
   Surjan, R
   Martino, R
   Makdissi, F
   Rocha-Santos, V
   Oliveira, A
   Rocha, JA
   Rocha, JP
   Galvao, FH
   Cancado, ELR
   Farias, AQ
   Sette, H
   Machado, MAC
   Carrilho, FJ
   Machado, MCC
AF Bacchella, T.
   Figueira, E.
   Barros, M.
   Cury, R.
   Abdala, E.
   Bonazzi, P.
   Medeiros, P.
   Surjan, R.
   Martino, R.
   Makdissi, F.
   Rocha-Santos, V.
   Oliveira, A.
   Rocha, J. A.
   Rocha, J. P.
   Galvao, F. H.
   Cancado, E. L. R.
   Farias, A. Q.
   Sette, H.
   Machado, M. A. C.
   Carrilho, F. J.
   Machado, M. C. C.
TI Liver transplantation in 35 patients with fulminant hepatic failure.
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th Annual Congress of the International-Liver-Transplantation-Society
CY JUN 20-23, 2007
CL Rio de Janeiro, BRAZIL
C1 Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil.
RI Abdala, Edson/H-5165-2012; Rocha-Santos, Vinicius/H-2984-2017; Galvao,
   Flavio Henrique Ferreira/D-3487-2017; Carrilho, Flair J/I-3046-2012;
   Cancado, Eduardo/K-1861-2016; machado, marcel/E-2129-2012; Rocha-Santos,
   Vinicius/O-9759-2018
OI Abdala, Edson/0000-0003-0765-6654; Rocha-Santos,
   Vinicius/0000-0002-2643-6094; Galvao, Flavio Henrique
   Ferreira/0000-0003-1924-3208; Cancado, Eduardo/0000-0002-9309-1524;
   machado, marcel/0000-0002-0729-1635; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2007
VL 13
IS 6
SU 1
MA 330
BP S156
EP S156
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 176KU
UT WOS:000247084700331
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Goncalves, LL
   Cancado, ELR
   Carrilho, FJ
AF Farias, A. Q.
   Goncalves, L. L.
   Cancado, E. L. R.
   Carrilho, F. J.
TI Bone disease in primary biliary cirrhosis and renal tubular acidosis
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Letter
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
RP Farias, AQ (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
EM albertofarias@terra.com.br
RI Farias, Alberto/ABB-1291-2020; Cancado, Eduardo/K-1861-2016; Farias,
   Alberto Q/H-7873-2013; Carrilho, Flair J/I-3046-2012
OI Farias, Alberto/0000-0002-5572-663X; Cancado,
   Eduardo/0000-0002-9309-1524; 
CR Allocca M, 2007, ALIMENT PHARM THER, V25, P219, DOI 10.1111/j.1365-2036.2006.03181.x
   Farias AQ, 2005, J GASTROEN HEPATOL, V20, P147, DOI 10.1111/j.1400-1746.2004.03517.x
NR 2
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0269-2813
J9 ALIMENT PHARM THERAP
JI Aliment. Pharmacol. Ther.
PD MAY 1
PY 2007
VL 25
IS 9
BP 1133
EP 1133
DI 10.1111/j.1365-2036.2007.03273.x
PG 1
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 155TX
UT WOS:000245602300015
PM 17439515
OA Bronze
DA 2020-12-08
ER

PT J
AU Engel, M
   Malta, FM
   Gomes, MMS
   Mello, IMGC
   Pinho, JRR
   Ono-Nita, SK
   Carrilho, FJ
AF Engel, Maricea
   Malta, Fernanda M.
   Gomes, Michele M. S.
   Mello, Isabel M. V. G. C.
   Pinho, Joao R. R.
   Ono-Nita, Suzane K.
   Carrilho, Flair J.
TI Acute hepatitis C virus infection assessment among chronic hemodialysis
   patients in the Southwest Parana State, Brazil
SO BMC PUBLIC HEALTH
LA English
DT Article
ID INTERFERON THERAPY; HCV INFECTION; FOLLOW-UP; TRANSMISSION; PREVALENCE;
   IMPACT; ALPHA; LOAD
AB Background: Chronic hemodialysis patients are at higher risk for acquiring hepatitis C virus (HCV). The prevalence varies among different countries and hemodialysis centers. Although guidelines for a comprehensive infection control program exist, the nosocomial transmission still accounts for the new cases of infection. The aim of this study was analyze the follow up of newly acquired acute hepatitis C cases, during the period from January 2002 to May 2005, in the Hemodialysis Center, located in the Southwest region of Parana State, Brazil and to analyze the effectiveness of the measures to restrain the appearance of new cases of acute hepatitis C.
   Methods: Patients were analyzed monthly with anti-HCV tests and ALT measurements. Patients with ALT elevations were monitored for possible acute hepatitis C.
   Results: During this period, 32 new cases were identified with acute hepatitis C virus infection. Blood screening showed variable ALT levels preceding the anti-HCV seroconversion. HCV RNA viremia by PCR analysis was intermittently and even negative in some cases. Ten out of 32 patients received 1 mcg/kg dose of pegylated interferon alfa-2b treatment for 24 weeks. All dialysis personnel were re-trained to strictly follow the regulations and recommendations regarding infection control, proper methods to clean and disinfect equipment were reviewed and HCV-positive patients were isolated.
   Conclusion: Laboratory tests results showed variable ALT preceding anti-HCV seroconversion and intermittent viremia. The applied recommendations contributed importantly to restrain the appearance of new cases of acute hepatitis C in this center and the last case was diagnosed in May 2004.
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, Sao Paulo, Brazil.
RP Carrilho, FJ (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, Sao Paulo, Brazil.
EM engel@superig.com.br; femalta@yahoo.com; gomesmic@hotmail.com;
   imvgcmello@uol.com.br; jrrpinho@usp.br; skon@usp.br; fjcarril@usp.br
RI Carrilho, Flair J/I-3046-2012; Malta, Fernanda/B-1316-2013; Pinho, Joao
   R. R./G-2850-2012; Ono, Suzane/I-3107-2012; de carvalho-Mello, Isabel
   Maria V G/D-3641-2012
OI Malta, Fernanda/0000-0001-8887-5060; Pinho, Joao R.
   R./0000-0003-3999-0489; 
CR [Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117
   *ANVISA, 2004, EST REG TECN FUNC SE, V154
   Barril G, 2003, ANTIVIR RES, V60, P129, DOI 10.1016/j.antiviral.2003.08.008
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Castell Juan, 2005, Gac Sanit, V19, P214, DOI 10.1157/13075954
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Delarocque-Astagneau E, 2002, INFECT CONT HOSP EP, V23, P328, DOI 10.1086/502060
   dosSantos JP, 1996, NEPHROL DIAL TRANSPL, V11, P2017
   Espinosa M, 2001, CLIN NEPHROL, V55, P220
   Fabrizi F, 2003, J NEPHROL, V16, P467
   Fabrizi F, 2000, AM J KIDNEY DIS, V35, P122, DOI 10.1016/S0272-6386(00)70310-6
   Foster GR, 2004, ALIMENT PHARM THER, V20, P825, DOI 10.1111/j.1365-2036.2004.02170.x
   Galan F, 1998, NEPHROL DIAL TRANSPL, V13, P1211, DOI 10.1093/ndt/13.5.1211
   Gouveia Ericson Cavalcanti, 2004, Rev. Soc. Bras. Med. Trop., V37, P18, DOI 10.1590/S0037-86822004000100005
   GUH JY, 1995, NEPHRON, V69, P459, DOI 10.1159/000188520
   Gursoy M, 2001, J VIRAL HEPATITIS, V8, P70, DOI 10.1046/j.1365-2893.2001.00268.x
   Jadoul M, 1998, KIDNEY INT, V53, P1022, DOI 10.1111/j.1523-1755.1998.00823.x
   McLaughlin KJ, 1997, NEPHROL DIAL TRANSPL, V12, P304, DOI 10.1093/ndt/12.2.304
   Nomura H, 2004, HEPATOLOGY, V39, P1213, DOI 10.1002/hep.20196
   Petrosillo N, 2001, AM J KIDNEY DIS, V37, P1004, DOI 10.1016/S0272-6386(05)80017-4
   Pol S, 2002, SEMIN NEPHROL, V22, P331, DOI 10.1053/snep.2002.33674
   Pujol FH, 1996, J CLIN MICROBIOL, V34, P1633, DOI 10.1128/JCM.34.7.1633-1636.1996
   Saab S, 2001, AM J KIDNEY DIS, V37, P308, DOI 10.1053/ajkd.2001.21294
   Tokars JI, 1998, ASAIO J, V44, P98, DOI 10.1097/00002480-199801000-00019
   [Anonymous], 2001, MMWR Recomm Rep, V50, P1
   Urbanek P, 2004, BLOOD PURIFICAT, V22, P344, DOI 10.1159/000079871
   Yang CS, 2003, J FORMOS MED ASSOC, V102, P79
   YASUDA K, 1995, GASTROENTEROLOGY, V109, P1295, DOI 10.1016/0016-5085(95)90591-X
NR 28
TC 18
Z9 19
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD APR 4
PY 2007
VL 7
AR 50
DI 10.1186/1471-2458-7-50
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 160PP
UT WOS:000245955100001
PM 17408470
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Chagas, AL
   Kikuchi, LO
   Vezozzo, DP
   Mello, ES
   Silva, LS
   Cella, LC
   Oliveira, AC
   Oliveira, CP
   Caldwell, SH
   Bachella, T
   Alves, VA
   Carrilho, FJ
AF Chagas, Aline L.
   Kikuchi, Luciana O.
   Vezozzo, Denise P.
   Mello, Evandro S.
   Silva, Leonard S.
   Cella, Luciana C.
   Oliveira, Andre C.
   Oliveira, Claudia P.
   Caldwell, Steve H.
   Bachella, Telesforo
   Alves, Venancio A.
   Carrilho, Flair J.
TI Hepatocellular carcinoma (HCC) in biopsy proven nonalcoholic
   steatohepatitis (NASH)
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Digestive Disease Weeking Meeting/ASGE Postgraduate Course Meeting
CY MAY 19-24, 2007
CL Washington, DC
SP ASGE
RI Carrilho, Flair J/I-3046-2012; Chagas, Aline Lopes/X-2059-2019;
   Oliveira, Claudia PMS/D-1216-2014
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2007
VL 132
IS 4
SU 2
BP A812
EP A813
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 160FZ
UT WOS:000245927606471
DA 2020-12-08
ER

PT J
AU Furuya, CK
   de Oliveira, CPMS
   de Mello, ES
   Faintuch, J
   Raskovski, A
   Matsuda, M
   Vezozzo, DCP
   Halpern, A
   Garrido, AB
   Alves, VAF
   Carrilho, FJ
AF Furuya, Carlos K., Jr.
   de Oliveira, Claudia P. M. S.
   de Mello, Evandro S.
   Faintuch, Joel
   Raskovski, Alessandra
   Matsuda, Mitsunori
   Vezozzo, Denise C. P.
   Halpern, Alfredo
   Garrido, Arthur B., Jr.
   Alves, Venancio A. F.
   Carrilho, Flair J.
TI Effects of bariatric surgery on nonalcoholic fatty liver disease:
   Preliminary findings after 2 years
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE bariatric surgery; fatty liver; morbid obesity; nonalcoholic
   steatohepatitis
ID MORBIDLY OBESE-PATIENTS; INSULIN-RESISTANCE; METABOLIC SYNDROME; HEPATIC
   STEATOSIS; NATURAL-HISTORY; STEATOHEPATITIS; FIBROSIS; BYPASS
AB Background and Aim: Although nonalcoholic fatty liver disease (NAFLD) is very common among morbidly obese patients, the effect of weight loss after bariatric surgery on inflammation and fibrosis related to NAFLD is still a matter of debate. The aim of this study was to evaluate the impact of Roux-en-Y gastric bypass (RYGB) surgery on NAFLD with a follow up of 2 years.
   Methods: Eighteen consecutive NAFLD patients with body mass index >40 kg/m(2) undergoing gastroplasty with RYGB were enrolled, and wedge liver biopsy was obtained at the operation. After 2 years, these patients underwent percutaneous liver biopsy.
   Results: At baseline, 67% of patients had nonalcoholic steatohepatitis (NASH) and 33% had steatosis, according to the NASH Clinical Research Network Scoring System (NAS) for biopsy. Cirrhosis was present in 5.5% of the patients with NASH. After a mean excess weight loss of 60%, steatosis disappeared in 84% and fibrosis disappeared in 75% of the patients. Hepatocellular ballooning disappeared in 50%. A slight lobular inflammatory infiltrate remained in 81%, apparently unrelated to fatty degeneration. As liver biochemical variables had been found within normal limits in 92.3% of patients at initial biopsy, no difference was found 2 years later. Lipid profile and blood sugar plasma concentration were closer to normal in all patients after 2 years (P < 0.05).
   Conclusions: Aspects of NAFLD including steatohepatitis improved significantly with massive weight loss at 2 years after RYGB surgery. No patient in this series had progression of hepatic fibrosis.
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Div Endocrinol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Div Endocrinol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Internal Med, Div Endocrinol, Sao Paulo, Brazil.
RP de Oliveira, CPMS (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol, Av Dr Eneas Carvalho Aguiar 255,ICHC 90 Andar,Sal, BR-05403000 Sao Paulo, Brazil.
EM cpm@usp.br
RI Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014; Oliveira, Claudia
   PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; 
CR Clark JM, 2005, OBES RES, V13, P1180, DOI 10.1038/oby.2005.140
   Crespo J, 2001, OBES SURG, V11, P254, DOI 10.1381/096089201321336548
   Dam-Larsen S, 2004, GUT, V53, P750, DOI 10.1136/gut.2003.019984
   Deitel M, 2003, OBES SURG, V13, P159, DOI 10.1381/096089203764467117
   Dixon JB, 2001, GASTROENTEROLOGY, V121, P91, DOI 10.1053/gast.2001.25540
   Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926
   Gholam PM, 2002, OBES SURG, V12, P49, DOI 10.1381/096089202321144577
   GRIMM IS, 1992, AM J GASTROENTEROL, V87, P775
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Hocking MP, 1998, DIGEST DIS SCI, V43, P2493, DOI 10.1023/A:1026698602714
   HOPPER KD, 1995, AM J ROENTGENOL, V164, P221, DOI 10.2214/ajr.164.1.7998543
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Kral JG, 2004, SURGERY, V135, P48, DOI 10.1016/j.surg.2003.10.003
   Luyckx FH, 2000, DIABETES METAB, V26, P98
   MacDonald K G Jr, 1997, J Gastrointest Surg, V1, P213, DOI 10.1016/S1091-255X(97)80112-6
   McCullough AJ, 2002, J CLIN GASTROENTEROL, V34, P255, DOI 10.1097/00004836-200203000-00013
   Moretto M, 2003, OBES SURG, V13, P622, DOI 10.1381/096089203322190853
   Mottin CC, 2005, OBES SURG, V15, P788, DOI 10.1381/0960892054222830
   Oliveira CPMS, 2005, OBES SURG, V15, P502, DOI 10.1381/0960892053723493
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   Spaulding L, 2003, OBES SURG, V13, P347, DOI 10.1381/096089203765887633
   Tan CE, 2004, DIABETES CARE, V27, P1182, DOI 10.2337/diacare.27.5.1182
   Tchernof A, 2002, CIRCULATION, V105, P564, DOI 10.1161/hc0502.103331
   Torjesen PA, 1997, DIABETES CARE, V20, P26, DOI 10.2337/diacare.20.1.26
   Zafrani ES, 2004, VIRCHOWS ARCH, V444, P3, DOI 10.1007/s00428-003-0943-7
NR 25
TC 136
Z9 140
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD APR
PY 2007
VL 22
IS 4
BP 510
EP 514
DI 10.1111/j.1440-1746.2007.04833.x
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 164VT
UT WOS:000246263600011
PM 17376042
DA 2020-12-08
ER

PT J
AU de Lima, VMR
   de Oliveira, CPMS
   Sawada, LY
   Barbeiro, HV
   de Mello, ES
   Soriano, FG
   Avancini, V
   Alves, F
   Caldwell, SH
   Carrilho, FJ
AF Rodrigues de Lima, Vicencia Mara
   Marques Souza de Oliveira, Claudia Pinto
   Sawada, Leticia Yumi
   Barbeiro, Hermes Vieira
   de Mello, Evandro Sobroza
   Soriano, Francisco Garcia
   Avancini, Venancio
   Alves, Ferreira
   Caldwell, Stephen H.
   Carrilho, Flair Jose
TI Yo Jyo Hen Shi Ko, a novel Chinese herbal, prevents nonalcoholic
   steatohepatitis in ob/ob mice fed a high fat or
   methionine-choline-deficient diet
SO LIVER INTERNATIONAL
LA English
DT Article
DE Henshiko; nonalcoholic steatohepatitis; oxidative stress; Yo Jyo Hen Shi
   Ko
ID LIVER-DISEASE; ANTIOXIDANT DEFENSE; OXIDATIVE STRESS; NATURAL-HISTORY;
   EXTRACT; RESISTANCE; K-17.22; PLASMA; LIPIDS
AB Background: Oxidative stress plays a role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Yo Jyo Hen Shi Ko (YHK) is a complex compound purported to reduce reactive oxygen species (ROS) by blocking the propagation of radical-induced reactions. The aim of this study was to evaluate the role of the effect of YHK in experimental NASH. Methods: NASH was induced in male ob/ob mice by a high-fat (HF) diet or methionine/choline-deficient (MCD) diet for 4 weeks. YHK-treated animals received YHK solution orally (20 mg/kg/day) in both experimental diets (n=6; each group) while control animals received only vehicle. Results: The MCD and HF groups developed moderate diffuse macrosteatosis, hepatocellular ballooning, and a diffuse inflammatory infiltrate. With the addition of YHK, there was a marked reduction in macrosteatosis in both groups. This was associated with decreased lipoperoxide and reduced glutathione-GSH concentrations as well as reduced serum aminotransferases and improved histological markers of inflammation. These changes were also associated with weight loss in the MCD+YHK group and diminished weight gain in the HF+YHK group. Conclusion: YHK therapy blunts the development of macrosteatosis in these models of NASH and significantly reduces markers of oxidative stress. YHK also diminishes weight gain in this obesity prone model. Our findings warrant further study on the mechanisms involved with these effects.
C1 Univ Sao Paulo, Dept Gastroenterol, Sch Med, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Emergency, Sch Med, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Pathol, Sch Med, BR-05403000 Sao Paulo, Brazil.
   Univ Virginia, Div Gastroenterol & Hepatol, Charlottesville, VA 22903 USA.
RP de Oliveira, CPMS (corresponding author), Univ Sao Paulo, Dept Gastroenterol, Sch Med, Av Dr Eneas de Carvalho Aguiar 255 ICHC,9 Andar,S, BR-05403000 Sao Paulo, Brazil.
EM cpm@usp.br
RI Oliveira, Claudia PMS/D-1216-2014; Soriano, Francisco/C-3382-2012;
   Barbeiro, Hermes V/S-5926-2016; Barbeiro, Hermes V/E-2814-2010;
   Carrilho, Flair J/I-3046-2012
OI Soriano, Francisco/0000-0003-4898-0135; Barbeiro, Hermes
   V/0000-0002-8209-4463; Barbeiro, Hermes V/0000-0002-8209-4463; 
CR Armanini D, 2002, EXP CLIN ENDOCR DIAB, V110, P257, DOI 10.1055/s-2002-34587
   Chande N, 2006, DIGEST DIS SCI, V51, P1183, DOI 10.1007/s10620-006-8030-y
   Chen HB, 2001, J ETHNOPHARMACOL, V74, P225, DOI 10.1016/S0378-8741(00)00359-7
   Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927
   Choi SB, 2002, BIOSCI BIOTECH BIOCH, V66, P2036, DOI 10.1271/bbb.66.2036
   CURZIO M, 1985, INT J TISSUE REACT, V7, P137
   Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2
   Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926
   Fuhrman B, 2002, NUTRITION, V18, P268, DOI 10.1016/S0899-9007(01)00753-5
   Grattagliano I, 2000, J NUTR, V130, P2131
   Hensley K, 2000, CARCINOGENESIS, V21, P983, DOI 10.1093/carcin/21.5.983
   Hui JM, 2003, J GASTROEN HEPATOL, V18, P1115, DOI 10.1046/j.1440-1746.2003.03170.x
   Ikura Y, 2006, HEPATOLOGY, V43, P506, DOI 10.1002/hep.21070
   Jeon SM, 2004, J MED FOOD, V7, P358, DOI 10.1089/1096620041938687
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932
   LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304
   Lee MK, 2005, DIABETES RES CLIN PR, V67, P22, DOI 10.1016/j.diabres.2004.05.013
   Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5
   Marotta F, 2001, BIOMED RES-TOKYO, V22, P167, DOI 10.2220/biomedres.22.167
   Marotta F, 2001, BIOMED RES-TOKYO, V22, P221, DOI 10.2220/biomedres.22.221
   Nakagawa K, 2004, BIOL PHARM BULL, V27, P1775, DOI 10.1248/bpb.27.1775
   NAKASA T, 1995, NIPPON NOGEIK KAISHI, V69, P1491
   Nanji Amin A, 2004, Clin Liver Dis, V8, P559, DOI 10.1016/j.cld.2004.04.002
   Oliveira CPMS, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-9
   Oliveira C, 2006, GASTROENTEROLOGY, V130, pA826
   Oliveira CPMS, 2002, J CELL MOL MED, V6, P399, DOI 10.1111/j.1582-4934.2002.tb00518.x
   OSHIMA Y, 1987, J NAT PROD, V50, P188, DOI 10.1021/np50050a010
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   Robertson Graham, 2001, American Journal of Physiology, V281, pG1135
   RUSHMORE TH, 1984, CANCER LETT, V24, P251, DOI 10.1016/0304-3835(84)90020-X
   SHA S, JUN 2 7 2000 IASL AS
   SOTANIEMI EA, 1995, DIABETES CARE, V18, P1373, DOI 10.2337/diacare.18.10.1373
   WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P3155, DOI 10.1210/jc.80.11.3155
   Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829
NR 35
TC 9
Z9 9
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-3223
EI 1478-3231
J9 LIVER INT
JI Liver Int.
PD MAR
PY 2007
VL 27
IS 2
BP 227
EP 234
DI 10.1111/j.1478-3231.2006.01405.x
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 137FK
UT WOS:000244278200010
PM 17311618
DA 2020-12-08
ER

PT J
AU Mattar, R
   Marques, SB
   Monteiro, MD
   dos Santos, AF
   Iriya, K
   Carrilho, FJ
AF Mattar, Rejane
   Marques, Sergio Barbosa
   Monteiro, Maria do Socorro
   dos Santos, Anibal Ferreira
   Iriya, Kiyoshi
   Carrilho, Flair Jose
TI Helicobacter pylori cag pathogenicity island genes: clinical relevance
   for peptic ulcer disease development in Brazil
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID GASTRIC EPITHELIAL-CELLS; KAPPA-B ACTIVATION; TYROSINE PHOSPHORYLATION;
   GASTRODUODENAL DISEASE; INDUCTION; SECRETION; VIRULENCE; PROTEIN;
   CANCER; VACA
AB The purpose of this study was to verify whether the presence of any of the Helicobacter pylori cagPAl genes or segments - cagA, cagA promoter, cagE, cagM, tnpB, tnpA, cagT and the left end of the cag II (LEC) region - would be a useful marker for the risk of peptic ulcer disease development. H. pylori DNA extracted from positive urease tests of 1 E 0 peptic ulcer patients and 65 dyspeptic controls was analysed by PCR. Duodenal ulcers were present in 110, gastric ulcers in 23 and both gastric and duodenal ulcers in 17 patients. A significant association (P < 0.001) was found between a conserved cagPAI and peptic ulcer disease (34 %). The positivity of the cagA gene varied according to the region of the gene that was amplified. The region near to the promoter was present in almost all of the H. pylon isolates (97.2 %). The segment from nt 1764 to 2083 and the extreme right end were frequently deleted in the isolates from the controls (P < 0.01). The positivity of the promoter region of cagA and cagT, cagE, cagM and LEC showed a significant difference between the isolates from peptic ulcer patients and from the controls (P < 0.01). Patients usually had moderate gastritis; however, the intensity of the active inflammation was higher in the peptic ulcer group (P < 0.001). cagT, cagM, LEC and the right end terminus of the cagA-positive H. pylori isolates were associated with a 27-fold, 8-fold, 4-fold and 4-fold risk of peptic ulcer disease, respectively, and may be useful markers to identify individuals at higher risk of peptic ulcer disease development in Brazil
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Mattar, R (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM rejane-mattar@ig.com.br
RI Mattar, Rejane/AAO-4842-2020; Mattar, Rejane/K-3883-2012; Carrilho,
   Flair J/I-3046-2012
OI Mattar, Rejane/0000-0001-7870-8867; 
CR Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x
   Audibert C, 2001, INFECT IMMUN, V69, P1625, DOI 10.1128/IAI.69.3.1625-1629.2001
   Backert S, 2004, INFECT IMMUN, V72, P1043, DOI 10.1128/IAI.72.2.1043-1056.2004
   Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648
   COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791
   Covacci A, 2000, J EXP MED, V191, P587, DOI 10.1084/jem.191.4.587
   Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001
   Dong WG, 2004, WORLD J GASTROENTERO, V10, P3377, DOI 10.3748/wjg.v10.i22.3377
   Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x
   Fujioka N, 2001, JPN J CANCER RES, V92, P829, DOI 10.1111/j.1349-7006.2001.tb01168.x
   Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998
   HAMMAR M, 1992, J CLIN MICROBIOL, V30, P54, DOI 10.1128/JCM.30.1.54-58.1992
   Higashi H, 2005, J BIOL CHEM, V280, P23130, DOI 10.1074/jbc.M503583200
   Hsu PI, 2002, AM J GASTROENTEROL, V97, P2231, DOI 10.1111/j.1572-0241.2002.05977.x
   Ikenoue T, 2001, CLIN DIAGN LAB IMMUN, V8, P181, DOI 10.1128/CDLI.8.1.181-186.2001
   Jenks PJ, 1998, GUT, V43, P752, DOI 10.1136/gut.43.6.752
   Kauser F, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-32
   Kauser F, 2004, J CLIN MICROBIOL, V42, P5302, DOI 10.1128/JCM.42.11.5302-5308.2004
   Kidd M, 2001, GUT, V49, P11, DOI 10.1136/gut.49.1.11
   Liu ES, 2001, J GASTROEN HEPATOL, V16, P740, DOI 10.1046/j.1440-1746.2001.02506.x
   Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200
   Maeda S, 1999, GUT, V44, P336, DOI 10.1136/gut.44.3.336
   Mattar R, 2005, HELICOBACTER, V10, P601, DOI 10.1111/j.1523-5378.2005.00360.x
   Nilsson C, 2003, INFECT IMMUN, V71, P6573, DOI 10.1128/IAI.71.11.6573-6581.2003
   Owen RJ, 2003, J CLIN MICROBIOL, V41, P3112, DOI 10.1128/JCM.41.7.3112-3118.2003
   Peek RM, 2005, SPRINGER SEMIN IMMUN, V27, P197, DOI 10.1007/s00281-005-0204-8
   Rohde M, 2003, MOL MICROBIOL, V49, P219, DOI 10.1046/j.1365-2958.2003.03549.x
   Rudi J, 1998, J CLIN MICROBIOL, V36, P944, DOI 10.1128/JCM.36.4.944-948.1998
   Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559
   Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595
   Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200
   Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x
   Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x
   Zhang YL, 2005, J CLIN MICROBIOL, V43, P786, DOI 10.1128/JCM.43.2.786-790.2005
NR 34
TC 36
Z9 40
U1 1
U2 1
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-2615
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD JAN
PY 2007
VL 56
IS 1
BP 9
EP 14
DI 10.1099/jmm.0.46824-0
PG 6
WC Microbiology
SC Microbiology
GA 122GA
UT WOS:000243212500003
PM 17172510
OA Bronze
DA 2020-12-08
ER

PT J
AU Medeiros-Filho, JE
   Mello, IMVGD
   Pinho, JRR
   Neumann, AU
   Malta, FD
   da Silva, LC
   Carrilho, FJ
AF Medeiros-Filho, Jose Eymard
   Guedes de Carvalho Mello, Isabel Maria Vicente
   Rebello Pinho, Joao Renato
   Neumann, Avidan U.
   de Mello Malta, Fernanda
   da Silva, Luiz Caetano
   Carrilho, Flair Jose
TI Differences in viral kinetics between genotypes 1 and 3 of hepatitis C
   virus and between cirrhotic and non-cirrhotic patients during antiviral
   therapy
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE hepatitis C virus; treatment; early kinetics; cirrhosis; genotypes
ID INTERFERON-ALPHA; PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A; COMBINATION
   THERAPY; INITIAL TREATMENT; CORE PROTEIN; IN-VIVO; DYNAMICS; STEATOSIS;
   CLEARANCE
AB AIM: To evaluate the impact of hepatitis C virus (HCV) infection with genotype 1 or 3 and the presence or absence of liver cirrhosis (LC) in the early viral kinetics response to treatment.
   METHODS: Naive patients (n = 46) treated with interferon-alpha (IFN-alpha) and ribavirin and followed up with frequent early HCV-RNA determinations were analysed. Patients were infected with genotype 1 (n = 28, 7 with LC) or 3 (n = 18, 5 with LC).
   RESULTS: The first phase decline was larger in genotype 3 patients than in genotype 1 patients (1.72 vs 0.95 log IU/mL, P < 0.001). The second phase slope decline was also larger in genotype 3 patients than in genotype 1 patients (0.87 vs 0.15 log/wk, P < 0.001). Differences were found in both cirrhotic and non-cirrhotic patients. Genotype 1 cirrhotic patients had a slower 2(nd) phase slope than non-cirrhotic patients (0.06 vs 0.18 log/wk, P < 0;02). None of genotype 1 cirrhotic patients had a 1(st) phase decline larger than 1 log (non-cirrhotic patients: 55%, P < 0.02). A similar trend toward a slower 2(nd) phase slope was observed in genotype 3 cirrhotic patients but the 1(st) phase slope decline was not different, Sustained viral response was higher in genotype 3 patients than in genotype 1 patients (72% vs 14%, P < 0.001) and in genotype I non-cirrhotic patients than in genotype I cirrhotic patients (19% vs 0%). A second phase decline slower than 0.3 log per week was predictive of non-response in all groups.
   CONCLUSION: Genotype 3 has faster early viral decline than genotype 1. Cirrhosis correlates with a slower 2(nd) phase decline and possibly with a lower 1st phase slope decline in genotype 1 patients. (c) 2006 The WJG Press. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Hepatol Branch, Dept Gastroenterol, Sao Paulo, Brazil.
   Inst Butantan, Viral Immunol Lab, Sao Paulo, Brazil.
   Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel.
   Adolfo Lutz Inst, Virol Branch, Sao Paulo, Brazil.
RP Pinho, JRR (corresponding author), Inst Med Trop, Ave Doutor Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM jrrpinho@usp.br
RI Malta, Fernanda/B-1316-2013; Pinho, Joao R. R./G-2850-2012; Carrilho,
   Flair J/I-3046-2012
OI Malta, Fernanda/0000-0001-8887-5060; Pinho, Joao R.
   R./0000-0003-3999-0489; 
CR Abid K, 2005, J HEPATOL, V42, P744, DOI 10.1016/j.jhep.2004.12.034
   Afdhal NH, 2004, SEMIN LIVER DIS, V24, P3, DOI 10.1055/s-2004-832922
   [Anonymous], 2002, NIH CONSENS STATE SC, V19, P1
   Asselah T, 2006, GUT, V55, P123, DOI 10.1136/gut.2005.069757
   Asselah T, 2003, GUT, V52, P1638, DOI 10.1136/gut.52.11.1638
   Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Ferenci P, 2004, J ANTIMICROB CHEMOTH, V53, P15, DOI 10.1093/jac/dkh015
   Grassi A, 2005, ALIMENT PHARM THER, V22, P79, DOI 10.1111/j.1365-2036.2005.02603.x
   Halfon P, 2003, J VIRAL HEPATITIS, V10, P351, DOI 10.1046/j.1365-2893.2003.00433.x
   Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302
   Kaba S, 1998, J GASTROEN HEPATOL, V13, P914, DOI 10.1111/j.1440-1746.1998.tb00761.x
   KOHARA M, 1995, J INFECT DIS, V172, P934, DOI 10.1093/infdis/172.4.934
   Lam NP, 1997, HEPATOLOGY, V26, P226
   Layden JE, 2002, J VIRAL HEPATITIS, V9, P340, DOI 10.1046/j.1365-2893.2002.00377.x
   Layden TJ, 2002, J VIRAL HEPATITIS, V9, P334, DOI 10.1046/j.1365-2893.2002.00376.x
   Layden-Almer JE, 2003, HEPATOLOGY, V37, P1343, DOI 10.1053/jhep.2003.50217
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   McHutchison JG, 1999, SEMIN LIVER DIS, V19, P57
   Nakajima H, 2003, ACTA MED OKAYAMA, V57, P217
   Neumann AU, 2000, J INFECT DIS, V182, P28, DOI 10.1086/315661
   Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103
   PAWLOTSKY JM, 1995, J INFECT DIS, V171, P1607, DOI 10.1093/infdis/171.6.1607
   Rubbia-Brandt L, 2004, GUT, V53, P406, DOI 10.1136/gut.2003.018770
   Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   Spahr L, 2001, J HEPATOL, V35, P308, DOI 10.1016/S0168-8278(01)00082-4
   Torre F, 2001, J MED VIROL, V64, P455, DOI 10.1002/jmv.1071
   Zeuzem S, 2005, J HEPATOL, V43, P250, DOI 10.1016/j.jhep.2005.05.016
   Zeuzem S, 2001, GASTROENTEROLOGY, V120, P1438, DOI 10.1053/gast.2001.24006
   Zeuzem S, 1996, HEPATOLOGY, V23, P366
NR 33
TC 16
Z9 16
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD DEC 7
PY 2006
VL 12
IS 45
BP 7271
EP 7277
DI 10.3748/wjg.v12.i45.7271
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 113XV
UT WOS:000242632200005
PM 17143940
OA Other Gold, Green Published
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Carrilho, FJ
AF Farias, Alberto Queiroz
   Carrilho, Flair Jose
TI Hemorrhagic hereditary telangiectasia
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Editorial Material
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Farias, AQ (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Farias, Alberto/ABB-1291-2020; Farias,
   Alberto Q/H-7873-2013
OI Farias, Alberto/0000-0002-5572-663X; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD NOV
PY 2006
VL 64
IS 5
BP 813
EP 813
DI 10.1016/j.gie.2006.04.011
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 099YR
UT WOS:000241634300029
PM 17055882
DA 2020-12-08
ER

PT J
AU de Oliveira, CPMS
   Stefano, JT
   de Lima, VMR
   de Sa, SV
   Simplicio, FI
   de Mello, ES
   Correa-Giannella, ML
   Alves, VAF
   Laurindo, FRM
   de Oliveira, MG
   Giannella, D
   Carrilho, FJ
AF Marques Souza de Oliveira, Claudia Pinto
   Stefano, Jose Tadeu
   Rodrigues de Lima, Vicencia Mara
   de Sa, Sandra Valeria
   Simplicio, Fernanda Ibanez
   de Mello, Evandro Sobrosa
   Correa-Giannella, Maria Lucia
   Ferreira Alves, Venancio Avancini
   Martins Laurindo, Francisco Rafael
   de Oliveira, Marcelo Ganzarolli
   Giannella-Neto, Daniel
   Carrilho, Flair Jose
TI Hepatic gene expression profile associated with non-alcoholic
   steatohepatitis protection by S-nitroso-N-acetylcysteine in ob/ob mice
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE nitric oxide; S-nitroso-N-acetylcysteine; hepatic gene expression;
   non-alcoholic steatohepatitis
ID NITRIC-OXIDE; MITOCHONDRIAL; CHOLINE; LIPOPROTEINS; ONTOLOGY; PROTEIN
AB Background/Aims: To understand the molecular mechanisms underlying non-alcoholic steatohepatitis (NASH) prevention by S-nitroso-N-acetylcysteine (SNAC), an NO donor that inhibits lipid peroxidation, we examined hepatic differentially expressed genes between ob/ob mice receiving or not SNAC treatment concomitantly with a methionine-choline deficient (MCD) diet.
   Methods: Ob/ob mice were assigned to receive oral SNAC fed solution (MCD+SNAC group) or vehicle (MCD group) by gavage. After four weeks, histopathological analysis and microarray hybridizations were conducted in liver tissues from groups. GeneSifter (R) system was used to identify differentially expressed genes and pathways according to Gene Ontology.
   Results: NASH was absent in the MCD+SNAC group and no significant changes in food intake or body weight were observed in comparison to MCD group. After SNAC treatment, several genes belonging to oxidative phosphorylation, fatty acid biosynthesis, fatty acid metabolism and glutathione metabolism pathways were down-regulated in comparison to the MCD group.
   Conclusions: SNAC treatment promotes down regulation of several genes from fatty acid (FA) metabolism related pathways, possibly through abrogation of the cytotoxic effects of reactive oxygen species and lipid peroxides with consequent prevention of mitochondrial overload. Further studies are required to investigate the clinical implications of these findings, in attempt to develop novel therapeutic strategies for NAFLD treatment. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Internal Med, Div Endocrinol, Sao Paulo, Brazil.
   Univ Estadual Campinas, Dept Chem, Campinas, SP, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, InCor, Sao Paulo, Brazil.
RP de Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM cpm@usp.br
RI Laurindo, Francisco R/J-6575-2015; Stefano, Jose T/H-4792-2013;
   Carrilho, Flair J/I-3046-2012; Giannella-Neto, Daniel/B-1475-2008;
   Oliveira, Claudia PMS/D-1216-2014; Giannella, Maria Lucia/N-3834-2019;
   de Oliveira, Marcelo Ganzarolli/B-4709-2013; Stefano, Jose
   Tadeu/AAH-5419-2020
OI de Oliveira, Marcelo Ganzarolli/0000-0002-9371-9975; Stefano, Jose
   Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bartels ED, 2002, DIABETES, V51, P1233, DOI 10.2337/diabetes.51.4.1233
   Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003
   BRADY LJ, 1985, BIOCHEM J, V231, P439, DOI 10.1042/bj2310439
   Carvalho MA, 2005, DIABETES, V54, P959, DOI 10.2337/diabetes.54.4.959
   Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927
   CURZIO M, 1985, INT J TISSUE REACT, V7, P137
   de Oliveira CPMS, 2006, WORLD J GASTROENTERO, V12, P1905, DOI 10.3748/wjg.v12.i12.1905
   Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7
   GHOSHAL AK, 1970, EXP MOL PATHOL, V12, P31, DOI 10.1016/0014-4800(70)90072-9
   Giustarini D, 2003, CLIN CHIM ACTA, V330, P85, DOI 10.1016/S0009-8981(03)00046-9
   Haque M, 2002, HEPATOLOGY, V36, p403A
   Hensley K, 2000, CARCINOGENESIS, V21, P983, DOI 10.1093/carcin/21.5.983
   Hogg N, 1999, BBA-BIOENERGETICS, V1411, P378, DOI 10.1016/S0005-2728(99)00027-4
   HUBBO H, 1996, CHEM RES TOXICOL, V9, P809
   Jefferies H, 2003, ANZ J SURG, V73, P517, DOI 10.1046/j.1445-1433.2003.02682.x
   Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932
   LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304
   McCullough AJ, 2002, J CLIN GASTROENTEROL, V34, P255, DOI 10.1097/00004836-200203000-00013
   OBrien RM, 1996, PHYSIOL REV, V76, P1109
   Perez-Carreras M, 2003, HEPATOLOGY, V38, P999, DOI 10.1053/jhep.2003.50398
   Pessayre D, 2001, SEMIN LIVER DIS, V21, P57, DOI 10.1055/s-2001-12929
   Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877
   RUSHMORE TH, 1984, CANCER LETT, V24, P251, DOI 10.1016/0304-3835(84)90020-X
   SANTOS KFR, 2002, NITRIC OXIDE-BIOL CH, V7, P57
   Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256
   Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200
   Violi F, 1999, DIABETES-METAB RES, V15, P283, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<283::AID-DMRR42>3.0.CO;2-U
   Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829
NR 29
TC 15
Z9 15
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD NOV
PY 2006
VL 45
IS 5
BP 725
EP 733
DI 10.1016/j.jhep.2006.05.017
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 104RF
UT WOS:000241975700013
PM 16935387
DA 2020-12-08
ER

PT J
AU Oliveira, CP
   Alves, VA
   Debbas, V
   Lima, VR
   Stefano, JT
   Sa, SV
   Wakamatsu, A
   Giannella, MLC
   Havaki, S
   Tiniakos, D
   Marinos, EM
   Gianella-Neto, D
   de Oliveira, MG
   Laurindo, FR
   Caldwell, S
   Carrilho, FJ
AF Oliveira, Claudia P.
   Alves, Venancio A.
   Debbas, Victor
   Lima, Vicencia R.
   Stefano, Jose T.
   Sa, Sandra V.
   Wakamatsu, Alda.
   Giannella, Maria Lucia C.
   Havaki, Sofia
   Tiniakos, Dina
   Marinos, E. Marinos
   Gianella-Neto, Daniel
   de Oliveira, Marcelo G.
   Laurindo, Francisco R.
   Caldwell, Stephen
   Carrilho, Flair J.
TI Steatohepatitis in OB/OB mice treated with S-nitroso-N-acetylcysteine
   (SNAC): Effects on microsomal triglyceride transfer protein (MTP)
   detection
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 27-31, 2006
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Univ Estadual Campinas, Inst Chem, Sao Paulo, Brazil.
   Univ Athens, Sch Med, Lab Histol & Embryol, Athens, Greece.
   Univ Virginia, Dept Gastroenterol & Hepatol, Charlottesville, VA USA.
RI Carrilho, Flair J/I-3046-2012; Laurindo, Francisco R/J-6575-2015;
   Stefano, Jose Tadeu/AAH-5419-2020; de Oliveira, Marcelo
   Ganzarolli/B-4709-2013; Giannella-Neto, Daniel/B-1475-2008; Tiniakos,
   Dina G/AAA-5708-2020; Oliveira, Claudia PMS/D-1216-2014; Debbas,
   Victor/J-9475-2012; Stefano, Jose T/H-4792-2013
OI Stefano, Jose Tadeu/0000-0002-0218-1920; de Oliveira, Marcelo
   Ganzarolli/0000-0002-9371-9975; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2006
VL 44
IS 4
SU 1
MA 148
BP 244A
EP 244A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 096FF
UT WOS:000241362300149
DA 2020-12-08
ER

PT J
AU Paranagua-Vezozzo, DC
   Matielo, CE
   Chagas, AL
   Kikuchi, LO
   Mello, ES
   Alves, VA
   Ono-Nita, SK
   Carrilho, FJ
AF Paranagua-Vezozzo, Denise C.
   Matielo, Celso E.
   Chagas, Aline L.
   Kikuchi, Luciana O.
   Mello, Evandro S.
   Alves, Venancio A.
   Ono-Nita, Suzane K.
   Carrilho, Flair J.
TI Incidence of hepatocellular carcinoma in cirrhotic patients in Sao
   Paulo, Brazil
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 27-31, 2006
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014; Chagas, Aline Lopes/X-2059-2019; Ono,
   Suzane/I-3107-2012
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; 
NR 0
TC 1
Z9 2
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2006
VL 44
IS 4
SU 1
MA 850
BP 504A
EP 505A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 096FF
UT WOS:000241362301391
DA 2020-12-08
ER

PT J
AU Nogueira, J
   Alves, V
   Souza, M
   Nita, M
   Ono-Nita, S
   Scapulatempo, C
   Mello, E
   Wakamatsu, A
   Carrilho, F
AF Nogueira, Jeronimo
   Alves, Venancio
   Souza, Marcelo
   Nita, Marcelo
   Ono-Nita, Suzane
   Scapulatempo, Cristovam
   Mello, Evandro
   Wakamatsu, Alda
   Carrilho, Flair
TI An aflatoxin-related mutation at codon 249 in p53 gene in hepatocellular
   carcinomas from Brazil
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 26th International Congress of the International-Academy-of-Pathology
CY SEP 16-21, 2006
CL Montreal, CANADA
SP Int Acad Pathol, United States & Canadian Acad Pathol
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
J9 MODERN PATHOL
JI Mod. Pathol.
PD SEP
PY 2006
VL 19
SU 3
MA 625
BP 135
EP 136
PG 2
WC Pathology
SC Pathology
GA 077AF
UT WOS:000239999400626
DA 2020-12-08
ER

PT J
AU Bertolini, DA
   Pinho, JRR
   Saraceni, CP
   Moreira, RC
   Granato, CFH
   Carrilho, FJ
AF Bertolini, D. A.
   Pinho, J. R. R.
   Saraceni, C. P.
   Moreira, R. C.
   Granato, C. F. H.
   Carrilho, F. J.
TI Prevalence of serological markers of hepatitis B virus in pregnant women
   from Parana State, Brazil
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hepatitis B virus; Brazil; serological markers; pregnant women
ID UNITED-STATES; EPIDEMIOLOGY
AB The prevalence of hepatitis B virus (HBV) in Brazil increases from South to North but moderate to elevated prevalence has been detected in the Southwest of Parana State. The prevalence of serological markers of HBV was evaluated in 3188 pregnant women from different counties in Parana State and relevant epidemiological features were described. The prevalence of HBV markers in pregnant women for the state as a whole was 18.5% (95% CI = 17.2-19.9), ranging from 7.2% in Curitiba to 38.5% in Francisco Beltrao. The endemicity of HBV marker prevalence in pregnant women was intermediate in Cascavel, Foz do Iguacu, and Francisco Beltrao, and low in Curitiba, Londrina, Maringa, and Paranagua. Multiple logistic regression showed that HBV marker prevalence increased with age, was higher among black women, among women of Italian and German descent, and among women who had family members in neighboring Rio Grande do Sul State. Univariate analysis showed that HBV marker prevalence was also higher among women with no education or only primary education, with a lower family income and whose families originated from the South Region of Brazil. Pregnant women not having positive HBV markers (anti-HBc, HBsAg or anti-HBs detected by ELISA) corresponded to 73.7% of the population studied, implying that HBV vaccination needs to be reinforced in Parana State. The highest prevalence was found in three counties that received the largest number of families from Santa Catarina and Rio Grande do Sul, where most immigrants were of German or Italian ascendance. This finding probably indicates that immigrants that came to this area brought HBV infection to Southwestern Parana State.
C1 Univ Sao Paulo, Dept Gastroenterol, Inst Trop Med, Fac Med, BR-05508000 Sao Paulo, Brazil.
   Univ Estadual Maringa, Lab Imunol Clin, Dept Anal CLin, Maringa, Parana, Brazil.
   Inst Adolfo Lutz Registro, Serv Virol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
RP Pinho, JRR (corresponding author), Univ Sao Paulo, Dept Gastroenterol, Inst Trop Med, Fac Med, Av Dr Eneas Carvalho Aguiar 470, BR-05508000 Sao Paulo, Brazil.
EM jrrpinho@usp.br
RI Moreira, Regina C/B-1488-2016; Bertolini, Dennis/ABG-1427-2020; Pinho,
   Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Moreira, Regina C/0000-0002-8208-8776; Pinho, Joao R.
   R./0000-0003-3999-0489; 
CR ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218
   Andrade C. A., 1999, Revista de Patologia Tropical, V28, P41
   [Anonymous], 2006, STAT PACK SOC SCI
   Bensabath G, 1973, Rev Inst Med Trop Sao Paulo, V15, P284
   Cardosa D das D, 1996, Rev Soc Bras Med Trop, V29, P349
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   Carvalho S.P., 1995, REV BRAS ANAL CLIN, V27, P77
   Clemens S A, 2000, Rev Soc Bras Med Trop, V33, P1, DOI 10.1590/S0037-86822000000100001
   DEAN AG, 1998, EPI INFO VERSION 6 0
   FAY OH, 1990, VACCINE S, V8, pS82
   Ferreira C. R. B., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P89, DOI 10.1590/S0036-46651993000100013
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   Goldstein ST, 2002, J INFECT DIS, V185, P713, DOI 10.1086/339192
   *IBGE PNUD, 1998, ATL DES HUM BRAS
   KANE M, 1995, VACCINE S1, V13, P47
   MARGOLIS HS, 1991, SEMIN LIVER DIS, V11, P84, DOI 10.1055/s-2008-1040427
   MAYNARD JE, 1990, VACCINE S, V8, P18
   Miranda LVG, 2000, REV SAUDE PUBL, V34, P286, DOI 10.1590/S0034-89102000000300012
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   Silveira T R, 1999, Rev Panam Salud Publica, V6, P378
   Souto FJD, 1998, J MED VIROL, V56, P4, DOI 10.1002/(SICI)1096-9071(199809)56:1&lt;4::AID-JMV2&gt;3.0.CO;2-3
   STROZZI JB, 1997, SUS PENSE REFLEXAO E
   Tanaka J, 2000, VACCINE, V18, pS17, DOI 10.1016/S0264-410X(99)00455-7
   Treitinger A, 2000, Braz J Infect Dis, V4, P192
   VASCONCELOS HCFF, 1994, MEM I OSWALDO CRUZ, V89, P503, DOI 10.1590/S0074-02761994000400002
NR 25
TC 28
Z9 30
U1 1
U2 2
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD AUG
PY 2006
VL 39
IS 8
BP 1083
EP 1090
DI 10.1590/S0100-879X2006000800011
PG 8
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 076DJ
UT WOS:000239936900011
PM 16906283
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Vezozzo, DCP
   Farias, AQ
   Cerri, GG
   Da Silva, LC
   Carrilho, FJ
AF Vezozzo, Denise Cerqueira Paranagua
   Farias, Alberto Queiroz
   Cerri, Giovanni Guido
   Da Silva, Luiz Caetano
   Carrilho, Flair Jose
TI Assessment of portal hemodynamics by doppler ultrasound and of liver
   morphology in the hepatosplenic and hepatointestinal forms of
   schistosomiasis mansoni
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE schistosomiasis; portal hypertension; doppler; ultrasound; blood flow
ID HEPATIC HEMODYNAMICS; BLOOD-FLOW; HYPERTENSION; DIAGNOSIS; VEIN;
   PATHOPHYSIOLOGY; SONOGRAPHY; FLOWMETRY; CIRRHOSIS; BIOPSY
AB The aim of this study was to compare portal and splenic blood flows and the liver morphology in hepatosplenic (HS) and hepatointestinal (HI) schistosomiasis. Doppler ultrasound measurements were performed in 48 adult patients with schistosomiasis, according to the criteria of the World Health Organization, and compared with those performed in 20 healthy controls. Portal flow was significantly higher (P < 0.0001) in both HS and HI (2481 +/- 1467 and 2159 +/- 1446 ml/min, respectively) than in normal individuals (842 +/- 322 ml/min). There was no difference in splenic blood flow (822 +/- 685 and 458 +/- 292 ml/min, respectively) between HS and HI, but these values were significantly higher than those of normal controls (243 +/- 94 ml/min). Portal and splenic overflow are found in both the HS and the HI forms of schistosomiasis.
C1 Univ Sao Paulo, Sch Med, Dept Radiol, Sao Paulo, Brazil.
RP Vezozzo, DCP (corresponding author), Rua Itapicuru,380 Ap 113, BR-05006000 Sao Paulo, Brazil.
EM denisecpv@uol.com.br
RI Carrilho, Flair J/I-3046-2012; Farias, Alberto Q/H-7873-2013; Farias,
   Alberto/ABB-1291-2020; Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014
OI Farias, Alberto/0000-0002-5572-663X; Paranagua-Vezozzo, Denise
   Cerqueira/0000-0002-9606-4935
CR ANDRADE ZA, 1963, AM J TROP MED HYG, V12, P854, DOI 10.4269/ajtmh.1963.12.854
   BOGLIOLO L, 1957, Ann Trop Med Parasitol, V51, P1
   CERRI GG, 1984, RADIOLOGY, V153, P777, DOI 10.1148/radiology.153.3.6387793
   CERRI GG, 1992, J ECHOGRAPH MED ULTR, V13, P31
   Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4
   DASILVA LC, 1992, GASTROENTEROL CLIN N, V21, P163
   DIMMETTE RM, 1955, GASTROENTEROLOGY, V29, P219
   El-Garem AA, 1998, DIGESTION, V59, P589, DOI 10.1159/000007534
   Elliott DE, 1996, GASTROENTEROL CLIN N, V25, P599, DOI 10.1016/S0889-8553(05)70265-X
   Fevery J, 2000, J GASTROEN HEPATOL, V15, P842, DOI 10.1046/j.1440-1746.2000.02211.x
   Gawish Y, 2001, INT SURG, V85, P325
   Haag K, 1999, AM J ROENTGENOL, V172, P631, DOI 10.2214/ajr.172.3.10063849
   HOMEIDA M, 1988, AM J TROP MED HYG, V38, P86, DOI 10.4269/ajtmh.1988.38.86
   JENKINS JM, 1992, ACTA TROP, V51, P45
   KASHIWAGI T, 1975, GASTROENTEROLOGY, V69, P1292
   Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397
   Lambertucci JR, 2001, MEM I OSWALDO CRUZ, V96, P147, DOI 10.1590/S0074-02762001000900022
   LYRA LG, 1976, GASTROENTEROLOGY, V71, P641
   Martins RD, 2000, DIGEST DIS SCI, V45, P1013, DOI 10.1023/A:1005501930808
   Mies S, 1997, DIGEST DIS SCI, V42, P751, DOI 10.1023/A:1018803911915
   MORIYASU F, 1986, J CLIN ULTRASOUND, V14, P579, DOI 10.1002/jcu.1870140802
   PARANAGUAVEZOZZO DC, 1992, MEM I OSWALDO CRUZ, V87, P149, DOI 10.1590/S0074-02761992000800022
   PINTO P L S, 1988, Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, V43, P288
   Richter J, 2001, MEM I OSWALDO CRUZ, V96, P151, DOI 10.1590/S0074-02762001000900023
   Richter J, 2003, LANCET, V362, P900, DOI 10.1016/S0140-6736(03)14334-6
   Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396
   SABBA C, 1995, HEPATOLOGY, V21, P428, DOI 10.1002/hep.1840210225
   Sacerdoti D, 1995, HEPATOLOGY, V22, P1689, DOI 10.1002/hep.1840220612
   SIRINGO S, 1994, J HEPATOL, V20, P11, DOI 10.1016/S0168-8278(05)80461-1
   SOZA JCE, 2000, GASTROENTEROLOGIA HE, V23, P466
   ZIRONI G, 1992, J HEPATOL, V16, P298, DOI 10.1016/S0168-8278(05)80660-9
   ZOLI M, 1986, J CLIN ULTRASOUND, V14, P429, DOI 10.1002/jcu.1870140605
   1990, J HEPATOL, V10, P353
NR 33
TC 13
Z9 16
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD AUG
PY 2006
VL 51
IS 8
BP 1413
EP 1419
DI 10.1007/s10620-005-9020-1
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 078AM
UT WOS:000240073300018
PM 16868833
DA 2020-12-08
ER

PT J
AU Brandao, C
   Barone, A
   Carrilho, F
   Silva, A
   Patelli, M
   Caramori, C
   Focaccia, R
   Pereira, L
   Pedroso, M
   Tatsch, F
   Pessoa, M
AF Brandao, C.
   Barone, A.
   Carrilho, F.
   Silva, A.
   Patelli, M.
   Caramori, C.
   Focaccia, R.
   Pereira, L.
   Pedroso, M.
   Tatsch, F.
   Pessoa, M.
CA Pegasys Brazilian Study Grp
TI The results of a randomized trial looking at 24 weeks vs 48 weeks of
   treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination
   therapy in patients with chronic hepatitis C genotype 1
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
DE hepatitis C; peginterferon alpha-2a; ribavirin; treatment duration
ID PLUS RIBAVIRIN; INTERFERON-ALPHA-2B; PEGYLATION
AB Peginterferon-alpha plus ribavirin is the most effective therapy for chronic hepatitis C. This study was designed to evaluate the effect of peginterferon alpha-2a (40 kDa) plus ribavirin on sustained virological response (SVR) when administered for 24 vs 48 weeks in genotype 1 naive patients. One hundred and seventeen patients were enrolled in this controlled trial. Genotype 1 patients were randomized to 24 weeks treatment vs 48 weeks treatment. Genotype non-1 patients received 24 weeks treatment as an observational group. Outcomes were SVR (defined by hepatitis C virus-RNA-negative at week 24 of follow-up) and tolerability across the study period. The end-of-treatment response was 59% for genotype 1 (24 weeks treatment), 80% for genotype 1 (48 weeks treatment) and 92% for genotype non-1 (24 weeks treatment). The end-of-follow-up response was 19% (95% confidence interval (CI): 7.2-36.4) (genotype 1, 24 weeks) and 48% (95% CI: 30.2-66.9; P = 0.0175) (genotype 1, 48 weeks). Among genotype non-1, SVR was 76% (95% CI: 62.3-86.5). There were no unexpected adverse events.Almost half of the genotype 1 patients achieved an SVR after 48 weeks treatment with peginterferon alpha-2a (40 kDa) and low-dose ribavirin and confirmed that they should be treated for 48 weeks. Safety profile was acceptable.
C1 Hosp Univ Gaffree & Guinle, BR-20270004 Rio De Janeiro, Brazil.
   Univ Sao Paulo, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Sao Paulo, Brazil.
   PUC, Campinas, Brazil.
   Univ Estadual Paulista, Botucatu, SP, Brazil.
   Emilio Ribas Hosp, Sao Paulo, Brazil.
   State Univ Pernambuco, Recife, PE, Brazil.
   Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil.
   Roche, Sao Paulo, Brazil.
RP Brandao, C (corresponding author), Hosp Univ Gaffree & Guinle, Rua Mariz & Barros 775, BR-20270004 Rio De Janeiro, Brazil.
EM cebrandao@terra.com.br
RI Carrilho, Flair J/I-3046-2012; FOCACCIA, ROBERTO/I-3970-2013; Barone,
   Antonio A/C-5531-2013; Caramori, Carlos Antonio/A-7949-2008
OI Barone, Antonio A/0000-0001-9895-3886; Caramori, Carlos
   Antonio/0000-0002-0390-1061
CR *AD R D, 1999, DRUGS R&D, V2, P278
   [Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117
   Boyer N, 2000, J HEPATOL, V32, P98, DOI 10.1016/S0168-8278(00)80419-5
   Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102
   Ferenci P, 2003, HEPATOLOGY, V38, p635A
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   Foster GR, 2004, ALIMENT PHARM THER, V20, P825, DOI 10.1111/j.1365-2036.2004.02170.x
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010
   Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005
   Herrine SK, 2002, ANN INTERN MED, V136, P747, DOI 10.7326/0003-4819-136-10-200205210-00010
   Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107
   McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101
   Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4
   Reddy KR, 2000, ANN PHARMACOTHER, V34, P915
   *WHO, 1999, 49 WHO, V74, P421
   *WHO, 2005, 164 WHO
NR 17
TC 13
Z9 13
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD AUG
PY 2006
VL 13
IS 8
BP 552
EP 559
DI 10.1111/j.1365-2893.2006.00758.x
PG 8
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA 065WW
UT WOS:000239191800008
PM 16901286
DA 2020-12-08
ER

PT J
AU Goncalves, LL
   Farias, AQ
   Goncalves, PL
   D'Amico, EA
   Carrilho, FJ
AF Goncalves, Luciana Lofego
   Farias, Alberto Queiroz
   Goncalves, Patricia Lofego
   D'Amico, Elbio Antonio
   Carrilho, Flair Jose
TI Branch retinal vein thrombosis and visual loss probably associated with
   pegylated interferon therapy of chronic hepatitis C
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE hepatitis C; interferon; visual loss
AB Ophthalmological complications with interferon therapy are usually mild and reversible, not requiring the withdrawal of the treatment. We report a case of a patient who had visual loss probably associated with interferon therapy. Chronic hepatitis C virus infection (genotype 1a) was diagnosed in a 33-year old asymptomatic man. His past medical history was unremarkable and previous routine ophthalmologic check-up was normal. Pegylated interferon alpha and ribavirin were started. Three weeks later he reported painless reduction of vision. Ophthalmologic examination showed extensive intraretinal hemorrhages and cotton-wool spots, associated with inferior branch retinal vein thrombosis. Antiviral therapy was immediately discontinued, but one year later he persists with severely decreased visual acuity. This case illustrates the possibility of unpredictable and severe complications during pegylated interferon therapy. (C) 2006 The WJG Press. All rights reserved.
C1 Escola Super Ciencias Santa Casa Misericor Vitoria, Vitoria, Espirito Santo, Brazil.
   Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
   Univ Fed Espirito Santo, Sch Med, Vitoria, Espirito Santo, Brazil.
RP Goncalves, LL (corresponding author), Rua Inacio Higino 198-201, ES-29101430 Vila Velha, Spain.
EM lucianalofego@terra.com.br
RI Farias, Alberto/ABB-1291-2020; Farias, Alberto Q/H-7873-2013; Carrilho,
   Flair J/I-3046-2012
OI Farias, Alberto/0000-0002-5572-663X; 
CR Fried MW, 2002, HEPATOLOGY, V36, pS237, DOI 10.1053/jhep.2002.36810
   Nadir A, 2000, J VIRAL HEPATITIS, V7, P466, DOI 10.1046/j.1365-2893.2000.00245.x
   Rubio JE, 2003, RETINA-J RET VIT DIS, V23, P546, DOI 10.1097/00006982-200308000-00019
   Sugano S, 1998, AM J GASTROENTEROL, V93, P2441, DOI 10.1111/j.1572-0241.1998.00701.x
   Thomas RH, 2001, ARCH INTERN MED, V161, P2433, DOI 10.1001/archinte.161.20.2433
NR 5
TC 16
Z9 16
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUL 28
PY 2006
VL 12
IS 28
BP 4602
EP 4603
DI 10.3748/wjg.v12.i28.4602
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 076ZR
UT WOS:000239997900032
PM 16874884
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Alencar, RSSM
   Pinho, JRR
   Gomes, MMS
   Malta, FM
   Sitnik, R
   Mello, IMVG
   Mello, ES
   Bacchella, T
   Machado, MCC
   Alves, VAF
   Carrilho, FJ
AF Alencar, R. S. S. M.
   Pinho, J. R. R.
   Gomes, M. M. S.
   Malta, F. M.
   Sitnik, R.
   Mello, I. M. V. G.
   Mello, E. S.
   Bacchella, T.
   Machado, M. C. C.
   Alves, V. A. F.
   Carrilho, F. J.
TI Low occurrence of occult hepatitis B virus infection (HBV) in patients
   with liver cirrhosis due to hepatitis C virus (HCV) with or without
   hepatocellular carcinoma (HCC)
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Meeting Abstract
CT 12th International Symposium on Viral Hepatitis and Liver Disease
CY JUL 01-05, 2006
CL Paris, FRANCE
SP Pan-Amer Soc Clin Virol, European Soc Clin Virol
C1 Univ Sao Paulo, Fac Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   Inst Adolfo Lutz Registro, Serv Virol, Sao Paulo, Brazil.
   Hosp Israelita Albert Einstein, Dept Patol Clin, Sao Paulo, Brazil.
   Inst Butantan, Lab Imunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Patol, Sao Paulo, Brazil.
RI de carvalho-Mello, Isabel Maria V G/D-3641-2012; Carrilho, Flair
   J/I-3046-2012; Malta, Fernanda/B-1316-2013; Sitnik, Roberta/N-4740-2017;
   machado, marcel/E-2129-2012; Pinho, Joao R. R./G-2850-2012
OI Malta, Fernanda/0000-0001-8887-5060; Sitnik,
   Roberta/0000-0002-6243-8118; machado, marcel/0000-0002-0729-1635; Pinho,
   Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2006
VL 36
SU 2
BP S61
EP S61
DI 10.1016/S1386-6532(06)80186-1
PG 1
WC Virology
SC Virology
GA 064CR
UT WOS:000239067300177
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Goncalves, LL
   Bittencourt, PL
   De Melo, ES
   Abrantes-Lemos, CP
   Porta, G
   Nakhle, MC
   Carrilho, FJ
   Cancado, ELR
AF Farias, Alberto Queiroz
   Goncalves, Luciana Lofego
   Bittencourt, Paulo Lisboa
   De Melo, Evandro Sobroza
   Abrantes-Lemos, Clarice Pires
   Porta, Gilda
   Nakhle, Maria Cristina
   Carrilho, Flair Jose
   Rachid Cancado, Eduardo Luiz
TI Applicability of the IAIHG scoring system to the diagnosis of
   antimitochondrial/anti-M2 seropositive variant form of autoimmune
   hepatitis
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE antimitochondrial antibodies; autoimmune hepatitis; IAIHG criteria;
   immunogenetics
ID PRIMARY BILIARY-CIRRHOSIS; OVERLAP SYNDROME; ANTIBODIES; AUTOANTIGENS
AB Background and Aims: According to the International Autoimmune Hepatitis Group (IAIHG) criteria, circulating antimitochondrial antibodies (AMA) do not support the diagnosis of autoimmune hepatitis (AIH). The aims of this study were to characterize a subset of patients with AIH who have AMA and antiM2 seropositivity, and to assess the applicability of the revised scoring system of the IAIHG in the diagnosis of this variant form of AIH.
   Methods:Eighteen patients with AMA-AIH were enrolled and compared with 206 classical AIH and 85 primary biliary cirrhosis (PBC) controls. Human leukocyte antigen (HLA) class II alleles were determined by polymerase chain reaction (PCR) amplification with sequence-specific primers, and biopsies were blindly reevaluated.
   Results:The patients with AMA-AIH were, on average, older than patients with classical AIH and had an hepatocellular pattern of elevated liver enzymes, hypergammaglobulinemia and lower levels of cholesterol, when compared with PBC controls. There were no histological signs of PBC or overlapping forms in any AMA-AIH biopsies. The majority of patients with AMA-AIH carried HLA antigens associated with classical AIH (DRB1*03, n = 5; DRB1*04, n = 7, and DRB1*13, n = 6). Pretreatment scores classified all AMA-AIH patients with probable (n = 17) or improbable (n = 1) AIH. After treatment, only 28% of AMA-AIH patients reached scores for definite diagnosis, compared with 90.1% of AIH-1 and 96.4 AIH-2. In the AMA-AIH group, only patients who relapsed after immunosuppressive drug withdrawal could be classified with definite AIH.
   Conclusions:AMA-AIH shares common features with classical AIH. The diagnosis of AMA-AIH may be swayed by the IAIHG criteria, rendering questionable the applicability of the revised scoring system to this variant form of AIH.(c) 2006 Blackwell Publishing Asia Pty Ltd.
C1 Univ Sao Paulo, Sch Med, Childrens Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Trop Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Pathol, Sao Paulo, Brazil.
   Portuguese Hosp, Gastroenterol & Liver Unit, Salvador, BA, Brazil.
RP Farias, AQ (corresponding author), Rua Cristiano Viana 671-71, BR-05411001 Sao Paulo, Brazil.
EM albertofarias@terra.com.br
RI BITTENCOURT, PAULO l/I-5817-2014; Carrilho, Flair J/I-3046-2012; Farias,
   Alberto Q/H-7873-2013; Farias, Alberto/ABB-1291-2020; Cancado,
   Eduardo/K-1861-2016
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; Farias,
   Alberto/0000-0002-5572-663X; Cancado, Eduardo/0000-0002-9309-1524
CR Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   Angulo P, 2001, AM J GASTROENTEROL, V96, P3021
   Ben-Ari Z, 2001, GUT, V49, P589, DOI 10.1136/gut.49.4.589
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   Cancado ELR, 2001, J AUTOIMMUN, V17, P223, DOI 10.1006/jaut.2001.0540
   Chazouilleres O, 1998, HEPATOLOGY, V28, P296, DOI 10.1002/hep.510280203
   Czaja AJ, 2002, J HEPATOL, V37, P302, DOI 10.1016/S0168-8278(02)00182-4
   CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1522, DOI 10.1016/0016-5085(93)90160-E
   Czaja AJ, 1996, ANN INTERN MED, V125, P588, DOI 10.7326/0003-4819-125-7-199610010-00009
   Dahlan Y, 2003, GASTROENTEROLOGY, V125, P1476, DOI 10.1016/j.gastro.2003.08.022
   Goldberg AC, 1998, GENET MOL BIOL, V21, P301, DOI 10.1590/S1415-47571998000300001
   Gregorio GV, 1997, J HEPATOL, V27, P751, DOI 10.1016/S0168-8278(97)80093-1
   ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6
   Jones DEJ, 2000, J CLIN PATHOL, V53, P813, DOI 10.1136/jcp.53.11.813
   KENNY RP, 1986, DIGEST DIS SCI, V31, P705, DOI 10.1007/BF01296447
   Kim WR, 2000, AM J GASTROENTEROL, V95, P1130
   Kurien BT, 1998, INDIAN J BIOCHEM BIO, V35, P41
   LINDENBORNFOTINOS J, 1985, HEPATOLOGY, V5, P763, DOI 10.1002/hep.1840050510
   Lohse AW, 1999, HEPATOLOGY, V29, P1078, DOI 10.1002/hep.510290409
   McFarlane IG, 2002, SEMIN LIVER DIS, V22, P317, DOI 10.1055/s-2002-35702
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Muratori P, 2002, CLIN EXP IMMUNOL, V127, P172, DOI 10.1046/j.1365-2249.2002.01719.x
   Nakajima M, 1999, J GASTROENTEROL, V34, P607, DOI 10.1007/s005350050380
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P55
   SCHEUER PJ, 1967, P ROY SOC MED, V60, P1257, DOI 10.1177/003591576706001205
   Strassburg CP, 2002, SEMIN LIVER DIS, V22, P339, DOI 10.1055/s-2002-35704
   Weyman RL, 2001, AM J GASTROENTEROL, V96, P585
NR 28
TC 27
Z9 29
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD MAY
PY 2006
VL 21
IS 5
BP 887
EP 893
DI 10.1111/j.1440-1746.2006.04130.x
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 041OD
UT WOS:000237464600018
PM 16704541
DA 2020-12-08
ER

PT J
AU Nogueira, JA
   Nita, ME
   Tavares, MM
   Ono-Nita, SK
   Scapulatempo, C
   Mello, ES
   Wakamatsu, A
   Bacchella, T
   Carrilho, FJ
   Alves, VA
AF Nogueira, Jeronimo A.
   Nita, Marcelo E.
   Tavares, Marcelo M.
   Ono-Nita, Suzane K.
   Scapulatempo, Cristovam
   Mello, Evandro S.
   Wakamatsu, Alda
   Bacchella, Telesforo
   Carrilho, Flair J.
   Alves, Venancio A.
TI An aflatoxin-associated mutational hotspot at codom 249 in the p53 tumor
   suppressor gene in Hepatocellular Carcinomas from Brazil
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Digestive Disease Week Meeting/107th Annual Meeting of the
   American-Gastroenterlogical-Association
CY MAY 20-25, 2006
CL Los Angeles, CA
SP Amer Gastroenterlog Assoc Inst
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2006
VL 130
IS 4
SU 2
BP A812
EP A812
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 034WQ
UT WOS:000236961706188
DA 2020-12-08
ER

PT J
AU Oliveira, C
   Stefano, J
   Lima, V
   Simplicio, F
   Mello, E
   Sa, S
   Correa-Giannella, M
   Laurindo, F
   Alves, V
   Oliveira, M
   Giannella-Neto, D
   Carrilho, F
AF Oliveira, Cpms
   Stefano, Jt
   Lima, Vmr
   Simplicio, Fi
   Mello, Es
   Sa, Sv
   Correa-Giannella, Mlc
   Laurindo, Frm
   Alves, Vaf
   Oliveira, Mg
   Giannella-Neto, D.
   Carrilho, Fj
TI Protective effect of S-nitroso-N-acetyleysteine (SNAC) in nonalcoholic
   steatohepatitis (NASH) in ob/ob mice: Downregulation of genes belonging
   to mitochondrial fatty acids oxidation pathways
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Digestive Disease Week Meeting/107th Annual Meeting of the
   American-Gastroenterlogical-Association
CY MAY 20-25, 2006
CL Los Angeles, CA
SP Amer Gastroenterlog Assoc Inst
RI Giannella-Neto, Daniel/B-1475-2008; Laurindo, Francisco R/J-6575-2015;
   Stefano, Jose T/H-4792-2013; Giannella, Maria Lucia/N-3834-2019;
   Stefano, Jose Tadeu/AAH-5419-2020; de Oliveira, Marcelo
   Ganzarolli/B-4709-2013; Carrilho, Flair J/I-3046-2012
OI Stefano, Jose Tadeu/0000-0002-0218-1920; de Oliveira, Marcelo
   Ganzarolli/0000-0002-9371-9975; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
NR 0
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2006
VL 130
IS 4
SU 2
BP A826
EP A826
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 034WQ
UT WOS:000236961706253
DA 2020-12-08
ER

PT J
AU Oliveira, C
   Silva, L
   Mazo, D
   Rabelo, F
   Bertges, E
   Furuya, C
   Mello, E
   Alves, V
   Carrilho, F
AF Oliveira, Cpms
   Silva, Ls
   Mazo, Dfc
   Rabelo, F.
   Bertges, Er
   Furuya, Ck, Jr.
   Mello, Es
   Alves, Vaf
   Carrilho, Fj
TI N-acetyleysteine (NAC) associated with metformin (MTF) improves
   steatosis and fibrosis in patients with nonalcoholic steatohepatitis: A
   pilot study
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Digestive Disease Week Meeting/107th Annual Meeting of the
   American-Gastroenterlogical-Association
CY MAY 20-25, 2006
CL Los Angeles, CA
SP Amer Gastroenterlog Assoc Inst
RI Mazo, Daniel FC/D-5631-2015; Carrilho, Flair J/I-3046-2012
OI Mazo, Daniel FC/0000-0002-2164-2630; 
NR 0
TC 0
Z9 0
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2006
VL 130
IS 4
SU 2
BP A824
EP A824
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 034WQ
UT WOS:000236961706244
DA 2020-12-08
ER

PT J
AU Stefano, JT
   Oliveira, C
   Lima, V
   Sa, S
   Branches, R
   Correa-Giannella, M
   Giannella-Neto, D
   Carrilho, F
AF Stefano, J. T.
   Oliveira, Cpms
   Lima, Vmr
   Sa, Sv
   Branches, Rmb
   Correa-Giannella, Mlc
   Giannella-Neto, D.
   Carrilho, Fj
TI Protective effect of Yo Jyo Hen Shi Ko (YHK) in nonalcoholic
   steatohepatitis (NASH) in ob/ob mice: Increased PPAR-alpha gene
   expression
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Digestive Disease Week Meeting/107th Annual Meeting of the
   American-Gastroenterlogical-Association
CY MAY 20-25, 2006
CL Los Angeles, CA
SP Amer Gastroenterlog Assoc Inst
RI Stefano, Jose T/H-4792-2013; Carrilho, Flair J/I-3046-2012; Stefano,
   Jose Tadeu/AAH-5419-2020; Giannella, Maria Lucia/N-3834-2019;
   Giannella-Neto, Daniel/B-1475-2008
OI Stefano, Jose Tadeu/0000-0002-0218-1920; Correa-Giannella, Maria
   Lucia/0000-0003-3655-4446
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2006
VL 130
IS 4
SU 2
BP A827
EP A827
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 034WQ
UT WOS:000236961706259
DA 2020-12-08
ER

PT J
AU de Oliveira, CPMS
   Simplicio, FI
   de Lima, VMR
   Yuahasi, K
   Lopasso, FP
   Alves, VAF
   Abdalla, DSP
   Carrilho, FJ
   Laurindo, FRM
   de Oliveira, MG
AF de Oliveira, Claudia P. M. S.
   Simplicio, Fernanda I.
   de Lima, Vicencia M. R.
   Yuahasi, Katia
   Lopasso, Fabio P.
   Alves, Venancio A. F.
   Abdalla, Dulcineia S. P.
   Carrilho, Flair J.
   Laurindo, Francisco R. M.
   de Oliveira, Marcelo G.
TI Oral administration of S-nitroso-N-acetylcysteine prevents the onset of
   non alcoholic fatty liver disease in rats
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE nitric oxide; S-nitroso-N-acetylcysteine; oxidative stress; nonalcoholic
   fatty liver disease
ID LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE REGULATION; HUMAN BLOOD-PLASMA;
   LIPID-PEROXIDATION; OXIDATIVE STRESS; INSULIN-RESISTANCE;
   ATHEROSCLEROSIS; RADICALS; CELLS; PEROXYNITRITE
AB AIM: To evaluate the potential of 5-nitroso-N-acetylcysteine (SNAC) in inhibition of lipid peroxidation and the effect of oral SNAC administration in the prevention of nonalcoholic fatty liver disease (NAFLD) in an animal model.
   METHODS: NAFLD was induced in Wistar male rats by choline-deficient diet for 4 wk. SNAC-treated animals (n=6) (1.4 mg/kg/day of SNAC, orally) were compared to 2 control groups: one (n=6) received PBS solution and the other (n=6) received NAC solution (7 mg/kg/d). Histological variables were semiquantitated with respect to macro and microvacuolar fat changes, its zonal distribution, foci of necrosis, portal and perivenular fibrosis, and inflammatory infiltrate with zonal distribution. LOOHs from samples of liver homogenates were quantified by HPLC. Nitrate levels in plasma of portal vein were assessed by chemiluminescence. Aqueous low-density lipoprotein (LDL) suspensions (200 mu g protein/mL) were incubated with CuCl2 (300 mu mol/L) in the absence and presence of SNAC (300 mu mol/L) for 15 h at 37 degrees C. Extent of LDL oxidation was assessed by fluorimetry. Linoleic acid (LA) (18.8 mu mol/L) oxidation was induced by soybean lipoxygenase (SLO) (0.056 mu mol/L) at 37 degrees C in the presence and absence of N-acetylcysteine (NAC) and SNAC (56 and 560 mu mol/L) and monitored at 234 nm.
   RESULTS: Animals in the control, group developed moderate macro and microvesicular fatty changes in periportal area. SNAC-treated animals displayed only discrete histological alterations with absence of fatty changes and did not develop liver steatosis. The absence of NAFLD in the SNAC-treated group was positively correlated with a decrease in the concentration of LOOH in liver homogenate, compared to the control group (0.7+/-0.2 nmol/mg vs 3.2+/-0.4 nmol/mg protein, respectively, P<0.05), while serum levels of aminotransferases were unaltered. The ability of SNAC in preventing lipid peroxidation was confirmed in in vitro experiments using LA and LDL as model substrates.
   CONCLUSION: Oral administration of SNAC prevents the onset of NAFLD in Wistar rats fed with choline-deficient diet. This effect is correlated with the ability of SNAC to block the propagation of lipid peroxidation in vitro and in vitro. (C) 2006 The WJG Press. All rights reserved.
C1 Univ Estadual Campinas, Inst Quim, Dept Chem, BR-13083970 Campinas, SP, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, InCor, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
RP de Oliveira, CPMS (corresponding author), Univ Estadual Campinas, Inst Quim, Dept Chem, CP 6154, BR-13083970 Campinas, SP, Brazil.
EM mgo@iqm.unicamp.br
RI Oliveira, Claudia PMS/D-1216-2014; de Oliveira, Marcelo
   Ganzarolli/B-4709-2013; Carrilho, Flair J/I-3046-2012; Laurindo,
   Francisco R/J-6575-2015
OI de Oliveira, Marcelo Ganzarolli/0000-0002-9371-9975; 
CR Carvalho MA, 2005, DIABETES, V54, P959, DOI 10.2337/diabetes.54.4.959
   CURZIO M, 1985, INT J TISSUE REACT, V7, P137
   de Oliveira FG, 2000, CARDIOVASC RES, V47, P567, DOI 10.1016/S0008-6363(00)00121-8
   de Oliveira MG, 2002, J PHYS CHEM A, V106, P8963, DOI 10.1021/jp025756u
   Ewing JF, 1998, FREE RADICAL BIO MED, V25, P621, DOI 10.1016/S0891-5849(98)00083-5
   GILBERT BC, 1981, J CHEM SOC P2, V10, P1392
   Giustarini D, 2003, CLIN CHIM ACTA, V330, P85, DOI 10.1016/S0009-8981(03)00046-9
   Grattagliano I, 2000, J NUTR, V130, P2131
   Hamilton CA, 1997, PHARMACOL THERAPEUT, V74, P55, DOI 10.1016/S0163-7258(96)00202-1
   Hogg N, 1999, BBA-BIOENERGETICS, V1411, P378, DOI 10.1016/S0005-2728(99)00027-4
   Jaworski K, 2001, EUR J PHARMACOL, V425, P11, DOI 10.1016/S0014-2999(01)01166-9
   Kashyap MK, 2005, MOL CELL BIOCHEM, V277, P89, DOI 10.1007/s11010-005-5424-7
   Kockx MM, 1996, CIRCULATION, V94, P1255, DOI 10.1161/01.CIR.94.6.1255
   Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932
   Krieger MH, 2006, NITRIC OXIDE-BIOL CH, V14, P12, DOI 10.1016/j.niox.2005.07.011
   Kuhn H, 2002, FREE RADICAL BIO MED, V33, P154, DOI 10.1016/S0891-5849(02)00855-9
   Lapenna D, 2003, FREE RADICAL BIO MED, V35, P1203, DOI 10.1016/S0891-5849(03)00508-2
   LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304
   Letteron P, 1996, J HEPATOL, V24, P200, DOI 10.1016/S0168-8278(96)80030-4
   Lima ES, 2003, J LIPID RES, V44, P1660, DOI 10.1194/jlr.M200467-JLR200
   Lima ES, 2002, BIOCHEMISTRY-US, V41, P10717, DOI 10.1021/bi025504j
   Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5
   McCullough AJ, 2002, J CLIN GASTROENTEROL, V34, P255, DOI 10.1097/00004836-200203000-00013
   Napolitano A, 2002, J ORG CHEM, V67, P1125, DOI 10.1021/jo015973b
   Oliveira CPMS, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-9
   Oliveira CPMS, 2002, J CELL MOL MED, V6, P399, DOI 10.1111/j.1582-4934.2002.tb00518.x
   PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079
   Patel RP, 2000, CARDIOVASC RES, V47, P465, DOI 10.1016/S0008-6363(00)00086-9
   PLATIS IE, 1993, BIOCHEMISTRY-US, V32, P12761, DOI 10.1021/bi00210a027
   Ricardo KFS, 2002, NITRIC OXIDE-BIOL CH, V7, P57, DOI 10.1016/S1089-8603(02)00009-5
   Robertson Graham, 2001, American Journal of Physiology, V281, pG1135
   RUBBO H, 1994, J BIOL CHEM, V269, P26066
   Rubbo H, 2002, BIOL CHEM, V383, P547, DOI 10.1515/BC.2002.055
   Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q
   Senna SM, 1998, BIOCHEM MOL BIOL INT, V46, P1007
   STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928
   STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603
   Stocker P, 2003, BBA-GEN SUBJECTS, V1621, P1, DOI 10.1016/S0304-4165(03)00008-4
   Violi F, 1999, DIABETES-METAB RES, V15, P283, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<283::AID-DMRR42>3.0.CO;2-U
   VONSONNTAG C, 1990, NATO ADV SCI I A-LIF, V197, P359
   WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3
   YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3
   Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829
NR 43
TC 28
Z9 28
U1 0
U2 5
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAR 28
PY 2006
VL 12
IS 12
BP 1905
EP 1911
DI 10.3748/wjg.v12.i12.1905
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 076ZA
UT WOS:000239996000011
PM 16609997
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Campiotto, S
   Pinho, JRR
   Carrilho, FJ
   Da Silva, LC
   Souto, FJD
   Spinelli, V
   Pereira, LMMB
   Coelho, HSM
   Silva, AO
   Fonseca, JC
   Rosa, H
   Lacet, CMC
   Bernardini, AP
AF Campiotto, S
   Pinho, JRR
   Carrilho, FJ
   Da Silva, LC
   Souto, FJD
   Spinelli, V
   Pereira, LMMB
   Coelho, HSM
   Silva, AO
   Fonseca, JC
   Rosa, H
   Lacet, CMC
   Bernardini, AP
TI Geographic distribution of hepatitis C virus genotypes in Brazil (vol
   38, pg 41, 2005)
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Correction
RI Coelho, Henrique Sergio Moraes/AAB-3973-2019; Pinho, Joao R.
   R./G-2850-2012; Carrilho, Flair J/I-3046-2012; Souto,
   Francisco/J-6751-2012; Lacet, Celina/G-7645-2014
OI Pinho, Joao R. R./0000-0003-3999-0489; Lacet, Celina/0000-0002-4846-8206
CR Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
NR 1
TC 1
Z9 1
U1 0
U2 2
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD MAR
PY 2006
VL 39
IS 3
BP 419
EP 419
PG 1
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 029LU
UT WOS:000236565000014
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Oliveira, CPMS
   Coelho, AMM
   Barbeiro, HV
   Lima, VMR
   Soriano, F
   Ribeiro, C
   Molan, NAT
   Alves, VAF
   Souza, HP
   Machado, MCC
   Carrilho, FJ
AF Oliveira, CPMS
   Coelho, AMM
   Barbeiro, HV
   Lima, VMR
   Soriano, F
   Ribeiro, C
   Molan, NAT
   Alves, VAF
   Souza, HP
   Machado, MCC
   Carrilho, FJ
TI Liver mitochondrial dysfunction and oxidative stress in the pathogenesis
   of experimental nonalcoholic fatty liver disease
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hepatic mitochondrial dysfunction; oxidative stress; nonalcoholic fatty
   liver disease; choline-deficient diet; high-fat diet
ID INSULIN-RESISTANCE; HEPATIC STEATOSIS; STEATOHEPATITIS; OBESITY; ALPHA;
   ACID; RATS; MICE
AB Oxidative stress and hepatic mitochondria play a role in the pathogenesis of nonalcoholic fatty liver disease. The aim of the present study was to evaluate the role of hepatic mitochondrial dysfunction and oxidative stress in the pathogenesis of the disease. Fatty liver was induced in Wistar rats with a choline-deficient diet (CD; N = 7) or a high-fat diet enriched with PUFAs-omega-3 (H; N = 7) for 4 weeks. The control group (N = 7) was fed a standard diet. Liver mitochondrial oxidation and phosphorylation were measured polarographically and oxidative stress was estimated on the basis of malondialdehyde and glutathione concentrations. Moderate macrovacuolar liver steatosis was observed in the CD group and mild liver steatosis was observed in the periportal area in the H group. There was an increase in the oxygen consumption rate by liver mitochondria in respiratory state 4 (S4) and a decrease in respiratory control rate (RCR) in the CD group (S4: 32.70 +/- 3.35; RCR: 2.55 +/- 0.15 ng atoms Of O-2 min(-1) mg protein(-1)) when compared to the H and control groups (S4: 23.09 +/- 1.53, 17.04 +/- 2.03, RCR: 3.15 +/- 0.15, 3.68 +/- 0.15 ng atoms Of O-2 min(-1) mg protein(-1), respectively), P < 0.05. Hepatic lipoperoxide concentrations were significantly increased and the concentration of reduced glutathione was significantly reduced in the CD group. A choline-deficient diet causes moderate steatosis with disruption of liver mitochondrial function and increased oxidative stress. These data suggest that lipid peroxidation products can impair the flow of electrons along the respiratory chain, causing overreduction of respiratory chain components and enhanced mitochondrial reactive oxygen species. These findings are important in the pathogenesis of nonalcoholic fatty liver disease.
C1 Univ Sao Paulo, Fac Med, Dept Gastroenterol LIM 07, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Cirurgia LIM 37, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Emergencia LIM 51, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Patol LIM 14, Sao Paulo, Brazil.
RP Oliveira, CPMS (corresponding author), USP, Fac Med, Dept Gastroenterol, Av Dr Eneas C Aguiar 255,Inst Cent,9 Andar,S 9159, BR-05403000 Sao Paulo, Brazil.
EM cpm@usp.br
RI Coelho, Ana/E-5605-2013; Souza, Heraldo P/C-2498-2012; Oliveira, Claudia
   PMS/D-1216-2014; Barbeiro, Hermes V/E-2814-2010; Barbeiro, Hermes
   V/S-5926-2016; machado, marcel/E-2129-2012; Soriano,
   Francisco/C-3382-2012; Carrilho, Flair J/I-3046-2012
OI Coelho, Ana/0000-0002-0606-6532; Barbeiro, Hermes V/0000-0002-8209-4463;
   Barbeiro, Hermes V/0000-0002-8209-4463; machado,
   marcel/0000-0002-0729-1635; Soriano, Francisco/0000-0003-4898-0135; 
CR Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927
   CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503
   CURZIO M, 1985, INT J TISSUE REACT, V7, P137
   Estabrook R.W., 1967, METHOD ENZYMOL, P41, DOI DOI 10.1016/0076-6879(67)10010-4
   Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926
   LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304
   Letteron P, 1996, J HEPATOL, V24, P200, DOI 10.1016/S0168-8278(96)80030-4
   Luyckx FH, 2000, DIABETES METAB, V26, P98
   Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
   Mehta K, 2002, NUTR REV, V60, P289, DOI 10.1301/002966402320387224
   Oliveira CPMS, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-9
   Oliveira CPMS, 2002, J CELL MOL MED, V6, P399, DOI 10.1111/j.1582-4934.2002.tb00518.x
   Pessayre D, 2002, AM J PHYSIOL-GASTR L, V282, pG193, DOI 10.1152/ajpgi.00426.2001
   Scheen AJ, 2003, ACTA CLIN BELG, V58, P81
   Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028
   TERAMOTO K, 1993, TRANSPLANTATION, V55, P737, DOI 10.1097/00007890-199304000-00010
   Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007
   Wigg AJ, 2001, GUT, V48, P206, DOI 10.1136/gut.48.2.206
   WILLUMSEN N, 1993, LIPIDS, V28, P683, DOI 10.1007/BF02535987
   Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829
NR 20
TC 59
Z9 64
U1 0
U2 12
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD FEB
PY 2006
VL 39
IS 2
BP 189
EP 194
DI 10.1590/S0100-879X2006000200004
PG 6
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 014AZ
UT WOS:000235452400004
PM 16470305
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Cancado, ELR
   Medeiros, DM
   Deguti, MM
   dos Santos, MSC
   de Mello, ES
   Vendramini, MBG
   Carrilho, FJ
AF Cancado, ELR
   Medeiros, DM
   Deguti, MM
   dos Santos, MSC
   de Mello, ES
   Vendramini, MBG
   Carrilho, FJ
TI Celiac disease associated with nodular regenerative hyperplasia,
   pulmonary abnormalities, and IgA anticardiolipin antibodies
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE celiac disease; nodular regenerative hyperplasia; portal hypertension;
   hepatopulmonary syndrome; anticardiolipin antibodies
ID HEPATOPULMONARY SYNDROME; PORTOPULMONARY HYPERTENSION;
   PORTAL-HYPERTENSION; LIVER-DISEASE; PATIENT; TRANSPLANTATION;
   SCHISTOSOMIASIS; DYSFUNCTION; INJURY; DIET
AB The association of nodular regenerative hyperplasia with celiac disease is not as well established as it is with hepatopulmonary syndrome and portopulmonary hypertension. IgA anticardiolipin antibodies were reported recently in celiac patients with nodular regenerative hyperplasia. The subject of this study was the description of pulmonary abnormalities and IgA anticardiolipin antibodies in celiac patients with noncirrhotic portal hypertension. Five patients with portal hypertension were investigated to diagnose its etiology. Celiac disease was diagnosed by means of autoantibody reactivity and duodenal biopsies. Liver histology revealed nodular regenerative hyperplasia in four patients and suggested its presence in 1 case. Two cyanotic patients had severe hypoxemia with a confirmed diagnosis of hepatopulmonary syndrome. Another case exhibited features of hepatopulmonary syndrome with increased levels of arterial pulmonary pressure. The remaining 2 cases had slight abnormalities of arterial oxygenation. Three patients had reactivity to IgA anticardiolipin antibodies. The concomitance of celiac disease and nodular regenerative hyperplasia, two infrequent conditions, raises suspicion of there being a nonfortuitous coincidence. Pulmonary abnormalities, and especially hepatopulmonary syndrome, are described for the first time in association with celiac disease and nodular regenerative hyperplasia.
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Lab Immunopathol,Inst Trop Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Lab Immunopathol,Inst Trop Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Schistosomiasis, Lab Immunopathol,Inst Trop Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Transplant Unit, Dept Internal Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Discipline Rheumatol, Dept Internal Med, Sao Paulo, Brazil.
RP Cancado, ELR (corresponding author), Rua Alves Guimaraes,1133-102 Jardim Amer, BR-05410002 Sao Paulo, Brazil.
EM edulrc@uol.com.br
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016
OI Cancado, Eduardo/0000-0002-9309-1524
CR Abdo A, 2004, CLIN GASTROENTEROL H, V2, P107, DOI 10.1016/S1542-3565(03)00313-6
   Arguedas MR, 2003, HEPATOLOGY, V37, P192, DOI 10.1053/jhep.2003.50023
   Arnott IDR, 2000, EUR J GASTROEN HEPAT, V12, P569, DOI 10.1097/00042737-200012050-00016
   Arvanitaki M, 2001, HEPATO-GASTROENTEROL, V48, P1425
   Austin A, 2004, GUT, V53, P1032, DOI 10.1136/gut.2003.036806
   BARDELLA MT, 1995, HEPATOLOGY, V22, P833, DOI 10.1002/hep.1840220322
   BENARI Z, 1995, EUR J GASTROEN HEPAT, V7, P87
   Cadranel JF, 1996, GASTROEN CLIN BIOL, V20, P901
   Corley DA, 1997, GASTROENTEROLOGY, V113, P728, DOI 10.1053/gast.1997.v113.agast971130728
   Fallon MB, 2000, HEPATOLOGY, V32, P859, DOI 10.1053/jhep.2000.7519
   Gandolfi L, 2000, AM J GASTROENTEROL, V95, P689, DOI 10.1111/j.1572-0241.2000.01847.x
   HAGANDER B, 1977, LANCET, V2, P270
   Hoeper MM, 2004, LANCET, V363, P1461, DOI 10.1016/S0140-6736(04)16107-2
   HOURANI JM, 1991, AM J MED, V90, P693
   Kaymakoglu S, 2003, DIGEST DIS SCI, V48, P556, DOI 10.1023/A:1022549018807
   Levy S, 1998, EUR J GASTROEN HEPAT, V10, P721
   LINDGREN S, 1994, SCAND J GASTROENTERO, V29, P661, DOI 10.3109/00365529409092489
   Martinez-Palli G, 1999, J HEPATOL, V31, P1075, DOI 10.1016/S0168-8278(99)80321-3
   MORAN CA, 1991, AM J SURG PATHOL, V15, P449, DOI 10.1097/00000478-199105000-00004
   Naeije R, 2003, SWISS MED WKLY, V133, P163
   NAKANUMA Y, 1990, J CLIN GASTROENTEROL, V12, P460
   OGRADY JG, 1984, GASTROENTEROLOGY, V87, P1326
   OMRAN SA, 1995, HAEMOSTASIS, V25, P218
   PETTEI MJ, 1995, J PEDIATR GASTR NUTR, V20, P343, DOI 10.1097/00005176-199504000-00014
   Riestra S, 2001, J CLIN GASTROENTEROL, V33, P323, DOI 10.1097/00004836-200110000-00014
   RUIZ FP, 1991, SEMIN ARTHRITIS RHEU, V21, P47, DOI 10.1016/0049-0172(91)90056-6
   STRAUSS E, 1986, J HEPATOL, V2, P340, DOI 10.1016/S0168-8278(86)80045-9
   WANLESS IR, 1990, HEPATOLOGY, V11, P787, DOI 10.1002/hep.1840110512
   WEINBREN K, 1984, J PATHOL, V143, P81, DOI 10.1002/path.1711430203
   YUTANI C, 1988, HUM PATHOL, V19, P726, DOI 10.1016/S0046-8177(88)80180-1
NR 30
TC 9
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0192-0790
EI 1539-2031
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD FEB
PY 2006
VL 40
IS 2
BP 135
EP 139
DI 10.1097/01.mcg.0000196462.53304.bf
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 007JX
UT WOS:000234966200009
PM 16394874
DA 2020-12-08
ER

PT J
AU Furuya, CK
   Oliveira, CPMS
   Mello, ES
   Faintuch, J
   Rascovski, A
   Vezzozo, DCP
   Halpern, A
   Matsuda, M
   Zilberstein, B
   Alves, VAF
   Carrilho, FJ
AF Furuya, C. K., Jr.
   Oliveira, C. P. M. S.
   Mello, E. S.
   Faintuch, J.
   Rascovski, A.
   Vezzozo, D. C. P.
   Halpern, A.
   Matsuda, M.
   Zilberstein, B.
   Alves, V. A. F.
   Carrilho, F. J.
TI Effects of bariatric surgery (Fobi-Capella) in non-alcoholic fatty liver
   disease: Study after 2 years
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 26-30, 2006
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Endocrinol, Sao Paulo, Brazil.
RI Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012;
   Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2006
VL 44
SU 2
MA 667
BP S246
EP S246
DI 10.1016/S0168-8278(06)80667-7
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 039SU
UT WOS:000237328100667
DA 2020-12-08
ER

PT J
AU Lima, VMR
   Oliveira, CPMS
   Sawada, LY
   Barbeiro, HV
   Mello, ES
   Soriano, FG
   Alves, VAF
   Carrilho, FJ
AF Lima, V. M. R.
   Oliveira, C. P. M. S.
   Sawada, L. Y.
   Barbeiro, H. V.
   Mello, E. S.
   Soriano, F. G.
   Alves, V. A. F.
   Carrilho, F. J.
TI Yo Jyo Hen Shi Ko (YHK) in the prevention of non-alcoholic
   steatohepatitis induced by different diets in ob/ob mice: Decrease of
   oxidative stress
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 26-30, 2006
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Emergency, Sao Paulo, Brazil.
RI Soriano, Francisco/C-3382-2012; Carrilho, Flair J/I-3046-2012; Barbeiro,
   Hermes V/E-2814-2010; Oliveira, Claudia PMS/D-1216-2014; Barbeiro,
   Hermes V/S-5926-2016
OI Soriano, Francisco/0000-0003-4898-0135; Barbeiro, Hermes
   V/0000-0002-8209-4463; Barbeiro, Hermes V/0000-0002-8209-4463
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2006
VL 44
SU 2
MA 668
BP S247
EP S247
DI 10.1016/S0168-8278(06)80668-9
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 039SU
UT WOS:000237328100668
DA 2020-12-08
ER

PT J
AU Mattar, R
   dos Santos, AF
   Eisig, JN
   Rodrigues, TN
   Silva, FM
   Lupinacci, RM
   Iriya, K
   Carrilho, FJ
AF Mattar, R
   dos Santos, AF
   Eisig, JN
   Rodrigues, TN
   Silva, FM
   Lupinacci, RM
   Iriya, K
   Carrilho, FJ
TI No correlation of babA2 with vacA and cagA genotypes of Helicobacter
   pylori and grading of gastritis from peptic ulcer disease patients in
   Brazil
SO HELICOBACTER
LA English
DT Article
DE Helicobacter pylori; cagA; vacA; babA2; peptic ulcer
ID ANTIGEN-BINDING ADHESIN; GASTRODUODENAL DISEASE; PATHOGENICITY ISLAND;
   CYTOTOXIN PRODUCTION; CLINICAL-RELEVANCE; DUODENAL-ULCER; INFECTION;
   CANCER; GENES; ASSOCIATION
AB Background. The babA2 gene, which encodes a blood-group antigen-binding adhesin that mediates attachment of Helicobacter pylori to human Lewis(b) antigens on gastric epithelial cells, has been associated with a higher risk of peptic ulcer and gastric cancer. The purpose of this study was to ascertain the frequency of babA2 genotype in H. pylori strains of patients with peptic ulcer and to correlate with other virulence factors.
   Materials and Methods. vacA, cagA, and babA2 genotypes of H. pylori were determined by using polymerase chain reaction (PCR). DNA was extracted from positive urease test gastric samples of 150 patients with peptic ulcer. Antrum and corpus biopsies were taken for histologic examination according to the updated Sydney system classification.
   Results. babA2 genotype was present in 104 (69.3%) and cagA in 113 (75.3%) gastric samples. No significant correlation was observed between babA2 and vacAs1 genotype or between babA2 and cagA status. The correlation of vacAs1 genotype with positive cagA was statistically significant (p < .001). The babA2-positive strain was more frequently found from the gastric samples of men, than of women (p = .01). Strains harboring cagA, vacAs1, and babA2 genotypes had no association to the grading of gastritis, presence of glandular atrophy, or intestinal metaplasia. The simultaneous presence of cagA, vacAs1, and babA2 was found in 32.6% of the H. pylori strains.
   Conclusions. babA2 genotype is frequently found in H. pylori strains from peptic ulcer disease in Brazil, although it has no significant correlation to the worsening of the gastritis and to other virulence markers such as vacAs1 and cagA.
C1 Univ Sao Paulo, Hosp Clin, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Hosp Clin, Sch Med, Dept Pathol, BR-05403000 Sao Paulo, Brazil.
RP Mattar, R (corresponding author), Univ Sao Paulo, Hosp Clin, Sch Med, Dept Gastroenterol, Av Dr Eneas Carvalho Aguiar 255,9 Andar,Sala 9159, BR-05403000 Sao Paulo, Brazil.
EM rmattar@hcnet.usp.br
RI Mattar, Rejane/AAO-4842-2020; Carrilho, Flair J/I-3046-2012; Mattar,
   Rejane/K-3883-2012; Rodriguez, TOMAS NAVARRO/I-3170-2012
OI Mattar, Rejane/0000-0001-7870-8867; Rodriguez, TOMAS
   NAVARRO/0000-0002-3458-699X
CR ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771
   BarretoZuniga R, 1997, J GASTROENTEROL, V32, P289, DOI 10.1007/BF02934482
   Basso D, 2004, CRIT REV CL LAB SCI, V41, P313, DOI 10.1080/10408360490472804
   Bernstein CN, 1999, DIGEST DIS SCI, V44, P668, DOI 10.1023/A:1026689103952
   Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI 10.1172/JCI200420925
   Bravo LE, 2002, AM J GASTROENTEROL, V97, P2839, DOI 10.1111/j.1572-0241.2002.07031.x
   Castro LD, 1998, CAN J GASTROENTEROL, V12, P509
   COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791
   CRABTREE JE, 1998, DIG DIS SCI S, V43, P46
   Del Giudice G, 2001, ANNU REV IMMUNOL, V19, P523, DOI 10.1146/annurev.immunol.19.1.523
   Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001
   Dong WG, 2004, WORLD J GASTROENTERO, V10, P3377, DOI 10.3748/wjg.v10.i22.3377
   FORMAN D, 1993, LANCET, V341, P1359
   Fujioka N, 2001, JPN J CANCER RES, V92, P829, DOI 10.1111/j.1349-7006.2001.tb01168.x
   Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871
   Gerhard M, 1999, P NATL ACAD SCI USA, V96, P12778, DOI 10.1073/pnas.96.22.12778
   HAMMAR M, 1992, J CLIN MICROBIOL, V30, P54, DOI 10.1128/JCM.30.1.54-58.1992
   Hennig EE, 2004, INFECT IMMUN, V72, P3429, DOI 10.1128/IAI.72.6.3429-3435.2004
   Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373
   Kidd M, 1999, GUT, V45, P499, DOI 10.1136/gut.45.4.499
   Kidd M, 2001, GUT, V49, P11, DOI 10.1136/gut.49.1.11
   Kim JH, 2001, J GASTROEN HEPATOL, V16, P969, DOI 10.1046/j.1440-1746.2001.02568.x
   Lai CH, 2002, J CLIN MICROBIOL, V40, P3860, DOI 10.1128/JCM.40.10.3860-3862.2002
   Levenstein S, 1999, CAN J GASTROENTEROL, V13, P753, DOI 10.1155/1999/521393
   Liu ES, 2001, J GASTROEN HEPATOL, V16, P740, DOI 10.1046/j.1440-1746.2001.02506.x
   Malfertheiner P, 1997, DIGESTION, V58, P17, DOI 10.1159/000201517
   Mattar R, 2000, Rev Hosp Clin Fac Med Sao Paulo, V55, P155, DOI 10.1590/S0041-87812000000500001
   Mattar Rejane, 2004, Rev. Hosp. Clin., V59, P172, DOI 10.1590/S0041-87812004000400004
   Mattar Rejane, 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P3, DOI 10.1590/S0036-46651999000100002
   Mattar Rejane, 2002, Rev. Hosp. Clin., V57, P89, DOI 10.1590/S0041-87812002000300001
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Miwa H, 2002, AM J GASTROENTEROL, V97, P1106, DOI 10.1111/j.1572-0241.2002.05663.x
   Mizushima T, 2001, J CLIN MICROBIOL, V39, P2463, DOI 10.1128/JCM.39.7.2463-2465.2001
   Oliveira AG, 2003, J CLIN MICROBIOL, V41, P3964, DOI 10.1128/JCM.41.8.3964-3966.2003
   Podzorski RP, 2003, DIAGN MICR INFEC DIS, V46, P83, DOI 10.1016/S0732-8893(03)00034-8
   Pride DT, 2001, INFECT IMMUN, V69, P1160, DOI 10.1128/IAI.69.2.1160-1171.2001
   Prinz C, 2001, CANCER RES, V61, P1903
   Reshetnikov OV, 2001, HELICOBACTER, V6, P331, DOI 10.1046/j.1523-5378.2001.00045.x
   Rudi J, 1998, J CLIN MICROBIOL, V36, P944, DOI 10.1128/JCM.36.4.944-948.1998
   Sheu BS, 2003, GUT, V52, P927, DOI 10.1136/gut.52.7.927
   Slater E, 1999, GASTROENTEROLOGY, V117, P1308, DOI 10.1016/S0016-5085(99)70281-7
   Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263
   Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483
   van Doorn LJ, 1999, GASTROENTEROLOGY, V116, P823, DOI 10.1016/S0016-5085(99)70065-X
   Yu J, 2002, GUT, V51, P480, DOI 10.1136/gut.51.4.480
   Zambon CF, 2003, J CLIN PATHOL, V56, P287, DOI 10.1136/jcp.56.4.287
NR 46
TC 45
Z9 51
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1083-4389
J9 HELICOBACTER
JI Helicobacter
PD DEC
PY 2005
VL 10
IS 6
BP 601
EP 608
DI 10.1111/j.1523-5378.2005.00360.x
PG 8
WC Gastroenterology & Hepatology; Microbiology
SC Gastroenterology & Hepatology; Microbiology
GA 982FY
UT WOS:000233144600006
PM 16302986
DA 2020-12-08
ER

PT J
AU Padua, MA
   Fonseca, AM
   Carrilho, FJ
   Bagnoli, VR
   Farias, AQ
   Halbe, HW
   Paixao, JS
AF Padua, MA
   Fonseca, AM
   Carrilho, FJ
   Bagnoli, VR
   Farias, AQ
   Halbe, HW
   Paixao, JS
TI Menopause's women with liver disease (hepatitis C), taking hormonal
   therapy, (hepatic lesion and blood coagulation)
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Meeting Abstract
CT 16th Annual Meeting of the North-American-Menopause-Society
CY SEP 28-OCT 01, 2005
CL San Diego, CA
SP N Amer Menopause Soc
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD NOV-DEC
PY 2005
VL 12
IS 6
BP 805
EP 805
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 986MM
UT WOS:000233453700131
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Marin, ML
   Porta, G
   Cancado, EL
   Miura, IK
   Carrilho, FJ
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Marin, ML
   Porta, G
   Cancado, EL
   Miura, IK
   Carrilho, FJ
   Kalil, J
   Goldberg, AC
TI Polymorphisms of MHC and non-MHC genes and susceptibility to primary
   sclerosing cholangitis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 11-15, 2005
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 Portuguese Hosp, Salvador, BA, Brazil.
   Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Childrens Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Chem, Sao Paulo, Brazil.
RI BITTENCOURT, PAULO l/I-5817-2014; Goldberg, Anna Carla/H-8594-2014;
   Cancado, Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012; KALIL,
   JORGE/C-8029-2012
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; Goldberg, Anna
   Carla/0000-0003-2600-7940; Cancado, Eduardo/0000-0002-9309-1524; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2005
VL 42
IS 4
SU 1
BP 296A
EP 296A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 972VC
UT WOS:000232480300248
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Pinho, JR
   Ono-Nita, SK
   Madruga, CL
   Mello, IM
   Carrilho, FJ
AF Da Silva, LC
   Pinho, JR
   Ono-Nita, SK
   Madruga, CL
   Mello, IM
   Carrilho, FJ
TI Pegylated interferons (PEG-IFNs) do not present viral rebound after
   short-term administration of consensus interferon (CIFN) to IFN-naive
   patients (PTS) with chronic hepatites C (CHC), genotype 1.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 11-15, 2005
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Ono, Suzane/I-3107-2012; Carrilho, Flair J/I-3046-2012; de
   carvalho-Mello, Isabel Maria V G/D-3641-2012; Pinho, Joao R.
   R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2005
VL 42
IS 4
SU 1
BP 694A
EP 694A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 972VC
UT WOS:000232480302317
DA 2020-12-08
ER

PT J
AU Carrilho, FJ
   Ono-Nita, SK
   Cardoso, RA
   Cancado, ELR
   Pinho, JRR
   Alves, VAF
   Da Silva, LC
AF Carrilho, FJ
   Ono-Nita, SK
   Cardoso, RA
   Cancado, ELR
   Pinho, JRR
   Alves, VAF
   Da Silva, LC
TI A prospective study of hepatitis B virus markers in patients with
   chronic HBV infection from Brazilian families of Western and Asian
   origin
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hepatitis B; familial clustering; HBsAg; vertical transmission;
   anti-HBc; anti-HBs
ID CHRONIC CARRIER STATE; HEPATOCELLULAR-CARCINOMA; RECESSIVE INHERITANCE;
   INTRAFAMILIAL SPREAD; CONSENSUS STATEMENT; SURFACE-ANTIGEN;
   TRANSMISSION; VACCINATION; MANAGEMENT; HBSAG
AB The purpose of the present study was to determine the frequency of hepatitis B virus (HBV) markers in families of HBsAg-positive patients with chronic liver disease. Serum anti-HBc, HBsAg and anti-HBs were determined by enzyme immunoassay and four subpopulations were considered: genetically related (consanguineous) and nongenetically related (non-consanguineous) Asian subjects and genetically related and non-genetically related Western subjects. A total of 165 and 186 relatives of Asian and Western origin were enrolled, respectively. The occurrence of HBsAg and anti-HBs antibodies was significantly higher (P < 0.0001) in family members of Asian origin (81.8%) than in family members of Western origin (36.5%). HBsAg was also more frequent among brothers (79.6 vs 8.5%; P < 0.0001), children (37.9 vs 3.3%; P < 0.0001) and other family members (33.9 vs 16.7%; P < 0.0007) of Asian than Western origin, respectivelly. No difference between groups was found for anti-HBs, which was more frequently observed in fathers, spouses and other non-genetic relatives. HBV infection was significantly higher in children of Asian than Western mothers (P < 0.0004). In both ethnic groups, the mothers contributed more to their children's infection than the fathers (P < 0.0001). Furthermore, HJBsAg was more frequent among consanguineous members and anti-HBs among non-consanguineous members. These results suggest the occurrence of vertical transmission of HBV among consanguineous members and probably horizontal sexual transmission among non-consanguineous members of a family cluster. Thus, the high occurrence of dissemination of HBV infection characterizes family members as a high-risk group that calls for immunoprophylaxis. Finally, the study showed a high familial aggregation rate for both ethnic groups, 18/19 (94.7%) and 23/26 (88.5%) of the Asian and Western origin, respectively.
C1 Univ Sao Paulo, Dept Gastroenterol, Setor Hepatol, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Patol, Sao Paulo, Brazil.
RP Carrilho, FJ (corresponding author), R Silva Correia 153,Apto 41, BR-04537040 Sao Paulo, Brazil.
EM fjcarril@usp.br
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; Cancado,
   Eduardo/K-1861-2016; Ono, Suzane/I-3107-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Cancado,
   Eduardo/0000-0002-9309-1524; 
CR BEASLEY RP, 1983, HEPATOLOGY, V3, P135
   BERNIER RH, 1982, AM J EPIDEMIOL, V116, P199, DOI 10.1093/oxfordjournals.aje.a113406
   Beutels P, 2002, PHARMACOECONOMICS, V20, P1, DOI 10.2165/00019053-200220010-00001
   BOSCH J, 1973, LANCET, V2, P457
   BOSS LP, 1981, AM J EPIDEMIOL, V114, P95, DOI 10.1093/oxfordjournals.aje.a113178
   BRUGUERA M, 1973, NEW ENGL J MED, V289, P1144
   BRUGUERA M, 1974, BRIT MED J, V3, P495, DOI 10.1136/bmj.3.5929.495
   BRUGUERA M, 1980, GASTROENTEROL HEPATO, V3, P13
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   CHANG MH, 1984, CANCER, V53, P1807, DOI 10.1002/1097-0142(19840415)53:8<1807::AID-CNCR2820530835>3.0.CO;2-J
   CLEMENTE CM, 2003, THESIS U SAO PAULO S
   Conjeevaram HS, 2003, J HEPATOL, V38, pS90, DOI 10.1016/S0168-8278(02)00431-2
   DERSO A, 1978, BRIT MED J, V1, P949, DOI 10.1136/bmj.1.6118.949
   *EASL JUR, 2003, J HEPATOL, V38, P533
   FOLLETT EAC, 1978, BRIT MED J, V1, P1279, DOI 10.1136/bmj.1.6122.1279-d
   GRIZZLE JE, 1969, BIOMETRICS, V25, P489, DOI 10.2307/2528901
   HADZIYANNIS SJ, 1975, AM J MED SCI, V270, P313
   HELSKE T, 1973, J MED GENET, V10, P270, DOI 10.1136/jmg.10.3.270
   HOLLAND PV, 1985, HEPATITIS B, P5
   Kashiwagi S, 1978, Fukuoka Igaku Zasshi, V69, P156
   KOCH GG, 1984, LECT NOTES ANAL CATE
   Lee CL, 1997, PEDIATRICS, V99, P351, DOI 10.1542/peds.99.3.351
   Liaw YF, 2003, J GASTROEN HEPATOL, V18, P239, DOI 10.1046/j.1440-1746.2003.03037.x
   Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839
   Lok ASF, 2001, HEPATOLOGY, V34, P1225, DOI 10.1053/jhep.2001.29401
   NASRALLAH SM, 1978, GASTROENTEROLOGY, V75, P302
   OHBAYASHI A, 1972, GASTROENTEROLOGY, V62, P618
   Ono-Nita Suzane Kioko, 2004, BMC Fam Pract, V5, P7, DOI 10.1186/1471-2296-5-7
   PASTORE G, 1981, HEPATO-GASTROENTEROL, V28, P20
   PONGPIPAT D, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P582
   RATNAM S, 1987, J CLIN MICROBIOL, V25, P432, DOI 10.1128/JCM.25.2.432-433.1987
   SAMPLINER RE, 1981, TISSUE ANTIGENS, V18, P247, DOI 10.1111/j.1399-0039.1981.tb01388.x
   SAMPLINER RE, 1981, AM J EPIDEMIOL, V113, P50, DOI 10.1093/oxfordjournals.aje.a113065
   SAS Institute Inc, 1985, SAS US GUID STAT, P956
   SKINHOJ P, 1983, J MED VIROL, V11, P125, DOI 10.1002/jmv.1890110206
   SZMUNESS W, 1975, AM J MED SCI, V270, P293, DOI 10.1097/00000441-197509000-00009
   Tong M J, 1981, Prog Med Virol, V27, P137
   TONG MJ, 1979, DIGEST DIS SCI, V24, P286, DOI 10.1007/BF01296542
   TONG MJ, 1979, J INFECT DIS, V140, P506, DOI 10.1093/infdis/140.4.506
   VYAS GN, 1974, NATURE, V248, P159, DOI 10.1038/248159a0
NR 40
TC 7
Z9 7
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD SEP
PY 2005
VL 38
IS 9
BP 1399
EP 1408
DI 10.1590/S0100-879X2005000900015
PG 10
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 962ZZ
UT WOS:000231773600015
PM 16138224
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Lyra, AC
   Pinho, JRR
   Silva, LK
   Sousa, L
   Saraceni, CP
   Braga, EL
   Pereira, JE
   Zarife, MAS
   Reis, MG
   Lyra, LGC
   da Silva, LC
   Carrilho, FJ
AF Lyra, AC
   Pinho, JRR
   Silva, LK
   Sousa, L
   Saraceni, CP
   Braga, EL
   Pereira, JE
   Zarife, MAS
   Reis, MG
   Lyra, LGC
   da Silva, LC
   Carrilho, FJ
TI HEV, TTV and GBV-C/HGV markers in patients with acute viral hepatitis
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE acute hepatitis; hepatitis E; TTV; GBV-C/HGV; genotype; Brazil
ID DNA VIRUS TTV; RIO-DE-JANEIRO; NON-B-HEPATITIS; NON-A; UNKNOWN ETIOLOGY;
   POSTTRANSFUSION HEPATITIS; HIGH PREVALENCE; LIVER-DISEASES; BRAZIL;
   INFECTION
AB The aim of the present study was to evaluate the prevalence of HEV, TTV and GBV-C/GBV-C/HGV in patients with acute viral hepatitis A, B and non-A-C. We evaluated sera of 94 patients from a sentinel program who had acute hepatitis A (N = 40), B (N = 42) and non-A-C (N = 12); 71 blood donors served as controls. IgM and anti-HEV IgG antibodies were detected by enzyme immunoassay using commercial kits. TTV and GBV-C/HGV were detected by nested PCR; genotyping was done by sequencing and phylogenetic analysis. Anti-HEV IgG was present in 3 8, 10 and 17% of patients with hepatitis A, B and non-A-C. Four patients with hepatitis A and I with non-A-C hepatitis also had anti-HEV IgM detected in serum. TTV was detected in 21% of patients with acute hepatitis and in 31% of donors. GBV-C/HGV was detected in 9% of patients with hepatitis, and in 10% of donors. We found TTV isolates of genotypes 1, 2, 3, and 4 and GBV-C/HGV isolates of genotypes 1 and 2. Mean aminotransferase levels were lower in patients who were TTV or GBV-C/HGV positive. In conclusion, the detection of anti-HEV IgM in some acute hepatitis A cases suggests co-infection with HEV and hepatitis E could be the etiology of a few cases of sporadic non-A-C hepatitis in Salvador, Brazil. TTV genotype 1, 2, 3 and 4 isolates and GBV-C/HGV genotype I and 2 strains are frequent in the studied population. TTV and GBV-C/HGV infection does not appear to have a role in the etiology of acute hepatitis.
C1 Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
   Inst Adolfo Lutz Registro, Sao Paulo, Brazil.
   Univ Fed Bahia, Serv Gastrohepatol, Salvador, BA, Brazil.
   Univ Fed Bahia, Hosp Sao Rafael, Salvador, BA, Brazil.
   Fdn Oswaldo Cruz FioCruz, Salvador, BA, Brazil.
   Lab Cent Bahia LACEN, Salvador, BA, Brazil.
RP Lyra, AC (corresponding author), R Socrates Guanaes Gomes 84-401, BR-40283320 Salvador, BA, Brazil.
EM aclyra@atarde.com.br
RI Silva, Luciano K/L-9041-2013; Carrilho, Flair J/I-3046-2012; Pinho, Joao
   R. R./G-2850-2012; Reis, Mitermayer/AAO-9742-2020
OI Silva, Luciano K/0000-0002-7739-4082; Pinho, Joao R.
   R./0000-0003-3999-0489; Reis, Mitermayer/0000-0002-3051-9060; Silva,
   Luciano/0000-0002-8216-2489
CR ABUZWAIDA ARN, 1987, REV I MED TROP, V29, P219, DOI 10.1590/S0036-46651987000400006
   BRADLEY V, 1991, AAMR NEWS NOTES, V4, P1
   BRYAN JP, 1994, J INFECT DIS, V170, P517, DOI 10.1093/infdis/170.3.517
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Clemens S A, 2000, Rev Soc Bras Med Trop, V33, P1, DOI 10.1590/S0037-86822000000100001
   DOSSANTOS JI, 1995, REV INST MED TROP SP, V37, P343
   Erker JC, 1998, J VIROL METHODS, V70, P1, DOI 10.1016/S0166-0934(97)00162-6
   Ferraz M L, 1998, Sao Paulo Med J, V116, P1695
   Gimenez-Barcons M, 1999, J HEPATOL, V30, P1028, DOI 10.1016/S0168-8278(99)80256-6
   Goncales NSL, 2000, CLIN DIAGN LAB IMMUN, V7, P813, DOI 10.1128/CDLI.7.5.813-816.2000
   Halasz R, 2001, SCAND J INFECT DIS, V33, P572, DOI 10.1080/00365540110027123
   HYAMS KC, 1992, J INFECT DIS, V165, P1001, DOI 10.1093/infdis/165.6.1001
   Ikeda H, 1999, J HEPATOL, V30, P205, DOI 10.1016/S0168-8278(99)80063-4
   Kanda T, 1999, HEPATOLOGY, V29, P1905, DOI 10.1002/hep.510290613
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Leary TP, 1996, J VIROL METHODS, V56, P119, DOI 10.1016/0166-0934(95)01956-1
   Lewis-Ximenez LL, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-26
   Loureiro CL, 2002, J MED VIROL, V68, P357, DOI 10.1002/jmv.10211
   Mushahwar IK, 1999, P NATL ACAD SCI USA, V96, P3177, DOI 10.1073/pnas.96.6.3177
   Naoumov NV, 1998, LANCET, V352, P195, DOI 10.1016/S0140-6736(98)04069-0
   Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765
   Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X
   PANNUTI CS, 1985, TROP GEOGR MED, V37, P136
   Parana R, 1999, HEPATOLOGY, V30, P289, DOI 10.1002/hep.510300143
   Parana R, 1997, AM J TROP MED HYG, V57, P60, DOI 10.4269/ajtmh.1997.57.60
   PAUL DA, 1994, J INFECT DIS, V169, P801, DOI 10.1093/infdis/169.4.801
   Pinho JRR, 1999, J CLIN MICROBIOL, V37, P1634, DOI 10.1128/JCM.37.5.1634-1637.1999
   REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574
   Silva LK, 2000, AM J TROP MED HYG, V62, P257, DOI 10.4269/ajtmh.2000.62.257
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Souto FJD, 1997, AM J TROP MED HYG, V57, P149, DOI 10.4269/ajtmh.1997.57.149
   Tanaka H, 1998, J MED VIROL, V56, P234, DOI 10.1002/(SICI)1096-9071(199811)56:3&lt;234::AID-JMV10&gt;3.0.CO;2-E
   Tanaka Y, 1998, AM J TROP MED HYG, V59, P462, DOI 10.4269/ajtmh.1998.59.462
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Vitral CL, 1998, MEM I OSWALDO CRUZ, V93, P1, DOI 10.1590/S0074-02761998000100001
   Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
NR 39
TC 22
Z9 24
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD MAY
PY 2005
VL 38
IS 5
BP 767
EP 775
DI 10.1590/S0100-879X2005000500015
PG 9
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 933DR
UT WOS:000229605000015
PM 15917959
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Kikuchi, L
   Deguti, M
   Mello, E
   Tani, C
   Cancado, E
   Carrilho, F
AF Kikuchi, L
   Deguti, M
   Mello, E
   Tani, C
   Cancado, E
   Carrilho, F
TI Hepatobiliary and pancreatic: Hepatic granulomas and hepatitis C
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Editorial Material
C1 Univ Sao Paulo, Dept Gastroenterol & Hepatol, BR-05403010 Sao Paulo, Brazil.
RP Kikuchi, L (corresponding author), Univ Sao Paulo, Dept Gastroenterol & Hepatol, Ave Dr Eneas de Carvalho Aguiar 255, BR-05403010 Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016
OI Cancado, Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD MAY
PY 2005
VL 20
IS 5
BP 792
EP 792
DI 10.1111/j.1440-1746.2005.03935.x
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 913EF
UT WOS:000228133700024
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Pinho, JRR
   Ono-Nita, SK
   Carrilho, FJ
AF Da Silva, LC
   Pinho, JRR
   Ono-Nita, SK
   Carrilho, FJ
TI Viral kinetics of hepatitis B virus (HBV) must include serial Hbeag
   semi-quantitative determinations in order to distinguish three different
   patterns of viral response to antiviral therapy
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Gastroenterological-Association/Digestive-Disease-Week
CY MAY 14-19, 2005
CL Chicago, IL
SP Amer Gastroenterolog Assoc
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; Ono,
   Suzane/I-3107-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2005
VL 128
IS 4
SU 2
BP A738
EP A738
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 919LK
UT WOS:000228619306090
DA 2020-12-08
ER

PT J
AU Oliveira, CP
   Furuya, CK
   Souza, FG
   Mello, ES
   Fernandes, EZ
   Vezozzo, DC
   Alves, VA
   Carrilho, FJ
AF Oliveira, CP
   Furuya, CK
   Souza, FG
   Mello, ES
   Fernandes, EZ
   Vezozzo, DC
   Alves, VA
   Carrilho, FJ
TI N-acetylcysteine (NAC) not improves inflammation and fibrosis in
   patients with nonalcoholic steatohepatitis : a pilot study.
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Gastroenterological-Association/Digestive-Disease-Week
CY MAY 14-19, 2005
CL Chicago, IL
SP Amer Gastroenterolog Assoc
RI Oliveira, Claudia PMS/D-1216-2014; Carrilho, Flair J/I-3046-2012
NR 0
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2005
VL 128
IS 4
SU 2
BP A769
EP A769
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 919LK
UT WOS:000228619306237
DA 2020-12-08
ER

PT J
AU Oliveira, CPMS
   Faintuch, J
   Rascovski, A
   Furuya, CK
   Bastos, MD
   Matsuda, M
   Nina, BI
   Yahnosi, K
   Abdala, DSP
   Vezozzo, DCP
   Alves, VAF
   Zilberstein, B
   Garrido, AB
   Halpern, A
   Carrilho, FJ
   Gama-Rodrigues, JJ
AF Oliveira, CPMS
   Faintuch, J
   Rascovski, A
   Furuya, CK
   Bastos, MD
   Matsuda, M
   Nina, BI
   Yahnosi, K
   Abdala, DSP
   Vezozzo, DCP
   Alves, VAF
   Zilberstein, B
   Garrido, AB
   Halpern, A
   Carrilho, FJ
   Gama-Rodrigues, JJ
TI Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver
   disease (NAFLD) preliminary findings
SO OBESITY SURGERY
LA English
DT Article
DE morbid obesity; nonalcoholic steatohepatitis; fatty liver; oxidative
   stress; bariatric surgery; metabolic syndrome
ID OXIDATIVE STRESS; STEATOHEPATITIS; PATHOGENESIS
AB Background: Pathogenesis of nonalcoholic fatty liver disease (NAFLD) remains incompletely known, and oxidative stress is one of the mechanisms incriminated. The aim of this study was to evaluate the role of liver oxidative stress in NAFLD affecting morbidly obese patients.
   Methods: 39 consecutive patients with BMI > 40 kg/m(2) submitted to Roux-en-Y gastric bypass were enrolled, and wedge liver biopsy was obtained during operation. Oxidative stress was measured by concentration of hydroperoxides (CEOOH) in liver tissue.
   Results: Female gender was dominant (89.7%) and median age was 43.6 +/- 11.1 years. Histology showed fatty liver in 92.3%, including 43.6% with nonalcoholic steatohepatitis (NASH), 48.7% with isolated steatosis and just 7.7% with normal liver. Liver cirrhosis was present in 11.7% of those with nonalcoholic steatohepatitis. Concentration of CEOOH was increased in the liver of patients with NASH when compared to isolated steatosis and normal liver (0.26 +/- 0.17, 0.20 +/- 0.01 and 0.14 +/- 0.00 nmol/mg protein, respectively) (P < 0.01). Liver biochemical variables were normal in 92.3% of all cases, and no difference between NASH and isolated steatosis could be demonstrated.
   Conclusions: 1) Nonalcoholic steatosis, steatohepatitis and cirrhosis were identified in substantial numbers of morbidly obese patients; 2) Concentration of hydroperoxides was increased in steatohepatitis, consistent with a pathogenetic role for oxidative stress in this condition.
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Endocrinol, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Toxicol Anal, Sao Paulo, Brazil.
RP Oliveira, CPMS (corresponding author), Av Eneias Ccarvalho Aguiar,255-ICHC-Sala 9159, BR-05403900 Sao Paulo, SP, Brazil.
RI Zilberstein, Bruno/K-2087-2016; Oliveira, Claudia PMS/D-1216-2014;
   Carrilho, Flair J/I-3046-2012
CR Baltasar A, 2004, OBES SURG, V14, P77, DOI 10.1381/096089204772787338
   Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927
   Cuadrado A, 2005, OBES SURG, V15, P442, DOI 10.1381/0960892053576596
   CURZIO M, 1985, INT J TISSUE REACT, V7, P137
   Dam-Larsen S, 2004, GUT, V53, P750, DOI 10.1136/gut.2003.019984
   Emery MG, 2003, HEPATOLOGY, V38, P428, DOI 10.1053/jhep.2003.50342
   Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926
   Feher J, 2003, J INT MED RES, V31, P537, DOI 10.1177/147323000303100610
   Festi D, 2004, Obes Rev, V5, P27, DOI 10.1111/j.1467-789X.2004.00126.x
   Kral JG, 2004, SURGERY, V135, P48, DOI 10.1016/j.surg.2003.10.003
   LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304
   Letteron P, 1996, J HEPATOL, V24, P200, DOI 10.1016/S0168-8278(96)80030-4
   Luyckx FH, 2000, DIABETES METAB, V26, P98
   Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
   Mehta K, 2002, NUTR REV, V60, P289, DOI 10.1301/002966402320387224
   Oliveira CPMS, 2002, J CELL MOL MED, V6, P399, DOI 10.1111/j.1582-4934.2002.tb00518.x
   Papadia FS, 2004, OBES SURG, V14, P952, DOI 10.1381/0960892041719644
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   Shalhub S, 2004, OBES SURG, V14, P54, DOI 10.1381/096089204772787293
   Sreekumar R, 2003, HEPATOLOGY, V38, P244, DOI 10.1053/jhep.2003.50290
   Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007
   YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3
NR 22
TC 32
Z9 32
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0960-8923
EI 1708-0428
J9 OBES SURG
JI Obes. Surg.
PD APR
PY 2005
VL 15
IS 4
BP 502
EP 505
DI 10.1381/0960892053723493
PG 4
WC Surgery
SC Surgery
GA 923LI
UT WOS:000228911000008
PM 15946429
DA 2020-12-08
ER

PT J
AU Campiotto, S
   Pinho, JRR
   Carrilho, FJ
   Da Silva, LC
   Souto, FJD
   Spinelli, V
   Pereira, LMMB
   Coelho, HSM
   Silva, AO
   Fonseca, JC
   Rosa, H
   Lacet, CMC
   Bernardini, AP
AF Campiotto, S
   Pinho, JRR
   Carrilho, FJ
   Da Silva, LC
   Souto, FJD
   Spinelli, V
   Pereira, LMMB
   Coelho, HSM
   Silva, AO
   Fonseca, JC
   Rosa, H
   Lacet, CMC
   Bernardini, AP
TI Geographic distribution of hepatitis C virus genotypes in Brazil
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hepatitis C; hepatitis C virus; genotypes; Brazil
ID SEQUENCE-ANALYSIS; INFECTION; DIVERSITY; REGIONS; CORE
AB Brazil is a country of continental dimension with a population of different ethnic backgrounds. Thus, a wide variation in the frequencies of hepatitis C virus (HCV) genotypes is expected to occur. To address this point, 1,688 sequential samples from chronic HCV patients were analyzed. HCV-RNA was amplified by the RT-PCR from blood samples collected from 1995 to 2000 at different laboratories located in different cities from all Brazilian States. Samples were collected in tubes containing a gel separator, centrifuged in the site of collection and sent by express mail in a refrigerated container to Laboratorio Bioquimico Jardim Paulista, Sao Paulo, SP, Brazil. HCV-RNA was extracted from serum and submitted to RT and nested PCR using standard procedures. Nested PCR products were submitted to cycle sequencing reactions without prior purification. Sequences were analyzed for genotype determination and the following frequencies were found: 64.9% (1,095) for genotype 1, 4.6% (78) for genotype 2. 30.2% (510) for genotype 3, 0.2% (3) for genotype 4, and 0.1 /a (2) for genotype 5. The frequencies of HCV genotypes were statistically different among Brazilian regions (P = 0.00017). In all regions, genotype 1 was the most frequent (51.7 to 74.1 %). reaching the highest value in the North; genotype 2 was more prevalent in the Center-West region (11.4%), especially in Mato Grosso State (25.8 %,), while genotype 3,vas more common in the South (43.2%). Genotypes 4 and 5 were rarely found and only in the Southeast, in Sao Paulo State. The present data indicate the need for careful epidemiological surveys throughout Brazil since knowing the frequency and distribution of the genotypes would provide key information for understanding the spread of HCV.
C1 Inst Adolfo Lutz Registro, Serv Virol, BR-01246902 Sao Paulo, Brazil.
   Lab Bioquim Jardim Paulista, Dept Biol Mol, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Fed Mato Grosso, Ctr Pesquisas Doencas Trop & Infecciosas Mato Gro, Cuiaba, MT, Brazil.
   Univ Fed Pernambuco, Dept Med Interna, Recife, PE, Brazil.
   Univ Fed Pernambuco, Dept Gastroenterol, Recife, PE, Brazil.
   Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
   Hosp Beneficencia Portuguesa, Unidade Figado, Sao Paulo, Brazil.
   Fdn Med Trop Amazonas, Div Virol, Manaus, Amazonas, Brazil.
   Univ Fed Goias, Fac Med, Unidade Gastroenterol & Hepatol, Goiania, Go, Brazil.
   Univ Fed Alagoas, Unidade Gastroenterol & Hepatol, Maceio, AL, Brazil.
RP Pinho, JRR (corresponding author), Inst Adolfo Lutz Registro, Serv Virol, Av Dr Arnaldo 355, BR-01246902 Sao Paulo, Brazil.
EM jrrpinho@usp.br
RI Coelho, Henrique Sergio Moraes/AAB-3973-2019; Souto,
   Francisco/J-6751-2012; Carrilho, Flair J/I-3046-2012; Pinho, Joao R.
   R./G-2850-2012; Lacet, Celina/G-7645-2014
OI Pinho, Joao R. R./0000-0003-3999-0489; Lacet,
   Celina/0000-0002-4846-8206; Souto, Francisco Jose
   Dutra/0000-0002-2529-4119
CR Bassit L, 1999, HEPATOLOGY, V29, P994, DOI 10.1002/hep.510290313
   BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451
   *EASL, 1999, J HEPATOL S1, V31, P3
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W
   GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H
   GASPAR A M C, 1987, Memorias do Instituto Oswaldo Cruz, V82, P253, DOI 10.1590/S0074-02761987000200013
   Germer JJ, 1999, J CLIN MICROBIOL, V37, P2625, DOI 10.1128/JCM.37.8.2625-2630.1999
   Giannini C, 1999, J LAB CLIN MED, V134, P68, DOI 10.1016/S0022-2143(99)90055-0
   Halfon P, 2001, J CLIN MICROBIOL, V39, P1771, DOI 10.1128/JCM.39.5.1771-1773.2001
   Holland PV, 1996, J CLIN MICROBIOL, V34, P2372, DOI 10.1128/JCM.34.10.2372-2378.1996
   Krug LP, 1996, BRAZ J MED BIOL RES, V29, P1629
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107
   Lee JH, 1997, J HEPATOL, V26, P1001, DOI 10.1016/S0168-8278(97)80108-0
   Levi JE, 2002, J CLIN MICROBIOL, V40, P2645, DOI 10.1128/JCM.40.7.2645-2647.2002
   MAERTENS G, 1997, MOL MED VIRAL HEPATI
   Martins RMB, 1998, MEM I OSWALDO CRUZ, V93, P299, DOI 10.1590/S0074-02761998000300004
   Matsubara T, 1996, J PEDIATR GASTR NUTR, V22, P79, DOI 10.1097/00005176-199601000-00013
   MELLOR J, 1995, J GEN VIROL, V76, P2493, DOI 10.1099/0022-1317-76-10-2493
   Oliveira GC, 1999, TRANSFUSION, V39, P1194, DOI 10.1046/j.1537-2995.1999.39111194.x
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P279, DOI 10.1590/S0100-879X1999000300005
   Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321
   Robertson B, 1998, ARCH VIROL, V143, P2493, DOI 10.1007/s007050050479
   Roque-Afonso AM, 2002, J VIRAL HEPATITIS, V9, P385, DOI 10.1046/j.1365-2893.2002.00362.x
   Silva LK, 2000, AM J TROP MED HYG, V62, P257, DOI 10.4269/ajtmh.2000.62.257
   SIMMONDS P, 1994, J GEN VIROL, V75, P1053, DOI 10.1099/0022-1317-75-5-1053
   SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7
   Simmonds P, 2001, J GEN VIROL, V82, P693, DOI 10.1099/0022-1317-82-4-693
   SMITH DB, 1995, J GEN VIROL, V76, P1749, DOI 10.1099/0022-1317-76-7-1749
   STUYVER L, 1995, VIRUS RES, V38, P137, DOI 10.1016/0168-1702(95)00052-R
   STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093
   TOKITA H, 1994, P NATL ACAD SCI USA, V91, P11022, DOI 10.1073/pnas.91.23.11022
   Zylberberg H, 2000, ANN INTERN MED, V132, P845, DOI 10.7326/0003-4819-132-10-200005160-00029
NR 37
TC 117
Z9 128
U1 0
U2 15
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JAN
PY 2005
VL 38
IS 1
BP 41
EP 49
DI 10.1590/S0100-879X2005000100007
PG 9
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 892PX
UT WOS:000226663600007
PM 15665987
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Lyra, AC
   Pinho, JRR
   Mello, IMVGC
   Malta, FD
   Gomes, MMS
   Di Bisceglie, AM
   Lyra, LGC
   Carrilho, FJ
   da Silva, LC
AF Lyra, AC
   Pinho, JRR
   Mello, IMVGC
   Malta, FD
   Gomes, MMS
   Di Bisceglie, AM
   Lyra, LGC
   Carrilho, FJ
   da Silva, LC
TI Distribution of hepatitis B virus (HBV) genotypes among patients with
   acute viral hepatitis
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Letter
ID PHYLOGENETIC RELATEDNESS; SEQUENCE; STRAINS
C1 Univ Sao Paulo, Div Gastroenterol, Sao Paulo, Brazil.
   Inst Adolfo Lutz Registro, Sao Paulo, Brazil.
   Univ Fed Bahia & Hosp, Div Gastroenterol, San Rafael, Brazil.
   St Louis Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, St Louis, MO 63103 USA.
RP Lyra, AC (corresponding author), Univ Sao Paulo, Div Gastroenterol, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Malta, Fernanda/B-1316-2013; de
   carvalho-Mello, Isabel Maria V G/D-3641-2012; Carrilho, Flair
   J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; 
CR Blitz L, 1998, J CLIN MICROBIOL, V36, P648, DOI 10.1128/JCM.36.3.648-651.1998
   Chu CJ, 2002, HEPATOLOGY, V35, P1274, DOI 10.1053/jhep.2002.33161
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   NORDER H, 1994, VIROLOGY, V198, P489, DOI 10.1006/viro.1994.1060
   OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575
   OKAMOTO H, 1987, BIOCHEM BIOPH RES CO, V148, P500, DOI 10.1016/0006-291X(87)91139-9
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
NR 9
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD JAN
PY 2005
VL 39
IS 1
BP 81
EP 82
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 881YD
UT WOS:000225904500023
PM 15599222
DA 2020-12-08
ER

PT J
AU Farias, AQ
   Goncalves, LL
   Cancado, EL
   Seguro, AC
   Campos, SB
   Abrantes-Lemos, CP
   Carrilho, FJ
AF Farias, AQ
   Goncalves, LL
   Cancado, EL
   Seguro, AC
   Campos, SB
   Abrantes-Lemos, CP
   Carrilho, FJ
TI Bone disease in primary biliary cirrhosis: Lack of association with
   distal renal tubular acidosis
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE bone disease; osteoporosis; primary biliary cirrhosis; renal tubular
   acidosis
ID METABOLIC-ACIDOSIS; LIVER-DISEASE; OSTEOPOROSIS
AB Background and Aims: Primary biliary cirrhosis (PBC) might be complicated by osteoporosis. whose etiology remains unknown but seems to be multifactorial. Prevalence rates of 30% to 60% for distal renal tubular acidosis (DRTA) have been reported in PBC patients, generally as incomplete DRTA. Although it is undisputed that a reduced bone mineral density (BMD) is the expected outcome among patients who have been suffering from longstanding chronic metabolic acidosis, it is unclear if incomplete DRTA is also associated with metabolic bone disease in PBC patients. The present study was undertaken to compare the BMD of PBC patients with and without DRTA.
   Methods: The BMD of 23 PBC patients (11 with DRTA and 12 without), all with normal clearance of creatinine, was assessed by dual energy radiograph absorptiometry. The diagnosis of DRTA was made if the urine pH was above 5.4 in all samples after the oral acid overload, showing tubular inability, to acidify,; urine in the presence of test-induced systemic metabolic acidosis.
   Results: Densitometric signs of osteoporosis were found in 82% of DRTA cases and in 83% of patients without DRTA (difference not significant). There were no significant differences in BMD measurement, T and Z scores of patients with and without DRTA.
   Conclusions: The present study could not support a correlation between the presence of DRTA and the bone loss observed in PBC patients. (C) 2004 Blackwell Publishing Asia Pry Ltd.
C1 Univ Sao Paulo, Sch Med, Inst Trop Med, Lab Immunopathol Schistosomiasis, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Nephrol, Sao Paulo, Brazil.
RP Farias, AQ (corresponding author), Rua Cristiano Viana 671-82, BR-05411001 Sao Paulo, Brazil.
EM albertosp@bol.com.br
RI Carrilho, Flair J/I-3046-2012; Farias, Alberto Q/H-7873-2013; Farias,
   Alberto/ABB-1291-2020; Cancado, Eduardo/K-1861-2016
OI Farias, Alberto/0000-0002-5572-663X; Cancado,
   Eduardo/0000-0002-9309-1524
CR Alpern RJ, 1997, AM J KIDNEY DIS, V29, P291, DOI 10.1016/S0272-6386(97)90045-7
   Backman U, 1976, Scand J Urol Nephrol, VSuppl 35, P33
   BARZEL US, 1969, CLIN SCI, V36, P517
   BATLLE DC, 1987, NEW ENGL J MED, V316, P140, DOI 10.1056/NEJM198701153160305
   BRENNER RJ, 1982, NEW ENGL J MED, V307, P217, DOI 10.1056/NEJM198207223070403
   COMPSTON JE, 1977, LANCET, V1, P721
   GOLDING PL, 1971, GUT, V12, P153, DOI 10.1136/gut.12.2.153
   HARRINGTON TM, 1983, MAYO CLIN PROC, V58, P354
   HODGSON SF, 1985, ANN INTERN MED, V103, P855, DOI 10.7326/0003-4819-103-6-855
   JANES CH, 1995, J CLIN INVEST, V95, P2581, DOI 10.1172/JCI117959
   KAPLAN MM, 1987, NEW ENGL J MED, V316, P521, DOI 10.1056/NEJM198702263160907
   KRIEGER NS, 1992, AM J PHYSIOL, V262, P442
   Lucey M R, 1997, Liver Transpl Surg, V3, P628
   Menon KVN, 2001, J HEPATOL, V35, P316, DOI 10.1016/S0168-8278(01)00144-1
   Newton J, 2001, GUT, V49, P282, DOI 10.1136/gut.49.2.282
   PARE P, 1984, ARCH INTERN MED, V144, P941, DOI 10.1001/archinte.144.5.941
   Pereira SP, 1999, EUR J GASTROEN HEPAT, V11, P323, DOI 10.1097/00042737-199903000-00018
   SCHEUER PJ, 1967, P ROY SOC MED, V60, P1257, DOI 10.1177/003591576706001205
   STRIFE CF, 1993, J PEDIATR-US, V122, P60, DOI 10.1016/S0022-3476(05)83487-0
   Weger M, 1999, OSTEOPOROSIS INT, V10, P325, DOI 10.1007/s001980050235
   Weger W, 2000, NEPHROL DIAL TRANSPL, V15, P975, DOI 10.1093/ndt/15.7.975
   *WHO STUD GROUP, 1994, WHO TECHN REP SER, V843, P1129
   WRONG O, 1959, Q J MED, V28, P259
NR 23
TC 6
Z9 6
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD JAN
PY 2005
VL 20
IS 1
BP 147
EP 152
DI 10.1111/j.1400-1746.2004.03517.x
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 892UE
UT WOS:000226674700022
PM 15610460
DA 2020-12-08
ER

PT J
AU Souza, LO
   Pinho, JRR
   Carrilho, FJ
   da Silva, LC
AF Souza, LO
   Pinho, JRR
   Carrilho, FJ
   da Silva, LC
TI Absence of hepatitis B virus DNA in patients with hepatitis C and
   non-A-E hepatitis in the State of Sao Paulo, Brazil
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hepatitis B virus; non-A-E hepatitis; polymerase chain reaction
ID POLYMERASE CHAIN-REACTION; PRIMARY LIVER CANCERS; SURFACE-ANTIGEN;
   SENSITIVE METHOD; DISEASE; COINFECTION; INFECTIONS; VIREMIA
AB Occult hepatitis B virus (HBV) infection has been reported as cases in which HBV DNA was detected despite the absence of any HBV serological markers or in cases in which anti-HBc antibody was the sole marker. The aim of the present study was to determine, using the polymerase chain reaction (PCR), whether HBV infection occurs in hepatitis C and non-A-E hepatitis patients without serological evidence of hepatitis B infection in Sao Paulo State. Two different populations were analyzed: 1) non-A-E hepatitis patients, including 12 patients with acute and 50 patients with chronic hepatic disorders without serological evidence of infection with known hepatitis viruses; 2) 43 patients previously diagnosed as hepatitis C with positive results for anti-HCV and HCV RNA. Among hepatitis C patients, anti-HBc was detected in 18.6% of the subjects. Three different sets of primers were employed for HBV DNA detection by nested PCR, covering different HBV genes: C, S and X. HBV-DNA was not detected in any sample, whereas the positive controls did produce signals. The lack of HBV DNA detection with these pairs of primers could be due to a very low viral load or to the presence of mutations in their annealing sites. The latter is unlikely as these primers were screened against an extensive dataset of HBV sequences. The development of more sensitive methods, such as real time PCR, to detect circular covalent closed DNA is necessary in order to evaluate this question since previous studies have shown that cryptic hepatitis B might occur.
C1 Inst Adolfo Lutz Registro, Serv Virol, BR-01246902 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo, SP, Brazil.
   Lab Bioquim Jardim Paulista, Sao Paulo, SP, Brazil.
RP Pinho, JRR (corresponding author), Inst Adolfo Lutz Registro, Serv Virol, Av Dr Arnaldo,335, BR-01246902 Sao Paulo, SP, Brazil.
EM jrrpinho@usp.br
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
CR BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503
   Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104
   Chemin I, 2001, ANTIVIR RES, V52, P117, DOI 10.1016/S0166-3542(01)00176-0
   Colloredo G, 1996, J HEPATOL, V25, P644, DOI 10.1016/S0168-8278(96)80233-9
   DaSilva LC, 1996, J GASTROENTEROL, V31, P696, DOI 10.1007/BF02347619
   FEITELSON M, 1994, HEPATOLOGY, V19, P558, DOI 10.1002/hep.1840190304
   FEITELSON MA, 1995, J INFECT DIS, V172, P713, DOI 10.1093/infdis/172.3.713
   Fukuda R, 2001, J MED VIROL, V63, P220, DOI 10.1002/1096-9071(200103)63:3&lt;220::AID-JMV1004&gt;3.0.CO;2-3
   He ML, 2002, BIOCHEM BIOPH RES CO, V295, P1102, DOI 10.1016/S0006-291X(02)00813-6
   KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989
   PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q
   PATERLINI P, 1990, NEW ENGL J MED, V323, P80, DOI 10.1056/NEJM199007123230202
   Pinho J. R. R., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P515
   RUIZ J, 1992, HEPATOLOGY, V16, P637, DOI 10.1002/hep.1840160305
   Sagnelli E, 2001, J MED VIROL, V64, P350, DOI 10.1002/jmv.1057
   Saito T, 1999, J MED VIROL, V58, P325, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt;325::AID-JMV2&gt;3.0.CO;2-L
   Santos EA, 2003, EUR J CLIN MICROBIOL, V22, P92, DOI 10.1007/s10096-002-0868-0
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   UCHIDA T, 1994, LIVER, V14, P251
   Yotsuyanagi H, 1998, HEPATOLOGY, V27, P1377, DOI 10.1002/hep.510270526
NR 20
TC 4
Z9 5
U1 0
U2 2
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD NOV
PY 2004
VL 37
IS 11
BP 1665
EP 1668
DI 10.1590/S0100-879X2004001100011
PG 4
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 871JX
UT WOS:000225128700011
PM 15517082
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Franca, AVC
   Junior, JE
   Lima, BLG
   Martinelli, ALC
   Carrilho, FJ
AF Franca, AVC
   Junior, JE
   Lima, BLG
   Martinelli, ALC
   Carrilho, FJ
TI Diagnosis, staging and treatment of hepatocellular carcinoma
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hepatocellular carcinoma; tumor diagnosis; tumor staging; carcinoma
   therapy; liver cirrhosis; Barcelona Classification
ID PERCUTANEOUS ETHANOL INJECTION; NEEDLE-ASPIRATION BIOPSY;
   LIVER-TRANSPLANTATION; RADIOFREQUENCY ABLATION; CIRRHOTIC-PATIENTS;
   TREATMENT STRATEGY; NATURAL-HISTORY; CHEMOEMBOLIZATION; PROGNOSIS;
   RESECTION
AB Hepatocellular carcinomas are aggressive tumors with a high dissemination power. An early diagnosis of these tumors is of great importance in order to offer the possibility of curative treatment. For an early diagnosis, abdominal ultrasound and serum alpha-fetoprotein determinations at 6-month intervals are suggested for all patients with cirrhosis of the liver, since this disease is considered to be the main risk factor for the development of the neoplasia. Helicoidal computed tomography, magnetic resonance and/or hepatic arteriography are suggested for diagnostic confirmation and tumor staging. The need to obtain a fragment of the focal lesion for cytology and/or histology for a diagnosis of hepatocellular carcinoma depends on the inability of imaging methods to diagnose the lesion. Several classifications are currently available for tumor staging in order to determine patient prognosis. All take into consideration not only the stage of the tumor but also the degree of hepatocellular dysfunction, which is known to be the main factor related to patient survival. Classifications, however, fail to correlate treatment with prognosis and cannot suggest the ideal treatment for each tumor stage. The Barcelona Classification (BCLC) attempts to correlate tumor stage with treatment but requires prospective studies for validation. For single tumors smaller than 5 cm or up to three nodules smaller than 3 cm, surgical resection, liver transplantation and percutaneous treatment may offer good anti-tumoral results, as well as improved patient survival. Embolization or chemoembolization are therapeutic alternatives for patients who do not benefit from curative therapies.
C1 Univ Sao Paulo, FMRP, Dept Clin Med, Div Gastroenterol, BR-14048900 Ribeirao Preto, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Serv Radiodiagnost, BR-14048900 Ribeirao Preto, Brazil.
   Univ Sao Paulo, Fac Med, Dept Gastroenterol, Setor Hepatol, Sao Paulo, Brazil.
RP Franca, AVC (corresponding author), Univ Sao Paulo, FMRP, Dept Clin Med, Div Gastroenterol, Av Bandeirantes 3900, BR-14048900 Ribeirao Preto, Brazil.
EM avcfranca@hcrp.fmrp.usp.br
RI Junior, Jorge Elias/A-6683-2008; Carrilho, Flair J/I-3046-2012
OI Junior, Jorge Elias/0000-0002-1158-1045; 
CR Arii S, 2000, HEPATOLOGY, V32, P1224, DOI 10.1053/jhep.2000.20456
   BARBARA L, 1992, HEPATOLOGY, V16, P132, DOI 10.1002/hep.1840160122
   Bizollon TR, 1998, J HEPATOL, V28, P491, DOI 10.1016/S0168-8278(98)80324-3
   Boix L, 1996, HEPATOLOGY, V24, P889
   Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117
   Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1
   Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089
   Buscarini L, 2001, EUR RADIOL, V11, P914, DOI 10.1007/s003300000659
   CARRILHO FJ, 1993, THESIS U SAO PAULO S
   CASTELLS A, 1995, J HEPATOL, V22, P410, DOI 10.1016/0168-8278(95)80103-0
   Chevret S, 1999, J HEPATOL, V31, P133, DOI 10.1016/S0168-8278(99)80173-1
   Chow PKH, 2002, HEPATOLOGY, V36, P1221, DOI 10.1053/jhep.2002.36824
   DODD GD, 1992, AM J ROENTGENOL, V159, P727, DOI 10.2214/ajr.159.4.1326883
   EBARA M, 1989, Annals Academy of Medicine Singapore, V18, P83
   EBARA M, 1986, RADIOLOGY, V159, P371, DOI 10.1148/radiology.159.2.3008213
   Figueras J, 1997, HEPATOLOGY, V25, P1485, DOI 10.1002/hep.510250629
   Fong YM, 1999, ANN SURG, V229, P790, DOI 10.1097/00000658-199906000-00005
   Franca AVC, 2003, ACTA CYTOL, V47, P332, DOI 10.1159/000326529
   FRANCA AVC, 2004, IN PRESS ARQUIVOS GA
   FRANCA AVC, 1997, THESIS U SAO PAULO S
   FRANCA AVC, 2002, GASTROENTEROLOGIA HE, V25, P153
   Fuster J, 1996, ANN SURG, V223, P297, DOI 10.1097/00000658-199603000-00011
   Greene FL, 2002, AJCC CANC STAGING MA, P145
   IKEDA K, 1994, HEPATOLOGY, V20, P82, DOI 10.1016/0270-9139(94)90137-6
   Jonas S, 2001, HEPATOLOGY, V33, P1080, DOI 10.1053/jhep.2001.23561
   Koda M, 2001, CANCER, V92, P1516, DOI 10.1002/1097-0142(20010915)92:6<1516::AID-CNCR1477>3.0.CO;2-I
   LESCANO M, 2002, GASTROENTEROLOGIA S2, V25
   Leung TWT, 2002, CANCER, V94, P1760, DOI 10.1002/cncr.10384
   Livraghi T, 1999, RADIOLOGY, V210, P655, DOI 10.1148/radiology.210.3.r99fe40655
   LIVRAGHI T, 1995, J HEPATOL, V22, P522, DOI 10.1016/0168-8278(95)80445-5
   LIVRAGHI T, 1995, RADIOLOGY, V197, P101, DOI 10.1148/radiology.197.1.7568806
   Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122
   Llovet JM, 2003, J HEPATOL, V38, pS136, DOI 10.1016/S0168-8278(02)00432-4
   Llovet JM, 1998, HEPATOLOGY, V27, P1572, DOI 10.1002/hep.510270616
   Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X
   Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629
   LOHMANN R, 1995, TRANSPLANT P, V27, P1245
   Manghisi G, 1998, HEPATOLOGY, V28, P751
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   MICHEL J, 1995, TRANSPLANT P, V27, P1798
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   NOMURA F, 1989, CANCER, V64, P1700, DOI 10.1002/1097-0142(19891015)64:8<1700::AID-CNCR2820640824>3.0.CO;2-Z
   OBERTI F, 1995, NEW ENGL J MED, V332, P1256
   OHASHI I, 1993, RADIOLOGY, V189, P851, DOI 10.1148/radiology.189.3.8234715
   OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E
   OKUDA K, 1997, DIAGNOSIS TREATMENT
   Perrone F, 2000, HEPATOLOGY, V31, P840
   RUMMENY E, 1989, AM J ROENTGENOL, V152, P63, DOI 10.2214/ajr.152.1.63
   SHELL JC, 1985, CANCER, V56, P660, DOI 10.1002/1097-0142(19850801)56:3<660::AID-CNCR2820560338>3.0.CO;2-F
   SHIMAMOTO K, 1992, RADIOLOGY, V182, P149, DOI 10.1148/radiology.182.1.1309215
   Solmi L, 1996, AM J GASTROENTEROL, V91, P1189
   SPREAFICO C, 1994, RADIOLOGY, V192, P687, DOI 10.1148/radiology.192.3.8058934
   SUMIDA M, 1986, AM J ROENTGENOL, V147, P531, DOI 10.2214/ajr.147.3.531
   TAKAYASU K, 1986, AM J ROENTGENOL, V147, P525, DOI 10.2214/ajr.147.3.525
   TANAKA K, 1993, AM J ROENTGENOL, V160, P1279, DOI 10.2214/ajr.160.6.8388620
   Venook A P, 1995, Liver Transpl Surg, V1, P242, DOI 10.1002/lt.500010409
   VILANA R, 1993, AM J ROENTGENOL, V160, P1285, DOI 10.2214/ajr.160.6.8388621
   VILANA R, 1992, HEPATOLOGY, V16, P353, DOI 10.1002/hep.1840160212
   Yamamoto J, 2001, HEPATOLOGY, V34, P707, DOI 10.1053/jhep.2001.27950
   Yao FY, 2001, HEPATOLOGY, V33, P1394, DOI 10.1053/jhep.2001.24563
NR 60
TC 46
Z9 48
U1 0
U2 3
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD NOV
PY 2004
VL 37
IS 11
BP 1689
EP 1705
DI 10.1590/S0100-879X2004001100015
PG 17
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 871JX
UT WOS:000225128700015
PM 15517086
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Medeiros, JE
   Neumann, AU
   Mello, IM
   Pinho, JR
   Malta, FM
   Da Silva, LC
   Carrilho, FJ
AF Medeiros, JE
   Neumann, AU
   Mello, IM
   Pinho, JR
   Malta, FM
   Da Silva, LC
   Carrilho, FJ
TI Genotype 1 versus 3 and cirrhosis status have stronger effect on
   hepatitis C viral kinetics during combination treatment than interferon
   dosage
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 55th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY OCT 29-NOV 02, 2004
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 Univ Fed Paraiba, BR-58059900 Joao Pessoa, Paraiba, Brazil.
   Bar Ilan Univ, Ramat Gan, Israel.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012; Malta,
   Fernanda/B-1316-2013; de carvalho-Mello, Isabel Maria V G/D-3641-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2004
VL 40
IS 4
SU 1
BP 401A
EP 401A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 857FR
UT WOS:000224102100546
DA 2020-12-08
ER

PT J
AU Oliveira, CP
   Debbas, V
   Cavaleiro-Luna, AMF
   Oliveira, MG
   Avancini, V
   Carrilho, FJ
   Gianella-Neto, D
   Laurindo, FR
AF Oliveira, CP
   Debbas, V
   Cavaleiro-Luna, AMF
   Oliveira, MG
   Avancini, V
   Carrilho, FJ
   Gianella-Neto, D
   Laurindo, FR
TI Protective effect of S-nitroso-N-acetilcysteine (SNAC) in nonalcoholic
   fatty liver disease in rats: Increase hepatic expression of microsomal
   triglyceride transfer protein (MTP).
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 55th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY OCT 29-NOV 02, 2004
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   State Univ Campinas, Sao Paulo, Brazil.
RI Laurindo, Francisco R/J-6575-2015; Carrilho, Flair J/I-3046-2012;
   Oliveira, Claudia PMS/D-1216-2014; Giannella-Neto, Daniel/B-1475-2008;
   Debbas, Victor/J-9475-2012; de Oliveira, Marcelo Ganzarolli/B-4709-2013
OI de Oliveira, Marcelo Ganzarolli/0000-0002-9371-9975
NR 0
TC 2
Z9 2
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2004
VL 40
IS 4
SU 1
BP 430A
EP 430A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 857FR
UT WOS:000224102100615
DA 2020-12-08
ER

PT J
AU Sollano, J
   Schiff, E
   Carrilho, F
   Raptopoulou-Gigi, M
   Cooney, E
   Hindes, R
   Cross, A
   Dehertogh, D
AF Sollano, J
   Schiff, E
   Carrilho, F
   Raptopoulou-Gigi, M
   Cooney, E
   Hindes, R
   Cross, A
   Dehertogh, D
CA BEHoLD Study Grp
TI Entecavir is well-tolerated for treatment of chronic hepatitis B: Phase
   III safety analysis in nucleoside-naive and lamivudine-refractory
   patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 55th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY OCT 29-NOV 02, 2004
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 Univ Santo Tomas, Manila, Philippines.
   Univ Miami, Miami, FL 33152 USA.
   Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece.
   Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 6
Z9 6
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2004
VL 40
IS 4
SU 1
BP 665A
EP 665A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 857FR
UT WOS:000224102101155
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Farias, AQ
   Abrantes-Lemos, CP
   Goncalves, LL
   Goncalves, PL
   Magalhaes, EP
   Carrilho, FJ
   Laudanna, AA
   Canado, ELR
AF Bittencourt, PL
   Farias, AQ
   Abrantes-Lemos, CP
   Goncalves, LL
   Goncalves, PL
   Magalhaes, EP
   Carrilho, FJ
   Laudanna, AA
   Canado, ELR
TI Prevalence of immune disturbances and chronic liver disease in family
   members of patients with primary biliary cirrhosis
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE auto-antibodies; antimitochondrial antibody; family members; immune
   disturbances; prevalence; primary biliary cirrhosis
ID ANTIMITOCHONDRIAL ANTIBODIES; MITOCHONDRIAL; RELATIVES; PROTEINS
AB Background and Aims: Primary biliary cirrhosis (PBC) has been reported in up to 4-6% of first degree relatives of patients with the disease. In addition, immune abnormalities, including hypergammaglobulinemia, autoantibodies and increased frequency of autoimmune disorders, were reported in family members of PBC patients. The aim of the present study was to investigate the prevalence of PBC in relatives of patients with PBC, and to investigate the occurrence of chronic liver disease (CLD) and immune abnormalities in these subjects.
   Methods: One-hundred first degree relatives of 26 patients with PBC were interviewed and submitted to physical examination and determination of liver enzymes, gamma-globulin, bilirubin and auto-antibodies, including antinuclear (ANA), antismooth muscle (SMA), antimitochondrial antibodies (AMA) by indirect immunofluorescence (IIF) and anti-M2 antibody by immunoblotting (IB).
   Results: Immune disturbances were rarely observed in relatives of PBC patients. Higher gamma-globulin levels, SMA and ANA were detected in four, eight and two family members, respectively. In most subjects, these autoantibodies were either in low titers or associated with concurrent diseases. Only four relatives had extrahepatic autoimmune diseases and another eight exhibited other CLD. Primary biliary cirrhosis was detected in a sister of one patient. Additionally, two other relatives of PBC patients who tested negative for AMA by IIF showed reactivity for anti-M2 by IB.
   Conclusions: Immune disturbances, including ANA and SMA, are uncommon in family members of PBC patients. Conversely, anti-M2 antibodies and overt PBC do occur in relatives of PBC patients, even in Brazil where the disease is quite rare. (C) 2004 Blackwell Publishing Asia Pty Ltd.
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Portuguese Hosp Salvador, Bahia Blanca, Argentina.
   Univ Sao Paulo, Sch Med, Inst Trop Med, Lab Med Invest, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302 A, Salvador, BA, Brazil.
EM plbbr@uol.com.br
RI Carrilho, Flair J/I-3046-2012; Farias, Alberto Q/H-7873-2013; Cancado,
   Eduardo/K-1861-2016; Farias, Alberto/ABB-1291-2020; BITTENCOURT, PAULO
   l/I-5817-2014
OI Cancado, Eduardo/0000-0002-9309-1524; Farias,
   Alberto/0000-0002-5572-663X; BITTENCOURT, PAULO l/0000-0003-0883-4870
CR BACH N, 1994, J HEPATOL, V20, P698, DOI 10.1016/S0168-8278(05)80137-0
   BEAUFAY H, 1964, BIOCHEM J, V92, P184, DOI 10.1042/bj0920184
   BRIND AM, 1995, GUT, V36, P615, DOI 10.1136/gut.36.4.615
   CALDWELL SH, 1992, HEPATOLOGY, V16, P899, DOI 10.1002/hep.1840160408
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   COPPEL RL, 1995, IMMUNOL REV, V144, P17, DOI 10.1111/j.1600-065X.1995.tb00064.x
   FARIAS AQ, 2001, DIS LIVER BILIARY TR, V2, P1121
   FEIZI T, 1972, CLIN EXP IMMUNOL, V10, P609
   Floreani A, 1997, J HEPATOL, V26, P737, DOI 10.1016/S0168-8278(97)80444-8
   GALBRAITH RM, 1974, NEW ENGL J MED, V290, P63, DOI 10.1056/NEJM197401102900201
   HAMLYN AN, 1983, GUT, V24, P940, DOI 10.1136/gut.24.10.940
   JAUP BH, 1980, GASTROENTEROLOGY, V78, P549
   Jones DEJ, 1999, J HEPATOL, V30, P402, DOI 10.1016/S0168-8278(99)80097-X
   Kaplan MM, 1996, NEW ENGL J MED, V335, P1570, DOI 10.1056/NEJM199611213352107
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Mattalia A, 1998, HEPATOLOGY, V27, P656, DOI 10.1002/hep.510270303
   Metcalf JV, 1996, LANCET, V348, P1399, DOI 10.1016/S0140-6736(96)04410-8
   MITCHISON HC, 1986, HEPATOLOGY, V6, P1279, DOI 10.1002/hep.1840060609
   Parikh-Patel A, 1999, CLIN IMMUNOL, V91, P206, DOI 10.1006/clim.1999.4690
   SHU S, 1975, J LAB CLIN MED, V86, P259
   SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595
   STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147
   Tanaka A, 2001, AM J GASTROENTEROL, V96, P8
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Tsuji K, 1999, J AUTOIMMUN, V13, P171, DOI 10.1006/jaut.1999.0299
   Zein CO, 2003, CLIN GASTROENTEROL H, V1, P89, DOI 10.1053/cgh.2003.50014
NR 26
TC 18
Z9 19
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD AUG
PY 2004
VL 19
IS 8
BP 873
EP 878
DI 10.1111/j.1440-1746.2004.03396.x
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 835LW
UT WOS:000222485800007
PM 15242489
DA 2020-12-08
ER

PT J
AU Sitnik, R
   Pinho, JRR
   Bertolini, DA
   Bernardini, AP
   da Silva, LC
   Carrilho, FJ
AF Sitnik, R
   Pinho, JRR
   Bertolini, DA
   Bernardini, AP
   da Silva, LC
   Carrilho, FJ
TI Hepatitis B virus genotypes and precore and core mutants in Brazilian
   patients
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID SURFACE-ANTIGEN MUTANTS; HBV GENOTYPE; S GENE; MUTATIONS; INFECTION;
   VARIANTS; PROMOTER; SEQUENCE; GENOME; REGION
AB A method for genotyping hepatitis B virus by partial HBsAg gene sequencing with primers common to all known genotypes was developed. Mutations related to anti-HBs resistance are also detected with this method. Samples from 103 Brazilian patients were analyzed. Precore and core region of these viruses were also sequenced in 101 patients. Genotypes A, B, C, D, and F were found with frequencies of 49.5, 2.9, 13.6, 24.3, and 9.7%, respectively. Genotypes B and C were found only in Asian patients, whereas genotypes A, D, and F were more common in patients without an Asian background. Precore mutants were found in 32 (31.7%) of 101 patients, with a higher frequency in those infected with genotype D (22 of 25 [88.0%]). Analysis of nucleotide 1858 showed presence of thymine in all patients with genotypes B, C, and D and in a few patients with genotypes A (10.0%) and F (30.0%), who showed more frequently the presence of cytosine. This nucleotide was closely related to the presence of precore mutants. Mutations in the basal core promoter were found in 64 of 101 (63.4%) samples. These mutations were more frequent in patients infected with genotype F (90.0%) and less frequent in patients infected with genotype B (33.3%). Deletions in this region were found in two genotype C-infected patients.
C1 Univ Sao Paulo, Inst Adolfo Lutz, Serv Virol, BR-01401002 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Lab Bioquim Jardim Paulista, BR-01401002 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Fac Med, Dept Gastroenterol, BR-01401002 Sao Paulo, SP, Brazil.
RP Pinho, JRR (corresponding author), Univ Sao Paulo, Inst Adolfo Lutz, Serv Virol, Av Brigadeiro Luiz Antonio,4701, BR-01401002 Sao Paulo, SP, Brazil.
EM jrrpinho@terra.com.br
RI Sitnik, Roberta/N-4740-2017; Carrilho, Flair J/I-3046-2012; Bertolini,
   Dennis/ABG-1427-2020; Pinho, Joao R. R./G-2850-2012
OI Sitnik, Roberta/0000-0002-6243-8118; Pinho, Joao R.
   R./0000-0003-3999-0489
CR Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   ArauzRuiz P, 1997, J MED VIROL, V51, P305, DOI 10.1002/(SICI)1096-9071(199704)51:4&lt;305::AID-JMV8&gt;3.0.CO;2-9
   Baumert TF, 1996, J CLIN INVEST, V98, P2268, DOI 10.1172/JCI119037
   BRUNETTO MR, 1990, J HEPATOL, V10, P258, DOI 10.1016/0168-8278(90)90062-V
   Carman W, 1998, VIRAL HEPATITIS, P141
   Carman WF, 1999, J HEPATOL, V31, P195, DOI 10.1016/S0168-8278(99)80213-X
   CARMAN WF, 1995, LANCET, V345, P1406, DOI 10.1016/S0140-6736(95)92599-6
   Carrilho FJ, 2001, HEPATOLOGY, V34, p612A
   CASTRO LD, 2001, BMC MICROBIOL, V1, P10
   Chan HLY, 1999, HEPATOLOGY, V29, P976, DOI 10.1002/hep.510290352
   Chong-Jin O, 1999, J INFECT DIS, V179, P259, DOI 10.1086/314553
   Ding X, 2001, INTERVIROLOGY, V44, P43, DOI 10.1159/000050029
   Gust I, 1986, CLIN TROP MED COMMUN, V1, P281
   HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7
   HSU HY, 1995, J INFECT DIS, V171, P776, DOI 10.1093/infdis/171.4.776
   KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989
   Kao JH, 2000, GASTROENTEROLOGY, V118, P554, DOI 10.1016/S0016-5085(00)70261-7
   Kao JH, 2000, J HEPATOL, V33, P998, DOI 10.1016/S0168-8278(00)80135-X
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kramvis A, 1999, J VIRAL HEPATITIS, V6, P415, DOI 10.1046/j.1365-2893.1999.00189.x
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   LI JS, 1993, J VIROL, V67, P5402, DOI 10.1128/JVI.67.9.5402-5410.1993
   Lindh M, 1997, J INFECT DIS, V175, P1285, DOI 10.1086/516458
   Lindh M, 1998, J VIROL METHODS, V72, P163, DOI 10.1016/S0166-0934(98)00026-3
   LIU HF, 2001, J PEDIAT GASTROENTER, V32, P244
   Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839
   LOK ASF, 1994, P NATL ACAD SCI USA, V91, P4077, DOI 10.1073/pnas.91.9.4077
   Magnius LO, 1995, INTERVIROLOGY, V38, P24, DOI 10.1159/000150411
   Mayerat C, 1999, J VIRAL HEPATITIS, V6, P299, DOI 10.1046/j.1365-2893.1999.00174.x
   Mizokami M, 1999, FEBS LETT, V450, P66, DOI 10.1016/S0014-5793(99)00471-8
   Moraes MTB, 1996, ARCH VIROL, V141, P1767, DOI 10.1007/BF01718299
   NEURATH AR, 1990, IMMUNOCHEMISTRY VIRU, V2, P403
   Nishizono A, 1997, J MED VIROL, V53, P266, DOI 10.1002/(SICI)1096-9071(199711)53:3<266::AID-JMV15>3.0.CO;2-F
   NORDER H, 1992, J GEN VIROL, V73, P3141, DOI 10.1099/0022-1317-73-12-3141
   NORDER H, 1992, J GEN VIROL, V73, P1201, DOI 10.1099/0022-1317-73-5-1201
   NORDER H, 1994, VIROLOGY, V198, P489, DOI 10.1006/viro.1994.1060
   OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575
   OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990
   OKAMOTO H, 1992, PEDIATR RES, V32, P264, DOI 10.1203/00006450-199209000-00002
   Oon CJ, 1996, LANCET, V348, P1524, DOI 10.1016/S0140-6736(05)65950-8
   Oon CJ, 1998, J VIRAL HEPATITIS, V5, P17, DOI 10.1046/j.1365-2893.1998.0050s2017.x
   Orito E, 2001, HEPATOLOGY, V33, P218, DOI 10.1053/jhep.2001.20532
   Orito E, 2001, HEPATOLOGY, V34, P590, DOI 10.1053/jhep.2001.27221
   Rodriguez-Frias F, 1999, LIVER, V19, P177, DOI 10.1111/j.1478-3231.1999.tb00032.x
   RodriguezFrias F, 1995, HEPATOLOGY, V22, P1641, DOI 10.1016/0270-9139(95)90185-X
   Sanchez-Tapias JM, 2003, GASTROENTEROLOGY, V125, P1560, DOI 10.1016/j.gastro.2003.09.012
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708
   TAKAHASHI K, 1995, J GEN VIROL, V76, P3159, DOI 10.1099/0022-1317-76-12-3159
   Teles SA, 1999, ARTIF ORGANS, V23, P1074, DOI 10.1046/j.1525-1594.1999.06310.x
   Theamboonlers A, 2001, TOHOKU J EXP MED, V193, P197, DOI 10.1620/tjem.193.197
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tong CYW, 2000, CURR OPIN INFECT DIS, V13, P481, DOI 10.1097/00001432-200010000-00009
   Zhang XX, 1996, J MED VIROL, V48, P8, DOI 10.1002/(SICI)1096-9071(199601)48:1<8::AID-JMV2>3.0.CO;2-E
NR 56
TC 78
Z9 82
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2004
VL 42
IS 6
BP 2455
EP 2460
DI 10.1128/JCM.42.6.2455-2460.2004
PG 6
WC Microbiology
SC Microbiology
GA 829AS
UT WOS:000222015800015
PM 15184419
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Medeiros, DM
   Oliveira, AC
   Barros, MFA
   Cury, RA
   Sette-Junior, H
   Abdala, E
   Canedo, LF
   Makdissi, FF
   Andraus, W
   Martino, RB
   Rocha-Santos, V
   Figueira, ERR
   Machado, MAC
   Carrilho, FJ
   Cancado, ELR
   Bacchella, T
   Machado, MCC
AF Medeiros, DM
   Oliveira, AC
   Barros, MFA
   Cury, RA
   Sette-Junior, H
   Abdala, E
   Canedo, LF
   Makdissi, FF
   Andraus, W
   Martino, RB
   Rocha-Santos, V
   Figueira, ERR
   Machado, MAC
   Carrilho, FJ
   Cancado, ELR
   Bacchella, T
   Machado, MCC
TI Early mortality in liver transplantation: Bilirubin as predictor of
   outcome
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the
   International-Pancreas-and-Islet-Transplant-Association
CY JUL 08-11, 2003
CL DUBLIN, IRELAND
SP Int Pancreas & Islet Transplant Assoc
ID SURVIVAL; MODEL
AB The shortage of donor organs and the long waiting lists have increased the need to better select liver transplant candidates using predictors of success. We reviewed the results of 29 liver transplantations performed from January 2002 to February 2003 analyzing the correlations with early mortality (30 days) of patient data, pretransplant laboratory data, warm ischemia time, intraoperations blood unit transfusions, and postoperative complications of prolonged mechanical ventilation, dialysis, and infection. Overall early mortality was 27.6% and 44% in fulminant hepatic failure (n = 9), there were four retransplants with one death, and two intraoperative deaths. Only pretransplant bilirubin (P = .045) and postoperative lactate levels (P = .002) were significantly different between alive versus dead patients. In this small population bilirubin was more related to death than the MELD score. Lactate levels, nonspecific predictor of death in shock syndromes were probably related to septic complications.
C1 Univ Sao Paulo, Sch Med, Liver Transplantat Unit, Hosp Clin, Sao Paulo, Brazil.
RP Medeiros, DM (corresponding author), Univ Sao Paulo, Fac Med, Transplante & Cirurgia Figado, Av Dr Arnaldo 544, BR-05403900 Sao Paulo, Brazil.
EM de.medeiros@uol.com.br
RI Machado, Marcel Autran/Y-5220-2019; Cancado, Eduardo/K-1861-2016;
   Andraus, Wellington/G-1860-2012; Rocha-Santos, Vinicius/H-2984-2017;
   Canedo, Leonardo Fernandes/AAE-7846-2020; Figueira, Estela
   RR/G-9850-2012; Rocha-Santos, Vinicius/O-9759-2018; Figueira, Estela R
   R/P-1863-2015; Carrilho, Flair J/I-3046-2012; Martino,
   Rodrigo/C-3416-2013; Abdala, Edson/H-5165-2012; machado,
   marcel/E-2129-2012
OI Machado, Marcel Autran/0000-0002-4981-7607; Cancado,
   Eduardo/0000-0002-9309-1524; Andraus, Wellington/0000-0002-5162-138X;
   Rocha-Santos, Vinicius/0000-0002-2643-6094; Canedo, Leonardo
   Fernandes/0000-0003-4400-4508; Figueira, Estela RR/0000-0002-7856-8670;
   Figueira, Estela R R/0000-0002-7856-8670; Abdala,
   Edson/0000-0003-0765-6654; machado, marcel/0000-0002-0729-1635
CR Fernandez-Aguilar JL, 2003, TRANSPL P, V35, P705, DOI 10.1016/S0041-1345(03)00056-3
   Ghobrial RM, 2002, ANN SURG, V236, P315, DOI 10.1097/00000658-200209000-00008
   Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172
   Onaca NN, 2003, LIVER TRANSPLANT, V9, P117, DOI 10.1053/jlts.2003.50027
NR 4
TC 4
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2004
VL 36
IS 4
BP 931
EP 932
DI 10.1016/j.transproceed.2004.03.112
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 829QD
UT WOS:000222063800046
PM 15194321
DA 2020-12-08
ER

PT J
AU Carrilho, FJ
   Moraes, CR
   Pinho, JRR
   Mello, IMVGC
   Bertolini, DA
   Lemos, MF
   Moreira, RC
   Bassit, LC
   Cardoso, RA
   Ribeiro-dos-Santos, G
   Da Silva, LC
AF Carrilho, FJ
   Moraes, CR
   Pinho, JRR
   Mello, IMVGC
   Bertolini, DA
   Lemos, MF
   Moreira, RC
   Bassit, LC
   Cardoso, RA
   Ribeiro-dos-Santos, G
   Da Silva, LC
TI Hepatitis B virus infection in haemodialysis centres from Santa Catarina
   State, southern Brazil. Predictive risk factors for infection and
   molecular epidemiology
SO BMC PUBLIC HEALTH
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; C VIRUS; DIALYSIS PATIENTS; SURFACE-ANTIGEN;
   ANTIBODIES; TRANSMISSION; MARKERS; HCV; PREVALENCE; GENOTYPE
AB Background: Patients under haemodialysis are considered at high risk to acquire hepatitis B virus (HBV) infection. Since few data are reported from Brazil, our aim was to assess the frequency and risk factors for HBV infection in haemodialysis patients from 22 Dialysis Centres from Santa Catarina State, south of Brazil.
   Methods: This study includes 813 patients, 149 haemodialysis workers and 772 healthy controls matched by sex and age. Serum samples were assayed for HBV markers and viraemia was detected by nested PCR. HBV was genotyped by partial S gene sequencing. Univariate and multivariate statistical analyses with stepwise logistic regression analysis were carried out to analyse the relationship between HBV infection and the characteristics of patients and their Dialysis Units.
   Results: Frequency of HBV infection was 10.0%, 2.7% and 2.7% among patients, haemodialysis workers and controls, respectively. Amidst patients, the most frequent HBV genotypes were A (30.6%), D (57.1%) and F (12.2%). Univariate analysis showed association between HBV infection and total time in haemodialysis, type of dialysis equipment, hygiene and sterilization of equipment, number of times reusing the dialysis lines and filters, number of patients per care-worker and current HCV infection. The logistic regression model showed that total time in haemodialysis, number of times of reusing the dialysis lines and filters, and number of patients per worker were significantly related to HBV infection.
   Conclusions: Frequency of HBV infection among haemodialysis patients at Santa Catarina state is very high. The most frequent HBV genotypes were A, D and F. The risk for a patient to become HBV positive increase 1.47 times each month of haemodialysis; 1.96 times if the dialysis unit reuses the lines and filters greater than or equal to 10 times compared with haemodialysis units which reuse < 10 times; 3.42 times if the number of patients per worker is more than five. Sequence similarity among the HBV S gene from isolates of different patients pointed out to nosocomial transmission.
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Virol Branch, Sao Paulo, Brazil.
   Fdn Pro Sangue Hemoctr Sao Paulo, Ctr Blood, Sao Paulo, Brazil.
   Univ Sao Paulo, Biosci Inst, BR-05508 Sao Paulo, Brazil.
RP Carrilho, FJ (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, Sao Paulo, Brazil.
EM fjcarril@usp.br; crem@zaz.com.br; jrrpinho@usp.br;
   imvgcmello@uol.com.br; dabertolini@hotmail.com;
   marcilio.lemos@uol.com.br; rmoreira@ial.sp.gov.br; zyv0@cdc.gov;
   rita@statistika.com.br; gabrs@uol.com.br; cepahe@terra.com.br
RI Carrilho, Flair J/I-3046-2012; de carvalho-Mello, Isabel Maria V
   G/D-3641-2012; Pinho, Joao R. R./G-2850-2012; Bertolini,
   Dennis/ABG-1427-2020; Moreira, Regina C/B-1488-2016
OI Pinho, Joao R. R./0000-0003-3999-0489; Moreira, Regina
   C/0000-0002-8208-8776
CR Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   ASHRAF SJ, 1986, J MED VIROL, V19, P41, DOI 10.1002/jmv.1890190107
   AYOOLA EA, 1991, J MED VIROL, V35, P155, DOI 10.1002/jmv.1890350303
   BECCARI M, 1993, NEPHRON, V63, P238
   BRANCROFT WH, 1976, BIBL HAEMATO, V42, P42
   Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
   CARY NC, 1989, SAS STAT USERS GUIDE, V2
   CASTROFIGUEIREDO JF, 1986, BRAZ J MED BIOL RES, V19, P735
   *CDCP, 1989, DIALYSIS TRANSPLANT, P543
   CHAN TM, 1991, NEPHROL DIAL TRANSPL, V6, P944, DOI 10.1093/ndt/6.12.944
   COUROUCEPAUTY AM, 1983, VOX SANG, V44, P197, DOI 10.1111/j.1423-0410.1983.tb01885.x
   Cox D.R., 1970, ANAL BINARY DATA
   Dumpis U, 2001, J HEPATOL, V35, P99, DOI 10.1016/S0168-8278(01)00064-2
   DUSSOL B, 1995, AM J KIDNEY DIS, V25, P399, DOI 10.1016/0272-6386(95)90100-0
   DUSSOL B, 1993, AM J KIDNEY DIS, V22, P574, DOI 10.1016/S0272-6386(12)80931-0
   ELISAF M, 1991, NEPHROL DIAL TRANSPL, V6, P476, DOI 10.1093/ndt/6.7.476
   FABRIZI F, 1993, NEPHROL DIAL TRANSPL, V8, P744, DOI 10.1093/ndt/8.8.744
   Favero MS, 1996, SEMIN DIALYSIS, V9, P373, DOI 10.1111/j.1525-139X.1996.tb00867.x
   Fernandes JV, 1999, REV SAUDE PUBL, V33, P122, DOI 10.1590/S0034-89101999000200003
   GARCIA VD, 1994, J BRAS NEFROL, V16, P55
   GARIBALDI RA, 1973, JAMA-J AM MED ASSOC, V225, P384, DOI 10.1001/jama.225.4.384
   GASPAR A M C, 1987, Memorias do Instituto Oswaldo Cruz, V82, P253, DOI 10.1590/S0074-02761987000200013
   GOFFIN E, 1995, NEPHROL DIAL TRANSPL, V10, P88, DOI 10.1093/ndt/10.supp6.88
   IANHEZ L E, 1985, Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, V40, P53
   KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989
   Kellerman S, 1999, HEPATOLOGY, V29, P291, DOI 10.1002/hep.510290132
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   KOPSTEIN J, 1984, J BRAS NEFROL, V6, P9
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   LEVY BS, 1977, AM J EPIDEMIOL, V106, P330, DOI 10.1093/oxfordjournals.aje.a112469
   LIN DY, 1993, AM J KIDNEY DIS, V21, P288, DOI 10.1016/S0272-6386(12)80748-7
   Lyerla R, 1999, INFECT CONT HOSP EP, V20, P156, DOI 10.1086/503087
   MACHIDA J, 1992, NEPHRON, V60, P117, DOI 10.1159/000186719
   MATTOS AA, 1999, GASTROENTEROL ENDOSC, V18, P193
   MORAES CR, 1998, THESIS U SAO PAULO S
   NETO MC, 1995, NEPHROL DIAL TRANSPL, V10, P240
   NETO MC, 1995, ARTIF ORGANS, V19, P251, DOI 10.1111/j.1525-1594.1995.tb02323.x
   NORDER H, 1992, J GEN VIROL, V73, P3141, DOI 10.1099/0022-1317-73-12-3141
   NORDER H, 1992, J GEN VIROL, V73, P1201, DOI 10.1099/0022-1317-73-5-1201
   OGUCHI H, 1992, CLIN NEPHROL, V38, P36
   OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575
   PARANA R, 1991, ACTA HEPATOL, V1, P23
   PINHO JRR, 1994, REV SOC BRAS MED T S, V27, P372
   ROMAO JE, 1094, J BRAS NEFROL, V6, P2
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Sitnik R, 2000, HEPATOLOGY, V32, p578A
   SNYDMAN DR, 1976, J INFECT DIS, V134, P562, DOI 10.1093/infdis/134.6.562
   STURM JA, 1993, REV BRAS PAT CLIN, V29, P14
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Teles SA, 1999, ARTIF ORGANS, V23, P1074, DOI 10.1046/j.1525-1594.1999.06310.x
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
NR 51
TC 52
Z9 55
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD APR 27
PY 2004
VL 4
AR 13
DI 10.1186/1471-2458-4-13
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 828ZE
UT WOS:000222011600002
PM 15113436
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU de Almeida, TMB
   Leitao, RC
   Andrade, JD
   Becak, W
   Carrilho, FJ
   Sonohara, S
AF de Almeida, TMB
   Leitao, RC
   Andrade, JD
   Becak, W
   Carrilho, FJ
   Sonohara, S
TI Detection of micronuclei formation and nuclear anomalies in regenerative
   nodules of human cirrhotic livers and relationship to hepatocellular
   carcinoma
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article
ID IN-SITU HYBRIDIZATION; EXFOLIATED HUMAN-CELLS; CHROMOSOMAL-ABERRATIONS;
   HUMAN-LYMPHOCYTES; NITRIC-OXIDE; DNA-DAMAGE; ASSAY;
   HEPATOCARCINOGENESIS; INFECTION; DISEASE
AB Human cirrhosis is considered an important factor in hepatocarcinogenesis. The lack of substantial genetics and cytogenetics data in human cirrhosis led us to investigate spontaneous micronuclei formation, as an indicator of chromosomal damage. The analysis was performed in hepatocytes of regenerative, macroregenerative, and tumoral nodules from 30 cases of cirrhosis (paraffin-embedded archival material), retrospectively selected: cryptogenic, hepatitis C virus, and hepatitis C virus associated with hepatocellular carcinoma (HCC). Thirteen control liver samples of healthy organ donors were included. Micronucleated hepatocytes were analyzed with Feulgen-fast-green dyeing techniques. The spontaneous frequency of micronucleated hepatocytes in both regenerative and macroregenerative nodules of all cirrhotic patients was significantly higher than for the normal control group. There was no significant difference in frequency of micronucleated hepatocytes in regenerative nodules compared with macroregenerative nodules for all cases analyzed, whereas a significantly higher frequency of micronucleated hepatocytes was detected in tumoral nodules, compared with cirrhotic regenerative nodules and normal parenchyma. A higher frequency of the nuclear anomalies termed broken-eggs was observed in hepatitis C virus-related samples. Chromatinic losses and genotoxicity already existed in the cirrhotic regenerative nodules, which might predispose to development of HCC. (C) 2004 Elsevier Inc. All rights reserved.
C1 FMUSP, Dept Radiol, Disciplina Oncol, BR-01246903 Sao Paulo, Brazil.
   Inst Butantan, Genet Lab, Sao Paulo, Brazil.
   Lab Anat Patol Diagnost, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Escola Paulista Med, Dept Morphol, Disciplina Genet, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Gastroenterol, Disciplina Gastroenterol Clin Hepatol, Sao Paulo, Brazil.
RP Sonohara, S (corresponding author), FMUSP, Dept Radiol, Disciplina Oncol, Av Dr Arnaldo,455,4 Andar,Sala 4112, BR-01246903 Sao Paulo, Brazil.
EM shigueko@lim24.fm.usp.br
RI Carrilho, Flair J/I-3046-2012
CR ARLETT CF, 1989, MUTAGENESIS, V4, P482, DOI 10.1093/mutage/4.6.482
   BRAITHWAITE I, 1988, MUTAT RES, V203, P23, DOI 10.1016/0165-1161(88)90004-0
   Cardin R, 2001, J HEPATOL, V34, P587, DOI 10.1016/S0168-8278(00)00098-2
   COUNTRYMAN PI, 1976, MUTAT RES, V41, P321, DOI 10.1016/0027-5107(76)90105-6
   DOMINGUEZMALAGO.H, ULTRSTRUCT PATHOL, V25, P497
   EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812
   Edmondson H, 1954, CANCER, V1, P462
   Farinati F, 1999, FREE RADICAL BIO MED, V27, P1284, DOI 10.1016/S0891-5849(99)00161-6
   Fenech M, 1999, MUTAT RES-FUND MOL M, V428, P271, DOI 10.1016/S1383-5742(99)00053-8
   FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9
   Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8
   Fenech M, 2002, MUTAT RES-FUND MOL M, V504, P131, DOI 10.1016/S0027-5107(02)00086-6
   FURUYA K, 1988, CANCER, V61, P99, DOI 10.1002/1097-0142(19880101)61:1<99::AID-CNCR2820610117>3.0.CO;2-U
   HEDDLE JA, 1991, ENVIRON MOL MUTAGEN, V18, P277, DOI 10.1002/em.2850180414
   Hon WM, 2002, ANN NY ACAD SCI, V962, P275, DOI 10.1111/j.1749-6632.2002.tb04074.x
   Huang SF, 1999, CANCER GENET CYTOGEN, V111, P21, DOI 10.1016/S0165-4608(98)00215-5
   HYTIROGLOU P, 1995, HEPATOLOGY, V21, P703, DOI 10.1002/hep.1840210316
   Jen MH, 2002, MUTAT RES-GEN TOX EN, V520, P39, DOI 10.1016/S1383-5718(02)00177-8
   Kane JM, 1997, J SURG RES, V69, P321, DOI 10.1006/jsre.1997.5057
   Livezey KW, 2002, MUTAT RES-FUND MOL M, V505, P63, DOI 10.1016/S0027-5107(02)00140-9
   Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426
   Nasarek A, 1995, VIRCHOWS ARCH, V427, P373
   NORPPA H, 1993, ENVIRON HEALTH PERSP, V101, P139, DOI 10.2307/3431715
   SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N
   STICH HF, 1984, CANCER LETT, V22, P241, DOI 10.1016/0304-3835(84)90159-9
   THEISE ND, 1995, SEMIN LIVER DIS, V15, P360, DOI 10.1055/s-2007-1007287
   TITENKOHOLLAND N, 1994, MUTAT RES, V312, P39, DOI 10.1016/0165-1161(94)90007-8
   TOLBERT PE, 1992, MUTAT RES, V271, P69, DOI 10.1016/0165-1161(92)90033-I
   Umegaki K, 2000, MUTAGENESIS, V15, P261, DOI 10.1093/mutage/15.3.261
   VANGOETHEM F, 1993, CARCINOGENESIS, V14, P2397, DOI 10.1093/carcin/14.11.2397
   VIG BK, 1986, MUTAGENESIS, V1, P464
   WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341
   *WHO, 1997, IARC SCI PUBL, P5
   Zimmermann U, 1997, HEPATOLOGY, V26, P1492
NR 34
TC 19
Z9 19
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD APR 1
PY 2004
VL 150
IS 1
BP 16
EP 21
DI 10.1016/j.cancergencyto.2003.08.001
PG 6
WC Oncology; Genetics & Heredity
SC Oncology; Genetics & Heredity
GA 808RR
UT WOS:000220586700003
PM 15041218
DA 2020-12-08
ER

PT J
AU Deguti, MM
   Genschel, J
   Cancado, ELR
   Barbosa, ER
   Bochow, B
   Mucenic, M
   Porta, G
   Lochs, H
   Carrilho, FJ
   Schmidt, HHJ
AF Deguti, Marta M.
   Genschel, Janine
   Cancado, Eduardo L. R.
   Barbosa, Egberto R.
   Bochow, Bettina
   Mucenic, Marcos
   Porta, Gilda
   Lochs, Herbert
   Carrilho, Flair J.
   Schmidt, Hartmut H. -J.
TI Wilson Disease: Novel Mutations in the ATP7B Gene and Clinical
   Correlation in Brazilian Patients
SO HUMAN MUTATION
LA English
DT Article
DE ATP7B gene; Wilson disease; mutation; sequencing; cirrhosis; neurology;
   psychiatry
AB Wilson disease (WD) is a rare inherited autosomal recessive disorder caused by a defect in a metal transporting P-type ATPase, resulting in copper overload in various tissues and cells. The aim was to assess both the phenotype in Brazilian WD patients and the corresponding ATP7B genotype. Sixty subjects belonging to 46 pedigrees diagnosed as WD were included in this study. Direct sequencing of all 21 exons within ATP7B and their flanking introns was performed. Demographic, clinical, laboratory and histopathological data at the time of diagnosis were obtained. We identified twenty-five mutations, twelve of them reported for the first time. The c.3402delC mutation had the highest allelic frequency (30.8%), followed by the c.2123T>C (p.L708P) (16.7%). Exons 8 and 15 were the site of 62.5% of the mutations. The common European mutation c. 3207C>A (p.H1069Q) was not present at all. Phenotype varied greatly among individuals with the same ATP7B genotype. Our data confirm the heterogeneity of ATP7B genotype in Brazilian WD patients. The mutational spectrum is compatible with the Brazilian history of Mediterranean immigration; however, new mutations, and different frequencies and phenotype associated with the previously known mutations characterize this population. Exons 8 and 15 should be preferentially screened in WD cases from Brazil. Phenotype variation among subjects with the same ATP7B genotype suggests that modifying factors play an additional role in the pathogenesis of WD. (C) 2004 Wiley-Liss, Inc.
C1 [Deguti, Marta M.; Cancado, Eduardo L. R.; Mucenic, Marcos; Carrilho, Flair J.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Barbosa, Egberto R.] Univ Sao Paulo, Sch Med, Dept Neurol, Sao Paulo, Brazil.
   [Porta, Gilda] Univ Sao Paulo, Sch Med, Dept Pediat Hepatol, Sao Paulo, Brazil.
   [Genschel, Janine; Bochow, Bettina; Lochs, Herbert; Schmidt, Hartmut H. -J.] Charite, Med Klin Gastroenterol Hepatol & Endokrinol, Berlin, Germany.
RP Schmidt, HHJ (corresponding author), Campus Charite Mitte, Med Klin Schwerpunkt Gastroenterol Hepatol & Endo, Schumannstr 20-21, D-10117 Berlin, Germany.
EM hartmut.schmidt@charite.de
RI Carrilho, Flair J/I-3046-2012; Mucenic, Marcos/AAB-6899-2020; Cancado,
   Eduardo/K-1861-2016
OI Mucenic, Marcos/0000-0001-9389-2236; Cancado,
   Eduardo/0000-0002-9309-1524; Reis Barbosa, Egberto/0000-0002-6996-9130
FU German Academic Exchange ServiceDeutscher Akademischer Austausch Dienst
   (DAAD) [A/01/17629]
FX Grant sponsor: German Academic Exchange Service; Grant number: DAAD
   #A/01/17629
CR BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327
   Caca K, 2001, J HEPATOL, V35, P575, DOI 10.1016/S0168-8278(01)00219-7
   Compston A., 1912, BRAIN, P34, DOI DOI 10.1093/BRAIN/34.4.295
   Deguti MM, 2002, AM J GASTROENTEROL, V97, P2153, DOI 10.1111/j.1572-0241.2002.05948.x
   FIGUS A, 1995, AM J HUM GENET, V57, P1318
   Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163
   Garcia-Villarreal L, 2000, HEPATOLOGY, V32, P1329, DOI 10.1053/jhep.2000.20152
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Hoogenraad T, 1996, WILSONS DIS, P14
   HOPPE B, 1993, NEPHRON, V65, P460, DOI 10.1159/000187530
   Loudianos G, 1996, HUM GENET, V98, P640, DOI 10.1007/s004390050275
   PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647
   Riordan SM, 2001, J HEPATOL, V34, P165, DOI 10.1016/S0168-8278(00)00028-3
   Scheinberg IH, 1984, MAJOR PROBLEMS INTER
   Shah AB, 1997, AM J HUM GENET, V61, P317, DOI 10.1086/514864
   Sozeri E, 1997, PEDIATR NEPHROL, V11, P307, DOI 10.1007/s004670050282
   TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344
   THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210
   Waldenstrom E, 1996, GENOMICS, V37, P303, DOI 10.1006/geno.1996.0564
NR 19
TC 72
Z9 83
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD APR
PY 2004
VL 23
IS 4
BP 398
EP +
DI 10.1002/humu.9227
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA V30GH
UT WOS:000208804000006
PM 15024742
OA Bronze
DA 2020-12-08
ER

PT J
AU Ono-Nita, SK
   de Moraes, CR
   Carrilho, FJ
   Pinho, JRR
   Bassit, L
   da Silva, LC
AF Ono-Nita, SK
   de Moraes, CR
   Carrilho, FJ
   Pinho, JRR
   Bassit, L
   da Silva, LC
TI A prospective study of the prevalence of hepatitis B and C virus
   co-infection among patients with chronic renal disease under
   hemodialysis
SO JOURNAL OF HEPATOLOGY
LA English
DT Letter
ID CORE PROTEIN; INFECTION
C1 Univ Sao Paulo, Sch Med, Hepatol Branch, Dept Gastroenterol, S Burlington, VT 05403 USA.
RP Ono-Nita, SK (corresponding author), Univ Sao Paulo, Sch Med, Hepatol Branch, Dept Gastroenterol, S Burlington, VT 05403 USA.
EM skon@usp.br
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012; Pinho, Joao R.
   R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
CR CHAN TM, 1991, NEPHROL DIAL TRANSPL, V6, P944, DOI 10.1093/ndt/6.12.944
   CHAN TM, 1993, HEPATOLOGY, V17, P5, DOI 10.1016/0270-9139(93)90183-N
   CHAN TM, 1993, GASTROENTEROLOGY, V104, P862, DOI 10.1016/0016-5085(93)91023-B
   Chen SY, 2003, J BIOL CHEM, V278, P591, DOI 10.1074/jbc.M204241200
   Dai CY, 2001, J GASTROEN HEPATOL, V16, P636, DOI 10.1046/j.1440-1746.2001.02494.x
   Fabrizi F, 2002, J NEPHROL, V15, P463
   Jardi R, 2001, HEPATOLOGY, V34, P404, DOI 10.1053/jhep.2001.26511
   SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995
   Zarski JP, 1998, J HEPATOL, V28, P27, DOI 10.1016/S0168-8278(98)80198-0
NR 9
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2004
VL 40
IS 4
BP 715
EP 716
DI 10.1016/j.jhep.2003.11.035
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 809MQ
UT WOS:000220641200023
PM 15030993
DA 2020-12-08
ER

PT J
AU Oliveira, CPM
   Raskovisk, A
   Furuya, CK
   Faintuch, J
   Bastos, MDSCB
   Della Nina, B
   Matsuda, M
   Vezozo, DP
   Zilberstein, B
   Gayotto, LCC
   Halpern, A
   Carrilho, FJ
   Rodrigues, JG
   Abdalla, DSP
AF Oliveira, CPM
   Raskovisk, A
   Furuya, CK
   Faintuch, J
   Bastos, MDSCB
   Della Nina, B
   Matsuda, M
   Vezozo, DP
   Zilberstein, B
   Gayotto, LCC
   Halpern, A
   Carrilho, FJ
   Rodrigues, JG
   Abdalla, DSP
TI Oxidative stress in NAFLD of morbid obesity patients.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 54th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Disease
CY OCT 24-28, 2003
CL BOSTON, MASSACHUSETTS
SP Amer Assoc Study Liver Diseases
C1 Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508 Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2003
VL 38
IS 4
SU 1
MA 727
BP 509A
EP 509A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 730ER
UT WOS:000185816700731
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Farias, AQ
   Abrantes-Lemos, CP
   Cancado, ELR
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Farias, AQ
   Abrantes-Lemos, CP
   Cancado, ELR
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Analysis of major histocompatibility complex and CTLA-4 alleles in
   Brazilian patients with primary biliary cirrhosis
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE CTLA-4 gene polymorphisms; genetic susceptibility; HLA-DR antigens;
   primary biliary cirrhosis; tumor necrosis factor alpha; TNFA
   polymorphisms
ID TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA PROMOTER; GENE POLYMORPHISM;
   AUTOIMMUNE-DISEASES; HLA DRW8; PCR-SSP; SUSCEPTIBILITY; ASSOCIATION;
   TRANSPLANTATION; PROGRESSION
AB Background and Aims: Predisposition to primary biliary cirrhosis (PBC) has been classically linked to HLA-DRB1 locus. However, the presence of the HLA-DRB1*08 antigen has been reported in less than one-third of PBC patients from Northern Europe and Japan. Recently, polymorphisms in the tumor necrosis factor alpha (TNFA) gene promoter at position -308 and in exon 1 of the cytotoxic T lymphocyte antigen-4 (CTLA-4) gene at position 49 have been associated with susceptibility to PBC in Caucasians. In addition, the presence of HLA-DRB1*08 and the TNFA*1 allele was also linked to progression to end-stage liver disease. The aims of the present study were to investigate the frequencies of HLA-DR and DQ antigens and TNFA and CTLA-4 alleles in PBC patients from a different genetic background, as well as to assess the role of TNFA alleles and HLA-DR antigens in disease progression.
   Methods: Determination of HLA-DRB1, DQB1, TNFA and CTLA-4 alleles was performed in patients with PBC and healthy controls using polymerase chain reaction-based techniques.
   Results: Frequencies of HLA-DR and DQ antigens were similar in PBC patients and healthy controls. Accordingly, no association between TNFA and CTLA-4 alleles was observed in PBC patients. The histological stage at admission of patients with PBC also showed no correlation with HLA antigens and TNFA and CTLA-4 alleles.
   Conclusions: Susceptibility to PBC in Brazil is not associated with HLA-DR and DQ antigens and CTLA-4 genotypes. TNFA alleles were not shown to influence disease progression. (C) 2003 Blackwell Publishing Asia Pty Ltd.
C1 Portuguese Hosp Salvador, Bahia Blanca, Argentina.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302 A,Rio Vermelho, BR-41940040 Salvador, BA, Brazil.
RI Carrilho, Flair J/I-3046-2012; Farias, Alberto/ABB-1291-2020; Farias,
   Alberto Q/H-7873-2013; KALIL, JORGE/C-8029-2012; BITTENCOURT, PAULO
   l/I-5817-2014; Goldberg, Anna Carla/H-8594-2014; Cancado,
   Eduardo/K-1861-2016
OI Farias, Alberto/0000-0002-5572-663X; KALIL, JORGE/0000-0001-8415-4274;
   BITTENCOURT, PAULO l/0000-0003-0883-4870; Goldberg, Anna
   Carla/0000-0003-2600-7940; Cancado, Eduardo/0000-0002-9309-1524
CR Agarwal K, 1999, EUR J GASTROEN HEPAT, V11, P603, DOI 10.1097/00042737-199906000-00004
   Agarwal K, 2000, J HEPATOL, V32, P538, DOI 10.1016/S0168-8278(00)80213-5
   Beutler BA, 1999, J RHEUMATOL, V26, P16
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3
   COPPEL RL, 1995, IMMUNOL REV, V144, P17, DOI 10.1111/j.1600-065X.1995.tb00064.x
   DONALDSON P, 1994, HEPATOLOGY, V20, P225, DOI 10.1002/hep.1840200133
   Donaldson P, 2001, GUT, V48, P397, DOI 10.1136/gut.48.3.397
   Donaldson PT, 1999, J HEPATOL, V31, P366, DOI 10.1016/S0168-8278(99)80238-4
   FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81
   Goldman JM, 1998, BONE MARROW TRANSPL, V21, P1, DOI 10.1038/sj.bmt.1701089
   Gordon MA, 1999, J HEPATOL, V31, P242, DOI 10.1016/S0168-8278(99)80220-7
   GREGORY WL, 1993, Q J MED, V86, P393
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Jones DEJ, 1999, J HEPATOL, V30, P232, DOI 10.1016/S0168-8278(99)80067-1
   Kaplan MM, 1996, NEW ENGL J MED, V335, P1570, DOI 10.1056/NEJM199611213352107
   Kouki T, 2000, J IMMUNOL, V165, P6606, DOI 10.4049/jimmunol.165.11.6606
   Kristiansen OP, 2000, GENES IMMUN, V1, P170, DOI 10.1038/sj.gene.6363655
   Louis E, 1998, CLIN EXP IMMUNOL, V113, P401
   MAEDA T, 1992, GASTROENTEROLOGY, V103, P1118, DOI 10.1016/0016-5085(92)90069-B
   MANNS MP, 1991, GASTROENTEROLOGY, V101, P1367, DOI 10.1016/0016-5085(91)90090-8
   MEHAL WZ, 1994, HEPATOLOGY, V20, P1213, DOI 10.1002/hep.1840200517
   MELLA JG, 1995, HEPATOLOGY, V21, P398, DOI 10.1002/hep.1840210221
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P55
   ONISHI S, 1994, J HEPATOL, V21, P1053, DOI 10.1016/S0168-8278(05)80617-8
   Parikh-Patel A, 1999, CLIN IMMUNOL, V91, P206, DOI 10.1006/clim.1999.4690
   SCHEUER PJ, 1967, P ROY SOC MED, V60, P1257, DOI 10.1177/003591576706001205
   SEKI T, 1993, HEPATOLOGY, V18, P73
   STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147
   Stone J, 2002, J HEPATOL, V36, P8, DOI 10.1016/S0168-8278(01)00237-9
   Tanaka A, 1999, J HEPATOL, V30, P826, DOI 10.1016/S0168-8278(99)80135-4
   UNDERHILL J, 1992, HEPATOLOGY, V16, P1404, DOI 10.1002/hep.1840160616
   UNDERHILL JA, 1995, HEPATOLOGY, V21, P959, DOI 10.1016/0270-9139(95)90240-6
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
NR 36
TC 41
Z9 43
U1 0
U2 4
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 0815-9319
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD SEP
PY 2003
VL 18
IS 9
BP 1061
EP 1066
DI 10.1046/j.1440-1746.2003.03091.x
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 711CL
UT WOS:000184721300010
PM 12911663
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Cytotoxic T lymphocyte antigen-4 gene polymorphisms do not confer
   susceptibility to autoimmune hepatitis types 1 and 2 in Brazil
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID HLA; CTLA-4; DIAGNOSIS; CLASSIFICATION; HETEROGENEITY; EXPRESSION;
   DISEASES
AB OBJECTIVES: Susceptibility to autoimmune hepatitis (AIH) has been linked to different HLA-DR antigens in distinct populations. Recently, an A-G polymorphism in exon 1 of the cytotoxic T lymphocyte antigen-4 (CTLA-4) gene was associated with predisposition to AIH type 1 (AIH-1) in white individuals in North America. This polymorphism has been associated with several other autoimmune diseases, presumably because of its effect in the expression of CTLA-4, an adhesion molecule that downregulates peripheral T cell responses. The aims of this study were to assess the frequency of CTLA-4 genotypes in Brazilian patients with AIH-1 and AIH type 2 (AIH-1), as well as to investigate the influence of these genotypes in disease expression.
   METHODS: Determination of CTLA-4 genotypes was carried out in 106 patients with AIH-1, 26 subjects with AIH-2, and 67 healthy control subjects by polymerase chain reaction (PCR)-based techniques.
   RESULTS: No difference in the distribution of CTLA-4 genotypes was observed in subjects with AIH-1 and AIH-2 as compared to healthy controls. Patients with AIH-1 and AIH-2 with the GG genotype exhibited lower gamma-globulin and ALT levels, respectively.
   CONCLUSIONS: Susceptibility to AIH-1 and AIH-2 in Brazilian patients is not influenced by exon 1 CTLA-4 gene polymorphisms at position 49. (C) 2003 by Am. Coll. of Gastroenterology.
C1 Portuguese Hosp Salvador, Salvador, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit,Lab Immunol,Heart Inst, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302A, Salvador, BA, Brazil.
RI BITTENCOURT, PAULO l/I-5817-2014; Cancado, Eduardo/K-1861-2016;
   Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; Cancado,
   Eduardo/0000-0002-9309-1524; Goldberg, Anna Carla/0000-0003-2600-7940;
   KALIL, JORGE/0000-0001-8415-4274
CR ABUAF N, 1992, HEPATOLOGY, V16, P892, DOI 10.1002/hep.1840160407
   Agarwal K, 2000, HEPATOLOGY, V31, P49, DOI 10.1002/hep.510310110
   Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
   Bittencourt PL, 1998, AM J GASTROENTEROL, V93, P1394, DOI 10.1111/j.1572-0241.1998.1394a.x
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bittencourt PL, 2001, J HEPATOL, V35, P24, DOI 10.1016/S0168-8278(01)00072-1
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3
   CORDONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   Czaja AJ, 2002, HEPATOLOGY, V36, P479, DOI 10.1053/jhep.2002.34944
   Czaja AJ, 2002, J HEPATOL, V37, P302, DOI 10.1016/S0168-8278(02)00182-4
   Czaja AJ, 2000, IMMUNOL REV, V174, P250, DOI 10.1034/j.1600-0528.2002.017401.x
   DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
   Djilali-Saiah I, 2001, HUM IMMUNOL, V62, P1356, DOI 10.1016/S0198-8859(01)00344-5
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81
   Goldberg AC, 2001, HUM IMMUNOL, V62, P165, DOI 10.1016/S0198-8859(00)00234-2
   Goldman JM, 1998, BONE MARROW TRANSPL, V21, P1, DOI 10.1038/sj.bmt.1701089
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Kouki T, 2000, J IMMUNOL, V165, P6606, DOI 10.4049/jimmunol.165.11.6606
   Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   Kristiansen OP, 2000, GENES IMMUN, V1, P170, DOI 10.1038/sj.gene.6363655
   Ligers A, 2001, GENES IMMUN, V2, P145, DOI 10.1038/sj.gene.6363752
   Manns MP, 2001, GASTROENTEROLOGY, V120, P1502, DOI 10.1053/gast.2001.24227
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
NR 30
TC 43
Z9 50
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUL
PY 2003
VL 98
IS 7
BP 1616
EP 1620
DI 10.1016/S0002-9270(03)00307-1
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 702GP
UT WOS:000184216400027
PM 12873588
DA 2020-12-08
ER

PT J
AU Deguti, MM
   Sipahi, AM
   Gayotto, LCC
   Palacios, SA
   Bittencourt, PL
   Goldberg, AC
   Laudanna, AA
   Carrilho, FJ
   Cancado, ELR
AF Deguti, MM
   Sipahi, AM
   Gayotto, LCC
   Palacios, SA
   Bittencourt, PL
   Goldberg, AC
   Laudanna, AA
   Carrilho, FJ
   Cancado, ELR
TI Lack of evidence for the pathogenic role of iron and HFE gene mutations
   in Brazilian patients with nonalcoholic steatohepatitis
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE fatty liver; nonalcoholic steatohepatitis; iron overload; HFE gene;
   alanine aminotransferase
ID EXPANDED CLINICAL ENTITY; HEPATIC IRON; LIVER-DISEASE; FATTY LIVER;
   HEMOCHROMATOSIS; OVERLOAD; PERMEABILITY
AB The hypothesis of the role of iron overload associated with HFE gene mutations in the pathogenesis of nonalcoholic steatohepatitis (NASH) has been raised in recent years. In the present study, biochemical and histopathological evidence of iron overload and HFE mutations was investigated in NASH patients. Thirty-two NASH patients, 19 females (59%), average 49.2 years, 72% Caucasians, 12% Mulattoes and 12% Asians, were submitted to serum aminotransferase and iron profile determinations. Liver biopsies were analyzed for necroinflammatory activity, architectural damage and iron deposition. In 31 of the patients, C282Y and H63D mutations were tested by PCR-RFLP. Alanine aminotransferase levels were increased in 30 patients, 2.42 +/- 1.12 times the upper normal limit on average. Serum iron concentration, transferrin saturation and ferritin averages were 99.4 +/- 31.3 g/dl, 33.1 +/- 12.7% and 219.8 +/- 163.8 mug/dl, respectively, corresponding to normal values in 93.5, 68.7 and 78.1% of the patients. Hepatic siderosis was observed in three patients and was not associated with architectural damage (P = 0.53) or with necroinflammatory activity (P = 0.27). The allelic frequencies (N = 31) found were 1.6 and 14.1% for C282Y and H63D, respectively, which were compatible with those described for the local population. In conclusion, no evidence of an association of hepatic iron overload and HFE mutations with NASH was found. Brazilian NASH patients comprise a heterogeneous group with many associated conditions such as hyperinsulinism, environmental hepatotoxin exposure and drugs, but not hepatic iron overload, and their disease susceptibility could be related to genetic and environmental features other than HFE mutations.
C1 Univ Sao Paulo, Fac Med, Dept Gastroenterol, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Pathol, Lab Invest Med, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, LIM 07, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, LIM 06, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Coracao, Lab Immunol & Transplante, BR-01246903 Sao Paulo, Brazil.
RP Deguti, MM (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol, Av Eneas C Aguiar 255,S 9159, BR-01246903 Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Goldberg, Anna Carla/H-8594-2014;
   BITTENCOURT, PAULO l/I-5817-2014; Sipahi, Aytan Miranda/O-7768-2019;
   Cancado, Eduardo/K-1861-2016
OI Goldberg, Anna Carla/0000-0003-2600-7940; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Sipahi, Aytan Miranda/0000-0002-9686-1627;
   Cancado, Eduardo/0000-0002-9309-1524; Maria dos Santos,
   Fabiana/0000-0003-1785-7388
CR Adams PC, 1999, HEPATOLOGY, V29, P1324, DOI 10.1002/hep.510290425
   Agostinho MF, 1999, BLOOD CELL MOL DIS, V25, P324, DOI 10.1006/bcmd.1999.0260
   Alves-Silva J, 2000, AM J HUM GENET, V67, P444, DOI 10.1086/303004
   BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6
   Bonkovsky HL, 2000, J HEPATOL, V33, P1025, DOI 10.1016/S0168-8278(00)80143-9
   Bonkovsky HL, 1999, J HEPATOL, V31, P421, DOI 10.1016/S0168-8278(99)80032-4
   Cotrim HP, 1999, LIVER, V19, P299, DOI 10.1111/j.1478-3231.1999.tb00053.x
   Datz C, 1997, J HEPATOL, V27, P773, DOI 10.1016/S0168-8278(97)80312-1
   DIEHL AM, 1988, GASTROENTEROLOGY, V95, P1056, DOI 10.1016/0016-5085(88)90183-7
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   FRANCO LJ, 1996, DIABETES RES CLIN PR, V34, P51
   George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2
   Gochee PA, 2002, GASTROENTEROLOGY, V122, P646, DOI 10.1016/S0016-5085(02)80116-0
   Guillygomarc'h A, 2000, J HEPATOL, V33, P515, DOI 10.1016/S0168-8278(00)80294-9
   ITOH S, 1987, AM J GASTROENTEROL, V82, P650
   James OFW, 1998, J HEPATOL, V29, P495, DOI 10.1016/S0168-8278(98)80073-1
   LEE RG, 1989, HUM PATHOL, V20, P594, DOI 10.1016/0046-8177(89)90249-9
   LONARDO A, 1995, AM J GASTROENTEROL, V90, P2072
   LUDWIG J, 1980, MAYO CLIN PROC, V55, P434
   LUMENG L, 1994, GASTROENTEROLOGY, V107, P572, DOI 10.1016/0016-5085(94)90185-6
   Mendler MH, 1999, GASTROENTEROLOGY, V117, P1155, DOI 10.1016/S0016-5085(99)70401-4
   Moirand R, 2000, J HEPATOL, V33, P1024, DOI 10.1016/S0168-8278(00)80142-7
   NeuschwanderTetri BA, 1996, MED CLIN N AM, V80, P1147, DOI 10.1016/S0025-7125(05)70483-1
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   PROPST A, 1995, GASTROENTEROLOGY, V108, P1607, DOI 10.1016/0016-5085(95)90724-6
   Schimpl G, 1999, EUR J PEDIATR SURG, V9, P224, DOI 10.1055/s-2008-1072249
   Ueno T, 1997, J HEPATOL, V27, P103, DOI 10.1016/S0168-8278(97)80287-5
   VAZQUEZ CM, 1988, DIGESTION, V40, P168, DOI 10.1159/000199651
   Wigg AJ, 2001, GUT, V48, P206, DOI 10.1136/gut.48.2.206
   Younossi ZM, 1999, HEPATOLOGY, V30, P847, DOI 10.1002/hep.510300407
NR 30
TC 30
Z9 32
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JUN
PY 2003
VL 36
IS 6
BP 739
EP 745
DI 10.1590/S0100-879X2003000600009
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 696BX
UT WOS:000183866400009
PM 12792703
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Navarro-Rodriguez, T
   Hashimoto, CL
   Carrilho, FJ
   Strauss, E
   Laudanna, AA
   Moraes, JPP
AF Navarro-Rodriguez, T
   Hashimoto, CL
   Carrilho, FJ
   Strauss, E
   Laudanna, AA
   Moraes, JPP
TI Reduction of abdominal pressure in patients with ascites reduces
   gastroesophageal reflux
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE 24-h pH-metry; ascites; esophageal manometry; gastroesophageal reflux
ID LOWER ESOPHAGEAL SPHINCTER; NITRIC-OXIDE; CIRRHOSIS; HEARTBURN;
   PREGNANCY; VARICES; OBESE
AB The effect of the reduction of intra-abdominal pressure on the lower esophageal sphincter pressure (LESP) and the 24-hour pH monitoring were studied in 16 patients with ascites before and after paracentesis. LESP did not change (P > 0.05) with the reduction of intra-abdominal pressure (before paracentesis: 17.48 mmHg and postparacentesis: 18.67 mmHg). The results were divided into two groups according to the achieved reduction in intra-abdominal pressure group A were those in who the reduction was greater than 70% and B consisted of those a reduction of less than 70%. LESP did not change even when results for each group were considered separately (P > 0.05): group A (before: 15.60 mmHg; after: 18.09 mmHg); group B (before: 23.09 mmHg; after: 20.40 mmHg). However the 24-h pH monitoring showed pathological reflux in patients with ascites that was reduced with the paracentesis (P < 0.05; total number of reflux episodes before paracentesis was 520.26, and after, 136.26). All pH-monitoring parameters were statistically different (P < 0.05) before and after the reduction of intra-abdominal pressure for group A but not for group B. LESP does not change significantly (P > 0.05) when the intra-abdominal pressure is significantly reduced (P < 0.05). Patients with ascites showed gastroesophageal reflux. Intra-abdominal pressure reduction greater than 70% lead to a significant reduction in gastroesophageal reflux.
C1 Univ Sao Paulo, Fac Med, Dept Gastroenterol, BR-05707001 Sao Paulo, Brazil.
   Heliopolis Hosp, Serv Gastroenterol, Sao Paulo, Brazil.
RP Moraes, JPP (corresponding author), Univ Sao Paulo, Fac Med, Dept Gastroenterol, Rua Itapaiuna 1165 C 28, BR-05707001 Sao Paulo, Brazil.
EM joaquim.prado@uol.com.br
RI Rodriguez, TOMAS NAVARRO/I-3170-2012; Carrilho, Flair J/I-3046-2012
OI Rodriguez, TOMAS NAVARRO/0000-0002-3458-699X; 
CR ANGGIANSAH A, 1993, AM J GASTROENTEROL, V88, P842
   Bhatia S J, 1999, Indian J Gastroenterol, V18, P63
   COHEN S, 1972, GASTROENTEROLOGY, V63, P1066
   COHEN S, 1970, GASTROENTEROLOGY, V58, P937
   ECKARDT VF, 1976, GASTROENTEROLOGY, V71, P185
   ECKARDT VF, 1979, GASTROENTEROLOGY, V76, P39
   FISHER RS, 1977, GASTROENTEROLOGY, V72, P19
   FYKE FE, 1956, GASTROENTEROLOGIA BA, V86, P135
   HAGEN J, 1987, INT SURG, V72, P1
   JOHNSON LF, 1974, AM J GASTROENTEROL, V62, P325
   JOHNSON LF, 1986, J CLIN GASTROENTEROL, V8, P52, DOI 10.1097/00004836-198606001-00008
   Kjellin A, 1996, SCAND J GASTROENTERO, V31, P1047, DOI 10.3109/00365529609036885
   Martin PY, 1998, NEW ENGL J MED, V339, P533, DOI 10.1056/NEJM199808203390807
   McDougall NI, 1996, GUT, V38, P481, DOI 10.1136/gut.38.4.481
   NAGLER R, 1961, J CLIN INVEST, V40, P954, DOI 10.1172/JCI104335
   Navarro-Rodriguez Tomas, 1997, Arquivos de Gastroenterologia, V34, P148
   NEBEL OT, 1977, AM J DIG DIS, V22, P1101, DOI 10.1007/BF01072865
   PREIKSAITIS HG, 1994, DIGEST DIS SCI, V39, P770, DOI 10.1007/BF02087422
   RICHTER JE, 1987, ESOPHAGEAL MOTILITY, P79
   SCHINDLBECK NE, 1991, AM J GASTROENTEROL, V86, P1138
   SIMPSON JA, 1968, GASTROENTEROLOGY, V55, P17
   TITO L, 1990, GASTROENTEROLOGY, V98, P146, DOI 10.1016/0016-5085(90)91303-N
   TOLIN RD, 1979, GASTROENTEROLOGY, V76, P1402
   TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385
   VANTHIEL DH, 1977, GASTROENTEROLOGY, V72, P666
   VANTHIEL DH, 1977, GASTROENTEROLOGY, V72, P842
   YAMATO S, 1992, GASTROENTEROLOGY, V103, P197, DOI 10.1016/0016-5085(92)91113-I
NR 27
TC 23
Z9 28
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1442-2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PY 2003
VL 16
IS 2
BP 77
EP 82
DI 10.1046/j.1442-2050.2003.00303.x
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 691GU
UT WOS:000183598300007
PM 12823202
DA 2020-12-08
ER

PT J
AU Caly, WR
   Strauss, E
   Carrilho, FJ
   Laudanna, AA
AF Caly, Wanda Regina
   Strauss, Edna
   Carrilho, Flair Jose
   Laudanna, Antonio Atlio
TI Different degrees of malnutrition and immunological alterations
   according to the aetiology of cirrhosis: a prospective and sequential
   study
SO NUTRITION JOURNAL
LA English
DT Article
AB Objectives: In this work we investigated how immunological dysfunction and malnutrition interact in alcoholic and viral aetiologies of cirrhosis.
   Methods: To investigate the matter, 77 cirrhotic patients divided in three aetiologies [Alcohol, HCV and Alcohol + HCV) and 32 controls were prospectivelly and sequentially studied. Parameters of humoral immunity (Components 3 and 4 of seric complement and immunoglobulins A M, G and E) and of cellular immunity (total leukocytes and lymphocytes in peripheral blood, T lymphocytes subpopulations, CD4+ and CD8+, CD4+/CD8+ ratio and intradermic tests of delayed hypersensitivity), as well as nutrititional parameters: anthropometric measures, serum albumin and transferrin were evaluated.
   Results: Multiple statistical comparisons showed that IgM was higher in HCV group; IgG was significantly elevated in both HCV and Alcohol + HCV, whereas for the Alcohol group, IgE was found at higher titles. The analysis of T-lymphocytes subpopulations showed no aetiologic differences, but intradermic tests of delayed hypersensitivity did show greater frequency of anergy in the Alcohol group. For anthropometric parameters, the Alcohol + HCV group displayed the lowest triceps skinfold whereas creatinine - height index evaluation was more preserved in the HCV group. Body mass index, arm muscle area and arm fat area showed that differently from alcohol group, the HCV group was similar to control.
   Conclusion: Significant differences were found among the main aetiologies of cirrhosis concerning immunological alterations and nutritional status: better nutrition and worse immunology for HCV and vice-versa for alcohol.
C1 [Caly, Wanda Regina; Strauss, Edna; Carrilho, Flair Jose; Laudanna, Antonio Atlio] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
RP Carrilho, FJ (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
EM wanda.caly@bol.com.br; edna.strauss@hcnet.usp.br;
   fjcarril@netpoint.com.br; laudanna@usp.br
RI Carrilho, Flair J/I-3046-2012
CR AKALIN HE, 1985, Q J MED, V56, P431
   ALLISON MED, 1989, J CLIN LAB IMMUNOL, V30, P127
   Blackburn G L, 1977, JPEN J Parenter Enteral Nutr, V1, P11, DOI 10.1177/014860717700100111
   CAPOCACCIA L, 1994, J HEPATOL, V21, P317
   Caregaro L, 1996, AM J CLIN NUTR, V63, P602
   CATALONA W J, 1972, New England Journal of Medicine, V286, P399, DOI 10.1056/NEJM197202242860804
   CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087
   COUZIGOU P, 1984, GASTROEN CLIN BIOL, V8, P915
   CRAWFORD DHG, 1993, J GASTROEN HEPATOL, V8, P89, DOI 10.1111/j.1440-1746.1993.tb01180.x
   Crawford HG, 1994, GASTROENTEROLOGY, V106, P1611
   FELIX LR, 1987, REV CLIN ESP, V180, P496
   FRANCO D, 1981, GASTROEN CLIN BIOL, V5, P839
   FRISANCHO AR, 1984, AM J CLIN NUTR, V40, P808
   FRISANCHO AR, 1981, AM J CLIN NUTR, V34, P2540
   GARCIATSAO G, 1985, HEPATOLOGY, V5, P419, DOI 10.1002/hep.1840050313
   GIRON JA, 1992, HEPATOLOGY, V16, P664, DOI 10.1002/hep.1840160309
   GLUUD C, 1984, DIGESTION, V30, P1, DOI 10.1159/000199084
   GROSS RL, 1980, PHYSIOL REV, V60, P188
   Heetderks JE, 1996, CHAPMAN HALL SERIES, P30
   LAUTZ HU, 1992, CLIN INVESTIGATOR, V70, P478, DOI 10.1007/BF00210228
   LIEBER CS, 1994, GASTROENTEROLOGY, V106, P1085, DOI 10.1016/0016-5085(94)90772-2
   LIU YK, 1980, SEMIN HEMATOL, V17, P130
   LOGUERCIO C, 1990, BRIT J CLIN PRACT, V44, P98
   LOMBARDO L, 1995, INT J CLIN LAB RES, V25, P153, DOI 10.1007/BF02592558
   MADDEN AM, 1994, J HEPATOL, V21, P878, DOI 10.1016/S0168-8278(94)80253-X
   MAINOUS MR, 1994, SURG CLIN N AM, V74, P659, DOI 10.1016/S0039-6109(16)46335-8
   MENDENHALL CL, 1984, AM J MED, V76, P211, DOI 10.1016/0002-9343(84)90776-9
   MENDENHALL CL, 1992, ALCOHOL HEALTH RES W, V16, P23
   MEZEY E, 1991, SEMIN LIVER DIS, V11, P340, DOI 10.1055/s-2008-1040451
   MEZEY E, 1980, AM J CLIN NUTR, V33, P2709
   MILLS PR, 1983, AM J CLIN NUTR, V38, P849
   Morgan MY, 1996, EUR J NUCL MED, V23, P213, DOI 10.1007/BF01731849
   MULLER C, 1991, SCAND J GASTROENTERO, V26, P295, DOI 10.3109/00365529109025045
   MULLER MJ, 1995, J HEPATOL, V23, P31
   MULLER MJ, 1994, EUR J CLIN CHEM CLIN, V32, P749
   OKEEFE SJ, 1980, LANCET, V2, P615
   PRIJATMOKO D, 1993, GASTROENTEROLOGY, V105, P1839, DOI 10.1016/0016-5085(93)91083-T
   RIMOLA A, 1984, HEPATOLOGY, V4, P53, DOI 10.1002/hep.1840040109
   Rimola A, 1987, MTA MED INTERNA, V5, P161
   Sarin AK, 1997, AM J GASTROENTEROL, V92, P777
   SCRIMSHAW NS, 1959, AM J MED SCI, V237, P367
   Sherlock S, 1997, DIS LIVER BILIARY SY, P371
   SMITH WI, 1980, ALCOHOL CLIN EXP RES, V4, P199, DOI 10.1111/j.1530-0277.1980.tb05635.x
   Sobhonslidsuk Abhasnee, 2001, Journal of the Medical Association of Thailand, V84, P982
   Strauss E, 1993, J HEPATOL, V18, P535
   Thornton PA, 1979, MED CLIN N AM, V63, P103
   VIDAL C, 1994, CLIN EXP ALLERGY, V24, P540, DOI 10.1111/j.1365-2222.1994.tb00951.x
   Wright R, 1973, LANCET, V30, P1494
   Yao ZQ, 2001, J IMMUNOL, V167, P5264, DOI 10.4049/jimmunol.167.9.5264
NR 49
TC 40
Z9 41
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2891
J9 NUTR J
JI Nutr. J.
PY 2003
VL 2
AR 10
DI 10.1186/1475-2891-2-10
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA V40MC
UT WOS:000209481700010
PM 14613508
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Oliveira, CPMS
   Gayotto, LCD
   Tatai, C
   Della Nina, BI
   Lima, ES
   Abdalla, DSP
   Lopasso, FP
   Laurindo, FRM
   Carrilho, FJ
AF Oliveira, Claudia P. M. S.
   da Costa Gayotto, Luiz Carlos
   Tatai, Caroline
   Della Nina, Bianca Ishimoto
   Lima, Emerson S.
   Abdalla, Dulcineia S. P.
   Lopasso, Fabio P.
   Laurindo, Francisco R. M.
   Carrilho, Flair Jose
TI Vitamin C and Vitamin E in Prevention of Nonalcoholic Fatty Liver
   Disease (NAFLD) in Choline Deficient Diet Fed Rats
SO NUTRITION JOURNAL
LA English
DT Article
AB Aim: Oxidative stress has been implicated in the pathogenesis of Nonalcoholic Fatty Liver Disease (NAFLD). Vitamin C and vitamin E are known to react with reactive oxygen species (ROS) blocking the propagation of radical reactions in a wide range of oxidative stress situations. The potential therapeutic efficacy of antioxidants in NAFLD is unknown. The aim of this study was to evaluate the role of antioxidant drugs (vitamin C or vitamin E) in its prevention.
   Methods: Fatty liver disease was induced in Wistar rats by choline-deficient diet for four weeks. The rats were randomly assigned to receive vitamin E (n = 6) - (200 mg/day), vitamin C (n = 6) (30 mg/Kg/day) or vehicle orally.
   Results: In the vehicle and vitamin E-treated rats, there were moderate macro and microvesicular fatty changes in periportal area without inflammatory infiltrate or fibrosis. Scharlach stain that used for a more precise identification of fatty change was strong positive. With vitamin C, there was marked decrease in histological alterations. Essentially, there was no liver steatosis, only hepatocellular ballooning. Scharlach stain was negative. The lucigenin-enhanced luminescence was reduced with vitamin C (1080 +/- 330 cpm/mg/minx10(3)) as compared to those Vitamin E and control (2247 +/- 790; 2020 +/- 407 cpm/mg/minx10(3), respectively) (p < 0.05). Serum levels of aminotransferases were unaltered by vitamin C or vitamin E.
   Conclusions: 1) Vitamin C reduced oxidative stress and markedly inhibited the development of experimental liver steatosis induced by choline-deficient diet; 2) Vitamin E neither prevented the development of fatty liver nor reduced the oxidative stress in this model.
C1 [Oliveira, Claudia P. M. S.; Tatai, Caroline; Della Nina, Bianca Ishimoto; Lopasso, Fabio P.; Carrilho, Flair Jose] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-09500900 Sao Paulo, Brazil.
   [da Costa Gayotto, Luiz Carlos] Univ Sao Paulo, Sch Med, Dept Pathol LIM14, BR-09500900 Sao Paulo, Brazil.
   [Laurindo, Francisco R. M.] Univ Sao Paulo, Sch Med, Departament Heart Inst, BR-09500900 Sao Paulo, Brazil.
   [Lima, Emerson S.; Abdalla, Dulcineia S. P.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-09500900 Sao Paulo, Brazil.
RP Oliveira, CPMS (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-09500900 Sao Paulo, Brazil.
EM mauclaud@uol.com.br; luiz.gayotto@hcnet.usp.br; ctatai@yahoo.com;
   binina@hotmail.com; dspa@usp.br; dspa@usp.br; fabio_lopasso@uol.com.br;
   expfrancisco@incor.usp.br; fjcarril@netpoint.com.br
RI Carrilho, Flair J/I-3046-2012; Oliveira, Claudia PMS/D-1216-2014; Lima,
   Emerson S/L-4553-2016
OI Lima, Emerson S/0000-0002-9367-2812
CR Brandes RP, 1997, J PHYSIOL-LONDON, V500, P331, DOI 10.1113/jphysiol.1997.sp022024
   Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927
   CURZIO M, 1985, INT J TISSUE REACT, V7, P137
   Day CP, 1998, HEPATOLOGY, V27, P1463, DOI 10.1002/hep.510270601
   Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926
   Grattagliano I, 2000, J NUTR, V130, P2131
   Hasegawa T, 2001, ALIMENT PHARM THERAP, V15, P1667, DOI 10.1046/j.1365-2036.2001.01083.x
   Lavine JE, 2000, J PEDIATR-US, V136, P734, DOI 10.1016/S0022-3476(00)05040-X
   LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304
   LEE RG, 1989, HUM PATHOL, V20, P594, DOI 10.1016/0046-8177(89)90249-9
   Letteron P, 1996, J HEPATOL, V24, P200, DOI 10.1016/S0168-8278(96)80030-4
   Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015
   Luyckx FH, 2000, DIABETES METAB, V26, P98
   Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
   Okamoto K, 2002, PREV MED, V34, P364, DOI 10.1006/pmed.2001.0993
   Oliveira CPMS, 2002, J CELL MOL MED, V6, P399, DOI 10.1111/j.1582-4934.2002.tb00518.x
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   TERAMOTO K, 1993, TRANSPLANTATION, V55, P737, DOI 10.1097/00007890-199304000-00010
   Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007
   Wigg AJ, 2001, GUT, V48, P206, DOI 10.1136/gut.48.2.206
   Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829
   Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557
   Zeisel SH, 1994, MODERN NUTR HLTH DIS, P449
NR 23
TC 56
Z9 59
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2891
J9 NUTR J
JI Nutr. J.
PY 2003
VL 2
AR 9
DI 10.1186/1475-2891-2-9
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA V40MC
UT WOS:000209481700009
PM 14613504
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Ono-Nita, SK
   Madruga, CL
   Bassit, L
   Pinho, JRR
   Mello, IMVGC
   Malta, FM
   Yamaguchi, M
   Carrilho, FJ
AF Da Silva, LC
   Ono-Nita, SK
   Madruga, CL
   Bassit, L
   Pinho, JRR
   Mello, IMVGC
   Malta, FM
   Yamaguchi, M
   Carrilho, FJ
TI High resistance to therapy in cirrhotic patients carrying HCV RNA
   genotype 3
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT Workshop on Therapies for Viral Hepatitis
CY OCT 29-31, 2002
CL BOSTON, MASSACHUSETTS
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI de carvalho-Mello, Isabel Maria V G/D-3641-2012; Pinho, Joao R.
   R./G-2850-2012; Ono, Suzane/I-3107-2012; Malta, Fernanda/B-1316-2013;
   Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PD DEC
PY 2002
VL 7
IS 4
MA 70
BP L128
EP L129
PG 2
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 662VP
UT WOS:000181969800083
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Ono-Nita, SK
   Pinho, JRR
   Carrilho, FJ
AF Da Silva, LC
   Ono-Nita, SK
   Pinho, JRR
   Carrilho, FJ
TI Unpredictable outcome in lamivudine P-resistant patients under high
   daily doses and early effects of combined therapy of lamivudine plus
   pegylated interferon
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT Workshop on Therapies for Viral Hepatitis
CY OCT 29-31, 2002
CL BOSTON, MASSACHUSETTS
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Ono, Suzane/I-3107-2012; Carrilho, Flair
   J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PD DEC
PY 2002
VL 7
IS 4
MA 35
BP L104
EP L105
PG 2
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 662VP
UT WOS:000181969800048
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Ono-Nita, SK
   Pinho, JRR
   Medeiros, JE
   Carrilho, FJ
AF Da Silva, LC
   Ono-Nita, SK
   Pinho, JRR
   Medeiros, JE
   Carrilho, FJ
TI Rapid and profound drop of HCV RNA viraemia induced by high dose of
   consensus interferon just before starting pegylated interferon plus
   ribavirin in chronic hepatitis C patients previously resistant to
   combined therapy: preliminary report
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT Workshop on Therapies for Viral Hepatitis
CY OCT 29-31, 2002
CL BOSTON, MASSACHUSETTS
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012; Pinho, Joao R.
   R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PD DEC
PY 2002
VL 7
IS 4
MA 36
BP L105
EP L105
PG 1
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 662VP
UT WOS:000181969800049
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Ono-Nita, SK
   Medeiros, JEM
   Pinho, JRR
   Carrilho, FJ
AF Da Silva, LC
   Ono-Nita, SK
   Medeiros, JEM
   Pinho, JRR
   Carrilho, FJ
TI A twelve-week period of follow-up after an end-of-treatment response in
   patients with chronic hepatitis C submitted to combined therapy is a
   reliable period to characterize a sustained response
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT Workshop on Therapies for Viral Hepatitis
CY OCT 29-31, 2002
CL BOSTON, MASSACHUSETTS
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012; Ono,
   Suzane/I-3107-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PD DEC
PY 2002
VL 7
IS 4
MA 20
BP L92
EP L93
PG 2
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 662VP
UT WOS:000181969800033
DA 2020-12-08
ER

PT J
AU Marques, SB
   Notaroberto, S
   Medeiros, JEM
   Tani, CM
   Marques, JMSB
   Notaroberto, S
   Tani, CM
   Oliveira, JM
   Matielo, CEL
   Goncalves, LL
   Ono-Nita, SK
   Clemente, C
   Carrilho, FJ
AF Marques, SB
   Notaroberto, S
   Medeiros, JEM
   Tani, CM
   Marques, JMSB
   Notaroberto, S
   Tani, CM
   Oliveira, JM
   Matielo, CEL
   Goncalves, LL
   Ono-Nita, SK
   Clemente, C
   Carrilho, FJ
TI High dose amantadine triple therapy is ineffective on treating HCV
   non-responder patients
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT Workshop on Therapies for Viral Hepatitis
CY OCT 29-31, 2002
CL BOSTON, MASSACHUSETTS
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PD DEC
PY 2002
VL 7
IS 4
MA 40
BP L108
EP L108
PG 1
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 662VP
UT WOS:000181969800053
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Carrilho, FJ
   Porta, G
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Carrilho, FJ
   Porta, G
   Kalil, J
   Goldberg, AC
TI Susceptibility to primary sclerosing cholangitis in Brazil is associated
   with HLA-DRB1*13 but not with tumour necrosis factor alpha-308 promoter
   polymorphism
SO GUT
LA English
DT Letter
ID PRIMERS PCR-SSP; AUTOIMMUNE HEPATITIS; DISEASE
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Portuguese Hosp, Salvador, BA, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302A, Salvador, BA, Brazil.
RI Cancado, Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012; KALIL,
   JORGE/C-8029-2012; BITTENCOURT, PAULO l/I-5817-2014; Goldberg, Anna
   Carla/H-8594-2014
OI Cancado, Eduardo/0000-0002-9309-1524; KALIL, JORGE/0000-0001-8415-4274;
   BITTENCOURT, PAULO l/0000-0003-0883-4870; Goldberg, Anna
   Carla/0000-0003-2600-7940
CR Bernal W, 1999, J HEPATOL, V30, P237, DOI 10.1016/S0168-8278(99)80068-3
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bittencourt PL, 2001, J HEPATOL, V35, P24, DOI 10.1016/S0168-8278(01)00072-1
   BUNCE M, 1995, TISSUE ANTIGENS, V45, P81, DOI 10.1111/j.1399-0039.1995.tb02422.x
   CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870
   Czaja AJ, 2001, DIGEST DIS SCI, V46, P140, DOI 10.1023/A:1005670111068
   Donaldson PT, 1998, HEPATOLOGY, V28, p392A
   FARRANT JM, 1992, HEPATOLOGY, V16, P390, DOI 10.1002/hep.1840160217
   MEHAL WZ, 1994, GASTROENTEROLOGY, V106, P160, DOI 10.1016/S0016-5085(94)95085-7
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1995, GASTROENTEROLOGY, V108, P937
   Spurkland A, 1999, TISSUE ANTIGENS, V53, P459, DOI 10.1034/j.1399-0039.1999.530502.x
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
NR 13
TC 13
Z9 14
U1 0
U2 1
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
J9 GUT
JI Gut
PD OCT
PY 2002
VL 51
IS 4
BP 609
EP 610
DI 10.1136/gut.51.4.609
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 597WK
UT WOS:000178243600031
PM 12235090
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Brandao, CE
   Perez-Gomez, R
   Pessoa, MG
   Olivera-Martinez, MA
   Caramori, C
   Bazan-Perez, CV
   Patelli, M
   Torres-Ibarra, R
   Barone, A
   Dehesa-Violante, M
   Carrilho, F
   Vivar, R
   Tatsch, F
AF Brandao, CE
   Perez-Gomez, R
   Pessoa, MG
   Olivera-Martinez, MA
   Caramori, C
   Bazan-Perez, CV
   Patelli, M
   Torres-Ibarra, R
   Barone, A
   Dehesa-Violante, M
   Carrilho, F
   Vivar, R
   Tatsch, F
TI Prospective evaluation of early virological response associated with
   peginterferon alfa-2a (40KD) (Pegasys (R)) and ribavirin from a phase
   IV, randomized study examining the effects of treatment duration-in
   hepatitis C patients infected with genotype 1.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases
   (AASLD)
CY NOV 01-05, 2002
CL BOSTON, MASSACHUSETTS
SP Amer Assoc Study Liver Dis
C1 Graffee & Guinle Hosp, Gaffree, Brazil.
   Civil Hosp Guadalajara, Guadalajara, Jalisco, Mexico.
   Emilio Ribas Infect Dis Hosp, Sao Paulo, Brazil.
   Natl Inst Med Sci & Nutr, Mexico City, DF, Mexico.
   Univ Estadual Paulista Julio Mesquita Filho, Botucatu, SP, Brazil.
   Tijuana Gen Hosp, Tijuana, Mexico.
   PUCAMP, Sao Paulo, Brazil.
   Infect Dis Hosp, Guadalajara, Jalisco, Mexico.
   Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
   Natl Med Ctr, Mexico City, DF, Mexico.
   Roche Mexico, Mexico City, DF, Mexico.
   F Hoffmann La Roche & Co Ltd, Sao Paulo, Brazil.
RI Caramori, Carlos Antonio/A-7949-2008; Carrilho, Flair J/I-3046-2012;
   Barone, Antonio A/C-5531-2013
OI Caramori, Carlos Antonio/0000-0002-0390-1061; Barone, Antonio
   A/0000-0001-9895-3886
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2002
VL 36
IS 4
SU S
MA 805
BP 364A
EP 364A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 598XK
UT WOS:000178301700787
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Analysis of major histocompatibility complex antigens and CTLA-4 alleles
   in patients with primary sclerosing chotangitis.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases
   (AASLD)
CY NOV 01-05, 2002
CL BOSTON, MASSACHUSETTS
SP Amer Assoc Study Liver Dis
C1 Portuguese Hosp Salvador, Salvador, BA, Brazil.
   Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; BITTENCOURT,
   PAULO l/I-5817-2014; Carrilho, Flair J/I-3046-2012; Cancado,
   Eduardo/K-1861-2016
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940; BITTENCOURT, PAULO l/0000-0003-0883-4870;
   Cancado, Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2002
VL 36
IS 4
SU S
MA 1325
BP 494A
EP 494A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 598XK
UT WOS:000178301701306
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Ono-Nita, SK
   Medeiros, JEM
   Pinho, JRR
   Carrilho, FJ
AF Da Silva, LC
   Ono-Nita, SK
   Medeiros, JEM
   Pinho, JRR
   Carrilho, FJ
TI A twelve-week period of follow-up after an end of treatment response
   (ETR) to antiviral therapy in patients with chronic hepatitis C (CH-C)
   is a reliable period to characterize a sustained response.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases
   (AASLD)
CY NOV 01-05, 2002
CL BOSTON, MASSACHUSETTS
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012; Pinho, Joao R.
   R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2002
VL 36
IS 4
SU S
MA 1736
BP 597A
EP 597A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 598XK
UT WOS:000178301701719
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Ono-Nita, SK
   Madruga, CL
   Bassit, L
   Pinho, JRR
   Carrilho, FJ
AF Da Silva, LC
   Ono-Nita, SK
   Madruga, CL
   Bassit, L
   Pinho, JRR
   Carrilho, FJ
TI HCV RNA genotype 3 is frequently found among Brazilian patients with
   liver cirrhosis (LC) unresponsive to combined therapy with interferon
   and ribavirin (IFN plus RB).
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases
   (AASLD)
CY NOV 01-05, 2002
CL BOSTON, MASSACHUSETTS
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Ono, Suzane/I-3107-2012; Pinho, Joao R. R./G-2850-2012; Carrilho, Flair
   J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2002
VL 36
IS 4
SU S
MA 1739
BP 598A
EP 598A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 598XK
UT WOS:000178301701721
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Ono-Nita, SK
   Pinho, JRR
   Carrilho, FJ
AF Da Silva, LC
   Ono-Nita, SK
   Pinho, JRR
   Carrilho, FJ
TI Variable and unpredictable outcome in chronic hepatitis B (CHB) patients
   during and after therapy with high daily doses of lamwudine (LAM)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases
   (AASLD)
CY NOV 01-05, 2002
CL BOSTON, MASSACHUSETTS
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; Ono,
   Suzane/I-3107-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2002
VL 36
IS 4
SU S
MA 1899
BP 638A
EP 638A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 598XK
UT WOS:000178301701881
DA 2020-12-08
ER

PT J
AU Lyra, AC
   Pinho, JR
   Silva, LK
   Braga, EL
   Mello, IM
   Saraceni, CP
   Reis, M
   Pereira, J
   Lyra, MC
   Carrilho, F
   de Silva, LC
AF Lyra, AC
   Pinho, JR
   Silva, LK
   Braga, EL
   Mello, IM
   Saraceni, CP
   Reis, M
   Pereira, J
   Lyra, MC
   Carrilho, F
   de Silva, LC
TI The role of acute hepatitis E, TTV and HGV infection in patients with
   acute viral hepatitis from a sentinel program in Brazil.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases
   (AASLD)
CY NOV 01-05, 2002
CL BOSTON, MASSACHUSETTS
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Sao Paulo, Brazil.
   Univ Fed Bahia, Sao Paulo, Brazil.
   Inst Adolfo Lutz Registro, Sao Paulo, Brazil.
   Fiocruz MS, Salvador, BA, Brazil.
   Univ Fed Bahia, Salvador, BA, Brazil.
   Inst Adolfo Lutz Registro, Sao Paulo, Brazil.
RI de carvalho-Mello, Isabel Maria V G/D-3641-2012; Carrilho, Flair
   J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2002
VL 36
IS 4
SU S
MA 1959
BP 653A
EP 653A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 598XK
UT WOS:000178301701941
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Bassit, L
   Ono-Nita, SK
   Pinho, JRR
   Nishiya, A
   Madruga, CL
   Carrilho, FJ
AF Da Silva, LC
   Bassit, L
   Ono-Nita, SK
   Pinho, JRR
   Nishiya, A
   Madruga, CL
   Carrilho, FJ
TI High rate of sustained response to consensus interferon plus ribavirin
   in chronic hepatitis C patients resistant to alpha-interferon and
   ribavirin: a pilot study
SO JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE consensus-interferon; ribavirin; retreatment; hepatitis C
ID COMBINATION; STANDARD
AB Background. The aim of this study was to evaluate an alternative treatment (consensus interferon plus ribavirin) for chronic hepatitis C patients resistant to combined therapy. Methods. Fourteen patients previously resistant to interferon alpha plus ribavirin were consecutively assigned to receive 15mug of consensus interferon plus ribavirin (1000mg) daily for 4 weeks, and 9-15mug every other day plus daily ribavirin for the following 44 weeks. Alanine aminotransferase and hepatitis C virus (HCV) RNA (Amplicor Monitor; Roche) levels were monitored during therapy and for 24 weeks after its completion. Results. A rapid and marked decrease of HCV RNA viremia of more than 2 logs was observed in 10 (71%) of 14 patients at week 2 of treatment. At the end of therapy, 10 (71%) of 14 patients had undetectable HCV RNA. The end-of-treatment response rates were 6 of 9 (67%) patients for genotype 1 and 4 of 5 (80%) for other genotypes. Sustained response was observed in 4 (36%) of 11 patients who completed 24 weeks of follow-up. Conclusions. A marked and rapid decrease of viral load was observed during therapy with high doses of consensus interferon plus ribavirin in patients previously resistant to combined therapy, even in those infected with genotype 1. Of 11 patients who completed the post-treatment follow-up, 36% presented a sustained response.
C1 Univ Sao Paulo, Sch Med, Inst Trop Med, BR-05508 Sao Paulo, Brazil.
   Sao Paulo Pro Sangue Hemoctr Fdn, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch,Hosp Clin,FMUSP,ICHC, BR-05403000 Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RP Ono-Nita, SK (corresponding author), Univ Sao Paulo, Sch Med, Inst Trop Med, BR-05508 Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Ono, Suzane/I-3107-2012; Carrilho, Flair
   J/I-3046-2012; Nishiya, Anna/Q-8156-2016
OI Pinho, Joao R. R./0000-0003-3999-0489; 
CR Bekkering FC, 1998, J HEPATOL, V28, P960, DOI 10.1016/S0168-8278(98)80343-7
   BERNSTEIN DE, 2000, GASTROENTEROLOGY, V118, P1425
   Brillanti S, 2000, HEPATOLOGY, V32, P630, DOI 10.1053/jhep.2000.16235
   Da Silva LC, 2000, HEPATOLOGY, V32, p566A
   Everson GT, 1999, HEPATOLOGY, V30, P271, DOI 10.1002/hep.510300116
   Heathcote EJL, 1999, HEPATOLOGY, V30, P562, DOI 10.1002/hep.510300202
   Heathcote EJL, 1998, HEPATOLOGY, V27, P1136, DOI 10.1002/hep.510270431
   Kaiser S, 2000, GASTROENTEROLOGY, V118, pA950, DOI 10.1016/S0016-5085(00)85941-7
   MANNS MP, 2001, THERAPY HEPATOLOGY, P251
   McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101
   Ono S K, 1996, Rev Hosp Clin Fac Med Sao Paulo, V51, P180
   Reddy RK, 1999, HEPATOLOGY, V30, p198A
   Schalm SW, 1999, J HEPATOL, V31, P184, DOI 10.1016/S0168-8278(99)80398-5
   Shiffman ML, 2000, AM J GASTROENTEROL, V95, P2928, DOI 10.1111/j.1572-0241.2000.02321.x
   Sjogren MH, 2000, HEPATOLOGY, V32, p352A
   Tong MJ, 1997, HEPATOLOGY, V26, P747, DOI 10.1002/hep.510260330
   Zeuzem S, 2001, GASTROENTEROLOGY, V120, P1438, DOI 10.1053/gast.2001.24006
NR 17
TC 15
Z9 16
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0944-1174
EI 1435-5922
J9 J GASTROENTEROL
JI J. Gastroenterol.
PD SEP
PY 2002
VL 37
IS 9
BP 732
EP 736
DI 10.1007/s005350200119
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 601WH
UT WOS:000178471300008
PM 12375147
DA 2020-12-08
ER

PT J
AU Ono-Nita, SK
   Kato, N
   Shiratori, Y
   Carrilho, FJ
   Omata, M
AF Ono-Nita, SK
   Kato, N
   Shiratori, Y
   Carrilho, FJ
   Omata, M
TI Novel nucleoside analogue MCC-478 (LY582563) is effective against
   wild-type or lamivudine-resistant hepatitis B virus
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ADEFOVIR DIPIVOXIL; INTERFERON TREATMENT; REPLICATION; THERAPY;
   COMBINATION; FAMCICLOVIR; POLYMERASE; MUTATIONS; SELECTION; MUTANTS
AB The emergence of resistant hepatitis B virus (HBV) with the L528M mutation and/or the M552V and M552I mutations in the polymerase gene following long-term lamivudine treatment is becoming an important clinical problem. The aim of this study was to investigate the susceptibility of wild-type and lamivudine-resistant HBV to MCC-478 (LY582563), a novel nucleoside analogue derivative of phosphonomethoxyethyl purine. The susceptibility of wild-type HBV and lamivudine-resistant mutants (M552I, M552V, and L528M/M552V) to MCC-478 was examined by transient transfection of full-length HBV DNA into human hepatoma cells. HBV DNA replication was monitored by Southern blot hybridization, and the effective concentration required to reduce replication by 50% (EC50) was determined. The replicative intermediates of wild-type and lamivudine-resistant mutants were progressively diminished by treatment with increasing doses of MCC-478. The MCC-478 EC(50)s were 0.027 muM for wild-type HBV (about 20 times more efficient than lamivudine), 2.6 muM for M552I,3.3 muM for M552V, and 2.0 muM for L528M/M552V. Wild-type HBV and lamivudine-resistant mutants are susceptible to MCC-478. MCC-478 appears to be a candidate for the treatment of HBV infection and exhibits potent activity against lamivudine-resistant HBV.
C1 Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
RP Kato, N (corresponding author), Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM kato-2im@h.u-tokyo.ac.jp
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012
CR Bartholomew MM, 1997, LANCET, V349, P20, DOI 10.1016/S0140-6736(96)02266-0
   Ben-Ari Z, 1999, TRANSPLANTATION, V68, P232, DOI 10.1097/00007890-199907270-00012
   Bessesen M, 1999, CLIN INFECT DIS, V28, P1032, DOI 10.1086/514750
   Colledge D, 1997, HEPATOLOGY, V26, P216
   Gilson RJC, 1999, J VIRAL HEPATITIS, V6, P387, DOI 10.1046/j.1365-2893.1999.00182.x
   Gordon D, 1998, GASTROENTEROLOGY, V114, P236, DOI 10.1016/S0016-5085(98)70469-X
   GUNTHER S, 1995, J VIROL, V69, P5437
   Honkoop P, 1997, HEPATOLOGY, V26, P211
   Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507
   Kahn J, 1999, JAMA-J AM MED ASSOC, V282, P2305, DOI 10.1001/jama.282.24.2305
   Korba BE, 1996, ANTIVIR RES, V29, P49, DOI 10.1016/0166-3542(95)00915-9
   Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201
   Lau GKKK, 2000, HEPATOLOGY, V32, P394, DOI 10.1053/jhep.2000.9143
   Liaw YF, 1999, HEPATOLOGY, V30, P567, DOI 10.1002/hep.510300221
   Liaw YF, 2000, GASTROENTEROLOGY, V119, P172, DOI 10.1053/gast.2000.8559
   Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347
   Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   Omata M, 1998, NEW ENGL J MED, V339, P114, DOI 10.1056/NEJM199807093390209
   OMATA M, 1985, GASTROENTEROLOGY, V88, P870, DOI 10.1016/S0016-5085(85)80002-0
   Ono SK, 2001, J CLIN INVEST, V107, P449, DOI 10.1172/JCI11100
   Ono-Nita SK, 1999, HEPATOLOGY, V29, P939, DOI 10.1002/hep.510290340
   Ono-Nita SK, 1999, J CLIN INVEST, V103, P1635, DOI 10.1172/JCI5882
   Perrillo R, 2000, HEPATOLOGY, V32, P129, DOI 10.1053/jhep.2000.8626
   Pichoud C, 1999, HEPATOLOGY, V29, P230, DOI 10.1002/hep.510290119
   Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1002/hep.510240340
   TSURIMOTO T, 1987, P NATL ACAD SCI USA, V84, P444, DOI 10.1073/pnas.84.2.444
   WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011
NR 28
TC 28
Z9 35
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2002
VL 46
IS 8
BP 2602
EP 2605
DI 10.1128/AAC.46.8.2602-2605.2002
PG 4
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 575VG
UT WOS:000176968700042
PM 12121939
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Bassit, L
   Van Heuverswyn, H
   De Bosschere, K
   Nishiya, AS
   Carrilho, FJ
   Moraes, CR
   Sablon, E
AF Bassit, L
   Van Heuverswyn, H
   De Bosschere, K
   Nishiya, AS
   Carrilho, FJ
   Moraes, CR
   Sablon, E
TI Comparative study of two anti-HCV screening tests in a large genotyped
   population of Brazilian dialysis patients
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Article
ID HEPATITIS-C VIRUS; HEMODIALYSIS-PATIENTS; PREVALENCE; RISK
C1 Fundacao ProSangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   Flanders Interuniv Inst Biotechnol, Ghent, Belgium.
   Innogenet NV, Zwijnaarde, Belgium.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Bassit, L (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral Hepatitis, 1600 Clifton Rd NE,Mail Stop A-33, Atlanta, GA 30333 USA.
RI Nishiya, Anna/Q-8156-2016; Carrilho, Flair J/I-3046-2012
OI van heuverswyn, hugo/0000-0002-4086-3615
CR Abacioglu YH, 2000, EUR J CLIN MICROBIOL, V19, P182, DOI 10.1007/s100960050456
   Bassit L, 1999, HEPATOLOGY, V29, P994, DOI 10.1002/hep.510290313
   Carneiro MAS, 2001, MEM I OSWALDO CRUZ, V96, P765, DOI 10.1590/S0074-02762001000600003
   Dhaliwal SK, 1996, J MED VIROL, V48, P184
   Dou XG, 2002, J CLIN MICROBIOL, V40, P61, DOI 10.1128/JCM.40.1.61-67.2002
   Espinosa M, 2001, NEPHROL DIAL TRANSPL, V16, P1669, DOI 10.1093/ndt/16.8.1669
   KHUDYAKOV YE, 2001, 8 INT S HEP C VIR RE
   Krug LP, 1996, BRAZ J MED BIOL RES, V29, P1629
   Mison LM, 1997, TRANSFUSION, V37, P73, DOI 10.1046/j.1537-2995.1997.37197176954.x
   Natov SN, 2000, SEMIN DIALYSIS, V13, P393, DOI 10.1046/j.1525-139x.2000.00108.x
   Roth WK, 2001, TRANSFUS CLIN BIOL, V8, P282, DOI 10.1016/S1246-7820(01)00115-X
   Schneeberger PM, 1998, J CLIN MICROBIOL, V36, P1711, DOI 10.1128/JCM.36.6.1711-1715.1998
NR 12
TC 6
Z9 6
U1 0
U2 3
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0934-9723
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
PD MAY
PY 2002
VL 21
IS 5
BP 404
EP 406
DI 10.1007/s10096-002-0734-0
PG 3
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 568WD
UT WOS:000176567100012
PM 12072929
DA 2020-12-08
ER

PT J
AU Medeiros, JEM
   Neumann, AU
   Pinho, JRR
   Mello, IM
   Da Silva, LC
   Laudanna, AA
   Carrilho, FJ
AF Medeiros, JEM
   Neumann, AU
   Pinho, JRR
   Mello, IM
   Da Silva, LC
   Laudanna, AA
   Carrilho, FJ
TI Longitudinal changes on treatment schedules for hepatitis C virus:
   Effect of ribavirin addition in early kinetics
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
RI de carvalho-Mello, Isabel Maria V G/D-3641-2012; Pinho, Joao R.
   R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2002
VL 122
IS 4
SU 1
MA M1608
BP A679
EP A679
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 548AW
UT WOS:000175366603458
DA 2020-12-08
ER

PT J
AU Medeiros, JEM
   Pinho, JRR
   Neumann, AU
   Mello, IM
   Lemos, MF
   Da Silva, LC
   Laudanna, AA
   Carrilho, FJ
AF Medeiros, JEM
   Pinho, JRR
   Neumann, AU
   Mello, IM
   Lemos, MF
   Da Silva, LC
   Laudanna, AA
   Carrilho, FJ
TI Viral kinetics of hepatitis C virus (HCV) genotype 3 is faster than
   genotype 1 HCV: Effect of different treatment schedules
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
RI de carvalho-Mello, Isabel Maria V G/D-3641-2012; Pinho, Joao R.
   R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2002
VL 122
IS 4
SU 1
MA M1606
BP A679
EP A679
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 548AW
UT WOS:000175366603456
DA 2020-12-08
ER

PT J
AU Farias, A
   Goncalves, L
   Seguro, AC
   Campos, SB
   Assuncao, S
   Abrantes-Lemos, C
   Porta, G
   Carrilho, F
   Bittencourt, P
   Miura, I
   Laudanna, A
   Cancado, E
AF Farias, A
   Goncalves, L
   Seguro, AC
   Campos, SB
   Assuncao, S
   Abrantes-Lemos, C
   Porta, G
   Carrilho, F
   Bittencourt, P
   Miura, I
   Laudanna, A
   Cancado, E
TI Risk factors for distal renal tubular acidosis in chronic liver diseases
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Nephrol, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, BR-05508 Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; BITTENCOURT, PAULO l/I-5817-2014;
   Cancado, Eduardo/K-1861-2016
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; Cancado,
   Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2002
VL 36
SU 1
MA 144
BP 46
EP 46
DI 10.1016/S0168-8278(02)80143-X
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 553YG
UT WOS:000175704700144
DA 2020-12-08
ER

PT J
AU de Mello, E
   Alves, V
   Carrilho, F
   Vezozzo, D
   Gayotto, L
AF de Mello, E
   Alves, V
   Carrilho, F
   Vezozzo, D
   Gayotto, L
TI Macronodules in cirrhotic liver: Proliferation and apoptosis
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Hosp Clin, Div Anat Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2002
VL 36
SU 1
MA 764
BP 214
EP 214
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 553YG
UT WOS:000175704700761
DA 2020-12-08
ER

PT J
AU de Mello, E
   Alves, V
   Carrilho, F
   Vezozzo, D
   Gayotto, L
AF de Mello, E
   Alves, V
   Carrilho, F
   Vezozzo, D
   Gayotto, L
TI Macronodules in cirrhotic liver: Morphological findings with emphasis in
   gross features
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Hosp Clin, Div Anat Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2002
VL 36
SU 1
MA 763
BP 214
EP 214
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 553YG
UT WOS:000175704700760
DA 2020-12-08
ER

PT J
AU Clemente, CM
   Carrilho, FJ
   Ono-Nita, SK
   Lemos, MF
   Mello, IMVGC
   Pinho, JRR
   Laudanna, AA
AF Clemente, CM
   Carrilho, FJ
   Ono-Nita, SK
   Lemos, MF
   Mello, IMVGC
   Pinho, JRR
   Laudanna, AA
TI Study of hepatitis B virus (HBV) genotypes in families of patients with
   chronic HBV infection: Comparison of Asian and ocidental origin people
   in Brazil
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Virol Branch, Sao Paulo, Brazil.
RI Ono, Suzane/I-3107-2012; Pinho, Joao R. R./G-2850-2012; Carrilho, Flair
   J/I-3046-2012; de carvalho-Mello, Isabel Maria V G/D-3641-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2002
VL 36
SU 1
MA 791
BP 221
EP 222
DI 10.1016/S0168-8278(02)80792-9
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 553YG
UT WOS:000175704700788
DA 2020-12-08
ER

PT J
AU Medeiros, JEM
   Neumann, AU
   Pinho, JRR
   Mello, IMVGC
   Lemos, MF
   Da Silva, LC
   Laudann, AA
   Carrilho, FJ
AF Medeiros, JEM
   Neumann, AU
   Pinho, JRR
   Mello, IMVGC
   Lemos, MF
   Da Silva, LC
   Laudann, AA
   Carrilho, FJ
TI Longitudinal analysis of changes in early HCV kinetics following the
   addition of ribavirin to IFN monotherapy
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Virol Branch, Sao Paulo, Brazil.
   Bar Ilan Univ, Fac Life Sci, IL-52100 Ramat Gan, Israel.
RI de carvalho-Mello, Isabel Maria V G/D-3641-2012; Carrilho, Flair
   J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2002
VL 36
SU 1
MA 803
BP 224
EP 224
DI 10.1016/S0168-8278(02)80804-2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 553YG
UT WOS:000175704700800
DA 2020-12-08
ER

PT J
AU Medeiros, JEM
   Pinho, JRR
   Neumann, AU
   Mello, IMVGC
   Lemos, MF
   Da Silva, LC
   Laudanna, AA
   Carrilho, FJ
AF Medeiros, JEM
   Pinho, JRR
   Neumann, AU
   Mello, IMVGC
   Lemos, MF
   Da Silva, LC
   Laudanna, AA
   Carrilho, FJ
TI Early viral kinetics of hepatitis C virus (HCV) genotype 3 with very
   frequent sampling analysis
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, BR-05508 Sao Paulo, Brazil.
   Adolfo Lutz Inst, Virol Branch, Sao Paulo, Brazil.
   Bar Ilan Univ, Fac Life Sci, IL-52100 Ramat Gan, Israel.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; de
   carvalho-Mello, Isabel Maria V G/D-3641-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2002
VL 36
SU 1
MA 804
BP 225
EP 225
DI 10.1016/S0168-8278(02)80805-4
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 553YG
UT WOS:000175704700801
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Ono-Nita, SK
   Carrilho, FJ
   Medeiros, JEM
   Pinho, JRR
AF Da Silva, LC
   Ono-Nita, SK
   Carrilho, FJ
   Medeiros, JEM
   Pinho, JRR
TI Early clearance kinetics of hepatitis C virus (HCV) in patients with
   chronic hepatitis C under therapy with pegylated-interferon (Peg-IFN)
   alpha-2b or consensus-interferon (CIFN) plus ribavirin
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Hepatol Branch, BR-05508 Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012; Ono,
   Suzane/I-3107-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2002
VL 36
SU 1
MA 867
BP 241
EP 241
DI 10.1016/S0168-8278(02)80868-6
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 553YG
UT WOS:000175704700864
DA 2020-12-08
ER

PT J
AU Bittencourt, P
   Palacios, S
   Cancado, E
   Porta, G
   Carrilho, F
   Laudanna, A
   Kalil, J
   Goldberg, AC
AF Bittencourt, P
   Palacios, S
   Cancado, E
   Porta, G
   Carrilho, F
   Laudanna, A
   Kalil, J
   Goldberg, AC
TI Lack of association of CTLA-4 polymorphisms with autoimmune hepatitis
   types 1 and 2 in Brazilian patients
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; BITTENCOURT, PAULO l/I-5817-2014; KALIL,
   JORGE/C-8029-2012; Cancado, Eduardo/K-1861-2016; Goldberg, Anna
   Carla/H-8594-2014
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; KALIL,
   JORGE/0000-0001-8415-4274; Cancado, Eduardo/0000-0002-9309-1524;
   Goldberg, Anna Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2002
VL 36
SU 1
MA 943
BP 261
EP 262
DI 10.1016/S0168-8278(02)80944-8
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 553YG
UT WOS:000175704700940
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Couto, CA
   Cancado, ELR
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Gayotto, LCC
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Couto, CA
   Cancado, ELR
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Gayotto, LCC
   Goldberg, AC
TI Analysis of HLA-A antigens and C282Y and H63D mutations of the HFE gene
   in Brazilian patients with hemochromatosis
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hemochromatosis; HFE mutations; iron overload; HLA-A3 mutation; C282Y
   mutation; H63D mutation; chromosome 6
ID HEREDITARY HEMOCHROMATOSIS; JUVENILE HEMOCHROMATOSIS; CANDIDATE GENE;
   IRON OVERLOAD; POPULATION; EXPRESSION; FAMILIES; PREVALENCE; PROBANDS;
   DISEASE
AB The hemochromatosis gene, HFE, is located on chromosome 6 in close proximity to the HLA-A locus. Most Caucasian patients with hereditary hemochromatosis (HH) are homozygous for HLA-A3 and for the C282Y mutation of the HFE gene, while a minority are compound heterozygotes for C282Y and H63D. The prevalence of these mutations in non-Caucasian patients with HH is lower than expected. The objective of the present study was to evaluate the frequencies of HLA-A antigens and the C282Y and H63D mutations of the 14FE gene in Brazilian patients with HH and to compare clinical and laboratory profiles of C282Y-positive and -negative patients with HH. The frequencies of HLA-A and C282Y and H63D mutations were determined by PCR-based methods in 15 male patients (median age 44 (20-72) years) with HH. Eight patients (53%) were homozygous and one (7%) was heterozygous for the C282Y mutation. None had compound heterozygosity for C282Y and H63D mutations. All but three C282Y homozygotes were positive for HLA-A3 and three other patients without C282Y were shown to be either heterozygous (N = 2) or homozygous (N = 1) for HLA-A3. Patients homozygous for the C282Y mutation had higher ferritin levels and lower age at onset, but the difference was not significant. The presence of C282Y homozygosity in roughly half of the Brazilian patients with HH, together with the findings of HLA-A homozygosity in C282Y-negative subjects, suggest that other mutations in the HFE gene or in other genes involved in iron homeostasis might also be linked to HH in Brazil.
C1 Hosp Portugues Salvador, Salvador, BA, Brazil.
   Hosp Portugues Salvador, Salvador, BA, Brazil.
   Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Coracao, Lab Imunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Anat Patol, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302A, BR-4190040 Salvador, BA, Brazil.
RI Cancado, Eduardo/K-1861-2016; Couto, Claudia Alves/H-7420-2013; KALIL,
   JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; BITTENCOURT, PAULO
   l/I-5817-2014; Carrilho, Flair J/I-3046-2012
OI Cancado, Eduardo/0000-0002-9309-1524; Couto, Claudia
   Alves/0000-0002-9776-4757; KALIL, JORGE/0000-0001-8415-4274; Goldberg,
   Anna Carla/0000-0003-2600-7940; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; 
CR Adams PC, 1997, HEPATOLOGY, V26, P986, DOI 10.1002/hep.510260428
   Agostinho MF, 1999, BLOOD CELL MOL DIS, V25, P324, DOI 10.1006/bcmd.1999.0260
   Alves-Silva J, 2000, AM J HUM GENET, V67, P444, DOI 10.1086/303004
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Bacon BR, 2001, GASTROENTEROLOGY, V120, P718, DOI 10.1053/gast.2001.21913
   Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1
   BART BY, 1993, TERAPEVT ARKH, V65, P25
   Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129
   Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027
   Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211
   Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172
   Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534
   Camaschella C, 1999, HEPATOLOGY, V29, P1563, DOI 10.1002/hep.510290509
   Carella M, 1997, AM J HUM GENET, V60, P828
   Carvalho-Silva DR, 2001, AM J HUM GENET, V68, P281, DOI 10.1086/316931
   Datz C, 1997, J HEPATOL, V27, P773, DOI 10.1016/S0168-8278(97)80312-1
   FARIAS AQ, 2000, DOENCAS FIGADO VIAS
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025
   Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143
   GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249
   Jouanolle AM, 1997, HUM GENET, V100, P544, DOI 10.1007/s004390050549
   Kelly AL, 1998, QJM-INT J MED, V91, P607, DOI 10.1093/qjmed/91.9.607
   Marshall DS, 1999, INT J MOL MED, V4, P389
   McNamara L, 1998, BRIT J HAEMATOL, V102, P1176
   MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275
   Monaghan KG, 1998, AM J HEMATOL, V58, P213, DOI 10.1002/(SICI)1096-8652(199807)58:3<213::AID-AJH9>3.0.CO;2-U
   Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505
   Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534
   Pereira AC, 2001, HUM BIOL, V73, P145, DOI 10.1353/hub.2001.0009
   Piperno A, 1998, GASTROENTEROLOGY, V114, P996, DOI 10.1016/S0016-5085(98)70319-1
   Rivard SR, 2000, BLOOD CELL MOL DIS, V26, P10, DOI 10.1006/bcmd.2000.0271
   Robson KJH, 1997, GUT, V41, P841
   Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379
   Salter-Cid L, 1999, P NATL ACAD SCI USA, V96, P5434, DOI 10.1073/pnas.96.10.5434
   SIMON M, 1987, AM J HUM GENET, V41, P89
   SIMON M, 1977, CLIN GENET, V11, P327
   Wallace DF, 1999, GASTROENTEROLOGY, V116, P1409, DOI 10.1016/S0016-5085(99)70505-6
NR 40
TC 8
Z9 16
U1 0
U2 2
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD MAR
PY 2002
VL 35
IS 3
BP 329
EP 335
DI 10.1590/S0100-879X2002000300007
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 536GQ
UT WOS:000174692700007
PM 11887210
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Figueiredo, LC
   Carrilho, FJ
   de Andrade, HF
   Migliari, DA
AF Figueiredo, LC
   Carrilho, FJ
   de Andrade, HF
   Migliari, DA
TI Oral lichen planus and hepatitis C virus infection
SO ORAL DISEASES
LA English
DT Article
DE lichen planus; oral; liver disease; hepatitis C infection
ID LIVER-DISEASE; HCV INFECTION; ITALIAN PATIENTS; ASSOCIATION; RNA
AB OBJECTIVE: This investigation was conducted to determine the possible association between oral lichen planus (OLP) and hepatitis C virus infection (HCV) In the population of Sao Paulo (Brazil).
   MATERIALS AND METHODS: Three groups of patients were studied: group 1 was composed of 68 patients with OLP lesions; group 2 had 126 patients with HCV infection; and the control group consisted of 898 individuals seeking dental treatment at our school, used to determine the prevalence of lichen planus in the general population. The prevalence of HCV in group 1 was determined and compared with that of the population of Sao Paulo (Focaccia et al (1998) Brazilian J Infec Dis 2: 269), while the prevalence of OLP in group 2 was determined and compared with that of the control group.
   RESULTS: The results showed that the frequency of HCV in OLP patients was 8.8%, significantly higher than in the general population of Sao Paulo, which is 1.4% (P = 0.002), and the frequency of OLP in HCV patients (4.7%) was also significantly higher (P = 0.0003) than that of the control group (0.6%).
   dCONCLUSION: These data suggest that, at least in Sao Paulo, there is an association between OLP and HCV infection.
C1 Univ Sao Paulo, Dept Oral Diagnosis, Sch Dent, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Clin Hepatol Branch, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Dermatol & Trop Dis, Sao Paulo, Brazil.
RP Migliari, DA (corresponding author), Univ Sao Paulo, Fac Odontol, Dept Estomatol Disciplina Semiol, Prof Lineu Prestes 2227,Cidade Univ, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; de Andrade Junior, Heitor
   Franco/AAP-4689-2020; de Andrade Junior, Heitor Franco/F-7082-2012
OI de Andrade Junior, Heitor Franco/0000-0003-4697-4647; de Andrade Junior,
   Heitor Franco/0000-0003-4697-4647
CR Arrieta JJ, 2000, HEPATOLOGY, V32, P97, DOI 10.1053/jhep.2000.8533
   AYALA F, 1986, J AM ACAD DERMATOL, V14, P139, DOI 10.1016/S0190-9622(86)80397-8
   Bagan JV, 1998, ORAL SURG ORAL MED O, V85, P532, DOI 10.1016/S1079-2104(98)90286-4
   BELLMAN B, 1995, LANCET, V346, P1234, DOI 10.1016/S0140-6736(95)92945-2
   CAINELLI T, 1990, BRIT MED J, V300, P227
   Carrozzo M, 1996, J ORAL PATHOL MED, V25, P527, DOI 10.1111/j.1600-0714.1996.tb01726.x
   Carrozzo M, 2001, BRIT J DERMATOL, V144, P803, DOI 10.1046/j.1365-2133.2001.04136.x
   CRIBIER B, 1994, J AM ACAD DERMATOL, V31, P1070, DOI 10.1016/S0190-9622(09)80092-3
   ELKABIR M, 1993, CLIN EXP DERMATOL, V18, P12, DOI 10.1111/j.1365-2230.1993.tb00957.x
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   GANDOLFO S, 1994, J ORAL PATHOL MED, V23, P119, DOI 10.1111/j.1600-0714.1994.tb01098.x
   IMHOF M, 1996, DERMATOLOGY, V195, P1
   Ingafou M, 1998, INT J ORAL MAX SURG, V27, P65, DOI 10.1016/S0901-5027(98)80101-X
   Lodi G, 2000, J ORAL PATHOL MED, V29, P39, DOI 10.1034/j.1600-0714.2000.290107.x
   Lodi G, 1997, J ORAL PATHOL MED, V26, P381, DOI 10.1111/j.1600-0714.1997.tb00235.x
   Mignogna MD, 1998, INT J DERMATOL, V37, P575, DOI 10.1046/j.1365-4362.1998.00510.x
   Nagao Y, 1996, EUR J CLIN INVEST, V26, P495, DOI 10.1046/j.1365-2362.1996.167314.x
   Nagao Y, 1995, EUR J CLIN INVEST, V25, P910, DOI 10.1111/j.1365-2362.1995.tb01966.x
   Nagao Y, 2000, J ORAL PATHOL MED, V29, P259, DOI 10.1034/j.1600-0714.2000.290604.x
   REBORA A, 1984, J AM ACAD DERMATOL, V10, P840, DOI 10.1016/S0190-9622(84)80140-1
   Roy KM, 1999, ORAL DIS, V5, P270
   SanchezPerez J, 1996, BRIT J DERMATOL, V134, P715, DOI 10.1111/j.1365-2133.1996.tb06977.x
   Scully C, 1998, CRIT REV ORAL BIOL M, V9, P86, DOI 10.1177/10454411980090010501
   SCULLY C, 1985, J ORAL PATHOL MED, V14, P224, DOI 10.1111/j.1600-0714.1985.tb00485.x
   van der Meij EH, 2000, J ORAL PATHOL MED, V29, P255
   *WHO COLL CTR OR P, 1978, ORAL SURG ORAL MED O, V46, P518
NR 26
TC 46
Z9 48
U1 0
U2 4
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1354-523X
J9 ORAL DIS
JI Oral Dis.
PD JAN
PY 2002
VL 8
IS 1
BP 42
EP 46
DI 10.1034/j.1601-0825.2002.10763.x
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 533XT
UT WOS:000174556100007
PM 11939174
DA 2020-12-08
ER

PT J
AU Goldberg, AC
   Palacios, SA
   Bittencourt, PL
   Cancado, ELR
   Carrilho, FJ
   Kalil, J
AF Goldberg, AC
   Palacios, SA
   Bittencourt, PL
   Cancado, ELR
   Carrilho, FJ
   Kalil, J
TI A study of 19 hemochromatosis (HH) patients in Sao Paulo, Brazil
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Millenium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
RI Cancado, Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014;
   Carrilho, Flair J/I-3046-2012; Goldberg, Anna Carla/H-8594-2014; KALIL,
   JORGE/C-8029-2012
OI Cancado, Eduardo/0000-0002-9309-1524; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PY 2002
VL 59
SU 2
BP 109
EP 109
PG 1
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 564JM
UT WOS:000176311300355
DA 2020-12-08
ER

PT J
AU Cancado, ELR
   Abrantes-Lemos, CP
   Vilas-Boas, LS
   Novo, NF
   Carrilho, FJ
   Laudanna, AA
AF Cancado, ELR
   Abrantes-Lemos, CP
   Vilas-Boas, LS
   Novo, NF
   Carrilho, FJ
   Laudanna, AA
TI Thermolabile and calcium-dependent serum factor interferes with
   polymerized actin, and impairs anti-actin antibody detection
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE anti-smooth antibody; autoantibodies; autoimmune hepatitis;
   microfilaments; gelsolin
ID GEL-SOL TRANSFORMATION; ANTIACTIN ANTIBODY; REGULATORY PROTEIN;
   GELSOLIN; HEPATITIS; FILAMENTS; PLASMA; IDENTIFICATION; AUTOANTIBODY;
   PHALLOTOXIN
AB The detection of anti-actin (AAA) by immunofluorescence is hindered by the presence of a serum factor. To better understand how it interferes with AAA detection, we tested sera from 20 patients with autoimmune hepatitis, and from 21 healthy adults, diluted 1:10 and prepared as follows: (A) diluted with PBS; (B) inactivated at 56 degreesC, and diluted with PBS; (C) diluted with 34 mM EDTA/PBS; (D) heated and diluted with EDTA/PBS. To reveal AAA, a fluorescein-labelled anti-human IgG was used in the process of indirect immunofluorescence. In a parallel assay, the substrate, acetone-fixed human fibroblasts, was preincubated with-sera prepared as if it were to identify AAA, but instead, a rhodamine-phalloidin was used to identify F-actin, by direct immunofluorescence. All sera from patients were reactive to AAA when heat-inactivated and/or calcium-chelated, and 60% of them when diluted with unmodified sera (P = 0.004). F-actin continued to be present after preincubation with heat-inactivated or calcium-chelated sera from patients and healthy controls, and in 41.5% of reactions with unmodified serum (P = 0.0000001). The heat inactivation and the calcium chelation were both efficient procedures for maintaining the microfilament structure intact after serum incubation and, therefore, for identifying AAA. (C) 2001 Academic Press.
C1 Univ Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Trop Med, Sch Med, Lab Med Invest Immunopathol Schistosomiasis, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Trop Med, Sch Med, Lab Med Invest Virol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
RP Cancado, ELR (corresponding author), Inst Trop Med, Rua Dr Eneas Carvalho Aguiar 500,2 Andar, BR-05403000 Cerqueira Cesar, SP, Brazil.
RI Carrilho, Flair J/I-3046-2012; Novo, Neil/AAP-8238-2020; Cancado,
   Eduardo/K-1861-2016
OI Cancado, Eduardo/0000-0002-9309-1524
CR Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   BOTTAZZO GF, 1976, J CLIN PATHOL, V29, P403, DOI 10.1136/jcp.29.5.403
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   CHAPONNIER C, 1979, EXPERIENTIA, V35, P1039, DOI 10.1007/BF01949928
   FAGRAEUS A, 1983, ANN NY ACAD SCI, V420, P297, DOI 10.1111/j.1749-6632.1983.tb22215.x
   FAGRAEUS A, 1975, CLIN EXP IMMUNOL, V20, P469
   GABBIANI G, 1973, AM J PATHOL, V72, P473
   GALBRAITH RM, 1976, LANCET, V1, P930
   GONSIOR S, 1995, CELL MOTIL CYTOSKEL, V31, P196, DOI 10.1002/cm.970310303
   HARRIS DA, 1981, P NATL ACAD SCI-BIOL, V78, P6798, DOI 10.1073/pnas.78.11.6798
   HUANG ZJ, 1992, ANAL BIOCHEM, V200, P199, DOI 10.1016/0003-2697(92)90299-M
   ITO H, 1992, GASTROENTEROLOGY, V102, P1686, DOI 10.1016/0016-5085(92)91731-I
   JANMEY PA, 1987, BLOOD, V70, P524
   LEE WM, 1992, NEW ENGL J MED, V326, P1335
   LIDMAN K, 1976, CLIN EXP IMMUNOL, V24, P266
   LIND SE, 1988, AM REV RESPIR DIS, V138, P429, DOI 10.1164/ajrccm/138.2.429
   *MOL PROB EUR BV, 1995, PHALL REV PROT, P1
   NISHIOKA M, 1986, MICROBIOL IMMUNOL, V30, P1291, DOI 10.1111/j.1348-0421.1986.tb03061.x
   NODES BR, 1987, J BIOL CHEM, V262, P5422
   NORBERG R, 1979, EUR J BIOCHEM, V100, P575, DOI 10.1111/j.1432-1033.1979.tb04204.x
   SANGER JM, 1987, EUR J CELL BIOL, V43, P421
   SENECAL JL, 1987, J CLIN INVEST, V80, P778, DOI 10.1172/JCI113134
   SHARON N, 1976, AM J CLIN PATHOL, V66, P65, DOI 10.1093/ajcp/66.1.65
   WOODRUFF T, 1994, J RHEUMATOL, V21, P197
   WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498
   YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0
   YIN HL, 1981, J CELL BIOL, V91, P901, DOI 10.1083/jcb.91.3.901
NR 27
TC 17
Z9 20
U1 0
U2 1
PU ACADEMIC PRESS LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
J9 J AUTOIMMUN
JI J. Autoimmun.
PD NOV
PY 2001
VL 17
IS 3
BP 223
EP 228
DI 10.1006/jaut.2001.0540
PG 6
WC Immunology
SC Immunology
GA 496ZC
UT WOS:000172427400007
PM 11712860
DA 2020-12-08
ER

PT J
AU Medeiros, JEM
   Neumann, AU
   Mello, IM
   Levy-Drummer, RS
   Da Silva, LC
   Pinho, JRR
   Carrilho, FJ
AF Medeiros, JEM
   Neumann, AU
   Mello, IM
   Levy-Drummer, RS
   Da Silva, LC
   Pinho, JRR
   Carrilho, FJ
TI Early and rapid growth of Hepatitis C virus in relapsers but not in
   sustained responders revealed by very frequent sampling during followup.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Bar Ilan Univ, Ramat Gan, Israel.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; de
   carvalho-Mello, Isabel Maria V G/D-3641-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 172
BP 216A
EP 216A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224700172
DA 2020-12-08
ER

PT J
AU Medeiros, JE
   Mello, IM
   Pinho, JR
   Anjos, LC
   Carrilho, FJ
AF Medeiros, JE
   Mello, IM
   Pinho, JR
   Anjos, LC
   Carrilho, FJ
TI Evidence of intrafamilial transmission of hepatitis C virus: Analysis of
   relatives and spouses of hepatitis C virus patients.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; de carvalho-Mello, Isabel Maria V
   G/D-3641-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 227
BP 230A
EP 230A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224700226
DA 2020-12-08
ER

PT J
AU Medeiros, JE
   Goncalves, LL
   Cancado, EL
   Guardia, BD
   Farias, AQ
   Anjos, LC
   Abrantes-Lemos, C
   Carrilho, FJ
AF Medeiros, JE
   Goncalves, LL
   Cancado, EL
   Guardia, BD
   Farias, AQ
   Anjos, LC
   Abrantes-Lemos, C
   Carrilho, FJ
TI Serological behaviour of anti-liver kidney microsome, antimitochondrial,
   anti-smooth muscle/antiactin antibodies before and after treatment for
   chronic hepatitis B and C.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016
OI Cancado, Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 1254
BP 485A
EP 485A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224701245
DA 2020-12-08
ER

PT J
AU Medeiros, JE
   Neumann, AU
   Carrilho, FJ
   Mello, IM
   Pinho, JR
   Gatura, S
   Moreira, R
   Silva, LC
   Parise, AS
   Nascimento, AS
   Lemos, MF
AF Medeiros, JE
   Neumann, AU
   Carrilho, FJ
   Mello, IM
   Pinho, JR
   Gatura, S
   Moreira, R
   Silva, LC
   Parise, AS
   Nascimento, AS
   Lemos, MF
TI Interferon efficacy on blocking virus production and/or virus releasing
   is variable according to virus genotype and is independent of ribavirin.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Bar Ilan Univ, Ramat Gan, Israel.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; de
   carvalho-Mello, Isabel Maria V G/D-3641-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 1559
BP 562A
EP 562A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224701550
DA 2020-12-08
ER

PT J
AU De Moraes, CR
   Carrilho, FJ
   Bassit, L
   Pinho, JRR
   Moreira, R
   Mello, IM
   Cardoso, RA
   Da Silva, LC
   Laudanna, AA
AF De Moraes, CR
   Carrilho, FJ
   Bassit, L
   Pinho, JRR
   Moreira, R
   Mello, IM
   Cardoso, RA
   Da Silva, LC
   Laudanna, AA
TI Hepatitis C virus infection in hemodialysis centers from Santa Catarina
   State, southern Brazil. Predictive risk factors for infection and
   molecular epidemiology.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Moreira, Regina C/B-1488-2016; de carvalho-Mello, Isabel Maria V
   G/D-3641-2012; Carrilho, Flair J/I-3046-2012; Pinho, Joao R.
   R./G-2850-2012
OI Moreira, Regina C/0000-0002-8208-8776; Pinho, Joao R.
   R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 1576
BP 566A
EP 566A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224701568
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Bassit, LC
   Ono-Nita, SK
   Nishiya, A
   Madruga, CL
   Carrilho, FJ
AF Da Silva, LC
   Bassit, LC
   Ono-Nita, SK
   Nishiya, A
   Madruga, CL
   Carrilho, FJ
TI High rate of sustained response after consensus interferon (CIFN) plus
   ribavirin (RB) in chronic hepatitis C patients previously resistant to
   combined therapy (IFN plus RB).
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Ono, Suzane/I-3107-2012; Nishiya, Anna/Q-8156-2016; Carrilho, Flair
   J/I-3046-2012
NR 0
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 1658
BP 586A
EP 586A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224701649
DA 2020-12-08
ER

PT J
AU Medeiros, JE
   Neumann, AU
   Mello, IM
   Pinho, JR
   Silva, LC
   Carrilho, FJ
AF Medeiros, JE
   Neumann, AU
   Mello, IM
   Pinho, JR
   Silva, LC
   Carrilho, FJ
TI Hepatitis C viral load is constant in patients without antiviral
   treatment.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Bar Ilan Univ, Ramat Gan, Israel.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012; de
   carvalho-Mello, Isabel Maria V G/D-3641-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 1660
BP 587A
EP 587A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224701652
DA 2020-12-08
ER

PT J
AU Silva, LC
   Medeiros, JE
   Pinho, JR
   Carrilho, FJ
AF Silva, LC
   Medeiros, JE
   Pinho, JR
   Carrilho, FJ
TI Treatment of naive chronic hepatitis C patients with induction therapy
   of interferon plus ribavirin shows similar results to those found with
   pegylated interferons plus ribavirin therapy.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 1662
BP 587A
EP 587A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224701653
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Bassit, LC
   Ono-Nita, SK
   Pinho, JR
   Carrilho, FJ
AF Da Silva, LC
   Bassit, LC
   Ono-Nita, SK
   Pinho, JR
   Carrilho, FJ
TI HCV genotype 3a: High degree of resistance to antiviral therapy in
   chronic hepatitis C patients non responding to previous combined therapy
   with interferon (IFN) plus ribavirin (RB).
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Ono, Suzane/I-3107-2012; Carrilho, Flair J/I-3046-2012; Pinho, Joao R.
   R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 1732
BP 605A
EP 605A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224701724
DA 2020-12-08
ER

PT J
AU Carrilho, FJ
   De Moraes, CR
   Pinho, JRR
   Moreira, R
   Bertolini, D
   Mello, IM
   Gatura, S
   Bassit, L
   Cardoso, RA
   Da Silva, LC
   Laudanna, AA
AF Carrilho, FJ
   De Moraes, CR
   Pinho, JRR
   Moreira, R
   Bertolini, D
   Mello, IM
   Gatura, S
   Bassit, L
   Cardoso, RA
   Da Silva, LC
   Laudanna, AA
TI Hepatitis B virus infection in hemodialysis centers from Santa Catarina
   State, southern Brazil. Predictive risk factors for infection and
   molecular epidemiology.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Moreira, Regina C/B-1488-2016; Bertolini,
   Dennis/ABG-1427-2020; Carrilho, Flair J/I-3046-2012; de carvalho-Mello,
   Isabel Maria V G/D-3641-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Moreira, Regina
   C/0000-0002-8208-8776; 
NR 0
TC 3
Z9 3
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 1759
BP 612A
EP 612A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224701750
DA 2020-12-08
ER

PT J
AU Pinho, JRR
   Alves, VAF
   Vieira, AF
   Moralez, MOS
   Fonseca, LEP
   Guz, B
   Wakamatsu, A
   Cancado, ELR
   Carrilho, FJ
   da Silva, LC
   Bernardini, AP
   Durigon, EL
AF Pinho, JRR
   Alves, VAF
   Vieira, AF
   Moralez, MOS
   Fonseca, LEP
   Guz, B
   Wakamatsu, A
   Cancado, ELR
   Carrilho, FJ
   da Silva, LC
   Bernardini, AP
   Durigon, EL
TI Detection of human parvovirus B19 in a patient with hepatitis
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE parvovirus B19; hepatitis non-A-E; autoimmune hepatitis; polymerase
   chain reaction; immunohistochemistry
ID FULMINANT-HEPATITIS; APLASTIC-ANEMIA; INFECTION; DISEASE;
   AUTOANTIBODIES; DNA
AB Parvovirus B19 has been associated by some investigators with cases of severe hepatitis. The aim of the present study was to determine the presence of active parvovirus B19 infection among 129 Brazilian patients with non-A-E hepatitis. The patients were assayed for antibodies against parvovirus B19. IgM class, by ELISA. In IgM-positive cases, parvovirus B 19 DNA was assayed by PCR in serum and liver tissue and parvovirus VPI antigen in liver tissue was assayed by immunohistochemistry. Antibodies against parvovirus B19, IgM class, were detected in 3 (2.3%) of 129 patients with non-A-E hepatitis. Previous surgery and blood transfusions were reported by these 3 patients. One patient was a 56-year-old female with severe hepatitis, with anti mitochondrial antibody seropositivity and submassive necrosis at liver biopsy, who responded to corticosteroid therapy. Strong evidence for active parvovirus B19 infection was found in this patient, with parvovirus B 19 DNA being detected by PCR in liver tissue. Furthermore, parvovirus VPI antigen was also detected in liver tissue by immunohistochemistry. The other two IgM-positive patients were chronic hepatitis cases, but active infection was not proven, since neither viral DNA nor antigen were detected in their liver tissues. This and other reports suggest a possible relation between parvovirus B19 infection and some cases of hepatitis.
C1 Inst Adolfo Lutz Registro, Serv Virol, BR-01246902 Sao Paulo, Brazil.
   Inst Adolfo Lutz Registro, Div Patol, BR-01246902 Sao Paulo, Brazil.
   Lab Bioquim Jardim Paulist, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Patol & Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo, Brazil.
   Hosp Servidor Publ Estadual, Sao Paulo, Brazil.
RP Pinho, JRR (corresponding author), Inst Adolfo Lutz Registro, Serv Virol, Av Doutor Arnaldo 355, BR-01246902 Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Cancado, Eduardo/K-1861-2016; Carrilho,
   Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Cancado,
   Eduardo/0000-0002-9309-1524; Durigon, Edison/0000-0003-4898-6553
CR ABUAF N, 1991, AUTOIMMUNE LIVER DIS, P93
   Assy N, 1997, J HEPATOL, V27, P934, DOI 10.1016/S0168-8278(97)80334-0
   BERG PA, 1991, AUTOIMMUNE LIVER DIS, P122
   Bernuau J, 1999, LANCET, V353, P754, DOI 10.1016/S0140-6736(05)76124-9
   BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117
   BROWN KE, 1989, J VIROL METHODS, V26, P189, DOI 10.1016/0166-0934(89)90148-1
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156
   COSSART YE, 1975, LANCET, V1, P72
   DURIGON EL, 1993, J VIROL METHODS, V44, P155, DOI 10.1016/0166-0934(93)90051-R
   ERDMAN DD, 1991, J MED VIROL, V35, P110, DOI 10.1002/jmv.1890350207
   Erdman DD, 1995, DIAGNOSTIC PROCEDURE, P495
   GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W
   GARSON JA, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92384-T
   Hansen KE, 1998, SEMIN ARTHRITIS RHEU, V27, P263, DOI 10.1016/S0049-0172(98)80047-4
   Hillingso JG, 1998, LANCET, V351, P955, DOI 10.1016/S0140-6736(00)80016-1
   JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435
   KAJIGAYA S, 1991, P NATL ACAD SCI USA, V88, P4646, DOI 10.1073/pnas.88.11.4646
   Kerr JR, 1996, J MED VIROL, V48, P68
   Kerr JR, 1996, J INFECTION, V32, P41, DOI 10.1016/S0163-4453(96)80008-9
   Langnas AN, 1995, HEPATOLOGY, V22, P1661, DOI 10.1002/hep.1840220608
   Longo G, 1998, CLIN INFECT DIS, V26, P994, DOI 10.1086/517644
   MCORNISH F, 1993, J CLIN MICROBIOL, V31, P323
   MUIR K, 1992, LANCET, V339, P1139, DOI 10.1016/0140-6736(92)90735-L
   Naides SJ, 1996, LANCET, V347, P1563, DOI 10.1016/S0140-6736(96)90720-5
   Ndimbie OK, 1996, CLIN DIAGN LAB IMMUN, V3, P756, DOI 10.1128/CDLI.3.6.756-760.1996
   OHGA S, 1993, AM J PEDIAT HEMATOL, V15, P291
   Pardi DS, 1998, AM J GASTROENTEROL, V93, P468, DOI 10.1111/j.1572-0241.1998.468_1.x
   PATTISON J R, 1987, Blood Reviews, V1, P58, DOI 10.1016/0268-960X(87)90020-8
   SASAKI T, 1995, LANCET, V346, P851, DOI 10.1016/S0140-6736(95)91673-3
   Sokal EM, 1998, LANCET, V352, P1739, DOI 10.1016/S0140-6736(98)06165-0
   TOROK TJ, 1992, ADV INTERNAL MED, V37, P431
   TSUDA H, 1993, AM J GASTROENTEROL, V88, P1463
   WOOD GS, 1981, J HISTOCHEM CYTOCHEM, V29, P1196, DOI 10.1177/29.10.7028859
   Yamamoto T, 1996, AM J GASTROENTEROL, V91, P1857
   YOTO Y, 1994, LANCET, V344, P624, DOI 10.1016/S0140-6736(94)92014-1
   Yoto Y, 1996, LANCET, V347, P868, DOI 10.1016/S0140-6736(96)91348-3
NR 37
TC 13
Z9 13
U1 0
U2 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD SEP
PY 2001
VL 34
IS 9
BP 1131
EP 1138
DI 10.1590/S0100-879X2001000900005
PG 8
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 474QD
UT WOS:000171117600005
PM 11514836
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Pinho, JRR
   Sitnik, R
   Da Fonseca, LEP
   Carrilho, FJ
AF Da Silva, LC
   Pinho, JRR
   Sitnik, R
   Da Fonseca, LEP
   Carrilho, FJ
TI Efficacy and tolerability of long-term therapy using high lamivudine
   doses for the treatment of chronic hepatitis B
SO JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE lamivudine; 3TC; HBV; PCR; chronic hepatitis B; treatment
ID POLYMERASE CHAIN-REACTION; FIBROSING CHOLESTATIC HEPATITIS;
   DECOMPENSATED LIVER-DISEASE; VIRUS-DNA; YMDD MOTIF; ANTIVIRAL THERAPY;
   NATURAL-HISTORY; IN-VIVO; INFECTION; RESISTANCE
AB Purpose. A long-term follow-up study was carried out to evaluate the tolerability and efficacy of long-term therapy (1 to 3 years) with high doses (150 or 300mg daily) of lamivudine for chronic hepatitis B. Methods. Thirty-two patients were studied, including those who were seronegative for hepatitis B e antigen (HBeAg), as well as those with decompensated liver cirrhosis. Viral DNA clearance was monitored by using end-point dilution polymerase chain reaction (PCR), a highly sensitive method. Hepatitis B virus (HBV) polymerase gene mutations associated with resistance were determined by sequencing. Results. Response to lamivudine in the sixth month was observed in 19/32 (59.4%) patients. With one exception, viral DNA. results observed at this time were maintained. The YMDD mutation was detected in 12 nonresponder patients (9 YVDD, 2 YIDD, and 1 mixed population Y(V/I)DD),generally associated with the L528M mutation. Re-takeover by the wild type was observed 6 to 18 months after lamivudine withdrawal. Lamivudine response rates:in noncirrhotic and cirrhotic patients were 9/18 (50%) and 10/14 (71.4%), respectively. HBeAg to anti-HBe seroconversion was found after different periods in all responder patients. Hepatitis B surface antigen (HBsAg) clearance and anti-HBs seroconversion were occasionally found. Conclusions. In nonresponder patients, resistant mutants appeared up to the second year of lamivudine therapy. In spite of the presence of resistant mutants, maintenance of therapy was usually associated with a lower viral load. In responder patients, maintenance of therapy was associated with continued absence of detectable HBV DNA in serum, as monitored by highly sensitive methods. No significant side effects caused by lamivudine were observed in our patients, even in those with liver cirrhosis.
C1 Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Pinho, JRR (corresponding author), Adolfo Lutz Inst, Serv Virol, Avenida Doutor Arnaldo 355, BR-01246902 Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Sitnik, Roberta/N-4740-2017; Pinho, Joao
   R. R./G-2850-2012
OI Sitnik, Roberta/0000-0002-6243-8118; Pinho, Joao R.
   R./0000-0003-3999-0489
CR AlFaraidy K, 1997, TRANSPLANTATION, V64, P926
   Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628
   Atkins M, 1998, HEPATOLOGY, V28, p319A
   Aye TT, 1997, J HEPATOL, V26, P1148, DOI 10.1016/S0168-8278(97)80125-0
   Bain VG, 1996, TRANSPLANTATION, V62, P1456, DOI 10.1097/00007890-199611270-00013
   Bartholomeusz A., 1998, VIRAL HEPATITIS REV, V4, P167
   Bartholomew MM, 1997, LANCET, V349, P20, DOI 10.1016/S0140-6736(96)02266-0
   Boni C, 1998, J CLIN INVEST, V102, P968, DOI 10.1172/JCI3731
   Chan TM, 1998, GASTROENTEROLOGY, V115, P177, DOI 10.1016/S0016-5085(98)70380-4
   Chayama K, 1998, HEPATOLOGY, V27, P1711, DOI 10.1002/hep.510270634
   CHEN DS, 1993, J GASTROEN HEPATOL, V8, P470, DOI 10.1111/j.1440-1746.1993.tb01551.x
   Chien RN, 1999, HEPATOLOGY, V30, P770, DOI 10.1002/hep.510300313
   DaSilva LC, 1996, J GASTROENTEROL, V31, P696, DOI 10.1007/BF02347619
   DASILVA LC, 2000, REV INST MED TROP SP, V42, P179
   DEMAN RA, 1995, SCAND J GASTROENTERO, V30, P100, DOI 10.3109/00365529509090307
   DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501
   Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702
   Dienstag JL, 1999, HEPATOLOGY, V30, P1082, DOI 10.1002/hep.510300427
   Han SHB, 1998, AM J GASTROENTEROL, V93, P859, DOI 10.1111/j.1572-0241.1998.00859.x
   Honkoop P, 1998, J VIRAL HEPATITIS, V5, P307, DOI 10.1046/j.1365-2893.1998.00121.x
   Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X
   Honkoop P, 1997, HEPATOLOGY, V26, P1204
   Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507
   Jarvis B, 1999, DRUGS, V58, P101, DOI 10.2165/00003495-199958010-00015
   KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989
   KANEKO S, 1990, GASTROENTEROLOGY, V99, P799
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201
   Lai CL, 1997, HEPATOLOGY, V25, P241, DOI 10.1002/hep.510250144
   LAU DTY, 1997, HEPATOLOGY, V26, P429
   Leung N, 1998, HEPATOLOGY, V28, p587A
   Liaw YF, 1999, HEPATOLOGY, V30, P567, DOI 10.1002/hep.510300221
   LIN R, 1996, HEPATOLOGY, V24, P711
   Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347
   LOK A, 1999, TREATMENT LIVER DIS, P261
   Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243
   Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520
   Niitsuma H, 1997, AM J GASTROENTEROL, V92, P119
   Nowak MA, 1996, P NATL ACAD SCI USA, V93, P4398, DOI 10.1073/pnas.93.9.4398
   Ono-Nita SK, 1999, HEPATOLOGY, V29, P939, DOI 10.1002/hep.510290340
   Sokal EM, 2000, ANTIMICROB AGENTS CH, V44, P590, DOI 10.1128/AAC.44.3.590-597.2000
   Sponseller CA, 2000, LIVER TRANSPLANT, V6, P715, DOI 10.1053/jlts.2000.18501
   Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321
   Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1002/hep.510240340
   VanThiel DH, 1997, HEPATO-GASTROENTEROL, V44, P808
   Villeneuve JP, 2000, HEPATOLOGY, V31, P207, DOI 10.1002/hep.510310130
   WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011
   Wong WWS, 1998, THERAPIES FOR VIRAL HEPATITIS, P353
   Zeuzem S, 1997, J HEPATOL, V27, P431, DOI 10.1016/S0168-8278(97)80345-5
NR 49
TC 19
Z9 19
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0944-1174
EI 1435-5922
J9 J GASTROENTEROL
JI J. Gastroenterol.
PD JUL
PY 2001
VL 36
IS 7
BP 476
EP 485
DI 10.1007/s005350170071
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 454KM
UT WOS:000169971800005
PM 11480792
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Porta, G
   Drigo, S
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Porta, G
   Drigo, S
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Autoimmune hepatitis in Brazilian patients is not linked to tumor
   necrosis factor alpha polymorphisms at position-308
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE tumor necrosis factor alpha gene polymorphisms; tumor necrosis factor
   alpha; autoimmune hepatitis; HLA-DR antigens; genetic susceptibility
ID MAJOR HISTOCOMPATIBILITY COMPLEX; PCR-SSP; TYPE-1; HLA; SUSCEPTIBILITY;
   PROMOTER; CLASSIFICATION; HETEROGENEITY; ASSOCIATION; DIAGNOSIS
AB Background/Aims: Susceptibility to autoimmune hepatitis (AIH) has been linked to different HLA-DR antigens, Recently, AIH type 1 was associated with polymorphisms in the tumor necrosis factor alpha gene promotes (TNFA) at position -308. In this respect, the frequency of the TNFA*2 allele, in linkage disequilibrium with HLA-DRB1*0301, was shown to be significantly increased in whites with AIH type 1. The aim of this study was to assess the role of TNFA alleles in conferring susceptibility to AIH, studying a population where the disease is not primarily associated with HLA-DRB1*03.
   Methods: The determination of HLA-DRB1 and TNFA alleles was performed in 92 patients with ALH type 1, 29 subjects with AIH type 2 and 53 healthy controls by polymerase chain reaction-based techniques.
   Results: The distribution of TNFA alleles was similar in patients with AIH types 1 and 2, when compared with controls. In addition, the TNFA*2 allele was identified in patients carrying HLA-DR antigens other than HLA-DRB1*03. Interestingly, higher gammaglobulin levels were observed in TNFA*2 positive patients.
   Conclusions: Our data indicate that susceptibility to AIH remains primarily linked to the HLA-DRB1 locus, and suggest that the association of AIH with TNFA*2 previously observed in whites might be secondary to a linkage disequilibrium with MLA-DRB1*0301, (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
   Howard Hughes Med Inst, Bethesda, MD 20815 USA.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302A,Rio Vermelho, BR-41940040 Salvador, BA, Brazil.
EM plbbr@uol.com.br
RI LINDE, SANDRA/S-3128-2019; KALIL, JORGE/C-8029-2012; Cancado,
   Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014; Drigo, Sandra
   A/I-6514-2012; Carrilho, Flair J/I-3046-2012; Goldberg, Anna
   Carla/H-8594-2014
OI LINDE, SANDRA/0000-0001-6747-6642; KALIL, JORGE/0000-0001-8415-4274;
   Cancado, Eduardo/0000-0002-9309-1524; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Drigo, Sandra A/0000-0001-6747-6642; Goldberg,
   Anna Carla/0000-0003-2600-7940
CR ABUAF N, 1992, HEPATOLOGY, V16, P892, DOI 10.1002/hep.1840160407
   Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   Beutler BA, 1999, J RHEUMATOL, V26, P16
   Bittencourt PL, 1998, AM J GASTROENTEROL, V93, P1394, DOI 10.1111/j.1572-0241.1998.1394a.x
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   Cancado ELR, 2000, FALK SYMP, V114, P82
   Cookson S, 1999, HEPATOLOGY, V30, P851, DOI 10.1002/hep.510300412
   CORDONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434
   Czaja AJ, 1999, GASTROENTEROLOGY, V117, P645, DOI 10.1016/S0016-5085(99)70458-0
   DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81
   Goldman JM, 1998, BONE MARROW TRANSPL, V21, P1, DOI 10.1038/sj.bmt.1701089
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
   Jurado A, 1997, J HEPATOL, V26, P983, DOI 10.1016/S0168-8278(97)80106-7
   KRAKAUER T, 2000, FUNDAMENTALS IMMUNOL, P775
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   LENZI M, 1997, HEPATOLOGY, V26, P443
   Louis E, 1998, CLIN EXP IMMUNOL, V113, P401
   Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093
   McManus R, 1996, EUR J IMMUNOL, V26, P2113, DOI 10.1002/eji.1830260923
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P55
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   POCIOT F, 1993, EUR J IMMUNOL, V23, P3050, DOI 10.1002/eji.1830231148
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   WILSON AG, 1994, EUR J IMMUNOL, V24, P191, DOI 10.1002/eji.1830240130
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557
NR 36
TC 31
Z9 35
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD JUL
PY 2001
VL 35
IS 1
BP 24
EP 28
DI 10.1016/S0168-8278(01)00072-1
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 455HN
UT WOS:000170021600006
PM 11495038
DA 2020-12-08
ER

PT J
AU Goldberg, AC
   Bittencourt, PL
   Mougin, B
   Cancado, ELR
   Porta, G
   Carrilho, F
   Kalil, J
AF Goldberg, AC
   Bittencourt, PL
   Mougin, B
   Cancado, ELR
   Porta, G
   Carrilho, F
   Kalil, J
TI Analysis of HLA haplotypes in autoimmune hepatitis type 1: Identifying
   the major susceptibility locus
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE HLA genes; autoimmune hepatitis; genetic susceptibility; peptide
   presentation
ID ALLELES; GENES
AB Susceptibility to autoimmune hepatitis type I (AIH-1) has been associated with HLA-DR3, DR52, acid DR4 antigens in Caucasian and Oriental patients. However, in Brazil, disease susceptibility is primarily linked to DR13 and DR52. In this highly admired population, we find different DR13-associated haplotypes, presenting a unique opportunity to discriminate relevant genes within a tightly linked genomic region. To identify the primary susceptibility locus, we sequenced DR13 alleles of 39 patients with AIH-1 and 22 controls. Patients were almost exclusively DRB1*1301, bur half of controls typed DRB1*1302. HLA-DQ haplotypes were varied. Oligotyping of DRD3 locus of all patients and also within the HLA-DR13 positive group showed an allele distribution comparable to controls, confirming that the stronger association lies in the DRB1 locus. On the other hand, if DRB1*1301 is the major susceptibility factor in our sample, the only amino acid different from DRB1*1302 in position 86, corresponding to pocket 1 in the peptide-presenting groove, may be important. We Propose that peptide presentation leading to pathogenesis of AIH-1 may ie quite stringent, but will also be affected by other strong genetic or environmental susceptibility factors, which would explain the various HLA molecules associated to the disease in the different populations. (C) American Society for Histocompatibility and Immunogenetics, 2001. Published by Elsevier Science Inc.
C1 Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
   Biomerieux, Dept Sondes Nucl, Lyon, France.
   Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Goldberg, AC (corresponding author), HCFMUSP, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 500,3 Andar, BR-05403000 Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; BITTENCOURT, PAULO l/I-5817-2014;
   Cancado, Eduardo/K-1861-2016; KALIL, JORGE/C-8029-2012; Goldberg, Anna
   Carla/H-8594-2014
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; Cancado,
   Eduardo/0000-0002-9309-1524; KALIL, JORGE/0000-0001-8415-4274; Goldberg,
   Anna Carla/0000-0003-2600-7940
CR BIGNON JD, 1995, HLA GENETIC DIVERSIT
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bodmer JG, 1999, TISSUE ANTIGENS, V53, P407, DOI 10.1034/j.1399-0039.1999.530421.x
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   CROS P, 1992, LANCET, V340, P873
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434
   DAVENPORT MP, 1995, P NATL ACAD SCI USA, V92, P6567, DOI 10.1073/pnas.92.14.6567
   DIELPOLDER HM, 1998, CLIN EXP IMMUNOL, V113, P244
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   FAINBOIM L, 1994, HUM IMMUNOL, V41, P146, DOI 10.1016/0198-8859(94)90008-6
   FAINBOIM L, 1997, P 12 IHWC GEN DIV HL
   Goldberg AC, 1998, GENET MOL BIOL, V21, P301, DOI 10.1590/S1415-47571998000300001
   GORSKI J, 1986, NATURE, V322, P6770
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435
   Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406
   KRAWITT EL, 1994, AM J MED, V90, pS23
   MANNS M, 1991, HEPATOLOGY, V14, P60
   MANNS MP, 1994, GASTROENTEROLOGY, V106, P1676, DOI 10.1016/0016-5085(94)90427-8
   MCGINNIS MD, 1995, TISSUE ANTIGENS, V46, P173, DOI 10.1111/j.1399-0039.1995.tb03116.x
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0
NR 23
TC 52
Z9 58
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD FEB
PY 2001
VL 62
IS 2
BP 165
EP 169
DI 10.1016/S0198-8859(00)00234-2
PG 5
WC Immunology
SC Immunology
GA 405CZ
UT WOS:000167141200010
PM 11182227
DA 2020-12-08
ER

PT J
AU Ono, SK
   Kato, N
   Shiratori, Y
   Kato, J
   Goto, T
   Schinazi, RF
   Carrilho, FJ
   Omata, M
AF Ono, SK
   Kato, N
   Shiratori, Y
   Kato, J
   Goto, T
   Schinazi, RF
   Carrilho, FJ
   Omata, M
TI The polymerase L528M mutation cooperates with nucleotide binding-site
   mutations, increasing hepatitis B virus replication and drug resistance
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID YMDD-MOTIF; REVERSE-TRANSCRIPTASE; LAMIVUDINE RESISTANCE; CELL-LINES;
   IN-VIVO; THERAPY; DNA; IDENTIFICATION; NUCLEOSIDE; CLEARANCE
AB After receiving lamivudine for 3 years to treat chronic hepatitis B, 67-75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virus (HBV) drug-resistant. The aim of this study was to evaluate the influence of these mutations on viral replication and resistance to antiviral agents. We investigated the replication fitness and susceptibility of the wild-type and five mutant HBVs (L528M, M552I, M552V, L528M/M552I, and L528M/M552V) to 11 compounds [lamivudine, adefovir, entecavir (BMS-200475) (+)-BCH-189 (+/-)-FTC (racivir) (-)-FTC (emtricitabine) (+)-FTC, L-D4FC, L-FMAU (clevudine), D-DAPD, and (-)-carbovir] by transfecting HBV DNA into hepatoma cells and monitoring viral products by Southern blotting. The replication competency of the single C-domain mutants M552I and M552V was markedly decreased compared With that of wild-type HBV. However, addition of the B-domain mutation L528M restored replication competence. Only adefovir and entecavir were effective against all five HBV mutants, and higher doses of these compounds were necessary to inhibit the double mutants compared with the single mutants. The B-domain mutation (L528M) of HBV polymerase not only restores the replication competence of C-domain mutants, but also increases resistance to nucleoside analogues.
C1 Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
   Vet Affairs Med Ctr, Atlanta, GA 30033 USA.
RP Kato, N (corresponding author), Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM kaco-2im@h.u-tokyo.ac.jp
RI Carrilho, Flair J/I-3046-2012; Schinazi, Raymond F/B-6777-2017
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI041980, R01-AI-41980] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI041980, R01AI041980, R01AI041980] Funding Source:
   NIH RePORTER
CR Aguesse-Germon S, 1998, ANTIMICROB AGENTS CH, V42, P369
   Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628
   Balzarini J, 1999, BIOCHEM PHARMACOL, V58, P1
   Bartholomeusz A., 1998, VIRAL HEPATITIS REV, V4, P167
   Bartholomew MM, 1997, LANCET, V349, P20, DOI 10.1016/S0140-6736(96)02266-0
   Ben-Ari Z, 1999, TRANSPLANTATION, V68, P232, DOI 10.1097/00007890-199907270-00012
   Benhamou Y, 1999, HEPATOLOGY, V30, P1302, DOI 10.1002/hep.510300525
   Bessesen M, 1999, CLIN INFECT DIS, V28, P1032, DOI 10.1086/514750
   Chayama K, 1998, HEPATOLOGY, V27, P1711, DOI 10.1002/hep.510270634
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   Condra JH, 1998, ANN INTERN MED, V128, P951, DOI 10.7326/0003-4819-128-11-199806010-00017
   Cullen JM, 1997, ANTIMICROB AGENTS CH, V41, P2076, DOI 10.1128/AAC.41.10.2076
   Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702
   Fu L, 1998, BIOCHEM PHARMACOL, V55, P1567, DOI 10.1016/S0006-2952(98)00050-1
   FURMAN PA, 1992, ANTIMICROB AGENTS CH, V36, P2686, DOI 10.1128/AAC.36.12.2686
   Genovesi EV, 1998, ANTIMICROB AGENTS CH, V42, P3209, DOI 10.1128/AAC.42.12.3209
   Genovesi EV, 1999, ANTIMICROB AGENTS CH, V43, P726
   Gordon D, 1998, GASTROENTEROLOGY, V114, P236, DOI 10.1016/S0016-5085(98)70469-X
   GUNTHER S, 1995, J VIROL, V69, P5437
   Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006
   HEIJTINK RA, 1993, ANTIVIR RES, V21, P141, DOI 10.1016/0166-3542(93)90050-S
   Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984
   Honkoop P, 1997, LIVER, V17, P103
   Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444, DOI 10.1128/AAC.41.7.1444
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320
   JANSEN RW, 1993, ANTIMICROB AGENTS CH, V37, P441, DOI 10.1128/AAC.37.3.441
   KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269
   Korba BE, 2000, ANTIMICROB AGENTS CH, V44, P1757, DOI 10.1128/AAC.44.6.1757-1760.2000
   KRUINING J, 1995, J HEPATOL, V22, P263, DOI 10.1016/0168-8278(95)80277-0
   Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201
   Lai CL, 1999, J GASTROEN HEPATOL, V14, pS19, DOI 10.1046/j.1440-1746.1999.01879.x
   LAU D, 2000, ANTIVIR THER, V5, P43
   Le Guerhier F, 1999, HEPATOLOGY, V30, p344A
   Liaw YF, 1999, HEPATOLOGY, V30, P567, DOI 10.1002/hep.510300221
   Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347
   Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243
   MERCHANT Z, 1997, BIOORG MED CHEM LETT, V7, P127
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   Omata M, 1998, NEW ENGL J MED, V339, P114, DOI 10.1056/NEJM199807093390209
   Ono-Nita SK, 1999, HEPATOLOGY, V29, P939, DOI 10.1002/hep.510290340
   Pai SB, 1996, ANTIMICROB AGENTS CH, V40, P380, DOI 10.1128/AAC.40.2.380
   PETERS M, 2000, ANTIVIRAL THER SU, V5, P45
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   SCHINAZI RF, 1991, SYNERGISM ANTAGONISM, P110
   Seigneres B, 2000, J INFECT DIS, V181, P1221, DOI 10.1086/315368
   SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005
   Shi JX, 1999, J MED CHEM, V42, P859, DOI 10.1021/jm980510s
   Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1002/hep.510240340
   Togo G, 1996, CANCER RES, V56, P5620
   Tsiang M, 1999, HEPATOLOGY, V29, P1863, DOI 10.1002/hep.510290626
   *WHO, WHO WARNS GROW CRIS
   Yeh CT, 2000, HEPATOLOGY, V31, P1318, DOI 10.1053/jhep.2000.7296
   YOKOSUKA O, 1985, HEPATOLOGY, V5, P728, DOI 10.1002/hep.1840050505
   Zhu YL, 1998, ANTIMICROB AGENTS CH, V42, P1805, DOI 10.1128/AAC.42.7.1805
NR 54
TC 209
Z9 232
U1 0
U2 13
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD FEB
PY 2001
VL 107
IS 4
BP 449
EP 455
DI 10.1172/JCI11100
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 403YY
UT WOS:000167071700009
PM 11181644
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Ona-Nita, SK
   Kato, N
   Shiratori, Y
   Yoshida, H
   Kato, J
   Goto, T
   Schinazi, RF
   Carrilho, FJ
   Omata, M
AF Ona-Nita, SK
   Kato, N
   Shiratori, Y
   Yoshida, H
   Kato, J
   Goto, T
   Schinazi, RF
   Carrilho, FJ
   Omata, M
TI Influence of B domain mutation (L528M) of the hepatitis B virus
   polymerase on replication ability and resistance to nucleoside
   analogues.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Tokyo, Tokyo, Japan.
   Emory Univ, VA Med Ctr, Decatur, GA USA.
   Univ Sao Paulo, Sao Paulo, Brazil.
RI Schinazi, Raymond F/B-6777-2017; Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2000
VL 32
IS 4
MA 935
BP 393A
EP 393A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 359PZ
UT WOS:000089622400920
DA 2020-12-08
ER

PT J
AU Moraes, CR
   Carrilho, FJ
   Bassit, L
   Renato, J
   Pinho, R
   Curi, M
   Antonelli, RC
   Da Silva, LC
   Laudana, AA
AF Moraes, CR
   Carrilho, FJ
   Bassit, L
   Renato, J
   Pinho, R
   Curi, M
   Antonelli, RC
   Da Silva, LC
   Laudana, AA
TI Hepatitis C virus infection in hemodialysis patients from Southern
   Brazil. Epidemiological data and genotypes.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2000
VL 32
IS 4
MA 1547
BP 546A
EP 546A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 359PZ
UT WOS:000089622401531
DA 2020-12-08
ER

PT J
AU Vezozzo, DP
   Mello, ES
   Carrilho, FJ
   Af Alves, V
   Anjos, LC
   Medeiros, JE
   Della-Guardia, B
   Gayotto, LCC
   Cerri, GG
   Laudanna, AA
AF Vezozzo, DP
   Mello, ES
   Carrilho, FJ
   Af Alves, V
   Anjos, LC
   Medeiros, JE
   Della-Guardia, B
   Gayotto, LCC
   Cerri, GG
   Laudanna, AA
TI Evaluation of ultrasound as a tool to diagnosis of cirrhosis in
   hepatitis C virus (HCV) infected patients.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Paranagua-Vezozzo, Denise Cerqueira/N-7270-2014; Carrilho, Flair
   J/I-3046-2012
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2000
VL 32
IS 4
MA 1557
BP 549A
EP 549A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 359PZ
UT WOS:000089622401542
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Bassit, L
   Carrilho, FJ
   Pinho, JRR
AF Da Silva, LC
   Bassit, L
   Carrilho, FJ
   Pinho, JRR
TI Early hepatitis C virus (HCV) kinetics during daily therapy with
   consensus interferon (CIFN) and ribavirin (RB) in patients infected with
   genotype 3 or 1 previously resistant to IFN and RB.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil.
   Fund Pro Sangue Hemoctr Sao Paulo, Sao Paulo, SP, Brazil.
   Lab Bioquim Jd Paulista, Sao Paulo, SP, Brazil.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2000
VL 32
IS 4
MA 1626
BP 566A
EP 566A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 359PZ
UT WOS:000089622401612
DA 2020-12-08
ER

PT J
AU Sitnik, R
   Pinho, JR
   Da Silva, LC
   Fonseca, LE
   Carrilho, FJ
   Bernardini, AP
AF Sitnik, R
   Pinho, JR
   Da Silva, LC
   Fonseca, LE
   Carrilho, FJ
   Bernardini, AP
TI Hepatitis B virus genotypes and pre core mutants in chronic hepatitis B
   patients from Sao Paulo city, Brazil.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Lab Bioquim Jardim Paulista, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   FMUSP, Dept Gastroenterol, Sao Paulo, Brazil.
RI Sitnik, Roberta/N-4740-2017; Carrilho, Flair J/I-3046-2012; Pinho, Joao
   R. R./G-2850-2012
OI Sitnik, Roberta/0000-0002-6243-8118; Pinho, Joao R.
   R./0000-0003-3999-0489
NR 0
TC 3
Z9 3
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2000
VL 32
IS 4
MA 1675
BP 578A
EP 578A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 359PZ
UT WOS:000089622401659
DA 2020-12-08
ER

PT J
AU Pinho, JR
   Moreira, RC
   Lemos, MF
   Takahashi, DA
   Ferreira, JL
   Fava, AL
   Da Silva, LC
   Goncales, N
   Goncales, FL
   Carrilho, FJ
   Stucchi, RS
   Bernardini, AP
AF Pinho, JR
   Moreira, RC
   Lemos, MF
   Takahashi, DA
   Ferreira, JL
   Fava, AL
   Da Silva, LC
   Goncales, N
   Goncales, FL
   Carrilho, FJ
   Stucchi, RS
   Bernardini, AP
TI GB-C and TT viruses infection in different Brazilian populations.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Lab Bioquim Jardim Paulista, Sao Paulo, Brazil.
   Inst Adolfo Lutz, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Univ Campinas, Fac Ciencias Med, BR-13081 Campinas, Brazil.
RI Cancado, Eduardo/K-1861-2016; Pinho, Joao R. R./G-2850-2012; Carrilho,
   Flair J/I-3046-2012; Moreira, Regina C/B-1488-2016
OI Cancado, Eduardo/0000-0002-9309-1524; Pinho, Joao R.
   R./0000-0003-3999-0489; Moreira, Regina C/0000-0002-8208-8776
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2000
VL 32
IS 4
MA 1734
BP 593A
EP 593A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 359PZ
UT WOS:000089622401720
DA 2020-12-08
ER

PT J
AU Lyra, AC
   Braga, E
   Pereira, J
   Kalabric, L
   Lyra, M
   Parana, R
   Lyra, LG
   Takahashi, DA
   Souza, L
   Pinho, JR
   Carrilho, FJ
   Silva, LC
AF Lyra, AC
   Braga, E
   Pereira, J
   Kalabric, L
   Lyra, M
   Parana, R
   Lyra, LG
   Takahashi, DA
   Souza, L
   Pinho, JR
   Carrilho, FJ
   Silva, LC
TI TTV and HGV infection in acute virus hepatitis and blood donors in
   Northeast-Brazil.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Fed Bahia, Salvador, BA, Brazil.
   FIOCRUZ, Salvador, BA, Brazil.
   Inst Adolfo Lutz, Sao Paulo, Brazil.
   Univ Sao Paulo, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2000
VL 32
IS 4
MA 1737
BP 594A
EP 594A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 359PZ
UT WOS:000089622401722
DA 2020-12-08
ER

PT J
AU Anjos, LC
   Carrilho, FJ
   Pinho, JR
   Alves, VA
   Lemos, MF
   Dores, GB
   Gallo, C
   Da Silva, LC
AF Anjos, LC
   Carrilho, FJ
   Pinho, JR
   Alves, VA
   Lemos, MF
   Dores, GB
   Gallo, C
   Da Silva, LC
TI Hepatitis B virus replication markers: Camparison of methods of
   molecular biology, serological and immunohistochemical methods.
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
   Digene Brasil, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2000
VL 118
IS 4
SU 2
MA 176
BP A936
EP A936
DI 10.1016/S0016-5085(00)85884-9
PN 1
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 309RU
UT WOS:000086783703808
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Carrilho, FJ
   Medeiros, JEM
   Anjos, LC
   Pinho, JR
   Laudanna, AA
AF Da Silva, LC
   Carrilho, FJ
   Medeiros, JEM
   Anjos, LC
   Pinho, JR
   Laudanna, AA
TI Induction therapy with interferon plus ribavirin for naive patients with
   chronic hepatitis C: A preliminary report.
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 Adolfo Lutz Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2000
VL 118
IS 4
SU 2
MA 6507
BP A1433
EP A1433
DI 10.1016/S0016-5085(00)81628-5
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 309RY
UT WOS:000086784101580
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Farias, AQ
   Carrilho, FJ
   Marin, ML
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Farias, AQ
   Carrilho, FJ
   Marin, ML
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI HLA class II antigens and tumor necrosis factor (TNF) gene polymorphism
   in patients with autoimmune cholestatic liver diseases.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sao Paulo, Brazil.
RI Cancado, Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014;
   Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; Carrilho,
   Flair J/I-3046-2012
OI Cancado, Eduardo/0000-0002-9309-1524; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1999
VL 30
IS 4
SU S
MA 1608
BP 562A
EP 562A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 239XE
UT WOS:000082794701605
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Carrilho, FJ
   Drigo, S
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Carrilho, FJ
   Drigo, S
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Analysis of -308 tumor necrosis factor (TNF) polymorphism in patients
   with autoimmune hepatitis types 1 and 2.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016; KALIL,
   JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; BITTENCOURT, PAULO
   l/I-5817-2014
OI Cancado, Eduardo/0000-0002-9309-1524; KALIL, JORGE/0000-0001-8415-4274;
   Goldberg, Anna Carla/0000-0003-2600-7940; BITTENCOURT, PAULO
   l/0000-0003-0883-4870
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1999
VL 30
IS 4
SU S
MA 1634
BP 569A
EP 569A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 239XE
UT WOS:000082794701632
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Farias, AQ
   Palacios, SA
   Chiarella, JM
   Abrantes-Lemos, CP
   Baggio, VL
   Laudanna, AA
   Kalil, J
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Farias, AQ
   Palacios, SA
   Chiarella, JM
   Abrantes-Lemos, CP
   Baggio, VL
   Laudanna, AA
   Kalil, J
TI Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1
   and 2
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID CHRONIC ACTIVE HEPATITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIMERS
   PCR-SSP; LIVER-DISEASE; C VIRUS; ANTIBODY TYPE-1; HLA; SEQUENCE;
   AUTOANTIBODIES; ASSOCIATION
AB OBJECTIVE: Susceptibility to autoimmune hepatitis (AIH) type 1 has been associated with DRB1*03, DRB1*04, and DRB3 alleles in European and North-American whites, with DRB1*04 in Japan, and with DRB1*04 and DRB1*13 in Latin America. Very few studies have been performed on AIH type 2. The aim of the present study was to evaluate the association of AIH types 1 and 2 with HLA-DR and DQ loci.
   METHODS: We performed HLA-DRB and -DQB1 typing by polymerase chain reaction amplification with sequence-specific primers (PCR-SSP) in 139 AIH patients. Most had AIH type 1 associated with circulating anti-smooth muscle antibody with F-actin specificity or antinuclear antibody. Twenty-eight patients presented AIH type 2 with anti-liver/kidney microsome type 1 or anti-liver cytosol type 1 antibodies.
   RESULTS: We observed a significant increase of DRB1*13 (70% vs 26% of controls, p < 0.00001) and DRB3 (93% vs 69% of controls, p < 0.00001) in AIH type 1 patients. Analysis of patients without DRB1*13 disclosed a secondary association with DRB1*03 (70% vs 30% of controls, p = 0.0001) and either the DRB1*13 or the DRB1*03 alleles were present in the majority of these patients (91% vs 48% of controls, p = 0.001). Comparison of DRB1*13- and DRB1*03-positive subjects revealed that the former alleles conferred susceptibility to younger patients with AIH type I. DQB1 typing showed a significant increase in DQB1*06 (68% vs 41% of controls, p = 0.00007) in strong linkage disequilibrium with DRB1*13,and a decrease in DQB1*0301 (8% vs 47% of controls, p(c) = 0.0003). On the other hand, HLA typing of patients with AIH type 2 disclosed a significant increase in the DRB1*07 (68% vs 20% of controls, p(c) < 0.00014), DRB4 (79% vs 43% of controls, p(c) = 0.004), and DQB1*02 (86% vs 42%, p = 0.00002) alleles. After exclusion of DRB1*07, a secondary association with HLA-DRB1*03 was further observed in these patients (78% vs 30%, p = 0.007) and most of them had either DRB1*07 or DRB1*03 (93% vs 44% of controls, p(c) < 0.0001).
   CONCLUSIONS: Our data indicate that predisposition to AIH types 1 and 2 is associated, respectively, with the DRB1*13 or DRB1*03 and DRB1*07 or DRB1*03 alleles, and suggest that protection against type 1 disease may be conferred by DQB1*0301. In addition, the cluster of DRB1*13 in children with AIH type 1 also supports the concept that different HLA alleles might influence the onset of the disease. (Am J Gastroenterol 1999;94:1906-1913. (C) 1999 by Am. Coll. of Gastroenterology).
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Lab Transplantat Immunol,Heart Inst, BR-01246000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, BR-01246000 Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Univ Sao Paulo, Fac Med, Unidade Figado, Av Dr Arnaldo 455,3 Andar, BR-01246000 Sao Paulo, Brazil.
RI Cancado, Eduardo/K-1861-2016; Goldberg, Anna Carla/H-8594-2014;
   Carrilho, Flair J/I-3046-2012; Farias, Alberto/ABB-1291-2020; Farias,
   Alberto Q/H-7873-2013; KALIL, JORGE/C-8029-2012; BITTENCOURT, PAULO
   l/I-5817-2014
OI Cancado, Eduardo/0000-0002-9309-1524; Goldberg, Anna
   Carla/0000-0003-2600-7940; Farias, Alberto/0000-0002-5572-663X; KALIL,
   JORGE/0000-0001-8415-4274; BITTENCOURT, PAULO l/0000-0003-0883-4870
CR ABUAF N, 1992, HEPATOLOGY, V16, P892, DOI 10.1002/hep.1840160407
   ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
   Bittencourt PL, 1998, AM J GASTROENTEROL, V93, P1394, DOI 10.1111/j.1572-0241.1998.1394a.x
   Bittencourt PL, 1996, HEPATOLOGY, V24, P423
   BODMER JG, 1994, TISSUE ANTIGENS, V44, P1, DOI 10.1111/j.1399-0039.1994.tb02351.x
   BUNCE M, 1993, HUM IMMUNOL, V37, P201, DOI 10.1016/0198-8859(93)90502-R
   Cancado E. L. R., 1996, Hepatology, V24, p492A
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   CORDONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434
   Czaja AJ, 1997, AM J GASTROENTEROL, V92, P2197
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   DOHERTY DG, 1994, AUTOIMMUNITY, V18, P243, DOI 10.3109/08916939409009525
   DONALDSON P, 1994, HEPATOLOGY, V20, P225, DOI 10.1002/hep.1840200133
   DUCLOSVALLEE JC, 1995, GASTROENTEROLOGY, V108, P470, DOI 10.1016/0016-5085(95)90076-4
   Fainboim L, 1997, HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION, PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND CONFERENCE (12TH IHWC), VOL I: WORKSHOP, P418
   FAINBOIM L, 1994, HUM IMMUNOL, V41, P146, DOI 10.1016/0198-8859(94)90008-6
   Goldberg A. C., 1996, Human Immunology, V47, P32, DOI 10.1016/0198-8859(96)84848-8
   Goldberg AC, 1998, GENET MOL BIOL, V21, P301, DOI 10.1590/S1415-47571998000300001
   GOLDBERG AC, 1997, HLA 1997, P330
   GORSKI J, 1986, NATURE, V322, P67, DOI 10.1038/322067a0
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   HEARD R, 1994, HLA DIS, P123
   HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
   JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435
   Jurado A, 1997, J HEPATOL, V26, P983, DOI 10.1016/S0168-8278(97)80106-7
   Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O
   Lenzi M., 1997, Hepatology, V26, p443A
   LENZI M, 1991, J HEPATOL, V16, P59
   LIDMAN K, 1976, CLIN EXP IMMUNOL, V24, P266
   MANABE K, 1994, GASTROENTEROLOGY, V106, P1321, DOI 10.1016/0016-5085(94)90025-6
   MANNS M, 1991, HEPATOLOGY, V14, pA60
   MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949
   MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443
   MANNS MP, 1994, GASTROENTEROLOGY, V106, P1676, DOI 10.1016/0016-5085(94)90427-8
   MARCOS Y, 1994, HEPATOLOGY, V19, P1371, DOI 10.1016/0270-9139(94)90230-5
   MURATORI L, 1995, GUT, V37, P406, DOI 10.1136/gut.37.3.406
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   REDDY KR, 1995, J VIRAL HEPATITIS, V2, P175, DOI 10.1111/j.1365-2893.1995.tb00026.x
   SCULLY LJ, 1993, GASTROENTEROLOGY, V104, P1478, DOI 10.1016/0016-5085(93)90359-K
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345
   STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0
   Strettell MDJ, 1997, HEPATOLOGY, V26, P1023, DOI 10.1053/jhep.1997.v26.pm0009328330
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
   WHITTINGHAM S, 1981, CLIN EXP IMMUNOL, V43, P80
   WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597
NR 50
TC 112
Z9 124
U1 2
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUL
PY 1999
VL 94
IS 7
BP 1906
EP 1913
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 212NW
UT WOS:000081224000034
PM 10406258
DA 2020-12-08
ER

PT J
AU Ono-Nita, SK
   Kato, N
   Shiratori, Y
   Lan, KH
   Yoshida, H
   Carrilho, FJ
   Omata, M
AF Ono-Nita, SK
   Kato, N
   Shiratori, Y
   Lan, KH
   Yoshida, H
   Carrilho, FJ
   Omata, M
TI Susceptibility of lamivudine-resistant hepatitis B virus to other
   reverse transcriptase inhibitors
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID LIVER-TRANSPLANTATION; DNA-POLYMERASE; IN-VITRO; INTERFERON TREATMENT;
   INFECTION; PENCICLOVIR; REPLICATION; THERAPY; FAMCICLOVIR; MUTATIONS
AB The emergence of resistant hepatitis B virus (HBV), with mutations in the YMDD motif of the polymerase gene after treatment with lamivudine, is becoming an important clinical problem. In this study, susceptibility of wild-type and lamivudine-resistant HBV M552I, M552V, and L528M/M552V mutants to other reverse transcriptase inhibitors was investigated by transient transfection of full-length HBV DNA into human hepatoma cells. HBV DNA replication was monitored by Southern blot hybridization, which showed the presence of a single-stranded band (representative of the HBV replicative intermediates) in the drug-free, wild-type HBV-transfected cells. This band was diminished in the samples of wild-type HBV DNA treated with either lamivudine, adefovir, or lobucavir. The band intensities from the lamivudine-resistant mutants were not decreased by treatment with lamivudine, but were decreased by the treatments with adefovir or lobucavir. In contrast, penciclovir and nevirapine did not diminish the intensity of the single-stranded band of wild-type HBV or the lamivudine-resistant mutants. These results demonstrate that lamivudine-resistant HBV is susceptible to adefovir and lobucavir. Lamivudine-resistant HBV should be treated with adefovir or lobucavir, and combination therapy with lamivudine and adefovir/lobucavir may prevent the emergence of lamivudine-resistant HBV.
C1 Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
RP Kato, N (corresponding author), Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012
CR Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628
   Aye TT, 1997, J HEPATOL, V26, P1148, DOI 10.1016/S0168-8278(97)80125-0
   Bacon TH, 1996, INT J ANTIMICROB AG, V7, P119, DOI 10.1016/0924-8579(96)00303-2
   BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332
   Bartholomew MM, 1997, LANCET, V349, P20, DOI 10.1016/S0140-6736(96)02266-0
   BLOOMER J, 1997, 2 INT C THER VIR HEP, P23
   BOKER KHW, 1994, TRANSPLANTATION, V57, P1706
   BOYD MR, 1993, ANTIVIR CHEM CHEMOTH, V4, P3, DOI 10.1177/095632029300401S01
   Cherrington JM, 1996, ANTIMICROB AGENTS CH, V40, P2212, DOI 10.1128/AAC.40.9.2212
   Colledge D, 1997, HEPATOLOGY, V26, P216
   DECASTRO LM, 1991, ANTIVIR RES, V16, P101, DOI 10.1016/0166-3542(91)90062-V
   Deeks SG, 1997, J INFECT DIS, V176, P1517, DOI 10.1086/514150
   DEHERTOGH D, 1997, 2 INT C THER VIR HEP
   DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501
   Fischer KP, 1996, ANTIMICROB AGENTS CH, V40, P1957, DOI 10.1128/AAC.40.8.1957
   Flaherty JF, 1996, AM J HEALTH-SYST PH, V53, pS4, DOI 10.1093/ajhp/53.8_Suppl_2.S4
   Gilson R. J. C., 1996, Hepatology, V24, p281A
   GUNTHER S, 1995, J VIROL, V69, P5437
   HEITJINK RA, 1993, ANTIVINAL RES, V21, P141
   Hong JH, 1998, ARCH PHARM RES, V21, P89, DOI 10.1007/BF02974012
   Honkoop P, 1997, LIVER, V17, P103
   Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X
   IMMAIMO SF, 1997, ANTIMICROB AGENTS CH, V41, P1444
   JEFFERS L, 1998, ANTIVIR RES, V37, pA197
   KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269
   Klein M, 1997, TRANSPLANTATION, V64, P162, DOI 10.1097/00007890-199707150-00028
   KORBA BE, 1992, ANTIVIR RES, V19, P55, DOI 10.1016/0166-3542(92)90056-B
   Korba BE, 1996, ANTIVIR RES, V29, P49, DOI 10.1016/0166-3542(95)00915-9
   Korba BE, 1996, ANTIMICROB AGENTS CH, V40, P1282, DOI 10.1128/AAC.40.5.1282
   Lai C. L., 1997, Hepatology, V26, p259A
   Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201
   Lau GKK, 1999, J GASTROEN HEPATOL, V14, P3, DOI 10.1046/j.1440-1746.1999.01812.x
   Lin E, 1998, ANTIMICROB AGENTS CH, V42, P2132, DOI 10.1128/AAC.42.8.2132
   Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   Omata M, 1998, NEW ENGL J MED, V339, P114, DOI 10.1056/NEJM199807093390209
   Ono-Nita SK, 1999, HEPATOLOGY, V29, P939, DOI 10.1002/hep.510290340
   Sambrook J, 1989, MOL CLONING LAB MANU
   Shaw T, 1996, HEPATOLOGY, V24, P996
   Singh N, 1997, TRANSPLANTATION, V63, P1415, DOI 10.1097/00007890-199705270-00008
   SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321
   SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X
   TERRY BJ, 1991, MOL PHARMACOL, V40, P591
   Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1002/hep.510240340
   Togo G, 1996, CANCER RES, V56, P5620
   WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011
   YANG H, 1996, ANTIVINAL RES, V26, P1
   YOKOSUKA O, 1985, HEPATOLOGY, V5, P728, DOI 10.1002/hep.1840050505
   YOKOTA T, 1991, ANTIMICROB AGENTS CH, V35, P394, DOI 10.1128/AAC.35.2.394
NR 49
TC 97
Z9 101
U1 0
U2 8
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA ROOM 4570 KRESGE I, 200 ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 1999
VL 103
IS 12
BP 1635
EP 1640
DI 10.1172/JCI5882
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 251VZ
UT WOS:000083468200005
PM 10377169
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Pinho, JRR
   Zanotto, PMDA
   Ferreira, JLP
   Sumita, LM
   Carrilho, FJ
   da Silva, LC
   Capacci, ML
   Silva, AO
   Guz, B
   Goncalves, FL
   Goncalves, NSL
   Buck, GA
   Meyers, GA
   Bernardini, AP
AF Pinho, JRR
   Zanotto, PMDA
   Ferreira, JLP
   Sumita, LM
   Carrilho, FJ
   da Silva, LC
   Capacci, ML
   Silva, AO
   Guz, B
   Goncalves, FL
   Goncalves, NSL
   Buck, GA
   Meyers, GA
   Bernardini, AP
TI High prevalence of GB virus C in Brazil and molecular evidence for
   intrafamilial transmission
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HEPATITIS-G VIRUS; A-E HEPATITIS; SEXUAL TRANSMISSION; LIVER-DISEASE;
   INFECTION; SEQUENCES; IDENTIFICATION; PRIMERS; REGION; RNA
AB The prevalence of GB virus C (GBV-C) in candidate Brazilian blood donors with normal and elevated alanine aminotransferase levels was found to be 5.2% (5 of 95) and 6.5% (5 of 76), respectively. Among Brazilian patients, GBV-C was Found in 9.5% (13 of 137) of cases of hepatitis not caused by hepatitis A,virus (HAV), HBV, HCV, HDV, or HEV (non-A-E hepatitis) and in 18.2% (8 of 44) of individuals infected with HCV. Molecular characterization of GBV-C by partial sequencing of the NS3 region showed clustering between members of a single family, implying intrafamilial transmission. In conclusion, these results together suggest that contagion mechanisms which facilitate intrafamiliar transmission of GBV-C may partially explain the high prevalence of viremic carriers worldwide.
C1 Inst Adolfo Lutz, Serv Virol, BR-01246902 Sao Paulo, Brazil.
   Lab Bioquim Jardim Paulista, Sao Paulo, Brazil.
   UNIFESP, EPM, Disciplina Doencas Infecciosas & Parasitarias, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Inst Trop Med, Lab Hepatol, Sao Paulo, Brazil.
   Hosp Beneficencia Portugesa, Sao Paulo, Brazil.
   Hosp Servidor Publ Estadual, Sao Paulo, Brazil.
   UNICAMP, Hemoctr, Campinas, SP, Brazil.
   Fac Ciencias Med, Disciplina Molestias Infecciosas, Campinas, SP, Brazil.
   Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA.
   Commonwealth Biotechnol Inc, Richmond, VA USA.
RP Pinho, JRR (corresponding author), Inst Adolfo Lutz, Serv Virol, Ave Doutor Arnaldo 355, BR-01246902 Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012; de A.
   Zanotto, Paolo M./B-9286-2019
OI Pinho, Joao R. R./0000-0003-3999-0489; de A. Zanotto, Paolo
   M./0000-0002-8167-0625
CR Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102
   Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101
   Brown KE, 1997, J INFECT DIS, V175, P450, DOI 10.1093/infdis/175.2.450
   Dawson GJ, 1996, J MED VIROL, V50, P97, DOI 10.1002/(SICI)1096-9071(199609)50:1&lt;97::AID-JMV16&gt;3.0.CO;2-V
   Egawa K, 1996, J MED VIROL, V49, P110, DOI 10.1002/(SICI)1096-9071(199606)49:2&lt;110::AID-JMV7&gt;3.0.CO;2-8
   Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4
   Fiordalisi G, 1996, J INFECT DIS, V174, P181, DOI 10.1093/infdis/174.1.181
   Fiordalisi G, 1997, J INFECT DIS, V175, P1025, DOI 10.1086/517488
   Kao JH, 1997, J MED VIROL, V52, P381, DOI 10.1002/(SICI)1096-9071(199708)52:4&lt;381::AID-JMV6&gt;3.0.CO;2-Y
   Kao JH, 1997, J MED VIROL, V53, P348, DOI 10.1002/(SICI)1096-9071(199712)53:4&lt;348::AID-JMV6&gt;3.0.CO;2-7
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Leary TP, 1996, J VIROL METHODS, V56, P119, DOI 10.1016/0166-0934(95)01956-1
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Miyakawa Y, 1997, NEW ENGL J MED, V336, P795, DOI 10.1056/NEJM199703133361109
   Muerhoff AS, 1996, J VIROL METHODS, V62, P55, DOI 10.1016/0166-0934(96)02088-5
   Muerhoff AS, 1997, J VIROL, V71, P6501, DOI 10.1128/JVI.71.9.6501-6508.1997
   Pinho J. R. R., 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P243, DOI 10.1590/S0036-46651996000300016
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Sugai Y, 1997, J MED VIROL, V51, P175, DOI 10.1002/(SICI)1096-9071(199703)51:3&lt;175::AID-JMV6&gt;3.0.CO;2-3
   Wang HL, 1997, J INFECT DIS, V175, P1229, DOI 10.1086/593676
   Zanetti AR, 1998, J MED VIROL, V54, P107, DOI 10.1002/(SICI)1096-9071(199802)54:2&lt;107::AID-JMV7&gt;3.0.CO;2-A
   Zhang XH, 1997, J MED VIROL, V52, P385, DOI 10.1002/(SICI)1096-9071(199708)52:4&lt;385::AID-JMV7&gt;3.0.CO;2-Y
NR 22
TC 17
Z9 18
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 1999
VL 37
IS 5
BP 1634
EP 1637
DI 10.1128/JCM.37.5.1634-1637.1999
PG 4
WC Microbiology
SC Microbiology
GA 187NG
UT WOS:000079792400083
PM 10203545
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Ono-Nita, SK
   Kato, N
   Shiratori, Y
   Masaki, T
   Lan, KH
   Carrilho, FJ
   Omata, M
AF Ono-Nita, SK
   Kato, N
   Shiratori, Y
   Masaki, T
   Lan, KH
   Carrilho, FJ
   Omata, M
TI YMDD motif in hepatitis B virus DNA polymerase influences on replication
   and lamivudine resistance: A study by in vitro full-length viral DNA
   transfection
SO HEPATOLOGY
LA English
DT Article
ID TYPE-1 REVERSE-TRANSCRIPTASE; LIVER-TRANSPLANTATION; INTERFERON
   TREATMENT; CONFERS RESISTANCE; MUTATIONS; INHIBITION; MUTANTS;
   2',3'-DIDEOXY-3'-THIACYTIDINE; CIRRHOSIS; INFECTION
AB Recently lamivudine used to treat patients with hepatitis B virus (HBV) infection was revealed to have potent antiviral activity. However, HBV resistance to lamivudine has been reported and shown to have amino acid substitutions in the methionine residue of the conserved tyrosine (Y), methionine (M), aspartate (D), aspartate (D) motif of RNA-dependent DNA polymerase. To explore the consequences of substitutions in this motif (YMDD), we made 7 variants by substituting the methionine of the YMDD motif with isoleucine (I), valine (V), alanine (A), leucine (L), lysine (K), arginine (R), and threonine (T). Replication ability of these variants was evaluated by transfection into human hepatoma cells. Sensitivity to lamivudine was tested for replication-competent variants. Four variants with hydrophobic substitutions (I, V; A, and L) remained replication competent, whereas 3 others with hydrophilic substitutions (K, R, and T) exhibited impaired replication. Of the 4 replication-competent variants, 2 (I and V) were resistant, and 2 (A and L) were sensitive to lamivudine. Because the polymerase and the surface gene overlap, the introduction of these mutations affected the secretion of hepatitis B surface antigen (HBsAg), namely 4 variants (I, V, L, and R) secreted HBsAg, whereas 3 variants (A, K, and T) did not. Our study elucidated that only one amino acid substitution in the YMDD motif was sufficient to cause lamivudine resistance in vitro. As a result of replication competence and lamivudine sensitivity, only viruses having YIDD or YVDD sequences may appear during treatment with lamivudine. This in vitro system could be used to study HBV mutations, replication competence, and their susceptibility to antivirals.
C1 Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, Tokyo 113, Japan.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RP Kato, N (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.
RI Carrilho, Flair J/I-3046-2012; Ono, Suzane/I-3107-2012
CR Aye TT, 1997, J HEPATOL, V26, P1148, DOI 10.1016/S0168-8278(97)80125-0
   Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x
   Bain VG, 1996, TRANSPLANTATION, V62, P1456, DOI 10.1097/00007890-199611270-00013
   Balter M, 1996, SCIENCE, V274, P1988, DOI 10.1126/science.274.5295.1988
   Bartholomew MM, 1997, LANCET, V349, P20, DOI 10.1016/S0140-6736(96)02266-0
   BenAri Z, 1997, TRANSPLANTATION, V63, P393, DOI 10.1097/00007890-199702150-00011
   Benhamou Y, 1996, ANN INTERN MED, V125, P705, DOI 10.7326/0003-4819-125-9-199611010-00001
   BRUSS V, 1991, J VIROL, V65, P3813, DOI 10.1128/JVI.65.7.3813-3820.1991
   CHANG CN, 1992, J BIOL CHEM, V267, P13938
   DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501
   DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495
   Fischer KP, 1996, ANTIMICROB AGENTS CH, V40, P1957, DOI 10.1128/AAC.40.8.1957
   FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601
   Grellier L, 1996, LANCET, V348, P1212, DOI 10.1016/S0140-6736(96)04444-3
   GUNTHER S, 1995, J VIROL, V69, P5437
   Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507
   INOUYE S, 1993, REVERSE TRANSCRIPTAS, P391
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320
   KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269
   Keulen W, 1997, J VIROL, V71, P3346, DOI 10.1128/JVI.71.4.3346-3350.1997
   Lai CL, 1997, HEPATOLOGY, V25, P241, DOI 10.1002/hep.510250144
   Lange JMA, 1997, SCIENCE, V276, P548, DOI 10.1126/science.276.5312.548
   Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347
   Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561
   Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   Richman DD, 1996, SCIENCE, V272, P1886, DOI 10.1126/science.272.5270.1886
   Sambrook J, 1989, MOL CLONING LAB MANU
   SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672
   Smith RA, 1997, J VIROL, V71, P2357, DOI 10.1128/JVI.71.3.2357-2362.1997
   SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665
   Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1002/hep.510240340
   Togo G, 1996, CANCER RES, V56, P5620
   Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282
   WAINBERG MA, 1996, AIDS S, V10, P53
   WAKEFIELD JK, 1992, J VIROL, V66, P6806, DOI 10.1128/JVI.66.11.6806-6812.1992
   *WHO, WHO WARNS GROWING CR
   WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011
   YOKOSUKA O, 1985, HEPATOLOGY, V5, P728, DOI 10.1002/hep.1840050505
   YOKOSUKA O, 1985, GASTROENTEROLOGY, V89, P610, DOI 10.1016/0016-5085(85)90458-5
NR 43
TC 137
Z9 146
U1 0
U2 11
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD MAR
PY 1999
VL 29
IS 3
BP 939
EP 945
DI 10.1002/hep.510290340
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 172FB
UT WOS:000078911700044
PM 10051501
OA Bronze
DA 2020-12-08
ER

PT B
AU Roxo, JMC
   Carrilho, F
AF Roxo, JMC
   Carrilho, F
BE Alten, T
   Backer, L
   Bollingmo, P
   Broch, E
   Holmoy, K
   Holter, KG
   Nielsen, K
TI Design and site investigation for the rehabilitation of old railway
   tunnels
SO CHALLENGES FOR THE 21ST CENTURY, VOL. 2: COMMUNICATION
   TUNNELS/MISCELLANEOUS INCLUDING WATER TUNNELS/MECHANISED TUNNELLING
LA English
DT Proceedings Paper
CT World Tunnel Congress 1999 on Challenges for the 21st Century
CY MAY 31-JUN 03, 1999
CL OSLO, NORWAY
SP Norwegian Tunnelling Soc, Andersen Mek Verksted AS, Dyno Nobel, Norconsult ASA, VS Int, Veidekke-Selmer
AB The Portuguese railway network, dating mainly from the last century, has about 120 tunnels. Those tunnels, with different lengths, sections and overburden, cross several types of rocks, ranging from hard to soft ones.
   The main problems frequently identified, in some of the tunnels mentioned, are related with important water inflows and seepage, lack or insufficient drainage systems, sidewalls and vault deformations, collapse of the masonry support due to excessively opened or weathered joints, the existence of voids behind the lining and finally, rock falls problems in the slope portals. Other situations, which contributed to increase the risk of those tunnels, are the absence of safety cells and monitoring instrumentation.
   REFER, the entity responsible for the operation and safety of all the railway tunnels is interested in the renovation and rehabilitation of some tunnels. Therefore, several studies were developed in order to identify the risk assessment of their situation, enabling the design and implementation of the most adequate solutions. In this article, we point out the main problems of some old tunnels, with a special emphasis on the site investigations which had to be done without interfering with the normal train circulation, as well as on the design solutions chosen for the complex task of renovating a tunnel. Two case studies are presented, one related with the rehabilitation design and other with the rehabilitation works.
C1 Independent Univ, Civil Dept, DHV Grp, FBO Consultores, Alges, Portugal.
RP Roxo, JMC (corresponding author), Independent Univ, Civil Dept, DHV Grp, FBO Consultores, Alges, Portugal.
RI Carrilho, Flair J/I-3046-2012
CR Beaver P., 1972, HIST TUNNELS
   CABRAL V, 1987, 2 ENC NAC GEOT LISB, P103
   *COBA, 1997, PROJ BEN REF LINH OE
   *LNEC, 1996, PROSP COM GEOR NOS T
   ROXO JMC, 1995, CONTRIBUICAO PROJECT
NR 5
TC 0
Z9 0
U1 0
U2 0
PU A A BALKEMA PUBLISHERS
PI LEIDEN
PA SCHIPHOLWEG 107C, PO BOX 447, 2316 XC LEIDEN, NETHERLANDS
BN 90-5809-065-5
PY 1999
BP 623
EP 631
PG 3
WC Engineering, Civil; Engineering, Geological
SC Engineering
GA BN41M
UT WOS:000081860000021
DA 2020-12-08
ER

PT J
AU Ono-Nita, SK
   Kato, N
   Shiratori, Y
   Lan, KH
   Yoshida, H
   Kato, J
   Carrilho, FJ
   Omata, M
AF Ono-Nita, SK
   Kato, N
   Shiratori, Y
   Lan, KH
   Yoshida, H
   Kato, J
   Carrilho, FJ
   Omata, M
TI Susceptibility of lamivudine resistant hepatitis B virus to other
   antivirals: Adefovir and lobucavir.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Tokyo, Fac Med, Dept Internal Med 2, Tokyo 113, Japan.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
RI Ono, Suzane/I-3107-2012; Carrilho, Flair J/I-3046-2012
NR 0
TC 7
Z9 7
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1998
VL 28
IS 4
SU S
MA 12
BP 165A
EP 165A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 125VQ
UT WOS:000076258100013
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Farias, AQ
   Laudanna, A
   Kalil, J
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Farias, AQ
   Laudanna, A
   Kalil, J
TI Different HLA profiles confer susceptibility to autoimmune hepatitis
   types 1 and 2.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Lab Transplantat Immunol, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
RI BITTENCOURT, PAULO l/I-5817-2014; KALIL, JORGE/C-8029-2012; Carrilho,
   Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016; Goldberg, Anna
   Carla/H-8594-2014
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; KALIL,
   JORGE/0000-0001-8415-4274; Cancado, Eduardo/0000-0002-9309-1524;
   Goldberg, Anna Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1998
VL 28
IS 4
SU S
MA 303
BP 238A
EP 238A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 125VQ
UT WOS:000076258100302
DA 2020-12-08
ER

PT J
AU Da Silva, LC
   Pinho, JRR
   Sitnik, R
   Fonesca, EP
   Carrilho, FJ
   Bernardini, AP
AF Da Silva, LC
   Pinho, JRR
   Sitnik, R
   Fonesca, EP
   Carrilho, FJ
   Bernardini, AP
TI Virologic factors associated with non response to lamivudine (LAM) and
   viral mutations associated with drug resistance in Brazilian patients
   with chronic hepatitis B (CHB).
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Clin Hepatol Branch, Sao Paulo, Brazil.
   Bioquim Jardim Paulista, Sao Paulo, Brazil.
RI Sitnik, Roberta/N-4740-2017; Carrilho, Flair J/I-3046-2012; Pinho, Joao
   R. R./G-2850-2012
OI Sitnik, Roberta/0000-0002-6243-8118; Pinho, Joao R.
   R./0000-0003-3999-0489
NR 0
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1998
VL 28
IS 4
SU S
MA 2256
BP 726A
EP 726A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 125VQ
UT WOS:000076258102254
DA 2020-12-08
ER

PT J
AU Cancado, ELR
   Leitao, RMC
   Carrilho, FJ
   Laudanna, AA
AF Cancado, ELR
   Leitao, RMC
   Carrilho, FJ
   Laudanna, AA
TI Unexpected clinical remission of cholestasis after rifampicin therapy in
   patients with normal or slightly increased levels of gamma-glutamyl
   transpeptidase
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article; Proceedings Paper
CT Meeting of the International-Association-for-the-Study-of-the-Liver
   (IASL)
CY MAY   19, 1994
CL CANCUN, MEXICO
SP Int Assoc Study Liver
ID PRIMARY BILIARY-CIRRHOSIS; RECURRENT INTRAHEPATIC CHOLESTASIS; HEPATIC
   CHOLESTASIS; PRURITUS; BILE; LIVER; ACID; METABOLISM; CHILDREN; DISEASE
AB Objective: Rifampicin is an effective drug against pruritus in intrahepatic cholestasis. However, there is no specific hepatic disease in which its use could cause undoubtedly biochemical improvement. The aim of this study was to describe patients with complete remission of cholestatic symptoms after rifampicin therapy. Methods: We reported three female patients with intrahepatic cholestasis with no evidence of viral, metabolic, or autoimmune liver diseases. Total bilirubin levels ranged from 13.2 to 27.2 mg/dl (before the first treatment,vith rifampicin), and in ail of them gamma-glutamyl transpeptidase values were within the normal range or slightly increased. Rifampicin therapy was administered orally, without any concomitant drug, with an effective dosage of 5-17 mg/kg/day, Results: In all patients, pruritus ceased completely and bilirubin returned to normal values, The symptoms recurred after rifampicin withdrawal on, at least, three occasions in each patient, and these symptoms were always eliminated after its reintroduction, The patients had a total of 16 cholestatic episodes during a follow-up of 8 yr, with a complete clinical recovery in all of them. Undergoing therapy with a suitable dosage of rifampicin, none of the patients had a cholestatic crisis even during a period for as long as 12 months. The diagnosis of two patients was consistent with benign recurrent intrahepatic cholestasis, and it was not well defined in the remaining. Conclusion: Rifampicin may induce clinical remission, and perhaps prevent clinical relapses of intrahepatic cholestasis with normal or slightly increased levels of gamma-glutamyl transpeptidase, (Am J Gastroenterol 1998;93: 1510-1517, (C) 1998 by Am. Cell. of Gastroenterology).
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Surg, Liver Unit, Sao Paulo, Brazil.
RP Cancado, ELR (corresponding author), Hosp Clin, Disciplina Gastroenterol Clin, Sala 9159,Av Dr Eneas de Carvalho Aguiar 255, BR-05403000 Sao Paulo, Brazil.
RI Cancado, Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012
OI Cancado, Eduardo/0000-0002-9309-1524; 
CR BACHS L, 1989, LANCET, V1, P574
   BACHS L, 1992, GASTROENTEROLOGY, V102, P2077, DOI 10.1016/0016-5085(92)90335-V
   Balsells F, 1997, CLIN PEDIATR, V36, P483, DOI 10.1177/000992289703600809
   BILJLEVELD CM, 1989, GASTROENTEROLOGY, V97, P427
   BJORKHEM I, 1994, SCAND J GASTROENTERO, V29, P68, DOI 10.3109/00365529409103629
   BOLT HM, 1977, ACTA ENDOCRINOL-COP, V85, P189
   BRENARD R, 1989, J CLIN GASTROENTEROL, V11, P546, DOI 10.1097/00004836-198910000-00011
   COLOMBO C, 1995, HRLR, V25, pR11
   CYNAMON HA, 1990, GASTROENTEROLOGY, V98, P1013, DOI 10.1016/0016-5085(90)90027-X
   Desmet V. J., 1994, P425
   FAHAL IH, 1992, BRIT MED J, V304, P882, DOI 10.1136/bmj.304.6831.882
   GALEAZZI R, 1980, DIGEST DIS SCI, V25, P108, DOI 10.1007/BF01308307
   GHENT CN, 1987, AM J GASTROENTEROL, V82, P117
   GHENT CN, 1988, GASTROENTEROLOGY, V94, P488, DOI 10.1016/0016-5085(88)90442-8
   GREGORIO GV, 1993, ARCH DIS CHILD, V69, P141, DOI 10.1136/adc.69.1.141
   JACQUEMIN E, 1988, GASTROEN CLIN BIOL, V12, P768
   KHANDELWAL M, 1994, DIGEST DIS SCI, V39, P1, DOI 10.1007/BF02090052
   KUIPERS F, 1985, CLIN SCI, V68, P127, DOI 10.1042/cs0680127
   LONNING PE, 1989, J STEROID BIOCHEM, V33, P631, DOI 10.1016/0022-4731(89)90052-6
   MAGGIORE G, 1991, J PEDIATR GASTR NUTR, V12, P21, DOI 10.1097/00005176-199101000-00005
   PARES A, 1981, GASTROENTEROLOGY, V80, P681
   PODESTA A, 1991, DIGEST DIS SCI, V36, P216, DOI 10.1007/BF01300759
   POUPON RE, 1994, NEW ENGL J MED, V330, P1342, DOI 10.1056/NEJM199405123301903
   PUTTERMAN C, 1987, POSTGRAD MED J, V63, P295, DOI 10.1136/pgmj.63.738.295
   REYES H, 1992, GASTROENTEROL CLIN N, V21, P905
   RIELY CA, 1987, SEMIN LIVER DIS, V7, P119, DOI 10.1055/s-2008-1040571
   SHENFIELD GM, 1993, DRUG SAFETY, V9, P21, DOI 10.2165/00002018-199309010-00003
   SONDAG D, 1987, GASTROEN CLIN BIOL, V11, P711
   STIEHL A, 1994, SCAND J GASTROENTERO, V29, P59, DOI 10.3109/00365529409103626
   SUMMERSKILL WH, 1965, AM J MED, V38, P298, DOI 10.1016/0002-9343(65)90184-1
   TYGSTRUP N, 1969, ACTA MED SCAND, V185, P523
   WHITINGTON PF, 1988, GASTROENTEROLOGY, V95, P130, DOI 10.1016/0016-5085(88)90301-0
   Whitington PF, 1996, PEDIATR CLIN N AM, V43, P1, DOI 10.1016/S0031-3955(05)70395-3
   Wietholtz H, 1996, J HEPATOL, V24, P713, DOI 10.1016/S0168-8278(96)80268-6
   WILLIAMS R, 1964, Q J MED, V131, P387
NR 35
TC 69
Z9 71
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD SEP
PY 1998
VL 93
IS 9
BP 1510
EP 1517
DI 10.1111/j.1572-0241.1998.00472.x
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 116VU
UT WOS:000075746400025
PM 9732934
DA 2020-12-08
ER

PT J
AU Pinho, JRR
   Zanotto, PMA
   Sumita, LM
   Carrilho, FJ
   Capacci, ML
   Silva, AO
   Goncales, FL
   Goncales, NSL
   Buck, GA
   Meyers, GA
   daSilva, LC
   Bernardini, AP
AF Pinho, JRR
   Zanotto, PMA
   Sumita, LM
   Carrilho, FJ
   Capacci, ML
   Silva, AO
   Goncales, FL
   Goncales, NSL
   Buck, GA
   Meyers, GA
   daSilva, LC
   Bernardini, AP
TI Hepatitis G virus GB virus C in Brazil: Prevalence in hepatitis. Cases
   and evidences for household transmission
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 INST ADOLFO LUTZ REGISTRO,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,FAC MED,DEPT GASTROENTEROL,BR-05508 SAO PAULO,BRAZIL.
   UNIV FED SAO PAULO,DEPT DOENCAS INFECCIOSAS & PARASITARIAS,SAO PAULO,BRAZIL.
   UNIV ESTADUAL CAMPINAS,FAC CIENCIAS MED,DISC MOL INFECCIOSAS,BR-13081970 CAMPINAS,SP,BRAZIL.
   UNIV ESTADUAL CAMPINAS,HEMOCTR,BR-13081970 CAMPINAS,SP,BRAZIL.
   COMMONWEALTH BIOTECHNOL,RICHMOND,VA.
RI de A. Zanotto, Paolo M./B-9286-2019; Pinho, Joao R. R./G-2850-2012;
   Carrilho, Flair J/I-3046-2012
OI de A. Zanotto, Paolo M./0000-0002-8167-0625; Pinho, Joao R.
   R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1997
VL 26
IS 4
SU S
BP 1227
EP 1227
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA XY874
UT WOS:A1997XY87401226
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Marin, MLC
   Carrilho, F
   daSilva, LC
   Kalil, J
   Laudanna, AA
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Marin, MLC
   Carrilho, F
   daSilva, LC
   Kalil, J
   Laudanna, AA
TI Association of primary sclerosing cholangitis with HLA-DR and -DQ
   antigens in Brazil.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,CHILDRENS INST,DEPT GASTROENTEROL,LIVER UNIT,BR-05508 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST HEART,LAB TRANSPLANTAT IMMUNOL,BR-05508 SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Goldberg, Anna Carla/H-8594-2014; KALIL,
   JORGE/C-8029-2012; Cancado, Eduardo/K-1861-2016; BITTENCOURT, PAULO
   l/I-5817-2014
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; Cancado, Eduardo/0000-0002-9309-1524;
   BITTENCOURT, PAULO l/0000-0003-0883-4870
NR 0
TC 8
Z9 8
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1997
VL 26
IS 4
SU S
BP 1420
EP 1420
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA XY874
UT WOS:A1997XY87401420
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Baggio, VL
   Marin, MLC
   Carrilho, F
   Kalil, J
   Laudanna, AA
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Baggio, VL
   Marin, MLC
   Carrilho, F
   Kalil, J
   Laudanna, AA
TI HLA-DQ association to autoimmune hepatitis types 1 and 2.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,CHILDRENS INST,DEPT GASTROENTEROL,LIVER UNIT,BR-05508 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST HEART,LAB TRANSPLANTAT IMMUNOL,BR-05508 SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016; Goldberg,
   Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; BITTENCOURT, PAULO
   l/I-5817-2014
OI Cancado, Eduardo/0000-0002-9309-1524; Goldberg, Anna
   Carla/0000-0003-2600-7940; KALIL, JORGE/0000-0001-8415-4274;
   BITTENCOURT, PAULO l/0000-0003-0883-4870
NR 0
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1997
VL 26
IS 4
SU S
BP 1421
EP 1421
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA XY874
UT WOS:A1997XY87401421
DA 2020-12-08
ER

PT J
AU daSilva, LC
   Carrilho, FJ
   Pinho, JRR
   Sitnik, R
   Bernardini, AP
AF daSilva, LC
   Carrilho, FJ
   Pinho, JRR
   Sitnik, R
   Bernardini, AP
TI Virological patterns during lamivudine therapy in patients with HBV
   chronic infection.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,HEPATOL BRANCH,DISCIPLINE CLIN GASTROENTEROL,SAO PAULO,BRAZIL.
   BIOQUIM JD PAULISTA & ADOLFO LUTZ INST,SAO PAULO,BRAZIL.
RI Pinho, Joao R. R./G-2850-2012; Sitnik, Roberta/N-4740-2017; Carrilho,
   Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Sitnik,
   Roberta/0000-0002-6243-8118; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1997
VL 26
IS 4
SU S
BP 1472
EP 1472
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA XY874
UT WOS:A1997XY87401472
DA 2020-12-08
ER

PT J
AU Bassit, L
   daSilva, LC
   Carrilho, FJ
   Mendes, LCA
   Fonseca, LEP
   Pereira, AL
   Alves, VAF
   Gayotto, LCC
   SaezAlquezar, A
AF Bassit, L
   daSilva, LC
   Carrilho, FJ
   Mendes, LCA
   Fonseca, LEP
   Pereira, AL
   Alves, VAF
   Gayotto, LCC
   SaezAlquezar, A
TI Genotype 2, rather than 1 and 3a, is predictive responsive factor to
   therapy in Brazilian patients with chronic hepatitis C infection.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 HSP,FPS,FDN PROSANGUE HEMOCTR SAO PAULO,DEPT DIAGNOST & PESQUISA,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1996
VL 24
IS 4
SU S
BP 137
EP 137
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VL285
UT WOS:A1996VL28500137
DA 2020-12-08
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Baggio, VL
   Silva, LC
   Carrilho, F
   Kalil, J
   Laudanna, AA
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Baggio, VL
   Silva, LC
   Carrilho, F
   Kalil, J
   Laudanna, AA
TI Association of autoimmune hepatitis (AIH) and primary sclerosing
   cholangitis (PSC) with HLA-DR antigens in Brazil.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,CHILDRENS INST,DEPT GASTROENTEROL,LIVER UNIT,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,LAB TRANSPLANTAT IMMUNOL,INST HEART,SAO PAULO,BRAZIL.
RI Cancado, Eduardo/K-1861-2016; KALIL, JORGE/C-8029-2012; BITTENCOURT,
   PAULO l/I-5817-2014; Carrilho, Flair J/I-3046-2012; Goldberg, Anna
   Carla/H-8594-2014
OI Cancado, Eduardo/0000-0002-9309-1524; KALIL, JORGE/0000-0001-8415-4274;
   BITTENCOURT, PAULO l/0000-0003-0883-4870; Goldberg, Anna
   Carla/0000-0003-2600-7940
NR 0
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1996
VL 24
IS 4
SU S
BP 423
EP 423
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VL285
UT WOS:A1996VL28500422
DA 2020-12-08
ER

PT J
AU Alves, VAF
   Carrilho, FJ
   Vianna, R
   Cardoso, RA
   DaSilva, LC
   Laudanna, AA
   Gayotto, LCC
AF Alves, VAF
   Carrilho, FJ
   Vianna, R
   Cardoso, RA
   DaSilva, LC
   Laudanna, AA
   Gayotto, LCC
TI Would large-cell dysplasia (LCD) and adenomatous hyperplasia (AH) be
   related to hepatocellular carcinoma (HCC) in cirrhotics?
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,CLIN HEPATOL BRANCH,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DEPT PATHOL,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1996
VL 24
IS 4
SU S
BP 884
EP 884
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VL285
UT WOS:A1996VL28500883
DA 2020-12-08
ER

PT J
AU Carrilho, FJ
   Nita, SKO
   DaSilva, LC
   Cardoso, RA
   Fonseca, LEP
   Laudanna, AA
   Alves, VAF
   Gayotto, LCC
AF Carrilho, FJ
   Nita, SKO
   DaSilva, LC
   Cardoso, RA
   Fonseca, LEP
   Laudanna, AA
   Alves, VAF
   Gayotto, LCC
TI Behavior of HBV markers in Brazilian families of occidental and oriental
   origin of patients with chronic HBV infection.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,CLIN HEPATOL BRANCH,DEPT GASTROENTEROL & PATHOL,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1996
VL 24
IS 4
SU S
BP 1467
EP 1467
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VL285
UT WOS:A1996VL28501463
DA 2020-12-08
ER

PT J
AU Carrilho, FJ
   Nita, SKO
   DaSilva, LD
   Cardoso, RA
   Fonseca, LEP
   Laudanna, AA
   Alves, VAF
   Gayotto, LCC
AF Carrilho, FJ
   Nita, SKO
   DaSilva, LD
   Cardoso, RA
   Fonseca, LEP
   Laudanna, AA
   Alves, VAF
   Gayotto, LCC
TI The influence of the ethnical groups and kinship in the dissemination of
   the HBV infection in Brazilian families of oriental and occidental
   origin.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,CLIN HEPATOL BRANCH,DEPT GASTROENTEROL & PATHOL,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1996
VL 24
IS 4
SU S
BP 1468
EP 1468
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VL285
UT WOS:A1996VL28501465
DA 2020-12-08
ER

PT J
AU Mendes, LCA
   DaSilva, LC
   Carrilho, FJ
   Pinho, JRR
   Santos, CA
   Fonseca, LEP
   Laudanna, AA
AF Mendes, LCA
   DaSilva, LC
   Carrilho, FJ
   Pinho, JRR
   Santos, CA
   Fonseca, LEP
   Laudanna, AA
TI Response to alpha interferon therapy according to quantitation of
   HCV-RNA by RT-PCR.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,CLIN HEPATOL BRANCH,SAO PAULO,BRAZIL.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1996
VL 24
IS 4
SU S
BP 1682
EP 1682
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VL285
UT WOS:A1996VL28501679
DA 2020-12-08
ER

PT J
AU Mendes, LCA
   DaSilva, LC
   Carrilho, FJ
   Pinho, JRR
   Santos, CA
   Laudanna, AA
AF Mendes, LCA
   DaSilva, LC
   Carrilho, FJ
   Pinho, JRR
   Santos, CA
   Laudanna, AA
TI Ribavirin monotherapy or in association with interferon. Analysis of 72
   patients.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,CLIN HEPATOL BRANCH,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1996
VL 24
IS 4
SU S
BP 1683
EP 1683
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VL285
UT WOS:A1996VL28501678
DA 2020-12-08
ER

PT J
AU Pinho, JRR
   Capacci, ML
   Carrilho, FJ
   Santos, CA
   Sumita, LM
   Mendes, LCA
   Guz, B
   Bernardini, AP
   DaSilva, LC
AF Pinho, JRR
   Capacci, ML
   Carrilho, FJ
   Santos, CA
   Sumita, LM
   Mendes, LCA
   Guz, B
   Bernardini, AP
   DaSilva, LC
TI GB virus C hepatitis G virus in Brazil.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,ADOLFO LUTZ INST,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,CLIN HEPATOL BRANCH,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,VIROL SECT,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1996
VL 24
IS 4
SU S
BP 1745
EP 1745
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VL285
UT WOS:A1996VL28501740
DA 2020-12-08
ER

PT J
AU DaSilva, LC
   Madruga, CLDA
   Carrilho, FJ
   Pinho, JRR
   SaezAlquezar, A
   Santos, C
   Bassit, L
   Barreto, C
   DaFonseca, LEP
   Alves, VAF
   Leitao, R
   Vianna, R
   Cardoso, RA
   Franca, AVC
   Gayotto, LCDC
AF DaSilva, LC
   Madruga, CLDA
   Carrilho, FJ
   Pinho, JRR
   SaezAlquezar, A
   Santos, C
   Bassit, L
   Barreto, C
   DaFonseca, LEP
   Alves, VAF
   Leitao, R
   Vianna, R
   Cardoso, RA
   Franca, AVC
   Gayotto, LCDC
TI Spontaneous hepatitis B surface antigen clearance in a long-term
   follow-up study of patients with chronic type B hepatitis. Lack of
   correlation with hepatitis C and D virus superinfection
SO JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE hepatitis B; chronic hepatitis B; spontaneous HBsAg clearance
ID POLYMERASE CHAIN-REACTION; HBSAG CLEARANCE; HEPATOCELLULAR-CARCINOMA;
   MONONUCLEAR-CELLS; NEGATIVE PATIENTS; ALPHA-INTERFERON;
   PERIPHERAL-BLOOD; NATURAL-HISTORY; LIVER-DISEASE; HBV-DNA
AB We investigated the frequency of HBsAg clearance and the possible role of viral superinfection in a long-term follow-up of 184 patients with chronic hepatitis B (CHB). Our subjects were 184 patients with chronic hepatitis B and the follow-up was 12-216 months (mean 66.2 +/- 53.7 months). The investigative methods used were: immunoenzymatic assays for HBV, HCV, HDV, and HIV markers; polymerase chain reaction (PCR) for HBV DNA; and liver biopsy and immunoperoxidase. During the follow-up, 20 of the 184 patients cleared serum HBsAg. A comparison of patients with persistent HBsAg (group I) and of those who cleat-ed this marker (group TI) showed a significant difference in mortality (P = 0.002) between the two groups and a tendency to a more severe exacerbation (flare) in group II (P = 0.07). Antibodies to hepatitis C and D virus as well as antibodies to HIV were equally distributed in both groups. Thirteen patients (7.9%) from group I, but none from group II, subsequently developed hepatocellular carcinoma. These results suggest that the frequency of spontaneous clearance of HBsAg during chronic HBV infection is low. No determinant factor for the clearance was found, including the presence of liver cirrhosis. Serum HBV DNA was undetectable by PCR after clearance in 16 out of 17 patients.
RP DaSilva, LC (corresponding author), UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,HEPATOL BRANCH,BR-05508 SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; Saez-Alquezar,
   Amadeo/0000-0001-5230-4741
CR ADACHI H, 1992, HEPATOLOGY, V16, P1334, DOI 10.1002/hep.1840160605
   ALWARD WLM, 1985, J INFECT DIS, V151, P604, DOI 10.1093/infdis/151.4.604
   BAKER BL, 1991, HEPATOLOGY, V13, P632, DOI 10.1002/hep.1840130404
   BORTOLOTTI F, 1981, GUT, V22, P499, DOI 10.1136/gut.22.6.499
   DOOLEY JS, 1986, GASTROENTEROLOGY, V90, P150, DOI 10.1016/0016-5085(86)90087-9
   DORMEYER HH, 1981, J INFECT DIS, V144, P33, DOI 10.1093/infdis/144.1.33
   DRAELOS M, 1987, JAMA-J AM MED ASSOC, V258, P1193, DOI 10.1001/jama.258.9.1193
   FONG TL, 1991, HEPATOLOGY, V14, pA130
   FONG TL, 1991, HEPATOLOGY, V14, P264
   HADCHOUEL M, 1988, J MED VIROL, V24, P27, DOI 10.1002/jmv.1890240105
   HOOFNAGLE JH, 1982, PROG LIVER DIS, V7, P469
   HSU HY, 1992, HEPATOLOGY, V15, P382, DOI 10.1002/hep.1840150304
   KANEKO S, 1989, P NATL ACAD SCI USA, V86, P312, DOI 10.1073/pnas.86.1.312
   KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629
   KUHNS M, 1992, GASTROENTEROLOGY, V103, P1649, DOI 10.1016/0016-5085(92)91191-6
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   LAURE F, 1987, BRIT J HAEMATOL, V65, P181, DOI 10.1111/j.1365-2141.1987.tb02262.x
   LAURE F, 1985, SCIENCE, V229, P561, DOI 10.1126/science.2410981
   LIAW YF, 1991, HEPATOLOGY, V13, P627, DOI 10.1002/hep.1840130403
   LIAW YF, 1991, INFECTION, V19, P250, DOI 10.1007/BF01644957
   LIEINJO LE, 1983, DNA-J MOLEC CELL BIO, V2, P301, DOI 10.1089/dna.1983.2.301
   LOK ASF, 1987, GASTROENTEROLOGY, V92, P1839, DOI 10.1016/0016-5085(87)90613-5
   MARCELLIN P, 1990, ANN INTERN MED, V112, P227, DOI 10.7326/0003-4819-112-3-227
   MASON A, 1992, HEPATOLOGY, V16, P36, DOI 10.1002/hep.1840160108
   MORGAN TR, 1986, DIGEST DIS SCI, V31, P700, DOI 10.1007/BF01296446
   PASQUINELLI C, 1986, J HEPATOL, V3, P95, DOI 10.1016/S0168-8278(86)80152-0
   PINHO JRR, 1989, REV I MED TROP, V31, P328, DOI 10.1590/S0036-46651989000500006
   PORALLA T, 1986, DIGESTION, V33, P53, DOI 10.1159/000199274
   REALDI G, 1980, GASTROENTEROLOGY, V79, P195
   ROSNER B, 1982, FUNDAMENTALS BIOSTAT, P288
   SAMPLINER RE, 1979, AM J MED SCI, V277, P17, DOI 10.1097/00000441-197901000-00002
   SANCHEZTAPIAS JM, 1984, J HEPATOL, V1, P15
   SHEEN IS, 1992, J INFECT DIS, V165, P831, DOI 10.1093/infdis/165.5.831
   STEMBERGER LA, 1970, J HISTOCHEM CYTOCHEM, V8, P315
   VIOLA LA, 1981, LANCET, V2, P1156
   WU TT, 1987, J HEPATOL, V4, P45, DOI 10.1016/S0168-8278(87)80008-9
NR 36
TC 36
Z9 38
U1 0
U2 3
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0944-1174
J9 J GASTROENTEROL
JI J. Gastroenterol.
PD OCT
PY 1996
VL 31
IS 5
BP 696
EP 701
DI 10.1007/BF02347619
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VJ728
UT WOS:A1996VJ72800011
PM 8887037
DA 2020-12-08
ER

PT J
AU BASSIT, L
   DASILVA, LC
   CARRILHO, FJ
   VANDERBORGHT, B
   CHAMONE, DAF
   SAEZALQUEZAR, A
AF BASSIT, L
   DASILVA, LC
   CARRILHO, FJ
   VANDERBORGHT, B
   CHAMONE, DAF
   SAEZALQUEZAR, A
TI SUBTYPING OF HEPATITIS-C VIRUS IN PATIENTS WITH CHRONIC HEPATITIS USING
   A LINE PROBE ASSAY (LIPA)
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 FMUSP, DEPT GASTROENTEROL HOSP CLIN, DEPT GASTROENTEROL, FUNDACAO PRO SANGUE HEMOTR SAO PAULO, SAO PAULO, BRAZIL.
   INNOGENET, GHENT, BELGIUM.
RI Carrilho, Flair J/I-3046-2012; Vanderborght, Bram/A-1599-2008
OI Vanderborght, Bram/0000-0003-4881-9341
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 1995
VL 108
IS 4
SU S
BP A1030
EP A1030
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA QT863
UT WOS:A1995QT86304101
DA 2020-12-08
ER

PT J
AU ALVES, VAF
   CARRILHO, FJ
   GAYOTTO, LCC
   WAKAMATSU, A
   GROSSO, SNA
   LAUDANNA, AA
   DASILVA, LC
AF ALVES, VAF
   CARRILHO, FJ
   GAYOTTO, LCC
   WAKAMATSU, A
   GROSSO, SNA
   LAUDANNA, AA
   DASILVA, LC
TI IMMUNOHISTOCHEMISTRY OF P53 IN HEPATOCELLULAR-CARCINOMA (HCC) IN
   SAO-PAULO, BRAZIL
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,DEPT PATHOL,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,DEPT GASTROENTEROL,HEPATOL BRANCH,SAO PAULO,BRAZIL.
   INST ADOLFO LUTZ REGISTRO,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD APR
PY 1994
VL 19
IS 4
BP I39
EP I39
DI 10.1016/0270-9139(94)90325-5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ND702
UT WOS:A1994ND70200045
DA 2020-12-08
ER

PT J
AU CANCADO, ELR
   FARIAS, AQ
   SOARES, MA
   CARRILHO, FJ
   DAMIAO, ACM
   LAUDANNA, AA
AF CANCADO, ELR
   FARIAS, AQ
   SOARES, MA
   CARRILHO, FJ
   DAMIAO, ACM
   LAUDANNA, AA
TI TOTAL REMISSION OF INTRAHEPATIC CHOLESTASIS (IHC) WITH SLIGHT INCREASES
   IN CANALICULAR ENZYMES, BY TREATING WITH RIFAMPIN (RMP) - COULD IT
   DEPEND ON THE RMP ESTROGEN-RELATED EFFECTS
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,HEPATOL BRANCH,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016
OI Cancado, Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD APR
PY 1994
VL 19
IS 4
BP I48
EP I48
DI 10.1016/0270-9139(94)90362-X
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ND702
UT WOS:A1994ND70200082
DA 2020-12-08
ER

PT J
AU CARRILHO, FJ
   ALVES, VAF
   CARDOSO, RA
   FRANCA, AVC
   FONSECA, LEP
   LAUDANNA, AA
   GAYOTTO, LCC
   DASILVA, LC
AF CARRILHO, FJ
   ALVES, VAF
   CARDOSO, RA
   FRANCA, AVC
   FONSECA, LEP
   LAUDANNA, AA
   GAYOTTO, LCC
   DASILVA, LC
TI CASE-CONTROL STUDY OF CLINICAL, LABORATORIAL AND MORPHOLOGICAL DATA ON
   HEPATOCELLULAR-CARCINOMA AND LIVER-CIRRHOSIS - AN UNIVARIATE AND
   MULTIVARIATE STEPWISE LOGISTIC-REGRESSION ANALYSIS
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,HEPATOL BRANCH,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DEPT PATHOL,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD APR
PY 1994
VL 19
IS 4
BP I50
EP I50
DI 10.1016/0270-9139(94)90367-0
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ND702
UT WOS:A1994ND70200087
DA 2020-12-08
ER

PT J
AU DASILVA, LC
   FONSECA, LEP
   CARRILHO, FJ
   ONO, SK
   FARIAS, AQ
   MENDES, LCA
AF DASILVA, LC
   FONSECA, LEP
   CARRILHO, FJ
   ONO, SK
   FARIAS, AQ
   MENDES, LCA
TI PATTERNS OF SERUM ALT ACTIVITIES DURING AND AFTER RECOMBINANT
   ALPHA-INTERFERON (IFN) IN 40 PATIENTS (PTS) WITH CHRONIC HEPATITIS-C
   (CH-C) - A LONG-TERM FOLLOW-UP-STUDY AND FURTHER THERAPEUTIC TRIALS WITH
   RIBAVIRIN (RB) OR URSODEOXYCOLIC ACID (UDCA)
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,HEPATOL BRANCH,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST TROP MED,SAO PAULO,BRAZIL.
RI Ono, Suzane/I-3107-2012; Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD APR
PY 1994
VL 19
IS 4
BP I56
EP I56
DI 10.1016/0270-9139(94)90394-8
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ND702
UT WOS:A1994ND70200114
DA 2020-12-08
ER

PT J
AU GRIEGO, AG
   ALBAJKES, VR
   HERRERA, U
   JULIA, O
   LACUNA, V
   TORRES, J
   CARRILHO, F
   ZUMAETA, E
   FERNANDIZ, J
AF GRIEGO, AG
   ALBAJKES, VR
   HERRERA, U
   JULIA, O
   LACUNA, V
   TORRES, J
   CARRILHO, F
   ZUMAETA, E
   FERNANDIZ, J
TI DYNAMIC OF THE IMMUNE-RESPONSE WITH RECOMBINANT ANTI-HBV CUBAN VACCINE
   IN LATIN-AMERICAN COUNTRIES
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 HIGHER INST MED SCI,HAVANA,CUBA.
   CTR GENET ENGN & BIOTECHNOL,HAVANA,CUBA.
   NATL HLTH INST,BOGOTA,COLOMBIA.
   CLIN HOSP SAO PABLO,SAO PABLO,BRAZIL.
   CENT UNIV VENEZUELA,CARACAS,VENEZUELA.
RI Julia, Olga/G-1716-2015; Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD APR
PY 1994
VL 19
IS 4
BP I69
EP I69
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ND702
UT WOS:A1994ND70200163
DA 2020-12-08
ER

PT J
AU DASILVA, LD
   MADRUGA, CL
   CARRILHO, FJ
   PINHO, JRR
   SAEZALQUEZAR, A
   SANTOS, CA
   BASSITT, L
   BARRETO, CC
   ALVES, VAF
   GAYOTTO, LCC
   CHAMONE, DAF
AF DASILVA, LD
   MADRUGA, CL
   CARRILHO, FJ
   PINHO, JRR
   SAEZALQUEZAR, A
   SANTOS, CA
   BASSITT, L
   BARRETO, CC
   ALVES, VAF
   GAYOTTO, LCC
   CHAMONE, DAF
TI SPONTANEOUS CLEARANCE (SC) OF SERUM HBSAG IN 20 PATIENTS WITH CHRONIC
   HEPATITIS-B (CHB) - HBV-DNA STATUS BY POLYMERASE CHAIN-REACTION (PCR)
   AND ROLE OF VIRAL SUPERINFECTION
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
NR 0
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 1993
VL 104
IS 4
SU S
BP A688
EP A688
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA KX957
UT WOS:A1993KX95702731
DA 2020-12-08
ER

PT J
AU PINHO, JRR
   SAEZALQUEZAR, A
   SANTOS, CA
   BASSITT, L
   BARRETO, CC
   CHAMONE, DAF
   MADRUGA, CL
   FONSECA, LEP
   FRANCA, AVC
   CARRILHO, FJ
   ALVES, VAF
   DASILVA, LC
AF PINHO, JRR
   SAEZALQUEZAR, A
   SANTOS, CA
   BASSITT, L
   BARRETO, CC
   CHAMONE, DAF
   MADRUGA, CL
   FONSECA, LEP
   FRANCA, AVC
   CARRILHO, FJ
   ALVES, VAF
   DASILVA, LC
TI MARKERS OF HEPATITIS-B VIRUS (HBV) REPLICATION, INCLUDING POLYMERASE
   CHAIN-REACTION (PCR) IN CHRONIC HEPATITIS-B (CHB)
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
ID SERUM; DNA
C1 UNIV SAO PAULO,SCH MED,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Pinho, Joao R. R./G-2850-2012
OI Pinho, Joao R. R./0000-0003-3999-0489
CR KANEKO S, 1990, GASTROENTEROLOGY, V99, P799
   PINHO JRR, 1989, REV I MED TROP, V31, P328, DOI 10.1590/S0036-46651989000500006
NR 2
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 1993
VL 104
IS 4
SU S
BP A763
EP A763
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA KX957
UT WOS:A1993KX95703028
DA 2020-12-08
ER

PT J
AU DASILVA, LC
   MADRUGAGONZALES, CL
   CARRILHO, FJ
   FONSECA, LEP
   MUSZKAT, R
   VIANNA, R
   ALVES, VAF
   GAYOTTO, LCC
AF DASILVA, LC
   MADRUGAGONZALES, CL
   CARRILHO, FJ
   FONSECA, LEP
   MUSZKAT, R
   VIANNA, R
   ALVES, VAF
   GAYOTTO, LCC
TI CLEARANCE OF SERUM HBSAG IN PATIENTS WITH CHRONIC TYPE-B HEPATITIS (BCH)
   - A LONG-TERM FOLLOW-UP-STUDY
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DEPT PATHOL,HEPATOL SECT,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,LIM 47,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD AUG
PY 1992
VL 16
IS 2
BP 528
EP 528
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JH147
UT WOS:A1992JH14700094
DA 2020-12-08
ER

PT J
AU PARANAQUAVEZZOZO, D
   CERRI, GG
   CARRILHO, FJ
   DASILVA, LC
   LAUDANNA, AA
AF PARANAQUAVEZZOZO, D
   CERRI, GG
   CARRILHO, FJ
   DASILVA, LC
   LAUDANNA, AA
TI NONINVASIVE PORTAL HEMODYNAMIC MEASURES IN SCHISTOSOMIASIS-MANSONI USING
   ULTRASOUND DOPPLER DUPLEX SYSTEM
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT RADIOL,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Paranagua-Vezozzo, Denise
   Cerqueira/N-7270-2014
OI Paranagua-Vezozzo, Denise Cerqueira/0000-0002-9606-4935
CR ZOLI M, 1986, J CLIN ULTRASOUND, V14, P429, DOI 10.1002/jcu.1870140605
NR 1
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD AUG
PY 1992
VL 16
IS 2
BP 583
EP 583
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JH147
UT WOS:A1992JH14700306
DA 2020-12-08
ER

PT J
AU SANTOS, VA
   ALVES, VAF
   VANDERBORGHT, B
   FONSECA, LEP
   CARRILHO, FJ
   DASILVA, LC
   GAYOTTO, LCC
AF SANTOS, VA
   ALVES, VAF
   VANDERBORGHT, B
   FONSECA, LEP
   CARRILHO, FJ
   DASILVA, LC
   GAYOTTO, LCC
TI DETECTION OF ANTI-HCV ANTIBODIES - A PRACTICAL PROPOSAL FOR IMPROVEMENT
   OF SPECIFICITY THROUGH THE COMBINATION OF 2 ELISA TESTS
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT PATHOL & GASTROENTEROL,SAO PAULO,BRAZIL.
   INST ADOLFO LUTZ REGISTRO,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Vanderborght, Bram/A-1599-2008
OI Vanderborght, Bram/0000-0003-4881-9341
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD AUG
PY 1992
VL 16
IS 2
BP 589
EP 589
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JH147
UT WOS:A1992JH14700330
DA 2020-12-08
ER

PT J
AU DASILVA, LC
   CARRILHO, FJ
AF DASILVA, LC
   CARRILHO, FJ
TI HEPATOSPLENIC SCHISTOSOMIASIS - PATHOPHYSIOLOGY AND TREATMENT
SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
ID PORTAL-HYPERTENSION; MANSONI INFECTIONS; SYMMERS FIBROSIS; RANDOMIZED
   TRIAL; FOLLOW-UP; PRAZIQUANTEL; SURGERY; CHEMOTHERAPY; ULTRASOUND;
   DISEASE
C1 INST MED TROP SAO PAULO,SAO PAULO,BRAZIL.
RP DASILVA, LC (corresponding author), UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,CLIN HEPATOL BRANCH,RUA SILVA CORREIA 153 41,BR-04537 SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
CR ABDELWAHAB MF, 1989, AM J TROP MED HYG, V40, P72, DOI 10.4269/ajtmh.1989.40.72
   ANDRADE Z A, 1987, Memorias do Instituto Oswaldo Cruz, V82, P325, DOI 10.1590/S0074-02761987000300003
   ANDRADE ZA, 1989, MEM I OSWALDO CRUZ, V84, P58, DOI 10.1590/S0074-02761989000500007
   BINA JC, 1984, ASPECTOS PECULIARES, P13
   BINA JC, 1977, THESIS F MED BAHIA
   BOGLIOLO L, 1957, REV ASSOC MED BRAS, V2, P263
   BORGES DR, 1989, REV ASSOC MED BRAS, V35, P39
   CERRI GG, 1984, RADIOLOGY, V153, P777, DOI 10.1148/radiology.153.3.6387793
   COLLEY DG, 1986, AM J TROP MED HYG, V35, P793, DOI 10.4269/ajtmh.1986.35.793
   CORDEIRO F, 1990, GASTROINTEST ENDOSC, V36, P475, DOI 10.1016/S0016-5107(90)71118-2
   Coura J. R., 1981, REV SOC BRAS MED TRO, V14, P93
   COUTINHO A, 1968, AM J MED, V44, P547, DOI 10.1016/0002-9343(68)90055-7
   COUTINHO AD, 1990, REV INST MED TROP SP, V32, P73, DOI 10.1590/S0036-46651990000200001
   DASILVA LC, 1990, REV INST MED TROP SP, V32, P328, DOI 10.1590/S0036-46651990000500004
   DASILVA LC, 1985, TROP MED PARASITOL, V36, P150
   DASILVA LC, 1986, ANN SURG, V204, P148, DOI 10.1097/00000658-198608000-00008
   DASILVA LC, 1986, REV INST MED TROP SP, V28, P174, DOI 10.1590/S0036-46651986000300007
   DASILVA LC, UNPUB PORTAL HYPERTE
   DEBRITO T, 1985, LIVER, V5, P64
   EZZAT FA, 1990, ANN SURG, V212, P97, DOI 10.1097/00000658-199007000-00013
   HOMEIDA MMA, 1988, AM J TROP MED HYG, V38, P496, DOI 10.4269/ajtmh.1988.38.496
   KELNER S, 1982, REV COLEGIO BRASILEI, V9, P140
   LYRA LG, 1976, GASTROENTEROLOGY, V71, P645
   MADIWAR MA, 1989, T R SOC TROP MED HYG, V83, P233
   MANOUKIAN N, 1984, REV I MED TROP, V26, P237, DOI 10.1590/S0036-46651984000500001
   Mies S, 1980, Rev Hosp Clin Fac Med Sao Paulo, V35, P136
   MIES S, 1980, GASTROENTEROLOGY, V78, P1314
   MIES S, 1988, REV ASSOC MED BRAS, V34, P24
   MORGAN JS, 1990, HEPATOLOGY, V11, P98, DOI 10.1002/hep.1840110117
   NETO OB, 1988, THESIS F MED U SAO P
   Prata A., 1982, P105
   RAIA S, 1980, MED SURGICAL PROBLEM, P301
   SAKAI P, 1990, ENDOSCOPY, V22, P5, DOI 10.1055/s-2007-1012777
   SILVEIRA GSM, 1980, THESIS U FEDERAL BAH
   STRAUSS E, 1990, HEPATOLOGY, V12, P854
   STRAUSS E, 1986, HEPATITES AGUDAS CRO, P172
   Tavares-Neto J, 1989, Rev Soc Bras Med Trop, V22, P13, DOI 10.1590/S0037-86821989000100003
   TAVARESNETO J, 1987, REV SAUDE PUBL, V21, P342, DOI 10.1590/S0034-89101987000400008
   WARREN KS, 1966, AM J PATHOL, V49, P477
   WARREN KS, 1965, ANN INTERN MED, V62, P1113, DOI 10.7326/0003-4819-62-6-1113
   ZEITUNE J M R, 1980, Arquivos de Gastroenterologia, V17, P88
   ZEITUNE JMR, 1980, THESIS IBEPEGE SAO P
   ZWINGENBERGER K, 1990, T ROY SOC TROP MED H, V84, P252, DOI 10.1016/0035-9203(90)90277-L
   1985, SERIE INFORMES TECNI, V728
NR 44
TC 25
Z9 27
U1 0
U2 4
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0889-8553
J9 GASTROENTEROL CLIN N
JI Gastroenterol. Clin. North Am.
PD MAR
PY 1992
VL 21
IS 1
BP 163
EP 177
PG 15
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HF207
UT WOS:A1992HF20700011
PM 1568771
DA 2020-12-08
ER

PT J
AU CARRILHO, FJ
   QUEIROZ, ML
   DAFONSECA, LEP
   OBARA, L
   DASILVA, LC
AF CARRILHO, FJ
   QUEIROZ, ML
   DAFONSECA, LEP
   OBARA, L
   DASILVA, LC
TI ACTIVE IMMUNIZATION AGAINST HEPATITIS-B VIRUS (HBV) WITH LOW-DOSES OF
   PLASMA-DERIVED VACCINE BY INTRADERMAL ROUTE - ANTI-HBS RESPONSE AFTER 3
   YEARS OF FOLLOW-UP
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Letter
C1 HOSP OSWALDO CRUZ,SAO PAULO,BRAZIL.
RP CARRILHO, FJ (corresponding author), UNIV SAO PAULO,SCH MED,DISCIPLINE CLIN GASTROENTEROL,CLIN HEPATOL BRANCH,BR-05403 SAO PAULO,SP,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
CR CARRILHO FJ, 1989, REV I MED TROP, V31, P91, DOI 10.1590/S0036-46651989000200005
NR 1
TC 2
Z9 3
U1 0
U2 1
PU INST MEDICINA TROPICAL
PI SAO PAULO
PA AV DR ENEIAS C AGUIAR CAIXA POSTAL 2921, SAO PAULO, BRAZIL
SN 0036-4665
J9 REV I MED TROP
PD MAR-APR
PY 1991
VL 33
IS 2
BP 167
EP 167
DI 10.1590/S0036-46651991000200013
PG 1
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FR381
UT WOS:A1991FR38100013
PM 1844387
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU PINHO, JRR
   DAFONSECA, LEP
   SONG, Y
   MIYAMOTO, Y
   CARRILHO, FJ
   GRANATO, CFH
   DASILVA, LC
AF PINHO, JRR
   DAFONSECA, LEP
   SONG, Y
   MIYAMOTO, Y
   CARRILHO, FJ
   GRANATO, CFH
   DASILVA, LC
TI COMPARISON OF SERUM HEPATITIS-B VIRUS-REPLICATION MARKERS IN PATIENTS
   WITH CHRONIC HEPATITIS-B - STUDIES ON HBEAG/ANTI-HBE SYSTEM, VIRAL-DNA
   POLYMERASE AND HBV-DNA
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
C1 UNIV SAO PAULO,FAC MED,INST MED TROP,HEPATOL LAB,SAO PAULO,SP,BRAZIL.
   INST ADOLFO LUTZ REGISTRO,DIV VIROL,HEPATITIS BRANCH,SAO PAULO,BRAZIL.
   INST ADOLFO LUTZ REGISTRO,DIV VIROL,MOLEC BIOL BRANCH,SAO PAULO,BRAZIL.
RP PINHO, JRR (corresponding author), UNIV SAO PAULO,FAC MED,INST MED TROP,DEPT GASTROENTEROL,CLIN HEPATOL BRANCH,LIM 07,BR-05403 SAO PAULO,BRAZIL.
RI Pinho, Joao R. R./G-2850-2012; Carrilho, Flair J/I-3046-2012
OI Pinho, Joao R. R./0000-0003-3999-0489; 
CR BERNINGER M, 1982, J MED VIROL, V9, P57, DOI 10.1002/jmv.1890090109
   BONINO F, 1981, HEPATOLOGY, V1, P386, DOI 10.1002/hep.1840010503
   BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503
   BRECHOT C, 1981, LANCET, V2, P756
   CARRILHO FJ, 1986, HEPATITES AGUDAS CRO, P47
   CHAUSSADE S, 1986, GASTROEN CLIN BIOL, V10, P744
   CHU CM, 1985, HEPATOLOGY, V5, P431, DOI 10.1002/hep.1840050315
   CRAXI A, 1983, GUT, V24, P143, DOI 10.1136/gut.24.2.143
   FEINMAN SV, 1984, J VIROL METHODS, V8, P199, DOI 10.1016/0166-0934(84)90014-4
   FIGUS A, 1984, HEPATOLOGY, V4, P364, DOI 10.1002/hep.1840040303
   GENESCA J, 1986, MED CLIN-BARCELONA, V87, P665
   GERBER MA, 1985, LAB INVEST, V52, P572
   GRANATO CFH, 1988, THESIS FM U SAO PAUL
   GUST ID, 1986, INTERVIROLOGY, V25, P14, DOI 10.1159/000149651
   HARRISON TJ, 1985, BRIT MED J, V290, P663, DOI 10.1136/bmj.290.6469.663
   KAPLAN PM, 1973, J VIROL, V12, P995, DOI 10.1128/JVI.12.5.995-1005.1973
   KARAYIANNIS P, 1985, J HEPATOL, V1, P99, DOI 10.1016/S0168-8278(85)80759-5
   LIEBERMAN HM, 1983, HEPATOLOGY, V3, P285
   LIN HJ, 1984, CLIN CHEM, V30, P549
   MANIATIS T, 1982, MOL CLONING
   MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X
   MORACE G, 1985, J VIROL METHODS, V12, P235, DOI 10.1016/0166-0934(85)90134-X
   NORDENFELT E, 1975, INTERVIROLOGY, V5, P225, DOI 10.1159/000149918
   RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3
   RINTJES PJM, 1985, AM J PATHOL, V120, P411
   SCOTTO J, 1983, HEPATOLOGY, V3, P279
   STANDRING DN, 1986, PROG LIVER DIS, V8, P311
   VANDITZHUIJSEN TJM, 1985, J MED VIROL, V15, P49, DOI 10.1002/jmv.1890150107
   WALTER E, 1987, HEPATOLOGY, V7, P557, DOI 10.1002/hep.1840070323
   WELLER IVD, 1982, J MED VIROL, V9, P273, DOI 10.1002/jmv.1890090405
   ZELDIS JB, 1986, J VIROL METHODS, V14, P153, DOI 10.1016/0166-0934(86)90046-7
NR 31
TC 3
Z9 3
U1 0
U2 2
PU INST MEDICINA TROPICAL
PI SAO PAULO
PA AV DR ENEIAS C AGUIAR CAIXA POSTAL 2921, SAO PAULO, BRAZIL
SN 0036-4665
J9 REV I MED TROP
PD SEP-OCT
PY 1989
VL 31
IS 5
BP 328
EP 335
DI 10.1590/S0036-46651989000500006
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CA079
UT WOS:A1989CA07900006
PM 2629062
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU CARRILHO, FJ
   QUEIROZ, ML
   DASILVA, LC
   DAFONSECA, LEP
   GRANATO, C
   OBA, I
   OBARA, L
AF CARRILHO, FJ
   QUEIROZ, ML
   DASILVA, LC
   DAFONSECA, LEP
   GRANATO, C
   OBA, I
   OBARA, L
TI ACTIVE IMMUNIZATION AGAINST HEPATITIS-B VIRUS (HBV) WITH LOW DOSES OF
   PLASMA-DERIVED VACCINE BY INTRADERMAL ROUTE
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
C1 HOSP OSVALDO CRUZ,SAO PAULO,BRAZIL.
   INST ADOLFO LUTZ,DIV VIROL,HEPATITIS BRANCH,SAO PAULO,BRAZIL.
   INST PAULISTA PATOL CLIN,BIESP,SAO PAULO,BRAZIL.
RP CARRILHO, FJ (corresponding author), UNIV SAO PAULO,FAC MED,DEPT GASTROENTEROL,CLIN HEPATOL BRANCH,AV DR ARNALDO 455,BR-01246 SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
CR ALTER MJ, 1985, JAMA-J AM MED ASSOC, V254, P3200, DOI 10.1001/jama.254.22.3200
   DAVIDSON M, 1986, J INFECTION, V13, P31, DOI 10.1016/S0163-4453(86)92653-8
   DIENSTAG JL, 1984, ANN INTERN MED, V101, P34, DOI 10.7326/0003-4819-101-1-34
   FRANCIS DP, 1982, ANN INTERN MED, V97, P362, DOI 10.7326/0003-4819-97-3-362
   FRAZER IH, 1987, MED J AUSTRALIA, V146, P242, DOI 10.5694/j.1326-5377.1987.tb120230.x
   FULTON JP, 1986, AM J PUBLIC HEALTH, V76, P1339, DOI 10.2105/AJPH.76.11.1339
   GOUDEAU A, 1987, POSTGRAD MED J, V63, P125
   HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401
   HALSEY NA, 1986, VACCINE, V4, P228, DOI 10.1016/0264-410X(86)90134-9
   IRVING WL, 1986, LANCET, V2, P1340
   MILLER KD, 1983, LANCET, V2, P1454, DOI 10.1016/S0140-6736(83)90800-0
   MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103
   PAPAEVANGELOU G, 1983, J INFECTION, V7, P69, DOI 10.1016/S0163-4453(83)96718-X
   REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P3203, DOI 10.1001/jama.254.22.3203
   SZMUNESS W, 1982, NEW ENGL J MED, V307, P1481, DOI 10.1056/NEJM198212093072403
   ZOULEK G, 1984, LANCET, V1, P568
   ZUCKERMAN AJ, 1987, LANCET, V1, P435
NR 17
TC 6
Z9 6
U1 0
U2 1
PU INST MEDICINA TROPICAL
PI SAO PAULO
PA AV DR ENEIAS C AGUIAR CAIXA POSTAL 2921, SAO PAULO, BRAZIL
SN 0036-4665
J9 REV I MED TROP
PD MAR-APR
PY 1989
VL 31
IS 2
BP 91
EP 94
DI 10.1590/S0036-46651989000200005
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA U9484
UT WOS:A1989U948400005
PM 2602806
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU STRAUSS, E
   GAYOTTO, LCC
   DASILVA, LC
   ALVES, VAF
   CARRILHO, F
   CHAMONE, DAF
   DASILVA, EF
   PORTA, G
   GRANATO, C
   TREPO, C
AF STRAUSS, E
   GAYOTTO, LCC
   DASILVA, LC
   ALVES, VAF
   CARRILHO, F
   CHAMONE, DAF
   DASILVA, EF
   PORTA, G
   GRANATO, C
   TREPO, C
TI UNEXPECTED LOW PREVALENCE OF DELTA ANTIBODIES IN THE EAST AMAZON REGION
   AND SAO-PAULO - EVIDENCE FOR REGIONAL DIFFERENCES IN THE EPIDEMIOLOGY OF
   DELTA-HEPATITIS VIRUS WITHIN BRAZIL
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
RP STRAUSS, E (corresponding author), UNIV SAO PAULO,FAC MED,SCH MED,LIVER UNIT,AV DR ARNALDO 455,BR-01246 SAO PAULO,SP,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
CR CHEN DS, 1984, HEPATOLOGY, V4, P502, DOI 10.1002/hep.1840040324
   GAYOTTO LCC, 1984, GED, V3, P106
   HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339
   MENDES TF, 1984, MODERNA HEPATOLOGIA, V9, P16
   RIZZETTO M, 1979, LANCET, V2, P986
   RIZZETTO M, 1977, GUT, V18, P997, DOI 10.1136/gut.18.12.997
   RIZZETTO M, 1984, 1984 P INT S VIR HEP, P371
NR 7
TC 9
Z9 9
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PY 1987
VL 81
IS 1
BP 73
EP 74
DI 10.1016/0035-9203(87)90288-4
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA G2245
UT WOS:A1987G224500018
PM 3445327
DA 2020-12-08
ER

PT J
AU DASILVA, LC
   CARRILHO, FJ
   DIPIETRO, A
   BORISCHAVEZ, A
   ALBORNOZ, P
   SETTE, H
   FRANCO, CFF
   ANTONELLI, R
   SAEZALQUEZAR, A
AF DASILVA, LC
   CARRILHO, FJ
   DIPIETRO, A
   BORISCHAVEZ, A
   ALBORNOZ, P
   SETTE, H
   FRANCO, CFF
   ANTONELLI, R
   SAEZALQUEZAR, A
TI EPIDEMIOLOGIC ASPECTS OF ACUTE VIRAL-HEPATITIS IN SAO-PAULO, BRAZIL
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
C1 UNIV SAO PAULO,FAC MED,DEPT GASTROENTEROL,SAO PAULO,SP,BRAZIL.
   UNIV SAO PAULO,FAC MED,DEPT CIRURGIA EXPTL,SAO PAULO,SP,BRAZIL.
RP DASILVA, LC (corresponding author), INST MED TROP SAO PAULO,AV DR ENEAS CARVALHO AGUIAR 470,BR-05403 SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
OI Saez-Alquezar, Amadeo/0000-0001-5230-4741
CR ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886
   BAMBER M, 1983, GUT, V24, P561, DOI 10.1136/gut.24.6.561
   Bernstein L M, 1980, Ann Intern Med, V93, P183
   BORTOLOTTI F, 1982, SCAND J INFECT DIS, V14, P161, DOI 10.3109/inf.1982.14.issue-3.01
   BRADLEY DW, 1977, J CLIN MICROBIOL, V5, P521
   BRUGUERA M, 1982, GASTROENTEROL HEPATO, V5, P237
   BURRELL CJ, 1980, CLIN GASTROENTEROL, V9, P47
   DIENSTAG JL, 1980, CLIN GASTROENTEROL, V9, P135
   Dienstag JL, 1981, NON A NON B HEPATITI, P119
   DUERMEYER W, 1978, LANCET, V2, P684
   FINDOR JA, 1983, JORNADAS LATINOAMERI, V8, P25
   FLEISS JL, 1980, STATISTICAL METHODS
   FOCACCIA R, THESIS USP
   FRANCIS DP, 1984, AM J MED, V76, P69, DOI 10.1016/0002-9343(84)90752-6
   HOOFNAGLE JH, 1981, NON A NON B HEPATITI, P23
   KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4
   KOFF RS, 1982, HEPATOLOGY, V2, P445
   KOFF RS, 1982, DISEASES LIVER, P461
   KRUGMAN S, 1978, VIRAL HEPATITIS, P30
   LOCARNINI SA, 1979, J CLIN MICROBIOL, V9, P459
   MATHIESEN LR, 1979, SCAND J GASTROENTERO, V14, P849, DOI 10.3109/00365527909181415
   MATHIESEN LR, 1980, J CLIN MICROBIOL, V11, P297, DOI 10.1128/JCM.11.3.297-300.1980
   MILICUA JM, 1981, GASTROENT HEPAT, V4, P221
   NORKRANS G, 1978, SCAND J GASTROENTERO, V13, P873, DOI 10.3109/00365527809182206
   NORKRANS G, 1979, SCAND J INFECT DIS, V11, P259, DOI 10.3109/inf.1979.11.issue-4.01
   PANNUTI CS, 1985, TROP GEOGR MED, V37, P136
   RAMONET M, 1982, JORNADAS LATINOAMERI, V8, P27
   SILVA LC, 1981, JORNADA CIENTIFICA I, V1, P64
   Snedecor G. W., 1980, STATISTICAL METHODS
   VILLAREJOS VM, 1975, NEW ENGL J MED, V293, P1350, DOI 10.1056/NEJM197512252932606
   WEILAND O, 1981, SCAND J INFECT DIS, V13, P247, DOI 10.3109/inf.1981.13.issue-4.02
   WONG DC, 1980, LANCET, V2, P876
   ZACARIAS J, 1981, REV MED CHILE, V109, P833
NR 33
TC 2
Z9 2
U1 0
U2 1
PU INST MEDICINA TROPICAL
PI SAO PAULO
PA AV DR ENEIAS C AGUIAR CAIXA POSTAL 2921, SAO PAULO, BRAZIL
SN 0036-4665
J9 REV I MED TROP
PD NOV-DEC
PY 1986
VL 28
IS 6
BP 400
EP 405
DI 10.1590/S0036-46651986000600004
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA F7440
UT WOS:A1986F744000004
PM 3602825
OA Other Gold
DA 2020-12-08
ER

PT J
AU DASILVA, LC
   CARRILHO, FJ
   DIPIETRO, A
   ALVES, VAF
   GAYOTTO, LCC
AF DASILVA, LC
   CARRILHO, FJ
   DIPIETRO, A
   ALVES, VAF
   GAYOTTO, LCC
TI A PROSPECTIVE-STUDY OF 100 PATIENTS WITH HEPATITIS A AS SEEN IN
   SAO-PAULO, BRAZIL
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DEPT GASTROENTEROL,HEPATOL BRANCH,SAO PAULO,SP,BRAZIL.
   UNIDADE FIGADO SAO PAULO,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD OCT
PY 1986
VL 31
IS 10
SU S
BP S424
EP S424
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA E2170
UT WOS:A1986E217001685
DA 2020-12-08
ER

PT J
AU SAEZALQUEZAR, A
   DASILVA, LC
   CARRILHO, FJ
   RAIA, S
AF SAEZALQUEZAR, A
   DASILVA, LC
   CARRILHO, FJ
   RAIA, S
TI BILIARY PIGMENTS IN THE METABOLISM OF BILIRUBIN
SO REVISTA BRASILEIRA DE MEDICINA
LA Portuguese
DT Article
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOREIRA JR EDITORA LTDA
PI SAO PAULO
PA RUA HENRIQUE MARTINS 493, 04504 SAO PAULO, BRAZIL
SN 0034-7264
J9 REV BRAS MED
PY 1984
VL 41
IS 2
BP 68
EP 71
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA SM238
UT WOS:A1984SM23800002
DA 2020-12-08
ER

PT J
AU DASILVA, LC
   CARRILHO, FJ
   SETTE, H
   CHAVEZ, BA
   ALBORNOZ, P
   MORAES, C
   ALQUEZAR, AS
   RAIA, S
AF DASILVA, LC
   CARRILHO, FJ
   SETTE, H
   CHAVEZ, BA
   ALBORNOZ, P
   MORAES, C
   ALQUEZAR, AS
   RAIA, S
TI FREQUENCY OF A, B, AND NON-A,NON-B VIRAL-HEPATITIS IN SAO-PAULO LIVER
   UNIT
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 SAO PAULO LIVER UNIT,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PY 1983
VL 84
IS 5
BP 1369
EP 1369
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA QN290
UT WOS:A1983QN29001128
DA 2020-12-08
ER

PT J
AU DASILVA, LC
   MATTAR, E
   CARRILHO, FJ
   TAKEDA, A
   SETTE, H
   GAYOTTO, LCC
AF DASILVA, LC
   MATTAR, E
   CARRILHO, FJ
   TAKEDA, A
   SETTE, H
   GAYOTTO, LCC
TI EFFECTS OF ABRUPT WITHDRAWAL OF PREDNISOLONE AZA THIOPRINE IN CHRONIC
   TYPE-B HEPATITIS
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 SAO PAULO LIVER UNIT,SAO PAULO,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PY 1983
VL 84
IS 5
BP 1370
EP 1370
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA QN290
UT WOS:A1983QN29001129
DA 2020-12-08
ER

PT J
AU MIES, S
   SETTE, H
   CARRILHO, FJ
   RAIA, S
   DASILVA, LC
AF MIES, S
   SETTE, H
   CARRILHO, FJ
   RAIA, S
   DASILVA, LC
TI PERITONEOVENOUS SHUNT IN 34 PATIENTS WITH ASCITES
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,FAC MED,LIVER GRP,SAO PAULO,SP,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PY 1983
VL 84
IS 5
BP 1385
EP 1385
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA QN290
UT WOS:A1983QN29001189
DA 2020-12-08
ER

PT J
AU SETTE, H
   MIES, S
   CHAMONE, D
   CARRILHO, FJ
   RAIA, S
   DASILVA, LC
AF SETTE, H
   MIES, S
   CHAMONE, D
   CARRILHO, FJ
   RAIA, S
   DASILVA, LC
TI BLOOD-COAGULATION FACTORS AFTER LEVEEN PERITONEO VENOUS SHUNT
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,FAC MED,LIVER GRP,SAO PAULO,SP,BRAZIL.
RI Carrilho, Flair J/I-3046-2012; Chamone, Dalton/I-8852-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PY 1983
VL 84
IS 5
BP 1395
EP 1395
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA QN290
UT WOS:A1983QN29001231
DA 2020-12-08
ER

PT J
AU SAEZALQUEZAR, A
   CARRILHO, FJ
   RAIA, SA
   DASILVA, LC
AF SAEZALQUEZAR, A
   CARRILHO, FJ
   RAIA, SA
   DASILVA, LC
TI SERIC LEVELS OF ENZYMATIC-ACTIVITY IN HEPATIC DISEASES
SO REVISTA BRASILEIRA DE MEDICINA
LA Portuguese
DT Article
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOREIRA JR EDITORA LTDA
PI SAO PAULO
PA RUA HENRIQUE MARTINS 493, 04504 SAO PAULO, BRAZIL
SN 0034-7264
J9 REV BRAS MED
PY 1983
VL 40
IS 8
BP 284
EP 293
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA RK309
UT WOS:A1983RK30900002
DA 2020-12-08
ER

PT J
AU DASILVA, LC
   SAEZALQUEZAR, A
   CARRILHO, FJ
   RAIA, S
AF DASILVA, LC
   SAEZALQUEZAR, A
   CARRILHO, FJ
   RAIA, S
TI SERUM-PROTEINS - ELECTROPHORESIS AND CLINICAL IMPORTANCE
SO REVISTA BRASILEIRA DE MEDICINA
LA Portuguese
DT Article
RP DASILVA, LC (corresponding author), UNIV SAO PAULO,FAC MED,DEPT CLIN,MED DISCIPLINA GASTROENTEROL CLIN,UNIDADE FIGADO,SAO PAULO,SP,BRAZIL.
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOREIRA JR EDITORA LTDA
PI SAO PAULO
PA RUA HENRIQUE MARTINS 493, 04504 SAO PAULO, BRAZIL
SN 0034-7264
J9 REV BRAS MED
PY 1983
VL 40
IS 10
BP 386
EP 392
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA RT171
UT WOS:A1983RT17100003
DA 2020-12-08
ER

PT J
AU DASILVA, LC
   GRANATO, CFH
   CARRILHO, FJ
   SAEZALQUEZAR, A
   SETTE, H
   CARLOS, L
AF DASILVA, LC
   GRANATO, CFH
   CARRILHO, FJ
   SAEZALQUEZAR, A
   SETTE, H
   CARLOS, L
TI SIGNIFICANCE AND EVOLUATION OF THE SEROLOGIC PROFILE OF PATIENTS
   INFECTED WITH HEPATITIS-VIRUS
SO REVISTA BRASILEIRA DE MEDICINA
LA Portuguese
DT Article
RI Carrilho, Flair J/I-3046-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOREIRA JR EDITORA LTDA
PI SAO PAULO
PA RUA HENRIQUE MARTINS 493, 04504 SAO PAULO, BRAZIL
SN 0034-7264
J9 REV BRAS MED
PY 1983
VL 40
IS 11-1
BP 413
EP 418
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA RX092
UT WOS:A1983RX09200002
DA 2020-12-08
ER

EF